<SEC-DOCUMENT>0000318154-22-000010.txt : 20220216
<SEC-HEADER>0000318154-22-000010.hdr.sgml : 20220216
<ACCEPTANCE-DATETIME>20220216163953
ACCESSION NUMBER:		0000318154-22-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		146
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220216
DATE AS OF CHANGE:		20220216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		22644136

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>amgn-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2bb320c8-0f12-4641-8309-e0606e56f5e9,g:0e6120fc-59ff-4bff-bbf3-39bc007e06fc,d:2a971cfaef98424f9692041d6ed3a222--><html xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:amgn="http://www.amgen.com/20211231" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8wLTEtMS0xLTU1NTU0_2acfe96f-9f78-4c9a-9b5d-b457633e8448">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8xLTEtMS0xLTU1NTU0_f6c09dbc-bf27-424b-90b6-8f76b0f4e4a4">false</ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8yLTEtMS0xLTU1NTU0_8587aee8-1720-40a2-9914-499c7ccc4e2a">2021</ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8zLTEtMS0xLTU1NTU0_ad94484f-e797-41e5-8bd2-e498ff176540">FY</ix:nonNumeric><ix:nonNumeric contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_8e72894d-153e-4a5c-a949-14e5e6efb449">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_aa058334-0aaf-49a3-8af4-aa023d961fb9">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_425f51cf-a3fa-4258-bdbe-9af1266d73f5">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_ea705079-dbdc-4ad1-8743-a06d3d2376ba">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_b89a7ea2-fc91-480e-bd31-38a43ceb270a">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_f7f1087e-27ba-483f-bdb7-bd0cc9f4c25f">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387dbf98d1b24d5f83cd817582c5b3af_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if9cbde08232d47f1b1397109661d89c3_I20220211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa4009b79ae4a1aaa88901012cdc38c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9dfed05d2a4cc7b238e87a2395d611_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5666794b15d1495f894c2e5fa67e1ff5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4e5e657f16482091a0d8f7d0722737_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dfa3d2f9c9049c0a19ece84de2ff2ff_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie07c6d9499a1435a873c87b9197752bb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i883c7889246b4351952e694e54ad42f3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if37f4705aa9b489a9965276d6b9e48de_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib936adc316344e80a16bdf77c98d380b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8de5ba86f046cdb69fc0f4c708fc92_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59abc98712f3458ba5b91a6534b6a125_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace73d6c035d4a77a2cbffa4ce90f25e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661e28e3d2d84263805b3d206b050c22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea207d0ec0394b108fc793525231d205_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1a1b1a0dce4a0f9ea205178fdca9c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719c98f9ce454a51b25b0be7d1e61269_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490a73e325c3475f986e675f73de9c08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69699f22fd2341d793a1b05ac851fe93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2ab0ebd9f7498a91b623bb412e8f34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i810c9e939c3947a6b2840daa5f56ecbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc2047b094b4f3391b29249a580f128_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2766f3376fe7415ab521166b30e8525e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d57a8001b04306923d18707df004a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b12895707c4d109b2ebe044f17363e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i198f13e9ae764a128ee94408e59bd0e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64483c0647e5467db4e1fb64385c92da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac218800d9e4f97b70805d4885f19de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5a12fd9b94548e0a6d019cff9050821_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>amgn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i43850937751e42548fbb66e789879cef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61e545057e747e8b5917b8708e7bbf0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-19</xbrli:startDate><xbrli:endDate>2021-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd31e4ab273d40649861d236ae32fc27_I20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c5cd2aa30845ed99aa434901b0d817_I20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i478925270fe1447f980033f781c7fe54_I20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f3a35884aa4230bf0c3a5ae22cbc37_I20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:MoleculeTypeAxis">amgn:AMG340Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7b6973dd21459c98dd74519c04349f_D20211019-20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-19</xbrli:startDate><xbrli:endDate>2021-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0cb85e7f8b470988475352b8970a11_D20211019-20211019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-19</xbrli:startDate><xbrli:endDate>2021-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87696c073dc9445795bb552e00095165_D20210416-20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a658c14aef44e0cbf1c161341c595a2_I20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f6477d9cdaa4150a5f594b11b70839a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="market"><xbrli:measure>amgn:market</xbrli:measure></xbrli:unit><xbrli:context id="iece52d145d314403bfe12e67331edc59_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30125d0ac2b49b99dedfab8ab62d268_I20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b09ca2dd3744c7ace9c82038d6088e_I20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb825857cbe9452cb4d3fdead6eadad7_I20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae11cd746d46413ea3fdec017bcaa8da_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16d2f30b24a4021ae737b2878c082c2_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">amgn:AssembledWorkforceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71cdf38101c24a728fe566e9c8f95072_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21358fdcfee142efb4e3f013e87d4e7c_D20191121-20191121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312f9fef123d41a09674e4d6ef7b0632_D20190715-20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-15</xbrli:startDate><xbrli:endDate>2019-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f809eda07244ef59df9c01c24fcb962_D20190715-20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-15</xbrli:startDate><xbrli:endDate>2019-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d08f130fae446808d4e5f6792b4477d_I20190715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9859eb8505743f1b3da7314c2873003_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122e8f06671c4fd2959f297cfb936b40_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b29f9a84bd403788979c7c9655c7f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic461d7a3b3e14e9d9f9edf67703a28a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2ec1c2699c4f75baab1192500e0ea8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30ef6be9e72c458d8eb025c1d314c9a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9352d3542ba4641b31259a6145356d4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6338b51a744e2ba61b90799c71483a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39684b43bb94026ba38cc4efb929d6f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f12f30e019c442caffd84baf0cf6f58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id824580714f14645861336df6b9234d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d377423aea4783859ef42175fb0740_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0d3e2283c44651a1eb8f9a780b8dbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967209b4b4c84e76b9b0f7a497310bce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54c41e6f0b54a38a252ee5e94de98a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i989b6283d29a4b4c851c78cd48583e8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b813a299ccd4e28afe5bbb0576b487d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5c8a7d9df04367a21590c9c29fd269_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40878748d11247a087bb8456c38f461b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb6c05be38b46a0a66d8019c30f41f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b1aeb912604f64a39deebff1f224b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied8dfc99854e4c9a8e28f37c644909fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35fd136605f54042b5bff6d375c0e5a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165ce47df9044130bc2739fba82a949b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0c0fc9a5c549fe95bfb0a1d9f0cff5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ac36e2ce074ccd9ae5750b82cd3469_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512f3b69b8d744cba5ed5ccf09f3f93e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9e422d984343799da5efa61983dbc4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dcdb5108a874cfcbdd8b792226e2b87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31c0360db44649d0a20ab30019d4726f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5084637c7a7340da84829b4511548a9b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6556904df3ab4367ad18978f9b68d5ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68f620dbefa34330a378e5ed07d62563_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbaf8798276a40dfb14013a2f2c650ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983f5a9292ac40f4a3da11e27da9ebb9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0d758076054681926e066e61927847_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823d72e733d04847bac4115a76bc88d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i927d3e095b5f4aa59c0a266db71e1970_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i068d095d40cd4db2974af05b034cdc53_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i183bf5775ef447918eb6b6e9ba438bf6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0446449664249d586f43b4ab973920a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5db1424a06489da055b9a4d4e9586a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5bd4a1f6b184369845ffe664e69f8c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36247d9eda1441289af859ad6b549ad5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdcea96c498b412ea276b523469efb7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9bd7649ab404e7b84591d36bb2baa43_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdbb2a2df8dd4a688aa35f134c78985b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866795ca32e048e8bf0d0a64e1e48428_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic529e4ce045d4f18bf4eb6e91d16750e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961bb9f5333e4fb7a4343811368337f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1cedc1286e435db02a41c255e0aea4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0d7fa648b44bf4b5f6ab3d243b3379_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf1a44c568f248928074918ec2942de6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31ae78b9ba034a46abf7a36f2b0f0200_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122ba16c86614e1c968b2254fd76300f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb60fa2c2944183bf45dfb60666df8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d943ea15f1a4586994e9ac4e411be31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8467a81094b048fb8b342e412bd92615_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77cef9372919476794b87f18a0ccd73c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2dbf9c7559f438aa4cb0fd8e3bd05df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc140436757d4c8b8b0f16f5c3d24f73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be7cae3f58843ba99977a2b0ef10946_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c266403b0e40b8a06f2641ca3a0a6d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7946d27038d14bb2aa1d01148f309fce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f835d6c583e4df99d995013745f7e0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dbe0c7d5d6b4242b1252f5fcb8be12f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4708f4aef9e64cb5ad424e50c8dc709d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a458f529ef74a5e96517e593dec14f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4010fa4de94f1f9c1f6362f8ec685e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70cba4592c834e3e8d094a23a2fcaa5b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib066bf92577d482b9105bb3d4d131f35_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c7e88092ac49d78f2b821816062d7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e280126ffb45dd8d20fc69bcf08ce6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia437ec7f284c49d6a65b54737b247969_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794fd5a1ff8d49928a90b66d34aae6b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie08cb03dda2a4cbeace3bd8fec2bf082_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa8459da664468b847514e8360e549b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0e82165e6ed4ce0870f8f592e298c7f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe308e8cce24a29bfe153c46d6eed91_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2a9a63cb37432fa884cace4bab4206_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5877faf81e455bb0d9482eb25bd1ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb6b177906644a8ba787927952e1e6ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cedf86849344ad185dd0473b29aa1f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ee7a4be4a741f49a25afd921009f06_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9fd64f276d4139aea96a0883ba58ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2365d4e32b64cd087bbb41137067445_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dda7d1128174280bf5cb5fd5f91bc58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35d3d6d4b644346b1122b986aa9fe50_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abfdddf9be24f51a5a6754cc8ad2888_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f26fd68cfa4c65a24d973779fd0e1a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0795e4a54f5843d393051071fa6d5f9b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2014a7861a48b799fb3652e82edcd5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676e864b987849b3b20c91a321c3dda8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i116d123386f643908f969672fc7551ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0adce9b11c444f0992f20820cf3828f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a71c3bfd064ff09a900ad9f82e3ff4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8aa15dac8a479aa274d63cceb3e3cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1f469a4b2e4de98ca61b255d39fffb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbe8a4fa56d4704aacdf9825e608952_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d6910ca4184832834d336a96a65391_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a1575152424f7d8ace591bcbc21966_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0b7b5c89644713988c1ec6f68bb082_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99cd8f4d101d41ada52bea1b7f7707dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie389e5de5a4d478db22bca7314e7c2e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b16e7fedb4e4c24ae45b97df7a610b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef86d4467f84eb1bb360dfad6d77585_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e2955a78f1c41a08c3ed208c99513da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef9644ae27a4c1a8fe31454e5457a11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>amgn:customer</xbrli:measure></xbrli:unit><xbrli:context id="i293bc5a8ad2541879fe865ae5d2417d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44fe8e6898034d56a3a0bdcfc063bc2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5aee82520bc437a8e545732608e5e33_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie45ea7d90fd9496098876205bd24f226_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d011b83be41426c8583d49144da9518_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127aa134bb05481bae71c4068800e12a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6de6025ba0e4e2690eec1546e065897_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f412791f92490e9d982b4d75831aeb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf19b5b37714e80a93f4933d02ef7d6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie689ea75a1044f2d984398ed617833af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id620434bf9034620994881cbe32601bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5f3303e39f4bc0b7b331b548b22fd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie439637f4a754340a91825cf8855bd2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb155843fbb43a4845a41a3a8dd1ff1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c176348e21b4ba1a3156259d8a42916_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f3ff89fdeeb41748a0d6033b1bd4fa9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3022ab55cbe34d28a3a4a40e97b0e2f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i378c1ff5055142c89725880372cbf969_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07aa01d299e2400ca85cb51dfeac2827_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5e991692b349cf9019705e77e8295a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if882d889ea614a7891f8c06a940d0411_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13da767a4eec472cacf227f166d68782_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc399ea0ce04799a09de06e546eceb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19cf357e0ed44f0a9240d63f761e319f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:ExpirationInTaxYearsBetween2023And2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876ecb33b93d407bbf54fbff636fcbcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea7e54e88b146f383ed2ca43d4cc454_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2022And2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46afb35127d450e9e5b64faa1484510_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e3f4af542345b1913d9608046945a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2022And2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1607fbba52af401f822b87f6c9ca7b4d_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69e5cff7c72466aa64106c866eef4f2_I20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib96fb2589f6d4eb6be9dc2329f9e3e9a_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3e83663ab7448f9d89322ae4c89d53_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f3367e2504432e9241fb90f97792c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbd73363fbf4d9f8ecace3f93987d50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e5fbb50886445c0a5885afd85d45f80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e3c18d48c546e08d8c78658032b099_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19738ccb7dec4ff194a1f820e6610a46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558ccb32284541ab8aa7100457c3f800_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03daed3f241a433a99f8a3e456d25e18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47ecb19fa54443e6a1c8180a5b4978c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20c274ca8254d83931002497f749d6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22383ad8ad98490387eb40c5fefbfaa1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ded1767e5544259a8f3222f3f0b097_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83cee794a408414492622e90651c37e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0758ef280b4ca39e8e5f8ec2aab3e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f36a12191440cbbf96604a76e7170e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8816fa7e9c49cba0ab2b9df683b53e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bdd4a592dc14b00a7340e260c55ac4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d3a97a52f545c186e429329ac5c396_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd76882af6a14d589b489655ffae4b5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746af9fdf7bf446bb8052c84b495b30a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c8bf716a3045cab5d5c381fde23d68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id95f26b95bbc46e58dd92512a74406b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811e98c080a8445ab332e5093987caf0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4b2c07d94924b70a99e1b31e4959623_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6bedbb0fb8544608b6b4b38788612de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id775784f91834b37bd5778c4af33ff82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0685790a88a441c3b4731096daf74bcb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc49ed11c95a425c91f0d42a0e3a802b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356b9dbd15c04f05b6aa947471d7ecc0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9d7263c2934799ad99b2e304ed9c06_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26bf44881b14ed4b71997783873d549_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bdea1c8311e41d9a8dd2e5681a38379_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2bdf24151064c60a96102ab1941f91f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05cf3220a1054a8f8f5e45eba0b0f1b1_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3795b0430f51414baeabe5e24d635ce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e3474cb0114feba5cd13cc8ae2c916_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf2649fff4c4de298cd836c69f79d22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96eda76077d241f081c28bb4ab52763e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa8066544024fa19ebe0b52eeaba353_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a675d05a0804539a7d21138c1722b7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a6e2eaf0994cebafac018b5e3fe2b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a0a9ca1a0cd4f579495b0fabf37ebe5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieccfdc26f7e24e8784d8e7068a04a895_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf9f313b68c4865a53543614de8354e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8902072edc954d06a4fa32d21142b284_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5451fcd71feb4721a719c87aa7225d50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:FixedEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice11863ea1f641c982d327a9700952dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaff719184b24d3c8e81d58f99addf22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie80ef32cb43043a09a41633946a002ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac8514d57744567b3fefdd3b73af1a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if24c03a5fa36492bb701fd1cf35c078e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9b0d86322746389e6bcdfa6dca160c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873c3b8314524d3fad876f18c5598ab3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87470154c5964bf885e913dea7bf3103_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697e8dd993f14956a1d252e84ed707d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39392b4b995449a590f6320c08ce61e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idafcf86294d042a097451c547386436c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9afda65b678547869ef5990f59bf488a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b135991cad418282667c91fa819593_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641193dfa12140ac8063f9a64824a74f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6fec59b238425ea04b200b698f4eaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae35a0ac1214710b7c190312232e3a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c22c6a79774622a0b10ce923ca150e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d95d8ba10643ef98491d2fb2c2e0c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa636f63d01f499bbc23a8871f6dac49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff6483f2d4ab4e57a98ea68547e64b32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c996cd5afc4b66986324061c0fd03b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa9036d3707491ba2a27c213ba7af11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:FavorableContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a62dfd4c2d440e88628b7259f5b5158_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:AbandonedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied090dfe9b534fd38d657521d8581f48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i201a72549edc46dd976f10480c16db04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e359c669dcf409083123e716b593d81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3115a2e5d2b648bb866394e00f7e6265_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ib927e41cd49b4bcda2eea7a252c62906_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4ded6128cc4111af96fa1184ea3cdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56cb2b9855fe4608b5d0321fa7ba2bc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf3d349c123746008f444a2b21e4dc29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac644eb4ce441cab9fe07e3d012948e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9030955f37e9430a99c50565728d5f24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf619b21445f463d85928fc668c93d2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b857ada0494363b1816eed0b185516_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i28d5c7dae0c9470d9de4d136b31872a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c9361f0899452b92a78f57514f9339_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb35d257f424b58b378b933e22c6e16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i059fdacf21234e8ea4393764e3826ae1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3ece76323354edab6344395cebe3bba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728c44682ed441d0ac7d57d3f4f20961_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a9f89f55144c7383b92a1e2a084413_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab56d58779141ceb2afcc0c4b3c034e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb12c286c5b04cdda990afcad1d3f906_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09e03b111064a778c3c0f67fa5ceca5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0fc0421471445c09ad2091231e1ebd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb361ad83d5412a809267468ed87948_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i4474d10ca0a044769c40e2e8fe8ba5c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64fa2b6c75f84ce9b2d6f2c73986f8c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf325c2ad564616a25134ef5af769ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec40a5633cc44bf78f5770c8d2eca6e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db5be88f2184c5c83f07cb2e96fa2ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b66dea34d04457952516f934bfa710_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i365214c0e6504d3fba7ccd3e791c85e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57500a573714861937e2948abb1c417_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if39aebc177504df78daf24169177353e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86def4b22434c24861ce1aea3a31420_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i932124c0f7a5410abab4ba175c13bfb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i193e18f2a5ad4e6d9490bcfe10dacd22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4283cce94284118a0034337aac219b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0205d38f0748461e9cefc43080126f92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d7a63a419144cf0aca9c1b14bf3aff1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f57518a37364ab085186556dc6f209b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d7e93cc83149e6bd46d9c7b5b95be3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfdd983a38394043a29f22f15239cdb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08afea356a38453090c19b18d61b4a71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93bbfe5fa69940c08425fb453c4429a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c53473bc8014e44b15542181f09808a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id612d8d410b345cf9c48f162584e09ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34f197c292c0446c9383e5222324d6c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2169d5c603a14255b95c241f6c3323ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689ad4255db545eda69e365f169f332a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee3977d9de514e63894403ca1ca898f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29adc72b130b479ea45a8aaa03b088d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965cc877b8694f78b1c2b606c84f7f38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i364ca273078a47eca7c0fe7c36707bf5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea96f4e89df43b18b9bd6729d02ad77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2eb0ad81574e8e8c6e79ecedad6dd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66cf2c987b9f46568650effba9da5361_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c13c24eff8b47b6b20d9d46230a1c57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6253005b2a4664a03ad8f8f5898630_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17bac99f15a4fd08c57b8d625475683_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b860697a584413f99229019ccec2aa9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f42705f67d145a8bcd98e79844df3dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccec61d10cf24b1f9a049d503b7a1dad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5fe83762b5347d3b5b16cc99dd81437_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i102f385c304b406995d8b7e6800cb786_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c06f986336b4293934da0346e70a8ef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062455b6853247eba1cd91fb4b7af879_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e3042dc4e974d1bb2015139dbedb73e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37fc7e470e2e4805af580456ed7f0010_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6540ef5c27054d6e9c7985f2b141767a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f26a3a0d594e26854ea76bb3c6743d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1863ab64829b4fabbec539235c0ac7d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd810185a212412e83638c36004bad29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e1283c932d4edcbb8cc22fd4ab8960_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ae1c03870043a08889cc2ff6ed20b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8710c24c464449b8fa26275c77a6e58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10a62100d1e4b0e9d7ab8a2ba247c8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia850706d72994599bff9431d2e8b1a5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2a64b79a0c404dba15ff2230fc371d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fefa5369ca248188f3e2d24acec7468_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ba559d13f24efc9fdf4abebc7c8924_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeaf9de7e4f74c20b1108870b6ea1974_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44afd752e7745c885bb3c653ec2d9f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5edec977c0494db1989203785b65a079_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i832afb5f09ff42f8972ccf47b59012a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7991c3b6e9984fe98b17e71a271b7557_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0d27fa96204770aed6605e64628c8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04bf222f1adc48dbad767adfdca6631f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6bc114e2ad04b349cc3973ecba76b7f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9278d061be544509ac7ccfcae7335101_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581122c175be46309a19781a1813a543_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787a1f1611f040bdb13bd41c6d2e7221_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac386b55791042908ad00f98e5e6a2ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29bd0ebc2ef643d89e8a4df0e1f5a0a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34aa68b41c90434093ba0c86e0923545_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b1b2aa03f54c1aac5954067859bd2b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b1c907d2284f46b65c2993a8518ee2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i880cd534575949e3abab9e8a7d2a0235_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b4dae7d4c14e8d81c11fcee49b8148_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae894d8f94e84e9eb8cc52ce4c1e5efd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc259e1f874437e8de85f6ffd31abd9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie151d775f0614294815a86857329b491_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e0eaf522434115aef33c9b0f4b32fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1502d4ddb0b4ea78f2bfbbf53ace156_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie619fdd6365143709fe3ef8c6e3e1cb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f3ef7ef219414d9621fb4cbdaf429d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29f8a9193ed4db1ad73321b122e4e45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d7cd08a4ec4828acd8e3620f7b4d78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A200NotesDue20322002032NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ba4ba7693a5434e9b35ca55c38722ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A280NotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd12628ec78f4499a7e276a61e90e99b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0cbb29ec00d4533a3e1155ce9550ede_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55367f6c3ff34f7cb01d46d89ee2c379_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf9c596023174e558d6631c3ca855b65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b742eeadacf4b658c093123bb55c0fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070b4afa879f4c5fb36fc518fe1cfec4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b11859028a1422083400b2109fb068f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4f6ca5c74d48349c15921ae8a0933a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide87aaebcc2a4447a457f81d1aa31c9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfd131a231b493da0babaf4c3b5395f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a1311f688d45e5a1f460915c39e581_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c22a3e15e54b178cf491b39cbfbbd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5477a7c207054d569f2eca1cdcac36a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab353bc1f2344a55b1479a0f118d799c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97511afa493447da0eb4625d1fbf9ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if97696feb118453eb13e08998850ad56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf411ca29d03476a953c14fc1769501d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e3b5bf697b4cf0bfb5716a830f11db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id189fc4607ae4a208ed0437205c4c7f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3ed5ae8257400c9ca750016aa502ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0682f6237def4973ae5a5cc46f9d59e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3291bf95ec2416b94e22bd933d142ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b2177f702640cd8b47f293f2ad22a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d97e7f0efe4261b956189daec4c902_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8269488a684ef385c1e94d4f756b8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46f97dcfd2c4ee5b216081269ea57b0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84d8db7b345b4458ae3f758755659354_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if87fc1146c544c828abfcec0fe2987c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2c8de012264cf89c56a2b6158356f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e964a7c87d14059977b9c5c2746d0d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd842d4f03947599d399bf5eba13005_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a6ccbf40d94c65aaafe7871e4a210a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id608276fe2a6484594c7c005d1cd220d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b52d16bd6d4af083d152823f4b96ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i104a960196594625971a4b192145a8c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82257eb313254ec0ab7249ac84b173fd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f6bff492829406da23ff2efa25558e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165f3ecafa0a4de4b1c4b6db200d90b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib46494b393a34b9f8c60e96025f45f23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i845d5c989f794e06bd6777c9e801b93b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff27566615ea4d2bb9437ebad4ab002f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if93f0a53c32847ae98f3c48eb087f0d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ae88e4533c4b4cb0927518f3740856_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fec9853ccc64441ade8c731c993d7bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5344d1029ee4871879edd955c41939b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d68f7e07a094edd9e2461d6c0fdd4fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3894bb298da842feac52ee9f09993b0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib38c6961bd484a1aaeb68b6dd42b1548_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034a224066ae4802b5005e8a780dcba3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99e95ece1544f458f56a09770d012f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c48563bcda143618f52c18180794c29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16fe501f4d234ba3bc01f6fd307e4f03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1708fe50d04fdb89f763085b73c7a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53460a2e2c54b1eb6ba01dd799c1956_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85ecb4c22c6d4edd9158a292a2b738c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e71d687a124355ab2c2f4d216034fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fb3b4b36f14d56bd098848256071d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf7b496d1968423ca0b81cb87f205866_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d539e441f54f7987471e03eeb9fc39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d56a45dc3ab43509ef66161e0e3fa63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib05b839f30d040bebcd89a0c1fb92f5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i367d9d22b1c34ce1b4cdcd7cc2620446_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b46f3feeb0e47c0a2c7e9a4c6f05a7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec7fdb2956cb4333b6f9bcb209040ea5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35713b5b6ffa49349b004817c7c9da42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie614baae5549413b95d0a5b95b79a24b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie558eaebb0734ac988923b72ab5749e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33af7431531e4906871dc1c72260a8f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c65ad1961624e6fb50c1eb26eb83dcd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03447162cb44ded9a9e6203334836ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0f0acd616746d5b35dd8a2dbf392d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie320a4dc28964d3e945ea0199a471f76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e84ea875e544c9937c0c203818dead_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85976d51465e4619a93074b54175b619_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i304433386dd64f7b8b7c9d12385a8ff0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3f69cfacea4717a178488113e7724c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>amgn:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0423efbfc4c49a3a0c6e8782283b9e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if751ec72d1334a0aa3244e35632460fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd3e56f17777422db7fd7146740984bf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da70484870944a2be74c9435a52ba12_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cae36825a8244718a036f07b201a220_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d25f0b06be4a2ca6927d47f49abd4e_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i893df3cf158b4ab2a0c0d1c82a28c1bd_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5154a4b4a2bd4af983bf6185d3daba74_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfca6c2819ef49179fc85b016ce6016f_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7cba5195f24f829ec32f1b71cfd77c_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eaa406cdfdd4c51b6756655cc712766_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7254d1d0af7c46758551512b7d50361d_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fabc5abd9df4b559effd9eb67abea89_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b33af0508754ca28e72f99a484d9cf0_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39b8f49d86e9448ab5f6101aa9d1fc57_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a8d1cde152d418a976984815e041aa2_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323451cad3a2466080975105981c98c8_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a85ddddc43a4b40bf86ad5da75e8de4_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a63a090508f49fdaacb88df082eb50b_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c13f8bb98d4f9b86238d8564507387_D20220308-20220308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-08</xbrli:startDate><xbrli:endDate>2022-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309108b032084722a376b8a102fdb202_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb9c001d530444d809bab4daa3b3248_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4494701f92e4c3497b69ce57bf3c5db_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a6854354df440da13fa35f04216a12_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4295abe2e530430ca537010e380381f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79b493edfda4614928afa72235cd218_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab69b9f5c1b4692a5c95f9a65dc9566_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c41d891d134edd86170c260149c788_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e3518c83274b19a2f3f3b2116e682d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9cfb6c5904e48c7bbfba692c97f5afb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2c015276b143d1902156c9b84463e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b69b0fa4326426ba338b1b8a382b779_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef7a11bc8b34811a438f59e60dba040_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d33d7ade654ad299e31d14b471a5bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbbfb42202ea4564988889ffa1175789_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04a925f891f9422095e83c9bfcfb8e7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac308cc20ed14c5cace71b3353e328da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258fcbb2c8764cbb987b87e8e1c787ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000812ada76e42979388c4d128fa90de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0914f3d7dcd6426aa7c1a21fa7f2d1fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34745a1b911c4d30a56546635c8aa0de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99bd951fd41947b592b8c02d8f1c27c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fd5e2c85c274498bad48e922806e3ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2f149e177b4bc3b630018b36f6e49c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad2966682ec4e37bbcfa6626b7183ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4dd663b9fc4f028f2085d56886e460_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35372b79111c40a58a07694440d9622c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd31886569fd4668bfb1bce453953983_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a842d09a06449083eeab3521739d0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35320f15f6674855866c5c06e985c83d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3749d6c99c044fd49a6d259f74ef6c99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1e6522010e42beb2d5a512da981242_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69f61d55abb54285bdf1fa8615440956_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfaf46a638094fa5b126a5684fbeec50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6203c3d089a640c88db71d0303989c08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d32c14a32b146d491c15b7db4b291f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b247dc676e4516bae8242fab1601e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bae52b8579846bf94e3c6a5aedc9878_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed17b422b8a4a51b6f39304fe4350a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b00e4e2c4742499d53a470e0343c3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2471fcfa074988acc387470355b7a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if844eb33233f407fab5a2d1540261d05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1100eb5cd384e00b09db36c3d0a2866_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f18fc869d74053929c46a2c61d88f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac281d4e27f4175b82ae37df330c749_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c953f5c148c48d182cf8f1587a75aaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb66166118bd4add9f632ee3b805827f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddf499ee3f344b5b42a90e01e741b82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb7d6eb6e0ea47e19bdbc24585673349_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6231133c44412abb1a5cee2a4babf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81fa5de4d71466aad60dae129ee4fb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bea7ddb5d2b4c51a7e8fcffe813ebfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff7bb5325c6416cae92c622ff045f13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d6fad6c8dd462eaf5fde3ea0c3ff70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004a939dc0024ba59fe2c2766322fdd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f15e114d3c64fe7946425ca3fc21f73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbe1823365054cc481d757a51d3eb3f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a924c3505e43a9b71b7be707de1ac1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eafc754316345619b018dfaaebc87f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5354f3fcd8644c87860ba3a5544fad9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceba7ccd82584acda921d0e558528e50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1ed82dd0d54655985037c85ddd3ede_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3b3a83ca454eaabd5077059293ed84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad26877e4a04bd7bb26b8a8c7c28eb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46082d9efffb4b3c95fe13c8f220bd0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9405eeed0ae040f5a34607effb78d146_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b00be27f6e4944a30922c5c0fe6670_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1180ce65c8843b4991f543dc49f55be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5662300e135747438ae3581b6b70a657_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c59ef250904a0c8c3737d73fef0bc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607d4a85aba9437d83f47c041399a92e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dc42b4f17b2415db5b78c0f90591e04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie630eb784ad2416794c05aa8a219fd58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62f25224e2b54616985641a3771ed55c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0614eede5b234c61be2259d587e7b43a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99958e30da4d4cbfa5e3d682930d68fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f2b4195bd34883bf7b39bc3b2efe92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b26de6dcae348c4a7d727d21d2b83ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2c7782342094a07a4240eb1534d6ac4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f94e6a78404c5c928e7256392dfe2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i089ac98960b04b439f83de38bd8c51dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefb49b4259114419a84f22f50981dca8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5427fc4b2ce14c1f83b6ee82f6be8aec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a08253dadcd44d2b7a7f73f8fb62ba6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b282aad63a4bcaaf14002bae397df0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7211fd50bd2642b3aca55c89862f86d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a63aa87c0224ee98ac2fd8fd67ddaee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68179a299576480aa8d41a7687749389_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c684a9063940959ca5882be53b9b80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ec6c587d9b4e62aee06a72a1f73f9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da09ffb67c742d795348bf45a166d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe2830b43b44d79b43091fb7f32ea57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8359101653f44adbb212efe4e4294a95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec9d656079e405f82e3bf12e4d8c37a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i665816818e0a44d58309ed1a320f177a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaabba1893af44ce9e672215ac116ce8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i730ee854cf6c432ab6aaa706614c8632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fdabb7d166a4746adca1c02c5f92d88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb0ddc693254332b142eabe8b6a28aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ecb51f1a572468b8e76872013008be7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0cdd08ffa245b5b14a99b5ae9342c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c071ab35a1441a7ab265cde48d713e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dafda6691b84625923472fe59fa12bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i632df15458d646f08f1906bc1e27b8fa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cce474dbbd049c4984d8bf485ab3a19_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29069e42d7524b4db8c509bf319d9680_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2c56acaf30d4dce85c3d989ea151652_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i665b76a3b3b3476c84386f9224fe17a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eba7e66fb7849818cac30465266bf74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc742c16678e447d8a1223755190162f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i806e9dc1988340d9b23b17a31bc072d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d30d400605402ca45a9146fa90bd76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:InterestRateSwapAtThenCurrentInterestRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52186ecfa5c2464a9932151770b9a053_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc4882cfbc084ea5ae95c042bf24548e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b50391be4bb48db8dc8f419683a2218_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739fe173b25a47189a34271891a4159b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da02963523c4db1b9d260cbec5d9af3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied61ab999fde4db3b59917ff3e2febd4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2aae7469fe64dcd8bac1076dd7692d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForeignCurrencyAndCrossCurrencySwapsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i760d8f96eac94b7f88f95302db5dd2d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a34b1b31c7e425a8ee9baab7f3c59db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e6675ffd9f4a3998395c7c583d88f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i089ec9cec29f4c7ca63544d5e4b387da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f066d29e5c45d0ba4c511e73c8df4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i794004d7dfa741ea84b274eb42d3ec54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d0846cbb0548819c01c3db53240ca0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3377db1e364448a198a868926553f9b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i050bfd34fd664c4086976b07e6af5cdc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e65e212078b47438c294f4cc92afbe1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a6728c58d4145b3887b604065653c19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc161492cc64bd983de97ee811b16fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic268132426814d8eb399e70d427d8801_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie510af3eca8f4a73a86d9d56fbd815f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i479675435c2d49f99965cf557ed29fbf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44666b59eba54e9a95bb28abe178e8f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9952aa6a3b134df69afed008d9e67bf4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>amgn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i19d673199032476d834451d22f3f5dc6_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ImmunexAndSamsungBioepisCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="affiliate"><xbrli:measure>amgn:affiliate</xbrli:measure></xbrli:unit><xbrli:context id="i1d65a5d55e5642be9bee7decb061fd66_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>amgn:patent</xbrli:measure></xbrli:unit><xbrli:context id="id07a2cf432c24ff9a1f851f3d46e53b5_D20160201-20160228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4cd2176c02454e86da12e52b785bfb_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a349ce4f68f4e62ac77c54575a7b956_I20190520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amgn:claim</xbrli:measure></xbrli:unit><xbrli:context id="iaf846f658f5942ce82b4f681a169e2fa_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>amgn:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i84504b4b6730469e9a42aebe34756f62_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42713d0e16f04d26a1b1ce71cf3aecd4_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c633c2c74b0432094a5ea889bbccf99_I20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiffs"><xbrli:measure>amgn:plaintiffs</xbrli:measure></xbrli:unit><xbrli:context id="i1ab8018abbdc4ab1bcbc87cc2571878a_D20190430-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-30</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac324416a7c4f1f83e593ede6d076bd_D20190731-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba78d537ea54a03a6bd4d13b80aea70_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e56044cea924d89ae341cd4198e2725_D20190301-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="complaints"><xbrli:measure>amgn:complaints</xbrli:measure></xbrli:unit><xbrli:context id="id63608bd810a4daabb58c50a1d92c7fc_I20190604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>amgn:installment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i2a971cfaef98424f9692041d6ed3a222_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE1_b1ab2310-7a8a-428e-83ff-d927724f577c">10-K</ix:nonNumeric> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:5.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6NTQ5YTk1N2VjOWM2NGNlYWFhNzgxOWU0MmIwNmIxNTkvdGFibGVyYW5nZTo1NDlhOTU3ZWM5YzY0Y2VhYWE3ODE5ZTQyYjA2YjE1OV8wLTAtMS0xLTU1NTU0_e4aea066-54eb-424b-a79d-2cab8aea2dff">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8xMjc_0b635e0a-0541-4c70-a7ec-bd1e16a640e6"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8xMjc_9701eba6-ee42-4e25-aacf-1fc69969e96f">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:5.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6NjM0MmEzZTExNWIzNGQ3NWEyNDA4MThlOTEyOWQ3NTUvdGFibGVyYW5nZTo2MzQyYTNlMTE1YjM0ZDc1YTI0MDgxOGU5MTI5ZDc1NV8wLTAtMS0xLTU1NTU0_fb2c12f6-4bfb-4220-b8c6-bdf9773e6314">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDA4_24fc1dff-b524-479d-b471-9290e7e7d935">001-37702</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDA5_53e7c2b5-f174-42ce-a1b6-92b8766c41a4">Amgen Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8wLTAtMS0xLTU1NTU0_1e0e13b8-7459-4c28-9175-9d0d14a59322">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8wLTItMS0xLTU1NTU0_bf6e8dd2-29ce-4f3d-b77f-baf34c9a9207">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8yLTAtMS0xLTU1NTU0_a144d91b-c810-4f83-ad07-64748e21fc28">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8yLTItMS0xLTU1NTU0_10d6a9e0-fc15-4372-9af0-30d317065d1b">91320-1799</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8zLTAtMS0xLTU1NTU0_e5da8ed3-56d4-4990-905f-9d26f278eb52">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF80LTAtMS0xLTU1NTU0_06fabe7d-8b4e-45ad-bb6a-06b17d022bc7">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEw_fc6a4378-a6e9-44f3-b515-c77663c64b99">805</ix:nonNumeric>) <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEx_4ef63034-5e17-4b02-9e6b-7ca35547c147">447-1000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol (s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8xLTAtMS0xLTU1NTU0_25b2b998-d05e-477a-a559-e20b809ac420">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8xLTEtMS0xLTU1NTU0_643b6945-28ae-4b7e-aaaf-5e35bda9be68">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8xLTItMS0xLTU1NTU0_87422197-b414-4870-9890-bd76831f2bde">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8zLTAtMS0xLTU1NTU0_648908b5-d9c1-44a6-9de4-1fc39417eb7e">2.00% Senior Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8zLTEtMS0xLTU1NTU0_b28f44ad-fcfd-4446-9340-15b03d462e87">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8zLTItMS0xLTU1NTU0_2e6d7377-0d20-41c7-b21e-0d2b382f214b">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> None</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8xMTU0NDg3MjA5NTI0Mw_35fc6abb-73d5-477b-9ec4-e7aef54c27cd">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEy_035d09b8-9ba0-4d9f-9202-30d54e577cde">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or Section&#160;15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE3_91667049-a7f4-4762-9bac-f908a6ca7ea3">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEz_70a47703-751a-46a2-972e-7f9914ced498">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:1pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6MzJkMjAyY2RkNDE3NGIxNTk0MzM2ODllZjFjMzg4ZTEvdGFibGVyYW5nZTozMmQyMDJjZGQ0MTc0YjE1OTQzMzY4OWVmMWMzODhlMV8wLTAtMS0xLTU1NTU0_e0d72b2d-5178-4bd1-8628-440aadcc855d">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6MzJkMjAyY2RkNDE3NGIxNTk0MzM2ODllZjFjMzg4ZTEvdGFibGVyYW5nZTozMmQyMDJjZGQ0MTc0YjE1OTQzMzY4OWVmMWMzODhlMV8xLTMtMS0xLTU1NTU0_ac31c0ee-d856-42df-97b4-547f46488b48">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6MzJkMjAyY2RkNDE3NGIxNTk0MzM2ODllZjFjMzg4ZTEvdGFibGVyYW5nZTozMmQyMDJjZGQ0MTc0YjE1OTQzMzY4OWVmMWMzODhlMV8xLTQtMS0xLTU1NTU0_8bea7e12-fe14-4ad4-a032-99fb85811cfd">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:8pt;margin-top:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.     </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE4_a3d445f4-d0f5-4497-857a-f7d8dfbacc03">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:2pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE5_1c4d23ae-e104-4f8a-b893-88ed43cf3eaf">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approximate aggregate market value of voting and non-voting stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="usd" contextRef="i387dbf98d1b24d5f83cd817582c5b3af_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8yNjAy_0c0a3319-0290-4edb-b164-311462dcdd5d">137,531,019,585</ix:nonFraction> as of June&#160;30, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(A)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(A)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.41pt">Excludes 811,415 shares of common stock held by directors and executive officers, and any stockholders whose ownership exceeds ten percent of the shares outstanding, at June&#160;30, 2021. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if9cbde08232d47f1b1397109661d89c3_I20220211" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zMTEw_77118236-ac7a-41b6-808c-d420f1fb95aa">557,029,370</ix:nonFraction></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Number of shares of common stock outstanding as of February 11, 2022)</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE0_597f332e-d8df-4363-a812-53ba43263a81" escape="true"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s Proxy Statement with respect to the 2022 Annual Meeting of Stockholders to be held May 17, 2022, are incorporated by reference into Part&#160;III of this annual report.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_2138">Defined Terms and Products</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_2138">ii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_13">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_16">Significant Developments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_19">Marketing, Distribution and Selected Marketed Products</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_22">Reimbursement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_22">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_25">Manufacturing, Distribution and Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_25">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_28">Government Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_28">12</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_31">Research and Development and Selected Product Candidates</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_31">16</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_34">Business Relationships</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_34">21</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_37">Human Capital Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_37">22</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_40">Information about our Executive Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_40">24</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_43">Geographic Area Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_43">25</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_46">Investor Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_46">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_49">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_49">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_52">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_52">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_55">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_55">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_58">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_58">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_61">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_61">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_64">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_64">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_67">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_67">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_70">RESERVED</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_70">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_73">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_73">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_109">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_109">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_112">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_112">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_115">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_115">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_118">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_118">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_127">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_127">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_130">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_130">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_133">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_133">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_139">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_139">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_142">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_142">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_151">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_151">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_154">PRINCIPAL ACCOUNT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_154">ANT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_154"> FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_154">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_157">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_157">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_160">EXHIBITS</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_160"> AND</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_160"> FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_160">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_163">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_163">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_166">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_166">88</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_2138"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Terms and Products </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined terms</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use several terms in this Form 10-K&#8212;including but not limited to those that are finance, regulation and disease-state related&#8212;as well as names of other companies, which are given below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affordable Care Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">aHUS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">atypical hemolytic uremic syndrome</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acute lymphoblastic leukemia</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">age-related macular degeneration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended 2009 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2009 Equity Incentive Plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANDA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abbreviated New Drug Application</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accumulated other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca plc</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAFF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell activating factor</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bispecific T-cell engager</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics License Application</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol Myers Squibb Company</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BPCIA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics Price Competition and Innovation Act of 2009</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene Corporation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CGRP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">calcitonin gene-related peptide</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chemotherapy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">anticancer medicines</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHMP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Committee for Medicinal Products for Human Use</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIT</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chemotherapy-induced thrombocytopenia</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CKD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chronic kidney disease</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COSO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Committee of Sponsoring Organizations of the Treadway Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">coronavirus disease 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cardiovascular</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DLL3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">delta-like ligand 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DOJ</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Justice</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DoR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">duration of response</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medicines Agency</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">earnings per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ERG</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">employee resource group</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">erythropoiesis-stimulating agent</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESG</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">environmental, social and governance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESRD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">end-stage renal disease</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Union</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Foreign Corrupt Practices Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDCA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Food, Drug, and Cosmetic Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FGFR2b</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">fibroblast growth factor receptor 2b</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch Ratings, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime Therapeutics, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FOMBPR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Oversight and Management Board for Puerto Rico</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Trade Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. generally accepted accounting principles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GDPR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Data Protection Regulation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GEJ</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">gastroesophageal junction</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeFH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">heterozygous familial hypercholesterolemia</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HER2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">human epidermal growth factor receptor 2</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HGRAC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Genetic Resources Administration of China</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HHS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health &amp; Human Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HLE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">half-life extended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HoFH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">homozygous familial hypercholesterolemia</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICOSL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">inducible costimulatory ligand</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">interleukin</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigational New Drug Application</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in-process research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">international reference pricing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">immune thrombocytopenia </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J&amp;J</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K-A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirin-Amgen, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirin</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirin Holdings Company, Limited</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KKC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyowa Kirin Co., Ltd.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDL-C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">low-density lipoprotein cholesterol</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">London Interbank Offered Rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">metastatic castrate-resistant prostate cancer</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">management&#8217;s discussion and analysis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MFN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">most favored nation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s Investors Service, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">minimal residual disease</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neumora</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neumora Therapeutics, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Pharma AG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-small cell lung cancer</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nuevolution</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nuevolution AB</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OECD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organization for Economic Co-operation and Development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OIG</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office of Inspector General</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">objective response rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PBM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pharmacy benefit manager</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PCSK9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proprotein convertase subtilisin/kexin type 9</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDE4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">phosphodiesterase 4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDUFA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Drug User Fee Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">progression-free survival</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PNH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">paroxysmal nocturnal hemoglobinuria</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit Sharing Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Profit Sharing Plan for Employees in Ireland</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROMESA</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico Oversight, Management, and Economic Stability Act</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTAB</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent Trial and Appeal Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RANKL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">receptor activator of nuclear factor kappa-B ligand</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Agent Report</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REMS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">risk evaluation and mitigation strategy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">right-of-use</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">rest of world</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s Financial Services LLC</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Securities and Exchange Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">siRNA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">small interfering RNA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">sNDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">supplemental New Drug Application</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SoC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">standard of care</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOFR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secured Overnight Financing Rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SRE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">skeletal-related event</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TDAPA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">transitional drug add-on payment adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teneobio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teneobio, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">tumor necrosis factor</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TPO-RA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">thrombopoietin receptor agonist</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Treasury</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCLA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University of California, Los Angeles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USPTO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Patent and Trademark Office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UTB</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">unrecognized tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VEGFR</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">vascular endothelial growth factor receptor</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acapatamab</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acapatamab (formerly AMG 160)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (erenumab-aooe)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(adalimumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (adalimumab-atto)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (darbepoetin alfa)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AutoTouch</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AutoTouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (infliximab-axxq)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (blinatumomab)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Efavaleukin alfa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Efavaleukin alfa (formerly AMG 592)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (etanercept)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL Mini</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL Mini</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (epoetin alfa)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (romosozumab-aqqg)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMLYGIC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (talimogene laherparepvec)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (trastuzumab-anns)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (carfilzomib)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> / LUMYKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (sotorasib)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (bevacizumab-awwb)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (pegfilgrastim)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filgrastim)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (romiplostim)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran (formerly AMG 890)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onpro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordesekimab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordesekimab (formerly AMG 714)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (apremilast)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (etelcalcetide)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pavurutamab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pavurutamab (formerly AMG 701)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (evolocumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rituximab-arrx)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rozibafusp alfa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rozibafusp alfa (formerly AMG 570)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar/Mimpara</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/Mimpara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (cinacalcet)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureClick</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureClick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab (formerly AMG 757)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(tezepelumab-ekko)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (panitumumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products referenced in this report that are not included in the above list are trademarks of their respective owners. They are Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cosentyx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fulphila</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, POMALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/IMNOVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PROMACTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/REVOLADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RINVOQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rituxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MabThera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Skyrizi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOLIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Taltz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tremfya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UDENYCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Xeljanz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_13"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BUSINESS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people&#8217;s lives. A biotechnology pioneer, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. We have a presence in approximately 100 countries worldwide. Amgen operates in one business segment: human therapeutics.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_16"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Developments </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of significant developments affecting our business that have occurred and that we have reported since the filing of our Annual Report on Form 10-K for the year ended December 31, 2020. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Five Prime Therapeutics acquisition</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">On April 16, 2021, Amgen completed its acquisition of Five Prime, a public clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for approximately $1.6 billion in cash, net of cash acquired.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In April 2021, the FDA granted Breakthrough Therapy designation for bemarituzumab as first-line treatment for patients with FGFR2b overexpressing and HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with fluoropyrimidine, leucovorin and oxaliplatin based on an FDA-approved companion diagnostic assay showing at least 10% of tumor cells overexpressing FGFR2b.</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KKC collaboration</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">We and KKC entered into an agreement, effective July 30, 2021, to jointly develop and commercialize KKC&#8217;s potential first-in-class, phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teneobio acquisition</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">On October 19, 2021, Amgen completed its acquisition of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain, for $900 million as well as future contingent milestone payments potentially worth up to an additional $1.6 billion upon the achievement of certain developmental and regulatory events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products/Pipeline</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflammation</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2021, we announced that the FDA had approved the expanded indication for Otezla for the treatment of adult patients with plaque psoriasis, who are candidates for phototherapy or systemic therapy, across all severities.</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEZSPIRE</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2021, we and AstraZeneca announced that the FDA had approved TEZSPIRE for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology/Hematology</span></div><div style="margin-bottom:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUMAKRAS/LUMYKRAS</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In May 2021, we announced that the FDA had approved LUMAKRAS for the treatment of adult patients with KRAS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS received accelerated approval based on ORR and DoR. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial or trials.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In January 2022, we announced that the EC had granted conditional marketing authorization for LUMYKRAS for the treatment of adults with advanced NSCLC with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. We also announced that LUMAKRAS had been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent NSCLC that has progressed after systemic anticancer therapy.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In December 2021, we announced that the FDA had approved the expansion of the KYPROLIS prescribing information to include its use in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operations</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New manufacturing facilities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced plans to expand our United States&#8211;based manufacturing footprint.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In August 2021, we announced plans to build a drug substance plant in North Carolina that will increase our manufacturing network capacity to reliably supply more medicines for patients.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In November 2021, we broke ground to build an advanced assembly and packaging plant in Ohio. The new facility will assemble and package vials and syringes to support the growing demand for our medicines.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that both of these facilities will be built faster and at lower cost than traditional plants. Once completed, both will also utilize cutting-edge technologies to be more efficient and environmentally friendly than traditional plants.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 pandemic</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A novel strain of coronavirus (SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2, causing COVID-19) was declared a global pandemic by the World Health Organization on March 11, 2020. Since the onset of the pandemic in 2020, we have been closely monitoring the pandemic&#8217;s effects on our global operations. To date, we have not experienced disruptions to or shortages of our supply of medicines. We continue to take appropriate steps to minimize risks to our employees. Employee access to company facilities has been in accordance with applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic. The pandemic has shifted how we work as an organization and in the fourth quarter of 2021, we enabled our U.S. based workforce to return to the workplace for work that benefits from face-to-face interaction, while maintaining appropriate safety measures to ensure staff well-being. For further discussion, see Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Overview, Selected Financial Information and Results of Operations. For a discussion of the risks presented by the COVID-19 pandemic to our results, see Risk Factors in Item 1A.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing, Distribution and Selected Marketed Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest concentration of our sales and marketing forces is based in the United States and Europe. In recent years, we have expanded the commercialization and marketing of our products into other geographic territories, including China and Japan and other parts of Asia, the Middle East and Latin America. This expansion has occurred, and is expected to continue to occur, by establishing our own affiliates, by acquiring existing third-party businesses or product rights or by collaborating with third parties. See Business Relationships for our significant alliances. Whether we use our own sales and marketing forces or a third party&#8217;s services varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, substantially all of our sales are to pharmaceutical wholesale distributors, which are the principal means of distributing our products to healthcare providers. We also market certain products through direct-to-consumer channels, including print, television and online media. For further discussion, see Government Regulation&#8212;Regulation in the United States&#8212;Regulation of Product Marketing and Promotion. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. In the Asia Pacific region, we also sell our products in partnership with other companies, including BeiGene, Daiichi Sankyo, KKC and Takeda.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product sales to three large wholesalers, McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2021, 2020 and 2019. On a combined basis, these wholesalers accounted for 82%, 83% and 81% of worldwide gross revenues for 2021, 2020 and 2019, respectively. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are marketed around the world, with the United States as our largest market. The following chart shows our product sales by principal product, and the table below (dollar amounts in millions) shows product sales by geography for the years 2021, 2020 and 2019.</span></div><div style="margin-bottom:8pt;text-align:center"><img src="amgn-20211231_g1.jpg" alt="amgn-20211231_g1.jpg" style="height:550px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Sales by Geography:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market ENBREL, a tumor necrosis factor blocker, in the United States and Canada. ENBREL was launched in 1998 and is used primarily in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prolia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Prolia in many countries around the world. Prolia contains the same active ingredient as XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but is approved for different indications, patient populations, doses and frequencies of administration. Prolia was launched in the United States and Europe in 2010. In the United States, it is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk of fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or in patients who have failed or are intolerant to other available osteoporosis therapy. In Europe, Prolia is used primarily for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Otezla, a small molecule that inhibits PDE4, in many countries around the world. Otezla was acquired from BMS in November 2019 after their acquisition of Celgene. Otezla is an oral therapy approved for the treatment of adult patients with plaque psoriasis across all severities for whom phototherapy or systemic therapy is appropriate, patients with active psoriatic arthritis and patients with oral ulcers associated with Beh&#231;et&#8217;s disease. In Europe, Otezla is approved for second-line use in the treatment of psoriatic arthritis and psoriasis and for patients with oral ulcers associated with Beh&#231;et&#8217;s disease who are candidates for systemic therapy. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XGEVA</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market XGEVA in many countries around the world. XGEVA was launched in 2010 and is used primarily in the indication for prevention of SREs (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in patients with bone metastases from solid tumors and multiple myeloma.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neulasta</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta was launched in 2002 and is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count in patients with certain types of cancer (nonmyeloid) who receive anticancer medicines (chemotherapy) that can cause fever and a low blood cell count. In 2015, the Neulasta Onpro kit became available in the United States. The Neulasta Onpro kit provides physicians the opportunity to initiate administration of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the same day as chemotherapy, with drug delivery of the recommended dose of Neulasta at home the day after chemotherapy, thereby saving the patient a trip back to the doctor.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aranesp</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Aranesp primarily in the United States and Europe. It was launched in 2001 and is indicated to treat a lower-than-normal number of red blood cells (anemia) caused by CKD in both patients on dialysis and patients not on dialysis. Aranesp is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in certain patients with nonmyeloid malignancies and when chemotherapy will be used for at least two months after starting Aranesp.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Repatha, a PCSK9 inhibitor, in many countries around the world. Repatha was launched in 2015 and is indicated to reduce the risks of myocardial infarction, stroke and coronary revascularization in adults with established CV disease. Repatha is also indicated to reduce LDL-C in adults with primary hyperlipidemia, including HeFH; in pediatric patients aged 10 years and older with HeFH; and in adults and pediatric patients aged 10 years and older with HoFH.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market KYPROLIS primarily in the United States and Europe. KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was launched in 2012 and is indicated in combination with (i) dexamethasone, (ii) lenalidomide plus dexamethasone and (iii) DARZALEX plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. It is also approved as a single agent for patients with relapsed or refractory multiple myeloma who have received one or more previous therapies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Nplate in many countries around the world. Nplate was launched in 2008 and is indicated to treat thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Marketed Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also market a number of other products in various markets worldwide, including MVASI, Vectibix, KANJINTI, EVENITY, EPOGEN, BLINCYTO, AMGEVITA, Aimovig, Parsabiv, NEUPOGEN, LUMAKRAS/LUMYKRAS, Sensipar/Mimpara, AVSOLA, RIABNI and TEZSPIRE. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists our outstanding material patents for the indicated product by territory, general subject matter and latest expiry date. Certain of the European patents are subjects of&#160;supplemental protection certificates that provide additional protection for the products in certain European countries beyond the dates listed in the table. See footnotes to the patent table below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more patents with the same or earlier expiry dates may fall under the same general subject matter and are not listed separately.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(etanercept)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment using aqueous formulations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/8/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/19/2037</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fusion protein and pharmaceutical compositions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/22/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DNA encoding fusion protein and methods of making fusion protein</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/24/2029</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(denosumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/25/2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nucleic acids encoding RANKL antibodies and methods of producing RANKL antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/30/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies, including sequences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/19/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RANKL antibodies, including sequences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/25/2022</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(apremilast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions and compounds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/16/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystalline form</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/9/2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/29/2034</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions, compounds and methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/20/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (darbepoetin alfa)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Glycosylation analogs of erythropoietin proteins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2024</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (carfilzomib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions and compounds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2027</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/14/2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of making</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/8/2033</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions, compounds and methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2025</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(evolocumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/25/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/8/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compositions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/22/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/10/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/3/2033</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(romiplostim)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/12/2028</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thrombopoietic compounds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/20/2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(panitumumab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Human monoclonal antibodies to epidermal growth factor receptor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/5/2018</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(romosozumab-aqqg)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/25/2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/11/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation and methods of using formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/28/2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/18/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation and methods of using formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2031</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (blinatumomab)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical compositions and bifunctional polypeptides</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/6/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of administration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/28/2027</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bifunctional polypeptides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/26/2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of administration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/6/2029</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (erenumab-aooe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CGRP receptor antibodies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/17/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/22/2036</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CGRP receptor antibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/10/2035</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(etelcalcetide)</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compound and pharmaceutical composition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/7/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/27/2034</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of making</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2035</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compound and pharmaceutical composition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/29/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/27/2034</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LUMAKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> /LUMYKRAS&#8482;(sotorasib)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compounds and pharmaceutical compositions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/21/2038</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crystalline form, pharmaceutical compositions and methods of treatment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/20/2040</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compounds, pharmaceutical compositions and methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/21/2038</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TEZSPIRE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (tezepelumab-ekko)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polypeptides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/3/2029</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/23/2038</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2028</span></td></tr></table></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A European patent with this subject matter may also be entitled to supplemental protection in one or more countries in Europe, and the length of any such extension will vary by country. For example, supplementary protection certificates have been issued related to the indicated products for patents in at least the following countries:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#010202;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">denosumab &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2025</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">apremilast &#8212; Italy, Spain and the United Kingdom expiring in 2028</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">carfilzomib &#8212; France, Germany, Italy, Spain and the United Kingdom expiring in 2030</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">evolocumab &#8212; France, Spain and the United Kingdom, expiring in 2030</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">romiplostim &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2024</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">panitumumab &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2022</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">romosozumab &#8212; France, Italy and Spain, expiring in 2031</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">blinatumomab &#8212; France, Italy and Spain, expiring in 2029</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">erenumab &#8212; France, Italy and Spain, expiring in 2033</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.3pt">etelcalcetide &#8212; France, Germany, Italy, Spain and the United Kingdom, expiring in 2031</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">U.S. Patent No. 10,092,541 was held invalid by the New Jersey District Court. We disagree with the court&#8217;s holding and we are in the process of appealing this judgment. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements, Amgen Inc. vs. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A patent with this subject matter may be entitled to patent term extension in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. A number of our marketed products are indicated for disease areas in which other products or treatments are currently available or are being pursued by our competitors through R&amp;D activities. Additionally, some competitor-marketed products target the same genetic pathways as our recently launched marketed products or are currently in development. This competition could impact the pricing and market share of our products. We continue to pursue ways of increasing the value of our medicines through innovations during their life cycles, which can include expanding the disease areas for which our products are indicated and finding new methods to make the delivery of our medicines easier and less costly. Such activities can offer important opportunities for differentiation. For example, we market the Neulasta Onpro kit, which provides physicians the opportunity to initiate administration of the recommended dose of Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the same day as chemotherapy, with drug delivery at home the day after chemotherapy, thereby saving the patient a trip back to the doctor. We plan to continue pursuing innovation efforts to strengthen our competitive position. Such position may be based on, among other things, safety, efficacy, reliability, availability, patient convenience, delivery devices, price, reimbursement, access to and timing of market entry and patent position and expiration.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the existing patents on our principal products have expired, and we face new and increasing competition, including from biosimilars and generics. A biosimilar is another version of a biological product for which marketing approval is sought or has been obtained based on a demonstration that it is &#8220;highly similar&#8221; to the original reference product. We have experienced adverse effects from biosimilar competition on our originator product sales. Companies have launched biosimilar versions of EPOGEN, NEUPOGEN and Neulasta and have approved biosimilars for ENBREL. Once multiple biosimilar versions of one of our originator products have launched, competition has intensified rapidly, resulting in greater net price declines for both reference and biosimilar products, and a greater effect on product sales. See also Government Regulation&#8212;Regulation in the United States&#8212;Approval of Biosimilars. Although competitor biosimilars compete on price, we believe many patients, providers and payers will continue to place high value on the reputation, supply reliability and safety of our products. As additional biosimilar competitors come to market, we will continue to leverage our global experience to distinguish against both branded and biosimilar competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have our own biosimilar products both in the United States and outside of U.S. markets that are competing against branded and biosimilar versions of our competitors&#8217; products. In 2019, Amgen launched MVASI, a biosimilar to Avastin, and KANJINTI, a biosimilar to Herceptin; and in 2018, Amgen launched AMGEVITA, a biosimilar to Humira in ex-U.S. markets. We have also received FDA approval of AMJEVITA, a biosimilar to Humira for the U.S. market, and plan to launch in the United States in January 2023. In 2020, we launched AVSOLA, a biosimilar to Remicade;</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in January 2021, we launched RIABNI, a biosimilar to Rituxan. We expect additional biosimilar competition against both our branded and biosimilar products in the future across markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although most of our products are biologics, some are small molecule products. Because the FDA approval process permits generic manufacturers to rely on the safety and efficacy data of the innovator product rather than having to conduct their own costly and time-consuming clinical trials, generic manufacturers can often develop and market their competing versions of our small molecule products at much lower prices. For example, following loss of exclusivity of patents directed to cinacalcet, the active ingredient in our small molecule calcimimetic Sensipar, we lost a significant share of the market and corresponding revenues in a very short period of time. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The introduction of new products, the development of new processes or technologies by competitors or the emergence of new information about existing products may result in (i) increased competition for our marketed products, even for those protected by patents and/or (ii) reductions in the prices we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical trials of our product candidates. (As used in this document, the term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may include prospective clinical trials, observational studies, registries and other studies.) See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products face substantial competition and our product candidates are also likely to face substantial competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and expect to face increasing competition from biosimilars and generics in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our significant competitors and is not exhaustive.</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competitor-marketed product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competitors</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUMIRA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xeljanz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RINVOQ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alendronate, raloxifene and zoledronate generics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="6" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cosentyx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skyrizi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methotrexate generics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoledronate generics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UDENYCA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coherus BioSciences, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fulphila</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mylan Institutional Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filgrastim biosimilars</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epoetin alfa biosimilars</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRALUENT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals, Inc.<br/>Sanofi</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VELCADE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Millennium Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POMALYST/IMNOVID</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. &amp; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROMACTA/REVOLADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Approved biosimilars available in Europe and Canada.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of J&amp;J.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Dermatology only.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Other biosimilars under regulatory review in the United States and Europe.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">PROCRIT competes with Aranesp in supportive cancer care and predialysis settings.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">KYPROLIS is facing increased competition from several recently approved products.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of Takeda.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">A subsidiary of BMS.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_22"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our principal products are dependent on the availability and extent of coverage and reimbursement from third-party payers. In many markets around the world, these payers, including government health systems, private health insurers and other organizations, remain focused on reducing the cost of healthcare; and their efforts have intensified as a result of rising healthcare costs, economic pressures and broader challenges generated by the COVID-19 pandemic. Drugs remain heavily scrutinized for cost containment. As a result, payers are becoming more restrictive regarding the use of biopharmaceutical products and are scrutinizing the prices of these products while requiring a higher level of clinical evidence to support the benefits such products bring to patients and the broader healthcare system.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pressures become intensified when our products become subject to competition, including from biosimilars.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, healthcare providers and other entities such as pharmacies and PBMs are reimbursed for covered services and products they deliver through both private-payer and government healthcare programs such as Medicare and Medicaid. We provide negotiated rebates to healthcare providers, private payers, government payers and PBMs. In addition, we are required to (i) provide rebates or discounts on our products that are reimbursed through certain government programs, including Medicare and Medicaid, and (ii) provide discounts to qualifying healthcare providers under the federal 340B Drug Pricing Program. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both private and some government payers use formularies to manage access to and utilization of drugs. A drug&#8217;s inclusion and favorable positioning on a formulary are essential to ensure patients have access to a particular drug. Even when access is available, some patients abandon their prescriptions for economic reasons. Payers continue to institute cost reduction and containment measures that lower drug utilization and/or spending altogether and/or shift a greater portion of the costs to patients. Such measures include, but are not limited to, more-limited benefit plan designs, higher patient co-pays or coinsurance obligations, limitations on patients&#8217; use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs), stricter utilization management criteria before a patient may get access to a drug, higher-tier formulary placement that increases the level of patient out-of-pocket costs and formulary exclusion, which effectively encourages patients and providers to seek alternative treatments or pay 100% of the cost of a drug. The use of such measures by PBMs and insurers has continued to intensify and has thereby limited Amgen product usage and sales. Furthermore, during the past few years, many PBMs and insurers have consolidated, resulting in a smaller number of PBMs and insurers overseeing a large portion of total covered lives in the United States. As a result, PBMs and insurers have greater market power and negotiating leverage to mandate stricter utilization criteria and/or exclude drugs from their formularies in favor of competitor drugs or alternative treatments. In highly competitive treatment markets such as the markets for ENBREL, Otezla, Repatha and Aimovig, PBMs are also able to exert negotiating leverage by requiring incremental rebates from manufacturers in order for them to gain and/or maintain their formulary position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to market actions taken by private and government payers in the United States, policy makers in both of the major U.S. political parties are pursuing policies to lower drug costs. Potential policies cover a wide range of areas, including allowing the importation of drugs from other countries; instituting IRP schemes, which would set the prices of certain drugs based on those available in other countries; implementing policies that in effect would require manufacturers to accept government-set prices for certain drugs, with price ceilings based on a domestic reference-pricing scheme; redesigning the Medicare Part D benefit so as to establish a cap on patient out-of-pocket costs, paired with new requirements that manufacturers cover a share of the costs of Part D drugs; stipulating penalties if drug price benchmarks rise faster than inflation; increasing transparency in drug pricing; and using third-party value assessments to determine drug prices. Examples of such policies include, but are not limited to, the previous Administration&#8217;s November 2020 interim final rule, which attempts to institute an MFN IRP model in Medicare Part B and a final rule instituting rebate reform in Medicare Part D. Both of the resulting rules are being challenged in court and have not yet been implemented. Further, although CMS withdrew the MFN IRP, policy makers continue to express strong interest in policies to address drug pricing. See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Infrastructure Investment and Jobs Act signed into law on November 15, 2021, delays implementation of the rebate reform rule until 2026 and requires manufacturers of certain Part B&#8211;covered drugs packaged in single-use containers to give refunds to the government starting in 2023 for discarded amounts. Although the direction of drug-pricing-policy reforms remains unclear at this time, Congress is continuing to consider prescription-drug-pricing reforms, including legislative proposals for a number of the concepts discussed above (including a full repeal of the prior Administration&#8217;s Part D rebate reform rule).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries other than the United States, government-sponsored healthcare systems are the primary payers for drugs and biologics. With increasing budgetary constraints and/or difficulty in understanding the value of medicines, governments and payers in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing, increases in mandates, incentives for generic substitution and biosimilar usage and government-mandated price cuts. In this regard, many countries have health technology assessment organizations that use formal economic metrics such as cost-effectiveness to determine prices, coverage and reimbursement of new therapies; and these organizations are expanding in both established and emerging markets. Many countries also limit coverage to populations narrower than those specified on our product labels or impose volume caps to limit utilization. We expect that countries will continue taking aggressive actions to seek to reduce expenditures on drugs and biologics. Similarly, fiscal constraints may also affect the extent to which countries are willing to approve new and innovative therapies and/or allow access to new technologies. The EU is currently undergoing a review and possible revision of its pharmaceutical legislation, scheduled to conclude at the end 2022. There is a risk that this review will lead to proposals that may reduce intellectual property protection for new products, as well as change the reimbursement and regulatory landscape in ways that are difficult to predict at this point.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The dynamics and developments discussed above create pressures on the pricing and potential usage of our products and on the industry. Given the diverse interests in play between payers, biopharmaceutical manufacturers, policy makers, healthcare providers and independent organizations, if and whether the parties involved can achieve alignment on the matters discussed above remain unclear, and the outcome of any such alignment is difficult to predict. We remain focused on pricing our products responsibly and delivering breakthrough treatments for unmet medical needs. Amgen is committed to working with the entire healthcare community to ensure continued innovation and to facilitate patient access to needed medicines. We do this by:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">investing billions of dollars annually in R&amp;D;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">pricing our medicines to reflect the value they provide;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">partnering with payers to share risk and accountability for health outcomes;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">providing patient support and education programs; </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">helping patients in financial need access our medicines; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">working with policy makers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_25"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing, Distribution and Raw Materials</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are a leader in the manufacture of biologics and that our manufacturing capabilities represent a competitive advantage. The products we manufacture consist of both biologics and small molecule drugs. The majority of our products are biologics that are produced in living cells and that are inherently complex due to naturally occurring molecular variations. Highly specialized knowledge and extensive process and product characterization are required to transform laboratory-scale processes into reproducible commercial manufacturing processes. Further, our expertise in the manufacture of biologics positions us well for leadership in the global biosimilars market. For additional information regarding manufacturing facilities, see Item&#160;2. Properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been innovating our manufacturing facilities designed to extend our manufacturing advantage by optimizing our manufacturing network and/or by mitigating risks while continuing to ensure adequate supply of our products. For example, our licensed next-generation biomanufacturing plant operating in Singapore, and our recently FDA approved facility in West Greenwich, Rhode Island, incorporate multiple innovative technologies into a single facility. Next-generation biomanufacturing plants require smaller manufacturing footprints and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions. Within such plants, the equipment is portable and smaller, which provides greater flexibility and speed in the manufacture of different medicines simultaneously. This enables Amgen to respond to changing demands for its medicines with increased agility. The Singapore site also has a plant that has been approved by several agencies, including the FDA and EMA, to produce small molecule drugs for commercial manufacturing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal manufacturing network has commercial production capabilities for bulk manufacturing, formulation, fill, finish, tableting and device assembly. These activities are performed within the United States and its territories in our Puerto Rico, Rhode Island and California facilities as well as internationally in our Ireland, Netherlands and Singapore facilities. In addition, we use third-party contract manufacturers to supplement the capacity or capability of our commercial manufacturing network.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support our clinical trials, we manufacture product candidates primarily at our California facilities. We also use third-party contract manufacturers to supplement the capacity or capability of our overall clinical manufacturing network.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate distribution centers in Puerto Rico, Kentucky, California and the Netherlands for worldwide distribution of the majority of our commercial and clinical products. We also use third-party distributors to supplement distribution of our products worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the manufacturing and distribution activities noted above, each of our manufacturing locations includes key manufacturing support functions such as quality control, process development, engineering, procurement, production scheduling and warehousing. Certain of those manufacturing and distribution activities are highly regulated by the FDA as well as international regulatory agencies. See Government Regulation&#8212;Regulation in the United States&#8212;Regulation of Manufacturing Standards.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Initiatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, we have been expanding capacity and advancing new innovations with multiple ongoing projects.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next-generation biomanufacturing plant at our West Greenwich, Rhode Island, campus, the first of its kind in the United States, received FDA approval in January 2022. This plant expands our capacity to manufacture certain products for U.S. and global markets, as we receive regulatory approval in those markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated projects in 2019 to expand our clinical and commercial manufacturing capabilities in Thousand Oaks, California, which we have completed.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we initiated a project to build a new multi-product drug substance manufacturing facility in Holly Springs, North Carolina. The new plant will support both traditional stainless steel-fed batch manufacturing and next-generation single-use technologies, allowing flexibility in the production of multiple products in one plant.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we broke ground for our newest biomanufacturing plant located in New Albany, Ohio. This final product assembly and packaging plant will support the growing demand for Amgen&#8217;s medicines in the United States and will use state-of-the-art technologies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Raw Materials and Medical Devices</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain raw materials, medical devices (including companion diagnostics) and components necessary for the commercial and/or clinical manufacturing of our products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be our only sources for such materials. We currently attempt to manage the risk associated with such suppliers by means of inventory management, relationship management and evaluation of alternative sources when feasible. We also monitor the financial condition of certain suppliers and their ability to supply our needs. See Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform various procedures to help authenticate the sources of raw materials, including intermediary materials used in the manufacture of our products; the procedures include verification of country of origin and are incorporated into the manufacturing processes we and our third-party contract manufacturers perform.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To better ensure supply, Amgen has a risk mitigation strategy that uses a combination of methods, including multiple sources or backup inventory of critical raw materials. In response to the COVID-19 pandemic and as part of our ongoing business continuity efforts, we continue to closely monitor our inventory levels and have taken additional measures to mitigate against raw material supply interruption. See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_28"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation by government authorities in the United States and other countries is a significant factor in the production and marketing of our products and our ongoing R&amp;D activities. To clinically test, manufacture and market products for therapeutic use, we must satisfy mandatory procedures and safety and effectiveness standards established by various regulatory bodies. Compliance with these standards is complex, and failure to comply with any of these standards can result in significant implications. See Item 1A. Risk Factors for a discussion of factors, including global regulatory implications, that can adversely impact our development and marketing of commercial products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation in the United States</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Public Health Service Act; the FDCA; and the regulations promulgated thereunder as well as other federal and state statutes and regulations govern, among other things, the production, research, development, testing, manufacture, quality control, labeling, storage, record keeping, approval, advertising, promotion and distribution of our products in addition to the reporting of certain payments and other transfers of value to healthcare professionals and teaching hospitals.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development and Product Approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug development in our industry is complex, challenging and risky, and failure rates are high. Product development cycles are typically very long&#8212;approximately 10 to 15 years from discovery to market. A potential new medicine must undergo many years of preclinical and clinical testing to establish its safety and efficacy for use in humans at appropriate dosing levels and with an acceptable risk&#8211;benefit profile. We continue to work toward reducing cycle times by applying our expertise in human genetics and innovation in technology, clinical trials and real-world evidence.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After laboratory analysis and preclinical testing in animals, we file an IND with the FDA to begin human testing. Typically, we undertake an FDA-designated three-phase human clinical testing program.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase 1, we conduct small clinical trials to investigate the safety and proper dose ranges of our product candidates in a small number of human subjects.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase 2, we conduct clinical trials to investigate side-effect profiles and the efficacy of our product candidates in a patient population larger than phase 1 but still relatively small, who have the disease or condition under study.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In phase&#160;3, we conduct clinical trials to investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA monitors the progress of each trial conducted under an IND and may, at its discretion, reevaluate, alter, suspend or terminate the testing based on data accumulated to that point and the FDA&#8217;s risk&#8211;benefit assessment with regard to the patients enrolled in the trial. The results of preclinical and clinical trials are submitted to the FDA in the form of either a BLA for biologic products or a New Drug Application for small molecule products. We are not permitted to market or promote a new product until the FDA has approved our marketing application.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. The pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on the nonclinical-trial and clinical-trial data of an originator product to which the biosimilar has been demonstrated to be &#8220;highly similar&#8221; and to have no clinically meaningful differences with regard to safety, purity and potency. The relevance of demonstrating &#8220;similarity&#8221; is that in many cases, biosimilars can be brought to market without conducting the full suite of clinical trials typically required of originators, because risk&#8211;benefit has previously been established. To preserve incentives for future innovation, the law establishes a period of exclusivity for originators&#8217; products, which in general prohibits biosimilars from gaining FDA approval based in part on reliance on or reference to the originator&#8217;s data in their application to the FDA for 12 years after initial FDA approval of the originator product. The law does not change the duration of patents granted on biologic products. As part of the implementation of the abbreviated approval pathway for biosimilars, the FDA released a number of guidance documents, some of which remain in draft form.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Product Marketing and Promotion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA regulates the marketing and promotion of drug products. Our product promotions for approved product indications must comply with the statutory standards of the FDCA and the FDA&#8217;s implemented regulations and guidance. The FDA&#8217;s review of marketing and promotional activities encompasses but is not limited to direct-to-consumer advertising, healthcare-provider-directed advertising and promotion, sales representative communications to healthcare professionals, promotional programming and promotional activities involving electronic media. The FDA may also review industry-sponsored scientific and educational activities that make representations regarding product safety or efficacy in a promotional context. The FDA may take enforcement action against a company for promoting unapproved uses of a product or for other violations of the FDA&#8217;s advertising and labeling laws and regulations. Enforcement action may include product seizures, injunctions, civil or criminal penalties or regulatory letters, which may require corrective advertising or other corrective communications to healthcare professionals. Failure to comply with the FDA&#8217;s regulations also can result in adverse publicity or increased scrutiny of company activities by the U.S. Congress or other legislators. Additionally, as described below, such failure may lead to additional liability under U.S. healthcare fraud and abuse laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Manufacturing Standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA regulates and inspects the equipment, facilities, laboratories and processes used in the manufacturing and testing of products prior to granting approval to market products. If after receiving approval from the FDA we make a material change in manufacturing equipment, location or process, additional regulatory review may be required. We also must adhere to current Good Manufacturing Practice regulations and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA conducts regular, periodic visits to reinspect our equipment, facilities, laboratories and processes following an initial approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Combination Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Combination products are defined by the FDA as products composed of two or more regulated components (e.g., a biologic and/or drug and a device). Biologics/drugs and devices each have their own regulatory requirements, and combination products may have additional requirements. A number of our marketed products meet this definition and are regulated under this framework, and we expect that a number of our pipeline product candidates will be evaluated for regulatory approval under this framework as well.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation outside the United States</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In EU countries as well as in the United Kingdom, Switzerland, Canada, Australia and Japan, regulatory requirements and approval processes are similar in principle to those in the United States.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, there are currently two potential tracks for seeking marketing approval for a product not authorized in any EU member state: a decentralized procedure and a centralized procedure. In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">decentralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, identical applications for marketing authorization are submitted simultaneously to the national regulatory agencies. Regulatory review is led by one member state (the reference-member state), and its assessment&#8212;based on safety, quality and efficacy&#8212;is reviewed and approved (assuming there are no concerns that the product poses a serious risk to public health) by the other member states from which the applicant is seeking approval (the concerned-member states). The decentralized procedure leads to a series of single national approvals in all relevant countries. In the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">centralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is required of all products derived from biotechnology, a company submits a single Marketing Authorisation Application to the EMA, which conducts an evaluation of the dossier, drawing upon its scientific resources across Europe. If the drug product is proven to fulfill requirements for quality, safety and efficacy, the EMA&#8217;s CHMP adopts a positive opinion, which is transmitted to the EC for final decision on granting of the marketing authorization. Even though the EC generally follows the CHMP&#8217;s opinion, it is not bound to do so. Subsequent commercialization is enabled by country-by-country reimbursement approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biosimilars are approved under a specialized pathway of the centralized procedure. As with the U.S. pathway, an applicant seeks and obtains regulatory approval for a biosimilar once the data exclusivity period for the original reference product has expired, relying in part on the data submitted for the originator product together with data evidencing that the biosimilar is &#8220;highly similar&#8221; with regard to quality, safety and efficacy to the original reference product authorized in the European Economic Area.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other countries such as Russia, Turkey and those in Latin America and the Middle East have review processes and data requirements similar to those of the EU and in some cases can rely on prior marketing approval from U.S. or EU regulatory authorities. The regulatory process in these countries may include manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Asia Pacific, a number of countries such as China, Japan, South Korea and Taiwan may require local clinical-trial data for bridging purposes as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. In most of the Asian markets, registration timelines depend on marketing approval in the United States or the EU. In some markets in Asia, such as China, Indonesia and Thailand, regulatory timelines can be less predictable. The regulatory process may also include manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements. Countries such as Australia and Japan have more-mature systems that would allow for submissions under more-competitive time frames. With regard to biosimilars, several of these countries have pathways to register biosimilars (e.g., Australia, India, Singapore, South Korea and Taiwan), and biosimilar products are already present on the markets (e.g., Australia and South Korea).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, such as Japan and those in the EU, medical devices may be subject to regulatory regimes whereby manufacturers must establish that their medical devices conform to essential requirements set out in the law for the particular device category. For example, in the EU, with limited exceptions, medical devices placed on the market must bear the Conformit&#233; Europ&#233;enne marking to indicate their conformity with legal requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Postapproval Phase</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, we continue to monitor adverse events and product complaints reported following the use of our products through routine postmarketing surveillance and studies when applicable. We report such events to the appropriate regulatory agencies as required by local regulations for individual cases and aggregate reports. We proactively monitor (according to good pharmacovigilance practices) and ensure the implementation of signal detection, assessment and the communication of adverse events that may be associated with the use of our products. We also proactively monitor product complaints through our quality systems, which includes assessing our drug delivery devices for device complaints, adverse events and malfunctions. We may also be required by regulatory agencies to conduct further clinical trials on our marketed products as a condition of their approval or to provide additional information on safety and efficacy. Health regulators, including the FDA, have authority to mandate labeling changes to products at any point in a product&#8217;s life cycle based on new safety information or as part of an evolving label change to a particular class of products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health regulators, including the FDA, also have authority both before and after approval to require that a company implement a risk management program for a product to ensure that the benefits of the drug outweigh the risks. Each risk management program is unique and varies depending on the specific factors required. In the United States, such a risk management program is known as a REMS; and we currently have REMSs for Prolia, Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and BLINCYTO.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various laws pertaining to healthcare fraud and abuse, including antikickback laws and false-claims laws. Antikickback laws make it illegal to solicit, offer, receive or pay any remuneration in exchange for or to induce the referral of business, including the purchase or prescribing of a particular drug that is reimbursed by a state or federal program. False-claims laws prohibit knowingly and willingly presenting or causing to be presented for payment to third-party payers (including Medicare and Medicaid) any claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as by the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). Liability under false-claims laws may also arise when violation of certain laws or regulations related to the underlying product (e.g., a violation regarding improper promotional activity or unlawful payments) contributes to the submission of a false claim.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2019, we entered into a settlement agreement with the DOJ and the OIG of the HHS to settle certain allegations related to our support of independent charitable organizations that provide patients with financial assistance to access medicines. Additionally, we entered into a corporate integrity agreement that requires us to both maintain a corporate compliance program and undertake a set of defined corporate integrity obligations for a period of five years. Due to the breadth of the statutory provisions and the absence of guidance in the form of regulations or court decisions addressing some of our practices, it is possible that in the future, our practices might be further challenged under antikickback or similar laws. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA arguably includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anticorruption laws and/or regulations. Failure by our employees, agents, contractors, vendors, licensees, partners or collaborators to comply with the FCPA and other anticorruption laws and/or regulations could result in significant civil or criminal penalties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations globally with regard to privacy and data protection. These laws and regulations involve the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environments regarding privacy and data protection are continually evolving and developing because these issues are subjects of increasing amounts of attention in countries globally. For example, we are subject to the EU&#8217;s GDPR, which became effective on May 25, 2018, the California Consumer Privacy Act of 2018, which became effective on January 1, 2020 and China&#8217;s Personal Information Protection Law, which became effective on November 1, 2021. Other jurisdictions where we operate have enacted or proposed similar legislation and/or regulations. For example, the Virginia Consumer Data Protection Act and the Colorado Privacy Act are set to become effective on January 1, 2023, and July 1, 2023, respectively. Failure to comply with these laws could result in significant penalties.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been and will continue to be subject to various other U.S. and foreign laws, rules and regulations. See Reimbursement section above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development and Selected Product Candidates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our R&amp;D on novel human therapeutics for the treatment of serious illness. We capitalize on our strengths in human genetics, novel biology and protein engineering. We leverage our biologic expertise and seek to choose the optimal modality for a drug target and disease. And we use cutting-edge science and technology to study subtle biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discovery research programs may therefore yield targets that lead to the development of human therapeutics delivered as large molecules, small molecules, other combination modalities or new modalities. We have reshaped our portfolio and have increasingly focused our efforts on human genetics when possible to enhance the likelihood of success.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since early 2021, COVID-19 global vaccination efforts have been under way to control the pandemic. However, uncertainty remains as to the length of time required for vaccination of a meaningful portion of the population and as to the efficacy of such vaccinations on the trajectory of the pandemic. Challenges to vaccination efforts, new variants and other causes of virus spread may require governments to issue additional restrictions and/or order shutdowns in various geographies. As a result, we expect to see continued volatility for at least the duration of the pandemic as governments respond to current local conditions. With regard to our drug development activities, we are continuously monitoring COVID-19 infection rates, including changes from new variants; we are working to mitigate effects on future study enrollment in our clinical trials; and we are evaluating the impact in all countries where clinical trials occur. We remain focused on supporting our active clinical sites in their providing care for patients and in our providing investigational drug supply.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020 and 2019, our R&amp;D expenses were $4.8 billion, $4.2 billion and $4.1 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have major R&amp;D centers in Thousand Oaks and San Francisco, California; Iceland; and the United Kingdom, as well as smaller research centers and development facilities globally. See Item&#160;2. Properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial activities are conducted by both our internal staff and third-party contract clinical trial service providers. To increase the number and diversity of patients available for enrollment in our clinical trials, we have opened clinical sites and will continue opening clinical sites and enrolling patients in a number of geographic locations. See Government Regulation&#8212;Regulation in the United States&#8212;Clinical Development and Product Approval for a discussion of government regulation over clinical development. Also see Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors are actively engaged in R&amp;D in areas in which we have products or in which we are developing product candidates or new indications for existing products. For example, we compete with other clinical trials for eligible patients, which may limit the number of available patients who meet the criteria for certain clinical trials. The competitive marketplace for our product candidates is greatly dependent on the timing of entry into the market. Early entry may have important advantages in gaining product acceptance, thereby contributing to a product&#8217;s eventual success and profitability. Accordingly, we expect that in some cases, the relative speed with which we can develop products, complete clinical testing, receive regulatory approval and supply commercial quantities of a product to the market will be important to our competitive position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to product candidates and marketed products generated from our internal R&amp;D efforts, we acquire companies, acquire and license certain product and R&amp;D technology rights and establish R&amp;D arrangements with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D capabilities, product pipeline and marketed product base. In pursuing these R&amp;D arrangements and licensing or acquisition activities, we face competition from other pharmaceutical and biotechnology companies that also seek to license or acquire technologies, product candidates or marketed products from those entities performing the R&amp;D.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a selection of certain of our product candidates by phase of development in our therapeutic areas of focus as of February&#160;8, 2022, unless otherwise indicated. Additional product candidate information can be found on our website at www.amgen.com. (The website address is not intended to function as a hyperlink, and the information contained on our website is not intended to be a part of this filing.) The information in this section does not include other, nonregistrational clinical trials that we may conduct for purposes other than for submission to regulatory agencies for their approval of a new product indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may conduct nonregistrational clinical trials for various reasons, including to evaluate real-world outcomes or to collect additional safety information with regard to the use of products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investigational indication</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 3 programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interchangeability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bemarituzumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">GEJ adenocarcinoma</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ph-negative B-cell precursor Acute lymphoblastic leukemia</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Male osteoporosis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weekly dosing for relapsed multiple myeloma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chemotherapy-induced thrombocytopenia</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genital psoriasis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic rhinosinusitis with nasal polyps<br/>Severe asthma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 654</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational biosimilar to STELARA (ustekinumab)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 938</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational biosimilar to EYLEA (aflibercept)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABP 959</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational biosimilar to SOLIRIS (eculizumab)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 2 programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Efavaleukin alfa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Systemic lupus erythematosus<br/>Ulcerative colitis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Advanced colorectal cancer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NSCLC monotherapy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other solid tumors with KRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> mutations</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cardiovascular disease</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordesekimab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Celiac disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Palmoplantar pustulosis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rozibafusp alfa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Small cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease<br/>Chronic spontaneous urticaria</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 451/KHK 4083</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1 programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acapatamab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pavurutamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multiple myeloma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarlatamab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Small-cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asthma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Small-cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obesity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 176</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hematologic malignancies</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 193</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 199</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metastatic GEJ cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 256</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 330</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute myeloid leukemia</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 340</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 404</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 427</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acute myeloid leukemia</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 506</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 509</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMG 609</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 994</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate the short- and long-term safety and efficacy of our product candidates, compared to commonly used treatments, in a large number of patients who have the disease or condition under study.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate side-effect profiles and efficacy of product candidates in a larger patient population than phase 1, but still relatively small, who have the disease or condition under study.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical trials investigate the safety and proper dose ranges of product candidates in a small number of human subjects.</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Product Candidate Program Changes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 2, 2021, we had 13 phase 3 programs. As of February 8, 2022, we continued to have 13 phase 3 programs, as regulatory approvals were received for three programs, four programs initiated phase 3 studies and one program was terminated. These changes are set forth in the following table.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investigational indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NSCLC with KRAS G12C mutations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved by the FDA and conditional marketing approval by the EC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Otezla</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mild-to-moderate psoriasis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved by the FDA</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RIABNI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-Hodgkin&#8217;s lymphoma</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved by the FDA</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMJEVITA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interchangeability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bemarituzumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GEJ adenocarcinoma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ph-negative B-cell precursor Acute lymphoblastic leukemia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic rhinosinusitis with nasal polyps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated phase 3 study</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Terminated</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Product Candidate Patent Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes our composition-of-matter patents that have been issued thus far for our product candidates in phase 3 development that have yet to be approved for any indication in the United States or the EU. Patents for products already approved for one or more indications in the United States or the EU but that are currently undergoing phase 3 clinical trials for additional indications have been previously described. See Marketing, Distribution and Selected Marketed Products&#8212;Patents.</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General subject matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;expiration*</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bemarituzumab</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polypeptides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">* Patent expiration estimates are based on issued patents, which may be challenged, invalidated or circumvented by competitors. The estimates do not include any term adjustments, extensions or supplemental protection certificates that may be obtained in the future and thereby extend these dates. Corresponding patent applications are pending in other jurisdictions. Additional patents may be filed or issued and may provide additional exclusivity for the product candidate or its use.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phases 3 and 2 Program Descriptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides additional information about selected product candidates that have advanced into human clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMJEVITA</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMJEVITA is a biosimilar to HUMIRA, which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bemarituzumab</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bemarituzumab is a monoclonal antibody that inhibits FGFR2b. It is being investigated for the treatment of advanced GEJ adenocarcinoma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Amgen announced that the FDA had granted Breakthrough Therapy designation for bemarituzumab.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLINCYTO</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BLINCYTO is an anti-CD19 x anti-CD3 BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> molecule. It is being investigated in newly diagnosed adults age 40 and older with Ph negative B-Cell precursor ALL.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efavaleukin alfa</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efavaleukin alfa is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of systemic lupus erythematosus and ulcerative colitis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EVENITY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being evaluated as a treatment for male osteoporo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sis. EVENITY is being developed in collaboration with UCB.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KYPROLIS is a small molecule proteasome inhibitor. It is being investigated for weekly dosing in combinations with lenalidomide and dexamethasone for relapsed multiple myeloma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, we announced that the FDA had approved the expansion of the KYPROLIS prescribing information to include its use in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">LUMAKRAS/LUMYKRAS</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMAKRAS is a KRAS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> small molecule inhibitor. It is being investigated as treatment for a variety of solid tumors, including NSCLC, colorectal cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other solid tumor cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we announced that the&#160;FDA had approved LUMAKRAS&#160;for the treatment of adult patients with&#160;KRAS&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G12C&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced that the EMA&#8217;s CHMP had adopted a positive opinion and recommended conditional marketing authorization of LUMYKRAS, known as LUMAKRAS&#160;in the&#160;United States, for the treatment of adults with advanced NSCLC with&#160;KRAS&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G12C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mutation and who have progressed after at least one prior line of systemic therapy.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced that the&#160;EC had granted conditional marketing authorization for LUMYKRAS&#160;for the treatment of adults with advanced NSCLC with&#160;KRAS&#160;G12C mutation and who have progressed after at least one prior line of systemic therapy. We also announced that LUMAKRAS had been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent NSCLC that has progressed after systemic anticancer therapy.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nplate is a TPO-RA. It is being investigated for the treatment of CIT.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Olpasiran</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olpasiran is an siRNA that lowers lipoprotein(a), also known as Lp(a). It is being investigated in phase 2 for the treatment of atherosclerotic CV disease.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ordesekimab</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordesekimab is a monoclonal antibody that inhibits the action of IL-15. It is being investigated for the treatment of celiac disease and is being developed in collaboration with Provention Bio, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Otezla</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla is a small molecule that inhibits PDE4. It is being investigated in phase 3 studies for the treatment of patients with moderate-to-severe genital psoriasis. It is being investigated in a phase 2 study for treatment of palmoplantar pustulosis.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we announced the submission of an sNDA to the FDA for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we announced that the FDA had accepted for review our sNDA for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA had set a PDUFA action date of December 19, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced that the FDA had approved the expanded indication for Otezla for the treatment of adult patients with plaque psoriasis, who are candidates for phototherapy or systemic therapy, across all severities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a human monoclonal antibody that inhibits PCSK9. It is being investigated as a treatment for atherosclerotic CV disease in high-risk patients with high LDL-C without prior heart attack or stroke.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Rozibafusp alfa </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rozibafusp alfa is a novel antibody-peptide conjugate that simultaneously blocks the BAFF and ICOSL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity. It is being investigated as a treatment for systemic lupus erythematosus.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tarlatamab</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tarlatamab is an HLE anti- DLL3 x anti-CD3 BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> molecule. It is being investigated for the treatment of small cell lung cancer.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEZSPIRE</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TEZSPIRE is a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin. It is being evaluated in phase 3 studies as a treatment for severe asthma and chronic rhinosinusitis with nasal polyps. It is also being investigated in phase 2 studies as a treatment for chronic obstructive pulmonary disease and chronic spontaneous urticaria. TEZSPIRE is being developed jointly in collaboration with AstraZeneca.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we announced that our partner&#160;AstraZeneca had submitted a BLA to the&#160;FDA for tezepelumab, a potential first-in-class medicine in severe asthma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced that the FDA had accepted a BLA and granted Priority Review of TEZSPIRE for the treatment of asthma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced that the FDA had approved&#160;Amgen&#160;and AstraZeneca's&#160;TEZSPIRE for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced that TEZSPIRE is available for shipment to wholesalers in the&#160;United States.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG 451/KHK4083</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG 451/KHK4083 is a monoclonal antibody that inhibits OX-40. It is being investigated for the treatment of moderate-to-severe atopic dermatitis. AMG 451/KHK4083 is being developed in collaboration with KKC.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 654</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 654, a biosimilar candidate to STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ustekinumab), is a monoclonal antibody that inhibits IL-12 and IL-23. It is being investigated in a phase 3 study for biosimilarity to STELARA. The reference-product primary conditions are psoriasis, psoriatic arthritis and Crohn&#8217;s disease.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 938</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 938, a biosimilar candidate to EYLEA, is a VEGFR Fc fusion protein. It is being investigated in a phase 3 study for biosimilarity to EYLEA. The reference-product primary conditions are wet AMD, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ABP 959</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABP 959, a biosimilar candidate to SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5. It is being investigated in a phase 3 study for biosimilarity to SOLIRIS. The reference-product primary conditions are PNH and aHUS.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Relationships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into business relationships, including joint ventures and collaborative arrangements, for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. In addition, we acquire product and R&amp;D technology rights and establish R&amp;D collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our R&amp;D capabilities, product pipeline and marketed-product base. These arrangements generally provide for nonrefundable, upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success, and each is unique in nature.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we generally require counterparties to execute confidentiality agreements upon commencement of a business relationship with us. However, others could either develop independently the same or similar information or unlawfully obtain access to our information.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangement through December 31, 2021</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal, recognized product sales of Aimovig in the United States, shared U.S. commercialization costs with Novartis and paid Novartis a significant royalty on net sales in the United States. Novartis held global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangement after January 1, 2022</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the amendment effective January 1, 2022, Novartis retains the ex-U.S. Novartis Rights and will continue to pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen manufactures and supplies Aimovig worldwide.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a six-year supply agreement with DaVita, which superseded the previously existing, seven-year supply agreement that commenced in 2012. Pursuant to the 2017 agreement, we supply EPOGEN and Aranesp in amounts necessary to meet specified annual percentages of DaVita&#8217;s and its affiliates&#8217; requirements for ESAs used in providing dialysis services in the United States and Puerto Rico. Such percentages vary during the term of the agreement, but in each year are at least 90%. The agreement expires in December 2022. The agreement may be terminated by either party before expiration of its term in the event of certain breaches of the agreement by the other party.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial information about our significant collaborative arrangements, see Part IV&#8212;Note 8, Collaborations, to the Consolidated Financial Statements.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_37"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen&#8217;s approach to human capital resource management starts with our mission to serve patients. We strive to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. The way we approach our business is guided by our Amgen Values:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#0063c3;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amgen Values</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Be Science-Based</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compete Intensely and Win</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Create Value for Patients, Staff and Stockholders</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Be Ethical</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trust and Respect Each Other</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ensure Quality</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Work in Teams</span></div></td><td colspan="3" style="border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Collaborate, Communicate and Be Accountable</span></div></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our staff are also guided by the Company&#8217;s Code of Conduct, which is designed to help every person who does business on our behalf worldwide (including all staff, management, consultants, contract workers and temporary workers) to understand what is expected of them.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry exists in a complex regulatory and reimbursement environment. The unique demands of our industry, together with the challenges of running an enterprise focused on the discovery, development, manufacture and commercialization of innovative medicines, requires a highly engaged and committed workforce.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Amgen had approximately 24,200 staff members in over 50 countries, and we have had relatively low global turnover rates. We also supplement our workforce with independent contractors, contingent workers and temporary workers, as needed. Outside of the United States, some of our employees are represented by unions or works councils. We consider our staff relations to be good, supported by regular assessments of staff engagement surveys on a wide range of topics (including engagement in the COVID-19 environment, diversity, inclusion and belonging, and maintaining a culture of compliance). We discuss the results of these surveys with our workforce and our Board of Directors. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation, Benefits and Development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to employee compensation and benefits is designed to deliver cash, equity and benefit programs that are competitive with those offered by leading companies in the biotechnology and pharmaceutical industries to attract, motivate and retain talent with a focus on encouraging performance, promoting accountability and adherence to Company values and alignment with the interests of the Company&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our base pay program aims to compensate staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform each position, as well as the experience brought to the job. We also provide annual incentive programs to reward our staff in alignment with achievement of Company-wide goals that are established annually and designed to drive aspects of our strategic priorities that support and advance our strategy across our Company. The majority of our staff members are also eligible for the grant of equity awards under our long-term incentive program that are designed to align the experience of these staff with that of our shareholders. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All staff also participate in a regular performance measurement process through which staff receive performance and development feedback, and pay is aligned to performance. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support the development of our staff, we provide a variety of programs, including leadership development programs, virtual instructor-led courses and self-paced learning options.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit programs are also generally broad-based, promote health and overall well-being and emphasize saving for retirement. All regular U.S. staff members are eligible to participate in the same core health and welfare and retirement savings plans. Other U.S. employee benefits include medical plans, dental plans, adoption assistance, paid parental leave programs, access to childcare, employee assistance programs, employee stock purchase plan, flexible spending accounts, life, long-term care and business travel accident insurance, short and long-term disability benefits, wellness benefits and work-life resources and referrals. Comparable programs and benefits are available globally, with the same health and well-being intent, consistent with statutory requirements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation and Management Development Committee provides oversight of our compensation plans, policies and programs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Safety and Wellness and Our Response to COVID-19</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Creating a safe and healthy workplace for our staff is a priority at Amgen. Our goal is to have a world class safety record through safety leadership, risk management practices and integrating safety throughout our business processes. To foster our safety culture, we implement a comprehensive safety program, driving to understand and mitigate the root cause of safety incidents and manage and control variability. We use leading indicators to assess the effectiveness of our safety programs and make course corrections as needed. Additionally, we perform formal executive management review of functional safety performance for Operations, Global Commercial Operations and R&amp;D on a quarterly basis with a focus on identifying early signals and taking action to drive continuous improvement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic and as part of our commitment to work to ensure the safety and well-being of our employees, for 2020 and much of 2021, we have activated our applicable business continuity plans, including having those of our employees who were able to work from home to do so, and for employees returning to the workplace and the field, we took additional safety measures, including implementing occupancy limits, restricting business travel, providing and requiring the use of personal protective equipment, temperature screening and COVID-19 testing to access our workplaces. Staff member access to our facilities has been in accordance with applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, and in 2021 we required staff members in the United States and Puerto Rico to be fully vaccinated against COVID-19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the fourth quarter of 2021, we enabled our U.S. based workforce to return to the workplace for work that benefits from face-to-face interactions, while maintaining appropriate safety measures to ensure staff well-being. This approach intentionally combines the benefits of remote and in-person working at Amgen for the future as COVID-19 restrictions ease around the globe. We will continue to learn and adapt this approach as needed for the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate Responsibility and Compliance Committee provides general oversight of our safety programs and initiatives, while our Board of Directors, as a whole, has overseen our specific responses to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Inclusion and Belonging</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that a diverse and inclusive culture fosters innovation, which supports our ability to serve patients. Further, we also believe our global presence is strengthened by having a workforce that reflects the diversity of the patients we serve. It is with these beliefs in mind that we have continued to strengthen and grow our culture of diversity, inclusion and belonging. Our internal efforts include, in 2019, establishing a Diversity, Inclusion and Belonging Council chaired by our Chief Executive Officer. In 2020, we implemented a global unconscious-bias training program, and we launched an ongoing learning journey with tools and resources that guides staff on the role they play in creating diversity, inclusion and belonging throughout the organization. Each of Amgen&#8217;s ERGs is sponsored by an executive leader who reports to the CEO. We are leveraging our ERGs to represent and support the diversity of Amgen staff, while also providing opportunities to Amgen&#8217;s business and the community. </span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The vaccination requirement did not apply to staff who were unable to receive a COVID-19 vaccine because of qualifying religious or medical reasons.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#0063c3;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Employee Resource Groups</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Asian Association (AAA)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Black Employee Network (ABEN)</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ability Bettered through Leadership and Education (ABLE), a resource group for those with disabilities, <br/>visible and invisible, including those conditions also experienced by the patients that Amgen serves.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Early Career Professionals (AECP)</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Indian Subcontinent Network (AISN)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Latin Employee Network (ALEN)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen LGBTQ and Allies Network (PRIDE)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen Veterans Employees Network (AVEN)</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women Empowered to be Exceptional (WE2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women in Information Systems Enrichment (WISE)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #929292;border-left:1pt solid #929292;border-right:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amgen International Network (AIN)</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, to tangibly deepen and drive our diversity, inclusion and belonging activities enterprise-wide and actively communicate our culture of belonging to all staff, we established an annual diversity, inclusion and belonging goal for leaders at executive director and above levels to establish, document and execute diversity, inclusion and belonging action plans, with a target goal of 75% participation, which we achieved and exceeded in 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In areas of underrepresentation, we develop plans with a goal of bringing our representation in line with availability. We engage in outreach efforts to attract, retain and advance more women and minorities in our workforce. For example, we have worked to enhance our diverse candidate recruiting pool by developing relationships with organizations that can serve as a source of diverse candidates, such as the National Black MBA Association and National Sales Network, as well as historically black colleges and universities. In 2021, a fellowship program between Amgen and Howard University was established to expand the talent pool and diversify ranks in research and development. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, at the end of 2020, we became a founding member of OneTen, a coalition of the world&#8217;s largest, best-known companies, that aims to hire one million Black Americans (with a specific focus on those without four-year college degrees) into good-paying, family-sustaining jobs over the next ten years. As a member of OneTen, Amgen is taking a leadership role in the greater Los Angeles region, where the company is headquartered, to help expand the coalition organizations that share our desire to offer opportunities to diverse talent. Other examples of actions that we are taking in this area include investment and participation in the Healthcare Businesswomen&#8217;s Association (a global organization focused on development and business networking for women in healthcare) and the UCLA Anderson School of Management leadership programs for women and underrepresented talent.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Consolidated EEO-1 Report can be viewed on our website at www.amgen.com (the website address is not intended to function as a hyperlink, and the information contained in our website is not intended to be a part of this filing).</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our Corporate Responsibility and Compliance Committee provided oversight of our policies, programs and initiatives focusing on workforce diversity and inclusion. In 2022, oversight of diversity, inclusion and belonging shifted to the Compensation and Management Development Committee, which also provides oversight of our human capital management.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_40"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about Our Executive Officers</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The executive officers of the Company as of February&#160;16, 2022, are set forth below. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Robert A. Bradway, age 59, has served as a director of the Company since 2011 and Chairman of the Board of Directors since 2013. Mr. Bradway has been the Company&#8217;s President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as the Company&#8217;s President and Chief Operating Officer. Mr. Bradway joined the Company in 2006 as Vice President, Operations Strategy, and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining the Company, Mr. Bradway was a Managing Director at Morgan Stanley in London, where, beginning in 2001, he had responsibility for the firm&#8217;s banking department and corporate finance activities in Europe. Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes, defense, space and securities systems, since 2016. He has served on the board of trustees of the University of Southern California since 2014. From 2011 to 2017, Mr. Bradway was a director of Norfolk Southern Corporation, a transportation company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Murdo Gordon, age 55, became Executive Vice President, Global Commercial Operations, in 2018. Prior to joining the Company, Mr. Gordon was Chief Commercial Officer at BMS, a pharmaceutical company, from 2016 to 2018. Mr. Gordon served as Head of Worldwide Markets at BMS from 2015 to 2016. Prior to this, Mr. Gordon served in a variety of leadership roles at BMS for more than 25 years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Jonathan P. Graham, age 61, became Executive Vice President, General Counsel and Secretary in 2019. Mr. Graham joined the Company in 2015. From 2015 to 2019, Mr. Graham was Senior Vice President, General Counsel and Secretary. Prior to joining Amgen, from 2006 to 2015, Mr. Graham was Senior Vice President and General Counsel at Danaher Corporation. From 2004 to 2006, Mr. Graham was Vice President, Litigation and Legal Policy, at General Electric Company (GE). Prior to GE, Mr. Graham was a partner at Williams &amp; Connolly LLP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Peter H. Griffith, age 63, became Executive Vice President and Chief Financial Officer in 2020. Mr. Griffith joined the Company in 2019 as Executive Vice President, Finance. Prior to joining Amgen, Mr. Griffith was President of Sherwood Canyon Group, LLC, a private equity firm. From 1997 to 2019, Mr. Griffith was a partner at EY, an accounting and professional services firm, and served in a variety of senior leadership roles, with his last position being Global Vice Chair, Corporate Development. Prior to EY, Mr. Griffith was a Managing Director and head of the investment banking division of Wedbush Securities Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Nancy A. Grygiel, age 54, became Senior Vice President and Chief Compliance Officer in 2020. Ms. Grygiel joined the Company in 2015. From 2016 to 2020, Ms. Grygiel was Vice President, Compliance. Prior to joining Amgen, from 2011 to 2015, Ms. Grygiel served as Vice President, Compliance, Corporate &amp; International, at Allergan, Inc. (Allergan). Prior to Allergan, Ms. Grygiel held several management positions at Mylan Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Lori A. Johnston, age 57, became Executive Vice President, Human Resources, in 2019. From 2016 to 2019, Ms. Johnston served as the Company&#8217;s Senior Vice President, Human Resources. From 2012 to 2016, Ms. Johnston was Executive Vice President and Chief Administrative Officer of Celanese Corporation (Celanese). Prior to Celanese, Ms. Johnston served in a series of progressive leadership roles at Amgen from 2001 to 2012, with her last position being Vice President, Human Resources. Prior to joining the Company, Ms. Johnston held human resources and other positions at Dell Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Rachna Khosla, age 49, became Senior Vice President, Business Development, in 2021. Ms. Khosla joined the Company in 2013 as Corporate Development Director. From 2016 to 2018, Ms. Khosla was Executive Director, Business Development, and from 2018 to 2021, was Vice President, Business Development. Prior to joining the Company, Ms. Khosla was a Director at Lazard Ltd. (Lazard) responsible for healthcare mergers and acquisitions. Prior to Lazard, Ms. Khosla had various roles at Credit Suisse Group AG, Sanofi Aventis, Aventis Capital, J.P. Morgan Chase &amp; Co., and Salomon Brothers, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. David M. Reese, age 59, became Executive Vice President, R&amp;D, in 2018. Dr. Reese joined the Company in 2005 and has held leadership roles in development, medical sciences and discovery research. Dr. Reese was Senior Vice President, Translational Sciences and Oncology, from 2017 to 2018 and Senior Vice President, Translational Sciences, from 2015 to 2017. Prior to joining Amgen, Dr. Reese was director of Clinical Research at the Breast Cancer International Research Group from 2001 to 2003 and a cofounder, president and chief medical officer of Translational Oncology Research International, a not-for-profit academic clinical research organization, from 2003 to 2005. Dr. Reese previously served on the faculty at UCLA and the University of California, San Francisco.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Esteban Santos, age 54, became Executive Vice President, Operations, in 2016. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. From 2008 to 2013, Mr. Santos held a number of Vice President roles at the Company in engineering, manufacturing, site operations and drug product. From 2013 to 2016, Mr. Santos was Senior Vice President, Manufacturing. Prior to joining the Company, Mr. Santos served as Site General Manager of J&amp;J&#8217;s Cordis operation in Puerto Rico. Prior to J&amp;J, Mr. Santos held several management positions in GE&#8217;s industrial and transportation businesses.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_43"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Area Financial Information</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial information concerning the geographic areas in which we operate, see Part IV&#8212;Note 3, Revenues and Note 11, Property, plant and equipment, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about us is available on our website at www.amgen.com. We make available on our website, free of charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or furnish it to the U.S. Securities and Exchange Commission (SEC). In addition, we have previously filed registration statements and other documents with the SEC. Any document we file may be inspected without charge at the SEC&#8217;s website at www.sec.gov. (These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing.)</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_49"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:9.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Economic Conditions and Operating a Global Business, Including During the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Government Regulations and Third-Party Policies</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business may be affected by litigation and government investigations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Competition</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our products face substantial competition and our product candidates are also likely to face substantial competition.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Research and Development</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not be able to develop commercial products despite significant investments in R&amp;D.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our current products and products in development cannot be sold without regulatory approval.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sale of our products.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Operations</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The effects of global climate change and related natural disasters could negatively affect our business and operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our stock price is volatile.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO ECONOMIC CONDITIONS AND OPERATING A GLOBAL BUSINESS, INCLUDING DURING THE COVID-19 PANDEMIC</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus identified in late 2019, SARS-CoV-2, which causes the disease known as COVID-19, is an ongoing global pandemic that has resulted in public and governmental efforts to contain or slow the spread of the disease, including widespread shelter-in-place orders, social distancing interventions, quarantines, travel restrictions and various forms of operational shutdowns. The COVID-19 pandemic and the resulting measures implemented in response to the pandemic are adversely affecting, and are expected to continue to adversely affect, our business (including our R&amp;D, clinical trials, operations, manufacturing, supply chains, distribution systems, product development and sales activities), the business activities of our suppliers, customers, third-party payers and our patients. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">see also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Due to the pandemic and these measures and their effects, we have experienced, and expect to continue to experience, unpredictable reductions in demand for certain of our products, exacerbated by COVID-19 surges resulting in repeated shutdowns and/or disruptions in certain geographies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and local, and international governmental policies and initiatives designed to reduce the transmission of COVID-19 also have resulted in the cancellation or delay of diagnostic, elective, specialty and other procedures and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. For example, an NPR/Harvard poll in 2021 found that, with hospitals crowded from COVID-19, one in five U.S. households has had to delay care for serious illnesses. These measures and challenges will likely continue to varying degrees for the duration of the pandemic and have significantly reduced patient access to, and administration of, certain of our drugs. For example, Prolia requires administration by a healthcare provider in doctors&#8217; offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia instructs healthcare professionals who discontinue Prolia to transition the patient to an alternative antiresorptive, including oral treatments that do not require administration by a healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting therapies that are less immunosuppressive or therapies that do not require administration in a hospital setting, potentially adversely affecting sales of certain of our products. Also, new patients have been, and are expected to continue to be, less likely to be diagnosed and/or to start therapeutics during the pandemic, and these effects, together with the lower treatment rates during the pandemic, have had, and are expected to continue to have, a cumulative negative effect on the commercial performance of our business. The decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business. Once the pandemic subsides, we anticipate there could be a backlog of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate lower provider capacity, and this lower provider capacity could have a continued adverse effect on our sales following the opening up of various geographies and/or the end of the pandemic. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences among healthcare professionals and patients toward treatments that do not require administration by healthcare professionals or visits to medical facilities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the pandemic continues, and if conditions worsen or if the duration of the pandemic extends significantly, we expect to experience additional adverse effects on our development, operational and commercial activities, customer purchases and our collections of accounts receivable. It remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections as conditions begin to improve. There was a resurgence in COVID-19 infections in numerous jurisdictions in 2021, resulting in the reinstatement of stricter restrictions and shutdowns in a number of jurisdictions, including in the United States, Europe and Asia Pacific regions. It is expected that the pandemic will continue to ebb and flow, with different jurisdictions having higher levels of infections than others over the course of the pandemic. New variants of the SARS-CoV-2 virus have emerged, including the delta and omicron variants, and have been shown to be present in many geographies and appear to spread more easily and quickly than other variants. Further, although some studies suggest that antibodies generated with currently authorized vaccines may be effective against these variants, it remains uncertain whether currently available vaccines will retain their efficacy against future variants of the virus. Further, even while vaccine booster shots are available for certain patients, persistent vaccine hesitancy may result in under-vaccinated populations which may prolong the duration of the COVID-19 pandemic and continue to disrupt the availability of healthcare services to the patients we serve. Jurisdictions may implement, continue or reinstate border closures, impose or reimpose prolonged quarantines and further restrict travel and business activity. These measures could significantly affect our ability to support our operations and customers and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, disrupt the movement of our products through the supply chain, and further prevent or discourage patients from participating in our clinical trials, seeking healthcare services and the administration of certain of our products. The increased availability of remote working arrangements in response to the COVID-19 pandemic has expanded the pool of companies that can compete for our employees and employment candidates. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliers may elect to, or governments may require us or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships and financial results. In the United States, on January 21, 2021, President Biden issued an Executive Order instructing federal agencies to use all available legal authorities, including the Defense Production Act, to improve current and future pandemic response and biological threat preparedness. The rapid reallocation of resources for the treatment and prevention of COVID-19 (including the production of COVID-19 vaccinations or related therapies, such as our agreement to contribute to the production of COVID-19 antibody therapies for Lilly) and/or disruptions and shortages in the global supply chain caused by the pandemic, could also result in increased competition for, or reduced availability of, materials or components used in the development, manufacturing, distribution, or administration of our products. For example, during the second quarter of 2021, an industry-wide shortage of certain lab kit supplies necessary for some activities that support our clinical trials has developed that we are actively monitoring and managing. We have also experienced challenges in obtaining certain COVID-19-related supplies, including COVID-19 antigen rapid test kits for our staff, as a result of high demand and limited supplies during the omicron variant surge. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the volatile global economic conditions stemming from it may precipitate or amplify the other risks described in this &#8220;Risk Factors&#8221; section, which could materially adversely affect our business, operations and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial condition and results. For example, if a natural disaster or other potentially disruptive event occurs concurrently with the COVID-19 pandemic, such disaster or event could deplete our inventory levels and we could experience a disruption to our manufacturing or ability to supply our products.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid development and fluidity of the pandemic precludes any prediction as to the ultimate effect of COVID-19 on us. The duration of the measures being taken by the authorities to mitigate against the spread of COVID-19 (including the distribution and/or availability of vaccines and boosters), and the extent to which such measures are effective, if at all, remain highly uncertain. The magnitude and degree of COVID-19&#8217;s adverse effect on our business (including our product development, product sales, operating results and resulting cash flows) and financial condition will be driven by the severity and duration of the pandemic, the pandemic&#8217;s effect on the United States and global economies and the timing, scope and effectiveness of federal, state, local and international governmental responses to the pandemic. If mitigation of the pandemic continues to require further shelter-in-place and shutdown orders and/or restrictions on individual and/or group conduct, any adverse effects of the COVID-19 pandemic will likely grow and could be enduring, and our business and financial position could be materially adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve our business objectives, we rely on sophisticated information technology systems, including software, mobile applications, cloud services and network-connected control systems, some of which are managed, hosted, provided or serviced by third parties. Internal or external events that compromise the confidentiality, integrity and availability of our systems and data may significantly interrupt the operation of our business, result in significant costs and/or adversely affect our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems are highly integrated into our business, including our R&amp;D efforts, our clinical and commercial manufacturing processes and our product sales and distribution processes. Further, as the majority of our employees are working remotely, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase. The complexity and interconnected nature of our systems makes them potentially vulnerable to breakdown or other service interruptions. Upgrades or changes to our systems or the software that we use may result in the introduction of new cybersecurity vulnerabilities and risks. Our systems are also subject to frequent cyberattacks. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of harmful and virulent malware, including ransomware or other denials of service, that can be deployed through various means, including the software supply chain, e-mail, malicious websites and/or the use of social engineering. We have also experienced denial of service attacks against our network, and although such attacks did not succeed, there can be no assurance that our efforts to guard against the wide and growing variety of potential attack techniques will be successful in the future. Attacks such as those experienced by governmental entities (including those that approve and/or regulate our products, such as the EMA) and other multi-national companies, including some of our peers, could leave us unable to utilize key business systems or access or protect important data, and could have a material adverse effect on our ability to operate our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. For example, in 2017, a pharmaceutical company experienced a cyberattack involving virulent malware that significantly disrupted its operations, including its research and sales operations and the production of some of its medicines and vaccines. As a result of the cyberattack, its orders and sales for certain products in certain markets were negatively affected. In December 2020, SolarWinds Corporation, a leading provider of software for monitoring and managing information technology infrastructure, disclosed that it had suffered a cybersecurity incident whereby attackers had inserted malicious code into legitimate software updates for its products that were installed by myriad private and government customers, enabling the attackers to access a backdoor to such systems. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systems also contain and utilize a high volume of sensitive data, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials and/or personal information belonging to us, our staff, our patients, customers and/or other parties. In some cases, we utilize third-party service providers to process, store, manage or transmit such data, which may increase our risk. Intentional or inadvertent data privacy or security breaches (including cyberattacks) resulting from attacks or lapses by employees, service providers (including providers of information technology-specific services), nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, &#8220;hacktivists&#8221; or others, create risks that our sensitive data may be exposed to unauthorized persons, our competitors, or the public. For example, a supplier recently experienced a data breach in which an unauthorized third party acquired access to certain information provided to the supplier in the course of its provision of services to us, including business documents and certain personally identifiable patient information (not including social security or other financial or health insurance information). As required, we promptly notified the applicable state attorneys general and the individuals whose personally identifiable information was affected of this data breach at the supplier. Although the supplier data breach did not result in a material adverse effect on our business, there can be no assurance that a similar </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future cybersecurity incident would not result in a material adverse effect on our business or results of operations. Another vendor experienced a cyberattack and, while initially reporting that our information was not involved, the vendor subsequently informed us that the attacker had accessed limited, non-significant information. Although this breach did not have a significant adverse effect on us, we may not receive timely reporting of future breaches. Cyberattackers are increasingly exploiting vulnerabilities in commercially available software from shared or open-source code. We rely on third party commercial software that may have such vulnerabilities, but as use of open-source code is frequently not disclosed, our ability to fully assess this risk to our systems is limited. For example, in December 2021, a remote code execution vulnerability was discovered in a widely used software library that is used in a variety of commercially available software and services. Although this vulnerability has not resulted in any significant adverse effects on us, there can be no assurances that a similar future vulnerability in the software and services that we use would not result in a material adverse effect on our business or results of operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and global government regulators, our business partners, suppliers with whom we do business, companies that provide us or our partners with business services, and companies we have or may acquire face similar risks, and security breaches of their systems or service outages could adversely affect our security, leave us without access to important systems, products, raw materials, components, services or information or expose our confidential data or sensitive personal information. For example, in 2019, two vendors that perform testing and analytical services that we use in developing and manufacturing our products experienced cyberattacks, and in April and September of 2020, vendors that provide us with information technology services and clinical data services, respectively, each experienced ransomware attacks. Although there was no breach of our systems, each of these incidents required us to disconnect our systems from those vendors&#8217; systems. While we were able to reconnect our systems following restoration of these vendors&#8217; capabilities without significantly affecting product availability, a more extended service outage affecting these or other vendors, particularly where such vendor is the single source from which we obtain the services, could have a material adverse effect on our business or results of operations. In addition, we distribute our products in the United States primarily through three pharmaceutical wholesalers, and a security breach that impairs the distribution operations of our wholesalers could significantly impair our ability to deliver our products to healthcare providers and patients.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have experienced system breakdowns, attacks and information security breaches, we do not believe such breakdowns, attacks and breaches have had a material adverse effect on our business or results of operations. We continue to invest in the monitoring, protection and resilience of our critical and/or sensitive data and systems. However, there can be no assurances that our efforts will detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks and/or breaches of our systems that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in material financial, legal, business or reputational harm to us or negatively affect our stock price. While we maintain cyber-liability insurance, our insurance is not sufficient to cover us against all losses that could potentially result from a service interruption, breach of our systems or loss of our critical or sensitive data.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, we are subject to the European Union&#8217;s General Data Protection Regulation, which became effective in May 2018, and the California Consumer Privacy Act of 2018 (CCPA), which became effective in January 2020, both of which provide for substantial penalties for non-compliance. The CCPA was amended in late 2020, to create the California Privacy Rights Act to create opt-in requirements for the use of sensitive personal data and the formation of a new dedicated agency for the enforcement of the law, the California Privacy Protection Agency. Since then, Virginia and Colorado both passed similar consumer privacy laws that will go into effect in 2023. Other jurisdictions where we operate have passed, or continue to propose, similar legislation and/or regulations. Failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue our expansion efforts in emerging markets around the world, through acquisitions and licensing transactions as well as through the development and introduction, both independently and through collaborations such as our collaboration with BeiGene, of our products in new markets, we face numerous risks to our business. There is no guarantee that our efforts and strategies to expand sales in emerging markets will succeed. Our international business, including in China and emerging market countries, may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability, including issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues. If relations between the United States and other governments deteriorate, our business and investments such markets may also be adversely affected. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements including those previously utilized by companies we partner with or acquire </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in emerging markets. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our expansion efforts in China and emerging markets around the world is dependent upon the establishment of an environment that is predictable, navigable and supportive of biopharmaceutical innovation, sustained access for our products and predictable pricing controls. For example, China continues to strengthen regulations on the collection, use and transmission of Chinese human genetic resources, and has expanded regulations on the conduct of biotechnology R&amp;D activities in China. Our applications to the HGRAC seeking approval to conduct clinical trials in China are delayed pending further guidance from HGRAC. Our international operations and business may also be subject to less protective intellectual property or other applicable laws, diverse data privacy and protection requirements, changing tax laws and tariffs, trade restrictions or other barriers designed to protect industry in the home country against foreign competition, far-reaching antibribery and anticorruption laws and regulations and/or evolving legal and regulatory environments. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand internationally, we are subject to fluctuations in foreign currency exchange rates relative to the U.S. dollar. While we have a program in place that is designed to reduce our exposure to foreign currency exchange rate fluctuations through foreign currency hedging arrangements, our hedging efforts do not completely offset the effect of these fluctuations on our revenues and earnings. In addition, we have a number of financial instruments referencing the LIBOR. On July 27, 2017, the U.K. Financial Conduct Authority, which regulates LIBOR, announced that it will no longer require banks to submit rates for the calculation of LIBOR to the LIBOR administrator after 2021, and it is anticipated that LIBOR will be completely phased out and replaced by 2023. In March 2020 and in January 2021, the FASB issued a new accounting standard to ease the financial burdens of the expected market transition from LIBOR and other interbank offered rates to alternative reference rates. While it appears likely that SOFR will be the replacement reference rate adopted in the market, the specific mechanisms to replace LIBOR in our existing LIBOR-linked financial instruments have not been finalized. As such, the replacement of LIBOR could have an adverse effect on the market for, or value of, our LIBOR-linked financial instruments. See Part IV&#8212;Note 1, Summary of significant accounting policies&#8212;Recent accounting pronouncements. We are also subject to the economic and political uncertainties stemming from the United Kingdom&#8217;s exit from the EU, commonly referred to as &#8220;Brexit,&#8221; which occurred on January 31, 2020. While our manufacturing and packaging activities take place largely outside the United Kingdom, minimizing the need to make costly and significant changes to those operations, we have nevertheless been working to put in place contingency plans to attempt to mitigate the effects of Brexit on us. Overall, the legal and operational challenges of our international business operations, along with government controls, the challenges of attracting and retaining qualified personnel and obtaining and/or maintaining necessary regulatory or pricing approvals of our products, may result in material adverse effects on our international product sales, business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO GOVERNMENT REGULATIONS AND THIRD-PARTY POLICIES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. These payers are increasingly focused on costs, which have resulted, and are expected to continue to result, in lower reimbursement rates for our products or narrower populations for whom payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced in an attempt to lower drug prices. These include proposals that would allow the U.S. government to negotiate drug prices directly, limit drug reimbursement in Medicare and/or the commercial market based on reference prices or permit importation of drugs from Canada. Additional proposals would require a rebate to the government for any price increase in excess of the Consumer Price Index for All Urban Consumers and/or to shift some of the costs of these Medicare Part D reforms to manufacturers to offset the cost. Certain proposals focused on drug pricing have been adopted and additional proposals are likely to be adopted and implemented in some form. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing U.S. federal coverage and reimbursement policies and practices have affected, and may continue to affect access to, pricing and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See Part I, Item 1. Business&#8212;Reimbursement. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. Congress has been focused on drug pricing reforms and oversight since 2018, and this activity is still ongoing and has intensified.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, 2020 and 2021, a number of Congressional committees debated drug pricing reform proposals and, in 2020, Amgen participated in House Oversight and Reform Committee hearings on drug pricing practices. In 2019, the Senate Finance Committee advanced a bill that would, among other things, penalize pharmaceutical manufacturers for raising prices on drugs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covered by Medicare Parts B and/or D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries and require higher/additional manufacturer discounts in Medicare Part D. Additionally, in late 2019, a drug-pricing bill, H.R. 3, passed the House of Representatives, which would, among other things, enable direct price negotiations by the federal government on certain drugs (with the maximum price paid by Medicare capped by prices derived from an international index), include a penalty for failing to reach agreement with the government and require that manufacturers offer these negotiated prices to other payers. In 2021, proposals from H.R. 3 were incorporated and adapted into other proposed legislation. These proposals, which included penalties if drug price benchmarks rise faster than inflation, Medicare price setting for certain drugs paid for under Parts B and D (whereby manufacturers must accept a price established by the government or face a penalty on all U.S. sales), and Part D redesign including a cap on beneficiary spending and a new manufacturer discount program, are also likely to be considered in a reconciliation bill that remains to be further debated between the Senate, House and White House. This framework remains in discussion with policymakers in Congress and the Administration. There are other outstanding proposals that, if enacted and implemented in whole or in part, could also affect access to and sales of our products, including, but not limited to, proposals to allow importation of prescription medications from Canada or other countries. In July 2021, the Administration issued an Executive Order designed to address anticompetitive behavior across multiple sectors, and for the healthcare sector, called for, among other things, the FDA to work with states and Indian Tribes to develop prescription drug importation programs, more scrutiny of anticompetitive activity by the FTC, emphasized the need for actions to allow for greater competition from generics and biosimilars, and included a process and timeline for federal agencies to deliver ideas to address drug pricing to the Administration. Subsequently, in September 2021, HHS released a report that presented guiding principles for the Administration&#8217;s drug pricing proposals, including changes to promote competition throughout the prescription drug industry, highlighting potential legislative policies that Congress could pursue (including drug price negotiation in Medicare Parts B and D, making those negotiated prices available to commercial plans and legislation to speed the entry of biosimilar and generic drugs) and examples of potential administrative tools available to the HHS (including testing various models and enhanced focus of the FTC and the USPTO to address impediments to generic drug and biosimilar competition). Also, in response to the July 2021 Executive Order, the FDA sent a letter to the USPTO describing ways to strengthen coordination between the two agencies, offering training to help identify prior art, and seeking USPTO&#8217;s views on practices that extend market exclusivities, whether pharmaceutical patent examiners need additional resources, and the effect of post-grant challenges at the PTAB on drug patents. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted in 2021 has also contained drug pricing reforms, including the Infrastructure Investment and Jobs Act and the American Rescue Plan Act of 2021 that include provisions requiring, starting in 2023, manufacturers to provide refunds to the government for discarded amounts of drugs from single use containers under Medicare Part B, and starting in 2024, increases the Medicaid rebate liability for certain medicines that raise prices in excess of inflation, respectively. The Infrastructure Investment and Jobs Act also delays implementation until January 1, 2026 of a final rule issued by HHS, that revises regulations under the federal antikickback statute to encourage PBMs to use rebates received from biopharmaceutical manufacturers to reduce patient cost-sharing at the point of sale under Medicare Part D. This rule is also subject to litigation, has numerous logistical hurdles to overcome before it can be effectively implemented, and it is unclear how PBMs will respond to the implementation of such rule. Further, a permanent repeal of this rule is also being considered in other legislation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been, and is expected to continue to be, affected by changes in U.S. federal reimbursement policy resulting from federal regulations and federal demonstration projects. Over the past several years, federal agencies, including the CMS, announced a number of recommendations, policies, proposals and demonstration projects addressing drug pricing. The Administration has also developed and sought to advance a range of policy proposals that could impact U.S. federal reimbursement policy for drugs and biologics, including changes to Medicare Parts B and D. For example, in 2020, in response to an Executive Order, HHS released a rule to allow states to potentially enable the importation of certain drugs from Canada. While this rule is in litigation, should such litigation be unsuccessful, it could allow for the importation of Canadian versions of certain of Amgen&#8217;s products (including Otezla), that could have a material adverse effect on Amgen&#8217;s business. Also in response to an Executive Order, CMS released an interim final rule to implement the MFN pricing approach aimed at setting the reimbursement rate for 50 Medicare Part B drugs (including our products, such as Prolia, XGEVA, KYPROLIS, Neulasta, Nplate, EPOGEN and Aranesp) equal to the lowest adjusted price in 22 OECD nations for these drugs. In December 2021, subsequent to challenges, including procedural defects, CMS announced it was withdrawing the MFN rule. Notwithstanding the withdrawal of the rule, the MFN rule&#8217;s approach to drug pricing and other similar approaches remain of interest to policymakers. In connection with its withdrawal of the MFN rule, CMS noted that it will &#8220;&#8230; explore all options to incorporate value into payments for Medicare Part B drugs, improve beneficiaries&#8217; access to evidence-based care, and reduce drug spending for consumers and throughout the health care system.&#8221; Further, we expect continued significant focus on healthcare and similar drug pricing proposals for the foreseeable future, including proposals under which the government would set drug prices or limit drug reimbursement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS policy changes and demonstration projects to test new care, delivery and payment models can also significantly affect how drugs, including our products, are covered and reimbursed. For example, we believe that CMS&#8217; Oncology Care Model demonstration (which has since 2016 provided participating physician practices with performance-based financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incentives that aim to manage or reduce Medicare costs without negatively affecting the efficacy of care) has reduced utilization of certain of our oncology products by participating physician practices and expect that it will continue to do so in the future. Further, HHS&#8217;s September 2021 comprehensive plan to address drug pricing included potential future mandatory models that link payment for prescription drugs and biologics to factors such as: improved patient outcomes, reductions in health disparities, patient affordability and lower overall costs; bundled payment models; total cost of care models; models in which Medicare Part B savings from utilization of biosimilars, generics, or other high-value products are shared between prescribing providers and the government; additional Medicare Part D cost-sharing support for biosimilars and generics; and potential expansion of the Part D Senior Savings Model to additional classes of drugs. CMS also recently proposed a national coverage determination for Medicare which limits coverage of certain Alzheimer&#8217;s disease medications approved by the FDA only to patients in qualifying clinical trials, suggesting that regulatory approval does not necessarily result in full Medicare coverage. In this dynamic environment, particularly in light of the pressures on healthcare budgets as a result of the pandemic, we are unable to predict which or how many federal policy, legislative, regulatory, executive or administrative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that these or other federal government initiatives further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our U.S. products, or limit our ability to offer co-pay payment assistance to commercial patients, such actions could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require a biopharmaceutical manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts. CMS finalized a rule in December 2020 providing that, starting January 1, 2023, unless a manufacturer can ensure that the full amount of manufacturer patient assistance programs is passed on to the patient, such amount will be treated as a price reduction that will be taken into account when reporting our Best Price and/or Average Manufacturer Price. Given the use by PBMs and insurers of copay accumulator adjustment programs to apply such patient assistance for the benefit of such companies and not to defray costs to patients, it could be difficult to impossible for manufacturers to ensure that the full value of such amounts is being passed on to the patient. This new policy, if implemented, would have significant implications for our ability to offer copay assistance programs. Although implementation has been delayed by the current Administration, the prior Administration finalized a rule (which was to be effective January 1, 2022) mandating price and cost-sharing transparency for almost all health plans and insurers in the individual and group commercial markets. Additionally, the Administration recently finalized transparency provisions required under the Consolidated Appropriations Act of 2021 for health plans and insurer reporting of certain drug pricing information by December 27, 2022, and each June thereafter, resulting in a biennial public report highlighting drug pricing trends and the impact of prescription drug costs on premiums and out-of-pocket costs. It is unclear how group health plans and health insurers may respond.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing reimbursement and pricing actions in various states have negatively affected, and may continue to negatively affect, access to, and have affected, and may continue to affect, sales of our products</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, government actions or ballot initiatives can also affect how our products are covered and reimbursed and/or create additional pressure on our pricing decisions. A number of states have adopted, and many other states are considering, drug importation programs or other new pricing actions, including proposals designed to require biopharmaceutical manufacturers publicly to report proprietary pricing information, limit price increases or place a maximum price ceiling or cap on biopharmaceutical products. Existing and proposed state pricing laws have added complexity to the pricing of drugs and may already be affecting industry pricing decisions. For example, a California law, the constitutionality of which is currently being challenged, purports to require biopharmaceutical manufacturers to notify health insurers and government health plans at least 60 days before scheduled prescription drug price increases that exceed certain thresholds. Similar laws exist in Oregon and Washington. States are also seeking to change the way they pay for drugs for patients covered by state programs. California adopted a 2020-21 budget that incorporates international pricing into Medicaid supplemental rebate negotiations and allows its Medicaid program to seek federal approval to extend supplemental rebates to non-Medicaid populations. New York, Massachusetts and Ohio have established Medicaid drug spending caps, and additional states may consider doing so as they face budget deficits from the effects of COVID-19. Additionally, Colorado, Florida, Maine, New Hampshire, New Mexico and Vermont have enacted laws, and several other states have proposed laws, to facilitate the importation of drugs from Canada. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs. Ultimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;U.S. commercial payer actions have affected and may continue to affect access to and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from the consolidation of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient copay or coinsurance obligations and more significant limitations on patients&#8217; use of manufacturer commercial copay assistance programs. Further, government regulation of payers may affect these trends. For example, CMS finalized a policy in May 2020 (for plan years starting on or after January 1, 2021, and remains standing policy for 2022) that has caused commercial payers to more widely adopt copay accumulator adjustment programs. Payers have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, particularly in treatment areas where the payer has taken the position that multiple branded products are therapeutically comparable. Payers also control costs by imposing restrictions on access to or usage of our products, such as Step Therapy, or requiring that patients receive the payer&#8217;s prior authorization before covering the product or that patients use a mail-order pharmacy or a limited network of payer fully-owned mail-order or specialty pharmacies. Payers have also chosen to exclude certain indications for which our products are approved or chosen to exclude coverage entirely. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet payer utilization management criteria, and these requirements have limited, and may continue to limit, patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers, including PBMs that administer Medicare Part D prescription drug plans. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. For example, in late 2018 and early 2019, in response to a very high percentage of Medicare patients abandoning their Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescriptions rather than pay their co-pay payment, we introduced a set of new National Drug Codes to make Repatha available at a lower list price to attempt to address affordability for patients, particularly those on Medicare, and on December 31, 2019, we discontinued the higher list price option for Repatha. Despite these net and list price reductions, some payers have restricted, and may continue to restrict, patient access and have and may continue to change formulary coverage for Repatha, seek further discounts or rebates or take other actions that could reduce our sales of Repatha. These factors have limited, and may continue to limit, patient affordability and use, and negatively affect Repatha sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in the United States, as of the beginning of 2021, the top five integrated health plans and PBMs controlled about 85% of all pharmacy prescriptions. The consolidation among insurers, PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers, and has resulted in greater price discounts, rebates and service fees realized by those payers. In 2019, 2020 and 2021, CVS, Express Scripts and United Health Group, respectively, each created Rebate Management Organizations that further increase their respective leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage or plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse effect on our product sales, business and results of operations. Policy reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or consequences for our business and how we interact with these entities. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Part I, Item 1. Business&#8212;Reimbursement. IRP has been widely used by many countries outside the United States to control costs based on an external benchmark of a product&#8217;s price in other countries. IRP policies can change quickly and frequently and may not reflect differences in the burden of disease, indications, market structures, or affordability differences across countries or regions. Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and percentage caps on price increases, are used in various foreign jurisdictions as well. In addition, countries may refuse to reimburse or may restrict the reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA&#8217;s approval of Repatha for the treatment of patients with established atherosclerotic disease, the reimbursement for Repatha in France prior to 2020 was limited to a narrower patient population (such as those with HoFH) following a national health technology assessment, which had limited our efforts in France to expand Repatha access to the broader patient population covered by the approved label. Some countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement, or a decline in the timeliness or certainty of payment by payers to physicians and other providers has negatively affected, and may further negatively affect, the ability or willingness of healthcare providers to prescribe our products for their patients and otherwise negatively affect the use of our products or the prices we realize for them. Such changes have had, and could in the future have, a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guidelines and recommendations published by various organizations can reduce the use of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies promulgate regulations and guidelines directly applicable to us and to our products. Professional societies, practice management groups, insurance carriers, physicians&#8217; groups, private health and science foundations and organizations involved in various diseases also publish guidelines and recommendations to healthcare providers, administrators and payers, as well as patient communities. Recommendations by government agencies or other groups and organizations may relate to such matters as usage, dosage, route of administration and use of related therapies. In addition, a growing number of organizations are providing assessments of the value and pricing of biopharmaceutical products, and even organizations whose guidelines have historically been focused on clinical matters have begun to incorporate analyses of the cost effectiveness of various treatments into their treatment guidelines and recommendations. Value assessments may come from private organizations that publish their findings and offer recommendations relating to the products&#8217; reimbursement by government and private payers. Some companies and payers have announced pricing and payment decisions based in part on the assessments of private organizations. In addition, government health technology assessment organizations in many countries make reimbursement recommendations to payers in their jurisdictions based on the clinical effectiveness, cost-effectiveness and service effects of new, emerging and existing medicines and treatments. Such health technology assessment organizations have recommended, and may in the future recommend, reimbursement for certain of our products for a narrower indication than was approved by applicable regulatory agencies or may recommend against reimbursement entirely. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such recommendations or guidelines may affect our reputation, and any recommendations or guidelines that result in decreased use, dosage or reimbursement of our products could have a material adverse effect on our product sales, business and results of operations. In addition, the perception by the investment community or stockholders that such recommendations or guidelines will result in decreased use and dosage of our products could adversely affect the market price of our common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and other taxes in the United States and other jurisdictions in which we do business. As a result, our provision for income taxes is derived from a combination of applicable tax rates in the various places we operate. Significant judgment is required for determining our provision for income tax.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts, and such tax authorities (including the IRS) are becoming more aggressive in their audits and are particularly focused on such matters. In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS administrative appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for 2010, 2011 and 2012 that we received in May and July 2021 which seek to increase our U.S. taxable income. We firmly believe that the IRS&#8217;s positions set forth in the Notices are without merit, and are contesting the Notices through the judicial process. See Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations, Income Taxes, and Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office. We were unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a statutory notice of deficiency for these years as well. We expect to contest any such notice related to 2013&#8211;15 through the judicial process. We are also currently under examination by the IRS for the years 2016, 2017 and 2018 and by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes and results of operations in the future could be adversely affected by changes to our operating structure, changes in the mix of income and expenses in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities and changes in applicable tax laws, regulations or administrative interpretations thereof. The 2017 Tax Act is complex and a large volume of regulations and guidance has been issued and could be subject to different interpretations. We could face audit challenges to our application of the 2017 Tax Act. The Administration proposed and Congress is considering significant changes to existing tax law. These changes, if enacted, could substantially increase taxes we pay to the U.S. government. Further, the OECD recently reached agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, this agreement could result in tax increases in both the United States and foreign jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning 2023, which will increase our U.S. tax liability. The U.S. territory of Puerto Rico is considering changes to its tax system that may minimize or eliminate this impact, but the outcome of such potential changes are uncertain. Changes to existing tax law in the United States, the U.S. territory of Puerto Rico, or other jurisdictions, including the potential changes discussed above, could result in tax increases where we do business and could have a material adverse effect on the results of our operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are involved in legal proceedings. See Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. Civil and criminal litigation is inherently unpredictable, and the outcome can result in costly verdicts, fines and penalties, exclusion from federal healthcare programs and/or injunctive relief that affect how we operate our business. Defense of litigation claims can be expensive, time consuming and distracting, and it is possible that we could incur judgments or enter into settlements of claims for monetary damages or change the way we operate our business, which could have a material adverse effect on our product sales, business and results of operations. In addition, product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and for products we sell after regulatory approval. Product liability claims, regardless of their merits, could be costly and divert management&#8217;s attention and could adversely affect our reputation and the demand for our products. We and certain of our subsidiaries have previously been named as defendants in product liability actions for certain of our products.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in government investigations that arise in the ordinary course of our business. In recent years, there has been a trend of increasing government investigations and litigations against companies operating in our industry, both in the United States and around the world. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our business activities outside of the United States are subject to the FCPA and similar antibribery or anticorruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. We cannot ensure that all our employees, agents, contractors, vendors, licensees, partners or collaborators will comply with all applicable laws and regulations. On April 25, 2019, we entered into a settlement agreement with the DOJ and the OIG of the HHS to settle certain allegations relating to our support of independent charitable organizations that provide patients with financial assistance to access their medicines. As a result, we entered into a corporate integrity agreement with the OIG that requires us to maintain a corporate compliance program and to undertake a set of defined corporate integrity obligations for a period of five years. While we expect to fully comply with all of our obligations under the corporate integrity agreement, failure to do so could result in substantial penalties and potential exclusion from government healthcare programs. We may also see new government investigations of or actions against us citing novel theories of recovery. For example, prosecutors are placing greater scrutiny on patient support programs, including commercial copay assistance programs, and further enforcement actions and investigations regarding such programs could limit our ability to provide co-pay assistance to commercial patients. Greater scrutiny has also been placed on sponsorships, speaker programs and other arrangements where healthcare professionals receive remuneration, travel or other value to participate in certain events, and further enforcement actions could limit our ability to participate in such arrangements. Any of these results could have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO COMPETITION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products face substantial competition and our product candidates are also likely to face substantial competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. We expect that our products and product candidates will compete with existing drugs, new drugs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently in development, drugs currently approved for other indications that may later be approved for the same indications as those of our products and drugs approved for other indications that are used off-label. Large pharmaceutical companies and generics manufacturers of pharmaceutical products have expanded into, and are expected to continue expanding into, the biotechnology field, and some pharmaceutical companies and generics manufacturers have formed partnerships to pursue biosimilars. With the proliferation of companies pursuing biopharmaceuticals, a number of our product candidates may enter markets with one or more competitors or with competitors soon to arrive. For example, several of our biosimilar products have entered into markets with one or more existing competitors. In addition, some of our competitors may have technical, competitive or other advantages over us for the development of technologies and processes or greater experience in particular therapeutic areas, and consolidation among pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to compete with them successfully to discover, develop and market new products and for our current products to compete with new products or new product indications they may bring to market. As a result, our products have been competing and may continue to compete, and our product candidates may compete, against products or product candidates that offer higher rebates or discounts, lower prices, equivalent or superior efficacy, better safety profiles, easier administration, earlier market availability or other competitive features. If we are unable to compete effectively, this could reduce sales, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often involve complex legal, scientific and factual questions. Driven by cost pressures, efforts to limit or weaken patent protection for our industry are increasing. For example, the COVID-19 pandemic has resulted in increased interest in compulsory licenses, march-in rights or other governmental interventions, both in the United States and internationally, related to the procurement of drugs. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties have challenged and may continue to challenge, invalidate or circumvent our patents and patent applications relating to our products, product candidates and technologies. Challenges to patents may come from potential competitors or from parties other than those who seek to market a potentially-infringing product. In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not infringe our patents. For certain of our product candidates, there are third parties who have patents or pending patent applications that they may claim necessitate payment of a royalty or prevent us from commercializing these product candidates in certain territories. Patent disputes are frequent, costly and can preclude, delay or increase the cost of commercialization of products. We have been in the past, are currently and expect to be in the future, involved in patent litigation. These matters have included, and may in the future include, litigation with manufacturers of products that purport to be biosimilars of certain of our products for patent infringement and for failure to comply with certain provisions of the BPCIA. A determination made by a court, agency or tribunal concerning infringement, validity, enforceability, injunctive or economic remedy, or the right to patent protection, for example, are typically subject to appellate or administrative review. Upon review, such initial determinations may be afforded little or no deference by the reviewing tribunal and may be affirmed, reversed or made the subject of reconsideration through further proceedings. A patent dispute or litigation has not discouraged, and may not in the future discourage, a potential violator from bringing the allegedly infringing product to market prior to a final resolution of the dispute or litigation. The period from inception until resolution of a patent dispute or litigation is subject to the availability and schedule of the court, agency or tribunal before which the dispute or litigation is pending. We have been, and may in the future be, subject to competition during this period and may not be able to recover fully from the losses, damages and harms we incur from infringement by the competitor product even if we prevail. Moreover, if we lose or settle current or future litigations at certain stages or entirely, we could be subject to competition and/or significant liabilities, be required to enter into third-party licenses for the infringed product or technology or be required to cease using the technology or product in dispute. In addition, we cannot guarantee that such licenses will be available on terms acceptable to us, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the Hatch&#8211;Waxman Act, our products approved by the FDA under the FDCA have been, and may in the future be, the subject of patent litigation with generics competitors before expiry of the five-year period of data exclusivity provided for under the Hatch-Waxman Act and prior to the expiration of the patents listed for the product. Likewise, our innovative biologic products have been, and may in the future be, the subject of patent litigation prior to the expiration of our patents and, with respect to competitors seeking approval as a biosimilar or interchangeable version of our products, prior to the 12-year exclusivity period provided under the BPCIA. In addition, we have faced, and may in the future face, patent litigation involving claims that the biosimilar product candidates we are working to develop infringe the patents of other companies, including those that manufacture, market or sell the applicable reference products or who are developing or have developed other biosimilar versions of such products. Alternatively, patents held by other entities have contributed, and may in the future </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contribute, to a decision by us to not pursue all of the same labeled indications as are held by these companies. Due to the COVID-19 pandemic, there have been delays in ongoing or new patent office and court proceedings in the United States and abroad that have delayed the outcome of such proceedings. While we have attempted, and expect to continue to attempt, to challenge the patents held by other companies, our efforts may be unsuccessful. For examples of and information related to our patent litigation, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the existing patents on our products have expired or will soon expire. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Patents. As our patents expire, competitors are able to legally produce and market similar products or technologies, including biosimilars, which has had, and may continue to have, a material adverse effect on our product sales, business and results of operations. In addition, competitors have been, and may continue to be, able to invalidate, design around or otherwise circumvent our patents and sell competing products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics in most of the territories in which we operate, including the United States and Europe, and we expect to face increasing biosimilar and/or generics competition this year and beyond. Expiration or successful challenge of applicable patent rights or expiration of an applicable exclusivity period has accelerated such competition, and we expect to face more litigation regarding the validity and/or scope of our patents. Our products have also experienced greater competition from lower cost biosimilars or generics that come to market when branded products that compete with our products lose their own patent protection. To the extent that governments adopt more permissive regulatory approval standards and competitors are able to obtain broader or expedited marketing approval for biosimilars and generics, the rate of increased competition for our products could accelerate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biosimilars are evaluated for marketing authorization pursuant to a set of general and product class-specific guidelines. In addition, in an effort to spur biosimilar utilization and/or increase potential healthcare savings, some EU countries and some Canadian provinces have adopted, or are considering the adoption of, biosimilar uptake measures such as physician prescribing quotas or automatic pharmacy substitution of biosimilars for the corresponding reference products. Some EU countries impose automatic price reductions upon market entry of one or more biosimilar competitors. While the degree of competitive effects of biosimilar competition differs between EU countries and between products, in the EU the overall use of biosimilars and the rate at which product sales of innovative products are being affected by biosimilar competition is increasing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the BPCIA authorizes the FDA to approve biosimilars via a separate, abbreviated pathway. See Item 1. Business&#8212;Government Regulation&#8212;Regulation in the United States&#8212;Approval of Biosimilars. In the United States, the FDA has approved numerous biosimilars, including biosimilar versions of Neulasta, EPOGEN and ENBREL, and a growing number of companies have announced that they are also developing biosimilar versions of our products. Four biosimilar versions of Neulasta are now marketed in the United States, and we expect other biosimilar versions of Neulasta to receive approval in 2022 and beyond. Impact to our Neulasta sales has accelerated as additional competitors have launched. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. An approved biosimilar version of EPOGEN has also launched in the United States. Manufacturers of biosimilars have attempted, and may in the future attempt, to compete with our products by offering lower list prices, greater discounts or rebates, or contracts that offer longer-term pricing or a broader portfolio of other products. Companies pursuing development of biosimilar versions of our products have challenged and may continue to challenge our patents well in advance of the expiration of our material patents. For examples of and information related to our biosimilars and generics patent litigation, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail to prevail in current and future intellectual property litigation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. biosimilar pathway includes the option for biosimilar products that meet certain criteria to be approved as interchangeable with their reference products. Some companies currently developing or already marketing biosimilars may seek to obtain interchangeable status from the FDA, which could potentially allow pharmacists to substitute those biosimilars for our reference products without prior approval from the prescriber in most states. The FDA approved the first interchangeable biosimilar in July 2021, and subsequently granted an interchangeability designation to a second biosimilar in October 2021. In November 2019, the FDA issued draft guidance that provides that comparative immunogenicity studies will not generally be expected for biosimilar and interchangeable insulin products. This may open the door for other product-specific guidance development and the removal of the expectation for certain studies, which may contribute to increased biosimilar competition for our innovative products. For example, the FDA 2021 guidance agenda lists four guidances related to biosimilars, including documents that address exclusivity for the first interchangeable biological product, and product class-specific recommendations for developing biosimilars and interchangeables.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, critics of the 12-year exclusivity period in the biosimilar pathway law will likely continue to seek to shorten the data exclusivity period and/or to encourage the FDA to interpret narrowly the law&#8217;s provisions regarding which new </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products receive data exclusivity. In late 2019, the previous Administration agreed to remove from the United States-Mexico-Canada Agreement a requirement for at least 10 years of data exclusivity for biologic products. Also, the FDA is considering whether subsequent changes to a licensed biologic would be protected by the remainder of the reference product&#8217;s original 12-year exclusivity period (a concept known in the generic drug context as &#8220;umbrella exclusivity&#8221;). If the FDA were to decide that umbrella exclusivity does not apply to biological reference products or were to make other changes to the exclusivity period, this could expose us to biosimilar competition at an earlier time. There also have been, and may continue to be, legislative and regulatory efforts to promote competition through policies enabling easier generic and biosimilar approval and commercialization, including efforts to lower standards for demonstrating biosimilarity or interchangeability, limit patents that may be litigated and/or patent settlements, implement preferential reimbursement policies for biosimilars and pass new laws requiring more disclosure in the FDA&#8217;s Orange and Purple Books. For example, in 2021 the FDA sent a letter to the USPTO describing ways to strengthen coordination between the two agencies, offered training to help identify prior art, and seeking USPTO&#8217;s views on practices that extend market exclusivities, whether pharmaceutical patent examiners need additional resources, and the effect of post-grant challenges at the PTAB on drug patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the expiration or loss of patent protection and/or applicable exclusivity for one of our small molecule products, we can lose the majority of revenues for that product in a very short period of time. See Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. Additionally, if one of our small molecule products is the subject of an FDA Written Request for pediatric studies and we are unable to adequately complete these studies, we may not obtain the pediatric exclusivity award that extends existing patents and unexpired regulatory exclusivity for the product by an additional six months. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are unable to predict the precise effects of biosimilars and generics on our products, we are currently facing and expect to face greater competition in the United States, Europe and elsewhere as a result of biosimilar and generic competition and, in turn, downward pressure on our product prices and sales. This competition has had, and could increasingly have, a material adverse effect on our product sales, business and results of operations. State laws may also have an impact on our business. For example, California is the first state to have passed legislation, effective on January 1, 2020, against &#8220;pay for delay&#8221; settlements of patent infringement claims filed by manufacturers of generics or biosimilars where anything of value is given in exchange for settlement. Under this law, such settlement agreements are presumptively anticompetitive. The law may result in prolonged litigation and fewer settlements. Other states, including Connecticut, New York, Illinois and Minnesota, may adopt similar laws or a similar law could be adopted at the federal level.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our distributors, customers and payers have substantial purchasing leverage, due to the volume of our products they purchase or the number of patient lives for which they provide coverage. The substantial majority of our U.S. product sales is made to three pharmaceutical product wholesaler distributors: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc. These distributors, in turn, sell our products to their customers, which include physicians or their clinics, dialysis centers, hospitals and pharmacies. One of our products, EPOGEN, is sold primarily to free-standing dialysis clinics. DaVita owns or manages a large number of the outpatient dialysis facilities located in the United States and accounts for approximately 90% of all EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales. Similarly, as discussed above, there has been significant consolidation in the health insurance industry, including that a small number of PBMs now oversee a substantial percentage of total covered lives in the United States. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three largest PBMs in the United States are now part of major health insurance providers. The growing concentration of purchasing and negotiating power by these entities has, and may continue to, put pressure on our pricing due to their ability to extract price discounts on our products, fees for other services or rebates, negatively affecting our bargaining position, sales and/or profit margins. In addition, decisions by these entities to purchase or cover less or none of our products in favor of competing products could have a material adverse effect on our product sales, business and results of operations due to their purchasing volume. Further, if one of our significant wholesale distributors encounters financial or other difficulties and becomes unable or unwilling to pay us all amounts that such distributor owes us on a timely basis, or at all, it could negatively affect our business and results of operations. In addition, if one of our significant wholesale distributors becomes insolvent or otherwise unable to continue its commercial relationship with us in its present form, it could significantly disrupt our business and adversely affect our product sales, our business and results of operations unless suitable alternatives are timely found or lost sales are absorbed by another distributor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO RESEARCH AND DEVELOPMENT</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to develop commercial products despite significant investments in R&amp;D.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen invests heavily in R&amp;D. Successful product development in the biotechnology industry is highly uncertain, and very few R&amp;D projects yield approved and commercially viable products. Product candidates, including biosimilar product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates, or new indications for existing products (collectively, product candidates) that appear promising in the early phases of development have failed to reach the market for a number of reasons, such as:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate did not demonstrate acceptable clinical trial results even though it achieved its primary endpoints and/or demonstrated positive preclinical or early clinical trial results, for reasons that could include changes in the standard of care of medicine or expectations of health authorities;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate was not effective or not more effective than currently available or potentially competitive therapies in treating a specified condition or illness;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate was not cost effective in light of existing or potentially competitive therapeutics;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate had harmful side effects in animals or humans;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the necessary regulatory bodies, such as the FDA or EMA, did not approve the product candidate for an intended use;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">reimbursement for the product candidate is limited despite regulatory approval;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the product candidate was not economical for us to manufacture and commercialize;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">other parties had or may have had proprietary rights relating to our product candidate, such as patent rights, and did not let us sell it on reasonable terms, or at all;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">we and certain of our licensees, partners, contracted organizations or independent investigators failed to effectively conduct clinical development or clinical manufacturing activities; </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the pathway to regulatory approval or reimbursement for product candidates was uncertain or not well-defined;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the biosimilar product candidate failed to demonstrate the requisite biosimilarity to the applicable reference product, or was otherwise determined by a regulatory authority to not meet applicable standards for approval; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a companion diagnostic device that is required with the use of a product candidate is not approved by the necessary regulatory authority.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have spent considerable time, energy and resources developing our expertise in human genetics and acquiring access to libraries of genetic information with the belief that genetics could meaningfully aid our search for new medicines and help guide our R&amp;D decisions and investments. We have focused our R&amp;D strategy on drug targets validated by genetic or other compelling human evidence. However, product candidates based on genetically validated targets remain subject to the uncertainties of the drug development process and may not reach the market for a number of reasons, including the factors listed above.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We must conduct clinical trials in humans before we commercialize and sell any of our product candidates or existing products for new indications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a product may be sold, we must conduct clinical trials to demonstrate that our product candidates are safe and effective for use in humans. The results of those clinical trials are used as the basis to obtain approval from regulatory authorities such as the FDA and EMA. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are required to conduct clinical trials using an appropriate number of trial sites and patients to support the product label claims. The length of time, number of trial sites and number of patients required for clinical trials vary substantially, and we may spend several years and incur substantial expense in completing certain clinical trials. In addition, we may have difficulty finding a sufficient number of clinical trial sites and patients to participate in our clinical trials, particularly if competitors are conducting clinical trials in similar patient populations. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients may withdraw from clinical trials at any time, and privacy laws and/or other restrictions in certain countries may restrict the ability of clinical trial investigators to conduct further follow-up on such patients, which may adversely affect the interpretation of study results. Delays and complications in planned clinical trials can result in increased development costs, associated delays in regulatory approvals and in product candidates reaching the market and revisions to existing product labels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to increase the number of patients available for enrollment in our clinical trials, we have opened, and will continue to open, clinical sites and enroll patients in a number of locations where our experience conducting clinical trials is more limited, including Russia, India, China, South Korea, the Philippines, Singapore and some Central and South American countries, either through utilization of third-party contract clinical trial providers entirely or in combination with local staff. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials in locations where we have limited experience requires substantial time and resources to understand the unique regulatory environments of individual countries. For other examples of the risks of conducting clinical trials in China, see also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, we must ensure the timely production, distribution and delivery of the clinical supply of our product candidates to numerous and varied clinical trial sites. Additionally, regional disruptions, including natural and man-made disasters or health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19), have significantly disrupted, and in the future could disrupt, the timing of clinical trials. If we fail to adequately manage the design, execution and diverse regulatory aspects of our large and/or complex clinical trials or to manage the production or distribution of our clinical supply, or such sites experience disruptions as a result of a natural/man-made disaster or health emergency, corresponding regulatory approvals may be delayed or we may fail to gain approval for our product candidates or could lose our ability to market existing products in certain therapeutic areas or altogether. For example, our clinical trials have been adversely affected by the COVID-19 pandemic. See </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to market and sell our products or product candidates or to obtain approvals in the timeframe needed to execute our product strategies, our business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on independent third-party clinical investigators to recruit patients and conduct clinical trials on our behalf in accordance with applicable study protocols, laws and regulations. Further, we rely on unaffiliated third-party vendors to perform certain aspects of our clinical trial operations. In some circumstances, we enter into co-development arrangements with other pharmaceutical and medical devices companies that provide for the other company to conduct certain clinical trials for the product we are co-developing or to develop a diagnostic test used in screening or monitoring patients in our clinical trials. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sale of our products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may acquire companies that have past or ongoing clinical trials or rights to products or product candidates for which clinical trials have been or are being conducted. These trials may not have been conducted to the same standards as ours; however, once an acquisition has been completed we assume responsibility for the conduct of these trials, including any potential risks and liabilities associated with the past and prospective conduct of those trials. If regulatory authorities determine that we or others, including our licensees or co-development partners, or the independent investigators or vendors selected by us, our co-development partners or by a company we have acquired or from which we have acquired rights to a product or product candidate, have not complied with regulations applicable to the clinical trials, those authorities may refuse or reject some or all of the clinical trial data or take other actions that could delay or otherwise negatively affect our ability to obtain or maintain marketing approval of the product or indication. In addition, delays or failures to develop diagnostic tests for our clinical trials can affect the timely enrollment of such trials and lead to delays or inability to obtain marketing approval. If we were unable to market and sell our products or product candidates, our business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of our clinical trials utilize drugs manufactured and marketed by other pharmaceutical companies. These drugs may be administered in clinical trials in combination with one of our products or product candidates or in a head-to-head study comparing the products&#8217; or product candidates&#8217; relative efficacy and safety. In the event that any of these vendors or pharmaceutical companies have unforeseen issues that negatively affect the quality of their work product or create a shortage of supply, or if we are otherwise unable to obtain an adequate supply of these other drugs, our ability to complete our applicable clinical trials and/or evaluate clinical results may also be negatively affected. As a result, such quality or supply problems could adversely affect our ability to timely file for, gain or maintain regulatory approvals worldwide.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must generally be designed based on the current standard of medical care. However, in certain diseases, such as cancer, the standard of care is evolving rapidly. In some cases, we may design a clinical trial based on the standard of care we anticipate will exist at the time our study is completed. The duration of time needed to complete certain clinical trials may result in the design of such clinical trials being based on standards of medical care that are no longer or that have not become the current standards by the time such trials are completed, limiting the utility and application of such trials. Additionally, the views of regulatory agencies relating to the requirements for accelerated approval may change over time, and trial designs that were sufficient to support accelerated approvals for some oncology products may not be considered sufficient for later candidates. We may not obtain favorable clinical trial results and therefore may not be able to obtain regulatory approval for new product candidates or new indications for existing products and/or maintain our current product labels. Participants in clinical trials of our products and product candidates may also suffer adverse medical events or side effects that could, among other factors, delay or terminate clinical trial programs and/or require additional or longer trials to gain approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a product is on the market, safety concerns may require additional or more extensive clinical trials as part of a risk management plan for our product or for approval of a new indication. Additional clinical trials we initiate, including those required by the FDA, could result in substantial additional expense, and the outcomes could result in further label restrictions or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the loss of regulatory approval for an approved indication, each of which could have a material adverse effect on our product sales, business and results of operations. Additionally, any negative results from such trials could materially affect the extent of approvals, the use, reimbursement and sales of our products, our business and results of operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to extensive regulation by numerous state and federal government authorities in the United States, including the FDA, and by foreign regulatory authorities, including the EMA. We are required in the United States and in the other regions and countries in which we, or our partners and affiliates, sell to obtain approval from regulatory authorities before we manufacture, market and sell our products. Once our products are approved, the FDA and other U.S. and ex-U.S. regulatory agencies have substantial authority to require additional testing and reporting, perform inspections, change product labeling or mandate withdrawals of our products. Failure to comply with applicable regulatory requirements may subject us to administrative and/or judicially imposed sanctions or monetary penalties as well as reputational and other harms. The sanctions could include the FDA&#8217;s or ex-U.S. regulatory authorities&#8217; refusals to approve pending applications, delays in obtaining or withdrawals of approvals, delays or suspensions of clinical trials, warning letters, product recalls or seizures, total or partial suspensions of our operations, injunctions, fines, civil penalties and/or criminal prosecutions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approvals have been, and will continue to be, increasingly difficult, time-consuming and costly. Legislative bodies or regulatory agencies could enact new laws or regulations, change existing laws or regulations or change their interpretations of laws or regulations at any time, which could affect our ability to obtain or maintain approval of our products or product candidates. The rate and degree of change in existing laws and regulations and regulatory expectations have accelerated in established markets, and regulatory expectations continue to evolve in emerging markets.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict whether and when any further changes to laws or regulatory policies affecting our business could occur, such as changes to laws or regulations governing manufacturer communications concerning drug products and drug product candidates and whether such changes could have a material adverse effect on our product sales, business and results of operations. Further, we are reliant on regulators having the resources necessary to evaluate and approve our products. In the United States, a partial federal government shutdown halted the work of many federal agencies and their employees from late December 2018 through late January 2019. A subsequent extended shutdown could result in reductions or delays of FDA&#8217;s activities, including with respect to our ongoing clinical programs, our manufacturing of our products and product candidates and our product approvals.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have questioned, and may in the future question, the sufficiency for approval of the endpoints we select for our clinical trials. A number of our products and product candidates have been evaluated in clinical trials using surrogate endpoints that measure an effect that is known to correlate with an ultimate clinical benefit. For example, a therapeutic oncology product candidate may be evaluated for its ability to reduce or eliminate MRD, or to extend the length of time during and after the treatment that a patient lives without the disease worsening, measured by PFS. Demonstrating that the product candidate induces MRD-negative responses or produces a statistically significant improvement in PFS does not necessarily mean that the product candidate will show a statistically significant improvement in overall survival or the time that the patients remain alive. In the CV setting, a heart disease therapeutic candidate may be evaluated for its ability to reduce LDL-C levels, as an elevated LDL-C level has been a surrogate endpoint for CV events such as death, heart attack and stroke. The use of surrogate endpoints such as PFS and LDL-C reduction, in the absence of other measures of clinical benefit, may not be sufficient for broad usage or approval even when such results are statistically significant. Regulatory authorities could also add new requirements, such as the completion of enrollment in a confirmatory study or the completion of an outcomes study or a meaningful portion of an outcomes study, as conditions for obtaining approval or obtaining an indication. For example, despite demonstrating that Repatha reduced LDL-C levels in a broad patient population, only after our large phase 3 outcomes study evaluating the ability of Repatha to prevent CV events met certain of its primary composite endpoint and key secondary composite endpoint did the FDA grant a broader approval of Repatha to reduce the risk of certain CV events. There may also be situations in which demonstrating the efficacy and safety of a product candidate may not be sufficient to gain regulatory approval unless superiority to other existing treatment options can be shown. The imposition of additional requirements or our inability to meet them in a timely fashion, or at all, has delayed, and may in the future delay, our clinical development and regulatory filing efforts, delay or prevent us from obtaining regulatory approval for new product candidates or new indications for existing products, or prevent us from maintaining our current product labels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our products have been approved by U.S. and ex-U.S. regulatory authorities on an accelerated or conditional basis with full approval conditioned upon fulfilling the requirements of regulators. For example, in March 2018, we announced that the FDA approved BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under accelerated approval for the treatment of certain patients with B-cell precursor ALL. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Regulatory authorities are placing greater focus on monitoring products originally approved on an accelerated or conditional basis and on whether the sponsors of such products have met the conditions of the accelerated or conditional approvals. If we are unable to fulfill the regulators&#8217; requirements that were conditions of a product&#8217;s accelerated or conditional approval and/or if regulators reevaluate the data or risk-benefit profile of our product, the conditional approval may not result in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">full approval or may be revoked or not renewed. Alternatively, we may be required to change the product&#8217;s labeled indications or even withdraw the product from the market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities can also impose post-marketing pediatric study requirements. Failure to fulfill such requirements may result in regulatory or enforcement action, including financial penalties or the invalidation of a product&#8217;s marketing authorization.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Safety problems or signals can arise as our products and product candidates are evaluated in clinical trials, including investigator sponsored studies, or as our marketed products are used in clinical practice. We are required continuously to collect and assess adverse events reported to us and to communicate to regulatory agencies these adverse events and safety signals regarding our products. Regulatory agencies periodically perform inspections of our pharmacovigilance processes, including our adverse event reporting. In the United States, for our products with approved REMS (see Item 1. Business&#8212;Government Regulation&#8212;Postapproval Phase), we are required to submit periodic assessment reports to the FDA to demonstrate that the goals of the REMS are being met. REMS and other risk management programs are designed to ensure that a drug&#8217;s benefits outweigh the risks and vary in the elements they contain. If the FDA is not satisfied with the results of the periodic assessment reports we submit for any of our REMS, the FDA may also modify our REMS or take other regulatory actions, such as implementing revised or restrictive labeling. The drug delivery devices approved for use in combination with our products are also subject to regulatory oversight and review for safety and malfunctions. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory agencies determine that we or other parties (including our clinical trial investigators, those operating our patient support programs or licensees of our products) have not complied with the applicable reporting, other pharmacovigilance or other safety or quality assessment requirements, we may become subject to additional inspections, warning letters or other enforcement actions, including fines, marketing authorization withdrawal and other penalties. Our product candidates and marketed products can also be affected by safety problems or signals occurring with respect to products that are similar to ours or that implicate an entire class of products. Further, as a result of clinical trials, including sub-analyses or meta-analyses of earlier clinical trials (a meta-analysis involves the use of various statistical methods to combine results from previous separate but related studies) performed by us or others, concerns may arise about the sufficiency of the data or studies underlying a product&#8217;s approved label. Such actual or perceived safety problems or concerns can lead to:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">revised or restrictive labeling for our products, or the potential for restrictive labeling that has resulted, and may in the future result, in our decision not to commercialize a product candidate;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">requirement of risk management or minimization activities or other regulatory agency compliance actions related to the promotion and sale of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">post-marketing commitments, mandated post-marketing requirements or pharmacovigilance programs for our approved products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product recalls of our approved products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">required changes to the processes used in the manufacture of our products, which could increase our manufacturing costs and affect the availability of contract manufacturers we may utilize to assist in such manufacturing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">revocation of approval for our products from the market completely, or within particular therapeutic areas or patient types;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">increased timelines or delays in being approved by the FDA or other regulatory bodies; and/or</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">treatments or product candidates not being approved by regulatory bodies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, after an imbalance in positively adjudicated CV serious adverse events was observed in one of the phase 3 clinical trials for EVENITY but not in another, larger phase 3 study, in April 2019 the FDA approved EVENITY for the treatment of osteoporosis in postmenopausal women at high risk for fracture, along with a post-marketing requirement. The requirement includes a five-year observational feasibility study that could be followed by a comparative safety study or trial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our innovative products, we are working to develop and commercialize biosimilar versions of a number of products currently manufactured, marketed and sold by other pharmaceutical companies. In some markets, there is not yet a legislative or regulatory pathway for the approval of biosimilars. In the United States, the BPCIA provided for such a pathway; while the FDA continues to develop regulatory and scientific policies for biosimilars, discussions continue as to the evidence needed to demonstrate biosimilarity or interchangeability for specific products. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Delays or uncertainties in the development or implementation of such pathways, or changes in existing regulatory pathways, including degradation of regulatory standards, could result in delays or difficulties in getting our biosimilar products approved by regulatory authorities, subject us to unanticipated development costs or otherwise reduce the value of the investments we have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made in the biosimilars area. Further, we cannot predict whether any repeal or reform of the ACA or other legislation or policy initiatives would affect the biosimilar pathway or have a material adverse effect on our development of biosimilars or on our marketed biosimilars. In addition, if we are unable to bring our biosimilar products to market on a timely basis and secure &#8220;first-to-market&#8221; or other advantageous positions, our future biosimilar sales, business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our products are used with drug delivery or companion diagnostic devices that have their own regulatory, manufacturing and other risks.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products and product candidates may be used in combination with a drug delivery device, such as an injector or other delivery system. For example, Neulasta is available as part of the Neulasta Onpro kit, and our AutoTouch reusable autoinjector is used with ENBREL Mini single-dose prefilled cartridges. In addition, some of our products or product candidates, including many of our oncology product candidates and products, including LUMAKRAS, may also require the use of a companion or other diagnostic device such as a device that determines whether the patient is eligible to use our drug or that helps ensure its safe and effective use. In some regions, including the United States, regulatory authorities may require contemporaneous approval of the companion diagnostic device and the therapeutic product; in others the regulatory authorities may require a separate study of the companion diagnostic device. Our product candidates or expanded indications of our products used with such devices may not be approved or may be substantially delayed in receiving regulatory approval if development or approval of such devices is delayed, such devices do not also gain or maintain regulatory approval or clearance, or if such devices do not remain commercially available. When approval of the product and device is sought under a single marketing drug application, the increased complexity of the review process may delay receipt of regulatory approval. In addition, some of these devices may be provided by single-source unaffiliated third-party companies. We are dependent on the sustained cooperation and effort of those third-party companies to supply and/or market the devices and, in some cases, to conduct the studies required for approval or clearance by the applicable regulatory agencies. We are also dependent on those third-party companies continuing to meet applicable regulatory or other requirements. Failure to successfully develop, modify, or supply the devices, delays in or failures of the Amgen or third-party studies, or failure of us or the third-party companies to obtain or maintain regulatory approval or clearance of the devices could result in increased development costs; delays in, or failure to obtain or maintain, regulatory approval; and/or associated delays in a product candidate reaching the market or in the addition of new indications for existing products. We are also required to collect and assess user complaints, adverse events and malfunctions regarding our devices, and actual or perceived safety problems or concerns with a device used with our product can lead to regulatory actions and adverse effects on our products. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, regulatory agencies conduct routine monitoring and inspections to identify and evaluate potential issues with our devices. For example, in 2017, the FDA reported on its adverse event reporting system that it was evaluating our Neulasta Onpro kit. Subsequently, we implemented device and labeling enhancements to address product complaints received on this device. We continuously monitor complaints and adverse events and implement additional enhancements as needed. Loss of regulatory approval or clearance of a device that is used with our product may also result in the removal of our product from the market. Further, failure to successfully develop, supply, or gain or maintain approval for these devices could adversely affect sales of the related approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of our pharmaceutical pipeline and our commercial product sales rely on collaborations with third parties, which may adversely affect the development and sale of our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on alliances with other companies, including pharmaceutical and biotechnology companies, vendors and service providers, for the development of a portion of the products in our pharmaceutical pipeline and for the commercialization and sales of certain of our commercial products. For example, we have collaborations with third parties under which we share development rights, obligations and costs and/or commercial rights and obligations. See Item 1. Business&#8212;Business Relationships.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failures by these parties to meet their contractual, regulatory, or other obligations to us or any disruption in the relationships between us and these third parties, could have a material adverse effect on our pharmaceutical pipeline and business. In addition, our collaborative relationships for R&amp;D and/or commercialization and sales often extend for many years and have given, and may in the future give, rise to disputes regarding the relative rights, obligations and revenues of us and our collaboration partners, including the ownership or prosecution of intellectual property and associated rights and obligations. This could result in the loss of intellectual property rights or protection, delay the development and sale of potential pharmaceutical products, affect the effective sale and delivery of our commercialized products and lead to lengthy and expensive litigation, administrative proceedings or arbitration. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek innovation through significant investment in both internal R&amp;D and external transactions, including collaborations, partnering, alliances, licenses, joint ventures, mergers and acquisitions (collectively, acquisition activity). Acquisition activities may be subject to regulatory approvals or other requirements that are not within our control. There can be no assurance that such regulatory or other approvals will be obtained or that all closing conditions required in connection with our acquisition activities will be satisfied or waived, which could result in us being unable to complete the planned acquisition activities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition activities are complex, time consuming and expensive and may result in unanticipated costs, delays or other operational or financial problems related to integrating the acquired company and business with our company, which may divert our management&#8217;s attention from other business issues and opportunities and restrict the full realization of the anticipated benefits of such transactions within the expected timeframe or at all. We may pay substantial amounts of cash, incur debt or issue equity securities to pay for acquisition activities, which could adversely affect our liquidity or result in dilution to our stockholders, respectively. Further, failures or difficulties in integrating or retaining new personnel or in integrating the operations of the businesses, products or assets we acquire (including related technology, commercial operations, compliance programs, manufacturing, distribution and general business operations and procedures) may affect our ability to realize the benefits of the transaction and grow our business and may result in us incurring asset impairment or restructuring charges. These and other challenges may arise in connection with our acquisition of Otezla, Five Prime, Teneobio and/or our collaborations with BeiGene and KKC, or with other acquisition activities, which could have a material adverse effect on our business, results of operations and stock price.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global supply of our products and product candidates for commercial sales and for use in our clinical trials is significantly dependent on the uninterrupted and efficient operation of our manufacturing facilities, in particular those in the U.S. territory of Puerto Rico and Thousand Oaks, California. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform a substantial majority of our clinical manufacturing that supports our product candidates at our facility in Thousand Oaks, California. A substantial disruption in our ability to operate our Thousand Oaks manufacturing facility could materially and adversely affect our ability to supply our product candidates for use in our clinical trials, leading to delays in development of our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico. In recent years, Puerto Rico has been affected by natural disasters, including droughts in mid-2020, earthquakes in early 2020 and Hurricane Maria in 2017. These natural disasters have affected, and may continue to affect, public and private properties and Puerto Rico&#8217;s electric grid and communications networks in the future. While the critical manufacturing areas of our commercial manufacturing facility were not significantly affected by these natural disasters, the restoration of electrical service on the island after Hurricane Maria was a slow process, and our facility operated with electrical power from backup diesel powered generators for some time. We also operated on backup generators for a few weeks after the early 2020 earthquakes in Puerto Rico. In 2021, the baseload power generation units of the Puerto Rico Electric Power Authority malfunctioned due to the lack of adequate maintenance for over a decade. The problems experienced by these units, which are among the oldest in North America, have led to selective outages across the island. Further instability of the electric grid and unreliability on the generation units could require us to increase the use of our generators or to continue using them exclusively. In addition, future storms, earthquakes or other natural disasters or events could cause a more significant effect on our manufacturing operations. Puerto Rico and the rest of the world are facing the effects of the COVID-19 pandemic and the associated health and economic implications. In March 2020, the Governor of Puerto Rico issued Executive Orders requiring the lockdown of businesses and government facilities, imposing restrictions on business operations and a curfew on residents. Our operations and employees were exempted from the lockdown and curfew, but we cannot predict whether the Governor will issue future Executive Orders imposing stricter lockdown and curfew measures should COVID-19 cases rise in Puerto Rico. Additionally, during the summer of 2021, a labor dispute arose between the maritime terminal operation company and its employees, represented by the International Longshoremen&#8217;s Association (ILA), which resulted in a strike that delayed cargo movement from the San Juan Port Zone for several days. Although our ability to manufacture and supply our products has not, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to date, been significantly affected by these natural disasters, the unreliability of the electric service, the ILA strike or the COVID-19 pandemic, a combination of these challenges or other issues that could give rise to any substantial disruption to our ability to operate our Puerto Rico manufacturing facility or get supplies and manufactured products transported to and from that location could materially and adversely affect our ability to supply our products and affect our product sales. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hurricane Maria, the earthquakes of early 2020 and the COVID-19 pandemic have placed greater stress on the island&#8217;s already challenged economy. Beginning in 2016, the government of Puerto Rico defaulted on its roughly $72 billion in debt. In response, the U.S. Congress passed the PROMESA, which established the FOMBPR to provide fiscal oversight. Title III of PROMESA provides Puerto Rico with a judicial process for restructuring its debt similar to, but not identical to, Chapter 9 of the U.S. Bankruptcy Code, including a stay of debtholder litigation. In 2017, the FOMBPR approved and certified the filing in the U.S. District Court for the District of Puerto Rico of a voluntary petition under Title III of PROMESA for the government of Puerto Rico and certain of its governmental entities, including the Puerto Rico Electric Power Authority, which recently privatized its transmission and distribution infrastructure. After years of negotiations with bondholders and other creditors, the FOMBPR reached an agreement with the same and presented a Plan of Adjustment to the Title III Court. The Plan of Adjustment requires the Puerto Rico government to enact legislation authorizing the issuance of new bonds in exchange for older bonds and a reduction of the U.S. territory&#8217;s debt. On October 26, 2021, Act 53-2021, known as the &#8220;Law to End the Bankruptcy of Puerto Rico,&#8221; was enacted. From November to December 2021, the Court held several hearings regarding the approval of the Plan of Adjustment, and the Modified Eighth Plan of Adjustment was confirmed by the Court on January 18, 2022, to be effective on March 15, 2022. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year since 2017, the FOMBPR has updated Puerto Rico&#8217;s fiscal plans implementing various measures intended to achieve fiscal responsibility and to restore Puerto Rico&#8217;s access to the capital markets, including significant expense reductions and suggested measures for economic growth. Each plan has stressed the need for fiscal and structural reforms to address Puerto Rico&#8217;s challenging economic and demographic trends. However, the government has not made significant progress during 2021 on the implementation of the fiscal and structural reforms required in the fiscal plan, in part due to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the government and the FOMBPR have authorized emergency relief packages due to the COVID-19 pandemic, it is uncertain how, or the degree to which, the pandemic will impact Puerto Rico&#8217;s fiscal and structural reforms and its economy. In addition, the 2017 Tax Act no longer permits deferral of U.S. taxation on Puerto Rico earnings, although these earnings generally will be taxed in the United States at a reduced rate. Given Puerto Rico&#8217;s challenged economy, disaster recovery needs and impact from the COVID-19 pandemic, it may be difficult for Puerto Rico to sustain or grow its manufacturing base, which contributes significantly to Puerto Rico&#8217;s economy, due to competition from other locations subject to similar levels of taxation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While PROMESA and the actions above continue to be important factors in moving Puerto Rico toward economic stability, Puerto Rico&#8217;s ongoing economic and demographic trend challenges and political situation, the effects of natural disasters, the unreliability of its electric system, the COVID-19 pandemic and the effects of the 2017 Tax Act or other potential tax law changes have negatively affected, and may in the future negatively affect, the territorial government&#8217;s provision of utilities or other services in Puerto Rico that we use in the operation of our business and could create the potential for increased taxes or fees to operate in Puerto Rico, result in a migration of workers from Puerto Rico to the mainland United States, or make it more expensive or difficult for us to operate in Puerto Rico. These factors could have a material adverse effect on our ability to supply our products, on our business and on our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party suppliers for certain of our raw materials, medical devices and components.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on unaffiliated third-party suppliers for certain raw materials, medical devices and components necessary for the manufacturing of our commercial and clinical products. Certain of those raw materials, medical devices and components are proprietary products of those unaffiliated third-party suppliers and are specifically cited in our drug applications with regulatory agencies so that they must be obtained from that specific sole source or sources and could not be obtained from another supplier unless and until the regulatory agency approved such supplier. For example, we rely on a single source for the SureClick</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">autoinjectors used in the drug delivery of Repatha, ENBREL, Aimovig, AMGEVITA and Aranesp. Also, certain of the raw materials required in the commercial and clinical manufacturing of our products are sourced from other countries and/or derived from biological sources, including mammalian tissues, bovine serum and human serum albumin.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the reasons we may be unable to obtain these raw materials, medical devices and components include:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">regulatory requirements or action by regulatory agencies or others;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">adverse financial or other strategic developments at or affecting the supplier, including bankruptcy;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">unexpected demand for or shortage of raw materials, medical devices or components;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">failure to comply with our quality standards which results in quality and product failures, product contamination and/or recall;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a material shortage, contamination, recall and/or restrictions on the use of certain biologically derived substances or other raw materials;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">discovery of previously unknown or undetected imperfections in raw materials, medical devices or components;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cyberattacks on supplier systems; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">labor disputes or shortages, including from the effects of health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19) and natural disasters.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in prior years we have experienced shortages in certain components necessary for the formulation, fill and finish of certain of our products in our Puerto Rico facility. Further quality issues that result in unexpected additional demand for certain components have resulted in shortages, and in the future may lead to shortages, of required raw materials or components (such as we have experienced with EPOGEN glass vials). We may experience similar or other shortages in the future resulting in delayed shipments, supply constraints, clinical trial delays, contract disputes and/or stock-outs of our products. These or other similar events could negatively affect our ability to satisfy demand for our products or conduct clinical trials, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biologic and small molecule human therapeutic products is difficult, complex and highly regulated. We manufacture many of our commercial products and product candidates internally. In addition, we currently use third-party contract manufacturers to produce, or assist in the production of, a number of our products, and we currently use contract manufacturers to produce, or assist in the production of, a number of our late-stage product candidates and drug delivery devices. See Item 1. Business&#8212;Manufacturing, Distribution and Raw Materials&#8212;Manufacturing. Our ability to adequately and timely manufacture and supply our products (and product candidates to support our clinical trials) is dependent on the uninterrupted and efficient operation of our facilities and those of our third-party contract manufacturers, which may be affected by:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">capacity of manufacturing facilities;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">contamination by microorganisms or viruses, or foreign particles from the manufacturing process;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">natural or other disasters, including hurricanes, earthquakes, volcanoes or fires;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">labor disputes or shortages, including the effects of health emergencies (such as novel viruses or pandemics such as the one we are currently experiencing with COVID-19) or natural disasters;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">compliance with regulatory requirements;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">changes in forecasts of future demand;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">timing and actual number of production runs and production success rates and yields;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">updates of manufacturing specifications;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">contractual disputes with our suppliers and contract manufacturers;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">timing and outcome of product quality testing;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">power failures and/or other utility failures;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cyberattacks on supplier systems;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">breakdown, failure, substandard performance or improper installation or operation of equipment (including our information technology systems and network-connected control systems or those of our contract manufacturers or third-party service providers); and/or</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">delays in the ability of the FDA or foreign regulatory agencies to provide us necessary reviews, inspections and approvals, including as a result of a subsequent extended U.S. federal or other government shutdowns. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these or other problems affect production in one or more of our facilities or those of our third-party contract manufacturers, or if we do not accurately forecast demand for our products or the amount of our product candidates required in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials, we may be unable to start or increase production in our unaffected facilities to meet demand. If the efficient manufacture and supply of our products or product candidates is interrupted, we may experience delayed shipments, delays in our clinical trials, supply constraints, stock-outs, adverse event trends, contract disputes and/or recalls of our products. From time to time, we have initiated recalls of certain lots of our products. For example, in July 2014 we initiated a voluntary recall of an Aranesp lot distributed in the EU after particles were detected in a quality control sample following distribution of that lot, and in April 2018 we initiated a precautionary recall of two batches of Vectibix distributed in Switzerland after potential crimping defects were discovered in the metal seals on some product vials. If we are at any time unable to provide an uninterrupted supply of our products to patients, we may lose patients and physicians may elect to prescribe competing therapeutics instead of our products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing processes, those of our third-party contract manufacturers and those of certain of our third-party service providers must undergo regulatory approval processes and are subject to continued review by the FDA and other regulatory authorities. It can take longer than five years to build, validate and license another manufacturing plant, and it can take longer than three years to qualify and license a new contract manufacturer or service provider. If we elect or are required to make changes to our manufacturing processes because of new regulatory requirements, new interpretations of existing requirements or other reasons, this could increase our manufacturing costs and result in delayed shipments, delays in our clinical trials, supply constraints, stock-outs, adverse event trends or contract negotiations or disputes. Such manufacturing challenges may also occur if our existing contract manufacturers are unable or unwilling to timely implement such changes, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regulatory agencies conduct routine monitoring and inspections of our manufacturing facilities and processes as well as those of our third-party contract manufacturers and service providers. If regulatory authorities determine that we or our third-party contract manufacturers or certain of our third-party service providers have violated regulations, they may mandate corrective actions and/or issue warning letters, or even restrict, suspend or revoke our prior approvals, prohibiting us from manufacturing our products or conducting clinical trials or selling our marketed products until we or the affected third-party contract manufacturers or third-party service providers comply, or indefinitely. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current products and products in development cannot be sold without regulatory approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such issues may also delay the approval of product candidates we have submitted for regulatory review, even if such product candidates are not directly related to the products, devices or processes at issue with regulators. Because our third-party contract manufacturers and certain of our third-party service providers are subject to the FDA and foreign regulatory authorities, alternative qualified third-party contract manufacturers and third-party service providers may not be available on a timely basis, or at all. If we or our third-party contract manufacturers or third-party service providers cease or interrupt production or if our third-party contract manufacturers and third-party service providers fail to supply materials, products or services to us, we may experience delayed shipments, delays in our clinical trials, supply constraints, contract disputes, stock-outs and/or recalls of our products. Additionally, we distribute a substantial volume of our commercial products through our primary distribution centers in Louisville, Kentucky for the United States and in Breda, Netherlands for Europe and much of the rest of the world. We also conduct most of the labeling and packaging of our products distributed in Europe and much of the rest of the world in Breda. Our ability to timely supply products is dependent on the uninterrupted and efficient operations of our distribution and logistics centers, our third-party logistics providers and our labeling and packaging facility in Breda. Further, we rely on commercial transportation, including air and sea freight, for the distribution of our products to our customers, which may be negatively affected by natural disasters, security threats and/or the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been legislative and administrative proposals seeking to incentivize greater drug manufacturing in the United States with the stated goal of improving supply reliability in the United States. For example, on August 6, 2020, the previous Administration issued an Executive Order aimed at boosting domestic production of essential medicines, medical countermeasures, and critical inputs titled &#8220;Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States.&#8221; Additionally, one legislative proposal would prohibit the U.S. Department of Veterans Affairs from purchasing certain drugs that have active pharmaceutical ingredients manufactured outside the United States. While we perform a substantial majority of our commercial manufacturing activities in the United States, including in the U.S. territory of Puerto Rico, and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California, the passage of such legislation could result in foreign governments enacting retaliatory legislation or regulatory actions, which may have an adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work towards operating our business in an environmentally responsible and socially inclusive manner. Stakeholders, including our investors and our employees, have increasingly focused on, and are expected to continue to focus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on, our ESG practices. If our ESG practices fail to meet these stakeholders&#8217; expectations and standards, there could be a material adverse effect on our reputation, business and, ultimately, our stock price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ESG report is made available on our website and describes our ESG goals and the progress we have made on the ESG issues deemed most important to our external and internal stakeholders, based on surveys, interviews and certain frameworks for corporate responsibility. Achieving our ESG goals requires long-term investments and broad, coordinated activity, and we may be required to incur additional costs or allocate additional resources towards monitoring, reporting and implementing our ESG practices. Further, we may fail to accurately assess our stakeholders&#8217; ESG priorities, as such priorities have evolved and will continue to evolve. While we have achieved most of our goals set in prior years, whether we can achieve our current and future ESG goals continues to be uncertain and remains subject to numerous risks, including evolving regulatory requirements and social expectations affecting ESG practices, our ability to recruit, develop and retain a diverse workforce, the availability of suppliers and collaboration partners that can meet our ESG goals, the effects of the organic growth of our business and potential acquisitions of other businesses on our ESG performance, and the availability and cost of technologies or resources, such as carbon credits, that support our goals. Any failure or perceived failure to meet our ESG program priorities could result in a material adverse effect on our reputation, business and stock price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The effects of global climate change and related natural disasters could negatively affect our business and operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our operations and facilities, including those essential to our manufacturing, R&amp;D and distribution activities, are in locations that are subject to natural disasters, including droughts, fires, hurricanes, tropical storms, and/or floods. For example, in 2017 Hurricane Maria caused catastrophic damage to the U.S. territory of Puerto Rico, where we perform a substantial majority of our commercial manufacturing activities. Although our site was well-protected and suffered minimal damage, there can be no assurances that we would have similar results in the face of future natural disasters. The severity and frequency of weather-related natural disasters has been amplified, and is expected to continue to be amplified by, global climate change. Such natural disasters have caused, and in the future may cause, damage to and/or disrupt our operations, which may result in a material adverse effect on our product sales, business and results of operations. Our suppliers, vendors and business partners also face similar risks, and any disruption to their operations could have an adverse effect on our supply and manufacturing chain. Further, many of our key facilities are located on islands, including Puerto Rico, Singapore and Ireland, which rely on essential port facilities that may be vulnerable to climate change-related or other natural disasters. Although we have detailed business continuity plans in place and periodic assessments of our natural disaster risk, any natural disaster may also result in prolonged interruption to our critical operational and business activities, and we may be required to incur significant costs to remedy the effects of such natural disasters and fully resume operations, which may result in a material adverse effect on our product sales, business and results of operations. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California; significant disruptions or production failures at these facilities could significantly impair our ability to supply our products or continue our clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing difficulties, disruptions or delays could limit supply of our products and limit our product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions. The economic downturn resulting from the COVID-19 pandemic has precipitated a global recession which may be of an extended duration. Additionally, financial pressures may cause government or other third-party payers to more aggressively seek cost containment measures. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships (including inflation) may also affect patients&#8217; ability to afford health care as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our products, which could have a material adverse effect on our product sales, business and results of operations. The current inflationary environment related to increased aggregate demand and supply chain constraints have also increased our operating expenses and may continue to affect our operating expenses. Economic conditions may also adversely affect the ability of our distributors, customers and suppliers to obtain the liquidity required to buy inventory or raw materials and to perform their obligations under agreements with us, which could disrupt our operations. Although we monitor our distributors&#8217;, customers&#8217; and suppliers&#8217; financial condition and their liquidity to mitigate our business risks, some of our distributors, customers and suppliers may become insolvent, which could have a material adverse effect on our product sales, business and results of operations. A significant worsening of global economic conditions could materially increase these risks we face.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a significant portfolio of investments disclosed as cash equivalents and marketable securities on our consolidated balance sheets. The global spread of COVID-19 has also led to disruption and volatility in the global capital markets. We have certain assets, including equity investments, that are exposed to market fluctuations that could, in a sustained or recurrent series of market disruptions, result in impairments. The value of our investments may also be adversely affected by interest rate fluctuations, inflation, downgrades in credit ratings, illiquidity in the capital markets and other factors that may result in other-than-temporary declines in the value of our investments. Any of those events could cause us to record impairment charges with respect to our investment portfolio or to realize losses on sales of investments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price is volatile.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price, like that of our peers in the biotechnology and pharmaceutical industries, is volatile. Our revenues and operating results may fluctuate from period to period for a number of reasons. Events such as a delay in product development, changes to our expectations or strategy or even a relatively small revenue shortfall may cause financial results for a period to be below our expectations or projections. As a result, our revenues and operating results and, in turn, our stock price may be subject to significant fluctuations. Announcements or discussions, including via social media channels, of possible restrictive actions by government or private payers that would negatively affect our business or industry if ultimately enacted or adopted may also cause our stock price to fluctuate, whether or not such restrictive actions ever actually occur. Similarly, actual or perceived safety issues with our products or similar products or unexpected clinical trial results can have an immediate and rapid effect on our stock price, whether or not our operating results are materially affected.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The capital and credit markets may experience extreme volatility and disruption, which may lead to uncertainty and liquidity issues for both borrowers and investors. For example, early in 2020, there were significant disruptions in the commercial paper market and several borrowers were unable to obtain funding at normal rates or maturities, which resulted in a significant increase in draws of corporate credit lines with banks. Similarly, the bond markets experienced extreme volatility in terms of interest rates and credit spreads, with several days without new issuances of corporate bonds. We expect to access the capital markets, from time to time, to supplement our existing funds and cash generated from operations in satisfying our needs for working capital; capital expenditure and debt service requirements; our plans to pay dividends and repurchase stock; and other business initiatives we strategically plan to pursue, including acquisitions and licensing activities. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on similar favorable terms, or at all, which could have a material adverse effect on our business and results of operations. Changes in credit ratings issued by nationally recognized credit-rating agencies could adversely affect our ability to obtain capital market financing and the cost of such financing and have an adverse effect on the market price of our securities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_52"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNRESOLVED STAFF COMMENTS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTIES</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:1pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we owned or leased approximately 160 properties. The locations and primary functions of significant properties are summarized in the following tables:</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Administrative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales &amp; marketing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warehouse</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution center</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thousand Oaks, CA*</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Francisco, CA</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisville, KY</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge, MA</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Juncos, Puerto Rico</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Greenwich, RI</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tampa, FL</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other U.S. cities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate headquarters</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Administrative</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales &amp; marketing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warehouse</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution center</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China </span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iceland</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other countries</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluded from the information above are (i) undeveloped land and leased properties that have been abandoned and (ii) certain buildings we still own but that are no longer used in our business. There are no material encumbrances on our owned properties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our facilities are suitable for their intended uses and, in conjunction with our third-party contract manufacturing agreements, provide adequate capacity and are sufficient to meet our expected needs. See Item&#160;1A. Risk Factors&#160;for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1. Business&#8212;Manufacturing, Distribution and Raw Materials.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_58"></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LEGAL PROCEEDINGS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the legal proceedings in which we are involved are discussed in Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements and are hereby incorporated by reference.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_61"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MINE SAFETY DISCLOSURES</span></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_67"></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the NASDAQ Global Select Market under the symbol AMGN. As of February 11, 2022, there were approximately 5,069 holders of record of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance graph</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows the value of an investment of $100 on December&#160;31, 2016, in each of Amgen common stock, the Amex Biotech Index, the Amex Pharmaceutical Index and Standard&#160;&amp; Poor&#8217;s 500 Index. All values assume reinvestment of the pretax value of dividends and are calculated as of December&#160;31 of each year. The historical stock price performance of the Company&#8217;s common stock shown in the performance graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-bottom:6pt;text-align:justify"><img src="amgn-20211231_g2.jpg" alt="amgn-20211231_g2.jpg" style="height:500px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen (AMGN)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$122.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$140.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$179.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$176.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$177.59</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amex Biotech (BTK)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$137.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$138.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$166.41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$189.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$182.34</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amex Pharmaceutical (DRG)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$116.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$125.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$148.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$161.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$199.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s 500 (SPX)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$121.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$116.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$153.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$181.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$233.47</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material in the above performance graph is not soliciting material, is not deemed filed with the SEC and is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made on, before or after the date of this filing and irrespective of any general incorporation language in such filing.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months and year ended December 31, 2021, we had one outstanding stock repurchase program, under which the repurchasing activity was as follows:</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>number of<br/>shares<br/>purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">price&#160;paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;number<br/>of&#160;shares<br/>purchased as<br/>part&#160;of<br/>publicly<br/>announced<br/>program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum dollar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">value that may</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">yet be purchased</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">under the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,960,277,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,442,554,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,889,377,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1 - December&#160;31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,730,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,730,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Average price paid per share includes related expenses.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">In October 2021 and December 2021, our Board of Directors increased the amount authorized under the stock repurchase program by an additional $4.5 billion and an additional $5.0 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, we paid quarterly dividends. We expect to continue to pay quarterly dividends, although the amount and timing of any future dividends are subject to approval by our Board of Directors. Additional information required by this item is incorporated herein by reference to Part IV&#8212;Note 16, Stockholders&#8217; equity, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Authorized for Issuance Under Existing Equity Compensation Plans</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about securities authorized for issuance under existing equity compensation plans is incorporated by reference from Item 12&#8212;Securities Authorized for Issuance Under Existing Equity Compensation Plans.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_70"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESERVED</span></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following MD&amp;A is intended to assist the reader in understanding Amgen&#8217;s business. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and accompanying notes. Our results of operations discussed in MD&amp;A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;assume&#8221; and &#8220;continue&#8221; as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Part I, Item 1A. Risk Factors. We have based our forward-looking statements on our management&#8217;s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal products are ENBREL, Prolia, Otezla, XGEVA, Neulasta, Aranesp, Repatha, KYPROLIS and Nplate. We also market a number of other products, including MVASI, Vectibix, KANJINTI, EVENITY, EPOGEN, BLINCYTO, AMGEVITA, Aimovig, Parsabiv, NEUPOGEN, LUMAKRAS/LUMYKRAS, Sensipar/Mimpara and TEZSPIRE. For additional information about our products, see Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy includes integrated activities intended to maintain and strengthen our competitive position in the industry. We focus on six commercial areas: inflammation, oncology/hematology, bone health, CV disease, nephrology and neuroscience. And we conduct discovery research primarily in three therapeutic areas: inflammation, oncology/hematology and general medicine. In 2021, we advanced our innovative pipeline, launched new products, completed several strategic transactions to augment our pipeline and research capabilities, and continued providing uninterrupted supplies of our medicines globally through the second year of the COVID-19 pandemic. We accomplished these objectives while maintaining a strategic and disciplined approach to capital allocation and while advancing our ESG efforts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we continued to advance our pipeline, including achieving key regulatory approvals for LUMAKRAS and TEZSPIRE. Our external business development activities for 2021 included: (i) acquiring Five Prime, including a later-stage gastric cancer bemarituzumab program; (ii) entering into a license agreement with KKC to develop a later-stage molecule for atopic dermatitis and other diseases; and (iii) acquiring Teneobio for its proprietary technologies and oncology programs in development. We also continued to advance our biosimilar program with the launch of RIABNI in the United States and introduced our other biosimilars into new markets. Our biosimilars are expected to continue launching in new markets throughout 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, while meeting the challenges of a global pandemic and facing increased competition from biosimilars and generics, total product sales were relatively flat as volume growth was offset by lower net selling prices. Product sales decreased 4% in the United States, driven by lower net selling prices, partially offset by volume growth, and increased 12% ROW, driven by volume growth, partially offset by lower net selling prices. Total operating expenses increased 13%, driven by IPR&amp;D expense from the Five Prime acquisition and the upfront payment associated with the KKC licensing agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities totaled $9.3 billion, which supported investment in our business while returning capital to shareholders through the payment of cash dividends and stock repurchases. For 2021, we increased our quarterly cash dividend by 10% to $1.76 per share of common stock. In December 2021, we declared a cash dividend of $1.94 per share of common stock for the first quarter of 2022, an increase of 10% for this period, to be paid in March 2022. We also repurchased 21.7 million shares of our common stock during 2021 at an aggregate cost of $5.0 billion. In 2021, we issued $4.9 billion and repaid $4.2 billion of debt that was coming due in 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen&#8217;s approach to, and investment in, human capital resource management is directed at attracting, motivating, developing and retaining talent to tackle the challenges of running an enterprise focused on the discovery, development and commercialization of innovative medicines. Our compensation, benefits and development programs are designed to encourage performance, promote accountability and adherence to Company values, and align with the interests of the Company&#8217;s shareholders. Further, we believe that a diverse and inclusive culture fosters innovation, which supports our ability to serve patients. We are engaging in activities and setting goals to improve our focus on diversity, inclusion and belonging. For further information on these and other efforts, see Part I, Item 1. Business&#8212;Human Capital Resources.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a long-standing ambition to be environmentally responsible, and we regularly set targets to challenge ourselves to deliver further improvements. In 2020, we met or exceeded our environmental sustainability targets set out in 2013 that called for reducing fleet carbon output by up to 20%, facility carbon output by 10%, water consumption by 10% and waste disposal by 35%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We achieved our 2020 targets while growing revenues, increasing production capacity and expanding to approximately 100 countries over the same 2013&#8211;20 period. To continue on our path to greater environmental sustainability, in January 2021 we announced a new set of long-term environmental targets to achieve by 2027, including achieving carbon neutrality, reducing water consumption by 40% and reducing waste disposed by 75%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2, 3</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents reductions against established baselines, taking into account only verified reduction projects, and does not take into account changes associated with contraction or expansion of the Company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Carbon neutrality goal refers to Scope 1 and 2.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends, to a great extent, on our ability to continue to discover, develop and commercialize innovative products and acquire or collaborate on therapies currently in development by other companies. We must develop new products to achieve revenue growth and to offset revenue losses from when products lose their exclusivity or when competing products are launched. Certain of our products face increasing pressure from competition, including biosimilars and generics. For additional information, including information on the expirations of patents for various products, see Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Patents, and Part I, Item&#160;1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition. We devote considerable resources to R&amp;D activities, but successful product development in the biotechnology industry is highly uncertain. We also face increasing regulatory scrutiny of safety and efficacy both before and after products launch.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rising healthcare costs and uncertain economic conditions continue to pose challenges to our business, including increasing pressure by third-party payers, such as governments and private payers, to reduce healthcare expenditures. As a result of public and private healthcare-provider focus, the industry continues to be subject to cost containment measures and significant pricing pressures, including net price declines. Finally, wholesale and end-user buying patterns can affect our product sales. These buying patterns can cause fluctuations in quarterly product sales but have generally not been significant to date when comparing full-year product performance to the prior year. See Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products, and Part I, Item 1A. Risk Factors for further discussion of certain factors that could impact our future product sales.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the onset of the pandemic in 2020, we have been closely monitoring the pandemic&#8217;s effects on our global operations. We continue to take appropriate steps to minimize risks to our employees, a significant number of whom have continued to work virtually. Employee access to company facilities has been in accordance with applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations, and we have not experienced disruptions to or shortages of our supply of medicines. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the COVID-19 pandemic, we have seen changes in demand for some of our products driven by changes in the frequency of patient visits to doctors&#8217; offices that has impacted the provision of treatments to existing patients and reduced diagnoses in new patients. During 2021, there was gradual recovery in both patient visits and diagnoses that approached pre-COVID-19 levels early in the fourth quarter. However late in 2021, the Omicron variant began to impact the healthcare sector and as a result we expect ongoing variability in demand patterns in the first half of 2022. The cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business. We will continue to closely monitor the effects of emerging COVID-19 variants on patient behavior and access to care.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since early 2021, global vaccination efforts have been under way to control the pandemic. However, uncertainty remains as to the length of time required for vaccination of a meaningful portion of the population and as to the efficacy of such vaccinations with regard to the trajectory of the pandemic. Challenges to vaccination efforts, new variants and other causes of virus spread may require governments to issue additional restrictions and/or order shutdowns in various geographies. As a result, we expect to see continued volatility for at least the duration of the pandemic as governments respond to current local conditions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our drug development activities, we are continuously monitoring COVID-19 infection rates, including changes from new variants, and working to mitigate effects on future study enrollment in our clinical trials and evaluating the impacts in all countries where our clinical trials occur. We remain focused on supporting our active clinical sites in their provision of care to patients and in our provision of investigational drug supply.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the ongoing pandemic and business impacts noted above, we believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures and debt service requirements as well as to engage in capital-return and other business initiatives that we plan to pursue. For a discussion of the risks the COVID-19 pandemic presents to our results, see Risk Factors in Part I, Item 1A. Risk Factors of this Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Financial Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is an overview of our results of operations (in millions, except percentages and per-share data):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in the purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales were relatively flat for 2021, as volume growth was offset by declines in net selling prices. For 2022, we expect that net selling prices will continue to decline at a portfolio level driven by increased competition.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Further, the first quarter of a year historically represents the lowest product sales quarter for the year, in part due to plan changes, insurance reverifications and higher co-pay expenses as U.S. patients work through deductibles, particularly for products acquired through pharmacy benefit programs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician&#8211;patient interactions, which has led to delays in diagnoses and treatments, with varying degrees of impact across our portfolio. In general, declines in the sales of our products that were impacted by the dynamics of the pandemic were most significant in the early months of the pandemic with product demand beginning to show some recovery in late 2020. During 2021, we observed gradual recovery from the COVID-19 pandemic, with patient visits and diagnosis rates that approached pre-pandemic levels early in the fourth quarter. However, late in the year, the Omicron variant began to impact the healthcare sector and as a result, we have seen some shift back to virtual engagement by our field staff and variability in demand patterns. The cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business. Given the unpredictable nature of the pandemic, we expect there could be ongoing intermittent disruptions in physician&#8211;patient interactions, and as a result, we continue to expect quarter-to-quarter variability. In addition, other changes in the healthcare ecosystem have the potential to introduce variability into product sales trends. For example, changes in U.S. employment have led to changes to the insured population. Growth in numbers of Medicaid enrollees and uninsured individuals may have a negative impact on product demand and sales. Overall, uncertainty remains around the timing and magnitude of our sales during the COVID-19 pandemic. See Risk Factors in Part I, Item 1A. of this Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues increased for 2021, primarily driven by the sale of COVID-19 antibody material resulting from our manufacturing collaboration.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses increased for 2021, driven by IPR&amp;D expense related to the bemarituzumab program acquired as part of the Five Prime acquisition and by the upfront payment associated with the KKC licensing agreement.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is partially offset by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Our hedging activities seek to offset the impacts, both positive and negative, that foreign currency exchange rate changes may have on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros. The net impact from changes in foreign currency exchange rates was not material in 2021, 2020 or 2019.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide product sales were as follows (dollar amounts in millions): </span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S.</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products&#8217; significant competitors, see Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products&#8212;Competition.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total ENBREL sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL&#160;&#8212;&#160;Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ENBREL</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in ENBREL sales for 2021 was driven by lower net selling price, unit demand and unfavorable changes in inventory. For 2022, we expect ENBREL to follow the historical pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increased co-pay expenses as U.S. patients work through deductibles. In addition, for 2022, we expect net selling price to decline.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in ENBREL sales for 2020 was driven by lower unit demand and net selling price, partially offset by favorable changes to estimated sales deductions and inventory.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Prolia sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Prolia</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2021 was primarily driven by higher unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Prolia sales for 2020 was driven by higher unit demand and net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Otezla sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla&#160;&#8212;&#160;U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla&#160;&#8212;&#160;ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Otezla</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2021 was driven by higher unit demand, partially offset by lower net selling price and unfavorable changes to inventory. For 2022, we expect Otezla to follow the historical pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increased co-pay expenses as U.S. patients work through deductibles.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was acquired on November 21, 2019, and generated $2.2 billion and $178 million in global sales for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing litigation related to Otezla, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XGEVA</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total XGEVA sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total XGEVA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global XGEVA sales for 2021 was primarily driven by higher unit demand, partially offset by lower net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global XGEVA sales for 2020 was driven by lower unit demand as a result of the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neulasta</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Neulasta sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta &#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neulasta</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in global Neulasta sales for 2021 and 2020 was primarily driven by lower net selling price and unit demand. Increased competition as a result of biosimilar versions of Neulasta has had and will continue to have a significant adverse impact on brand sales, including accelerating net price erosion and lower unit demand. We also expect other biosimilar versions, including biosimilars that will use an on-body injector that would compete with our Onpro injector, to be approved in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a discussion of ongoing patent litigations related to biosimilars, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aranesp</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Aranesp sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp&#160;&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Aranesp</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp sales for 2021 was primarily driven by lower net selling price due to competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp sales for 2020 was driven by declines in net selling price and unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aranesp continues to face competition from a long-acting ESA and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from a biosimilar version of EPOGEN, which will continue to impact sales in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Repatha sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Repatha</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in global Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for 2021 and 2020 was driven by higher unit demand, partially offset by lower net selling price. Contracting changes to improve Medicare Part D patient access resulted in the decrease to net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing litigation related to Repatha, see Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total KYPROLIS sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS&#160;&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total KYPROLIS</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global KYPROLIS sales for 2021 was primarily driven by higher unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global KYPROLIS sales for 2020 was primarily driven by an increase in net selling price and favorable changes in inventory, partially offset by lower unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has reported that it has granted tentative or final approval of ANDAs for generic carfilzomib products filed by a number of companies. The date of approval of those ANDAs for generic carfilzomib products is governed by the Hatch&#8211;Waxman Act and any applicable settlement agreements between us and certain companies that seek to develop generic carfilzomib products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Nplate sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate&#160;&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Nplate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in global Nplate sales for 2021 and 2020 was primarily driven by higher unit demand.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI &#8212; U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO &#8212; U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMYKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar/Mimpara &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. &#8212; other products</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ROW &#8212; other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%.</span></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A = not applicable</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Change in excess of 100%</span></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A = not applicable</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased to 24.8% of total revenues for 2021, driven by unfavorable product mix and higher profit share and royalties, partially offset by lower amortization expense from acquisition-related assets and lower manufacturing costs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased to 24.2% of total revenues for 2020, primarily driven by the amortization of expenses related to our acquisition of Otezla and by higher royalty expenses and profit share, partially offset by lower manufacturing costs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company groups all of its R&amp;D activities and related expenditures into three categories: (i)&#160;research and early pipeline, (ii)&#160;later-stage clinical programs and (iii)&#160;marketed products. These categories are described below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and early pipeline </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism, and process development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later-stage clinical programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the United States or the EU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses incurred in support of the Company&#8217;s marketed products that are authorized to be sold primarily in the United States or the EU. Includes clinical trials designed to gather information on product safety (certain of which may be required by regulatory authorities) and their product characteristics after regulatory approval has been obtained, as well as the costs of obtaining regulatory approval of a product in a new market after approval in either the United States or the EU has been obtained</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense by category was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and early pipeline</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Later-stage clinical programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&amp;D expense for 2021 was driven by a licensing-related expense from our collaboration with KKC included in later-stage clinical programs and higher spend in research and early pipeline, including other business development activities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&amp;D expense for 2020 was driven by higher spend for later-stage clinical programs, including LUMAKRAS, biosimilar programs and Otezla, and higher spend for Otezla included in marketed-product support. These increases were partially offset by recoveries from our collaboration with BeiGene that reduced expenses in later-stage clinical programs and in research and early pipeline, and lower spend in certain oncology programs included in research and early pipeline.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expense for 2021 was related to the bemarituzumab program acquired as part of the Five Prime acquisition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in SG&amp;A expense for 2021 was primarily driven by lower spend for marketed products and lower general and administrative expenses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in SG&amp;A expense for 2020 was driven by investments in certain marketed products, primarily Otezla, and preparation for product launches, partially offset by a reduction in conference-related expenses due to the impact of COVID-19.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2021 primarily consisted of expenses related to cost-savings initiatives and a legal judgment.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2020 primarily consisted of legal settlement expenses.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for 2019 primarily consisted of expenses related to cost-savings initiatives.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_88"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonoperating expenses/income and income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Interest expense, net, for 2021 was primarily due to net higher costs associated with the early retirement of debt in 2020 and lower LIBOR rates in 2021 on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps, partially offset by higher overall debt outstanding.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Interest expense, net, for 2020 was primarily due to lower LIBOR rates on debt for which we effectively pay a variable rate of interest, partially offset by net costs associated with the early retirement of debt.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Other income, net, for 2021 was primarily due to lower losses incurred in connection with our BeiGene investment compared with 2020, partially offset by lower income on our interest-bearing investments in 2021 and other nonrecurring gains recognized in 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Other income, net, for 2020 was primarily due to reduced interest income as a result of lower average cash balances and a decline in interest yields and losses incurred in connection with our BeiGene investment, partially offset by gains recognized on our investments in publicly traded equity securities and limited partnerships. See Part IV&#8212;Note 9, Investments, to the Consolidated Financial Statements.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our effective tax rate for 2021 compared with 2020 was primarily driven by the non-deductible IPR&amp;D expense arising from the acquisition of Five Prime, partially offset by earnings mix and adjustments to prior-year tax liabilities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for 2020 compared with 2019 was primarily driven by favorable items, including audit settlements, adjustments to prior-year tax liabilities, lower interest expense on uncertain tax positions and amortization related to the Otezla acquisition, partially offset by changes in valuation allowance.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administration proposed and Congress is considering significant changes to existing tax law. These changes, if enacted, could substantially increase taxes we pay to the U.S. government. Further, the OECD recently reached agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, this agreement could result in tax increases in both the United States and foreign jurisdictions. The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning in 2023, which will increase our U.S. tax liability. The U.S. territory of Puerto Rico is considering changes to its tax system that may minimize or eliminate this impact, but the outcome of such potential changes is uncertain. Changes to existing tax law in the United States, the U.S. territory of Puerto Rico, or other jurisdictions, including the potential changes discussed above, could result in tax increases where we do business and could have a material adverse effect on the results of our operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021 which seek to increase our U.S. taxable income. The Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS&#8217;s positions set forth in the Notices are without merit, and we are contesting the Notices through the judicial process. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office. We were unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a statutory notice of deficiency for these years as well. We expect to contest any such notice related to 2013&#8211;15 through the judicial process. We are also currently under examination by the IRS for the years 2016, 2017 and 2018 and by a number of state and foreign tax jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and the uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part II, Item 7. MD&amp;A&#8212;Critical Accounting Policies and Estimates&#8212;Income taxes; and Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements for further discussion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial data was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance of cash, cash equivalents and marketable securities was $8.0 billion at December 31, 2021. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital allocation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), repayment of debt, payment of dividends and stock repurchases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to continue investing in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business and our desire to optimize our cost of capital. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company&#8217;s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include block purchases, tender offers, accelerated share repurchases and market transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors declared quarterly cash dividends of $1.76, $1.60 and $1.45 per share of common stock paid in 2021, 2020 and 2019, respectively, an increase of 10% over the prior year in both 2021 and 2020. In December 2021, the Board of Directors declared a cash dividend of $1.94 per share of common stock for the first quarter of 2022, an increase of 10% for this period, to be paid in March 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also returned capital to stockholders through our stock repurchase program. During 2021, we repurchased and had cash settlements of $5.0 billion of common stock. In 2020, we repurchased and had cash settlements of $3.5 billion of common stock. In 2019, we repurchased $7.6 billion of common stock and had cash settlements of $7.7&#160;billion. In March 2021, October 2021 and December 2021, the Board of Directors increased the amount authorized under our stock repurchase program by $3.4 billion, $4.5 billion and $5.0 billion, respectively. As of December 31, 2021, $10.9 billion remained available under the stock repurchase program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of December 31, 2021 and 2020. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our expected continued profitability and strong financial position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, our plans to pay dividends and repurchase stock, and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities, and access to other domestic and foreign debt markets and equity markets. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help meet our liquidity requirements, we have entered into various financing arrangements. The noncurrent portions of our long-term borrowings as of December 31, 2021 and 2020, were $33.2 billion and $32.9 billion, respectively. The carrying values of our long-term borrowings are net of fair value adjustments for interest rate swaps and unamortized discounts, premiums and offering costs. As of December 31, 2021, S&amp;P, Moody&#8217;s and Fitch assigned credit ratings to our outstanding senior notes of A&#8211; with a stable outlook, Baa1 with a stable outlook and BBB+ with a stable outlook, respectively, which are considered investment grade. Unfavorable changes to these ratings may have an adverse impact on future financings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2020, we issued debt with aggregate principal amounts of $5.0 billion and $9.0 billion, respectively. During 2019, we did not issue any debt or debt securities. During 2021, 2020 and 2019, we repaid/redeemed debt of $4.2 billion, $6.5 billion and $4.5 billion, respectively. In addition, during 2020, we exchanged $0.7 billion of certain of our outstanding note issuances with $0.9 billion of newly issued notes with a lower interest rate and later maturity date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted a fixed-rate interest coupon for certain of our debt issuances to a floating, LIBOR-based coupon over the lives of the respective notes. These interest rate swap contracts qualify and are designated as fair value hedges. As of December 31, 2021 and 2020, we had interest rate swap contracts with aggregate notional amounts of $6.7 billion and $5.9 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts, which effectively convert the interest payments and principal repayment of the respective notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts qualify and are designated as cash flow hedges. As of both December 31, 2021 and 2020, we had cross-currency swap contracts with aggregate notional amounts of $3.4 billion and $4.8 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. During 2021, 2020 and 2019, we did not issue any commercial paper. No commercial paper was outstanding as of December 31, 2021 and 2020.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1%. The agreement contains provisions related to the determination of successor rates to address the possible phaseout or unavailability of designated reference rates. As of December 31, 2021 and 2020, no amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is anticipated that the U.S. dollar LIBOR rate will be phased out and replaced by 2023. The Alternative Reference Rates Committee, a group of private-market participants convened by the Federal Reserve Board and the Federal Reserve Bank of New York to help ensure a successful transition from U.S. dollar LIBOR to a more robust reference rate, recommends SOFR as the U.S. dollar LIBOR alternative. As such, we expect SOFR to become widely adopted by market participants. We do not expect this change to have a material impact on our financial statements. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This shelf registration statement expires in February 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These financing arrangements are more fully discussed in Part IV&#8212;Note 15, Financing arrangements, and Note 18, Derivative instruments, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our summarized cash flow activity was as follows (in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities decreased during 2021 primarily due to the monetization of interest rate swaps that occurred in 2020 and the timing of payments for sales incentives and discounts. Cash provided by operating activities increased during 2020 primarily due to higher Net income after adding back the noncash amortization related to the acquisition of Otezla, the monetization of interest rate swap contracts and working-capital adjustments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during 2021 was primarily due to net cash inflows related to marketable securities of $4.3 billion, partially offset by cash used in the acquisitions of Teneobio and Five Prime of $2.5 billion. Cash used in investing activities during 2020 was primarily due to our $3.2 billion of purchases of equity method investments, primarily BeiGene, and net cash outflows related to marketable securities of $1.5 billion. Cash provided by investing activities during 2019 was primarily due to net cash inflows related to marketable securities of $20.0 billion which occurred primarily to fund our acquisition of Otezla and investment in BeiGene. Capital expenditures were $880 million, $608 million and $618 million in 2021, 2020 and 2019, respectively. We currently estimate 2022 spending on capital projects to be approximately $950 million. A majority of the increase in expenditures relates to expansion of manufacturing capacity to enable supply of products and product candidates.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during 2021 was primarily due to payments to repurchase our common stock of $5.0 billion and the payment of dividends of $4.0 billion, partially offset by proceeds from the issuance of debt, net of repayments of $0.8 billion. Cash used in financing activities during 2020 was primarily due to the payment of dividends of $3.8 billion and payments to repurchase our common stock of $3.5 billion, partially offset by proceeds from issuance of debt, net of repayments of $2.5 billion. Cash used in financing activities during 2019 was primarily due to payments to repurchase our common stock of $7.7 billion, repayment of debt of $4.5 billion and payments of dividends of $3.5 billion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part IV&#8212;Note 9, Investments; Note 15, Financing arrangements; and Note 16, Stockholders&#8217; equity, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital requirements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have material cash requirements to pay third parties under various contractual obligations discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay interest and repay principal under our various financing arrangements, including amounts under interest rate swap and cross-currency swap contracts related to certain of our long-term debt obligations. For information on scheduled debt maturities and payments under derivative contracts associated with our long-term debt obligations, see Part IV&#8212;Note 15, Financing arrangements, and Note 18, Derivative instruments, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make payments for operating leases, including rental commitments on abandoned leases and leases that have not yet commenced. For information on these obligations, see Part IV&#8212;Note 13, Leases, to the Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. For information on the remaining scheduled repatriation tax installments, see Part IV&#8212;Note 19, Contingencies and commitments&#8212;Commitments&#8212;U.S. Repatriation tax, to the Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have purchase obligations of $3.2 billion primarily related to (i) R&amp;D commitments (including those related to clinical trials) for new and existing products, (ii) capital expenditures and (iii) open purchase orders for the acquisition of goods and services in the ordinary course of business. Most of these obligations are expected to be paid within one year, and payment of certain of these amounts may be reduced based on certain future events.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the purchase obligations noted above, we are contractually obligated to pay additional amounts that in the aggregate are significant, upon the achievement of various development, regulatory and commercial milestones for agreements we have entered into with third parties, including contingent consideration incurred in the acquisitions of Teneobio and K-A. These payments are contingent upon the occurrence of various future events, substantially all of which have a high degree of uncertainty of occurring, and any resulting cash requirements are managed through our operational budgeting processes. Except with respect to the fair value of the contingent consideration of approximately $0.3 billion, these obligations are not recorded on our Consolidated Balance Sheets. As of December 31, 2021, the maximum amount that may be payable in the future for agreements we have entered into with third parties is $7.4 billion, including $1.6 billion of contingent consideration payments in connection with our Teneobio acquisition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded liabilities for UTBs that, because of their nature, have a high degree of uncertainty regarding the timing of future cash payment and other events that extinguish these liabilities. See Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_103"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Our significant accounting policies are included in Part IV&#8212;Note 1, Summary of significant accounting policies. The following are considered critical to our consolidated financial statements because they require the most difficult, subjective or complex judgments, often because of the need to make estimates about matters that are inherently uncertain.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate. Accruals are also adjusted to reflect actual results. Amounts recorded in Accrued liabilities in the Consolidated Balance Sheets for sales deductions were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,985)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2021, 2020 and 2019, total sales deductions were 47%, 44% and 41% of gross product sales, respectively. The increase in the total sales deductions balance as of December 31, 2021, compared with December 31, 2020, was primarily driven by the impact of higher U.S. chargeback and commercial rebate discount rates and an increase in gross sales, partially offset by timing of payments. Included in the amounts are immaterial net adjustments related to prior-year sales due to changes in estimates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we use wholesalers as the principal means of distributing our products to healthcare providers such as physicians or their clinics, dialysis centers, hospitals and pharmacies. Products we sell in Europe are distributed principally to hospitals and/or wholesalers depending on the distribution practice in each country where the products are sold. We monitor the inventory levels of our products at our wholesalers by using data from our wholesalers and other third parties, and we believe wholesaler inventories have been maintained at appropriate levels (generally two to three weeks) given end-user demand. Accordingly, historical fluctuations in wholesaler inventory levels have not significantly affected our method of estimating sales deductions and returns.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given year, can be affected by the mix of products sold.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates include primarily amounts paid to payers and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements that vary by product, by payer and by individual payer plans. As we sell products, we estimate the amount of rebate we will pay based on the product sold, contractual terms, estimated patient population, historical experience and wholesaler inventory levels; and we accrue these rebates in the period the related sales are recorded. We then adjust the rebate accruals as more information becomes available and to reflect actual claims experience. Estimating such rebates is complicated, in part because of the time delay between the date of sale and the actual settlement of the liability. We believe the methodology we use to accrue for rebates is reasonable and appropriate given current facts and circumstances, but actual results may differ. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wholesaler chargebacks relate to our contractual agreements to sell products to healthcare providers in the United States at fixed prices that are lower than the prices we charge wholesalers. When healthcare providers purchase our products through wholesalers at these reduced prices, wholesalers charge us for the difference between their purchase prices and the contractual prices between Amgen and the healthcare providers. The provision for chargebacks is based on expected sales by our wholesaler customers to healthcare providers. Accruals for wholesaler chargebacks are less difficult to estimate than rebates are, and they closely approximate actual results because chargeback amounts are fixed at the date of purchase by the healthcare providers and because we generally settle the liability for these deductions within a few weeks.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated by comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. In each of the past three years, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-year sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is measured based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We believe our estimates for uncertain tax positions are appropriate and sufficient for any assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are included in our tax return at different times than they are reflected in the financial statements, and they cause temporary differences between the tax bases of assets and liabilities and their reported amounts. Such temporary differences create deferred tax assets and liabilities. Deferred tax assets are generally items that can be used as tax deductions or credits in tax returns in future years but for which we have already recorded the tax benefit in the consolidated financial statements. We establish valuation allowances against our deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities are either (i)&#160;tax expenses recognized in the consolidated financial statements for which payment has been deferred, (ii)&#160;expenses for which we have already taken a deduction on the tax return but have not yet recognized in the consolidated financial statements or (iii) liabilities for the difference between the book basis and the tax basis of the intangible assets acquired in many business combinations, because future expenses associated with these assets most often will not be tax deductible.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a vertically integrated enterprise with operations in the United States and various foreign jurisdictions. In the jurisdictions where we conduct operations, we are subject to income tax based on the tax laws and principles of such jurisdictions and on the functions, risks and activities performed therein. Our pretax income is therefore attributed to domestic or foreign sources based on the operations performed and risks assumed in each location and the tax laws and principles of the respective taxing jurisdictions. For example, we conduct significant operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes, pertaining to manufacturing, distribution and other related functions to meet our worldwide product demand. Income from our operations in Puerto Rico is subject to tax incentive grants through 2035.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021, which seek to increase our U.S. taxable income. The Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS&#8217;s positions set forth in the Notices are without merit, and we are contesting the Notices through the judicial process. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico and that are similar to those proposed for the years 2010, 2011 and 2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office. We were unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a statutory notice of deficiency for these years as well. We expect to contest any such notice related to 2013&#8211;15 through the judicial process. We are also currently under examination by the IRS for the years 2016, 2017 and 2018 and by a number of state and foreign tax jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not li</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">kely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part II, Item 7. MD&amp;A&#8212;Income Taxes; and Part IV&#8212;Note 6, Income taxes, to the Consolidated Financial Statements for further discussion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to the tax laws, regulations and administrative practices of the United States, the U.S. territory of Puerto Rico, U.S. state jurisdictions and other countries in which we do business. Significant changes in these rules could have a material adverse effect on our results of operations. See Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters such as intellectual property disputes, contractual disputes and class action suits that are complex in nature and have outcomes that are difficult to predict. We describe our legal proceedings and other matters that are significant or that we believe could become significant in Part IV&#8212;Note 19, Contingencies and commitments, to the Consolidated Financial Statements. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of assets and liabilities in connection with acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired and continue to acquire intangible assets in connection with business combinations and asset acquisitions. These intangible assets consist primarily of technology associated with currently marketed human therapeutic products and IPR&amp;D product candidates. Discounted cash flow models are typically used to determine the fair values of these intangible assets for purposes of allocating consideration paid to the net assets acquired in an acquisition. See Part IV&#8212;Note 2, Acquisitions, to the Consolidated Financial Statements. These models require the use of significant estimates and assumptions, including but not limited to:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">determining the timing and expected costs to complete in-process projects, taking into account the stage of completion at the acquisition date;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">projecting the probability and timing of obtaining marketing approval from the FDA and other regulatory agencies for product candidates;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">estimating the timing of and future net cash flows from product sales resulting from completed products and in-process projects; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">developing appropriate discount rates to calculate the present values of the cash flows. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions are also required to determine the business combination date fair values of any contingent consideration obligations incurred in connection with business combinations. In addition, we must revalue these obligations each subsequent reporting period until the related contingencies are resolved and record changes in their fair values in earnings. The acquisition date fair values of contingent consideration obligations incurred or assumed in the acquisitions were determined using a combination of valuation techniques. Significant estimates and assumptions required for these valuations included but were not limited to the timing and probability of achieving regulatory milestones, product sales projections under various scenarios and discount rates used to calculate the present value of the required payments. These estimates and assumptions are required to be updated in order to revalue these contingent consideration obligations each reporting period. Accordingly, subsequent changes in underlying facts and circumstances could result in changes in these estimates and assumptions, which could have a material impact on the estimated future fair values of these obligations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the fair values used to record intangible assets acquired and contingent consideration obligations incurred in connection with business combinations and asset acquisitions are based on reasonable estimates and assumptions given the facts and circumstances as of the related valuation dates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of our property, plant and equipment and our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such circumstances exist, an estimate of undiscounted future cash flows to be generated by the long-lived asset is compared with the carrying value to determine whether an impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, composed of IPR&amp;D projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition, are reviewed for impairment annually, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable and upon establishment of technological feasibility or regulatory approval. We determine impairment by comparing the fair value of the asset to its carrying value. If the asset&#8217;s carrying value exceeds its fair value, an impairment charge is recorded for the difference, and its carrying value is reduced accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating future cash flows of an IPR&amp;D product candidate for purposes of an impairment analysis requires us to make significant estimates and assumptions regarding the amount and timing of costs to complete the project and the amount, timing and probability of achieving revenues from the completed product similar to how the acquisition date fair value of the project was determined, as described above. There are often major risks and uncertainties associated with IPR&amp;D projects as we are required to obtain regulatory approvals in order to be able to market these products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods which could have a material adverse effect on our results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our estimations of future cash flows used for assessing impairment of long-lived assets are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of equity method investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of our equity method investments whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time and the extent to which the fair value is below the carrying value, volatility of the security price, the financial condition of the issuer, changes in technology that may impair the earnings potential of the investment and our intent and ability to retain the investment to allow for a recovery in fair value. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our judgments used in assessing impairment of equity method investments are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.</span></div><div id="i2a971cfaef98424f9692041d6ed3a222_106"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="text-align:justify;text-indent:24.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part IV&#8212;Note 1, Summary of significant accounting policies, to the Consolidated Financial Statements for a discussion of recently issued accounting pronouncements not yet adopted as of December 31, 2021.</span></div><div style="text-align:justify;text-indent:24.57pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_109"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks that may result from changes in interest rates, foreign currency exchange rates and prices of equity instruments as well as changes in general economic conditions in the countries where we conduct business. To reduce certain of these risks, we enter into various types of foreign currency and interest rate derivative hedging transactions as part of our risk management program. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discussion that follows, we assumed a hypothetical change in interest rates of 100 basis points from those as of December 31, 2021 and 2020. Except as noted below, we also assumed a hypothetical 20% change in foreign currency exchange rates against the U.S. dollar based on its position relative to other currencies as of December 31, 2021 and 2020.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-rate-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of available-for-sale investments as of December 31, 2021 and 2020, was composed almost entirely of U.S. Treasury securities and money market mutual funds. The fair values of our available-for-sale investments were $7.3 billion and $9.8 billion as of December 31, 2021 and 2020, respectively. Duration is a sensitivity measure that can be used to approximate the change in the value of a security that will result from a 100 basis point change in interest rates. Applying a duration model, a hypothetical 100 basis point increase in interest rates as of December 31, 2021 and 2020, would not have resulted in a material reduction in the fair values of these securities. In addition, a hypothetical 100 basis point decrease in interest rates as of December 31, 2021 and 2020, would not result in a material effect on income in the respective ensuing year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had outstanding debt with a carrying value of $33.3 billion and a fair value of $37.9 billion. As of December 31, 2020, we had outstanding debt with a carrying value of $33.0 billion and a fair value of $39.4 billion. Our outstanding debt was composed of debt with fixed interest rates. Changes in interest rates do not affect interest expense on fixed-rate debt. Changes in interest rates would, however, affect the fair values of fixed-rate debt. A hypothetical 100 basis point decrease in interest rates relative to interest rates as of December 31, 2021 and 2020, would have resulted in an increase of $4.5 billion in the aggregate fair value of our outstanding debt on both of these dates. Analysis of the debt does not consider the impact that hypothetical changes in interest rates would have on related interest rate swap contracts and cross-currency swap contracts, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified and were designated for accounting purposes as fair value hedges for certain of our fixed-rate debt. These interest rate swap contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective notes. Interest rate swap contracts with aggregate notional amounts of $6.7 billion and $5.9 billion were outstanding as of December 31, 2021 and 2020, respectively. A hypothetical 100 basis point increase in interest rates relative to interest rates as of December 31, 2021 and 2020, would have resulted in reductions in fair values of approximately $330 million and $230 million, respectively, on our interest rate swap contracts on these dates. Analysis of the interest rate swap contracts does not consider the impact that hypothetical changes in interest rates would have on the related fair values of debt that these interest-rate-sensitive instruments were designed to offset. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had outstanding cross-currency swap contracts with aggregate notional amounts of $3.4 billion and $4.8 billion, respectively, that hedge our foreign-currency-denominated debt and related interest payments. These contracts effectively convert interest payments and principal repayment of this debt to U.S. dollars from euros, pounds sterling and Swiss francs and are designated for accounting purposes as cash flow hedges. A hypothetical 100 basis point adverse movement in interest rates relative to interest rates as of December 31, 2021 and 2020, would have resulted in reductions in the fair values of our cross-currency swap contracts of approximately $170 million and $250 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign-currency-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations are affected by fluctuations in the value of the U.S. dollar compared with foreign currencies, predominantly the euro. Increases and decreases in our international product sales from movements in foreign currency exchange rates are partially offset by corresponding increases or decreases in our international operating expenses. Increases and decreases in our foreign-currency-denominated assets from movements in foreign currency exchange rates are partially offset by corresponding increases or decreases in our foreign-currency-denominated liabilities. To further reduce our net exposure to foreign currency exchange rate fluctuations on our results of operations, we enter into foreign currency forward and cross-currency swap contracts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had outstanding euro-, pound-sterling- and Swiss-franc-denominated debt with a principal carrying value and a fair value of $3.2 billion and $3.6 billion, respectively. As of December 31, 2020, we had outstanding euro-, pound-sterling- and Swiss-franc-denominated debt with a principal carrying value and a fair value of $4.8 billion and $5.4 billion, respectively. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2021, would have resulted in an increase in fair value of this debt of approximately $710 million on this date and a reduction in income in the ensuing year of approximately $640 million. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2020, would have resulted in an increase in fair value of this debt of $1.1 billion on this date and a reduction in income in the ensuing year of $1.0 billion. The impact on income from these hypothetical changes in foreign currency exchange rates would be substantially offset by the impact such changes would have on related cross-currency swap contracts, which are in place for the related foreign-currency-denominated debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have cross-currency swap contracts that are designated as cash flow hedges of our debt denominated in euros, pounds sterling and Swiss francs, with aggregate notional amounts of $3.4 billion and $4.8 billion as of December 31, 2021 and 2020, respectively. A hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates on these dates would have resulted in reductions in the fair values of these contracts of approximately $700 million and $1.1 billion on these dates, respectively. The impact of this hypothetical adverse movement in foreign currency exchange rates on ensuing years&#8217; income from these contracts would be fully offset by corresponding hypothetical changes in the carrying amounts of the related hedged debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts that are designated for accounting purposes as cash flow hedges of certain anticipated foreign currency transactions. As of December 31, 2021, the fair values of these contracts were a $183 million asset and a $39 million liability. As of December 31, 2020, the fair values of these contracts were a $28 million asset and a $237 million liability. As of December 31, 2021, we had primarily euro-based open foreign currency forward contracts with notional amounts of $5.7 billion. As of December 31, 2020, we had primarily euro-based open foreign currency forward contracts with notional amounts of $5.1 billion. With regard to foreign currency forward contracts that were open as of December 31, 2021, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2021, would have resulted in a reduction in fair value of these contracts of approximately $1.1 billion on this date and in the ensuing year, a reduction in income of approximately $390 million. With regard to contracts that were open as of December 31, 2020, a hypothetical 20% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December 31, 2020, would have resulted in a reduction in fair value of these contracts of $1.1 billion on this date and in the ensuing year, a reduction in income of $420 million. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on anticipated transactions that these foreign-currency-sensitive instruments were designed to offset.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had open, short-duration, foreign currency forward contracts that mature in one month or less, that had notional amounts of $0.7 billion and $1.0 billion, respectively, and that hedged fluctuations of certain assets and liabilities denominated in foreign currencies but were not designated as hedges for accounting purposes. These contracts had no material net unrealized gains or losses as of December 31, 2021 and 2020. With regard to these foreign currency forward contracts that were open as of December 31, 2021 and 2020, a hypothetical 5% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates on these dates would not have a material effect on the fair values of these contracts or related income in the respective ensuing years. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on assets and liabilities that these foreign-currency-sensitive instruments were designed to offset.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-price-sensitive financial instruments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we were exposed to price risk on equity securities included in our portfolio of investments, which were acquired primarily for the promotion of business and strategic objectives. These investments include publicly and privately held small-capitalization stocks, limited partnerships that invest in early-stage biotechnology companies and our investment in BeiGene. A 20% decrease in the aggregate value of our equity investment portfolio as of December 31, 2021 and 2020, would result in losses in fair value of approximately $1.4 billion and $1.2 billion, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Counterparty credit risks</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments, including derivatives, are subject to counterparty credit risk, which we consider as part of the overall fair value measurement. Our financial risk management policy limits derivative transactions by requiring that transactions be made only with institutions with minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch; and it places exposure limits on the amount with any individual counterparty. In addition, we have an investment policy that limits investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_112"></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to the financial statements and schedule listed in Item&#160;15(a)1 and (a)2 of Part IV and included in this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_115"></div><div style="margin-bottom:2pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined under the Securities Exchange Act Rule&#160;13a-15(e), that are designed to ensure that information required to be disclosed in Amgen&#8217;s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to Amgen&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen&#8217;s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgen&#8217;s management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation under the supervision and with the participation of our management, including Amgen&#8217;s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen&#8217;s disclosure controls and procedures. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determined that as of December 31, 2021, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter then ended that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_121"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP in the United States. However, all internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and reporting.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the COSO in Internal Control&#8212;Integrated Framework (2013 framework). Based on our assessment, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report appearing below, which expresses an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Amgen Inc. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Amgen Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Amgen Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and the financial statement schedule listed in the Index at Item&#160;15(a)2 and our report dated February 16, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-align:right;text-indent:22.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xMjQvZnJhZzpjNGQyNjU5YTE5ZGI0OWIwOTdhMjExMDE2ODU2ZmM3Mi90ZXh0cmVnaW9uOmM0ZDI2NTlhMTlkYjQ5YjA5N2EyMTEwMTY4NTZmYzcyXzEwOTk1MTE2MjgyMDUz_4b944334-039e-480a-b24b-47ba56c129e2">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xMjQvZnJhZzpjNGQyNjU5YTE5ZGI0OWIwOTdhMjExMDE2ODU2ZmM3Mi90ZXh0cmVnaW9uOmM0ZDI2NTlhMTlkYjQ5YjA5N2EyMTEwMTY4NTZmYzcyXzEwOTk1MTE2MjgyMDU0_516bffeb-710f-4acc-87cf-1631c5bfa97c">Los Angeles, California</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;16, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_127"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER INFORMATION</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_130"></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_133"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our Directors is incorporated by reference from the section entitled ITEM&#160;1&#8212;ELECTION OF DIRECTORS in our Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2021 (the Proxy Statement). Information about the procedures by which stockholders may recommend nominees for the Board of Directors is incorporated by reference from APPENDIX A&#8212;AMGEN INC. BOARD OF DIRECTORS GUIDELINES FOR DIRECTOR QUALIFICATIONS AND EVALUATIONS and OTHER MATTERS&#8212;Stockholder Proposals for the 2023 Annual Meeting in our Proxy Statement. Information about our Audit Committee, members of the committee and our Audit Committee financial experts is incorporated by reference from the section entitled CORPORATE GOVERNANCE&#8212;Audit Committee in our Proxy Statement. Information about our executive officers is contained in the discussion entitled Part I&#8212;Item&#160;1. Business&#8212;Information about our Executive Officers.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_136"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a Code of Ethics for the Chief Executive Officer and Senior Financial Officers applicable to our principal executive officer, principal financial officer, principal accounting officer or controller and other persons performing similar functions. To view this code of ethics free of charge, please visit our website at www.amgen.com. (The website address is not intended to function as a hyperlink, and the information contained in our website is not intended to be a part of this filing.) We intend to satisfy the disclosure requirements under Item&#160;5.05 of Form 8-K regarding an amendment to or a waiver from a provision of this code of ethics, if any, by posting such information on our website as set forth above.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_139"></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXECUTIVE COMPENSATION</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about director and executive compensation is incorporated by reference from the section entitled EXECUTIVE COMPENSATION in our Proxy Statement. Information about compensation committee matters is incorporated by reference from the sections entitled CORPORATE GOVERNANCE&#8212;Compensation and Management Development Committee and CORPORATE GOVERNANCE&#8212;Compensation Committee Report in our Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></td></tr></table></div><div><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_145"></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Existing Equity Compensation Plans</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information as of December 31, 2021, concerning the shares of our common stock that may be issued under any form of award granted under our equity compensation plans in effect as of December 31, 2021 (including upon the exercise of options, upon the vesting of awards of RSUs or when performance units are earned and related dividend equivalents have been granted).</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:54.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities to be issued upon exercise of outstanding options and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price of outstanding options and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by Amgen security holders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2009 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,217,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,987,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 1991 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,280,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total approved plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,220,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,267,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plan not approved by Amgen security holders:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Profit Sharing Plan for Employees in Ireland</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unapproved plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total all plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,220,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,509,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:7pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">The Amended and Restated 2009 Equity Incentive Plan employs a fungible share-counting formula for determining the number of shares available for issuance under the plan. In accordance with this formula, each option or stock appreciation right counts as one share, while each RSU, performance unit or dividend equivalent counts as 1.9 shares. The number under column (a) represents the actual number of shares issuable under our outstanding awards without giving effect to the fungible share-counting formula. The number under column (c) represents the number of shares available for issuance under this plan based on each such available share counting as one share. Commencing with the grants made in April 2012, RSUs and performance units accrue dividend equivalents that are payable in shares only to the extent and when the underlying RSUs vest or underlying performance units have been earned and the related shares are issued to the grantee. The performance units granted under this plan are earned based on the accomplishment of specified performance goals at the end of their respective three-year performance periods; the number of performance units granted represent target performance, and the maximum number of units that could be earned based on our performance is 200% of the performance units granted in 2019, 2020 and 2021. </span></div><div style="margin-bottom:5pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the number of outstanding awards under column (a) includes (i) 5,138,659 shares issuable upon the exercise of outstanding options with a weighted-average exercise price of $197.27; (ii) 3,362,823 shares issuable upon the vesting of outstanding RSUs (including 292,972 related dividend equivalents); and (iii) 1,715,660 shares subject to outstanding 2019, 2020 and 2021 performance units (including 88,269 related dividend equivalents). The weighted-average exercise price shown in column (b) is for the outstanding options only. The number of available shares under column (c) represents the number of shares that remain available for future issuance under this plan as of December 31, 2021, employing the fungible share formula and presumes the issuance of target shares under the performance units granted in 2019, 2020 and 2021 and related dividend equivalents. The numbers under columns (a) and (c) do not give effect to the additional shares that could be issuable in the event above target performance on the performance goals under these outstanding performance units is achieved. Maximum performance under these goals could result in 200% of target shares being awarded for performance units granted in 2019, 2020 and 2021.</span></div><div style="margin-bottom:5pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">This plan has terminated as to future grants. The number under column (a) with respect to this plan includes 3,550 shares issuable upon the settlement of deferred RSUs (including 774 related dividend equivalents).</span></div><div style="margin-bottom:5pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">The Profit Sharing Plan was approved by the Board of Directors on July 28, 2011. The Profit Sharing Plan permits eligible employees of the Company&#8217;s subsidiaries located in Ireland who participate in the Profit Sharing Plan to apply a portion of their qualifying bonus and salary to the purchase of the Company&#8217;s common stock on the open market at the market price by a third-party trustee as described in the Profit Sharing Plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Directors and Executive Officers and Certain Beneficial Owners</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about security ownership of certain beneficial owners and management is incorporated by reference from the sections entitled SECURITY OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS and SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS in our Proxy Statement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_151"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about certain relationships and related transactions and director independence is incorporated by reference from the sections entitled CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS and CORPORATE GOVERNANCE&#8212;Director Independence in our Proxy Statement.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_154"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the fees for professional services rendered by our independent registered public accountants is incorporated by reference from the section entitled AUDIT MATTERS&#8212;Independent Registered Public Accountants in our Proxy Statement.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_160"></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Index to Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Consolidated Financial Statements are included herein:</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page<br/>number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNjAvZnJhZzoyOTdkODRlZjkzODM0YzI3OGUwZDdlZTczM2UxNmE2ZC90YWJsZTo5MTNkMjgxMDEzNTA0MzM3OTc0YTVlY2NlY2ViYTQyYy90YWJsZXJhbmdlOjkxM2QyODEwMTM1MDQzMzc5NzRhNWVjY2VjZWJhNDJjXzEtMC0xLTEtODg1NDUvdGV4dHJlZ2lvbjo1ODEyMzE3ZjdmZjk0MGU2YTJlYWQyYmZhYzI2NGNkNV84Nzk2MDkzMDIyMjg0_c3697f78-d5c5-40c1-9ee7-3b228158d31e">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_175">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_175">1</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Income for each of the three years in the period ended December 31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_178">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_178">4</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_181">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_181">5</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_184">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_184">6</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_187">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_187">7</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_190">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_190">8</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_193">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_193">9</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Index to Financial Statement Schedules</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Schedule is filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:1pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page<br/>number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule II. Valuation and Qualifying Accounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_262">F-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a971cfaef98424f9692041d6ed3a222_262">55</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules are omitted because they are not applicable, not required or because the required information is included in the consolidated financial statements or notes thereto.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.34pt">Exhibits</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex21.htm">Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519270139/d655928dex101.htm">Amendment No. 1 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on October 17, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a23amendmentno2toapa.htm">Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a24letteragreementv3.htm">Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgen&#8217;s acquisition of Otezla</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex22.htm">Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/amgn-ex27_202193021xq3.htm">Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential)(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000144530513001107/amgn-exh31_2013331xq1.htm">Restated Certificate of Incorporation of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516466178/d46204dex31.htm">Amended and Restated Bylaws of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-97-000008.txt">Form of stock certificate for the common stock, par value $.0001 of the Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508040431/dex43.htm">Agreement of Resignation, Appointment and Acceptance dated February 15, 2008.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001006.txt">First Supplemental Indenture, dated February 26, 1997.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">8-1/8% Debentures due April 1, 2097.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">Officer&#8217;s Certificate of Amgen Inc., dated April 8, 1997, establishing a series of securities entitled &#8220;8 1/8% Debentures due April 1, 2097.&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000104746903026118/a2115639zex-4_1.htm">Indenture, dated August 4, 2003.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-98-000005.txt">Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede &amp; Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March&#160;31, 1998 on May&#160;13, 1998 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312507126045/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 30, 2007, including form of the Company&#8217;s 6.375% Senior Notes due 2037.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508121768/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 23, 2008, including form of the Company&#8217;s 6.90% Senior Notes due 2038.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312509007552/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated January 16, 2009, including form of the Company&#8217;s 6.40% Senior Notes due 2039.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510055545/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated March 12, 2010, including form of the Company&#8217;s 5.75% Senior Notes due 2040.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510211595/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 16, 2010, including form of the Company&#8217;s 4.95% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511178620/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated June 30, 2011, including form of the Company&#8217;s 5.65% Senior Notes due 2042.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511306300/d254287dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated November 10, 2011, including form of the Company&#8217;s 5.15% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511329468/d265264dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated December 5, 2011, including form of the Company&#8217;s 5.50% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512234621/d352967dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 15, 2012, including form of the Company&#8217;s 5.375% Senior Notes due 2043.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 15, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512390074/d410209dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 13, 2012, including form of the Company&#8217;s 4.000% Senior Notes due 2029.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex41.htm">Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 22, 2014, including form of the Company&#8217;s 3.625% Senior Notes due 2024.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312515165541/d919213dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated May 1, 2015, including forms of the Company&#8217;s 3.125% Senior Notes due 2025 and 4.400% Senior Notes due 2045. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on May 1, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516476783/d129782dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 25, 2016, including form of the Company&#8217;s  2.000% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex41.htm">Form of Permanent Global Certificate for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex42.htm">Terms of the Bonds for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516621372/d203675dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of June 14, 2016, including forms of the Company&#8217;s 4.563% Senior Notes due 2048 and 4.663% Senior Notes due 2051.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 14, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516686451/d187158dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 19, 2016, including forms of the Company&#8217;s 2.250% Senior Notes due 2023 and 2.600% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 19, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312517331065/d472956dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of November 2, 2017, including in the form of the Company&#8217;s 3.200% Senior Notes due 2027.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 2, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520044757/d894000dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 21, 2020, including forms of the Company&#8217;s 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes due 2030, 3.150% Senior Notes due 2040 and 3.375% Senior Notes due 2050.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on February 21, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520134934/d925911dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of May 6, 2020, including form of the Company&#8217;s 2.300% Senior Notes due 2031.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 6, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520222579/d60848dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Company&#8217;s 2.770% Senior Notes due 2053.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312520222579/d60848dex43.htm">Registration Rights Agreement, dated as of August 17, 2020, by and among Amgen Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP Paribas Securities Corp., Deutsche Bank Securities Inc., RBC Capital Markets, LLC, Blaylock Van, LLC and Siebert Williams Shank &amp; Co., LLC, as co-dealer managers. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex432_202131xq4.htm">Description of Amgen Inc.&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513145924/d475543ddef14a.htm#toc475543_21">Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as Appendix C to the Definitive Proxy Statement on Schedule 14A on April 8, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815415000010/amgn-ex102_2015331xq1.htm">First Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 4, 2015.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2015 on April 27, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000035/amgn-ex103_2016331xq1.htm">Second Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 2, 2016</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2016 on May 2, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20211231xq4.htm">Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20211231xq4.htm">and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20211231xq4.htm">on December </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex104_20211231xq4.htm">2, 2021.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20211231xq4.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20211231xq4.htm">and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20211231xq4.htm">on December </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex105_20211231xq4.htm">2, 2021.)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815418000004/exhibit106performanceaward.htm">Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2017 on February 13, 2018 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20211231xq4.htm">Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20211231xq4.htm">and Reinstated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20211231xq4.htm">on December </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex107_20211231xq4.htm">2, 2021.)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/amgn-ex108_20201231xq4.htm">Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on October 21, 2020.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312509105621/dex107.htm">Form of Grant of Non-Qualified Stock Option Agreement for the Amgen Inc. 2009 Director Equity Incentive Program.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1010-amgenxdirectorrs.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1010-amgenxdirectorrs.htm"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1011-amgenxdirectorca.htm">Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex109_20131231x10k.htm">Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1012_2016930xq3.htm">First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1014-secondamendmento.htm">Second Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 23, 2019.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex1015_20211231xq4.htm">Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000095012311048073/v58996exv10w9.htm">Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508228861/dex1019.htm">Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January&#160;1, 2009.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September&#160;30, 2008 on November&#160;7, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000144530513000364/amgn-ex1017_2012123110k.htm">First Amendment to the Amgen Inc. Executive Incentive Plan, effective December 13, 2012.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2012 on February 27, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000009/amgn-ex1016_2017033110q.htm">Second Amendment to the Amgen Inc. Executive Incentive Plan, effective January 1, 2017.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex1015_20131231x10k.htm">Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1017_2016930xq3.htm">First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1021-secondamendmentt.htm">Second Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2020.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex1023_20211231xq4.htm">Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/petergriffith-signedof.htm">Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex1025_20211231xq4.htm">Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519312129/d834361dex101.htm">Second Amended and Restated Credit Agreement, dated December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., as syndication agent.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 12, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513312834/d573775dex1054.htm">Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited dated May 10, 2002 (portions of the exhibit have been omitted pursuant to a request for confidential treatment) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K/A for the year ended December 31, 2012 on July 31, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000004/amgn-ex1032_20161231x10k.htm">Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2016 on February 14, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815419000037/amgn-ex282019630xq2.htm">Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012311047784/f58570exv10w1wi.htm">Collaboration Agreement, dated April 22, 1994, by and between Bayer Corporation (formerly Miles, Inc.) and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 by Onyx Pharmaceuticals, Inc. on May 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095014906000261/f20295exv10w1xiy.htm">Amendment to Collaboration Agreement, dated April 24, 1996, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095014906000261/f20295exv10w12.htm">Amendment to Collaboration Agreement, dated February 1, 1999, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000119312512081975/d265452dex101v.htm">Settlement Agreement and Release, dated October 11, 2011, by and between Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Pharma AG and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000119312512081975/d265452dex101iv.htm">Fourth Amendment to Collaboration Agreement, dated October 11, 2011, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815415000022/amgn-ex1043_2015630xq2.htm">Side Letter Regarding Collaboration Agreement, dated May 29, 2015, by and between Bayer HealthCare LLC and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2015 on August 5, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/sideletterregardingcol.htm">Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000009/amgn-exhibit1040_2017033110q.htm">Sourcing and Supply Agreement, dated January 6, 2017, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1041amgenxnovartism.htm">Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1042amend1tolicense.htm">Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1043amend2tonovarti.htm">Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/d275986dex101.htm">Amendment No. 3 to the Exclusive License and Collaboration Agreement, dated January 31, 2022, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential). (Filed as an exhibit to the Company&#8217;s Current Report on Form 8-K on January 31, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1041bridgecollaborati.htm">Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1042guaranteeagreement.htm">Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex991.htm">Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex992.htm">Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/a1046restatedamendment.htm">Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/d312223dex1055.htm">Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2012 on May 8, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/amgn-ex1037_20141231x10k.htm">Amendment No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-K for the year ended December 31, 2014 on February 19, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/amgn-ex10492020630xq2.htm">Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/amgn-ex1050_20201231xq4.htm">Amendment No. 7 to the Collaboration Agreement, dated December 17, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-1051_20211231xq4.htm">Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/amgn-ex1049_2021630xq2.htm">License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc. and Kyowa Kirin Co., Ltd. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2021 on August 4, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex21_20211231xq4.htm">Subsidiaries of the Company.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of the Independent Registered Public Accounting Firm. The consent is set forth on page 89 of this Annual Report on the 10-K.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney. The Power of Attorney is set forth on page 90 of this Annual Report on Form 10-K.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex31_20211231xq4.htm">Rule 13a-14(a) Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex32_20211231xq4.htm">Section 1350 Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(* = filed herewith)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(** = furnished herewith and not &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+ = management contract or compensatory plan or arrangement)</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_163"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K SUMMARY</span></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEN INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;PETER H. GRIFFITH</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23</span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-3 No. 333-236351) of Amgen Inc.,</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 No. 333-159377) pertaining to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, </span></div><div style="padding-left:40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 No. 33-39183) pertaining to the Amgen Inc. Amended and Restated Employee Stock Purchase Plan, </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 No. 33-39104, as amended by Form S-8 Nos. 333-144581 and 333-216719) pertaining to the Amgen Retirement and Savings Plan,</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 Nos. 33-47605, 333-144580 and 333-216715) pertaining to The Retirement and Savings Plan for Amgen Manufacturing, Limited (formerly known as the Retirement and Savings Plan for Amgen Manufacturing, Inc.), </span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statements (Form S-8 Nos. 333-81284, 333-177868, 333-216723 and 333-260723) pertaining to the Amgen Nonqualified Deferred Compensation Plan, and</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration Statement (Form S-8 Nos. 333-176240 and 333-260724) pertaining to the Amgen Profit Sharing Plan for Employees in Ireland;</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February 16, 2022, with respect to the consolidated financial statements of Amgen Inc. and the effectiveness of internal control over financial reporting of Amgen Inc. included in this Annual Report (Form 10-K) of Amgen Inc. for the year ended December 31, 2021.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young LLP</span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 16, 2022 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 24</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert A. Bradway, Peter H. Griffith and Jonathan P. Graham, or any of them, his or her attorney-in-fact, each with the power of substitution and re-substitution, for him or her in any and all capacities, to sign any amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ROBERT A. BRADWAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board, Chief Executive Officer<br/>and President, and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert A. Bradway</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;PETER H. GRIFFITH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter H. Griffith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;LINDA H. LOUIE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance and<br/>Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Linda H. Louie</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;WANDA M. AUSTIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wanda M. Austin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;BRIAN J. DRUKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Brian J. Druker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ROBERT A. ECKERT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert A. Eckert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;GREG C. GARLAND</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greg C. Garland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;CHARLES M. HOLLEY, JR.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charles M. Holley, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;S. OMAR ISHRAK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S. Omar Ishrak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;TYLER JACKS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tyler Jacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ELLEN J. KULLMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ellen J. Kullman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;AMY E. MILES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amy E. Miles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;RONALD D. SUGAR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ronald D. Sugar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;R. SANDERS WILLIAMS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R. Sanders Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Amgen Inc.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Amgen Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and the financial statement schedule listed in the Index at Item&#160;15(a)2 (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 16, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:14.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales deductions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company recorded accrued sales deductions of $5.2 billion. As described in Note 1 to the financial statements under the caption &#8220;Product sales and sales deductions,&#8221; revenues from product sales are recognized net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively sales deductions), which are established at the time of sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the estimation of sales deductions, which are netted against product sales, is complex, requires significant judgment, and the amounts involved are material to the financial statements taken as a whole. Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, and is based on an amount that reflects the consideration to which the Company expects to be entitled, which represents an amount that is net of accruals for estimated sales deductions. The estimated sales deductions are based on current contractual and statutory requirements, market events and trends, internal and external historical data, and forecasted customer buying patterns.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the sales deduction processes. This included testing controls over management&#8217;s review of significant assumptions and inputs used in the estimate of sales deductions, including actual sales, contractual terms, historical experience, wholesaler inventory levels, demand data and estimated patient population. We also tested management&#8217;s controls over the accuracy of forecasting demand activity as well as the completeness and accuracy of the significant components included in the final sales deduction estimates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimated sales deductions, we obtained management&#8217;s calculations for the respective estimates and performed the following procedures, among others. We tested management&#8217;s estimation process over the determination of sales discount accruals by developing an independent expectation of the estimated accrual balances, including comparing accrual balances recorded by management to those implied by historical payment trends, performing a lookback analysis using actual historical data to evaluate the forecasted amounts, assessing subsequent events to determine whether there was any new information that would require adjustment to the initial accruals, evaluating trends in actual sales and discount accrual balances, comparing cash receipts to product sales, confirming terms and conditions for a sample of contracts with the Company&#8217;s customers, testing a sample of credits issued and payments made throughout the year, and agreeing rates to underlying contract terms.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 6 to the consolidated financial statements, the Company operates in various jurisdictions in which differing interpretations of complex tax laws and regulations create uncertainty and necessitate the use of significant judgment in the determination of the Company&#8217;s unrecognized tax benefits related to allocation of profits among various jurisdictions (&#8220;transfer pricing&#8221;), particularly in the U.S. federal tax jurisdiction where the Company has significant assets and operations. In this regard, the Company uses significant judgment in (1) determining whether a tax position&#8217;s technical merits are more-likely-than-not to be sustained and (2) measuring the amount of tax benefit that qualifies for recognition. As of December 31, 2021, the Company accrued $3.5 billion of gross unrecognized tax benefits including those related to transfer pricing. Auditing the assessment of the technical merits and measurement of the Company&#8217;s unrecognized tax benefits is challenging and can be complex, highly judgmental, and based on interpretations of tax laws and regulations and application of those interpretations to the Company&#8217;s facts and circumstances.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company&#8217;s process to assess the technical merits of its tax positions, as well as management&#8217;s process to measure the unrecognized tax benefits of those tax positions, particularly in regard to transfer pricing. This included testing controls over management&#8217;s review of the inputs, calculations, assumptions and methods selected to measure the amount of tax benefits that qualify for recognition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We involved tax and transfer pricing specialists to assist in assessing the technical merits and measurement of certain of the Company&#8217;s unrecognized tax benefits. Depending on the nature of the specific tax position and, as applicable, developments with the relevant tax authorities, our procedures included obtaining and reviewing the Company&#8217;s correspondence with such tax authorities and evaluating certain third-party advice to support the Company&#8217;s evaluations and recorded positions. We used our knowledge of and experience with how the income tax laws and regulations related to transfer pricing are applied by the relevant tax authorities to evaluate the Company&#8217;s accounting for its unrecognized tax benefits. We evaluated developments in the applicable regulatory environments to assess potential effects on the Company&#8217;s recorded positions. We analyzed the assumptions and data used by the Company when it determined the amount of tax benefits to recognize, including applicable interest and penalties, and we tested the accuracy of those underlying calculations. We have also evaluated the Company&#8217;s income tax disclosures included in Note 6 in relation to these matters.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzUvZnJhZzo5ZTQ5OWIxODMwYjE0ZjUyYTk2OGE0ODFjZmExNjMxYy90YWJsZTo0YmNlZmI0Y2Y0Zjk0NDQ4YjRkOTA1M2U1ZTQ4MDMzMC90YWJsZXJhbmdlOjRiY2VmYjRjZjRmOTQ0NDhiNGQ5MDUzZTVlNDgwMzMwXzUtMi0xLTEtNzg4MTEvdGV4dHJlZ2lvbjo2YmY1ODAwYWViNzU0MzVkOWJkMzQ3YzA4NGNkOGMzZV84Nzk2MDkzMDIyMjUx_5a50214e-8b27-4672-a471-e634ab978a4e">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td></tr></table></div><div style="padding-right:13.5pt;text-align:right"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 1980.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzUvZnJhZzo5ZTQ5OWIxODMwYjE0ZjUyYTk2OGE0ODFjZmExNjMxYy90ZXh0cmVnaW9uOjllNDk5YjE4MzBiMTRmNTJhOTY4YTQ4MWNmYTE2MzFjXzEwOTk1MTE2Mjg4ODY1_84f2765a-075e-4297-b450-f307adc1f746">Los Angeles, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 16, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2021, 2020 and 2019 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzItMS0xLTEtNTU1NTQ_7227de08-8cc8-47fe-85bc-f1ec1c7e0784">24,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzItMy0xLTEtNTU1NTQ_4c4cbf07-21e8-474d-b95e-d677dcaece6c">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzItNS0xLTEtNTU1NTQ_8606d566-e1c5-4286-9699-15eaeb9e810f">22,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa4009b79ae4a1aaa88901012cdc38c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMtMS0xLTEtNTU1NTQ_34511cd8-70d9-438b-8580-daf651422474">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9dfed05d2a4cc7b238e87a2395d611_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMtMy0xLTEtNTU1NTQ_2f9f8186-65c7-4b02-a291-efee68e136e8">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5666794b15d1495f894c2e5fa67e1ff5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMtNS0xLTEtNTU1NTQ_05b37d21-8e14-47ec-8b4c-533c319b7454">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzQtMS0xLTEtNTU1NTQ_f27e77bf-d4c8-42e1-8a9b-df6354b8d2a4">25,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzQtMy0xLTEtNTU1NTQ_02b2841e-d29b-4ecf-82d1-fb86473acb2b">25,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzQtNS0xLTEtNTU1NTQ_7fbb289f-6cec-465e-8cc8-bed6febcd00c">23,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzctMS0xLTEtNTU1NTQ_bc0adb6a-7301-4f63-be9e-8db0e6d33b84">6,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzctMy0xLTEtNTU1NTQ_e0f22518-e7f6-4aaa-9236-4883b2f45c60">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzctNS0xLTEtNTU1NTQ_05d77ddd-c993-4b42-aa86-004aabf05aaf">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzgtMS0xLTEtNTU1NTQ_89a0cbc0-e06a-4604-8c46-229b1b4347f6">4,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzgtMy0xLTEtNTU1NTQ_8d0dc1f9-cb44-4161-8473-484b1847549e">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzgtNS0xLTEtNTU1NTQ_5d1c9172-c22e-4f06-aeca-102970b9f233">4,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMS0xLTEtNzg0MDc_8cf94d6f-660e-4c08-889b-911fa7d383c8">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMy0xLTEtNzg0MTA_2a1472a3-f40f-48ea-af29-ad9ed60cbc16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktNS0xLTEtNzg0MTI_ac643572-75c0-4847-9951-413bf63ba0db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMS0xLTEtNTU1NTQ_ac19a5fe-f6d6-4718-b48c-fb81550b12c8">5,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMy0xLTEtNTU1NTQ_551ab1e3-f84f-469b-8967-47e839fdba63">5,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktNS0xLTEtNTU1NTQ_cbbf0012-ee39-4e90-b20c-7340681f649f">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEwLTEtMS0xLTU1NTU0_8b8aa5f5-75d5-4f6b-9bf1-b0afed728347">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEwLTMtMS0xLTU1NTU0_89856fa2-a585-4636-aab3-ef1ca972be32">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OtherGeneralExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEwLTUtMS0xLTU1NTU0_e751f1fc-b65b-4324-9b97-187d389c4820">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzExLTEtMS0xLTU1NTU0_fa40a75f-34c1-4535-a15c-be9749890015">18,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzExLTMtMS0xLTU1NTU0_0d4c7bf1-abd9-4143-a8e1-b59d61682a1d">16,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzExLTUtMS0xLTU1NTU0_aa657aad-9614-4d8d-a576-1882ac7899e0">13,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEzLTEtMS0xLTU1NTU0_9dc28e7c-323f-4c8d-9944-8b3d6e82e751">7,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEzLTMtMS0xLTU1NTU0_d92b9965-0724-48f1-95af-6d92396e39ff">9,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEzLTUtMS0xLTU1NTU0_937f4b6f-b60d-4287-83f0-eb816ece56ce">9,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE2LTEtMS0xLTU1NTU0_179644f7-8ab2-4cd0-913f-7ca22d1169d7">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE2LTMtMS0xLTU1NTU0_7399d86d-22cf-4479-a7e3-8e55a19d3a21">1,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE2LTUtMS0xLTU1NTU0_0d1ed789-b0d4-413f-9004-ad29802a08f7">1,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE3LTEtMS0xLTU1NTU0_c5035f41-97c4-4b56-9814-5ce5d60ec548">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE3LTMtMS0xLTU1NTU0_16cdc567-9efd-4fbc-a353-74734c04e39d">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE3LTUtMS0xLTU1NTU0_600b23d6-0189-46ac-ab01-28227a146fe1">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE5LTEtMS0xLTU1NTU0_58baacb7-1419-4fd1-b775-0bb542ca95e2">6,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE5LTMtMS0xLTU1NTU0_61eda238-fb4f-484b-a703-1845fa7e95c6">8,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE5LTUtMS0xLTU1NTU0_54a055cd-de00-4e52-8dce-f16a1062262f">9,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIxLTEtMS0xLTU1NTU0_299d0eac-2523-4115-93e0-11437c55268c">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIxLTMtMS0xLTU1NTU0_c8b86c66-4c5d-41c2-85f8-e30cf5cc349d">869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIxLTUtMS0xLTU1NTU0_0e6477fd-4a4f-4228-8211-5aff9b9fc9de">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIzLTEtMS0xLTU1NTU0_da1a388d-a634-4b45-ab99-61edc358abf9">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIzLTMtMS0xLTU1NTU0_8bcce490-5beb-4ced-acfc-32645677e6d3">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIzLTUtMS0xLTU1NTU0_49f2e5f1-c55e-4ba1-87e4-8ccf1852e398">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI2LTEtMS0xLTU1NTU0_7e0d204b-d80f-496e-9b61-4a5994ed79c0">10.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI2LTMtMS0xLTU1NTU0_a1a34e62-ab49-4b66-b356-22bf85314a40">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI2LTUtMS0xLTU1NTU0_0236bf44-0cf2-479d-9c46-7c772b7b5a8d">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI3LTEtMS0xLTU1NTU0_8b124835-8cb3-452c-8523-9106b91fd949">10.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI3LTMtMS0xLTU1NTU0_7370c7a8-58ee-4586-a527-fbeb1a18dbc4">12.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI3LTUtMS0xLTU1NTU0_e93d53c2-3af0-4400-9a63-f0e8d9318345">12.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in the calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMwLTEtMS0xLTU1NTU0_97200bcc-2442-4f14-abc0-308681eb0ef7">570</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMwLTMtMS0xLTU1NTU0_cbfffef2-1b9e-47f1-aad9-a7c6e826fb86">586</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMwLTUtMS0xLTU1NTU0_b0df7951-e203-4d72-9d29-5c57eabfbce9">605</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMxLTEtMS0xLTU1NTU0_f8c1437a-ca8c-4804-86cd-710209a850ec">573</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMxLTMtMS0xLTU1NTU0_b726ec00-aca0-4afb-be88-3cc413dc1d4e">590</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMxLTUtMS0xLTU1NTU0_038782c6-5bf3-4e3e-869a-7e11e374ef50">609</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2021, 2020 and 2019 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzEtMS0xLTEtNTU1NTQ_9f6ba638-3cc7-4ed9-9504-e3f7f706d317">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzEtMy0xLTEtNTU1NTQ_6f6a5c04-9ed0-4201-88a1-9c9b9468ccff">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzEtNS0xLTEtNTU1NTQ_14ab7bad-a871-4ae0-8b9b-224a8337f3e3">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of reclassification adjustments and taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzMtMS0xLTEtNTU1NTQ_d7c0d144-e124-4326-bfe2-f18ff797536b">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzMtMy0xLTEtNTU1NTQ_18e6da07-a794-464d-8a94-56fe93d4db3b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzMtNS0xLTEtNTU1NTQ_a181bb12-8c3e-4ea3-902a-e9236ed3a267">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzQtMS0xLTEtNTU1NTQ_561ed24b-ce24-448e-bcd2-1bc397915577">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzQtMy0xLTEtNTU1NTQ_960652cb-1c5c-4812-aba8-37d3095e2fc5">438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzQtNS0xLTEtNTU1NTQ_492b0f71-5a44-4a3d-97e5-d131cd192c4b">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzUtMS0xLTEtNTU1NTQ_28767772-181d-421c-bb37-051447ecf3bb">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzUtMy0xLTEtNTU1NTQ_bf4bcc22-38b6-49a7-8c0c-fa192241250b">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzUtNS0xLTEtNTU1NTQ_626ba57c-0b68-4e7c-8534-ca3542a30c5a">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzYtMS0xLTEtNTU1NTQ_e368f3fa-8d80-4401-81c0-180e81e74966">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzYtMy0xLTEtNTU1NTQ_357d77ce-9ade-43c5-93c0-b67783827ecd">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzYtNS0xLTEtNTU1NTQ_f1c669ee-88ad-45c2-ad5c-fcc223bec4f3">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzctMS0xLTEtNTU1NTQ_426c5fa2-c342-468f-ba47-342ebce885ae">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzctMy0xLTEtNTU1NTQ_99711c90-1059-42ce-9ca4-4a5b8df321c8">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzctNS0xLTEtNTU1NTQ_6cce17d0-e6f2-4e25-ae30-49948c6dba7f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzgtMS0xLTEtNTU1NTQ_8c8d5f13-6965-458b-b097-f2092ac4fd35">6,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzgtMy0xLTEtNTU1NTQ_d48f1215-c614-460f-9c42-464b93ba11d2">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzgtNS0xLTEtNTU1NTQ_5022aa5d-befe-4a01-a997-3e8d1c34a64f">8,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021 and 2020 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMtMS0xLTEtNTU1NTQ_6f5e0670-2be9-4fa7-bda5-b325d7a4a4a7">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMtMy0xLTEtNTU1NTQ_327d62c0-30d3-40ff-b27b-07fa740f6a8c">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzQtMS0xLTEtNTU1NTQ_cc16f07e-d5b0-4ac3-92a9-cd64bf936550">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzQtMy0xLTEtNTU1NTQ_bb547790-d41c-4c71-92bf-a34305467e7f">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzUtMS0xLTEtNTU1NTQ_28e1c057-b1fd-46b5-8b6c-34929a7e62b4">4,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzUtMy0xLTEtNTU1NTQ_59e35f46-e18b-467c-b219-91d01b04b11d">4,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzYtMS0xLTEtNTU1NTQ_8ac1f156-dc03-4dcc-829d-29052bcf7828">4,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzYtMy0xLTEtNTU1NTQ_8ee9f433-1279-441f-b44b-1bdccd69980a">3,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzctMS0xLTEtNTU1NTQ_07a04e09-2883-4f0c-a5fc-26ba26bebf7c">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzctMy0xLTEtNTU1NTQ_8b42243e-a5a0-4689-9c22-6e00dae0c0ff">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzgtMS0xLTEtNTU1NTQ_e7712d53-5000-4fd9-8e4c-0425f5682829">19,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzgtMy0xLTEtNTU1NTQ_d50cb2ce-7361-4e25-a250-ec12472f140b">21,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEwLTEtMS0xLTU1NTU0_f9e6b26e-875e-498d-923b-30288a2baac2">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEwLTMtMS0xLTU1NTU0_d3e32e46-5355-4922-bfe9-7b04b85c67fc">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzExLTEtMS0xLTU1NTU0_3af9470d-d3e6-4201-a672-aa26196a591c">15,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzExLTMtMS0xLTU1NTU0_3b316478-f4a0-41e5-ae60-53e353e337ad">16,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEyLTEtMS0xLTU1NTU0_d25676a5-1acf-4046-afe3-3bf28d54ccbc">14,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEyLTMtMS0xLTU1NTU0_0a0ee5b1-0c1a-4f64-b8ff-cb95b1be58f7">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEzLTEtMS0xLTU1NTU0_2a0d5b19-dfa9-4d4b-a19e-fb4437208fad">6,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEzLTMtMS0xLTU1NTU0_8e2be61f-c48a-4c2e-bbe3-c97432393948">5,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE0LTEtMS0xLTU1NTU0_c7b481b3-d454-4494-824b-502886aeac91">61,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE0LTMtMS0xLTU1NTU0_d39a4bfd-6ce9-4a42-97a2-3351d351f829">62,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE4LTEtMS0xLTU1NTU0_153bbf31-f95e-44aa-b61a-0637d2f553dd">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE4LTMtMS0xLTU1NTU0_801dc95a-8b3b-419f-be24-c4c7100e657a">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE5LTEtMS0xLTU1NTU0_6a444282-57fe-408f-b25a-750af46b2812">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE5LTMtMS0xLTU1NTU0_8b5216bd-92ad-453f-a624-91dadd72b938">10,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIwLTEtMS0xLTU1NTU0_31d4bddc-f2db-4e0b-91eb-9e3dabb143db">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIwLTMtMS0xLTU1NTU0_b2fd9d93-9e13-4382-b743-027ee99421a5">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIxLTEtMS0xLTU1NTU0_ca34269e-b446-4130-adc3-b7426e36fc51">12,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIxLTMtMS0xLTU1NTU0_bfdb6d0c-faac-4cf2-b9b0-6fdd9cc1b138">11,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIzLTEtMS0xLTU1NTU0_ec15eaab-f857-4597-a4be-f8769b2f8766">33,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIzLTMtMS0xLTU1NTU0_92d463e8-201e-4f12-8c8d-a713b5749686">32,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI1LTEtMS0xLTU1NTU0_90b5f1bc-4ca0-411b-b778-772359168a10">6,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI1LTMtMS0xLTU1NTU0_f97f9af1-88ec-4055-b2e8-78285b20ff14">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI2LTEtMS0xLTU1NTU0_e04fa956-1209-4446-812a-3783677d3ddf">2,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI2LTMtMS0xLTU1NTU0_e614863e-900b-4ac7-9ad9-e06fe2e58224">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingencies and commitments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI4LTEtMS0xLTU1NTU0_66fc0b8f-ac44-4c29-979c-98d59751286d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI4LTMtMS0xLTU1NTU0_3e31997c-b046-4924-a69e-58bd2eb3f07d"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital; $<ix:nonFraction unitRef="usdPerShare" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNDk_23c071fa-bfc9-4229-a985-02bf1960e4fb"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNDk_4092ff15-305e-4a0e-8104-b8dcabdc2a03">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNzM_8e593125-9e6d-4a9e-a215-5330268c3a88"><ix:nonFraction unitRef="shares" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNzM_f7a75665-3bba-4f58-88e7-297142de6791">2,750.0</ix:nonFraction></ix:nonFraction> shares authorized; outstanding&#8212;<ix:nonFraction unitRef="shares" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfMTA4_59335bb2-9e73-4f96-8fda-bdebc0181354">558.3</ix:nonFraction> shares in 2021 and <ix:nonFraction unitRef="shares" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfMTMw_699f2105-3b38-451d-95a1-41549573c639">578.3</ix:nonFraction> shares in 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTEtMS0xLTU1NTU0_d2036425-8a6a-46e1-8977-cdb5bb207b65">32,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTMtMS0xLTU1NTU0_fb1a26f1-d9a6-486e-9424-9749a0ab53fe">31,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMyLTEtMS0xLTU1NTU0_42540228-ac7c-4035-a46c-d01af3b4b132">24,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMyLTMtMS0xLTU1NTU0_7453bddd-7e06-4c0f-80ed-ca5b0e291d98">21,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMzLTEtMS0xLTU1NTU0_935aab3b-66a3-40d8-882b-7f19972f1641">796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMzLTMtMS0xLTU1NTU0_fc857877-7b95-4229-81d8-f9be58f82e1f">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM0LTEtMS0xLTU1NTU0_d268dc95-10c0-4a27-abad-423ac0c6f0fc">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM0LTMtMS0xLTU1NTU0_5b38871f-d452-4839-bdf8-8c0ddced8b03">9,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM1LTEtMS0xLTU1NTU0_777f29e7-50de-4417-a521-cccafa25410e">61,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM1LTMtMS0xLTU1NTU0_99d40b08-833b-486b-b2d9-8694769a747a">62,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2021, 2020 and 2019 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares<br/>of&#160;common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>stock and<br/>additional<br/>paid-in&#160;capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>(loss) income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dfa3d2f9c9049c0a19ece84de2ff2ff_I20181231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtMS0xLTEtNTU1NTQ_32dcc8a5-c1bc-4b7e-85e6-d9e406e96895">629.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07c6d9499a1435a873c87b9197752bb_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtMy0xLTEtNTU1NTQ_dfe5a2eb-8242-4eda-8cc1-a08295591c2d">31,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i883c7889246b4351952e694e54ad42f3_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtNS0xLTEtNTU1NTQ_f3d00d7b-bd9f-4da1-a1d1-77c12402851f">17,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f4705aa9b489a9965276d6b9e48de_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtNy0xLTEtNTU1NTQ_a4ae3580-fdf6-4ac7-8981-8873b1108b0a">769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtOS0xLTEtNTU1NTQ_f615c16a-00de-4616-af70-83bda6dd1865">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzMtNS0xLTEtNTU1NTQ_be324798-1ae2-4370-b552-d91d851a4f42">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzMtOS0xLTEtNTU1NTQ_27056b99-1b7d-4082-866b-d25466b7d20d">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzQtNy0xLTEtNTU1NTQ_63a87a68-9634-4ef4-a273-b97913102207">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzQtOS0xLTEtNTU1NTQ_33d05379-2d75-4626-9c7c-da7d7e9dfd29">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzUtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0NzUwMTkxZmU3ZWU0NWRkOGE5MjE1ODI0OGVmMTM5NF84Nzk2MDkzMDIyMjc5_1c65bb51-df28-4d5e-a52a-cbb3d6d67614">5.95</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzUtNS0xLTEtNTU1NTQ_9b969393-3d84-4935-b471-a2c0426d5975">3,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzUtOS0xLTEtNTU1NTQ_51ae1f25-f28f-4427-a38f-f674bd32f8ff">3,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a8de5ba86f046cdb69fc0f4c708fc92_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzYtMS0xLTEtNTU1NTQ_e928d9f5-9f86-4b85-a8e2-d4639ac84fd0">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzYtMy0xLTEtNTU1NTQ_44bba085-2db7-4acc-a2f6-16d9eb589e3f">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzYtOS0xLTEtNTU1NTQ_58657854-e836-4a4f-843f-973744002597">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzctMy0xLTEtNTU1NTQ_32b0ebb4-8429-4685-8868-d7220bec1c23">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzctOS0xLTEtNTU1NTQ_d94ebf84-6c40-44da-be17-7c4e37d83267">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzgtMy0xLTEtNTU1NTQ_c0f301e7-0375-4c2d-8df3-b945bc6b6535">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzgtOS0xLTEtNTU1NTQ_975fd2a8-d6ac-498e-a19d-6266d11ea718">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1a8de5ba86f046cdb69fc0f4c708fc92_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzktMS0xLTEtNTU1NTQ_631c15aa-c45f-4185-aeb3-9e3321ad7764">40.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzktNS0xLTEtNTU1NTQ_9f426de0-2b56-4780-a6c4-714197bbe206">7,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzktOS0xLTEtNTU1NTQ_69dfc282-44f2-474a-bce7-999dca3c8d64">7,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59abc98712f3458ba5b91a6534b6a125_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTEtMS0xLTU1NTU0_c8ab1917-cfb5-4a5d-ac92-11c7340a87bc">591.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace73d6c035d4a77a2cbffa4ce90f25e_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTMtMS0xLTU1NTU0_2ae02194-b4b3-42eb-9ace-f2d5c2ebf084">31,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i661e28e3d2d84263805b3d206b050c22_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTUtMS0xLTU1NTU0_9d2fd1c2-4809-4d78-9512-a388aff8ffeb">21,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea207d0ec0394b108fc793525231d205_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTctMS0xLTU1NTU0_be5b828a-8b5b-4957-97ed-3cf3e1e2b6d0">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTktMS0xLTU1NTU0_280545d2-2046-45c1-84f2-93479df4c46f">9,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of changes in accounting principles, net of taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf1a1b1a0dce4a0f9ea205178fdca9c5_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzExLTUtMS0xLTc0NjQ0_f2851f60-4fdf-4153-a78d-53ce3c6772dc">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719c98f9ce454a51b25b0be7d1e61269_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzExLTktMS0xLTU1NTU0_b125439d-5b44-433d-bd9f-38f88cbe79f8">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEyLTUtMS0xLTU1NTU0_dd4607f3-bb52-4c40-8eb3-e017a3743434">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEyLTktMS0xLTU1NTU0_be674299-2a8e-4da8-a04a-e24087fe0669">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEzLTctMS0xLTU1NTU0_592782cd-f461-4d0b-9703-ac85320dee41">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEzLTktMS0xLTU1NTU0_617c2977-9d5c-4186-8bdb-a3f2755ef369">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246NmNhM2QxNjZiM2YxNDQ0MWJlZjBkYzg1OWY4ZTAyMmZfODc5NjA5MzAyMjI4NQ_afc6a6f8-906e-4b2d-9c6b-f80e1e02b46f">6.56</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE0LTUtMS0xLTU1NTU0_e1ed8585-815c-4969-9670-87dc853ca7f6">3,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE0LTktMS0xLTU1NTU0_f758cb48-cfc6-48d9-9238-f0ba7bb7388c">3,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69699f22fd2341d793a1b05ac851fe93_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE1LTEtMS0xLTU1NTU0_25104f3b-ecf3-42ff-8906-b1238b05a827">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE1LTMtMS0xLTU1NTU0_36b0926f-43a1-4e54-a073-d2ba3cb270cc">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE1LTktMS0xLTU1NTU0_88f61614-b059-4c72-8153-a5e1893294cb">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE2LTMtMS0xLTU1NTU0_b30dc13d-4bbf-4adf-a03d-58057f7bc07f">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE2LTktMS0xLTU1NTU0_7077a374-19ed-4ffe-ab4f-e6e18035c984">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE3LTMtMS0xLTU1NTU0_01a7239b-0099-4b5a-a377-a295397930b3">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE3LTktMS0xLTU1NTU0_21f7327f-9a9f-4779-8fa8-ea56fa3e2b5c">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i69699f22fd2341d793a1b05ac851fe93_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE4LTEtMS0xLTU1NTU0_48cc3420-8bfc-434d-8a80-faddf7a5cac9">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE4LTUtMS0xLTU1NTU0_3842de9a-fec6-4eb5-a504-c56567b3ca18">3,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE4LTktMS0xLTU1NTU0_e5086e29-a9de-4b4a-923b-62058fe2bc7e">3,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d2ab0ebd9f7498a91b623bb412e8f34_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTEtMS0xLTU1NTU0_eb951c49-f2e0-42f0-9b23-6fe8a1fc4059">578.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810c9e939c3947a6b2840daa5f56ecbb_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTMtMS0xLTU1NTU0_b535863b-b05a-43a0-8912-d70f3f859a4f">31,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc2047b094b4f3391b29249a580f128_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTUtMS0xLTU1NTU0_d9def424-3108-4020-bdc8-24c6280cc43e">21,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2766f3376fe7415ab521166b30e8525e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTctMS0xLTU1NTU0_f8df43d0-5b76-434f-99c4-1e836031615e">985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTktMS0xLTU1NTU0_b0ef75a1-e071-4915-aa6e-bc262c5f9da4">9,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIxLTUtMS0xLTU1NTU0_0b50ba35-6a2b-44fd-b546-d7382b64b8c2">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIxLTktMS0xLTU1NTU0_368bf1fd-2a16-4ba7-8cfd-d052e76feca3">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIyLTctMS0xLTU1NTU0_ca8a907e-bf2e-4f7c-8c0a-26df14e3e342">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIyLTktMS0xLTU1NTU0_069f6f3b-9b4f-49e7-8f84-9efc636be0e1">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NjY3MDRkYzA1NTYzNGY0MjliMWZmM2FiYmUzZDFiOTZfODc5NjA5MzAyMjI2OA_3836fada-ecd2-44e9-9afb-95e88c171aad">7.22</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIzLTUtMS0xLTU1NTU0_86222be2-294e-44d2-9817-d3cd3d4c6518">4,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIzLTktMS0xLTU1NTU0_f77e37ff-5b19-4420-845c-66dcdc2c771c">4,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71b12895707c4d109b2ebe044f17363e_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI0LTEtMS0xLTU1NTU0_97b90921-9909-4021-9c75-ab309f95da4c">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI0LTMtMS0xLTU1NTU0_4219e5d1-7205-4e7b-ab4e-035c3dad7e9d">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI0LTktMS0xLTU1NTU0_ba8442c7-cca7-4d61-8d94-8f5bb3998936">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI1LTMtMS0xLTU1NTU0_fb99e447-0ec5-420b-ab2b-6b433364692f">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI1LTktMS0xLTU1NTU0_29b473a1-46f2-463d-8d5a-474177bd51c0">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI2LTMtMS0xLTU1NTU0_02fd1a89-385a-4991-a01c-20244038764b">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI2LTktMS0xLTU1NTU0_8ea67ca8-cf44-462d-beb3-ed7e7a3c0827">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i71b12895707c4d109b2ebe044f17363e_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI3LTEtMS0xLTU1NTU0_77587b66-0ac1-42fc-891b-995c4b25ae4b">21.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI3LTUtMS0xLTU1NTU0_32530f0d-686a-431a-9e6b-f80a08c42d8f">4,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI3LTktMS0xLTU1NTU0_1b60e4d9-0928-46ca-adbf-fc1687169ca9">4,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i198f13e9ae764a128ee94408e59bd0e9_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTEtMS0xLTU1NTU0_33f9beec-44a4-440e-9d0a-13ea0255364c">558.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64483c0647e5467db4e1fb64385c92da_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTMtMS0xLTU1NTU0_559514d6-0620-40e1-a168-a07f4482ec51">32,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac218800d9e4f97b70805d4885f19de_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTUtMS0xLTU1NTU0_6a04a603-ff19-498c-9f1d-0f7041259413">24,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5a12fd9b94548e0a6d019cff9050821_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTctMS0xLTU1NTU0_6e7a97f3-a6ac-4904-8c93-d264425ce415">796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTktMS0xLTU1NTU0_685268c3-575c-48f8-962d-64497b7ae20a">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2021, 2020 and 2019 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzItMS0xLTEtNTU1NTQ_1909a243-dfdf-4297-ae75-342bf7b364de">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzItMy0xLTEtNTU1NTQ_15366c96-b798-48ca-a0a5-2add32de0df5">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzItNS0xLTEtNTU1NTQ_d365c01b-bf96-4517-bc07-290c16351600">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation, amortization and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMtMS0xLTEtNTU1NTQ_915b00fe-f408-43fc-82e6-546b8f40d75f">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMtMy0xLTEtNTU1NTQ_7bad2fc2-a89f-4fea-83e6-ae59ded63965">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMtNS0xLTEtNTU1NTQ_d7e17b01-5ba1-4515-929b-df40d1f431c7">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzQtMS0xLTEtNTU1NTQ_25c6684e-d8a9-468a-ae2c-40b88cc07c58">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzQtMy0xLTEtNTU1NTQ_ff80ed2c-580a-4ffd-bcbc-83a6057cb514">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzQtNS0xLTEtNTU1NTQ_77c00d07-0d4d-4542-a3d9-0de6b4f6b1ab">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzUtMS0xLTEtNTU1NTQ_a08e9ad1-08b2-424e-ac51-f06a9d132325">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzUtMy0xLTEtNTU1NTQ_be29b857-fbfc-4162-940a-0b77577a8bc5">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzUtNS0xLTEtNTU1NTQ_3ccea856-040f-4837-a49d-098da374c059">289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMS0xLTEtNjE5NzM_92d29478-9c5b-4d91-b150-89c6ae2dbfbc">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMy0xLTEtNjE5ODA_bbc8b4f7-f612-4e05-8e1c-3094388ba855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtNS0xLTEtNjE5ODM_1e3574f6-e9df-4cfa-bcee-1de7ab014ddf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMS0xLTEtNTU1NTQ_941e612b-5375-4c0b-8e5f-766b4d69707f">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMy0xLTEtNTU1NTQ_f397b279-2ac4-467b-8723-8aee1cefbec6">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtNS0xLTEtNTU1NTQ_91ed6d7c-8424-4da6-a0bf-a794efceace8">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzgtMS0xLTEtNTU1NTQ_f5a4e0e0-e3e7-4656-9981-da13d873c44a">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzgtMy0xLTEtNTU1NTQ_3b43e4f4-5310-42ae-b596-6244083ad888">427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzgtNS0xLTEtNTU1NTQ_4f0e4cc9-af7a-48f2-8bee-1360afbcb8da">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzktMS0xLTEtNTU1NTQ_b2640c87-569b-4ac4-b476-c46b8556c1fc">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzktMy0xLTEtNTU1NTQ_4d4073d7-da69-4263-81eb-bf353f7faad3">215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzktNS0xLTEtNTU1NTQ_409207a8-67e1-408f-8f9d-8217079e428b">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEwLTEtMS0xLTU1NTU0_e2216991-9723-4b99-9bd2-60f655f2e5c8">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEwLTMtMS0xLTU1NTU0_2f5d8920-80a9-491b-80d2-98d4a07a0e65">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEwLTUtMS0xLTU1NTU0_5c641afa-ba15-482b-98a9-ae08dca190e2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzExLTEtMS0xLTU1NTU0_36608f55-7395-4474-9b6d-5bea63614453">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzExLTMtMS0xLTU1NTU0_99b04bfd-bbcc-4dba-845f-7cc079a2930a">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzExLTUtMS0xLTU1NTU0_e84fcbcd-6db9-4178-8632-369fd298b495">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEyLTEtMS0xLTU1NTU0_8ca13632-5a3d-4ced-98fd-ef09ecfc5d56">854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEyLTMtMS0xLTU1NTU0_64bb12b0-4212-4ad1-8541-cd47279b6bbc">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEyLTUtMS0xLTU1NTU0_4270e590-147e-4169-9520-fe2cec68f687">585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEzLTEtMS0xLTU1NTU0_e52798cd-85e2-4e52-84b6-05cf51a0caff">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEzLTMtMS0xLTU1NTU0_ffb8300f-d5a4-46e9-ba67-bbef58f008ce">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEzLTUtMS0xLTU1NTU0_44ca753a-cf91-4771-a16a-22c0cb2437bd">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE0LTEtMS0xLTU1NTU0_e3a1bec3-b49a-4491-a99e-915054170e73">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE0LTMtMS0xLTU1NTU0_11116f21-962c-44d5-aecc-b73048f540e9">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE0LTUtMS0xLTU1NTU0_7d4477e7-f707-4654-9d02-5ebd9e53ed55">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE1LTEtMS0xLTU1NTU0_fac21cb6-2b37-4912-b03e-f348dcca6513">9,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE1LTMtMS0xLTU1NTU0_f3a5aa7b-5406-4e48-994b-d891131d4183">10,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE1LTUtMS0xLTU1NTU0_b0737e4d-258c-407b-9a2e-9fa884e09fbd">9,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE3LTEtMS0xLTU1NTU0_6232a027-6510-4db5-b0c6-1000e4f3e6ae">8,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE3LTMtMS0xLTU1NTU0_87a2b7ff-921c-4124-b890-f9b6f78c5fef">8,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE3LTUtMS0xLTU1NTU0_654c14e8-230b-4279-84fb-2b17ad42d61c">9,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE4LTEtMS0xLTU1NTU0_4c86f2d3-c7ce-4ea6-8245-33314b3a8c7d">4,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE4LTMtMS0xLTU1NTU0_0ada219b-451d-4b20-a533-22b095824dfe">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE4LTUtMS0xLTU1NTU0_69b244fb-ff2a-46b0-a292-dda4a8b96c27">8,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE5LTEtMS0xLTU1NTU0_875aa772-3bb1-46e3-ab01-80f29196151a">8,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE5LTMtMS0xLTU1NTU0_a7af7b36-921c-464c-8389-52ca1ad0d44a">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE5LTUtMS0xLTU1NTU0_7b1fb365-49eb-4d0c-a03e-63f37e9289df">20,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIwLTEtMS0xLTU1NTU0_bbc26e2b-c018-4f37-9d46-7fc418cca85b">880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIwLTMtMS0xLTU1NTU0_38430467-594c-48a4-b734-7d4fb7d42aec">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIwLTUtMS0xLTU1NTU0_085c4193-6862-4d19-a610-21aa0d4b039b">618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIxLTEtMS0xLTU1NTU0_6acb17e6-3115-4dba-8831-c5ea676ac022">2,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIxLTMtMS0xLTU1NTU0_6b63f3bf-ef50-44d8-9c3f-53491b0ef0ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIxLTUtMS0xLTU1NTU0_6e7a6b0f-6d9b-4d07-a8c4-7d447f803ac0">13,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIyLTEtMS0xLTU1NTU0_58aa8041-4880-4a25-88c0-773d52a4ee6b">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIyLTMtMS0xLTU1NTU0_bb4c793b-2c2f-4e69-b53a-33de1deef3ad">3,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIyLTUtMS0xLTU1NTU0_bb89f7f1-f905-407e-9b1d-f79d0ac131c3">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIzLTEtMS0xLTU1NTU0_686b5a6f-0a22-423a-aa25-da317beae134">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIzLTMtMS0xLTU1NTU0_5127af6e-f211-40bf-a0a4-5009256d1764">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIzLTUtMS0xLTU1NTU0_57572866-16b2-4dd5-b358-eb0c316f8373">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI0LTEtMS0xLTU1NTU0_b2812c39-7251-4051-81b6-490569f8228f">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI0LTMtMS0xLTU1NTU0_020782a8-ac58-40b8-afac-d6f9f41d3ca2">5,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI0LTUtMS0xLTU1NTU0_02c73839-72da-4121-abdd-17f56b45ade9">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI2LTEtMS0xLTU1NTU0_7183a8d6-9ca5-4218-a895-2a40ae278d43">4,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI2LTMtMS0xLTU1NTU0_f80a46df-9e07-4e32-92ae-9ed1612be967">8,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI2LTUtMS0xLTU1NTU0_8a04b431-93ea-4996-8507-911ada909942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI3LTEtMS0xLTU1NTU0_8f5ffced-02d9-4f01-8f27-de04cf9566f1">4,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI3LTMtMS0xLTU1NTU0_dd9b8591-63d1-4856-a500-4246388e9bc9">6,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI3LTUtMS0xLTU1NTU0_570e566d-c297-44d3-97c2-b0c6b6a1bcad">4,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI4LTEtMS0xLTU1NTU0_18c5c0cc-072c-4c57-a959-f08029c59128">4,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI4LTMtMS0xLTU1NTU0_e85cdb60-371c-4b2a-92bc-7b48881a2024">3,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI4LTUtMS0xLTU1NTU0_1d9b9282-dcce-4b7b-8918-4d99ea2f182d">7,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI5LTEtMS0xLTU1NTU0_57068e28-9f38-4b68-80b3-1198ce090414">4,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI5LTMtMS0xLTU1NTU0_0c7f1f68-5bf9-46ed-ab05-e9673f4fb2b7">3,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI5LTUtMS0xLTU1NTU0_ba80112f-c58b-4677-b4c0-5bab0729093d">3,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMxLTEtMS0xLTU1NTU0_d3b472f4-793c-4cc7-87e8-c8dc416aaae3">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMxLTMtMS0xLTU1NTU0_c34de9ce-82c5-4405-825c-bf5540291fb7">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMxLTUtMS0xLTU1NTU0_2973f4fc-d57a-4add-8ffd-413c3eb86126">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMyLTEtMS0xLTU1NTU0_c3adb482-dd93-4b21-8ac7-da67c1b8a62e">8,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMyLTMtMS0xLTU1NTU0_021fd17a-261b-4f97-bf42-db65469e8331">4,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMyLTUtMS0xLTU1NTU0_4f96ef8f-94d4-4472-838d-77379779e0b4">15,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMzLTEtMS0xLTU1NTU0_e9038253-7548-488e-a1b2-924acb4bae12">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMzLTMtMS0xLTU1NTU0_60f99738-d283-46ce-b1e6-cbc4b096f36c">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMzLTUtMS0xLTU1NTU0_61738c50-ecff-47f5-944d-56ee6e49375a">908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM0LTEtMS0xLTU1NTU0_75613c29-652b-4142-8d9e-e825ee22a88b">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM0LTMtMS0xLTU1NTU0_c45263cd-b512-4420-854d-3ee62da29bb4">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM0LTUtMS0xLTU1NTU0_ddda603f-22df-458f-9893-b33e394dbe75">6,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM1LTEtMS0xLTU1NTU0_53fff926-2253-4700-a83a-3cbb82539d1b">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM1LTMtMS0xLTU1NTU0_aee81569-3597-4564-a4e0-290547d2fcc9">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM1LTUtMS0xLTU1NTU0_dd9b821b-e547-48da-9c7b-01d785a1db5d">6,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021 </span></div><div id="i2a971cfaef98424f9692041d6ed3a222_196"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzEwOTk1MTE2NjY3NDY_b80923a1-74ec-429d-81f6-2c28d7c5273f" continuedAt="i0e0d4a3520d44cd285be2a144828bda1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i0e0d4a3520d44cd285be2a144828bda1" continuedAt="i0e7d9f666594458a813549277a734130"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:NatureOfOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTI3_a1ea30e6-e135-4682-afa0-f81859e845cc" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in <ix:nonFraction unitRef="segment" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI5MQ_83832797-5079-4ffc-959f-6848fdebbf1c">one</ix:nonFraction> business segment: human therapeutics.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTM3_ff7b06a3-881c-4c0a-a10a-41a8b25b7b98" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDQy_b7c22537-b63e-43d3-a479-aa519fd55174" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDA3_a4a5fa5b-e414-440a-b35e-d900d5ad3096" continuedAt="ibd8f45392c714fa3aa0f89db95c998fd" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than <ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="2" name="amgn:SalesReturnProvisionsAsPercentageOfProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI3MTU_93994400-7d56-493f-8245-c6fffc7021ef">1</ix:nonFraction>% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from <ix:nonNumeric contextRef="i43850937751e42548fbb66e789879cef_D20210101-20211231" name="amgn:RevenuePaymentArrangementTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzMwNDQ_a366eba3-f016-4114-af14-46a342c41421">30</ix:nonNumeric> to <ix:nonNumeric contextRef="ie61e545057e747e8b5917b8708e7bbf0_D20210101-20211231" name="amgn:RevenuePaymentArrangementTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzMwNTA_b0d5dd94-12ab-4b1f-b1c1-d21a599d0de0">120</ix:nonNumeric> days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;A expense in the Consolidated Statements of Income.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0e7d9f666594458a813549277a734130" continuedAt="i1b3f2845a47f4116bc116a2f2242f07a"><ix:continuation id="ibd8f45392c714fa3aa0f89db95c998fd"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the R&amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div></ix:continuation><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0Mzkw_4f91b904-1778-499f-8771-4cf956ac1efb" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDE1_468ea368-626d-47f9-ad28-7eb5abcca1f5" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzc3MDc_a604c471-4478-4a01-8dcd-f0201b188a09">843</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzc3MTE_b8179449-d28a-4563-9d1e-7b1c1374601c">962</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzc3MTg_b5089898-4175-4a22-bf46-52b575d31279">789</ix:nonFraction> million during the years ended December 31, 2021, 2020 and 2019, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDU5_32605fb4-12e9-4a0f-af83-528c7282129e" continuedAt="i06e07ad9caff4a9287a79106bad3bc8c" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1b3f2845a47f4116bc116a2f2242f07a" continuedAt="i0a1e851aafa142b1b5495125f5e73762"><ix:continuation id="i06e07ad9caff4a9287a79106bad3bc8c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div></ix:continuation><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDYw_5df305c0-f837-41cc-842f-b2a93d90df2b" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDMw_26bb8756-e5bb-4e6f-8ab5-65eea1309250" continuedAt="id28dcd6ea8ae4d6ca1a3d52d7aee8625" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id28dcd6ea8ae4d6ca1a3d52d7aee8625">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.</ix:continuation> </span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTMz_390c7ad5-2dfd-4aed-880e-5a01ba65328d" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;D projects with no alternative future use are recorded in R&amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDc2_df9323b1-14cc-4125-b9a0-c6b6a823247b" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0a1e851aafa142b1b5495125f5e73762" continuedAt="i816707ed532843e0b1ce19041a38f9db"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDc1_acaeec2d-b7cc-4481-a527-0737d4ea2029" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTAx_a18106eb-93c1-4aaa-8461-13220d184f9d" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDYx_4081de6d-5dcd-46f5-980b-cb319023c6cd" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0Mzk4_db5e063a-8eef-4299-8470-ea37a795d816" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTEy_0d1a4f89-130f-44a5-b31f-7e177c1068cb" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#8217; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i816707ed532843e0b1ce19041a38f9db" continuedAt="i39f36a0c2bd44a94ad258d11e39ad903"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDUx_5784774e-ac79-428f-8ac7-02d97782c553" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDk0_318a3ef2-4504-4339-afd7-415bc3596d00" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars by using average exchange rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:EquityInvestmentsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzg3OTYwOTMwNzA0MjQ_99a44415-4175-4fe1-b4b4-50ebfa93da55" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and nonmarketable equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other Income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other Income, net, in the Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTI2_640ddca5-c2e5-4110-8393-618ca7780b0f" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Equity method investments</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income, net, in the Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzEwOTk1MTE2NjY3NDE_7575bfdd-58b2-4c22-8b3d-4308bd03dce8" continuedAt="i5fafc17365eb4158a402555354026371" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39f36a0c2bd44a94ad258d11e39ad903"><ix:continuation id="i5fafc17365eb4158a402555354026371">In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</ix:continuation></ix:continuation></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_199"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzczNzc_2d02c882-74a0-48ae-ac28-f9f931bd5708" continuedAt="i03630736b476433caa9a8ae2403f8caa" escape="true">Acquisitions </ix:nonNumeric></span></div><ix:continuation id="i03630736b476433caa9a8ae2403f8caa" continuedAt="icaeac31ee44b4217bfc65e59fd056ebf"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teneobio, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#8217;s existing antibody capabilities and BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#8217;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2Mjk5ODAy_ad7c05ff-5ece-47f4-b16d-3f56dd53dc7a" continuedAt="i3a1fb3ea813545548cc8b2fd049b1a3a" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzEtMi0xLTEtOTQ1MzU_f6a308e5-c332-48a9-a2a1-2ccc773b30b8">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzItMi0xLTEtOTQ1NTA_aa92eec1-2df0-4f03-ac93-1ec6bf2e936a">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019" decimals="-6" name="amgn:Businessassetacquisitionconsiderationtransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzMtMi0xLTEtOTQ2MDQ_f2c7150f-8869-46be-b00e-260a140e6288">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzUtMi0xLTEtNzg2ODU_cfe6ba2e-a4b4-4b4b-b155-3bdcde8cb783">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd31e4ab273d40649861d236ae32fc27_I20211019" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzYtMi0xLTEtNzg2ODM_f1387254-e8ed-43bd-840a-411563149997">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; R&amp;D technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c5cd2aa30845ed99aa434901b0d817_I20211019" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzctMi0xLTEtNzg2ODc_0d9b924e-5b16-4fb8-b0fe-31300f0870be">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478925270fe1447f980033f781c7fe54_I20211019" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzgtMi0xLTEtNzg2ODc_d4d4cc7f-4e3b-43b4-ad52-a50b13fef5c9">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzktMi0xLTEtNzg2ODc_d515d540-2c19-4ebc-84b7-969d79bfdd57">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-6" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzEwLTItMS0xLTk0NjYy_7dc3b393-f656-442d-99af-a4959c3c11c4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzExLTItMS0xLTc4Njg3_111f126e-d10d-46e6-b479-f1a463c8288d">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-6" name="amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzEyLTItMS0xLTc4Njg3_14131882-28b4-4ddc-8626-95df157ad96a">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for this transaction were (i) an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NzE1ODQ_2204e386-2d07-4bf7-982f-ab22b33cded4">994</ix:nonFraction>&#160;million, which included a working-capital adjustment and (ii) future contingent milestone payments to Teneobio&#8217;s former equity holders of up to $<ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3MDc_98d80930-ab15-41eb-b5e5-5a277ba75d4f">1.6</ix:nonFraction>&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair value of the contingent consideration obligations aggregated $<ix:nonFraction unitRef="usd" contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3MjI_4c391530-40f9-4eff-a1ec-ee6a3dc0d87c">309</ix:nonFraction>&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pre-tax cost of debt. See Note 17, Fair value measurement, for information regarding the estimated fair value of these obligations as of December 31, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D assets totaled $<ix:nonFraction unitRef="usd" contextRef="icd31e4ab273d40649861d236ae32fc27_I20211019" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNDc1MTg_1dd191be-e46d-4758-bb3f-33a55fe5663a">1.1</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="id3f3a35884aa4230bf0c3a5ae22cbc37_I20211019" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNDc1NDQ_ca75170d-df1b-4d14-b196-cd41c359662c">784</ix:nonFraction>&#160;million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of mCRPC, and the balance relates to four separate preclinical oncology programs. The R&amp;D technology rights of $<ix:nonFraction unitRef="usd" contextRef="i0d7b6973dd21459c98dd74519c04349f_D20211019-20211019" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNjYwNDg_0c0ac9ea-1146-4695-8e3d-1d9429d5e3c5">94</ix:nonFraction>&#160;million relate to Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies and will be amortized over <ix:nonNumeric contextRef="i0d7b6973dd21459c98dd74519c04349f_D20211019-20211019" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NzE2MzE_911bede6-0cb5-4be3-a46e-c3b8422f78a5">ten years</ix:nonNumeric> using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $<ix:nonFraction unitRef="usd" contextRef="iab0cb85e7f8b470988475352b8970a11_D20211019-20211019" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNjYwMDM_15796452-52ae-4170-a298-43e88d0c5278">41</ix:nonFraction>&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icaeac31ee44b4217bfc65e59fd056ebf" continuedAt="i4cd14317840045db856fcaedf8de55d7"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NzE2MDI_b46b9eb1-6dd9-4684-828f-9e72000153e9">253</ix:nonFraction>&#160;million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3OTM_f8993095-8dd1-4767-b957-11d12a64f053">251</ix:nonFraction> million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Five Prime Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, Amgen acquired the outstanding stock of Five Prime for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i87696c073dc9445795bb552e00095165_D20210416-20210416" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3NDA_caa9aad0-52d5-47e4-aa55-9c59c5db1a08">1.6</ix:nonFraction>&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. The operations of Five Prime have been included in our consolidated financial statements commencing after the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Five Prime to the bemarituzumab IPR&amp;D program of $<ix:nonFraction unitRef="usd" contextRef="i87696c073dc9445795bb552e00095165_D20210416-20210416" decimals="-8" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3NTQ_2a130bca-6d80-4682-809d-219f25f86c54">1.5</ix:nonFraction>&#160;billion, which was expensed immediately in Acquired IPR&amp;D expense in the Consolidated Statements of Income; deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i0a658c14aef44e0cbf1c161341c595a2_I20210416" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2Mjk5ODA0_b734bfc1-ee89-4c46-a77f-ba311564734d">177</ix:nonFraction>&#160;million; and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i0a658c14aef44e0cbf1c161341c595a2_I20210416" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2Mjk5ODE4_295873ff-89b7-4220-9a0a-be3e5ba8fde5">47</ix:nonFraction>&#160;million. The acquired IPR&amp;D expense was not tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2019, we acquired worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene. Otezla is primarily used for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than <ix:nonFraction unitRef="market" contextRef="i1f6477d9cdaa4150a5f594b11b70839a_I20211231" decimals="INF" name="amgn:ApprovedMarkets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQ1NA_6577c4e3-f74a-4422-9061-89acd2707df8">50</ix:nonFraction> markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla. The operations of Otezla have been included in our consolidated financial statements commencing on the acquisition date.</span></div><ix:continuation id="i3a1fb3ea813545548cc8b2fd049b1a3a"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzEtMi0xLTEtNTU1NTQ_e2b99003-0c1f-4e85-8a12-c1d65c987316">13,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121" decimals="-6" name="amgn:Transactioncostsassetacquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzItMi0xLTEtNTU1NTQ_c3227ec7-e10a-4e45-a75f-74323df339ec">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated cost (consideration transferred)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121" decimals="-6" name="amgn:Businessassetacquisitionconsiderationtransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzMtMi0xLTEtNTU1NTQ_9111a2fc-006b-4ebd-adac-416ab596b3c5">13,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30125d0ac2b49b99dedfab8ab62d268_I20191121" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzYtMi0xLTEtNTU1NTQ_bcce589c-d289-43c6-aef8-e74715ea47a5">13,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b09ca2dd3744c7ace9c82038d6088e_I20191121" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzctMi0xLTEtNTU1NTQ_ed197e45-c857-4972-8a33-3ac1dac7fe78">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionInventoryacquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzgtMi0xLTEtNTU1NTQ_f9b343ba-f701-4982-8cbd-24afacd2ee9d">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzktMi0xLTEtNTU1NTQ_f42e61ca-c48b-49f3-a486-85772bf11261">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionDeferredCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzEwLTItMS0xLTU1NTU0_7af4697c-6f47-48b1-90ea-7fc90bb7095c">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzExLTItMS0xLTU1NTU0_29899974-a11c-49a9-80c3-1df8852041d4">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121" decimals="-6" name="amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzEyLTItMS0xLTU1NTU0_ea436662-94f4-4d69-85bc-9e91b570129d">13,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of <ix:nonNumeric contextRef="iae11cd746d46413ea3fdec017bcaa8da_D20191121-20191121" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzE4NzQ_336da0f0-4f9c-4b54-a023-030ca134b0b4">8.5</ix:nonNumeric> years by using the straight-line method.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4cd14317840045db856fcaedf8de55d7"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce is being amortized over a period of <ix:nonNumeric contextRef="ie16d2f30b24a4021ae737b2878c082c2_D20191121-20191121" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzIyNjE_29abb4e8-bce1-418a-97ff-b9c4eedbaef1">5</ix:nonNumeric> years by using the straight-line method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#8217;s effort are applied. Inventory fair value adjustments is being amortized as inventory turns over, which we estimate to approximate <ix:nonNumeric contextRef="i71cdf38101c24a728fe566e9c8f95072_D20210101-20211231" name="amgn:AcquiredFinitelivedAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzI2NzY_a8912623-c823-4a50-86fb-62f6abe27353">2.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $<ix:nonFraction unitRef="usd" contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121" decimals="-6" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMwMzY_37f8752b-811d-42dd-b9b7-76ac479866dd">119</ix:nonFraction>&#160;million, a net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121" decimals="-6" name="amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMwNzI_172b9e14-a7d3-4b6f-8004-b22e4752dad9">24</ix:nonFraction>&#160;million and a deferred credit of $<ix:nonFraction unitRef="usd" contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121" decimals="-6" name="amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMxMDA_1987cc0f-aca1-4a75-b239-3375a468d02b">96</ix:nonFraction>&#160;million. The tax effects of the acquisition are based on Amgen&#8217;s estimated blended statutory tax rate of <ix:nonFraction unitRef="number" contextRef="i21358fdcfee142efb4e3f013e87d4e7c_D20191121-20191121" decimals="2" name="amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMyMDA_54363b13-97e2-4e03-8509-cce3ecce4c3b">20</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuevolution AB</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2019, we acquired all of the outstanding stock of Nuevolution, a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i312f9fef123d41a09674e4d6ef7b0632_D20190715-20190715" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzM0NDk_86fca1b3-1dd8-412d-9e70-99ea9062c034">183</ix:nonFraction> million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution&#8217;s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i8f809eda07244ef59df9c01c24fcb962_D20190715-20190715" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzM4OTM_611b6df2-40a7-44d3-b9ef-e47e11f136c7">150</ix:nonFraction> million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of <ix:nonNumeric contextRef="i8f809eda07244ef59df9c01c24fcb962_D20190715-20190715" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQwMDE_d1f05bb4-14fc-4843-975e-3ea16f768ae9">10</ix:nonNumeric> years; goodwill of $<ix:nonFraction unitRef="usd" contextRef="i6d08f130fae446808d4e5f6792b4477d_I20190715" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQwMTc_de91e012-02b4-4c87-9fce-6e45280ed89a">26</ix:nonFraction> million, which is not tax deductible; deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i6d08f130fae446808d4e5f6792b4477d_I20190715" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQwNzg_aade8d4c-d8fc-44d6-b0b5-5f7e6096c81e">22</ix:nonFraction> million; and other net assets of $<ix:nonFraction unitRef="usd" contextRef="i6d08f130fae446808d4e5f6792b4477d_I20190715" decimals="-6" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQxMDY_c8f77830-bf7e-4b50-8d60-138f55ce1533">29</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE5OTA_86540549-5504-47fb-bcae-bff4db64c644" continuedAt="i5328bf6cdd5b42b780be107ed5cc7573" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="i5328bf6cdd5b42b780be107ed5cc7573" continuedAt="i6ad0197d3d4d4f3db8425d2e5964a657"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzMx_f278539a-f2af-4135-8dbf-5a23da735009">one</ix:nonFraction> business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of ROW revenues relates to products sold in Europe. </span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE5ODY_1234c6d2-a95c-47c2-b7f3-f188244a5081" continuedAt="i693082f39a55433b8884f1fdc5605a87" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9859eb8505743f1b3da7314c2873003_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMi0xLTEtNTU1NTQ_216deec3-c028-4a7d-8736-6ade34166cf5">4,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122e8f06671c4fd2959f297cfb936b40_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItNC0xLTEtNTU1NTQ_53f0836f-a478-49f9-ad6e-045230bd3496">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b29f9a84bd403788979c7c9655c7f2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItNi0xLTEtNTU1NTQ_ea27ca72-c794-4ab2-b14c-6ec693e80bc3">4,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic461d7a3b3e14e9d9f9edf67703a28a5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItOC0xLTEtNTU1NTQ_88cd232d-d311-4295-93b4-9e90c03b8d06">4,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2ec1c2699c4f75baab1192500e0ea8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTAtMS0xLTU1NTU0_159b1633-6ed9-4191-aaa5-60308ef226fb">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ef6be9e72c458d8eb025c1d314c9a7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTItMS0xLTU1NTU0_4ed67078-d0d8-4a5b-bdd3-a729383a2624">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9352d3542ba4641b31259a6145356d4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTQtMS0xLTU1NTU0_cf58c0ea-95b0-4a09-9783-6020c7afdcd9">5,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6338b51a744e2ba61b90799c71483a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTYtMS0xLTU1NTU0_a135760e-a31d-4ab1-ac44-a15a19ffeeb4">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39684b43bb94026ba38cc4efb929d6f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTgtMS0xLTU1NTU0_f304297f-f34f-4ed3-a9ff-a9b3d8fa54f8">5,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f12f30e019c442caffd84baf0cf6f58_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMi0xLTEtNTU1NTQ_5392fe44-0606-4ac9-9ce6-971eae8570c9">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id824580714f14645861336df6b9234d0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtNC0xLTEtNTU1NTQ_7aff1d3d-89f9-444c-a569-a9c56d4831e3">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d377423aea4783859ef42175fb0740_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtNi0xLTEtNTU1NTQ_72cbd0ca-706b-46ad-acdf-08d01bc4c97b">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0d3e2283c44651a1eb8f9a780b8dbb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtOC0xLTEtNTU1NTQ_5ea765a0-95d7-4957-9376-3dfd34a6a530">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967209b4b4c84e76b9b0f7a497310bce_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTAtMS0xLTU1NTU0_d2139ba3-33cc-4185-be85-73beae80a6dd">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54c41e6f0b54a38a252ee5e94de98a6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTItMS0xLTU1NTU0_1d2c5545-99f3-4e91-b752-ea49652f3a93">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i989b6283d29a4b4c851c78cd48583e8e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTQtMS0xLTU1NTU0_2b4f1682-4e68-42f3-8fff-08259637d3a9">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b813a299ccd4e28afe5bbb0576b487d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTYtMS0xLTU1NTU0_9792d916-fdbe-497c-a91a-9677481804c7">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5c8a7d9df04367a21590c9c29fd269_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTgtMS0xLTU1NTU0_a426eb32-8530-4345-bd34-34ac0d5acb87">2,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40878748d11247a087bb8456c38f461b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMi0xLTEtNjAxNjk_f4b681ea-ff5f-481d-88c8-a41a132a86fb">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb6c05be38b46a0a66d8019c30f41f8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNC0xLTEtNjAxNjk_51734c6c-970a-426a-aebc-9a317c2c3ea1">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b1aeb912604f64a39deebff1f224b4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNi0xLTEtNjAxNjk_bd40cbc2-b7c1-4fbb-b933-2f3c8cf6648c">2,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8dfc99854e4c9a8e28f37c644909fc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtOC0xLTEtNjAxNjk_69fe478e-772c-495c-8e6a-5b70d16e8b97">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35fd136605f54042b5bff6d375c0e5a6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTAtMS0xLTYwMTY5_082fc07e-b778-40d2-9a6b-71d5da4f2f18">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165ce47df9044130bc2739fba82a949b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTItMS0xLTYwMTY5_b79a5390-695f-4ea8-af15-cebbd1c1be7c">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0c0fc9a5c549fe95bfb0a1d9f0cff5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTQtMS0xLTYwMTY5_e4c9b225-2c13-4d6a-9299-6d5ad3d78f8a">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ac36e2ce074ccd9ae5750b82cd3469_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTYtMS0xLTYwMTY5_1c90d904-2dab-4384-9bf9-72784d1a34c6">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512f3b69b8d744cba5ed5ccf09f3f93e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTgtMS0xLTYwMTY5_18cc9277-d295-446d-897e-8c1e1e568ace">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9e422d984343799da5efa61983dbc4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMi0xLTEtNjAxNzc_0dd55be8-87ed-4087-b7ac-2d5b54ac6fd2">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcdb5108a874cfcbdd8b792226e2b87_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtNC0xLTEtNjAxNzc_b374e0ab-3925-444c-9276-06a529982ce0">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c0360db44649d0a20ab30019d4726f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtNi0xLTEtNjAxNzc_2e4c45c3-4cbb-4e84-bd32-868bb10cc418">2,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5084637c7a7340da84829b4511548a9b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtOC0xLTEtNjAxNzc_0674a415-73a2-46fb-8eeb-9085d197efea">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6556904df3ab4367ad18978f9b68d5ae_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTAtMS0xLTYwMTc3_74c7c799-e706-476d-9952-47e637d93998">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f620dbefa34330a378e5ed07d62563_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTItMS0xLTYwMTc3_038c09c3-2f14-46ad-8431-847e4d4b8dc2">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbaf8798276a40dfb14013a2f2c650ad_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTQtMS0xLTYwMTc3_dd0f1e43-5bca-42d4-b987-03b0fa08c0fd">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983f5a9292ac40f4a3da11e27da9ebb9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTYtMS0xLTYwMTc3_e9cb37a5-b6fa-42c3-b65e-01c88b2cbcf9">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0d758076054681926e066e61927847_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTgtMS0xLTYwMTc3_bd60fdd1-479a-4597-8460-a85b940003be">1,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823d72e733d04847bac4115a76bc88d4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMi0xLTEtNTU1NTQ_64666179-ffdf-41e2-8cd0-7e221eb6ea0f">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927d3e095b5f4aa59c0a266db71e1970_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNC0xLTEtNTU1NTQ_08e4227f-a8fb-457a-a4e9-b605e66d99d5">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i068d095d40cd4db2974af05b034cdc53_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNi0xLTEtNTU1NTQ_378e29da-c099-404f-a595-633a88546656">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i183bf5775ef447918eb6b6e9ba438bf6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtOC0xLTEtNTU1NTQ_37a2ef9e-8333-41d3-bf01-bc128f0b672f">2,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0446449664249d586f43b4ab973920a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTAtMS0xLTU1NTU0_dfde9a93-ebd9-44ff-8181-f5a421af7950">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5db1424a06489da055b9a4d4e9586a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTItMS0xLTU1NTU0_7243b737-846f-4f68-8832-4f7837870825">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bd4a1f6b184369845ffe664e69f8c8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTQtMS0xLTU1NTU0_ad1f6197-d376-4369-8747-a294a5019c2b">2,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36247d9eda1441289af859ad6b549ad5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTYtMS0xLTU1NTU0_d634c879-84e1-4f18-9b68-85ec8b839cfe">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdcea96c498b412ea276b523469efb7d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTgtMS0xLTU1NTU0_798301fb-9c40-41b7-bab4-246e0d26bc2d">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9bd7649ab404e7b84591d36bb2baa43_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMi0xLTEtNTU1NTQ_37bb221e-4624-418a-9511-72c987091ce0">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdbb2a2df8dd4a688aa35f134c78985b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctNC0xLTEtNTU1NTQ_8918f2df-979d-49ac-9cd5-a42297d3291b">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866795ca32e048e8bf0d0a64e1e48428_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctNi0xLTEtNTU1NTQ_fa507041-e5c2-4d90-ab77-2853a58ba7d6">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic529e4ce045d4f18bf4eb6e91d16750e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctOC0xLTEtNTU1NTQ_f67b510f-e7ce-4e9f-a5d5-5dc27d8d1578">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961bb9f5333e4fb7a4343811368337f0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTAtMS0xLTU1NTU0_c3648728-22f9-41fd-9223-19537a3d4379">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1cedc1286e435db02a41c255e0aea4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTItMS0xLTU1NTU0_be37d8cd-28db-4841-b074-2ea6afb32e51">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0d7fa648b44bf4b5f6ab3d243b3379_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTQtMS0xLTU1NTU0_9a0eaafa-c08a-4c1c-950f-34ab1bc9ca81">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1a44c568f248928074918ec2942de6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTYtMS0xLTU1NTU0_c0a0507a-798f-4978-9a39-be63e0e0ac43">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31ae78b9ba034a46abf7a36f2b0f0200_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTgtMS0xLTU1NTU0_e38cdd82-1b98-4690-9d6a-5f8e53293bce">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122ba16c86614e1c968b2254fd76300f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMi0xLTEtNjAxODg_1d5a11e0-a79c-42a1-9f9e-0fd405ab0690">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb60fa2c2944183bf45dfb60666df8b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktNC0xLTEtNjAxODg_601bd0db-7469-463f-91e8-5230084dce63">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d943ea15f1a4586994e9ac4e411be31_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktNi0xLTEtNjAxODg_addda7a9-514c-45d3-8f1e-bb869897c72d">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467a81094b048fb8b342e412bd92615_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktOC0xLTEtNjAxODg_0c0e337f-9cce-46f6-be91-a6ab6039f688">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cef9372919476794b87f18a0ccd73c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTAtMS0xLTYwMTg4_14e6abcc-0f2e-4a23-98c2-abc9e665a7bf">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2dbf9c7559f438aa4cb0fd8e3bd05df_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTItMS0xLTYwMTg4_02621444-2c2e-4d7d-9c55-c13c20f733f6">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc140436757d4c8b8b0f16f5c3d24f73_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTQtMS0xLTYwMTg4_f7c1a94a-4376-4c2d-a513-7ad17392c6f6">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be7cae3f58843ba99977a2b0ef10946_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTYtMS0xLTYwMTg4_63135597-38a3-479c-afbc-809ba6c045a4">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c266403b0e40b8a06f2641ca3a0a6d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTgtMS0xLTYwMTg4_8e157141-5b12-44a9-931d-05f1b996aa8b">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7946d27038d14bb2aa1d01148f309fce_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMi0xLTEtNTU1NTQ_e8f64ab5-54e9-481e-a098-84602953e644">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f835d6c583e4df99d995013745f7e0c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtNC0xLTEtNTU1NTQ_1c70b43c-9ea8-4da8-9fcb-6efb3e66f502">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dbe0c7d5d6b4242b1252f5fcb8be12f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtNi0xLTEtNTU1NTQ_f01f3141-b562-441e-a1e2-e996979a135f">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708f4aef9e64cb5ad424e50c8dc709d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtOC0xLTEtNTU1NTQ_834a0278-1011-4568-b879-d715a9eaea9d">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a458f529ef74a5e96517e593dec14f8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTAtMS0xLTU1NTU0_d0d8f9dc-a51e-4c90-a381-07a080ebff92">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4010fa4de94f1f9c1f6362f8ec685e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTItMS0xLTU1NTU0_67e07de1-196e-41e9-94d9-b57f7ba6110b">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cba4592c834e3e8d094a23a2fcaa5b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTQtMS0xLTU1NTU0_78f1dfe5-ada2-4cf4-9eb5-bbb7e1a6b65f">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib066bf92577d482b9105bb3d4d131f35_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTYtMS0xLTU1NTU0_b44c21ea-9e0d-405a-827d-0c5723bdc3dd">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c7e88092ac49d78f2b821816062d7d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTgtMS0xLTU1NTU0_4fefcbc8-80e4-4a73-aa05-e9f4049f7a84">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e280126ffb45dd8d20fc69bcf08ce6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTItMS0xLTkyMjAx_40d31ff6-527c-46ae-9397-fdceff1df2a3">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia437ec7f284c49d6a65b54737b247969_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTQtMS0xLTkyMjA1_89262a17-566a-43b5-a1c9-c81e9e6f54fe">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794fd5a1ff8d49928a90b66d34aae6b2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTYtMS0xLTkyMjIw_9edad57b-1f3e-4481-9409-0eeb1064ca4e">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08cb03dda2a4cbeace3bd8fec2bf082_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTgtMS0xLTkyMjA4_d5851b69-becd-4b16-af6f-570858540292">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa8459da664468b847514e8360e549b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEwLTEtMS05MjIxMQ_08149f75-f7ea-48fb-929a-f2ed5909bdec">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0e82165e6ed4ce0870f8f592e298c7f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEyLTEtMS05NDQ5Mw_cb9de1eb-0c5f-4df1-a2d0-5df5e2140831">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe308e8cce24a29bfe153c46d6eed91_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE0LTEtMS05MjIxNA_bdaecac5-dc6d-44ec-954c-cc696d24884e">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2a9a63cb37432fa884cace4bab4206_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE2LTEtMS05MjIxNw_2e492137-7990-433a-9a02-8e8c01500df6">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5877faf81e455bb0d9482eb25bd1ca_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE4LTEtMS05NDQ5Nw_dbbcb2d6-ecf6-41ec-af0e-4b31908e78cf">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6b177906644a8ba787927952e1e6ec_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTItMS0xLTU1NTU0_cd7a235d-5859-4625-ae37-20ebb6c9a997">3,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cedf86849344ad185dd0473b29aa1f8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTQtMS0xLTU1NTU0_9badce48-5106-484d-89b0-c8f538c3fe31">2,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ee7a4be4a741f49a25afd921009f06_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTYtMS0xLTU1NTU0_9c654a1e-1bdc-4ed2-8f70-a0818759484c">5,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9fd64f276d4139aea96a0883ba58ae_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTgtMS0xLTU1NTU0_2406bdde-5a3a-4267-9da2-c8f3deb3c9a4">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2365d4e32b64cd087bbb41137067445_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEwLTEtMS01NTU1NA_af933f24-e568-4c40-977d-488d99b2bc35">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dda7d1128174280bf5cb5fd5f91bc58_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEyLTEtMS01NTU1NA_bc745110-f605-4587-85ab-ea14e7d7dbd0">5,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35d3d6d4b644346b1122b986aa9fe50_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE0LTEtMS01NTU1NA_43641b76-8523-4333-afff-5841f1d4002c">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abfdddf9be24f51a5a6754cc8ad2888_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE2LTEtMS01NTU1NA_91c231ef-92c9-487d-a1ea-0108049295e7">1,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f26fd68cfa4c65a24d973779fd0e1a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE4LTEtMS01NTU1NA_9bc33338-f159-4fb7-bef5-16ee902a0c8a">4,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0795e4a54f5843d393051071fa6d5f9b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTItMS0xLTU1NTU0_b6f6ff06-1311-4cd5-97b1-6e1619ff1604">17,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2014a7861a48b799fb3652e82edcd5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTQtMS0xLTU1NTU0_d97a4ef6-7946-4f1f-a531-6692ff2270f2">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTYtMS0xLTU1NTU0_f745bc97-5607-4fff-8d57-a5dcd9f5682f">24,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676e864b987849b3b20c91a321c3dda8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTgtMS0xLTU1NTU0_4c4d347c-6583-45b4-a7f9-95a1ba8f7fad">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116d123386f643908f969672fc7551ef_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTEwLTEtMS01NTU1NA_08398191-4b8d-4310-ba86-34378c79d1b9">6,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTEyLTEtMS01NTU1NA_291352f2-f050-44cd-9da6-05886b44ada6">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0adce9b11c444f0992f20820cf3828f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTE0LTEtMS01NTU1NA_28e4bd56-bb06-4ec0-9094-486deeaba330">16,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a71c3bfd064ff09a900ad9f82e3ff4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTE2LTEtMS01NTU1NA_606ce058-9de2-4e4b-83bb-4d10c25f3efc">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTE4LTEtMS01NTU1NA_b3632c68-6586-4dd5-a369-71cd02754467">22,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d8aa15dac8a479aa274d63cceb3e3cf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTItMS0xLTU1NTU0_a72e05ca-dccf-42d4-880e-34858cb95a57">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1f469a4b2e4de98ca61b255d39fffb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTQtMS0xLTU1NTU0_c56affa3-6c76-4881-8389-91ba1800ff4f">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa4009b79ae4a1aaa88901012cdc38c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTYtMS0xLTU1NTU0_a0bcad92-ac70-4ae1-9b63-0ca0e20a97fd">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbe8a4fa56d4704aacdf9825e608952_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTgtMS0xLTU1NTU0_708f683f-1f3c-4600-94bc-734be97c6ddb">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d6910ca4184832834d336a96a65391_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTEwLTEtMS01NTU1NA_2b800e97-0b30-4448-af95-fcfba5cd8126">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9dfed05d2a4cc7b238e87a2395d611_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTEyLTEtMS01NTU1NA_af1a0f36-07b3-4a6f-8cb3-a6ac4d2e603f">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a1575152424f7d8ace591bcbc21966_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTE0LTEtMS01NTU1NA_60412d0a-0f77-492e-897c-efe8208144e5">693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0b7b5c89644713988c1ec6f68bb082_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTE2LTEtMS01NTU1NA_53862b8e-f4e8-4d68-94c3-d6906f804f47">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5666794b15d1495f894c2e5fa67e1ff5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTE4LTEtMS01NTU1NA_760085e5-e082-4036-a6f6-eb32337bb0c5">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cd8f4d101d41ada52bea1b7f7707dd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTItMS0xLTU1NTU0_b8801cae-7ca0-4558-a41a-9f0db5af9868">18,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie389e5de5a4d478db22bca7314e7c2e6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTQtMS0xLTU1NTU0_fb33ebf9-704b-4091-8325-00b60ddaa761">7,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTYtMS0xLTU1NTU0_c7400ab4-da1f-4f1d-8d88-c48b090ed03c">25,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b16e7fedb4e4c24ae45b97df7a610b3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTgtMS0xLTU1NTU0_3770c813-5271-46d0-ba48-ce79da0ce6ed">18,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef86d4467f84eb1bb360dfad6d77585_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTEwLTEtMS01NTU1NA_f4fd40b4-be79-45a5-b4e1-100a425dcbb5">6,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTEyLTEtMS01NTU1NA_848c5915-e7d4-4764-81ef-a69df2c4a181">25,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2955a78f1c41a08c3ed208c99513da_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTE0LTEtMS01NTU1NA_e40a886e-95c9-4197-bbbb-6136072d7de8">17,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef9644ae27a4c1a8fe31454e5457a11_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTE2LTEtMS01NTU1NA_d43a969c-7d1d-4547-956b-201e5e035c5c">6,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTE4LTEtMS01NTU1NA_5fd92b5b-69a2-4885-9658-e80a1c3f85f5">23,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla was acquired on November 21, 2019.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i693082f39a55433b8884f1fdc5605a87" continuedAt="i155aee291fe147feb6fa84bd8f826f79">(2)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i155aee291fe147feb6fa84bd8f826f79">Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had product sales to <ix:nonFraction unitRef="customer" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEyMDc_10f44b59-cd13-43ff-9b68-7ca74be05ee9"><ix:nonFraction unitRef="customer" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEyMDc_4498db88-87fe-41e9-8ae2-0abcee6e05b4"><ix:nonFraction unitRef="customer" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEyMDc_8e56425e-d4b9-4267-8888-baf3e95f569b">three</ix:nonFraction></ix:nonFraction></ix:nonFraction> customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2021, 2020 and 2019. For the year ended December 31, 2021, on a combined basis, these customers accounted for <ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="2" name="amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEzOTg_d804264f-6173-42bb-b0ec-6b3abb635603">82</ix:nonFraction>% of total gross revenues as shown in the following table. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE5ODg_5636de42-117a-49bf-8eaf-7e9e4660fbb7" continuedAt="i5511d5f111d049b09cb2966c04c0532f" escape="true">Certain information with respect to these customers was as follows (dollar amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="i5511d5f111d049b09cb2966c04c0532f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293bc5a8ad2541879fe865ae5d2417d1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMS0xLTEtOTA5NTQ_13238b35-cdaf-4ced-8fc7-2838bc9df3af">15,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44fe8e6898034d56a3a0bdcfc063bc2b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMy0xLTEtOTA5NTQ_ae798d2c-b51c-4e20-b2a3-9959a8f01086">13,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5aee82520bc437a8e545732608e5e33_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtNS0xLTEtOTA5NTQ_f85cbf84-3023-487b-9620-519ec311d3ca">11,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i293bc5a8ad2541879fe865ae5d2417d1_D20210101-20211231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMS0xLTEtOTA5NTQ_b4e97a9e-47c4-4e22-875a-5d538f2ee740">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i44fe8e6898034d56a3a0bdcfc063bc2b_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMy0xLTEtOTA5NTQ_85cdd7d9-aef7-4b0b-9bbc-bbc5d4bde07f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5aee82520bc437a8e545732608e5e33_D20190101-20191231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtNS0xLTEtOTA5NTQ_84a2c949-a673-4963-917f-71761462930b">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45ea7d90fd9496098876205bd24f226_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMS0xLTEtNTU1NTQ_5f3a1bff-748a-4324-be10-b7a11546f587">14,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d011b83be41426c8583d49144da9518_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMy0xLTEtNTU1NTQ_58c07aed-ede9-417c-8042-139ac8ba9cf9">14,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127aa134bb05481bae71c4068800e12a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtNS0xLTEtNTU1NTQ_1c67e7a8-78b1-4baa-b27d-e4760a9aa84d">12,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie45ea7d90fd9496098876205bd24f226_D20210101-20211231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMS0xLTEtNTU1NTQ_c39fd090-9b7e-404b-b58c-2b8c30d0314f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d011b83be41426c8583d49144da9518_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMy0xLTEtNTU1NTQ_590098ca-1531-40ca-bbd6-9e1e85eff879">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i127aa134bb05481bae71c4068800e12a_D20190101-20191231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtNS0xLTEtNTU1NTQ_6dd41616-a019-4744-aef6-eb2e0c9ba015">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6de6025ba0e4e2690eec1546e065897_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzktMS0xLTEtNTU1NTQ_f37b58a0-f1a8-4b90-b386-d32f4baa38e1">7,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f412791f92490e9d982b4d75831aeb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzktMy0xLTEtNTU1NTQ_16fc845d-56e9-4a06-916c-4a5154604163">7,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf19b5b37714e80a93f4933d02ef7d6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzktNS0xLTEtNTU1NTQ_4e692a75-db2d-4385-b9f3-e19779d54a7f">6,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6de6025ba0e4e2690eec1546e065897_D20210101-20211231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzEwLTEtMS0xLTU1NTU0_302378e8-f268-4667-aea4-4f7595a44897">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37f412791f92490e9d982b4d75831aeb_D20200101-20201231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzEwLTMtMS0xLTU1NTU0_b0f84194-e685-46a3-b542-c0263949a06a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbf19b5b37714e80a93f4933d02ef7d6_D20190101-20191231" decimals="2" name="amgn:PercentageOfGrossRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzEwLTUtMS0xLTU1NTU0_cf417114-b499-481a-92b9-cc8fbc4fa87d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ad0197d3d4d4f3db8425d2e5964a657">As of December 31, 2021 and 2020, amounts due from these <ix:nonFraction unitRef="customer" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE1OTc_4e77bddd-d658-493a-924d-d9bd20b886c8"><ix:nonFraction unitRef="customer" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE1OTc_6d730040-18cc-4ddc-8493-93e5fb403212">three</ix:nonFraction></ix:nonFraction> customers each exceeded 10% of gross trade receivables and accounted for <ix:nonFraction unitRef="number" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="2" name="amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE2NzM_5d1feb59-0fb5-425b-b411-e88c6df60075">73</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="2" name="amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE2ODA_7f8cd217-fab8-4df6-8369-6de01c4bb02c">74</ix:nonFraction>%, respectively, of net trade receivables on a combined basis. As of December 31, 2021 and 2020, <ix:nonFraction unitRef="number" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="2" name="amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE3NjE_e28ec069-969f-4bc0-b0a0-dbccbcf02cfa">27</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="2" name="amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE3Njg_4aa4b35a-c6d7-4abb-8f49-5200806b4c8a">28</ix:nonFraction>%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2021 and 2020, was not material.</ix:continuation></span></div><div id="i2a971cfaef98424f9692041d6ed3a222_205"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MjQ_fbae9268-c2a9-4268-958a-284ce9128956" continuedAt="ib0433550609c48bbb1c43638748ad419" escape="true">Stock-based compensation</ix:nonNumeric></span></div><ix:continuation id="ib0433550609c48bbb1c43638748ad419" continuedAt="i18c69f7f8e6140d68c2e8ef1ec973292"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by <ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM5OQ_e35828f4-d796-463f-87ab-c76e8b302d5a">one</ix:nonFraction> share for each stock option granted and by <ix:nonFraction unitRef="shares" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQ0NQ_4089222c-4ba2-44ce-abe2-63f05b4787aa"><ix:nonFraction unitRef="shares" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="INF" name="amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQ0NQ_690ef843-c212-4242-bbf4-0fb305133c7e">1.9</ix:nonFraction></ix:nonFraction> shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of <ix:nonFraction unitRef="shares" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="INF" name="amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzEwMjI_a412567f-9c3b-4a29-8c9c-f542db06af7f"><ix:nonFraction unitRef="shares" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="INF" name="amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzEwMjI_be646eca-2d93-4c05-b316-637f79344f06">1.9</ix:nonFraction></ix:nonFraction> shares. As of December 31, 2021, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately <ix:nonFraction unitRef="shares" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzExMzI_c8c18c26-ce76-4120-ba64-42ac2c1713a4">19</ix:nonFraction> million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MDU_726df507-f632-4629-8ce9-09e81a94c453" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzItMS0xLTEtNTU1NTQ_8b55b02a-9e36-43a1-8756-687f4d3be9a5">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie689ea75a1044f2d984398ed617833af_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzItMy0xLTEtNTU1NTQ_c209e7b1-7a1a-4795-80a1-7635263041f4">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzItNS0xLTEtNTU1NTQ_ae5e1260-8896-4faa-85ff-57567cf11671">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzMtMS0xLTEtNTU1NTQ_12db82a9-f199-446d-96dd-9d7e2243458a">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzMtMy0xLTEtNTU1NTQ_be079cf3-d803-4fb9-bea9-0bf034606ba8">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzMtNS0xLTEtNTU1NTQ_04e23aa8-9056-463c-8648-2f1f28d8e4b3">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzQtMS0xLTEtNTU1NTQ_4ac6f0c2-b6cf-49c9-a9dc-828af73b3906">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzQtMy0xLTEtNTU1NTQ_1b5096b1-8565-47b5-9d2d-64aeb447f3d3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzQtNS0xLTEtNTU1NTQ_74136c1f-f749-4f6a-a5f1-8b95e25e49a0">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzUtMS0xLTEtNTU1NTQ_fd6e7680-fa70-450c-8ded-a737c8ab66c0">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzUtMy0xLTEtNTU1NTQ_ab68707e-0ac0-4a89-a43c-4879a1acbf29">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzUtNS0xLTEtNTU1NTQ_08dec69f-12c0-4fb3-9365-24cb3ecff839">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzYtMS0xLTEtNTU1NTQ_c7afd424-c627-4b66-81de-2939e76322d6">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzYtMy0xLTEtNTU1NTQ_f493a082-18dd-4622-bf30-a0cf12ac5008">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzYtNS0xLTEtNTU1NTQ_6e01dbeb-b12d-4580-b324-7bba449c025f">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzctMS0xLTEtNTU1NTQ_4b49600e-6ee5-40c5-803e-1489c622d470">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzctMy0xLTEtNTU1NTQ_f6404a76-1fe9-4278-8ab0-858b277db0a2">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="amgn:StockBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzctNS0xLTEtNTU1NTQ_a5ad8692-edee-4541-9a57-c340ff913fe2">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units and stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#8217;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MTk_15bd2116-ead1-4806-b7a7-8d0d3c8b627b">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.</ix:nonNumeric> RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2021, 2020 and 2019, were $<ix:nonFraction unitRef="usdPerShare" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzI4MTA_29703698-e73d-4ad7-aeae-58ea6d171ebb">233.10</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie689ea75a1044f2d984398ed617833af_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzI4MTQ_f590cdb7-7241-41d5-8453-667d41d1a638">235.63</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzI4MjE_23681d0d-856a-4945-bd95-9d3c9a5c0eab">182.12</ix:nonFraction>, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i18c69f7f8e6140d68c2e8ef1ec973292" continuedAt="ic3f97d28bb1e4ed4b4b78c53f3592f9d"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MzA_fb07d07a-8743-4739-8bac-f2b8d9383c14" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c5f3303e39f4bc0b7b331b548b22fd1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzItMS0xLTEtNTU1NTQ_5dc70c62-a3f0-483d-9e58-1eed5e2a99a9">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c5f3303e39f4bc0b7b331b548b22fd1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzItMy0xLTEtNTU1NTQ_f8e54861-05ce-46eb-be87-e486349fb320">198.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzMtMS0xLTEtNTU1NTQ_a7725ed7-5165-4bd1-9786-92f7dfed0e5f">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzMtMy0xLTEtNTU1NTQ_08718a93-6345-4510-b24c-0d9711ee093d">233.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzQtMS0xLTEtNTU1NTQ_90ea0a1b-9b98-421f-9e12-0d769fb5a56f">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzQtMy0xLTEtNTU1NTQ_979580bb-4905-4ae9-abac-c26658cc726b">177.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzUtMS0xLTEtNTU1NTQ_9d64e957-5086-4953-a979-f61aa67823c6">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzUtMy0xLTEtNTU1NTQ_932a7c96-5435-4239-a826-4e772555626f">213.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie439637f4a754340a91825cf8855bd2e_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzYtMS0xLTEtNTU1NTQ_8cf3889c-90b4-4f96-aa92-d03ddb3ea1ef">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie439637f4a754340a91825cf8855bd2e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzYtMy0xLTEtNTU1NTQ_ca730bcd-92dd-4480-bc62-8a9c42848f48">217.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair values of RSUs that vested during the years ended December 31, 2021, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMwMTQ_3a5b574a-d516-45e7-bd36-a8e50c5be49a">166</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie689ea75a1044f2d984398ed617833af_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMwMTg_94371469-dc93-4075-8687-0d8157acfb33">161</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMwMjU_09517306-8863-433f-8abe-ca77c3e02f95">160</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire <ix:nonNumeric contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMyNDc_48f04975-e206-4d16-8b71-528b62cb0786">10</ix:nonNumeric> years from the date of grant. We use the Black&#8211;Scholes option valuation model to estimate the grant date fair value of stock options. </span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MDg_1fbe0f00-93ed-4947-aa3e-ca3a329798c8" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzItMS0xLTEtNTU1NTQ_259e4d14-a3db-4944-91f5-d1a12c5039bc">237.17</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzItMy0xLTEtNTU1NTQ_0f0c42a8-cdd2-4f3a-a6dd-edde0d786d2f">236.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzItNS0xLTEtNTU1NTQ_4b95014e-5dce-43c2-afaa-ecf17fe50c02">177.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzMtMS0xLTEtNTU1NTQ_b685dba9-e915-45a2-bfd2-89e7f0a5f652">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzMtMy0xLTEtNTU1NTQ_a541840e-e0e3-49af-ba38-80313752108d">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzMtNS0xLTEtNTU1NTQ_646d6492-da80-42b6-89b1-6d2bf9c5bcf8">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzQtMS0xLTEtNTU1NTQ_75e1d74c-0235-4969-b784-223ea4b63d44">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzQtMy0xLTEtNTU1NTQ_ae4c758d-8cdd-41f8-8900-3740be130a4d">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzQtNS0xLTEtNTU1NTQ_48df24f7-3d90-4df2-b0ff-53a33aad7f43">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzUtMS0xLTEtNTU1NTQ_06b7dc0c-e71b-4f70-8632-40e3b86dec3a">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzUtMy0xLTEtNTU1NTQ_54e67161-da85-4879-a12a-7082fe7e4541">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzUtNS0xLTEtNTU1NTQ_b1826e6f-4455-4f88-a327-dc7d063c3c91">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzYtMS0xLTEtNTU1NTQ_87b5b5f9-ecc5-4353-9857-6e538ab704fe">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzYtMy0xLTEtNTU1NTQ_dbfced6d-a714-449e-a207-170ef3ae2ad6">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzYtNS0xLTEtNTU1NTQ_3be56844-c5e2-447f-9edf-13786fafa61f">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzctMS0xLTEtNTU1NTQ_fb7e62f1-5459-48be-8105-6b157ad79eae">40.43</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzctMy0xLTEtNTU1NTQ_da532166-123f-42f8-bd3c-ccbc0f6d7ed3">42.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzctNS0xLTEtNTU1NTQ_f3ba1578-83ba-4aef-8d50-c128b3acf112">30.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzczOTA_46c652c9-a47c-4ba0-8f43-fbc727373bd3" escape="true"><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafb155843fbb43a4845a41a3a8dd1ff1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzItMS0xLTEtNTU1NTQ_5180df7f-488f-4c4e-b32d-6a4e27ff9b76">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafb155843fbb43a4845a41a3a8dd1ff1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzItMy0xLTEtNTU1NTQ_d2f260d8-4e39-4cf4-8010-6cae41509394">179.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzMtMS0xLTEtNTU1NTQ_69085da1-f56d-4e33-b2e0-56143b8c340c">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzMtMy0xLTEtNTU1NTQ_850fd72a-1975-4dea-878a-997f462ff41f">237.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzQtMS0xLTEtNTU1NTQ_d8bd9e39-66a1-409f-8a39-bdba556c26b5">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzQtMy0xLTEtNTU1NTQ_9de34e0c-0037-405d-89d1-e662658eda29">137.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzUtMS0xLTEtNTU1NTQ_71643d59-c9ed-4c47-b364-b1d9ed29df92">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzUtMy0xLTEtNTU1NTQ_46382b02-b019-4df6-badf-dc1568589a44">208.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtMS0xLTEtNTU1NTQ_51384953-36c0-4dc8-803f-b5b3ade3ac21">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtMy0xLTEtNTU1NTQ_c76ba95c-ef7c-4028-a69c-fa840fc844c1">197.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtNS0xLTEtNTU1NTQ_d77aa471-db68-4165-b559-d79e27b74a48">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtNy0xLTEtNTU1NTQ_3900956b-6dc7-4ed8-be52-bf49adb428ce">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctMS0xLTEtNTU1NTQ_0366d634-afb6-4c8a-b4d2-00d00a385c34">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctMy0xLTEtNTU1NTQ_e81e6f83-3e55-46cf-a86f-1ee04c740874">195.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctNS0xLTEtNTU1NTQ_7710316d-57cc-4fda-8219-e8fc5c5f5290">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctNy0xLTEtNTU1NTQ_3ee1d57f-1052-4be5-829e-ed967f763f1e">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtMS0xLTEtNTU1NTQ_9c540729-e10e-491d-ba92-2642a1b37c7b">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtMy0xLTEtNTU1NTQ_5df5dcfb-3512-47df-b125-d71ca1892e18">165.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtNS0xLTEtNTU1NTQ_66ce01f7-78ec-427d-97da-b873ff8fcf6b">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtNy0xLTEtNTU1NTQ_5e85fa54-edaa-4605-bf4e-d6acdae2283a">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised during the years ended December 31, 2021, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM3MTQ_ff260f0d-f098-402e-a128-c2c51ce4258c">56</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM3MTg_797fe0c4-bc35-4f5f-95dd-ddd649477dd5">98</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM3MjU_5b2e07fc-c745-4c6f-bfde-0316b51866bd">68</ix:nonFraction> million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2021, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM4NjE_3755eb16-47f8-4473-b770-70e9d2ebc5f6">12</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM4NjU_3b9b0c78-2e90-4e55-a0e5-5a56a873f53b">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM4NzI_a14e8ae0-5ce9-4dd5-a648-79285f659c10">15</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM5MDA_a8a2e8e6-a99d-4894-9c7e-be27b1fbe599">346</ix:nonFraction> million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQwNjQ_ec83bae3-eb90-4c26-9dd4-16ecaf540277">1.8</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic3f97d28bb1e4ed4b4b78c53f3592f9d" continuedAt="i0a0fc38f20a74e048b30d4518de569a1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQzNTM_40a3b5f0-d43b-44a1-b26b-54176d6ddbdc">three years</ix:nonNumeric>. The performance goals for the units granted during the years ended December 31, 2021, 2020 and 2019, which are accounted for as equity awards, are based on (i) Amgen&#8217;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#8217;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a <ix:nonFraction unitRef="shares" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="INF" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzUyMTg_72c1b835-a366-4597-88db-beda86844cbf"><ix:nonFraction unitRef="shares" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="INF" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzUyMTg_9bc726c2-977a-4391-b71d-1f39112a7083"><ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzUyMTg_c7ed7429-373e-4fa7-8cdb-f01c848991a9">one</ix:nonFraction></ix:nonFraction></ix:nonFraction>-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a payout simulation model to estimate the grant date fair value of performance units. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzczOTE_a9a97ae2-f4fe-4cdd-b36a-8c47f8badd96" continuedAt="ifad50e5a2e5b46c78d63c3113a93fc62" escape="true">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><ix:continuation id="ifad50e5a2e5b46c78d63c3113a93fc62"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzItMS0xLTEtNTU1NTQ_59e8b046-416a-41d1-81d5-29c604e9cdc1">239.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzItMy0xLTEtNTU1NTQ_de39b4db-a206-464d-ba92-af63b0fc7c73">236.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231" decimals="2" name="amgn:CommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzItNS0xLTEtNTU1NTQ_e1de37b4-8480-465c-aebc-7e0326f25ddf">177.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzMtMS0xLTEtNTU1NTQ_1088140e-8011-4332-ba4d-48879a743e9e">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzMtMy0xLTEtNTU1NTQ_ce01ffa1-15c1-4f71-8c4a-1ccf7ea0747a">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzMtNS0xLTEtNTU1NTQ_347f35c7-9fd1-4168-966e-7b8deec2bce5">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzQtMS0xLTEtNTU1NTQ_fe19b0db-f8f0-4b1b-9e80-e0ffb5e637d3">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzQtMy0xLTEtNTU1NTQ_8abacb8e-9d5b-44e3-a12b-5be704e19b0d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzQtNS0xLTEtNTU1NTQ_e8b66fe9-29a7-4e36-995f-ddf871a6a45a">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzUtMS0xLTEtNTU1NTQ_53673ea9-95ac-4715-8d21-13c93f95837b">254.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzUtMy0xLTEtNTU1NTQ_badc74ee-e805-44f7-8dec-a7fdd5deea20">249.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzUtNS0xLTEtNTU1NTQ_9ec0ad67-a8d8-4e98-9bc5-924c96bc56a4">188.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, <ix:nonFraction unitRef="shares" contextRef="i5c176348e21b4ba1a3156259d8a42916_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY1ODI_a345d215-b167-479c-84a7-8fbd53e2ea8c">1.6</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i7f3ff89fdeeb41748a0d6033b1bd4fa9_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY1ODk_01bc3934-ef7d-4079-96e0-3e4a1304c2ba">1.8</ix:nonFraction> million performance units were outstanding, with weighted-average grant date fair values per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5c176348e21b4ba1a3156259d8a42916_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY2ODQ_6a4d41e8-a172-44e1-8da9-8362923bad4a">229.39</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f3ff89fdeeb41748a0d6033b1bd4fa9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY2OTE_4a18cfec-18db-40b0-a2dc-63d71d337362">207.52</ix:nonFraction> per unit, respectively. During the year ended December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY3NDQ_79110f87-e318-418c-b3d0-8e242f31b883">0.6</ix:nonFraction> million performance units with a weighted-average grant date fair value per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY4MjM_d4ef60cf-339a-4968-b614-2ffe7df5cab4">254.68</ix:nonFraction> were granted, and <ix:nonFraction unitRef="shares" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY4NDQ_9616840c-0d9a-429e-9a81-7c459e197a77">0.2</ix:nonFraction> million performance units with a weighted-average grant date fair value per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY5MjM_66cba7b1-d9d4-4bcd-a183-b1b88e1453ea">226.32</ix:nonFraction> were forfeited.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair values of performance units paid during the years ended December 31, 2021, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcwNDU_d8214e4e-829a-4e0e-a106-194472179aff">149</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcwNDk_ef39d9af-9051-4a99-a1ce-7705069cc744">230</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcwNTY_3c33bbd2-f0e8-463c-8bf7-05402b015922">176</ix:nonFraction> million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a0fc38f20a74e048b30d4518de569a1">As of December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i5c176348e21b4ba1a3156259d8a42916_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcyMzM_836edff4-5e86-4674-8e8b-801de9d6803f">130</ix:nonFraction> million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzczODM_735c55eb-ccbb-4718-a82a-593061fa7b97">one year</ix:nonNumeric>.</ix:continuation> </span></div><div id="i2a971cfaef98424f9692041d6ed3a222_208"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0XzQzNQ_90fe9ed9-83cc-44ee-acff-f1aaed795d9d" continuedAt="iff24ba6ce14d4fd29a9c5525b64d27b6" escape="true">Defined contribution plan</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff24ba6ce14d4fd29a9c5525b64d27b6">The Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0Xzc2OTY1ODEzOTUwMTk_e0bae4af-6875-47c0-bde6-59e0e331573e">279</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0XzM3Ng_a30a8815-3572-4a36-abaf-b14198528803">231</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0XzM4Mw_cedbf985-9f1f-4d3d-a194-4a75a32483f4">220</ix:nonFraction> million for the years ended December 31, 2021, 2020 and 2019, respectively.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNjA_c46fe30f-dd99-4d24-8466-b1f7b08497d0" continuedAt="ic1d5a9fad4044cbda89c5f99c2c36144" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="ic1d5a9fad4044cbda89c5f99c2c36144" continuedAt="if8cb4e221f50440f9997f254ba6a32c9"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNjE_a768658d-bb4e-4965-93fc-7a35a1c60677" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3022ab55cbe34d28a3a4a40e97b0e2f6_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzItMS0xLTEtNTU1NTQ_025feaa4-779f-4d98-8ebc-e03737a46951">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378c1ff5055142c89725880372cbf969_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzItMy0xLTEtNTU1NTQ_3bc13665-c656-493e-a575-bbaf8f01266a">4,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07aa01d299e2400ca85cb51dfeac2827_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzItNS0xLTEtNTU1NTQ_328f485c-c349-4619-bf25-8a671054b2f1">4,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f5e991692b349cf9019705e77e8295a_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzMtMS0xLTEtNTU1NTQ_13b381a0-aca5-4d6e-9f51-ca26eff5f554">4,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if882d889ea614a7891f8c06a940d0411_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzMtMy0xLTEtNTU1NTQ_180a756d-130b-418c-be01-dbb798e5c389">4,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13da767a4eec472cacf227f166d68782_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzMtNS0xLTEtNTU1NTQ_8b25cc47-ad37-4130-92c5-69332b3dd0c6">4,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzQtMS0xLTEtNTU1NTQ_82c86379-6601-441c-ac0a-ead54c4885b3">6,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzQtMy0xLTEtNTU1NTQ_86fa78e2-2e63-424f-92a1-9408be9eb8c3">8,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzQtNS0xLTEtNTU1NTQ_ae0f1e50-f9c8-4266-a92f-91332c67d41a">9,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNzg_56319dbd-b4fa-46e5-a5d8-3891b342450b" escape="true"><div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzMtMS0xLTEtNTU1NTQ_ad66fc72-205a-478c-962a-815b07e55c99">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzMtMy0xLTEtNTU1NTQ_21d1a4ef-13d0-488b-9fb4-71c18187c3cc">921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzMtNS0xLTEtNTU1NTQ_93622c7d-57ba-4da1-a064-5073e82e99eb">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzQtMS0xLTEtNTU1NTQ_7cbd6b40-b2c7-4387-b727-e380d6e99039">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzQtMy0xLTEtNTU1NTQ_72385df0-b1c1-4651-8db4-eca16cb4fcc7">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzQtNS0xLTEtNTU1NTQ_4acdea9e-327a-4711-81f6-0bb637c041fa">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzUtMS0xLTEtNTU1NTQ_d3938043-cd7e-4af7-98f1-7a02ee2bfc04">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzUtMy0xLTEtNTU1NTQ_a29238d0-347d-42fe-98e0-270386639f85">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzUtNS0xLTEtNTU1NTQ_4e288745-85ea-438d-ad73-607435663420">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzYtMS0xLTEtNTU1NTQ_a324cfc0-7246-45b2-be4f-111d84643b02">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzYtMy0xLTEtNTU1NTQ_dd62a83b-e0c0-4dda-aff9-af0b377f6f78">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzYtNS0xLTEtNTU1NTQ_d1dba5bc-b6c1-4b10-9527-7a49132cfa51">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzgtMS0xLTEtNTU1NTQ_fc5b7d37-2bcc-45a5-ad45-f62b381274e8">308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzgtMy0xLTEtNTU1NTQ_69beef0b-cb7d-4b5c-9600-5867d8005277">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzgtNS0xLTEtNTU1NTQ_bd60ce12-6091-4cd7-8c4f-060b3427b9d2">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzktMS0xLTEtNTU1NTQ_b58517f3-54f4-4258-bcaf-54719c9bcde2">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzktMy0xLTEtNTU1NTQ_fb885bea-094b-4aac-952d-b0dc75591832">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzktNS0xLTEtNTU1NTQ_371b70be-ce45-406c-9a77-efc972590cc9">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEwLTEtMS0xLTU1NTU0_36d24bd7-c4f1-4f49-8e04-9aa58756e5b2">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEwLTMtMS0xLTU1NTU0_047b3446-944e-4cc4-9b1d-abde31f8c4c1">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEwLTUtMS0xLTU1NTU0_8e9961b0-690b-4b03-bacc-ed4628444381">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzExLTEtMS0xLTU1NTU0_44157af4-7d2d-4502-ac26-5b7549888b65">434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzExLTMtMS0xLTU1NTU0_1ef9cd7e-5440-43d5-add3-7e146e6c8cc4">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzExLTUtMS0xLTU1NTU0_25e5da62-825f-4ca5-bad1-d083a3cad1b4">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEyLTEtMS0xLTU1NTU0_b48445fb-ec42-49b2-8f08-987de66b7fca">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEyLTMtMS0xLTU1NTU0_df3fc5e1-556b-4c4f-9285-d92eb9afcb4f">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEyLTUtMS0xLTU1NTU0_c7e0383e-2be9-4779-8cd1-b669e9746bf9">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNDY_0bb6b117-99ec-4fa5-b5ef-ca2238f25b8d" continuedAt="i93b0873b976244748b90389f72cde747" escape="true">Significant components of our deferred tax assets and liabilities were as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><ix:continuation id="i93b0873b976244748b90389f72cde747"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzMtMS0xLTEtNTU1NTQ_8034a0d7-6344-4f55-a0c6-80ee36914542">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzMtMy0xLTEtNTU1NTQ_28e67c8b-9eeb-4759-9854-c51af96cb287">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzQtMS0xLTEtNTU1NTQ_942412bc-ac45-4ce8-b380-a6c4b62b2b00">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzQtMy0xLTEtNTU1NTQ_4a40e5a4-8477-4b65-8b8f-d2ed2dabda10">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzUtMS0xLTEtNTU1NTQ_d0dade87-d383-4727-b0cf-465c6a0b78e6">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzUtMy0xLTEtNTU1NTQ_0b175019-1adc-4ec2-a946-aca460921831">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzYtMS0xLTEtNTU1NTQ_6d247dc4-f9d9-4b31-b81f-d99cd9d0c3fa">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzYtMy0xLTEtNTU1NTQ_0793e80a-eb21-48c8-9692-2ca227735da3">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzgtMS0xLTEtNTU1NTQ_0d4d0187-600b-4df7-988b-f84fec2675e8">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzgtMy0xLTEtNTU1NTQ_55aeca39-34a1-4679-82c8-ac9c1b400cfc">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzktMS0xLTEtNTU1NTQ_b846340a-5c59-4fe2-a193-260ee5a30426">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzktMy0xLTEtNTU1NTQ_d02f2e16-8a04-4d15-9537-210c0cd0d91e">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzEwLTEtMS0xLTU1NTU0_f3198738-86e9-4f6a-8aa8-4bae4f531421">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzEwLTMtMS0xLTU1NTU0_37bab24a-2e63-48ff-bc5d-9243116c9502">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzExLTEtMS0xLTU1NTU0_fdd552b5-685c-4222-a1da-ac63599a0bdb">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzExLTMtMS0xLTU1NTU0_d33785af-a1e0-4c76-9481-d109ba682984">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE0LTEtMS0xLTU1NTU0_c7ddb40d-f1bc-4256-aded-0b4339d0f8bc">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE0LTMtMS0xLTU1NTU0_0b4a829b-f295-45eb-b70b-1246bcb25c97">903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE1LTEtMS0xLTU1NTU0_bdab623d-05f8-4d34-9fda-382cf8a36a5a">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE1LTMtMS0xLTU1NTU0_bc32b066-eded-4d9f-91a8-f71ac1dd5575">282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE2LTEtMS0xLTU1NTU0_5ab0379f-3ba4-47c5-b9f0-23751618d3d9">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE2LTMtMS0xLTU1NTU0_26ddceca-0cc1-4ace-9c73-b30b9f8584d4">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE3LTEtMS0xLTU1NTU0_ce9fd0c0-994c-47de-9364-7f8ebc3390ab">221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE3LTMtMS0xLTU1NTU0_2e8d6a6d-ca26-40e0-adef-00dc81cd6090">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE4LTEtMS0xLTU1NTU0_6e3af493-167e-4e9e-ae7f-a40a6b048652">1,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE4LTMtMS0xLTU1NTU0_d0d0f5e2-b4d1-49b4-ada5-d955b0c1cef5">1,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE5LTEtMS0xLTU1NTU0_061f7d12-16ab-4566-a91c-c01083a77f15">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE5LTMtMS0xLTU1NTU0_9d677367-d701-43fd-88fc-d52fba94b239">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if8cb4e221f50440f9997f254ba6a32c9" continuedAt="i2c934fd57e39426d8317e914827bc946"><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased in 2021, primarily driven by the Company&#8217;s expectation that some state R&amp;D credits will not be utilized and certain foreign and acquired net operating losses will expire unused.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEwNjI_4f0896a6-c33b-4b32-9c3b-fc9fbca07272">75</ix:nonFraction> million of federal tax credit carryforwards available to reduce future federal income taxes and have provided <ix:nonFraction unitRef="usd" contextRef="i19cf357e0ed44f0a9240d63f761e319f_I20211231" decimals="INF" name="us-gaap:TaxCreditCarryforwardValuationAllowance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzExNjc_deb512cb-5326-412f-94c9-8cc7b398bed6">no</ix:nonFraction> valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2040. We had $<ix:nonFraction unitRef="usd" contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEzMDg_a4e3e308-d1e5-48c9-91a1-c6e88d9e9d00">798</ix:nonFraction> million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE0MzU_c8d3f37c-4d70-4d98-8102-a75307f24612">709</ix:nonFraction> million of those state tax credit carryforwards.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE0OTY_de1d5384-51e5-4b35-97fd-9b4081e658c5">606</ix:nonFraction> million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE2MjA_1447f6be-4938-4e91-a967-fce07fb9e4c9">6</ix:nonFraction> million of those federal NOL carryforwards. For the federal NOL carryforwards for which <ix:nonFraction unitRef="usd" contextRef="i7ea7e54e88b146f383ed2ca43d4cc454_I20211231" decimals="INF" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE3MDA_699104a8-6aab-4f3e-a8b1-a3cd115d1705">no</ix:nonFraction> valuation allowance has been provided, $<ix:nonFraction unitRef="usd" contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3Xzg3OTYwOTMwNDQzMTQ_dc162291-dfd0-4087-8b39-c329bf603c91">426</ix:nonFraction>&#160;million have no expiration; the remainder begin to expire between 2022 and 2037. We had $<ix:nonFraction unitRef="usd" contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE3Nzk_7d6b74bb-f8b4-4db5-bda3-674f460786f0">391</ix:nonFraction> million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3Xzg3OTYwOTMwNDQzMzE_19f5e86f-a5fd-4309-b0e9-645ee8bc5406">330</ix:nonFraction>&#160;million of those state NOL carryforwards. We had $<ix:nonFraction unitRef="usd" contextRef="id46afb35127d450e9e5b64faa1484510_I20211231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE5NDI_3fcb5178-225c-4d29-8838-c46e6cbfae48">2.0</ix:nonFraction> billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $<ix:nonFraction unitRef="usd" contextRef="id46afb35127d450e9e5b64faa1484510_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzIwNjY_900be28d-fb50-4559-be4c-f9c5747e5472">561</ix:nonFraction> million of those foreign NOL carryforwards. For the foreign NOLs with <ix:nonFraction unitRef="usd" contextRef="i14e3f4af542345b1913d9608046945a8_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzIxMzE_3eab7172-91a7-41ee-8a08-44bf563a357a">no</ix:nonFraction> valuation allowance provided, $<ix:nonFraction unitRef="usd" contextRef="id46afb35127d450e9e5b64faa1484510_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzIxNjQ_3cc6c1ca-8941-4d32-88e4-584e26e83918">800</ix:nonFraction> million has no expiry; and the remainder will expire between 2022 and 2031.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNjg_517cc09a-38cf-4107-a249-12dbaf4bcc0d" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzItMS0xLTEtNTU1NTQ_db42c626-c43a-472f-98c9-3faa80e1255d">3,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzItMy0xLTEtNTU1NTQ_eee64919-dbfb-4497-97a3-49a9f3639805">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzItNS0xLTEtNTU1NTQ_c2cf3ced-d8e4-41c4-a304-009cfa6f7fba">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzMtMS0xLTEtNTU1NTQ_97097023-05d5-4c8d-8a97-87855e0200e1">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzMtMy0xLTEtNTU1NTQ_632d0fb6-ff69-47c1-8a5b-e5332503fb75">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzMtNS0xLTEtNTU1NTQ_e9d086c5-7299-423d-af09-4f4d90bf9b23">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzQtMS0xLTEtNTU1NTQ_1eaea427-4b71-4723-b1fd-89ec550c211f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzQtMy0xLTEtNTU1NTQ_c7928666-cd73-4de7-81ac-2e9e7f3d5cef">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzQtNS0xLTEtNTU1NTQ_8e7202e3-f257-44f0-9d83-b7dac9d347fa">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzUtMS0xLTEtNTU1NTQ_9f18faf2-84e1-484f-9242-132ef27a3e8e">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzUtMy0xLTEtNTU1NTQ_7ffec5b3-1195-4d97-a682-254645555beb">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzUtNS0xLTEtNTU1NTQ_76ed95e3-6f5d-4ee9-baea-4dc474fd8111">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzctMS0xLTEtNTU1NTQ_d154ec71-0d37-4432-a611-dcd955777d03">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzctMy0xLTEtNTU1NTQ_03b6e3fb-2017-4ee5-9a68-c985d49eece0">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzctNS0xLTEtNTU1NTQ_f98a2cf1-494a-40d4-bab5-50b0a05c06fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzgtMS0xLTEtNTU1NTQ_83663934-6ff1-44f3-8c28-b889b534d8b2">3,546</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzgtMy0xLTEtNTU1NTQ_13cef463-88ae-46d1-a726-7c380171d18f">3,352</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzgtNS0xLTEtNTU1NTQ_d3a94da8-069f-4b6f-bf31-090f2a83c8e4">3,287</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the UTBs as of December 31, 2021, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2021, 2020 and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzI3MTE_9ae1c881-49e8-44f3-bcb8-bccffbc92b70">98</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzI3MTU_6e371402-4f62-440a-8410-69d79b2055bc">116</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzI3MjI_4eedcf1d-2be6-4a78-ad17-afabce5e53dd">198</ix:nonFraction> million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2021, was primarily due to lower interest rates during 2021 and settlement of a prior year audit. As of December 31, 2021 and 2020, accrued interest and penalties associated with UTBs were $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzMwNDA_40b4f0ab-e842-4d9c-bab9-f5b8ad628716">881</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzMwNDc_6b7d0873-1d01-467b-9f6c-f3d94140da1f">783</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2c934fd57e39426d8317e914827bc946" continuedAt="ic73c65745e8443c8bf57eacd3af88628"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNzA_f54bc673-92b5-41ab-953b-b99691c4341c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzItMS0xLTEtNTU1NTQ_6995032d-172e-4a61-9a51-c332c30faff0">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzItMy0xLTEtNTU1NTQ_45b3f948-c4a0-4669-9074-32bcc753aac7">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzItNS0xLTEtNTU1NTQ_e293cc8b-5145-4cd0-b3f0-5700b8ddf5d8">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzMtMS0xLTEtNTU1NTQ_f2ce497f-22ee-4818-8014-fe2893ea0061">7.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzMtMy0xLTEtNTU1NTQ_d1a4f7aa-8bd2-4367-bf98-13801e62484c">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzMtNS0xLTEtNTU1NTQ_3553e147-2ee6-4589-881f-3143ab8c94f6">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzQtMS0xLTEtNTU1NTQ_8ce21228-e989-4391-868b-e2b3e456080d">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzQtMy0xLTEtNTU1NTQ_d806336d-9ad6-458c-bc6e-b136c897ab29">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzQtNS0xLTEtNTU1NTQ_d177ca96-96f5-4f01-95a4-631cd8e917ce">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzUtMS0xLTEtNTU1NTQ_3dea4780-3e1b-4d57-b23c-252b63f0b64f">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzUtMy0xLTEtNTU1NTQ_3a23b40f-6ad5-4f1e-b902-46cb9321814d">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzUtNS0xLTEtNTU1NTQ_d1499823-6a64-4fef-812c-7c07f8d600c2">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzctMS0xLTEtNTU1NTQ_65f644d2-7caa-4aa2-b117-576b1822baf1">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzctMy0xLTEtNTU1NTQ_e4e00ee5-647b-4175-be30-b2b6c1cfb6f6">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzctNS0xLTEtNTU1NTQ_ac2b53e3-1e33-400f-894b-7b5e809f09de">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzgtMS0xLTEtNTU1NTQ_42b65d52-00e6-44a7-993e-8e6acc4af8fb">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzgtMy0xLTEtNTU1NTQ_36bad039-8a0d-45dc-8aba-f6aaa7d73243">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzgtNS0xLTEtNTU1NTQ_62f5873c-1b99-4be2-9af3-0893bb3c89f1">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMS0xLTEtOTQ0Njg_61e1f2c4-deae-44a8-872f-bd4a5aeca27a">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMy0xLTEtOTQ4ODE_6b76cbdf-f6c1-47ef-a77e-c7e19fff645b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktNS0xLTEtOTQ4ODk_fb81ef3b-c939-48bc-aa20-5ecc8776ffe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMS0xLTEtNTU1NTQ_3b93776c-9e90-4aa2-98ae-bf9e38345eec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMy0xLTEtNTU1NTQ_dc614636-d34b-43c9-b5fe-93cb0ad3b293">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktNS0xLTEtNTU1NTQ_33537be4-c75d-4323-b36f-bb5a356f5e10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzEwLTEtMS0xLTU1NTU0_9b790add-8de9-440c-b9c7-c905915102c2">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzEwLTMtMS0xLTU1NTU0_2af173d0-753a-4beb-999b-fb1789869376">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzEwLTUtMS0xLTU1NTU0_5471149e-ee19-4e04-8d4b-cfcf47395fec">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzExLTEtMS0xLTU1NTU0_69329ffe-ef1f-4922-8f2e-8276c5a8ba3b">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzExLTMtMS0xLTU1NTU0_9208c3bb-a0a7-4734-badb-8e24d5223c9a">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzExLTUtMS0xLTU1NTU0_567875ea-6a64-41f4-bf80-56101374d287">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the years ended December 31, 2021, 2020 and 2019, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#8217;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2035. Additionally, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing site in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes in 2021, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid during the years ended December 31, 2021, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzQ0OTM_7820dd21-877f-4952-b747-f1421abacba1">1.9</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzQ0OTc_e6c0ef39-9da6-4b5d-af54-b7ed8b841682">1.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzQ1MDQ_e3568364-d4b8-483c-bbdf-f5038e90cc0b">1.9</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities (including the IRS) are becoming more aggressive and are particularly focused on such matters. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest <ix:nonFraction unitRef="usd" contextRef="i1607fbba52af401f822b87f6c9ca7b4d_I20210531" decimals="INF" name="amgn:NumberOfNoticesOnProposedAdditionalTax" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3Xzg3OTYwOTMwNDQzMTI_53801ddc-c53a-4abb-9de6-fdda7d4adbc6">two</ix:nonFraction> duplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021, which seek to increase our U.S. taxable income. The Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $<ix:nonFraction unitRef="usd" contextRef="i1607fbba52af401f822b87f6c9ca7b4d_I20210531" decimals="-8" name="amgn:ProposedAdditionalIncomeTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEwOTk1MTE2NDk4ODI_86467cbe-7e86-4804-b124-68c282c1bd6f">3.6</ix:nonFraction>&#160;billion plus interest. Any additional tax that could be imposed would be reduced by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i1607fbba52af401f822b87f6c9ca7b4d_I20210531" decimals="-6" name="amgn:RepatriationTaxOnProposedAdditionalTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEwOTk1MTE2NDk4OTY_36c5a19c-3b0b-474c-a9ce-180522e3bc96">900</ix:nonFraction>&#160;million of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS&#8217;s positions set forth in the Notices are without merit, and we are contesting the Notices through the judicial process. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office. We were unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a statutory notice of deficiency for these years as well. We expect to contest any such notice related to 2013&#8211;15 through the judicial process. We are also currently under examination by the IRS for the years 2016, 2017 and 2018 and by a number of state and foreign tax jurisdictions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic73c65745e8443c8bf57eacd3af88628"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div></ix:continuation><div id="i2a971cfaef98424f9692041d6ed3a222_214"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90ZXh0cmVnaW9uOjE4ODZiYzBhZDdjYTRiMjJiOTc5OGIxOTE5NzY3ZDNlXzc2OQ_e163bbd3-815a-44e5-a194-904ffea970f5" continuedAt="ib660d924c00e45eb9d03f2f71059bc5f" escape="true">Earnings per share</ix:nonNumeric></span></div><ix:continuation id="ib660d924c00e45eb9d03f2f71059bc5f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90ZXh0cmVnaW9uOjE4ODZiYzBhZDdjYTRiMjJiOTc5OGIxOTE5NzY3ZDNlXzc3Nw_d2922cf7-de9e-4699-a166-a55efc05830c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzMtMS0xLTEtNTU1NTQ_9f6ba638-3cc7-4ed9-9504-e3f7f706d317">5,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzMtMy0xLTEtNTU1NTQ_6f6a5c04-9ed0-4201-88a1-9c9b9468ccff">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzMtNS0xLTEtNTU1NTQ_14ab7bad-a871-4ae0-8b9b-224a8337f3e3">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzYtMS0xLTEtNTU1NTQ_97200bcc-2442-4f14-abc0-308681eb0ef7">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzYtMy0xLTEtNTU1NTQ_cbfffef2-1b9e-47f1-aad9-a7c6e826fb86">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzYtNS0xLTEtNTU1NTQ_b0df7951-e203-4d72-9d29-5c57eabfbce9">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzctMS0xLTEtNTU1NTQ_31802af7-00eb-47c8-afde-4aeb24c9a65a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzctMy0xLTEtNTU1NTQ_a49ac65c-7eac-4217-aba1-19f078eed05f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzctNS0xLTEtNTU1NTQ_7f9b8de6-8dc4-4c9d-9a9a-2876dfa064b2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzgtMS0xLTEtNTU1NTQ_20e78705-4988-4dc6-8ccc-d83397db202a">573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzgtMy0xLTEtNTU1NTQ_c98cea95-3ba4-4c9e-a2ec-13312e09ba33">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzgtNS0xLTEtNTU1NTQ_bc0f3d43-a459-4df0-af3c-b887f2eb6ab3">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzEwLTEtMS0xLTU1NTU0_e587c2e9-85fe-4eab-af7c-cff409ce283e">10.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzEwLTMtMS0xLTU1NTU0_2084c95d-eb56-49e8-b166-bb6d3264f9d6">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzEwLTUtMS0xLTU1NTU0_f47c7c7d-c31a-45c9-a00b-5af092b41722">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzExLTEtMS0xLTU1NTU0_9a524d7c-8e53-4256-8cdd-08be269c712e">10.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzExLTMtMS0xLTU1NTU0_54f2857c-a07c-4340-93c3-2dbe1d1e02d9">12.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzExLTUtMS0xLTU1NTU0_112402f4-07d0-4bfe-be88-e31762d8ab6e">12.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div></ix:continuation><div id="i2a971cfaef98424f9692041d6ed3a222_217"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzgxNTc_4f153580-99a0-4c4e-8292-84b377e1e32f" continuedAt="i4dc82e831bd34822ab87300b191a6a29" escape="true">Collaborations</ix:nonNumeric></span></div><ix:continuation id="i4dc82e831bd34822ab87300b191a6a29" continuedAt="i621bf90b7a3d4b3f866b26bf7702256c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a <ix:nonFraction unitRef="number" contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEzODk_0735a70d-9c22-45bb-98fb-08e2e0372e4d">20.5</ix:nonFraction>% stake in BeiGene for approximately $<ix:nonFraction unitRef="usd" contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzE0NDQ_e6c1da8e-303c-4bb5-b56b-769ac508495f">2.8</ix:nonFraction>&#160;billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i621bf90b7a3d4b3f866b26bf7702256c" continuedAt="i95b2e2a681e34ba0936163427847074c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash and development services of up to $<ix:nonFraction unitRef="usd" contextRef="ib96fb2589f6d4eb6be9dc2329f9e3e9a_D20200102-20200102" decimals="INF" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzIwNzU_2cb9450e-ab17-43c0-abcb-b02a499f8a76">1.25</ix:nonFraction>&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $<ix:nonFraction unitRef="usd" contextRef="i0f3e83663ab7448f9d89322ae4c89d53_D20210101-20211231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzkzNDU4NDg4NzMzMjM_5ba56690-2b08-454d-9d28-ca50dca58e28">220</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i27f3367e2504432e9241fb90f97792c4_D20200101-20201231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzI1NzE_eb90a917-adc2-457a-887a-bd033a2a17dc">225</ix:nonFraction>&#160;million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the year ended December 31, 2021, product sales from Amgen to BeiGene under the collaboration were $<ix:nonFraction unitRef="usd" contextRef="i5cbd73363fbf4d9f8ecace3f93987d50_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzAxMzE_18ce9359-92c7-4511-ada2-6c21460c9d19">72</ix:nonFraction>&#160;million and were recorded in Product sales in the Consolidated Statements of Income. During the year ended December 31, 2021, profit and loss share expenses related to the initial product-specific commercialization period were $<ix:nonFraction unitRef="usd" contextRef="i4e5fbb50886445c0a5885afd85d45f80_D20210101-20211231" decimals="-6" name="amgn:ProfitAndLossShareOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NjkzMjI_a6508401-7a58-47b3-8909-62bf35f2af3b">64</ix:nonFraction>&#160;million and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $<ix:nonFraction unitRef="usd" contextRef="i81e3c18d48c546e08d8c78658032b099_I20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3NTA_8bed0b27-86ff-4934-8fbf-670f13425f36">21</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i19738ccb7dec4ff194a1f820e6610a46_I20201231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3NjM_e8328b45-0127-45d1-b4d1-364f91ded1e3">22</ix:nonFraction>&#160;million as of December 31, 2021 and 2020, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $<ix:nonFraction unitRef="usd" contextRef="i558ccb32284541ab8aa7100457c3f800_I20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3NzY_e3c29f60-8ecd-466b-9e16-754f11a9ddba">61</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i03daed3f241a433a99f8a3e456d25e18_I20201231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3ODk_756b07d7-3a4d-425f-ac87-3561062aea5f">99</ix:nonFraction>&#160;million as of December 31, 2021 and 2020, respectively, which are included in Other current assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Note 19, Contingencies and commitments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangement through December 31, 2021</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal, recognized product sales of Aimovig in the United States, shared U.S. commercialization costs with Novartis and paid Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to make a payment to Amgen of up to $<ix:nonFraction unitRef="usd" contextRef="i47ecb19fa54443e6a1c8180a5b4978c1_I20211231" decimals="-6" name="amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEwOTk1MTE2NTk2NDQ_5befbc0b-b03d-4f21-b0d6-e48c05649141">100</ix:nonFraction>&#160;million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangement after January 1, 2022</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the amendment effective January 1, 2022, Novartis retains the ex-U.S. Novartis Rights and will continue to pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide. In the United States, Novartis will no longer collaborate with Amgen or share Aimovig commercialization costs and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen manufactures and supplies Aimovig worldwide. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, net costs recovered from Novartis for migraine products were $<ix:nonFraction unitRef="usd" contextRef="ic20c274ca8254d83931002497f749d6a_D20210101-20211231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzE2NDkyNjc0NTU3NTk_7654101a-aa4f-41a2-a101-1a4ce9d50e79">160</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i22383ad8ad98490387eb40c5fefbfaa1_D20200101-20201231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ0MDY_69816b01-c9fe-4607-838a-4b4a668cec61">192</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id5ded1767e5544259a8f3222f3f0b097_D20190101-20191231" decimals="-6" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ0MTM_ed7edfac-9b5d-4da4-ae2e-c1ccb28df5e5">187</ix:nonFraction> million, respectively, and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due to Novartis for Aimovig were $<ix:nonFraction unitRef="usd" contextRef="i83cee794a408414492622e90651c37e8_D20210101-20211231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ3ODI_41d68a12-3359-4974-aa13-18a06d20ebc1">116</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ida0758ef280b4ca39e8e5f8ec2aab3e1_D20200101-20201231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ3ODY_1830f9ba-0d04-48b9-ac7e-8f0540d32649">139</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1f36a12191440cbbf96604a76e7170e_D20190101-20191231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ3OTM_7bccdea9-3e82-475d-8e8c-fc49b5765205">115</ix:nonFraction> million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due from Novartis for Aimovig were not material. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kyowa Kirin Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize an anti-OX40 fully human monoclonal antibody (AMG 451) worldwide, except in Japan. AMG 451 is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we will lead the global development, manufacture and commercialization of AMG 451, except in Japan. KKC will co-promote AMG 451 with Amgen in the United States and have opt-in rights to co-promote AMG 451 in various other markets outside the United States, including in Europe and Asia. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i95b2e2a681e34ba0936163427847074c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i4c8816fa7e9c49cba0ab2b9df683b53e_D20210701-20210930" decimals="-6" name="amgn:UpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEwOTk1MTE2NDIwNzY_80ac00f7-fb5d-4637-9d79-53896447daaa">400</ix:nonFraction>&#160;million to KKC that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and KKC will share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i8bdd4a592dc14b00a7340e260c55ac4d_I20211231" decimals="-6" name="amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEwOTk1MTE2NDIxMjI_0321ce7d-5fd8-45a2-ac30-6a58c2c0f643">850</ix:nonFraction>&#160;million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan. Net costs due to KKC were not material during the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.</span></div></ix:continuation><div id="i2a971cfaef98424f9692041d6ed3a222_220"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxNDE_153a4d1e-8bad-4e3f-9812-dbb812ac40c0" continuedAt="i28c433c32bd2476c993cc3c30e35d2c7" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i28c433c32bd2476c993cc3c30e35d2c7" continuedAt="i0100ecb994b14f599e4e7b6230adf765"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxNTA_fa6a0e7e-da14-4d7a-a922-47e4aa6b0593" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtMi0xLTEtNTU1NTQ_17cf73ed-9a2e-476f-8d3b-181b16a80d3e">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtNC0xLTEtNTU1NTQ_f0c8b686-51f7-4bde-bfe8-ebfec447b1f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtNi0xLTEtNTU1NTQ_761740f8-2bc3-49d9-8d5b-765858908283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtOC0xLTEtNTU1NTQ_41930ac8-8959-4169-bacb-d8e2ca594f0e">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItMi0xLTEtNTU1NTQ_6e7e0bf2-be88-4718-86da-e18796e7de4a">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItNC0xLTEtNTU1NTQ_06df8371-0044-46a1-a74f-afbdadb7e790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItNi0xLTEtNTU1NTQ_6cbca5f9-c70d-4ce7-a390-f7d643754bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItOC0xLTEtNTU1NTQ_9e00b630-22a7-4438-ad79-c1187653823e">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktMi0xLTEtNTU1NTQ_5d907719-08b4-4820-b7f1-17dd9b38278c">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktNC0xLTEtNTU1NTQ_80e74373-63e8-4651-a858-97acc7f7567d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktNi0xLTEtNTU1NTQ_836c3e38-2605-4e71-8da5-c229106348d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktOC0xLTEtNTU1NTQ_8d608975-f968-4102-ac5d-592f479bc608">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTItMS0xLTU1NTU0_702c270a-668e-4431-bc89-33eae90bb100">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTQtMS0xLTU1NTU0_38f21fc2-fed4-4333-8776-79c729f5f62f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTYtMS0xLTU1NTU0_ec10c2f0-65a8-48aa-bde9-4e97b60a619b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTgtMS0xLTU1NTU0_3a5ba063-26d5-4767-9aa4-1e77b53a2ee7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTItMS0xLTU1NTU0_3ae9d687-c754-4ecb-a033-013797aebaff">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTQtMS0xLTU1NTU0_5e4f9ce8-7025-47bb-abb6-711398d5762c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTYtMS0xLTU1NTU0_da50eb9c-0c0e-46d4-b9c6-84b8caca3533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTgtMS0xLTU1NTU0_b806429f-6289-4c88-af99-36f60ce1aa22">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtMi0xLTEtNTU1NTQ_cf910fce-39f1-440c-9f58-0155aa12629d">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtNC0xLTEtNTU1NTQ_fcd3becd-75a4-4771-ac39-aadcc6a94a1a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtNi0xLTEtNTU1NTQ_66ce7809-55a6-4c78-be3b-38eba67491c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtOC0xLTEtNTU1NTQ_121c137d-d6e8-4e30-8dc3-43c0424ceb4f">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItMi0xLTEtNTU1NTQ_11714b60-1f54-4d54-ae8b-5631ad6de043">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItNC0xLTEtNTU1NTQ_d775bf79-cd24-44fe-9c38-4a1339a44b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItNi0xLTEtNTU1NTQ_10c8c52b-1b53-4506-8402-a429b101595a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItOC0xLTEtNTU1NTQ_d576bb46-bd06-4d5a-bb70-de2cc79e8d6e">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktMi0xLTEtNTU1NTQ_7037222f-d30e-488f-8116-01db283a8422">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktNC0xLTEtNTU1NTQ_b3452e55-ea6b-4977-87de-51502744d498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktNi0xLTEtNTU1NTQ_a8c81482-2a5e-4c16-9d3d-6da386fb0465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktOC0xLTEtNTU1NTQ_126d1bd2-afa7-4f7b-93b2-09dfbd27f6b5">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811e98c080a8445ab332e5093987caf0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTItMS0xLTU1NTU0_f87b91d5-9f3b-4547-8a7f-7c2f1a7ac152">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811e98c080a8445ab332e5093987caf0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTQtMS0xLTU1NTU0_a9e9e270-cf32-463d-8eda-1049df300133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811e98c080a8445ab332e5093987caf0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTYtMS0xLTU1NTU0_b0849009-fa0d-4297-94fb-7018649515c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811e98c080a8445ab332e5093987caf0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTgtMS0xLTU1NTU0_ac3f679e-cff5-43ff-8f8e-69ce38b10db3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTItMS0xLTU1NTU0_a49e6463-93e4-47ee-a2bb-06c85f65f2be">9,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTQtMS0xLTU1NTU0_8f3cd67f-0ae1-498c-80a3-cf913b028e19">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTYtMS0xLTU1NTU0_3dd02012-aab6-4741-b1ea-47282450781c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTgtMS0xLTU1NTU0_9464426e-863c-4c34-a330-b7405d4adf6f">9,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxMzA_63947dfd-5e69-48f3-82ae-fed3a93a8c34" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b2c07d94924b70a99e1b31e4959623_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzItMi0xLTEtNTU1NTQ_b2c18254-56e0-4ade-8b59-38ac358e249f">7,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzItNC0xLTEtNTU1NTQ_0226f139-50e5-4270-8192-fdad6a741d0c">5,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b2c07d94924b70a99e1b31e4959623_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzMtMi0xLTEtNTU1NTQ_66bceca9-3b9c-448c-8b89-ee10f2d917fc">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzMtNC0xLTEtNTU1NTQ_a353fb02-1352-4900-8a4a-ab146f14a702">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b2c07d94924b70a99e1b31e4959623_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzUtMi0xLTEtNTU1NTQ_9e1a9d99-5edf-4b92-8626-86a62e863e0f">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzUtNC0xLTEtNTU1NTQ_08c0b8aa-724b-4235-b63b-94c20e05167d">9,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQ3NQ_766af9e5-9e9e-40c1-934c-b9a87abef4d6">733</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQ4Mg_6f456231-5e0e-4ed5-9242-94fef0d988af">802</ix:nonFraction> million as of December 31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0100ecb994b14f599e4e7b6230adf765" continuedAt="i430517febc45468ab6032d08952dcc0d"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxMzU_e7d45af0-416f-4f11-9b9a-680409cc9f93" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by contractual maturity were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual maturities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzItMi0xLTEtNTU1NTQ_0cac917d-d147-4167-84e2-f21a206e97bc">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzItNC0xLTEtNTU1NTQ_cf0346e4-c6a2-4224-93cb-b6d0627f72c0">9,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through three years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzMtMi0xLTEtNTU1NTQ_ebfbed0c-7e91-47b2-b2cd-0158f9eefb7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzMtNC0xLTEtNTU1NTQ_1b41d623-9059-4eca-b095-a79895fa3a69">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzgtMi0xLTEtNTU1NTQ_990d5ff3-3d59-4ac5-9142-bda567410e3f">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzgtNC0xLTEtNTU1NTQ_03b64c65-28b3-48f7-a2f2-1c2fa3f9adb0">9,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, realized gains and losses on interest-bearing securities were not material. For the year ended December 31, 2019, realized gains on interest-bearing securities were $<ix:nonFraction unitRef="usd" contextRef="ic6bedbb0fb8544608b6b4b38788612de_D20190101-20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzgxMQ_f5c47ff2-e51e-4e08-801c-62021f51af3b">92</ix:nonFraction> million and realized losses were not material. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="id775784f91834b37bd5778c4af33ff82_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI0NTA_24b15fef-1079-4102-a4d7-df34ede09af6">611</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0685790a88a441c3b4731096daf74bcb_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI0NTc_eac96ac7-cafa-4ec3-8dda-cacea59b2b78">477</ix:nonFraction> million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2021, 2020 and 2019, net unrealized gains on publicly traded securities were $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNDAzODY_1d85c37b-fae2-4d5a-b284-e5248eb10aca">161</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI2NzI_8e1c1464-dcde-4f0b-8ec2-538eb3181758">174</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI2NzY_75ad99db-b0bb-427b-8ff0-163bfebc28bc">112</ix:nonFraction>&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2021, 2020 and 2019, were not material. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $<ix:nonFraction unitRef="usd" contextRef="id775784f91834b37bd5778c4af33ff82_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI4NTQ_86061f95-005c-4c61-959e-4f9fae474cc4">262</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0685790a88a441c3b4731096daf74bcb_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI4NjE_73fe75ba-806e-4932-b19f-246f727851d6">203</ix:nonFraction> million in equity securities without readily determinable fair values as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ets in the Consolidated Balance Sheets. For the year ended December 31, 2021, gains due to upward adjustments on these securities were $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4NjIyMTg_1cd66b31-6c66-47a2-9c26-b77892d03f06">152</ix:nonFraction>&#160;million, and gains realized on the dispositions of these securities were $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="amgn:EquitySecuritiesRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4NjIyMzI_829f9b79-b1c9-4311-8fda-f85600e1006e">41</ix:nonFraction>&#160;million; for the years ended December 31, 2020 and 2019, gains due to upward adjustments and gains realized upon dispositions of these securities were not material. For the years ended December 31, 2021, 2020 and 2019, downward adjustments to the carrying values of these securities were not material. Adjustments were based on observable price transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a <ix:nonFraction unitRef="number" contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQxMjY_6044e9b1-fa6e-4b49-985d-964bbc987044">20.5</ix:nonFraction>% ownership interest in BeiGene for $<ix:nonFraction unitRef="usd" contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQxNjM_199c2f2c-67c0-41b5-af24-64808826c6d6">2.8</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQxNzY_167e00ff-7867-496d-9b91-c218f9aee533">2.6</ix:nonFraction>&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;D. Our equity investment in BeiGene is included in Other noncurrent assets in the Consolidated Balance Sheets.</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our equity investment is accounted for under the equity method of accounting due to our ability to exert significant influence over BeiGene. See Note 1, Summary of significant accounting policies, for factors in concluding our ability to exert significant influence over BeiGene. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sets of BeiGene by approximately $<ix:nonFraction unitRef="usd" contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102" decimals="-8" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQ1NDc_b87d1ef5-7aaf-408b-bb27-53586ae62b0a">2.4</ix:nonFraction>&#160;billion. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity method of accounting requires us to identify and allocate amounts to items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Other income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from <ix:nonNumeric contextRef="icc49ed11c95a425c91f0d42a0e3a802b_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzUyNDk_ff92e33c-93d5-4b46-9b5a-75e54e71b0a5">8</ix:nonNumeric> to <ix:nonNumeric contextRef="i356b9dbd15c04f05b6aa947471d7ecc0_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzUyNTU_89a42988-b5e3-413d-9cec-fb7f9c786a43">15</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the carrying value of the investment was reduced by our share of BeiGene&#8217;s net losses of $<ix:nonFraction unitRef="usd" contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczNDA_7f34f84a-3e66-439d-bc85-27321fc71900">265</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczMjc_cdd4d582-886b-4fac-b183-a72a41bec832">229</ix:nonFraction>&#160;million, respectively, and amortization of the basis difference of $<ix:nonFraction unitRef="usd" contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4Njg5NjM_97f52f07-cddb-4d03-b01c-dc37860bc3c0">172</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczNjE_427dc9d4-a35a-4b1a-b3e7-dc53339f1263">109</ix:nonFraction>&#160;million, respectively. During the years ended December 31, 2021 and 2020, we increased the carrying value by $<ix:nonFraction unitRef="usd" contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0MDU_8853ed36-1ad7-4db4-a8f2-c2a0d01c826d">50</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczODk_64033b27-ac36-48fd-94c8-6c840ee2dd18">569</ix:nonFraction>&#160;million, respectively, as a result of our purchase of additional shares of BeiGene. In addition, during the years ended December 31, 2021 and 2020, the carrying value increased by $<ix:nonFraction unitRef="usd" contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTQ4NTc_e49aef8d-2532-4636-afc7-b7838d627aa7">265</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4Njg5NDg_f2bb85a0-3208-4951-942b-a0a8bd6d7bf0">34</ix:nonFraction>&#160;million, respectively, from the impact of other BeiGene ownership transactions. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i430517febc45468ab6032d08952dcc0d"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, our ownership interest in BeiGene was approximately <ix:nonFraction unitRef="number" contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkwMjI_da3bfb21-ec8c-475d-8c9c-16205a85b24c">18.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkzMTQ_c374f9df-9d6f-4dc0-b13c-43b0c1585ae1">20.5</ix:nonFraction>%, respectively. As of December 31, 2021 and 2020, the carrying value of our investment in BeiGene was $<ix:nonFraction unitRef="usd" contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzU4NDU_bf19de0a-795f-42e4-8436-37b7b4cd35c4">2.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkyODE_f16d13aa-dc71-488b-a74e-844dacb70270">2.9</ix:nonFraction> billion, respectively. As of December 31, 2021 and 2020, the fair value of our investment in BeiGene was $<ix:nonFraction unitRef="usd" contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkyODk_7cc6b98b-b781-43b6-bce5-01ed27a89690">5.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkyOTQ_8d936709-5a1f-42ee-b65d-22eac2ceff25">4.9</ix:nonFraction> billion, respectively. We believe that as of December 31, 2021, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 30, 2021, we acquired an approximately <ix:nonFraction unitRef="number" contextRef="ie26bf44881b14ed4b71997783873d549_I20210930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0MjY_56d74636-2dbb-45cb-b6eb-246a5e59d85b">25.9</ix:nonFraction>% ownership interest in Neumora, a privately held company, for $<ix:nonFraction unitRef="usd" contextRef="ie26bf44881b14ed4b71997783873d549_I20210930" decimals="-6" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0MzQ_62d21149-c351-4b9f-88a7-f2dd00d23665">257</ix:nonFraction>&#160;million, which is included in Other noncurrent assets in the Consolidated Balance Sheets, in exchange for a $<ix:nonFraction unitRef="usd" contextRef="i8bdea1c8311e41d9a8dd2e5681a38379_D20210930-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0NDc_e0e76844-3cab-4a68-b715-a71a39a0405f">100</ix:nonFraction>&#160;million cash payment and $<ix:nonFraction unitRef="usd" contextRef="i8bdea1c8311e41d9a8dd2e5681a38379_D20210930-20210930" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0NDk_b4e9396c-f648-44a4-a4bc-28fbec4121e8">157</ix:nonFraction>&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of December 31, 2021, our ownership interest in Neumora remained at approximately <ix:nonFraction unitRef="number" contextRef="id2bdf24151064c60a96102ab1941f91f_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTQ5MjE_2d97655c-5be2-4bfd-bb3c-ec4b29c6d00f">25.9</ix:nonFraction>%, and the fair value of our investment was $<ix:nonFraction unitRef="usd" contextRef="id2bdf24151064c60a96102ab1941f91f_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTUwMzc_6a965b3e-e4bc-43e5-a2f0-5cdfcac5ef24">220</ix:nonFraction>&#160;million. Accordingly, during the fourth quarter of 2021, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i05cf3220a1054a8f8f5e45eba0b0f1b1_D20211001-20211231" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4NjI5NDc_7c266b91-670e-480b-addd-fed48ac5d517">37</ix:nonFraction>&#160;million for the reduction in the fair value in Other income, net, in the Consolidated Statements of Income. For information on determination of fair values, see Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnerships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $<ix:nonFraction unitRef="usd" contextRef="i3795b0430f51414baeabe5e24d635ce9_I20211231" decimals="-6" name="us-gaap:AlternativeInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDI5NDg_00654ddf-b986-44ab-a374-d144a9868c0c">573</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic5e3474cb0114feba5cd13cc8ae2c916_I20201231" decimals="-6" name="us-gaap:AlternativeInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDI5NTY_622de112-cc9e-4072-aa1a-c59b8be1f500">496</ix:nonFraction> million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. These investments, which are primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2021, unfunded additional commitments to be made for these investments during the next several years were $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTE5Mzk_33d4bf0a-0c6d-4455-b17b-8c45cc39cbbe">185</ix:nonFraction>&#160;million. For the years ended December 31, 2021, 2020 and 2019, net gains recognized from our limited partnership investments were $<ix:nonFraction unitRef="usd" contextRef="idaf2649fff4c4de298cd836c69f79d22_D20210101-20211231" decimals="-6" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0ODg_41089115-e487-41c8-917f-b57ff8b43d56">143</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i96eda76077d241f081c28bb4ab52763e_D20200101-20201231" decimals="-6" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDM3MjU_e4746730-c205-4b21-a2da-b09583821dba">241</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idfa8066544024fa19ebe0b52eeaba353_D20190101-20191231" decimals="-6" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDM3MzA_d7b32b17-4004-4d1f-a488-8702891b4bee">27</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i2a971cfaef98424f9692041d6ed3a222_223"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90ZXh0cmVnaW9uOjc4MGExNTNlYjM1MDQ2NTU5MDVjMjc4YWUyMTk1Nzk5Xzgy_787af64a-4b92-42a0-93fd-a17e13693200" continuedAt="i7873395bde1e4dcd8b1fac0b7331e828" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i7873395bde1e4dcd8b1fac0b7331e828"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90ZXh0cmVnaW9uOjc4MGExNTNlYjM1MDQ2NTU5MDVjMjc4YWUyMTk1Nzk5Xzgx_8e9ff5ed-395a-4287-af7e-cbd8802fe96c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzItMS0xLTEtNTU1NTQ_6dd1fa9a-86df-479f-8dbd-ae4280255cbf">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzItMy0xLTEtNTU1NTQ_f409a983-b7b6-4bf3-89cb-641b2b20570e">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzMtMS0xLTEtNTU1NTQ_7e51d5e5-f782-44da-9b0c-8ccb5dd83715">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzMtMy0xLTEtNTU1NTQ_cbe90735-bb3a-4105-95f6-1676fd9b5f49">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzQtMS0xLTEtNTU1NTQ_0b3da261-5595-436b-9f0e-9ebd6249d28e">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzQtMy0xLTEtNTU1NTQ_1993acb7-c7d6-4df9-8cd8-a84c4d78bf06">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzUtMS0xLTEtNTU1NTQ_d2d5748f-1824-4b72-b5db-07d62e6cccb9">4,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzUtMy0xLTEtNTU1NTQ_ca3db049-e875-43aa-a623-0f832abcc200">3,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzQ3NA_b4e0d5c9-de21-4dff-8043-180b5ad20e63" continuedAt="i0f102f03ba8b4b6aa1ef60c7ade7674c" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><ix:continuation id="i0f102f03ba8b4b6aa1ef60c7ade7674c"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzQ2NA_b6424a38-5ee4-4b98-8c7f-e17579efb3b0" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzItMy0xLTEtNTU1NTQ_13cad7e8-dd0e-403c-9aff-d3ccc7898efe">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzItNS0xLTEtNTU1NTQ_5471489c-f502-4583-ab01-401d2e6c71b0">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a675d05a0804539a7d21138c1722b7c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiYzA3ZWY2MGY4NTc0NzBmOGY3Mzc2MzYzMWNkMDBmN180_dda30299-cd98-4087-a7e4-e9ad3dc9cbf2">10</ix:nonNumeric>-<ix:nonNumeric contextRef="if6a6e2eaf0994cebafac018b5e3fe2b3_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiYzA3ZWY2MGY4NTc0NzBmOGY3Mzc2MzYzMWNkMDBmN183_385b1c4b-51c7-4e8c-8236-58e8347f7c96">40</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtMy0xLTEtNTU1NTQ_f84bae1a-1798-4b10-b59b-266f56883a79">4,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtNS0xLTEtNTU1NTQ_a2f526bf-96c2-41e9-8be6-48652d6808d4">3,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a0a9ca1a0cd4f579495b0fabf37ebe5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2YzRhN2ZlY2Y3ZjU0NWUzYmZmY2NiZjQ1MjE4NjA4MF80_8fe72b11-4fad-413e-a285-f4cc27d2abce">8</ix:nonNumeric>-<ix:nonNumeric contextRef="ieccfdc26f7e24e8784d8e7068a04a895_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2YzRhN2ZlY2Y3ZjU0NWUzYmZmY2NiZjQ1MjE4NjA4MF83_b74b31af-314f-4cd3-9679-77eb605dbc14">12</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtMy0xLTEtNTU1NTQ_0df83310-b863-4fa4-a283-af1f38b1ad05">3,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtNS0xLTEtNTU1NTQ_d6e2ead3-9a43-41fb-bb0f-d09972da38fe">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3cf9f313b68c4865a53543614de8354e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiOWQwYjI1MzhhZDQ0Mjc5YjA1MGJkZjIyOThkNDM4NF80_26cf4178-54fa-43f9-8e80-bb0ad4e36284">8</ix:nonNumeric>-<ix:nonNumeric contextRef="i8902072edc954d06a4fa32d21142b284_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiOWQwYjI1MzhhZDQ0Mjc5YjA1MGJkZjIyOThkNDM4NF83_fcebd41e-3374-4692-8a9b-eb5d65ead25a">12</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:LaboratoryEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtMy0xLTEtNTU1NTQ_707cc371-c7c7-41e7-a611-af3953ecb6e8">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:LaboratoryEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtNS0xLTEtNTU1NTQ_fa986fe4-94ce-4724-a5d7-c063628b71f0">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5451fcd71feb4721a719c87aa7225d50_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzYtMS0xLTEtNTU1NTQ_1675a3f6-5bfb-4342-8832-ce903318809d">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:FixedEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzYtMy0xLTEtNTU1NTQ_6ab1ab2d-7f6c-4eee-8a01-c3d5692e6906">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:FixedEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzYtNS0xLTEtNTU1NTQ_c9dc1f26-ed6c-44bf-ab33-1b860098e6af">2,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice11863ea1f641c982d327a9700952dc_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2ODdlODE2YTU5MTc0ZmI5YmRjNTg0OTczM2Y5NjhmOV80_5b18dd9e-c29c-4b24-b6ba-a5f3d3d58ef7">3</ix:nonNumeric>-<ix:nonNumeric contextRef="iaaff719184b24d3c8e81d58f99addf22_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2ODdlODE2YTU5MTc0ZmI5YmRjNTg0OTczM2Y5NjhmOV83_906af8b7-26c4-4869-bc4a-1db6a5598fb9">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctMy0xLTEtNTU1NTQ_38333e52-4f9b-498e-bfe7-7eff05349dbe">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctNS0xLTEtNTU1NTQ_4be13fa8-8e22-468d-ae61-797ff87918b7">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie80ef32cb43043a09a41633946a002ae_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjoyYTAwOGMxMDhiZWM0OGRlYjNhMGM3OGE2OTAwY2EyNF80_0b6f89b3-1d68-4bac-b0ee-ca137a97351f">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i2ac8514d57744567b3fefdd3b73af1a4_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjoyYTAwOGMxMDhiZWM0OGRlYjNhMGM3OGE2OTAwY2EyNF83_7979d1b7-62f9-4155-8f4b-63e31d2db98e">10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtMy0xLTEtNTU1NTQ_fcc6ebe6-d37c-4ec5-9c8c-03fff49a1662">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtNS0xLTEtNTU1NTQ_a3ae27d3-7882-411a-8092-16b4079e4234">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzktMy0xLTEtNTU1NTQ_282dc28e-442a-4fd6-815c-4e97bd794481">987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzktNS0xLTEtNTU1NTQ_029ea2f1-3276-49f0-a5df-10dfd4687f91">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEwLTMtMS0xLTU1NTU0_f570686a-5218-4099-84d9-8820de352f79">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEwLTUtMS0xLTU1NTU0_26aca78a-2085-4b84-b70f-dc28cd769a99">13,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzExLTMtMS0xLTU1NTU0_346ec80a-906d-4df3-84aa-8585ddfd4565">8,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzExLTUtMS0xLTU1NTU0_21d28b73-c8e8-401c-94d6-e346ef49c4b1">8,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEyLTMtMS0xLTU1NTU0_b5bdc160-fc53-4989-854b-244377b9dc4d">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEyLTUtMS0xLTU1NTU0_ca9d73c9-e360-4bbc-952d-6e2cd778aba5">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, we recognized depreciation and amortization expense associated with our property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzI3Mg_c529b6d1-2cc2-4ff1-a3d3-d1b12ba53b35">644</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzI3Ng_41fa86c1-c4db-468c-9058-d925acab6769">640</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzI4Mw_88d7a941-2628-4ee2-9304-49c5d0050d30">635</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic information</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzQ3OA_c09bc52e-e0fc-4e5f-8ee0-5e3b699aceef" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24c03a5fa36492bb701fd1cf35c078e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzItMS0xLTEtNTU1NTQ_315dd3be-7c33-4fc9-b7ac-446ea88aba5e">2,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9b0d86322746389e6bcdfa6dca160c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzItMy0xLTEtNTU1NTQ_8e7d1ff7-eeb1-40c4-8114-729e6242de8a">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873c3b8314524d3fad876f18c5598ab3_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzMtMS0xLTEtNTU1NTQ_5435f5af-b547-4f5c-859c-4dce602d8683">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87470154c5964bf885e913dea7bf3103_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzMtMy0xLTEtNTU1NTQ_d868c0b2-708f-4dfa-8adf-bcbad68306b0">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697e8dd993f14956a1d252e84ed707d4_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzQtMS0xLTEtNTU1NTQ_06651446-d6d2-4791-918b-37b71d3fc787">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39392b4b995449a590f6320c08ce61e5_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzQtMy0xLTEtNTU1NTQ_6f441adb-4425-435d-8a8b-2518bcf2aa77">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzUtMS0xLTEtNTU1NTQ_174ec3db-4b61-49a1-bc87-adb0f0b95c58">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzUtMy0xLTEtNTU1NTQ_dc0b5ea4-3124-41c9-999c-a8318e59da92">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2a971cfaef98424f9692041d6ed3a222_229"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3NjI_1cda1802-ddf2-4188-a08c-9eb222d0b6c2" continuedAt="i0fcddfe6932445c5b756792472bbdcdb" escape="true">Goodwill and other intangible assets</ix:nonNumeric></span></div><ix:continuation id="i0fcddfe6932445c5b756792472bbdcdb" continuedAt="ic543f82bde324ecda14b98e66c53b270"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3NTk_5cdd2cbc-079e-4fb5-ab6f-923e7b894e0a" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzItMS0xLTEtNTU1NTQ_53963025-e8d1-4a37-a856-a71d69965875">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzItMy0xLTEtNTU1NTQ_97f2adf6-f2c8-4194-905a-f2328c8503a0">14,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition from acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzMtMS0xLTEtNTU1NTQ_d9d4ec6d-f69d-4943-a320-eedb174227bb">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzMtMy0xLTEtNTU1NTQ_bb45de70-c32a-4503-a90c-4696d83a9faf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzQtMS0xLTEtNTU1NTQ_0cf9eef6-351e-4088-96a5-d5656b40058b">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzQtMy0xLTEtNTU1NTQ_df36ac3f-3b37-4753-bd8f-af605c1b85dc">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzUtMS0xLTEtNTU1NTQ_0052af8c-133d-408e-800f-32408b8ff2e2">14,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzUtMy0xLTEtNTU1NTQ_47d27b8a-751d-4994-b86d-3c173c010c4b">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic543f82bde324ecda14b98e66c53b270" continuedAt="iad3624c303ae4fecbb32d5f5575877fe"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:ScheduleOfIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3NTg_7e84fbff-4739-47a8-9f0d-b5a8b8eb0b46" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcf86294d042a097451c547386436c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtMS0xLTEtNTU1NTQ_13540bfa-74b0-4953-9973-fa15677ee146">25,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idafcf86294d042a097451c547386436c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtMy0xLTEtNTU1NTQ_d4662484-9681-4cb3-8dd0-e0c6d72ba645">12,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafcf86294d042a097451c547386436c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtNS0xLTEtNTU1NTQ_191c29d2-c4cb-481d-806f-fe03fa96a954">12,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtNy0xLTEtNTU1NTQ_c409665f-4f6b-4cc7-9c0d-900e97d4d018">25,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtOS0xLTEtNTU1NTQ_066e28b7-9066-47d9-a077-2a8c9d3dff81">10,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtMTEtMS0xLTU1NTU0_52ce625c-71c4-40cd-a143-07b7c193df43">15,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9afda65b678547869ef5990f59bf488a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtMS0xLTEtNTU1NTQ_de8a8a1e-7c02-455d-ad9e-a46e8d392b6e">3,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9afda65b678547869ef5990f59bf488a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtMy0xLTEtNTU1NTQ_702e89bb-493e-4617-b8cc-939bb27cffdc">2,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9afda65b678547869ef5990f59bf488a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtNS0xLTEtNTU1NTQ_91b1d3aa-a29b-4308-906d-32ec9c2c2f76">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b135991cad418282667c91fa819593_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtNy0xLTEtNTU1NTQ_54abfd87-c27f-455b-96fe-005f17af4f3f">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2b135991cad418282667c91fa819593_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtOS0xLTEtNTU1NTQ_83325d38-6ebf-40d6-908c-1d77c5c250f9">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b135991cad418282667c91fa819593_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtMTEtMS0xLTU1NTU0_45a1b4ff-f493-46fd-a662-68f1e5751db1">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641193dfa12140ac8063f9a64824a74f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtMS0xLTEtNTU1NTQ_697224da-b8b1-410b-9761-08cc5f75b21e">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i641193dfa12140ac8063f9a64824a74f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtMy0xLTEtNTU1NTQ_ecafb192-3d46-4ca7-8cdc-c36cffaf5c9f">1,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641193dfa12140ac8063f9a64824a74f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtNS0xLTEtNTU1NTQ_8df61f6a-7a01-4495-aff8-0428e4c1a6e5">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6fec59b238425ea04b200b698f4eaf_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtNy0xLTEtNTU1NTQ_90ca41f0-23e4-4294-8dc1-251e4feaf59c">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf6fec59b238425ea04b200b698f4eaf_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtOS0xLTEtNTU1NTQ_ce1d98cf-50f5-414d-9fde-4505e5b979e9">1,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6fec59b238425ea04b200b698f4eaf_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtMTEtMS0xLTU1NTU0_db026349-73fa-4c17-b036-321becf0a350">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae35a0ac1214710b7c190312232e3a7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctMS0xLTEtNTU1NTQ_020e6275-15dd-465a-9b9f-dc2e1bbd0f55">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ae35a0ac1214710b7c190312232e3a7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctMy0xLTEtNTU1NTQ_bdf8a6d9-f741-4d9c-87c5-cf171c2e26c9">1,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae35a0ac1214710b7c190312232e3a7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctNS0xLTEtNTU1NTQ_b583aeb3-bc02-4482-a270-543e2973dfe3">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c22c6a79774622a0b10ce923ca150e_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctNy0xLTEtNTU1NTQ_5149da3d-ee18-4cf1-b7ea-f2d887e870fc">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6c22c6a79774622a0b10ce923ca150e_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctOS0xLTEtNTU1NTQ_2698662a-4c0a-4392-8245-2d6a5883a42d">1,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c22c6a79774622a0b10ce923ca150e_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctMTEtMS0xLTU1NTU0_57c57d4b-ecdc-4eec-bf15-6e7f815b279e">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtMS0xLTEtNTU1NTQ_c914741c-4a99-4c4c-b1d6-77dbdcbe7193">32,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtMy0xLTEtNTU1NTQ_4c83d606-27b4-4944-a0a3-363d0b9c36d6">17,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtNS0xLTEtNTU1NTQ_fd47561a-42ad-492d-95e2-5fc530e7c284">14,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtNy0xLTEtNTU1NTQ_33a04e49-869f-4033-a349-fa93da493b41">32,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtOS0xLTEtNTU1NTQ_9a38773b-bffd-45fb-949b-30dd658bdad4">15,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtMTEtMS0xLTU1NTU0_4de1e0cf-3423-4c23-82cb-ab10c514b7a6">16,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d95d8ba10643ef98491d2fb2c2e0c4_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTEtMS0xLTU1NTU0_40c3cae1-b3ce-4e9f-aae6-992d37ca102f">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d95d8ba10643ef98491d2fb2c2e0c4_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTUtMS0xLTU1NTU0_d2b2362f-0db7-44a7-9d63-b4e4aa93e832">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa636f63d01f499bbc23a8871f6dac49_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTctMS0xLTU1NTU0_c8fdeb27-293a-4f83-a2b4-0e8c2cd57bf0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa636f63d01f499bbc23a8871f6dac49_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTExLTEtMS01NTU1NA_9455773b-e637-42ed-a36e-64b4f3020cbe">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTEtMS0xLTU1NTU0_00a1b799-d368-4f02-810d-f7fda9ac5e8d">33,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTMtMS0xLTU1NTU0_96cae39d-57eb-45d4-9c6c-95f087318ff1">17,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTUtMS0xLTU1NTU0_7c02c86e-cd90-432a-a660-5cd64c2c27f3">15,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTctMS0xLTU1NTU0_62c9d4bb-5ff6-49b6-8425-9b8d5c621f21">32,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTktMS0xLTU1NTU0_ee0166b9-7c81-4b24-96c2-b5ba3eba3385">15,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTExLTEtMS01NTU1NA_dcc604b6-b7ae-48a2-82ac-865ffa5ff747">16,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we acquired certain finite-lived and indefinite-lived intangible assets as a result of the Teneobio acquisition, including IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="iff6483f2d4ab4e57a98ea68547e64b32_I20211231" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzEwOTk1MTE2MzEwNDQ_bf1eb55d-6b19-4bca-88f7-c64190efecc2">1.1</ix:nonFraction>&#160;billion, R&amp;D technology rights of $<ix:nonFraction unitRef="usd" contextRef="if0c996cd5afc4b66986324061c0fd03b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzEwOTk1MTE2MzEwNTY_32f4b447-7ef5-4066-98b5-87059a3ab74c">94</ix:nonFraction>&#160;million and licensing rights of $<ix:nonFraction unitRef="usd" contextRef="ibaa9036d3707491ba2a27c213ba7af11_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzEwOTk1MTE2MzEwNjg_a5160a64-2195-4235-a211-0098dd50db56">41</ix:nonFraction>&#160;million. See Note 2, Acquisitions.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad3624c303ae4fecbb32d5f5575877fe">During the years ended December 31, 2021, 2020 and 2019, we recognized amortization associated with our finite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI0MjY_837ca2d5-39c5-4f0a-8073-4d47f67159e7">2.6</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI0MzA_b69b3aaa-7b72-4557-bd6f-3567a4994fcb">2.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI0Mzc_45071a86-884c-4513-bec9-26df9cf1a072">1.4</ix:nonFraction> billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2022, 2023, 2024, 2025 and 2026, are $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MTM_007ed592-c66e-48ea-abde-d7e4d09973fb">2.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MTc_d02fb988-8ff6-4bf7-97d0-9a10c38c9f4a">2.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MjE_4721d818-ec15-46c6-a03b-e69fef7f2ea5">2.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MjU_e3bd2246-6c29-43ad-9c14-76f69b57e5d4">2.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MzI_67259113-1cdb-4a60-b711-7d2f4ca8ae6b">1.8</ix:nonFraction> billion, respectively.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIyMjY_af19ce16-98b2-49e9-953d-688659737a4f" continuedAt="i1955c4f1f98840d3ac8b43d068d85cd0" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i1955c4f1f98840d3ac8b43d068d85cd0" continuedAt="i605cde2c6b3544a69e2116eeca3ae7bf"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain facilities and equipment related primarily to administrative, R&amp;D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most leases include one or more options to renew, with renewal terms that may extend the lease term up to <ix:nonNumeric contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzY4Mw_e09957a4-ba59-47a0-8ea2-abbec0d57b4d">seven years</ix:nonNumeric>. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;D and administrative space.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIyMjc_1dd22e8f-24b9-4cef-b6a1-a19a42ddebf3" continuedAt="i279497aa92ab4f4eb78200ebf454818e" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_8e72894d-153e-4a5c-a949-14e5e6efb449"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_aa058334-0aaf-49a3-8af4-aa023d961fb9">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMi0xLTEtNTU1NTQ_924c35ad-9712-475b-9e1d-3091dddd2cdd">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtNC0xLTEtNTU1NTQ_7c34bfb1-ecc4-45a2-99f4-e54e794978c5">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_425f51cf-a3fa-4258-bdbe-9af1266d73f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_ea705079-dbdc-4ad1-8743-a06d3d2376ba">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMi0xLTEtNTU1NTQ_55263ecb-ad0c-4559-969c-22bc9bd12103">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtNC0xLTEtNTU1NTQ_cf0dce57-ef24-4652-85c4-99060bc75308">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_b89a7ea2-fc91-480e-bd31-38a43ceb270a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_f7f1087e-27ba-483f-bdb7-bd0cc9f4c25f">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMi0xLTEtNTU1NTQ_3d6e973d-dcbf-42a5-846b-c5931e615486">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtNC0xLTEtNTU1NTQ_2e82cdd0-5fb3-4926-9f8e-b102e057bd85">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzctMi0xLTEtNTU1NTQ_449ff219-0b71-4b69-8580-23618b2a7ec1">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzctNC0xLTEtNTU1NTQ_bcebdb8c-2708-40a6-93ad-c4fd72cb6012">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzItNC0xLTEtNTU1NTQ_559c4d7f-94f3-4d0d-bb41-eee18b6f1aca">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzItNi0xLTEtNTU1NTQ_33eba411-a671-4a13-a131-64571c33a6d9">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzItOC0xLTEtNjExMjA_12e25332-dff6-4b23-89b1-d01c6dbbfd81">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzktNC0xLTEtNTU1NTQ_aa14f2cf-5109-44e6-8286-922b5683b77b">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzktNi0xLTEtNTU1NTQ_57f1c0cb-e464-45d9-9b3e-27f811a41ec5">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzktOC0xLTEtNjExMjc_0f45f71a-0c87-4042-ac91-e83947cf6671">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzEwLTQtMS0xLTU1NTU0_fc450106-38fb-4066-b2d1-dfc5581e596f">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzEwLTYtMS0xLTU1NTU0_7c0357f9-c300-4bd7-85f7-0a060d6bc3e7">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzEwLTYtMS0xLTc1MzY3_09b07446-e184-45cb-b8ed-583b99db1a28">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2021, 2020 and 2019.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIyMjg_2052f8d1-5661-49f5-ac36-37331929cec2" continuedAt="i892a0dcb64cc43bb96fb30a7d8ee25ad" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2021, were as follows (in millions): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzEtMi0xLTEtNTU1NTQ_d5770dc9-ec8a-4dc6-ab47-b0c6e3131e91">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzItMi0xLTEtNTU1NTQ_eef5e43b-00f1-4616-880e-e0accfaf8f41">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzMtMi0xLTEtNTU1NTQ_5f339eae-b974-4d03-913b-e91b488122d4">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzQtMi0xLTEtNTU1NTQ_5b940321-1022-4908-9e35-8c9018f38a5e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzUtMi0xLTEtNTU1NTQ_8fbc31ca-157d-426d-be08-043ac15bf320">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzYtMi0xLTEtNTU1NTQ_81fdbb80-c6a6-418c-943c-037fb22d1dcf">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzctMi0xLTEtNTU1NTQ_87d26419-8a28-4e00-9a2b-59a04cf00ed8">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzgtMi0xLTEtNTU1NTQ_2df67009-23f3-4fbb-a289-f753ee052c5b">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzktMi0xLTEtNTU1NTQ_46874589-7d58-4a4a-86c5-6c9b6bbd2a2f">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i892a0dcb64cc43bb96fb30a7d8ee25ad" continuedAt="ia78b6a861d674ab485febcca642741d2">(1)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia78b6a861d674ab485febcca642741d2">Includes future rental commitments for abandoned leases of $<ix:nonFraction unitRef="usd" contextRef="i6a62dfd4c2d440e88628b7259f5b5158_I20211231" decimals="-6" name="amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzE2MjY_7938aab0-333b-4ac4-84db-6f8eada23db5">138</ix:nonFraction>&#160;million. We expect to receive total future rental income of $<ix:nonFraction unitRef="usd" contextRef="i6a62dfd4c2d440e88628b7259f5b5158_I20211231" decimals="-6" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzE2ODE_8ff1dc29-196a-4f1c-a5ac-cfee4a35910b">108</ix:nonFraction>&#160;million related to noncancelable subleases for abandoned facilities.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i605cde2c6b3544a69e2116eeca3ae7bf"><ix:continuation id="i279497aa92ab4f4eb78200ebf454818e"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzItNC0xLTEtNTU1NTQ_cda5d874-191c-4955-bda4-6681365d52ae">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzItNi0xLTEtNTU1NTQ_b0994e49-1364-4680-ba14-3f9753d4cf40">3.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzMtNC0xLTEtNTU1NTQ_e148d498-9f2e-4648-89e9-9a4627a75754">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzMtNi0xLTEtNTU1NTQ_23cb0555-9e76-43e8-926d-56889d523b09">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzMtNC0xLTEtNTU1NTQ_8a81f9d5-07d6-4a74-9dfa-f67911c381b1">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzMtNi0xLTEtNTU1NTQ_afe646bf-f24e-44ae-86a4-1c02e4f03f81">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzMtOC0xLTEtNjE4MzA_28412e6d-1865-4ab9-b4ab-03cc848d84d8">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzctNC0xLTEtNTU1NTQ_0000059f-9e0c-40ce-959b-61f465f2cadd">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzctNi0xLTEtNTU1NTQ_2d8b171c-f8a2-4970-842c-a9224fcc2df0">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzctOC0xLTEtNjE4MzY_544ce419-e97a-4f3c-9a6b-d87ca0f92b6f">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIwNDQ_6da40f7e-b61e-4582-8742-a34684aefa97">35</ix:nonFraction>&#160;million. These leases will commence in 2022 with lease terms from <ix:nonNumeric contextRef="ied090dfe9b534fd38d657521d8581f48_I20211231" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIxMDU_32bb58b7-1090-4565-9c8b-46009f152d3a">4</ix:nonNumeric> to <ix:nonNumeric contextRef="i201a72549edc46dd976f10480c16db04_I20211231" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIxMTE_ac3263b4-9458-4631-a576-6039639771b4">6</ix:nonNumeric> years.</span></div></ix:continuation><div id="i2a971cfaef98424f9692041d6ed3a222_235"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:AccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90ZXh0cmVnaW9uOmE4YzAyZDhiZjI4ODQ1MzRhNmQ3NGU3Y2ZmYzFmZGE4XzE4Mw_1a6341db-298e-4b24-8845-ad4d56b470f3" continuedAt="i2845d778ad1a4c0f93cbce74093ce573" escape="true">Other current assets and accrued liabilities</ix:nonNumeric></span></div><ix:continuation id="i2845d778ad1a4c0f93cbce74093ce573"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90ZXh0cmVnaW9uOmE4YzAyZDhiZjI4ODQ1MzRhNmQ3NGU3Y2ZmYzFmZGE4XzE4Mg_2ae3c5ff-bb2e-41fd-8def-442d0958f8df" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzItMS0xLTEtNTU1NTQ_aa6b901d-a3c3-488a-8f10-0eda9da54fec">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzItMy0xLTEtNTU1NTQ_8c9f121b-8c34-4339-81f9-9f4b70dfa281">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzMtMS0xLTEtNTU1NTQ_e9668e34-b580-4316-85ef-f8f8c5de0485">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherReceivablesGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzMtMy0xLTEtNTU1NTQ_38fae02c-1f2a-41b7-b20a-ac9b908f53dc">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzQtMS0xLTEtNTU1NTQ_42f28ca8-e078-4eb7-93cf-1b4b0204b03a">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzQtMy0xLTEtNTU1NTQ_0a997cd9-686f-4578-b35b-d5b8cb4e02e7">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzUtMS0xLTEtNTU1NTQ_7190c880-9227-411e-bf0c-94a29c2918b3">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzUtMy0xLTEtNTU1NTQ_8bfc112b-a8c4-4114-8e8a-d233cb1b41cf">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzYtMS0xLTEtNTU1NTQ_ca5a527b-0941-424b-958a-d7d909894864">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzYtMy0xLTEtNTU1NTQ_dcfc39a3-ff6b-4a97-80de-38a3a6fd84de">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90ZXh0cmVnaW9uOmE4YzAyZDhiZjI4ODQ1MzRhNmQ3NGU3Y2ZmYzFmZGE4XzE5Mg_0b8bf714-c243-492d-920d-f9e78d528293" escape="true"><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:AccruedSalesDeductionsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzItMS0xLTEtNTU1NTQ_85dd3467-9f99-44ae-b288-d8babca29cb4">5,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:AccruedSalesDeductionsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzItMy0xLTEtNTU1NTQ_55c59ec2-921a-4b1e-a7e6-911c6d228e7a">4,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMS0xLTEtODc1ODE_853b290e-b36d-4e32-b37e-5c7917b918ca">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMy0xLTEtODc1ODE_60248b9d-48b4-4701-beb1-75ab960a4f26">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMS0xLTEtNTU1NTQ_27003ec1-ede0-4830-b494-7291c5ce8aed">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMy0xLTEtNTU1NTQ_a529776b-37f0-4cd1-a1e8-3ff15adf7a10">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzUtMS0xLTEtNTU1NTQ_008c507a-8ebc-47e1-bf12-573d3dd57eaa">701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzUtMy0xLTEtNTU1NTQ_46becf79-2105-4e4c-aaf5-e73aa70ad180">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:AccruedSalesReturnReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzYtMS0xLTEtNTU1NTQ_765c1a95-8f54-4e0c-bb30-618cc9c8c019">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="amgn:AccruedSalesReturnReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzYtMy0xLTEtNTU1NTQ_5bb9bb38-9a43-4416-aa9d-94bd68364339">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzctMS0xLTEtNTU1NTQ_cee3d998-2302-423f-bbc2-8347ebe8dba5">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzctMy0xLTEtNTU1NTQ_abdd905e-24f8-4ef3-a24d-f9e5364d14d7">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzgtMS0xLTEtNTU1NTQ_ca585e62-d886-46ad-a529-346506b77a76">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzgtMy0xLTEtNTU1NTQ_93bdea35-d2d7-45ac-896b-cff9d237e590">10,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcyNTY3NzY3NDU1MTg5_28372b5b-f486-4573-8130-c7faa2c9c6ca" continuedAt="i9dca3cc2fb534e968156bdeccc25e0c9" escape="true">Financing arrangements</ix:nonNumeric></span></div><ix:continuation id="i9dca3cc2fb534e968156bdeccc25e0c9" continuedAt="i0be4f2d3f6a34a44b4aeac22fa70eeaf"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5OTI_9f82b7bd-a178-431c-88ba-0b9ab173d440" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e359c669dcf409083123e716b593d81_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NDQyZmMxNzNkNjU1NDczYzgzNzMyZWJhYzJhMjNlYzZfNA_f81c28ee-95da-4777-aebc-2ee761e01a8b">1.25</ix:nonFraction>% &#8364;<ix:nonFraction unitRef="eur" contextRef="i3115a2e5d2b648bb866394e00f7e6265_I20211231" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NDQyZmMxNzNkNjU1NDczYzgzNzMyZWJhYzJhMjNlYzZfNw_d507f740-d481-44ec-a893-396a0b5d9ba5">1,250</ix:nonFraction> million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib927e41cd49b4bcda2eea7a252c62906_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEwLTMtMS0xLTU1NTU0_74360d52-bcc0-46bf-ace1-33860d8a7429">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d4ded6128cc4111af96fa1184ea3cdb_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzExLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NmQzOTI5ZjkzYTc1NDBjMmExODU5ZWRhN2ZmODNiNzJfNA_7b821a46-6846-4850-b78c-20fd37f9722f">2.70</ix:nonFraction>% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4ded6128cc4111af96fa1184ea3cdb_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzExLTEtMS0xLTU1NTU0_fe43ee69-9a57-407d-8672-dc3668fdcd66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56cb2b9855fe4608b5d0321fa7ba2bc5_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzExLTMtMS0xLTU1NTU0_9cf64149-9661-4d53-8ccc-44cfb934dcf8">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf3d349c123746008f444a2b21e4dc29_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEyLTAtMS0xLTU1NTU0L3RleHRyZWdpb246YmZiNjNjNzU1MDg2NDQ4NGI5N2VjNDEwMzI1YWVkNjJfNA_57623e00-d86d-402b-8af1-57c6c4e8856d">2.65</ix:nonFraction>% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf3d349c123746008f444a2b21e4dc29_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEyLTEtMS0xLTU1NTU0_2e889caf-8f2b-4c6f-80e3-92fae883f1b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac644eb4ce441cab9fe07e3d012948e_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEyLTMtMS0xLTU1NTU0_976ca674-dfac-4b52-b800-d1e96d7b0294">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9030955f37e9430a99c50565728d5f24_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NDQ2MDJkNjE2ODY0NDc5OGI2YzA0NzBjMTI2OTdiMDZfNA_afb15aa5-5eeb-4cf5-a579-e5d561282175">3.625</ix:nonFraction>% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf619b21445f463d85928fc668c93d2b_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEzLTMtMS0xLTU1NTU0_7eac9573-1bf6-4807-b14c-0665903957a5">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99b857ada0494363b1816eed0b185516_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246OTZiOWFhOGFhNWQwNGFjYjk5YTg1OGRlNTAwYzU4YThfNA_5b263fd5-8301-44d8-88ff-a538d50d3f1f">0.41</ix:nonFraction>% CHF<ix:nonFraction unitRef="chf" contextRef="i99b857ada0494363b1816eed0b185516_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246OTZiOWFhOGFhNWQwNGFjYjk5YTg1OGRlNTAwYzU4YThfNw_252a5a0f-a38d-4e25-9f4c-ea62fcb94889">700</ix:nonFraction> million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b857ada0494363b1816eed0b185516_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTEtMS0xLTU1NTU0_42c606b4-8212-4acf-b50b-22f3f497b04b">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d5c7dae0c9470d9de4d136b31872a7_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTMtMS0xLTU1NTU0_0ea73d86-1cb3-4c31-99e0-af28fc6a9650">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05c9361f0899452b92a78f57514f9339_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE1LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzcyZTUyNTg3NzQ0NDM2NGFmNWU2ZWJlMTNhMWJkNDZfNA_28669c0e-2579-4b05-a1de-405ca598b387">2.25</ix:nonFraction>% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c9361f0899452b92a78f57514f9339_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE1LTEtMS0xLTU1NTU0_c794a914-e516-40ea-9b4d-fec9cd97f517">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb35d257f424b58b378b933e22c6e16_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE1LTMtMS0xLTU1NTU0_ba1af27b-7ac6-40d4-bd4a-31aefc69ff8c">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i059fdacf21234e8ea4393764e3826ae1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YWIxYzc1N2VmMDc1NDU3MGE5M2Y3YzYzYzMzYzNkZjJfNA_de87c254-f298-4963-a69d-e9f32b4ac657">3.625</ix:nonFraction>% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059fdacf21234e8ea4393764e3826ae1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTEtMS0xLTU1NTU0_d43bf291-f5fc-450f-ae79-8403252e6337">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ece76323354edab6344395cebe3bba_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTMtMS0xLTU1NTU0_4f1a0269-bbd6-4873-aa96-90ccf70caa94">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i728c44682ed441d0ac7d57d3f4f20961_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE3LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MDU3MTdkMjg4MDk1NDEzY2EyMjYwMmUxODBkYjg3YWZfNA_4fa79c87-b2f1-4caa-8464-b4bf733adcf4">1.90</ix:nonFraction>% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728c44682ed441d0ac7d57d3f4f20961_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE3LTEtMS0xLTU1NTU0_a0348edb-6a30-41e7-af5f-978a3792b104">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a9f89f55144c7383b92a1e2a084413_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE3LTMtMS0xLTU1NTU0_58957b81-4d24-4aac-8a4a-eac01e075412">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaab56d58779141ceb2afcc0c4b3c034e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE4LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzU1ZTdlYTFlNmIzNGQ5MWFjOGExYzRkYjhkODc2NTZfNA_87b4a973-a5f1-48c8-ad7b-12e20db8d41c">3.125</ix:nonFraction>% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab56d58779141ceb2afcc0c4b3c034e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE4LTEtMS0xLTU1NTU0_e7e3996b-8759-4804-9b28-29f6a9a8b650">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12c286c5b04cdda990afcad1d3f906_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE4LTMtMS0xLTU1NTU0_2f46b905-1755-4942-8e29-0d991e472af8">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzM3YzU5ZmQ5ZTFhNGY0ZDkzYTQyZjAzZDU1NjA1YzNfNA_947e354e-21a9-4e11-a903-6b231bc4620d">2.00</ix:nonFraction>% &#8364;<ix:nonFraction unitRef="eur" contextRef="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzM3YzU5ZmQ5ZTFhNGY0ZDkzYTQyZjAzZDU1NjA1YzNfNw_ab42fafe-8206-429c-b2e4-4d0665836959">750</ix:nonFraction> million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTEtMS0xLTU1NTU0_a2781f7b-670d-4852-adfa-1cb062f65f08">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09e03b111064a778c3c0f67fa5ceca5_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTMtMS0xLTU1NTU0_9bddcdf8-94dd-4121-a840-f57f705e288f">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0fc0421471445c09ad2091231e1ebd5_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246YzFjZjVjY2FlZWZmNDhmYzk2YzNjMmY4N2I4MjU3Y2NfNA_4d368655-854b-43b1-8048-29c83580dc11">2.60</ix:nonFraction>% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fc0421471445c09ad2091231e1ebd5_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTEtMS0xLTU1NTU0_13e83ee7-6fb7-4534-b95d-1d9b5ef88749">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb361ad83d5412a809267468ed87948_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTMtMS0xLTU1NTU0_c93ff6fb-0b5b-4d14-a168-cac2adcafe28">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NTZlMWI0MTkyZmVmNGYwZThmMjI5OTUyOTg3NjhmYmRfNA_a4ab4139-d584-4248-b096-d4e2be934153">5.50</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NTZlMWI0MTkyZmVmNGYwZThmMjI5OTUyOTg3NjhmYmRfNw_63980570-3dc7-48b7-af77-4dafeb0d9552">475</ix:nonFraction> million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTEtMS0xLTU1NTU0_8de405a7-519f-4f2c-b1ae-92cbc3b8416c">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4474d10ca0a044769c40e2e8fe8ba5c9_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTMtMS0xLTU1NTU0_dd98879e-1f28-4013-85b1-1fde20abece7">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64fa2b6c75f84ce9b2d6f2c73986f8c9_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIyLTAtMS0xLTU1NTU0L3RleHRyZWdpb246YzA3ZDI2YjA5Mzk2NDZiZDk3NjViN2Q5MmFjYzNlMWRfNA_210e3148-8f48-4231-b51d-c094d10e9fc2">2.20</ix:nonFraction>% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fa2b6c75f84ce9b2d6f2c73986f8c9_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIyLTEtMS0xLTU1NTU0_0ee67563-272b-480b-991f-2b102b932191">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf325c2ad564616a25134ef5af769ea_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIyLTMtMS0xLTU1NTU0_e072c22a-1912-43e2-ab05-d49f4a834530">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec40a5633cc44bf78f5770c8d2eca6e9_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZjJkMzgxY2ZiMTQwNGUxMThlNjAzODY2Mjc3NGE5NDVfNA_74f5c7a6-6e33-4c14-89c6-d32fb3218289">3.20</ix:nonFraction>% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec40a5633cc44bf78f5770c8d2eca6e9_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIzLTEtMS0xLTU1NTU0_86e97e33-62cd-4351-ab7a-9f43b2cc46b3">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db5be88f2184c5c83f07cb2e96fa2ea_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIzLTMtMS0xLTU1NTU0_030adcee-6fbb-4f65-8e2f-79a0662545f5">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTAtMS0xLTYxNTkyL3RleHRyZWdpb246Yjg0NWE2ZGY1NmU4NDYzYTg4MGE1N2UwNzU3YmIyZDNfNjU5NzA2OTc2NjcwOQ_d2c523da-f3c0-45da-be4c-f1bc4f22d650">1.65</ix:nonFraction>% notes due in 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTEtMS0xLTYxNjEx_180b1d31-c1e3-4029-838f-2ee189c2651a">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzU2ZDNmMDYyMDlhNDg3OTk3Mzg0ODc2MzdlMzY5Y2NfNA_9faa9e6b-0136-4fac-8a0c-489012c85905">4.00</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzU2ZDNmMDYyMDlhNDg3OTk3Mzg0ODc2MzdlMzY5Y2NfNw_31448696-f740-4247-937b-c3a92cf59e53">700</ix:nonFraction> million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTEtMS0xLTU1NTU0_e6c288ac-e554-4266-b856-ee8d1b7674e2">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b66dea34d04457952516f934bfa710_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTMtMS0xLTU1NTU0_a3540e47-fa50-4c3c-9efc-8f4ec15f9731">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI1LTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZTc4MjgwZTE5OTI5NDk1NmE4MTM5N2MxNjU3MjQ0NWJfNA_a94753c9-0232-46f9-9e5a-ad2a9f77ae91">2.45</ix:nonFraction>% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI1LTEtMS0xLTU1NTU0_20f66b08-4d6a-4e4d-a4ba-1ec62baffb45">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57500a573714861937e2948abb1c417_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI1LTMtMS0xLTU1NTU0_fab280a5-65e1-4cfd-9472-cb592f6bcafa">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if39aebc177504df78daf24169177353e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YTU5MGFhYjE5YzQ0NDdhMzgxMDQ3YTczMWFjZGMwNTRfNA_4584d362-e736-41ec-8e28-f1a35d2373a2">2.30</ix:nonFraction>% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if39aebc177504df78daf24169177353e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTEtMS0xLTU1NTU0_508169a4-2fb3-4e3d-97a0-79ee3a5b95e8">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86def4b22434c24861ce1aea3a31420_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTMtMS0xLTU1NTU0_9a7a60eb-ed4c-4ace-b8c8-9976ab0533cc">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i932124c0f7a5410abab4ba175c13bfb4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTAtMS0xLTYxNzY1L3RleHRyZWdpb246ZWVkYWQ4NjIzY2UwNDhlOWJhMThhNDQ3YzUxZTRkNTFfNjU5NzA2OTc2NjcwNA_732ae6db-6287-499f-b392-09f377ff483c">2.00</ix:nonFraction>% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932124c0f7a5410abab4ba175c13bfb4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTEtMS0xLTYxNjM0_a74055ea-cae9-4506-ad44-95668fbdc9dd">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i193e18f2a5ad4e6d9490bcfe10dacd22_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI3LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MDEwMmEzNTFlMTlhNDIxYmI3NzliMzEyMDgwMzFlN2RfNA_7f130a4c-89b4-4ed2-b2d0-ebf0a052e4e0">6.375</ix:nonFraction>% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193e18f2a5ad4e6d9490bcfe10dacd22_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI3LTEtMS0xLTU1NTU0_e2a159f1-a806-4d6b-aea9-a477ffb21e1b">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4283cce94284118a0034337aac219b4_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI3LTMtMS0xLTU1NTU0_fe381adb-05ca-4da9-952b-7596d4cdf892">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0205d38f0748461e9cefc43080126f92_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI4LTAtMS0xLTU1NTU0L3RleHRyZWdpb246NzdkMTRiMDRkNzQ0NGMxZGI3MTdlMWQzYjNiNGUyYjhfNA_2aed1166-6fc3-4906-a66c-0d9892104c4f">6.90</ix:nonFraction>% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0205d38f0748461e9cefc43080126f92_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI4LTEtMS0xLTU1NTU0_90896628-92f2-40ca-8c32-8517646302d6">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7a63a419144cf0aca9c1b14bf3aff1_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI4LTMtMS0xLTU1NTU0_c71a6fec-0fe6-405a-b7fe-6ea34b60857e">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f57518a37364ab085186556dc6f209b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MWQ1ZjFlZDNiODdkNGM1M2E5MzUzMThmNjYwN2M0ZGNfNA_7108598d-9232-461c-9c07-defa399ab060">6.40</ix:nonFraction>% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f57518a37364ab085186556dc6f209b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI5LTEtMS0xLTU1NTU0_02d94791-5298-4cc7-a4b8-718f724a9c2f">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d7e93cc83149e6bd46d9c7b5b95be3_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI5LTMtMS0xLTU1NTU0_a97a505b-faa6-4606-8965-7a8ed9161723">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfdd983a38394043a29f22f15239cdb1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246OWM0ZjUxNjNiODcxNGYxYjkwOTYyNzVhMTU0NzBhYzFfNA_a2c56bf6-3570-405d-97f1-5f464c78909f">3.15</ix:nonFraction>% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdd983a38394043a29f22f15239cdb1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMwLTEtMS0xLTU1NTU0_fd3dd1b8-2865-4e07-a591-70e4b76150bf">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMwLTMtMS0xLTU1NTU0_b09ab538-d9b4-4143-a4c9-4f318485b627">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08afea356a38453090c19b18d61b4a71_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZjFmNmE2MWNiMDAyNDk0NDkzZTZkNjU2MDk5MzlmZmRfNA_3832d2fe-5952-49d7-8a61-996fd4f6276e">5.75</ix:nonFraction>% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08afea356a38453090c19b18d61b4a71_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMxLTEtMS0xLTU1NTU0_9df4862a-bbfe-410c-a0d3-6d3a70847e44">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93bbfe5fa69940c08425fb453c4429a2_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMxLTMtMS0xLTU1NTU0_25d35563-7c6d-4895-a2ea-785ad9d5b025">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c53473bc8014e44b15542181f09808a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTAtMS0xLTYxNzY3L3RleHRyZWdpb246M2ZkMzNjNmRjNGQwNGNmZjkwYzEyMzNkMGNjNzk4OTdfNjU5NzA2OTc2NjcwMw_a9bc1cbb-f31d-49bd-b81c-9b68687662c7">2.80</ix:nonFraction>% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c53473bc8014e44b15542181f09808a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTEtMS0xLTYxNjQ4_5aad2390-bdef-4316-97c8-07a33df3b3d1">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id612d8d410b345cf9c48f162584e09ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMyLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZDU0NmNkZWY1MmQxNDkyZmIxY2UwZWIxYmU3ZGZhNjdfNA_139d20ac-2d1c-4040-93ac-b22c456e7a17">4.95</ix:nonFraction>% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id612d8d410b345cf9c48f162584e09ec_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMyLTEtMS0xLTU1NTU0_a56f0c6b-e1db-4609-9bf0-2c5ef7385aa7">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f197c292c0446c9383e5222324d6c5_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMyLTMtMS0xLTU1NTU0_53248082-9522-40bf-8f4d-3a104ae0584c">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2169d5c603a14255b95c241f6c3323ed_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246Y2I1ZDRlOTRjYzI0NDA3YjkyNjkzNjUyYjQ1NDM0MDBfNA_ff4a666c-10b1-4043-acc4-beda653bb1f2">5.15</ix:nonFraction>% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2169d5c603a14255b95c241f6c3323ed_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMzLTEtMS0xLTU1NTU0_a8a1b71c-2f1e-4e5c-8a3b-0bd14b274e79">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689ad4255db545eda69e365f169f332a_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMzLTMtMS0xLTU1NTU0_28adfc03-3344-4bde-b9ac-57adf34b81e8">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee3977d9de514e63894403ca1ca898f2_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YmI4Njk1Y2Q0MjhkNDczZWEzYTc5OWNhZDRhMGQ4MDJfNA_a8c66533-e929-46b0-b417-22258a4b217f">5.65</ix:nonFraction>% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3977d9de514e63894403ca1ca898f2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM0LTEtMS0xLTU1NTU0_c42600bf-e9a4-438c-b74e-857105f3b99e">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29adc72b130b479ea45a8aaa03b088d5_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM0LTMtMS0xLTU1NTU0_cd6f8c8c-4e35-44c1-9716-4be19eb090fc">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i965cc877b8694f78b1c2b606c84f7f38_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YmU1N2U5YzMxMzUxNGM2NjgwYzU1ODRiYzZhNzJjY2ZfNA_17b9c944-0281-48ad-bff8-343630e4427b">5.375</ix:nonFraction>% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965cc877b8694f78b1c2b606c84f7f38_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTEtMS0xLTU1NTU0_9d40cc6d-3d49-4d03-ab3a-3931ec87a788">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i364ca273078a47eca7c0fe7c36707bf5_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTMtMS0xLTU1NTU0_6d0f75e0-0d80-4522-ba93-81b43ab8b417">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idea96f4e89df43b18b9bd6729d02ad77_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM2LTAtMS0xLTU1NTU0L3RleHRyZWdpb246N2EwMzRjMjY4NmY2NDk3ZGE4ZGZkYmIzNzUyMTg3NDhfNA_38c2e7a2-c035-4166-a1c9-24d45847842f">4.40</ix:nonFraction>% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea96f4e89df43b18b9bd6729d02ad77_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM2LTEtMS0xLTU1NTU0_a140a5d3-3a51-41bc-ad40-9d3620316259">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2eb0ad81574e8e8c6e79ecedad6dd7_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM2LTMtMS0xLTU1NTU0_e734e72f-1218-4f0b-9fd6-fc73e39ec43f">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM3LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MWQzODE1YTI1MmQyNDI3MGJkMDZlNTJhNDI0YWY4NTRfNA_d10be45d-18d7-43fe-9a02-5be20fc53692">4.563</ix:nonFraction>% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM3LTEtMS0xLTU1NTU0_d87e0234-d762-48e9-9c4b-80c2cc328676">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66cf2c987b9f46568650effba9da5361_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM3LTMtMS0xLTU1NTU0_3aa6c3b6-9156-49c3-8985-354ef99147ab">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c13c24eff8b47b6b20d9d46230a1c57_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM4LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MTczMmE4MjFkMzQ0NGQyYWJkNDI0NzYzNGFlYTg4YzRfNA_ddaaeb9f-df0a-4ee1-9866-75d9d6a7ea92">3.375</ix:nonFraction>% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c13c24eff8b47b6b20d9d46230a1c57_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM4LTEtMS0xLTU1NTU0_4a107195-3f90-474c-8182-ede2414050f7">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6253005b2a4664a03ad8f8f5898630_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM4LTMtMS0xLTU1NTU0_11d36814-c28b-43b1-beed-70b375dfb0e6">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MDI3YjUzZWM0NzZlNDNkNGJlMDI3ZmEyMTg3OTZkZjBfNA_43592d16-7332-46e3-97bf-db79122656ff">4.663</ix:nonFraction>% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM5LTEtMS0xLTU1NTU0_0f8b706e-61c5-4c85-bf99-831d29f349d5">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b860697a584413f99229019ccec2aa9_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM5LTMtMS0xLTU1NTU0_82ab52be-c5a8-4ea6-9fc4-00f4aeee7ec6">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTAtMS0xLTYzNDI2L3RleHRyZWdpb246Njc2ZWNjMzMzODgxNDM0Y2IxODAwMzU0Mjg4Njk2MGVfMTA5OTUxMTYyNzgyNA_297bb2e9-e0d8-428c-b413-d1eeabb208e9">3.00</ix:nonFraction>% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTEtMS0xLTYzNDE5_876b94d3-8656-4e81-86c4-40c858216b73">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzEwNjcwYTc4OWNiNGM5MGI3ZDc3NTk2ZjlkNzVlMDNfNA_0286a533-a17c-484a-a0c4-a8acd1f31a30">2.77</ix:nonFraction>% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQwLTEtMS0xLTU1NTU0_368048fc-de44-443a-ba09-99251766e64d">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQwLTMtMS0xLTU1NTU0_aff28902-3172-4190-b958-261eee98dff4">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccec61d10cf24b1f9a049d503b7a1dad_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQxLTEtMS0xLTU1NTU0_0308dbff-4b1e-4faa-85c9-c586e2685206">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5fe83762b5347d3b5b16cc99dd81437_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQxLTMtMS0xLTU1NTU0_075a938b-dc85-463d-a00a-96b1e7d3ea37">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQyLTEtMS0xLTU1NTU0_9cf983ba-8c47-4ed0-8ebf-7534af514d71">1,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQyLTMtMS0xLTU1NTU0_3195a356-c99b-4af9-886b-954f75dc829a">1,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQzLTEtMS0xLTU1NTU0_4c743830-4b99-4e97-87c9-08b64c9998fd">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQzLTMtMS0xLTU1NTU0_cc33b58e-77d6-4bb9-8b01-f05b50171ca5">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ0LTEtMS0xLTU1NTU0_49871025-7a72-4618-b3c1-4405d3ea0310">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ0LTMtMS0xLTU1NTU0_f95b0eb1-05f5-49ea-ae56-ffb61c36cb81">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ1LTEtMS0xLTU1NTU0_199455c7-6b85-4e10-9c39-f6a708c9781e">33,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ1LTMtMS0xLTU1NTU0_a5b614a7-316d-4708-afda-762fbdc64106">32,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ2LTEtMS0xLTU1NTU0_5706c878-6fa8-40b4-8bdc-af4a9f23dfa9">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ2LTMtMS0xLTU1NTU0_75a591e7-48d2-4a92-8306-e4091dce2bd9">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ3LTEtMS0xLTU1NTU0_a09efa87-ddaa-44ce-980a-f5c53f82274c">33,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ3LTMtMS0xLTU1NTU0_ca6ac939-3a9c-44f5-a43d-21eeee9a23e1">32,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the <ix:nonFraction unitRef="number" contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIyNA_c4684f35-7c52-42f1-9f97-af9f431572be">4.563</ix:nonFraction>% 2048 Notes, the <ix:nonFraction unitRef="number" contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0Mw_947ef470-1574-4790-b999-9577a075fed7">4.663</ix:nonFraction>% 2051 Notes and the <ix:nonFraction unitRef="number" contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI2NQ_6e458cf0-2af8-4c94-ac76-5526a126996e">2.77</ix:nonFraction>% 2053 Notes, which have effective interest rates of <ix:nonFraction unitRef="number" contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMxOQ_b853162d-0b2c-4f00-984b-3c9a2a507171">6.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMyMw_a94bbb86-5337-4dde-888c-4c6113a14d9e">5.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMzMA_d0e5e441-379c-4896-81d4-a53633673556">5.2</ix:nonFraction>%, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0be4f2d3f6a34a44b4aeac22fa70eeaf" continuedAt="id556bc17c1a04342ac3a691c9f5b3201"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to <ix:nonFraction unitRef="number" contextRef="i102f385c304b406995d8b7e6800cb786_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_014bf800-b926-49de-8a88-eb1c6bfff35e"><ix:nonFraction unitRef="number" contextRef="i1c06f986336b4293934da0346e70a8ef_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_0b6ce5c5-6094-4580-b692-769f3000fb70"><ix:nonFraction unitRef="number" contextRef="i062455b6853247eba1cd91fb4b7af879_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_11e8948e-7225-4932-bd06-da45f018685d"><ix:nonFraction unitRef="number" contextRef="i7e3042dc4e974d1bb2015139dbedb73e_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_1b43c38f-69c4-497e-bb36-ae7a1e68c664"><ix:nonFraction unitRef="number" contextRef="i37fc7e470e2e4805af580456ed7f0010_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_1ea86725-fb93-4541-b104-7162f6819708"><ix:nonFraction unitRef="number" contextRef="i6540ef5c27054d6e9c7985f2b141767a_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_26c71c28-f172-405a-8a71-006cce24e22b"><ix:nonFraction unitRef="number" contextRef="i48f26a3a0d594e26854ea76bb3c6743d_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_302a3502-230d-4173-8421-2dcf8011de13"><ix:nonFraction unitRef="number" contextRef="i1863ab64829b4fabbec539235c0ac7d1_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_302cd1ac-09fc-4189-99f3-2a90206de7ae"><ix:nonFraction unitRef="number" contextRef="ifd810185a212412e83638c36004bad29_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_34efd3c9-585d-4371-ad96-d9effba80642"><ix:nonFraction unitRef="number" contextRef="i53e1283c932d4edcbb8cc22fd4ab8960_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_35312396-9841-471b-8e01-234bf6a39a9d"><ix:nonFraction unitRef="number" contextRef="i88ae1c03870043a08889cc2ff6ed20b1_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_35399fd1-f7d1-4f65-9aab-a7319614bf3e"><ix:nonFraction unitRef="number" contextRef="ib8710c24c464449b8fa26275c77a6e58_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_3cdbc11e-2bd3-4831-9d0d-5eedf251d332"><ix:nonFraction unitRef="number" contextRef="ie10a62100d1e4b0e9d7ab8a2ba247c8a_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_41d99db7-bd43-4498-96a9-a777b7c2c0e7"><ix:nonFraction unitRef="number" contextRef="ia850706d72994599bff9431d2e8b1a5a_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_48a80050-22b5-4732-9072-29ff4d905c5e"><ix:nonFraction unitRef="number" contextRef="i9f2a64b79a0c404dba15ff2230fc371d_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_54cbe8d0-541b-4aa9-8b55-be9b291e61fb"><ix:nonFraction unitRef="number" contextRef="i7fefa5369ca248188f3e2d24acec7468_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_5aaf3834-7baa-44fc-92c0-e0da1ab0926c"><ix:nonFraction unitRef="number" contextRef="i55ba559d13f24efc9fdf4abebc7c8924_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_6be46848-74bb-47dd-8cd3-de51b93b5494"><ix:nonFraction unitRef="number" contextRef="iaeaf9de7e4f74c20b1108870b6ea1974_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_6ce77e1a-3ae3-4a1c-acdc-de1c7f25fcba"><ix:nonFraction unitRef="number" contextRef="ic44afd752e7745c885bb3c653ec2d9f4_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_6fed14fd-8142-468f-a520-e0a85dee9353"><ix:nonFraction unitRef="number" contextRef="i5edec977c0494db1989203785b65a079_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_7121936d-5263-40bd-be26-da882dfd9a26"><ix:nonFraction unitRef="number" contextRef="i832afb5f09ff42f8972ccf47b59012a5_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_72b1964c-1f96-4c4a-8e40-5b50313874bb"><ix:nonFraction unitRef="number" contextRef="i7991c3b6e9984fe98b17e71a271b7557_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_754ef522-a879-42f3-b98f-1068ce9d0951"><ix:nonFraction unitRef="number" contextRef="i6d0d27fa96204770aed6605e64628c8a_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_8465c54d-a682-4cfa-a8ef-c6c02c01a70e"><ix:nonFraction unitRef="number" contextRef="i04bf222f1adc48dbad767adfdca6631f_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_8f8563ab-d241-4021-ba5e-06fa7b962231"><ix:nonFraction unitRef="number" contextRef="ic6bc114e2ad04b349cc3973ecba76b7f_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_8fce14f9-02be-414f-984c-6177fdb022e5"><ix:nonFraction unitRef="number" contextRef="i9278d061be544509ac7ccfcae7335101_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_a3ce6a93-1fef-4b63-8766-6c1891c4e1b1"><ix:nonFraction unitRef="number" contextRef="i581122c175be46309a19781a1813a543_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_a719a18c-52db-44b5-ac83-ee156353352c"><ix:nonFraction unitRef="number" contextRef="i787a1f1611f040bdb13bd41c6d2e7221_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_b998db18-5954-487c-87d0-10879eddd776"><ix:nonFraction unitRef="number" contextRef="iac386b55791042908ad00f98e5e6a2ea_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_b9cab92e-1c96-4a52-94ea-f39daf1fdd42"><ix:nonFraction unitRef="number" contextRef="i29bd0ebc2ef643d89e8a4df0e1f5a0a9_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_c0ba5ed9-27b0-4221-a35d-43e710304d34"><ix:nonFraction unitRef="number" contextRef="i34aa68b41c90434093ba0c86e0923545_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_c162bed6-ffff-496c-a6e6-580ca36e6932"><ix:nonFraction unitRef="number" contextRef="i04b1b2aa03f54c1aac5954067859bd2b_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_c3e79286-eb6c-4912-bed9-ac4584e91e8e"><ix:nonFraction unitRef="number" contextRef="i42b1c907d2284f46b65c2993a8518ee2_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_d6ff7ab0-2043-4e22-998b-c014e617dd48"><ix:nonFraction unitRef="number" contextRef="i880cd534575949e3abab9e8a7d2a0235_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_d7c62120-76e3-4338-9441-c5d31388a4f5"><ix:nonFraction unitRef="number" contextRef="i11b4dae7d4c14e8d81c11fcee49b8148_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_d9e7ccdf-3137-42e4-85c3-29c79a393c03"><ix:nonFraction unitRef="number" contextRef="iae894d8f94e84e9eb8cc52ce4c1e5efd_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_da9aa2e0-8f44-454b-869e-6640a3110387"><ix:nonFraction unitRef="number" contextRef="i3dc259e1f874437e8de85f6ffd31abd9_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_e2aed8ca-c739-4753-91c1-6c5caa9ab017"><ix:nonFraction unitRef="number" contextRef="ie151d775f0614294815a86857329b491_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_e8209e12-78e3-435f-b0d6-ed5c8f67991f"><ix:nonFraction unitRef="number" contextRef="i50e0eaf522434115aef33c9b0f4b32fd_D20210101-20211231" decimals="INF" name="amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_eb6773c3-a6e5-4a64-a8ea-4ec72a410885">101</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#8212;except our <ix:nonFraction unitRef="number" contextRef="ib1502d4ddb0b4ea78f2bfbbf53ace156_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcwMw_b19f24b7-93b7-4e10-bf40-d200662644e6">0.41</ix:nonFraction>% 2023 Swiss franc Bonds and Other notes due 2097&#8212;may be redeemed at any time at our option&#8212;in whole or in part&#8212;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from <ix:nonNumeric contextRef="ie619fdd6365143709fe3ef8c6e3e1cb8_D20210101-20211231" name="amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzExNzU_2b46b9b1-b4e3-4dfc-b362-465a8eca26bc">one month</ix:nonNumeric> to <ix:nonNumeric contextRef="i32f3ef7ef219414d9621fb4cbdaf429d_D20210101-20211231" name="amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzExODE_d70e799e-07ae-4bf3-a809-b3fa169c02d4">six months</ix:nonNumeric> prior to maturity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt issuances</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, we issued debt securities in the following offerings:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we issued $<ix:nonFraction unitRef="usd" contextRef="ic29f8a9193ed4db1ad73321b122e4e45_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU4NzM_2563e143-fdd9-4258-9de0-d7007a3e4fed">5.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU4ODc_b08fe1aa-dae5-4088-adaf-eddf9156ca2e">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU5MzI_71aeaf6f-3cbd-4148-8620-23cd352ef593">1.65</ix:nonFraction>% 2028 Notes, $<ix:nonFraction unitRef="usd" contextRef="i71d7cd08a4ec4828acd8e3620f7b4d78_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU5MTE_6428e37c-b544-46f2-9c3b-b80fd691f69a">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i71d7cd08a4ec4828acd8e3620f7b4d78_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2NjQ_b8c8bbc9-2f09-4c37-ab60-e7ea265b73ba">2.00</ix:nonFraction>% 2032 Notes, $<ix:nonFraction unitRef="usd" contextRef="i3ba4ba7693a5434e9b35ca55c38722ec_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2NzE_71de60bf-6691-464d-a248-126886f0fe3d">1.15</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i3ba4ba7693a5434e9b35ca55c38722ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2ODY_0cc7f29c-fc36-4512-b704-ab48c2a67630">2.80</ix:nonFraction>% 2041 Notes and $<ix:nonFraction unitRef="usd" contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2OTM_23329b71-00d4-4c9e-ba48-a8b42f94f93e">1.35</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk3MTA_6dcc4b83-067b-4f0d-a1d4-37e07f50b8bb">3.00</ix:nonFraction>% 2052 Notes. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="ifd12628ec78f4499a7e276a61e90e99b_I20201231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI5NTc_340e39f0-f9cc-4d0e-a099-a4a36cfab379">9.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="i50a9f89f55144c7383b92a1e2a084413_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEzNjY_87ed8929-60fd-4483-ba82-6df782071129">500</ix:nonFraction>&#160;million of the <ix:nonFraction unitRef="number" contextRef="i50a9f89f55144c7383b92a1e2a084413_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEzNzY_3497d4d0-6929-4423-95c3-7cdd80a84086">1.90</ix:nonFraction>% 2025 Notes, $<ix:nonFraction unitRef="usd" contextRef="iaaf325c2ad564616a25134ef5af769ea_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMwMTc_8f35a86e-96a2-4b09-827d-58d63c30c6ed">1.75</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="iaaf325c2ad564616a25134ef5af769ea_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0MDE_61c24d2b-8268-4588-8ea6-5b8e282e07cd">2.20</ix:nonFraction>% 2027 Notes, $<ix:nonFraction unitRef="usd" contextRef="ib57500a573714861937e2948abb1c417_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0MTY_c9b1a73a-f4d4-467f-a9a1-99e486e4d494">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ib57500a573714861937e2948abb1c417_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0MjY_ad25239c-899d-4032-a6a3-925024d0a800">2.45</ix:nonFraction>% 2030 Notes, $<ix:nonFraction unitRef="usd" contextRef="ic86def4b22434c24861ce1aea3a31420_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMwOTg_cc40693b-9fce-4794-9a2f-c78408ea6bee">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="ic86def4b22434c24861ce1aea3a31420_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMxMTk_ae7a7320-6f89-49ca-9ad6-546100925bf0">2.30</ix:nonFraction>% 2031 Notes, $<ix:nonFraction unitRef="usd" contextRef="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMxNzY_dd2653aa-9d96-4239-ac34-63723cbde5ea">2.0</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0NTE_7e03645e-a574-46e0-874a-2dc0cd1d8b3b">3.15</ix:nonFraction>% 2040 Notes and $<ix:nonFraction unitRef="usd" contextRef="i5e6253005b2a4664a03ad8f8f5898630_I20201231" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMyMDY_74ce8e81-60b2-4e03-b0ad-9c3ac0f8f825">2.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i5e6253005b2a4664a03ad8f8f5898630_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0Nzk_440ee6b0-8ce9-452e-a821-766bb773091a">3.375</ix:nonFraction>% 2050 Notes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any debt or debt securities during the year ended December 31, 2019. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt repayments/redemptions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made debt repayments/redemptions during the years ended December 31, 2021, 2020 and 2019, as follows:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we redeemed $<ix:nonFraction unitRef="usd" contextRef="ie0cbb29ec00d4533a3e1155ce9550ede_D20210101-20211231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2ODc_ac5dc7f7-5f91-49ab-9772-12a300b300ce">4.2</ix:nonFraction>&#160;billion of debt, including the &#8364;<ix:nonFraction unitRef="eur" contextRef="i55367f6c3ff34f7cb01d46d89ee2c379_D20210101-20211231" decimals="-7" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMDA_35937f2d-6bc3-448e-ae84-b5abe2753bb3">1.25</ix:nonFraction>&#160;billion aggregate principal amount ($<ix:nonFraction unitRef="usd" contextRef="icf9c596023174e558d6631c3ca855b65_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2NTE_dfef1af6-db47-4b3c-90f9-0b29fd42dcc6">1.4</ix:nonFraction>&#160;billion upon settlement of the related cross-currency swap) of the <ix:nonFraction unitRef="number" contextRef="i7b742eeadacf4b658c093123bb55c0fe_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMTY_778fca82-4eb0-48a2-81f7-6b9fbf5ae010">1.25</ix:nonFraction>% 2022 euro Notes, the $<ix:nonFraction unitRef="usd" contextRef="i070b4afa879f4c5fb36fc518fe1cfec4_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMjM_68da7150-5f70-4653-9d99-2f9a287b9689">500</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i8b11859028a1422083400b2109fb068f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMzc_7d7869b5-26ed-43b0-945c-eff64ab90c81">2.70</ix:nonFraction>% 2022 Notes, the $<ix:nonFraction unitRef="usd" contextRef="ibf4f6ca5c74d48349c15921ae8a0933a_D20200101-20201231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxNDQ_aecf8950-c194-4cf0-a27e-c7c41209ec2f">1.5</ix:nonFraction>&#160;billion aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="ide87aaebcc2a4447a457f81d1aa31c9a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxODM_6eed520a-14f5-41aa-8026-b88d87e14dbc">2.65</ix:nonFraction>% 2022 Notes and the $<ix:nonFraction unitRef="usd" contextRef="i1863ab64829b4fabbec539235c0ac7d1_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxNjA_21d186f9-6289-407a-acdb-b6973c2b1363">750</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i9030955f37e9430a99c50565728d5f24_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxNzQ_375901ce-e8a9-4cc7-ab0f-5793b4217b3e">3.625</ix:nonFraction>% 2022 Notes. In connection with the redemption of these notes, we paid a total of $<ix:nonFraction unitRef="usd" contextRef="ie0cbb29ec00d4533a3e1155ce9550ede_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxOTA_95c770d6-5a2d-4825-9961-99c9011d48ca">24</ix:nonFraction>&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we repaid/redeemed $<ix:nonFraction unitRef="usd" contextRef="iebfd131a231b493da0babaf4c3b5395f_D20200101-20201231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIwMzI_f64b3093-3721-4705-acc8-99171a389ae9">6.5</ix:nonFraction>&#160;billion of debt, including the repayment at maturity of the $<ix:nonFraction unitRef="usd" contextRef="ie9a1311f688d45e5a1f460915c39e581_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIwODc_ecbe84a5-e5bb-490f-a31e-f7f8cf16029b">300</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i54c22a3e15e54b178cf491b39cbfbbd5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxMjQ_2acd5e01-ab56-44dd-9a8f-434751a0d1d3">4.50</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="i5477a7c207054d569f2eca1cdcac36a7_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxNDM_87a455cb-2724-48f5-b6e5-cec8f8b489ad">750</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="iab353bc1f2344a55b1479a0f118d799c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxODA_3e5679da-082e-4170-978d-83b278cb5fd4">2.125</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="id97511afa493447da0eb4625d1fbf9ae_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxOTk_e151c83a-dc2b-4b3d-85e1-06e8e485e256">300</ix:nonFraction>&#160;million Floating Rate Notes due 2020 and the $<ix:nonFraction unitRef="usd" contextRef="if97696feb118453eb13e08998850ad56_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIyMzk_28d28b2a-709b-451a-b7db-cd4d37a76c64">700</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="idf411ca29d03476a953c14fc1769501d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIyNzY_4cf7dfdb-f664-4e7f-af71-4b34c9b123bf">2.20</ix:nonFraction>% 2020 Notes. In connection with the redemption of the $<ix:nonFraction unitRef="usd" contextRef="id9e3b5bf697b4cf0bfb5716a830f11db_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIzMzI_e33c40d1-9530-4604-b252-8e49ba301e39">900</ix:nonFraction>&#160;million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="id189fc4607ae4a208ed0437205c4c7f4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIzNjk_22c28039-3b44-4a93-84d5-fc717e2a61c5">3.45</ix:nonFraction>% 2020 Notes, the $<ix:nonFraction unitRef="usd" contextRef="ifb3ed5ae8257400c9ca750016aa502ef_D20200101-20201231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIzODg_34799c3d-89f6-4fad-8a21-df86c2c8efcc">1.0</ix:nonFraction>&#160;billion aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i0682f6237def4973ae5a5cc46f9d59e2_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0MjY_c585cca2-83b8-4834-a2aa-e2e1c21c595f">4.10</ix:nonFraction>% 2021 Notes, the $<ix:nonFraction unitRef="usd" contextRef="ia3291bf95ec2416b94e22bd933d142ad_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0NDU_e9077c6b-079d-4a96-b0cd-4a9f6b4567c0">750</ix:nonFraction>&#160;million aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="ie1b2177f702640cd8b47f293f2ad22a1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0ODM_f8d18506-7776-40ca-888e-942e2377e5a4">1.85</ix:nonFraction>% 2021 Notes and the $<ix:nonFraction unitRef="usd" contextRef="if3d97e7f0efe4261b956189daec4c902_D20200101-20201231" decimals="-7" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI1MDU_e907dd8c-b150-45dd-9aa3-be527a13ed78">1.75</ix:nonFraction>&#160;billion aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i4b8269488a684ef385c1e94d4f756b8b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI1NDM_38f83a33-71ee-4124-aa7e-a0ca9e0d8eae">3.875</ix:nonFraction>% 2021 Notes, we paid a total of $<ix:nonFraction unitRef="usd" contextRef="iebfd131a231b493da0babaf4c3b5395f_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI1Nzc_30a4d1df-67d5-4c8a-a057-b96c70c03b15">96</ix:nonFraction>&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2019, we repaid $<ix:nonFraction unitRef="usd" contextRef="ie46f97dcfd2c4ee5b216081269ea57b0_D20190101-20191231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDQwMzE_f86bcc15-9874-44de-b1e5-90b38a736e97">4.5</ix:nonFraction> billion of debt, including the $<ix:nonFraction unitRef="usd" contextRef="i84d8db7b345b4458ae3f758755659354_D20190101-20191231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI3ODk_ca85052a-41d9-4ba5-81ff-b3af30b2587e">1.4</ix:nonFraction> billion aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="if87fc1146c544c828abfcec0fe2987c9_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI4MjY_93d90277-0efb-4491-9d2b-d766f698248e">2.20</ix:nonFraction>% 2019 Notes, the $<ix:nonFraction unitRef="usd" contextRef="i3f2c8de012264cf89c56a2b6158356f6_D20190101-20191231" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI4NDU_68759696-4e81-4c3b-b5d1-3c74bd17e543">1.0</ix:nonFraction> billion aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i0e964a7c87d14059977b9c5c2746d0d2_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI4ODI_ab791b8e-0363-42de-aeb3-a6a78740df7d">5.70</ix:nonFraction>% 2019 Notes, the &#8364;<ix:nonFraction unitRef="eur" contextRef="icfd842d4f03947599d399bf5eba13005_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI5MDE_35c31f20-95a0-41e7-982b-b546f2146abf">675</ix:nonFraction> million aggregate principal amount ($<ix:nonFraction unitRef="usd" contextRef="i09a6ccbf40d94c65aaafe7871e4a210a_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAwNzQ_45e54436-1430-40d3-a4dc-f4222b95b52f">864</ix:nonFraction>&#160;million upon settlement of the related cross-currency swap) of the <ix:nonFraction unitRef="number" contextRef="id608276fe2a6484594c7c005d1cd220d_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI5OTQ_671d3229-45e5-4abc-90b2-cba3395605d4">2.125</ix:nonFraction>% 2019 euro Notes, the $<ix:nonFraction unitRef="usd" contextRef="i29b52d16bd6d4af083d152823f4b96ca_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMwMTg_53fec4a5-31f5-4e21-9b84-c09d2ae3df41">700</ix:nonFraction> million aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i104a960196594625971a4b192145a8c8_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMwNTU_1abb17c0-c8a5-454d-bbd8-6d9a0a921e0e">1.90</ix:nonFraction>% 2019 Notes and the $<ix:nonFraction unitRef="usd" contextRef="i82257eb313254ec0ab7249ac84b173fd_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMwNzc_4420f7bb-8efa-4abb-897d-24ea157c2ca8">550</ix:nonFraction> million Floating Rate Notes due 2019.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgwOTQ_fbdab0ce-509a-4d1b-88a4-2ea9518c0483">1.0</ix:nonFraction>&#160;billion with respect to the <ix:nonFraction unitRef="number" contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgwODA_de7ab43e-27ac-4758-ae23-be5aa76769d5">2.45</ix:nonFraction>% 2030 Notes and an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="if39aebc177504df78daf24169177353e_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2Mjk5NzA2_99ecf30e-85dc-48e9-9886-9edc397860d8">500</ix:nonFraction>&#160;million with respect to the <ix:nonFraction unitRef="number" contextRef="if39aebc177504df78daf24169177353e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgwODc_10e08214-dfe5-4b15-b03d-8cf565904dfb">2.30</ix:nonFraction>% 2031 Notes. In connection with the redemption of the <ix:nonFraction unitRef="number" contextRef="idf619b21445f463d85928fc668c93d2b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzg3NjA_dabdfa74-3631-4985-93ee-d6428b654215">3.625</ix:nonFraction>% 2022 Notes, discussed above, associated interest rate swap contracts with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231" decimals="-6" name="amgn:DerivativeNotionalAmountAmountTerminated" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzg3Njg_dbedd088-d2b0-495f-b65b-e618de4c259e">750</ix:nonFraction>&#160;million were terminated.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id556bc17c1a04342ac3a691c9f5b3201" continuedAt="ibdd5bd455b464866aa776e87a704bb8f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of certain of the notes during the year ended December 31, 2020, discussed above, associated interest rate swap contracts with an aggregate notional value of $<ix:nonFraction unitRef="usd" contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231" decimals="-7" name="amgn:DerivativeNotionalAmountAmountTerminated" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzM4MjM_7856c55b-c380-4d4c-935f-8a74cda5f08c">3.65</ix:nonFraction>&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i165f3ecafa0a4de4b1c4b6db200d90b9_I20201231" decimals="-8" name="amgn:DerivativeNotionalAmountAmountTerminated" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwMTI_8bd7d83d-cc7a-43e7-aa53-6f9f3e5fbf2e">5.2</ix:nonFraction>&#160;billion that hedged the <ix:nonFraction unitRef="number" contextRef="ia3ece76323354edab6344395cebe3bba_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwMzE_54973948-e23d-462a-9435-3e17b25d48d3">3.625</ix:nonFraction>% 2024 Notes, the <ix:nonFraction unitRef="number" contextRef="i2cb361ad83d5412a809267468ed87948_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwNTA_9fdd30a6-6252-4783-ab63-8d2819df086e">2.60</ix:nonFraction>% 2026 Notes, the <ix:nonFraction unitRef="number" contextRef="i9b860697a584413f99229019ccec2aa9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwNjk_f59e6cfe-08f6-4a08-9ac5-5e45e667627d">4.663</ix:nonFraction>% 2051 Notes and portions of the <ix:nonFraction unitRef="number" contextRef="idf619b21445f463d85928fc668c93d2b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQxMDM_0475bd2d-7067-445e-8f8d-631e176887d0">3.625</ix:nonFraction>% 2022 Notes and the <ix:nonFraction unitRef="number" contextRef="ibb12c286c5b04cdda990afcad1d3f906_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQxMjU_e46f681f-af27-4022-8402-f05008caea37">3.125</ix:nonFraction>% 2025 Notes, which resulted in the receipt of $<ix:nonFraction unitRef="usd" contextRef="ib46494b393a34b9f8c60e96025f45f23_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQxNzM_9733cd63-c6c8-4866-9e6c-995deb26a3a6">576</ix:nonFraction> million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $<ix:nonFraction unitRef="usd" contextRef="i845d5c989f794e06bd6777c9e801b93b_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQzNzQ_8991f516-aa63-4a8a-a9ca-92d5233a2a46">5.2</ix:nonFraction> billion principal amount of notes. See Note 18, Derivative instruments.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDE3_e4d914b5-f84c-48d8-a3e9-859922c66a5c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff27566615ea4d2bb9437ebad4ab002f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjozM2EwNmZkNTA0MGQ0MmNiYTc5YmRjMGY4NjU1NjJhNl80_acdaebff-f215-498f-bc13-1b9576cbe648">3.625</ix:nonFraction>% 2022 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff27566615ea4d2bb9437ebad4ab002f_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtMi0xLTEtNTU1NTQ_ad1ca5d3-6835-4bc1-9974-33a2be9504c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93f0a53c32847ae98f3c48eb087f0d0_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtNS0xLTEtNTU1NTQ_4b9aa1c1-a8b3-4f25-8fcd-c08781826b87">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ib2ae88e4533c4b4cb0927518f3740856_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjowMGFmMWI0MjA0OTc0MjI5YWU1ZjlmNGQ1Njk5YjJlNF8xMg_e43af0f7-610f-4214-9e27-be5657e7b673">2.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fec9853ccc64441ade8c731c993d7bd_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1N2E1YmNiMmQyMmE0MDYzOWExNWFhOTZlY2Q5ZDFkMV80_863e7a43-8f03-4305-875b-baf4f6b38917">3.625</ix:nonFraction>% 2024 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fec9853ccc64441ade8c731c993d7bd_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMi0xLTEtNTU1NTQ_b173cde6-dd04-49ee-a311-79e9ebc3aaf9">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="ic5344d1029ee4871879edd955c41939b_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1NmE0N2E1NTNjN2I0NzBhYWEwMDkxMjBjNThjZDNiZl8xMg_658cba63-8930-4e02-a909-0815e17e25d3">3.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d68f7e07a094edd9e2461d6c0fdd4fc_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtNS0xLTEtNTU1NTQ_82a95a5e-4ba9-46aa-b345-f20d5515a213">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i3894bb298da842feac52ee9f09993b0a_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo5MzYzYWY4MjRmOTk0NWMwOGI3ZGE1MGVhZGMwYjhkOV8xMg_c89607f1-63e5-4be6-8f5c-f14198376c87">3.2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib38c6961bd484a1aaeb68b6dd42b1548_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0YzM1NGY5ZjdmYjI0ODNiOTM4OTIyMWMwMDg3Mjg3MF80_6079228a-c38b-41fb-8094-fe032bd5c584">3.125</ix:nonFraction>% 2025 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38c6961bd484a1aaeb68b6dd42b1548_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMi0xLTEtNTU1NTQ_412c9a4b-1e1c-4f37-9fad-d880f4a61753">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i034a224066ae4802b5005e8a780dcba3_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjozZmI0ZmQ2NzQ3ZGE0MGNhODNlMDhjMDRmYzIzNjRkMF8xMg_c7bcc352-5e36-40c0-9803-e7e39c38b791">1.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99e95ece1544f458f56a09770d012f6_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctNS0xLTEtNTU1NTQ_1544db97-7a6e-4024-94ca-cead7184a621">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i4c48563bcda143618f52c18180794c29_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1NzJkNWEzNWVhYmI0ZDU3OTY4NDA3ZTg5NzIyZTRlYl8xMg_736dbc04-d9a0-430e-83b8-538dd4f36c49">1.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16fe501f4d234ba3bc01f6fd307e4f03_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0ZjZkNzNkN2M2ODg0YzNmODAxODFhODViYzRmNzgyZV80_e3485ce5-5b8a-4691-b4b7-c4dc9cb93f95">2.60</ix:nonFraction>% 2026 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fe501f4d234ba3bc01f6fd307e4f03_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtMi0xLTEtNTU1NTQ_74167e81-c0bf-4fce-801a-fbcfe36d6727">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i7b1708fe50d04fdb89f763085b73c7a2_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo4N2JjY2ExNDU1ZWM0NWUwYTkwY2QzOGRhNWYwNzY2OF8xMg_9b4c2fdf-14b7-4722-923c-55277baecedb">1.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie53460a2e2c54b1eb6ba01dd799c1956_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtNS0xLTEtNTU1NTQ_55992813-6ad1-4e83-8a55-98639b3a943c">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i85ecb4c22c6d4edd9158a292a2b738c1_I20201231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0MWJkYzY0NDNlODU0ZWE3OTZjM2E1OTk3MjFjMWE5OV8xMg_bc944c53-1e49-42c1-8a84-36c9e60a49a6">1.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77e71d687a124355ab2c2f4d216034fb_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMC0xLTEtNjg1NDcvdGV4dHJlZ2lvbjozMTRlNGFhNmIxOWQ0NzZkYmU1MDBiY2Y4MmEzY2UyN184Nzk2MDkzMDIyMjMz_71d547ac-c708-48ac-b1cb-315f3e0cfab3">2.45</ix:nonFraction>% 2030 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e71d687a124355ab2c2f4d216034fb_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMi0xLTEtNjg1MzM_30702e08-8b5e-4652-90f8-de81e11f9798">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i27fb3b4b36f14d56bd098848256071d3_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMy0xLTEtNjgyODQvdGV4dHJlZ2lvbjpmNDJiN2IxY2Q4ZDE0NzczOGNmYTdiNzE2ZWJiMDRiMV84Nzk2MDkzMDIyMjI4_8ebe0fe4-ca5f-4220-b136-889542894745">1.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7b496d1968423ca0b81cb87f205866_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtNS0xLTEtOTU1ODM_704379cc-3718-4e00-89fd-7bffdc1277eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10d539e441f54f7987471e03eeb9fc39_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMC0xLTEtNjg1NTMvdGV4dHJlZ2lvbjpkYTVjNjA4ZjkzYTU0OGY3YWRiMTlkYmY5OTNmMjU3OF84Nzk2MDkzMDIyMjMz_42715a68-68a7-4fbf-9194-fd6899703cf0">2.30</ix:nonFraction>% 2031 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d539e441f54f7987471e03eeb9fc39_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMi0xLTEtNjg1MzM_a8e452c7-ed63-4a18-9836-c1e272c0031d">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i9d56a45dc3ab43509ef66161e0e3fa63_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMy0xLTEtNjgyODIvdGV4dHJlZ2lvbjoyNjVhNWUzZDA3OGY0Mjc2ODhlOGYyYzIzNTUwMjQ2Yl84Nzk2MDkzMDIyMjI4_de017450-75b0-4144-a285-342938ab7d53">0.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05b839f30d040bebcd89a0c1fb92f5a_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctNS0xLTEtOTU1ODU_0c37fded-6749-4375-84ce-cf8ec1024321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i367d9d22b1c34ce1b4cdcd7cc2620446_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2ZjAzYTFkZWYzZTI0NGUxOTdhMGZhMTc0YzVkMDAzMV80_049a6ba5-534a-4a4a-ac35-7de53f30518e">4.663</ix:nonFraction>% 2051 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367d9d22b1c34ce1b4cdcd7cc2620446_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktMi0xLTEtNTU1NTQ_992413df-2b11-481e-b7d3-73f8fe891451">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR +<ix:nonFraction unitRef="number" contextRef="i3b46f3feeb0e47c0a2c7e9a4c6f05a7d_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpkNGMyYTAyN2YyMzE0NDUzYjhlMDBhYjk0NmZlZjlhYV84Nzk2MDkzMDIyMjM3_85fd230c-07a8-4c5f-b062-9f921edf0c86">4.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7fdb2956cb4333b6f9bcb209040ea5_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktNS0xLTEtNTU1NTQ_eaebf3cf-090c-49ba-b9c9-6196c5ef6062">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + <ix:nonFraction unitRef="number" contextRef="i3b46f3feeb0e47c0a2c7e9a4c6f05a7d_I20211231" decimals="3" name="us-gaap:DerivativeBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjozNWZiMzMzYWQyZjQ0MzVjODliYTE2YTIwNzM5NmIwNF84Nzk2MDkzMDIyMjM2_85fd230c-07a8-4c5f-b062-9f921edf0c86">4.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35713b5b6ffa49349b004817c7c9da42_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzEwLTItMS0xLTU1NTU0_0d08513a-704c-4edc-b7c1-49af1804c93b">6,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614baae5549413b95d0a5b95b79a24b_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzEwLTUtMS0xLTU1NTU0_28d2ceef-d364-4cb4-a4de-ee3b693e0809">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A = not applicable</span></div></ix:nonNumeric><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt exchange</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $<ix:nonFraction unitRef="usd" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgxMTQ_6790987d-26f7-47e4-a5f1-a46c91ee7d2b">940</ix:nonFraction>&#160;million principal amount of the newly issued <ix:nonFraction unitRef="number" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgxMjg_b760409c-9c2b-4766-b66c-dbde0c51263e">2.77</ix:nonFraction>% 2053 Notes (the Exchange Offer).</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDI3_4bcbfe82-c378-4b4a-a4eb-83471f35addc" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4283cce94284118a0034337aac219b4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzEtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1MjgwZTQ0NjMyNDU0ZTc5YjY3OGJlNDMwNDk0ZTZhOV80_553de637-27ba-461b-b5d3-86133fd5aa66">6.375</ix:nonFraction>% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie558eaebb0734ac988923b72ab5749e5_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzEtMS0xLTEtNTU1NTQ_a8ef1ebb-f8fc-477c-aa3d-9db4bf484da3">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d7a63a419144cf0aca9c1b14bf3aff1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzItMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjphOWNkMWIzZDlkN2U0MjIwODc4ZDM5MzYxZTg2MmFlOV80_6a4dc4da-0224-4347-b62d-2def74e747fa">6.90</ix:nonFraction>% 2038 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33af7431531e4906871dc1c72260a8f4_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzItMS0xLTEtNTU1NTQ_6940e88f-fb29-4087-a6bc-a4e80e26a897">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29d7e93cc83149e6bd46d9c7b5b95be3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzMtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo5YjRkZmViMTg5OWM0NmU2ODRmOGE3MjU0Yzk2MWJhYV80_b3dbd208-0d53-4446-9737-18f3a19173c0">6.40</ix:nonFraction>% 2039 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c65ad1961624e6fb50c1eb26eb83dcd_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzMtMS0xLTEtNTU1NTQ_5b0bfc86-b40f-4ee4-896b-85afa3c328b7">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93bbfe5fa69940c08425fb453c4429a2_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzQtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiN2Y2MDhlNzY3Y2U0NGFlODM5NDBhZTEzMzJlMjdkMl80_33b5b776-f656-4d8e-bba3-1e85c240c938">5.75</ix:nonFraction>% 2040 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03447162cb44ded9a9e6203334836ae_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzQtMS0xLTEtNTU1NTQ_d401647c-3b5e-45ea-8aac-880813f662bd">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i689ad4255db545eda69e365f169f332a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzUtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjplZmExYjFkMDQ2ZGQ0MWI4YWQzYmEwNjllYWU5YjdkY180_79288eed-1425-47b8-a5f0-c91164fb37b5">5.15</ix:nonFraction>% 2041 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0f0acd616746d5b35dd8a2dbf392d7_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzUtMS0xLTEtNTU1NTQ_4ee60c54-b8a3-4e3b-b708-95a86ec449a3">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29adc72b130b479ea45a8aaa03b088d5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzYtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo4ODZmNzllNTUyZjI0NWQ2YmI0YTRlOGU3MTA1YmZkMF80_94d84804-8e34-4867-9f23-bef1a7c9b2ca">5.65</ix:nonFraction>% 2042 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie320a4dc28964d3e945ea0199a471f76_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzYtMS0xLTEtNTU1NTQ_d12eb813-99a6-46f1-a900-66a486c5dbd9">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i364ca273078a47eca7c0fe7c36707bf5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzctMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjoxNzc5ZmI0NTYzZWI0NTYzYjhmMDgzNmYxZmE0MjBiNF80_795f6e91-4626-464e-b18e-539ebd31da70">5.375</ix:nonFraction>% 2043 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e84ea875e544c9937c0c203818dead_D20200101-20201231" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzctMS0xLTEtNTU1NTQ_630478e3-8595-4ede-80a5-3cc02a6895d7">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzUyNjk_a97ca2c3-906a-4da9-8bef-51c3dc84d795">2.77</ix:nonFraction>% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the <ix:nonFraction unitRef="number" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU1MzY_0a7cd5ff-1d7a-4f83-881d-bc17558869c8">2.77</ix:nonFraction>% 2053 Notes. In connection with the Exchange Offer, $<ix:nonFraction unitRef="usd" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="-6" name="amgn:DebtExchangeAdditionalCashConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU1OTA_f7a96d04-0266-4f28-b2d0-c23da181eafa">85</ix:nonFraction> million was paid to holders of the Old Notes (the cash consideration).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $<ix:nonFraction unitRef="usd" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU4MzU_b1d80c94-82c0-4e8b-9dcf-6bb28d3c8148">264</ix:nonFraction> million discount associated with the <ix:nonFraction unitRef="number" contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU4Njc_c07e03b4-0a70-4693-bd40-c5f8a7422082">2.77</ix:nonFraction>% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibdd5bd455b464866aa776e87a704bb8f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our <ix:nonFraction unitRef="number" contextRef="i85976d51465e4619a93074b54175b619_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzYzNjY_25260897-f8e5-4dd5-a47e-107c7dfd753a">0.41</ix:nonFraction>% 2023 Swiss franc Bonds, <ix:nonFraction unitRef="number" contextRef="i304433386dd64f7b8b7c9d12385a8ff0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzYzOTM_8e06de45-df3f-4a96-9378-3c0d894aa341">2.00</ix:nonFraction>% 2026 euro Notes, <ix:nonFraction unitRef="number" contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzY0MTM_4081980a-0bc4-42d5-89bd-2e76dde579ca">5.50</ix:nonFraction>% 2026 pound sterling Notes and <ix:nonFraction unitRef="number" contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzY0NDY_1b35ed9c-8ee1-4765-87da-81a6d39b84ce">4.00</ix:nonFraction>% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of the <ix:nonFraction unitRef="number" contextRef="i3115a2e5d2b648bb866394e00f7e6265_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2NjU_0fb0d36b-47a7-47af-b315-11adff808d9d">1.25</ix:nonFraction>% 2022 euro Notes, discussed above, associated cross-currency swap contracts with an aggregate notional amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i3115a2e5d2b648bb866394e00f7e6265_I20211231" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2MTM_d507f740-d481-44ec-a893-396a0b5d9ba5">1.25</ix:nonFraction> billion were terminated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement and other facilities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have a commercial paper program that allows us to issue up to $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="amgn:MaximumBorrowingCapacityUnderCommercialPaper" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzY4MzM_39475a59-96ba-40ec-ba6b-8f401e06cfbe">2.5</ix:nonFraction> billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2021 and 2020, we had no amounts outstanding under our commercial paper program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $<ix:nonFraction unitRef="usd" contextRef="i3f3f69cfacea4717a178488113e7724c_I20211231" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcwMzg_99e4a8d7-36c4-4fbe-970e-b9c311f72b30">2.5</ix:nonFraction> billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $<ix:nonFraction unitRef="usd" contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231" decimals="-6" name="amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcyODE_c4ee5265-3247-4f6b-8693-edee0de45ba9">750</ix:nonFraction> million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of <ix:nonNumeric contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231" name="amgn:LineOfCreditFacilityInitialCommitmentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzczOTQ_c8131925-6a5b-4146-ba12-e933180a9765">five years</ix:nonNumeric>. This term may be extended for up to <ix:nonFraction unitRef="renewal_option" contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231" decimals="INF" name="amgn:LineofCreditFacilityNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc0MzQ_51da4eb9-b6ad-4d74-9ad2-d4c41fbee822">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231" name="amgn:LineOfCreditFacilityExtensionOfCommitmentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDAx_4fae9202-38a0-4b0b-8458-574441c50319">one-year</ix:nonNumeric> periods with the agreement of the banks. Annual commitment fees for this agreement are <ix:nonFraction unitRef="number" contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc1NDM_678d1e36-82e2-4535-bfed-9a8437aed3af">0.09</ix:nonFraction>% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus <ix:nonFraction unitRef="number" contextRef="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc3NjA_d9c73842-403d-4acd-bb74-69ffa70e019c">1</ix:nonFraction>% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus <ix:nonFraction unitRef="number" contextRef="ib0423efbfc4c49a3a0c6e8782283b9e4_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc4ODk_05997eb6-58ee-458a-a33d-25337fff1404">0.50</ix:nonFraction>% or (C) <ix:nonNumeric contextRef="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5OTU_c7ccd4b3-d705-490a-a4a6-8826f612e9f1">one-month LIBOR</ix:nonNumeric> plus <ix:nonFraction unitRef="number" contextRef="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc5MjA_18c062f8-59ce-42a2-8e53-0d797e976899">1</ix:nonFraction>%. The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2021 and 2020, <ix:nonFraction unitRef="usd" contextRef="i3f3f69cfacea4717a178488113e7724c_I20211231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzgxMDc_3031d9d8-8707-49b8-bc1e-e4d17983ca62"><ix:nonFraction unitRef="usd" contextRef="if751ec72d1334a0aa3244e35632460fc_I20201231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzgxMDc_ef3a1381-86bc-4d86-a4eb-83e4e824bfcc">no</ix:nonFraction></ix:nonFraction> amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual maturities of debt obligations</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDIw_485946bb-f829-4051-ab20-276cb65f8eb6" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2021, are as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzEtMi0xLTEtNTU1NTQ_47b4c6b4-e1f5-4c6f-8da0-f9adea8e824a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzItMi0xLTEtNTU1NTQ_fecd8146-5e1c-4478-a086-9cb44a89bbf2">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzMtMi0xLTEtNTU1NTQ_bd76eb4c-6bf2-4700-8aab-99cc3ff235bd">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzQtMi0xLTEtNTU1NTQ_4f6cad3d-9cf3-4f63-b0de-d80047dff907">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzUtMi0xLTEtNTU1NTQ_c707aaea-b841-467b-8fc5-4af6bce1cc17">2,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzYtMi0xLTEtNTU1NTQ_9a786abe-1b7e-4568-84e1-c358df3e9309">27,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzctMi0xLTEtNTU1NTQ_c8410799-0ea0-4c54-8ce1-55fd34d311f3">34,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2021, 2020 and 2019, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2021, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-8" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5NjU_531408fe-f09b-4ba7-97f9-dad573c0525d">1.2</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-8" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5Njk_fc2eca58-4ce7-4733-ab76-333c7907001b">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-8" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5NzY_5a6fdfe3-379d-479c-bd97-fbad874b12b1">1.3</ix:nonFraction> billion, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMzE_ba2d221d-225a-46d9-b8cf-5fb495d3a76d" continuedAt="i06d55a8a32954ab6b2ac6ad274a022f8" escape="true">Stockholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="i06d55a8a32954ab6b2ac6ad274a022f8" continuedAt="ie61e829cf224498aa1e4d94b5cc80304"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:StockRepurchaseProgramTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMjI_ccbb7948-bcc3-467c-b9f9-74eb363341f5" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtMS0xLTEtNTU1NTQ_43ce3e45-af96-4f4f-95ed-4a8f23141eab">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtMy0xLTEtNTU1NTQ_2fd7ccfe-694f-4261-b5c5-04594b6e96e1">865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtNS0xLTEtNTU1NTQ_4130e974-04d2-4c8e-a1ad-20f9a83c66ee">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtNy0xLTEtNTU1NTQ_38235627-d334-4588-ad9b-78d043c911ae">933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtOS0xLTEtNTU1NTQ_c5817b05-261c-474f-ab0e-ffb522f46b40">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtMTEtMS0xLTU1NTU0_2c9de23f-91e7-4d4b-8b34-022dad98d63b">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtMS0xLTEtNTU1NTQ_bcbc7591-e5ac-40e9-a314-637c0976cca4">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtMy0xLTEtNTU1NTQ_efe32a7f-674e-4425-94a1-ba28e25803ef">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtNS0xLTEtNTU1NTQ_9d03f421-c48b-40a2-a77b-fa6af9bc30bb">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtNy0xLTEtNTU1NTQ_d22a17e1-26e6-4e99-909c-827293cf973c">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtOS0xLTEtNTU1NTQ_8e65bdde-f157-43a2-9798-38668502455e">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtMTEtMS0xLTU1NTU0_68ceedbb-7aa4-4e55-8858-4ca3b0b59358">2,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtMS0xLTEtNTU1NTQ_4cf2e996-bc50-4b66-bdac-f03e8331b5a2">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtMy0xLTEtNTU1NTQ_0d1faf3e-1a21-4892-a2c1-c82943d53661">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtNS0xLTEtNTU1NTQ_79722a40-a2fb-400a-b875-995f60ed988d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtNy0xLTEtNTU1NTQ_4b0572de-362f-423c-9b03-82f29b4c409b">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd3e56f17777422db7fd7146740984bf_D20190701-20190930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtOS0xLTEtNTU1NTQ_9b40e469-cf89-40cd-9001-dbf00dd928fc">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3e56f17777422db7fd7146740984bf_D20190701-20190930" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtMTEtMS0xLTU1NTU0_cf497197-895f-453a-8e43-1ecccd0d5f3b">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtMS0xLTEtNTU1NTQ_b2da0214-edd3-4358-86e9-5951380a2400">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtMy0xLTEtNTU1NTQ_d3d4f900-21ff-4b15-ad51-a9432b7c1be6">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5da70484870944a2be74c9435a52ba12_D20201001-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtNS0xLTEtNTU1NTQ_9a7e2527-60b0-4c5f-830e-c8a13cb5a268">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da70484870944a2be74c9435a52ba12_D20201001-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtNy0xLTEtNTU1NTQ_1f8ab06e-6d84-4575-aade-267836cfc8b5">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtOS0xLTEtNTU1NTQ_7e27fd9d-4d76-4f2b-ab14-33dfccfbd08f">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtMTEtMS0xLTU1NTU0_862ebf61-e8a1-4753-9f09-75ffbdf61c79">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctMS0xLTEtNTU1NTQ_948b9c71-6387-4e45-9e81-b402b6ddcd71">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctMy0xLTEtNTU1NTQ_fabaa075-5430-444b-bbb3-ad9eac324dfe">4,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctNS0xLTEtNTU1NTQ_0e1b95b7-9b0e-445c-a849-9643b6950280">15.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctNy0xLTEtNTU1NTQ_2a215277-d574-4c7a-970d-06a3fa31372b">3,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctOS0xLTEtNTU1NTQ_c4252065-50bc-4da8-b149-b0a81923c62c">40.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctMTEtMS0xLTU1NTU0_fa1635ba-ef08-4c3e-9dbf-2a92ccefcd25">7,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Total shares do not add due to rounding.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, October 2021 and December 2021, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $<ix:nonFraction unitRef="usd" contextRef="i5cae36825a8244718a036f07b201a220_I20210331" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzMyMw_8822b562-97b4-4b83-8957-043aaf00ff2a">3.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="if1d25f0b06be4a2ca6927d47f49abd4e_I20211031" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEwOTk1MTE2MzEwNjc_d880accd-e79e-4616-9ae7-9a9677647511">4.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1Xzg3OTYwOTMwMjU4MTI_54707672-ca4f-456d-ad63-e9bd7d2227b9">5.0</ix:nonFraction>&#160;billion, respectively. As of December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzMzNw_992fa5a1-64d2-46ff-93e6-754fa53ce7e2">10.9</ix:nonFraction> billion remained available under our stock repurchase program. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors declared quarterly dividends per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i893df3cf158b4ab2a0c0d1c82a28c1bd_D20211001-20211031" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_2ac64e40-5260-49cf-afdc-57c1b7550228"><ix:nonFraction unitRef="usdPerShare" contextRef="i5154a4b4a2bd4af983bf6185d3daba74_D20210701-20210731" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_37b9f524-9fc6-4fa3-8f1c-5664b4c761cd"><ix:nonFraction unitRef="usdPerShare" contextRef="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_45a47744-5d2c-4cd0-b732-c40fd344e758"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_52d52d8c-59c8-41fe-849e-923b9ade4145"><ix:nonFraction unitRef="usdPerShare" contextRef="icfca6c2819ef49179fc85b016ce6016f_D20201201-20201231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_722cce9c-2975-4438-b26d-85e2a8a1d974"><ix:nonFraction unitRef="usdPerShare" contextRef="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_b0640032-3f6f-4345-a8f8-7696bb67543f"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f7cba5195f24f829ec32f1b71cfd77c_D20210301-20210331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_babe7c61-3728-41eb-b024-05d71dec1047"><ix:nonFraction unitRef="usdPerShare" contextRef="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_f7a20ca3-96fb-4cc6-929e-2fe45d1b8ced">1.76</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_03cd5030-96f9-4f45-9071-d85d7a782f11"><ix:nonFraction unitRef="usdPerShare" contextRef="i5da70484870944a2be74c9435a52ba12_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_04bd71e4-d126-4973-88fd-b1c2a515e8e2"><ix:nonFraction unitRef="usdPerShare" contextRef="i4eaa406cdfdd4c51b6756655cc712766_D20200701-20200731" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_71eac9d8-8c94-434b-881f-5b70db93b1e2"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_b8686433-06cf-459b-b63a-0d2496174ab8"><ix:nonFraction unitRef="usdPerShare" contextRef="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_cb360cd7-c636-4cd9-85df-359c430c2076"><ix:nonFraction unitRef="usdPerShare" contextRef="i7254d1d0af7c46758551512b7d50361d_D20201001-20201031" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_d0b36cd3-91c0-4d82-8d41-e95b02e72070"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fabc5abd9df4b559effd9eb67abea89_D20191201-20191231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_e24c8796-532f-4af0-b268-77f650a2c336"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b33af0508754ca28e72f99a484d9cf0_D20200301-20200331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_e87adaa3-d05a-41f4-9cca-d43951897c2d">1.60</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i39b8f49d86e9448ab5f6101aa9d1fc57_D20190301-20190331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_065fe602-8579-436f-a948-c397b4b71ee8"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_075be703-a8a6-4929-b222-b2eb6569a12b"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_2b64cc56-6e60-4d73-bc94-f27507a8d94c"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a8d1cde152d418a976984815e041aa2_D20181201-20181231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_4defe74a-35c5-4f1a-956e-b166443f3497"><ix:nonFraction unitRef="usdPerShare" contextRef="i323451cad3a2466080975105981c98c8_D20190701-20190731" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_57034503-b948-4a2d-8733-3762e67d1ac5"><ix:nonFraction unitRef="usdPerShare" contextRef="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_7270c19d-6488-4df6-8a34-86bbe0b9533a"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a85ddddc43a4b40bf86ad5da75e8de4_D20191001-20191031" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_839140d3-4c9a-4f92-85b8-961aeec35ad1"><ix:nonFraction unitRef="usdPerShare" contextRef="icd3e56f17777422db7fd7146740984bf_D20190701-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_cfe148f0-8a4b-4b4e-96a2-7c16915945e4">1.45</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>, which were paid in each of the four quarters of 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 3, 2021, the Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a63a090508f49fdaacb88df082eb50b_D20211203-20211203" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzkyMA_57ee4ea1-c400-4003-ba7c-e0dbf4c3654e"><ix:nonFraction unitRef="usdPerShare" contextRef="i67c13f8bb98d4f9b86238d8564507387_D20220308-20220308" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzkyMA_80f99692-de30-4eb4-b716-4443b97d9f15">1.94</ix:nonFraction></ix:nonFraction> per share of common stock, which will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie61e829cf224498aa1e4d94b5cc80304"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMTc_3cf36598-a208-4247-b5b7-b8ed0efca809" escape="true"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i309108b032084722a376b8a102fdb202_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtMS0xLTEtNTU1NTQ_dd7e343d-f9b2-4504-b799-b466935ca82a">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb9c001d530444d809bab4daa3b3248_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtMy0xLTEtNTU1NTQ_b505650e-d37a-4571-9e6c-37751a766c61">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4494701f92e4c3497b69ce57bf3c5db_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtNS0xLTEtNTU1NTQ_b6347297-2a1f-46db-8aed-22f7a45b2a3f">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22a6854354df440da13fa35f04216a12_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtNy0xLTEtNTU1NTQ_5df4dc43-269a-4988-bfc3-86666251f9e2">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f4705aa9b489a9965276d6b9e48de_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtOS0xLTEtNTU1NTQ_728ff407-da1d-4315-bcc3-81ca5b062151">769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4295abe2e530430ca537010e380381f0_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzMtMS0xLTEtNTU1NTQ_45ae5c4d-d094-42b3-8192-580c69487e0f">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzMtOS0xLTEtNTU1NTQ_9f3a0a97-677d-4186-9730-ea7adf965e3e">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79b493edfda4614928afa72235cd218_D20190101-20191231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzQtMy0xLTEtNTU1NTQ_cbc0c18b-7bc7-4306-9511-4baa2ab8c5f6">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzQtNS0xLTEtNTU1NTQ_eb8e7d6b-0dfc-49d7-a5aa-8d28ecfaf7ff">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzQtOS0xLTEtNTU1NTQ_26d5f496-da91-406e-9808-0c0a7b118364">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if79b493edfda4614928afa72235cd218_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzUtMy0xLTEtNTU1NTQ_8da60dd5-a776-4cda-bfaa-8caf2ac80462">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzUtNS0xLTEtNTU1NTQ_10bf1ba1-a277-4009-acfe-432bb48ab5a0">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzUtOS0xLTEtNTU1NTQ_4223f7be-ef37-42a1-97b9-0885981e143d">267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ab69b9f5c1b4692a5c95f9a65dc9566_D20190101-20191231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzYtNy0xLTEtNTU1NTQ_eca08c65-3d4f-4ba8-a4f3-70601fb1d8a2">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzYtOS0xLTEtNTU1NTQ_0d5fa5fe-37e8-4077-a5eb-ae6fc6a8d1df">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4295abe2e530430ca537010e380381f0_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctMS0xLTEtNTU1NTQ_2dd581c4-95e5-40ba-afa6-ac7511d49138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79b493edfda4614928afa72235cd218_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctMy0xLTEtNTU1NTQ_7ba11eff-e80b-443b-b094-7f7bc286b114">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctNS0xLTEtNTU1NTQ_86fbf402-549e-4f26-b447-691819968b47">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctOS0xLTEtNTU1NTQ_7fd5475e-832c-4916-9970-0df886c06a73">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98c41d891d134edd86170c260149c788_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtMS0xLTEtNTU1NTQ_30593eec-fdf6-4579-9108-810579aca7f7">718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e3518c83274b19a2f3f3b2116e682d_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtMy0xLTEtNTU1NTQ_4b33dd22-c40d-4cee-94ac-f05696815917">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9cfb6c5904e48c7bbfba692c97f5afb_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtNS0xLTEtNTU1NTQ_c56eb19f-55bf-4fce-9ee3-da4b2f7a6ef3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b2c015276b143d1902156c9b84463e2_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtNy0xLTEtNTU1NTQ_219c198d-cb21-4784-b071-e8c03095049b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea207d0ec0394b108fc793525231d205_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtOS0xLTEtNTU1NTQ_861f6b62-4790-4ee8-a89d-4ba29a5aab16">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b69b0fa4326426ba338b1b8a382b779_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEwLTEtMS0xLTU1NTU0_104c6c64-ab09-4c6a-a844-19fc3af825b4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEwLTktMS0xLTU1NTU0_de520191-54bc-4a85-88e9-d0bc4f16ffa3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzExLTMtMS0xLTU1NTU0_672dff8e-773b-414c-8038-d1211b4f71cf">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzExLTUtMS0xLTU1NTU0_97acb0a7-d7b3-403d-bd5f-69c4b75064dc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzExLTktMS0xLTU1NTU0_f98dfa48-7fa3-4db0-ad1f-14463cc9fa84">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEyLTMtMS0xLTU1NTU0_e33d3d53-58b4-4bec-bd62-e974888aed67">501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEyLTUtMS0xLTU1NTU0_6349301b-1f83-4c2d-83ac-f206b7118b70">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEyLTktMS0xLTU1NTU0_5111b0ef-9b9d-40a5-b379-3d73be041066">534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieef7a11bc8b34811a438f59e60dba040_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEzLTctMS0xLTU1NTU0_c696b537-8bdd-47b7-bb0e-536b9facb8f8">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEzLTktMS0xLTU1NTU0_dbd334ac-54e2-4cec-ac98-b27e03644a04">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b69b0fa4326426ba338b1b8a382b779_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTEtMS0xLTU1NTU0_bc3a8c9e-2b36-4ce7-890d-b5c71c336e7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTMtMS0xLTU1NTU0_6c187673-a4d2-4a46-bdc4-e126e0c73521">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTUtMS0xLTU1NTU0_bb37250a-99ab-48e8-8c17-5cc0aa10c8a5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTktMS0xLTU1NTU0_3aa59c9d-c25f-4d58-a5ea-ec6c7c131153">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53d33d7ade654ad299e31d14b471a5bb_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTEtMS0xLTU1NTU0_ff50ba09-a09b-4d78-a05a-97420becc34e">709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbbfb42202ea4564988889ffa1175789_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTMtMS0xLTU1NTU0_e3b6ce41-fc5d-423d-a411-1c2e5f3f561b">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a925f891f9422095e83c9bfcfb8e7e_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTUtMS0xLTU1NTU0_e1d3dc90-c680-4779-99ea-0fcf2729624b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac308cc20ed14c5cace71b3353e328da_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTctMS0xLTU1NTU0_933ce352-0720-4c29-88e8-00f79a7deb20">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2766f3376fe7415ab521166b30e8525e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTktMS0xLTU1NTU0_1f9ea6d4-7bac-4247-ab72-410b47d8cde7">985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i258fcbb2c8764cbb987b87e8e1c787ea_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE3LTEtMS0xLTU1NTU0_05f81bdc-df83-4151-b57b-32a24d9a235d">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE3LTktMS0xLTU1NTU0_af57340f-dbe2-4458-8984-88e690eb3262">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE4LTMtMS0xLTU1NTU0_48987d63-d94a-4bf1-a504-b041296f9a07">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE4LTUtMS0xLTU1NTU0_6e863f8c-fd4e-4ad7-a95f-d089f2caf35e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE4LTktMS0xLTU1NTU0_33a9bcac-2f67-4b11-8f3e-6458fde879f0">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE5LTMtMS0xLTU1NTU0_661d0972-477d-415a-976b-fa9b0ad1d858">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE5LTUtMS0xLTU1NTU0_31af02b4-1512-4ddd-a644-caa0a64ffe1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE5LTktMS0xLTU1NTU0_862555ea-a416-4877-885a-158bd8037b1c">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000812ada76e42979388c4d128fa90de_D20210101-20211231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIwLTctMS0xLTU1NTU0_86edff0a-4b97-4c4e-89db-9496eef09ecf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIwLTktMS0xLTU1NTU0_01d14e19-a374-41c3-9f0b-2317ad18e34f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258fcbb2c8764cbb987b87e8e1c787ea_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTEtMS0xLTU1NTU0_f5717ba7-4f8e-44d1-acc7-37f1ce345afa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTMtMS0xLTU1NTU0_565c8d98-1920-4407-88fc-7d62e1262bd6">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTUtMS0xLTU1NTU0_eae993d0-f55e-4162-a968-eedf81ad61ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTktMS0xLTU1NTU0_4235f375-3021-4369-9f72-5785aee884c4">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0914f3d7dcd6426aa7c1a21fa7f2d1fb_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTEtMS0xLTU1NTU0_7dcfcfb2-c6b5-4c9e-a339-cea76035a3d3">844</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34745a1b911c4d30a56546635c8aa0de_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTMtMS0xLTU1NTU0_3eb274e1-8545-4f28-a182-1109a8df6c00">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99bd951fd41947b592b8c02d8f1c27c0_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTUtMS0xLTU1NTU0_c7a5c0ec-35fc-4272-877d-34de9e980abf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fd5e2c85c274498bad48e922806e3ae_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTctMS0xLTU1NTU0_0fb49484-ab61-491b-b74b-383c6ce8b5fb">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5a12fd9b94548e0a6d019cff9050821_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTktMS0xLTU1NTU0_95f64898-c5eb-4d7c-a358-d1906afd34a0">796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzNDA_72707def-51bf-4482-a7cd-95fe90fef467">33</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzNTc_32b92e7e-2f2d-4431-9086-8f5eecc2158b">55</ix:nonFraction> million expense in 2021, a $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzNzc_35c5adb5-3b24-4091-b0a7-185613a489f1">14</ix:nonFraction> million benefit and a $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzOTQ_39f02b13-95d2-4041-947c-3ace2b163689">110</ix:nonFraction> million benefit in 2020 and a $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE0MTc_edc0e859-7f17-41c9-882c-574c39e8c50a">28</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE0MzQ_a52047e0-4e42-4411-9470-6b7a9a72f6f1">46</ix:nonFraction> million benefit in 2019, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE2NjM_510cdb74-cf41-40e9-9bb7-85f5ebcac65a">1</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE2ODA_a5154d33-4e64-4179-a659-3664ca8a51ab">7</ix:nonFraction> million benefit in 2020 and a $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE3MDM_0b1a15d3-1ecf-4481-9990-7bcc963e5054">22</ix:nonFraction> million expense and a $<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE3MjA_8ed581aa-c653-4832-9a61-290badc573f3">14</ix:nonFraction> million benefit in 2019, respectively.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMjU_17973fef-ca36-4a24-ab7d-f44885596b18" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract (losses) gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b2f149e177b4bc3b630018b36f6e49c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzMtMi0xLTEtNTU1NTQ_c7ddbdf6-1398-4864-b9b4-09d0ad47243f">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad2966682ec4e37bbcfa6626b7183ec_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzMtNC0xLTEtNTU1NTQ_97d94ec5-44dd-48d8-afd9-5e129ef9a591">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4dd663b9fc4f028f2085d56886e460_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzMtNi0xLTEtNTU1NTQ_0ceb126f-a6cd-4e5b-8c14-7af8263cb4c5">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35372b79111c40a58a07694440d9622c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzQtMi0xLTEtNTU1NTQ_21545584-9072-4211-bc8b-9799527d201f">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd31886569fd4668bfb1bce453953983_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzQtNC0xLTEtNTU1NTQ_97771b98-602c-4b26-9713-06e7e1e0f50b">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a842d09a06449083eeab3521739d0d_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzQtNi0xLTEtNTU1NTQ_1a23efcc-70c0-4b57-b659-da7f06bb343b">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzYtMi0xLTEtNTU1NTQ_685c68cc-d9e1-4b4a-b5b9-17e2c7d61261">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzYtNC0xLTEtNTU1NTQ_9984dd83-ba07-41e9-b153-c6b52c4e2605">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzYtNi0xLTEtNTU1NTQ_c0f97ff3-fc18-4941-b00c-81d78b5ebf41">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzctMi0xLTEtNTU1NTQ_cace139b-504f-473a-9a04-690e322a5d99">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzctNC0xLTEtNTU1NTQ_06a0efc9-32e8-48ba-a6d8-f7ec9d66a35a">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzctNi0xLTEtNTU1NTQ_d79b8afc-1ad8-4786-90c4-3355572e61fd">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzgtMi0xLTEtNTU1NTQ_5b570fe1-6802-4eb7-8cab-35e8deccb6f9">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzgtNC0xLTEtNTU1NTQ_ec3337e5-cef9-4c6f-84cb-b6c8bbfded20">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzgtNi0xLTEtNTU1NTQ_228394a0-8aba-4359-b32e-dcc8c646a836">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEwLTItMS0xLTU1NTU0_b9b8014c-2d7c-4f43-8cd2-12d5cac62af8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEwLTQtMS0xLTU1NTU0_4d6f8bb7-a3f4-442e-8112-88e31d8d862a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35320f15f6674855866c5c06e985c83d_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEwLTYtMS0xLTU1NTU0_e8014c68-b951-4abe-b3f8-11ca38b77781">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzExLTItMS0xLTU1NTU0_7fb395c0-7a39-463e-908e-c4e95ab5b85d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzExLTQtMS0xLTU1NTU0_f6316a4c-af65-4f03-8a5e-827f5af4a3d2">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35320f15f6674855866c5c06e985c83d_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzExLTYtMS0xLTU1NTU0_878e1b42-840b-4cd9-9b52-0b451b805fc0">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEyLTItMS0xLTU1NTU0_5f9eea10-5455-470d-8782-fe3348d588ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEyLTQtMS0xLTU1NTU0_a6c79d98-5963-4db4-b607-f80de4d7ed72">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35320f15f6674855866c5c06e985c83d_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEyLTYtMS0xLTU1NTU0_ad805297-8dc3-429e-b185-d6b15ad018e6">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to common stock, our authorized capital includes <ix:nonFraction unitRef="shares" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5MDA_f482fe9c-412a-449d-bb7c-f7b37cee1f49">5</ix:nonFraction> million shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5MzA_ae3ecc1c-9f22-4b0b-983e-169920217d29">0.0001</ix:nonFraction> par value. As of December 31, 2021 and 2020, <ix:nonFraction unitRef="shares" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_2fc625a6-b1dc-4855-a27c-708ef1450106"><ix:nonFraction unitRef="shares" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_97432e8c-06d6-4b8b-8931-578eeb6466f5"><ix:nonFraction unitRef="shares" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_b0b915e4-9deb-4fe8-8ac4-6429029c80c6"><ix:nonFraction unitRef="shares" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_c2b139f5-9cc3-4150-98f8-1a721d4e6c8f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock were issued or outstanding.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_244"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyNzY_be58fc97-9d4e-473c-a5e9-7f8ed0d5ffa1" continuedAt="i5b3e98ce1b4a42c395c10115f16be30d" escape="true">Fair value measurement</ix:nonNumeric></span></div><ix:continuation id="i5b3e98ce1b4a42c395c10115f16be30d" continuedAt="ica361b4f3128482bb8233df14c6f9755"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyNzM_4095b313-aa24-465f-a428-8ec3590389a2" continuedAt="i942936d2f8324b8eb181116425362c27" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3749d6c99c044fd49a6d259f74ef6c99_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtMi0xLTEtNTU1NTQ_ab1c4c58-da3d-4459-9f9c-db274e78353f">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1e6522010e42beb2d5a512da981242_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtNC0xLTEtNTU1NTQ_06be2146-0147-4e30-8efb-43bdbc06d2ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f61d55abb54285bdf1fa8615440956_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtNi0xLTEtNTU1NTQ_90b38d6d-80a4-4fc4-a1dd-e79ff5fe3574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtOC0xLTEtNTU1NTQ_16be45f0-6a0d-4092-b80b-a36b0ba5f821">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfaf46a638094fa5b126a5684fbeec50_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtMi0xLTEtNTU1NTQ_e74ef756-507e-4147-abcf-455138fed28e">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6203c3d089a640c88db71d0303989c08_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtNC0xLTEtNTU1NTQ_c45b0d3c-0d1a-4abc-9676-8b8a408e58b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d32c14a32b146d491c15b7db4b291f5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtNi0xLTEtNTU1NTQ_caf2db4f-3eb4-44da-815d-0ce9c19fb47c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtOC0xLTEtNTU1NTQ_2bbb2a9f-c105-4a71-b8a7-942bb1ef2cee">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b247dc676e4516bae8242fab1601e0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTItMS0xLTU1NTU0_0339ae60-c548-492e-9c07-7dd0fa8f6059">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bae52b8579846bf94e3c6a5aedc9878_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTQtMS0xLTU1NTU0_c7c0c210-49be-44f5-9671-68d1183af9e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed17b422b8a4a51b6f39304fe4350a6_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTYtMS0xLTU1NTU0_a2016a7f-42a6-4f6f-8a2e-46371b801203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTgtMS0xLTU1NTU0_6f4eb004-2818-45c8-abad-beae5cf45a95">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b00e4e2c4742499d53a470e0343c3b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTItMS0xLTU1NTU0_c35e37bb-4d16-4025-9e99-b094caa381b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2471fcfa074988acc387470355b7a8_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTQtMS0xLTU1NTU0_78a00093-7f58-40ee-9eb8-d18366187246">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if844eb33233f407fab5a2d1540261d05_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTYtMS0xLTU1NTU0_654414cc-69a9-474e-96bd-37cb2d7d2467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTgtMS0xLTU1NTU0_63caa8dc-6a06-43b6-9529-a46225c28486">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTItMS0xLTU1NTU0_6cded592-40f3-4487-a4b4-c41af5a7e5e6">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTQtMS0xLTU1NTU0_21297f52-a5e7-4f66-97a5-2c0d03706a94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTYtMS0xLTU1NTU0_f21877b9-fb2f-4eb4-849d-5d1d416511e3">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTgtMS0xLTU1NTU0_3f16fcc0-0b35-4e7e-8a9e-c1eb44724f40">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c953f5c148c48d182cf8f1587a75aaf_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTItMS0xLTU1NTU0_5dc92dc9-b0da-46f2-b624-c7753f9806eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb66166118bd4add9f632ee3b805827f_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTQtMS0xLTU1NTU0_d1ee22c2-185b-4e02-a7b0-467b8f4310e6">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddf499ee3f344b5b42a90e01e741b82_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTYtMS0xLTU1NTU0_12f2ea9f-9959-42e8-9a3f-df283c034d25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7d6eb6e0ea47e19bdbc24585673349_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTgtMS0xLTU1NTU0_fb20fd0e-aa04-48ff-938d-6c82a99ba35a">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6231133c44412abb1a5cee2a4babf6_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTItMS0xLTU1NTU0_56212184-31f9-4003-b2a6-4227894e376b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81fa5de4d71466aad60dae129ee4fb4_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTQtMS0xLTU1NTU0_daabe189-5e49-4448-a867-24f8bc821edd">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bea7ddb5d2b4c51a7e8fcffe813ebfb_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTYtMS0xLTU1NTU0_4124cdf9-b238-49a1-98e1-6d365aa264c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff7bb5325c6416cae92c622ff045f13_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTgtMS0xLTU1NTU0_7c08e3c3-8376-47d9-ad01-677807f34ad6">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d6fad6c8dd462eaf5fde3ea0c3ff70_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTItMS0xLTU1NTU0_5c50bb00-3b0f-4765-a123-b302ff77d4d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i004a939dc0024ba59fe2c2766322fdd3_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTQtMS0xLTU1NTU0_ad6bcd41-9fbb-4050-8bb2-8b5cacbecfd8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f15e114d3c64fe7946425ca3fc21f73_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTYtMS0xLTU1NTU0_68a935c8-372c-4c53-8cf5-d51471b23770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe1823365054cc481d757a51d3eb3f8_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTgtMS0xLTU1NTU0_b453caec-a4f6-47e4-9bc5-9c0af544a332">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTItMS0xLTU1NTU0_a7649abb-962b-4e93-90f4-2091cfa7a5f3">7,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTQtMS0xLTU1NTU0_25e64b77-8ee8-4acd-a67f-3cec2dd44b03">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTYtMS0xLTU1NTU0_e7e7c42a-dac1-4496-bdc9-ee8e1f6647f4">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTgtMS0xLTU1NTU0_15f31e1c-c067-47f8-871c-2b1c4425fa22">8,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c953f5c148c48d182cf8f1587a75aaf_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTItMS0xLTU1NTU0_a1b8c00d-0357-4340-b475-a3d8e4efe3e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb66166118bd4add9f632ee3b805827f_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTQtMS0xLTU1NTU0_260b3a8d-55dd-44f7-80fa-70b10efd2972">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddf499ee3f344b5b42a90e01e741b82_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTYtMS0xLTU1NTU0_ba4d86d1-587f-4037-ab16-3e6300aa299e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7d6eb6e0ea47e19bdbc24585673349_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTgtMS0xLTU1NTU0_9f2ca49d-baf1-42d4-adb4-6ce053814c60">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6231133c44412abb1a5cee2a4babf6_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTItMS0xLTU1NTU0_038415de-3e1f-457c-bfc4-5f72369ab67c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81fa5de4d71466aad60dae129ee4fb4_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTQtMS0xLTU1NTU0_a92c81b9-ccba-496f-9168-4f2e104631c1">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bea7ddb5d2b4c51a7e8fcffe813ebfb_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTYtMS0xLTU1NTU0_aedcc644-9cf8-4f93-96e9-dbaef33b7da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff7bb5325c6416cae92c622ff045f13_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTgtMS0xLTU1NTU0_7c4ba9e6-6f56-492b-b6d5-4ad8838695fe">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d6fad6c8dd462eaf5fde3ea0c3ff70_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTItMS0xLTU1NTU0_86ce378c-bb61-4636-acce-8bc2214082fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i004a939dc0024ba59fe2c2766322fdd3_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTQtMS0xLTU1NTU0_9dad2f5a-fdcc-4c01-ab01-b281ee929a8a">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f15e114d3c64fe7946425ca3fc21f73_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTYtMS0xLTU1NTU0_dabcc686-0bf0-42ac-abef-8d41fc32e9a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe1823365054cc481d757a51d3eb3f8_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTgtMS0xLTU1NTU0_7abe8644-96cd-4fa8-afaa-fb0ac281903a">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTItMS0xLTU1NTU0_6994f6d7-a299-4eb5-88fa-e86e03f9ea0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTQtMS0xLTU1NTU0_7e9c8442-b13e-4bd5-8a09-e3bff9a5d1b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTYtMS0xLTU1NTU0_6b8c04e6-a38a-455f-9dc7-72218db5cdd5">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTgtMS0xLTU1NTU0_b2778885-48eb-49e1-934b-59ec44caa8ad">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTItMS0xLTU1NTU0_375214d0-1c35-4169-becf-e43c7c594993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTQtMS0xLTU1NTU0_40f49fec-5923-4125-ab9c-016d9533a5df">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTYtMS0xLTU1NTU0_16d5f034-fe00-4232-a5be-82d594200a7f">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTgtMS0xLTU1NTU0_2a0c9259-ca3f-43e1-9eaf-aff6a2d92c04">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ica361b4f3128482bb8233df14c6f9755" continuedAt="i21cb065e527e42ff8adfdb8e37d71653"><div style="margin-bottom:3pt"><ix:continuation id="i942936d2f8324b8eb181116425362c27"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a924c3505e43a9b71b7be707de1ac1_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtMi0xLTEtNTU1NTQ_0290619d-b2ef-4384-a31b-7c5055be3a4d">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eafc754316345619b018dfaaebc87f3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtNC0xLTEtNTU1NTQ_1c6bf370-ea28-4ab6-b598-cde448da37a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5354f3fcd8644c87860ba3a5544fad9d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtNi0xLTEtNTU1NTQ_94398aee-658d-4252-9e9d-5bf95a9be89c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtOC0xLTEtNTU1NTQ_6c2cb14f-45b1-4206-b0e8-6439672513fc">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceba7ccd82584acda921d0e558528e50_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtMi0xLTEtNTU1NTQ_56abaaf1-1f99-457c-8e25-4a52f7d861d5">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1ed82dd0d54655985037c85ddd3ede_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtNC0xLTEtNTU1NTQ_7b45571f-9c37-43c7-af2c-f56b82c6e204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3b3a83ca454eaabd5077059293ed84_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtNi0xLTEtNTU1NTQ_3a6b0fad-d611-4ed3-8c8e-6dba5bc0146a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtOC0xLTEtNTU1NTQ_fac2eb69-0381-49ef-ac05-c2f8f0903cbe">4,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad26877e4a04bd7bb26b8a8c7c28eb4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTItMS0xLTU1NTU0_1928fdf0-e5be-4ae6-a7aa-004e210b0885">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46082d9efffb4b3c95fe13c8f220bd0c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTQtMS0xLTU1NTU0_fe2c147e-040b-4d38-98b0-73a740faab9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9405eeed0ae040f5a34607effb78d146_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTYtMS0xLTU1NTU0_cf0cf29f-1e7b-441f-857c-e9d5415d5b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTgtMS0xLTU1NTU0_0ec7a49a-f612-4f2a-b599-9973eec5347d">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b00be27f6e4944a30922c5c0fe6670_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTItMS0xLTU1NTU0_0a84a53f-8f0f-4d69-bbaa-ca60947ed8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1180ce65c8843b4991f543dc49f55be_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTQtMS0xLTU1NTU0_79670d8c-3286-4c59-a058-24585b0bb6a9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5662300e135747438ae3581b6b70a657_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTYtMS0xLTU1NTU0_4968ddd6-7957-49d0-b461-83d925975c71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i811e98c080a8445ab332e5093987caf0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTgtMS0xLTU1NTU0_35449109-3cc0-4250-a7e1-2a66a7e67f87">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTItMS0xLTU1NTU0_65b47d57-2848-48f6-bfd9-54a71f027182">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTQtMS0xLTU1NTU0_dac64837-bd84-4c2e-b749-b51a3ac8a809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTYtMS0xLTU1NTU0_9a19844f-7833-4965-9b88-a65e811a7f7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTgtMS0xLTU1NTU0_8d9a9115-0641-44ab-aab4-6f14b376cae0">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie630eb784ad2416794c05aa8a219fd58_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTItMS0xLTU1NTU0_d0ceeb1b-f862-4066-921e-1d7e5e0ee020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f25224e2b54616985641a3771ed55c_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTQtMS0xLTU1NTU0_fcc33044-3611-4950-9a71-08f277c2d1e2">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0614eede5b234c61be2259d587e7b43a_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTYtMS0xLTU1NTU0_9f93384c-ef5a-4775-8ff4-7095edeb769e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99958e30da4d4cbfa5e3d682930d68fe_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTgtMS0xLTU1NTU0_ac738d81-64e2-496a-80d8-79dab5d016b3">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f2b4195bd34883bf7b39bc3b2efe92_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTItMS0xLTU1NTU0_defe7110-e016-4906-9e76-4cb8fca5e112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b26de6dcae348c4a7d727d21d2b83ed_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTQtMS0xLTU1NTU0_9f3ab852-bb11-4911-b0d7-b73205968a1f">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c7782342094a07a4240eb1534d6ac4_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTYtMS0xLTU1NTU0_d7a776e0-0796-4f16-880b-a9f73d960e47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f94e6a78404c5c928e7256392dfe2f_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTgtMS0xLTU1NTU0_3b0d7b22-9cf4-4216-85d7-53fcc11df723">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089ac98960b04b439f83de38bd8c51dc_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTItMS0xLTU1NTU0_a519cde0-8da7-4c6b-b869-8be991c83478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb49b4259114419a84f22f50981dca8_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTQtMS0xLTU1NTU0_2ab4ae52-36bc-4272-aa99-1bc8cba3ab3c">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5427fc4b2ce14c1f83b6ee82f6be8aec_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTYtMS0xLTU1NTU0_68db29db-b6a1-4828-ab61-4526b2b7e0ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a08253dadcd44d2b7a7f73f8fb62ba6_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTgtMS0xLTU1NTU0_94db9afb-791f-4f73-95a9-676da460f5c3">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTItMS0xLTU1NTU0_5f2daec4-38c6-474a-a16f-218fd9dd9884">10,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTQtMS0xLTU1NTU0_a1b4d8a2-8079-4ba2-8251-d8f1a54a400b">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTYtMS0xLTU1NTU0_7496ca7c-ceda-42f9-b355-81a702f1a7c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTgtMS0xLTU1NTU0_89d55e6a-6116-4c0d-991b-bf4f7912c5bb">10,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie630eb784ad2416794c05aa8a219fd58_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTItMS0xLTU1NTU0_f0d9be30-0278-452a-9653-90af67aacfef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f25224e2b54616985641a3771ed55c_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTQtMS0xLTU1NTU0_1b635eb0-e1ff-44a3-9be6-eed678c45fe1">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0614eede5b234c61be2259d587e7b43a_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTYtMS0xLTU1NTU0_657b6eef-14df-4636-8e80-f845f38415ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99958e30da4d4cbfa5e3d682930d68fe_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTgtMS0xLTU1NTU0_85d1b694-fa2c-4982-ac40-92c485f529d6">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f2b4195bd34883bf7b39bc3b2efe92_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTItMS0xLTU1NTU0_9dd8835d-3c69-4d7c-b287-d057fd3a7ad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b26de6dcae348c4a7d727d21d2b83ed_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTQtMS0xLTU1NTU0_9fb3a10d-e119-4a80-ba74-a345f7555093">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c7782342094a07a4240eb1534d6ac4_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTYtMS0xLTU1NTU0_18e90218-dc54-44e1-990e-1403898b0d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f94e6a78404c5c928e7256392dfe2f_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTgtMS0xLTU1NTU0_3b444f12-ae04-4495-9db4-34f07124dae0">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089ac98960b04b439f83de38bd8c51dc_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTItMS0xLTU1NTU0_127b4dae-4eb5-49d7-aad3-72c1c0234f7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb49b4259114419a84f22f50981dca8_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTQtMS0xLTU1NTU0_a7716be3-90f9-4af8-a0ea-cdd8ba920873">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5427fc4b2ce14c1f83b6ee82f6be8aec_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTYtMS0xLTU1NTU0_33d48217-1ddf-4c68-acda-ec352b62b49b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a08253dadcd44d2b7a7f73f8fb62ba6_I20201231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTgtMS0xLTU1NTU0_38319454-4c71-468b-a463-fe6f522185d6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTItMS0xLTU1NTU0_0003aea6-419f-42a0-aaa5-519fbe6753b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTQtMS0xLTU1NTU0_9432dd1e-a0fd-4cc9-8867-b7780ada9a37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTYtMS0xLTU1NTU0_e75ad618-bd13-4030-bd1e-f9ae9e57993c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTgtMS0xLTU1NTU0_e67a5299-1387-4924-9700-e2f76e421ae8">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTItMS0xLTU1NTU0_14ba2d17-878b-4aa6-ad2f-decd98eef7a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTQtMS0xLTU1NTU0_11b70b19-442f-4442-89f2-ec0444d93a4c">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTYtMS0xLTU1NTU0_7812a10e-e0cf-4faa-9851-263ad07889c5">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTgtMS0xLTU1NTU0_c882aff1-eb56-473f-ac38-bed69d2d1698">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair values of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available information for similar companies that have actively traded equity securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our foreign currency forward and option derivative contracts have maturities of <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzMyMTk_57bc4d1c-f656-45ec-8ae4-da217cfd1600">three years</ix:nonNumeric> or less, and all are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i21cb065e527e42ff8adfdb8e37d71653"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzExNTQ0ODcyMTEzNjk5_d60bdbd0-ba44-47cb-b2c5-166ab341e407" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzItMi0xLTEtODMxMzA_64ec987a-d56f-4a1e-9608-9c4b1bd4677c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzItNC0xLTEtODMyMjc_0309b5d5-2ffb-4adb-9477-ceabdb9ddc89">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzItNi0xLTEtODMyNDU_6a1a8e03-9746-4947-9f16-5d31235cf9cc">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzMtMi0xLTEtODMyMDg_a01174dc-1abd-43eb-8296-92c2785abc24">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzMtNC0xLTEtODMyMjc_abcbf730-80cc-4d58-8f5e-90390371fcef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzMtNi0xLTEtODMyNDU_2c420d55-e183-46a9-a9e7-da9f5f0a7fab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzQtMi0xLTEtODMyMTU_a22cc3b1-4d3a-4d57-8737-7338496da793">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzQtNC0xLTEtODMyMjc_98c73f51-ce17-44ac-8352-abcf7926266d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzQtNi0xLTEtODMyNDU_d60fc8e5-5f6c-4f86-a5f5-60901090c386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzUtMi0xLTEtODMyMjE_e5313912-d92f-4e9b-b643-28b69e4d17ac">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzUtNC0xLTEtODMyMjc_d226c3f8-db0a-4cfa-ada9-1c305d07002d">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzUtNi0xLTEtODMyNDU_9beaa545-ea19-4459-a995-5de21aa56051">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzYtMi0xLTEtODMyMzM_16c0ef1e-30b6-472c-9b6f-9e75bf8517ae">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzYtNC0xLTEtODMyMzQ_e10ea60b-576c-4ecb-90b3-46a240d14211">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzYtNi0xLTEtOTQ1NTY_59a4f6eb-e8b6-4967-ae79-ea9bbb568e77">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Teneobio in 2021, we are obligated to pay its former shareholders up to $<ix:nonFraction unitRef="usd" contextRef="ic2b282aad63a4bcaaf14002bae397df0_I20211231" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzEwOTk1MTE2NDc1NTU_1c54af8f-1df5-4bed-9272-776b2ea067b1">1.6</ix:nonFraction>&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;D programs. See Note 2, Acquisitions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of BioVex Group Inc. in 2011, we were obligated to pay its former shareholders upon achieving separate sales-related milestones with regard to IMLYGIC if certain sales thresholds were met. During the year ended December 31, 2020, we determined that the likelihood of achieving these milestones was no longer probable, and accordingly, the obligations were written off.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2021 and 2020, the aggregate fair values of our borrowings were $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzU5OTI_04b50bc3-6d31-4a81-a33b-b78e2225f9b0">37.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-8" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzU5OTk_15ecbfc8-09af-492a-aec2-31160858c7af">39.4</ix:nonFraction> billion, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYwNDY_5f5aadcf-1587-4413-8e71-59b7f00c70c0">33.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYwNTM_e0e81b06-c01f-406a-854b-9a616a2785ed">33.0</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2021 and 2020, the fair values were $<ix:nonFraction unitRef="usd" contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyMzk_b4fa6c7d-17ed-4c87-9bcf-0068bf5b5f31">5.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzEwOTk1MTE2NDk3OTQ_e5ac3ba3-1554-4b15-a734-f35a3a623a97">4.9</ix:nonFraction>&#160;billion, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyNDY_4e3e02dd-0bc6-42e0-98a6-230e95e3a409">2.8</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzEwOTk1MTE2NDk4MDg_c25d72c6-32d2-434d-9007-0eaf7f76b646">2.9</ix:nonFraction>&#160;billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_247"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzA4_f8082475-d573-4495-95e6-07b6cb805cb3" continuedAt="ia82eb2fab27243ca9a53bc6141a2140c" escape="true">Derivative instruments</ix:nonNumeric></span></div><ix:continuation id="ia82eb2fab27243ca9a53bc6141a2140c" continuedAt="idbcdf35200bb446ea324417de9a4aead"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:DerivativeInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzExNTQ0ODcyMTExNjcy_0da98a90-7f26-42ee-906c-5fc205c39535">three years</ix:nonNumeric> into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019, we had outstanding foreign currency forward contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i7211fd50bd2642b3aca55c89862f86d3_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE1NjA_3f6e12de-6b3c-4c01-880e-d03a9c8bb90a">5.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i4a63aa87c0224ee98ac2fd8fd67ddaee_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE1NjQ_8faec7b8-e11e-405a-8aaa-04c5aaad81a9">5.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i68179a299576480aa8d41a7687749389_I20191231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE1NzE_29210174-14cb-4cf0-84b9-badd2790cee4">5.0</ix:nonFraction> billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzI0_8d19b7cc-440c-438e-96ca-611f51a06921" continuedAt="i535a0e4f4994495888b4070c044ec1ac" escape="true">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2021, were as follows (notional amounts in millions):</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><ix:continuation id="i535a0e4f4994495888b4070c044ec1ac"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="chf" contextRef="id5c684a9063940959ca5882be53b9b80_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtMi0xLTEtNTU1NTQ_0c8b8cc6-6115-48db-97ba-0d31b249d5f3">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71ec6c587d9b4e62aee06a72a1f73f9e_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtNC0xLTEtNTU1NTQ_1d367342-a34b-4ab0-9fd8-a2df8d0e55d2">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c684a9063940959ca5882be53b9b80_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtNi0xLTEtNTU1NTQ_a1cc878a-c436-4fce-a5dc-b26c04bc24ba">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5da09ffb67c742d795348bf45a166d74_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtOC0xLTEtNTU1NTQ_46ec8f83-a26a-45f6-b9e7-ad4b8ba890af">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i5fe2830b43b44d79b43091fb7f32ea57_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtMi0xLTEtNTU1NTQ_b4b46a90-81f0-404d-af19-45ed1c3c04d7">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8359101653f44adbb212efe4e4294a95_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtNC0xLTEtNTU1NTQ_fea7147f-9a8b-4cab-9822-edf010a2cc09">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe2830b43b44d79b43091fb7f32ea57_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtNi0xLTEtNTU1NTQ_f9723f94-a644-488e-824b-8e5977f95a4c">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibec9d656079e405f82e3bf12e4d8c37a_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtOC0xLTEtNTU1NTQ_f572adcf-a4d4-4cd0-99b2-5bd860748ff9">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i665816818e0a44d58309ed1a320f177a_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtMi0xLTEtNTU1NTQ_990615b9-90d7-4cd3-87eb-658b0d2a1153">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifaabba1893af44ce9e672215ac116ce8_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtNC0xLTEtNTU1NTQ_5283192a-3e43-41de-aa85-f7fdac556fe0">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665816818e0a44d58309ed1a320f177a_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtNi0xLTEtNTU1NTQ_2fa161dc-2db3-4b6d-9521-1df81317bdf2">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i730ee854cf6c432ab6aaa706614c8632_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtOC0xLTEtNTU1NTQ_81d02151-4ebc-4cca-9bd9-9787877cad81">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i8fdabb7d166a4746adca1c02c5f92d88_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctMi0xLTEtNTU1NTQ_6d732f6c-9a98-46a3-ad35-599225d426da">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1bb0ddc693254332b142eabe8b6a28aa_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctNC0xLTEtNTU1NTQ_83c86aa1-359b-4052-be6b-75e3b03669f9">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fdabb7d166a4746adca1c02c5f92d88_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctNi0xLTEtNTU1NTQ_555ed936-9379-4697-ab78-b5991691925f">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ecb51f1a572468b8e76872013008be7_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctOC0xLTEtNTU1NTQ_60f68c1d-64fc-4b97-ab35-1f9ff85b4e44">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, our <ix:nonFraction unitRef="number" contextRef="ib927e41cd49b4bcda2eea7a252c62906_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzg3OTYwOTMwNDIyNTE_522801f9-ba66-4202-aafb-ed19757bab3b">1.25</ix:nonFraction>% euro Notes were redeemed, and the related cross-currency swaps were settled, resulting in an immaterial loss. During the year ended December 31, 2019, our <ix:nonFraction unitRef="number" contextRef="ibc0cdd08ffa245b5b14a99b5ae9342c3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzM2NDI_0b948c74-5fd0-4dda-b5e1-495b6fc5ca4f">2.125</ix:nonFraction>% 2019 euro Notes matured, and the related cross-currency swaps were settled. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts to hedge variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2021, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idbcdf35200bb446ea324417de9a4aead" continuedAt="iffd6265f0e244710b26284b3e19ced73"><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzQ0_16979273-79b3-4629-a57f-66a08caf8a8b" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c071ab35a1441a7ab265cde48d713e8_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzItNC0xLTEtNTU1NTQ_514b2ce7-a642-4e71-922a-10b438a7e514">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dafda6691b84625923472fe59fa12bf_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzItNi0xLTEtNTU1NTQ_7226f545-e7f1-4a13-be4e-7aa35de4d6b7">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632df15458d646f08f1906bc1e27b8fa_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzItOC0xLTEtNTU1NTQ_a7e7ef59-b915-46b4-8277-6876b9aeacd5">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cce474dbbd049c4984d8bf485ab3a19_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzMtNC0xLTEtNTU1NTQ_fbbc8e94-f980-4d3d-a2c0-6a0c62901554">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29069e42d7524b4db8c509bf319d9680_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzMtNi0xLTEtNTU1NTQ_b57d0817-c027-40fb-95a3-3a0c02002f45">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2c56acaf30d4dce85c3d989ea151652_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzMtOC0xLTEtNTU1NTQ_a45fef1b-efc8-4cde-9e7f-aa22fe31a0fd">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665b76a3b3b3476c84386f9224fe17a9_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzUtNC0xLTEtNTU1NTQ_a738ec2c-0d62-442c-86f2-34a7b34f86f8">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eba7e66fb7849818cac30465266bf74_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzUtNi0xLTEtNTU1NTQ_4264aee5-acd3-427b-bc23-a2158661834d">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc742c16678e447d8a1223755190162f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzUtOC0xLTEtNTU1NTQ_9f4977c6-19cb-4a94-aecb-e267f4a0ec26">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2021 and 2020, we had interest rate swap contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzM1MTg0MzcyMTA3NjMx_2447a531-fb00-4559-b972-39ef3859962f">6.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzUwOTk_05cd413c-0ae9-4e92-b288-7b430909a1f3">5.9</ix:nonFraction> billion, respectively, that hedge certain portions of our long-term debt issuances. See Note 15, Financing arrangements, for information on our interest rate swaps.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231" decimals="-8" name="amgn:DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzg3OTYwOTMwMzY5MzM_a4abb069-2293-41ab-9e65-db06f5127c39">1.5</ix:nonFraction>&#160;billion. Interest rate swaps with an aggregate notional value of $<ix:nonFraction unitRef="usd" contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231" decimals="-6" name="amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwOTk1MTE2NDc3ODY_220ad18c-0e03-49de-9e82-f513865bd82d">750</ix:nonFraction>&#160;million were terminated in connection with the redemption of certain of our notes. The resulting gain on these terminations was immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, interest rate swaps with an aggregate notional value of $<ix:nonFraction unitRef="usd" contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231" decimals="-8" name="amgn:DerivativeNotionalAmountAmountTerminated" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzUyMzQ_31294d24-4335-478f-9112-5fc533be1912">3.7</ix:nonFraction>&#160;billion were terminated in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $<ix:nonFraction unitRef="usd" contextRef="i806e9dc1988340d9b23b17a31bc072d3_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeGainOnDerivative" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzU0MjE_e89e2d14-7cb2-480d-86e4-6a1879294a79">40</ix:nonFraction>&#160;million, recognized in Interest expense, net, in the Consolidated Statements of Income. Additionally, we terminated $<ix:nonFraction unitRef="usd" contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231" decimals="-8" name="amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzU1MzI_a92ca46f-47b0-47e3-9f0e-23f8be83c775">5.2</ix:nonFraction>&#160;billion aggregate notional amount of interest rate swaps, which resulted in receipt of $<ix:nonFraction unitRef="usd" contextRef="ib46494b393a34b9f8c60e96025f45f23_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzU2MTg_d5a6196f-d2c1-4a68-acb2-20eabae9d8c0">576</ix:nonFraction>&#160;million from the counterparties and which was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2020. This amount is being recognized as a reduction in Interest expense, net, in the Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $<ix:nonFraction unitRef="usd" contextRef="i16d30d400605402ca45a9146fa90bd76_I20201231" decimals="-8" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzYxMjQ_c9015ea5-c7fb-4f20-a55a-dc1042808dd2">5.2</ix:nonFraction>&#160;billion principal amount of notes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzI3_49162cb9-3f37-4576-9343-72ab50341217" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtMi0xLTEtNTU1NTQ_5f1b66da-c5be-45bc-beea-0d6137d60147">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtNC0xLTEtNTU1NTQ_acedc978-9c20-426c-bcc1-aee960f69769">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtNi0xLTEtNTU1NTQ_a46645eb-a0f3-4c0c-821e-c6c5d9ae0374">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtOC0xLTEtNTU1NTQ_1e7f041f-0da1-47a3-9809-dc49c778bdfc">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtMi0xLTEtNTU1NTQ_677028e7-b2eb-445f-b15a-40c68df02205">6,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtNC0xLTEtNTU1NTQ_570458ca-1c45-472d-b7d4-793a9d5e7c84">6,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtNi0xLTEtNTU1NTQ_b6053d8e-2fac-4f51-8f21-6a532e6bcf88">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtOC0xLTEtNTU1NTQ_5eb18f91-701c-4812-8eef-9e4c0b87a766">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzcyMDQ_7d6a43bc-f2bb-4db1-a39e-b8447d15ec95">85</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE2NDkyNjc0NTQ3NDA_6d4ebd26-c394-48e2-b2b4-3118d0c77063">89</ix:nonFraction> million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzczMTQ_923f4dd5-31b4-4d37-a6e7-a82dcdbc4542">440</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzczMjE_062bf57a-1f90-471c-9980-e91ac02e577a">525</ix:nonFraction> million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzc0NzA_2689f3a8-9f87-47c2-bbe3-6e3cf4df2562">85</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE2NDkyNjc0NTQ4MDA_3afde7af-c738-4a31-8eac-b89f3bbd9dd1">89</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzc1ODM_52c4ac36-89d6-4d89-92f4-676416adf712">340</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzc1OTA_aa5ab670-ac2a-472d-8254-ff964759bf62">425</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iffd6265f0e244710b26284b3e19ced73" continuedAt="i050a67f8d3c940978a38a95a712a9f55"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzI4_97c4220a-fa46-4984-a50e-3bb374e68644" continuedAt="i26bfb4d59dbd4d1bb2f93940e5afeac3" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzItMi0xLTEtNTU1NTQ_c7cdc7fc-110f-4f3c-82d0-01f63f77fecf">24,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzItNC0xLTEtNTU1NTQ_a32af547-8f3a-4a5e-bba0-d9dcc2a8b188">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzItNi0xLTEtNTU1NTQ_21de69c3-edc9-4842-8fe8-b5d92aa81c6d">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b2f149e177b4bc3b630018b36f6e49c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzUtMi0xLTEtNTU1NTQ_f00838c4-c613-4cea-9b82-a189641de36b">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35372b79111c40a58a07694440d9622c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzYtNC0xLTEtNTU1NTQ_7c30c0f4-b56d-4f3b-8451-9acbd890d8b0">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739fe173b25a47189a34271891a4159b_D20210101-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzgtNi0xLTEtNTU1NTQ_19b31399-ff01-4a2c-ad2c-1dcc6a118537">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i739fe173b25a47189a34271891a4159b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzktNi0xLTEtNTU1NTQ_0b625db2-d731-496c-9619-226b0ed94eb4">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzItMi0xLTEtNTU1NTQ_da9a7d3d-8e66-4fa1-a835-a38eae40cd25">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzItNC0xLTEtNTU1NTQ_3a09f168-a082-488f-8470-2bea5be6d52b">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzItNi0xLTEtNTU1NTQ_30b7ae8c-7f45-4fe4-8488-96f202dfc642">1,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad2966682ec4e37bbcfa6626b7183ec_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzUtMi0xLTEtNTU1NTQ_2acc082d-216c-4bbf-aa3f-7bdad634c2de">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd31886569fd4668bfb1bce453953983_D20200101-20201231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzYtNC0xLTEtNTU1NTQ_1d2a092d-204c-41c8-a1bf-8365b6a0d129">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7da02963523c4db1b9d260cbec5d9af3_D20200101-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzgtNi0xLTEtNTU1NTQ_3255ecc7-ee99-4135-bf75-8768e17acd4c">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7da02963523c4db1b9d260cbec5d9af3_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzktNi0xLTEtNTU1NTQ_c735cb19-95f6-4852-ba9c-47413f1e155f">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzItMi0xLTEtNTU1NTQ_ab01c394-4556-45a2-8faf-ab0a0d0f6d67">22,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzItNC0xLTEtNTU1NTQ_c43e6f80-07a2-4d85-81fa-674872d05b00">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzItNi0xLTEtNTU1NTQ_7e6ff3d7-9a19-44b4-b999-c492549d5e19">1,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4dd663b9fc4f028f2085d56886e460_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzUtMi0xLTEtNTU1NTQ_71fa0f1d-f8df-4f41-a0df-abd1da5c99f4">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a842d09a06449083eeab3521739d0d_D20190101-20191231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzYtNC0xLTEtNTU1NTQ_4d9f4305-fef2-4120-9f9e-1bf9f41a63a9">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied61ab999fde4db3b59917ff3e2febd4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzktNi0xLTEtNTU1NTQ_0276d3c5-371e-4fc2-a5c4-b8f492020efc">349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied61ab999fde4db3b59917ff3e2febd4_D20190101-20191231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzEwLTYtMS0xLTU1NTU0_864c7fb9-5bef-4f8b-9937-15f86a50d67d">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div></ix:nonNumeric><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i26bfb4d59dbd4d1bb2f93940e5afeac3" continuedAt="idee33c8d94934b81a71751f7340e0f61">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idee33c8d94934b81a71751f7340e0f61">&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2021, we expected to reclassify $<ix:nonFraction unitRef="usd" contextRef="ic2aae7469fe64dcd8bac1076dd7692d9_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzg0OTk_93a3da01-f7a8-478b-b40b-a3fe0fbe325b">19</ix:nonFraction> million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i050a67f8d3c940978a38a95a712a9f55"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2021, 2020 and 2019, the total notional amounts of these foreign currency forward contracts were $<ix:nonFraction unitRef="usd" contextRef="i760d8f96eac94b7f88f95302db5dd2d4_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzkwNTE_b4bc3d13-1831-4985-ab1c-3d83d309d641">680</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3a34b1b31c7e425a8ee9baab7f3c59db_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzkwNTU_b8d76710-669f-4680-a0f7-fe086521bb70">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i71e6675ffd9f4a3998395c7c583d88f3_I20191231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzkwNjI_9b7d5179-904d-4cf6-952a-6305ecd09ef2">1.2</ix:nonFraction> billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2021, 2020 and 2019. </span></div><ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzE0_bbb8f059-6f37-434d-b8d4-a4ee3dd45d2d" escape="true"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089ec9cec29f4c7ca63544d5e4b387da_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzMtNC0xLTEtNTU1NTQ_7445131c-5b3f-4f31-9bbb-2731bba5cb5b">183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f066d29e5c45d0ba4c511e73c8df4b_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzMtOC0xLTEtNTU1NTQ_217e60d8-b041-4d28-87d5-5df88c59d150">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794004d7dfa741ea84b274eb42d3ec54_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzQtNC0xLTEtNTU1NTQ_47251c71-4de9-470f-b54b-fadc79eb3874">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d0846cbb0548819c01c3db53240ca0_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzQtOC0xLTEtNTU1NTQ_d967a971-ec15-4741-b692-cfd1d2548319">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3377db1e364448a198a868926553f9b0_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzUtNC0xLTEtNTU1NTQ_04c07122-1fca-4a45-8dda-f0c85840900d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050bfd34fd664c4086976b07e6af5cdc_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzUtOC0xLTEtNTU1NTQ_1f2e15db-8869-4284-afdd-a8a7447d0b7a">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e65e212078b47438c294f4cc92afbe1_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzYtNC0xLTEtNTU1NTQ_bf6b9fcf-3e30-41f6-9163-7b1aa3c4d733">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e65e212078b47438c294f4cc92afbe1_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzYtOC0xLTEtNTU1NTQ_aa4f2e34-dd90-44a5-bc27-f2a0f330acaf">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzEwLTQtMS0xLTU1NTU0_c6a71076-39a3-411d-bd14-12b724f4ebf5">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzEwLTgtMS0xLTU1NTU0_357ef686-9aaf-4201-bb8f-020cb94355dc">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6728c58d4145b3887b604065653c19_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE1LTQtMS0xLTU1NTU0_13f1bde4-372f-420d-bfc5-a4eb66016409">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc161492cc64bd983de97ee811b16fa_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE1LTgtMS0xLTU1NTU0_a581d3ca-1fcf-4182-9eea-c3db0cfd507f">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic268132426814d8eb399e70d427d8801_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE2LTQtMS0xLTU1NTU0_a8d6fa97-a44d-42f9-bf97-e1b218ba0e1a">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie510af3eca8f4a73a86d9d56fbd815f9_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE2LTgtMS0xLTU1NTU0_60fa5e88-9583-4b2a-a62c-332634036dad">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479675435c2d49f99965cf557ed29fbf_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE3LTQtMS0xLTU1NTU0_b58ad7cb-9d63-4d78-a515-7a5128eddd2e">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44666b59eba54e9a95bb28abe178e8f7_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE3LTgtMS0xLTU1NTU0_c66d74d1-6c37-44ea-a095-edcf5970cd94">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9952aa6a3b134df69afed008d9e67bf4_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE4LTQtMS0xLTU1NTU0_59e8c290-4fdc-420f-883f-d935010453db">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9952aa6a3b134df69afed008d9e67bf4_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE4LTgtMS0xLTU1NTU0_1a76f0f9-8a48-4269-b746-c379c7cca92c">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzIyLTQtMS0xLTU1NTU0_0b9aadd3-4772-473e-b101-932cb2cc7cce">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzIyLTgtMS0xLTU1NTU0_d8676477-02d7-4b47-8628-a40e74c7c189">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative contracts that were in liability positions as of December 31, 2021, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our, or the surviving entity&#8217;s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_250"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2Mjgy_445a4883-d7c3-4dad-9c10-dea705ee675f" continuedAt="i07ab5c37d1c34b34896f38eac7a7c5db" escape="true">Contingencies and commitments </ix:nonNumeric></span></div><ix:continuation id="i07ab5c37d1c34b34896f38eac7a7c5db" continuedAt="ia9f6008248dc401690d9ce4c3a0dea41"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in June 2018, Celgene filed <ix:nonFraction unitRef="lawsuit" contextRef="ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzkzMTE_6dd6f615-2357-4b74-baef-48307e78888b">19</ix:nonFraction> separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC (Amneal); Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited (MSN); Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc. (Sandoz); Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc. (Zydus), each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#8217;940 Patent), 7,208,516 (the &#8217;516 Patent), 7,427,638 (the &#8217;638 Patent), 7,659,302 (the &#8217;302 Patent), 7,893,101 (the &#8217;101 Patent), 8,455,536 (the &#8217;536 Patent), 8,802,717 (the &#8217;717 Patent), 9,018,243 (the &#8217;243 Patent) and 9,872,854 (the &#8217;854 Patent), which are listed in the Orange Book for Otezla. Each of these lawsuits was based on each defendant&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla. The New Jersey District Court consolidated these <ix:nonFraction unitRef="lawsuit" contextRef="ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630" decimals="INF" name="amgn:GainContingencyNumberofLawsuitsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwNzc1_f5bf0bc5-4a1d-444a-becd-a261f5478976">19</ix:nonFraction> lawsuits for discovery and case management purposes into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Celgene filed amended complaints against Alkem, Amneal, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz, Actavis, Unichem and Zydus additionally asserting U.S. Patent No. 9,724,330 (the &#8217;330 Patent), which is listed in the Orange Book for Otezla. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN, Pharmascience, Prinston, Sandoz, Actavis, Torrent, Unichem and Zydus additionally asserting U.S. Patent No. 10,092,541 (the &#8217;541 Patent), which is listed in the Orange Book for Otezla. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#8217;940, &#8217;302, &#8217;536, &#8217;243 and &#8217;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#8217;283 Patent) and 8,629,173, which are not listed in the Orange Book for Otezla. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia9f6008248dc401690d9ce4c3a0dea41" continuedAt="i0a3ca65e58044ab4ac86d0714ac03c68"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz, Shilpa, Actavis, Torrent, Unichem and Zydus filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Amgen&#8217;s acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;854 and &#8217;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the &#8217;717, &#8217;516 and &#8217;854 Patents, leaving the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#8217;s apremilast product during the term of the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#8217; apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal&#8217;s apremilast product during the term of the &#8217;101, &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#8217;s apremilast product during the term of the &#8217;638, &#8217;101 and &#8217;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#8217; apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;536, &#8217;717, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston&#8217;s apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent&#8217;s apremilast product during the term of the &#8217;101, &#8217;638, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0a3ca65e58044ab4ac86d0714ac03c68" continuedAt="i571792459fab4e53ad8f94cdfc8dba4a"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience&#8217;s apremilast product during the term of the &#8217;243, &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;536 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 2 and 27 of the &#8217;283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the &#8217;101 Patent and claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus&#8217;s ANDA must be after expiration of the three infringed patents (the &#8217;638, &#8217;536 and &#8217;283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus&#8217;s generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the &#8217;638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 1 and 15 of the &#8217;101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz&#8217;s ANDA must be after expiration of the three infringed patents (the &#8217;638, &#8217;536 and &#8217;101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz&#8217;s generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the &#8216;638 and &#8216;101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2019, <ix:nonFraction unitRef="affiliate" contextRef="i19d673199032476d834451d22f3f5dc6_D20190401-20190430" decimals="INF" name="amgn:GainContingencyNumberofAffiliates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzI5MTY1_dab93ba1-4ff0-4a8a-b520-cca0a78e2a06">two</ix:nonFraction> affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis&#8217; submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#8217;s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the &#8217;522 Patent), 7,915,225, 8,119,605 and 8,722,631. By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis&#8217; etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court&#8217;s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche&#8217;s &#8217;522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties&#8217; submission.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i571792459fab4e53ad8f94cdfc8dba4a" continuedAt="i3394a154627a463883de8260be4f84db"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Amgen initiated a series of lawsuits that were consolidated by the U.S. District Court for the District of Delaware (Delaware District Court) in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing <ix:nonFraction unitRef="patent" contextRef="i1d65a5d55e5642be9bee7decb061fd66_D20141001-20141031" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzMxMDEz_16071788-3969-4b6a-b6e1-8f016a72971f">seven</ix:nonFraction> of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#8217;165 Patent); 8,859,741 (the &#8217;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to PCSK9. By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#8217;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#8217;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#8217;s infringement of Amgen&#8217;s patents is willful.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT infringe certain of Amgen&#8217;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a <ix:nonNumeric contextRef="id07a2cf432c24ff9a1f851f3d46e53b5_D20160201-20160228" name="amgn:LitigationSettlementLengthofTrial" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2MjY1_30add478-8894-4672-8c95-fdc7aee476ac">five-day</ix:nonNumeric> jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#8217;s post-trial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#8217;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#8217;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on <ix:nonFraction unitRef="patent" contextRef="i3b4cd2176c02454e86da12e52b785bfb_D20180301-20180331" decimals="INF" name="amgn:GainContingencyNumberOfChallenges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzMzNDM3_527f661e-1c97-4199-a01d-3917766dc3f4">two</ix:nonFraction> of Sanofi and Regeneron&#8217;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s conclusion that the judgment affirming the validity of Amgen&#8217;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#8217;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#8217;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#8217;s claim of willful infringement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, a jury of the Delaware District Court again unanimously upheld the validity of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. The jury also found that claims 7 and 15 of the &#8217;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse the jury verdict against them or for a new trial, and Amgen filed a motion for a permanent injunction. On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron&#8217;s request for a new trial and their request to reverse the jury verdict that the &#8217;165 Patent and the &#8217;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court and based on the subsequent hearing, on February 11, 2021 the Federal Circuit Court issued a decision affirming the Delaware District Court&#8217;s ruling. Amgen filed a petition for rehearing en banc which was denied on June 21, 2021. On November 18, 2021, Amgen filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the invalidation of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent as lacking an enabling disclosure of the invention. On January 11, 2022, the U.S. Supreme Court requested that Sanofi and Regeneron file a response to Amgen&#8217;s petition, which is due March 14, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany, Spain and Japan. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3394a154627a463883de8260be4f84db" continuedAt="i526b298e46fc4b48840ae598b7e3077f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#8217;s patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#8217;s patent. In November 2018, the EPO confirmed the validity of Amgen&#8217;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA&#8217;s decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA&#8217;s October 29, 2020 ruling.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#8217;s appeals making final the Japanese High Court&#8217;s decisions that PRALUENT infringes Amgen&#8217;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#8217;s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. The Japanese Patent Office dismissed Regeneron&#8217;s invalidity trials and Regeneron has appealed the decisions to the Japanese High Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEUPOGEN (filgrastim)/Neulasta Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Hospira Inc. et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Hospira Inc. and Pfizer Inc. (collectively, Pfizer). This lawsuit stems from Pfizer&#8217;s submission of an application for FDA licensure of a pegfilgrastim product as biosimilar to Amgen&#8217;s Neulasta. Amgen has asserted infringement of U.S. Patent No. 8,273,707 (the &#8217;707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#8217;707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the &#8217;707 Patent. In June 2020, the FDA approved Pfizer&#8217;s NYVEPRIA, a biosimilar to Amgen&#8217;s Neulasta. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2021, the Delaware District Court stayed further proceedings in the matter pending claim construction of the patent claims and, based on a subsequent hearing, determined on June 11, 2021 that the term at issue required no construction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently pending before the Delaware District Court is Pfizer&#8217;s motion for summary judgment of noninfringement, which has been fully briefed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No date has been set for argument on the motion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Trial and Appeal Board (PTAB) Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Apotex PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the PTAB of the USPTO granted Apotex&#8217;s petition to institute inter partes review (IPR) proceeding of U.S. Patent No. 8,952,138 (the &#8217;138 Patent), challenging claims of the &#8217;138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but <ix:nonFraction unitRef="claim" contextRef="i5a349ce4f68f4e62ac77c54575a7b956_I20190520" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQxMzg3_fec627e2-776e-43cf-a32a-192b6c5cda34">one</ix:nonFraction> claim of the &#8217;138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2019, the PTAB issued a decision denying Apotex&#8217;s request for rehearing on the PTAB&#8217;s finding and sua sponte amending the final decision with a finding that the <ix:nonFraction unitRef="claim" contextRef="i5a349ce4f68f4e62ac77c54575a7b956_I20190520" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQxNjYw_23553a13-f88c-42ef-9786-46c8ca96a019">one</ix:nonFraction> remaining claim in Amgen&#8217;s &#8217;138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court&#8217;s decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inc. v. Smith &amp; Nephew, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., 941 F.3d 1320 (Fed. Cir. 2019). </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the &#8217;138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the &#8217;138 Patent, for proceedings consistent with its decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex Inc. v. Smith &amp; Nephew, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requesting that such remanded cases be held pending the U.S. Supreme Court&#8217;s disposition of the petition for writ of certiorari in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Arthrex, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government&#8217;s petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i526b298e46fc4b48840ae598b7e3077f" continuedAt="if88c0da350b846a0ad7a93412ec22193"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2021, the U.S. Supreme Court decided</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> United States v. Arthrex, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 28, 2021, the U.S. Supreme Court granted the government&#8217;s pending certiorari petition and vacated and remanded the Federal Circuit Court&#8217;s judgment for further consideration under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2021, the Federal Circuit Court issued a remand to permit Amgen to request rehearing of the PTAB&#8217;s final written decision holding that all claims of the &#8217;138 Patent as unpatentable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2021, Amgen filed a request for the USPTO Director for a rehearing and review of the Final Written Decision pursuant to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On November 22, 2021, the Director denied this request. On December 6, 2021, Amgen filed the Notice of Director review with the patent office.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2021, Pfizer filed a petition to institute IPR proceeding at the USPTO of U.S. Patent No. 8,273,707 (the &#8217;707 Patent), challenging claims of the &#8217;707 Patent as unpatentable. Amgen&#8217;s preliminary response was filed on May 18, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the PTAB of the USPTO granted Pfizer&#8217;s petition to institute IPR of the &#8217;707 Patent. On August 23, 2021, the PTAB issued the schedule for the proceeding, including oral argument (if requested) on May 18, 2022. On November 17, 2021, Amgen filed its Patent Owner&#8217;s Response.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breach of Contract Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG v. Amgen Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York (the New York Southern District Court) against Novartis seeking a declaratory judgment that Novartis materially breached <ix:nonFraction unitRef="agreement" contextRef="iaf846f658f5942ce82b4f681a169e2fa_D20190401-20190430" decimals="INF" name="amgn:GainContingencyNumberOfAgreementsBreached" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQzNDQ5_f4728cdf-0045-44b7-8ec8-d288fcc2b2b6">two</ix:nonFraction> collaboration agreements Amgen and Novartis entered into in 2015 and 2017 (the 2015 Agreement and the 2017 Agreement, respectively) related to the development and commercialization of Aimovig due to Novartis&#8217; affiliate Sandoz GmbH entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig and entrant in the CGRP-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis&#8217; complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz GmbH entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. On July 16, 2019, Novartis filed an amended complaint adding a claim for breach of contract alleging Novartis is owed amounts associated with 2018 budget overruns, and Amgen responded with a counterclaim alleging additional breaches by Novartis of the collaboration agreements. On September 17, 2019 and October 8, 2019, Novartis and Amgen, respectively, each filed its motion for judgment on the pleadings. On February 3, 2020, Amgen was granted leave to file its amended counterclaims. On February 4, 2020, Amgen filed its amended answer to Novartis&#8217; first amended complaint and second amended counterclaims for affirmative relief to add a fraudulent inducement claim. On February 18, 2020, Novartis filed its answer and affirmative defenses to Amgen&#8217;s second amended counterclaims. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, the New York Southern District Court entered an order granting Novartis&#8217; motion for judgment on the pleadings that Novartis did not breach the 2017 Agreement, and denying Amgen&#8217;s motions for judgment on the pleadings seeking dismissal of Novartis&#8217; amended complaint that Novartis did not breach the 2015 Agreement or the 2017 Agreement, and Novartis timely cured any breach. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the June 9, 2020 order, which was denied on September 14, 2020. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, the parties executed agreements to settle <ix:nonFraction unitRef="claim" contextRef="i84504b4b6730469e9a42aebe34756f62_I20210602" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MjA_e5c7486f-d6c0-4420-a278-1bcae781d94e">two</ix:nonFraction> claims in the litigation, relating to the 2018 budget overrun dispute and certain counterclaims alleging breaches by Novartis of the 2015 and 2017 Agreements related to the development and commercialization of Aimovig, and to amend and restate the 2017 collaboration agreement. As part of the agreement, Amgen paid $<ix:nonFraction unitRef="usd" contextRef="i42713d0e16f04d26a1b1ce71cf3aecd4_D20210602-20210602" decimals="-6" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MjI_06a73ee5-0955-4732-816e-3659d6802b79">48</ix:nonFraction>&#160;million to Novartis to resolve the 2018 budget dispute.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the New York Southern District Court held a status conference with the parties and set the dates for Novartis&#8217; opening brief for its motion for partial summary judgment on <ix:nonFraction unitRef="claim" contextRef="i7c633c2c74b0432094a5ea889bbccf99_I20211026" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MzQ_2da86a16-ffed-4fb3-aa2c-95713502689e">two</ix:nonFraction> claims, fraudulent inducement and negligent misrepresentation.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the parties resolved all claims in the litigation.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if88c0da350b846a0ad7a93412ec22193" continuedAt="if520fbf80f2d47fd8dcd7631b7d07c52"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Class Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From February to April 2019, <ix:nonFraction unitRef="plaintiffs" contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ2MzMw_fb3ddb33-45f6-400c-bea2-6588af9d4da8">four</ix:nonFraction> plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceuticals USA, Inc. (Teva) alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. <ix:nonFraction unitRef="claim" contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ2NTY0_203942d3-009f-4397-8bb4-f93415731ef9">Two</ix:nonFraction> of those actions were brought in the Delaware District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 21, 2019) (Local 1500) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cesar Castillo, Inc. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 14, 2019) (Local 237) and the <ix:nonFraction unitRef="claim" contextRef="i1ab8018abbdc4ab1bcbc87cc2571878a_D20190430-20190430" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODQ3Mjg_54a0e7e4-8150-4a44-9316-a945613b6461">four</ix:nonFraction>th action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar and alleges that the plaintiffs have overpaid for Sensipar as a result of Amgen&#8217;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson Laboratories, Inc. (Watson) and Teva of the parties&#8217; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#8217; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the <ix:nonFraction unitRef="lawsuit" contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430" decimals="INF" name="amgn:LossContingencyNumberOfLawsuitsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ3ODQ0_956480cb-7b16-4e74-9f44-9ffc75c4b369">four</ix:nonFraction> lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the <ix:nonFraction unitRef="lawsuit" contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430" decimals="INF" name="amgn:LossContingencyNumberOfLawsuitsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ4MDQz_82ae9f09-d884-4aac-80a2-3a39497e4194">four</ix:nonFraction> lawsuits, along with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cipla Ltd. v. Amgen Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated and designated as an MDL in the Delaware District Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the <ix:nonFraction unitRef="lawsuit" contextRef="i3ac324416a7c4f1f83e593ede6d076bd_D20190731-20190731" decimals="INF" name="amgn:LossContingencyNumberOfLawsuitsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MzY_5ec911a1-bf75-437e-b8e5-1abd9741fd57">four</ix:nonFraction> class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#8217; consolidated class action complaint and the indirect purchaser end payor plaintiffs&#8217; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#8217;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Delaware District Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#8217;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#8217; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#8217;s recommendation in part and denied it in part, denying Amgen&#8217;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#8217;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#8217; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#8217;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the plaintiffs in the antitrust class action lawsuit brought on behalf of putative classes of direct or indirect purchasers of Sensipar filed their amended complaints. On March 4, 2021, a stipulation and order regarding the filing of a second amended complaint were filed to add another plaintiff: Teamsters Western Region &amp; Local 177 Health Care Fund. On March 17, 2021, a defendant, MSP Recovery Claims, Series LLC, filed its notice of voluntary dismissal. On March 30, 2021, the remaining defendants, including Amgen, filed their motions to dismiss the second amended complaint.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2021, plaintiffs filed their oppositions to defendants&#8217; (including Amgen&#8217;s) motion to dismiss, and defendants&#8217; reply was filed on May 25, 2021. A hearing on defendants&#8217; motion to dismiss was held in the Delaware District Court on July 13, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humira Biosimilar Antitrust Class Actions </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From March to May 2019, <ix:nonFraction unitRef="claim" contextRef="ibba78d537ea54a03a6bd4d13b80aea70_I20200531" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzUwNTQ4_b6c361a8-029e-4ceb-b92e-1f46b09add12">twelve</ix:nonFraction> purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie), were filed in the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court). The cases are captioned: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 18, 2019) (Local 1500); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 20, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mayor and City Council of Baltimore v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 22, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pipe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trades Services MN Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">St. Paul Electrical Workers&#8217; Health Plan v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C and 137R v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 1, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if520fbf80f2d47fd8dcd7631b7d07c52" continuedAt="i96431673a72546c3aaa975f9bd1cff41"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 9, 2019) (Law Enforcement); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 16, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sheet Metal Workers&#8217; Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 19, 2019) (Sheet Metal Workers&#8217;); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Locals 302 &amp; 612 of The International Union of Operating Engineers-Employers Construction Industry Health And Security Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 25, 2019) (Construction Industry); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Louisiana Health Service &amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 30, 2019) (Louisiana Health); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (May 10, 2019) (Cleveland Bakers) (collectively, Humira Antitrust Class Actions).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the Humira Antitrust Class Actions, the plaintiffs bring federal antitrust claims along with various state law claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully monopolized the alleged market for Humira and biosimilars of Humira, including by creating an allegedly unlawful so-called patent thicket around Humira. In the Local 1500, Sheet Metal Workers&#8217; and Construction Industry cases, the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira biosimilars, including Bioepis, Mylan, Sandoz, Fresenius Kabi USA, LLC (Fresenius), Pfizer Inc. and Momenta Pharmaceuticals, Inc., in connection with the settlement of patent litigation relating to Humira, whereby Amgen and the other defendants that have developed Humira biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA, its Humira biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira biosimilar in that market for five months, beginning in January 2023. In each of the Humira Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney&#8217;s fees on behalf of a putative class of third-party payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira in the United States. Defendants&#8217; responses to the first <ix:nonFraction unitRef="complaints" contextRef="i7e56044cea924d89ae341cd4198e2725_D20190301-20190531" decimals="INF" name="amgn:LossContingencyNumberOfComplaintsStayedByTheCourt" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU0MTE5_ed0a5c6f-a895-419e-bcaa-2f9599dc1f23">six</ix:nonFraction> complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the <ix:nonFraction unitRef="claim" contextRef="id63608bd810a4daabb58c50a1d92c7fc_I20190604" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU0MjQ4_806c16ed-2cc3-420c-a857-7aab3409f376">twelve</ix:nonFraction> purported class action cases for pre-trial purposes. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz and Fresenius. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual motions), challenging the legal sufficiency of the plaintiffs&#8217; allegations to state any claim for relief under the law. On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support of the motion to dismiss. On June 8, 2020, the Illinois Northern District Court issued an order granting the motion by the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the FTC and one on behalf of 20 states, each filed on October 13, 2020. On December 21, 2020, the defendants-appellees filed their opposition brief. Defendants-appellees amicus briefs, including one by the DoJ, were filed on December 28, 2020. On February 25, 2021, oral argument was held by the U.S. Court of Appeals for the Seventh Circuit on the appeal by plaintiffs-appellants of the lower court&#8217;s dismissal of the consolidated complaint with prejudice. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6, Income taxes, for discussion of the IRS tax dispute and the Company&#8217;s petition in the U.S. Tax Court.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i96431673a72546c3aaa975f9bd1cff41"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments &#8211; U.S. repatriation tax</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in <ix:nonFraction unitRef="installment" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="INF" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2MDI4_c01a038b-6158-48a1-bb5a-dd57809fd16e">eight</ix:nonFraction> annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. <ix:nonNumeric contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" name="amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2Mjgx_f8ad8b79-44e2-4342-9bdd-4ef864c366d9" continuedAt="i78749e4b49414de4906d572bc9bd0506" escape="true">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2021 (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><ix:continuation id="i78749e4b49414de4906d572bc9bd0506"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzItMS0xLTEtNTU1NTQ_67372e55-1e64-4e42-bcbd-787b6dc8ba47">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzMtMS0xLTEtNTU1NTQ_a0ad568b-6fdd-403b-b49f-16abaa3381f5">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzQtMS0xLTEtNTU1NTQ_ca1629c5-38a1-4375-8809-6d894c3c53f7">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzUtMS0xLTEtNTU1NTQ_7a981e6e-56b3-45ce-8c6a-848c49843a95">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzYtMS0xLTEtNTU1NTQ_ba35a7ce-551f-4baa-9b22-e41c11994fbd">4,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><div id="i2a971cfaef98424f9692041d6ed3a222_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90ZXh0cmVnaW9uOjMyZWU0MjliMzhhYTRhMzE4MzUyMDdlMWJhODY1OWUyXzEwOQ_a8968493-5464-42d8-878c-77e574249a6e" escape="true"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2021, 2020 and 2019 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at beginning<br/>of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>charged&#160;to<br/>costs and<br/>expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end<br/>of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtMi0xLTEtNTU1NTQ_7b5e5eb6-6e39-476b-a3ff-5949c5aac16e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtNC0xLTEtNTU1NTQ_60bc209c-6163-455d-9c9b-87a189bd5c1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtNi0xLTEtNTU1NTQ_d7fc4a0e-85ab-4a5c-8055-b3e5f1e6f0dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtOC0xLTEtNTU1NTQ_2ba0e377-b17a-455e-a6e8-1c6e5148db7b">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtMTAtMS0xLTU1NTU0_d1623324-d87c-4948-9789-229cca7a9897">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItMi0xLTEtNTU1NTQ_da5fbbdd-31b9-428f-b6d5-1024f5f7ee4d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItNC0xLTEtNTU1NTQ_d3f528df-f1ed-49a0-819e-75a319edf466">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItNi0xLTEtNTU1NTQ_a409fe56-ca73-4dda-9d73-73e2c8c5ffac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItOC0xLTEtNTU1NTQ_3e1f6bdf-f308-46a2-a9ad-b18d0c18d470">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItMTAtMS0xLTU1NTU0_ba136f75-b2ba-4c8f-b5b9-4e1e1cdb2c21">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtMi0xLTEtNTU1NTQ_de0a77cb-6477-4612-8301-33cb315bb055">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtNC0xLTEtNTU1NTQ_56fd499c-730d-4dfa-b1e6-2fa0bd984a39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtNi0xLTEtNTU1NTQ_f2dea520-8c1f-4172-94de-4b67737e2ced">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtOC0xLTEtNTU1NTQ_a4837839-e7d9-4b3f-bb73-a7f3ef4adb1d">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtMTAtMS0xLTU1NTU0_e7e84dd0-f92d-4af6-969b-efa11fea46c6">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.32
<SEQUENCE>2
<FILENAME>amgn-ex432_202131xq4.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i89a71eabb90647eaa9842ae0de714213_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 4.32 </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF AMGEN INC.&#8217;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF THE<br>SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of February 14, 2022, Amgen Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#58; (1) our common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;)&#59; and (2) our 2.000% Senior Notes due 2026 (the &#8220;Notes&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following description of our capital stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our restated certificate of incorporation, as amended (&#8220;certificate of incorporation&#8221;) and our amended and restated bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K (&#8220;Annual Report&#8221;). The terms &#8220;Amgen&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer solely to Amgen Inc. and not its subsidiaries.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our authorized capital stock includes 2,750,000,000 shares of Common Stock.  Each holder of our Common Stock is entitled to one vote per share on all matters to be voted upon by our stockholders. Upon any liquidation, dissolution or winding up of our business, the holders of our Common Stock are entitled to share equally in all assets available for distribution after payment of all liabilities, subject to the liquidation preference of shares of preferred stock, if any, then outstanding. Our Common Stock has no preemptive or conversion rights. All outstanding shares of common stock are fully paid and non-assessable. Our outstanding shares of common stock are quoted on the Nasdaq Global Select Market under the symbol &#8220;AMGN.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividends</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to preferences that may be applicable to any preferred stock (if any such stock be issued and outstanding), the holders of Common Stock are entitled ratably to receive dividends, if any, declared by our board of directors out of funds legally available for the payment of dividends. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-Takeover Effects of Delaware Law</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">prior to such time, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Section&#160;203, a &#8220;business combination&#8221; includes&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation involving the interested stockholder&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any transaction which results in the issuance or transfer by the corporation or by any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder, subject to limited exceptions&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation which has the effect, directly or indirectly, of increasing the proportionate share of the stock of any class or series, or securities convertible into the stock of any class or series, of the corporation or of any such subsidiary which is owned by the interested stockholder&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation or any direct or indirect majority-owned subsidiary of the corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In general, Section&#160;203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer Agent</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The transfer agent and registrar for our Common Stock is the American Stock Transfer&#160;&#38; Trust Company.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF THE NOTES</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following description of our Notes is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the indenture, dated as of May&#160;22, 2014 (the &#8220;Indenture&#8221;), between us and The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;Trustee&#8221;), which are incorporated by reference as exhibits to the Annual Report of which this Exhibit 4.32 is a part. The Notes are traded on The Nasdaq Stock Market LLC under the trading symbol of &#8220;AMGN26.&#8221; We encourage you to read the above referenced Indenture for additional information. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We issued &#8364;750,000,000 in aggregate principal amount of 2.000% Senior Notes, maturing February 25, 2026 and bearing interest at a rate of 2.000% per annum, payable annually on February&#160;25 of each year. As of February 14, 2022, &#8364;750,000,000 aggregate principal amount of the Notes was outstanding.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;We may, without notice to or the consent of the holders or beneficial owners of the Notes of any series, create and issue additional Notes and&#47;or notes having the same ranking, interest rate, maturity and other terms as the Notes of that series. Any additional debt securities having such similar terms, together with that series of Notes, could be considered part of the same series of Notes under the Indenture&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that, in the case of any notes represented by global notes, for so long as may be required by the United States Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the procedures of the common depositary, the Euroclear System (&#8220;Euroclear&#8221;) or Clearstream Banking, S.A. (&#8220;Clearstream&#8221;) (or a successor or clearing system), such additional Notes will be represented by one or more separate global notes in accordance with the terms of the Indenture and subject to applicable transfer or other restrictions. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are redeemable prior to maturity as described below under the headings &#8220;&#8212;Optional Redemption&#8221; and &#8220;&#8212;Redemption Upon Changes in Withholding Taxes.&#8221; The Notes do not have the benefit of any sinking funds. The Notes of each series are issued only in registered form without coupons attached in minimum denominations of &#8364;100,000 and any integral multiple of &#8364;1,000 in excess thereof. Each series of Notes are represented by one or more global securities deposited with, or on behalf of, a common depositary for Euroclear and Clearstream (the &#8220;global notes&#8221;).  </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Definitions </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As used herein, the following terms have the meanings set forth below. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Attributable Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means in connection with a sale and lease-back transaction the lesser of&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the fair market value of the assets subject to such transaction&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the present value (discounted at a rate per annum equal to the average interest borne by all outstanding debt securities issued under the Indenture (which may include debt securities in addition to the Notes) determined on a weighted average basis and compounded semi-annually) of the obligations of the lessee for rental payments during the term of the related lease.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any day on which commercial banks and foreign exchange markets are open for business in New York and London and which is a day on which the Trans-European Automated Real-Time Gross Settlement Express Transfer System (TARGET2) is operating. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Calculation Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an independent financial institution appointed by Amgen, which may include the paying agent, any of the managers or their respective affiliates who agree to serve in such capacity. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Capital Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Indebtedness represented by a lease obligation of a Person incurred with respect to real property or equipment acquired or leased by such Person and used in its business that is required to be recorded as a capital lease in accordance with GAAP. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consolidated Net Worth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, the Stockholders&#8217; Equity of us and our Consolidated Subsidiaries on that date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consolidated Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination and with respect to any Person, any Subsidiary of that Person whose financial data is, in accordance with GAAP, reflected in that Person&#8217;s consolidated financial statements. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Credit Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, one or more debt facilities (including, without limitation, the revolving credit agreement and the term loan credit agreement, as applicable) or commercial paper facilities, in each case, with banks or other institutional lenders providing for revolving credit loans, term loans, receivables financing (including through the sale of receivables to such lenders or to special purpose entities formed to borrow from such lenders against such receivables) or letters of credit, in each case, as amended, restated, modified, renewed, refunded, replaced (whether upon or after termination or otherwise) or refinanced (including by means of sales of debt securities to institutional investors) in whole or in part from time to time. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exempted Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the sum of the following as of the date of determination&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">our Indebtedness incurred after the first issue date of the Notes and secured by Liens not permitted by the first sentence under &#8220;&#8212;Limitation on Liens&#8221; below&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">our and our Subsidiaries&#8217; Attributable Liens in respect of sale and lease-back transactions entered into after the first issue date of the Notes pursuant to the second paragraph of &#8220;&#8212;Limitation on Sale and Lease-Back Transactions&#8221; below.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means accounting principles generally accepted in the United States set forth in the Accounting Standards Codification of the Financial Accounting Standards Board or in such other documents by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Governmental Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any foreign, federal, state, county or municipal government, or political subdivision thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any governmental or quasi-governmental agency, authority, board, bureau, commission, department, instrumentality or public body&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any court or administrative tribunal&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">with respect to any Person, any arbitration tribunal or other nongovernmental authority to whose jurisdiction that Person has consented.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any specified Person, the obligations of such Person under&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">interest rate swap agreements (whether from fixed to floating or from floating to fixed), interest rate cap agreements and interest rate collar agreements&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">other agreements or arrangements designed to manage interest rates or interest rate risk&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">other agreements or arrangements designed to protect such Person against fluctuations in currency exchange rates or commodity prices.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any Person means, without duplication, any indebtedness, whether or not contingent, in respect of borrowed money or evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements with respect thereto) or representing the balance deferred and unpaid of the purchase price of any Property (including pursuant to Capital Leases), except any such balance that constitutes an accrued expense or trade payable, if and to the extent any of the foregoing indebtedness would appear as a liability upon a balance sheet of such Person prepared on a consolidated basis in accordance with GAAP (but does not include </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">contingent liabilities which appear only in a footnote to a balance sheet), and shall also include, to the extent not otherwise included, the guaranty of items which would be included within this definition. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, collectively, all foreign, federal, state and local statutes, treaties, rules, regulations, ordinances, codes and administrative or controlling precedents of any Governmental Agency. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any lien, security interest, charge or encumbrance of any kind (including any conditional sale or other title retention agreement, any lease in the nature thereof, and any agreement to give any security interest). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Make-Whole Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the excess of (1)&#160;the net present value, on the redemption date, of the principal being redeemed or paid and the amount of interest (exclusive of interest accrued to the date of redemption) that would have been payable if such redemption had not been made, over (2)&#160;the aggregate principal amount of the Notes being redeemed or paid. Net present value shall be determined by discounting, on a semi-annual basis, such principal and interest at the Reinvestment Rate (as defined below and as determined on the third Business Day preceding the date such notice of redemption is given) from the respective dates on which such principal and interest would have been payable if such redemption had not been made. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens securing Indebtedness under Credit Facilities&#59;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on accounts receivable, merchandise inventory, equipment, and patents, trademarks, trade names and other intangibles, securing our Indebtedness&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on any of our assets, any of our Subsidiaries&#8217; assets, or the assets of any joint venture to which we or any of our Subsidiaries is a party, created solely to secure obligations incurred to finance the refurbishment, improvement or construction of such asset, which obligations are incurred no later than 24 months after completion of such refurbishment, improvement or construction, and all renewals, extensions, refinancings, replacements or refundings of such obligations&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(a) Liens given to secure the payment of the purchase price incurred in connection with the acquisition (including acquisition through merger or consolidation) of Property (including shares of stock), including Capital Lease transactions in connection with any such acquisition, and (b)&#160;Liens existing on Property at the time of acquisition thereof or at the time of acquisition by us or one of our Subsidiaries of any Person then owning such Property whether or not such existing Liens were given to secure the payment of the purchase price of the Property to which they attach&#59; provided that, with respect to clause (a), the Liens shall be given within 24 months after such acquisition and shall attach solely to the Property acquired or purchased and any improvements then or thereafter placed thereon&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens upon specific items of inventory or other goods and proceeds of any Person securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(7)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens securing reimbursement obligations with respect to letters of credit that encumber documents and other Property relating to such letters of credit and the products and proceeds thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on key-man life insurance policies granted to secure our Indebtedness against the cash surrender value thereof&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(9)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens encumbering customary initial deposits and margin deposits and other Liens in the ordinary course of business, in each case securing Hedging Obligations and forward contract, option, futures contracts, futures options or similar agreements or arrangements designed to protect us or any of our Subsidiaries from fluctuations in interest rates, currencies or the price of commodities&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by us or any of our Subsidiaries in the ordinary course of business&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(11)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">pre-existing Liens on assets acquired by us or any of our Subsidiaries after the first issue date of the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(12)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens in our favor or the favor of any of our Subsidiaries&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(13)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">inchoate Liens incident to construction or maintenance of real property, or Liens incident to construction or maintenance of real property, now or hereafter filed of record for sums not yet delinquent or being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made therefor&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">statutory Liens arising in the ordinary course of business with respect to obligations which are not delinquent or are being contested in good faith, if reserves or other appropriate provisions, if any, as shall be required by GAAP shall have been made therefor&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of pledges or deposits to secure obligations under workers&#8217; compensation laws or similar legislation, including Liens of judgments thereunder which are not currently dischargeable&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of pledges or deposits of Property to secure performance in connection with operating leases made in the ordinary course of business to which we or any of our Subsidiaries is a party as lessee, provided the aggregate value of all such pledges and deposits in connection with any such lease does not at any time exceed 16&#160;2&#8260;3% of the annual fixed rentals payable under such lease&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(17)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of deposits of Property to secure our statutory obligations or statutory obligations of any of our Subsidiaries in the ordinary course of its business&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens consisting of deposits of Property to secure (or in lieu of) surety, appeal or customs bonds in proceedings to which we or any of our Subsidiaries is a party in the ordinary course of its business, but not in excess of $75,000,000&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">purchase money Liens or purchase money security interests upon or in any Property acquired or held by us or any of our Subsidiaries in the ordinary course of business to secure the purchase price of such Property or to secure indebtedness incurred solely for the purpose of financing the acquisition of such Property&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(20)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on an asset created in connection with the acquisition, construction or development of additions, extensions or improvements to such asset which shall be financed by obligations described in Sections 142, 144(a) or 144(c) of the Code, or by obligations entitled to substantially similar tax benefits under other legislation or regulations in effect from time to time&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(21)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liens on Property subject to escrow or similar arrangements established in connection with litigation settlements.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any property or asset, whether real, personal or mixed, or tangible or intangible. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reference Bund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Federal Government Bond of Bundesrepublik Deutschland due&#160;February 15, 2026, with ISIN 0001102390. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reference Dealers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means each of the four banks selected by a Calculation Agent which are primary European government security dealers, and their respective successors, or market makers in pricing corporate bond issues. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reinvestment Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means 0.300% plus the average of the four quotations given by the Reference Dealers of the mid-market annual yield to maturity of the Reference Bund at 11&#58; 00 a.m. (Central European time (&#8220;CET&#8221;)) on the fourth Business Day preceding such redemption date and if the Reference Bund is no longer outstanding, a Similar Security will be chosen by the Calculation Agent at 11&#58; 00 a.m. (CET) on the third Business Day in London preceding such redemption date, quoted in writing by the Calculation Agent to us. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Similar Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a reference bond or reference bonds issued by the German Federal Government having an actual or interpolated maturity comparable with the remaining term of the Notes that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stockholders&#8217; Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, as of any date of determination, stockholders&#8217; equity as of that date determined in accordance with GAAP&#59; provided that there shall be excluded from Stockholders&#8217; Equity any amount attributable to capital stock that is, directly or indirectly, required to be redeemed or repurchased by the issuer thereof at a specified date or upon the occurrence of specified events or at the election of the holder thereof. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paying Agent and Registrar </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Bank of New York Mellon, London Branch, is the principal paying agent for the Notes (the &#8220;principal paying agent&#8221;). The Bank of New York Mellon Trust Company, N.A., is the security registrar for the Notes. Upon notice to the Trustee, we may change any paying agent or security registrar, and we or any of our subsidiaries may act as paying agent or registrar. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes accrue interest at a rate of 2.000% per annum. The Notes accrue interest on their stated principal amounts from the most recent interest payment date on which interest has been paid or duly provided for. Accrued and unpaid interest on the Notes are payable annually in arrears on February&#160;25 of each year. In each case, interest is paid to the holder in whose name a note is registered at the close of business on the day that is one Business Day prior to the relevant interest payment date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on the Notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the Notes, to but excluding the next scheduled interest payment date. This payment convention is referred to as Actual&#47;Actual (ICMA) as defined in the rulebook of the International Capital Market Association. If any date on which interest, principal or premium is payable on the Notes is not a Business Day, then payment of such amounts payable on such date will be made on the next succeeding day that is a Business Day (and, except as provided under &#8220;&#8212;Payment of Additional Amounts,&#8221; without any interest or other payment in respect of any such delay) with the same force and effect as if made on such interest payment date or maturity date, as the case may be. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any amounts payable on any Notes that are not punctually paid on any payment date will cease to be payable to the person in whose name such Notes are registered on the relevant record date, and such defaulted payment will instead be payable to the person in whose name such Notes are registered on the special record date or other specified date determined in accordance with the Indenture. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ranking </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are senior unsecured obligations of Amgen. The Notes rank&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">equal in right of payment to all of our other existing and future senior unsecured indebtedness&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">senior in right of payment to all of our existing and future subordinated indebtedness&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">effectively subordinated in right of payment to all of our subsidiaries&#8217; obligations (including secured and unsecured obligations) and subordinated in right of payment to our secured obligations, to the extent of the assets securing such obligations.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes and the Indenture do not limit our ability to incur additional indebtedness. We may incur substantial additional amounts of indebtedness in the future. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Optional Redemption </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes may be redeemed prior to maturity at our option, at any time in whole or from time to time in part. If the Notes are redeemed before November&#160;25, 2025 (three months prior to the maturity date of the Notes), the redemption price will equal the sum of (1)&#160;100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date, and (2)&#160;the Make-Whole Amount, if any. If the Notes are redeemed on or after November&#160;25, 2025 (three months prior to the maturity date of the Notes), the redemption price will equal 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but not including, the redemption date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we give notice as provided in the Indenture and funds for the redemption of any Notes called for redemption sufficient to pay the redemption price have been deposited with the principal paying agent on or before 10&#58;00 a.m., London time, on the redemption date, such Notes will cease to bear interest on the date fixed for redemption. Thereafter, the only right of the holders of such Notes will be to receive payment of the redemption price. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon surrender of a note that is redeemed in part, we shall execute and the Trustee shall authenticate for the holder a new note of the same series and the same maturity equal in principal amount to the unredeemed portion of the note surrendered. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are redeemable prior to maturity as described below under the headings &#8220;&#8212;Optional Redemption&#8221; and &#8220;&#8212;Redemption Upon Changes in Withholding Taxes.&#8221; The Notes do not have the benefit of any sinking funds. The Notes of each series are issued only in registered form without coupons attached in minimum denominations of &#8364;100,000 and any integral multiple of &#8364;1,000 in excess thereof. Each series of Notes are represented by one or more global securities deposited with, or on behalf of, a common depositary for Euroclear and Clearstream (the &#8220;global notes&#8221;). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on the global notes are made through the principal paying agent (as defined herein under the heading &#8220;&#8212;Paying Agent and Registrar&#8221;). Payments on the Notes are made at the specified office or agency of the principal paying agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that all such payments with respect to Notes represented by one or more global notes registered in the name of or held by a nominee of Euroclear or Clearstream, as applicable, will be by wire transfer of immediately available funds to the account specified by the holder or holders thereof. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, at our option, if certificated notes are issued, we may make payments by check mailed to the holder&#8217;s registered address or by wire transfer to the account shown on the register for the certificated notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If certificated notes are issued, they will be issued only in minimum denominations of &#8364;100,000 principal amount and integral multiples of &#8364;1,000 in excess thereof upon receipt by the applicable registrar of instructions relating thereto and any certificates and other documentation required under the Indenture. It is expected that such instructions will be based upon directions received by Euroclear or Clearstream, as applicable, from the participant which owns the relevant book-entry interests. Certificated notes issued in exchange for book-entry interests will, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">except as provided in the Indenture, be subject to, and will have a legend with respect to the restrictions on transfer summarized below. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the restrictions on transfer referred to above, Notes issued as certificated notes may be transferred or exchanged, in whole or in part, in minimum denominations of &#8364;100,000 principal amount and integral multiples of &#8364;1,000 in excess thereof to persons who take delivery thereof in the form of certificated notes. In connection with any such transfer or exchange, the Indenture requires the transferring or exchanging holder to, among other things, furnish appropriate endorsements and transfer documents, to furnish information regarding the account of the transferee at Euroclear or Clearstream, where appropriate, to furnish certain certificates and opinions, and to pay any tax or other governmental charge in connection with such transfer or exchange. Any such transfer or exchange will otherwise be made without charge to the holder. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, we are not required to register the transfer or exchange of any Notes&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for a period of 15 days prior to any date fixed for the redemption of the Notes&#59; </font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">for a period of 15 days immediately prior to the date fixed for selection of Notes to be redeemed in part&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">for a period of 15 days prior to the record date with respect to any interest payment date&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">which the holder has tendered (and not withdrawn) for repurchase in connection with a change of control offer.</font></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption Upon Changes in Withholding Taxes </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If (a)&#160;as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated thereunder) of the United States (or any political subdivision or taxing authority thereof or therein having power to tax) (a &#8220;Relevant Taxing Jurisdiction&#8221;), or any change in, or amendment to, the official position regarding the application or interpretation of such laws, regulations or rulings (including by virtue of a holding, judgment or order by a court of competent jurisdiction or a change in published administrative practice), which change or amendment is announced on or after the date of the applicable prospectus supplement, we become or will become obligated to pay additional amounts as described herein under the heading &#8220;&#8212;Payment of Additional Amounts&#8221; or (b)&#160;any act is taken by a Relevant Taxing Jurisdiction on or after the date of the applicable prospectus supplement, whether or not such act is taken with respect to us or any affiliate, that results in a substantial probability that we will or may be required to pay such additional amounts, then we may, at our option, redeem the Notes of any affected series, as a whole but not in part, upon not less than 15 days&#8217; nor more than 60 days&#8217; published notice in accordance with the applicable notice requirement, at 100% of their principal amount, together with interest accrued thereon to the date fixed for redemption&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that we determine, in our business judgment, that the obligation to pay such additional amounts cannot be avoided by the use of reasonable measures available to us (which does not include substitution of the obligor under the Notes). No redemption pursuant to (a)&#160;or (b)&#160;above may be made unless we have received an opinion of independent counsel to the effect that as a result of such change or amendment we will, or that an act taken by a Relevant Taxing Jurisdiction has resulted in a substantial probability that we will, or may, be required to pay the additional amounts described herein under the heading &#8220;&#8212;Payment of Additional Amounts,&#8221; and we shall have delivered to the Trustee a certificate, signed by a duly authorized officer, stating that based on such opinion we are entitled to redeem the Notes pursuant to their terms. </font></div><div style="margin-top:18pt;text-align:justify"><font><br></font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notice of Redemption </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will publish a notice of any redemption of any affected series of Notes described above in accordance with the applicable notice provisions. If fewer than all of the Notes are to be redeemed at any time, the principal paying agent will select the Notes to be redeemed in accordance with the rules of the principal securities exchange, if any, on which the Notes are listed at such time or, if the not Notes are not listed on a securities exchange, in accordance with the rules of Euroclear or Clearstream, or absent any such rules, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, by lot&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no such partial redemption shall reduce the portion of the principal amount of a note not redeemed to less than &#8364;100,000. The principal paying agent shall not be liable for any selections made by it in accordance with this paragraph. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will give notice of any optional redemption to the registered holders of Notes at least 15 but not more than 60 days before a redemption date. The notice shall identify the Notes to be redeemed and shall state&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the redemption date&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the redemption price&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the name and address of the paying agent&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">if any Notes are being redeemed in part, the portion of the principal amount of such notes to be redeemed and that, after the redemption date and upon surrender of such Notes, a new note or notes in principal amount equal to the unredeemed portion of the original note shall be issued in the name of the holder of the Notes thereof upon cancellation of the original note&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">that the notes called for redemption must be surrendered to the paying agent to collect the redemption price&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">that interest on the Notes called for redemption ceases to accrue on and after the redemption date unless we default in the deposit of the redemption price&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the CUSIP and&#47;or ISIN number of the Notes.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At our request, the Trustee shall give the notice of redemption in our name and at our expense. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment of Additional Amounts </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All payments of principal and interest on the Notes will be made free and clear of and without withholding or deduction for or on account of any present or future tax, assessment or other governmental charge (collectively, &#8220;Taxes&#8221;) imposed by any Relevant Taxing Jurisdiction, unless the withholding of such Taxes is required by law or the official interpretation or administration thereof. We will, subject to the exceptions and limitations set forth below, pay such additional amounts as are necessary in order that the net payment of the principal of and interest on the applicable series of Notes to a holder who is not a U.S. person for U.S. federal income tax purposes, after deduction for any present or future Taxes of any Relevant Taxing Jurisdiction, imposed by withholding with respect to the payment, will not be less than the amount provided in such Notes to be then due and payable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#59; provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the foregoing obligation to pay additional amounts shall not apply&#58; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of the holder or beneficial owner, or a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) &#160;&#160;&#160;&#160;being or having been present or engaged in a trade or business in the United States or having or having had a permanent establishment in the United States&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) &#160;&#160;&#160;&#160;having a current or former relationship with the United States, including a relationship as a citizen or resident thereof&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;being or having been a foreign or domestic personal holding company, a passive foreign investment company or a controlled foreign corporation with respect to the United States or a corporation that has accumulated earnings to avoid U.S. federal income tax&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) &#160;&#160;&#160;&#160;being or having been a &#8220;10-percent shareholder&#8221; of the obligor under the Notes within the meaning of section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or any successor provision&#59; or </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) &#160;&#160;&#160;&#160;being or having been a bank receiving interest described in section 881(c)(3)(A) of the Code or any successor provision&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) &#160;&#160;&#160;&#160;to any holder that is not the sole beneficial owner of the note, or a portion thereof, or that is a fiduciary or partnership, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">owner or member of the partnership would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of the failure to (a)&#160;comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with a Relevant Taxing Jurisdiction of the holder or beneficial owner of such note, if compliance is required by statute or by regulation of the Relevant Taxing Jurisdiction as a precondition to relief or exemption from such Taxes (including the submission of an applicable U.S. Internal Revenue Service (&#8220;IRS&#8221;) Form W-8 (with any required attachments)) or (b)&#160;comply with any informational gathering and reporting requirements or to take any similar action (including entering into any agreement with the IRS), in each case, that are required to obtain the maximum available exemption from withholding by a Relevant Taxing Jurisdiction that is available to payments received by or on behalf of the holder&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) &#160;&#160;&#160;&#160;to any Taxes that are imposed otherwise than by withholding from the payment&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later&#59; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6) &#160;&#160;&#160;&#160;to any estate, inheritance, gift, sales, excise, transfer, wealth or personal property tax or a similar tax, assessment or governmental charge&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7) &#160;&#160;&#160;&#160;to any Taxes required to be withheld by any paying agent from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8) &#160;&#160;&#160;&#160;to any Taxes that are imposed or levied by reason of the presentation (where presentation is required in order to receive payment) of such notes for payment on a date more than 30 days after the date on which such payment became due and payable, except to the extent that the holder or beneficial owner thereof would have been entitled to additional amounts had the notes been presented for payment on any date during such 30 day period&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9) &#160;&#160;&#160;&#160;to any Taxes that are imposed or withheld pursuant to Sections 1471 through 1474 of the Code, as of the issue date (or any amended or successor version of such sections), any U.S. Treasury Regulations promulgated thereunder, any official interpretations thereof, any similar law or regulation adopted pursuant to an intergovernmental agreement between a non-U.S. jurisdiction and the United States with respect to the foregoing or any agreements entered into pursuant to Section&#160;1471(b)(1) of the Code&#59; or </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10) &#160;&#160;&#160;&#160;in the case of any combination of any items (1)&#160;through (9). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notes are subject in all cases to any tax, fiscal or other law or regulation or administrative or judicial interpretation applicable thereto. Except as specifically provided under this heading &#8220;&#8212;Payment of Additional Amounts,&#8221; we are not required to make any payment with respect to any tax, assessment or governmental charge imposed by any government or a political subdivision or taxing authority thereof or therein. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control Offer </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a change of control triggering event occurs, unless we have exercised our option to redeem the notes as described above, we will be required to make an offer (the &#8220;change of control offer&#8221;) to each holder of the notes to repurchase all or any part (equal to &#8364;100,000 or integral multiples of &#8364;1,000 in excess thereof) of that holder&#8217;s notes on the terms set forth in such notes. In the change of control offer, we will be required to offer payment in cash equal to 101&#160;% of the aggregate principal amount of notes repurchased, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase (the &#8220;change of control payment&#8221;). Within 30 days following any change of control triggering event, a notice will be provided to holders of the notes describing the transaction that constitutes the change of control triggering event and offering to repurchase the notes on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is provided (the &#8220;change of control payment date&#8221;)&#59; provided, however, that in no event will the change of control payment date occur prior to the date 90 days following the first issue date of the notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On the change of control payment date, we will, to the extent lawful&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">accept for payment all notes or portions of notes properly tendered pursuant to the change of control offer&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">by 10&#58;00 a.m., London time, deposit with the principal paying agent an amount equal to the change of control payment in respect of all notes or portions of notes properly tendered&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">deliver or cause to be delivered to the Trustee the notes properly accepted together with an officer&#8217;s certificate stating the aggregate principal amount of notes or portions of notes being repurchased.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not repurchase any notes if there has occurred and is continuing on the change of control payment date an event of default under the Indenture, other than a default in the payment of the change of control payment upon a change of control triggering event. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will comply with the requirements of Rule 14e-1 under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes as a result of a change of control triggering event. To the extent that the provisions of any such securities laws or regulations conflict with the change of control offer provisions of the notes, we will comply with those securities laws and regulations and will not be deemed to have breached our obligations under the change of control offer provisions of the notes by virtue of any such conflict. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of the change of control offer provisions of the notes, the following terms will be applicable&#58; </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Beneficial owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be determined in accordance with Rules 13d-3 and 13d-5 under the Exchange Act or any successor provisions, except that a person will be deemed to have beneficial ownership of all shares that person has the right to acquire irrespective of whether that right is exercisable immediately or only after the passage of time. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change of control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following&#58; (1)&#160;the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any person or group (other than our company or one of our subsidiaries) becomes the beneficial owner, directly or indirectly, of more than 50% of our voting stock or other voting stock into which our voting stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares&#59; provided, however, that a person shall not be deemed beneficial owner of, or to own beneficially, (A)&#160;any securities tendered pursuant to a tender or exchange offer made by or on behalf of such person or any of such person&#8217;s affiliates until such tendered securities are accepted for purchase or exchange thereunder, or (B)&#160;any securities if such beneficial ownership (i)&#160;arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii)&#160;is not also then reportable on Schedule 13D (or any successor schedule) under the Exchange Act&#59; (2)&#160;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of our assets and the assets of our subsidiaries, taken as a whole, to one or more persons or groups (other than our company or one of our subsidiaries), provided that none of the circumstances in this clause (2)&#160;will be a change of control if the persons that beneficially own our voting stock immediately prior to the transaction own, directly or indirectly, shares with a majority of the total voting power of all outstanding voting securities of the surviving or transferee person that are entitled to vote generally in the election of that person&#8217;s board of directors, managers or trustees immediately after the transaction&#59; (3)&#160;we consolidate with, or merge with or into any person, or any person consolidates with, or merges with or into, us, in any such event pursuant to a transaction in which any of our </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">outstanding voting stock or the voting stock of such other person is converted into or exchanged for cash, securities or other property, other than such transaction where the shares of our voting stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the voting stock of the surviving person or any direct or indirect parent company of the surviving person immediately after giving effect to such transaction&#59; or (4)&#160;the adoption of a plan relating to our liquidation or dissolution. Notwithstanding the foregoing, a transaction will not be deemed to involve a change of control under clause (1)&#160;above if (i)&#160;we become a direct or indirect wholly-owned subsidiary of a holding company and (ii)&#160;(A)&#160;the direct or indirect holders of the voting stock of such holding company immediately following that transaction are substantially the same as the holders of our voting stock immediately prior to that transaction or (B)&#160;immediately following that transaction no person (other than a holding company satisfying the requirements of this sentence) is the beneficial owner, directly or indirectly, of more than 50% of the voting stock of such holding company. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change of control triggering event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of both a change of control and a rating event. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Fitch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Fitch, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning given by Section&#160;13(d) and 14(d) of the Exchange Act or any successor provisions and includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the Exchange Act or any successor provision. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Investment grade rating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a rating equal to or higher than Baa3 (or the equivalent) by Moody&#8217;s, BBB&#8212;(or the equivalent) by S&#38;P and BBB&#8212;(or the equivalent) by Fitch, and the equivalent investment grade credit rating from any additional rating agency or rating agencies selected by us. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Moody&#8217;s Investors Service, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning given by Section&#160;13(d) and 14(d) of the Exchange Act or any successor provisions. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rating agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (1)&#160;each of Fitch, Moody&#8217;s and S&#38;P&#59; and (2)&#160;if any of Fitch, Moody&#8217;s or S&#38;P ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Section&#160;3(a)(62) of the Exchange Act selected by us (as certified by a resolution of our Board of Directors) as a replacement agency for Fitch, Moody&#8217;s or S&#38;P, or all of them, as the case may be. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rating event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the rating on the applicable series of notes is lowered by at least two of the three rating agencies and the notes are rated below an investment grade rating by at least two of the three rating agencies on any day during the period commencing 60 days prior to the first public notice of the occurrence of a change of control or our intention to effect a change of control and ending 60 days following consummation of such change of control (which period will be extended so long as the rating of the applicable series of notes is under publicly announced consideration for a possible downgrade by any of the rating agencies). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Standard&#160;&#38; Poor&#8217;s Rating Services, a division of The McGraw-Hill Companies, Inc., and its successors. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; as applied to stock of any person, means shares, interests, participations or other equivalents in the equity interest (however designated) in such person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence of a contingency. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Covenants </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Limitation on Liens </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, nor will we permit any of our Subsidiaries to, create or incur any Lien on any of our or their respective Properties, whether now owned or hereafter acquired, or upon any income or profits therefrom, in order to secure any of our Indebtedness, without effectively providing that each series of notes shall be equally and ratably secured until such time as such Indebtedness is no longer secured by such Lien, except&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Liens existing as of the first issue date of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) Liens granted after the first issue date of the notes on any of our or our Subsidiaries&#8217; Properties securing our Indebtedness created in favor of the holders of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) Liens securing our Indebtedness which are incurred to extend, renew or refinance Indebtedness which is secured by Liens permitted to be incurred under the Indenture&#59; provided that those Liens do not extend to or cover any of our or our Subsidiaries&#8217; Property other than the Property securing the Indebtedness being refinanced and that the principal amount of such Indebtedness does not exceed the principal amount of the Indebtedness being refinanced&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) Liens created in substitution of or as replacements for any Liens permitted by the clauses directly above, provided that, based on a good faith determination of one of our officers, the Property encumbered under any such substitute or replacement Lien is substantially similar in nature to the Property encumbered by the otherwise permitted Lien which is being replaced&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5) Permitted Liens. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, we and any of our Subsidiaries may, without securing any series of notes, create or incur Liens which would otherwise be subject to the restrictions set forth in the preceding paragraph, if after giving effect thereto, Exempted Debt does not exceed the greater of (a)&#160;35% of Consolidated Net Worth calculated as of the date of the creation or incurrence of the Lien or (b)&#160;35% of Consolidated Net Worth calculated as of the first issue date of the notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Limitation on Sale and Lease-Back Transactions </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, nor will we permit any of our Subsidiaries to, enter into any sale and lease-back transaction for the sale and leasing back of any Property, whether now owned or hereafter acquired, of ours or any of our Subsidiaries, unless&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) such transaction was entered into prior to the first issue date of the notes&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) such transaction was for the sale and leasing back to us of any Property by one of our Subsidiaries&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) such transaction involves a lease for less than three years&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) we would be entitled to incur Indebtedness secured by a mortgage on the property to be leased in an amount equal to the Attributable Liens with respect to such sale and lease-back transaction without equally and ratably securing the notes pursuant to the first paragraph of &#8220;&#8212;Limitation on Liens&#8221; above&#59; or </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5) we apply an amount equal to the fair value of the Property sold to the purchase of Property or to the retirement of our or any of our Subsidiaries&#8217; long-term Indebtedness within 120 days of the effective date of any such sale and lease-back transaction. In lieu of applying such amount to such retirement, we may, or may cause any of our Subsidiaries to, deliver debt securities to the Trustee therefor for cancellation, such debt securities to be credited at the cost thereof to us. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, we and any of our Subsidiaries may enter into any sale lease-back transaction which would otherwise be subject to the foregoing restrictions if after giving effect thereto and at the time of determination, Exempted Debt does not exceed the greater of (a)&#160;35% of Consolidated Net Worth calculated as of the closing date of the sale-leaseback transaction or (b)&#160;35% of Consolidated Net Worth calculated as of the first issue date of the notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Events of Default </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event of default means, with respect to each series of notes, any of the following&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">default in the payment of any interest on the notes of that series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the Trustee or with the principal paying agent prior to the expiration of the 30-day period)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">default in the payment of principal of the notes of that series at their maturity&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">default in the performance or breach of any other covenant or warranty by us in the Indenture (other than defaults pursuant to the previous two bullet points above or pursuant to a covenant or warranty that has been included in the Indenture solely for the benefit of a series of debt securities other than that series of notes), which default continues uncured for a period of 90 days after we receive written notice from the Trustee or we and the Trustee receive written notice from the holders of not less than a majority in principal amount of the outstanding Notes of the affected series as provided in the Indenture&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of our company.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No event of default with respect to the Notes (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default may constitute an event of default under our bank credit agreements in existence from time to time. In addition, the occurrence of certain events of default or an acceleration under the Indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will provide the Trustee written notice of any default or event of default within 30 days of becoming aware of the occurrence of such default or event of default, which notice will describe in reasonable detail the status of such default or event of default and what action we are taking or propose to take in respect thereof. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an event of default with respect to a series of Notes occurs and is continuing (other than an event of default regarding certain events of bankruptcy, insolvency or reorganization of our company), then the Trustee or the holders of not less than a majority in principal amount of the outstanding Notes of that series may, by a notice in writing to us (and to the Trustee if given by the holders), declare to be due and payable immediately the principal of, and accrued and unpaid interest, if any, on all Notes of that series. In the case of an event of default resulting from certain events of bankruptcy, insolvency or reorganization, the principal of and accrued and unpaid interest, if any, on all outstanding debt securities issued under the Indenture will become and be immediately due and payable without any declaration or other act on the part of the Trustee or any holder of outstanding debt securities, including the Notes. At any time after a declaration of acceleration with respect to a series of Notes has been made, and before a judgment or decree for payment of the money due has been obtained by the Trustee, the holders of a majority in principal amount of the outstanding Notes of that series may, by written notice to us and the Trustee, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal and interest, if any, with respect to the Notes of that series, have been cured or waived as provided in the Indenture. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture provides that the Trustee will be under no obligation to exercise any of its rights or powers under the Indenture at the request of any holder of notes, unless the Trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in exercising such right or power. Subject to certain rights of the Trustee, the holders of a majority in principal amount of the outstanding Notes of the affected series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the Notes of that series. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No holder of any Note of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the Indenture, or for the appointment of a receiver or Trustee, or for any remedy under the Indenture unless, among other things&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">that holder has previously given to the Trustee written notice of a continuing event of default with respect to the Notes of that series&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the holders of at least a majority in principal amount of the outstanding Notes of that series have made written request, and offered reasonable indemnity or security, to the Trustee to institute the proceeding as Trustee, and the Trustee has not received from the holders of a majority in principal amount of the outstanding Notes of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days.</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any other provision in the Indenture, the holder of any Note will have an absolute and unconditional right to receive payment of the principal of, premium and any interest on that Note on or after the due dates expressed in that Note and to institute suit for the enforcement of any such payment. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If any securities are outstanding under the Indenture, the Indenture requires us, within 120 days after the end of each fiscal year, to furnish to the Trustee a statement as to our compliance with the indenture. If a default or event of default occurs and is continuing with respect to notes of any series and if it is known to a responsible officer of the Trustee, the Trustee shall deliver to each holder of the Notes of that series notice of a default or event of default within 90 days after it occurs. The Indenture provides that the Trustee may withhold notice to the holders of the Notes of any default or event of default (except in the case of a default or event of default in payment of principal of or interest on any Note of that series) with respect to Notes of that series if it in good faith determines that withholding notice is in the interest of the holders of those Notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Modification and Waiver </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We and the Trustee may modify and amend the Indenture or Notes of any series without the consent of any holder of Notes&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to cure any ambiguity, defect or inconsistency&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to comply with the covenant described below under the heading &#8220;&#8212;Consolidation, Merger and Sale of Assets&#59;&#8221;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to provide for uncertificated notes in addition to or in place of certificated notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to add guarantees with respect to Notes of any series or secure notes of any series&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to surrender any of our rights or powers under the Indenture&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to add covenants or events of default for the benefit of the holders of Notes of any series&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to comply with the applicable procedures of the applicable depositary&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to make any change that would not adversely affect the rights of any holder of Notes in any material respect&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to provide for the issuance of and establish the form and terms and conditions of additional Notes of any series as permitted by the Indenture&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to effect the appointment of a successor trustee with respect to the Notes and to add to or change any of the provisions of the Indenture to provide for or facilitate administration by more than one trustee&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">to comply with requirements of the U.S. Securities and Exchange Commission in order to effect or maintain the qualification of the Indenture under the U.S. Trust Indenture Act of 1939.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may also modify and amend the Indenture with the consent of the holders of at least a majority in principal amount of the outstanding Notes of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected Note then outstanding if that amendment will&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">reduce the amount of Notes whose holders must consent to an amendment, supplement or waiver&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">reduce the rate of or extend the time for payment of interest (including any additional amounts) on the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">reduce the principal of or premium on or change the fixed maturity of the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">waive a default in the payment of the principal of, premium or interest on the notes (except a rescission of acceleration of the notes by the holders of at least a majority in aggregate principal amount of the then outstanding Notes of that series and a waiver of the payment default that resulted from such acceleration)&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">make the principal of or interest on the Notes payable in currency other than that stated in the Notes&#59;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">make any change to certain provisions of the Indenture relating to, among other things, the right of holders of the Notes to receive payment of the principal of, premium and interest on the Notes and to institute suit for the enforcement of any such payment and to waivers or amendments&#59; or</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">waive a redemption payment with respect to the Notes.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding Notes of the affected series may, on behalf of the holders of all the Notes of that series, waive our compliance with provisions of the Indenture. The holders of a majority in principal amount of the outstanding Notes of the affected series may, on behalf of the holders of all the Notes of such series, waive any past default under the Indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any Note of that series&#59; provided, however, that the holders of a majority in principal amount of the outstanding Notes of the affected series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No amendment to cure any ambiguity, defect or inconsistency in the Indenture made solely to conform the Indenture to the description of notes contained in the applicable prospectus supplement will be deemed to adversely affect the interests of the holders of the Notes. </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidation, Merger and Sale of Assets </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to, any person, which we refer to as a &#8220;successor person,&#8221; unless&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">we are the surviving corporation or the successor person (if other than Amgen) is organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes, pursuant to a supplemental Indenture, our obligations on the notes and under the Indenture&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing under the Indenture.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, any of our Subsidiaries may consolidate with, merge into or transfer all or part of its properties and assets to us. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defeasance and Covenant Defeasance </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Legal Defeasance </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture provides that we may be discharged from any and all obligations in respect of the Notes (subject to certain exceptions). We will be so discharged upon the deposit with the Trustee, in trust, of money, U.S. government obligations and&#47;or foreign government obligations that, through the payment of interest and principal in accordance with their terms, will provide money, U.S. government obligations or foreign government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on the Notes on the stated maturity of those payments in accordance with the terms of the Indenture and the Notes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This discharge may occur only if, among other things, we have delivered to the Trustee an opinion of counsel stating that we have received from, or there has been published by, the IRS a ruling or, since the date of execution of the Indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Defeasance of Certain Covenants </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture provides that upon compliance with certain conditions&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">we may omit to comply with the covenant described under the heading &#8220;&#8212;Consolidation, Merger and Sale of Assets&#8221; and certain other covenants set forth in the Indenture, as well as any additional covenants set forth in the applicable prospectus supplement&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">any omission to comply with those covenants will not constitute a default or an event of default with respect to the Notes, which we refer to as a &#8220;covenant defeasance.&#8221;</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The conditions include&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">depositing with the Trustee money, U.S. government obligations and&#47;or foreign government obligations that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on the notes on the stated maturity of those payments in accordance with the terms of the Indenture and the Notes&#59; and</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">delivering to the Trustee an opinion of counsel to the effect that the holders of the Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred.</font></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Covenant Defeasance and Events of Default </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event we exercise our option to effect covenant defeasance with respect to any series of the Notes and the Notes of that series are declared due and payable because of the occurrence of any event of default, the amount of money, U.S. government obligations and&#47;or foreign government obligations on deposit with the Trustee will be sufficient to pay amounts due on the Notes of that series at the time of their stated maturity but may not be sufficient to pay amounts due on the notes of that series at the time of the acceleration resulting from the event of default. In such a case, we would remain liable for those payments. </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Concerning the Trustee</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Bank of New York Mellon Trust Company, N.A. is Trustee under the Indenture.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governing Law </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture and the Notes, including any claim or controversy arising out of or relating to the Indenture or the Notes, are governed by the laws of the State of New York. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>amgn-ex104_20211231xq4.htm
<DESCRIPTION>FORM OF GRANT OF STOCK OPTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i626d7275cd5f4565b6a6025323f362a7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 10.4</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#93;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Price&#58; &#160;&#160;&#160;&#160;$________</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Shares</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covered by Option&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration Date&#58;&#160;&#160;&#160;&#160;The &#91;______ (__</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#93; anniversary of the Grant Date</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) carefully.&#160; If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.&#160; For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following the day on which this Award Notice is made available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.1pt;font-weight:400;line-height:100%;position:relative;top:-4.89pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">grant.  This step is necessary to process transactions related to your equity grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">If you do not open a brokerage account by this deadline, your grant will be cancelled.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;</font></div></div></div><div id="i626d7275cd5f4565b6a6025323f362a7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GRANT OF STOCK OPTION AGREEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SPECIFIC TERMS OF YOUR STOCK OPTION ARE FOUND IN THE PAGES RELATING TO THE GRANT OF STOCK OPTIONS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS GRANT OF STOCK OPTIONS.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On the Grant Date, specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has granted to you, the grantee named in the Award Notice, under the plan specified in the Award Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to purchase the number of shares of the $0.0001 par value common stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) specified in the Award Notice, pursuant to the terms set forth in this Stock Option Agreement, any additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the Award Notice (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Option is not intended to qualify and will not be treated as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986, as amended (together with the regulations and other official guidance promulgated thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The terms and conditions of your Option are as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;I.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms and conditions of the Plan and this Agreement, on each Vesting Date the Option shall vest with respect to the number of Shares indicated on the Vesting Schedule, provided that you have remained continuously and actively employed with the Company or an Affiliate (as defined in the Plan) through each applicable Vesting Date, unless &#91;(i) your employment has terminated due to your Voluntary Termination (as defined in Section IV(A)(5)) or (ii)&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> you experience a Qualified Termination (as defined in Section IV(B)(4)), or as otherwise determined by the Company in the exercise of its discretion as provided in Section IV(A)(7).  This Option may only be exercised for whole shares of the Common Stock, and the Company shall be under no obligation to issue any fractional Shares to you.  Subject to the limitations contained herein, this Option shall be exercisable with respect to each installment on or after the applicable Vesting Date.  Notwithstanding anything herein to the contrary, the Vesting Schedule may be accelerated (by notice in writing) by the Company in its sole discretion at any time during the term of this Option.  In addition, if not prohibited by local law, vesting may be suspended by the Company in its sole discretion during a leave of absence as provided from time to time according to Company policies and practices&#59; provided, that, in no event shall any such suspension extend the term of this Option beyond the Expiration Date set forth on the Award Notice and in this Agreement.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Section IV(A)(5) of this Agreement is not applicable to awards identified by the Administrator as new hire, retention or promotion grants and the provisions of such section shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;The per share exercise price of this Option is the Grant Price as defined in the Award Notice, being not less than the Fair Market Value of the Common Stock on the date of grant of this Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;To the extent permitted by applicable statutes and regulations, payment of the exercise price per share is due in full upon exercise of all or any part of each installment which has become exercisable by you by means of (i) cash or a check, (ii) any cashless exercise procedure through the use of a brokerage arrangement approved by the Company, or (iii) any other form of legal consideration that may be acceptable to the Board or the Committee in their discretion. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">(3)&#160;&#160;&#160;&#160;To the extent permitted by applicable statutes and regulations, if, at the time of exercise, the Company&#8217;s Common Stock is publicly traded and quoted regularly in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%;text-decoration:underline">Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">, payment of the exercise price may be made by delivery of already-owned Shares with a Fair Market Value equal to the exercise price of the Shares for which this Option is being exercised.  The already-owned Shares must have been owned by you for the period required to avoid adverse accounting treatment and owned free and clear of any liens, claims, encumbrances or security interests.  Payment may also be made by a combination of cash and already-owned Shares.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the Company reserves the right to restrict the methods of payment of the exercise price if necessary or advisable to comply with applicable law or regulation, as determined by the Company in its sole discretion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:21.03pt">Notwithstanding anything to the contrary contain herein, the Company shall not take any actions that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange. The Company, in its sole discretion, may impose any timing or other restrictions with respect to the exercise of this Option arising from compliance with any securities or tax laws or other rules or regulations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding anything to the contrary contained herein, this Option may not be exercised and no Shares underlying the Option will be issued unless such Shares are then registered under the Securities Act, or, if such Shares are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act, and that the issuance satisfies all other applicable legal requirements.  If the Option cannot be exercised and expires during this period, you will forfeit the Option and no Shares or value will be transferred to you.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IV.&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;The term of this Option commences on the Grant Date and, unless sooner terminated as set forth below or in the Plan, terminates on the &#91;_______ (__th)&#93; anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  This Option shall terminate prior to the Expiration Date as follows&#58;  three (3) months after the termination of your employment with the Company or an Affiliate (as defined in the Plan) for any reason or for no reason, including if your employment is terminated by the Company or an Affiliate without Cause (as defined below), or in the event of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any other termination of your employment caused directly or indirectly by the Company or an Affiliate, unless&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;such termination of your employment is due to your Permanent and Total Disability (as defined below), in which case the Option shall terminate on the earlier of the Expiration Date or five (5) years after termination of your employment and the vesting of the Option shall be accelerated and the Option shall be fully exercisable, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), as of the day immediately preceding such termination of your employment with respect to the Option, except that if the Option was granted in the calendar year in which such termination occurs, the Option shall be accelerated to vest with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Permanent and Total Disability without consideration therefor&#59;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;such termination of your employment is due to your death, in which case the Option shall terminate on the earlier of the Expiration Date or five (5) years after your death and the vesting of the Option shall be accelerated and the Option shall be fully exercisable as of the day immediately preceding your death with respect to the Option, except that if the Option was granted in the calendar year in which your death occurs the Option shall be accelerated to vest with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of termination of your active employment due to your death without consideration therefor&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3)&#160;&#160;&#160;&#160;during any part of such three (3) month period, this Option is not exercisable solely because of the condition set forth in Section III above, in which event this Option shall not terminate until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your employment&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#160;&#160;&#160;exercise of this Option within three (3) months after termination of your employment with the Company or with an Affiliate would result in liability under Section 16(b) of the Exchange Act, in which case this Option will terminate on the earliest of&#58;  (a) the tenth (10th) day after the last date upon which exercise would result in such liability&#59; (b) six (6) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">months and ten (10) days after the termination of your employment with the Company or an Affiliate&#59; or (c) the Expiration Date&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(5)&#160;&#160;&#160;&#160;&#91;such termination of your employment is due to your voluntary termination (and such voluntary termination is not the result of Permanent and Total Disability (as defined below)) after you are at least sixty five (65) years of age, or after you are at least fifty-five (55) years of age and have been an employee of the Company and&#47;or an Affiliate for at least ten (10) years in the aggregate as determined by the Company in its sole discretion according to Company policies and practices as in effect from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%;text-decoration:underline">Voluntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;), in which case this Option shall terminate on the earlier of the Expiration Date or five (5) years after termination of your employment and the unvested portions of this Option will become exercisable pursuant to the Vesting Schedule without regard to your Voluntary Termination of your employment prior to the Vesting Date, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), with respect to the Option&#59; if the Option was granted in the calendar year in which your Voluntary Termination occurs, the Option will become exercisable pursuant to the Vesting Schedule only with respect to a number of Shares equal to the number of Shares subject to the Option multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any portion of the Option (if any) that remains unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Voluntary Termination without consideration therefor&#59; notwithstanding the definition of Voluntary Termination set forth above, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in your jurisdiction that would likely result in the favorable treatment upon Voluntary Termination described above being deemed unlawful and&#47;or discriminatory, then the Committee will not apply the favorable treatment described above&#59;&#93;&#91;Reserved&#93;*</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:9.1pt;font-weight:400;line-height:111%;position:relative;top:-4.89pt;vertical-align:baseline"> 3</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;such termination of your employment is due to a Qualified Termination, in which case, the Option shall terminate on the earlier of (a) the date that is three (3) months following the date of such Qualified Termination or (b) the Expiration Date, and, to the extent permitted by applicable law, the vesting of the Option shall be accelerated and the Option shall be fully exercisable as of the day immediately prior to the Qualified Termination&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7)&#160;&#160;&#160;&#160;the Company determines, in its sole discretion at any time during the term of this Option, in writing, to otherwise extend the period of time during which this Option will vest and may be exercised after termination of your employment&#59; provided, that, in no event shall any such extension extend the term of this Option beyond the Expiration Date set forth on the Award Notice and in this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Section IV(A)(5) of this Agreement is not applicable to awards identified by the Administrator as new hire, retention or promotion grants and the provisions of such section shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;However, in any and all circumstances and except to the extent the Vesting Schedule has been accelerated by the Company in its sole discretion during the term of this Option or as a result of your Permanent and Total Disability or death as provided in Sections IV(A)(1) or IV(A)(2) above, respectively, &#91;as a result of your Voluntary Termination as provided in Section IV(A)(5) above,&#93;* as a result of a Qualified Termination as provided in Section IV(A)(6) above or as otherwise determined by the Company in the exercise of its discretion as provided in Section IV(A)(7) above, this Option may be exercised following termination of your employment only as to that number of Shares as to which it was exercisable on the date of termination of your employment under the provisions of Section I of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;For purposes of this Option&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as a Director to the Company or an Affiliate&#59; in the event of termination of your employment (whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive options and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, active employment would not include any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any).  Your right, if any, to exercise the Option after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law.  The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of this Agreement (including whether you may still be considered to be providing services while on a leave of absence)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) your conviction of a felony (or similar crime under applicable law, as determined by the Company), or (ii) your engaging in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out your duties, resulting, in either case, in material economic harm to the Company or any Affiliate, unless you believed in good faith that such conduct was in, or not contrary to, the best interests of the Company or any Affiliate.  For purposes of clause (ii) above, no act, or failure to act, on your part shall be deemed &#8220;willful&#8221; unless done, or omitted to be done, by you not in good faith&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(3) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term under Section 22(e)(3) of the Code and with such permanent and total disability being certified prior to termination of your employment by (a) the U.S. Social Security Administration, (b) the comparable governmental authority applicable to an Affiliate, (c) such other body having the relevant decision-making power applicable to an Affiliate, or (d) an independent medical advisor appointed by the Company in its sole discretion, as applicable, in any such case&#59; </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;if you are an employee who participates in the Change of Control Plan (as defined below), your termination of employment within two (2) years following a Change of Control (i) by the Company other than for Cause, Disability (as defined below) or as a result of your death, or (ii) by you for Good Reason (as defined in the Change of Control Plan)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;if you are an employee who does not participate in the Change of Control Plan or the Change of Control Plan is no longer in effect, your termination of employment within two (2) years following a Change of Control by the Company other than for Cause, Disability (as defined below) or as a result of your death&#59; </font></div><div><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:111%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">(5) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; shall mean the occurrence of any of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;the acquisition (other than from the Company) by any person, entity or &#8220;group,&#8221; within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or any of its Affiliates, or any employee benefit plan of the Company or any of its Affiliates which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then outstanding Shares or the combined voting power of the Company&#8217;s then outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;the consummation by the Company of a reorganization, merger, consolidation, (in each case, with respect to which persons who were the stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than fifty percent (50%) of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company&#8217;s then outstanding voting securities) or a liquidation or dissolution of the Company or of the sale of all or substantially all of the assets of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything herein or in any Award Agreement to the contrary, if a Change of Control constitutes a payment event with respect to any Award that is subject to United States income tax and which provides for a deferral of compensation that is subject to Section 409A of the Code, the transaction or event described in subsection (a) or (b), (c) above must also constitute a &#8220;change in control event,&#8221; as defined in U.S. Treasury Regulation &#167;1.409A-3(i)(5), in order to constitute a Change of Control for purposes of payment of such Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(6) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s change of control and severance plan, including the Amgen Inc. Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010 (and any subsequent amendments thereto), or any equivalent plan governing the provision of benefits to eligible employees upon the occurrence of a Change of Control (including resulting from a termination of employment that occurs within a specified time period following a Change of Control), as in effect immediately prior to a Change of Control&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be determined in accordance with the Company&#8217;s long-term disability plan as in effect immediately prior to a Change of Control.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;To the extent specified above, this Option may be exercised by delivering a notice of exercise in person, by mail, via electronic mail or facsimile or by other authorized method designated by the Company, together with the exercise price to the Company Stock </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Administrator, or to such other person as the Company Stock Administrator may designate, during regular business hours, together with such additional documents as the Company may then require pursuant to Section 7.2(b) of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer&#58; (a) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Option grant or the underlying Shares, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends&#59; and (b) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate your liability for Tax Obligations or achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(C)&#160;&#160;&#160;&#160;Prior to any relevant taxable or tax withholding event, as applicable, you shall pay or make adequate arrangements satisfactory to the Company and&#47;or your Employer to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47;or your Employer, or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares acquired upon exercise of the Option either through your voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;withholding in Shares issuable, or cash to be paid, upon exercise of the Option, provided that, if such Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value not to exceed the Tax Obligations as determined in the discretion of the Company or your Employer, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates. If the Tax Obligations are satisfied by withholding in Shares, for tax purposes you are deemed to have been issued the full number of Shares subject to the exercised Option, notwithstanding that a number of the Shares is held back and not issued solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(D)&#160;&#160;&#160;&#160;Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be or were not satisfied by the means previously described.  You agree to take any further actions and execute any additional documents as may be necessary to effectuate the provisions of this Section V.  Notwithstanding anything to the contrary contained herein, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VI.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option is not transferable, except by will or the laws of descent and distribution, and is exercisable during your life only by you except if you have named a trust created for the benefit of you, your spouse, or members of your immediate family (a &#8220;Trust&#8221;) as beneficiary of this Option, this Option may be exercised by the Trust after your death.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VII.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any notices provided for in this Option or the Plan shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;VIII.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Option is subject to all the provisions of the Plan and its provisions are hereby made a part of this Option, including without limitation the provisions of Articles 6 and 7 of the Plan relating to Options, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Option and those of the Plan, the provisions of the Plan shall control.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In order for the Company to facilitate your participation in the Plan, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan (&#8220;personal data&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received upon exercise of this Option may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Options or other equity awards and administer or maintain such awards.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;X.&#160;&#160;&#160;&#160;The terms of this Option shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Option is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt">Notwithstanding any provision of this Option to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Option granted hereunder shall be subject to any additional terms and conditions for your country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the following additional terms and conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the terms and conditions of this Option, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration to the Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;if applicable, the effectiveness of this Option is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59; and</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">the Company may take any other action before or after the date of this Option that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt"> (A)&#160;&#160;&#160;&#160;In accepting this Option, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;the grant of this Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of options, or benefits in lieu of options even if options have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;your participation in the Plan is voluntary&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;the grant of Options, the underlying Shares, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;neither the grant of options nor any provision of this Option, the Plan or the policies adopted pursuant to the Plan confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7)&#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Option shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8)&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable, and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9)&#160;&#160;&#160;&#160;if the underlying Shares do not increase in value, this Option will have no value&#59; if you exercise this Option and obtain Shares, the value of those Shares acquired upon exercise may increase or decrease in value, even below the Grant Price per Share&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10)&#160;&#160;&#160;&#160;in consideration of the grant of this Option, no claim or entitlement to compensation or damages arises from forfeiture of options resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(11)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Options, the underlying Shares, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12) &#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Options and the benefits evidenced by this Agreement do not create any entitlement to have the Options or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(13)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;for employment law purposes outside the United States, the Option, underlying Shares, and the income from and value of same, are not part of normal or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Option or of any amounts due to you pursuant to the exercise of the Option or the subsequent sale of any Shares acquired upon exercise of the Option.</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares.  You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt">If one or more of the provisions of this Option shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Option to be construed so as to foster the intent of this Option and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt">By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Furthermore, if you have received this Option or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt">This Option is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Code Section 409A, but rather is intended to be exempt from the application of Code Section 409A.  To the extent that this Option is nevertheless deemed to be subject to Code Section 409A for any reason, this Option shall be interpreted in accordance with Code Section 409A and U.S. Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date.  Notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee (as defined in the Plan) determines that this Option may be or become subject to Code Section 409A, the Committee may adopt such amendments to the Plan and&#47;or this Option or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan and&#47;or this Option from the application of Code Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Option, or (b) comply with the requirements of Code Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt">By electing to accept this Option, you acknowledge receipt of this Option and hereby confirm your understanding that the terms set forth in this Option constitute, subject to the terms of the Plan, which terms shall control in the event of any conflict between the Plan and this Option, the entire agreement and understanding of the parties with respect to the matters contained herein and supersede any and all prior agreements, arrangements and understandings, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">both oral and written, between the parties concerning the subject matter of this Option.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt">The Company reserves the right to impose other requirements on your participation in the Plan, on this Option and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.71pt">This Option and all compensation payable with respect to it shall be subject to recovery by the Company pursuant to&#160;any and all of the Company&#8217;s policies with respect to the recovery of compensation, as they shall be in effect and may be amended from time to time, to the maximum extent permitted by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt">You acknowledge that a waiver by the Company of breach of any provision of this Option shall not operate or be construed as a waiver of any other provision of this Option, or of any subsequent breach by you or any other grantee.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Very truly yours,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMGEN INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Duly authorized on behalf</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  of the Board of Directors</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><div id="i626d7275cd5f4565b6a6025323f362a7_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GRANT OF STOCK OPTION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(BY COUNTRY)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern any Options granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern any Options granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2021.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you exercise the Options and acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision replaces Section II(3)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent permitted by applicable statutes and regulations, payment of the exercise price per Share is due in full in cash or check upon exercise of all or any part of this Option which has become exercisable by you.  Due to legal restrictions outside the U.S., you are not permitted to pay the exercise price by delivery of already-owned Shares of a value equal to the exercise price of the Shares for which this Option is being exercised.  Furthermore, payment may not be made by a combination of cash and already-owned Common Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section V(C) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your jurisdiction(s).  In the event of over-withholding, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be subject to insider trading restrictions and&#47;or market abuse laws</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., Options) or rights linked to the value of Shares during such times as you are considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). &#160;Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information. Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Asset&#47;Account, Tax Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision replaces Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to staffing-hrconnect&#64;amgen.com.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;personal data&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received upon exercise of this Option may be deposited.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARGENTINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in Argentina, you may be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; The following provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge, understand and agree that the grant of the Option is made by the Company (not your Employer) in its sole discretion and that the value of the Option or any Shares acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. &#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the Option nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Provided you are not required to purchase foreign currency and remit funds out of Argentina to acquire Shares under the Plan, local exchange control restrictions would not apply.  However, if so required, you personally are responsible for complying with any and all Argentine currency exchange regulations, approvals and reporting requirements.  Exchange control requirements in Argentina are subject to change&#59; you should consult with your personal advisor regarding any obligations you have under the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you acquire Shares under the Plan and offer the Shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law.  You should consult with your own legal advisor before making any such offer in Australia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Options granted under the Plan, such that the Options are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; If you are an Austrian resident and you hold Shares acquired under the Plapn outside of Austria, you may be subject to reporting obligations to the Austrian National Bank.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A separate reporting requirement applies when you sell Shares acquired under the Plan or receive a cash dividend paid on such Shares.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Taxation of the Option.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your tax consequences will vary depending on when you accept the Option.  If you accept the Option in writing within 60 days of the offer date, you will be subject to taxation on the 60th day after the offer date.  If you accept the Option more than 60 days after the offer date, you will be subject to taxation at exercise.  Please refer to the additional materials that will be delivered to you for a more detailed description of the tax consequences of accepting the Option.  You should consult your personal tax advisor prior to accepting the Option.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are a Belgian resident, you are required to report any taxable income attributable to the Option granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;A stock exchange tax applies to transactions executed by a Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker.  The stock exchange tax likely will apply when the Option is exercised and when Shares acquired under the Plan are sold.  It is your responsibility to comply with this tax obligation and you should consult your personal tax advisor for additional details on your obligations with respect to the stock exchange tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Securities Accounts Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;An annual securities accounts tax may be payable if the total value of securities held in a Belgian or foreign securities account (e.g., Shares acquired under the Plan) exceeds a certain threshold on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30).  In such case, the tax will be due on the value of the qualifying securities held in such account.  It is your responsibility to comply with this obligation and you should consult with your personal tax or financial advisor for additional details.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the Option, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the exercise of the Option, the sale of Shares acquired under the Plan and the payment of dividends on such Shares.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge (i) that you are making an investment decision, (ii) that the Options will be exercisable by you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$1,000,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv) leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$1,000,000 are not required to submit a declaration. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If funds are remitted to purchase Shares abroad, a declaration of the purpose of the remittance must be provided to the local bank that is transferring the funds.  If the funds are remitted to a bank outside the European Union and the amount exceeds a specified amount, documentation evidencing the underlying transaction (for instance a copy of the option agreement) must be provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds a specified amount as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Section IV(B)(1) of the Agreement is amended to read as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as Director to the Company or an Affiliate&#59; in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive the Option and vest under the Plan, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to the Option after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Options, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The following provisions will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that this Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention (&#171;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#187;), ainsi que de tous documents, avis et proc&#233;dures </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Nasdaq Global Select Market).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified foreign property, including Shares, Options and other rights to receive Shares of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such Options must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following terms apply only to nationals of the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221;) residing in the PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in the PRC, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To comply with requirements imposed by the State Administration of Foreign Exchange, to the extent that, under Section IV of the Agreement, you may exercise any Option after termination of your employment, you will be permitted to exercise such Option for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">shorter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the period set forth in Section IV of the Agreement and six (6) months from the date of termination of your employment&#59; any unexercised Option shall immediately lapse six (6) months following the termination of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company reserves the right to impose such further restrictions or conditions as may be necessary to comply with changes in applicable local laws in the PRC.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please note that the above provisions will apply to all Options granted to you under the Plan, as well as to any Options granted to you in the past under the Plan.    </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that, pursuant to PRC exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued upon the exercise of the Option to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds from the sale of the Shares may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You agree to bear any currency fluctuation risk between the date the Option is exercised and the time that (i) the Tax Obligations are converted to local currency and remitted to the tax authorities, and (ii) net proceeds are converted to local currency and distributed to you. You acknowledge that neither the Company nor any Affiliate will be held liable for any delay in delivering the proceeds to you.  You agree to sign any agreements, forms and&#47;or consents that may be requested by the Company or the Company&#8217;s designated broker to effectuate any of the remittances, transfers, conversions or other processes affecting the proceeds. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following provision supplements Section XII of the Agreement&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan and related benefits do not constitute a component of &#8220;salary&#8221; for any purpose. Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities</font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:14pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Investment in assets located abroad (such as Shares acquired under the Plan) does not require prior approval from the Central Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Banco de la Rep&#250;blica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shares acquired at exercise (every year as long as you keep them). This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US$22.000)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CROATIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you transfer funds into or out of Egypt in connection with the exercise of the Option or the receipt of sale proceeds, you are required to transfer the funds through a registered bank in Egypt.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> There are no specific reporting requirements with respect to foreign assets&#47;accounts. However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported. If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the grant, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise.  Vous acceptez les termes de ces documents en connaissance de cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained only in the unlikely event (i) you own at least 1% of the Company and the value of the Shares acquired exceeds &#8364;150,000 or (ii) you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of dividends), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) can be accessed via the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> website (www.bundesbank.de) and is available in both German and English.  You are responsible for satisfying any applicable reporting obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you exercise the Option through a cash exercise, withdraw funds from a bank in Greece and remit those funds out of Greece (in an amount exceeding a specified threshold), you may be required to submit a written application to the bank.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you exercise the Option by way of a cashless method of exercise as described in Section&#160;II(2)(ii) of the Agreement, this application will not be required because no funds will be remitted out of Greece. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Shares received at exercise are accepted as a personal investment.  In the event that Shares are issued in respect of the Options within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of the Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SECURITIES WARNING&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Option and any Shares issued in respect of the Option do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Option and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in Iceland, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan, regardless of the value of the Shares acquired under the Plan.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in India, you will not be permitted to pay the exercise price for Shares subject to the Option granted hereunder by a cashless &#8220;sell-to-cover&#8221; procedure, under which method a number of Shares with a value sufficient to cover the exercise price, brokerage fees and any applicable Tax Obligations would be sold upon exercise and you would receive only the remaining Shares subject to the exercised Option.  The Company reserves the right to permit this procedure for payment of the exercise price in the future, depending on the development of local law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you remit funds out of India to purchase Shares at exercise of the Option granted hereunder, you are responsible for complying with applicable exchange control regulations.  In particular, it will be your obligation to determine whether approval from the Reserve Bank of India is required prior to exercise or whether you have exhausted the investment limit of US$250,000 for the relevant fiscal year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You must repatriate any cash dividends paid on Shares acquired under the Plan to India, as well as any proceeds from the sale of Shares acquired under the Plan within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash dividends, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XII of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you acknowledge that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Due to legal restrictions in Italy, you will be required to pay the exercise price for any Shares subject to the Option granted hereunder by a cashless sell-all exercise, such that all Shares will be sold immediately upon exercise and the cash proceeds of sale, less the exercise price, any Tax Obligations and broker&#8217;s fees or commissions, will be remitted to you.  The Company reserves the right to provide additional methods of exercise depending on local developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In accepting this Option, you acknowledge that (1)&#160;you have received a copy of the Plan, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the Option granted, you further acknowledge that you have read and specifically and explicitly approve, without limitation, the following Sections of the Option Agreement&#58; Section I, Section IV, Section V, Section X, Section XII, Section XIII, Section XIV, Section XVII and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is subject to a foreign assets tax at a flat rate.  The fair market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you acquire Shares valued at more than &#165;100,000,000 in a single transaction, you must file a Securities Acquisition Report with the Ministry of Finance through the Bank of Japan within 20 days of the purchase of the Shares.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, if you pay more than &#165;30,000,000 in a single transaction for the purchase of Shares when you exercise the Option, you must file a Payment Report with the Ministry of Finance through the Bank of Japan by the 20th day of the month following the month in which the payment was made.  The precise reporting requirements vary depending on whether or not the relevant payment is made through a bank in Japan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Payment Report is required independently from a Securities Acquisition Report.  Therefore, if the total amount that you pay upon a one-time transaction for exercising the Option and purchasing Shares exceeds &#165;100,000,000, then you must file both a Payment Report and a Securities Acquisition Report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any outstanding Options, Shares or cash that you hold.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold on any month-end date during a calendar year.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible employees of your Employer, the Company or an Affiliate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares).  If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of the Agreement.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Option granted hereunder, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Option Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section XII of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of the Option granted and&#47;or Shares issued under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;In accepting the Option granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Spanish Translation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Al aceptar cualquier Opci&#243;n bajo el presente documento, usted reconoce que ha recibido una copia del Plan, que ha revisado el mismo en su totalidad, as&#237; como tambi&#233;n el Acuerdo de Opci&#243;n, incluyendo este Ap&#233;ndice, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan y del Opci&#243;n, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n XII del Acuerdo de Opci&#243;n, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el mismo son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de la opci&#243;n otorgada y&#47;o de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Al aceptar cualquier Opci&#243;n bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-M&#233;xico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Asimismo, usted entiende que su participaci&#243;n en el Plan es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Options and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Options may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="warninglabel.jpg" src="warninglabel.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return. Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration. Such information may then be pre-completed in a Norwegian resident&#8217;s tax return. However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Options will be considered assets and are, therefore, subject to wealth tax. An exemption from wealth tax may be available for non-transferrable awards. However, because the wealth tax regulations and the practice of the tax authorities are not well developed, Norwegian residents should provide the tax authorities with information concerning the Options in the annual tax return even if the Norwegian resident maintains that no wealth tax is payable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry. If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Conhecimento da Lingua.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of dividends in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RUSSIA </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You may be required to repatriate certain cash amounts received with respect to the Option to Russia (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, cash dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment.  If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia.  After the funds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.  Under the Directive N 5371-U of the Russian Central Bank (the &#8220;CBR&#8221;), the repatriation requirement may not apply in certain cases with respect to cash amounts received in an account that is considered by the CBR to be a foreign brokerage account.  Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You should consult with your personal legal advisor to determine the applicability of the repatriation requirement to any cash received in connection with your participation in the Plan and to ensure compliance with any applicable exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The Option granted hereunder, the Agreement, including this Appendix, the Plan and all other materials you may receive regarding your participation in the Plan or the Option granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares under the Plan has not and will not be registered in Russia&#59; therefore, Shares may not be offered or placed in public circulation in Russia.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will Shares acquired under the Plan be delivered to you in Russia&#59; any and all Shares will be maintained on your behalf in the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are not permitted to sell any Shares acquired under the Plan directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Option.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Russian residents are required to file the following reports or notifications with the Russian tax authorities, if applicable&#58; (i) annual cash flow reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; (ii) financial asset (including Shares) reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; and (ii) a one-time notification within one (1) month of opening, closing, or changing details of an offshore brokerage account.  You are encouraged to contact your personal tax advisor before remitting your proceeds from participation in the Plan to Russia to ensure compliance with applicable requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby agree that any Shares acquired pursuant to the Option will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The grant of the Option is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Option being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act, regardless of whether they are resident or employed in Singapore. Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Options, Shares, etc.) in the Company or any related company within two (2) business days of (i)&#160;its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> when the Shares are sold), or (iii) becoming a director. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The following provision supplements Section XII of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Option, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant the Option under the Plan to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision, which is entered into upon the express assumption and condition that the Option granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the Agreement, including this Appendix.  Consequently, you understand that the Option granted hereunder is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of the Option since the future value of the Option and the underlying Shares is unknown and unpredictable.  In addition, you understand that the Option granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of an Option or right to an Option shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, the vesting of the Option is expressly conditioned on your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Option may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section IV of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to a &#8220;despido improcedente&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Options that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you have read and specifically accept the conditions referred to in Section IV of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No &#8220;offer of securities to the public,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.&#160;&#160;After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of any previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Authorization to Withhold. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section V of the Agreement&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Options, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon exercise to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Neither this document nor any other materials relating to the Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company or one of its Subsidiaries or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of dividends) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you receive funds in connection with the Plan (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, dividends or sale proceeds) with a value equal to or greater than US$1,000,000 per transaction, you are required to immediately repatriate such funds to Thailand.  Any foreign currency repatriated to Thailand must be converted to Thai Baht or deposited into a foreign currency deposit account opened with any commercial bank in Thailand acting as the authorized agent within 360 days from the date the funds are repatriated to Thailand.  You are also required to inform the authorized agent of the details of the foreign currency transaction, including your identification information and the purpose of the transaction. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you do not comply with the above obligations, you may be subject to penalties assessed by the Bank of Thailand.  Because exchange control regulations change frequently and without notice, you should consult your legal advisor before selling any Shares (or receiving any other funds in connection with the Plan) to ensure compliance with current regulations.  It is your responsibility to comply with exchange control laws in Thailand, and neither the Company nor your Employer will be liable for any fines or penalties resulting from failure to comply with applicable laws.&#160;&#160;&#160;&#160;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Option is made available only to Employees of the Company and its Affiliates, and the offer of participation in the Plan is a private offering.  The grant of the Option and the issuance of Shares at exercise takes place outside of Turkey. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any activity related to investments in foreign securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the sale of Shares under the Plan or the receipt of cash dividends) must be conducted through a bank or financial intermediary institution licensed by the Turkish Capital Markets Board and should be reported to the Turkish Capital Markets Board by the bank or intermediary assisting with the transaction.  You should contact a personal legal advisor for further information regarding these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Options under the Plan are granted only to select Board members and Employees of the Company and its Affiliates and are for the purpose of providing equity incentives.  The Plan and the Agreement are intended for distribution only to such Board members and Employees and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Options offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section V of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section V of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are an executive officer or director within the meaning of Section 13(k) of the Exchange Act, as amended from time to time, you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the amount of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section V of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Option, as a condition of the Option granted hereunder, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which may be payable by the Company or your Employer with respect to the exercise of the Option and issuance of Shares subject to the Option, the assignment or release of the Option for consideration, or the receipt of any other benefit in connection with the Option.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law. You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer. You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section V of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Option, without any liability to the Company or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">TERMS AND CONDITIONS</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision replaces Section IV(B)(1) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not in breach of local labor laws), your right to exercise the Option and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed&#59; provided, however, that such right will be extended by any notice period mandated by law (e.g. the Worker Adjustment and Retraining Notification Act (&#8220;WARN Act&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  Your right, if any, to exercise the Option after termination of employment will be measured by the date of termination of your active employment&#59; provided, however, that such right will be extended by any notice period mandated by law (e.g. the Worker Adjustment and Retraining Notification Act (&#8220;WARN Act&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave, unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  Notwithstanding anything to the contrary herein, in no event shall the term of this Option extend beyond the Expiration Date set forth on the Award Notice and in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>amgn-ex105_20211231xq4.htm
<DESCRIPTION>FORM OF RESTRICED STOCK UNIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id2f86f6f69ae46538487503eadfcff60_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 10.5</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#93; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Price&#58; &#160;&#160;&#160;&#160;$________</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Shares&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Units</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;&#160; Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) carefully.&#160; If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.&#160; For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following the day on which this Award Notice is made available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of grant.  This step is necessary to process transactions related to your equity grant.  If you do not open a brokerage account by this deadline, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">your grant will be cancelled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="id2f86f6f69ae46538487503eadfcff60_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SPECIFIC TERMS OF YOUR GRANT OF RESTRICTED STOCK UNITS ARE FOUND IN THE PAGES RELATING TO THE GRANT OF RESTRICTED STOCK UNITS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS RESTRICTED STOCK UNIT AGREEMENT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On the Grant Date specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has granted to you, the grantee named in the Award Notice, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Number of Units with respect to the number of shares of the $0.0001 par value common stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) specified in the Award Notice, on the terms and conditions set forth in this Restricted Stock Unit Agreement, any additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the Award Notice (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Units shall constitute Restricted Stock Units under Section 9.5 of the Plan, which is incorporated herein by reference.  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Plan.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt;text-decoration:underline">Vesting Schedule and Termination of Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.68pt">General.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, on each Vesting Date, the Number of Units indicated on the Vesting Schedule shall vest, provided that you have remained continuously and actively employed with the Company or an Affiliate (as defined in the Plan) through each applicable Vesting Date, unless (i) &#91;your employment has terminated due to your Voluntary Termination (as defined in paragraph (d) of this Section I below) &#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;(ii)&#93; you experience a Qualified Termination (as defined below), or (iii)&#91;(ii)&#93; as otherwise determined by the Company in the exercise of its discretion as provided in paragraph (f) of this Section I.  The Units represent an unfunded, unsecured promise by the Company to deliver Shares.  Only whole Shares shall be issued upon vesting of the Units, and the Company shall be under no obligation to issue any fractional Shares to you.  If your employment with the Company or an Affiliate is terminated for any reason or for no reason, including if your active employment is terminated by the Company or an Affiliate without Cause (as defined below), or in the event of any other termination of your active employment caused directly or indirectly by the Company or an Affiliate, except as otherwise provided in paragraphs (b), (c), &#91;(d), &#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (e) or (f) of this Section I below, your unvested Units shall automatically expire and terminate on the date of termination of your active employment.  Notwithstanding anything herein to the contrary, the Vesting Schedule may be accelerated (by notice in writing) by the Company in its sole discretion at any time that the Units remain outstanding and unvested (in whole or in part).  In addition, if not prohibited by local law, vesting may be suspended by the Company in its sole discretion during a leave of absence as provided from time to time according to Company policies and practices.  </font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Paragraph (d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Permanent and Total Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding the provisions in paragraph (a) above, if your employment with the Company or an Affiliate terminates due to your Permanent and Total Disability (as defined below), then the vesting of Units granted under this Agreement shall be accelerated, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), to vest as of the day immediately preceding such termination of your employment with respect to all Units granted hereunder, except that if the Units were granted in the calendar year in which such termination occurs, the Units shall be accelerated to vest with respect to a number of Units equal to the number of Units subject to this Agreement multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested shall automatically expire and terminate on the date of the termination of your active employment due to your Permanent and Total Disability without consideration therefor.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.68pt">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions in paragraph (a) above, if your employment with the Company or an Affiliate terminates due to your death, then the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately preceding your death with respect to all Units granted hereunder, except that if the Units were granted in the calendar year in which your death occurs the Units shall be accelerated to vest with respect to a number of Units equal to the number of Units subject to this Agreement multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested shall automatically expire and terminate on the date of the termination of your active employment due to your death without consideration therefor.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">&#91;Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the provisions in paragraph (a) above, if you terminate your employment with the Company or an Affiliate due to your voluntary termination (and such voluntary termination is not the result of Permanent and Total Disability (as defined below)) after you are at least sixty-five (65) years of age, or after you are at least fifty-five (55) years of age and have been an employee of the Company and&#47;or an Affiliate for at least ten (10) years in the aggregate as determined by the Company in its sole discretion according to Company policies and practices as in effect from time to time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voluntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then the Units will vest pursuant to the Vesting Schedule without regard to the termination of employment prior to the Vesting Date, subject to your execution of a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company), with respect to all Units granted hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the Units were granted in the calendar year in which the Voluntary Termination occurs, the Units will vest pursuant to the Vesting Schedule provided in the Award Notice, provided, that each tranche of Units scheduled to vest upon each remaining Vesting Date in the Vesting Schedule will vest only with respect to the number of Units in such tranche multiplied by a fraction, the numerator of which is the number of complete months you remained continuously and actively employed during such calendar year, and the denominator of which is twelve (12), and any Units that remain unvested in excess of such number of Units shall automatically expire and terminate on the date of termination of your active employment due to your Voluntary Termination without consideration therefor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in the event of your death following your Voluntary Termination, any Units that remain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">outstanding as of the date of your death will become vested (and the Vesting Date with respect to such Units will occur) as of the day immediately preceding your death.  Notwithstanding the definition of Voluntary Termination set forth above, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in your jurisdiction that would likely result in the favorable treatment upon Voluntary Termination described above being deemed unlawful and&#47;or discriminatory, then the Committee will not apply the favorable treatment described above.&#93;&#91;Reserved&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9.68pt">Qualified Termination after a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions in paragraph (a) above, in the event of a Qualified Termination (as defined below), then, to the extent permitted by applicable law, the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately prior to the Qualified Termination.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:11.01pt">Continued Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions in paragraph (a) above, the Company may in its sole discretion at any time during the term of this Agreement, in writing, otherwise provide that the Units will vest pursuant to the Vesting Schedule without regard to the termination of employment prior to the Vesting Date, subject to any terms and conditions that the Company may determine.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are working or the terms of your employment agreement, if any), your right to receive Units and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively providing services and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, active employment would not include any period of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">garden leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any).  The Company shall have exclusive discretion to determine when you are no longer actively providing services for purposes of this Agreement (including whether you may still be considered to be providing services while on a leave of absence)&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (i) your conviction of a felony (or similar crime under applicable law, as determined by the Company), or (ii) your engaging in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out your duties, resulting, in either case, in material economic harm to the Company or any Affiliate, unless you believed in good faith that such conduct was in, or not contrary to, the best interests of the Company or any Affiliate.  For purposes of clause (ii) above, no act, or failure to act, on your part shall be deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">willful</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; unless done, or omitted to be done, by you not in good faith&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term under Section 22(e)(3) of the Code and with such permanent and total disability being certified prior to termination of your employment by (i) the U.S. Social Security Administration, (ii) the comparable governmental authority applicable to an Affiliate, (iii) such other body having the </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Paragraph(d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relevant decision-making power applicable to an Affiliate, or (iv) an independent medical advisor appointed by the Company in its sole discretion, as applicable, in any such case&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;if you are an employee who participates in the Change of Control Plan (as defined below), your termination of employment within two (2) years following a Change of Control (i) by the Company other than for Cause, Disability (as defined below), or as a result of your death or (ii) by you for Good Reason (as defined in the Change of Control Plan)&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if you are an employee who does not participate in the Change of Control Plan or the Change of Control Plan is no longer in effect, your termination of employment within two (2) years following a Change of Control by the Company other than for Cause, Disability (as defined below), or as a result of your death&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160; the acquisition (other than from the Company) by any person, entity or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (excluding, for this purpose, the Company or any of its Affiliates, or any employee benefit plan of the Company or any of its Affiliates which acquires beneficial ownership of voting securities of the Company), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then-outstanding Shares or the combined voting power of the Company&#8217;s then-outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160; the consummation by the Company of a reorganization, merger, consolidation, (in each case, with respect to which persons who were the stockholders of the Company immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own more than fifty percent (50%) of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company&#8217;s then-outstanding voting securities) or a liquidation or dissolution of the Company or of the sale of all or substantially all of the assets of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything herein or in the Agreement to the contrary, if a Change of Control constitutes a payment event with respect to any Unit that is subject to United States income tax and which provides for a deferral of compensation that is subject to Section 409A of the Code, the transaction or event described in subsection (A) or (B) above must also constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">change in control event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; as defined in U.S. Treasury Regulation &#167;&#160;1.409A-3(i)(5), in order to constitute a Change of Control for purposes of payment of such Unit.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s change of control and severance plan, including the Amgen Inc. Change of Control Severance Plan, as amended and restated, effective as of December 9, 2010 (and any subsequent amendments thereto), or equivalent plan governing the provision of benefits to eligible employees upon the occurrence of a Change of Control (including resulting from a termination of employment that occurs within a specified time period following a Change of Control), as in effect immediately prior to a Change of Control&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be determined in accordance with the Company&#8217;s long-term disability plan as in effect immediately prior to a Change of Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Form and Timing of Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to satisfaction of Tax Obligations or similar obligations as provided for in Section III, any vested Units shall be settled by the Company delivering to you a number of Shares equal to the number of such vested Units or in a lump sum in cash with a value equal to the Fair Market Value of the number of Shares subject to the vested Units as of the applicable Vesting Date (without interest thereon), or in a combination of Shares and cash, as determined by the Administrator at any time prior to settlement and in its discretion, as soon as practicable, and in any event within 90 days, after the applicable Vesting Date, which for purposes of this Section II, includes the date of any accelerated vesting, if any (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  &#91;(For the avoidance of doubt, in the event that any Units continue to vest following a Voluntary Termination in accordance with Section 1(d) above, the Vesting Date(s) for purposes of settlement pursuant to this Section II shall be the regularly scheduled Vesting Dates following such termination.)&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary in the foregoing, in the event that (i) the vesting and settlement of Units is conditioned on your execution and delivery of a release and (ii) the Settlement Period commences in one calendar year and ends in the next calendar year, the Units will be settled in the second calendar year.  Shares issued in respect of a Unit shall be deemed to be issued in consideration of past services actually rendered by you to the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.03pt;text-decoration:underline">Tax Withholding&#59; Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Obligations&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Units or the underlying Shares, including the grant of the Units, the vesting of Units, the conversion of the Units into Shares or the receipt of an equivalent cash payment, the subsequent sale of any Shares acquired at vesting and the receipt of any Dividends (as defined in Section IV, below) or Dividend Equivalents, and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units to reduce or eliminate your liability for Tax Obligations or achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, you shall pay, or make adequate arrangements satisfactory to the Company or to your Employer (in their sole discretion) to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47;or your Employer or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Paragraph (d) of Section I of this Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares acquired upon vesting or payment of the Units either through your voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;withholding in Shares issuable, or cash to be paid, upon vesting or payment of the Units, provided that, if such Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value not to exceed the Tax Obligations as determined in the discretion of the Company or your Employer, as applicable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes you are deemed to have been issued the full number of Shares subject to the vested Units, notwithstanding that a number of the Shares is held back and not issued solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan (any Shares withheld by the Company hereunder shall not be deemed to have been issued by the Company for any purpose under the Plan and shall remain available for issuance thereunder). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be or were not satisfied by the means previously described.&#160; You agree to take any further actions and execute any additional documents as may be necessary to effectuate the provisions of this Section III.  Notwithstanding Section II above, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Dividend Equivalents</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Crediting and Payment of Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to this Section IV, Dividend Equivalents shall be credited on each Unit granted to you under this Agreement in the manner set forth in the remainder of this Section IV.  If the Company declares one or more dividends or distributions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on its Common Stock with a record date which occurs during the period commencing on the Grant Date through and including the day immediately preceding the day the shares of Common Stock subject to the Units are issued to you, whether in the form of cash, Common Stock or other property, then on the date such Dividend is paid to the Company&#8217;s stockholders you shall be credited with an amount equal to the amount or fair market value of such Dividend which would have been payable to you if you held a number of shares of Common Stock equal to the number of your Units as of the record date for such Dividend, unless the Units have been forfeited between the record date and payment date for such Dividend.  Any such Dividend Equivalents shall be credited and deemed reinvested in the Common Stock as of the Dividend payment date.  Dividend Equivalents shall be payable in full shares of Common Stock, unless the Administrator determines, at any time prior to payment and in its discretion, that they shall be payable in cash.  Dividend Equivalents payable with respect to fractional shares of Common Stock shall be paid in cash.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise expressly provided in this Section IV, any Dividend Equivalents credited to you shall be subject to all of the provisions of this Agreement which apply to the Units with respect to which they have been credited and shall be payable, if at all, at the time and to the extent that the underlying Unit becomes payable.  Dividend Equivalents shall not be payable on any Units that do not vest, or are forfeited, pursuant to the terms of this Agreement.  Dividend Equivalent rights and any amounts that may become distributable in respect thereof shall be treated separately from the Units and the rights arising in connection therewith for purposes of the designation of time and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">form of payments required by Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No benefit payable under, or interest in, this Agreement or in the Shares that are scheduled to be issued to you hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or subject to, your or your beneficiary&#8217;s debts, contracts, liabilities or torts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, nothing in this Section V shall prevent transfer (i) by will or (ii) by applicable laws of descent and distribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement or the Plan shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or settlement of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is subject to all the provisions of the Plan, which provisions are hereby made a part of this Agreement, including without limitation the provisions of Section 9.5 of the Plan relating to Restricted Stock Units, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Agreement shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Agreement is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Code Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The time and form of payment of the Units is intended to comply with the requirements of Section 409A and this Agreement shall be interpreted in accordance with Section 409A.  Accordingly, no acceleration or deferral of any payment shall be permitted if it would cause the payment of the Units to violate Section 409A.  In addition, notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee (as defined in the Plan) determines that it may be necessary or appropriate to do so, the Committee may adopt such amendments to the Plan and&#47;or this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan and&#47;or the Units from the application of Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Award, or (b) comply with the requirements of Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.  For purposes of Section 409A, the right to receive payment of Units at each Vesting Date shall be treated as a right to receive separate and distinct payments. No payment hereunder shall be made to you during the six (6)-month period following your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (within the meaning of Section 409A) to the extent that the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determines that paying such amount at the time set forth herein would be a prohibited distribution under Section 409A(a)(2)(B)(i). If the payment of any such amounts is delayed as a result of the previous sentence, then within thirty (30) days following the end of such six (6)-month period (or, if earlier, your death), the Company shall pay to you (or to your estate) the cumulative amounts that would have otherwise been payable to you during such period, without interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electing to accept this Agreement, you acknowledge receipt of this Agreement and hereby confirm your understanding that the terms set forth in this Agreement constitute, subject to the terms of the Plan, which terms shall control in the event of any conflict between the Plan and this Agreement, the entire agreement and understanding of the parties with respect to the matters contained herein and supersede any and all prior agreements, arrangements and understandings, both oral and written, between the parties concerning the subject matter of this Agreement.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Acknowledgement of Nature of Plan and Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting this Agreement, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of Units, or benefits in lieu of Units even if Units have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;your participation in the Plan is voluntary&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the grant of Units, the Shares subject to the Units, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;neither the grant of Units nor any provision of this Agreement, the Plan or the policies adopted pursuant to the Plan confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Units shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;in consideration of the grant of Units hereunder, no claim or entitlement to compensation or damages arises from termination of Units, and no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59; </font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Units, the Shares subject to the Units, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k) &#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Units and the benefits evidenced by this Agreement do not create any entitlement to have the Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)  for employment law purposes outside the United States, the Units, Shares subject to the Units, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(ii)  neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Units or of any amounts due to you pursuant to the settlement of the Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">No Advice Regarding Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares.  You should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Units granted hereunder shall be subject to any additional terms and conditions for your country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and to the following additional terms and conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;the terms and conditions of this Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration of the Plan&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;if applicable, the effectiveness of your award of Units is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;to the extent necessary to comply with applicable foreign laws, the payment of any earned Units shall be made in cash or Common Stock, at the Company&#8217;s election&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the Company may take any other action, before or after an award of Units is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained herein, the Company shall not take any actions hereunder that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange.  Notwithstanding anything to the contrary contained herein, the Shares issuable upon vesting of the Unit shall not be issued unless such Shares are then registered under the Securities Act, or, if such Shares are not then so registered, the Company has determined that such vesting and issuance would be exempt from the registration requirements of the Securities Act, and that the issuance satisfied all other applicable legal requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:11.69pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">.  In order for the Company to facilitate your participation in the Plan, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Units may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Units or other equity awards and administer or maintain such awards.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Agreement to be construed so as to foster the intent of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Further, if you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on your participation in the Plan, on the Units and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.71pt;text-decoration:underline">Compensation Subject to Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160; The Units subject to this Award and all compensation payable with respect to them shall be subject to recovery by the Company pursuant to&#160;any and all of the Company&#8217;s policies with respect to the recovery of compensation, as they shall be in effect and may be amended from time to time, to the maximum extent permitted by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement&#8217;s section headings are for convenience only and shall not constitute a part of this Agreement or affect this Agreement&#8217;s meaning.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">_____________________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Name&#58; </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><div id="id2f86f6f69ae46538487503eadfcff60_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GRANT OF RESTRICTED STOCK UNITS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(BY COUNTRY)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern any Units granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern any Units granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2021.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you vest in the Units and acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the notifications are general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding&#59; Issuance of Certificates.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your jurisdiction(s).  In the event of over-withholding, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., Units) or rights linked to the value of Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Dividend Equivalents) during such times as you are considered to have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">inside information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).&#160; Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information.  Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">need to know</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; basis) and (ii)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account, Tax Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any Dividends or Dividend Equivalents received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision replaces Section XIV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to staffing-hrconnect&#64;amgen.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Units may be deposited.  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARGENTINA</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; The following provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Agreement, you acknowledge, understand and agree that the grant of the Units is made by the Company (not your Employer) in its sole discretion and that the value of the Units or any Shares acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;Neither the Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Exchange control regulations in Argentina are subject to frequent change.&#160; You should consult with your personal legal advisor regarding any exchange </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">control obligations that you may have prior to receiving proceeds from Dividend Equivalents, the sale of Shares or dividends.&#160; You must comply with any and all Argentine currency exchange restrictions, approvals and reporting requirements in connection with your participation in the Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Australia Offer Document.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The offer of the Award is intended to comply with the provisions of the Corporations Act 2001, ASIC Regulatory Guide 49 and ASIC Class Order CO 14&#47;1000.  Additional details are set forth in the Offer Document for the Offer of Restricted Stock Units to Australian Resident Employees.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Units granted under the Plan, such that the Units are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160; If you are an Austrian resident and you hold Shares acquired under the Plan outside of Austria, you may be subject to reporting obligations to the Austrian National Bank.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; A separate reporting requirement applies when you sell Shares acquired under the Plan, receive a cash Dividend paid on such Shares or Dividend Equivalents paid in cash.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you are a Belgian resident, you are required to report any taxable income attributable to the Units granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the foreign security and&#47;or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.nbb.be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;A stock exchange tax applies to transactions executed by a Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker.  The stock exchange tax likely will apply when Shares acquired under the Plan are sold.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is your responsibility to comply with this tax obligation and y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ou should consult your personal tax advisor for additional details on your obligations with respect to the stock exchange tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Securities Accounts Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;An annual securities accounts tax may be payable if the total value of securities held in a Belgian or foreign securities account (e.g., Shares acquired under the Plan) exceeds a certain threshold on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30).  In such case, the tax will be due on the value of the qualifying securities held in such account.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is your responsibility to comply with this obligation and y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ou should consult with your personal tax or financial advisor for additional details.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the vesting of the Units, the sale of Shares acquired under the Plan, the payment of Dividends on such Shares and the receipt of any Dividend Equivalents paid in cash.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of Nature of Plan and Units.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Agreement, you acknowledge (i) that you are making an investment decision, (ii) that the Shares will be issued to you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$1,000,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv) leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$1,000,000 are not required to submit a declaration. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds BGN 50,000 as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Section I(i) of the Agreement is amended to read as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive any Units and vest under the Plan, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to the Units after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law.  You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting.  Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement &#8211; Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section&#160;9.5 of the Plan or anything to the contrary in the Agreement, the Units do not provide any right for you, as a resident of Canada, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The following provisions will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention (&#171;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#187;), ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XIV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Nasdaq Global Select Market). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified foreign property, including Shares, stock options and other rights to receive Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Units) of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such stock options and Units must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following terms apply only to individuals who are subject to exchange control restrictions in the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221;), as determined by the Company in its sole discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting of the Units. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;Notwithstanding anything to the contrary in Section I(d) of the Agreement, if your employment with the Company or an Affiliate terminates due to your Voluntary Termination, as defined in Section I(d), then the vesting of Units granted under this Agreement shall be accelerated to vest as of the day immediately preceding such Voluntary Termination with respect to all Units granted hereunder.&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in the Agreement, due to exchange control laws in the PRC, you agree that the Company reserves the right to require the immediate sale of any Shares issued upon settlement of the Units.  You understand and agree that any such immediate sale of Shares will occur as soon as is practical following settlement of the Units.  Alternatively, if the Shares are not immediately sold upon settlement of the Units, the Company will require the sale of any Shares you may then hold within six (6) months (or such other period as may be required under applicable legal or exchange control requirements) following the termination of your employment with the Company including its Affiliates.  </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Paragraph (d) of Section I of the Agreement is not applicable to awards identified by the Administrator as new hire, retention, special or promotion grants and the provisions of such paragraph shall be reserved and references thereto identified by an asterisk (*) shall be omitted from the agreements evidencing such grants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree that the Company is authorized to instruct Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company to assist with the sale of the Shares on your behalf pursuant to this authorization, and you expressly authorize such broker to complete the sale of such Shares.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company (or the Company&#8217;s designated broker) to effectuate the sale of the Shares (including, without limitation, as to the transfers of the proceeds and other exchange control matters noted below) and to otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur.  Upon the sale of the Shares, you will receive the cash proceeds from the sale, less any applicable Tax Obligations, brokerage fees or commissions, in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company is under no obligation to arrange for the sale of the Shares at any particular price.  Due to fluctuations in the Share price and&#47;or applicable exchange rates between the settlement date and (if later) the date on which the Shares are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the Shares on the settlement date (which is the amount relevant to determining your liability for Tax Obligations).  You understand and agree that the Company is not responsible for the amount of any loss that you may incur and that the Company assumes no liability for any fluctuations in the Share price and&#47;or any applicable exchange rate.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Designated Broker Account.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Shares issued upon the settlement of the Units are not immediately sold, you acknowledge that you are required to maintain the Shares in an account with Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company until the Shares are sold through such Company-designated broker.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that, pursuant to local exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued to you upon settlement of the Units and from the receipt of any Dividends or Dividend Equivalents to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; The following provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan and related benefits do not constitute a component of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for any purpose.  Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Investment in assets located abroad (such as Shares acquired under the Plan) does not require prior approval from the Central Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Banco de la Rep&#250;blica</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the Shares acquired at vesting (every year as long as you keep them).  This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US$22.000).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CROATIA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Units, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock Option Act.  To the extent more favorable to you and required to comply with the Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you transfer funds into Egypt in connection with the Units, you are required to transfer the funds through a registered bank in Egypt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  There are no specific reporting requirements with respect to foreign assets&#47;accounts.  However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported.  If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the grant, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained only in the unlikely event (i) you own at least 1% of the Company and the value of the Shares acquired exceeds &#8364;150,000 or (ii) you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of Dividends or Dividend Equivalents), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) can be accessed via the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> website (www.bundesbank.de) and is available in both German and English.  You are responsible for satisfying any applicable reporting obligation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement &#8211; Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section&#160;9.5 of the Plan or anything to the contrary in the Agreement, the Units do not provide any right for you to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Shares received at vesting are accepted as a personal investment.  In the event that Shares are issued in respect of the Units within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of the Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SECURITIES WARNING&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Units and any Shares issued in respect of the Units do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Units and any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan, regardless of the value of the Shares acquired under the Plan.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;You understand that you must repatriate any cash Dividends paid on Shares acquired under the Plan to India or any Dividend Equivalents paid in cash, as well as any proceeds from the sale of Shares acquired under the Plan within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash Dividends or Dividend Equivalents, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of Nature of Plan and Units.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XI of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Agreement, you understand and agree that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of Nature of Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In accepting this Agreement, you acknowledge that (1)&#160;you have received a copy of the Plan, the Agreement and this Appendix&#59; (2)&#160;you have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For any Units granted, you further acknowledge that you have read and specifically and explicitly approve, without limitation, the following sections of the Agreement&#58; Section&#160;I&#59; Section&#160;II&#59; Section&#160;III&#59; Section VIII&#59; Section X&#59; Section XI&#59; Section XVI&#59; Section XVII&#59; and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is subject to a foreign assets tax at a flat rate.  The fair market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any Shares or cash that you hold.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold on any month-end date during a calendar year.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible Employees of your Employer, the Company or an Affiliate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares).  If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of the Agreement.&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Award granted hereunder, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section XI of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan does not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of the Units granted and&#47;or Shares issued under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;In accepting any Award granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Spanish Translation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Al aceptar cualquier Otorgamiento bajo el presente documento, usted reconoce que ha recibido una copia del Plan, que ha revisado el mismo en su totalidad, as&#237; como tambi&#233;n el Acuerdo de Opci&#243;n, el Acuerdo, incluyendo este Ap&#233;ndice, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan y del Otorgamiento, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n XI del Acuerdo, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;El Plan y su participaci&#243;n en el mismo son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de Unidades o de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Al aceptar cualquier Otorgamiento de Acciones bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-M&#233;xico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Asimismo, usted entiende que su participaci&#243;n en el Plan es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Units and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="warninglabela.jpg" src="warninglabela.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return.  Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration.  Such information may then be pre-completed in a Norwegian resident&#8217;s tax return.  However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry.  If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Conhecimento da Lingua.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be required to repatriate certain cash amounts received with respect to the Units to Russia (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, cash Dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment.  If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia.  After the funds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.  Under the Directive N 5371-U of the Russian Central Bank (the &#8220;CBR&#8221;), the repatriation requirement may not apply in certain cases with respect to cash amounts received in an account that is considered by the CBR to be a foreign brokerage account.  Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You should consult with your personal legal advisor to determine the applicability of the repatriation requirement to any cash received in connection with your participation in the Plan and to ensure compliance with any applicable exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Any Units granted hereunder, the Agreement, including this Appendix, the Plan and all other materials you may receive regarding your participation in the Plan or any Units granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares under the Plan has not and will not be registered in Russia&#59; therefore, Shares may not be offered or placed in public circulation in Russia.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will Shares acquired under the Plan be delivered to you in Russia&#59; all Shares will be maintained on your behalf in the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are not permitted to sell any Shares acquired under the Plan directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge that if you continue to hold Shares acquired under the Plan after an involuntary termination of your employment, you will not be eligible to receive unemployment benefits in Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section XIV of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Units.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Russian residents are required to file the following reports or notifications with the Russian tax authorities, if applicable&#58; (i) annual cash flow reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; (ii) financial asset (including Shares) reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; and (ii) a one-time notification within one (1) month of opening, closing, or changing details of an offshore brokerage account.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are encouraged to contact your personal tax advisor before remitting your proceeds from participation in the Plan to Russia to ensure compliance with applicable requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby agree that any Shares acquired pursuant to the Units will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The grant of the Units is being made pursuant to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Units </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act, regardless of whether they are resident or employed in Singapore.  Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Units, Shares, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> when the Shares are sold), or (iii) becoming a director.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The following provision supplements Section XI of the Agreement&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Units granted hereunder, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant any Units under the Plan to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision, which is entered into upon the express assumption and condition that any Units granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the Agreement, including this Appendix.  Consequently, you understand that the Units granted hereunder are given on the assumption and condition that they shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of Units since the future value of the Units and the underlying Shares is unknown and unpredictable.  In addition, you understand that any Units granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of Units or right to Units shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, the vesting of the Units is expressly conditioned on your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Units may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section I of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">despido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or (5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Units that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you have read and specifically accept the conditions referred to in Section I of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">offer of securities to the public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.&#160;&#160;After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Authorization to Withhold.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Units, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon vesting or settlement to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Neither this document nor any other materials relating to the Awards (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company or one of its Subsidiaries or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">THAILAND</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If proceeds from the sale of Shares or the receipt of any Dividends or Dividend Equivalents exceed US$1,000,000, you must (i) immediately repatriate such funds to Thailand and (ii) report the inward remittance to the Bank of Thailand on a Foreign Exchange Transaction Form.  In addition, within three hundred and sixty (360) days of repatriation, you must either convert any funds repatriated to Thailand to Thai Baht or deposit the funds in a foreign exchange account with a Thai commercial bank.    Any such commercial bank must be duly authorized by the Bank of Thailand to engage in the purchase, exchange and withdrawal of foreign currency.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Units are made available only to employees of the Company and its Affiliates, and the offer of participation in the Plan is a private offering.  The grant of the Award and the issuance of Shares at vesting takes place outside of Turkey. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any activity related to investments in foreign securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the sale of Shares under the Plan, the receipt of cash Dividends or Dividend Equivalents) must be conducted through a bank or financial intermediary institution licensed by the Turkish Capital Markets Board and should be reported to the Turkish Capital Markets Board by the bank or intermediary assisting with the transaction.  You should contact a personal legal advisor for further information regarding these requirements.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Units under the Plan are granted only to select Board members and Employees of the Company and its Affiliates and are for the purpose of providing equity incentives.  The Plan and the Agreement are intended for distribution only to such Board members and Employees and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Units offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section III of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are an executive officer or director (as within the meaning of Section 13(k) of the Exchange Act, as amended from time to time), you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the amount of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section III of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Units, as a condition of the Units granted hereunder, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which may be payable by the Company or your Employer with respect to the Units and&#47;or payment of the Units and issuance of Shares pursuant to the Units, the assignment or release of the Units for consideration, or the receipt of any other benefit in connection with the Units.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs payments on any such gains shall be transferred to you to the fullest extent permitted by law. You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer. You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section III of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Units, without any liability to the Company or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision replaces Section I(i) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">termination of your active employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the last date that you are either an active employee of the Company or an Affiliate or actively engaged as a Director of the Company or an Affiliate&#59; in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive Units and vest under the Plan, if any, will terminate effective as of the date that you are no longer actively employed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such right will be extended by any notice period mandated by law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Worker Adjustment and Retraining Notification Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that notwithstanding the effect of any such extension, in no event will the Units be paid later than the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day following your termination of employment&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>amgn-ex107_20211231xq4.htm
<DESCRIPTION>FORM OF PERFORMANCE UNIT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib6f4cc8a64bb417aa12d3c453366ac23_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 10.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Award Notice</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank &#38; Trust Co., FSB).  This Award Notice shall be replaced by the equivalent pages on such website.  References to Award Notice in this Agreement shall then refer to the equivalent pages on such website.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#93; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This notice of Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth certain details relating to the grant by the Company to you of the Award identified below, pursuant to the Plan.  The terms of this Award Notice are incorporated into the Agreement that accompanies this Award Notice and made part of the Agreement.  Capitalized terms used in this Award Notice that are not otherwise defined in this Award Notice have the meanings given to such terms in the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award Type&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant ID&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan&#58;&#160;&#160;&#160;&#160;Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Program&#160;&#160;&#160;&#160;Amgen Inc. 2009 Performance Award Program, as amended and&#47;or restated from time to time</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of Shares&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Units&#58;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Period&#58;&#160;&#160;&#160;&#160;The Performance Period beginning on                           and ending on                           .</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Resolutions&#58;&#160;&#160;&#160;&#160;The Resolutions of the Compensation and Management Development Committee of the Board of Directors of Amgen Inc. establishing the performance goals and Performance Period applicable to this Award.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Means the vesting date indicated in the Vesting Schedule</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;&#160;&#160;&#160;&#160;Means the schedule of vesting set forth under Vesting Details </font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Details&#58;&#160;&#160;&#160;&#160;Means the presentation (tabular or otherwise) of the Vesting Date and the quantity of Shares vesting.</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-144pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">IMPORTANT NOTICE REGARDING ACCEPTANCE OF THE AWARD AND THE REQUIREMENT TO OPEN A BROKERAGE ACCOUNT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RESIDENTS OF THE U.S. AND PUERTO RICO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Please read this Award Notice, the Plan and the Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) carefully.  If you, as a resident of the U.S. or Puerto Rico, do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> wish to receive this Award and&#47;or you do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> consent and agree to the terms and conditions on which this Award is offered, as set forth in the Grant Documents, then you must reject the Award by contacting the Merrill Lynch call center (800) 97AMGEN (800-972-6436) within the U.S., Puerto Rico and Canada or +1 (609) 818-8910 from all other countries (Merrill Lynch will accept the charges for your call) no later than the forty-fifth calendar day following the day on which this Award Notice is made available to you, in which case the Award will be cancelled.  For the purpose of determining the forty-five calendar days, Day 1 will be the day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">immediately</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> following the day on which this Award Notice is made </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> This provision is only for use on the form of grant used for the U.S. and Puerto Rico.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available to you. Your failure to notify the Company of your rejection of the Award within this specified period will constitute your acceptance of the Award and your agreement with all terms and conditions of the Award, as set forth in the Grant Documents.  If you agree to the terms and conditions of your grant and you desire to accept it, then no further action is needed on your part to accept the grant.  However, you must still open a brokerage account as directed by the Company, by 1&#58;00 pm Pacific Time on or before the date that is 11 months after the date of grant.  This step is necessary to process transactions related to your equity grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">If you do not open a brokerage account by this deadline, your grant will be cancelled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><div id="ib6f4cc8a64bb417aa12d3c453366ac23_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERFORMANCE UNIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SPECIFIC TERMS OF YOUR GRANT OF PERFORMANCE UNITS ARE FOUND IN THE PAGES RELATING TO THE GRANT OF PERFORMANCE UNITS FOUND ON MERRILL LYNCH BENEFITS WEBSITE (OR THE WEBSITE OF ANY SUCCESSOR COMPANY TO MERRILL LYNCH BANK &#38; TRUST CO., FSB) (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AWARD NOTICE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;) WHICH ACCOMPANIES THIS DOCUMENT.  THE TERMS OF THE AWARD NOTICE ARE INCORPORATED INTO THIS PERFORMANCE UNIT AGREEMENT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;On the Grant Date specified in the Award Notice, Amgen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has granted to you, the grantee named in the Award Notice, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Number of Performance Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) specified in the Award Notice on the terms and conditions set forth in this Performance Unit Agreement (and any applicable additional terms and conditions for your country set forth in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (as described in greater detail in Section XIV below)) (collectively, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Plan, the Amgen Inc. 2009 Performance Award Program, as amended and&#47;or restated from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Resolutions (as defined in the Award Notice).  Capitalized terms not defined herein shall have the meanings assigned to such terms in the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Performance Period shall have the meaning set forth in the Award Notice.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Value of Performance Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The value of each Performance Unit is equal to a share of Common Stock.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.03pt;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An amount of the Performance Units up to the maximum amount specified in the Resolutions shall be earned, depending on the extent to which the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">achieves</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> objectively determinable performance goals established by the Committee pursuant to the Resolutions.  The Performance Units earned shall be calculated in accordance with the Resolutions and the Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Form and Timing of Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section XIII and subject to satisfaction of Tax Obligations or similar obligations as provided in Section V, and except as set forth in the Program, any Performance Units earned pursuant to Section III above shall be settled by the Company delivering to you a number of Shares equal to the number of Shares covered by the earned Performance Units or in a lump sum in cash with a value equal to the Fair Market Value of the number of Shares subject to the earned Performance Units as of the last day of the Performance Period (without interest thereon), or in a combination of Shares and cash, as determined by the Administrator at any time prior to settlement and in its discretion, as soon as practicable, and in any event within 90 days, after the last day of the Performance Period, in each case, subject to the terms of the Program (including Section 4.2 thereof).  Shares issued in respect of a Performance Unit shall be deemed to be issued in consideration of past services actually rendered by you to the Company or an Affiliate or for its benefit for which you have not previously been compensated or for future services to be rendered, as the case may be, which the Company deems to have a value at least equal to the aggregate par value thereof.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.02pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period by reason of your Voluntary Retirement and you are Retirement-Eligible on the date of such termination, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the full or prorated amount of your Award, if any, applicable to the Performance Period shall be paid in accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which your Voluntary Retirement occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which your Voluntary Retirement occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (b) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (b) shall supersede Section 7.1(a) of the Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Death and Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period by reason of your death or Permanent and Total Disability, the full or prorated amount of your Award, if any, applicable to such Performance Period shall be paid in accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which such termination occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which such termination occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, if your employment is terminated due to your Permanent and Total Disability, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (c) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (c) shall supersede Section 7.1(b) of the Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.02pt;text-decoration:underline">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that your employment with the Company or an Affiliate is terminated prior to the last business day of the Performance Period for any reason other than as specified in paragraphs (b) and (c) above, all of your rights to an Award for the Performance Period shall be forfeited, unless, prior to the payment date described in Article VI of the Program, the Company, in its sole discretion, makes a written determination to otherwise pay the full or prorated amount of your Award, if any, applicable to the Performance Period, which full or prorated amount shall be paid in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance with the provisions of Article VI of the Program.  For purposes of the foregoing, if the payment of your Award is prorated, the amount of your Award (rounded down to the nearest whole number) shall be determined based on the Company&#8217;s performance as compared to the Performance Goals for the Performance Period and (i) if the Award was granted with respect to a Performance Period commencing in a calendar year prior to the calendar year in which such termination occurs, the full amount of the Award is payable, and (ii) if the Award was granted with respect to the Performance Period commencing in the calendar year in which such termination occurs, the Award otherwise payable is multiplied by a fraction (rounded to two decimal places), the numerator of which is the number of complete months of employment during such calendar year, and the denominator of which is twelve (12).  Notwithstanding the foregoing, you shall not be entitled to such full or prorated amount of your Award pursuant to this paragraph (d) unless either you sign a general release and waiver in a form provided by the Company (for the purpose of resolving any potential or actual disputes arising from your employment and the termination of your employment with the Company) and deliver it to the Company no later than the date specified by the Company, or the Company waives such release requirement in writing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event shall payment of such full or prorated amount of your Award be made later than the specified payment date as set forth in Section 6.1 of the Program.  This paragraph (d) shall supersede Section 7.1(c) of the Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Issuance of Shares&#59; Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Regardless of any action the Company or your actual employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax (including federal, state and local taxes), social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to your participation in the Plan and the Program and legally applicable to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you acknowledge that the ultimate liability for all Tax Obligations is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or your Employer.  You further acknowledge that the Company and&#47;or your Employer (i) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Performance Units or the underlying Shares, including the grant of the Performance Units, the vesting of the Performance Units, the conversion of the Performance Units into shares or the receipt of an equivalent cash payment, the subsequent sale of any shares acquired at settlement and the receipt of any Dividends (as defined in Section VI, below) or Dividend Equivalents&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Performance Units to reduce or eliminate your liability for Tax Obligations or to achieve any particular tax result.  Furthermore, if you become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or your Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to any relevant taxable or tax withholding event, as applicable, you shall pay or make adequate arrangements satisfactory to the Company or to your Employer (in their sole discretion) to satisfy all Tax Obligations.  In this regard, you authorize the Company and&#47; or your Employer, or their respective agents, at their discretion, to satisfy all applicable Tax Obligations by one or a combination of the following&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a) &#160;&#160;&#160;&#160;withholding from your wages or other cash compensation paid to you by the Company and&#47;or your Employer&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;withholding from proceeds of the sale of Shares issued upon settlement of the Performance Units, either through your voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;withholding in Shares issuable, or cash to be paid, upon settlement of the Performance Units provided that, if such Shares are withheld, the Company and your Employer shall only withhold an amount of Shares with a fair market value not to exceed the Tax Obligations as determined in the discretion of the Company or your Employer, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depending on the withholding method, the Company may withhold or account for Tax Obligations by considering applicable minimum statutory withholding rates or other applicable withholding rates, including maximum applicable rates.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes you are deemed to have been issued the full number of Shares subject to the earned Performance Units, notwithstanding that a number of Shares is held back and not issued solely for the purpose of paying the Tax Obligations due as a result of any aspect of your participation in the Plan (any Shares withheld by the Company hereunder shall not be deemed to have been issued by the Company for any purpose under the Plan and shall remain available for issuance thereunder).</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you shall pay to the Company or your Employer any amount of Tax Obligations that the Company or your Employer may be required to withhold or account for as a result of your participation in the Plan and the Program that cannot be or were not satisfied by the means previously described.  You agree to take any further actions and to execute any additional documents as may be necessary to effectuate the provisions of this Section V.  Notwithstanding Section IV above, the Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if you fail to comply with your obligations in connection with the Tax Obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Dividend Equivalents</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Crediting of Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to this Section VI, Dividend Equivalents shall be credited on each Performance Unit granted to you under this Agreement in the manner set forth in the remainder of this Section VI.  If the Company declares one or more dividends or distributions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on its Common Stock with a record date which occurs during the period commencing on the Grant Date through and including the day immediately preceding the day the Shares subject to the Performance Units are issued to you, whether in the form of cash, Common Stock or other property, then, on the date such  Dividend is paid to the Company&#8217;s stockholders, you shall be credited with an amount equal to the amount or fair market value of such Dividend which would have been payable to you if you held a number of Shares equal to the number of Performance Units granted to you on the Grant Date (including any previously credited Dividends which have been deemed to have been reinvested in Common Stock as provided by the next succeeding sentence), as of each such record date for each such Dividend (not including on any Performance Units which were previously paid or forfeited) as if each such amount had been reinvested in Common Stock as of the date of the payment of such Dividend (such accumulated dividends, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Accumulated Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each such Dividend Equivalent shall be deemed to have been reinvested in Common Stock as of the Dividend payment date.  Dividend Equivalents shall be payable in full Shares, unless the Administrator determines, at any time prior to payment and in its discretion, that they shall be payable in cash.  Dividend Equivalents payable with respect to fractional Shares shall be paid in cash.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Treatment of Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise expressly provided in this Section VI any Dividend Equivalents credited to you shall be subject to all of the provisions of this Agreement which apply to the Performance Units with respect to which they have been credited and shall be payable, if at all, at the time and to the extent that the underlying Performance Unit becomes payable.  Dividend Equivalents shall not be payable on any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Units that do not vest, or are forfeited, pursuant to the terms of this Agreement.  Dividend Equivalent rights and any amounts that may become distributable in respect thereof shall be treated separately from the Performance Units and the rights arising in connection therewith for purposes of the designation of time and form of payments required by Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No benefit payable under, or interest in, this Agreement or in the Shares that may become issuable to you hereunder shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge and any such attempted action shall be void and no such benefit or interest shall be, in any manner, liable for, or subject to, your or your beneficiary&#8217;s debts, contracts, liabilities or torts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, nothing in this Section VII shall prevent transfer (i) by will or (ii) by applicable laws of descent and distribution. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">No Contract for Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is not an employment or service contract with the Company or an Affiliate and nothing in this Agreement shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment or service with the Company or an Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting the grant of Performance Units, you acknowledge, understand and agree that&#58; </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the Plan and the Program are established voluntarily by the Company, are discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, as provided in the Plan and in the Program&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the grant of the Performance Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future awards of Performance Units, or benefits in lieu of Performance Units, even if Performance Units have been awarded in the past&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;your participation in the Plan and the Program is voluntary&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the grant of Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;neither the grant of Performance Units nor any provision of this Agreement, the Plan, the Program or the policies adopted pursuant to the Plan or Program confer upon you any right with respect to employment or continuation of current employment and shall not interfere with the ability of your Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) &#160;&#160;&#160;&#160;in the event that you are not an employee of the Company or any Affiliate, the Performance Units shall not be interpreted to form an employment contract or relationship with the Company or any Affiliate&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;the future value of the Shares that may be earned upon the end of the Performance Period is unknown, indeterminable, and cannot be predicted with certainty&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160; in consideration of the grant of Performance Units hereunder, no claim or entitlement to compensation or damages arises from termination of Performance Units, and no claim or entitlement to compensation or damages shall arise from forfeiture of the Performance Units resulting from termination of your employment by the Company or an Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and you irrevocably release the Company and your Employer from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, you shall be deemed irrevocably to have waived your entitlement to pursue such claim&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;in the event of termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive Performance Units and receive shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, active employment would not include a period of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">garden leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of an Affiliate of the Company&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;except as otherwise provided in this Agreement or the Plan, the Performance Units and the benefits evidenced by this Agreement do not create any entitlement to have the Performance Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;the following provisions apply only if you are providing services outside the United States&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;for employment law purposes outside the United States, the Performance Units, the Shares subject to the Performance Units, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;neither the Company, your Employer nor any Affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Performance Units or of any amounts due to you pursuant to the settlement of the Performance Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan and the Program, or your acquisition or sale of the underlying Shares.  You should </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consult with your personal tax, legal and financial advisors regarding your participation in the Plan and the Program before taking any action related thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.35pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement, the Plan or the Program shall be given in writing or electronically and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail or equivalent foreign postal service, postage prepaid, addressed to you at such address as is currently maintained in the Company&#8217;s records or at such other address as you hereafter designate by written notice to the Company Stock Administrator.  Such notices may be given using any automated system for the documentation, granting or settlement of Awards, such as a system using an internet website or interactive voice response, as approved by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt;text-decoration:underline">Resolutions, Plan and Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is subject to all of the provisions of the Resolutions, the Plan and the Program and their provisions are hereby made a part of this Agreement and incorporated herein by reference, including, without limitation, the provisions of Articles 5 and 9 of the Plan (relating to Performance-Based Compensation and Performance Awards, respectively) and Section 13.2 of the Plan (relating to adjustments upon changes in the Common Stock), and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of this Agreement and those of the Resolutions, the Plan and the Program, the provisions of the Plan shall control.  Notwithstanding any provision of this Agreement or the Program to the contrary, any earned Performance Units paid in cash rather than Shares shall not be deemed to have been issued by the Company for any purpose under the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.37pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The time and form of payment of the Performance Units is intended to comply with the requirements of Section 409A and this Agreement shall be interpreted in accordance with Section 409A. Accordingly, no acceleration or deferral of any payment shall be permitted if it would cause the payment of the Performance Units to violate Section 409A.  In addition, notwithstanding any provision herein to the contrary, in the event that following the Grant Date, the Committee determines that it may be necessary or appropriate to do so, the Committee may adopt such amendments to the Plan, Program and&#47;or this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the Plan, Program and&#47;or the Performance Units from the application of Section 409A and&#47;or preserve the intended tax treatment of the benefits provided with respect to this Award, or (b) comply with the requirements of Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this paragraph shall not create an obligation on the part of the Committee to adopt any such amendment, policy or procedure or take any such other action.  No payment hereunder shall be made to you during the six (6)-month period following your &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (within the meaning of Section 409A) to the extent that the Company determines that paying such amount at the time set forth herein would be a prohibited distribution under Section 409A(a)(2)(B)(i). If the payment of any such amounts is delayed as a result of the previous sentence, then within thirty (30) days following the end of such six (6)-month period (or, if earlier, your death), the Company shall pay to you (or to your estate) the cumulative amounts that would have otherwise been payable to you during such period, without interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Provisions Applicable to Participants in Foreign Jurisdictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provision of this Agreement or the Program to the contrary, if you are employed by the Company or an Affiliate in any of the countries identified in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (which constitutes a part of this Agreement), are subject to the laws of any foreign jurisdiction, or relocate to one of the countries included in the attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, your award of Performance Units shall be subject to any additional terms and conditions for such country set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and to the following additional terms and conditions&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the terms and conditions of this Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, are deemed modified to the extent necessary or advisable to comply with applicable foreign laws or facilitate the administration of the Plan and the Program&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if applicable, the effectiveness of your Award is conditioned upon its compliance with any applicable foreign laws, regulations, rules or local governmental regulatory exemption and subject to receipt of any required foreign regulatory approvals&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;to the extent necessary to comply with applicable foreign laws, the payment of any earned Performance Units shall be made in cash or Common Stock, at the Company&#8217;s election&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;the Committee may take any other action, before or after an award of Performance Units is made, that it deems necessary or advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained herein, the Company shall not take any actions hereunder, and no Award of Performance Units shall be granted, and no Shares payable with respect to an Award shall be issued, that would violate the Securities Act, the Exchange Act, the Code, or any other securities or tax or other applicable law or regulation, or the rules of any Securities Exchange. Notwithstanding anything to the contrary contained herein, no Shares issuable with respect to an Award shall be issued unless such shares are then registered under the Securities Act, or, if such shares are not then so registered, the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act and that the issuance satisfied all other applicable legal requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:15.68pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">. In order for the Company to facilitate your participation in the Plan and the Program, the Company and your Employer must collect and use personal data about you.  In accordance with applicable laws, reasonable security measures will be implemented and maintained to protect the security of your personal data&#59; however, you understand that absolute security cannot be guaranteed.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You understand that the Company and your Employer may hold certain personal information about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor, for the purposes of implementing, administering and managing the Plan and the Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan and the Program to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan and the Program, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Performance Units may be deposited.  You understand that such authorized recipients of your personal data may be located in countries that do not provide the same level of data privacy laws and protections as the country in which your personal data originated.  Transfers of personal data among Company and its group entities follow applicable laws and our Binding Corporate Rules (BCRs). For more information on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company&#8217;s BCRs, please visit http&#58;&#47;&#47;www.amgen.com&#47;bcr&#47;.  You acknowledge that the collection, use and transfer of your personal data is necessary to facilitate to your participation in the Plan, as well as to grant you Performance Units or other equity awards and administer or maintain such awards.   </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You may correct or update your personal data previously provided to Company, by completing the form located at&#160;https&#58;&#47;&#47;preferences.amgen.com.  Subject to applicable law, you may have additional rights, including the right to object and&#47;or request destruction of your personal data.  To exercise these rights, where applicable, please contact your local human resources representative.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By electing to accept this Agreement, you acknowledge that you are sufficiently proficient in English, or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement.  Furthermore, if you have received this Agreement or any other document related to the Plan and&#47;or the Program translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this Agreement shall be governed by the laws of the State of Delaware without giving effect to principles of conflicts of laws.  For purposes of litigating any dispute that arises hereunder, the parties hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that such litigation shall be conducted in the courts of the State of Delaware, or the federal courts for the United States for the federal district located in the State of Delaware, and no other courts, where this Agreement is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XVIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.71pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Agreement to be construed so as to foster the intent of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XIX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide to&#160;deliver any documents related to current or future participation in the Plan and&#47;or the Program (including this Agreement) by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.68pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on your participation in the Plan and the Program, on the Performance Units and on any Shares acquired under the Plan and the Program, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XXI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.69pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">XXII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.7pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement&#8217;s section headings are for convenience only and shall not constitute a part of this Agreement or affect this Agreement&#8217;s meaning.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;___________________________<br>Name&#58; </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font></div></div></div><div id="ib6f4cc8a64bb417aa12d3c453366ac23_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. 2009 EQUITY INCENTIVE PLAN, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND&#47;OR RESTATED FROM TIME TO TIME</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AWARD OF PERFORMANCE UNITS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(BY COUNTRY)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix A shall have the meanings set forth in the Plan and&#47;or the Agreement to which this Appendix is attached.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern any Performance Units granted under the Plan if, under applicable law,&#160;you are a resident of, are deemed to be a resident of or are working in one of the countries listed below.&#160; Furthermore, the additional terms and conditions that govern the Performance Units granted hereunder may apply to you if you transfer employment and&#47;or residency to one of the countries listed below and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes notifications relating to exchange control and other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries to which this Appendix refers as of October 2021.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the notifications herein as the only source of information relating to the consequences of your participation in the Plan because the information may be outdated when you acquire Shares under the Plan, or when you subsequently sell Shares acquired under the Plan and the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the notifications are gen eral in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.  Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you or you may be subject to the provisions of one or more jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL NON-U.S. JURISDICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issuance of Certificates&#59; Tax Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section V. of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Company withholds or accounts for Tax Obligations by considering maximum applicable rates in your </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jurisdiction(s).  In the event of over-withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, you may receive a refund of any over-withheld amount in cash and will not be entitled to the equivalent amount in Shares, or if not refunded, you may seek a refund from the local tax authorities.  In the event of under-withholding, you may be required to pay any additional Tax Obligations directly to the applicable tax authority or to the Company and&#47;or your Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Insider Trading Restrictions&#47;Market Abuse Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker&#8217;s country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., Performance Units) or rights linked to the value of Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Dividend Equivalents) during such times as you are considered to have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">inside information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).&#160; Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you place before you possessed inside information.  Furthermore you could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees (other than on a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">need to know</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; basis) and (ii)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; You are responsible for ensuring your compliance with any applicable restrictions and you should speak with your personal legal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account, Tax Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your country of residence may have certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any Dividends or Dividend Equivalents received, or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside of your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt.  You are responsible for ensuring your compliance with such regulations, and you should speak with your personal legal advisor on this matter.  </font></div><div style="margin-bottom:12pt;text-indent:31.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ALL EUROPEAN ECONOMIC AREA (&#8220;EEA&#8221;) &#47; EUROPEAN UNION (&#8220;EU&#8221;) JURISDICTIONS, UNITED KINGDOM AND SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision replaces Section XV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Please refer to the Fair Processing Notice previously provided by your local human resources representative, which notice governs the collection, use and transfer of your personal data necessary for the Company to facilitate your participation in the Plan and the Program.  If you have any questions or concerns regarding the Fair Processing Notice, including questions about your rights afforded thereunder, you should contact your local human resources representative or send an email to staffing-hrconnect&#64;amgen.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">For purposes of implementing, administering and managing the Plan, Company and your Employer may hold certain personal data about you, including your name, home address and telephone number, email address, date of birth, social insurance&#47;security number (to the extent permitted under applicable local law), passport or other identification number, salary, nationality, job title&#47;work history&#47;service periods, residency status, citizenship, tax withholding and payroll data, any shares of stock or directorships held in the Company, details of all equity compensation or any other entitlement to Shares awarded, cancelled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">personal data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;).  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">You authorize the transfer of your personal data to Merrill Lynch Bank &#38; Trust Co., FSB, or any successor thereto, and any other third parties which may assist the Company (presently or in the future) with implementing, administering and managing your participation in the Plan and the Program to receive, possess, use, retain and transfer your personal data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan and the Program, including any requisite transfer of such personal data as may be required to any other broker, escrow agent or other third party with whom the Shares received in settlement of the Performance Units may be deposited.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARGENTINA</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Performance Units, you acknowledge, understand and agree that the grant of the Performance Units is made by the Company (not your Employer) in its sole discretion and that the value of the Performance Units or any Shares acquired under the Plan and the Program shall not constitute salary or wages for any purpose under Argentine labor law including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, etc., or (ii) any termination or severance indemnities or similar payments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;Neither the Performance Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; Exchange control regulations in Argentina are subject to frequent change.&#160; You should consult with your personal legal advisor regarding any exchange control obligations that you may have prior to receiving proceeds from Dividend Equivalents, the sale of Shares or dividends.&#160; You must comply with any and all Argentine currency exchange restrictions, approvals and reporting requirements in connection with your participation in the Plan and the Program. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Argentine resident, you are required to report certain information regarding any Shares you hold as of December 31 each year to the Argentine tax authorities on your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Australia Offer Document.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The offer of the Award is intended to comply with the provisions of the Corporations Act 2001, ASIC Regulatory Guide 49 and ASIC Class Order CO 14&#47;1000.  Additional details are set forth in the Offer Document for the Offer of Performance Units to Australian Resident Employees.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the Performance Units granted under the Plan, such that the Performance Units are intended to be subject to deferred taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on your behalf.  If there is no Australian bank involved in the transfer, you will be required to file the report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; If you are an Austrian resident and you hold Shares acquired under the Plan and the Program outside of Austria, you may be subject to reporting obligations to the Austrian National Bank. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A separate reporting requirement applies when you sell Shares acquired under the Plan and the Program, receive a cash Dividend paid on such Shares or Dividend Equivalents paid in cash.  In that case, there may be exchange control obligations if the cash proceeds are held outside of Austria.  If the transaction volume of all cash accounts abroad meets or exceeds a specified threshold, the movements and balances of all accounts must be reported monthly, as of the last day of the month, on or before the 15th day of the following month, on the prescribed form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Meldungen SI-Forderungen und&#47;oder SI-Verpflichtungen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Reporting&#59; Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;If you are a Belgian resident, you are required to report any taxable income attributable to the Award granted hereunder on your annual tax return.  You are also required to report any securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan and the Program) held and bank accounts (including brokerage accounts) opened and maintained outside of Belgium on your annual tax return.  The first time you report the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-4</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foreign security and&#47;or bank account on your annual income tax return you will have to provide the National Bank of Belgium Central Contact Point with the account details of any such foreign accounts (including the account number, bank name and country in which such account was opened) in a separate form.  This report, as well as information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Kredietcentrales &#47; Centrales des cr&#233;dits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> caption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;A stock exchange tax applies to transactions executed by a Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker.  The stock exchange tax likely will apply when Shares acquired under the Plan and the Program are sold.  It is your responsibility to comply with this tax obligation and you should consult your personal tax advisor for additional details on your obligations with respect to the stock exchange tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Securities Accounts Tax Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;An annual securities accounts tax may be payable if the total value of securities held in a Belgian or foreign securities account (e.g., Shares acquired under the Plan and the Program) exceeds a certain threshold on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30).  In such case, the tax will be due on the value of the qualifying securities held in such account.  It is your responsibility to comply with this obligation and you should consult with your personal tax or financial advisor for additional details.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BRAZIL</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the Performance Units, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the vesting of the Performance Units, the sale of Shares acquired under the Plan and the Program, the payment of Dividends on such Shares and the receipt of any Dividend Equivalents paid in cash.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Performance Units, you acknowledge (i) that you are making an investment decision, (ii) that the Shares will be issued to you only if the vesting conditions are met and any necessary services are rendered by you during the vesting period set forth in the Vesting Schedule, and (iii) that the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are resident or domiciled in Brazil, you will be required to submit annually a declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights on December 31 of each year exceeds US$1,000,000.  If such amount exceeds US$100,000,000, the referenced declaration must be submitted quarterly, in the month following the end of each quarter.  Assets and rights that must be reported include the following&#58; (i) bank deposits&#59; (ii) loans&#59; (iii) financing transactions&#59; (iv)&#160;leases&#59; (v) direct investments&#59; (vi) portfolio investments, including Shares acquired under the Plan and the Program&#59; (vii) financial derivatives investments&#59; and (viii) other investments, such as real estate.  Please note that foreign individuals holding Brazilian visas are considered Brazilian residents for purposes of this reporting requirement and must declare at least the assets held abroad that were acquired subsequent to the date of admittance as a resident of Brazil.  Individuals holding assets and rights outside of Brazil valued at less than US$1,000,000 are not required to submit a declaration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-5</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be required to annually file statistical forms with the Bulgarian National Bank regarding your receivables in bank accounts abroad as well as your securities abroad (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares acquired under the Plan) if the total sum of all such receivables and securities equals or exceeds BGN 50,000 as of the previous calendar year-end.&#160; The reports are due by March 31.  You should contact your bank in Bulgaria for additional information regarding this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination of Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section IX(j) of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the event of involuntary termination of your employment (regardless of the reason for such termination and whether or not later found to be invalid or unlawful, including for breaching employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to receive an Award and vest in such Award under the Plan and the Program, if any, will terminate effective as of the date that is the earlier of&#58; (1) the date you receive written notice of termination of employment from the Company or your Employer, or (2) the date you are no longer actively employed by the Company or your Employer regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law.  Your right, if any, to acquire Shares pursuant to an Award after termination of employment will be measured by the date of termination of your active employment and will not be extended by any notice period mandated under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the Performance Units, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement - Performance Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section 9.5 of the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Canada, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The following provisions will apply to you if you are a resident of Quebec&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif&#160;&#224; la Langue Utilis&#233;e.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention (&#171;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#187;), ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section XV of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-6</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representative to discuss with and obtain all relevant information from all personnel (professional or not) involved in the administration of the Plan and the Program.  You further authorize the Company, your Employer and Merrill Lynch Bank &#38; Trust Co., FSB (or any other stock plan service provider) to disclose and discuss your participation in the Plan with their advisors.  You also authorize the Company and your Employer to record such information and keep it in your file.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are permitted to sell Shares acquired through the Plan through the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Nasdaq Global Select Market).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified foreign property, including Shares, stock options and other rights to receive Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Performance Units) of a non-Canadian company held by a Canadian resident employee generally must be reported annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the employee&#8217;s specified foreign property exceeds C$100,000 at any time during the year.  Thus, such stock options and Performance Units must be reported &#8211; generally at nil cost &#8211; if the C$100,000 cost threshold is exceeded because other specified foreign property is held by the employee.  When Shares are acquired, their cost generally is the adjusted cost base (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ACB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Shares.  The ACB ordinarily would equal the fair market value of the Shares at the time of acquisition, but if the employee owns other shares of the same company, this ACB may have to be averaged with the ACB of the other shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CHINA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following terms apply only to individuals who are subject to exchange control restrictions in the People&#8217;s Republic of China (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">PRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221;), as determined by the Company in its sole discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting of the Performance Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary in Article 7.1 of the Program, if your employment with the Company or an Affiliate terminates at any time during the Performance Period, you shall forfeit all Performance Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in the Agreement, due to exchange control laws in the PRC, you agree that the Company reserves the right to require the immediate sale of any Shares acquired upon settlement of the Performance Units.  You understand and agree that any such immediate sale of Shares will occur as soon as is practical following settlement of the Performance Units.  Alternatively, if the Shares are not immediately sold upon settlement of the Performance Units, the Company will require the sale of any Shares you may then hold within six (6) months (or such other period as may be required under applicable legal or exchange control requirements) following the termination of your employment with the Company, including its Affiliates.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree that the Company is authorized to instruct Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company to assist with the sale of the Shares on your behalf pursuant to this authorization, and you expressly authorize such broker to complete the sale of such Shares.  You also agree to sign any agreements, forms and&#47;or consents that may be reasonably requested by the Company (or the Company&#8217;s designated broker) to effectuate the sale of the Shares (including, without limitation, as to the transfers of the proceeds </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-7</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other exchange control matters noted below) and to otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur.  Upon the sale of the Shares, you will receive the cash proceeds from the sale, less any applicable Tax Obligations, brokerage fees or commissions, in accordance with applicable exchange control laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company is under no obligation to arrange for the sale of the Shares at any particular price.  Due to fluctuations in the Share price and&#47;or applicable exchange rates between the settlement date and (if later) the date on which the Shares are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the Shares on the settlement date (which is the amount relevant to determining your liability for Tax Obligations).  You understand and agree that the Company is not responsible for the amount of any loss that you may incur and that the Company assumes no liability for any fluctuations in the Share price and&#47;or any applicable exchange rate.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Designated Broker Account.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Shares issued upon the settlement of the Performance Units are not immediately sold, you acknowledge that you are required to maintain the Shares in an account with Merrill Lynch Bank &#38; Trust Co., FSB or such other designated broker as may be selected by the Company until the Shares are sold through such Company-designated broker.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that, pursuant to local exchange control requirements, you will be required to repatriate the cash proceeds from the sale of the Shares issued upon settlement of the Performance Units and from the receipt of any Dividends or Dividend Equivalents to China.  You further understand that, under applicable laws, such repatriation of your cash proceeds will need to be effectuated through a special exchange control account established by the Company or any Affiliate, including your Employer, and you hereby consent and agree that any proceeds may be transferred to such special account prior to being delivered to you.  You also understand that the Company will deliver the proceeds to you as soon as possible, but that there may be delays in distributing the funds to you due to exchange control requirements in China.  Proceeds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  If the proceeds are paid to you in U.S. dollars, you will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account.  If the proceeds are paid to you in local currency, the Company is under no obligation to secure any particular currency conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions.  You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COLOMBIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that pursuant to Article 15 of Law 50&#47;1990 (Article 128 of the Colombian Labor Code), the Plan, the Program and related benefits do not constitute a component of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for any purpose. Therefore, they are considered to be of an extraordinary nature and will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amounts, subject to the limitations provided in Law 1393&#47;2010.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-8</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Shares are not and will not be registered with the Colombian registry of publicly traded securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registro Nacional de Valores y Emisores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and therefore the Shares may not be offered to the public in Colombia.  Nothing in this document should be construed as the making of a public offer of securities in Colombia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment in assets located abroad (such as Shares acquired under the Plan and the Program) does not require prior approval from the Central Bank (Banco de la Rep&#250;blica).  Nonetheless, such investments are subject to registration before the Central Bank as foreign investments held abroad, regardless of value.  In addition, you must file an annual informative return with the local tax authority detailing assets you hold abroad, which must include the Shares acquired at vesting (every year as long as you keep them).  This obligation is only applicable if the assets held abroad exceed the amount of 2,000 Tax Units (approx. US $22.000).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any payments for your investment originating in Colombia (and the liquidation of such investments) must be transferred through the Colombian foreign exchange market (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, local banks), which includes the obligation to correctly complete and file the appropriate foreign exchange form (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">declaraci&#243;n de cambio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CROATIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Croatian residents may be required to report any foreign investments (including Shares acquired under the Plan and the Program) to the Croatian National Bank for statistical purposes.  You should be aware that exchange control regulations in Croatia are subject to frequent change and you are solely responsible for ensuring your continued compliance with current Croatian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A Czech resident may be required to notify the Czech National Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CNB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the acquisition of Shares under the Plan or maintenance of a foreign account if (i) he or she maintains foreign direct investments with a value of 2,500,000 K&#269; or more in the aggregate, (ii) he or she maintains other foreign financial assets with a value of 200,000,000 K&#269; or more, or (iii) the Czech resident is specifically requested to do so by the CNB.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DENMARK</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Danish Stock Option Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Performance Units, you acknowledge that you have received an Employer Statement translated into Danish, which is being provided to comply with the Danish Stock Option Act.  To the extent more favorable to you and required to comply with the Stock Option Act, as amended with effect from January 1, 2019.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The requirement to report certain information to the Danish Tax Administration via Form V or K was eliminated effective January 1, 2019.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-9</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">However, you still must report the foreign bank&#47;brokerage accounts and their deposits, and Shares held in a foreign bank or brokerage account in your tax return under the section on foreign affairs and income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EGYPT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you transfer funds into Egypt in connection with the Performance Units, you are required to transfer the funds through a registered bank in Egypt.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no specific reporting requirements with respect to foreign assets&#47;accounts. However, please note that you must check your pre-completed tax return to confirm that the ownership of Shares and other securities (foreign or domestic) are correctly reported. If you find any errors or omissions, you must make the necessary corrections electronically or by sending specific paper forms to the local tax authorities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By accepting the Award, you confirm having read and understood the Plan and Agreement which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement Relatif &#224; la Langue Utilis&#233;e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  En acceptant l&#8217;prix, vous confirmez avoir lu et compris le Plan et le Contrat, qui ont &#233;t&#233; communiqu&#233;s en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  French residents and non-residents must declare to the Customs Authorities the cash and securities they import or export without the use of a financial institution when the value of such cash or securities exceeds &#8364;10,000.  French residents also must report all foreign bank and brokerage accounts on an annual basis (including accounts opened or closed during the tax year) on Form N&#176; 3916, together with the income tax return.  Failure to comply could trigger significant penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If your acquisition of Shares under the Plan leads to a qualified participation at any point during the calendar year, you will need to report the acquisition when you file your tax return for the relevant year.  A qualified participation is attained </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">only in the unlikely event (i) you own at least 1% of the Company and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the value of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-10</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shares acquired exceeds &#8364;150,000 or (ii) you hold Shares exceeding 10% of the Company&#8217;s total Common Stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In case of payments in connection with securities (including proceeds realized upon the sale of Shares or the receipt of Dividends or Dividend Equivalents), the report must be made by the 5th day of the month following the month in which the payment was received and must be filed electronically.  The form of report (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Allgemeines Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) can be accessed via the Bundesbank&#8217;s website (www.bundesbank.de) and is available in both German and English. You are responsible for satisfying any applicable reporting obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GREECE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The reporting of foreign assets (including Shares and other investments) is your own obligation and takes place through your annual tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Settlement - Performance Units Payable Only in Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Notwithstanding any discretion in Section 9.5 of the Plan or the Program or anything to the contrary in the Agreement, the Award does not provide any right for you, as a resident of Hong Kong, to receive a cash payment and shall be paid in Shares only.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sale of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Shares received at vesting are accepted as a personal investment.  In the event that Shares are issued in respect of Performance Units within six (6) months of the Grant Date, you agree that you will not offer to the public or otherwise dispose of such Shares prior to the six (6)-month anniversary of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SECURITIES WARNING&#58;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in doubt about any of the contents of the Agreement, including this Appendix, or the Plan, you should obtain independent professional advice.  The Performance Units and any Shares issued in respect of the Performance Units do not constitute a public offering of securities under Hong Kong law and are available only to members of the Board and Employees.  The Agreement, including this Appendix, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong.  The Performance Units and any documentation related thereto are intended solely for the personal use of each member of the Board and&#47;or Employee and may not be distributed to any other person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HUNGARY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-11</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ICELAND</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Approval by the Central Bank of Iceland is no longer required to participate in the Plan and the Program, regardless of the value of the Shares acquired under the Plan and the Program.  Despite the recent relaxation of the exchange control requirements, you should consult with your personal advisor to ensure compliance with applicable exchange control regulations in&#160;Iceland as such regulations are subject to frequent change.  You are responsible for ensuring compliance with all exchange control laws in&#160;Iceland.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;You understand that you must repatriate any cash Dividends paid on Shares acquired under the Plan and the Program to India or any Dividend Equivalents paid in cash, as well as any proceeds from the sale of Shares within a prescribed period of time (currently, within one hundred and eighty (180) days of receipt of cash Dividends or Dividend Equivalents, and within ninety (90) days of receipt of sale proceeds), or such other period of time as may be required under applicable regulations.  You will receive a foreign inward remittance certificate (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FIRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the bank where you deposit the foreign currency, and you must maintain the FIRC as proof of repatriation of funds in the event that the Reserve Bank of India or your Employer requests proof of repatriation.  It is your responsibility to comply with these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You are required to declare foreign bank accounts and any foreign financial assets (including Shares held outside of India) in your annual tax return.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor in this regard.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section IX of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the grant of Performance Units, you acknowledge that the benefits received under the Plan will not be taken into account for any redundancy or unfair dismissal claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In accepting the grant of Performance Units, you acknowledge that (1)&#160;you have received a copy of the Plan, the Program, the Agreement and this Appendix&#59; (2)&#160;you have reviewed the applicable documents in their entirety and fully understand the contents thereof&#59; and (3)&#160;you accept all provisions of the Plan, the Program, the Agreement and this Appendix.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further acknowledge that you have read and specifically and explicitly approve, without limitation, the following sections of the Agreement&#58; Section III, Section IV, Section V, Section IX, Section IV, Section XVI, Section XX and the Data Privacy Notice for All European Economic Area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) &#47; European Union (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Jurisdictions, United Kingdom and Switzerland in this Appendix.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-12</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Italian residents who, at any time during the fiscal year, hold foreign financial assets (including cash and Shares) which may generate income taxable in Italy are required to report these assets on their annual tax returns (UNICO Form, RW Schedule) for the year during which the assets are held, or on a special form if no tax return is due.  These reporting obligations will also apply to Italian residents who are the beneficial owners of foreign financial assets under Italian money laundering provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Financial Assets Tax.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The fair market value of any Shares held outside of Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is subject to a foreign assets tax at a flat rate.  The market value is considered to be the value of the Shares on the Nasdaq Global Select Market on December 31 of the applicable year in which you held the Shares (or when the Shares are acquired during the course of the year, the tax is levied in proportion to the actual days of holding over the calendar year).  No tax payment duties arise if the amount of the foreign financial assets tax calculated on all financial assets held abroad does not exceed a certain threshold.  You should consult with your personal tax advisor about the foreign financial assets tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAPAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You will be required to report to the Japanese tax authorities details of any assets held outside of Japan as of December 31st (including any Shares acquired under the Plan and the Program) to the extent such assets have a total net fair market value exceeding &#165;50,000,000.  Such report will be due by March 15 each year.  You should consult with your personal tax advisor as to whether the reporting obligation applies to you and whether you will be required to include in the report details of any Shares or cash that you hold.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare all foreign financial accounts (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> non-Korean bank accounts, brokerage accounts holding Shares, etc.) to the Korean tax authority and file a report regarding such accounts if the monthly balance of such accounts exceeds a certain threshold on any month-end date during a calendar year.  It is your responsibility to comply with this reporting obligation and you should consult your personal tax advisor to ensure compliance with this requirement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LEBANON</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offerings under the Plan are being made only to eligible Employees of your Employer, the Company or an Affiliate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LITHUANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-13</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you (i) hold certain job positions established by the law or (ii) donate to political parties or political campaigners, you must file an Annual Asset Return of the Individual (Family) in Form No. FR0001 with respect to assets held outside of Lithuania (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares). If you open an account in a foreign financial institution and annual turnover in the account exceeds EUR 15,000, you must file a foreign account report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acknowledgement of the Grant.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting the Award granted hereunder, you acknowledge that you have received a copy of the Plan and the Program, have reviewed the Plan and the Program and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan, the Program and the Agreement, including this Appendix.  You further acknowledge that you have read and specifically and expressly approve the terms and conditions of Section IX of the Agreement, in which the following is clearly described and established&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Your participation in the Plan and the Program do not constitute an acquired right. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The Plan and your participation in the Plan and the Program are offered by Amgen Inc. on a wholly discretionary basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Your participation in the Plan and the Program is voluntary. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. and its Affiliates are not responsible for any decrease in the value of any Shares issued with respect to the Award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement and Policy Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;In accepting any Award granted hereunder, you expressly recognize that Amgen Inc., with registered offices at One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Shares do not constitute an employment relationship between you and Amgen Inc. since you are participating in the Plan on a wholly commercial basis and your sole employer is Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Based on the foregoing, you expressly recognize that the Plan and the Program and the benefits that you may derive from participation in the Plan and the Program do not establish any rights between you and your Employer, Amgen-Mexico, and do not form part of the employment conditions and&#47;or benefits provided by Amgen-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You further understand that your participation in the Plan and the Program is as a result of a unilateral and discretionary decision of Amgen Inc.&#59; therefore, Amgen Inc. reserves the absolute right to amend and&#47;or discontinue your participation in the Plan at any time without any liability to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Amgen Inc. for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to Amgen&#160;Inc., its Affiliates, stockholders, officers, agents or legal representatives with respect to any claim that may arise. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Spanish Translation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-14</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento del Otorgamiento.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Al aceptar cualquier Otorgamiento de Acciones bajo el presente documento, usted reconoce que ha recibido una copia del Plan y del Programa, que ha revisado el Plan y el Programa, as&#237; como tambi&#233;n el Ap&#233;ndice en su totalidad, adem&#225;s que comprende y est&#225; de acuerdo con todas las disposiciones tanto del Plan, del Programa y del Otorgamiento, incluyendo este Ap&#233;ndice.  Asimismo, usted reconoce que ha le&#237;do y manifiesta espec&#237;ficamente y expresamente la conformidad con los t&#233;rminos y condiciones establecidos en la Secci&#243;n IX del Acuerdo del Otorgamiento, en los que se establece y describe claramente que&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan y en el Programa de ninguna manera constituye un derecho adquirido. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;Su participaci&#243;n en Plan y en el Programa son ofrecidos por Amgen Inc. de forma completamente discrecional. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;Su participaci&#243;n en el Plan y en el Programa es voluntaria. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;Amgen Inc. y sus Afiliados no son responsables de ninguna disminuci&#243;n en el valor de las Acciones Comunes emitidas mediante el Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reconocimiento de la Ley Laboral y Declaraci&#243;n de Pol&#237;tica. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Al aceptar cualquier Otorgamiento bajo el presente, usted reconoce expresamente que Amgen Inc., con oficinas registradas localizadas en One Amgen Center Drive, Thousand Oaks, California 91320, U.S.A., es la &#250;nica responsable de la administraci&#243;n del Plan y que su participaci&#243;n en el mismo y la adquisici&#243;n de Acciones Comunes no constituyen de ninguna manera una relaci&#243;n laboral entre usted y Amgen Inc., debido a que su participaci&#243;n en el Plan es &#250;nicamente una relaci&#243;n comercial y que su &#250;nico empleador es Amgen Mexico S.A. de C.V. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen-Mexico</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Derivado de lo anterior, usted reconoce expresamente que el Plan y el Programa y los beneficios a su favor que pudieran derivar de la participaci&#243;n en el mismo, no establecen ning&#250;n derecho entre usted y su empleador, Amgen &#8211; M&#233;xico, y no forman parte de las condiciones laborales y&#47;o los beneficios otorgados por Amgen &#8211; M&#233;xico, y cualquier modificaci&#243;n del Plan o la terminaci&#243;n del mismo no constituir&#225; un cambio o desmejora de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Asimismo, usted entiende que su participaci&#243;n en el Plan y en el Programa es resultado de la decisi&#243;n unilateral y discrecional de Amgen Inc., por lo tanto, Amgen Inc. se reserva el derecho absoluto de modificar y&#47;o descontinuar su participaci&#243;n en el Plan en cualquier momento y sin ninguna responsabilidad para usted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finalmente, usted manifiesta que no se reserva ninguna acci&#243;n o derecho que origine una demanda en contra de Amgen Inc., por cualquier compensaci&#243;n o da&#241;os y perjuicios, en relaci&#243;n con cualquier disposici&#243;n del Plan o de los beneficios derivados del mismo, y en consecuencia usted exime amplia y completamente a Amgen Inc. de toda responsabilidad, como as&#237; tambi&#233;n a sus Afiliadas, accionistas, directores, agentes o representantes legales con respecto a cualquier demanda que pudiera surgir.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Performance Units and the Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Performance Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and your Employer and these materials should not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-15</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Amgen-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="warninglabelb.jpg" src="warninglabelb.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Norwegian residents may be subject to foreign asset reporting as part of their ordinary tax return. Norwegian banks, financial institutions, limited companies etc. must report certain information to the Tax Administration. Such information may then be pre-completed in a Norwegian resident&#8217;s tax return. However, if the resident has traded, or is the owner of, financial instruments (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Shares) not pre-completed in the tax return, the Norwegian resident must enter this information in Form RF-1159, which is an appendix to the tax return.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In general, Norwegian residents should not be subject to any foreign exchange requirements in connection with their acquisition or sale of Shares under the Plan, except normal reporting requirements to the Norwegian Currency Registry. If any transfer of funds into or out of Norway is made through a Norwegian bank, the bank will make the registration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">POLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must file reports with the National Bank of Poland if the aggregate value of Shares and cash held in such foreign accounts exceeds PLN 7,000,000.  If required, the reports are due on a quarterly basis by the 20th day following the end of each quarter and must be filed on special forms available on the website of the National Bank of Poland.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In addition, Polish residents are required to transfer funds through a bank account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently &#8364;15,000 (or PLN 15,000 if such transfer of funds is associated with the business activity of a consultant)).  You must store all documents connected with any foreign exchange transactions you engage in for a period of five (5) years from the end of the year when such transactions were made.  Penalties may apply for failure to comply with exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-16</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PORTUGAL</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent to Receive Information in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan, the Program and Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Conhecimento da Lingua.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Por meio do presente, eu declaro expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condi&#231;&#245;es estabelecidas no Plano, no Programa e no Acordo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ROMANIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Certain transfers of funds may need to be reported to the National Office for Prevention and Control of Money Laundering on specific forms by the relevant bank or financial institution.  If you deposit proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents in a bank account in Romania, you may be required to provide the Romanian bank assisting with the transaction with appropriate documentation explaining the source of the income.  You should consult with a legal advisor to determine whether you will be required to submit such documentation to the Romanian bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RUSSIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may be required to repatriate certain cash </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amounts received with respect to the Award to Russia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, cash Dividends, sale proceeds) as soon as you intend to use those cash amounts for any purpose, including reinvestment. If the repatriation requirement applies, such funds must initially be credited to you through a foreign currency account at an authorized bank in Russia. After the funds are initially received in Russia, they may be further remitted to foreign banks in accordance with Russian exchange control laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Under the Directive N 5371-U of the Russian Central Bank (the &#8220;CBR&#8221;), the repatriation requirement may not apply in certain cases with respect to cash amounts received in an account that is considered by the CBR to be a foreign brokerage account. Statutory exceptions to the repatriation requirement also may apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You should consult with your personal legal advisor to determine the applicability of the repatriation requirement to any cash received in connection with your participation in the Plan and to ensure compliance with any applicable exchange control requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The Award granted hereunder, the Agreement, including this Appendix, the Program, the Plan and all other materials you may receive regarding your participation in the Plan and the Program or the Award granted hereunder do not constitute advertising or an offering of securities in Russia.  The issuance of Shares in respect of the Award has not and will not be registered in Russia&#59; therefore, such Shares may not be offered or placed in public circulation in Russia.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In no event will Shares acquired under the Plan and the Program be delivered to you in Russia&#59; all Shares will be maintained on your behalf in the United States.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-17</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are not permitted to sell any Shares acquired under the Plan and the Program directly to a Russian legal entity or resident.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge that if you continue to hold Shares acquired under the Plan and the Program after an involuntary termination of your employment, you will not be eligible to receive unemployment benefits in Russia.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision supplements Section XV of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that you must complete and return a Consent to Processing of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) form to the Company.  Further, you understand and agree that if you do not complete and return a Consent form to the Company, the Company will not be able to administer or maintain the Performance Units.  Therefore, you understand that refusing to complete a Consent form or withdrawing your consent may affect your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Russian residents are required to file the following reports or notifications with the Russian tax authorities, if applicable&#58; (i) annual cash flow reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; (ii) financial asset (including Shares) reporting for an offshore brokerage account (due by June 1 each year for the previous year, with the first reporting due by June 1, 2022 for calendar year 2021)&#59; and (ii) a one-time notification within one (1) month of opening, closing, or changing details of an offshore brokerage account.  You are encouraged to contact your personal tax advisor before remitting your proceeds from participation in the Plan to Russia to ensure compliance with applicable requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-Corruption Legislation Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Individuals holding public office in Russia, as well as their spouses and dependent children, may be prohibited from opening or maintaining a foreign brokerage or bank account and holding any securities, whether acquired directly or indirectly, in a foreign company (including Shares acquired under the Plan and the Program).  You should consult with your personal legal advisor to determine whether this restriction applies to your circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby agree that any Shares acquired pursuant to the Performance Units will not be offered for sale in Singapore prior to the six (6)-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; ), or pursuant to, and in accordance with the conditions of, any other applicable provisions of the SFA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The grant of the Performance Units is being made pursuant to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made with a view to the Performance Units being subsequently offered for sale to any other party.  The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-18</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Directors (including alternate, substitute, associate and shadow directors) of a Singapore Affiliate are subject to certain notification requirements under the Singapore Companies Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, regardless of whether they are resident or employed in Singapore. Directors of a Singapore Affiliate must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Performance Units, Shares, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> when the Shares are sold), or (iii) becoming a director.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVAK REPUBLIC</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SLOVENIA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Labor Law Acknowledgement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;The following provision supplements Section IX of the Agreement&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Award granted hereunder, you consent to participation in the Plan and the Program and acknowledge that you have received a copy of the Plan and the Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to grant the Award under the Plan and the Program to individuals who may be members of the Board or Employees of the Company or its Affiliates throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that the Awards granted will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis, other than as expressly set forth in the applicable Agreement, including this Appendix.  Consequently, you understand that the Award granted hereunder is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary grant of the Award since the future value of the Award and any Shares that may be issued in respect of such Award is unknown and unpredictable.  In addition, you understand that the Award granted hereunder would not be made but for the assumptions and conditions referred to above&#59; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then the grant of the Award or right to the Award shall be null and void.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, the vesting of the Performance Units is expressly conditioned your continued and active rendering of service, such that if your employment terminates for any reason whatsoever, the Performance Units may cease vesting immediately, in whole or in part, effective on the date of your termination of employment (unless otherwise specifically provided in Section I of the Agreement).  This will be the case, for example, even if (1) you are considered to be unfairly dismissed without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to a &#8220;d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">espido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (2) you are dismissed for disciplinary or objective reasons or due to a collective dismissal&#59; (3) you terminate service due to a change of work location, duties or any other employment or contractual condition&#59; (4) you terminate service due to a unilateral breach of contract by the Company or an Affiliate&#59; or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-19</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5) your employment terminates for any other reason whatsoever.  Consequently, upon termination of your employment for any of the above reasons, you may automatically lose any rights to Performance Units that were not vested on the date of your termination of employment, as described in the Plan and the Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge that you have read and specifically accept the conditions referred to in Section I of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">offer of securities to the public</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; as defined under&#160;Spanish&#160;law,&#160;has taken place or will take place in the Spanish territory. The Agreement (including this Appendix) has not been nor will it be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and does not constitute a public offering prospectus. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If you acquire Shares under the Plan, you must declare the acquisition to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Direccion General de Comercio e Inversiones </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DGCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If you acquire the Shares through the use of a Spanish financial institution, that institution will automatically make the declaration to the DGCI for you&#59; otherwise, you will be required to make the declaration by filing a D-6 form.  You must declare ownership of any Shares with the DGCI each January while the Shares are owned and must also report, in January, any sale of Shares that occurred in the previous year for which the report is being made, unless the sale proceeds exceed the applicable threshold, in which case the report is due within one (1) month of the sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset&#47;Account Reporting Information.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You are required to declare electronically to&#160;the Bank of Spain any securities accounts (including brokerage accounts held abroad), as well as the Shares held in such accounts if the&#160;value of the transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax year exceed &#8364;1,000,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that you hold Shares and&#47;or have bank accounts outside of Spain with a value in excess of &#8364;50,000 (for each type of asset) as of December 31 each year, you will be required to report information on such assets in your tax return (tax form 720) for such year.  After such Shares and&#47;or accounts are initially reported, the reporting obligation will apply for subsequent years only if the value of any previously-reported Shares or accounts increases by more than &#8364;20,000 or if you sell or otherwise dispose of previously-reported Shares or accounts.  If the value of such Shares and&#47;or accounts as of December 31 does not exceed &#8364;50,000, a summarized form of declaration may be presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Authorization to Withhold. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision supplements Section III of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax Obligations as set forth in the Agreement, in accepting the Performance Units, you authorize the Company to withhold Shares or to sell Shares otherwise issuable to you upon vesting or settlement to satisfy Tax Obligations, regardless of whether the Company and&#47;or Employer have an obligation to withhold such Tax Obligations, provided that such withholding would not, in the Company&#8217;s determination, result in adverse accounting consequences to the Company</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-20</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160; Neither this document nor any other materials relating to the Performance Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available to any person other than an employee of the Company or one of its Subsidiaries in Switzerland or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You may acquire and remit foreign currency (including proceeds from the sale of Shares or the receipt of Dividends or Dividend Equivalents) up to US$5,000,000 per year without justification.  If the transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more in a single transaction, you must also provide supporting documentation to the satisfaction of the remitting bank.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">THAILAND</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If proceeds from the sale of Shares or the receipt of any Dividends or Dividend Equivalents exceed US$1,000,000, you must (i) immediately repatriate such funds to Thailand and (ii) report the inward remittance to the Bank of Thailand on a Foreign Exchange Transaction Form.  In addition, within three hundred and sixty (360) days of repatriation, you must either convert any funds repatriated to Thailand to Thai Baht or deposit the funds in a foreign exchange account with a Thai commercial bank.  Any such commercial bank must be duly authorized by the Bank of Thailand to engage in the purchase, exchange and withdrawal of foreign currency.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TURKEY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Performance Units are made available only to employees of the Company and its Affiliates, and the offer of participation in the Plan is a private offering.  The grant of the Award and the issuance of Shares at vesting takes place outside of Turkey. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any activity related to investments in foreign securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the sale of Shares under the Plan, the receipt of cash Dividends or Dividend Equivalents) must be conducted through a bank or financial intermediary institution licensed by the Turkish Capital Markets Board and should be reported to the Turkish Capital Markets Board by the bank or intermediary assisting with the transaction.  You should contact a personal legal advisor for further information regarding these requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED ARAB EMIRATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-21</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Performance Units under the Plan are available only to Participants under the Program and are for the purpose of providing equity incentives.  The Plan, the Program and the Agreement are intended for distribution only to such Participants and must not be delivered to, or relied on by, any other person.  You should conduct your own due diligence on the Performance Units offered pursuant to this Agreement.  If you do not understand the contents of the Plan and&#47;or the Agreement, you should consult an authorized financial adviser.  The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  Further, the Ministry of the Economy and the Dubai Department of Economic Development have not approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This provision supplements Section V of the Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section V of the Agreement, you agree that you are liable for all Tax Obligations and hereby covenant to pay all such Tax Obligations as and when requested by the Company or your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and your Employer against any taxes that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are an executive officer or director (as within the meaning of Section 13(k) of the Exchange Act, as amended, from time to time), you understand that you may not be able to indemnify the Company or your Employer for the amount of income tax not collected from or paid by you, as it may be considered a loan.  In the event that you are an executive officer or director and income tax is not collected from you within ninety (90) days after the end of the tax year in which the Taxable Event occurs, the amount of any uncollected income tax may constitute an additional benefit to you on which additional income tax and national insurance contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be payable.  You acknowledge that you are responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying your Employer for the amount of any NICs due on this additional benefit, which the Company or your Employer may obtain from you by any of the means set forth in Section V of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the maximum applicable withholding rate is used, any over-withheld amount may be credited to you by the Company or your Employer (with no entitlement to the Common Stock equivalent) or if not so credited, you may seek a refund from the local tax authorities.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you are a resident of the United Kingdom between the Grant Date and the vesting of the Performance Units, as a condition of the Award, you agree to accept any liability for secondary Class 1 National Insurance Contributions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which may be payable by the Company or your Employer with respect to the earning and&#47;or payment of the Performance Units and issuance of Shares in respect of the Performance Units, the assignment or release of the Performance Units for consideration or the receipt of any other benefit in connection with the Performance Units.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to the foregoing, you agree to make an election (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in the form specified and&#47;or approved for such election by HMRC, that the liability for your Employer NICs </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-22</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payments on any such gains shall be transferred to you to the fullest extent permitted by law.  You further agree to execute such other elections as may be required between you and any successor to the Company and&#47;or your Employer.  You hereby authorize the Company and your Employer to withhold such Employer NICs by any of the means set forth in Section V of the Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Failure by you to enter into an Election, withdrawal of approval of the Election by HMRC or a joint revocation of the Election by you and the Company or your Employer, as applicable, shall be grounds for the forfeiture and cancellation of the Performance Units, without any liability to the Company or your Employer.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provision replaces Section IX(j) of the Award Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;in the event of termination of your employment (whether or not in breach of local labor laws), your right to receive Performance Units and receive Shares under the Plan and the Program, if any, will terminate effective as of the date that you are no longer actively employed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such right will be extended by any notice period mandated by law (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., the Worker Adjustment and Retraining Notification Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">WARN Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) notice period or similar periods pursuant to local law) and any paid administrative leave (as applicable), unless the Company shall provide you with written notice otherwise before the commencement of such notice period or leave.  In such event, payment of the Performance Units shall be made in accordance with Section IV&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that notwithstanding the effect of any such extension, subject to Section 4.2 of the Program, in no event will the Performance Units be paid later than the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day following the last day of the Performance Period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APPENDIX A-23</font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>6
<FILENAME>amgn-ex1015_20211231xq4.htm
<DESCRIPTION>THIRD AMENDMENT TO SUPPLEMENTAL RETIREMENT PLAN
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3a237e2fff39446ca2dd28c73392dc89_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 10.15</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Amgen Inc. Supplemental Retirement Plan, as Amended and Restated Effective October 16, 2013 (the &#8220;Plan&#8221;), is hereby amended, effective October 20, 2021, as follows&#58;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 2.27 is amended by adding the following at the end thereof&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you were employed by Five Prime Therapeutics, Inc. or any affiliate of Five Prime Therapeutics, Inc. (collectively &#8220;Five Prime&#8221;) immediately preceding the Closing Date (as defined in the Agreement and Plan of Merger by and among Amgen Inc., Franklin Acquisition Sub, Inc. and Five Prime Therapeutics, Inc., Dated as of March 4, 2021) and effective as of the Closing Date, your employment continues with Five Prime or you transition to employment with the Company, then for purposes of calculating your Years of Service under the Plan, you will receive credit for your years of service with Five Prime and with Five Prime-recognized predecessors prior to the Closing Date.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you were employed by Teneobio, Inc. or any affiliate of Teneobio, Inc. (collectively &#8220;Teneobio&#8221;) immediately preceding the Closing Date (as defined in the Agreement and Plan of Merger by and among Amgen Inc., Tuxedo Merger Sub, Inc., Teneobio, Inc. and Fortis Advisors LLC, Dated as of July 27, 2021) and effective as of the Closing Date, your employment continues with Teneobio or you transition to employment with the Company, then for purposes of calculating your Years of Service under the Plan, you will receive credit for your years of service with Teneobio and with Teneobio-recognized predecessors prior to the Closing Date.</font></div><div style="margin-bottom:24pt;margin-top:12pt;text-align:justify"><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To record this Third Amendment to the Plan as set forth herein</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company has caused its authorized officer to execute this document this 25th day of October, 2021.</font></div><div style="margin-bottom:42pt;padding-left:216pt"><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN INC.</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Lori A. Johnston&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Lori A. Johnston</font></div><div style="margin-bottom:8pt;padding-left:108pt;padding-right:108pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; Executive Vice President, Human Resources</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>7
<FILENAME>amgn-ex1023_20211231xq4.htm
<DESCRIPTION>THIRD AMENDMENT TO NONQUALIFIED DEFERRED COMPENSATION PLAN
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6f0fed20f6654c00a96da39e4fa19d49_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT 10.23</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Amgen Nonqualified Deferred Compensation Plan, as Amended and Restated Effective October 16, 2013 (the &#8220;Plan&#8221;), is hereby amended, effective January 1, 2022, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 3.3 (&#8220;Delayed Commencement Election&#8221;) is amended by adding the following at the end thereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The opportunity to delay the effective date of deferral elections as described in this Section 3.3 applies to Plan Years beginning prior to January 1, 2022.  In no event may a Participant delay the effective date of his or her deferral elections for Plan Years beginning on or after January 1, 2022.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 4.1 (&#8220;Short-Term Payout&#8221;) is amended by adding the following at the end thereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The ability to irrevocably elect a Short-Term Payout for Annual Deferral Amounts as described in this Article 4 applies to Plan Years beginning prior to January 1, 2022.  In no event may a Participant elect a Short-Term Payout for Annual Deferral Amounts for Plan Years beginning on or after January 1, 2022.</font></div><div style="margin-bottom:24pt;margin-top:18pt;text-align:justify"><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To record this Third Amendment to the Plan as set forth herein</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company has caused its authorized officer to execute this document this 25</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of October, 2021.</font></div><div style="margin-bottom:42pt;padding-left:216pt"><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN INC.</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Lori A. Johnston&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Lori A. Johnston</font></div><div style="margin-bottom:8pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58; Executive Vice President, Human Resources</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>8
<FILENAME>amgn-ex1025_20211231xq4.htm
<DESCRIPTION>AIRCRAFT TIME SHARING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icb56304b7291450db7bb4045d4c8bcaa_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 10.25</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">AIRCRAFT TIME SHARING AGREEMENT</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">This Agreement is made and entered into as of December 3, 2021 by and between Amgen Inc. (together with its subsidiaries and affiliates, &#8220;Lessor&#8221;), and Robert A. Bradway (&#8220;Lessee&#8221;). </font></div><div style="margin-top:13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WITNESSETH&#58; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Lessor is the operator and&#47;or registered owner of undivided interests in aircraft bearing the Manufacturer&#8217;s Serial Number(s) and the United States Federal Aviation Administration (&#8220;FAA&#8221;) Registration Number(s) listed on Schedule A hereto, as amended from time to time (collectively, the &#8220;Aircraft&#8221;)&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, from time to time, in connection with use of the Aircraft for Lessor&#8217;s business purposes, Lessee may desire to use the Aircraft for personal usage incidental to business travel&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the parties intend for Lessee to reimburse Lessor for certain costs associated with such personal usage incidental to business travel on a non-exclusive time sharing basis in accordance with FAR &#167; 91.501&#59; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the mutual covenants herein set forth, the parties agree as follows&#58; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provision of Aircraft and Crew</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to Aircraft availability, Lessor agrees to allow Lessee&#8217;s personal usage of the Aircraft incidental to business travel on a time sharing basis in accordance with the provisions of FAR &#167;&#167; 91.501(b)(6), (b)(10), (c)(1) and (d). Lessor shall provide, at its sole expense, fully qualified flight crew for all flight operations under this Agreement. If Lessor is no longer the operator of any of the Aircraft, Schedule A shall be deemed amended to delete any reference to such Aircraft and this Agreement shall be terminated as to such Aircraft but shall remain in full force and effect with respect to each of the other Aircraft, if any. No such termination shall affect any of the rights and obligations of the parties accrued or incurred prior to such termination. If Lessor becomes the operator of any aircraft not listed on Schedule A hereto, Schedule A shall be deemed amended to include such Aircraft, and this Agreement shall remain in full force and effect with respect to such Aircraft and each of the other Aircraft, if any. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The term of this Agreement (the &#8220;Term&#8221;) shall commence on the date hereof and shall continue until terminated by either party on written notice to the other party. This Agreement shall terminate immediately in the event that Lessee is no longer an employee or director of Lessor. Notwithstanding the foregoing, any provisions directly or indirectly related to Lessee&#8217;s payment obligations for flights completed prior to the date of termination shall survive the termination of this Agreement. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reimbursement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For each flight conducted under this Agreement involving personal usage incidental to business travel, Lessee shall pay Lessor an amount determined by Lessor for the expenses attributable to such personal usage incidental to business travel in an amount not to exceed that permitted by FAR &#167;91.501(d). The invoice to Lessee shall not exceed the aggregate cost of&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fuel, oil, lubricants, and other additives&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Travel expenses of the crew, including food, lodging, and ground transportation&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Hangar and tie-down costs away from the Aircraft&#8217;s base of operation&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance obtained for the specific flight&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landing fees, airport taxes, and similar assessments&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Customs, foreign permit, and similar fees directly related to the flight&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In-flight food and beverages&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Passenger ground transportation&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Flight planning and weather contract services&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An additional charge equal to one hundred percent (100%)&#160;of the expenses listed in subsection (a)&#160;above.</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Invoicing and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All payments to be made to Lessor by Lessee hereunder shall be paid in the manner set forth in this Section&#160;4. Lessor will pay, or cause to be paid, all expenses related to the operation of the Aircraft hereunder in the ordinary course. As soon as practicable after the relevant flight, Lessor shall provide or cause to be provided to Lessee an invoice detailing all amounts payable by Lessee pursuant to Section&#160;3 of this Agreement. Lessee shall pay all amounts due under the invoice not later than 60 days after receipt thereof unless otherwise specified in such invoice.  </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Flight Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessee will provide the designated representatives of Lessor with flight requests for Lessee&#8217;s personal usage incidental to business travel pursuant to this Agreement as far in advance of the relevant flight as possible and in accordance with all policies established by Lessor. Flight requests shall be in a form, whether oral or written, mutually convenient to the parties. Lessor shall have sole and exclusive authority over the scheduling of the Aircraft. Lessor shall not be liable to Lessee or any other person for loss, injury, or damage occasioned by the delay or failure to furnish the Aircraft and crew pursuant to this Agreement for any reason. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any flights or personal usage incidental to business travel scheduled under this Agreement are subject to cancellation by either party without incurring liability to the other party. In the event of a cancellation, the canceling party shall provide the maximum notice reasonably practicable. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Operational Authority and Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessor shall be responsible for the physical and technical operation of the Aircraft and the safe performance of all flights under this Agreement, and shall retain full authority and control, including exclusive operational control and exclusive possession, command and control of the Aircraft for all flights under this Agreement. Lessor shall furnish at its expense a fully qualified flight crew with appropriate credentials to conduct each flight undertaken under this Agreement. In accordance with applicable FARs, the qualified flight crew provided by Lessor will exercise all required and&#47;or appropriate duties and responsibilities in regard to the safety of each flight conducted hereunder. The pilot-in-command shall have absolute discretion in all matters concerning the preparation of the Aircraft for flight and the flight itself, the load carried and its distribution, the decision whether or not a flight shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be undertaken or personal usage incidental to business travel shall be permitted, the route to be flown, the place where landings shall be made, and all other matters relating to operation of the Aircraft. Lessee specifically agrees that the flight crew shall have final and complete authority to delay or cancel any flight or any personal usage incidental to business travel for any reason or condition that in the sole judgment of the pilot-in-command could compromise the safety of the flight, and to take any other action that in the sole judgment of the pilot-in-command is necessitated by considerations of safety. No such action of the pilot-in-command shall create or support any liability to Lessee or any other person for loss, injury, damage or delay. Lessor&#8217;s operation of the Aircraft hereunder shall be strictly within the guidelines and policies established by Lessor and FAR Part 91. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Aircraft Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessor shall, at its own expense, cause the Aircraft to be inspected, maintained, serviced, repaired, overhauled, and tested in accordance with FAR Part 91 so that the Aircraft will remain in good operating condition and in a condition consistent with its airworthiness certification and shall take such requirements into account in scheduling the Aircraft hereunder. Performance of maintenance, preventive maintenance or inspection shall not be delayed or postponed for the purpose of scheduling the Aircraft unless such maintenance or inspection can safely be conducted at a later time in compliance with applicable laws, regulations and requirements, and such delay or postponement is consistent with the sound discretion of the pilot-in-command. In the event that any non-standard maintenance is required during the term and will interfere with Lessee&#8217;s requested or scheduled personal usage incidental to business travel, Lessor, or Lessor&#8217;s pilot-in-command, shall notify Lessee of the maintenance required, the effect on the ability to comply with Lessee&#8217;s requested or scheduled personal usage incidental to business travel and the manner in which the parties will proceed with the performance of such maintenance and conduct of such flight(s). In no event shall Lessor be liable to Lessee or any other person for loss, injury or damage occasioned by the delay or failure to furnish the Aircraft under this Agreement, whether or not maintenance-related. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessor, at its expense, will maintain or cause to be maintained in full force and effect throughout the Term of this Agreement (i)&#160;comprehensive aircraft and liability insurance against bodily injury and property damage claims, including, without limitation, contractual liability, in respect of the Aircraft in such amount as is customarily maintained by prudent operators of similar aircraft&#59; and (ii)&#160;hull insurance for the full replacement cost of the Aircraft. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lessor shall use reasonable commercial efforts to provide such additional insurance for specific flights under this Agreement as Lessee may request in writing. Lessee acknowledges that any trips scheduled to the European Union may require Lessor to purchase additional insurance to comply with applicable regulations. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Aircraft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessee warrants that&#58; </font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) Lessee will use the Aircraft under this Agreement for and only for his or her own account, including the carriage of guests, and will not use the Aircraft for the purpose of providing transportation of passengers or cargo for compensation or hire or for common carriage&#59; </font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) Lessee will not permit any lien, security interest or other charge or encumbrance to attach against the Aircraft as a result of his or her actions or inactions, and shall not attempt to convey, mortgage, assign, lease or in any way alienate the Aircraft or Lessor&#8217;s rights hereunder or create any kind of lien or security interest involving the Aircraft or do anything or take any action that might mature into such a lien&#59; and </font></div><div style="margin-top:9pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) During the Term of this Agreement, Lessee will abide by and conform to all such laws, governmental and airport orders, rules, and regulations as shall from time to time be in effect relating in any way to the operation or use of the Aircraft by a lessee under a time sharing arrangement and all applicable policies of Lessor. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. NEITHER LESSOR (NOR ITS AFFILIATES) MAKES, HAS MADE OR SHALL BE DEEMED TO MAKE OR HAVE MADE ANY WARRANTY OR REPRESENTATION, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, WITH RESPECT TO ANY AIRCRAFT TO BE USED HEREUNDER OR ANY ENGINE OR COMPONENT THEREOF INCLUDING, WITHOUT LIMITATION, ANY WARRANTY AS TO DESIGN, COMPLIANCE WITH SPECIFICATIONS, QUALITY OF MATERIALS OR WORKMANSHIP, MERCHANTABILITY, FITNESS FOR ANY PURPOSE, USE OR OPERATION, AIRWORTHINESS, SAFETY, PATENT, TRADEMARK OR COPYRIGHT INFRINGEMENT OR TITLE. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN NO EVENT SHALL LESSOR OR ITS AFFILIATES BE LIABLE FOR OR HAVE ANY DUTY OF INDEMNIFICATION, CONTRIBUTION OR REIMBURSEMENT TO LESSEE, LESSEE&#8217;S EMPLOYEES, AGENTS OR GUESTS FOR ANY LOSS, CLAIM, DAMAGE OR EXPENSE OF ANY KIND UNLESS SUCH LOSS, CLAIM, DAMAGE OR EXPENSE IS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A NON-APPEALABLE JUDGMENT TO BE SOLELY DUE TO LESSOR&#8217;S BAD FAITH OR WILLFUL MISCONDUCT. The provisions of this Section&#160;10 shall survive the termination or expiration of this Agreement. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices and other communications under this Agreement shall be in writing (except as permitted in Section&#160;5) and shall be given (and shall be deemed to have been duly given upon receipt or refusal to accept receipt) by personal delivery, by facsimile (with a simultaneous confirmation copy sent by first class mail properly addressed and postage prepaid), by email, or by a reputable overnight courier service, addressed as follows&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.1pt;padding-left:0.02pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Lessor&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58; One Amgen Center Drive</font></div><div style="padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thousand Oaks, California 91320-1799</font></div><div style="padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Corporate Secretary</font></div><div style="padding-left:46.15pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fax&#58;        (805) 499-6751</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58;</font><font style="color:#44546a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen_Governance_and_Securities_Law&#64;amgen.com</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;padding-left:0.04pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.620%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Lessee&#58;</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58; One Amgen Center Drive</font></div><div style="padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thousand Oaks, California 91320-1799</font></div><div style="padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Robert A. Bradway</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fax&#58;        (805) 499-6751</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58;    Amgen_Governance_and_Securities_Law&#64;amgen.com</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to such other person or address as either party may from time to time designate in writing to the other party. Notices shall be effective upon receipt.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement constitutes the entire understanding between the parties with respect to its subject matter, and there are no representations, warranties, rights, obligations, liabilities, conditions, covenants, or agreements relating to such subject matter that are not expressly set forth herein. There are no third-party beneficiaries of this Agreement. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessor and Lessee shall from time to time perform such other and further acts and execute such other and further instruments as may be required by law or may be reasonably necessary (i)&#160;to carry out the intent and purpose of this Agreement, and (ii)&#160;to establish, maintain and protect the respective rights and remedies of the other party. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessee shall not have the right to assign, transfer or pledge this Agreement and any such attempted assignment, transfer or pledge shall be null and void. This Agreement shall be binding on the parties hereto and their respective heirs, executors, administrators, successors and assigns, and shall inure to the benefit of the parties hereto, and, except as otherwise provided herein, their respective heirs, executors, administrators, other legal representatives, successors and permitted assigns. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessee shall be responsible for paying, and Lessor shall be responsible for collecting from Lessee and paying over to the appropriate authorities, all applicable Federal excise taxes imposed under Internal Revenue Code &#167;4261 and all sales, use and other excise taxes imposed by any authority in connection with the use of the Aircraft by Lessee hereunder.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law and Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be governed by the laws of the State of New York without regard to its choice of law principles. The parties hereby consent and agree to submit to the exclusive jurisdiction and venue of any state or federal court in New York, New York in any proceedings hereunder, and each hereby waives any objection to any such proceedings based on improper venue or forum non-conveniens or similar principles. The parties hereto hereby further consent and agree to the exercise of such personal jurisdiction over them by such courts with respect to any such proceedings, waive any objection to the assertion or exercise of such jurisdiction and consent to process being served in any such proceedings in the manner provided for the giving of notices hereunder.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any provision of this Agreement is held to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions shall not be affected or impaired. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment or Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be amended, modified or terminated only in writing duly executed by the parties hereto. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which shall constitute one and the same Agreement, binding on all the parties notwithstanding that all the parties are not signatories to the same </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">counterpart. Each party may transmit its signature by facsimile, and any faxed counterpart of this Agreement shall have the same force and effect as a manually-executed original. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Truth-in-Leasing Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lessor, on behalf of Lessee, shall (i)&#160;deliver a copy of this Agreement to the Aircraft Registration Branch, Technical Section, of the FAA in Oklahoma City within 24 hours of its execution&#59; (ii)&#160;notify the appropriate Flight Standards District Office at least 48 hours prior to the first flight under this Agreement of the registration number of the Aircraft, and the location of the airport of departure and departure time for such flight&#59; and (iii)&#160;carry a copy of this Agreement onboard the Aircraft at all times when the Aircraft is being operated under this Agreement. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TRUTH IN LEASING STATEMENT PURSUANT TO SECTION 91.23 OF THE FEDERAL AVIATION REGULATIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) LESSOR CERTIFIES THAT EACH OF THE AIRCRAFT HAS BEEN INSPECTED AND MAINTAINED DURING THE 12-MONTH PERIOD PRECEDING THE DATE OF THIS AGREEMENT (OR SUCH SHORTER PERIOD AS LESSOR SHALL HAVE POSSESSED THE AIRCRAFT) IN ACCORDANCE WITH THE PROVISIONS OF PART 91 OF THE FEDERAL AVIATION REGULATIONS. EACH OF THE AIRCRAFT WILL BE MAINTAINED AND INSPECTED IN COMPLIANCE WITH THE MAINTENANCE AND INSPECTION REQUIREMENTS FOR ALL OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B) LESSOR AGREES, CERTIFIES AND ACKNOWLEDGES, AS EVIDENCED BY ITS SIGNATURE BELOW, THAT WHENEVER ANY OF THE AIRCRAFT IS OPERATED UNDER THIS AGREEMENT, LESSOR SHALL BE KNOWN AS, CONSIDERED, AND SHALL IN FACT BE THE OPERATOR OF THE AIRCRAFT, AND THAT LESSOR UNDERSTANDS ITS RESPONSIBILITIES FOR COMPLIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C) THE PARTIES UNDERSTAND THAT AN EXPLANATION OF FACTORS AND PERTINENT FEDERAL AVIATION REGULATIONS BEARING ON OPERATIONAL CONTROL CAN BE OBTAINED FROM THE NEAREST FAA FLIGHT STANDARDS DISTRICT OFFICE. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed on the day and year first above written. The persons signing below warrant their authority to sign. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.794%"><tr><td style="width:1.0%"></td><td style="width:8.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.308%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LESSOR&#58; Amgen Inc.</font></div><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LESSEE&#58; Robert A. Bradway</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan P. Graham</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jonathan P. Graham</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President, </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">General Counsel &#38; Secretary</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A legible copy of this Agreement shall be kept in the Aircraft for all operations conducted hereunder. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">List of Schedules Omitted from the Aircraft Time Sharing Agreement</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Referenced in Exhibit 10.25 Above</font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to Regulation&#160;S-K,&#160;Item 601(b)(2), the Schedule to the Aircraft Time Sharing Agreement referenced in Exhibit 10.25 above, as listed below, have not been filed. The Registrant agrees to furnish supplementally a copy of any omitted Schedule to the Securities and Exchange Commission (the &#8220;Commission&#8221;) upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule A &#8211; United States Federal Aviation Administration Registration Numbers</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.51
<SEQUENCE>9
<FILENAME>amgn-1051_20211231xq4.htm
<DESCRIPTION>AMENDMENT NO. 8 TO THE ASTRAZENECA COLLABORATION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie76748b96ef440739ea89bfb54511bf6_1"></div><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH &#8220;&#91;***&#93;&#8221;.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AMENDMENT NO. 8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLLABORATION AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Amendment No. 8 to the Collaboration Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) is entered into as of the 19th day of November, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amgen Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amgen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AstraZeneca Collaboration Ventures, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Amgen and Partner are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Amgen and Partner entered into that certain Collaboration Agreement, dated as of March 30, 2012, as amended by Amendment No.1 to the Collaboration Agreement, dated October 1, 2014, as further amended by Amendment No.2 to the Collaboration Agreement and Release, dated May 2, 2016, as further amended by Amendment No.3 to the Collaboration Agreement, dated May 27, 2016, as further amended by Amendment No.4 to the Collaboration Agreement, dated October 2, 2016, and as further amended by Amendment No.5 to the Collaboration Agreement, dated January 31, 2018, and as further amended by Amendment No. 6 to the Collaboration Agreement, dated May 15, 2020 and as further amended by Amendment No. 7 to the Collaboration Agreement, dated December 17, 2020 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the Parties have been &#91;***&#93;, and the Parties have agreed to include AZD8630 under the Collaboration Agreement, and in connection with the foregoing, Amgen and Partner wish to amend certain portions of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in consideration of the mutual promises and covenants hereinafter set forth, the Parties hereto agree to amend the Agreement as follows&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1 - AMENDMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Parties hereby acknowledge and agree that (a)&#160;notwithstanding Sections 9.4 and 7.2.8.2 of the Agreement, &#91;***&#93;, (b)&#160;in accordance with Section 9.3.3 (Inclusion) of the Agreement, all Development Costs and General Costs for AZD8630 and all Net Revenues for AZD8630 shall be shared on a &#91;***&#93; basis, and (c)&#160;Partner shall be the Development Lead&#47;Designated Regulatory Party, the Manufacturing Lead and the Commercial Lead for AZD8630.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Parties further acknowledge that either Party shall be permitted to conduct non clinical research and development on a Distracting Product pursuant to Section 9.4, and the Parties shall be permitted to use Amgen Intellectual Property, Partner Intellectual Property and Program Intellectual Property in such nonclinical research and development. The Parties acknowledge that &#91;***&#93;.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Amendment to Certain Schedules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Parties hereby agree that the following schedules to the Agreement are hereby deleted in their entirety and replaced with the schedules set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> attached hereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Development&#47;Commercial Lead Schedule&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Products Schedule&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Stage 1 Clinical Trial Schedule.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Amendment to Definition of &#8220;General Costs&#8221;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Parties hereby agree that, following the Amendment Effective Date, Section 1.65.7 of the Agreement shall be deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;1.65.7 all costs incurred in connection with Prosecution and Maintenance of Amgen Intellectual Property, Partner Intellectual Property and Program Intellectual Property in accordance with Section 10.6 (Prosecution and Maintenance) within or materially related to the Collaboration Scope&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Manufacturing Lead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Parties hereby agree that, notwithstanding the provisions of Section 4.1 (Allocation of Manufacturing Responsibility) of the Agreement to the contrary, Partner shall be the initial Manufacturing Lead for AZD8630, and the provisions of Section 4.1 will apply mutatis mutandis.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Distribution Lead&#47;Amendment to Section 4.4 (Distribution).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  From and after the Amendment Effective Date, Section 4.4 (Distribution) is hereby amended to add the following language immediately after the third sentence in Section 4.4&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;Notwithstanding the foregoing, the Parties agree that, for the commercialization of AZD8630, Partner will be the Distribution Party in all countries, and will be entitled to book sales of AZD8630 worldwide. The allocation of roles and responsibilities for the commercialization of AZD8630 will be as set forth in Section 5.4.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Amendment to Section 5.4 (All Sales by Distribution Party).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> From and after the Amendment Effective Date, Section 5.4 (All Sales by Distribution Party) is hereby amended to add the following language immediately after the fifth sentence in Section 5.4&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;Notwithstanding the foregoing, with respect to AZD8630 the Parties agree that a commercialization structure will be agreed by the Parties at least &#91;***&#93; years prior to anticipated first commercial launch of AZD8630 that is generally consistent with the roles and responsibilities as agreed by the Parties in the commercialization framework for Tezepelumab in asthma that was ratified by the JSC in May 2020, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Amendment to Section 7.2.8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> From and after the Amendment Effective Date, Section 7.2.8.2 is hereby amended to add the following language immediately after the first sentence and the Inventorship Margin table&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;Notwithstanding the foregoing, for AZD8630 no Inventorship Margin is applicable.&#8221;</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Amendment to Section 10.6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> From and after the Amendment Effective Date, Section 10.6.3 is hereby amended to add the following language immediately after the third sentence in Section 10.6.3&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;Notwithstanding the foregoing, solely with respect to AZD8630, subject to the provisions of Section 2.10 (Patent Coordinators), Partner will have the first right (but not the obligation) to control, through outside counsel, and have final decision making authority (after consultation with Amgen in accordance with the terms and conditions of this Agreement) with respect to the Prosecution and Maintenance of the Patents and Product Trademarks within the Program Intellectual Property (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Program Patents and Trademarks&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), and with respect to preparation and filing for any Patent Extensions.  If Partner desires to abandon the prosecution of a Program Patent or Trademark, then it will inform Amgen thereof in writing with sufficient advance notice to reasonably enable Amgen to assume the filing or prosecution of such Program Patent or Trademark (but in no event later than &#91;***&#93; days prior to the next deadline for any action that may be taken with respect such Program Patent or Trademark with the U.S. Patent and Trademark Office or any non-U.S. patent office) at Amgen&#8217;s non-reimbursable cost.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Amendment to Section 10.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> From and after the Amendment Effective Date, Section 10.8 is hereby amended to delete all language following the third sentence and add the following language immediately after the third sentence in Section 10.8&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;Notwithstanding the foregoing, solely with respect to AZD8630, Partner will have the first right (but not the obligation) to enforce the Program Intellectual Property against any Third Party that is developing, manufacturing, selling, or importing a product or service that competes with AZD8630&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that Amgen will have the right to approve in writing any settlement of any claim, suit or action involving its intellectual property that admits the invalidity or unenforceability of its intellectual property or imposes on Amgen restrictions or obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">If Partner fails to bring any such action or proceeding within forty-five (45) days (or twenty-five (25) days in the case of an action brought under the Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) or within the time frame of any other relevant regulatory or statutory framework that may govern) of a request by Amgen to do so (or, if sooner, five (5) days before the time limit, if any, set forth in the relevant laws and regulations for the filing of such actions), or earlier notifies Amgen in writing of its intent not to bring such action or proceeding, then Amgen will have the right (but not the obligation) to bring any such action or proceeding by counsel of its own choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that Partner will have the right to approve in writing any settlement of any claim, suit or action involving its intellectual property that admits the invalidity or unenforceability of its intellectual property or imposes on Partner restrictions or obligations. The non-enforcing Party will reasonably assist the enforcing Party with respect to any such enforcement in the Collaborative Territory, including, in the event that it is determined that the non-enforcing Party is an indispensable Party to such action, by being named as a Party in such action, and cooperate in any such action at the enforcing Party&#180;s request. Without limiting the foregoing, the enforcing Party will keep the non-enforcing Party advised of all material communications, actual and prospective filings or submissions regarding such action, and will provide the non-enforcing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the enforcing Party will have the right to redact any manufacturing information and any information relating to any product other than Products from any such materials). </font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Solely with respect to AD8630, all Recoveries will be retained by or paid to Partner (whether Partner is the enforcing Party or not), but to the extent such Recoveries were obtained with respect to AZD8630 or a product that competes directly with AZD8630, the same shall be included in the Net Revenues for the period in which such Recovery is made. With respect to all Products other than AZD8630, all Recoveries will be retained by or paid to Amgen (whether Amgen is the enforcing Party or not), but to the extent such Recoveries were obtained with respect to a Product or product that competes directly with a Product, the same shall be included in Net Revenues for the period in which such Recovery is made.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Amendment to Section 11.2 (Authorized Disclosure)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  From and after the Amendment Effective Date, Section 11.2 (Authorized Disclosure) is hereby amended to (x) delete the word &#8220;and&#8221; immediately prior to subclause (v) and (y) add the following words immediately after the words &#8220;to the extent mutually agreed by the parties&#8221; in subclause (v)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220; and (vi) to such Party&#8217;s actual or potential acquirers, investment bankers or other financial advisors, or actual or potential investors, lenders or other financial partners, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that, with respect to any potential acquirers, actual or potential investors, lenders or financial partners of such Party that are biopharmaceutical companies such Party shall only be permitted to share a copy of this Agreement and related financial information&#59; provided further, that, prior to any such disclosure, each such disclosee is bound by written obligations of confidentiality, non-disclosure, and non-use at least as restrictive as the obligations set forth in this Article XII to maintain the confidentiality thereof and not to use or disclose such Confidential Information except as expressly permitted by this Agreement.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Addition of a Section 11.7 (Data Privacy)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  From and after the Amendment Effective Date, a new Section 11.7 is hereby added as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Parties shall comply with the requirements listed in the Data Privacy Schedule when Personal Data (as defined in said schedule) related to a Product is transferred, acquired or Processed (as defined in said schedule) by Amgen or Partner.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Amendment to Section 14.6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> From and after the Amendment Effective Date, the phrase &#8220;10.5 (License Grant by Partner) (only with respect to the third sentence thereof)&#8221; contained in the first sentence of 14.6.3 shall be amended to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;10.5 (License Grant by Partner (only with respect to the third sentence thereof, and for AZD8630 only with respect to the transition period referenced in clause (vii) of Section 14.6.1.3 (Transition)).&#8221;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 2 &#8211; REFERENCE TO AND EFFECT ON THE AGREEMENT</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reference to Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon and after the effectiveness of this Amendment, each reference in the Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221; or words of like import referring to the Agreement shall mean and be a reference to the Agreement as modified and amended hereby.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Effectiveness of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon execution and delivery of this Amendment by both Parties, the amendments set forth above in sections 1.2 - 1.12 shall be effective as of the Amendment Effective Date.  Except as specifically amended above, the Agreement is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the Parties.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of either Party under the Agreement, nor constitute a waiver of any provision of the Agreement.</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 3 &#8211; MISCELLANEOUS</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Amendment will be governed by, and enforced and construed in accordance with, the laws of the State of New York without regard to its conflicts of law provisions.  Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the state and federal courts of the State of New York for any matter arising out of or relating to this Amendment and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts.  Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Amendment or the transactions contemplated hereby in the state and federal courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum.  The Parties agree that a final judgment in any such matter will be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law.  Any proceeding brought by either Party under this Amendment will be exclusively conducted in the English language.  The United Nations Convention for the International Sale of Goods will not apply to the transactions contemplated herein.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The heading for each article and section in this Amendment has been inserted for convenience of reference only and is not intended to limit or expand on the meaning of the language contained in the particular article or section.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signature page follows&#93;</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</font></div></div></div><div id="ie76748b96ef440739ea89bfb54511bf6_4"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS THEREOF, duly authorized representatives of the Parties hereto have executed this Amendment as of the date first set forth above.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASTRAZENECA COLLABORATION VENTURES, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Richard J. Kenny</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Murdo Gordon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Richard J. Kenny</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Murdo Gordon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assistant Secretary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EVP Global Commercial Operations</font></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix I</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedules</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development&#47;Commercial Lead</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:117.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.128%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partner</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG827</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG139</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG157</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG570</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG181</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AZD8630</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG827 Respiratory-</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">Specifically with regard to AMG827 at the global level, the Parties will work closely through the JPT on the commercial strategy for the Respiratory market for AMG827 with Amgen taking the primary responsibility for &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">The Parties will &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">The Parties will cooperate to ensure that &#91;***&#93; is made available to the JPT at both the global and regional level.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">This arrangement will be noted in the press release and other approved communications as &#91;***&#93; or with words of similar import.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG570-</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties hereby agree that Amgen shall be the initial Development Lead and Commercial Lead for AMG570.  The Parties shall &#91;***&#93; provided that, in the event that the Parties are unable to &#91;***&#93; if it elects to do so.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule &#8220;Data Privacy&#8221; Omitted from Amendment No. 8 to the Collaboration Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to Regulation S-K, Item 601(a)(5), Schedule &#8220;Data Privacy&#8221; to Amendment No. 8 to the Collaboration Agreement, as listed below, has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Products</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.057%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 139</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 157</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 181</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 557</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 827</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 570</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AZD8630</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stage 1 Clinical Trial</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:111.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.089%"><tr><td style="width:1.0%"></td><td style="width:33.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stage 1 Clinical Trial</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG139</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG157</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG181</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG827</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG570</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AZD8630</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>10
<FILENAME>amgn-ex21_20211231xq4.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i293a553492174c2db2965bbdb2f2ae97_1"></div><div style="min-height:43pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AMGEN INC.</font></div><div><font><br></font></div><div style="margin-bottom:15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following is a list of subsidiaries of the Company as of December 31, 2021, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.&#160;&#160;&#160;&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:47.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.634%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATE OR OTHER JURISDICTION OF</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Name under which subsidiary does business)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION OR ORGANIZATION</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen (Europe) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Canada Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Fremont Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Global Finance B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen GmbH Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Ila&#231; Ticaret Limited &#350;irketi</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen K-A, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Manufacturing, Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Research (Munich) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Rockville, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen S.A.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen S.p.A. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen SF, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Singapore Manufacturing Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Technology (Ireland) Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Technology, Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bermuda</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen USA Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Worldwide Holdings B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen, S.A. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioVex, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deCODE Genetics ehf </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iceland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five Prime Therapeutics Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gensenta &#304;la&#231; Sanayi ve Ticaret Anonim &#350;irketi</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunex Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunex Rhode Island Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KAI Pharmaceuticals, Inc. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llypsa, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onyx Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onyx Therapeutics, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Saga Investments Co&#246;peratief U.A. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TeneoBio, Inc. </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware</font></td></tr></table></div><div><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>11
<FILENAME>amgn-ex31_20211231xq4.htm
<DESCRIPTION>RULE 13A-14(A) CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iadac090635bf46d0ba06d4a77220762d_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-K of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this quarterly report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 16, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="iadac090635bf46d0ba06d4a77220762d_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-K of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this quarterly report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 16, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>12
<FILENAME>amgn-ex32_20211231xq4.htm
<DESCRIPTION>SECTION 1350 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4eb4038356394b298fa06c6b601c09f6_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Quarterly Report on Form 10-Q of the Company for the period ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 16, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i4eb4038356394b298fa06c6b601c09f6_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Quarterly Report on Form 10-Q of the Company for the period ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  February 16, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>amgn-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2bb320c8-0f12-4641-8309-e0606e56f5e9,g:0e6120fc-59ff-4bff-bbf3-39bc007e06fc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.amgen.com/role/Coverpage">
        <link:definition>000010001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.amgen.com/role/AuditInformation">
        <link:definition>000020002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome">
        <link:definition>100010003 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>100020004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets">
        <link:definition>100030005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>100050007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>100060008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>100070009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>210011001 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>220022001 - Disclosure - Summary of significant accounting policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesNarrativeDetails" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails">
        <link:definition>240034001 - Disclosure - Summary of significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.amgen.com/role/Acquisitions">
        <link:definition>210041002 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.amgen.com/role/AcquisitionsTables">
        <link:definition>230053001 - Disclosure - Acquisitions - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAggregateConsiderationPaidDetails" roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails">
        <link:definition>240064002 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails">
        <link:definition>240074003 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.amgen.com/role/Revenues">
        <link:definition>210081003 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.amgen.com/role/RevenuesTables">
        <link:definition>230093002 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails">
        <link:definition>240104004 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesCustomerConcentrationProductSalesDetails" roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails">
        <link:definition>240114005 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.amgen.com/role/Stockbasedcompensation">
        <link:definition>210121004 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTables" roleURI="http://www.amgen.com/role/StockbasedcompensationTables">
        <link:definition>230133003 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTextualDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails">
        <link:definition>240144006 - Disclosure - Stock-based compensation (Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails">
        <link:definition>240154007 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationSummaryofRSUsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails">
        <link:definition>240164008 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails">
        <link:definition>240174009 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationSummaryofStockOptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails">
        <link:definition>240184010 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails">
        <link:definition>240194011 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Definedcontributionplan" roleURI="http://www.amgen.com/role/Definedcontributionplan">
        <link:definition>210201005 - Disclosure - Defined contribution plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedcontributionplanDetails" roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails">
        <link:definition>240214012 - Disclosure - Defined contribution plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.amgen.com/role/Incometaxes">
        <link:definition>210221006 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://www.amgen.com/role/IncometaxesTables">
        <link:definition>230233004 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesIncomeBeforeIncomeTaxesDetails" roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails">
        <link:definition>240244013 - Disclosure - Income taxes (Income Before Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesProvisionforIncomeTaxesDetails" roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails">
        <link:definition>240254014 - Disclosure - Income taxes (Provision for Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>240264015 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTextualDetails" roleURI="http://www.amgen.com/role/IncometaxesTextualDetails">
        <link:definition>240274016 - Disclosure - Income taxes (Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails">
        <link:definition>240284017 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesReconciliationofFederalStatutoryTaxRateDetails" roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails">
        <link:definition>240294018 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.amgen.com/role/Earningspershare">
        <link:definition>210301007 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.amgen.com/role/EarningspershareTables">
        <link:definition>230313005 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareDetails" roleURI="http://www.amgen.com/role/EarningspershareDetails">
        <link:definition>240324019 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborations" roleURI="http://www.amgen.com/role/Collaborations">
        <link:definition>210331008 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsNovartisAGDetails" roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails">
        <link:definition>240344020 - Disclosure - Collaborations - Novartis AG (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsBeiGeneDetails" roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails">
        <link:definition>240354021 - Disclosure - Collaborations - BeiGene (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsKyowaKirinDetails" roleURI="http://www.amgen.com/role/CollaborationsKyowaKirinDetails">
        <link:definition>240364022 - Disclosure - Collaborations - Kyowa Kirin (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.amgen.com/role/Investments">
        <link:definition>210371009 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.amgen.com/role/InvestmentsTables">
        <link:definition>230383006 - Disclosure - Investments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleDetails" roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails">
        <link:definition>240394023 - Disclosure - Investments - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValuesbyClassificationDetails" roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails">
        <link:definition>240404024 - Disclosure - Investments - Fair Values by Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforsaleDetails" roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails">
        <link:definition>240414025 - Disclosure - Investments - Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValuesbyContractualMaturityDetails" roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails">
        <link:definition>240424026 - Disclosure - Investments - Fair Values by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsEquitySecuritiesDetails" roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails">
        <link:definition>240434027 - Disclosure - Investments - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsLimitedPartnershipInvestmentsDetails" roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails">
        <link:definition>240444028 - Disclosure - Investments - Limited Partnership Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsBeiGeneDetails" roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails">
        <link:definition>240454029 - Disclosure - Investments - BeiGene (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNeumoraTherapeuticsIncDetails" roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails">
        <link:definition>240464030 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amgen.com/role/Inventories">
        <link:definition>210471010 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amgen.com/role/InventoriesTables">
        <link:definition>230483007 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amgen.com/role/InventoriesDetails">
        <link:definition>240494031 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.amgen.com/role/Propertyplantandequipment">
        <link:definition>210501011 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables">
        <link:definition>230513008 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentScheduleDetails" roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails">
        <link:definition>240524032 - Disclosure - Property, plant and equipment (Schedule) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentGeographicInformationDetails" roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails">
        <link:definition>240534033 - Disclosure - Property, plant and equipment (Geographic Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwillandintangibleassets" roleURI="http://www.amgen.com/role/Goodwillandintangibleassets">
        <link:definition>210541012 - Disclosure - Goodwill and intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsTables" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables">
        <link:definition>230553009 - Disclosure - Goodwill and other intangible assets - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsGoodwillRollForwardDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails">
        <link:definition>240564034 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
        <link:definition>240574035 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsNarrativeDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails">
        <link:definition>240584036 - Disclosure - Goodwill and other intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.amgen.com/role/Leases">
        <link:definition>210591013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.amgen.com/role/LeasesTables">
        <link:definition>230603010 - Disclosure - Leases - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.amgen.com/role/LeasesNarrativeDetails">
        <link:definition>240614037 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeasesDetails" roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails">
        <link:definition>240624038 - Disclosure - Leases - Summary of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseCostsDetails" roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails">
        <link:definition>240634039 - Disclosure - Leases - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCashandNoncashInformationofLeasesDetails" roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails">
        <link:definition>240654041 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othercurrentassetsandaccruedliabilities" roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities">
        <link:definition>210661014 - Disclosure - Other current assets and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesTables" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables">
        <link:definition>230673011 - Disclosure - Other current assets and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails">
        <link:definition>240684042 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails">
        <link:definition>240694043 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financingarrangements" roleURI="http://www.amgen.com/role/Financingarrangements">
        <link:definition>210701015 - Disclosure - Financing arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsTables" roleURI="http://www.amgen.com/role/FinancingarrangementsTables">
        <link:definition>230713012 - Disclosure - Financing arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
        <link:definition>240724044 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsDebtIssuancesDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails">
        <link:definition>240734045 - Disclosure - Financing arrangements (Debt Issuances) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsDebtRepaymentsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails">
        <link:definition>240744046 - Disclosure - Financing arrangements (Debt Repayments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails">
        <link:definition>240754047 - Disclosure - Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails">
        <link:definition>240764048 - Disclosure - Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails">
        <link:definition>240774049 - Disclosure - Financing arrangements (Contractual Maturities of Long-term Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsInterestCostsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails">
        <link:definition>240784050 - Disclosure - Financing arrangements (Interest Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.amgen.com/role/Stockholdersequity">
        <link:definition>210791016 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.amgen.com/role/StockholdersequityTables">
        <link:definition>230803013 - Disclosure - Stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityStockRepurchaseProgramDetails" roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails">
        <link:definition>240814051 - Disclosure - Stockholders' equity (Stock Repurchase Program) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityDividendsDetails" roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails">
        <link:definition>240824052 - Disclosure - Stockholders' equity (Dividends) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityComponentsofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails">
        <link:definition>240834053 - Disclosure - Stockholders' equity (Components of AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails">
        <link:definition>240844054 - Disclosure - Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityReclassificationsoutofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails">
        <link:definition>240854055 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityOtherDetails" roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails">
        <link:definition>240864056 - Disclosure - Stockholders' equity (Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurement" roleURI="http://www.amgen.com/role/Fairvaluemeasurement">
        <link:definition>210871017 - Disclosure - Fair value measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementTables" roleURI="http://www.amgen.com/role/FairvaluemeasurementTables">
        <link:definition>230883014 - Disclosure - Fair value measurement - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>240894057 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementNarrativeDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails">
        <link:definition>240904058 - Disclosure - Fair value measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementContingentConsiderationObligationsDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails">
        <link:definition>240914059 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativeinstruments" roleURI="http://www.amgen.com/role/Derivativeinstruments">
        <link:definition>210921018 - Disclosure - Derivative instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsTables" roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables">
        <link:definition>230933015 - Disclosure - Derivative instruments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsNarrativeDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails">
        <link:definition>240944060 - Disclosure - Derivative instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsCrosscurrencySwapsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails">
        <link:definition>240954061 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
        <link:definition>240964062 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails">
        <link:definition>240974063 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
        <link:definition>240984064 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsFairValueofDerivativesDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails">
        <link:definition>240994065 - Disclosure - Derivative instruments - (Fair Value of Derivatives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandcommitments" roleURI="http://www.amgen.com/role/Contingenciesandcommitments">
        <link:definition>211001019 - Disclosure - Contingencies and commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsTables" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables">
        <link:definition>231013016 - Disclosure - Contingencies and commitments - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsSandozPatentLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails">
        <link:definition>241024066 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsImmunexandSandozLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails">
        <link:definition>241034067 - Disclosure - Contingencies and commitments (Immunex and Sandoz Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsRepathaPatentLitigationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails">
        <link:definition>241044068 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsAdditionalInformationDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails">
        <link:definition>241054069 - Disclosure - Contingencies and commitments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails">
        <link:definition>241064070 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS">
        <link:definition>211071020 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
        <link:definition>241084071 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_CustomerOneMember" abstract="false" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" abstract="true" name="OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FixedEquipment" abstract="false" name="FixedEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2024Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointZeroPercent2032NotesMemberMember" abstract="true" name="TwoPointZeroPercent2032NotesMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" abstract="true" name="AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherNotesDue2097Member" abstract="true" name="OtherNotesDue2097Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointSevenZeroPercentNotesDue2022Member" abstract="true" name="TwoPointSevenZeroPercentNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" abstract="true" name="TwoPointSixZeroNotesDueTwoZeroTwoSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointNineFivePercentNotesDue2041Member" abstract="true" name="FourPointNineFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DerivativeNotionalAmountAmountTerminated" abstract="false" name="DerivativeNotionalAmountAmountTerminated" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AssetsByDescriptionDomain" abstract="false" name="AssetsByDescriptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_MarketingRelatedRightsMember" abstract="true" name="MarketingRelatedRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A190NotesDue20251902025NotesMember" abstract="true" name="A190NotesDue20251902025NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" abstract="false" name="OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OtherShortTermInterestBearingSecuritiesMember" abstract="true" name="OtherShortTermInterestBearingSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NplateMember" abstract="true" name="NplateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" abstract="true" name="OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LaboratoryEquipmentMember" abstract="false" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" abstract="false" name="NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentChangeInCarryingValueOther" abstract="false" name="EquityMethodInvestmentChangeInCarryingValueOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AMG340Member" abstract="true" name="AMG340Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" abstract="false" name="ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_LineOfCreditFacilityInitialCommitmentTerm" abstract="false" name="LineOfCreditFacilityInitialCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_HumiraBiosimilarAntitrustClassActionsMember" abstract="true" name="HumiraBiosimilarAntitrustClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" abstract="true" name="ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" abstract="false" name="NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" abstract="true" name="TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePrimeTherapeuticsIncMember" abstract="true" name="FivePrimeTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AccruedLiabilitiesDisclosureTextBlock" abstract="false" name="AccruedLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_ThreePointFourFivePercentNotesDue2020Member" abstract="true" name="ThreePointFourFivePercentNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePointOneFivePercentNotesDue2041Member" abstract="true" name="FivePointOneFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EnbrelMember" abstract="false" name="EnbrelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AbandonedLeasesMember" abstract="true" name="AbandonedLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" abstract="false" name="PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" abstract="true" name="TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" abstract="false" name="BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" abstract="true" name="TwoPercentEuroNotesDueTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_InterestRateSwapTwoMember" abstract="true" name="InterestRateSwapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FixedEquipmentMember" abstract="true" name="FixedEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointFiveZeroPercentNotesDue2020Member" abstract="true" name="FourPointFiveZeroPercentNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LineofCreditFacilityNumberOfRenewalOptions" abstract="false" name="LineofCreditFacilityNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" abstract="false" name="NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_ManufacturingEquipmentMember" abstract="false" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointThreeZeroPercentNotesDue2031Member" abstract="true" name="TwoPointThreeZeroPercentNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointTwoZeroNotesDue2027Member" abstract="true" name="ThreePointTwoZeroNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointSixFiveNotesDue2022Member" abstract="true" name="TwoPointSixFiveNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" abstract="false" name="AcquiredFinitelivedAssetsWeightedAverageUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_OperatingLossesThatExpireBetween2022And2037Member" abstract="true" name="OperatingLossesThatExpireBetween2022And2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" abstract="true" name="TwoPointOneTwoFivePercentEuroNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" abstract="false" name="ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" abstract="false" name="DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NuevolutionMember" abstract="true" name="NuevolutionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_RepathaevolocumabMember" abstract="true" name="RepathaevolocumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_HedgedLiabilityDiscontinuedFairValueHedge" abstract="false" name="HedgedLiabilityDiscontinuedFairValueHedge" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" abstract="false" name="BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_StockRepurchaseProgramTableTextBlock" abstract="false" name="StockRepurchaseProgramTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" abstract="false" name="ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FloatingRateNotesDue2019Member" abstract="true" name="FloatingRateNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A280NotesDue2041Member" abstract="true" name="A280NotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" abstract="true" name="TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A300NotesDue20523002052NotesMember" abstract="true" name="A300NotesDue20523002052NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionInventoryacquired" abstract="false" name="BusinessacquiredassetacquisitionInventoryacquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_EquityInvestmentsPolicyPolicyTextBlock" abstract="false" name="EquityInvestmentsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" abstract="false" name="NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_RepatriationTaxOnProposedAdditionalTax" abstract="false" name="RepatriationTaxOnProposedAdditionalTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_DebtExchangeAdditionalCashConsideration" abstract="false" name="DebtExchangeAdditionalCashConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TeneobioMember" abstract="true" name="TeneobioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ForeignCurrencyAndCrossCurrencySwapsMember" abstract="true" name="ForeignCurrencyAndCrossCurrencySwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" abstract="true" name="TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SandozIncMember" abstract="true" name="SandozIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroNotesDue2020Member" abstract="true" name="TwoPointTwoZeroNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" abstract="false" name="AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" abstract="false" name="LossContingencyNumberOfComplaintsStayedByTheCourt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" abstract="true" name="TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_DerivativeInstrumentTerm" abstract="false" name="DerivativeInstrumentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" abstract="false" name="DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" abstract="true" name="AccumulatedOtherAdjustmentAttributabletoParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_GainContingencyNumberOfChallenges" abstract="false" name="GainContingencyNumberOfChallenges" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_NatureOfOperationsPolicyTextBlock" abstract="false" name="NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_CommonStockFairValue" abstract="false" name="CommonStockFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="amgn_OtezlaMember" abstract="true" name="OtezlaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" abstract="false" name="PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_TwoPointFourFivePercentNotesDue2030Member" abstract="true" name="TwoPointFourFivePercentNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" abstract="false" name="PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_SalesReturnProvisionsAsPercentageOfProductSales" abstract="false" name="SalesReturnProvisionsAsPercentageOfProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" abstract="true" name="DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_FivePointSevenZeroPercentNotesDue2019Member" abstract="true" name="FivePointSevenZeroPercentNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ProfitAndLossShareOfExpenses" abstract="false" name="ProfitAndLossShareOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" abstract="false" name="DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" abstract="false" name="PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" abstract="false" name="EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ExpirationInTaxYearsBetween2023And2040Member" abstract="true" name="ExpirationInTaxYearsBetween2023And2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointEightSevenFivePercentNotesDue2021Member" abstract="true" name="ThreePointEightSevenFivePercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_KyowaKirinCoLtdMember" abstract="true" name="KyowaKirinCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_MoleculeTypeDomain" abstract="true" name="MoleculeTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapAtThenCurrentInterestRatesMember" abstract="true" name="InterestRateSwapAtThenCurrentInterestRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AccruedSalesReturnReserveCurrent" abstract="false" name="AccruedSalesReturnReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FivePointSevenFivePercentNotesDue2040Member" abstract="true" name="FivePointSevenFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_NeumoraTherapeuticsIncMember" abstract="true" name="NeumoraTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SixPointThreeSevenFivePercentNotesDue2037Member" abstract="true" name="SixPointThreeSevenFivePercentNotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_LaboratoryEquipment" abstract="false" name="LaboratoryEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" abstract="true" name="OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointOneFivePercentNotesDue2040Member" abstract="true" name="ThreePointOneFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_GainContingencyNumberOfAgreementsBreached" abstract="false" name="GainContingencyNumberOfAgreementsBreached" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_NumberOfNoticesOnProposedAdditionalTax" abstract="false" name="NumberOfNoticesOnProposedAdditionalTax" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" abstract="true" name="FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" abstract="false" name="EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_GainContingencyNumberofAffiliates" abstract="false" name="GainContingencyNumberofAffiliates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_SensiparAntitrustClassActionsMember" abstract="true" name="SensiparAntitrustClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapDomain" abstract="true" name="InterestRateSwapDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BasicAndDilutedEarningPerShareAbstract" abstract="true" name="BasicAndDilutedEarningPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_CollaborativeArrangementwithNovartisPharmaAGMember" abstract="true" name="CollaborativeArrangementwithNovartisPharmaAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" abstract="false" name="IdentifiableIntangibleAssetsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" abstract="false" name="ComponentsOfStockBasedCompensationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_AssembledWorkforceMember" abstract="true" name="AssembledWorkforceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_XgevaMember" abstract="false" name="XgevaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NovartisBreachOfContractActionMember" abstract="true" name="NovartisBreachOfContractActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointOneZeroPercentNotesDue2021Member" abstract="true" name="FourPointOneZeroPercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" abstract="true" name="TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" abstract="true" name="FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPercentPoundSterlingNotesDue2029Member" abstract="true" name="FourPercentPoundSterlingNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FavorableContractMember" abstract="true" name="FavorableContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapAxis" abstract="true" name="InterestRateSwapAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroPercentNotesDue2019Member" abstract="true" name="TwoPointTwoZeroPercentNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TeneobioIncMember" abstract="true" name="TeneobioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_InterestRateSwapOneMember" abstract="true" name="InterestRateSwapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationContingentConsiderationArrangementsPayments" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CustomerTwoMember" abstract="false" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DerivativeAssetsFairValueDisclosureAbstract" abstract="true" name="DerivativeAssetsFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ProliaMember" abstract="false" name="ProliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" abstract="false" name="DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_Businessassetacquisitionconsiderationtransferred" abstract="false" name="Businessassetacquisitionconsiderationtransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2022Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A200NotesDue20322002032NotesMember" abstract="true" name="A200NotesDue20322002032NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionDeferredCredit" abstract="false" name="BusinessacquiredassetacquisitionDeferredCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" abstract="false" name="LineOfCreditFacilityExtensionOfCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_AranespMember" abstract="false" name="AranespMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_KyprolisMember" abstract="true" name="KyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" abstract="true" name="ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SixPointFourZeroPercentNotesDue2039Member" abstract="true" name="SixPointFourZeroPercentNotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AccruedSalesDeductionsCurrent" abstract="false" name="AccruedSalesDeductionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FivePointThreeSevenFivePercentNotesDue2043Member" abstract="true" name="FivePointThreeSevenFivePercentNotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FivePointSixFivePercentNotesDue2042Member" abstract="true" name="FivePointSixFivePercentNotesDue2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" abstract="true" name="AcquiredResearchAndDevelopmentTechnologyRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SanofiRegeneronPatentLitigationMember" abstract="true" name="SanofiRegeneronPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointNineZeroNotesDue2019Member" abstract="true" name="OnePointNineZeroNotesDue2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ImmunexAndSamsungBioepisCoMember" abstract="true" name="ImmunexAndSamsungBioepisCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" abstract="false" name="LongTermDebtMaturitiesRepaymentsOfPrincipalNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RDTechnologyrightsMember" abstract="true" name="RDTechnologyrightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NeulastaMember" abstract="false" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" abstract="false" name="NumberOfCommonSharesToBeReducedForEachStockOptionGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" abstract="false" name="BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_StockBasedCompensationExpenseNetOfTax" abstract="false" name="StockBasedCompensationExpenseNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ScheduleOfIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_OperatingLossesThatExpireBetween2022And2031Member" abstract="true" name="OperatingLossesThatExpireBetween2022And2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" abstract="true" name="ThreePointThreeSevenFivePercentNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AlternativeInvestmentNetGainLoss" abstract="false" name="AlternativeInvestmentNetGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CustomerThreeMember" abstract="false" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AssetsByDescriptionAxis" abstract="true" name="AssetsByDescriptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_LitigationSettlementLengthofTrial" abstract="false" name="LitigationSettlementLengthofTrial" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_IncreaseDecreaseInNoncurrentTaxLiability" abstract="false" name="IncreaseDecreaseInNoncurrentTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_MaximumBorrowingCapacityUnderCommercialPaper" abstract="false" name="MaximumBorrowingCapacityUnderCommercialPaper" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_Transactioncostsassetacquisition" abstract="false" name="Transactioncostsassetacquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_GainContingencyNumberofLawsuitsFiled" abstract="false" name="GainContingencyNumberofLawsuitsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentChangeInCarryingValue" abstract="false" name="EquityMethodInvestmentChangeInCarryingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" abstract="true" name="FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" abstract="true" name="FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_RevenuePaymentArrangementTerm" abstract="false" name="RevenuePaymentArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfLawsuitsFiled" abstract="false" name="LossContingencyNumberOfLawsuitsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_AvailableForSalesInvestmentsMember" abstract="true" name="AvailableForSalesInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointEightZeroPercent2041NotesMember" abstract="true" name="TwoPointEightZeroPercent2041NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_CrossCurrencySwapContractsMember" abstract="true" name="CrossCurrencySwapContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" abstract="false" name="TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" abstract="false" name="NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amgn_FloatingRateNotesDue2020Member" abstract="true" name="FloatingRateNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" abstract="false" name="AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_EquitySecuritiesRealizedGainLossOnDisposal" abstract="false" name="EquitySecuritiesRealizedGainLossOnDisposal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_PerformanceUnitsMember" abstract="false" name="PerformanceUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A165NotesDue20281652028NotesMember" abstract="true" name="A165NotesDue20281652028NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ApprovedMarkets" abstract="false" name="ApprovedMarkets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_MoleculeTypeAxis" abstract="true" name="MoleculeTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsGross" abstract="false" name="IdentifiableIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_BeiGeneMember" abstract="true" name="BeiGeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_UpFrontPayment" abstract="false" name="UpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ProposedAdditionalIncomeTax" abstract="false" name="ProposedAdditionalIncomeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_PercentageOfGrossRevenues" abstract="false" name="PercentageOfGrossRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_SixPointNineZeroPercentNotesDue2038Member" abstract="true" name="SixPointNineZeroPercentNotesDue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherCurrentNoncurrentAssetsMember" abstract="true" name="OtherCurrentNoncurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>amgn-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2bb320c8-0f12-4641-8309-e0606e56f5e9,g:0e6120fc-59ff-4bff-bbf3-39bc007e06fc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_db4b5d6d-f613-41c6-8276-42bb5bd81a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fbe49298-9e58-4ba8-a718-692f97fa5696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_db4b5d6d-f613-41c6-8276-42bb5bd81a09" xlink:to="loc_us-gaap_OperatingIncomeLoss_fbe49298-9e58-4ba8-a718-692f97fa5696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_eddd8b2b-9e50-485d-b952-aa8a8b52daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_db4b5d6d-f613-41c6-8276-42bb5bd81a09" xlink:to="loc_us-gaap_InterestExpenseDebt_eddd8b2b-9e50-485d-b952-aa8a8b52daa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_49a08e22-68b0-47bb-bc55-4ade90439898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_db4b5d6d-f613-41c6-8276-42bb5bd81a09" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_49a08e22-68b0-47bb-bc55-4ade90439898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_939236be-a675-4e3e-bdbf-ae7badc69d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fb58e083-2657-4caa-8435-064bb0003e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_939236be-a675-4e3e-bdbf-ae7badc69d83" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fb58e083-2657-4caa-8435-064bb0003e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_346ae7e8-f064-4bc8-8268-a1acb1d97ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_939236be-a675-4e3e-bdbf-ae7badc69d83" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_346ae7e8-f064-4bc8-8268-a1acb1d97ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b820b994-e436-41db-9ba5-6489cf983e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_939236be-a675-4e3e-bdbf-ae7badc69d83" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b820b994-e436-41db-9ba5-6489cf983e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_cf16e232-6025-4728-84f9-485f745d811f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_939236be-a675-4e3e-bdbf-ae7badc69d83" xlink:to="loc_us-gaap_OtherGeneralExpense_cf16e232-6025-4728-84f9-485f745d811f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0cff29b1-39ce-4494-b3f9-a9dad0281b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_939236be-a675-4e3e-bdbf-ae7badc69d83" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0cff29b1-39ce-4494-b3f9-a9dad0281b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a5974402-3bad-44d1-a846-9c8c20071aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21c52433-2a10-42e7-aa12-b2d203b7892d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a5974402-3bad-44d1-a846-9c8c20071aee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21c52433-2a10-42e7-aa12-b2d203b7892d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b2c2ec86-0d64-494b-8a52-c0070eecf36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a5974402-3bad-44d1-a846-9c8c20071aee" xlink:to="loc_us-gaap_CostsAndExpenses_b2c2ec86-0d64-494b-8a52-c0070eecf36d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6fd464b-948b-406a-ae6b-6255d815f911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb6638c4-5dc7-4ce7-81d8-fa1729e0e72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a6fd464b-948b-406a-ae6b-6255d815f911" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb6638c4-5dc7-4ce7-81d8-fa1729e0e72b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0171c456-a501-46c2-a6dc-630523be7190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a6fd464b-948b-406a-ae6b-6255d815f911" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0171c456-a501-46c2-a6dc-630523be7190" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_370f3ac7-e3ff-432b-8d11-74f421f71588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_56f98527-4540-4bd4-8358-b01b3b18e6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_370f3ac7-e3ff-432b-8d11-74f421f71588" xlink:to="loc_us-gaap_NetIncomeLoss_56f98527-4540-4bd4-8358-b01b3b18e6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fbe0625c-8c42-40e7-9887-429708d209b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_370f3ac7-e3ff-432b-8d11-74f421f71588" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fbe0625c-8c42-40e7-9887-429708d209b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_53e0a692-a08f-4806-b4ea-9ec881225f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8d43e252-e41a-4995-8f33-f7c483c4be55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_53e0a692-a08f-4806-b4ea-9ec881225f31" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8d43e252-e41a-4995-8f33-f7c483c4be55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_a9d31679-aa58-4ecb-babc-8cf840349fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_53e0a692-a08f-4806-b4ea-9ec881225f31" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_a9d31679-aa58-4ecb-babc-8cf840349fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a07f3e1f-ce11-4456-ab4c-5f55a933e41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_53e0a692-a08f-4806-b4ea-9ec881225f31" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a07f3e1f-ce11-4456-ab4c-5f55a933e41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_ffda3546-ea13-4f7d-9158-5f37eef2a9c2" xlink:href="amgn-20211231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_53e0a692-a08f-4806-b4ea-9ec881225f31" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_ffda3546-ea13-4f7d-9158-5f37eef2a9c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c1036b4-6d5d-4825-9abd-fe93447c1ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_2e9ebf79-0a35-4043-8ac4-16bc4228ab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c1036b4-6d5d-4825-9abd-fe93447c1ca7" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_2e9ebf79-0a35-4043-8ac4-16bc4228ab1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b9fa089-410b-445f-b9e4-a5236a7bce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c1036b4-6d5d-4825-9abd-fe93447c1ca7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7b9fa089-410b-445f-b9e4-a5236a7bce7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34118670-5ca3-40e0-aa41-f0d3961d0cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c1036b4-6d5d-4825-9abd-fe93447c1ca7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34118670-5ca3-40e0-aa41-f0d3961d0cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_845661c4-8950-412a-84b1-bf30432b3cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b812a8c2-fc98-40c3-8ddd-61498833c988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_845661c4-8950-412a-84b1-bf30432b3cc0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b812a8c2-fc98-40c3-8ddd-61498833c988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_24749daa-2793-415a-88d0-4cbd241a1f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_845661c4-8950-412a-84b1-bf30432b3cc0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_24749daa-2793-415a-88d0-4cbd241a1f2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8468cc70-e387-458f-8723-b17220276615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_845661c4-8950-412a-84b1-bf30432b3cc0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8468cc70-e387-458f-8723-b17220276615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1bf23ce3-f35a-4588-b50e-bb16be12fe03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_845661c4-8950-412a-84b1-bf30432b3cc0" xlink:to="loc_us-gaap_InventoryNet_1bf23ce3-f35a-4588-b50e-bb16be12fe03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_58af7215-96f4-4e6a-b136-d9e91807d369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_845661c4-8950-412a-84b1-bf30432b3cc0" xlink:to="loc_us-gaap_OtherAssetsCurrent_58af7215-96f4-4e6a-b136-d9e91807d369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9638ab78-4fc7-486f-aa4d-b817970d19ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_45478c0f-2728-4e4c-9228-f18429bf9fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9638ab78-4fc7-486f-aa4d-b817970d19ae" xlink:to="loc_us-gaap_LiabilitiesCurrent_45478c0f-2728-4e4c-9228-f18429bf9fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b7a1cc64-2e6c-4fa0-8ada-5c4da68b9ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9638ab78-4fc7-486f-aa4d-b817970d19ae" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b7a1cc64-2e6c-4fa0-8ada-5c4da68b9ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_51033bc4-a605-4a8d-86d1-d70a871881b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9638ab78-4fc7-486f-aa4d-b817970d19ae" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_51033bc4-a605-4a8d-86d1-d70a871881b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1015cc9f-6ede-4c93-9dd6-0ac42e30fd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9638ab78-4fc7-486f-aa4d-b817970d19ae" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1015cc9f-6ede-4c93-9dd6-0ac42e30fd22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d1d864c9-c8a5-4561-a491-945c078a4c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9638ab78-4fc7-486f-aa4d-b817970d19ae" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d1d864c9-c8a5-4561-a491-945c078a4c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_72d33b3b-532e-43d6-ae17-e704cd9d3b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9638ab78-4fc7-486f-aa4d-b817970d19ae" xlink:to="loc_us-gaap_StockholdersEquity_72d33b3b-532e-43d6-ae17-e704cd9d3b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_adba9e05-bc0f-4202-bcd0-f45cf3bc2fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dd0ca79b-9c7c-4465-a291-bca04a7982a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_adba9e05-bc0f-4202-bcd0-f45cf3bc2fcd" xlink:to="loc_us-gaap_AccountsPayableCurrent_dd0ca79b-9c7c-4465-a291-bca04a7982a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2ff9aef7-735c-42e7-ad47-a65364df9005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_adba9e05-bc0f-4202-bcd0-f45cf3bc2fcd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2ff9aef7-735c-42e7-ad47-a65364df9005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8c124d69-4bfb-4bdc-af02-bbc05fee33ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_adba9e05-bc0f-4202-bcd0-f45cf3bc2fcd" xlink:to="loc_us-gaap_LongTermDebtCurrent_8c124d69-4bfb-4bdc-af02-bbc05fee33ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_edab3b70-12f2-4a9c-ac41-a2efa655215e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0676fa8c-b3e0-4ccb-842a-dcf786696886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edab3b70-12f2-4a9c-ac41-a2efa655215e" xlink:to="loc_us-gaap_AssetsCurrent_0676fa8c-b3e0-4ccb-842a-dcf786696886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5cee9f7b-f758-4885-8853-d04cdd4dc478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edab3b70-12f2-4a9c-ac41-a2efa655215e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5cee9f7b-f758-4885-8853-d04cdd4dc478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_12ee7bdc-b0bc-43d6-b797-84cae662cfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edab3b70-12f2-4a9c-ac41-a2efa655215e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_12ee7bdc-b0bc-43d6-b797-84cae662cfad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9176eeb3-813d-484a-9647-e54a7a9d760b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edab3b70-12f2-4a9c-ac41-a2efa655215e" xlink:to="loc_us-gaap_Goodwill_9176eeb3-813d-484a-9647-e54a7a9d760b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f93ff1bf-1f5c-46a5-bd3c-cf868f6d6f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_edab3b70-12f2-4a9c-ac41-a2efa655215e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f93ff1bf-1f5c-46a5-bd3c-cf868f6d6f4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2d727b12-5c7f-4000-9edc-577d8681c814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2d727b12-5c7f-4000-9edc-577d8681c814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_14241d24-bb13-4434-88a3-2fbf01c1f863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_14241d24-bb13-4434-88a3-2fbf01c1f863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_304e1cb1-5826-4bfd-b456-da4643907122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_304e1cb1-5826-4bfd-b456-da4643907122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_27b78225-df20-4c55-ba70-1cc524f4b8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_27b78225-df20-4c55-ba70-1cc524f4b8a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_937c9c30-2e2e-455a-a292-2797aadcf637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_937c9c30-2e2e-455a-a292-2797aadcf637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_355db038-942a-40ea-8c4b-aacc973f601b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_355db038-942a-40ea-8c4b-aacc973f601b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_11db7bca-9fb7-47f1-a57b-c6eab4276342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6943f0bc-73c2-4d03-ae05-49419347a94c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_11db7bca-9fb7-47f1-a57b-c6eab4276342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d51378-86a0-45c7-8dd8-a2a9b780e957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_09ea828e-04b6-47d7-9ec0-c0d310cd9553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d51378-86a0-45c7-8dd8-a2a9b780e957" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_09ea828e-04b6-47d7-9ec0-c0d310cd9553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e1127ec3-3987-4721-b856-1a428c35e9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d51378-86a0-45c7-8dd8-a2a9b780e957" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e1127ec3-3987-4721-b856-1a428c35e9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d2bfddc0-caeb-4f60-a49e-1ae4fa806b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d51378-86a0-45c7-8dd8-a2a9b780e957" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d2bfddc0-caeb-4f60-a49e-1ae4fa806b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_63ca3c0b-26c4-4a18-af34-c03719d6f9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d51378-86a0-45c7-8dd8-a2a9b780e957" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_63ca3c0b-26c4-4a18-af34-c03719d6f9b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b5bc2534-e3e9-4f74-95c1-c8e7eb9bef12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d51378-86a0-45c7-8dd8-a2a9b780e957" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b5bc2534-e3e9-4f74-95c1-c8e7eb9bef12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d249efc1-939b-4667-af35-08669fb05317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_NetIncomeLoss_d249efc1-939b-4667-af35-08669fb05317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_59f39055-5440-4d99-aadd-83381c22760b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_59f39055-5440-4d99-aadd-83381c22760b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8a509678-8e92-4cc8-b177-c4db39a28121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_ShareBasedCompensation_8a509678-8e92-4cc8-b177-c4db39a28121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b99941c6-05e7-4893-96d7-0c420607d25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b99941c6-05e7-4893-96d7-0c420607d25e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b6d249b4-273a-4d4c-9e04-ac93c845e261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b6d249b4-273a-4d4c-9e04-ac93c845e261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e13eff03-e423-48a2-a895-0e87095d89f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e13eff03-e423-48a2-a895-0e87095d89f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f82b923d-71d2-4544-9805-1986eb82f36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f82b923d-71d2-4544-9805-1986eb82f36e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_11c6add7-90da-4fd6-84d1-cb99da7fc00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_11c6add7-90da-4fd6-84d1-cb99da7fc00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d3fd216c-c1b0-449b-bc73-e2ecbd5d7905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d3fd216c-c1b0-449b-bc73-e2ecbd5d7905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d9e7e100-39a7-476a-be2b-940930953d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d9e7e100-39a7-476a-be2b-940930953d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_eabfa2ad-aadb-45d8-a060-90b493ce1be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_eabfa2ad-aadb-45d8-a060-90b493ce1be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_784a3739-b757-4a25-bcdc-e3060b7118d5" xlink:href="amgn-20211231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_784a3739-b757-4a25-bcdc-e3060b7118d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_01f4c66d-838a-477a-abc0-b0a008a47d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6eed335f-f1de-484d-a4e4-b22ce11c1778" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_01f4c66d-838a-477a-abc0-b0a008a47d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aef6f700-e06d-4774-91ce-040860eb3a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f93ff204-f3b0-4e3b-bc1e-82ed2fdd822b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aef6f700-e06d-4774-91ce-040860eb3a43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f93ff204-f3b0-4e3b-bc1e-82ed2fdd822b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_491d05b7-b585-48a7-895d-a68cbc5ec984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aef6f700-e06d-4774-91ce-040860eb3a43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_491d05b7-b585-48a7-895d-a68cbc5ec984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd41e83e-c76b-4068-aded-6135b77c849d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aef6f700-e06d-4774-91ce-040860eb3a43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd41e83e-c76b-4068-aded-6135b77c849d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_32503f6b-a37f-4817-9bf2-dd355b74caed" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_32503f6b-a37f-4817-9bf2-dd355b74caed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6e7f5812-ac8e-4a85-8f4d-32ece811a333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6e7f5812-ac8e-4a85-8f4d-32ece811a333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c2331d15-a56f-4be0-83b0-d4c372ff2768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c2331d15-a56f-4be0-83b0-d4c372ff2768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_446c028f-6359-4e7e-8bab-690fe7ef38d9" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_446c028f-6359-4e7e-8bab-690fe7ef38d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_a0782f2d-f1b5-4ca4-a8f0-8325c991980d" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_a0782f2d-f1b5-4ca4-a8f0-8325c991980d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_986ebb14-bad0-45b9-893e-3931bddad4e0" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_986ebb14-bad0-45b9-893e-3931bddad4e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_efa0b078-efe7-41ff-9c4a-c318e4946a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_efa0b078-efe7-41ff-9c4a-c318e4946a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9bf31c32-14dd-4bd6-861e-056f5d6762aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_us-gaap_Goodwill_9bf31c32-14dd-4bd6-861e-056f5d6762aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_482f27d9-6bf0-4cd6-84dc-fb74ecb16ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41995714-73ad-41cb-b1fc-f343d6f0ac5b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_482f27d9-6bf0-4cd6-84dc-fb74ecb16ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_3af39e19-a321-44a0-84a2-89998201283a" xlink:href="amgn-20211231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ecb31270-0726-4369-8656-917ece167112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred_3af39e19-a321-44a0-84a2-89998201283a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ecb31270-0726-4369-8656-917ece167112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Transactioncostsassetacquisition_f1e8681e-94f7-440f-b7f5-b506684003c3" xlink:href="amgn-20211231.xsd#amgn_Transactioncostsassetacquisition"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred_3af39e19-a321-44a0-84a2-89998201283a" xlink:to="loc_amgn_Transactioncostsassetacquisition_f1e8681e-94f7-440f-b7f5-b506684003c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_f6ebc8d2-47e5-4ca5-8b52-17dfdc713e09" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred_3af39e19-a321-44a0-84a2-89998201283a" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_f6ebc8d2-47e5-4ca5-8b52-17dfdc713e09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_c55f00f7-8386-4a96-a2dc-72b3a6202153" xlink:href="amgn-20211231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_200c8c32-abb2-4d57-a499-f5687e256c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax_c55f00f7-8386-4a96-a2dc-72b3a6202153" xlink:to="loc_us-gaap_ShareBasedCompensation_200c8c32-abb2-4d57-a499-f5687e256c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_fc617be0-c98b-4182-a48d-8224dadd6c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax_c55f00f7-8386-4a96-a2dc-72b3a6202153" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_fc617be0-c98b-4182-a48d-8224dadd6c4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b9c7c7c0-2c7d-49fa-8596-90d600035c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_158cb368-149f-455f-8fd7-0f9bec9f28ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b9c7c7c0-2c7d-49fa-8596-90d600035c2c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_158cb368-149f-455f-8fd7-0f9bec9f28ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d66e1ce3-80bc-43d3-a28d-f7b59477d346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b9c7c7c0-2c7d-49fa-8596-90d600035c2c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d66e1ce3-80bc-43d3-a28d-f7b59477d346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_73d39b67-8c9b-442b-aaff-814f139ef330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b9c7c7c0-2c7d-49fa-8596-90d600035c2c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_73d39b67-8c9b-442b-aaff-814f139ef330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_161c8a09-d400-4f5f-affb-ac971d4d8232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4d7e5a3b-0c4c-4db8-b235-ef768590d3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_161c8a09-d400-4f5f-affb-ac971d4d8232" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4d7e5a3b-0c4c-4db8-b235-ef768590d3b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5c126619-902e-4db8-82b0-121e87961323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_161c8a09-d400-4f5f-affb-ac971d4d8232" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5c126619-902e-4db8-82b0-121e87961323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_15832c66-c14b-4a94-b025-36cd7d7debe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_161c8a09-d400-4f5f-affb-ac971d4d8232" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_15832c66-c14b-4a94-b025-36cd7d7debe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2add6ac7-0437-43eb-b7b4-ebe6921d6439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e1cc4e8b-fccd-4d3d-b34a-222765c569a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2add6ac7-0437-43eb-b7b4-ebe6921d6439" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e1cc4e8b-fccd-4d3d-b34a-222765c569a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f0188a77-c1b3-4c27-a17b-3a2d341e506e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2add6ac7-0437-43eb-b7b4-ebe6921d6439" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f0188a77-c1b3-4c27-a17b-3a2d341e506e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1204fa53-032b-409d-bcb8-07bd47979553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5ce890a4-f119-4709-855d-9756d8a03ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1204fa53-032b-409d-bcb8-07bd47979553" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5ce890a4-f119-4709-855d-9756d8a03ef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_4f2fc7ee-3213-40c6-9985-73413b255e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1204fa53-032b-409d-bcb8-07bd47979553" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_4f2fc7ee-3213-40c6-9985-73413b255e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bb71487f-d2c8-4b45-9e64-3dc4f992ead6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1204fa53-032b-409d-bcb8-07bd47979553" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bb71487f-d2c8-4b45-9e64-3dc4f992ead6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_92356fce-d909-477c-b951-7a7e7c41bb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1204fa53-032b-409d-bcb8-07bd47979553" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_92356fce-d909-477c-b951-7a7e7c41bb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d6876d08-4236-4fa0-855a-695516c9eb92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_453c872d-d624-420f-81e8-3fb687eb3452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d6876d08-4236-4fa0-855a-695516c9eb92" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_453c872d-d624-420f-81e8-3fb687eb3452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_60217714-9e20-4fb3-9425-537300e5d118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d6876d08-4236-4fa0-855a-695516c9eb92" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_60217714-9e20-4fb3-9425-537300e5d118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_131e5e7d-88a8-4a56-9693-3a92307d529f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_7f9b694b-72bd-4031-97a3-9c145af598c9" xlink:href="amgn-20211231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_131e5e7d-88a8-4a56-9693-3a92307d529f" xlink:to="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_7f9b694b-72bd-4031-97a3-9c145af598c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_6f4ab568-4b72-4f90-8b44-6017c3defdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_131e5e7d-88a8-4a56-9693-3a92307d529f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_6f4ab568-4b72-4f90-8b44-6017c3defdc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_ef7bb316-dbd8-4855-9e54-4516bbaffb34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_131e5e7d-88a8-4a56-9693-3a92307d529f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_ef7bb316-dbd8-4855-9e54-4516bbaffb34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4b55bd80-9eff-4f8d-9fc2-6dd4f5478276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_131e5e7d-88a8-4a56-9693-3a92307d529f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4b55bd80-9eff-4f8d-9fc2-6dd4f5478276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_40d7611c-7e1b-4513-a241-c7dc1a320735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_131e5e7d-88a8-4a56-9693-3a92307d529f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_40d7611c-7e1b-4513-a241-c7dc1a320735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a9104fe5-9834-4d63-a974-c6742765f4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1105106b-1124-4217-a0e4-0692a7e4797b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a9104fe5-9834-4d63-a974-c6742765f4f8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1105106b-1124-4217-a0e4-0692a7e4797b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a6b7a920-25a6-4afe-a72d-6560f26e2e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a9104fe5-9834-4d63-a974-c6742765f4f8" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a6b7a920-25a6-4afe-a72d-6560f26e2e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c788ddec-883e-4aab-a26b-63da0ad1c9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d5fa253e-d1cf-4d78-8003-3aa973d2ec78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c788ddec-883e-4aab-a26b-63da0ad1c9a1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d5fa253e-d1cf-4d78-8003-3aa973d2ec78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d53060c7-9b07-4322-b251-90cc651b275e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c788ddec-883e-4aab-a26b-63da0ad1c9a1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d53060c7-9b07-4322-b251-90cc651b275e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5d841ad8-2bd2-45e7-8471-d8a107b35aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5d841ad8-2bd2-45e7-8471-d8a107b35aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b157de45-8491-4d15-b85d-c4ed23431703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b157de45-8491-4d15-b85d-c4ed23431703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_e8088736-ccdf-4605-a8ef-2aa46fb95cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_e8088736-ccdf-4605-a8ef-2aa46fb95cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_904085ad-309e-4876-84ea-c907f08c1a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_904085ad-309e-4876-84ea-c907f08c1a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_ea027dbd-c09b-4b6e-ab44-5d101da74908" xlink:href="amgn-20211231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_ea027dbd-c09b-4b6e-ab44-5d101da74908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4e57a8f2-bd46-4610-890a-113ed89cde3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4e57a8f2-bd46-4610-890a-113ed89cde3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_4cb4f4a8-74e3-40eb-899f-5ae4aae5023a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_4cb4f4a8-74e3-40eb-899f-5ae4aae5023a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_1bbf3863-6391-4d18-9061-2d707dcf17d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_1bbf3863-6391-4d18-9061-2d707dcf17d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eca128af-6651-4e83-979e-9d7148979ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0444112c-2ad9-40a5-9990-1c204ba000cd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eca128af-6651-4e83-979e-9d7148979ae1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#EarningspershareDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d95650c1-e42b-4d51-ae7b-471e965ce1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dcdc6797-77d7-4829-bbf1-f6c4ac761fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d95650c1-e42b-4d51-ae7b-471e965ce1f7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dcdc6797-77d7-4829-bbf1-f6c4ac761fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e5d35699-3e9e-43e9-b7b2-894a038b8def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d95650c1-e42b-4d51-ae7b-471e965ce1f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e5d35699-3e9e-43e9-b7b2-894a038b8def" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3049b4f7-dcf3-41c8-92dd-f3a0b1d7e6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_904e0a85-eb4b-47dd-82d9-44e9a0ea2a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3049b4f7-dcf3-41c8-92dd-f3a0b1d7e6ee" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_904e0a85-eb4b-47dd-82d9-44e9a0ea2a1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3e6d4ed9-0e8f-44ba-8b48-007a498e9292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3049b4f7-dcf3-41c8-92dd-f3a0b1d7e6ee" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3e6d4ed9-0e8f-44ba-8b48-007a498e9292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50e60e9c-b1c7-46f0-bc0b-9178b9117687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3049b4f7-dcf3-41c8-92dd-f3a0b1d7e6ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50e60e9c-b1c7-46f0-bc0b-9178b9117687" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_890f48b2-5fbc-4939-a198-04ec53d21a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fce1f6bd-47da-44e8-8efc-5f44e118ee1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_890f48b2-5fbc-4939-a198-04ec53d21a3c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fce1f6bd-47da-44e8-8efc-5f44e118ee1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_799b1943-8527-437a-996b-0081d0db1b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_890f48b2-5fbc-4939-a198-04ec53d21a3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_799b1943-8527-437a-996b-0081d0db1b5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5d72decc-3e34-44f5-9c03-9d36b68b6bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ee124f00-3ad6-4b79-adc5-04f13fa6ec6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5d72decc-3e34-44f5-9c03-9d36b68b6bee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ee124f00-3ad6-4b79-adc5-04f13fa6ec6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_e79e7474-f2c4-4e6d-8e4b-5f69db0c15ce" xlink:href="amgn-20211231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5d72decc-3e34-44f5-9c03-9d36b68b6bee" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_e79e7474-f2c4-4e6d-8e4b-5f69db0c15ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a2aa63eb-5646-4217-b5a3-5eaa556ba623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_73d75ec9-e50d-40b1-82ac-a18111225c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a2aa63eb-5646-4217-b5a3-5eaa556ba623" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_73d75ec9-e50d-40b1-82ac-a18111225c22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_51bb96a5-07d1-4fa6-aba7-979fc532dccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a2aa63eb-5646-4217-b5a3-5eaa556ba623" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_51bb96a5-07d1-4fa6-aba7-979fc532dccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_27e178b9-53cc-4732-b698-5f2ddc8c6f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a2aa63eb-5646-4217-b5a3-5eaa556ba623" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_27e178b9-53cc-4732-b698-5f2ddc8c6f99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2cf180e6-26b1-43ac-b385-162093face1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0ac0973d-c862-42e0-a415-0d5302729495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2cf180e6-26b1-43ac-b385-162093face1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0ac0973d-c862-42e0-a415-0d5302729495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3a739925-126a-4584-a8aa-1e5efde230d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2cf180e6-26b1-43ac-b385-162093face1b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3a739925-126a-4584-a8aa-1e5efde230d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_9d289445-efd1-403a-8d55-024942a09a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_us-gaap_Land_9d289445-efd1-403a-8d55-024942a09a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_2636ddbc-4142-4c52-a975-a7781f00fedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_2636ddbc-4142-4c52-a975-a7781f00fedd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_79dee819-bc02-40e2-8485-2c8ca4b462fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_79dee819-bc02-40e2-8485-2c8ca4b462fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_047084ca-0560-4514-803d-7af83dcb46d0" xlink:href="amgn-20211231.xsd#amgn_LaboratoryEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_amgn_LaboratoryEquipment_047084ca-0560-4514-803d-7af83dcb46d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_45c993f7-d101-42ae-bb72-e5914bb4113c" xlink:href="amgn-20211231.xsd#amgn_FixedEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_amgn_FixedEquipment_45c993f7-d101-42ae-bb72-e5914bb4113c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_b5e06831-dfe1-49be-908f-31e90c961fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_b5e06831-dfe1-49be-908f-31e90c961fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_09787882-8d6f-459c-9387-641971c8dfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_09787882-8d6f-459c-9387-641971c8dfd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_7b3cf6f7-359b-4bb6-83b8-7973905a3325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_7f1d0e0e-ca04-4c65-bd31-2aeb0b001465" xlink:to="loc_us-gaap_ConstructionInProgressGross_7b3cf6f7-359b-4bb6-83b8-7973905a3325" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_81484dd7-1bed-46b5-8799-3aeb430e997e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f9fe172e-181b-492b-8c8e-a76dd081ed45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_81484dd7-1bed-46b5-8799-3aeb430e997e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f9fe172e-181b-492b-8c8e-a76dd081ed45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc1094fa-1ab7-4dee-ab95-3b062eb564af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_81484dd7-1bed-46b5-8799-3aeb430e997e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc1094fa-1ab7-4dee-ab95-3b062eb564af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dd407b3a-84e8-4f59-a794-5032740e277e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_c6313566-3835-4638-b895-b3bddf241c08" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dd407b3a-84e8-4f59-a794-5032740e277e" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_c6313566-3835-4638-b895-b3bddf241c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_b7252fb0-303c-44e4-87b5-d37c789c6900" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dd407b3a-84e8-4f59-a794-5032740e277e" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_b7252fb0-303c-44e4-87b5-d37c789c6900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_e83875dd-d97b-42d2-a4ee-e2a376bd23ea" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a51f396-834c-476a-8434-af4411051472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross_e83875dd-d97b-42d2-a4ee-e2a376bd23ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a51f396-834c-476a-8434-af4411051472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f6c41aea-22f0-4a5a-bdf7-9b7a60cf1c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross_e83875dd-d97b-42d2-a4ee-e2a376bd23ea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f6c41aea-22f0-4a5a-bdf7-9b7a60cf1c16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesSummaryofLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dff6c0df-1cbd-4674-a0b9-ae63eac940c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2a7215ce-a286-4661-be6f-f9806ac67252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_dff6c0df-1cbd-4674-a0b9-ae63eac940c5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2a7215ce-a286-4661-be6f-f9806ac67252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dba3ad14-3ce0-4e88-9c12-fe99d0dfa707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_dff6c0df-1cbd-4674-a0b9-ae63eac940c5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dba3ad14-3ce0-4e88-9c12-fe99d0dfa707" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_76b5f7ca-d351-4626-9b90-905ee1288d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_19a889bd-0bc5-4c20-b778-fa5323588a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_76b5f7ca-d351-4626-9b90-905ee1288d9f" xlink:to="loc_us-gaap_OperatingLeaseCost_19a889bd-0bc5-4c20-b778-fa5323588a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_b7fca09d-c5ab-464d-9e2b-6f1115989b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_76b5f7ca-d351-4626-9b90-905ee1288d9f" xlink:to="loc_us-gaap_SubleaseIncome_b7fca09d-c5ab-464d-9e2b-6f1115989b55" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_974143cc-b9c7-42c1-971a-2795ce43c453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2070b5cd-faa7-4865-b34e-b35b26da5853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_974143cc-b9c7-42c1-971a-2795ce43c453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2070b5cd-faa7-4865-b34e-b35b26da5853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_95fb412c-ae56-4e04-97c8-38ad9fdd3fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_974143cc-b9c7-42c1-971a-2795ce43c453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_95fb412c-ae56-4e04-97c8-38ad9fdd3fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5600c026-e33d-41bf-bf16-0c665bb79890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_974143cc-b9c7-42c1-971a-2795ce43c453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5600c026-e33d-41bf-bf16-0c665bb79890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_512c3000-d674-47f8-a149-970b8dd11c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_974143cc-b9c7-42c1-971a-2795ce43c453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_512c3000-d674-47f8-a149-970b8dd11c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fdb26f69-b41e-4ce6-8a48-622e69d860d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_974143cc-b9c7-42c1-971a-2795ce43c453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fdb26f69-b41e-4ce6-8a48-622e69d860d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ef72a2ce-2408-44bd-8842-af85338c4778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_974143cc-b9c7-42c1-971a-2795ce43c453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ef72a2ce-2408-44bd-8842-af85338c4778" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4427e0e-449f-4bed-a52f-b06261021311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d2a740dc-9901-4bc0-8df4-179d8867c46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4427e0e-449f-4bed-a52f-b06261021311" xlink:to="loc_us-gaap_OperatingLeaseLiability_d2a740dc-9901-4bc0-8df4-179d8867c46c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9c577aae-4327-47dd-a892-b45f173932c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e4427e0e-449f-4bed-a52f-b06261021311" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9c577aae-4327-47dd-a892-b45f173932c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_897d9c38-f467-45b6-bbc8-52a1ccd0cb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_9a0dfa81-4bc3-423d-9a11-5b766e79fabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_897d9c38-f467-45b6-bbc8-52a1ccd0cb2e" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_9a0dfa81-4bc3-423d-9a11-5b766e79fabf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_46b844d0-64d0-4b93-90b4-28e32ad45d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_897d9c38-f467-45b6-bbc8-52a1ccd0cb2e" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_46b844d0-64d0-4b93-90b4-28e32ad45d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_044a585a-e29d-4421-a51f-4a43c0b2a451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_897d9c38-f467-45b6-bbc8-52a1ccd0cb2e" xlink:to="loc_us-gaap_InterestReceivableCurrent_044a585a-e29d-4421-a51f-4a43c0b2a451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_2b518598-b8df-4b03-b4da-23dcf8f42d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_897d9c38-f467-45b6-bbc8-52a1ccd0cb2e" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_2b518598-b8df-4b03-b4da-23dcf8f42d90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_971f801b-7f93-4b4e-87dd-8185d5fbeba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent_d1938bb5-e2b8-448c-8a8e-688a4f42856c" xlink:href="amgn-20211231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_971f801b-7f93-4b4e-87dd-8185d5fbeba8" xlink:to="loc_amgn_AccruedSalesDeductionsCurrent_d1938bb5-e2b8-448c-8a8e-688a4f42856c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_59171328-7096-4c96-8912-3ab393e36fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_971f801b-7f93-4b4e-87dd-8185d5fbeba8" xlink:to="loc_us-gaap_DividendsPayableCurrent_59171328-7096-4c96-8912-3ab393e36fe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_25d9d580-3508-4ccf-9da4-b4c4d2f5f5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_971f801b-7f93-4b4e-87dd-8185d5fbeba8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_25d9d580-3508-4ccf-9da4-b4c4d2f5f5aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3a2e518c-8d18-4190-8f47-ec9a247750d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_971f801b-7f93-4b4e-87dd-8185d5fbeba8" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3a2e518c-8d18-4190-8f47-ec9a247750d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent_6720f4a9-8bdb-4366-b4d0-98db2041c1da" xlink:href="amgn-20211231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_971f801b-7f93-4b4e-87dd-8185d5fbeba8" xlink:to="loc_amgn_AccruedSalesReturnReserveCurrent_6720f4a9-8bdb-4366-b4d0-98db2041c1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_17041338-e868-4896-bbfc-425715e62ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_971f801b-7f93-4b4e-87dd-8185d5fbeba8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_17041338-e868-4896-bbfc-425715e62ec9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a8385917-d1a6-48f9-b015-2853cd5c3531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ee3a41c8-8f6d-484f-88a7-15220b3a5f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a8385917-d1a6-48f9-b015-2853cd5c3531" xlink:to="loc_us-gaap_LongTermDebtCurrent_ee3a41c8-8f6d-484f-88a7-15220b3a5f2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_38c91981-4eb4-43dc-a97d-67ad637b50c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a8385917-d1a6-48f9-b015-2853cd5c3531" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_38c91981-4eb4-43dc-a97d-67ad637b50c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_4653a43e-6806-4c95-ba68-7cb7ab5b3b8c" xlink:href="amgn-20211231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4d707680-cfca-4724-bb4c-9af0b765f251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_4653a43e-6806-4c95-ba68-7cb7ab5b3b8c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4d707680-cfca-4724-bb4c-9af0b765f251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_971d81a2-e6a6-4e55-9087-dd5e85ca1e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_4653a43e-6806-4c95-ba68-7cb7ab5b3b8c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_971d81a2-e6a6-4e55-9087-dd5e85ca1e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9bdb7371-9450-4c5d-9067-ba9de65b4226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_4653a43e-6806-4c95-ba68-7cb7ab5b3b8c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9bdb7371-9450-4c5d-9067-ba9de65b4226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fa9ea848-71fd-4c93-be0c-f35196d00c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_4653a43e-6806-4c95-ba68-7cb7ab5b3b8c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fa9ea848-71fd-4c93-be0c-f35196d00c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f2bf769d-7714-40e6-bb43-d80187b8d6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_4653a43e-6806-4c95-ba68-7cb7ab5b3b8c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f2bf769d-7714-40e6-bb43-d80187b8d6e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_26a9df86-44af-455b-bdc3-bf0b1d009bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_4653a43e-6806-4c95-ba68-7cb7ab5b3b8c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_26a9df86-44af-455b-bdc3-bf0b1d009bc0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_dc1d1547-06e6-45cd-84e4-7d336fdd7eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_02936ad6-b6e1-4205-a36f-39261f2b7a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_dc1d1547-06e6-45cd-84e4-7d336fdd7eaa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_02936ad6-b6e1-4205-a36f-39261f2b7a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0fbbee96-a4d4-4729-8389-918152831933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_dc1d1547-06e6-45cd-84e4-7d336fdd7eaa" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0fbbee96-a4d4-4729-8389-918152831933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_a3504e90-b813-4229-9196-254883f0495e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_dc1d1547-06e6-45cd-84e4-7d336fdd7eaa" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_a3504e90-b813-4229-9196-254883f0495e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_f19a3917-270b-4e91-bbaf-b40db164a4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_dc1d1547-06e6-45cd-84e4-7d336fdd7eaa" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_f19a3917-270b-4e91-bbaf-b40db164a4f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_23bbd2b6-d717-4884-82ef-bf3363294475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_902ee0e1-7ee4-4daa-b0a7-83f2d03e6181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_23bbd2b6-d717-4884-82ef-bf3363294475" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_902ee0e1-7ee4-4daa-b0a7-83f2d03e6181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_0452ac7a-fb2a-4bee-a1de-df45a2e541e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_23bbd2b6-d717-4884-82ef-bf3363294475" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_0452ac7a-fb2a-4bee-a1de-df45a2e541e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b7acb111-c664-4121-a1aa-c4d0bd287860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_23bbd2b6-d717-4884-82ef-bf3363294475" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b7acb111-c664-4121-a1aa-c4d0bd287860" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_2a658b0e-fb6f-40e8-b9fa-bdf82d3de2ff" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_f1c3a286-51ac-4929-a33b-2a7a9de55427" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_2a658b0e-fb6f-40e8-b9fa-bdf82d3de2ff" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_f1c3a286-51ac-4929-a33b-2a7a9de55427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_ded557a8-7cbf-4aca-999b-eda8c64b013f" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_2a658b0e-fb6f-40e8-b9fa-bdf82d3de2ff" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_ded557a8-7cbf-4aca-999b-eda8c64b013f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_913e36f2-e8be-43c0-b375-746aa70731b3" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_2a658b0e-fb6f-40e8-b9fa-bdf82d3de2ff" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_913e36f2-e8be-43c0-b375-746aa70731b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_afab3d93-0b60-43a8-a194-fc9afe3eaa86" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_2a658b0e-fb6f-40e8-b9fa-bdf82d3de2ff" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_afab3d93-0b60-43a8-a194-fc9afe3eaa86" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>amgn-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2bb320c8-0f12-4641-8309-e0606e56f5e9,g:0e6120fc-59ff-4bff-bbf3-39bc007e06fc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/Coverpage" xlink:type="simple" xlink:href="amgn-20211231.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/Coverpage" xlink:type="extended" id="i6213d9fd01e94065a3af1d3b7b4a5e54_Coverpage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_25b8dcf2-352a-4c59-b36d-9c1ee6387c1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentType_25b8dcf2-352a-4c59-b36d-9c1ee6387c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_39f5cad8-06f6-46e1-96bf-db2fa5f336a6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentAnnualReport_39f5cad8-06f6-46e1-96bf-db2fa5f336a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e1849ffc-57a5-497a-b662-94633568fe3c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentPeriodEndDate_e1849ffc-57a5-497a-b662-94633568fe3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e9a19639-9cd9-49ba-8f3e-5c6e9413f714" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentTransitionReport_e9a19639-9cd9-49ba-8f3e-5c6e9413f714" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7a75ee24-51b7-4d8a-b405-84fe3b96b6f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityFileNumber_7a75ee24-51b7-4d8a-b405-84fe3b96b6f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_62adedcb-94df-4b74-b6f1-787fa6b3408c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityRegistrantName_62adedcb-94df-4b74-b6f1-787fa6b3408c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fada973b-4e8f-4eea-8b83-d1417efc62b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fada973b-4e8f-4eea-8b83-d1417efc62b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7ee34009-a6c7-4711-b074-7d1b5d0423d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityTaxIdentificationNumber_7ee34009-a6c7-4711-b074-7d1b5d0423d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ac6dc3af-409d-4782-9f11-ab0d668b03bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressAddressLine1_ac6dc3af-409d-4782-9f11-ab0d668b03bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b9035bf8-9c0f-444b-8f26-b0bcbe6b6d55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressCityOrTown_b9035bf8-9c0f-444b-8f26-b0bcbe6b6d55" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ca5bd6b3-6cfd-43d9-b71a-f7d55a095ea1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressStateOrProvince_ca5bd6b3-6cfd-43d9-b71a-f7d55a095ea1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_279085da-7c82-40f2-bd16-a65e4552ca76" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressPostalZipCode_279085da-7c82-40f2-bd16-a65e4552ca76" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bc818aab-7d8e-40de-a8d3-e191a5dc355e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_CityAreaCode_bc818aab-7d8e-40de-a8d3-e191a5dc355e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3fd6cd03-e4eb-4d34-938c-849fbc2638c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_LocalPhoneNumber_3fd6cd03-e4eb-4d34-938c-849fbc2638c0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_66dda346-8764-4be7-b1a8-4d5f326abb7f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_Security12bTitle_66dda346-8764-4be7-b1a8-4d5f326abb7f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_565226d9-7e40-4e4e-874b-83b8e7946dee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_TradingSymbol_565226d9-7e40-4e4e-874b-83b8e7946dee" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a78cf963-3f15-467c-8159-3b3733a050a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_SecurityExchangeName_a78cf963-3f15-467c-8159-3b3733a050a9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5e3f2e66-2a15-4c06-a5ff-ed466f14e08d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5e3f2e66-2a15-4c06-a5ff-ed466f14e08d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_faa63083-02ad-4bae-9d39-ec014c807760" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityVoluntaryFilers_faa63083-02ad-4bae-9d39-ec014c807760" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1b1992c5-d3e3-4f30-a685-6b7136cbcb3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityCurrentReportingStatus_1b1992c5-d3e3-4f30-a685-6b7136cbcb3a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c15e3ee5-e70b-4c3b-b23f-19a408eb1f13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityInteractiveDataCurrent_c15e3ee5-e70b-4c3b-b23f-19a408eb1f13" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6528ac10-d7a7-48d3-8214-8386bdba6eb4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityFilerCategory_6528ac10-d7a7-48d3-8214-8386bdba6eb4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e6f21932-3714-4a69-b3aa-84f7e688623d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntitySmallBusiness_e6f21932-3714-4a69-b3aa-84f7e688623d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5fbd9933-d86e-4ca1-a711-660883a2a778" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityEmergingGrowthCompany_5fbd9933-d86e-4ca1-a711-660883a2a778" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_75afa9c3-d32c-4fdd-b84d-059e2e9fb675" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_IcfrAuditorAttestationFlag_75afa9c3-d32c-4fdd-b84d-059e2e9fb675" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_611cb501-4ac6-45a1-bcfc-f8baa3b7a43d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityShellCompany_611cb501-4ac6-45a1-bcfc-f8baa3b7a43d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e5bdbb40-390f-4fc6-a191-101e42b18b2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityPublicFloat_e5bdbb40-390f-4fc6-a191-101e42b18b2f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fc93206c-9904-4c40-9f1f-5839ff78985a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fc93206c-9904-4c40-9f1f-5839ff78985a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_02abbc98-cdaf-42ad-a750-23c8634f5687" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_02abbc98-cdaf-42ad-a750-23c8634f5687" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_33503841-562b-43ff-bc41-9cdce146c385" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityCentralIndexKey_33503841-562b-43ff-bc41-9cdce146c385" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eb9568e7-0d17-4124-8f93-826d55e54892" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_AmendmentFlag_eb9568e7-0d17-4124-8f93-826d55e54892" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b796845a-3342-4a58-8805-3c9f279eced8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentFiscalYearFocus_b796845a-3342-4a58-8805-3c9f279eced8" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5a56867d-c2d1-4fd0-a8e3-1f779f19cb2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5a56867d-c2d1-4fd0-a8e3-1f779f19cb2f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7d2bbb0e-65e1-47ef-86b7-d1af1be48999" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_CurrentFiscalYearEndDate_7d2bbb0e-65e1-47ef-86b7-d1af1be48999" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1ce7546b-7ff0-4669-89dd-0867449373d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1ce7546b-7ff0-4669-89dd-0867449373d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ce7546b-7ff0-4669-89dd-0867449373d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ce7546b-7ff0-4669-89dd-0867449373d0" xlink:to="loc_us-gaap_ClassOfStockDomain_1ce7546b-7ff0-4669-89dd-0867449373d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ce7546b-7ff0-4669-89dd-0867449373d0" xlink:to="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5467ef04-6207-4f26-bc68-4a729a6e1d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:to="loc_us-gaap_CommonStockMember_5467ef04-6207-4f26-bc68-4a729a6e1d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_2fd44069-3e63-479d-8ef3-9ca2bfc6df7b" xlink:href="amgn-20211231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_2fd44069-3e63-479d-8ef3-9ca2bfc6df7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_87f8a3ac-4859-4208-b627-7aa53733d766" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:to="loc_dei_EntityListingsExchangeAxis_87f8a3ac-4859-4208-b627-7aa53733d766" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_87f8a3ac-4859-4208-b627-7aa53733d766_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_87f8a3ac-4859-4208-b627-7aa53733d766" xlink:to="loc_dei_ExchangeDomain_87f8a3ac-4859-4208-b627-7aa53733d766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_87f8a3ac-4859-4208-b627-7aa53733d766" xlink:to="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_785742e6-ff17-4f67-9a04-b2dc68521ebd" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:to="loc_exch_XNGS_785742e6-ff17-4f67-9a04-b2dc68521ebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_2ce9d136-67d8-43c5-b789-3f91877cbf39" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:to="loc_exch_XNYS_2ce9d136-67d8-43c5-b789-3f91877cbf39" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i347c0366d1864a75859d32cf413e7357_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2476c3d9-7724-4953-a462-0787bad036bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_RevenuesAbstract_2476c3d9-7724-4953-a462-0787bad036bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d4653ca7-5328-42ea-a867-b552c66dbb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2476c3d9-7724-4953-a462-0787bad036bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d4653ca7-5328-42ea-a867-b552c66dbb69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_abf93727-2538-496b-9c05-af25abfe9238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_abf93727-2538-496b-9c05-af25abfe9238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e0ded7d0-0bc9-449d-8d9a-fba087f3659e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e0ded7d0-0bc9-449d-8d9a-fba087f3659e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_214e838e-56b0-4936-ba58-9be8696a113e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_214e838e-56b0-4936-ba58-9be8696a113e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a1e346a-fc0f-4fab-b397-384650afd047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a1e346a-fc0f-4fab-b397-384650afd047" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_4ba1fe1a-c394-4bb8-83fd-60c433414280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_OtherGeneralExpense_4ba1fe1a-c394-4bb8-83fd-60c433414280" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dda0aa7b-c53a-4d40-982c-2a05f1132feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_CostsAndExpenses_dda0aa7b-c53a-4d40-982c-2a05f1132feb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be0ad2e5-4151-470d-b30a-68799f00810b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_OperatingIncomeLoss_be0ad2e5-4151-470d-b30a-68799f00810b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6e939856-7bbd-4407-aa65-523fbb0c5e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_InterestExpenseDebt_6e939856-7bbd-4407-aa65-523fbb0c5e0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fa3dc9be-9680-478c-8c97-2981025aeac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fa3dc9be-9680-478c-8c97-2981025aeac8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dfc6775e-71fe-40ec-93d1-637e95a24e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dfc6775e-71fe-40ec-93d1-637e95a24e7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d632c58b-58f7-41aa-a7b6-fc762920023e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d632c58b-58f7-41aa-a7b6-fc762920023e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76149588-b2a3-4792-bb40-7ddf43267ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_NetIncomeLoss_76149588-b2a3-4792-bb40-7ddf43267ced" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7e2d7668-9808-4e9c-9336-917ef7ada78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:to="loc_us-gaap_EarningsPerShareBasic_7e2d7668-9808-4e9c-9336-917ef7ada78d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_735b0cd7-5bf3-4595-8fd9-c2a0656dadd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:to="loc_us-gaap_EarningsPerShareDiluted_735b0cd7-5bf3-4595-8fd9-c2a0656dadd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3cd37e65-ac2b-4afc-aaff-973ce9693ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3cd37e65-ac2b-4afc-aaff-973ce9693ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89cf3bbb-8caa-4ff9-97b8-e79c8f0f467a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89cf3bbb-8caa-4ff9-97b8-e79c8f0f467a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a301329d-0704-4ebe-a77f-9f5ef3870874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_StatementTable_a301329d-0704-4ebe-a77f-9f5ef3870874" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a301329d-0704-4ebe-a77f-9f5ef3870874" xlink:to="loc_srt_ProductOrServiceAxis_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d" xlink:to="loc_srt_ProductsAndServicesDomain_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d" xlink:to="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_43d73175-52c4-40dd-855c-a2abf87cbfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:to="loc_us-gaap_ProductMember_43d73175-52c4-40dd-855c-a2abf87cbfa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ca21ce29-c975-4973-a6b9-faad71b44a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ca21ce29-c975-4973-a6b9-faad71b44a76" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i48d140bb29284992a81e82fc0edf7f3e_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_873d34a7-4e9d-4ec4-bc62-e4646971910d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_873d34a7-4e9d-4ec4-bc62-e4646971910d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_43b6c72c-f75f-4861-a1d6-ed449ab8e9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_43b6c72c-f75f-4861-a1d6-ed449ab8e9e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2b5378b6-2cc1-4415-b78c-2e82a505d4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockholdersEquity_2b5378b6-2cc1-4415-b78c-2e82a505d4be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d740bb4-5f3b-44e9-8680-dc4c0353a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_NetIncomeLoss_3d740bb4-5f3b-44e9-8680-dc4c0353a9a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d8a8235e-310a-428e-b1be-67e541bda254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d8a8235e-310a-428e-b1be-67e541bda254" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a5ba29e7-6251-457d-a8ce-d4ef7a64d4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_DividendsCommonStockCash_a5ba29e7-6251-457d-a8ce-d4ef7a64d4d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a584d800-47f2-477b-869b-7e9dbf4f97d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a584d800-47f2-477b-869b-7e9dbf4f97d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_482b2f2f-0f63-4463-8ac3-9ff6c88f6f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_482b2f2f-0f63-4463-8ac3-9ff6c88f6f5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32f4fa58-204a-4512-a51f-d3a91961c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32f4fa58-204a-4512-a51f-d3a91961c5b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_77d9c70e-eca4-4cb5-a355-db70de44e970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_77d9c70e-eca4-4cb5-a355-db70de44e970" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_092d0aa8-be8f-423d-ae29-46c2b67d4649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_092d0aa8-be8f-423d-ae29-46c2b67d4649" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_35ef0cff-1b85-467d-9c96-3e3167fc9599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_35ef0cff-1b85-467d-9c96-3e3167fc9599" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_305105d1-c178-4ea5-95aa-85ba4b1709e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_301bd8de-58f1-4cc2-ba19-9c826e296a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_873d34a7-4e9d-4ec4-bc62-e4646971910d" xlink:to="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7918c984-70d8-4241-a25e-afd4ec3ce979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7918c984-70d8-4241-a25e-afd4ec3ce979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7918c984-70d8-4241-a25e-afd4ec3ce979_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7918c984-70d8-4241-a25e-afd4ec3ce979" xlink:to="loc_us-gaap_EquityComponentDomain_7918c984-70d8-4241-a25e-afd4ec3ce979_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7918c984-70d8-4241-a25e-afd4ec3ce979" xlink:to="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_410f3a97-295b-4182-8e0e-2ba5a6039871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_CommonStockMember_410f3a97-295b-4182-8e0e-2ba5a6039871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_30bae606-d6d8-4edc-826e-ad6daf247df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_30bae606-d6d8-4edc-826e-ad6daf247df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2b165f19-a884-41f8-b97f-893612d91fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_RetainedEarningsMember_2b165f19-a884-41f8-b97f-893612d91fbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6e8bb478-98b8-4755-8cb1-3cb517179d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6e8bb478-98b8-4755-8cb1-3cb517179d4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_808d78b5-34df-4920-8f92-08208f3c64b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_808d78b5-34df-4920-8f92-08208f3c64b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_808d78b5-34df-4920-8f92-08208f3c64b7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_808d78b5-34df-4920-8f92-08208f3c64b7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_808d78b5-34df-4920-8f92-08208f3c64b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc8f4db0-3e0f-4d86-a87f-fb06ccfb5f20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_808d78b5-34df-4920-8f92-08208f3c64b7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc8f4db0-3e0f-4d86-a87f-fb06ccfb5f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5295ddd6-6a67-4043-8d25-2517e64ebdf0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc8f4db0-3e0f-4d86-a87f-fb06ccfb5f20" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5295ddd6-6a67-4043-8d25-2517e64ebdf0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended" id="ia764dca65a9d4434b5c1af162783a85f_SummaryofsignificantaccountingpoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_23060f5f-86bb-4c2e-b948-9d32d1a7f3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_us-gaap_NumberOfOperatingSegments_23060f5f-86bb-4c2e-b948-9d32d1a7f3a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_65fea0cd-02fe-45fc-b305-cd3172e0db4c" xlink:href="amgn-20211231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_65fea0cd-02fe-45fc-b305-cd3172e0db4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm_1ab10d31-dcf4-4894-9f46-54b8e14a95eb" xlink:href="amgn-20211231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_amgn_RevenuePaymentArrangementTerm_1ab10d31-dcf4-4894-9f46-54b8e14a95eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_cdd56914-8432-41bb-aa0d-94b4dfeaf802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_us-gaap_AdvertisingExpense_cdd56914-8432-41bb-aa0d-94b4dfeaf802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45b70f7a-a165-4594-af36-142db9e808ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45b70f7a-a165-4594-af36-142db9e808ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3eb272a0-8a15-4160-b4a0-d720df797c47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45b70f7a-a165-4594-af36-142db9e808ed" xlink:to="loc_srt_RangeAxis_3eb272a0-8a15-4160-b4a0-d720df797c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3eb272a0-8a15-4160-b4a0-d720df797c47_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3eb272a0-8a15-4160-b4a0-d720df797c47" xlink:to="loc_srt_RangeMember_3eb272a0-8a15-4160-b4a0-d720df797c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3eb272a0-8a15-4160-b4a0-d720df797c47" xlink:to="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5576656a-c627-4b57-8c10-ffc72b6a17d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:to="loc_srt_MinimumMember_5576656a-c627-4b57-8c10-ffc72b6a17d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbd213d5-43a4-42c4-9c65-f66916c57fdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:to="loc_srt_MaximumMember_fbd213d5-43a4-42c4-9c65-f66916c57fdc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended" id="ib7f63a86729f446785e852fd526a531d_AcquisitionsAggregateConsiderationPaidDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9bd37995-b597-47d7-82ca-0213350402f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9bd37995-b597-47d7-82ca-0213350402f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_856f2ce0-6157-40b9-a0d9-3ec9e72f802e" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_856f2ce0-6157-40b9-a0d9-3ec9e72f802e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Transactioncostsassetacquisition_0c93cf72-61d0-4989-8871-98a48c9ed920" xlink:href="amgn-20211231.xsd#amgn_Transactioncostsassetacquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_Transactioncostsassetacquisition_0c93cf72-61d0-4989-8871-98a48c9ed920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_26b5b03c-5de6-4e2e-b4fc-f9d48bdc131f" xlink:href="amgn-20211231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_26b5b03c-5de6-4e2e-b4fc-f9d48bdc131f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_32f5cd4a-6328-4868-9401-5f0357431170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_32f5cd4a-6328-4868-9401-5f0357431170" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_191b72a1-de10-4545-b8c0-8975764a12e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_191b72a1-de10-4545-b8c0-8975764a12e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_695dc5a7-fd53-48f9-bb31-b32100f7a7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_695dc5a7-fd53-48f9-bb31-b32100f7a7e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_388de26a-53e0-406d-92f7-ed206e8a3214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_Goodwill_388de26a-53e0-406d-92f7-ed206e8a3214" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_465087cb-523a-40d8-beba-d3341d26f4ab" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_465087cb-523a-40d8-beba-d3341d26f4ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_84c32d6f-9134-44fe-a1d4-4257fd90f4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_84c32d6f-9134-44fe-a1d4-4257fd90f4d4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_2d29d183-61a4-4fdb-a772-5cb91d09f0d0" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_2d29d183-61a4-4fdb-a772-5cb91d09f0d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_d80278f3-3fc4-4f7c-941a-13271108bf85" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_d80278f3-3fc4-4f7c-941a-13271108bf85" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_8c32b966-a807-4540-baed-e4919aeef0fa" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_8c32b966-a807-4540-baed-e4919aeef0fa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_4bde8d99-951d-4eff-a591-ec1501bf0803" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_4bde8d99-951d-4eff-a591-ec1501bf0803" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_e7d6b49b-48e2-4620-a248-67f97f727f0d" xlink:href="amgn-20211231.xsd#amgn_TeneobioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:to="loc_amgn_TeneobioMember_e7d6b49b-48e2-4620-a248-67f97f727f0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_1ffe858a-8c55-4897-b6fc-efdb627ef3b0" xlink:href="amgn-20211231.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:to="loc_amgn_OtezlaMember_1ffe858a-8c55-4897-b6fc-efdb627ef3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_825299fd-6ef6-4ba0-933a-06f2c579b279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_825299fd-6ef6-4ba0-933a-06f2c579b279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_825299fd-6ef6-4ba0-933a-06f2c579b279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_825299fd-6ef6-4ba0-933a-06f2c579b279" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_825299fd-6ef6-4ba0-933a-06f2c579b279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd289ea4-03d4-4f15-baf9-d2e79002e448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_825299fd-6ef6-4ba0-933a-06f2c579b279" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd289ea4-03d4-4f15-baf9-d2e79002e448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0fefce19-4aca-4bdf-8468-f07ccb872456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd289ea4-03d4-4f15-baf9-d2e79002e448" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0fefce19-4aca-4bdf-8468-f07ccb872456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4437cb4-3595-4ab3-9225-db7d063c7de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4437cb4-3595-4ab3-9225-db7d063c7de7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4437cb4-3595-4ab3-9225-db7d063c7de7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4437cb4-3595-4ab3-9225-db7d063c7de7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4437cb4-3595-4ab3-9225-db7d063c7de7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4437cb4-3595-4ab3-9225-db7d063c7de7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_7ee3c158-be78-47fa-8efe-2f4297875c06" xlink:href="amgn-20211231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_amgn_RDTechnologyrightsMember_7ee3c158-be78-47fa-8efe-2f4297875c06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b6e36a4c-d894-4701-a810-9dd1d733ac9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_us-gaap_LicensingAgreementsMember_b6e36a4c-d894-4701-a810-9dd1d733ac9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d0320043-9667-4577-b8b3-42a15c3cab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d0320043-9667-4577-b8b3-42a15c3cab2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_afbc85e1-008e-413c-9d9d-4dfcb861c8d8" xlink:href="amgn-20211231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_amgn_MarketingRelatedRightsMember_afbc85e1-008e-413c-9d9d-4dfcb861c8d8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="ia0d4bca938a84bea82647dbc359aacdc_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_950accb5-fc23-4ea1-b534-104c5c01a8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_950accb5-fc23-4ea1-b534-104c5c01a8e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bd00b660-82ab-4ec3-8705-6bc2fd8d8dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bd00b660-82ab-4ec3-8705-6bc2fd8d8dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_bb79c51e-2e8d-481e-b410-6cedef41e2c0" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_bb79c51e-2e8d-481e-b410-6cedef41e2c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_86d0944f-2091-42df-bdb3-02cf7e150e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_86d0944f-2091-42df-bdb3-02cf7e150e7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7e997cf1-b89b-4c77-ae7b-78ec62a14cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7e997cf1-b89b-4c77-ae7b-78ec62a14cdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_29e5020f-7f44-4b0e-9156-a9fd7cfef572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_29e5020f-7f44-4b0e-9156-a9fd7cfef572" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2f78205-89e4-4a58-af8c-37b225b15f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2f78205-89e4-4a58-af8c-37b225b15f8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b7c8de2e-4339-4eec-9e3c-35745fac1c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_Goodwill_b7c8de2e-4339-4eec-9e3c-35745fac1c48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b6fd535-dbb6-4b21-b8e9-57588906138f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b6fd535-dbb6-4b21-b8e9-57588906138f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_81edfdb5-f219-496c-90e1-eee75cbfe88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_81edfdb5-f219-496c-90e1-eee75cbfe88a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_488d8dcb-3374-45a3-83fd-7ee509911c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_488d8dcb-3374-45a3-83fd-7ee509911c37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_4a53793e-66c6-48c7-a6ab-9d1485a92560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_4a53793e-66c6-48c7-a6ab-9d1485a92560" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedMarkets_3b66f2bb-d7be-4ee6-8530-8032e07b6651" xlink:href="amgn-20211231.xsd#amgn_ApprovedMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_ApprovedMarkets_3b66f2bb-d7be-4ee6-8530-8032e07b6651" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_22232115-6a68-4da1-b35a-4c9723a9af92" xlink:href="amgn-20211231.xsd#amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_22232115-6a68-4da1-b35a-4c9723a9af92" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_cd3016b7-c897-407f-93af-f1cc47bc8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_cd3016b7-c897-407f-93af-f1cc47bc8eea" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_e101e4d5-3bc3-485a-a3a3-2cc753ee31d0" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_e101e4d5-3bc3-485a-a3a3-2cc753ee31d0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_7affa31f-f37f-43e3-afbd-72a751c26198" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_7affa31f-f37f-43e3-afbd-72a751c26198" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_e5cfe5e0-1737-406c-8074-996587f973b3" xlink:href="amgn-20211231.xsd#amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_e5cfe5e0-1737-406c-8074-996587f973b3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0bbaf718-619c-4679-a5ef-6960865f7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0bbaf718-619c-4679-a5ef-6960865f7df8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_bbf73ed2-8c9c-4c42-ab4b-9a57ebef60c7" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_bbf73ed2-8c9c-4c42-ab4b-9a57ebef60c7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_9ffd71b6-1cf4-4a26-adf4-930d8299208f" xlink:href="amgn-20211231.xsd#amgn_TeneobioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_TeneobioMember_9ffd71b6-1cf4-4a26-adf4-930d8299208f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember_7033396b-ae94-4079-87e9-c2fd6249f461" xlink:href="amgn-20211231.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_FivePrimeTherapeuticsIncMember_7033396b-ae94-4079-87e9-c2fd6249f461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_c54dffa4-a3dd-4733-90d2-eee3bdae9802" xlink:href="amgn-20211231.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_OtezlaMember_c54dffa4-a3dd-4733-90d2-eee3bdae9802" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember_a0f84e42-a700-410e-a2d9-cc3532fa00cf" xlink:href="amgn-20211231.xsd#amgn_NuevolutionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_NuevolutionMember_a0f84e42-a700-410e-a2d9-cc3532fa00cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96234b72-3910-46c2-baa1-05c620b3e64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96234b72-3910-46c2-baa1-05c620b3e64a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96234b72-3910-46c2-baa1-05c620b3e64a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96234b72-3910-46c2-baa1-05c620b3e64a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96234b72-3910-46c2-baa1-05c620b3e64a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_625d4056-f1b0-44df-8b5d-5ec073d16c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96234b72-3910-46c2-baa1-05c620b3e64a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_625d4056-f1b0-44df-8b5d-5ec073d16c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3319732-b3fd-4f20-8faa-b10e1c15f62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_625d4056-f1b0-44df-8b5d-5ec073d16c0f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3319732-b3fd-4f20-8faa-b10e1c15f62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis_919017e7-1418-4d39-9787-79e452870524" xlink:href="amgn-20211231.xsd#amgn_MoleculeTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_amgn_MoleculeTypeAxis_919017e7-1418-4d39-9787-79e452870524" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_919017e7-1418-4d39-9787-79e452870524_default" xlink:href="amgn-20211231.xsd#amgn_MoleculeTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_MoleculeTypeAxis_919017e7-1418-4d39-9787-79e452870524" xlink:to="loc_amgn_MoleculeTypeDomain_919017e7-1418-4d39-9787-79e452870524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_884df7d5-fc1a-4fc0-b01f-ae3565227b61" xlink:href="amgn-20211231.xsd#amgn_MoleculeTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_MoleculeTypeAxis_919017e7-1418-4d39-9787-79e452870524" xlink:to="loc_amgn_MoleculeTypeDomain_884df7d5-fc1a-4fc0-b01f-ae3565227b61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member_24a77ace-9c1c-4d9e-8f33-7751ea3e43c3" xlink:href="amgn-20211231.xsd#amgn_AMG340Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_MoleculeTypeDomain_884df7d5-fc1a-4fc0-b01f-ae3565227b61" xlink:to="loc_amgn_AMG340Member_24a77ace-9c1c-4d9e-8f33-7751ea3e43c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04c53c5f-aa86-4bce-af30-ef1f3c6e8179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04c53c5f-aa86-4bce-af30-ef1f3c6e8179" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04c53c5f-aa86-4bce-af30-ef1f3c6e8179_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04c53c5f-aa86-4bce-af30-ef1f3c6e8179" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04c53c5f-aa86-4bce-af30-ef1f3c6e8179_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04c53c5f-aa86-4bce-af30-ef1f3c6e8179" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_18a03502-6ea2-4f3f-83e8-b5395ed2b72c" xlink:href="amgn-20211231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_amgn_RDTechnologyrightsMember_18a03502-6ea2-4f3f-83e8-b5395ed2b72c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3a052e9e-9bc4-4f0b-9dac-01367a77915d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_us-gaap_LicensingAgreementsMember_3a052e9e-9bc4-4f0b-9dac-01367a77915d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_63694db5-0f1d-4dfc-b3a3-469a4e816036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_63694db5-0f1d-4dfc-b3a3-469a4e816036" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_925c340c-5841-4915-9d52-ad68f0511a64" xlink:href="amgn-20211231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_amgn_MarketingRelatedRightsMember_925c340c-5841-4915-9d52-ad68f0511a64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_f7a9b651-9e73-44b1-a782-6d31e9be87b5" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_amgn_AssetsByDescriptionAxis_f7a9b651-9e73-44b1-a782-6d31e9be87b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_f7a9b651-9e73-44b1-a782-6d31e9be87b5_default" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_AssetsByDescriptionAxis_f7a9b651-9e73-44b1-a782-6d31e9be87b5" xlink:to="loc_amgn_AssetsByDescriptionDomain_f7a9b651-9e73-44b1-a782-6d31e9be87b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_AssetsByDescriptionAxis_f7a9b651-9e73-44b1-a782-6d31e9be87b5" xlink:to="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember_e3479d21-35ac-45c7-873a-595b1b3adddc" xlink:href="amgn-20211231.xsd#amgn_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:to="loc_amgn_AssembledWorkforceMember_e3479d21-35ac-45c7-873a-595b1b3adddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_19442935-043c-4471-993d-da014523b650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:to="loc_us-gaap_InventoriesMember_19442935-043c-4471-993d-da014523b650" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="idd66fa3c84ca48979ab4a2b32b969c60_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b4052cd7-d2dc-453c-a504-0a4ac91e4a2e" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b4052cd7-d2dc-453c-a504-0a4ac91e4a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_07b9f994-0f23-46f7-885b-4c5e34be3cea" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_07b9f994-0f23-46f7-885b-4c5e34be3cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_3398c5f2-584b-4b85-be62-892dc43b29f2" xlink:href="amgn-20211231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_3398c5f2-584b-4b85-be62-892dc43b29f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_cdb33512-b6b7-4014-910d-366b5df13355" xlink:href="amgn-20211231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_cdb33512-b6b7-4014-910d-366b5df13355" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9a94551b-e03d-41a4-b0e5-0631f3fded22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9a94551b-e03d-41a4-b0e5-0631f3fded22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_479bd1bc-391c-4856-833f-5e0b8990ff8c" xlink:href="amgn-20211231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_479bd1bc-391c-4856-833f-5e0b8990ff8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4f56de6f-0f6a-4003-be79-a9ded87130d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:to="loc_srt_MajorCustomersAxis_4f56de6f-0f6a-4003-be79-a9ded87130d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4f56de6f-0f6a-4003-be79-a9ded87130d2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4f56de6f-0f6a-4003-be79-a9ded87130d2" xlink:to="loc_srt_NameOfMajorCustomerDomain_4f56de6f-0f6a-4003-be79-a9ded87130d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4f56de6f-0f6a-4003-be79-a9ded87130d2" xlink:to="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_f63ab857-24ea-46b2-a073-041bfd340ed5" xlink:href="amgn-20211231.xsd#amgn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:to="loc_amgn_CustomerOneMember_f63ab857-24ea-46b2-a073-041bfd340ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_c0062283-ade8-4ab2-b01b-da4d9fb66cb7" xlink:href="amgn-20211231.xsd#amgn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:to="loc_amgn_CustomerTwoMember_c0062283-ade8-4ab2-b01b-da4d9fb66cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_3a3e7490-739a-4b06-a6a9-52fd784ca328" xlink:href="amgn-20211231.xsd#amgn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:to="loc_amgn_CustomerThreeMember_3a3e7490-739a-4b06-a6a9-52fd784ca328" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a3f9974-0386-4316-9cf7-912bb91e73ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:to="loc_srt_ProductOrServiceAxis_1a3f9974-0386-4316-9cf7-912bb91e73ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a3f9974-0386-4316-9cf7-912bb91e73ae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1a3f9974-0386-4316-9cf7-912bb91e73ae" xlink:to="loc_srt_ProductsAndServicesDomain_1a3f9974-0386-4316-9cf7-912bb91e73ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1a3f9974-0386-4316-9cf7-912bb91e73ae" xlink:to="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:to="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_3a64cfac-72e9-4b4c-b740-5b4f3cb3b4d1" xlink:href="amgn-20211231.xsd#amgn_EnbrelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_EnbrelMember_3a64cfac-72e9-4b4c-b740-5b4f3cb3b4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_8be05774-0373-4098-b257-93403d42a535" xlink:href="amgn-20211231.xsd#amgn_ProliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_ProliaMember_8be05774-0373-4098-b257-93403d42a535" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_6b805a0f-d3b8-4d2b-8ff3-cab7f303735e" xlink:href="amgn-20211231.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_OtezlaMember_6b805a0f-d3b8-4d2b-8ff3-cab7f303735e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_850b1251-5d0c-4446-8831-3fa23880eed8" xlink:href="amgn-20211231.xsd#amgn_XgevaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_XgevaMember_850b1251-5d0c-4446-8831-3fa23880eed8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_a2847be8-c160-4d58-8998-c02481abc0c9" xlink:href="amgn-20211231.xsd#amgn_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_NeulastaMember_a2847be8-c160-4d58-8998-c02481abc0c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_2a13b2c4-23f8-4dae-87b4-7fe3870b4828" xlink:href="amgn-20211231.xsd#amgn_AranespMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_AranespMember_2a13b2c4-23f8-4dae-87b4-7fe3870b4828" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_aa3c8190-49ff-456d-9d50-4255f8c70e47" xlink:href="amgn-20211231.xsd#amgn_RepathaevolocumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_RepathaevolocumabMember_aa3c8190-49ff-456d-9d50-4255f8c70e47" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_6d3e0193-20a6-4c40-a699-78bc9dbf6437" xlink:href="amgn-20211231.xsd#amgn_KyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_KyprolisMember_6d3e0193-20a6-4c40-a699-78bc9dbf6437" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_1441729e-7f8c-44da-84b6-f8e1dd736f64" xlink:href="amgn-20211231.xsd#amgn_NplateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_NplateMember_1441729e-7f8c-44da-84b6-f8e1dd736f64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_da386c16-c9cc-4b94-a055-df26359b9ca5" xlink:href="amgn-20211231.xsd#amgn_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_OtherProductsMember_da386c16-c9cc-4b94-a055-df26359b9ca5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d17ce085-1a7c-4b11-9c0c-10d0a12f2d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d17ce085-1a7c-4b11-9c0c-10d0a12f2d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9f4df996-2371-485d-90bf-35818e33c45c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:to="loc_srt_StatementGeographicalAxis_9f4df996-2371-485d-90bf-35818e33c45c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f4df996-2371-485d-90bf-35818e33c45c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9f4df996-2371-485d-90bf-35818e33c45c" xlink:to="loc_srt_SegmentGeographicalDomain_9f4df996-2371-485d-90bf-35818e33c45c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9f4df996-2371-485d-90bf-35818e33c45c" xlink:to="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac9ffc00-981a-487d-bf84-1f09cbe0e5c4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:to="loc_country_US_ac9ffc00-981a-487d-bf84-1f09cbe0e5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_78fe2300-9e8d-4010-8741-b1f1a360e052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:to="loc_us-gaap_NonUsMember_78fe2300-9e8d-4010-8741-b1f1a360e052" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#RevenuesCustomerConcentrationProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="extended" id="i6d5482557c814dcf822266ab206c9e19_RevenuesCustomerConcentrationProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b83d6802-3c65-4de3-a9e9-67fec5d5ef9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b83d6802-3c65-4de3-a9e9-67fec5d5ef9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues_64b81272-63bd-428a-a757-cca247322429" xlink:href="amgn-20211231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_amgn_PercentageOfGrossRevenues_64b81272-63bd-428a-a757-cca247322429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b7c01119-9feb-4331-bc00-6cb456837cc1" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b7c01119-9feb-4331-bc00-6cb456837cc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_ff0b974c-a7ba-4e14-8ed3-03b508af74d3" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_ff0b974c-a7ba-4e14-8ed3-03b508af74d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1ead18b0-f4ce-44f4-a971-590b122dbd1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:to="loc_srt_ProductOrServiceAxis_1ead18b0-f4ce-44f4-a971-590b122dbd1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1ead18b0-f4ce-44f4-a971-590b122dbd1a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1ead18b0-f4ce-44f4-a971-590b122dbd1a" xlink:to="loc_srt_ProductsAndServicesDomain_1ead18b0-f4ce-44f4-a971-590b122dbd1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61395aac-b89b-4085-af03-eec225afed5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1ead18b0-f4ce-44f4-a971-590b122dbd1a" xlink:to="loc_srt_ProductsAndServicesDomain_61395aac-b89b-4085-af03-eec225afed5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6b8554f2-bbcd-43c0-850c-aea3b7a52cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61395aac-b89b-4085-af03-eec225afed5a" xlink:to="loc_us-gaap_ProductMember_6b8554f2-bbcd-43c0-850c-aea3b7a52cea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:to="loc_srt_MajorCustomersAxis_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_5aafa2e3-c5cb-4ad8-a6bc-5fe174a078cb" xlink:href="amgn-20211231.xsd#amgn_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:to="loc_amgn_CustomerOneMember_5aafa2e3-c5cb-4ad8-a6bc-5fe174a078cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_dc7a7d4f-4c8f-4ddf-afd3-443e911495be" xlink:href="amgn-20211231.xsd#amgn_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:to="loc_amgn_CustomerTwoMember_dc7a7d4f-4c8f-4ddf-afd3-443e911495be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_dc609934-f855-46a9-a8af-fa5ae6ef2c2f" xlink:href="amgn-20211231.xsd#amgn_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:to="loc_amgn_CustomerThreeMember_dc609934-f855-46a9-a8af-fa5ae6ef2c2f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="extended" id="iab0d484c1d5b4ddfb13b588c9f058daa_StockbasedcompensationTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_6acc1674-f2ab-43a6-ba8c-e01cca3810f9" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_6acc1674-f2ab-43a6-ba8c-e01cca3810f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_cf9a6d31-cd38-419d-aa83-1312bdc3fecc" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_cf9a6d31-cd38-419d-aa83-1312bdc3fecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d4375c1e-299b-42b0-b5e3-aa1fe07d1534" xlink:href="amgn-20211231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d4375c1e-299b-42b0-b5e3-aa1fe07d1534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_54b791fb-68ea-4e64-92c6-65054ce9003c" xlink:href="amgn-20211231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_54b791fb-68ea-4e64-92c6-65054ce9003c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_73c953e0-254d-41fc-97dc-3a69a8dee715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_73c953e0-254d-41fc-97dc-3a69a8dee715" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa8c306c-09f9-4572-bded-2c96640dd12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa8c306c-09f9-4572-bded-2c96640dd12a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b2e32776-cc8d-4439-9748-bfdef392f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b2e32776-cc8d-4439-9748-bfdef392f5e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ab822bd9-bc68-41f3-be42-712d5de961aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ab822bd9-bc68-41f3-be42-712d5de961aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_92b266c2-1c8e-4e07-aa4f-8daa76eb3521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_92b266c2-1c8e-4e07-aa4f-8daa76eb3521" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdb5217d-270d-4405-91ba-ddcd8689672e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdb5217d-270d-4405-91ba-ddcd8689672e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95523337-6756-4a66-ac71-ff32eea25387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95523337-6756-4a66-ac71-ff32eea25387" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_577dcbe3-4c69-465f-bc06-f483c3222bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_577dcbe3-4c69-465f-bc06-f483c3222bcc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3b742fc4-346b-4330-b441-d6240eda68da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3b742fc4-346b-4330-b441-d6240eda68da" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_56d8945f-633c-4f79-82c6-fa0b9a5eab4e" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_56d8945f-633c-4f79-82c6-fa0b9a5eab4e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f63b0bc-40f6-4685-850d-f59686011410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f63b0bc-40f6-4685-850d-f59686011410" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59c1cb6e-0a0d-4fbe-a382-b8b83cd896ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59c1cb6e-0a0d-4fbe-a382-b8b83cd896ab" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d27b8181-c5c3-41d9-b376-d28d40b72d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d27b8181-c5c3-41d9-b376-d28d40b72d40" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94b6ce54-f216-4247-8fcf-e2294891c996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94b6ce54-f216-4247-8fcf-e2294891c996" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d3250d7c-f65e-41d8-a6de-2d4d20345623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d3250d7c-f65e-41d8-a6de-2d4d20345623" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5d370d4-b3f8-4dd5-855e-839ccd5a67cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5d370d4-b3f8-4dd5-855e-839ccd5a67cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5d370d4-b3f8-4dd5-855e-839ccd5a67cc" xlink:to="loc_us-gaap_AwardTypeAxis_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f69bee19-aa66-416a-890e-f389b6831638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f69bee19-aa66-416a-890e-f389b6831638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dd9aa7d8-42d9-4bcc-ae91-4d8e2f5b4bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dd9aa7d8-42d9-4bcc-ae91-4d8e2f5b4bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_9eec2245-b5e7-4cf3-848f-d13e8ef1433b" xlink:href="amgn-20211231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:to="loc_amgn_PerformanceUnitsMember_9eec2245-b5e7-4cf3-848f-d13e8ef1433b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i8a0e5768988641d4b36c0bed5bcf0bec_StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edfeba1a-7f44-4f0b-a625-3ca7bea84648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edfeba1a-7f44-4f0b-a625-3ca7bea84648" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b6b30304-7a79-4db9-a86f-234b1421dadf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:to="loc_us-gaap_ShareBasedCompensation_b6b30304-7a79-4db9-a86f-234b1421dadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_16a95cfc-a093-4d5d-9ee8-0ac6883bd8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_16a95cfc-a093-4d5d-9ee8-0ac6883bd8fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_9819981b-6ca4-448b-be55-4fab9b4f028f" xlink:href="amgn-20211231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:to="loc_amgn_StockBasedCompensationExpenseNetOfTax_9819981b-6ca4-448b-be55-4fab9b4f028f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eeaa51c-b8fd-40c0-83ba-0bcb67b3b0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edfeba1a-7f44-4f0b-a625-3ca7bea84648" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eeaa51c-b8fd-40c0-83ba-0bcb67b3b0da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5dcfcafb-e1be-4236-88dd-b8426ddb0795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eeaa51c-b8fd-40c0-83ba-0bcb67b3b0da" xlink:to="loc_us-gaap_AwardTypeAxis_5dcfcafb-e1be-4236-88dd-b8426ddb0795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcfcafb-e1be-4236-88dd-b8426ddb0795_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5dcfcafb-e1be-4236-88dd-b8426ddb0795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5dcfcafb-e1be-4236-88dd-b8426ddb0795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5dcfcafb-e1be-4236-88dd-b8426ddb0795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5aead4c5-63d0-41e3-8233-4152ed895b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5aead4c5-63d0-41e3-8233-4152ed895b19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_90903059-9601-4921-8f02-3773aecc1b63" xlink:href="amgn-20211231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:to="loc_amgn_PerformanceUnitsMember_90903059-9601-4921-8f02-3773aecc1b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7040162d-873a-44fa-96f0-245446b16255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7040162d-873a-44fa-96f0-245446b16255" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationSummaryofRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="extended" id="i1df61f5ddfd74961981589911bc8b45d_StockbasedcompensationSummaryofRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_81d8653c-3aac-40b1-93c9-e6f6ac2a9e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_81d8653c-3aac-40b1-93c9-e6f6ac2a9e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99d7f50e-441f-432a-b8f0-3f34353c5583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99d7f50e-441f-432a-b8f0-3f34353c5583" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87c0e380-fb0b-4777-9461-60eedc8804dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87c0e380-fb0b-4777-9461-60eedc8804dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1547ee34-de5b-44fb-bb35-e85f1c47e6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1547ee34-de5b-44fb-bb35-e85f1c47e6b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b7a07b1-0a6c-4d8c-9a70-9303258152ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39295040-87e2-4085-9310-6fb62e726478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39295040-87e2-4085-9310-6fb62e726478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_01bac566-e965-45a9-9874-3d272b9e37a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_01bac566-e965-45a9-9874-3d272b9e37a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e74142-7417-4229-a90b-7c13e831ba84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e74142-7417-4229-a90b-7c13e831ba84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3bfabecc-e5c0-4ba2-8f73-dfe93cc5640c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3bfabecc-e5c0-4ba2-8f73-dfe93cc5640c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6d75693-0437-4982-b0b7-4e00abc5cf42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45e2da3b-9772-4348-b48e-2b69f3311574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45e2da3b-9772-4348-b48e-2b69f3311574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_02078987-2948-4e6d-8802-0fe5688fe329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45e2da3b-9772-4348-b48e-2b69f3311574" xlink:to="loc_us-gaap_AwardTypeAxis_02078987-2948-4e6d-8802-0fe5688fe329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02078987-2948-4e6d-8802-0fe5688fe329_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_02078987-2948-4e6d-8802-0fe5688fe329" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02078987-2948-4e6d-8802-0fe5688fe329_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d563fd2d-e012-4491-9681-c9544afd5171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_02078987-2948-4e6d-8802-0fe5688fe329" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d563fd2d-e012-4491-9681-c9544afd5171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_feb18a45-9186-4ebc-ac88-de19e52ab2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d563fd2d-e012-4491-9681-c9544afd5171" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_feb18a45-9186-4ebc-ac88-de19e52ab2e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended" id="i1524a3adce57401d93907f34c0131f59_StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_937f2537-45af-4d86-b920-03a1ff950fd3" xlink:href="amgn-20211231.xsd#amgn_CommonStockFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_amgn_CommonStockFairValue_937f2537-45af-4d86-b920-03a1ff950fd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6969758c-262c-4be8-89d0-31632c914204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6969758c-262c-4be8-89d0-31632c914204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90cfe353-7692-4c6f-8b42-fd0f6c849935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90cfe353-7692-4c6f-8b42-fd0f6c849935" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93033cb7-da78-46f2-b57f-61da5f4a5992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93033cb7-da78-46f2-b57f-61da5f4a5992" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f65b3b9a-4a3a-486a-b676-4c7c53a721a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f65b3b9a-4a3a-486a-b676-4c7c53a721a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d1ea90-63f5-4b49-8831-68a400ae11c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d1ea90-63f5-4b49-8831-68a400ae11c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2575be-9734-4f8d-b365-d4437ec656b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2575be-9734-4f8d-b365-d4437ec656b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2e12f869-6d5c-48b3-b1bb-686a327a7d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2575be-9734-4f8d-b365-d4437ec656b6" xlink:to="loc_us-gaap_AwardTypeAxis_2e12f869-6d5c-48b3-b1bb-686a327a7d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e12f869-6d5c-48b3-b1bb-686a327a7d17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2e12f869-6d5c-48b3-b1bb-686a327a7d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e12f869-6d5c-48b3-b1bb-686a327a7d17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_756ea60c-c29d-4b28-aad4-f874195762f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2e12f869-6d5c-48b3-b1bb-686a327a7d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_756ea60c-c29d-4b28-aad4-f874195762f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_50874317-ba5f-452e-b1cd-62a582e1850f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_756ea60c-c29d-4b28-aad4-f874195762f1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_50874317-ba5f-452e-b1cd-62a582e1850f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended" id="ic3fb17cd33de4a99aad7a5a64ce318c0_StockbasedcompensationSummaryofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_066bed7d-c9fc-4b19-8988-171495014d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_066bed7d-c9fc-4b19-8988-171495014d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_818105c2-cdac-4a82-8078-55bc8a491225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_818105c2-cdac-4a82-8078-55bc8a491225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f75bd878-3ae8-48df-95c0-a2284a43b840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f75bd878-3ae8-48df-95c0-a2284a43b840" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c7b068ba-dfdd-4805-8ae6-44297a1ab9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c7b068ba-dfdd-4805-8ae6-44297a1ab9f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45fb5f5a-61ed-49d2-a27b-5b58b226d8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c1ad767b-45c4-49f2-a645-497d5c0cf6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c1ad767b-45c4-49f2-a645-497d5c0cf6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aab7a3d3-0f2b-4157-99e3-64121eb1f8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aab7a3d3-0f2b-4157-99e3-64121eb1f8a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cf60b86-b50c-4b3f-966f-54a5d54647dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cf60b86-b50c-4b3f-966f-54a5d54647dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_804fbe00-05fb-4e61-86db-e0d4ae720e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_804fbe00-05fb-4e61-86db-e0d4ae720e44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6465ff0b-57bc-4a4a-a702-2b7ddcfc361b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6465ff0b-57bc-4a4a-a702-2b7ddcfc361b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ed7e8e7c-0aca-46dd-8ae5-f5f872bfe507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ed7e8e7c-0aca-46dd-8ae5-f5f872bfe507" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d910ca7e-0c15-418a-8530-23a9c76d9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e61e3671-85c1-48d0-8ea9-6ee9f9ceab8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e61e3671-85c1-48d0-8ea9-6ee9f9ceab8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2af4942e-dd21-4c31-95c5-b0763a9e194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2af4942e-dd21-4c31-95c5-b0763a9e194d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5a7a70e2-c376-40ac-92a6-30c73c308609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5a7a70e2-c376-40ac-92a6-30c73c308609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6959bdff-6e94-46dd-89e4-cda64424a31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6959bdff-6e94-46dd-89e4-cda64424a31c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f9a61898-3c52-45cd-b750-9433b4abbec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f9a61898-3c52-45cd-b750-9433b4abbec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0b83fe0-683b-4632-b647-ef92b0d6aacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0b83fe0-683b-4632-b647-ef92b0d6aacb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1c076272-1edc-4118-8abd-30feb6023129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1c076272-1edc-4118-8abd-30feb6023129" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a0789d70-b1dd-4cec-8974-2d2cb6290381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a0789d70-b1dd-4cec-8974-2d2cb6290381" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3ea8038-ccce-4e4a-af1c-d4c383a4e571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3ea8038-ccce-4e4a-af1c-d4c383a4e571" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6fc3538c-f361-46c5-a60c-e019468b191b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3ea8038-ccce-4e4a-af1c-d4c383a4e571" xlink:to="loc_us-gaap_AwardTypeAxis_6fc3538c-f361-46c5-a60c-e019468b191b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fc3538c-f361-46c5-a60c-e019468b191b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6fc3538c-f361-46c5-a60c-e019468b191b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6fc3538c-f361-46c5-a60c-e019468b191b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04de7794-ea64-4689-ab66-7e07f88001ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6fc3538c-f361-46c5-a60c-e019468b191b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04de7794-ea64-4689-ab66-7e07f88001ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_55ac2351-0e8c-4b1b-adbd-b78f65d627db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04de7794-ea64-4689-ab66-7e07f88001ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_55ac2351-0e8c-4b1b-adbd-b78f65d627db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="i63120a380ad44cc4935cc2632a7fd0f1_StockbasedcompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81b64b4f-a748-47f4-a24d-c4022fc0e686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81b64b4f-a748-47f4-a24d-c4022fc0e686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_c37566f2-f796-4726-9767-4b7a7f99e401" xlink:href="amgn-20211231.xsd#amgn_CommonStockFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_amgn_CommonStockFairValue_c37566f2-f796-4726-9767-4b7a7f99e401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_440d1ca2-3599-4c68-a00b-e53accc00d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_440d1ca2-3599-4c68-a00b-e53accc00d95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9e889c4-59c9-440f-a556-3b5936b52b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9e889c4-59c9-440f-a556-3b5936b52b1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2657210f-afec-42e4-a1a2-d40cdb4d5f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2657210f-afec-42e4-a1a2-d40cdb4d5f5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40c2d965-6f5b-4df6-aa09-eddbabd02f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81b64b4f-a748-47f4-a24d-c4022fc0e686" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40c2d965-6f5b-4df6-aa09-eddbabd02f01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d91a1de-33a7-48d2-a459-84e00e8ddc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40c2d965-6f5b-4df6-aa09-eddbabd02f01" xlink:to="loc_us-gaap_AwardTypeAxis_8d91a1de-33a7-48d2-a459-84e00e8ddc06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d91a1de-33a7-48d2-a459-84e00e8ddc06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8d91a1de-33a7-48d2-a459-84e00e8ddc06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d91a1de-33a7-48d2-a459-84e00e8ddc06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2734b98a-661b-48d5-a954-d73773b627fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8d91a1de-33a7-48d2-a459-84e00e8ddc06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2734b98a-661b-48d5-a954-d73773b627fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_220f6864-7977-41f6-bc9b-89b74fda70a2" xlink:href="amgn-20211231.xsd#amgn_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2734b98a-661b-48d5-a954-d73773b627fb" xlink:to="loc_amgn_PerformanceUnitsMember_220f6864-7977-41f6-bc9b-89b74fda70a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesIncomeBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="extended" id="i4b606a77d8704c25bd2e36f6c7e45ee4_IncometaxesIncomeBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_bcedd4f9-bfdb-4dc2-aa09-afdb4bd75ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6a807bc2-a712-4058-99a0-6e027517db81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_bcedd4f9-bfdb-4dc2-aa09-afdb4bd75ed3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6a807bc2-a712-4058-99a0-6e027517db81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_f77609c4-918d-49e6-ae3f-7023205b7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_bcedd4f9-bfdb-4dc2-aa09-afdb4bd75ed3" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_f77609c4-918d-49e6-ae3f-7023205b7e85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a2898d83-3240-4522-97ac-1f4197d67283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_f77609c4-918d-49e6-ae3f-7023205b7e85" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a2898d83-3240-4522-97ac-1f4197d67283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a2898d83-3240-4522-97ac-1f4197d67283_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a2898d83-3240-4522-97ac-1f4197d67283" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a2898d83-3240-4522-97ac-1f4197d67283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a2898d83-3240-4522-97ac-1f4197d67283" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6b896f61-d846-4edc-ad96-e054c0c114f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:to="loc_us-gaap_DomesticCountryMember_6b896f61-d846-4edc-ad96-e054c0c114f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_f96eee7f-bfc1-4d7a-9f45-db001255b2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:to="loc_us-gaap_ForeignCountryMember_f96eee7f-bfc1-4d7a-9f45-db001255b2a8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="extended" id="i331582d904f14fc3b7f2730dff573913_IncometaxesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e190fb7b-571f-4f40-a817-c74355aa9f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e190fb7b-571f-4f40-a817-c74355aa9f52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_e676f55e-ba2f-44eb-bc78-ee0f67db8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_e676f55e-ba2f-44eb-bc78-ee0f67db8b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a166ef72-b038-4bb4-a64d-72bbdbc9c798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a166ef72-b038-4bb4-a64d-72bbdbc9c798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_39042a48-3941-45fa-9bf6-e869e6143102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_39042a48-3941-45fa-9bf6-e869e6143102" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_921baba6-3bbb-4670-89fb-aaa64e1f282a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_921baba6-3bbb-4670-89fb-aaa64e1f282a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b27a9531-e3c8-4a6d-8ee3-81df9127b3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b27a9531-e3c8-4a6d-8ee3-81df9127b3b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d26521b3-ae4d-464f-bb95-d8c384214681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d26521b3-ae4d-464f-bb95-d8c384214681" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_6e6061bb-d609-4a14-9aa7-fa9d4157d5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_IncomeTaxesPaid_6e6061bb-d609-4a14-9aa7-fa9d4157d5c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax_efb18714-16e9-4e2e-ba3a-68fee162130b" xlink:href="amgn-20211231.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_amgn_ProposedAdditionalIncomeTax_efb18714-16e9-4e2e-ba3a-68fee162130b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax_709e0a30-a033-44aa-a8f7-3322c53fc0c2" xlink:href="amgn-20211231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax_709e0a30-a033-44aa-a8f7-3322c53fc0c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_caadd6c4-5ba1-4141-ac7f-c151e96ddb8a" xlink:href="amgn-20211231.xsd#amgn_NumberOfNoticesOnProposedAdditionalTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_caadd6c4-5ba1-4141-ac7f-c151e96ddb8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_82cb5f12-a51e-43b3-a6cd-3ce5932f3474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_82cb5f12-a51e-43b3-a6cd-3ce5932f3474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_82cb5f12-a51e-43b3-a6cd-3ce5932f3474_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82cb5f12-a51e-43b3-a6cd-3ce5932f3474" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_82cb5f12-a51e-43b3-a6cd-3ce5932f3474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82cb5f12-a51e-43b3-a6cd-3ce5932f3474" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bbfb830f-24e0-4052-bc7e-3feac748d289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:to="loc_us-gaap_DomesticCountryMember_bbfb830f-24e0-4052-bc7e-3feac748d289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a37e651c-10bd-4ba6-9f81-0d8af42f6e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a37e651c-10bd-4ba6-9f81-0d8af42f6e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e7db11ea-c89f-4969-94b0-860c5672e471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:to="loc_us-gaap_ForeignCountryMember_e7db11ea-c89f-4969-94b0-860c5672e471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_a1761395-92cd-4e51-a4ee-92f5e08b33cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:to="loc_us-gaap_TaxPeriodAxis_a1761395-92cd-4e51-a4ee-92f5e08b33cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_a1761395-92cd-4e51-a4ee-92f5e08b33cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_a1761395-92cd-4e51-a4ee-92f5e08b33cd" xlink:to="loc_us-gaap_TaxPeriodDomain_a1761395-92cd-4e51-a4ee-92f5e08b33cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_a1761395-92cd-4e51-a4ee-92f5e08b33cd" xlink:to="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2040Member_70580d4d-fcfe-4d7d-a096-b266741e08c0" xlink:href="amgn-20211231.xsd#amgn_ExpirationInTaxYearsBetween2023And2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:to="loc_amgn_ExpirationInTaxYearsBetween2023And2040Member_70580d4d-fcfe-4d7d-a096-b266741e08c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2037Member_421459f9-37ab-4e1a-97a3-4369d6e6a614" xlink:href="amgn-20211231.xsd#amgn_OperatingLossesThatExpireBetween2022And2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2022And2037Member_421459f9-37ab-4e1a-97a3-4369d6e6a614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_600ba3f4-3117-4b7c-ac87-e983f8787bd7" xlink:href="amgn-20211231.xsd#amgn_OperatingLossesThatExpireBetween2022And2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_600ba3f4-3117-4b7c-ac87-e983f8787bd7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#CollaborationsNovartisAGDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="extended" id="i2eafd353e9474e3d992c370115a6577d_CollaborationsNovartisAGDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_b1e81e05-0d59-4fcb-a3f3-7c0e1d97e3f8" xlink:href="amgn-20211231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_b1e81e05-0d59-4fcb-a3f3-7c0e1d97e3f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_d15c2a8b-875e-4a4e-a559-9ada089d7668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_d15c2a8b-875e-4a4e-a559-9ada089d7668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_ac8df0a0-01a4-44ee-80c1-512fc1225452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:to="loc_us-gaap_RoyaltyExpense_ac8df0a0-01a4-44ee-80c1-512fc1225452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_56b4e9fc-eb1a-4996-bae1-aec967ce3cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_56b4e9fc-eb1a-4996-bae1-aec967ce3cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56b4e9fc-eb1a-4996-bae1-aec967ce3cac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_56b4e9fc-eb1a-4996-bae1-aec967ce3cac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56b4e9fc-eb1a-4996-bae1-aec967ce3cac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57b0f8a4-c961-42f0-a2b8-9f5e37d17aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_56b4e9fc-eb1a-4996-bae1-aec967ce3cac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57b0f8a4-c961-42f0-a2b8-9f5e37d17aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f13149bf-0903-4820-a8cb-42f628e36102" xlink:href="amgn-20211231.xsd#amgn_CollaborativeArrangementwithNovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57b0f8a4-c961-42f0-a2b8-9f5e37d17aed" xlink:to="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f13149bf-0903-4820-a8cb-42f628e36102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_44ab3564-cbf9-43a1-8683-ef20372a0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_44ab3564-cbf9-43a1-8683-ef20372a0e29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44ab3564-cbf9-43a1-8683-ef20372a0e29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44ab3564-cbf9-43a1-8683-ef20372a0e29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44ab3564-cbf9-43a1-8683-ef20372a0e29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44ab3564-cbf9-43a1-8683-ef20372a0e29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8bc16f6-df2e-46e6-b174-51e3a4a089d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8bc16f6-df2e-46e6-b174-51e3a4a089d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f0884ae1-a524-4fbe-ba6d-7e3e29d6adcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:to="loc_us-gaap_CostOfSalesMember_f0884ae1-a524-4fbe-ba6d-7e3e29d6adcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:to="loc_srt_ProductOrServiceAxis_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2" xlink:to="loc_srt_ProductsAndServicesDomain_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0155410b-969f-4060-8c62-c97e2c404506" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2" xlink:to="loc_srt_ProductsAndServicesDomain_0155410b-969f-4060-8c62-c97e2c404506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d7e55a29-e640-43ca-9393-cda08b965b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0155410b-969f-4060-8c62-c97e2c404506" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d7e55a29-e640-43ca-9393-cda08b965b70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#CollaborationsBeiGeneDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="extended" id="if5b5fa68e37e4bb78fae65107d3bd44e_CollaborationsBeiGeneDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_4c025bb8-2975-45e3-bfd2-762e012d85a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_4c025bb8-2975-45e3-bfd2-762e012d85a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_49676ab4-8794-4e84-8c93-8cfaf3a719bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_49676ab4-8794-4e84-8c93-8cfaf3a719bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f745ff30-3be1-4e25-a3c2-340d9ea5d08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f745ff30-3be1-4e25-a3c2-340d9ea5d08e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_ad6ba28c-339f-49cd-9db6-1614ce69e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_ad6ba28c-339f-49cd-9db6-1614ce69e1e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10a1439f-cc5d-4153-9003-468cd5b0f2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10a1439f-cc5d-4153-9003-468cd5b0f2ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_a3797652-a1a0-447f-a7aa-3c2944c58628" xlink:href="amgn-20211231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_a3797652-a1a0-447f-a7aa-3c2944c58628" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_17af0675-98ad-4cd5-9ab2-41b86fa53740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_17af0675-98ad-4cd5-9ab2-41b86fa53740" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7acee467-375b-4806-9028-0e36efb102c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7acee467-375b-4806-9028-0e36efb102c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7acee467-375b-4806-9028-0e36efb102c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7acee467-375b-4806-9028-0e36efb102c9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7acee467-375b-4806-9028-0e36efb102c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f726af8d-8e98-45a4-86bf-2d65edb19c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7acee467-375b-4806-9028-0e36efb102c9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f726af8d-8e98-45a4-86bf-2d65edb19c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_47047eaa-57cc-4158-b45f-b68a95168a0f" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f726af8d-8e98-45a4-86bf-2d65edb19c09" xlink:to="loc_amgn_BeiGeneMember_47047eaa-57cc-4158-b45f-b68a95168a0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_srt_CounterpartyNameAxis_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5e1bd44-6998-4e54-b168-084c21e523c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5e1bd44-6998-4e54-b168-084c21e523c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7749fc5-1e53-45a1-888e-e47e63da7ef2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_srt_ProductOrServiceAxis_a7749fc5-1e53-45a1-888e-e47e63da7ef2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7749fc5-1e53-45a1-888e-e47e63da7ef2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a7749fc5-1e53-45a1-888e-e47e63da7ef2" xlink:to="loc_srt_ProductsAndServicesDomain_a7749fc5-1e53-45a1-888e-e47e63da7ef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_71fbe8a6-baee-482b-96c1-e97464643912" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a7749fc5-1e53-45a1-888e-e47e63da7ef2" xlink:to="loc_srt_ProductsAndServicesDomain_71fbe8a6-baee-482b-96c1-e97464643912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_1f3d439f-a753-419e-9552-aab8704cecc0" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_71fbe8a6-baee-482b-96c1-e97464643912" xlink:to="loc_amgn_BeiGeneMember_1f3d439f-a753-419e-9552-aab8704cecc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1cd11090-e918-4932-affa-ccdee58d5aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1cd11090-e918-4932-affa-ccdee58d5aa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1cd11090-e918-4932-affa-ccdee58d5aa4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1cd11090-e918-4932-affa-ccdee58d5aa4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1cd11090-e918-4932-affa-ccdee58d5aa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1cd11090-e918-4932-affa-ccdee58d5aa4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bbac84c6-2d2e-4fb7-baa9-4ed233886aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bbac84c6-2d2e-4fb7-baa9-4ed233886aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f823824-1b47-477a-8801-bc186b4afb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f823824-1b47-477a-8801-bc186b4afb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_8d4a8b59-ef9a-49a2-ac7b-91175906d034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_8d4a8b59-ef9a-49a2-ac7b-91175906d034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_3a8b8437-5693-46c0-8017-24f3e77e173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_3a8b8437-5693-46c0-8017-24f3e77e173c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bb53c651-562b-4127-9d9d-622f2068134e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bb53c651-562b-4127-9d9d-622f2068134e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb53c651-562b-4127-9d9d-622f2068134e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb53c651-562b-4127-9d9d-622f2068134e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb53c651-562b-4127-9d9d-622f2068134e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4645d489-d897-4958-8db5-23df986afdde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb53c651-562b-4127-9d9d-622f2068134e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4645d489-d897-4958-8db5-23df986afdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_0f97d888-702c-4557-9a63-0db3d140bcb1" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4645d489-d897-4958-8db5-23df986afdde" xlink:to="loc_amgn_BeiGeneMember_0f97d888-702c-4557-9a63-0db3d140bcb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#CollaborationsKyowaKirinDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="extended" id="i554050ae274c461eac2694eeadd46f46_CollaborationsKyowaKirinDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UpFrontPayment_175c3e2f-0354-46a4-9f8e-ac426a9f9d9e" xlink:href="amgn-20211231.xsd#amgn_UpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:to="loc_amgn_UpFrontPayment_175c3e2f-0354-46a4-9f8e-ac426a9f9d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_8aa59652-d95d-4005-9648-f13b79bf3833" xlink:href="amgn-20211231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_8aa59652-d95d-4005-9648-f13b79bf3833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_509e706a-511d-4951-af48-4a172adbe560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_509e706a-511d-4951-af48-4a172adbe560" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b0bf06e9-f64c-4a40-9b61-9ab08904c359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_509e706a-511d-4951-af48-4a172adbe560" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b0bf06e9-f64c-4a40-9b61-9ab08904c359" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0bf06e9-f64c-4a40-9b61-9ab08904c359_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b0bf06e9-f64c-4a40-9b61-9ab08904c359" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0bf06e9-f64c-4a40-9b61-9ab08904c359_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d5a2175-7ac8-4f64-8c31-d6c43a472d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b0bf06e9-f64c-4a40-9b61-9ab08904c359" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d5a2175-7ac8-4f64-8c31-d6c43a472d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyowaKirinCoLtdMember_f1df9bfd-2c35-439a-b9c9-621dd0dcd3e3" xlink:href="amgn-20211231.xsd#amgn_KyowaKirinCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d5a2175-7ac8-4f64-8c31-d6c43a472d94" xlink:to="loc_amgn_KyowaKirinCoLtdMember_f1df9bfd-2c35-439a-b9c9-621dd0dcd3e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended" id="i078bd5c7bdff497580738d7e11a3414a_InvestmentsScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b9f3348c-1dca-4978-8552-b4855d2554ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b9f3348c-1dca-4978-8552-b4855d2554ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d957840c-ac4d-46c5-8da3-c21f1a49fc77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d957840c-ac4d-46c5-8da3-c21f1a49fc77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba379571-39c6-4a2d-ae24-94fed0cece32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba379571-39c6-4a2d-ae24-94fed0cece32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcdbf0f3-1b2b-4013-8298-28ae4420bc27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcdbf0f3-1b2b-4013-8298-28ae4420bc27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f931c92c-f0a8-4fe3-9ebe-2c64d3e27d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f931c92c-f0a8-4fe3-9ebe-2c64d3e27d18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6637b54b-49ee-4e45-8876-9cd31c3fb1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b9f3348c-1dca-4978-8552-b4855d2554ae" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6637b54b-49ee-4e45-8876-9cd31c3fb1ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b9403533-ffbd-463b-8ded-440d99a796f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6637b54b-49ee-4e45-8876-9cd31c3fb1ff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b9403533-ffbd-463b-8ded-440d99a796f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9403533-ffbd-463b-8ded-440d99a796f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9403533-ffbd-463b-8ded-440d99a796f3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9403533-ffbd-463b-8ded-440d99a796f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9403533-ffbd-463b-8ded-440d99a796f3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5130f6f1-8bd6-4d34-822c-479cb31ab5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5130f6f1-8bd6-4d34-822c-479cb31ab5bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_17e0d6f6-4411-449e-a21f-dbd94377bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_17e0d6f6-4411-449e-a21f-dbd94377bbdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cc6d8d27-9950-4c5d-901b-e474f516b2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cc6d8d27-9950-4c5d-901b-e474f516b2df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_913136c6-a9a0-4387-8def-9d1d1ad51872" xlink:href="amgn-20211231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_913136c6-a9a0-4387-8def-9d1d1ad51872" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended" id="i060434121afc47a3acdc91d4f58f986f_InvestmentsFairValuesbyClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5c8e6c9f-debe-46c1-b65d-ea56d0eb9d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5c8e6c9f-debe-46c1-b65d-ea56d0eb9d53" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10119148-274b-410f-8b9a-ba00fa086ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10119148-274b-410f-8b9a-ba00fa086ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e48f66b4-cbf0-4815-85eb-c03ffe17afe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e48f66b4-cbf0-4815-85eb-c03ffe17afe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ff7bc6e-c69a-43bd-8914-9fc81f5b2308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ff7bc6e-c69a-43bd-8914-9fc81f5b2308" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2a4d902c-e8a8-437a-a66d-718ea0006b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5c8e6c9f-debe-46c1-b65d-ea56d0eb9d53" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2a4d902c-e8a8-437a-a66d-718ea0006b08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2a4d902c-e8a8-437a-a66d-718ea0006b08" xlink:to="loc_us-gaap_FinancialInstrumentAxis_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4221636-55a3-4b03-b881-7f57a067c6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4221636-55a3-4b03-b881-7f57a067c6a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_6ea5b9d4-8050-4313-895d-955fc793e2df" xlink:href="amgn-20211231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4221636-55a3-4b03-b881-7f57a067c6a5" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_6ea5b9d4-8050-4313-895d-955fc793e2df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsAvailableforsaleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="extended" id="i5f900f0d5d16428bb066ca9f624c82d7_InvestmentsAvailableforsaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_6b4e890a-06c9-4aa4-a8c0-96e1cd1366a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:to="loc_us-gaap_Cash_6b4e890a-06c9-4aa4-a8c0-96e1cd1366a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_d802d3b8-6c38-4f9a-a007-27861868fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_d802d3b8-6c38-4f9a-a007-27861868fc9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_739954f2-27b5-495a-8a86-412d845bd30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:to="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_739954f2-27b5-495a-8a86-412d845bd30b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_739954f2-27b5-495a-8a86-412d845bd30b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_380a139d-8f5c-4da2-b0c4-6211320e7d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_380a139d-8f5c-4da2-b0c4-6211320e7d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_2092abf2-ed10-4462-b9f4-65d3e8342fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_380a139d-8f5c-4da2-b0c4-6211320e7d7a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_2092abf2-ed10-4462-b9f4-65d3e8342fd9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended" id="i26878a5a73f64734bdcff7db941747ee_InvestmentsEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cc4d7709-b759-435d-a685-e79fc330cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cc4d7709-b759-435d-a685-e79fc330cafa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b5794782-7d6b-4952-aa97-cae74fe8af30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b5794782-7d6b-4952-aa97-cae74fe8af30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2603fbc-e6f2-4f80-a1fc-3e88435fe122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2603fbc-e6f2-4f80-a1fc-3e88435fe122" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_45cfbe75-67be-4f8d-99a4-fc14cba8f995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_45cfbe75-67be-4f8d-99a4-fc14cba8f995" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_9b77f8e0-c909-4c53-8106-9068a9420069" xlink:href="amgn-20211231.xsd#amgn_EquitySecuritiesRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_9b77f8e0-c909-4c53-8106-9068a9420069" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f8f1ae4b-14f1-4d1b-a8e2-178ec9c01211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f8f1ae4b-14f1-4d1b-a8e2-178ec9c01211" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5d5500c-faf6-480e-8add-c9971098efe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f8f1ae4b-14f1-4d1b-a8e2-178ec9c01211" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5d5500c-faf6-480e-8add-c9971098efe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f5d5500c-faf6-480e-8add-c9971098efe0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5d5500c-faf6-480e-8add-c9971098efe0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f5d5500c-faf6-480e-8add-c9971098efe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ad231624-6146-42cf-8823-29c53f74510b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5d5500c-faf6-480e-8add-c9971098efe0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ad231624-6146-42cf-8823-29c53f74510b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_00084333-e7e3-4958-b77d-e5ec5db77a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ad231624-6146-42cf-8823-29c53f74510b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_00084333-e7e3-4958-b77d-e5ec5db77a0b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended" id="ib55dfc81d26b4401a56f417df8746d58_InvestmentsLimitedPartnershipInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_74d94a89-6c12-4857-8b47-e2b168311f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:to="loc_us-gaap_AlternativeInvestment_74d94a89-6c12-4857-8b47-e2b168311f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_961d4d08-3331-4d98-aba3-12c6f557c56c" xlink:href="amgn-20211231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_961d4d08-3331-4d98-aba3-12c6f557c56c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_b503ecc5-3af2-4235-8ada-c67592bf450e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:to="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_b503ecc5-3af2-4235-8ada-c67592bf450e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_60b840d6-3f43-42f7-a462-92a376e82dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:to="loc_us-gaap_InvestmentTypeAxis_60b840d6-3f43-42f7-a462-92a376e82dcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_60b840d6-3f43-42f7-a462-92a376e82dcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_60b840d6-3f43-42f7-a462-92a376e82dcf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_60b840d6-3f43-42f7-a462-92a376e82dcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cdf7636e-59a6-4b1a-9d37-ce6f8664e722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_60b840d6-3f43-42f7-a462-92a376e82dcf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cdf7636e-59a6-4b1a-9d37-ce6f8664e722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_9ab0ac45-e027-4597-a0b7-7b12ca4c342a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cdf7636e-59a6-4b1a-9d37-ce6f8664e722" xlink:to="loc_srt_PartnershipInterestMember_9ab0ac45-e027-4597-a0b7-7b12ca4c342a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da3733f0-fd21-4bd9-836e-b96d09ff1a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da3733f0-fd21-4bd9-836e-b96d09ff1a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3733f0-fd21-4bd9-836e-b96d09ff1a4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da3733f0-fd21-4bd9-836e-b96d09ff1a4b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3733f0-fd21-4bd9-836e-b96d09ff1a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5f97076-b1bb-4ed8-8d06-cf9f1934a785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da3733f0-fd21-4bd9-836e-b96d09ff1a4b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5f97076-b1bb-4ed8-8d06-cf9f1934a785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6e68bab2-2a26-4ca4-98a5-81449d072087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5f97076-b1bb-4ed8-8d06-cf9f1934a785" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6e68bab2-2a26-4ca4-98a5-81449d072087" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsBeiGeneDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended" id="id6783d535f014101bd884d909dea3ec9_InvestmentsBeiGeneDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5d05da86-6f92-4fd0-b36a-ed533fe25130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5d05da86-6f92-4fd0-b36a-ed533fe25130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e994b31e-215f-4b50-b11b-d573cb392451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e994b31e-215f-4b50-b11b-d573cb392451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bceeba58-0bb3-4365-bb12-f4a778688402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bceeba58-0bb3-4365-bb12-f4a778688402" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_737e15af-1850-49e8-93ae-6e7fd88a0b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_737e15af-1850-49e8-93ae-6e7fd88a0b55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_63dde000-92e6-41d4-bd5a-f0f3674bebdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_63dde000-92e6-41d4-bd5a-f0f3674bebdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_3db9def9-8c30-45af-9ff7-4d593c164549" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_3db9def9-8c30-45af-9ff7-4d593c164549" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_472d306b-cadb-4bc0-9a87-9cb5313f6044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_472d306b-cadb-4bc0-9a87-9cb5313f6044" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_f802744d-6a96-4835-a7cd-4f39c8b0795a" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_f802744d-6a96-4835-a7cd-4f39c8b0795a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_02b8db2c-e056-40f1-9832-198efc9e17b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_02b8db2c-e056-40f1-9832-198efc9e17b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_f668524f-0713-4a0b-9203-f6d0709e97eb" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_f668524f-0713-4a0b-9203-f6d0709e97eb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7155cab7-0f9f-44df-85e4-5eda1bef5056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestments_7155cab7-0f9f-44df-85e4-5eda1bef5056" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1ed18bb-5c01-40f7-a29f-f70e2b51514d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1ed18bb-5c01-40f7-a29f-f70e2b51514d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1ed18bb-5c01-40f7-a29f-f70e2b51514d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1ed18bb-5c01-40f7-a29f-f70e2b51514d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e1ed18bb-5c01-40f7-a29f-f70e2b51514d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1ed18bb-5c01-40f7-a29f-f70e2b51514d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_ae8ae3a3-cb3a-4836-b161-27e889ef1f81" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:to="loc_amgn_BeiGeneMember_ae8ae3a3-cb3a-4836-b161-27e889ef1f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_7367596f-35f3-4f46-8c9f-507b8457a875" xlink:href="amgn-20211231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_7367596f-35f3-4f46-8c9f-507b8457a875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05c73e7f-f314-4b80-8424-0967c277bf8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:to="loc_srt_RangeAxis_05c73e7f-f314-4b80-8424-0967c277bf8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05c73e7f-f314-4b80-8424-0967c277bf8a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_05c73e7f-f314-4b80-8424-0967c277bf8a" xlink:to="loc_srt_RangeMember_05c73e7f-f314-4b80-8424-0967c277bf8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_05c73e7f-f314-4b80-8424-0967c277bf8a" xlink:to="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5fa2303d-a887-41fb-906b-927216c7f16d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:to="loc_srt_MinimumMember_5fa2303d-a887-41fb-906b-927216c7f16d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_78cbe23b-d6df-4999-94fb-64932a1c8ca2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:to="loc_srt_MaximumMember_78cbe23b-d6df-4999-94fb-64932a1c8ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93522826-dbcf-4cde-bfdf-6ac6d79ad2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_7b063259-db16-4118-838b-a8547efbe2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93522826-dbcf-4cde-bfdf-6ac6d79ad2b1" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_7b063259-db16-4118-838b-a8547efbe2c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b0bb30a-b603-4404-93e6-5509db0a2bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93522826-dbcf-4cde-bfdf-6ac6d79ad2b1" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b0bb30a-b603-4404-93e6-5509db0a2bd0" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9b2974ff-c383-47a6-922f-46758fb633b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b0bb30a-b603-4404-93e6-5509db0a2bd0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9b2974ff-c383-47a6-922f-46758fb633b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9b2974ff-c383-47a6-922f-46758fb633b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddccd2a7-7f26-4ca1-b790-0cbb0fa28907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_bf7caaff-0b9e-4fd2-b951-1f912bcba8cf" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsNeumoraTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="extended" id="if0cd818f33864452bb5281db54067627_InvestmentsNeumoraTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d259d321-0416-4705-b28c-f226863940ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d259d321-0416-4705-b28c-f226863940ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_db274654-5c90-4a62-afbd-511097ebef02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_db274654-5c90-4a62-afbd-511097ebef02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_cbe15c19-43c5-43c6-9bfb-555d22732b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_cbe15c19-43c5-43c6-9bfb-555d22732b2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_a93d8fad-dc4b-49d3-b396-dced0be4410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_a93d8fad-dc4b-49d3-b396-dced0be4410f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_e1e0951c-8051-4c63-b48b-7ab303e9b4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_e1e0951c-8051-4c63-b48b-7ab303e9b4ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7954dfb6-de72-4437-b93a-95d7e01e8f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7954dfb6-de72-4437-b93a-95d7e01e8f2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee32099a-069d-4790-b2f1-adb8b19d87d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7954dfb6-de72-4437-b93a-95d7e01e8f2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee32099a-069d-4790-b2f1-adb8b19d87d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee32099a-069d-4790-b2f1-adb8b19d87d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee32099a-069d-4790-b2f1-adb8b19d87d8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee32099a-069d-4790-b2f1-adb8b19d87d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb1deebc-20a4-4192-af5f-fce337b43f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee32099a-069d-4790-b2f1-adb8b19d87d8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb1deebc-20a4-4192-af5f-fce337b43f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_0782491b-2ec3-4f07-835c-86062ce79813" xlink:href="amgn-20211231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb1deebc-20a4-4192-af5f-fce337b43f7d" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_0782491b-2ec3-4f07-835c-86062ce79813" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended" id="i78dfcb12d4e3432c9f4da08ac8955fbd_PropertyplantandequipmentScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5ce8aa12-5696-4d5f-933b-97bf2832db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5ce8aa12-5696-4d5f-933b-97bf2832db0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_ad8fed99-dafd-4a59-9329-f4f6d921da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_Land_ad8fed99-dafd-4a59-9329-f4f6d921da1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_23cce58f-1571-4601-898d-45aa81623f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_23cce58f-1571-4601-898d-45aa81623f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_b478aa32-9c5d-45cf-8bcc-bee7fbc8a929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_b478aa32-9c5d-45cf-8bcc-bee7fbc8a929" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_fffa20bc-360b-4e0b-b5de-682ecdd87fe4" xlink:href="amgn-20211231.xsd#amgn_LaboratoryEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_amgn_LaboratoryEquipment_fffa20bc-360b-4e0b-b5de-682ecdd87fe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_1eddd2d6-00c9-4091-9a21-d5a30288b4d5" xlink:href="amgn-20211231.xsd#amgn_FixedEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_amgn_FixedEquipment_1eddd2d6-00c9-4091-9a21-d5a30288b4d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_ebfbcc9a-95c7-47d5-90aa-ed9cfa7b2f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_ebfbcc9a-95c7-47d5-90aa-ed9cfa7b2f6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_4ed52be4-3d70-4cb6-bd4f-fee65aa21b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_4ed52be4-3d70-4cb6-bd4f-fee65aa21b9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_8593fb1d-9eb8-4871-ba8c-f2fcdb983e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_ConstructionInProgressGross_8593fb1d-9eb8-4871-ba8c-f2fcdb983e3a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_32012c24-9242-4793-a589-bb3c7a4a6a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_32012c24-9242-4793-a589-bb3c7a4a6a26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9ae850-8e9e-4178-a086-70480e805973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9ae850-8e9e-4178-a086-70480e805973" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e694078a-9b88-4a92-b4fc-6eb9f232e07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e694078a-9b88-4a92-b4fc-6eb9f232e07b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3cdd6a7a-de78-43c5-a58c-b1b220dcfde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_Depreciation_3cdd6a7a-de78-43c5-a58c-b1b220dcfde3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1062cd-76c4-4722-9f26-19caf6a1787b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1062cd-76c4-4722-9f26-19caf6a1787b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ec1062cd-76c4-4722-9f26-19caf6a1787b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1062cd-76c4-4722-9f26-19caf6a1787b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ec1062cd-76c4-4722-9f26-19caf6a1787b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1062cd-76c4-4722-9f26-19caf6a1787b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_b8a3187d-d6f2-44b8-acf5-033fc7ed40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_b8a3187d-d6f2-44b8-acf5-033fc7ed40f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember_a3cc945d-6b05-4c5c-bf27-6a3a17785ca6" xlink:href="amgn-20211231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_amgn_ManufacturingEquipmentMember_a3cc945d-6b05-4c5c-bf27-6a3a17785ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember_556d1243-b677-4716-a0c6-99624f4a7d63" xlink:href="amgn-20211231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_amgn_LaboratoryEquipmentMember_556d1243-b677-4716-a0c6-99624f4a7d63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember_b2f08dcd-3ca4-4b2d-8ba1-86ec5d943728" xlink:href="amgn-20211231.xsd#amgn_FixedEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_amgn_FixedEquipmentMember_b2f08dcd-3ca4-4b2d-8ba1-86ec5d943728" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b39b8d27-b54a-45a7-9bad-a02c5ceeb8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b39b8d27-b54a-45a7-9bad-a02c5ceeb8e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_730b2dc8-4005-44a7-af05-3e48a38c1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_730b2dc8-4005-44a7-af05-3e48a38c1b33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1820272-932c-4c97-8548-bd48bb8ce47e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:to="loc_srt_RangeAxis_d1820272-932c-4c97-8548-bd48bb8ce47e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1820272-932c-4c97-8548-bd48bb8ce47e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d1820272-932c-4c97-8548-bd48bb8ce47e" xlink:to="loc_srt_RangeMember_d1820272-932c-4c97-8548-bd48bb8ce47e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d1820272-932c-4c97-8548-bd48bb8ce47e" xlink:to="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbd2af4b-afc1-4bf9-bae1-5709a0e62ec4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:to="loc_srt_MinimumMember_dbd2af4b-afc1-4bf9-bae1-5709a0e62ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f0de0ac9-03de-4a95-bed9-6d6017565653" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:to="loc_srt_MaximumMember_f0de0ac9-03de-4a95-bed9-6d6017565653" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#PropertyplantandequipmentGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="extended" id="i3021ae2d8673464580aed89ece4d5743_PropertyplantandequipmentGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3290467-1ad8-4780-a46c-2dc087ea6a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8017e2b7-2dff-4747-afa7-b9d202f3ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3290467-1ad8-4780-a46c-2dc087ea6a01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8017e2b7-2dff-4747-afa7-b9d202f3ab59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6b2da032-b135-4f3d-9b01-0e0e576afb34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3290467-1ad8-4780-a46c-2dc087ea6a01" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6b2da032-b135-4f3d-9b01-0e0e576afb34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_25bd98de-da61-4b53-a59e-8a1e836c4fbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6b2da032-b135-4f3d-9b01-0e0e576afb34" xlink:to="loc_srt_StatementGeographicalAxis_25bd98de-da61-4b53-a59e-8a1e836c4fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_25bd98de-da61-4b53-a59e-8a1e836c4fbe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_25bd98de-da61-4b53-a59e-8a1e836c4fbe" xlink:to="loc_srt_SegmentGeographicalDomain_25bd98de-da61-4b53-a59e-8a1e836c4fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_25bd98de-da61-4b53-a59e-8a1e836c4fbe" xlink:to="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a406f876-70c9-40ea-89e3-4fae0ae6be31" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:to="loc_country_US_a406f876-70c9-40ea-89e3-4fae0ae6be31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_fe6f308b-8496-48a1-ad8e-2e45d7bdffbf" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:to="loc_country_PR_fe6f308b-8496-48a1-ad8e-2e45d7bdffbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember_d46ea67d-743f-4a66-b147-8dc0a392e926" xlink:href="amgn-20211231.xsd#amgn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:to="loc_amgn_RestOfWorldMember_d46ea67d-743f-4a66-b147-8dc0a392e926" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="ida2e9a9c86ab40479364f715b2d50875_GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f490fc1-cbf6-4187-9695-74c3149ff503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f490fc1-cbf6-4187-9695-74c3149ff503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24a50cd0-3a33-4ffa-bf68-17e202921222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24a50cd0-3a33-4ffa-bf68-17e202921222" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_353160fd-d108-45ed-bbb9-2b277a623a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_353160fd-d108-45ed-bbb9-2b277a623a44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c71959c4-ce13-42ec-bd2d-f02829799778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c71959c4-ce13-42ec-bd2d-f02829799778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a5e96ff-801d-4d97-ae15-4124d961dae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c71959c4-ce13-42ec-bd2d-f02829799778" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a5e96ff-801d-4d97-ae15-4124d961dae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_5a22f668-bb0a-431b-9f12-41bed5535b5e" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_5a22f668-bb0a-431b-9f12-41bed5535b5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_e3f5b2fa-f4e8-4f9a-bc5d-b8a5be001875" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_e3f5b2fa-f4e8-4f9a-bc5d-b8a5be001875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_953dc30b-effd-476a-919b-c8e46a57568d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_953dc30b-effd-476a-919b-c8e46a57568d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_96d44622-ab2f-40f7-a4cb-6c1244e4e217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_96d44622-ab2f-40f7-a4cb-6c1244e4e217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96d44622-ab2f-40f7-a4cb-6c1244e4e217_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_96d44622-ab2f-40f7-a4cb-6c1244e4e217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96d44622-ab2f-40f7-a4cb-6c1244e4e217_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_96d44622-ab2f-40f7-a4cb-6c1244e4e217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_550eedd9-395d-4c64-9cf8-5c572a675a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_550eedd9-395d-4c64-9cf8-5c572a675a8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_de2f7a9b-bf20-4417-b391-027fedd52335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_us-gaap_LicensingAgreementsMember_de2f7a9b-bf20-4417-b391-027fedd52335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_b8d28d4f-ff0d-49b3-a028-bb7589de8d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_b8d28d4f-ff0d-49b3-a028-bb7589de8d04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_00530d1e-df8a-4f35-bd9b-a6108e5bbe53" xlink:href="amgn-20211231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_00530d1e-df8a-4f35-bd9b-a6108e5bbe53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_86c46844-cec6-4334-ad1a-96c773252d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_86c46844-cec6-4334-ad1a-96c773252d44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86c46844-cec6-4334-ad1a-96c773252d44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_86c46844-cec6-4334-ad1a-96c773252d44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86c46844-cec6-4334-ad1a-96c773252d44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e50473d-0e9c-41a8-b29a-1d9254110109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_86c46844-cec6-4334-ad1a-96c773252d44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e50473d-0e9c-41a8-b29a-1d9254110109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d6ab0f32-f028-4c84-a96c-6dacd0511a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e50473d-0e9c-41a8-b29a-1d9254110109" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d6ab0f32-f028-4c84-a96c-6dacd0511a8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#GoodwillandotherintangibleassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="extended" id="i3563d76bcce34c33b8d36bdfc837e205_GoodwillandotherintangibleassetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b716697a-35a6-4f14-909d-01f5e01b3827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7307705a-38b3-42a8-8b82-fe17418319bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b716697a-35a6-4f14-909d-01f5e01b3827" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7307705a-38b3-42a8-8b82-fe17418319bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b716697a-35a6-4f14-909d-01f5e01b3827" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5372ba03-863b-47f0-a924-ec9563b45e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5372ba03-863b-47f0-a924-ec9563b45e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5372ba03-863b-47f0-a924-ec9563b45e2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5372ba03-863b-47f0-a924-ec9563b45e2d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5372ba03-863b-47f0-a924-ec9563b45e2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b243d21f-6dd9-4431-9269-308067205c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5372ba03-863b-47f0-a924-ec9563b45e2d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b243d21f-6dd9-4431-9269-308067205c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_8f1b1fd2-9be6-4f73-8ee3-5d1f04c652d2" xlink:href="amgn-20211231.xsd#amgn_TeneobioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b243d21f-6dd9-4431-9269-308067205c2c" xlink:to="loc_amgn_TeneobioIncMember_8f1b1fd2-9be6-4f73-8ee3-5d1f04c652d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_852eefee-c416-4792-a6f1-cb3f16f7cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_852eefee-c416-4792-a6f1-cb3f16f7cfa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_852eefee-c416-4792-a6f1-cb3f16f7cfa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_852eefee-c416-4792-a6f1-cb3f16f7cfa2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_852eefee-c416-4792-a6f1-cb3f16f7cfa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_852eefee-c416-4792-a6f1-cb3f16f7cfa2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b8268272-87a4-455c-b99e-b6a143aab99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b8268272-87a4-455c-b99e-b6a143aab99f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_fcf61b0b-4ad5-4b58-92fa-506c8235687b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_fcf61b0b-4ad5-4b58-92fa-506c8235687b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FavorableContractMember_41b12c86-dac1-4d55-969f-7a8eb8075b2b" xlink:href="amgn-20211231.xsd#amgn_FavorableContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:to="loc_amgn_FavorableContractMember_41b12c86-dac1-4d55-969f-7a8eb8075b2b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i03973f90f5114b019c68c0d5d2874ed0_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b912aedc-1deb-41a1-bdd8-9735cd6341b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b912aedc-1deb-41a1-bdd8-9735cd6341b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b3fa4fb-532c-4d61-b985-d972be67a791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b3fa4fb-532c-4d61-b985-d972be67a791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4fbc81c-3458-4955-8042-1d5236c87cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4fbc81c-3458-4955-8042-1d5236c87cc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_fa248297-0203-494b-a15f-d6276295544e" xlink:href="amgn-20211231.xsd#amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_fa248297-0203-494b-a15f-d6276295544e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_9eb2c749-b6a4-4432-a44d-4583d3463148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_9eb2c749-b6a4-4432-a44d-4583d3463148" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bdfc79c9-d30e-4b29-830e-ca130bcf52e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bdfc79c9-d30e-4b29-830e-ca130bcf52e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_89767b20-41e7-4e18-b29e-4f86a4ee87b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_89767b20-41e7-4e18-b29e-4f86a4ee87b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89767b20-41e7-4e18-b29e-4f86a4ee87b5" xlink:to="loc_srt_RangeAxis_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd" xlink:to="loc_srt_RangeMember_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd" xlink:to="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bab3a76-711c-40f2-8246-7c6447514885" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:to="loc_srt_MinimumMember_3bab3a76-711c-40f2-8246-7c6447514885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4045583-68c8-46d9-a2f5-656893ef699b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:to="loc_srt_MaximumMember_d4045583-68c8-46d9-a2f5-656893ef699b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="i2d2a2507396444ffa3a47332fec84dcb_LeasesMaturitiesofLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3df0393b-df32-4319-b0e9-86c5a8bb2905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3df0393b-df32-4319-b0e9-86c5a8bb2905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8a2b9e02-7edf-4364-a73e-046dc9c3cbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8a2b9e02-7edf-4364-a73e-046dc9c3cbc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fd1a7106-fb24-4ebc-9684-a02fbe02b874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fd1a7106-fb24-4ebc-9684-a02fbe02b874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_52db231d-3bfe-464c-a8d6-1999ab9bd7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_52db231d-3bfe-464c-a8d6-1999ab9bd7f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9ca1282c-6ee4-4193-8ae9-41b1f7066e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9ca1282c-6ee4-4193-8ae9-41b1f7066e96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8fd3609c-4c67-47af-9e7a-53164fecc556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8fd3609c-4c67-47af-9e7a-53164fecc556" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_246ca671-dfee-463c-b93b-87187035888b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_246ca671-dfee-463c-b93b-87187035888b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22ecb262-5054-404c-96d7-1a27f823b3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22ecb262-5054-404c-96d7-1a27f823b3e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_14aa855a-797b-435c-ab3c-fcf267358124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_OperatingLeaseLiability_14aa855a-797b-435c-ab3c-fcf267358124" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_36ee0e36-7a7b-43eb-97c9-9264754d59d5" xlink:href="amgn-20211231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_36ee0e36-7a7b-43eb-97c9-9264754d59d5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a6831a4b-95a4-464c-8b2b-1e26137a1c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a6831a4b-95a4-464c-8b2b-1e26137a1c49" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2ad0f3a0-7906-4dc9-8f15-b4d0096c9822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2ad0f3a0-7906-4dc9-8f15-b4d0096c9822" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e5a80fd-af09-45c1-8273-c5830af1ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2ad0f3a0-7906-4dc9-8f15-b4d0096c9822" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e5a80fd-af09-45c1-8273-c5830af1ad44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5a80fd-af09-45c1-8273-c5830af1ad44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e5a80fd-af09-45c1-8273-c5830af1ad44" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5a80fd-af09-45c1-8273-c5830af1ad44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6836da90-2bb3-4179-b4fb-14a1f9c972af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e5a80fd-af09-45c1-8273-c5830af1ad44" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6836da90-2bb3-4179-b4fb-14a1f9c972af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember_d90b9e9e-2aac-448e-a852-f7d834924e1d" xlink:href="amgn-20211231.xsd#amgn_AbandonedLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6836da90-2bb3-4179-b4fb-14a1f9c972af" xlink:to="loc_amgn_AbandonedLeasesMember_d90b9e9e-2aac-448e-a852-f7d834924e1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended" id="i8660eef6ac0c4cf7841d00fab1a97230_FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0eff85-9ab5-4981-99a2-3894fb789217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0eff85-9ab5-4981-99a2-3894fb789217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3564737d-796d-4a0a-860a-51643af6def8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3564737d-796d-4a0a-860a-51643af6def8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0654392-5d6f-4f77-a567-5628d4be5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0654392-5d6f-4f77-a567-5628d4be5ed3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b2765729-cbd3-4210-9d3a-a7db9e3cb472" xlink:href="amgn-20211231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b2765729-cbd3-4210-9d3a-a7db9e3cb472" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_2a60d625-2e1d-44bd-afbe-fb6021ff936e" xlink:href="amgn-20211231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_2a60d625-2e1d-44bd-afbe-fb6021ff936e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_63a84605-de2c-4d61-99d5-a4b118a18c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_63a84605-de2c-4d61-99d5-a4b118a18c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f4c5041f-28eb-4e09-80a9-c28abcd9c436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f4c5041f-28eb-4e09-80a9-c28abcd9c436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0cd0fc2d-4d8d-4664-84ea-c011f3f912e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0cd0fc2d-4d8d-4664-84ea-c011f3f912e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_7d8a0b71-3b16-45fd-99a0-875502f138c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_OtherLongTermDebt_7d8a0b71-3b16-45fd-99a0-875502f138c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c77d2948-1f54-4951-8deb-5521dc3b9dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_LongTermDebt_c77d2948-1f54-4951-8deb-5521dc3b9dc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ecc7d3cc-4c80-453b-bd21-da27ed42ac63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_LongTermDebtCurrent_ecc7d3cc-4c80-453b-bd21-da27ed42ac63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3bc2d908-16d8-4f19-a2f0-a8eaecce3d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3bc2d908-16d8-4f19-a2f0-a8eaecce3d57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_57aa52f5-24d1-4c3a-985d-adeee05de3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_57aa52f5-24d1-4c3a-985d-adeee05de3d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57aa52f5-24d1-4c3a-985d-adeee05de3d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_57aa52f5-24d1-4c3a-985d-adeee05de3d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57aa52f5-24d1-4c3a-985d-adeee05de3d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_57aa52f5-24d1-4c3a-985d-adeee05de3d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_40972c52-5607-4135-b3a7-01ad0fc895ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:to="loc_us-gaap_NotesPayableToBanksMember_40972c52-5607-4135-b3a7-01ad0fc895ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_508a348a-6c97-4497-a3bc-810f0e96c8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_508a348a-6c97-4497-a3bc-810f0e96c8fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_18d90b3e-5ba3-47f9-b722-07f5d4558ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:to="loc_us-gaap_DebtInstrumentAxis_18d90b3e-5ba3-47f9-b722-07f5d4558ebc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18d90b3e-5ba3-47f9-b722-07f5d4558ebc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_18d90b3e-5ba3-47f9-b722-07f5d4558ebc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18d90b3e-5ba3-47f9-b722-07f5d4558ebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_18d90b3e-5ba3-47f9-b722-07f5d4558ebc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_4d8b5e4a-50ea-48bf-bf2a-621db2a5aa07" xlink:href="amgn-20211231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_4d8b5e4a-50ea-48bf-bf2a-621db2a5aa07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_63f86d51-f3f0-4c1d-9af8-31a81eda1dd8" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_63f86d51-f3f0-4c1d-9af8-31a81eda1dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member_9b457af4-85ae-486e-a158-d6976eeee02f" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSixFiveNotesDue2022Member_9b457af4-85ae-486e-a158-d6976eeee02f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_4ac16374-1bc7-46f5-a9ce-c36a650efd20" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_4ac16374-1bc7-46f5-a9ce-c36a650efd20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_3a80998a-3434-4b40-a7da-0fe600c6245e" xlink:href="amgn-20211231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_3a80998a-3434-4b40-a7da-0fe600c6245e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_52f035d9-166e-45d4-8196-0aefe035ce1e" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_52f035d9-166e-45d4-8196-0aefe035ce1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_0822a846-e761-4f9c-8709-9f51ac4447d9" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_0822a846-e761-4f9c-8709-9f51ac4447d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_59712cfc-838c-4b8b-ac66-286a6c07e382" xlink:href="amgn-20211231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_59712cfc-838c-4b8b-ac66-286a6c07e382" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_cbef15c7-30ad-465f-8137-ce1bc54da8af" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_cbef15c7-30ad-465f-8137-ce1bc54da8af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_79f7d6f9-42d2-4970-aa53-51123ec55054" xlink:href="amgn-20211231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_79f7d6f9-42d2-4970-aa53-51123ec55054" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_1f5248ec-01e7-4c55-887d-86bce22478a5" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_1f5248ec-01e7-4c55-887d-86bce22478a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_4b630978-d81a-4a71-ac5f-58d5974350a9" xlink:href="amgn-20211231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_4b630978-d81a-4a71-ac5f-58d5974350a9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_51aacb7c-d6bd-4914-828b-ffd5ebc9aa11" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_51aacb7c-d6bd-4914-828b-ffd5ebc9aa11" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b022413d-27aa-4422-9ec1-5defb91bc524" xlink:href="amgn-20211231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b022413d-27aa-4422-9ec1-5defb91bc524" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_203988db-2a69-4703-99f3-afc08b06fbdd" xlink:href="amgn-20211231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_203988db-2a69-4703-99f3-afc08b06fbdd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_2c1a2bed-9537-4b00-b307-19fb495c4512" xlink:href="amgn-20211231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_2c1a2bed-9537-4b00-b307-19fb495c4512" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eee3f527-b7d5-40d2-946d-e3fd0697f76e" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eee3f527-b7d5-40d2-946d-e3fd0697f76e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_8549264c-1a1d-4055-833c-df29f80c02f1" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_8549264c-1a1d-4055-833c-df29f80c02f1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_7812a62c-ac11-4932-bdc5-2a8bb8f3fb78" xlink:href="amgn-20211231.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_7812a62c-ac11-4932-bdc5-2a8bb8f3fb78" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dae43093-34dd-44b4-90a3-3120dd10b467" xlink:href="amgn-20211231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dae43093-34dd-44b4-90a3-3120dd10b467" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_35c8fcc7-d392-4378-b5e0-5a56aa5207e9" xlink:href="amgn-20211231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_35c8fcc7-d392-4378-b5e0-5a56aa5207e9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_8c436d91-8b68-4264-9262-a615095acd64" xlink:href="amgn-20211231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_8c436d91-8b68-4264-9262-a615095acd64" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_401a4d7f-ab5c-4635-a2f0-8c6c729b034c" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_401a4d7f-ab5c-4635-a2f0-8c6c729b034c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_9efab306-23bb-4b04-bcd9-21abf3de8e79" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_9efab306-23bb-4b04-bcd9-21abf3de8e79" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_56b7fa78-e7aa-448d-beab-364c307d940d" xlink:href="amgn-20211231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_56b7fa78-e7aa-448d-beab-364c307d940d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_226b5041-e56f-4fe6-9345-e642060b09b6" xlink:href="amgn-20211231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_226b5041-e56f-4fe6-9345-e642060b09b6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_03d3a948-9453-4da1-b0ae-399ac7b78b0b" xlink:href="amgn-20211231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_03d3a948-9453-4da1-b0ae-399ac7b78b0b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_74a586da-8d7e-4a53-a8d6-e945af2a3431" xlink:href="amgn-20211231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_74a586da-8d7e-4a53-a8d6-e945af2a3431" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_750c7ae5-cac9-43d8-992a-77c48b24495d" xlink:href="amgn-20211231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_750c7ae5-cac9-43d8-992a-77c48b24495d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_761fb4e4-7bd2-49e7-8df4-eba9ffff11bb" xlink:href="amgn-20211231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_761fb4e4-7bd2-49e7-8df4-eba9ffff11bb" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_dfe421a9-96ca-42f2-bb3f-1d13aad309d5" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_dfe421a9-96ca-42f2-bb3f-1d13aad309d5" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_bc16463e-16ff-4113-a47b-55d5d7cb48cc" xlink:href="amgn-20211231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_bc16463e-16ff-4113-a47b-55d5d7cb48cc" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_9c4d32ef-3116-4b2f-bb56-7b93e5455f80" xlink:href="amgn-20211231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_9c4d32ef-3116-4b2f-bb56-7b93e5455f80" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_0f52eecd-ece1-4ba8-a29b-ff5c38016763" xlink:href="amgn-20211231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_0f52eecd-ece1-4ba8-a29b-ff5c38016763" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_ae9c4d91-51a8-4add-aa6d-0cf7ff56b81b" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_ae9c4d91-51a8-4add-aa6d-0cf7ff56b81b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_bd1ee74e-1dda-48a5-864f-977d6acb9cd9" xlink:href="amgn-20211231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_OtherNotesDue2097Member_bd1ee74e-1dda-48a5-864f-977d6acb9cd9" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_c2b9c62b-80fe-4954-b141-4008a7fbad89" xlink:href="amgn-20211231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_c2b9c62b-80fe-4954-b141-4008a7fbad89" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_3e6686d8-3502-4d28-92cc-f0f92612ef7b" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_3e6686d8-3502-4d28-92cc-f0f92612ef7b" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1880d77-88bd-4636-bd87-e60e9d8436c0" xlink:href="amgn-20211231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1880d77-88bd-4636-bd87-e60e9d8436c0" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_9eb5c2f5-95f9-4597-b366-795ab0188928" xlink:href="amgn-20211231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_9eb5c2f5-95f9-4597-b366-795ab0188928" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_b9a3ad85-b50a-4795-b33a-afce163c8b0b" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_b9a3ad85-b50a-4795-b33a-afce163c8b0b" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_b9435b33-dd3c-437a-b931-5bed3d64f3d2" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_b9435b33-dd3c-437a-b931-5bed3d64f3d2" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_773d1a78-56ae-4e26-95d6-f2e226a52157" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_773d1a78-56ae-4e26-95d6-f2e226a52157" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_35d58d3d-374b-4e7a-ad7b-744138605d1e" xlink:href="amgn-20211231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_35d58d3d-374b-4e7a-ad7b-744138605d1e" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dad4748-a9a9-4198-9e8d-916b95f65ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:to="loc_srt_RangeAxis_3dad4748-a9a9-4198-9e8d-916b95f65ad7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3dad4748-a9a9-4198-9e8d-916b95f65ad7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3dad4748-a9a9-4198-9e8d-916b95f65ad7" xlink:to="loc_srt_RangeMember_3dad4748-a9a9-4198-9e8d-916b95f65ad7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3dad4748-a9a9-4198-9e8d-916b95f65ad7" xlink:to="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_307bf1ca-efe7-450b-b278-ebee2a4228bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:to="loc_srt_MinimumMember_307bf1ca-efe7-450b-b278-ebee2a4228bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86387999-af88-42d0-93ca-d1b1413ba09e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:to="loc_srt_MaximumMember_86387999-af88-42d0-93ca-d1b1413ba09e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsDebtIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="extended" id="i985611e612d4494fa166141a11af470e_FinancingarrangementsDebtIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11191f2b-99eb-4207-81ab-c0e0ba012feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11191f2b-99eb-4207-81ab-c0e0ba012feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f684c9da-dc5d-443e-8796-27cadc3e8aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f684c9da-dc5d-443e-8796-27cadc3e8aa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_b94273c8-7163-4119-9cdc-975023913e62" xlink:href="amgn-20211231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:to="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_b94273c8-7163-4119-9cdc-975023913e62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:to="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e2876735-6b4b-4a31-9ed9-8d64d5e77c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e2876735-6b4b-4a31-9ed9-8d64d5e77c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e2876735-6b4b-4a31-9ed9-8d64d5e77c22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e2876735-6b4b-4a31-9ed9-8d64d5e77c22" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e2876735-6b4b-4a31-9ed9-8d64d5e77c22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b8fe3698-d6c4-449a-bf8f-d6e107cde8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e2876735-6b4b-4a31-9ed9-8d64d5e77c22" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b8fe3698-d6c4-449a-bf8f-d6e107cde8c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_987e6e4a-885e-4faf-b62a-c014c169abbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8fe3698-d6c4-449a-bf8f-d6e107cde8c9" xlink:to="loc_us-gaap_NotesPayableToBanksMember_987e6e4a-885e-4faf-b62a-c014c169abbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_881910ed-2c0b-49f2-aa92-1c947d9533b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:to="loc_us-gaap_DebtInstrumentAxis_881910ed-2c0b-49f2-aa92-1c947d9533b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_881910ed-2c0b-49f2-aa92-1c947d9533b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_881910ed-2c0b-49f2-aa92-1c947d9533b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_881910ed-2c0b-49f2-aa92-1c947d9533b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_881910ed-2c0b-49f2-aa92-1c947d9533b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_1c385b6c-e60c-42ad-a17b-da7f02687934" xlink:href="amgn-20211231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_1c385b6c-e60c-42ad-a17b-da7f02687934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember_978388a7-6ac0-4d37-aaeb-0b2ddc249071" xlink:href="amgn-20211231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A200NotesDue20322002032NotesMember_978388a7-6ac0-4d37-aaeb-0b2ddc249071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member_f18ac3c2-0cd1-48f1-b6ca-72191612e2f8" xlink:href="amgn-20211231.xsd#amgn_A280NotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A280NotesDue2041Member_f18ac3c2-0cd1-48f1-b6ca-72191612e2f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_08837202-16c7-4abe-9d64-e4e315f764db" xlink:href="amgn-20211231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_08837202-16c7-4abe-9d64-e4e315f764db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_5e7e2c84-eec9-45d2-9f95-c79c7e5a1d98" xlink:href="amgn-20211231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_5e7e2c84-eec9-45d2-9f95-c79c7e5a1d98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_1f05d1d0-8705-49e3-afdf-2158d3889be2" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_1f05d1d0-8705-49e3-afdf-2158d3889be2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_08bc0d2f-5f85-497e-a9b6-e6691ceab60d" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_08bc0d2f-5f85-497e-a9b6-e6691ceab60d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7f0082c-6005-4d67-b8d2-61943db1821d" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7f0082c-6005-4d67-b8d2-61943db1821d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_5cfca7a3-870f-4d87-8fb2-a65bfc5bad65" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_5cfca7a3-870f-4d87-8fb2-a65bfc5bad65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_b8d16ceb-f472-4e70-8adf-f53427348648" xlink:href="amgn-20211231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_b8d16ceb-f472-4e70-8adf-f53427348648" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_8968cf11-ca52-41ed-bc0c-3e682392ff7e" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:to="loc_amgn_AssetsByDescriptionAxis_8968cf11-ca52-41ed-bc0c-3e682392ff7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_8968cf11-ca52-41ed-bc0c-3e682392ff7e_default" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_AssetsByDescriptionAxis_8968cf11-ca52-41ed-bc0c-3e682392ff7e" xlink:to="loc_amgn_AssetsByDescriptionDomain_8968cf11-ca52-41ed-bc0c-3e682392ff7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_b37c99d4-fcdf-4f37-87b3-dc6492189e06" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_AssetsByDescriptionAxis_8968cf11-ca52-41ed-bc0c-3e682392ff7e" xlink:to="loc_amgn_AssetsByDescriptionDomain_b37c99d4-fcdf-4f37-87b3-dc6492189e06" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsDebtRepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="extended" id="i20e5d1bb7a134d0cb6ee323a744764fa_FinancingarrangementsDebtRepaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a31ced24-096e-4c1b-b891-857286b9876c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a31ced24-096e-4c1b-b891-857286b9876c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b8cd1dd-af82-493a-99ca-f00d2570a5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b8cd1dd-af82-493a-99ca-f00d2570a5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1454edd9-27ae-489b-b8e4-da5adb2c28ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:to="loc_us-gaap_InterestExpenseDebt_1454edd9-27ae-489b-b8e4-da5adb2c28ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:to="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_891fcb65-cbfe-4150-83c6-332e6adf9862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_891fcb65-cbfe-4150-83c6-332e6adf9862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_e76727ce-bbc1-448f-b745-6f388c2afbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_891fcb65-cbfe-4150-83c6-332e6adf9862" xlink:to="loc_us-gaap_NotesPayableToBanksMember_e76727ce-bbc1-448f-b745-6f388c2afbd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e043b189-0bfc-4bea-a3e3-52ed76f389ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:to="loc_us-gaap_DebtInstrumentAxis_e043b189-0bfc-4bea-a3e3-52ed76f389ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e043b189-0bfc-4bea-a3e3-52ed76f389ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e043b189-0bfc-4bea-a3e3-52ed76f389ec" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e043b189-0bfc-4bea-a3e3-52ed76f389ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e043b189-0bfc-4bea-a3e3-52ed76f389ec" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_16f061d9-7897-425f-9115-11ec65119e20" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_16f061d9-7897-425f-9115-11ec65119e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_17e2dc60-287a-42de-9cd4-eb11f252d9e5" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenZeroPercentNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_17e2dc60-287a-42de-9cd4-eb11f252d9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f3a74f46-6a72-4ede-8ef3-a84e6cdfc3f5" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f3a74f46-6a72-4ede-8ef3-a84e6cdfc3f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroNotesDue2019Member_a8f5f258-90fa-4bd5-a2de-b58d444b7750" xlink:href="amgn-20211231.xsd#amgn_OnePointNineZeroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_OnePointNineZeroNotesDue2019Member_a8f5f258-90fa-4bd5-a2de-b58d444b7750" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2019Member_41b470da-203b-40d8-93ea-be1ee5bc71cb" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FloatingRateNotesDue2019Member_41b470da-203b-40d8-93ea-be1ee5bc71cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_c7bd046c-f524-4999-89ac-a29d0137e655" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_c7bd046c-f524-4999-89ac-a29d0137e655" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_6ebd012d-9984-44be-91a0-7129fa8c0425" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_6ebd012d-9984-44be-91a0-7129fa8c0425" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7231446e-f3e9-4561-8be6-5feab62d8ffb" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7231446e-f3e9-4561-8be6-5feab62d8ffb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e075d606-02d2-401a-bcd6-9f2027e0d8dd" xlink:href="amgn-20211231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e075d606-02d2-401a-bcd6-9f2027e0d8dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_ab8ee464-67bf-4a55-a220-48ded87505a1" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_ab8ee464-67bf-4a55-a220-48ded87505a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b1259ff8-c1d0-4b12-aa13-1ad594321c82" xlink:href="amgn-20211231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b1259ff8-c1d0-4b12-aa13-1ad594321c82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_bd55ed00-2d2e-43cd-b9ca-d2c2dbe686c3" xlink:href="amgn-20211231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_bd55ed00-2d2e-43cd-b9ca-d2c2dbe686c3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_8aea02f9-68a1-49ef-a1c1-20477ff9c794" xlink:href="amgn-20211231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_8aea02f9-68a1-49ef-a1c1-20477ff9c794" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_b9a2f80a-cd5b-4b2e-a7ef-a74d747a1e62" xlink:href="amgn-20211231.xsd#amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_b9a2f80a-cd5b-4b2e-a7ef-a74d747a1e62" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_126972d7-2b97-4303-aad6-81a8c548400c" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenZeroPercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_126972d7-2b97-4303-aad6-81a8c548400c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_facc7fd3-d5dd-468b-9438-6e736ca39467" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_facc7fd3-d5dd-468b-9438-6e736ca39467" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_3aa49e3f-7d9a-4827-8592-d0a96336d51f" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_3aa49e3f-7d9a-4827-8592-d0a96336d51f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_8a31fcb2-321c-49d4-b2f3-b4e7a0a24896" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_8a31fcb2-321c-49d4-b2f3-b4e7a0a24896" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_de851134-0bfd-4a32-a55b-c291877cb7b4" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_de851134-0bfd-4a32-a55b-c291877cb7b4" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="extended" id="id02c500f0db24066a10e1f544f1e74c2_FinancingarrangementsInterestRateandCrosscurrencySwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb642a66-af62-48e6-82cd-363220878c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb642a66-af62-48e6-82cd-363220878c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_4058727e-dcb7-429c-949a-b12dfc769407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_4058727e-dcb7-429c-949a-b12dfc769407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8a041887-d57d-482c-8abd-f25e6a118550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8a041887-d57d-482c-8abd-f25e6a118550" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_08017425-dc4b-4821-ab19-42bd2a6db186" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_08017425-dc4b-4821-ab19-42bd2a6db186" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a2a3f59-0d0e-407a-8fe1-7bfa12ad085d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a2a3f59-0d0e-407a-8fe1-7bfa12ad085d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15e44146-cb14-4999-bf86-9a886af80dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15e44146-cb14-4999-bf86-9a886af80dec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ebc27597-6996-4483-b598-d9d5677544e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ebc27597-6996-4483-b598-d9d5677544e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration_9ab2e41d-4dd5-430a-bb81-3fc2f4d7d029" xlink:href="amgn-20211231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_amgn_DebtExchangeAdditionalCashConsideration_9ab2e41d-4dd5-430a-bb81-3fc2f4d7d029" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6112d237-ac80-4647-b5e9-65cc9cc3677b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6112d237-ac80-4647-b5e9-65cc9cc3677b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_70397161-4458-499b-837f-8c657ce2dbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_70397161-4458-499b-837f-8c657ce2dbdf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408b6e4b-6685-445a-ad41-4f903564e97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408b6e4b-6685-445a-ad41-4f903564e97a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408b6e4b-6685-445a-ad41-4f903564e97a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408b6e4b-6685-445a-ad41-4f903564e97a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408b6e4b-6685-445a-ad41-4f903564e97a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408b6e4b-6685-445a-ad41-4f903564e97a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_59daf2ba-6912-4e1a-809a-4424b9bc16a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_59daf2ba-6912-4e1a-809a-4424b9bc16a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_75fc05e5-eae8-4374-8608-fd0da8228fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:to="loc_us-gaap_NotesPayableToBanksMember_75fc05e5-eae8-4374-8608-fd0da8228fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a6c0fde2-7379-4025-b750-5e654996bb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_DebtInstrumentAxis_a6c0fde2-7379-4025-b750-5e654996bb1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6c0fde2-7379-4025-b750-5e654996bb1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6c0fde2-7379-4025-b750-5e654996bb1e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6c0fde2-7379-4025-b750-5e654996bb1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6c0fde2-7379-4025-b750-5e654996bb1e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_edfe87f7-bbe8-4bf3-8bfa-3c535b6e2a86" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_edfe87f7-bbe8-4bf3-8bfa-3c535b6e2a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_bbf68f5a-6b58-4e80-8e2b-e5d4cfdd131f" xlink:href="amgn-20211231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_bbf68f5a-6b58-4e80-8e2b-e5d4cfdd131f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_cecb2259-34dc-4157-a357-253389c66877" xlink:href="amgn-20211231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_cecb2259-34dc-4157-a357-253389c66877" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_a11edbd2-d3f2-44c3-82e8-05284db691dc" xlink:href="amgn-20211231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_a11edbd2-d3f2-44c3-82e8-05284db691dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_8e1d38e0-6ea9-4a21-927d-8adab8909ab9" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_8e1d38e0-6ea9-4a21-927d-8adab8909ab9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_15171216-285d-4eba-9998-f1e0228380c2" xlink:href="amgn-20211231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_15171216-285d-4eba-9998-f1e0228380c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_d98f5531-fd79-47e7-a2d0-90f071eec03d" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_d98f5531-fd79-47e7-a2d0-90f071eec03d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b3f75859-d3da-4e05-bfa4-5c025527bcd3" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b3f75859-d3da-4e05-bfa4-5c025527bcd3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_b1308dfc-2cd2-4e17-bca3-39141fb26511" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_b1308dfc-2cd2-4e17-bca3-39141fb26511" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_336ae34c-7276-4f2e-830d-c477989fb2f7" xlink:href="amgn-20211231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_336ae34c-7276-4f2e-830d-c477989fb2f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_74e34b48-11ef-48cd-88d8-86b8269d39c8" xlink:href="amgn-20211231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_74e34b48-11ef-48cd-88d8-86b8269d39c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_384793bf-50e0-422f-9a87-dfa99b6baaaf" xlink:href="amgn-20211231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_384793bf-50e0-422f-9a87-dfa99b6baaaf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_489ccd1e-a0f8-4c24-bf5b-0e1c65ca5f27" xlink:href="amgn-20211231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_489ccd1e-a0f8-4c24-bf5b-0e1c65ca5f27" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_239c6470-c939-4b52-bfca-4aa5f08c7327" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_239c6470-c939-4b52-bfca-4aa5f08c7327" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_09b4ce50-c825-402c-88d5-473d4655cc9c" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_09b4ce50-c825-402c-88d5-473d4655cc9c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_9d0222ac-e888-494e-a19c-392b26b2ffda" xlink:href="amgn-20211231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_9d0222ac-e888-494e-a19c-392b26b2ffda" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_524ea6c5-5242-496b-af4c-ac93322d329a" xlink:href="amgn-20211231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_524ea6c5-5242-496b-af4c-ac93322d329a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_5ebe8595-ecf3-4d05-a0ec-48c584f8452c" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_5ebe8595-ecf3-4d05-a0ec-48c584f8452c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b3bd5e64-1c62-43bc-9929-aea262674cee" xlink:href="amgn-20211231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b3bd5e64-1c62-43bc-9929-aea262674cee" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_58f09654-2d16-4036-9fd6-f21498026bff" xlink:href="amgn-20211231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_58f09654-2d16-4036-9fd6-f21498026bff" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_bbae9707-c856-4280-b664-20047b32576b" xlink:href="amgn-20211231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_bbae9707-c856-4280-b664-20047b32576b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_be10d960-d5de-44b6-8987-e0eac73e58da" xlink:href="amgn-20211231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_be10d960-d5de-44b6-8987-e0eac73e58da" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_0310a46d-cad7-4999-be5f-e8ebb471327c" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_0310a46d-cad7-4999-be5f-e8ebb471327c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_07183d7c-5590-4aa7-b3d6-cbe132f39eed" xlink:href="amgn-20211231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_07183d7c-5590-4aa7-b3d6-cbe132f39eed" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_98fa42d1-3f56-4cf0-90f7-1351a85ea5cf" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_98fa42d1-3f56-4cf0-90f7-1351a85ea5cf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6065a9cf-c08c-450e-99ae-07bf5c1647d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_VariableRateAxis_6065a9cf-c08c-450e-99ae-07bf5c1647d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6065a9cf-c08c-450e-99ae-07bf5c1647d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6065a9cf-c08c-450e-99ae-07bf5c1647d1" xlink:to="loc_us-gaap_VariableRateDomain_6065a9cf-c08c-450e-99ae-07bf5c1647d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ade08c89-0469-4a71-b6df-ba6e417ea64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6065a9cf-c08c-450e-99ae-07bf5c1647d1" xlink:to="loc_us-gaap_VariableRateDomain_ade08c89-0469-4a71-b6df-ba6e417ea64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_8b113af1-29dd-4285-bfef-4bd4dfec2c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ade08c89-0469-4a71-b6df-ba6e417ea64c" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_8b113af1-29dd-4285-bfef-4bd4dfec2c3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_6541f5db-21c4-4306-a721-82b33b1e826c" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_amgn_InterestRateSwapAxis_6541f5db-21c4-4306-a721-82b33b1e826c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_6541f5db-21c4-4306-a721-82b33b1e826c_default" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_InterestRateSwapAxis_6541f5db-21c4-4306-a721-82b33b1e826c" xlink:to="loc_amgn_InterestRateSwapDomain_6541f5db-21c4-4306-a721-82b33b1e826c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_InterestRateSwapAxis_6541f5db-21c4-4306-a721-82b33b1e826c" xlink:to="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember_72a145bc-39fd-4b70-99a5-ebc617acb309" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:to="loc_amgn_InterestRateSwapOneMember_72a145bc-39fd-4b70-99a5-ebc617acb309" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_c35dd8d5-4fd9-4dd6-a3fb-015a7a11cc22" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:to="loc_amgn_InterestRateSwapTwoMember_c35dd8d5-4fd9-4dd6-a3fb-015a7a11cc22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0d129bd9-b921-4fed-8929-06fc60c6d330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0d129bd9-b921-4fed-8929-06fc60c6d330" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0d129bd9-b921-4fed-8929-06fc60c6d330_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0d129bd9-b921-4fed-8929-06fc60c6d330" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0d129bd9-b921-4fed-8929-06fc60c6d330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0d129bd9-b921-4fed-8929-06fc60c6d330" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_9349ed51-6ed2-46d3-a20c-0cc6360cf0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:to="loc_us-gaap_InterestRateSwapMember_9349ed51-6ed2-46d3-a20c-0cc6360cf0b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_f5486f6e-392c-43ce-8e8e-269699493a4d" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_f5486f6e-392c-43ce-8e8e-269699493a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_956ba971-e4c9-4292-8b76-7f823d8acbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_HedgingDesignationAxis_956ba971-e4c9-4292-8b76-7f823d8acbcc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_956ba971-e4c9-4292-8b76-7f823d8acbcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_956ba971-e4c9-4292-8b76-7f823d8acbcc" xlink:to="loc_us-gaap_HedgingDesignationDomain_956ba971-e4c9-4292-8b76-7f823d8acbcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b712b203-c71e-495f-a211-ac89dbc38839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_956ba971-e4c9-4292-8b76-7f823d8acbcc" xlink:to="loc_us-gaap_HedgingDesignationDomain_b712b203-c71e-495f-a211-ac89dbc38839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62372e42-dc62-4cc8-aa06-4b41ca75e991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b712b203-c71e-495f-a211-ac89dbc38839" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62372e42-dc62-4cc8-aa06-4b41ca75e991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3a936b0d-f136-4a7f-94be-540af91e14e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3a936b0d-f136-4a7f-94be-540af91e14e7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3a936b0d-f136-4a7f-94be-540af91e14e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3a936b0d-f136-4a7f-94be-540af91e14e7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3a936b0d-f136-4a7f-94be-540af91e14e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a765cf6e-2215-43ee-ac90-7aeeac38f5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3a936b0d-f136-4a7f-94be-540af91e14e7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a765cf6e-2215-43ee-ac90-7aeeac38f5f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_512553ce-30dc-45b6-8e76-7d796cc673fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a765cf6e-2215-43ee-ac90-7aeeac38f5f5" xlink:to="loc_us-gaap_CashFlowHedgingMember_512553ce-30dc-45b6-8e76-7d796cc673fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="extended" id="i314de830604d477b966fab61105e6e44_FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96e345ff-a2b0-4261-b47e-1a2f793a9f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96e345ff-a2b0-4261-b47e-1a2f793a9f31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_58e64694-9a0a-40fd-a596-ae13ffbea6c5" xlink:href="amgn-20211231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_58e64694-9a0a-40fd-a596-ae13ffbea6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_46a6c3d2-ec84-4c83-aaa7-464484d1dd95" xlink:href="amgn-20211231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_46a6c3d2-ec84-4c83-aaa7-464484d1dd95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8ec3ad25-1fb3-4be1-ba39-619add8fbd81" xlink:href="amgn-20211231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8ec3ad25-1fb3-4be1-ba39-619add8fbd81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_e322601e-5950-4e40-97e0-8e319becb4d1" xlink:href="amgn-20211231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_e322601e-5950-4e40-97e0-8e319becb4d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_a7ae05ce-c5e6-47d1-bcd2-039ed23f2ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_a7ae05ce-c5e6-47d1-bcd2-039ed23f2ef8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bc48a514-2ccb-44a1-9025-f11b61522342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bc48a514-2ccb-44a1-9025-f11b61522342" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d9b7494e-e3b0-4594-b600-d36960029d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d9b7494e-e3b0-4594-b600-d36960029d00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_658d20e4-3657-49a6-9922-f3c0b1d05d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_LineOfCredit_658d20e4-3657-49a6-9922-f3c0b1d05d90" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_655577fd-aafc-4f52-ae42-df08f396235c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_655577fd-aafc-4f52-ae42-df08f396235c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_655577fd-aafc-4f52-ae42-df08f396235c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_655577fd-aafc-4f52-ae42-df08f396235c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_655577fd-aafc-4f52-ae42-df08f396235c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01536a3e-00e7-4e25-81c3-eec2032724e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_655577fd-aafc-4f52-ae42-df08f396235c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01536a3e-00e7-4e25-81c3-eec2032724e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cbcb0bfa-fd22-4ed8-abe6-9f93f63a7e31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01536a3e-00e7-4e25-81c3-eec2032724e5" xlink:to="loc_us-gaap_LineOfCreditMember_cbcb0bfa-fd22-4ed8-abe6-9f93f63a7e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:to="loc_us-gaap_VariableRateAxis_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8" xlink:to="loc_us-gaap_VariableRateDomain_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8" xlink:to="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_da496d14-4491-44aa-8294-7796557ce374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_da496d14-4491-44aa-8294-7796557ce374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3ce34193-42aa-45bd-8093-30014fb581d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3ce34193-42aa-45bd-8093-30014fb581d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="extended" id="i7012b271c0c2458f8db2a71a98dd3d63_StockholdersequityDividendsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_911ce317-e796-41e5-bdd0-f367aceaa9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_911ce317-e796-41e5-bdd0-f367aceaa9ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_12bf96fd-71a8-4458-a070-1ad40b822555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_12bf96fd-71a8-4458-a070-1ad40b822555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_913735b6-1bf5-4ef6-976a-98d84e84f1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_913735b6-1bf5-4ef6-976a-98d84e84f1ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_570c00bd-97d4-45bd-913c-64cb316214fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_913735b6-1bf5-4ef6-976a-98d84e84f1ab" xlink:to="loc_srt_StatementScenarioAxis_570c00bd-97d4-45bd-913c-64cb316214fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_570c00bd-97d4-45bd-913c-64cb316214fb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_570c00bd-97d4-45bd-913c-64cb316214fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_570c00bd-97d4-45bd-913c-64cb316214fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_660b24eb-6572-4ee7-841d-a930ed359f80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_570c00bd-97d4-45bd-913c-64cb316214fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_660b24eb-6572-4ee7-841d-a930ed359f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8103c579-dda8-4ead-b94c-b67c966c4156" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_660b24eb-6572-4ee7-841d-a930ed359f80" xlink:to="loc_srt_ScenarioForecastMember_8103c579-dda8-4ead-b94c-b67c966c4156" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended" id="if1011721212d4dfb9d3af9db652b2291_StockholdersequityComponentsofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9260a9ee-87dc-4b3a-80fe-f50c3edead12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9260a9ee-87dc-4b3a-80fe-f50c3edead12" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8074648f-093a-4df8-924e-b6fc59344d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_StockholdersEquity_8074648f-093a-4df8-924e-b6fc59344d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a68b54dd-9b99-493e-a425-1c217d54f132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a68b54dd-9b99-493e-a425-1c217d54f132" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_42b5bb68-185b-414f-af71-f8c158db51b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_42b5bb68-185b-414f-af71-f8c158db51b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4f0c3420-cd69-4fbc-9a75-7475b67734f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4f0c3420-cd69-4fbc-9a75-7475b67734f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_9da45e39-6317-4cd5-8087-d3166c1b245f" xlink:href="amgn-20211231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_9da45e39-6317-4cd5-8087-d3166c1b245f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_83ac021b-b3b7-4d1f-a8bd-6a74d33849db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_83ac021b-b3b7-4d1f-a8bd-6a74d33849db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8f63235-6418-47b2-a3c1-73e833b04e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9260a9ee-87dc-4b3a-80fe-f50c3edead12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e23cdf5c-91db-464a-9407-713539f3e1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e23cdf5c-91db-464a-9407-713539f3e1bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e23cdf5c-91db-464a-9407-713539f3e1bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e23cdf5c-91db-464a-9407-713539f3e1bc" xlink:to="loc_us-gaap_EquityComponentDomain_e23cdf5c-91db-464a-9407-713539f3e1bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e23cdf5c-91db-464a-9407-713539f3e1bc" xlink:to="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d1688776-b885-4d6e-9b2f-bcdf1fb53599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d1688776-b885-4d6e-9b2f-bcdf1fb53599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_49ce40e0-cdda-4b7a-ac29-3f5ef64daa18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_49ce40e0-cdda-4b7a-ac29-3f5ef64daa18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cfaeed03-9d54-4705-a732-21cd9c3f3bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cfaeed03-9d54-4705-a732-21cd9c3f3bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_283236c8-4f8b-4c02-8cfa-1a6f7357bd12" xlink:href="amgn-20211231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_283236c8-4f8b-4c02-8cfa-1a6f7357bd12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61d65b66-be3d-4c0d-a1d3-733af7c02924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61d65b66-be3d-4c0d-a1d3-733af7c02924" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9f2272c-f776-42ce-a4ce-bfe87a5ceb39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9f2272c-f776-42ce-a4ce-bfe87a5ceb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_040a4ee9-31a3-4457-9f70-d16ea66a44ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9f2272c-f776-42ce-a4ce-bfe87a5ceb39" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_040a4ee9-31a3-4457-9f70-d16ea66a44ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended" id="iedc37dc3caeb4287985e55f757b0fbdb_StockholdersequityReclassificationsoutofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd0cd6dd-ab2f-4c14-a24f-af711ec56bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd0cd6dd-ab2f-4c14-a24f-af711ec56bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_071e3bff-1997-4540-8b70-6d6ed61b607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_071e3bff-1997-4540-8b70-6d6ed61b607b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_850bbfac-dfad-496b-bfd3-26f3369e012e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_InterestExpenseDebt_850bbfac-dfad-496b-bfd3-26f3369e012e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_45c4cc98-1ad8-4abd-a40e-2f62b2537a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_45c4cc98-1ad8-4abd-a40e-2f62b2537a2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3cb4f67d-32c6-41e6-ad00-62d0cec3fc68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3cb4f67d-32c6-41e6-ad00-62d0cec3fc68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e49efa7-c6d2-49be-8c45-acbec489a006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_NetIncomeLoss_3e49efa7-c6d2-49be-8c45-acbec489a006" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f634eb0d-fa1d-43eb-b416-18a8fc0f2228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f634eb0d-fa1d-43eb-b416-18a8fc0f2228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f634eb0d-fa1d-43eb-b416-18a8fc0f2228_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f634eb0d-fa1d-43eb-b416-18a8fc0f2228" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f634eb0d-fa1d-43eb-b416-18a8fc0f2228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da4f28b8-5406-4c5c-ac44-c889c1ee50a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f634eb0d-fa1d-43eb-b416-18a8fc0f2228" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da4f28b8-5406-4c5c-ac44-c889c1ee50a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_06733936-3250-44ff-b7ca-a3ce15559c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da4f28b8-5406-4c5c-ac44-c889c1ee50a2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_06733936-3250-44ff-b7ca-a3ce15559c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d58c9844-fadf-444a-9b24-f74fd83930a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d58c9844-fadf-444a-9b24-f74fd83930a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_b620a936-6e10-4398-a3ba-d003805a076c" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_b620a936-6e10-4398-a3ba-d003805a076c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_srt_ProductOrServiceAxis_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd" xlink:to="loc_srt_ProductsAndServicesDomain_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_878125d7-7335-4bfe-8d0e-baadb357a078" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd" xlink:to="loc_srt_ProductsAndServicesDomain_878125d7-7335-4bfe-8d0e-baadb357a078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0da965be-26c3-4968-8a8f-649804de9a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_878125d7-7335-4bfe-8d0e-baadb357a078" xlink:to="loc_us-gaap_ProductMember_0da965be-26c3-4968-8a8f-649804de9a8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd" xlink:to="loc_us-gaap_EquityComponentDomain_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd" xlink:to="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_dc53befb-2b10-40b5-a831-e41b282b2ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_dc53befb-2b10-40b5-a831-e41b282b2ad2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0f4485f0-fade-435d-aea7-a7d08ea345cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0f4485f0-fade-435d-aea7-a7d08ea345cd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="i66b086fb19e146b7bb3a6c2026ec633a_FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c2cb4155-ec45-4e5e-b416-6eb3a11ecbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c2cb4155-ec45-4e5e-b416-6eb3a11ecbc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_63c9577f-f14b-49b0-9a9c-e631912337c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_63c9577f-f14b-49b0-9a9c-e631912337c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:href="amgn-20211231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_226a1d01-03fa-4ee8-94e1-5bf0be8d9b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_226a1d01-03fa-4ee8-94e1-5bf0be8d9b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_36908aa9-d6cc-4905-9060-ff7deee8a534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_36908aa9-d6cc-4905-9060-ff7deee8a534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_15f8b587-1690-46b8-bf2b-3c2ca40d4dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_15f8b587-1690-46b8-bf2b-3c2ca40d4dce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:href="amgn-20211231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2838bd3c-ec08-40a3-8551-ae3089f59aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2838bd3c-ec08-40a3-8551-ae3089f59aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_2a96713f-62f4-4736-9047-0f97bc16db32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_2a96713f-62f4-4736-9047-0f97bc16db32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c28f7cd4-b2ff-478a-b158-c6c4253a57d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c28f7cd4-b2ff-478a-b158-c6c4253a57d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8213e982-b278-4a8e-bbcd-7b6e9a7e83c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8213e982-b278-4a8e-bbcd-7b6e9a7e83c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8604d7-186e-442b-b310-58fa60800dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8604d7-186e-442b-b310-58fa60800dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a8604d7-186e-442b-b310-58fa60800dc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8604d7-186e-442b-b310-58fa60800dc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a8604d7-186e-442b-b310-58fa60800dc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8604d7-186e-442b-b310-58fa60800dc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0608739f-278a-4fb0-979d-4349a6e52b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0608739f-278a-4fb0-979d-4349a6e52b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0693b42b-9ff4-4bd8-aac7-25d71efa6afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0693b42b-9ff4-4bd8-aac7-25d71efa6afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1c50dabf-1f34-4fd9-bc57-36bee0fa45b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1c50dabf-1f34-4fd9-bc57-36bee0fa45b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_64b79d57-819f-4699-8999-1c172fe31038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_64b79d57-819f-4699-8999-1c172fe31038" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64b79d57-819f-4699-8999-1c172fe31038_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64b79d57-819f-4699-8999-1c172fe31038" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64b79d57-819f-4699-8999-1c172fe31038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64b79d57-819f-4699-8999-1c172fe31038" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a0546740-4969-482b-b942-7c2bec17f93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a0546740-4969-482b-b942-7c2bec17f93e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_5d058d8b-fd33-4314-a5a2-a760910949d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_5d058d8b-fd33-4314-a5a2-a760910949d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5e3f97f0-ff3f-4ff8-a44c-9a5c49bbb0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5e3f97f0-ff3f-4ff8-a44c-9a5c49bbb0d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f29d1542-99cd-4050-9d65-1debc27bf145" xlink:href="amgn-20211231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f29d1542-99cd-4050-9d65-1debc27bf145" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6c317898-79ed-4b7c-a70a-797a7bac1324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6c317898-79ed-4b7c-a70a-797a7bac1324" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6c317898-79ed-4b7c-a70a-797a7bac1324_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6c317898-79ed-4b7c-a70a-797a7bac1324" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6c317898-79ed-4b7c-a70a-797a7bac1324_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6c317898-79ed-4b7c-a70a-797a7bac1324" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_828c1ee0-48c2-4101-8a4b-52f8fc1a65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_828c1ee0-48c2-4101-8a4b-52f8fc1a65f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_4acb6fab-f664-4342-8f72-476d8ac4ae88" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_4acb6fab-f664-4342-8f72-476d8ac4ae88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_16b9a491-7c8f-407e-a921-f160a8a1950d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:to="loc_us-gaap_InterestRateSwapMember_16b9a491-7c8f-407e-a921-f160a8a1950d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="extended" id="i1ba3549551904515a7420c702756abf0_FairvaluemeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_11dc5259-680c-49b7-9d1d-7f3241c5860f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_11dc5259-680c-49b7-9d1d-7f3241c5860f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_6e1f0679-c85a-41cc-9e3a-f6e11a56065d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_6e1f0679-c85a-41cc-9e3a-f6e11a56065d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_14750b32-18b3-488f-82b6-33605e41f1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_LongTermDebt_14750b32-18b3-488f-82b6-33605e41f1e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8f5bee7e-feee-4011-b215-ed1f02036d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8f5bee7e-feee-4011-b215-ed1f02036d4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f9293a3b-9420-49fc-91a3-7a739598d58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_EquityMethodInvestments_f9293a3b-9420-49fc-91a3-7a739598d58d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8f3139b1-d007-483c-b5e5-3598dfa78dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8f3139b1-d007-483c-b5e5-3598dfa78dd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_11afe727-7866-44d8-bb3a-ed239f0c74cc" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:to="loc_amgn_BeiGeneMember_11afe727-7866-44d8-bb3a-ed239f0c74cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_66b2f463-8055-4f92-9e53-6d3d7d77345c" xlink:href="amgn-20211231.xsd#amgn_TeneobioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:to="loc_amgn_TeneobioIncMember_66b2f463-8055-4f92-9e53-6d3d7d77345c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a4cd7d07-57f4-4770-abd5-9c20e537ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a4cd7d07-57f4-4770-abd5-9c20e537ac55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a4cd7d07-57f4-4770-abd5-9c20e537ac55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a4cd7d07-57f4-4770-abd5-9c20e537ac55" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a4cd7d07-57f4-4770-abd5-9c20e537ac55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ef09a074-168e-4ac9-854a-cebc439eb330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a4cd7d07-57f4-4770-abd5-9c20e537ac55" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ef09a074-168e-4ac9-854a-cebc439eb330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8faafb6f-945f-4a7b-92dd-94de028d89d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ef09a074-168e-4ac9-854a-cebc439eb330" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8faafb6f-945f-4a7b-92dd-94de028d89d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementContingentConsiderationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="extended" id="ie3bb520fa45b49a6bea838fad3fc4f21_FairvaluemeasurementContingentConsiderationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db97b44a-3b02-4036-9bf1-6c9572ec5727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_88133a55-4e0c-4535-862d-0bb1b7517086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db97b44a-3b02-4036-9bf1-6c9572ec5727" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_88133a55-4e0c-4535-862d-0bb1b7517086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_895099c0-fb99-456b-a47b-8cd8959a265e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db97b44a-3b02-4036-9bf1-6c9572ec5727" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_895099c0-fb99-456b-a47b-8cd8959a265e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71087b45-4697-4a51-aa0e-87ca268f77af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_895099c0-fb99-456b-a47b-8cd8959a265e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71087b45-4697-4a51-aa0e-87ca268f77af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_71087b45-4697-4a51-aa0e-87ca268f77af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71087b45-4697-4a51-aa0e-87ca268f77af" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_71087b45-4697-4a51-aa0e-87ca268f77af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5622958-1190-4057-8c3d-339722cbe16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71087b45-4697-4a51-aa0e-87ca268f77af" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5622958-1190-4057-8c3d-339722cbe16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_b7afb634-b304-4df6-b523-bec1e26d6807" xlink:href="amgn-20211231.xsd#amgn_TeneobioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5622958-1190-4057-8c3d-339722cbe16b" xlink:to="loc_amgn_TeneobioIncMember_b7afb634-b304-4df6-b523-bec1e26d6807" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="extended" id="id8066dce4c76439d89b658fb23705566_DerivativeinstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeInstrumentTerm_385eabe0-5b41-43b4-85db-751a0cfdd6bf" xlink:href="amgn-20211231.xsd#amgn_DerivativeInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeInstrumentTerm_385eabe0-5b41-43b4-85db-751a0cfdd6bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_74e5e26c-656d-4c2f-ab41-c38054c1682a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_DerivativeNotionalAmount_74e5e26c-656d-4c2f-ab41-c38054c1682a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_205ad3df-7ac4-4d22-8d59-71854b2310bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_205ad3df-7ac4-4d22-8d59-71854b2310bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_64a558d7-e94e-460e-8fac-8a9a60552d44" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_64a558d7-e94e-460e-8fac-8a9a60552d44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c10a61f-95d2-4d34-8eb1-02c06eda0b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c10a61f-95d2-4d34-8eb1-02c06eda0b77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments_0494a79f-745f-4cd0-89f5-e12f66acf3f0" xlink:href="amgn-20211231.xsd#amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments_0494a79f-745f-4cd0-89f5-e12f66acf3f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_7ef242ea-ce51-4c77-b3fa-e08c09278fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainOnDerivative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_7ef242ea-ce51-4c77-b3fa-e08c09278fee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_6ff20f7f-d099-419e-bf6a-b5b8b74de644" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_6ff20f7f-d099-419e-bf6a-b5b8b74de644" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_1dc4ef3f-542c-443e-9cd9-8538f21ec0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_1dc4ef3f-542c-443e-9cd9-8538f21ec0c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_ca847e54-a14d-4976-be79-ef61675dd464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_ca847e54-a14d-4976-be79-ef61675dd464" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a0193924-f427-4606-b2fd-ccc0c32b4b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a0193924-f427-4606-b2fd-ccc0c32b4b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a0193924-f427-4606-b2fd-ccc0c32b4b68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a0193924-f427-4606-b2fd-ccc0c32b4b68" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a0193924-f427-4606-b2fd-ccc0c32b4b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ad85cb64-3266-4f34-98a4-b3f592887988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a0193924-f427-4606-b2fd-ccc0c32b4b68" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ad85cb64-3266-4f34-98a4-b3f592887988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_d9352adc-c66e-47f3-abe4-1af39695f95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ad85cb64-3266-4f34-98a4-b3f592887988" xlink:to="loc_us-gaap_NotesPayableToBanksMember_d9352adc-c66e-47f3-abe4-1af39695f95c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a47871ad-481d-4b26-afd5-ee9884676486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_DebtInstrumentAxis_a47871ad-481d-4b26-afd5-ee9884676486" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a47871ad-481d-4b26-afd5-ee9884676486_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a47871ad-481d-4b26-afd5-ee9884676486" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a47871ad-481d-4b26-afd5-ee9884676486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42ed0962-b74d-4eac-9aef-060a00997ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a47871ad-481d-4b26-afd5-ee9884676486" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42ed0962-b74d-4eac-9aef-060a00997ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f6091609-10e2-4ff4-b6e6-e2860953a7ce" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42ed0962-b74d-4eac-9aef-060a00997ca1" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f6091609-10e2-4ff4-b6e6-e2860953a7ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8cadb993-775a-4081-8d23-5b1a0a3c97f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_HedgingDesignationAxis_8cadb993-775a-4081-8d23-5b1a0a3c97f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8cadb993-775a-4081-8d23-5b1a0a3c97f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8cadb993-775a-4081-8d23-5b1a0a3c97f6" xlink:to="loc_us-gaap_HedgingDesignationDomain_8cadb993-775a-4081-8d23-5b1a0a3c97f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8cadb993-775a-4081-8d23-5b1a0a3c97f6" xlink:to="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a40f1ccc-dd36-4fbb-92b4-431714206f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a40f1ccc-dd36-4fbb-92b4-431714206f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8e673d99-da07-4e44-87e9-97619481b990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:to="loc_us-gaap_NondesignatedMember_8e673d99-da07-4e44-87e9-97619481b990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a5da5674-4e95-4791-82cc-1abdcb285c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a5da5674-4e95-4791-82cc-1abdcb285c17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a5da5674-4e95-4791-82cc-1abdcb285c17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a5da5674-4e95-4791-82cc-1abdcb285c17" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a5da5674-4e95-4791-82cc-1abdcb285c17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a5da5674-4e95-4791-82cc-1abdcb285c17" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_225841f5-e895-4c55-9509-5a1169383ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_us-gaap_ForwardContractsMember_225841f5-e895-4c55-9509-5a1169383ea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_bfe331c7-9d1d-4a7c-abd4-22e7d96aae21" xlink:href="amgn-20211231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_bfe331c7-9d1d-4a7c-abd4-22e7d96aae21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1f243086-477b-4bea-b02a-825efa17ae4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_us-gaap_InterestRateSwapMember_1f243086-477b-4bea-b02a-825efa17ae4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_cbb67774-f244-413f-b8ad-2248728789d6" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAtThenCurrentInterestRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_cbb67774-f244-413f-b8ad-2248728789d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_683d9dfc-55b4-4ba4-9d5c-b467d67a6836" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_amgn_InterestRateSwapAxis_683d9dfc-55b4-4ba4-9d5c-b467d67a6836" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_683d9dfc-55b4-4ba4-9d5c-b467d67a6836_default" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_InterestRateSwapAxis_683d9dfc-55b4-4ba4-9d5c-b467d67a6836" xlink:to="loc_amgn_InterestRateSwapDomain_683d9dfc-55b4-4ba4-9d5c-b467d67a6836_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_66923091-8b39-4643-ba02-28b7b9104ae4" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_InterestRateSwapAxis_683d9dfc-55b4-4ba4-9d5c-b467d67a6836" xlink:to="loc_amgn_InterestRateSwapDomain_66923091-8b39-4643-ba02-28b7b9104ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_69194502-a3c3-46fd-9bd0-f0fb092fc6fc" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_InterestRateSwapDomain_66923091-8b39-4643-ba02-28b7b9104ae4" xlink:to="loc_amgn_InterestRateSwapTwoMember_69194502-a3c3-46fd-9bd0-f0fb092fc6fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1da01a6e-2544-49fc-b607-70337774cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1da01a6e-2544-49fc-b607-70337774cb14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1da01a6e-2544-49fc-b607-70337774cb14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1da01a6e-2544-49fc-b607-70337774cb14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1da01a6e-2544-49fc-b607-70337774cb14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b43f238-b4aa-4516-a179-39f4320da46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1da01a6e-2544-49fc-b607-70337774cb14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b43f238-b4aa-4516-a179-39f4320da46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_f2d2325a-62b7-4e2d-b170-ad8f546d80f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b43f238-b4aa-4516-a179-39f4320da46f" xlink:to="loc_us-gaap_InterestExpenseMember_f2d2325a-62b7-4e2d-b170-ad8f546d80f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e95996f6-1745-4214-934c-50b99e75a4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e95996f6-1745-4214-934c-50b99e75a4af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e95996f6-1745-4214-934c-50b99e75a4af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e95996f6-1745-4214-934c-50b99e75a4af" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e95996f6-1745-4214-934c-50b99e75a4af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c222d634-f10c-436d-9207-1755f5aada88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e95996f6-1745-4214-934c-50b99e75a4af" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c222d634-f10c-436d-9207-1755f5aada88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_a98187cf-88d7-47f5-b115-1394f5c31c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c222d634-f10c-436d-9207-1755f5aada88" xlink:to="loc_us-gaap_LongTermDebtMember_a98187cf-88d7-47f5-b115-1394f5c31c5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended" id="i5e8b4f86e068495cb1a7743f8e846836_DerivativeinstrumentsCrosscurrencySwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e57029e6-cd6f-4df4-bfc7-b20bcd963e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e57029e6-cd6f-4df4-bfc7-b20bcd963e3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_7164173a-1686-492d-a1f0-8a9108fbc68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_7164173a-1686-492d-a1f0-8a9108fbc68d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02840255-e739-4a9c-b5f0-ed33a5f63de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02840255-e739-4a9c-b5f0-ed33a5f63de1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:to="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ab42c1d3-d0e8-4f1e-9822-893c55f9dedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ab42c1d3-d0e8-4f1e-9822-893c55f9dedb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_43802e0a-964d-43e4-a670-6031f0c68bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ab42c1d3-d0e8-4f1e-9822-893c55f9dedb" xlink:to="loc_us-gaap_CashFlowHedgingMember_43802e0a-964d-43e4-a670-6031f0c68bb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2d471a71-8241-4c14-9b99-bbf3928804a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2d471a71-8241-4c14-9b99-bbf3928804a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2d471a71-8241-4c14-9b99-bbf3928804a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d471a71-8241-4c14-9b99-bbf3928804a9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2d471a71-8241-4c14-9b99-bbf3928804a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_124f6a81-af99-427e-a3bd-5ef6bb1c2cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d471a71-8241-4c14-9b99-bbf3928804a9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_124f6a81-af99-427e-a3bd-5ef6bb1c2cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_415b3cab-33a3-4023-b4ae-b963caf91e06" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_124f6a81-af99-427e-a3bd-5ef6bb1c2cea" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_415b3cab-33a3-4023-b4ae-b963caf91e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_162d9be6-b11b-4a92-9921-9e9345d65d94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_srt_CurrencyAxis_162d9be6-b11b-4a92-9921-9e9345d65d94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_162d9be6-b11b-4a92-9921-9e9345d65d94_default" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_162d9be6-b11b-4a92-9921-9e9345d65d94" xlink:to="loc_currency_AllCurrenciesDomain_162d9be6-b11b-4a92-9921-9e9345d65d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_162d9be6-b11b-4a92-9921-9e9345d65d94" xlink:to="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_5e719616-97e2-44c3-80eb-faaae6fbb6a5" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_EUR_5e719616-97e2-44c3-80eb-faaae6fbb6a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_36e18a2b-5c40-44f9-850f-c98b6790a779" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_CHF_36e18a2b-5c40-44f9-850f-c98b6790a779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_c1251770-566a-4a3d-9617-8c7f4a4dd688" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_GBP_c1251770-566a-4a3d-9617-8c7f4a4dd688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_bf620947-3604-4c33-9254-88d4c6612fe6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_USD_bf620947-3604-4c33-9254-88d4c6612fe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_0cf85b58-f61e-44be-92cd-a4cdd8b4e8d0" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_0cf85b58-f61e-44be-92cd-a4cdd8b4e8d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ee33e834-a857-4ead-899b-075f7294e12f" xlink:href="amgn-20211231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ee33e834-a857-4ead-899b-075f7294e12f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_87232e89-175a-4688-a12a-4945e125703a" xlink:href="amgn-20211231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_87232e89-175a-4688-a12a-4945e125703a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_a372faba-aeb4-4dc6-b04b-99ab5874c0ad" xlink:href="amgn-20211231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_a372faba-aeb4-4dc6-b04b-99ab5874c0ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d954dd02-97ae-4c03-91a8-2370115c2d42" xlink:href="amgn-20211231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d954dd02-97ae-4c03-91a8-2370115c2d42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_0fe6d3b0-f558-4c2d-88bf-7b4524b01282" xlink:href="amgn-20211231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_0fe6d3b0-f558-4c2d-88bf-7b4524b01282" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f9b5a13-9757-437c-a77b-cbad22e113f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f9b5a13-9757-437c-a77b-cbad22e113f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3f9b5a13-9757-437c-a77b-cbad22e113f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f9b5a13-9757-437c-a77b-cbad22e113f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3f9b5a13-9757-437c-a77b-cbad22e113f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9d29c07d-7d11-4cd7-9504-061200efd6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f9b5a13-9757-437c-a77b-cbad22e113f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9d29c07d-7d11-4cd7-9504-061200efd6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_deadb642-0d68-4cc1-8b0d-76dfbf4486a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9d29c07d-7d11-4cd7-9504-061200efd6fc" xlink:to="loc_us-gaap_NotesPayableToBanksMember_deadb642-0d68-4cc1-8b0d-76dfbf4486a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended" id="i1ea340bb08ee4bbf93618045e7530d48_DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f99bde30-ea77-4365-950a-d18e1d6b36fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_9e95733d-9351-49fc-a452-02f06d708b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f99bde30-ea77-4365-950a-d18e1d6b36fe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_9e95733d-9351-49fc-a452-02f06d708b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f99bde30-ea77-4365-950a-d18e1d6b36fe" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_94acfa77-cfc8-4c26-b8e4-0471862c7237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_94acfa77-cfc8-4c26-b8e4-0471862c7237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_94acfa77-cfc8-4c26-b8e4-0471862c7237_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_94acfa77-cfc8-4c26-b8e4-0471862c7237" xlink:to="loc_us-gaap_HedgingRelationshipDomain_94acfa77-cfc8-4c26-b8e4-0471862c7237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_db6fbe43-f9ee-461b-8258-3c11e476ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_94acfa77-cfc8-4c26-b8e4-0471862c7237" xlink:to="loc_us-gaap_HedgingRelationshipDomain_db6fbe43-f9ee-461b-8258-3c11e476ba9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e12cf5fd-f061-4388-8760-d272871e270c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_db6fbe43-f9ee-461b-8258-3c11e476ba9b" xlink:to="loc_us-gaap_CashFlowHedgingMember_e12cf5fd-f061-4388-8760-d272871e270c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7100d5ca-41cf-4305-993e-ba6677b9682e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7100d5ca-41cf-4305-993e-ba6677b9682e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_104651ce-368e-42ef-ba50-ce733c2804d4" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_104651ce-368e-42ef-ba50-ce733c2804d4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="extended" id="i861b6152dd654c62a67d971a2fea0b56_DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_3fdd4158-3a1f-418a-9ad5-926209cfd98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_3fdd4158-3a1f-418a-9ad5-926209cfd98b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e2a13b9d-0cc9-4a87-a8bc-eaa969d6d100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e2a13b9d-0cc9-4a87-a8bc-eaa969d6d100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_631db59b-8e33-468d-aad3-c00673a937cf" xlink:href="amgn-20211231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_631db59b-8e33-468d-aad3-c00673a937cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_e3f6bd61-a350-48d8-b9a3-a61796d3d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_e3f6bd61-a350-48d8-b9a3-a61796d3d27a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_d6b2337f-3c74-444a-b0c0-1e82e5efbae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_us-gaap_DerivativeTable_d6b2337f-3c74-444a-b0c0-1e82e5efbae9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0c8a5a24-b467-489b-a42f-e3d84c5875b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_d6b2337f-3c74-444a-b0c0-1e82e5efbae9" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0c8a5a24-b467-489b-a42f-e3d84c5875b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0c8a5a24-b467-489b-a42f-e3d84c5875b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0c8a5a24-b467-489b-a42f-e3d84c5875b1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0c8a5a24-b467-489b-a42f-e3d84c5875b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0c8a5a24-b467-489b-a42f-e3d84c5875b1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_e003a21c-ed9b-4f8e-9291-265636684d85" xlink:href="amgn-20211231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_e003a21c-ed9b-4f8e-9291-265636684d85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_613d28ae-db29-4cd4-87fb-8115dae10fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:to="loc_us-gaap_LongTermDebtMember_613d28ae-db29-4cd4-87fb-8115dae10fb3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended" id="i3b8a5980a5bf4dcd9e84485d28fecd9f_DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_eac36226-ece4-48eb-a1ed-13d8f965d706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_eac36226-ece4-48eb-a1ed-13d8f965d706" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a95ca2af-6f0c-4bd9-be3b-17cbf4790cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a95ca2af-6f0c-4bd9-be3b-17cbf4790cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c60c2e93-01eb-497f-9554-17638b962853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_InterestExpenseDebt_c60c2e93-01eb-497f-9554-17638b962853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bad2197c-0ca0-43d6-bfab-9dc69e4a8756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bad2197c-0ca0-43d6-bfab-9dc69e4a8756" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e87c09da-6635-459c-94e2-1da7bf61a4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e87c09da-6635-459c-94e2-1da7bf61a4b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fbd35f3-6c03-46c7-9a76-8c47137ef522" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_srt_ProductOrServiceAxis_0fbd35f3-6c03-46c7-9a76-8c47137ef522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0fbd35f3-6c03-46c7-9a76-8c47137ef522_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0fbd35f3-6c03-46c7-9a76-8c47137ef522" xlink:to="loc_srt_ProductsAndServicesDomain_0fbd35f3-6c03-46c7-9a76-8c47137ef522_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_769965ba-0ba3-4456-9ab5-37a3f6574516" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0fbd35f3-6c03-46c7-9a76-8c47137ef522" xlink:to="loc_srt_ProductsAndServicesDomain_769965ba-0ba3-4456-9ab5-37a3f6574516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7f3b042c-2dd0-4061-b77b-d141df2ab084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_769965ba-0ba3-4456-9ab5-37a3f6574516" xlink:to="loc_us-gaap_ProductMember_7f3b042c-2dd0-4061-b77b-d141df2ab084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b4e62311-0197-4d5a-9a5c-90f193c994a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b4e62311-0197-4d5a-9a5c-90f193c994a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b4e62311-0197-4d5a-9a5c-90f193c994a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b4e62311-0197-4d5a-9a5c-90f193c994a3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b4e62311-0197-4d5a-9a5c-90f193c994a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ff6ff8cd-95a5-4857-ba58-34885c5bad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b4e62311-0197-4d5a-9a5c-90f193c994a3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ff6ff8cd-95a5-4857-ba58-34885c5bad9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b8d069-1f2a-4aa9-8923-a371295675c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ff6ff8cd-95a5-4857-ba58-34885c5bad9c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b8d069-1f2a-4aa9-8923-a371295675c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b2c3c9d-3503-4ce9-8267-4217c1734dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b2c3c9d-3503-4ce9-8267-4217c1734dc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b2c3c9d-3503-4ce9-8267-4217c1734dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b2c3c9d-3503-4ce9-8267-4217c1734dc4" xlink:to="loc_us-gaap_EquityComponentDomain_6b2c3c9d-3503-4ce9-8267-4217c1734dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e542134-17e1-45e3-8369-d74b531d2a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b2c3c9d-3503-4ce9-8267-4217c1734dc4" xlink:to="loc_us-gaap_EquityComponentDomain_2e542134-17e1-45e3-8369-d74b531d2a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a12bc0c3-9510-4ee7-abc9-21e792e00319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e542134-17e1-45e3-8369-d74b531d2a1b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a12bc0c3-9510-4ee7-abc9-21e792e00319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b9568646-7235-442d-be2a-7666fec64d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b9568646-7235-442d-be2a-7666fec64d27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b9568646-7235-442d-be2a-7666fec64d27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9568646-7235-442d-be2a-7666fec64d27" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b9568646-7235-442d-be2a-7666fec64d27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9568646-7235-442d-be2a-7666fec64d27" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_18c5536a-593a-4e28-84df-ec1c97802847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_18c5536a-593a-4e28-84df-ec1c97802847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_11541b93-bb61-4a63-bbb2-4b177d7c90f0" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_11541b93-bb61-4a63-bbb2-4b177d7c90f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bc5a1097-135a-4371-8d55-ea746a7e1927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:to="loc_us-gaap_InterestRateSwapMember_bc5a1097-135a-4371-8d55-ea746a7e1927" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended" id="i10caf436c9b742cdaab1f0acf14b4a60_DerivativeinstrumentsFairValueofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_562ea31b-a852-4a81-bb3f-c57eddec67af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_562ea31b-a852-4a81-bb3f-c57eddec67af" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_11ba6361-2913-4ff0-bb02-d287ae08c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_11ba6361-2913-4ff0-bb02-d287ae08c28e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1a752aad-1f54-498b-858d-0b636a3551f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_11ba6361-2913-4ff0-bb02-d287ae08c28e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1a752aad-1f54-498b-858d-0b636a3551f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_25a1eac0-9e4c-4f03-a028-e524bad1fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_25a1eac0-9e4c-4f03-a028-e524bad1fc95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a2c3908a-37da-42cd-9209-9809f90052fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_25a1eac0-9e4c-4f03-a028-e524bad1fc95" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a2c3908a-37da-42cd-9209-9809f90052fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_562ea31b-a852-4a81-bb3f-c57eddec67af" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:to="loc_us-gaap_HedgingDesignationAxis_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b" xlink:to="loc_us-gaap_HedgingDesignationDomain_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b" xlink:to="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09e9c0e9-d401-4901-bb07-106074bb6d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09e9c0e9-d401-4901-bb07-106074bb6d12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_25104b3d-d2d4-415f-bfc5-d65caac4ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:to="loc_us-gaap_NondesignatedMember_25104b3d-d2d4-415f-bfc5-d65caac4ef7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a494c4d0-377d-4d82-ae97-f576c11e7a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a494c4d0-377d-4d82-ae97-f576c11e7a63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a494c4d0-377d-4d82-ae97-f576c11e7a63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a494c4d0-377d-4d82-ae97-f576c11e7a63" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a494c4d0-377d-4d82-ae97-f576c11e7a63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a494c4d0-377d-4d82-ae97-f576c11e7a63" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_51af9a5c-61e5-4183-a49a-0efd31682b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:to="loc_us-gaap_ForeignExchangeContractMember_51af9a5c-61e5-4183-a49a-0efd31682b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_63765309-1d75-4ff8-8aed-6cae6e689b83" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_63765309-1d75-4ff8-8aed-6cae6e689b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b2d14f8a-3de1-417c-808d-f6dd7a3c2e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:to="loc_us-gaap_InterestRateSwapMember_b2d14f8a-3de1-417c-808d-f6dd7a3c2e41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_219e04d3-49ca-44f2-b501-8f6813f58e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_219e04d3-49ca-44f2-b501-8f6813f58e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_219e04d3-49ca-44f2-b501-8f6813f58e23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_219e04d3-49ca-44f2-b501-8f6813f58e23" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_219e04d3-49ca-44f2-b501-8f6813f58e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_219e04d3-49ca-44f2-b501-8f6813f58e23" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_a4aa27de-f6ad-44e6-9e8b-b7b1f8012133" xlink:href="amgn-20211231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_a4aa27de-f6ad-44e6-9e8b-b7b1f8012133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_680c5d03-28d9-4bba-835a-1fdb68a4b17f" xlink:href="amgn-20211231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_680c5d03-28d9-4bba-835a-1fdb68a4b17f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_253f1a21-c96b-4bdc-9ffc-56301112a006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_253f1a21-c96b-4bdc-9ffc-56301112a006" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsSandozPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="extended" id="ib821cdf96fc043d2b1112522accfb50f_ContingenciesandcommitmentsSandozPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_6cf8362f-96f6-48fb-af18-9ac9295c25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_a153319d-c941-44a5-908b-3628e61d762c" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_6cf8362f-96f6-48fb-af18-9ac9295c25a3" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_a153319d-c941-44a5-908b-3628e61d762c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_d594fcc8-cb91-401c-b9c1-c5d7025072cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_6cf8362f-96f6-48fb-af18-9ac9295c25a3" xlink:to="loc_us-gaap_GainContingenciesTable_d594fcc8-cb91-401c-b9c1-c5d7025072cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_77ae53df-1421-488b-b79b-93c4d997c637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_d594fcc8-cb91-401c-b9c1-c5d7025072cd" xlink:to="loc_srt_LitigationCaseAxis_77ae53df-1421-488b-b79b-93c4d997c637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_77ae53df-1421-488b-b79b-93c4d997c637_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_77ae53df-1421-488b-b79b-93c4d997c637" xlink:to="loc_srt_LitigationCaseTypeDomain_77ae53df-1421-488b-b79b-93c4d997c637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e0eb71c8-9734-4651-82bb-09b559bc3f3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_77ae53df-1421-488b-b79b-93c4d997c637" xlink:to="loc_srt_LitigationCaseTypeDomain_e0eb71c8-9734-4651-82bb-09b559bc3f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember_a9cbf08a-02d1-4f3f-8a13-11be6d5e99d0" xlink:href="amgn-20211231.xsd#amgn_SandozIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e0eb71c8-9734-4651-82bb-09b559bc3f3d" xlink:to="loc_amgn_SandozIncMember_a9cbf08a-02d1-4f3f-8a13-11be6d5e99d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsImmunexandSandozLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="extended" id="i27529096c2be497bbff20dd18f880643_ContingenciesandcommitmentsImmunexandSandozLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofAffiliates_d0e79db2-682b-484f-920c-4f3d2563e83a" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberofAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:to="loc_amgn_GainContingencyNumberofAffiliates_d0e79db2-682b-484f-920c-4f3d2563e83a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7775be11-8c90-4ea0-9087-6c04918e670c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7775be11-8c90-4ea0-9087-6c04918e670c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_33be480b-64bf-41ec-ac9f-f27dad1156ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:to="loc_us-gaap_OtherCommitmentsTable_33be480b-64bf-41ec-ac9f-f27dad1156ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_33be480b-64bf-41ec-ac9f-f27dad1156ac" xlink:to="loc_srt_LitigationCaseAxis_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6" xlink:to="loc_srt_LitigationCaseTypeDomain_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_799f6a79-6ee2-4846-a686-f451059cfcb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6" xlink:to="loc_srt_LitigationCaseTypeDomain_799f6a79-6ee2-4846-a686-f451059cfcb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSamsungBioepisCoMember_6f56470b-f59f-4096-93d9-9d35957f68ef" xlink:href="amgn-20211231.xsd#amgn_ImmunexAndSamsungBioepisCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_799f6a79-6ee2-4846-a686-f451059cfcb3" xlink:to="loc_amgn_ImmunexAndSamsungBioepisCoMember_6f56470b-f59f-4096-93d9-9d35957f68ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsRepathaPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="extended" id="i2b67ac3ddfae4bf6a82f8bea7d916881_ContingenciesandcommitmentsRepathaPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_dace2ce0-ec06-41ef-8490-932a0c8bde4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_dace2ce0-ec06-41ef-8490-932a0c8bde4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial_3b77fa7e-5dc0-4a06-9aba-819b724d0fff" xlink:href="amgn-20211231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:to="loc_amgn_LitigationSettlementLengthofTrial_3b77fa7e-5dc0-4a06-9aba-819b724d0fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges_65d28b5e-2a5d-474a-8912-da418560960d" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:to="loc_amgn_GainContingencyNumberOfChallenges_65d28b5e-2a5d-474a-8912-da418560960d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_51afdf5f-bbf9-45ca-9c7a-bf0db530874e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:to="loc_us-gaap_OtherCommitmentsTable_51afdf5f-bbf9-45ca-9c7a-bf0db530874e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_594f0c68-adf2-4a5d-9121-402875616801" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_51afdf5f-bbf9-45ca-9c7a-bf0db530874e" xlink:to="loc_srt_LitigationCaseAxis_594f0c68-adf2-4a5d-9121-402875616801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_594f0c68-adf2-4a5d-9121-402875616801_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_594f0c68-adf2-4a5d-9121-402875616801" xlink:to="loc_srt_LitigationCaseTypeDomain_594f0c68-adf2-4a5d-9121-402875616801_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_56c46e9b-3e11-4c41-83c0-e118db64b660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_594f0c68-adf2-4a5d-9121-402875616801" xlink:to="loc_srt_LitigationCaseTypeDomain_56c46e9b-3e11-4c41-83c0-e118db64b660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_7acdc28f-25c3-40c8-bbc9-000527e7d903" xlink:href="amgn-20211231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_56c46e9b-3e11-4c41-83c0-e118db64b660" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_7acdc28f-25c3-40c8-bbc9-000527e7d903" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="extended" id="i1561667266474ce78a5e54079a41dd96_ContingenciesandcommitmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b640bb36-6917-4038-a543-999aa18ea5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b640bb36-6917-4038-a543-999aa18ea5e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_e636a550-969c-4a03-8b3e-a5a3a20a675b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_e636a550-969c-4a03-8b3e-a5a3a20a675b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfAgreementsBreached_f23bc4ca-da7f-4491-9a4e-46a42fefd76e" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberOfAgreementsBreached"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_amgn_GainContingencyNumberOfAgreementsBreached_f23bc4ca-da7f-4491-9a4e-46a42fefd76e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ec23d3a6-e5e0-46cd-8a2e-81b7439d7df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ec23d3a6-e5e0-46cd-8a2e-81b7439d7df5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_77150012-14e0-49b6-8d64-c856e1d01006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_77150012-14e0-49b6-8d64-c856e1d01006" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled_fb9a9a24-6a6d-4c0f-bff8-57cd8226f6ac" xlink:href="amgn-20211231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_amgn_LossContingencyNumberOfLawsuitsFiled_fb9a9a24-6a6d-4c0f-bff8-57cd8226f6ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_dc199464-0726-4299-bdda-cb7f962ef1c6" xlink:href="amgn-20211231.xsd#amgn_LossContingencyNumberOfComplaintsStayedByTheCourt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_dc199464-0726-4299-bdda-cb7f962ef1c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ad3ef4df-1ea3-49d2-bd53-337298efe140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingenciesTable_ad3ef4df-1ea3-49d2-bd53-337298efe140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ad3ef4df-1ea3-49d2-bd53-337298efe140" xlink:to="loc_srt_LitigationCaseAxis_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c" xlink:to="loc_srt_LitigationCaseTypeDomain_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c" xlink:to="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisBreachOfContractActionMember_33c86be8-4c4c-4409-82fc-902e6a4e704c" xlink:href="amgn-20211231.xsd#amgn_NovartisBreachOfContractActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:to="loc_amgn_NovartisBreachOfContractActionMember_33c86be8-4c4c-4409-82fc-902e6a4e704c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_bb0ebb46-bb7f-498a-a361-aedf9572696e" xlink:href="amgn-20211231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_bb0ebb46-bb7f-498a-a361-aedf9572696e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_846e74c1-2882-4724-8f7f-0a419343e54e" xlink:href="amgn-20211231.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:to="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_846e74c1-2882-4724-8f7f-0a419343e54e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>amgn-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2bb320c8-0f12-4641-8309-e0606e56f5e9,g:0e6120fc-59ff-4bff-bbf3-39bc007e06fc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal_774b1cf5-da5f-41fd-85ee-26e3a8ebc852_terseLabel_en-US" xlink:label="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Realized Gain (Loss) on Disposal</link:label>
    <link:label id="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Realized Gain (Loss) on Disposal</link:label>
    <link:label id="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal_documentation_en-US" xlink:label="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:href="amgn-20211231.xsd#amgn_EquitySecuritiesRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:to="lab_amgn_EquitySecuritiesRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_659ed6da-a61c-43c7-ab1f-64bc6763f1cf_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b1abf0d0-5929-4ae7-b532-16db1892b208_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2040Member_dd7afba8-d651-4ef0-8a2b-84fec5c3d86a_terseLabel_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2040</link:label>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2040Member_label_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2040 [Member]</link:label>
    <link:label id="lab_amgn_ExpirationInTaxYearsBetween2023And2040Member_documentation_en-US" xlink:label="lab_amgn_ExpirationInTaxYearsBetween2023And2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in tax years between 2023 and 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2040Member" xlink:href="amgn-20211231.xsd#amgn_ExpirationInTaxYearsBetween2023And2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ExpirationInTaxYearsBetween2023And2040Member" xlink:to="lab_amgn_ExpirationInTaxYearsBetween2023And2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_13bcffbc-6934-4e12-9ad4-c5c5e0167457_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_deb79124-39fc-4071-b64c-2eb6a9859dcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_6346f388-bd65-42c9-b354-ed1f00672f78_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact related to employee stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_label_en-US" xlink:label="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:to="lab_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_7e4201db-b912-4c52-9af2-32ac10e46fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e16a49f-750f-49c2-886a-d37be973ea31_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8b4d3dff-d777-4ca3-9103-d1ad946ce09a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_3054fa53-a182-46b3-af34-5da646d819a1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_43d49e3c-b7e8-47ff-9d87-57aed97e7da9_terseLabel_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:href="amgn-20211231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_d14bbe50-5fae-4074-92af-91071dacf487_terseLabel_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% notes due 2050 (3.375% 2050 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_label_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_documentation_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:href="amgn-20211231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:to="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_a573a8ce-5506-4387-b323-1c4576a5b91e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a20e71b3-ec37-49f3-b7d2-ff2e28ac9de4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_dd81f44c-8df1-444d-ae84-3a836d25802d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_ff959301-601d-401f-b29c-bb18fa357943_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_86148741-abc4-451b-87bc-148823dcbf48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_366756d9-b2a2-4ef1-a495-70f743b19cb3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_13287443-27ab-4254-9839-2543857be744_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_d514af4a-427a-46a9-b329-dd1b4a4b0ec7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding&#8212;558.3 shares in 2021 and 578.3 shares in 2020</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_171d9240-42c0-436f-9546-a2dc8c2e6912_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f89ec477-7167-40ee-b55c-065d5e0fbe53_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b4958cd4-ee37-4ecc-8846-7a9eb48e45ff_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_111937b9-e474-47f8-9743-3b18e3f6e878_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_cb18f52f-5c3b-4806-ae7d-38de42a4ea98_terseLabel_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value with discontinued hedging relationships</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_label_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_documentation_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:href="amgn-20211231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:to="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_b7dcfaaf-17b8-4305-894e-9d592d07a824_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to deferred credit</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_label_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:to="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_488d1527-cb1f-4b1a-9ffa-ce0c72d8cc65_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b3f1b5e9-0a44-4d0e-a6eb-761f55d4de7c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_613aa99a-e5e9-4f28-993a-b168fd40bff5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dcec9f00-0ecc-4611-b0e7-87cb723c1b35_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_af33d18f-a50b-493a-aacd-eb414f8d28c6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable_11d54a5a-4947-423d-96eb-c77913fc509b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gain (Loss) on Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gain (Loss) on Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfGainLossOnInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_39f8cb7d-15c6-4e95-bace-c856d3a95fe9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4ebe105a-525e-41fe-9a4e-eb4b8f002f8c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ff7bc347-2917-41da-925e-af68c8a1a408_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3a8bb1b4-c379-44a0-b33f-f44d0e333a16_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross-currency swap contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_92e49239-b1e6-441b-bfde-35ec9399fcf6_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_603b63be-444e-417b-bc63-c2230640c939_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_43c04de9-ed2a-4d88-b9a5-703f62f3331f_totalLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Gross</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:to="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_7e38232a-e532-475b-bd8b-818e03e010bb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions charged&#160;to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9d414443-0444-44e2-9bee-338d4929268c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ef0d8ac1-36f0-404c-b15d-46e0b1694375_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7634e498-4fed-4786-bf92-0dafa855cd6c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed, deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_baef4238-ec58-49e8-9414-4f3a64f2ff6b_terseLabel_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% notes due 2042 (5.65% 2042 Notes)</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_label_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_documentation_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:href="amgn-20211231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:to="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d01e1f2d-0203-49cf-a0e9-d7d3f67a32d1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization charges associated with finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_231e28b7-f0fe-412b-9998-f2dc4825fbdf_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9ac453fe-92fc-4041-a9a3-578796c242a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_867bd70b-a15c-4e09-a9d7-e1baf28c1422_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of amortization</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_97993778-05b9-4deb-80bf-0e17e73c2209_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for stock repurchases under a board approved stock repurchase plan</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b805d299-d864-4200-9e33-a3b06da0f39b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_76d1a70c-03be-41f4-ae7c-f0eaef26db53_verboseLabel_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% notes due 2041 (4.95% 2041 Notes)</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:href="amgn-20211231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:to="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7ce979c6-a282-46cf-8479-c0cdd7d4fb72_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4fc6aaa7-b4b0-4f0c-8b69-523dab36988e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c6ea1b1a-e02f-481f-9ffb-db25bd17e38f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_238c587e-71d1-422c-86a4-a1406dcce8a1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_2055d98e-40d9-4c81-b16b-113a3dd50133_terseLabel_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% notes due 2020 (3.45% 2020 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_label_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:href="amgn-20211231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:to="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_182297ed-dbf0-403c-b289-085c6296a260_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_447558b5-3635-476a-afc1-796bc59d30ef_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amounts of hedged liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_0cc49ad1-3955-47fb-a3cf-85e9b47f1893_terseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_2f7a5bc1-9b8a-493a-85e4-4621e2cbd9fb_verboseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% 2026 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_label_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:href="amgn-20211231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:to="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_57e83cd5-34e5-42f8-89cb-75801c3518d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_a3dd9db8-56ee-4982-bc6d-c08da9921191_terseLabel_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.90% notes due 2038 (6.90% 2038 Notes)</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_label_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_documentation_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:href="amgn-20211231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:to="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_44a1532a-200a-48e0-83af-fda98a2c1e4f_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_68aa91e3-12b5-4f0d-9a10-f17e57846dac_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_8ff618c6-b68a-4dac-b964-fdc01016394b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_b2cb1cad-afc0-4ecd-af82-ad2a5fad823a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_XgevaMember_d2a5f255-646e-49eb-986e-56bf3c3c3f79_terseLabel_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_label_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_documentation_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember" xlink:href="amgn-20211231.xsd#amgn_XgevaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_XgevaMember" xlink:to="lab_amgn_XgevaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NovartisBreachOfContractActionMember_a14f66bc-6306-4016-9017-9a8c1d578d50_terseLabel_en-US" xlink:label="lab_amgn_NovartisBreachOfContractActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Breach Of Contract Action</link:label>
    <link:label id="lab_amgn_NovartisBreachOfContractActionMember_label_en-US" xlink:label="lab_amgn_NovartisBreachOfContractActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Breach Of Contract Action [Member]</link:label>
    <link:label id="lab_amgn_NovartisBreachOfContractActionMember_documentation_en-US" xlink:label="lab_amgn_NovartisBreachOfContractActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Breach Of Contract Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisBreachOfContractActionMember" xlink:href="amgn-20211231.xsd#amgn_NovartisBreachOfContractActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NovartisBreachOfContractActionMember" xlink:to="lab_amgn_NovartisBreachOfContractActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_037268c8-edbe-4e60-9ab9-1f177c61be47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_354cde2b-c31f-4d93-b981-eafc4eb35541_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f53d1335-aaa4-4113-ae71-2839daec7600_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options information [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ca0d2fe4-9f45-4060-bfaa-6054e0336b68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_40ce4943-b26e-4d8d-b3fe-15598cf6aed1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_91a409ab-b3bd-4e1b-9549-1746f182e28c_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale interest-bearing security investments by contractual maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9b1a3e7e-6020-4943-ba01-c5a8103fe928_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_72e3a78b-d72d-475f-aa85-944d254ba32b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NuevolutionMember_5c0b7c14-f98a-48be-bd12-1ed34e2f81de_terseLabel_en-US" xlink:label="lab_amgn_NuevolutionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuevolution</link:label>
    <link:label id="lab_amgn_NuevolutionMember_label_en-US" xlink:label="lab_amgn_NuevolutionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuevolution [Member]</link:label>
    <link:label id="lab_amgn_NuevolutionMember_documentation_en-US" xlink:label="lab_amgn_NuevolutionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuevolution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember" xlink:href="amgn-20211231.xsd#amgn_NuevolutionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NuevolutionMember" xlink:to="lab_amgn_NuevolutionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_7a17c70a-c10e-4e6a-a3bb-2ad5ec076436_verboseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_cd842880-e575-479f-9877-c9a7ecc1ef1b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_7d31e4c2-46fc-4690-b6be-fed1e66939b8_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_445eb7c5-570c-44af-bbf7-9fa678f97fed_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:to="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_6a08ca3a-b884-4ed0-a619-770b6de02657_terseLabel_en-US" xlink:label="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Novartis AG [Member]</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_label_en-US" xlink:label="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Novartis Pharma AG [Member]</link:label>
    <link:label id="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_documentation_en-US" xlink:label="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Novartis Pharma AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:href="amgn-20211231.xsd#amgn_CollaborativeArrangementwithNovartisPharmaAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:to="lab_amgn_CollaborativeArrangementwithNovartisPharmaAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3b3ae268-ef4f-4a0f-ba4e-e3d61282731a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_142a4743-ffc9-4f90-ae65-537dc2c6dd1e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-related rights [Member]</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SandozIncMember_8f383bce-077c-4966-8247-7c8db7a686de_terseLabel_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:label id="lab_amgn_SandozIncMember_label_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc. [Member]</link:label>
    <link:label id="lab_amgn_SandozIncMember_documentation_en-US" xlink:label="lab_amgn_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember" xlink:href="amgn-20211231.xsd#amgn_SandozIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SandozIncMember" xlink:to="lab_amgn_SandozIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9d2fb545-d0fd-4b79-ab30-761066c66424_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ae77c591-c736-4f33-b32b-551b4d65ddc8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8934e837-1a3f-405d-b91e-824047098e24_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_66e7611a-1c52-4c92-8f4d-74a1e09c4f41_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.70% notes due 2022 (2.70% 2022 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:to="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_b7042a56-8598-41a9-9d3d-75df61bd0e03_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20211231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A190NotesDue20251902025NotesMember_bcc24233-01b1-4eb4-bbc6-267ed87d7c0e_terseLabel_en-US" xlink:label="lab_amgn_A190NotesDue20251902025NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes)</link:label>
    <link:label id="lab_amgn_A190NotesDue20251902025NotesMember_label_en-US" xlink:label="lab_amgn_A190NotesDue20251902025NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A190NotesDue20251902025NotesMember_documentation_en-US" xlink:label="lab_amgn_A190NotesDue20251902025NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember" xlink:href="amgn-20211231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A190NotesDue20251902025NotesMember" xlink:to="lab_amgn_A190NotesDue20251902025NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_a83611c2-f769-4817-aca1-676b6828f8f8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_a9a49c49-6781-4aaa-8c69-5d700e6d9d09_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rates</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_39e37040-a899-49ab-8c68-73cec903509e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_808adfff-9d40-4dbe-ac21-1f015bc6c1ea_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_27411e3c-fc1f-48bf-add3-9af782e938d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A200NotesDue20322002032NotesMember_d16b3747-fc5c-4add-bf4c-aa01536adf34_terseLabel_en-US" xlink:label="lab_amgn_A200NotesDue20322002032NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes)</link:label>
    <link:label id="lab_amgn_A200NotesDue20322002032NotesMember_label_en-US" xlink:label="lab_amgn_A200NotesDue20322002032NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A200NotesDue20322002032NotesMember_documentation_en-US" xlink:label="lab_amgn_A200NotesDue20322002032NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember" xlink:href="amgn-20211231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A200NotesDue20322002032NotesMember" xlink:to="lab_amgn_A200NotesDue20322002032NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_613f51cb-d655-498d-a347-e588f15ac852_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_baab2734-4f5d-48fa-8abf-1d6d13459e49_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Stock Exchange</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_395a1d1a-3545-4420-a00c-9402e7f658db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9dda1741-4597-4cd2-9812-f8c47d7d90ef_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_94a6ada1-8a65-4f10-a06b-9123fff38955_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_5cf4def3-a7b7-4f7e-a7f9-4bc5a118d2db_terseLabel_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_label_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point zero percent 2032 Notes Member [Member]</link:label>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_documentation_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point zero percent 2032 Notes Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:to="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e8bcd314-6377-486e-9e1d-5ac62faaed76_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepathaevolocumabMember_178a83c2-8b56-424d-9bdb-b69b71361fdd_terseLabel_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_label_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_documentation_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember" xlink:href="amgn-20211231.xsd#amgn_RepathaevolocumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepathaevolocumabMember" xlink:to="lab_amgn_RepathaevolocumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_14fc7d66-8959-4f6a-8aa8-ab72377b2181_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_dbf5433e-27c7-4899-ba91-5bd2f16bde6a_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make-whole payments recognized in interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ImmunexAndSamsungBioepisCoMember_c08232d8-310c-4da9-8090-c7003be9a00d_terseLabel_en-US" xlink:label="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex/Samsung Bioepis Co.</link:label>
    <link:label id="lab_amgn_ImmunexAndSamsungBioepisCoMember_label_en-US" xlink:label="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex And Samsung Bioepis Co. [Member]</link:label>
    <link:label id="lab_amgn_ImmunexAndSamsungBioepisCoMember_documentation_en-US" xlink:label="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunex And Samsung Bioepis Co.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSamsungBioepisCoMember" xlink:href="amgn-20211231.xsd#amgn_ImmunexAndSamsungBioepisCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ImmunexAndSamsungBioepisCoMember" xlink:to="lab_amgn_ImmunexAndSamsungBioepisCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_acd5d35b-eff5-4d8a-8dfb-2a41a6f53ff2_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_cdaf587f-a175-4a03-a6e9-c135d9b5a948_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5a686fba-5158-436e-bc79-23d5e1f17997_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of changes in accounting principles, net of taxes</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ApprovedMarkets_4186b262-a4f6-4978-b98a-37fada6b8575_terseLabel_en-US" xlink:label="lab_amgn_ApprovedMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved markets</link:label>
    <link:label id="lab_amgn_ApprovedMarkets_label_en-US" xlink:label="lab_amgn_ApprovedMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved Markets</link:label>
    <link:label id="lab_amgn_ApprovedMarkets_documentation_en-US" xlink:label="lab_amgn_ApprovedMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedMarkets" xlink:href="amgn-20211231.xsd#amgn_ApprovedMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ApprovedMarkets" xlink:to="lab_amgn_ApprovedMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_ade6bc0f-3217-488f-959f-daa65336c69b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3aa90c0f-1890-4a79-80c2-86aedbcac88e_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_904a67e1-58ad-4c1f-a382-731af24d94bc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative assets, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_10807d5a-eb3b-459d-82c5-16c7f79f5a33_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a271463c-c3d2-49df-a2b2-54830ec00a61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f338f754-dcdf-4669-82cf-f11a8092bb31_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_145d81cf-f185-4750-9d8c-3a8d1ba4b2a6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c8e75576-5c60-41f4-89f2-0d9dd0c09fdf_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_092c3503-4681-44a6-b876-517316bd0125_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e5b1e823-5ec6-40b2-aaf0-1ba0363dbb6c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets (Level 1) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_64631fdb-6e0e-48e0-9553-fcf790a9c017_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_9044dccf-a717-4fd2-8ff4-0c8947f6a658_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_77eab0ad-3abe-4ebc-a136-414fe58358bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_82a5ee07-80b8-41ec-a8f1-9c1f54103fa6_verboseLabel_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_label_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sales Investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_documentation_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sales investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember" xlink:href="amgn-20211231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSalesInvestmentsMember" xlink:to="lab_amgn_AvailableForSalesInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_90c69734-cf79-4363-88dd-f1366d78e62c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7251c983-2315-4c7e-89ee-e4991688472f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_388a9bbb-b417-48db-a062-6e45944a83d1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_426e30b5-ffc3-49c8-9b8e-a8526b40600f_verboseLabel_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_label_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_documentation_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:href="amgn-20211231.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:to="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_98490492-e4ab-48e5-b9e5-2bcb5efdb8ce_terseLabel_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone payments</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_label_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone payments</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_documentation_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:href="amgn-20211231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:to="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_599fce32-1ce6-45d6-94fb-66c521415554_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointNineZeroNotesDue2019Member_52ecec27-e84b-4b68-bb85-bcb6f3417aa1_terseLabel_en-US" xlink:label="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2019 (1.90% 2019 Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroNotesDue2019Member_label_en-US" xlink:label="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroNotesDue2019Member" xlink:href="amgn-20211231.xsd#amgn_OnePointNineZeroNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointNineZeroNotesDue2019Member" xlink:to="lab_amgn_OnePointNineZeroNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_85ab7db1-4711-45f1-813a-9f459f8a1798_terseLabel_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2021 (3.875% 2021 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:href="amgn-20211231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:to="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapOneMember_601871d5-5845-419d-ba08-a45f516d7ca2_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapOneMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapOneMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapOneMember" xlink:to="lab_amgn_InterestRateSwapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cbc9b8db-1e85-40b0-b7ce-c5b9487e00e2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_b4b7c979-6afa-4833-83d3-3a46616873fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_afcb034f-9185-46b9-8112-3806f21af0de_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_e749b2c2-82a0-4130-baa4-1cb6e8d22a60_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b4d06cea-5c7a-439a-be3c-1e9e639a9683_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_01ebb6be-3765-484f-9bbe-086bc140a354_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_43917e84-66e9-45c3-aa5c-b103de0f3ed2_netLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap agreements [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_49fd6a0f-7e9f-46aa-a7ef-c3986b6d68bd_terseLabel_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions as a percentage of gross product sales (less than)</link:label>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_label_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Provisions As Percentage Of Product Sales</link:label>
    <link:label id="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales_documentation_en-US" xlink:label="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Provisions As Percentage Of Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:href="amgn-20211231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:to="lab_amgn_SalesReturnProvisionsAsPercentageOfProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_67c27e88-1d2a-4c64-9a40-adb6f617ef10_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e4499b27-7a34-419d-9702-3ef171627360_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a928b4da-695b-4396-aab5-639f956541b6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_ae052510-13b3-467f-8307-2908643f7f5b_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2024</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3dfb82a9-e72d-4a42-b350-5d2858694b8f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits, primarily federal R&amp;D</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_84431c3f-4576-48e8-97a2-455ac5b20134_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KyowaKirinCoLtdMember_6d157eb3-ba30-4a8c-b289-331c75fa31d1_terseLabel_en-US" xlink:label="lab_amgn_KyowaKirinCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd.</link:label>
    <link:label id="lab_amgn_KyowaKirinCoLtdMember_label_en-US" xlink:label="lab_amgn_KyowaKirinCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd. [Member]</link:label>
    <link:label id="lab_amgn_KyowaKirinCoLtdMember_documentation_en-US" xlink:label="lab_amgn_KyowaKirinCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyowaKirinCoLtdMember" xlink:href="amgn-20211231.xsd#amgn_KyowaKirinCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KyowaKirinCoLtdMember" xlink:to="lab_amgn_KyowaKirinCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_53a7f93f-4436-4ca7-9f60-cc2747399fb9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2037Member_520f581e-6b15-487d-8857-6d41f6682cdc_terseLabel_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2037</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2037Member_label_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2037 [Member]</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2037Member_documentation_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2037Member" xlink:href="amgn-20211231.xsd#amgn_OperatingLossesThatExpireBetween2022And2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OperatingLossesThatExpireBetween2022And2037Member" xlink:to="lab_amgn_OperatingLossesThatExpireBetween2022And2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_68bbb161-cd55-4aa8-9849-35c405590a0b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in valuations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_7a9cabae-0161-4a29-9d5e-ad93d4e4ecb8_terseLabel_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% notes due 2045 (4.40% 2045 Notes)</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_label_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_documentation_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:href="amgn-20211231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:to="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member_5c603bb7-f354-49a8-a1b9-5c75efddac6a_terseLabel_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2031</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member_label_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2031 [Member]</link:label>
    <link:label id="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member_documentation_en-US" xlink:label="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Losses That Expire Between 2022 and 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:href="amgn-20211231.xsd#amgn_OperatingLossesThatExpireBetween2022And2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:to="lab_amgn_OperatingLossesThatExpireBetween2022And2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_d655870c-0053-4975-984b-0bd1f349f5b1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_5256a5de-aa3e-45f1-bc64-615277c05177_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses capitalized for tax</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2a9e0211-d0f4-4889-a29e-bbd8770867d0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TeneobioMember_3fce796a-0534-4e33-b98d-3200adc5ce54_terseLabel_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio</link:label>
    <link:label id="lab_amgn_TeneobioMember_label_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio [Member]</link:label>
    <link:label id="lab_amgn_TeneobioMember_documentation_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember" xlink:href="amgn-20211231.xsd#amgn_TeneobioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TeneobioMember" xlink:to="lab_amgn_TeneobioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_0ccb4de9-ed95-4e84-a436-4b03dd5ff0c9_totalLabel_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_label_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal Net</link:label>
    <link:label id="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_documentation_en-US" xlink:label="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:href="amgn-20211231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:to="lab_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5b3b3690-683b-45a5-afed-fa194c840754_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5487d16a-88b1-43d0-838e-a7e906cbb45d_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0e12b5ee-6503-4125-aa75-1fb2a9c71839_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_60a522ba-ee1b-4109-9423-0f32d67650d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e5ef66cd-974d-4128-b957-0ea4fc2b56af_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c6e9059b-4fc4-4e56-be4f-738e42387be2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_5f003e22-5f82-44bd-a679-0509568c9410_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_ad7be1b3-4809-425f-a838-9dd013ea3914_terseLabel_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment [Member]</link:label>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_amgn_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_amgn_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember" xlink:href="amgn-20211231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ManufacturingEquipmentMember" xlink:to="lab_amgn_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments_9f714677-7dbd-4460-8004-e50983863d8a_terseLabel_en-US" xlink:label="lab_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Aggregate Notional Amount of New Instruments</link:label>
    <link:label id="lab_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments_label_en-US" xlink:label="lab_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Aggregate Notional Amount of New Instruments</link:label>
    <link:label id="lab_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments_documentation_en-US" xlink:label="lab_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Aggregate Notional Amount of New Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" xlink:href="amgn-20211231.xsd#amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" xlink:to="lab_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_45284efe-6744-4707-9177-bdb8b55fcf57_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_3bfab8f9-d6b9-4b9d-b3ae-4647b46e966b_totalLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:to="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_134d46f7-88b9-4d77-95ba-bec9f4ac6dd5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_008032b3-dd8b-4d77-95c3-13345ba2aab5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_af4a6ae7-c043-433a-8539-73c7683a22fa_totalLabel_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation Expense Net of Tax</link:label>
    <link:label id="lab_amgn_StockBasedCompensationExpenseNetOfTax_documentation_en-US" xlink:label="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, net of tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax" xlink:href="amgn-20211231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_StockBasedCompensationExpenseNetOfTax" xlink:to="lab_amgn_StockBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_74c3d533-724a-4dea-9d70-e8065448e8f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_203afd61-62ee-4040-8d0f-9fbedfba0390_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b8c83624-011d-4cce-b2df-3ed0fd6ca28e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties associated with unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_442eb7eb-e0cd-4734-a05d-6b6a9211b48a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_9c0114ce-b8fc-4b47-bcf4-957b2afd5ca0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cbf5ef92-5136-46d4-83a2-bdd92f70bbff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), unexercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_10ffbdb9-d97f-4713-8c6f-106fb22800bf_terseLabel_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.40% notes due 2039 (6.40% 2039 Notes)</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_label_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_documentation_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:href="amgn-20211231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:to="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9b0f5d1b-3392-44e1-94a5-e1c82eb8770d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_86148b24-bfc9-4dad-a8f7-91bc2aec6ece_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_4d01e8d3-b4bb-45ea-a9cf-a65c545a1fda_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5e939bd1-52d4-4f4f-a2bf-2de1f01d128f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberOfAgreementsBreached_9c4d2f6a-30e5-42eb-ba53-066d1b811a01_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements breached</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfAgreementsBreached_label_en-US" xlink:label="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Agreements Breached</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfAgreementsBreached_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Agreements Breached</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfAgreementsBreached" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberOfAgreementsBreached"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberOfAgreementsBreached" xlink:to="lab_amgn_GainContingencyNumberOfAgreementsBreached" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_13f9d6e2-4f04-418f-bcb5-013614b31dcb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2963ff7f-898c-4e23-a9be-c139cfa6b8b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57a76ee5-a46b-407f-951e-dc5213499427_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e420b1f4-9bbf-475e-8b35-85e5f88dc159_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c434c87d-411e-4a99-94f0-e8833d43bbb2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_81492c3e-29f1-4b32-ba37-4242de8e9298_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.77% notes due 2053 (2.77% 2053 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:to="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MoleculeTypeAxis_a65f9aea-94c8-4bfd-b5e3-0c4aba1cca23_terseLabel_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Axis]</link:label>
    <link:label id="lab_amgn_MoleculeTypeAxis_label_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Axis]</link:label>
    <link:label id="lab_amgn_MoleculeTypeAxis_documentation_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis" xlink:href="amgn-20211231.xsd#amgn_MoleculeTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MoleculeTypeAxis" xlink:to="lab_amgn_MoleculeTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_87b1fe06-2401-4478-99df-e01ef104464c_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets locations</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_877eb5ae-1114-481d-b179-42d081ccdc57_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ee13d090-ab5e-4223-9e8f-e3d2bf254705_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_9ae7b5e7-5f96-4545-a453-8aa9df55afb6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_c1f0ab75-169e-420c-9615-defa44ede183_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProfitAndLossShareOfExpenses_4e0c2544-fe42-4316-bf68-7bb8c36d914c_terseLabel_en-US" xlink:label="lab_amgn_ProfitAndLossShareOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit and loss share of expenses</link:label>
    <link:label id="lab_amgn_ProfitAndLossShareOfExpenses_label_en-US" xlink:label="lab_amgn_ProfitAndLossShareOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit and loss share of expenses</link:label>
    <link:label id="lab_amgn_ProfitAndLossShareOfExpenses_documentation_en-US" xlink:label="lab_amgn_ProfitAndLossShareOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit and loss share of expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses" xlink:href="amgn-20211231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProfitAndLossShareOfExpenses" xlink:to="lab_amgn_ProfitAndLossShareOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a920636c-b95c-49c1-ab17-6c88ee59acf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c7cc22a2-04a5-404d-ac6b-480c07af3863_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b3293cf8-71e3-4c2f-a65d-e6efdc1a26c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3817cb07-245d-47c1-b2c7-4615fb2ce4fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_aebb175d-394d-4fcb-bb6e-b2c03a4e82db_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ecad7c2f-eb28-4f4f-a814-c91bfc1991e8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_a4eb44cf-1740-43cf-ae3b-2f71613a21d1_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds [Member]</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_b934d9c1-ffb4-40d9-88f7-33df6848a6ca_terseLabel_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation</link:label>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_label_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_SanofiRegeneronPatentLitigationMember_documentation_en-US" xlink:label="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi/Regeneron Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember" xlink:href="amgn-20211231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SanofiRegeneronPatentLitigationMember" xlink:to="lab_amgn_SanofiRegeneronPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_bcfc7821-12f6-44c9-8a45-4a9352caba4c_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_bdadd9fa-dc2d-4b66-a47e-84a4d9bbdd32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_5673d2a3-e77a-4a7b-9a08-fc3dbd5fef3c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FloatingRateNotesDue2019Member_574e10f9-6e7a-44b1-a4c1-2960e7636a5d_terseLabel_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2019Member_label_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2019Member" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FloatingRateNotesDue2019Member" xlink:to="lab_amgn_FloatingRateNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_c47dd446-31c5-40c9-8d7b-6144780560b7_terseLabel_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL and credit carryforwards</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_label_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards</link:label>
    <link:label id="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_documentation_en-US" xlink:label="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:href="amgn-20211231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:to="lab_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_82d0bd95-09aa-4de2-b45f-d145c88c8d9b_terseLabel_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc.</link:label>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_label_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_documentation_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember" xlink:href="amgn-20211231.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePrimeTherapeuticsIncMember" xlink:to="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9be9e4f1-6229-4f9a-adab-dab21ae98e50_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_abfa2a5c-8989-4ecb-834a-2151ca7d8785_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_85016eb7-3f9e-4192-90bb-a1203f14fc3b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6b36b23a-6343-40a4-aae1-348f4ae0d963_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d1b5771-3d81-4bb6-9749-1deeff2409ab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d8fa56ed-8104-42c5-8372-7eb67d39dd54_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_f64efaae-5e42-402f-bd42-844753d6f525_terseLabel_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_label_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminated_documentation_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeNotionalAmountAmountTerminated" xlink:to="lab_amgn_DerivativeNotionalAmountAmountTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_28990442-f75a-48fe-b566-80b6420c0576_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cd666845-7ac4-4a78-979e-7d702156ac6c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a88dccfb-b033-4900-bd2f-528e8ac7b699_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_a7232459-90ff-4625-9ea7-1f3ecb469243_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, number of annual installments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0a679116-d279-495d-a532-bef72a3df75d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_42fd63fc-6dbf-43aa-a9a2-608c9aad25d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_733f50e2-43aa-4f6c-98d0-0bb31c3c2be9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs with no valuation allowance and no expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_e07e2d45-6591-4117-98bc-94ace4b5aee0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_c4263529-aa16-43a2-9bfe-b87f1c2f39bf_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable [Member]</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_94269128-2cdf-40c9-bd2f-d9c646b27071_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_efba7cd6-f3ee-4fe3-859f-3f5172531829_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of complaints stayed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Complaints Stayed By The Court</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Complaints Stayed By The Court</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:href="amgn-20211231.xsd#amgn_LossContingencyNumberOfComplaintsStayedByTheCourt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:to="lab_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_76753213-9a6c-4898-b1af-d9ef5e14b041_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ee0b7822-adc9-42a5-8117-c5087eab7327_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bf132fbe-86b1-400d-822d-5266b57ee621_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_d62e1722-e7ce-4267-85a8-2c2b29fcade3_terseLabel_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average assumptions used and the resulting weighted average grant date fair value of performance units</link:label>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_label_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Performance Units Fair Value Assumptions [Table Text Block]</link:label>
    <link:label id="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:to="lab_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_f9fae863-ac5f-491e-8ce1-c407f63ebbf1_terseLabel_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of trial</link:label>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_label_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Length of Trial</link:label>
    <link:label id="lab_amgn_LitigationSettlementLengthofTrial_documentation_en-US" xlink:label="lab_amgn_LitigationSettlementLengthofTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Length of Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial" xlink:href="amgn-20211231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LitigationSettlementLengthofTrial" xlink:to="lab_amgn_LitigationSettlementLengthofTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_451ae114-f228-4184-9065-a7c2dd95161c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1a3e8ff3-62a3-4f47-9232-5f6a3ab36c54_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseMember_0d03e870-7960-4de7-9c9c-54a10fae0f1f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_78bd650b-88cd-4f12-ab61-e7f3c9dee0a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_652e12de-6771-4422-bbf7-7bf4c09504f9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_9305790c-ab2c-48e4-9ec2-c1c12d5acba3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends paid per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6cf0c004-ce73-4bcd-b015-ae54f83def6e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_dc3a6fb8-874b-4370-8234-95d24cd10d6a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_6ec9927d-f465-4bbf-a8d5-07368b7de263_terseLabel_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and accrued liabilities</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesDisclosureTextBlock_documentation_en-US" xlink:label="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:href="amgn-20211231.xsd#amgn_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_amgn_AccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_98a9a5e0-7ad5-44d3-bf6a-319c1673a8a5_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3c925881-0d33-4e37-b938-6142b987e8a2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fb7496c9-039a-4687-9496-b529816c6e41_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2f7e3b3b-0b11-4d0f-989a-bb7cc98c1ad6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_c631baec-b552-4c3b-b436-883af8a6e2fe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7b03d094-bcaa-4b91-9598-866719d0b490_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b7c2927-9d04-4661-8d69-6f9d876391fa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_42561b0f-74cd-4ff2-b24c-30c6a2ec400c_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, At-Then Current Interest Rates [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, At-Then Current Interest Rates [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, At-Then Current Interest Rates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAtThenCurrentInterestRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:to="lab_amgn_InterestRateSwapAtThenCurrentInterestRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_01da8393-3889-4a16-82ef-d248c3c97486_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6084e245-a506-4fc7-9d83-4b43729ffcd8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_53122b10-8296-4dd8-81c3-d8c342946776_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_e00ac4ce-3df1-4bf0-9bda-7661b996dd65_terseLabel_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_label_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_documentation_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:href="amgn-20211231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:to="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0c00562c-b415-42f1-8b2c-40c8d4732a04_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9003313f-ae58-401c-a370-10c18258aec3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1d0833b1-9916-48ac-a837-286917961742_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0eb86019-68bb-4d53-8f0a-1ad8d0d2cf35_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c94f1e0e-9fd4-4f49-8fd7-b2b44e5c6294_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_935a0a0f-fb4d-442e-811e-f40fef3c94b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2c051171-8f1b-4cfe-a83c-7d4065955def_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired_9f65f9b9-3ab8-464c-b762-04f65d444a7d_terseLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Inventory acquired</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Inventory acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:to="lab_amgn_BusinessacquiredassetacquisitionInventoryacquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_35563c1e-3235-4e20-b81d-4809f52f0a3a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_ed9262f6-5379-4d6e-bc6d-5023b6ebd6dd_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_06b2fc19-83ee-45f9-afa3-d3e252af9e22_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_7ab2a001-9196-4095-a24e-8e758c4f7555_terseLabel_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041 (2.80% 2041 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_label_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point eight zero percent 2041 Notes [Member]</link:label>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_documentation_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point eight zero percent 2041 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:to="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79662c27-f891-430d-b2a2-13709d8d4101_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_c1410de2-7733-40b6-8fe5-511294bb760c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RestOfWorldMember_ca21bd4b-9ba2-480d-87bf-1ec6d9a54c2a_terseLabel_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW [Member]</link:label>
    <link:label id="lab_amgn_RestOfWorldMember_label_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_amgn_RestOfWorldMember_documentation_en-US" xlink:label="lab_amgn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember" xlink:href="amgn-20211231.xsd#amgn_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RestOfWorldMember" xlink:to="lab_amgn_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_ec471e52-1ec5-427c-9ac1-87ee099c2675_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a8244591-78ab-4919-881e-448bf2398789_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful&#160;life&#160;(in&#160;years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c7127275-3d17-4814-8bb7-617501ab30e9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_12685ef7-18a3-4a5a-bd96-a3ec4af74571_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of challenges</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_label_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Challenges</link:label>
    <link:label id="lab_amgn_GainContingencyNumberOfChallenges_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberOfChallenges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Challenges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberOfChallenges" xlink:to="lab_amgn_GainContingencyNumberOfChallenges" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock_262f0630-0b6c-40f3-a414-dc4042da91fb_terseLabel_en-US" xlink:label="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments, policy</link:label>
    <link:label id="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments, policy [Policy Text Block]</link:label>
    <link:label id="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the policy for investments in equity securities that are publicly traded and that do not have a readily determinable fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:href="amgn-20211231.xsd#amgn_EquityInvestmentsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:to="lab_amgn_EquityInvestmentsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_8cbd2ed2-1164-414d-93ad-247a4be60bb9_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_902517c7-7280-4c40-94a3-33ab92cacd6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AranespMember_f1db5677-4fea-4e9a-baf8-16018d211e77_terseLabel_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp&#174; (darbepoetin alfa) [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_label_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_documentation_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember" xlink:href="amgn-20211231.xsd#amgn_AranespMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AranespMember" xlink:to="lab_amgn_AranespMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_bb566ced-cba5-4350-8bb6-bab03f671265_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_39bd15b2-cf95-405e-b53d-8525ee8feff7_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9c58c1ca-073b-425d-a543-1212b46f7299_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherNotesDue2097Member_b283d91c-44c9-4a71-8126-4ecbbf973d2b_terseLabel_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes due 2097</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_label_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_documentation_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member" xlink:href="amgn-20211231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherNotesDue2097Member" xlink:to="lab_amgn_OtherNotesDue2097Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_d88ca5fd-98e3-4a5f-a416-c57722459307_verboseLabel_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of identifiable intangible assets</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a350e3f9-42d1-43f2-ad9d-2ae36bf22104_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_7000e278-a8ef-4cb5-b187-a6d52ca7a1cd_terseLabel_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Axis]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_label_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Axis]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionAxis_documentation_en-US" xlink:label="lab_amgn_AssetsByDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssetsByDescriptionAxis" xlink:to="lab_amgn_AssetsByDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_a6a387cd-49ec-44e2-8959-a16f123eaaea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PR_64bee367-d5d0-48c3-a220-2b091e379fe5_verboseLabel_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Puerto Rico [Member]</link:label>
    <link:label id="lab_country_PR_label_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PUERTO RICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PR" xlink:to="lab_country_PR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_f44193f7-b381-460b-a98d-8145676f33a5_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury bills [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b313098c-1a4a-4f0a-a7a7-20395715cd1f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_45232698-6951-4591-8733-65476007c206_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative costs</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_4d5b7ba6-2808-425c-91a1-b98d6ff8ff1d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_1abe3912-99b3-4137-a50f-fb7fe5d23495_terseLabel_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.375% notes due 2037 (6.375% 2037 Notes)</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_label_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_documentation_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:href="amgn-20211231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:to="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_a288caa4-1795-433f-b946-1fa4324c64e3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_88290f56-51fc-4505-b5b4-bdf1479dcda4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_fcfefc67-3f12-4e8f-b269-f35178295bb0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approximate carrying value of the company's equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d6b9a985-e9db-48a4-91ab-f0055bd2e14c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e1bb5204-691e-47a5-86d2-1d68f1d12697_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_bd18b899-a4cb-425e-a771-48395b283f1a_terseLabel_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future rental commitments for abandoned leases</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_label_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_documentation_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:href="amgn-20211231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:to="lab_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_96e2a88e-46c2-45c0-97e7-e79e41811b8c_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_b70aa83f-1aba-4b93-9636-eed71b909111_terseLabel_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares added back for tax withholding on full value awards</link:label>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_label_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Added Back for Tax Withholding on Full Value Awards</link:label>
    <link:label id="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_documentation_en-US" xlink:label="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Added Back for Tax Withholding on Full Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:href="amgn-20211231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:to="lab_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_4725058a-3944-49b3-ae80-046e18d4231a_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_360fdd6e-d631-4457-bae7-25d86ded22d9_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9b735bb6-7118-41de-b90b-d22029312e64_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6414f393-f24f-4264-8941-06bb79255309_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3352f428-510f-418f-8d31-68fce94a4933_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_21c0f10d-bbeb-4a32-9741-5b2cf4ebe0ee_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_569f7141-642a-4620-bb57-d086ff65efe7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_5a8e7669-15d3-43f8-ac97-4efe8b357dfb_terseLabel_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.663% notes due 2051 (4.663% 2051 Notes)</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_label_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_documentation_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:href="amgn-20211231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:to="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fc978764-b501-44ad-a7ce-e00346cdfccf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ad957c16-9949-4822-a086-9f163ac46309_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7818c90d-615c-4c12-9c47-bd0fcb29c728_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherProductsMember_00ce93ec-41e0-4c2b-acd6-eba0712d877a_terseLabel_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_label_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_documentation_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember" xlink:href="amgn-20211231.xsd#amgn_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherProductsMember" xlink:to="lab_amgn_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bc4d3019-2c6a-4f55-ab23-7f09a717ab1a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_053d01a0-e0c4-4518-826c-92c0652d4936_terseLabel_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% 2022 euro Notes [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:href="amgn-20211231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:to="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96313e0d-46da-4509-953a-80f12fe813c6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dfd675e9-4cc3-4527-9a7a-f451f5776cb2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8ae8e2f0-edee-495f-be53-a1b13ac9db05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d1095dee-6e40-46fe-8214-475fc7919440_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_59bacfc1-909f-44ee-875e-00404ea9c0e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProliaMember_95106e51-9b07-46a7-a6a7-3fde4e0e38fd_terseLabel_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_label_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_documentation_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember" xlink:href="amgn-20211231.xsd#amgn_ProliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProliaMember" xlink:to="lab_amgn_ProliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_9a135539-1903-4839-a07e-dd3d486b529b_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_de85b117-5a17-4b66-9a0b-f571c19717b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5087757f-6e0d-459f-99b2-a288a21193f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_36a590b5-016f-44e6-815d-296571608c3c_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_e7b47c79-2928-4975-8e5f-4b08e5956bda_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_07855e00-9fd8-459e-8b9b-4642c84c7940_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_686ac9e5-f97c-4ee0-9872-3a14195cadbe_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_93048dde-079c-4125-9038-f832c9b3039b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_199258df-6327-4229-926d-5296f7f76f69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_4c3f66d4-ca13-4e14-9acf-6d1bfde89fd1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Gain Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_07d08d4c-eb12-440c-aa83-2fc22c371422_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1ba03c21-bbd9-40d2-a5be-3d2c80c8a364_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8406f6c4-6900-4762-91f0-9c0a5b341e67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_fefcd81b-9dc2-4550-9c35-4d2d457964ff_terseLabel_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:href="amgn-20211231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:to="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4c59cfdf-3d03-45ed-9e6e-0e3afe9d7ba9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_a1bfb592-ad16-4698-9a81-7100f9ab1089_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_dba47901-aa8e-41ba-968e-4774b91f0459_terseLabel_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% notes due 2020 (4.50% 2020 Notes)</link:label>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_label_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Zero Percent Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Zero Percent Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:to="lab_amgn_FourPointFiveZeroPercentNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_cd4be375-71e0-4a3d-859b-5a032d578b5e_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_920fb124-8e5c-47b2-ac79-3325741ec110_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_681a7849-83c4-4ae4-ad08-9f7439a04ddc_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dab8a340-3635-440f-a5d2-719826f3d9ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_74e565a8-65ba-4b44-933c-cf1a3fcb78a2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f204b1c7-d031-4419-90ef-4dafa1478352_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (Level 2) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_4e37cd7f-1849-4e26-91e3-bd82246a8bc0_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_63cd2ac4-bb9a-4afd-bbaa-c982f963e033_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_284c01d8-f577-4856-b02b-cf2c76c830ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_391e5132-56d8-42d1-a174-e44a4b0f1776_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_3d7e36e0-6f57-4032-a093-59286b72e04e_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_194c3f2b-df7e-4354-aa9e-d6778f2bde6b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation for basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_81fc2ca6-09ec-4735-a0e9-41bcb58b5004_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_eb2e362e-1d42-4178-9ef2-cbfb645aede5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_94e5f032-1a63-42fb-bbf8-777ddeb1f0bf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_2e991f1c-cf84-4660-ba24-4ccac1a2dc04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9f3801a6-83f2-4871-89a7-1dc4d0b570f7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_e1917ae7-5b7c-4c17-90cf-c3af6278fbd5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit settlements</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_62d8fde1-4e55-4b82-807f-a63422fc6463_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_408f0a3f-1721-40df-94d8-0698cecd7cdc_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_b020845c-18b4-45d0-a8f6-25311a55fe1d_terseLabel_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional term extension options</link:label>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_label_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number Of Renewal Options</link:label>
    <link:label id="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:href="amgn-20211231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:to="lab_amgn_LineofCreditFacilityNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ce933a61-0c9a-46c6-900d-f1a270268324_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_0a7a82ad-62d8-4ae9-a16c-60cec0a3f023_terseLabel_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns reserve</link:label>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_label_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Return Reserve Current</link:label>
    <link:label id="lab_amgn_AccruedSalesReturnReserveCurrent_documentation_en-US" xlink:label="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent" xlink:href="amgn-20211231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedSalesReturnReserveCurrent" xlink:to="lab_amgn_AccruedSalesReturnReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_9c76bf6e-83a6-4022-914f-51b41f935632_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f3571ecc-b7a1-466e-9998-dc7462257079_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_fb30bf21-dd71-4673-8afc-3a90ec3cd2b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9bd64e56-919f-4566-ae90-553901e7aed8_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49078568-4de2-4950-a3cf-98423920be38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_62a4386f-c359-44f4-9655-3fa6fa6f4306_terseLabel_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional period for extension of commitment term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_label_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Extension of Commitment Term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_documentation_en-US" xlink:label="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Extension of Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:href="amgn-20211231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:to="lab_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_1cadffc6-7829-400b-9695-ce27df185760_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_label_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Combined Worldwide Gross Revenues From Major Customers</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_documentation_en-US" xlink:label="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:href="amgn-20211231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:to="lab_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e718dcce-15e5-4210-954e-52d7d7d16272_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary information, components of lease costs, cash and noncash information on leases and other lease information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_7d4d92a5-b0b0-4551-9a06-78ae49270ff6_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2025</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_cfa3110b-7503-4cf8-a281-727963e47b52_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1664a4a6-fabc-4a80-b2e4-9de70eb547a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8b2516da-5223-4671-825d-feb6f64ed23e_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_81785afd-3d33-499d-8a6a-f3891d871b5d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_a08a87e0-60b0-4bf4-a8d9-e74a23ab6af9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e673c2ea-6eef-4b97-8ec6-2371166589c9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_6522da58-538c-4c70-8fd4-9f7bcb3e36ef_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_61ab35fd-e626-4599-9048-3e7cf916ec7a_terseLabel_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future lease payment</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_label_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount</link:label>
    <link:label id="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_documentation_en-US" xlink:label="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:href="amgn-20211231.xsd#amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:to="lab_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_3f2cb8db-ecb1-442d-a1eb-7d36bf82ec46_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-bearing securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_b519e14d-9d35-4e59-88d2-8caa2bb09722_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Change In Carrying Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:to="lab_amgn_EquityMethodInvestmentChangeInCarryingValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e5d89c83-98db-4d5f-87c9-ea8ee835d6db_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_e64523be-10cf-436a-a17c-2b522be7013b_totalLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining U.S. repatriation tax commitments</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:to="lab_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6f5956d7-e616-4d48-9244-c130c217cb15_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in the calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c9323a7-cda6-4824-9d4f-05f76d4dc1aa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (Denominator):</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_f6d0b7a7-c5b4-4f78-81e6-c1d51355ed32_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties related to unrecognized tax benefits recognized in income tax provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a87f085e-793c-4b48-8a7d-f6e13609ae15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's share of profits (losses) of related party</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_ad7f9b75-a107-4970-92b9-7d0e74d80382_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7b69846f-cf32-460a-97a4-2a2d9dde9c3e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MoleculeTypeDomain_b4365e7e-cbc3-4cba-aa00-cf90868d2b95_terseLabel_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:label id="lab_amgn_MoleculeTypeDomain_label_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:label id="lab_amgn_MoleculeTypeDomain_documentation_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain" xlink:href="amgn-20211231.xsd#amgn_MoleculeTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MoleculeTypeDomain" xlink:to="lab_amgn_MoleculeTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58048cd2-a959-467c-853a-1abc435fbd74_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_68de8abd-6ee3-40ae-b62a-43f785a3801d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_08d36cfc-adaf-40be-b441-f14d2081900a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_965461cf-cab6-4b54-8d9c-11f8163451b4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_01af8f4e-c1bf-4181-a5a8-d4165a78aad7_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cross-Currency Swaps [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_55b03195-2247-4dad-9ef8-865c4f40e9f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestment_2f16731c-0bf5-42f5-8191-14b68211a40e_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestment_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestment" xlink:to="lab_us-gaap_AlternativeInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_80ed1502-fa28-49ec-b9b6-081b2eb0ed7a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_f42ede2b-b51d-4d7b-aede-7df6d7b5d389_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RDTechnologyrightsMember_42d2be6f-2a61-4efd-a007-0993db10cdf4_terseLabel_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_label_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_documentation_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember" xlink:href="amgn-20211231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RDTechnologyrightsMember" xlink:to="lab_amgn_RDTechnologyrightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5ffb88f4-4a92-43e3-837c-48978f6a8c28_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80bba8bd-e0f7-407a-9665-c742d68a13a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4e0d2699-70f5-4af2-a8d5-157a4df743c6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_24b0958c-c7fd-43d0-958a-cff54fcb2744_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b47cbc3d-c850-4d01-b03b-5f9f7a75ce9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_dc889239-b417-415d-a91b-4383ef299c02_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Investments Acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Investments Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_b75c93cb-fbd0-465b-b454-243ebfb559fb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c5b8793a-1852-422b-94f1-b7e27ed5dcef_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c7acce34-4f8c-4960-9529-92885d197bc0_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_1ae1c402-4d6b-485d-9cee-398f744abb23_terseLabel_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_label_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_documentation_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax" xlink:href="amgn-20211231.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProposedAdditionalIncomeTax" xlink:to="lab_amgn_ProposedAdditionalIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_866af09e-3416-401d-91f4-36fc2af4d779_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% notes due 2026 (2.60% 2026 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_a26e2983-57b5-4af3-a89e-384475b480e8_verboseLabel_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.600% notes due 2026 (2.60% 2026 notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_label_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:to="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_abfa9856-54cb-46e0-b43c-24824b0c1a61_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_863b6670-5cb7-46e4-9b40-2d0499f5b877_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_11bfa165-e776-42cf-8308-75fbbdb5e134_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2d150bba-affe-4d38-aecf-d97a289cf602_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_1b118fb7-d5c5-475f-81fb-b6282663bb13_terseLabel_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:href="amgn-20211231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_950b168e-1848-49f0-9565-fc1850499ffe_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ac1524cb-c102-4d46-afd0-b81bce372e1e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_84a5f209-5cfc-4bd5-b4f1-6bb16605117f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) gains on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_da16af44-0e44-47c5-949a-4823ff6624cc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_46168321-f622-45f8-90e1-16210ee54041_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_9641c416-8fa3-45de-8e0e-4ead2b278c46_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2022</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtezlaMember_7ff213de-7d4e-4c92-af4d-ee7c6928929e_terseLabel_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla</link:label>
    <link:label id="lab_amgn_OtezlaMember_e5050312-3a8b-43f2-a7f5-dc6b10a398f5_verboseLabel_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_label_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_documentation_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember" xlink:href="amgn-20211231.xsd#amgn_OtezlaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtezlaMember" xlink:to="lab_amgn_OtezlaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_54874791-5fd6-4b59-af2b-a579c80f20d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_ee63de59-63f3-4293-a1cb-97db1bf98226_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_ebc7f3d8-ad0e-46d9-8d62-6ee5a51dbaac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac6f1042-d2f5-4984-970d-05c72c32355e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8378dee6-aa5a-4cc4-926d-a629b9d93a8f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_196f99b3-b9bd-4403-8dac-a8aa95695eb9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_45f92e76-a624-4910-b2af-03097ba529dd_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_6fd7494f-89a7-4fb6-9b48-7df7fd03584c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_5919a50e-3365-40bd-83ff-cfbcceb3ad8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f8062e2f-4422-4dbc-a4e8-7b78d08e68f0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_aa3824bb-4a0c-42de-844c-bb793e10f87f_terseLabel_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_label_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:href="amgn-20211231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:to="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e20ba116-0e78-415f-8e56-fff80eccad85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant&#160;date fair&#160;value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_91181104-639d-49f8-a92d-51b9dfe75077_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6a6baf7a-4d2b-4023-9cd9-7ca88eec1ab6_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_446a6fa3-f373-4f47-beb1-bb4ef98e351f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US [Member]</link:label>
    <link:label id="lab_country_US_4e627c14-0751-49f8-ba39-dcc7f36ba34a_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US [Member]</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c8cca549-819b-4b5e-96f0-aeaf5e3dde81_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues earned from major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_63f67e3a-a028-45de-a205-8ac69b418617_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ac6067f1-1959-4464-92d8-78247b310e4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainOnDerivative_45b5ae33-f3d8-42d2-9d05-7fe211695434_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainOnDerivative_label_en-US" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainOnDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_us-gaap_DerivativeGainOnDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_69141134-352f-4577-854b-ff7c81bcb9d6_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR [Member]</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d0b93a3a-a96d-4405-ab2d-474c71eab976_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_726d620a-d2b1-402a-93fa-6fb6bb8bbf43_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments to income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_34ef7745-3cb6-4238-8c26-2af93792717a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6a3822e2-dfdf-4304-af94-fcbd6fbcff6e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and Arrangements with multiple performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4911857e-521b-478b-b52f-a47c316fe1a3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bbcd632b-53ca-4905-9b78-99f7233644a7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for diluted EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3ad935d6-7b15-4b25-a8b9-5c4c84cdccde_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_48537709-2120-46e7-9888-c00c526b1c32_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_eae7ae26-02fd-42c8-8ede-5e5fff7d28e5_terseLabel_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc.</link:label>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_label_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_documentation_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember" xlink:href="amgn-20211231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NeumoraTherapeuticsIncMember" xlink:to="lab_amgn_NeumoraTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3d35fc76-2915-4627-b8cc-639119c37936_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_88a6b8aa-dd94-4ffe-90aa-1a3ef1debb24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b3a8af79-a09d-45f5-ac1c-8c99c21fd6ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3ab61d8e-752f-4bc4-a912-56344b198873_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_69b732dd-38f1-452b-8ed2-3bdc0240141b_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_687c0b43-c4b6-4c0a-a185-0a2aa4c4fd32_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_91331ed1-d51a-4e24-8603-5793cf947f69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_cdbef2e7-d60f-4084-8b4d-9461756ba756_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of interest rate and cross currency swaps</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fdcc08fc-1815-436a-acff-5f6290e10aef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_af4c1de9-13fc-444e-9c38-5f62e7ea9e39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_505bd740-0d59-46db-87df-b7d1efff3bd7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76cb940a-59e8-431a-b65c-f6f88dde6227_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3cd66c20-1590-4df9-90c4-fe8afe0653d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_24b9ca8e-0fed-4ecf-8d79-3b8629d4215f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_abdfd2a4-2ee9-4113-a8bd-d8e0545998e6_terseLabel_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payment</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_label_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone Payment</link:label>
    <link:label id="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_documentation_en-US" xlink:label="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Future Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:href="amgn-20211231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:to="lab_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ee3c738e-a2f6-44b6-b642-bb1cc1e80a47_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e9652fbe-b38e-4763-8f41-dd0ee609e331_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_fc78c9fc-c721-4408-b858-cbd086df086c_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Hedged Items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberofAffiliates_2e25caa0-3cbf-4c34-85a8-c8bfe5b647c8_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberofAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, number of affiliates</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofAffiliates_label_en-US" xlink:label="lab_amgn_GainContingencyNumberofAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Affiliates</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofAffiliates_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberofAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofAffiliates" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberofAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberofAffiliates" xlink:to="lab_amgn_GainContingencyNumberofAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit_0f9d1321-0e1a-4576-aef8-c2a3ed860338_negatedLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred credit</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Deferred Credit</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Deferred Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:to="lab_amgn_BusinessacquiredassetacquisitionDeferredCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_d163f2e8-1a42-49ab-a6de-f3652f2534f3_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% notes due 2040 (3.15% 2040 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:to="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_7cafa0b7-4ff5-4326-9798-caabf03e4a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_72ff6154-4642-46c4-997c-39dd7c89231c_terseLabel_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% notes due 2021 (1.85% 2021 Notes)</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_label_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_documentation_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:href="amgn-20211231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:to="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3e47e874-7d16-47cc-af54-6f745ae71b4e_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market mutual funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_e83a9a11-5ab6-4d9f-a8ad-de45dabc4661_terseLabel_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments, 2023</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_label_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</link:label>
    <link:label id="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_documentation_en-US" xlink:label="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:to="lab_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6167d7fd-8c44-487f-8952-3b99651644ce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b348e65a-3199-45f9-ad46-b3d8da1af7ba_verboseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_c0bf453c-2d5f-45db-b818-683e7e839068_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_610be6f5-b900-4d81-b0be-9fdef35af1f3_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e921e10c-1abf-4905-a0a3-4abadd928aa6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_acb1adfc-15a1-49da-ac18-9a1fbeeeaea8_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NplateMember_02cf5a7b-7e75-42c6-ae09-b8c588cb8ff3_terseLabel_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate</link:label>
    <link:label id="lab_amgn_NplateMember_label_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate [Member]</link:label>
    <link:label id="lab_amgn_NplateMember_documentation_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember" xlink:href="amgn-20211231.xsd#amgn_NplateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NplateMember" xlink:to="lab_amgn_NplateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3fb79a4a-1c27-478f-9eb2-82c91438c0a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_75bfaf68-7bca-4841-9874-dcee03e6571c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested or expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member_61872ee5-5f6b-4ddd-83be-24122fccab73_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.70% notes due 2022 (2.70% 2022 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member_label_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Percent Notes Due Two Zero Two Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenZeroPercentNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:to="lab_amgn_TwoPointSevenZeroPercentNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member_debea05c-bb98-4c00-af77-9f5ce86c4e11_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2019 (2.20% 2019 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:to="lab_amgn_TwoPointTwoZeroPercentNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_693c98b3-0749-4fd9-ad73-6744033711ff_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_a24aa5a0-c687-4129-bc79-602f9bb7b987_negatedTerseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_label_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Payments</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationContingentConsiderationArrangementsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:to="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_67348a48-da65-490e-a770-db330615e2eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized bond discounts, premiums and issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A280NotesDue2041Member_2a6c078d-d76b-446d-b4c1-5368005ce9cc_terseLabel_en-US" xlink:label="lab_amgn_A280NotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041 (2.80% 2041 Notes)</link:label>
    <link:label id="lab_amgn_A280NotesDue2041Member_label_en-US" xlink:label="lab_amgn_A280NotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041 [Member]</link:label>
    <link:label id="lab_amgn_A280NotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_A280NotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member" xlink:href="amgn-20211231.xsd#amgn_A280NotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A280NotesDue2041Member" xlink:to="lab_amgn_A280NotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_71bbc14b-77fc-432a-8242-33fca7eb7698_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3bdaef31-ee9a-4c72-809b-a0a7981c0f75_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_646b04e2-7987-4bf5-9628-b5d22be6bace_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5e3d57dd-0298-4667-9b57-6d3be73f9bef_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1d085b2a-5b73-4bd0-8c44-2e3175e828ea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f3234b53-ee99-4de4-ad79-d29db2777ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e83861eb-e396-47fa-ad76-36923de851f2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to nonvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_db3de11b-e5fa-4716-8b87-a84138542cad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_7eb0913e-dcb4-4ff7-b204-e4127b2adb22_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_798e0481-41b1-4ffa-8205-73f32478f658_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_6b9a2744-c302-4583-a50a-053eed047c2c_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product sales to major customer (as defined) as a percentage of total gross revenues</link:label>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_label_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Gross Revenues</link:label>
    <link:label id="lab_amgn_PercentageOfGrossRevenues_documentation_en-US" xlink:label="lab_amgn_PercentageOfGrossRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product sales to major customer (as defined) as a percentage of total gross revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues" xlink:href="amgn-20211231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfGrossRevenues" xlink:to="lab_amgn_PercentageOfGrossRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_88e48754-c4a0-4fbd-b30f-405d80d5c06d_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d89271e8-5cd8-4101-bad5-33f2e97406cb_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_e37cea47-917c-450d-bc96-466150e5761f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8bce0cf4-feaa-43bb-a797-beb5d4346291_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_318d80f5-0f24-4e89-9a37-cf015a330eef_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6521c327-c5be-45d6-8d0e-488b5dd51c9d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6388c178-f876-4e50-86c3-d9762055de09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_25adae35-d644-438d-8d6f-fce7d93d4647_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars [Member]</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_595d0278-07f3-423b-8ede-0a311f3e486d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_176a8137-307a-4757-a74a-8b3334b5dade_verboseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_0d271f5e-1d84-407b-ae34-a1f3ace5844a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_920b3c50-27ac-40c6-90b0-5b95a35f371a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_54103509-eb65-4f06-85fd-acb7e8c828b0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of derivatives included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_51b9657f-cfed-4c48-bde1-16c21bee506a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_939cba7e-c8d6-4a35-adcb-3355ed42875d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1f9a1da4-3b7a-42f2-9f09-4a46bea1ad1e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_92962cc7-3a5e-4b4d-ab16-12f465163f50_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_c957312a-c668-483d-b367-f38017f9e0dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in&#160;capital</link:label>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_ae6c38cd-4884-4997-95f2-efda00aa1529_terseLabel_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through three years</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_label_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_documentation_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:href="amgn-20211231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:to="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_75f8e902-cd9b-4608-903f-4ac5622022be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), vested or expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_3d74241e-f678-4033-aa7f-42afadd0747e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_d988ccf9-9e0a-405c-8eb0-0f9327663014_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5784febc-fe34-49c9-bb51-52acd29fca36_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, additional authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_d22aece4-51f3-4a7d-81ab-68767d509f22_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a893888f-dddc-4605-a75f-6663f84a3cb6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_cdcfc043-dfdd-4ad5-b460-c4551cb03d87_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gains</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:href="amgn-20211231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91c60d9d-fb8b-4199-969b-79c5f9b4e2c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_744fc145-2540-4e87-9332-8d8858913925_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6badaa32-b3e1-461a-9812-f4823f722ed0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bc799b12-cc47-4d88-bd06-206bec409f5f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income for basic and diluted EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cdc28f3e-4b12-4aa8-ade4-053d13346ee6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LaboratoryEquipment_506695ee-4b66-4d18-b2dd-f9fe2ee25083_terseLabel_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_amgn_LaboratoryEquipment_label_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_amgn_LaboratoryEquipment_documentation_en-US" xlink:label="lab_amgn_LaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of laboratory equipment, gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment" xlink:href="amgn-20211231.xsd#amgn_LaboratoryEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LaboratoryEquipment" xlink:to="lab_amgn_LaboratoryEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87f955a6-ccf0-4e28-9fd3-6d57c8035623_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_afa87f3a-613a-4b70-9228-3d0ba75f6edb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7ea14492-f688-4ac6-ab7e-45ef0673f5a9_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e76299fa-ac34-473a-ae93-d4b601e99e67_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_55c510ab-ed52-4c1a-ac9e-9fcb6a823174_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate contractual maturities of long-term debt obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5e8e8ed6-a91b-4704-bf19-4b7389718506_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_8c223840-0e6d-417f-806f-c53994e595b9_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers (as defined) accounting for more than 10% of total revenue</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_label_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Customers Accounting for More Than Ten Percent of Revenue</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_documentation_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers (as defined) accounting for more than 10% of total revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:to="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_fb22a8fc-837b-4166-9b6a-58ba0b7253a3_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_7128907b-9d02-48a4-979d-5ccad6a41ad6_verboseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair values of contingent consideration obligations</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_label_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:to="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_9578d3b4-f994-4fca-b05a-fb9396b08046_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_beeafd4c-e06c-492b-8396-1f4e23930660_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PerformanceUnitsMember_feeced54-19e1-4afc-bcba-6fefbefa6edf_verboseLabel_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units [Member]</link:label>
    <link:label id="lab_amgn_PerformanceUnitsMember_label_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_amgn_PerformanceUnitsMember_documentation_en-US" xlink:label="lab_amgn_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember" xlink:href="amgn-20211231.xsd#amgn_PerformanceUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PerformanceUnitsMember" xlink:to="lab_amgn_PerformanceUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_97aca657-5b77-450a-9221-a38bf5cd78cf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_be69fc5e-3b25-4fe6-8c9e-64c851a419b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_7f603ca0-9b7e-496d-acfe-7afe5fd7a06c_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_8893eb03-c890-4b87-a6ff-3e86b3dd6f2c_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_23ff62a1-81bd-4e83-9a2b-61b1a4644f44_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_805899fc-1c1f-4f88-b159-5c9e10f376ec_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe</link:label>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_label_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Net Amount Due from Customers Located Outside Domestic Location</link:label>
    <link:label id="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_documentation_en-US" xlink:label="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:href="amgn-20211231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:to="lab_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8c0db650-6e28-4363-8d56-45fa02e66d79_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_eb67ed46-9d47-440e-9548-33d38a29cd0b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cf53725b-56fe-4d77-ad0b-fa6a0fd610d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_b92e7d29-feae-4a40-a96a-6e44195fc955_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in fair value hedging relationships</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralExpense_0cb062b6-466a-41ba-996a-04e03452080e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralExpense" xlink:to="lab_us-gaap_OtherGeneralExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45b8fc15-2926-4262-a5af-ca24f75276b6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_51bb43d3-3e30-4a6e-adbc-f3b6871ae5d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_28b8d752-7835-4e89-bc02-8b974568461a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_2e0985e6-af63-4a16-8e8b-17c272a9cd15_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Partnership [Member]</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_48d8e28b-7ea9-4543-bee3-9b6f2e9b3476_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_40683b3b-8af7-401f-b414-f1ea99555bff_verboseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_f8767241-08b4-4b0b-aab2-eecd5a2cfcd1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_7338ac6a-9e7f-4e4e-bc71-b35962e0ab85_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_e16bbccb-ba86-4e55-b307-0c6319cf1087_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual commitment fees for syndicated, unsecured, revolving credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d2f9fa88-78bf-48d5-b006-d120d09ac10b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of units that vested during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91a507e0-66a0-4be5-8745-ab921aa045da_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d16b6f59-26f5-4def-8cfc-c6489b120843_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9b51c4e7-6d2f-4d5e-a581-e942eae130dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of unit (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_eb5a63ff-4188-4f92-be1d-507a3760391d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging adjustments on discontinued hedging relationships</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_79ee77ee-9fe9-45b7-908e-27ca8b66c21d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerOneMember_1cf1281c-f12f-4fad-9513-ca7611c3772a_terseLabel_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_amgn_CustomerOneMember_label_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_amgn_CustomerOneMember_documentation_en-US" xlink:label="lab_amgn_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember" xlink:href="amgn-20211231.xsd#amgn_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerOneMember" xlink:to="lab_amgn_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_cafb6afb-77d1-4c59-b7cb-a88236818ce0_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_label_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Combined Net Trade Receivables from Major Customers</link:label>
    <link:label id="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_documentation_en-US" xlink:label="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:href="amgn-20211231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:to="lab_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_6d8cffab-ae4e-41cc-97d1-898adda30f59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of vesting of restricted stock units and stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_ea2d4137-fda0-49a6-a0eb-960a1e6be47d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ad8ec680-d89a-4cc0-b604-24f261fcf2f7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_2bde7da4-9153-4105-a1d0-e0275132d8a1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_0aab7717-561d-4614-81c5-c3c1343f1a43_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers (as defined) accounting for more than 10% of gross trade receivables</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_label_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Customers Accounting for More Than Ten Percent of Gross Trade Receivables</link:label>
    <link:label id="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_documentation_en-US" xlink:label="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers (as defined) accounting for more than 10% of gross trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:to="lab_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f2e585b1-a6d3-4c0e-b216-3ad7bab006e3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_99a580a8-6e29-42af-b5e9-320521876a65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested or expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c60c03ad-d494-4539-a7cd-b4ab16788d7c_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33d72489-8099-4fcc-af57-47f4b2951a1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8fab5e83-3cee-44f3-ac69-a44fecae0479_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e077fb7-1192-4de7-a135-b3dbf670bd78_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bed317fe-3175-4c90-863c-d5c8d8d8875c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_77eae85e-c682-4355-877a-602435b29f41_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_436fc718-5f3a-4213-a389-1e5fd713d00a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eece0b74-7723-44ce-a82b-2a29f85a5877_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e097151-8066-4cd8-8371-9984208c3b07_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance unexercised at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_1c72cadd-776f-42a9-bd57-99390585f318_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares by which the pool of available shares will be reduced for other types of awards granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Common Shares to be Reduced For Other Types Of Awards Granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for other types of awards granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:to="lab_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4e1c822d-4d64-46b6-b48c-3cf4a7b16b93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_069aa54b-6a33-4483-b316-5a21074f69dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases not yet commenced lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_f3cdca58-150a-4703-a493-a4cf324219db_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8e471461-2666-4682-886f-a23ddbc393ef_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_5ea9ba84-80e7-4c79-9525-71734c090a8e_terseLabel_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_label_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</link:label>
    <link:label id="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_documentation_en-US" xlink:label="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:to="lab_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_e5b283db-8960-440f-a325-70f90e486a36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_2c2c36cc-b479-4b53-b279-8533350934f4_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment by geographic information</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_15bbba3e-8863-4fa1-9472-02e0c1a75edd_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_459c63b6-7c48-4cab-836b-873001e758ad_terseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contract [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_e2c9b957-9d58-49fc-9de2-abaa7b85750a_verboseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_label_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Swap Contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_documentation_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency swap contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CrossCurrencySwapContractsMember" xlink:to="lab_amgn_CrossCurrencySwapContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_659f1b00-a7a4-46e5-9076-38cceea62c0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:to="lab_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8c841e02-6e13-4192-b89c-e88c4cb22074_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47bae2b8-0b0c-4b3a-92e3-6f2f0fa77206_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_7cc03e54-6d0d-4468-8295-9f9fee4bd21c_terseLabel_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits filed</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_label_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Lawsuits Filed</link:label>
    <link:label id="lab_amgn_GainContingencyNumberofLawsuitsFiled_documentation_en-US" xlink:label="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Lawsuits Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GainContingencyNumberofLawsuitsFiled" xlink:to="lab_amgn_GainContingencyNumberofLawsuitsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_68c666e7-5490-4055-98e6-540b893442ae_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_396271e6-3966-49f9-8fb0-864c444d2965_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8287dfb6-dc3a-4b3e-823f-85d61ac39a84_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_81b4a970-381b-4200-8b94-9100a6274ffb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96ba1c49-af39-48bc-956f-5e887c9bd8c7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cecc7911-497d-4635-b151-f3c2b2e2cbf4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a8bd50bc-89a7-4161-a2ff-c819ac55f59f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_44a248ac-394a-4b88-b455-3d993acd4efe_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue by product and by geographic area</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_603b3af8-08de-4d72-843c-55065c97178f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_c321933b-14f3-4698-86c6-ff31ad7932dd_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of notional amounts and interest rates for cross-currency swaps</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:to="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_6fb50d69-ef63-4ab5-a39f-9d5944f18139_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense attributed to Retirement and Savings Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_100d05e7-efc1-4c61-9a6a-bf5c35d1f655_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_6551b466-647c-4523-b407-aa6d5efb641a_terseLabel_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.30% notes due 2031 (2.30% 2031 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_label_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_documentation_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:to="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c55b3189-3f7a-4d50-adcf-8fc0c4cbfe73_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_98f08a31-9e35-4c16-9d09-dae6519f4525_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2d2e9236-e030-43e4-a341-b55c21099c00_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_aeec4bb4-7188-42d3-b53a-dd6b44568320_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_2b5bda31-abcc-46fa-9435-b2dce95e08fd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_4427524b-c94f-44aa-8778-f79befce80dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_cb63d146-1828-46d6-81d4-98d3d830b7a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_f8d77454-2112-4f99-a2ea-ab46528d13d1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_e233d66e-29fe-423b-a0cf-442cf28edcc3_verboseLabel_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity under our stock repurchase program</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_label_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_documentation_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:to="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_f2546cd8-323f-4ecc-9097-457c1667aa41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AuditInformationAbstract_label_en-US" xlink:label="lab_amgn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_amgn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_amgn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AuditInformationAbstract" xlink:href="amgn-20211231.xsd#amgn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AuditInformationAbstract" xlink:to="lab_amgn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ca8cf8cd-1625-4bf1-a678-80d42dbbe151_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c31b9ab2-5ed3-4314-9538-f7631c162ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5de640fb-5144-4c12-92f8-63fb5c85aa7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_e7b8e3f9-1b4b-48ff-91c3-a6547b7ab2d9_terseLabel_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_label_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_documentation_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:href="amgn-20211231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:to="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a7835931-33df-40b8-ad09-cde5cff4351f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8e928eaf-89f5-4009-8a22-b78b1c623144_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3a57046d-051a-47fc-83ba-fe85ddb7b48f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f70a461-7179-4723-83de-9bd970ef2d77_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_1834c4a4-ac4e-42ba-ba32-652483d8da55_terseLabel_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_label_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_documentation_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:href="amgn-20211231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:to="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_d41a3f97-70e0-44a1-b1c0-1a536fae1709_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected total future rental income to be received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_08918ee2-fa19-472b-9a8d-40ea39086a87_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_Transactioncostsassetacquisition_c3e12567-3a0d-4ab1-a788-fd6a31bac1f1_terseLabel_en-US" xlink:label="lab_amgn_Transactioncostsassetacquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_amgn_Transactioncostsassetacquisition_label_en-US" xlink:label="lab_amgn_Transactioncostsassetacquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs, asset acquisition</link:label>
    <link:label id="lab_amgn_Transactioncostsassetacquisition_documentation_en-US" xlink:label="lab_amgn_Transactioncostsassetacquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs, asset acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Transactioncostsassetacquisition" xlink:href="amgn-20211231.xsd#amgn_Transactioncostsassetacquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_Transactioncostsassetacquisition" xlink:to="lab_amgn_Transactioncostsassetacquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6fef6bae-c076-4b43-b994-2743501e30fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_77556b4f-f8ea-42e0-b89d-a65db2efd3f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b3d5ccbe-ad26-4392-a9a0-6083e7019cec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual tax benefits realized from tax deductions from option exercises</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_c7d6f443-7374-4f59-84f2-40e660cf9aeb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_25d3642f-0f34-418e-ad68-72ec6b4431f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross-currency swap contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e45faf5d-d637-4019-8cda-c9675a502496_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_bef35139-5aa6-4a82-90c3-189238fdfb19_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_2426fecb-b800-475c-a5ec-4234e1afa9e7_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for each stock option granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Shares To Be Reduced For Each Stock Option Granted</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the pool of available shares will be reduced for each stock option granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:to="lab_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfNoticesOnProposedAdditionalTax_e3616a2f-7209-4fa3-b335-5cbc8492e041_terseLabel_en-US" xlink:label="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of notices on proposed additional tax</link:label>
    <link:label id="lab_amgn_NumberOfNoticesOnProposedAdditionalTax_label_en-US" xlink:label="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of notices on proposed additional tax</link:label>
    <link:label id="lab_amgn_NumberOfNoticesOnProposedAdditionalTax_documentation_en-US" xlink:label="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of notices on proposed additional tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:href="amgn-20211231.xsd#amgn_NumberOfNoticesOnProposedAdditionalTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:to="lab_amgn_NumberOfNoticesOnProposedAdditionalTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_764b0310-eb8e-4f39-bce3-443c97d68d0b_terseLabel_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions</link:label>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_label_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_documentation_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:href="amgn-20211231.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:to="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fdef5b82-35c4-461f-a94d-dcc9efe5e71a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_192c9c2c-1a13-41ff-8a11-f045e42c7765_terseLabel_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</link:label>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_label_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</link:label>
    <link:label id="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_documentation_en-US" xlink:label="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:href="amgn-20211231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:to="lab_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_20416ea3-2d31-4ec9-947e-e960a8b4a4ff_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under syndicated, unsecured, revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_28494ff7-4a0a-41d8-92ea-1033bef7bf5a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9cd2d298-ff05-4b19-85db-216f358d81b8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b799f372-b601-44b3-8204-e685623ab617_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_43f87f0f-887a-4445-a3d7-af6208f0b7f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2c6364bb-3596-4c30-9c8c-8102418c7117_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_71da8b87-fb09-4b17-ae52-6b6255ce1546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_72e6da5e-92c8-45fa-a891-4a5754e99732_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5d9da2bd-337f-482b-8545-42daa3023526_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of reclassification adjustments and taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cb72e149-5f53-4b93-87c7-87272e673784_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_3ff7ba49-c28c-472d-8ca1-1aca2af1bcca_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_91d07ab6-a934-42d9-915c-c756eedbcdec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2e99f735-5d12-48c6-9366-4884175b6d85_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8fe5f59a-3f3f-4ff8-8e1e-63aa5c70318b_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_157eeff0-5d08-4a3d-8e63-33cacee897d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f96b8b23-f5a8-48d2-a810-5d7027a6e45d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_ea6cccb8-76bd-46b9-be8b-675184991a4a_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:to="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_65e5bbde-d309-4a2c-adb2-dc62cb93e865_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_836d7efa-34a3-4228-b7d4-5a707d2127dd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_6554a739-c96f-4b9b-a51d-d795af9e96eb_terseLabel_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.10% notes due 2021 (4.10% 2021 Notes)</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:href="amgn-20211231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:to="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66ce12b1-e56a-46ec-9b44-5b9506ffc875_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f08b42bd-90b1-44cb-abf8-ba3f52042b11_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_5b3965af-f107-4798-84d8-e4a8fe6705dd_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to deferred tax liability</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_label_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities</link:label>
    <link:label id="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:to="lab_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_4167c382-bc88-4768-9c59-9a34e582dfad_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_2660da0b-0bf2-4014-b529-e6730340ebda_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_224cab5e-4811-4918-b9bb-1e2a15ee2049_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_cd43c9cb-f3eb-4e19-90e4-b51288b68cc2_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_label_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:label id="lab_amgn_InterestRateSwapTwoMember_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap, Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapTwoMember" xlink:to="lab_amgn_InterestRateSwapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_0e64f2f4-fddb-4763-a687-307001441651_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.65% notes due 2022 (2.65% 2022 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Percent Notes Due Two Zero Two Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:to="lab_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a3a3f7e5-1f71-49ef-a103-dda7ef9bcb79_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_71a33473-2d6b-4e78-a859-41cf03092bf6_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_e273af8f-43a0-4127-bd76-50d1a03bc6b4_terseLabel_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Domain]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_label_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets By Description [Domain]</link:label>
    <link:label id="lab_amgn_AssetsByDescriptionDomain_documentation_en-US" xlink:label="lab_amgn_AssetsByDescriptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssetsByDescriptionDomain" xlink:to="lab_amgn_AssetsByDescriptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_4e12e3e5-7ba5-45d9-afa4-5d60c75611ab_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition from acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d778857a-0851-4f59-9702-bcfc0850c19e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_f7ba6b6e-1caa-4a7f-a5a3-ef2d270ccede_negatedLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Noncurrent Liabilities Other</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Noncurrent Liabilities Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:to="lab_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_17729987-1bca-4cc5-9565-4d8722f95538_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_d1a1f2a0-05c1-4391-b712-2c36a45230b5_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:href="amgn-20211231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_b5c2b728-1183-4ba2-a21e-ce7fe3e5d059_terseLabel_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated blended statutory rate</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_label_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_documentation_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:href="amgn-20211231.xsd#amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:to="lab_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2a9e85c5-ab7c-447f-bed7-f4be3991f4c3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_a7fc4f2b-8e50-4bbd-8c40-b92b672c6ff7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest rate derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FixedEquipmentMember_9989fcbb-4e23-4b10-a30b-23ebffa4f387_verboseLabel_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment [Member]</link:label>
    <link:label id="lab_amgn_FixedEquipmentMember_label_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment [Member]</link:label>
    <link:label id="lab_amgn_FixedEquipmentMember_documentation_en-US" xlink:label="lab_amgn_FixedEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember" xlink:href="amgn-20211231.xsd#amgn_FixedEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FixedEquipmentMember" xlink:to="lab_amgn_FixedEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_317ebb20-a1ba-4489-b50c-db77ba01191d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8587ab15-aa16-486a-a540-1596c6a54b01_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_d20da493-6e9b-48ae-a4d1-88400e7d316a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_daf0fa79-cf13-4710-bda3-3964dc277c82_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties due</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_39375727-7767-47b1-b6b9-b45abe202df2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_043be370-14e5-4955-ba76-c9d02d4999cb_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_8d044636-6778-4e7a-806e-9e2053f57afc_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The NASDAQ Global Select Market</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_b1411829-4f56-4d06-bc78-99213130cd76_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_715b5267-bf13-43ee-b6d2-db495242265b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ff36a2b5-ba2f-4c76-be54-59a7e9d08ead_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_79e34adb-71a3-4306-b927-74a785d404fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e9728ac0-3f4c-4b2f-acdb-6a849215e905_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7f1eb9b0-25b6-4a58-953d-cd8c82003fa2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_9defc2de-3ce7-4b83-b989-c8b30ecfba88_terseLabel_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial commitment term of each bank which is a party to the agreement</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_label_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Initial Commitment Term</link:label>
    <link:label id="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm_documentation_en-US" xlink:label="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Initial Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:href="amgn-20211231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:to="lab_amgn_LineOfCreditFacilityInitialCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_d8a9418c-66ad-4b5b-be62-5d7ac30f59e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits, Puerto Rico excise tax</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_041830ef-98b9-4211-b19b-e5dafbdb119a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_23479f45-a732-4642-8532-0831e7760f60_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_6b6491f8-f3e8-4e87-97ca-93c9317e0231_terseLabel_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% 2019 Euro Notes</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_label_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Euro Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Euro Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:to="lab_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EnbrelMember_af2872cf-b069-4f95-a645-c3882fefb23f_terseLabel_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel&#174; (etanercept) [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_label_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_documentation_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember" xlink:href="amgn-20211231.xsd#amgn_EnbrelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EnbrelMember" xlink:to="lab_amgn_EnbrelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4af9cb1e-233c-4ca9-885b-7ce6f773682e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_a9f392d5-71ab-45a2-9c50-d023dd340fff_terseLabel_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.15% notes due 2041 (5.15% 2041 Notes)</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:href="amgn-20211231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:to="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b961b50d-31d8-40f8-9038-6da1df8de826_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_3b95bd45-7de2-45b5-ac81-bfd702752378_terseLabel_en-US" xlink:label="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired assets, weighted useful life</link:label>
    <link:label id="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Assets, Weighted Average Useful Life</link:label>
    <link:label id="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_documentation_en-US" xlink:label="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:href="amgn-20211231.xsd#amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:to="lab_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30bc6f9e-cf4e-4b17-a30b-99f67f06cff3_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f77b8d2f-441a-4ce0-a3b2-8cd3647d4d22_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8c1f24ea-6e00-43d6-b947-5d49c5c1113f_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_b3d2b61b-da98-42e5-aad4-e00d6700f663_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_85ed0afa-b127-4ef5-92f2-6767aee24354_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4dd3ad5e-b475-47c2-afa3-4e311c9e7440_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense, pretax</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_7cb639ef-39d4-4dc4-9fbc-01b81d7c777b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_679d5c63-7acc-4a04-a2d5-ca9c6ac4944b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e42289b7-62b5-4da9-a45a-d69d709611e4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization charges associated with property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_089c8135-948c-49f8-81c7-76a836dc15aa_terseLabel_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_label_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_FloatingRateNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_FloatingRateNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FloatingRateNotesDue2020Member" xlink:to="lab_amgn_FloatingRateNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_17723ce8-30fe-4193-9c04-479f81b11df2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_f60f0026-bb0d-4b4a-a9dc-328958038f58_terseLabel_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales deductions</link:label>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_label_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Deductions Current</link:label>
    <link:label id="lab_amgn_AccruedSalesDeductionsCurrent_documentation_en-US" xlink:label="lab_amgn_AccruedSalesDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent" xlink:href="amgn-20211231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedSalesDeductionsCurrent" xlink:to="lab_amgn_AccruedSalesDeductionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f3760ff-8036-4caf-adc7-c4597937d9e0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0d04ab46-7021-40d6-81ed-e83e485b54d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9e1cd491-3f87-438c-88e2-749a345c49d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ac156474-7eb6-4690-9fcd-1399bf75b90c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_028ec53a-598e-4c41-bb93-7f03953574f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1097fb9c-742c-44b3-b903-2d0d9aa8113f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_38d30d56-a008-43ab-bf01-7e640e4106eb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_81d812e6-0f7e-4e1d-aa7d-8b4c760cd685_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards, valuation allowance</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_4b7e05ce-4412-40b4-b120-0fe2d2ee6c2d_terseLabel_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.20% notes due 2027 (3.20% 2027 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_label_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_documentation_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:href="amgn-20211231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:to="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BeiGeneMember_9531e6c5-1c04-4d47-bf35-67e27a928d61_terseLabel_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene</link:label>
    <link:label id="lab_amgn_BeiGeneMember_label_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:label id="lab_amgn_BeiGeneMember_documentation_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BeiGeneMember" xlink:to="lab_amgn_BeiGeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_0355b487-e987-467c-91fd-c4c079e85703_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_794b1eaf-51ee-497c-a64b-78133a724637_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_339d827e-c352-4be1-8e58-56f6fbf13886_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_85c87aac-1126-44ea-8088-7437034019df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ee3cfa3f-2390-4461-9217-8bfb36a81b59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, unexercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_72738c6a-15e1-40f8-8743-fa658affb9d4_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2027 (2.20% 2027 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:to="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5e267eff-d042-4a66-9fab-65982b9be4f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards available to reduce income taxes</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_18659a87-7339-49b7-89e6-beda10f617cd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_3351c346-fd51-40d0-83a3-8923a3dc0f30_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0abfa2e4-71bb-438b-9b40-625386129401_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_58fc2e58-8e57-4f48-bebe-dfc9845313b0_negatedLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Accumulated Amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets accumulated amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:to="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_65e10eb6-d826-411e-8d82-68c1b012e9f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4ef9c7a5-0ed7-4958-87d0-50ee02649402_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bb54b878-77b0-4929-852e-66f29b998d5e_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software [Member]</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NeulastaMember_faac0ca2-8cad-42cf-9599-36b4bf1b3a2a_terseLabel_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta&#174; (pegfilgrastim) [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_label_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_documentation_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember" xlink:href="amgn-20211231.xsd#amgn_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NeulastaMember" xlink:to="lab_amgn_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_64710ac6-02b5-471e-9e73-83e523270c76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_d0acde22-b0ec-491a-b022-7a75617788ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of stock-based compensation expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_de430ed4-8bf2-46f4-9260-25e056ba1ae7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapDomain_0b0c0ab5-f290-4789-9028-c595c343e1ca_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Domain]</link:label>
    <link:label id="lab_amgn_InterestRateSwapDomain_label_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Domain]</link:label>
    <link:label id="lab_amgn_InterestRateSwapDomain_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapDomain" xlink:to="lab_amgn_InterestRateSwapDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_c1faa9db-e778-482c-9550-5bdef859afb8_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing rights</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c2bca98b-f030-4304-88c6-689654e87ce7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred benefit:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_640b8a81-e198-4467-805f-62b3464d3c44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_91d42ccd-e8cc-4ddf-8940-5c4f260e104a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8dd0a982-c91c-409d-8084-4c226445d1a3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_50469a44-e8c7-46a5-8f8e-cad2d4569235_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_2e2dc889-0f35-4312-a81a-9e4056eb934b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3db65ffe-549f-495e-8412-e2b40c14ba36_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period of stock options from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a43d24d3-698d-4c04-bf93-bc15d9ba4efe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ece3b338-dc97-43dc-bdea-611bd09a09e3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dbc4e851-f7c9-4fb6-b547-dd1e21d29dfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_ee3d72b9-6b6c-46ef-85b3-2e646187eb90_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_4d0989ba-9408-488f-a8c2-9abeaa69649c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_a7984e4c-7b13-4e5b-9e8a-885d7ad13270_terseLabel_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% notes due 2020 (2.125% 2020 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_label_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]</link:label>
    <link:label id="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_documentation_en-US" xlink:label="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:to="lab_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_acc3725a-352a-43fa-8303-f8d3eccf6b28_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0413006e-07b6-4281-be40-ab65bb9d244e_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21132399-b69c-4840-bc77-1c71e4f47195_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7d52c0da-a93a-4423-bf9f-53ab0e14177f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3c73ce25-23ea-402a-b390-d5a2232c0dab_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3a7edc2e-66c9-4d78-8ec4-b38d006df00d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_98aab2a9-49b0-4347-a15b-5bb1a9e2a7b4_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d7462553-5c11-4bd8-a2a8-9f48e692a8f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_4b1bd188-4e6f-43fe-99f2-d8a352c35683_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_8d646688-4277-40c2-b44a-e161d3f5eba2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_813e6b72-0d09-4181-bd3b-171cca68ce63_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4fd45d87-66b3-4583-bbe0-61bf1a3589c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_9bf64f58-c18d-4ca8-a253-7cab208a1c9b_totalLabel_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_label_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_documentation_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:href="amgn-20211231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:to="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3673268f-0873-49c1-9355-d7ccf1ca5524_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1fe54ab9-af5e-4fed-9937-5d55027ce05e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b86734d2-3f69-4f57-bda1-eb3b29fd3607_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_85d9afe5-f67f-4b39-bad3-201cfe485311_terseLabel_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on uncertain tax positions</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_label_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:label id="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_documentation_en-US" xlink:label="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:href="amgn-20211231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:to="lab_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_fa4a1bc8-0960-46ec-8816-143ea9864799_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_c3cceb32-4f62-44a2-8301-7b7afe37afd8_terseLabel_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% notes due 2043 (5.375% 2043 Notes)</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_label_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_documentation_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:href="amgn-20211231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:to="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_fcbb23bf-9f36-461f-ace1-a7bf66398dae_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_66fa94d7-5977-4a82-a9ae-10f42ccc95b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ce1f3e5e-fae8-473f-a92f-e45fdd7b312f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d1d30bee-2f62-4313-8af6-caad60cb355f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_c482dca0-f910-45bd-8ddb-2180b111ac48_terseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_b5174066-6dfb-4a83-ad4b-0a0521f49255_verboseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% 2029 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_label_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_documentation_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:href="amgn-20211231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:to="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_c07e475c-7848-4614-ad8b-6fc9cb44b9dd_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% notes due 2025 (3.125% 2025 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_label_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_documentation_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:to="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_e7aa3c17-2d0f-4d96-adef-99e3145dbc94_verboseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_d691c7d4-a9e9-48d3-bc0b-dbda54c2f27a_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired and liabilities assumed, net other assets and liabilities</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_label_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:to="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9aca82ba-fbb3-49bc-9a3b-380a76d92a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_e396893f-af34-4a21-9af3-d98a00bb792e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_5f9c6fa2-712e-4b57-b4bb-8c99c0bfbb56_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes [Member]</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_UpFrontPayment_03cecedf-2026-4304-a83b-e18690f29d7d_terseLabel_en-US" xlink:label="lab_amgn_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment</link:label>
    <link:label id="lab_amgn_UpFrontPayment_label_en-US" xlink:label="lab_amgn_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment</link:label>
    <link:label id="lab_amgn_UpFrontPayment_documentation_en-US" xlink:label="lab_amgn_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UpFrontPayment" xlink:href="amgn-20211231.xsd#amgn_UpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_UpFrontPayment" xlink:to="lab_amgn_UpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4c6bcdb8-1ece-49bc-af11-8331e520e787_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_fb66c11f-c6de-4c44-a4fb-9a2a5eebc48b_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d930df23-481f-49cd-90c3-f18cdd0d8275_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_27b28253-1940-495e-9b59-18d9580180a2_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2020 (2.20% 2020 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:to="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d2dd6cce-24fe-4d49-a63d-0e67160bde46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average exercise&#160;price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_65e02efb-85ee-4bda-96e4-925baecb1b59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of amounts of income and expense line items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9705ee6d-0dbf-49b9-9359-cc909184fbf6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeInstrumentTerm_bc7c1ee2-fa82-4cb9-a35a-5b73ddfb385d_terseLabel_en-US" xlink:label="lab_amgn_DerivativeInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Term</link:label>
    <link:label id="lab_amgn_DerivativeInstrumentTerm_label_en-US" xlink:label="lab_amgn_DerivativeInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Term</link:label>
    <link:label id="lab_amgn_DerivativeInstrumentTerm_documentation_en-US" xlink:label="lab_amgn_DerivativeInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeInstrumentTerm" xlink:href="amgn-20211231.xsd#amgn_DerivativeInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeInstrumentTerm" xlink:to="lab_amgn_DerivativeInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_27882f1f-7ef4-4a4a-9b99-1be48e14532d_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_78e7efcf-ae30-456d-be09-4fd2851116f4_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_980887be-d3c7-428d-aada-49623ad4c0ab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8344f64f-dc8f-4807-9049-a36b42609c53_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_24a349e8-e8fc-4c71-a8f1-6473ab26be10_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-bearing securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_cee93ec4-5b46-41f1-8cf0-2b78d24c2bed_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional consideration due contingent on certain milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3ebb32ff-35f7-44cf-acc2-b1357fb5df17_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_488fbea5-819f-495a-89e5-81f8913c0c3d_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of lawsuits filed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits Filed</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuitsFiled_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:href="amgn-20211231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:to="lab_amgn_LossContingencyNumberOfLawsuitsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_cc0e28af-6f7d-44c9-a9d0-f0b360bd2e34_terseLabel_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes)</link:label>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_label_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_documentation_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember" xlink:href="amgn-20211231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A300NotesDue20523002052NotesMember" xlink:to="lab_amgn_A300NotesDue20523002052NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d5cf8744-f000-4ae9-bd54-c2f35cd4d538_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_e81ca6ca-91e7-44bb-baa0-94019da8735b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_a6ae482b-dd3b-4561-8a10-8d37e73c2ed9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_4716d1a8-8982-48b0-8e0c-026a712a1796_verboseLabel_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets/Other assets [Member]</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_label_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Noncurrent Assets [Member]</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_documentation_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets/other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:href="amgn-20211231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:to="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_671c12aa-f094-4b51-bda5-1b0b4efe515c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ca5adbf0-7854-4e44-8343-bdbde3aac8c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_fe2e60a0-c304-4453-85a6-3821b6626af6_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d168daf5-797a-4318-8831-23f2a3418d69_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_455a1bde-81fc-4f27-a3a1-88ba76f635e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_587fb928-6667-4792-b780-a8eb5c0fffd3_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_338c6f0d-5424-4d2a-ac3c-b6f8f6cc6434_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_eb619b1d-5e4b-4a73-b646-49c2da94c33e_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% notes due 2023 (2.25% 2023 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:to="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dd6bcb08-53dd-4e4e-8d54-b4b4532f555d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_5d76bc71-2dfa-4962-9de2-0450748b6ada_terseLabel_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_label_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_documentation_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember" xlink:href="amgn-20211231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SensiparAntitrustClassActionsMember" xlink:to="lab_amgn_SensiparAntitrustClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_5906ba1c-8334-4765-ae95-9cee027d2276_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.65% notes due 2022 (2.65% 2022 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_label_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixFiveNotesDue2022Member" xlink:to="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_d8b72dfc-470e-4321-903b-dfc083f08d1e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Numerator):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_07b2a45b-386f-4ad1-a08c-c49e9779f175_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member_6733d460-c858-4c10-8261-a659783ecb05_terseLabel_en-US" xlink:label="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.70% notes due 2019 (5.70% 2019 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member_label_en-US" xlink:label="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Zero Percent Notes Due 2019 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member_documentation_en-US" xlink:label="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Zero Percent Notes Due 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenZeroPercentNotesDue2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:to="lab_amgn_FivePointSevenZeroPercentNotesDue2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_52000924-29fc-450e-9572-c7b99d31029d_terseLabel_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_label_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_documentation_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:href="amgn-20211231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:to="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_5893dfb4-bbaa-437b-a13c-d64c6e63cdc0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MarketingRelatedRightsMember_4945a1bf-8880-4c4f-acb7-b2e54b986348_terseLabel_en-US" xlink:label="lab_amgn_MarketingRelatedRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Rights</link:label>
    <link:label id="lab_amgn_MarketingRelatedRightsMember_label_en-US" xlink:label="lab_amgn_MarketingRelatedRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Rights [Member]</link:label>
    <link:label id="lab_amgn_MarketingRelatedRightsMember_documentation_en-US" xlink:label="lab_amgn_MarketingRelatedRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember" xlink:href="amgn-20211231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MarketingRelatedRightsMember" xlink:to="lab_amgn_MarketingRelatedRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_448765d2-b059-423c-bfed-4e848c794e60_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_f46eba6a-34f8-4582-bdfa-f7172a37cb4d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_4803c326-5272-42fa-b1d0-9cdea31ee91e_verboseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_403e8181-2a7e-4e19-a6a2-fad3df9cfa15_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bca60e43-59d6-4952-b0ec-b38474f9e902_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_d491974b-d6eb-46d2-b3f7-dd07053c12b2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards available to reduce income taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_418d78d4-13a5-4b1a-9689-9913c6a36827_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca5f2b14-5057-4ea0-b333-c37b02f68f89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c70009e8-187d-47e9-a80d-a824cc8f112b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_39544c20-2e17-437a-ab10-dd8f407f29f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_41ea58aa-c7d2-4bdf-9ef3-2510950ccd93_terseLabel_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_label_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_documentation_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:href="amgn-20211231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:to="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_c4395a24-b0a0-4842-a430-20c184bd6f7e_terseLabel_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.563% notes due 2048 (4.563% 2048 Notes)</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_label_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_documentation_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:to="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_27482f03-c39d-4d4a-89df-879ec7318f6f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd11cea7-9d23-4ebe-bc30-8611f700145a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for basic EPS</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_fceab3c1-38b8-4839-a2fc-e228566669a9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_73e61efb-1c0e-46b4-9f5b-de7785e25cfa_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_a3766c85-990f-4ae3-a0d5-89bf9b6b2231_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_aed85249-5d2a-4e24-a2c0-aa6add59d329_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_59c8ebdd-a3fd-400d-af41-6e09c071bf3b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_cee33f1f-87bb-42e7-aa58-106c4059d0af_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs [Member]</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_3336fcdd-604e-44c9-a963-2953ebcda861_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ead6949a-078f-4473-8488-7581876a83bf_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3f790b47-fc71-424b-9aa3-257085777a88_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_344baa01-9dde-4e7d-bb63-a3ef2201df28_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_60a88f1b-5f11-4a34-bde2-033e190da952_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Financial Support to Investee Contractually Required, Amount</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Financial Support to Investee Contractually Required, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:to="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_2bad37b5-b4e7-48cd-b5b2-3654832f6459_terseLabel_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2030 (2.45% 2030 Notes)</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_label_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_documentation_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:to="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_1f05d647-48b7-4dc8-af12-46c098d686b1_terseLabel_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of common stock available under the plan for future grants and/or issuances (in shares)</link:label>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_label_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Common Stock Available Under Plan For Future Grants And Or Issuances</link:label>
    <link:label id="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_documentation_en-US" xlink:label="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of common stock available under the plan for future grants and/or issuances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:href="amgn-20211231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:to="lab_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_9ce6ed13-836d-4112-9db0-10ced2569b54_terseLabel_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% notes due 2040 (5.75% 2040 Notes)</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:to="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_57e3cf03-e263-4d21-acab-9acd6a0376ce_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost recoveries</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0dd5c81b-7f25-45a3-8536-12104b015796_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KyprolisMember_11fa4309-5c8c-4330-99d5-ffdc13c10b06_terseLabel_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_label_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_documentation_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember" xlink:href="amgn-20211231.xsd#amgn_KyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KyprolisMember" xlink:to="lab_amgn_KyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_de097abc-1b3e-4cd0-87ab-75e8fbfccbe0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_44d21c3f-7bb5-45db-a29c-e1fdfc65d0d2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_080bf432-0cff-4a94-9128-80f7425abedd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities payable [Member]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesPayableMember" xlink:to="lab_us-gaap_DebtSecuritiesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_58d83477-9a99-4ac0-bb02-89ed52e9e083_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_10ef4f1c-f62a-4be0-86b4-d6636b7d2103_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to carrying value of intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_6ccf28e9-2621-4078-b7c3-b49cd98af1b9_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d248562d-203c-4369-938f-edaeba043e08_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_57295140-8bb4-4bb2-87d6-0aacf10742b9_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, by Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_422470ec-d4db-4fb3-8f8b-7539255916ef_terseLabel_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption period without payment of make whole amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_label_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_documentation_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:href="amgn-20211231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:to="lab_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c8598725-bafd-458f-a30a-8e06548f6dcb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5b1cd35-ae70-4db1-8c0e-2614482ceb15_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_bdf902b6-d8b0-4f72-aa9b-ba49c445d9be_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25ef9683-d85c-4cf3-a586-1cec1719aa16_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6a0d01d3-7430-41e5-84af-a887d0cc60b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_82cbc713-9941-4736-a6d5-f9b08106f6ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581fe53c-fd23-4774-bd8f-659e3aae9e0f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_56004089-6753-46a1-973e-6e9e344cf65f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_a82e03bf-69e4-42ff-bbd8-5c5727bd6925_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% notes due 2024 (3.625% 2024 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6853e7e7-cadb-43b1-a204-480c78e11f9d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_d658806c-c0e8-482e-973b-d9421762badc_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_867884e0-3cb2-4bda-af32-364a8e592672_terseLabel_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of stock-based compensation expense recognized in the Consolidated Statements of Income</link:label>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_label_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Stock based Compensation Expense [Table Text Block]</link:label>
    <link:label id="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:to="lab_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_75f0acb2-bd06-4481-bc4b-728e5b1b3388_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_a49a76d4-8688-4217-9947-7a0cd6d4361b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Member]</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_522f6272-6960-407f-ac95-798853249dd9_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3266c18f-2969-47c1-b1c9-a34bbf7250f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerThreeMember_c382aaa0-8e16-45dd-a770-d979ed195f9a_terseLabel_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_amgn_CustomerThreeMember_label_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_amgn_CustomerThreeMember_documentation_en-US" xlink:label="lab_amgn_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember" xlink:href="amgn-20211231.xsd#amgn_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerThreeMember" xlink:to="lab_amgn_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_0d505433-525e-4b57-be58-6040fa9ec55f_terseLabel_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% notes due 2022 (1.25% 2022 Notes)</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Notes Due Two Zero Two Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:href="amgn-20211231.xsd#amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:to="lab_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2d14086f-4a89-4cce-988b-fd005766d807_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_fc079e82-2231-4c0a-af6a-88961fd66c3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_21163339-f9c2-43cc-9ea5-0d307ff85a66_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e7f058ca-4141-4ab7-afaf-55507b50eef0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_36db2aa0-1621-4cf0-a301-6a4f74baec49_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of time hedged in foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_0819488d-6e69-4057-83ab-3c778b32f320_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4ef4ff6f-b1e4-4bd7-bd15-f8542c0a24c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values and the fixed contractual coupon rates of long-term borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2095fdcf-4b53-45b0-9bf1-987fad76838e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6ac05dc5-c5d9-4c36-a3fc-1c31e8b11d65_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_12cb836a-913f-4485-bf9c-b25e16af29ad_terseLabel_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_label_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_documentation_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:href="amgn-20211231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:to="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_b5d8f9a9-4d99-426c-9706-55d19fcbf563_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_12ea74c7-10f3-4cc3-94f5-0d44a17fa69f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93bacb8d-c738-41e4-8d73-4290451abfc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ee244b20-cde6-47a5-851e-baf665856f6a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_80ec19ad-3ba4-4ef6-a319-aff2dc8f8490_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_1f1998a9-3482-4b03-80a5-f2a91a290455_verboseLabel_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments liabilities fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:href="amgn-20211231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6157cc9b-7185-4360-a85f-0cdb2d3bbbdd_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9be83e70-a169-4718-aecb-7a4254ca5174_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_18a38a28-1dba-4b56-80e9-847f90bcd308_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c4c96cc7-e535-4b0c-8186-7f21b422b08d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_9fad0851-22f8-4b0b-be11-c9d038f2d38b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_54e99991-6c8a-41c2-8c09-d716b8770c7a_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_5b2d77b4-423a-4a6b-9a23-951001faf052_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_1e3bcef7-72a4-45ba-9faa-b9496c357487_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A165NotesDue20281652028NotesMember_d505bc7b-7d81-4a20-a19c-171c9bac37eb_terseLabel_en-US" xlink:label="lab_amgn_A165NotesDue20281652028NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% notes due in 2028 (1.65% 2028 Notes)</link:label>
    <link:label id="lab_amgn_A165NotesDue20281652028NotesMember_label_en-US" xlink:label="lab_amgn_A165NotesDue20281652028NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% notes due 2028 (1.65% 2028 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A165NotesDue20281652028NotesMember_documentation_en-US" xlink:label="lab_amgn_A165NotesDue20281652028NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% notes due 2028 (1.65% 2028 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember" xlink:href="amgn-20211231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A165NotesDue20281652028NotesMember" xlink:to="lab_amgn_A165NotesDue20281652028NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_da76be8b-aac4-4d83-98e6-700b2ba9ff53_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_6a3d1efb-d3ae-48bc-a541-3d7ab916cb9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income before income tax, domestic and foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1aa3ea1f-0626-4bfc-b592-c6ff4c167f7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f1a86d4-a327-4dad-bfcf-f21e9c07de4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_335c7d78-a5a9-468d-9ee1-88e77080ac47_terseLabel_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment [Member]</link:label>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_amgn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_amgn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember" xlink:href="amgn-20211231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LaboratoryEquipmentMember" xlink:to="lab_amgn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d1d9caff-a8d3-4731-be9e-6e0f69e8a258_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_55c4c898-a866-4fa2-912f-a079d6613d6b_terseLabel_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D technology rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_label_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Research And Development Technology Rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_documentation_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired research and development technology rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:href="amgn-20211231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:to="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a98b906c-0cff-4cb1-aa91-ebf217f6e8de_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b4259109-f52f-45a3-b1dd-7c4f889dbdaa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_769d73ab-3535-472c-aa18-0535848c25bd_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_ead26ba5-ac9f-4ac7-89b4-b7ed9f5c914f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amounts</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FavorableContractMember_be31f657-a52f-4c8a-8f4c-7cf857765f15_terseLabel_en-US" xlink:label="lab_amgn_FavorableContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Contract</link:label>
    <link:label id="lab_amgn_FavorableContractMember_label_en-US" xlink:label="lab_amgn_FavorableContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Contract [Member]</link:label>
    <link:label id="lab_amgn_FavorableContractMember_documentation_en-US" xlink:label="lab_amgn_FavorableContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FavorableContractMember" xlink:href="amgn-20211231.xsd#amgn_FavorableContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FavorableContractMember" xlink:to="lab_amgn_FavorableContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_87e484ee-06f5-434a-b690-ec1b416430f2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_InterestRateSwapAxis_c2ff623e-a9de-47d9-9721-908ab584e088_terseLabel_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAxis_label_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:label id="lab_amgn_InterestRateSwapAxis_documentation_en-US" xlink:label="lab_amgn_InterestRateSwapAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_InterestRateSwapAxis" xlink:to="lab_amgn_InterestRateSwapAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AMG340Member_64267dff-81dc-4d93-91b3-d5854f9f665c_terseLabel_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340</link:label>
    <link:label id="lab_amgn_AMG340Member_label_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340 [Member]</link:label>
    <link:label id="lab_amgn_AMG340Member_documentation_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member" xlink:href="amgn-20211231.xsd#amgn_AMG340Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AMG340Member" xlink:to="lab_amgn_AMG340Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3a4cf89f-7c11-47bb-b2c0-fdd4dbf8e66d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CommonStockFairValue_19da2b50-7a9d-46d4-a86b-2d35535ded8d_terseLabel_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of our common stock on grant date (in usd per share)</link:label>
    <link:label id="lab_amgn_CommonStockFairValue_label_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Fair Value</link:label>
    <link:label id="lab_amgn_CommonStockFairValue_documentation_en-US" xlink:label="lab_amgn_CommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue" xlink:href="amgn-20211231.xsd#amgn_CommonStockFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CommonStockFairValue" xlink:to="lab_amgn_CommonStockFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299252f-5e42-4a57-9dcf-ac66e68f49c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_ba9d6677-2d68-4d36-aa69-e98d3896f5c8_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. repatriation tax commitments</link:label>
    <link:label id="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:to="lab_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d809bab4-1703-440b-a506-75afc5e5e276_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_d193ba20-738f-4f15-baad-b5e6e9307515_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which the grants of equity instruments vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ba0f5c6f-6a84-4174-8855-cb6fee28dd12_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b3e30de2-2544-4f51-b019-b59afd5a7665_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash&#160;flow hedges [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AbandonedLeasesMember_71cea0d0-8528-483a-8414-9db2e0bc5020_terseLabel_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:label id="lab_amgn_AbandonedLeasesMember_label_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:label id="lab_amgn_AbandonedLeasesMember_documentation_en-US" xlink:label="lab_amgn_AbandonedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abandoned Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember" xlink:href="amgn-20211231.xsd#amgn_AbandonedLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AbandonedLeasesMember" xlink:to="lab_amgn_AbandonedLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TeneobioIncMember_52814c33-914f-4715-995d-1ed89590694d_terseLabel_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio, Inc.</link:label>
    <link:label id="lab_amgn_TeneobioIncMember_label_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio, Inc. [Member]</link:label>
    <link:label id="lab_amgn_TeneobioIncMember_documentation_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember" xlink:href="amgn-20211231.xsd#amgn_TeneobioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TeneobioIncMember" xlink:to="lab_amgn_TeneobioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_294885c2-20cb-4d72-9089-2bf40b48058a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AssembledWorkforceMember_295a8dba-0fac-4b22-9ea0-4d64192caf9c_terseLabel_en-US" xlink:label="lab_amgn_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce</link:label>
    <link:label id="lab_amgn_AssembledWorkforceMember_label_en-US" xlink:label="lab_amgn_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:label id="lab_amgn_AssembledWorkforceMember_documentation_en-US" xlink:label="lab_amgn_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember" xlink:href="amgn-20211231.xsd#amgn_AssembledWorkforceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AssembledWorkforceMember" xlink:to="lab_amgn_AssembledWorkforceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_ca62748c-c815-49f1-b648-877b5a53263c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_285d7ec7-8761-40a5-a504-75699faff345_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_160c71a5-dc7c-46b2-ac2a-93b7b9324606_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CustomerTwoMember_d3525126-78d9-48ec-819b-ecdde3d80adf_terseLabel_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_amgn_CustomerTwoMember_label_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_amgn_CustomerTwoMember_documentation_en-US" xlink:label="lab_amgn_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember" xlink:href="amgn-20211231.xsd#amgn_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CustomerTwoMember" xlink:to="lab_amgn_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4167ad14-c93d-49f8-b1cc-15e250d73a9b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesGrossCurrent_2617f584-8aaf-48cc-9fd2-58be422c0d78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate partner receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesGrossCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Gross, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:to="lab_us-gaap_OtherReceivablesGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_9522b1a5-6805-43ce-8335-49503c1f89f2_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16302e0d-45a6-48d0-974a-52f50707dafc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5534efc7-ed7e-46fd-85a9-09fb9c42a39f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_88caa385-6752-45ab-a620-88c2dd6c00f8_terseLabel_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue payment term</link:label>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_label_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Payment Arrangement, Term</link:label>
    <link:label id="lab_amgn_RevenuePaymentArrangementTerm_documentation_en-US" xlink:label="lab_amgn_RevenuePaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Payment Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm" xlink:href="amgn-20211231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RevenuePaymentArrangementTerm" xlink:to="lab_amgn_RevenuePaymentArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_5f534d3e-bb62-4671-b512-97b844aaf1db_terseLabel_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issued for each performance unit earned</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_label_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Common Shares Issued for Each Performance Unit Earned</link:label>
    <link:label id="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_documentation_en-US" xlink:label="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issued for each performance unit earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:to="lab_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_529db5b6-1046-42d2-8baa-32fbee5d3dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7415bb50-0250-4523-86f8-301a6036d3ea_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_464958bb-5701-4ff1-8cca-1f6cd06042a9_terseLabel_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper, maximum borrowing capacity</link:label>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_label_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Borrowing Capacity Under Commercial Paper</link:label>
    <link:label id="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper_documentation_en-US" xlink:label="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Borrowing Capacity Under Commercial Paper Program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:href="amgn-20211231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:to="lab_amgn_MaximumBorrowingCapacityUnderCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_4b58365d-30bb-4325-af15-0817969c863a_terseLabel_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest-bearing securities [Member]</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_label_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short Term Interest Bearing Securities [Member]</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_documentation_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest bearing securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:href="amgn-20211231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:to="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_38293ee2-3c70-4d97-84cf-e5bd6b7c366a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_fa3e7c59-383c-4fce-a5f3-b28209840b1d_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro [Member]</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FixedEquipment_c2157eca-acc5-4ef0-b9f3-3af73ffcff68_terseLabel_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:label id="lab_amgn_FixedEquipment_label_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:label id="lab_amgn_FixedEquipment_documentation_en-US" xlink:label="lab_amgn_FixedEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment" xlink:href="amgn-20211231.xsd#amgn_FixedEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FixedEquipment" xlink:to="lab_amgn_FixedEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a37bcde8-923b-4479-a6c4-bbebca378a0e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_0d61ceb2-1c25-4ae3-9747-a5c1648e5c4e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d5225ca3-6c64-4046-9d97-ddde96480f3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_d25d7000-e045-4ac9-a2ac-32a001ecfd05_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_16fa053b-8e81-4429-8440-137b2a03336d_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f01250e2-0e5b-47bd-9df0-e74da0461ad4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_b4009815-fa64-4f30-986d-82e884bca9f7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_7d468399-3aa9-4922-a839-a18c1923c292_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising cost</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_96910651-e708-4914-a5fb-762f5b3eca4c_verboseLabel_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/Other noncurrent liabilities [Member]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities Other Non Current Liabilities [Member]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/other non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:href="amgn-20211231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:to="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_dc122f37-876d-48fa-91a2-7d1d134e29fd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeBasisSpreadOnVariableRate_321442f9-1bf4-44db-b64f-c4f30abf07f3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DerivativeBasisSpreadOnVariableRate_label_en-US" xlink:label="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:to="lab_us-gaap_DerivativeBasisSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_1b488124-5ab5-47ab-a3bf-d1ceaeb3fd42_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% notes due 2022 (3.625% 2022 Notes)</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_66a7fa6b-e7ee-468e-883f-774e80287000_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_f8bafd1f-aa23-427d-99fc-9a0d4dca8fa5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_7b1468ca-a5d1-43d3-8423-c1340f5f1657_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_26353526-a922-40d9-b77c-6e04a4594bfc_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_26371676-3d0d-45fd-854f-473aa1e91ddd_verboseLabel_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_label_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earning Per Share [Abstract]</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_documentation_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earning per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:href="amgn-20211231.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:to="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_8040010d-f3ed-45e8-b03a-2fbd178ab0aa_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_a2b7d2f4-b1f2-4b04-a8dd-907f76c32cdd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_170ce53b-5c69-445a-8bae-6a2a431cbf4c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9e9b4778-9508-4891-83d8-089f59cda833_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_dceef51e-e7d9-4bf1-9585-1a82368145e1_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_760d05f9-0bc2-42f8-ac1d-0bf033c2e20b_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_d7122080-524f-4996-8b3b-8f2d0bb023c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_9232de00-2b53-44bb-815a-f5b0ea19417b_verboseLabel_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross currency swap contracts [Member]</link:label>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_label_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency and Cross Currency Swaps [Member]</link:label>
    <link:label id="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_documentation_en-US" xlink:label="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross currency swaps.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:href="amgn-20211231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:to="lab_amgn_ForeignCurrencyAndCrossCurrencySwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee492e82-08ca-42fc-be02-15e23d86abdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>amgn-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2bb320c8-0f12-4641-8309-e0606e56f5e9,g:0e6120fc-59ff-4bff-bbf3-39bc007e06fc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/Coverpage" xlink:type="simple" xlink:href="amgn-20211231.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8cc26d2e-5c5d-4ea5-9f15-d390f8d14d22" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cc26d2e-5c5d-4ea5-9f15-d390f8d14d22" xlink:to="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1ce7546b-7ff0-4669-89dd-0867449373d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1ce7546b-7ff0-4669-89dd-0867449373d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ce7546b-7ff0-4669-89dd-0867449373d0" xlink:to="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5467ef04-6207-4f26-bc68-4a729a6e1d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:to="loc_us-gaap_CommonStockMember_5467ef04-6207-4f26-bc68-4a729a6e1d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_2fd44069-3e63-479d-8ef3-9ca2bfc6df7b" xlink:href="amgn-20211231.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5ee2526c-30d3-4530-a7b5-eed32b960211" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_2fd44069-3e63-479d-8ef3-9ca2bfc6df7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_87f8a3ac-4859-4208-b627-7aa53733d766" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:to="loc_dei_EntityListingsExchangeAxis_87f8a3ac-4859-4208-b627-7aa53733d766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_87f8a3ac-4859-4208-b627-7aa53733d766" xlink:to="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_785742e6-ff17-4f67-9a04-b2dc68521ebd" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:to="loc_exch_XNGS_785742e6-ff17-4f67-9a04-b2dc68521ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_2ce9d136-67d8-43c5-b789-3f91877cbf39" xlink:href="https://xbrl.sec.gov/exch/2021/exch-2021.xsd#exch_XNYS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_02ad2437-f043-4753-ac1c-a69b886f2af2" xlink:to="loc_exch_XNYS_2ce9d136-67d8-43c5-b789-3f91877cbf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9765286d-5797-4c77-bdf2-0b5043956576" xlink:to="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_25b8dcf2-352a-4c59-b36d-9c1ee6387c1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentType_25b8dcf2-352a-4c59-b36d-9c1ee6387c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_39f5cad8-06f6-46e1-96bf-db2fa5f336a6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentAnnualReport_39f5cad8-06f6-46e1-96bf-db2fa5f336a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e1849ffc-57a5-497a-b662-94633568fe3c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentPeriodEndDate_e1849ffc-57a5-497a-b662-94633568fe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e9a19639-9cd9-49ba-8f3e-5c6e9413f714" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentTransitionReport_e9a19639-9cd9-49ba-8f3e-5c6e9413f714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7a75ee24-51b7-4d8a-b405-84fe3b96b6f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityFileNumber_7a75ee24-51b7-4d8a-b405-84fe3b96b6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_62adedcb-94df-4b74-b6f1-787fa6b3408c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityRegistrantName_62adedcb-94df-4b74-b6f1-787fa6b3408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fada973b-4e8f-4eea-8b83-d1417efc62b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fada973b-4e8f-4eea-8b83-d1417efc62b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7ee34009-a6c7-4711-b074-7d1b5d0423d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityTaxIdentificationNumber_7ee34009-a6c7-4711-b074-7d1b5d0423d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ac6dc3af-409d-4782-9f11-ab0d668b03bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressAddressLine1_ac6dc3af-409d-4782-9f11-ab0d668b03bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b9035bf8-9c0f-444b-8f26-b0bcbe6b6d55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressCityOrTown_b9035bf8-9c0f-444b-8f26-b0bcbe6b6d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ca5bd6b3-6cfd-43d9-b71a-f7d55a095ea1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressStateOrProvince_ca5bd6b3-6cfd-43d9-b71a-f7d55a095ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_279085da-7c82-40f2-bd16-a65e4552ca76" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityAddressPostalZipCode_279085da-7c82-40f2-bd16-a65e4552ca76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bc818aab-7d8e-40de-a8d3-e191a5dc355e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_CityAreaCode_bc818aab-7d8e-40de-a8d3-e191a5dc355e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3fd6cd03-e4eb-4d34-938c-849fbc2638c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_LocalPhoneNumber_3fd6cd03-e4eb-4d34-938c-849fbc2638c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_66dda346-8764-4be7-b1a8-4d5f326abb7f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_Security12bTitle_66dda346-8764-4be7-b1a8-4d5f326abb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_565226d9-7e40-4e4e-874b-83b8e7946dee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_TradingSymbol_565226d9-7e40-4e4e-874b-83b8e7946dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a78cf963-3f15-467c-8159-3b3733a050a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_SecurityExchangeName_a78cf963-3f15-467c-8159-3b3733a050a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5e3f2e66-2a15-4c06-a5ff-ed466f14e08d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5e3f2e66-2a15-4c06-a5ff-ed466f14e08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_faa63083-02ad-4bae-9d39-ec014c807760" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityVoluntaryFilers_faa63083-02ad-4bae-9d39-ec014c807760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1b1992c5-d3e3-4f30-a685-6b7136cbcb3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityCurrentReportingStatus_1b1992c5-d3e3-4f30-a685-6b7136cbcb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c15e3ee5-e70b-4c3b-b23f-19a408eb1f13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityInteractiveDataCurrent_c15e3ee5-e70b-4c3b-b23f-19a408eb1f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6528ac10-d7a7-48d3-8214-8386bdba6eb4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityFilerCategory_6528ac10-d7a7-48d3-8214-8386bdba6eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e6f21932-3714-4a69-b3aa-84f7e688623d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntitySmallBusiness_e6f21932-3714-4a69-b3aa-84f7e688623d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5fbd9933-d86e-4ca1-a711-660883a2a778" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityEmergingGrowthCompany_5fbd9933-d86e-4ca1-a711-660883a2a778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_75afa9c3-d32c-4fdd-b84d-059e2e9fb675" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_IcfrAuditorAttestationFlag_75afa9c3-d32c-4fdd-b84d-059e2e9fb675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_611cb501-4ac6-45a1-bcfc-f8baa3b7a43d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityShellCompany_611cb501-4ac6-45a1-bcfc-f8baa3b7a43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e5bdbb40-390f-4fc6-a191-101e42b18b2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityPublicFloat_e5bdbb40-390f-4fc6-a191-101e42b18b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fc93206c-9904-4c40-9f1f-5839ff78985a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fc93206c-9904-4c40-9f1f-5839ff78985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_02abbc98-cdaf-42ad-a750-23c8634f5687" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_02abbc98-cdaf-42ad-a750-23c8634f5687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_33503841-562b-43ff-bc41-9cdce146c385" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_EntityCentralIndexKey_33503841-562b-43ff-bc41-9cdce146c385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eb9568e7-0d17-4124-8f93-826d55e54892" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_AmendmentFlag_eb9568e7-0d17-4124-8f93-826d55e54892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b796845a-3342-4a58-8805-3c9f279eced8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentFiscalYearFocus_b796845a-3342-4a58-8805-3c9f279eced8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5a56867d-c2d1-4fd0-a8e3-1f779f19cb2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5a56867d-c2d1-4fd0-a8e3-1f779f19cb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7d2bbb0e-65e1-47ef-86b7-d1af1be48999" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_071dc530-89c6-46f3-9565-93d554bc76de" xlink:to="loc_dei_CurrentFiscalYearEndDate_7d2bbb0e-65e1-47ef-86b7-d1af1be48999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AuditInformation" xlink:type="simple" xlink:href="amgn-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AuditInformationAbstract_63a16c68-9885-46f1-8293-775037ed85c3" xlink:href="amgn-20211231.xsd#amgn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_e82afe76-902a-4963-bef2-78d5e04c98dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AuditInformationAbstract_63a16c68-9885-46f1-8293-775037ed85c3" xlink:to="loc_dei_AuditorFirmId_e82afe76-902a-4963-bef2-78d5e04c98dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_b2153a08-f0a6-4554-a095-2ebcea0c571f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AuditInformationAbstract_63a16c68-9885-46f1-8293-775037ed85c3" xlink:to="loc_dei_AuditorName_b2153a08-f0a6-4554-a095-2ebcea0c571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b555718e-c643-45d0-976f-c6d678e621a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AuditInformationAbstract_63a16c68-9885-46f1-8293-775037ed85c3" xlink:to="loc_dei_AuditorLocation_b555718e-c643-45d0-976f-c6d678e621a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_55b8e63d-36fe-41c6-8c1e-650e5c81a151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a301329d-0704-4ebe-a77f-9f5ef3870874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_55b8e63d-36fe-41c6-8c1e-650e5c81a151" xlink:to="loc_us-gaap_StatementTable_a301329d-0704-4ebe-a77f-9f5ef3870874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a301329d-0704-4ebe-a77f-9f5ef3870874" xlink:to="loc_srt_ProductOrServiceAxis_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2c3dd73a-5227-4b9b-ab69-4c54d7b3ce4d" xlink:to="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_43d73175-52c4-40dd-855c-a2abf87cbfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:to="loc_us-gaap_ProductMember_43d73175-52c4-40dd-855c-a2abf87cbfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ca21ce29-c975-4973-a6b9-faad71b44a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e054bbbd-76cf-43e0-8b24-84f30a5984a3" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ca21ce29-c975-4973-a6b9-faad71b44a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a301329d-0704-4ebe-a77f-9f5ef3870874" xlink:to="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2476c3d9-7724-4953-a462-0787bad036bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_RevenuesAbstract_2476c3d9-7724-4953-a462-0787bad036bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d4653ca7-5328-42ea-a867-b552c66dbb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2476c3d9-7724-4953-a462-0787bad036bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d4653ca7-5328-42ea-a867-b552c66dbb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_abf93727-2538-496b-9c05-af25abfe9238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_abf93727-2538-496b-9c05-af25abfe9238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e0ded7d0-0bc9-449d-8d9a-fba087f3659e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e0ded7d0-0bc9-449d-8d9a-fba087f3659e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_214e838e-56b0-4936-ba58-9be8696a113e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_214e838e-56b0-4936-ba58-9be8696a113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a1e346a-fc0f-4fab-b397-384650afd047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a1e346a-fc0f-4fab-b397-384650afd047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralExpense_4ba1fe1a-c394-4bb8-83fd-60c433414280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_OtherGeneralExpense_4ba1fe1a-c394-4bb8-83fd-60c433414280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dda0aa7b-c53a-4d40-982c-2a05f1132feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ac5bfc48-4b70-4309-b60d-2c894735b0fe" xlink:to="loc_us-gaap_CostsAndExpenses_dda0aa7b-c53a-4d40-982c-2a05f1132feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be0ad2e5-4151-470d-b30a-68799f00810b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_OperatingIncomeLoss_be0ad2e5-4151-470d-b30a-68799f00810b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6e939856-7bbd-4407-aa65-523fbb0c5e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_InterestExpenseDebt_6e939856-7bbd-4407-aa65-523fbb0c5e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fa3dc9be-9680-478c-8c97-2981025aeac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fa3dc9be-9680-478c-8c97-2981025aeac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dfc6775e-71fe-40ec-93d1-637e95a24e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_dfc6775e-71fe-40ec-93d1-637e95a24e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d632c58b-58f7-41aa-a7b6-fc762920023e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d632c58b-58f7-41aa-a7b6-fc762920023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76149588-b2a3-4792-bb40-7ddf43267ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_NetIncomeLoss_76149588-b2a3-4792-bb40-7ddf43267ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7e2d7668-9808-4e9c-9336-917ef7ada78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:to="loc_us-gaap_EarningsPerShareBasic_7e2d7668-9808-4e9c-9336-917ef7ada78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_735b0cd7-5bf3-4595-8fd9-c2a0656dadd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_437acc5d-75bb-4fab-ac76-b2d601448882" xlink:to="loc_us-gaap_EarningsPerShareDiluted_735b0cd7-5bf3-4595-8fd9-c2a0656dadd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1736a0f-1221-4acd-b26a-97ee31b2854d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3cd37e65-ac2b-4afc-aaff-973ce9693ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3cd37e65-ac2b-4afc-aaff-973ce9693ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89cf3bbb-8caa-4ff9-97b8-e79c8f0f467a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_790b09a2-4d12-40d1-874c-2b492bec5e3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89cf3bbb-8caa-4ff9-97b8-e79c8f0f467a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2a1b5ce-2aba-4029-8f1c-b5fea7c1831f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cdd1069d-848c-4db8-a5bf-9281470b17ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2a1b5ce-2aba-4029-8f1c-b5fea7c1831f" xlink:to="loc_us-gaap_NetIncomeLoss_cdd1069d-848c-4db8-a5bf-9281470b17ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61217c24-352a-457c-b522-b249d68921ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2a1b5ce-2aba-4029-8f1c-b5fea7c1831f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61217c24-352a-457c-b522-b249d68921ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1ee9a862-2a6b-47d1-b8d3-532233dcd74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61217c24-352a-457c-b522-b249d68921ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1ee9a862-2a6b-47d1-b8d3-532233dcd74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_dd669c7b-8dd0-4c38-b899-12364d47fadb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61217c24-352a-457c-b522-b249d68921ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_dd669c7b-8dd0-4c38-b899-12364d47fadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2c948711-e413-4801-9f76-1162968e5508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61217c24-352a-457c-b522-b249d68921ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2c948711-e413-4801-9f76-1162968e5508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_1a438b50-24af-4f4c-b024-ec8af0b03c10" xlink:href="amgn-20211231.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61217c24-352a-457c-b522-b249d68921ad" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_1a438b50-24af-4f4c-b024-ec8af0b03c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ef4ba572-33c6-493f-ab46-327799ae9f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_61217c24-352a-457c-b522-b249d68921ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ef4ba572-33c6-493f-ab46-327799ae9f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_75a7cc8e-8cf1-4d0a-872e-4117519b2c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2a1b5ce-2aba-4029-8f1c-b5fea7c1831f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_75a7cc8e-8cf1-4d0a-872e-4117519b2c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_669431ec-bf5f-454a-b6d3-cc8c752ff31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_669431ec-bf5f-454a-b6d3-cc8c752ff31d" xlink:to="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3c3a505-25a8-45a6-9246-3b0e1ca3f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3c3a505-25a8-45a6-9246-3b0e1ca3f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_173d259e-369a-4da1-8b64-93ee6497e0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_173d259e-369a-4da1-8b64-93ee6497e0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2c4ce0db-5fdb-4998-858c-628dcf1d1fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2c4ce0db-5fdb-4998-858c-628dcf1d1fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d6637aa6-af9e-4594-bae7-18544abb1181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:to="loc_us-gaap_InventoryNet_d6637aa6-af9e-4594-bae7-18544abb1181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5e53953f-5f49-4dc8-91fa-755e2ef2121e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:to="loc_us-gaap_OtherAssetsCurrent_5e53953f-5f49-4dc8-91fa-755e2ef2121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ea44e74e-4d90-4990-949e-87a8c4bc4542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d7d1f3ce-dfb9-4815-a8ed-cfe15952675d" xlink:to="loc_us-gaap_AssetsCurrent_ea44e74e-4d90-4990-949e-87a8c4bc4542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b7d4e7ec-1eae-4c2c-8c43-6ee63e0177c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b7d4e7ec-1eae-4c2c-8c43-6ee63e0177c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64b940c9-f951-4362-8e96-ebd0fffae62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64b940c9-f951-4362-8e96-ebd0fffae62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b80a5a49-eea5-45ae-961f-22f718710c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:to="loc_us-gaap_Goodwill_b80a5a49-eea5-45ae-961f-22f718710c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_512b1bd1-fc93-4e96-9a40-20728a19cde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_512b1bd1-fc93-4e96-9a40-20728a19cde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a9b51468-edbb-4cb5-89e6-e50c24705ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_af54bbb6-edf3-4cf3-94af-6ae31bf289a7" xlink:to="loc_us-gaap_Assets_a9b51468-edbb-4cb5-89e6-e50c24705ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_669431ec-bf5f-454a-b6d3-cc8c752ff31d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_40f93f59-dc83-414a-ac0f-73ebd0d61a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_40f93f59-dc83-414a-ac0f-73ebd0d61a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3ca39fd9-b2bf-4b8f-b711-4275b86408f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40f93f59-dc83-414a-ac0f-73ebd0d61a6b" xlink:to="loc_us-gaap_AccountsPayableCurrent_3ca39fd9-b2bf-4b8f-b711-4275b86408f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_177b513a-31f0-4f0c-a9e4-51b7f5fad1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40f93f59-dc83-414a-ac0f-73ebd0d61a6b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_177b513a-31f0-4f0c-a9e4-51b7f5fad1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5f4e36dd-0c0d-47af-ad56-0151baeeb466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40f93f59-dc83-414a-ac0f-73ebd0d61a6b" xlink:to="loc_us-gaap_LongTermDebtCurrent_5f4e36dd-0c0d-47af-ad56-0151baeeb466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e20ea5e8-5745-41ad-8dd4-ca545304e1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40f93f59-dc83-414a-ac0f-73ebd0d61a6b" xlink:to="loc_us-gaap_LiabilitiesCurrent_e20ea5e8-5745-41ad-8dd4-ca545304e1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d6b5d7e3-dd0c-4716-b6e8-d6adf9409dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d6b5d7e3-dd0c-4716-b6e8-d6adf9409dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_399f8060-4928-485e-ae5d-4b3317673ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_399f8060-4928-485e-ae5d-4b3317673ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_24e14e81-750e-4d37-9060-b8440851c0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_24e14e81-750e-4d37-9060-b8440851c0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cb87f194-297f-4dfa-953e-66bc81e961f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cb87f194-297f-4dfa-953e-66bc81e961f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5cabb48e-9f06-4f6f-9728-f82011d14b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5cabb48e-9f06-4f6f-9728-f82011d14b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_0c82c12d-b399-4ec1-9116-17ba57b73311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5cabb48e-9f06-4f6f-9728-f82011d14b0b" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_0c82c12d-b399-4ec1-9116-17ba57b73311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d56ab31-87bb-4758-bb5f-6195b3a68e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5cabb48e-9f06-4f6f-9728-f82011d14b0b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d56ab31-87bb-4758-bb5f-6195b3a68e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e7c2a433-bf18-4d69-bb29-0f90ac43f937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5cabb48e-9f06-4f6f-9728-f82011d14b0b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e7c2a433-bf18-4d69-bb29-0f90ac43f937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f067e66-4c12-4b9a-89d9-041dec2334d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5cabb48e-9f06-4f6f-9728-f82011d14b0b" xlink:to="loc_us-gaap_StockholdersEquity_3f067e66-4c12-4b9a-89d9-041dec2334d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68c8d716-12a4-4f68-8ade-08cda8038760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09935d26-ee35-491d-9533-41579514ac5a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_68c8d716-12a4-4f68-8ade-08cda8038760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8ae0df15-5382-4777-afca-582b5560fbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a3910d81-7aee-49df-8ceb-d6d72a3d0798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ae0df15-5382-4777-afca-582b5560fbf2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a3910d81-7aee-49df-8ceb-d6d72a3d0798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8b3b1acb-4fc1-457b-ba30-72f5a4a09f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ae0df15-5382-4777-afca-582b5560fbf2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8b3b1acb-4fc1-457b-ba30-72f5a4a09f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a57bc432-271a-4306-aa78-f6452f8fddd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ae0df15-5382-4777-afca-582b5560fbf2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a57bc432-271a-4306-aa78-f6452f8fddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_44eefc27-e23c-4eb4-adbe-1d603cb72b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_44eefc27-e23c-4eb4-adbe-1d603cb72b46" xlink:to="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7918c984-70d8-4241-a25e-afd4ec3ce979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7918c984-70d8-4241-a25e-afd4ec3ce979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7918c984-70d8-4241-a25e-afd4ec3ce979" xlink:to="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_410f3a97-295b-4182-8e0e-2ba5a6039871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_CommonStockMember_410f3a97-295b-4182-8e0e-2ba5a6039871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_30bae606-d6d8-4edc-826e-ad6daf247df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_30bae606-d6d8-4edc-826e-ad6daf247df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2b165f19-a884-41f8-b97f-893612d91fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_RetainedEarningsMember_2b165f19-a884-41f8-b97f-893612d91fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6e8bb478-98b8-4755-8cb1-3cb517179d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eeb54601-4860-48ba-a3ad-35dc0d7f5a51" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6e8bb478-98b8-4755-8cb1-3cb517179d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_808d78b5-34df-4920-8f92-08208f3c64b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_808d78b5-34df-4920-8f92-08208f3c64b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc8f4db0-3e0f-4d86-a87f-fb06ccfb5f20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_808d78b5-34df-4920-8f92-08208f3c64b7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc8f4db0-3e0f-4d86-a87f-fb06ccfb5f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5295ddd6-6a67-4043-8d25-2517e64ebdf0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc8f4db0-3e0f-4d86-a87f-fb06ccfb5f20" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5295ddd6-6a67-4043-8d25-2517e64ebdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_873d34a7-4e9d-4ec4-bc62-e4646971910d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_010735ac-5c4c-4df3-b222-68658978c43d" xlink:to="loc_us-gaap_StatementLineItems_873d34a7-4e9d-4ec4-bc62-e4646971910d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_873d34a7-4e9d-4ec4-bc62-e4646971910d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_43b6c72c-f75f-4861-a1d6-ed449ab8e9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_43b6c72c-f75f-4861-a1d6-ed449ab8e9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2b5378b6-2cc1-4415-b78c-2e82a505d4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockholdersEquity_2b5378b6-2cc1-4415-b78c-2e82a505d4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d740bb4-5f3b-44e9-8680-dc4c0353a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_NetIncomeLoss_3d740bb4-5f3b-44e9-8680-dc4c0353a9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d8a8235e-310a-428e-b1be-67e541bda254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d8a8235e-310a-428e-b1be-67e541bda254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a5ba29e7-6251-457d-a8ce-d4ef7a64d4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_DividendsCommonStockCash_a5ba29e7-6251-457d-a8ce-d4ef7a64d4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a584d800-47f2-477b-869b-7e9dbf4f97d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a584d800-47f2-477b-869b-7e9dbf4f97d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_482b2f2f-0f63-4463-8ac3-9ff6c88f6f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_482b2f2f-0f63-4463-8ac3-9ff6c88f6f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32f4fa58-204a-4512-a51f-d3a91961c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32f4fa58-204a-4512-a51f-d3a91961c5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_77d9c70e-eca4-4cb5-a355-db70de44e970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet_77d9c70e-eca4-4cb5-a355-db70de44e970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_092d0aa8-be8f-423d-ae29-46c2b67d4649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_092d0aa8-be8f-423d-ae29-46c2b67d4649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_35ef0cff-1b85-467d-9c96-3e3167fc9599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_35ef0cff-1b85-467d-9c96-3e3167fc9599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_305105d1-c178-4ea5-95aa-85ba4b1709e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_305105d1-c178-4ea5-95aa-85ba4b1709e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_301bd8de-58f1-4cc2-ba19-9c826e296a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80ce5979-e6e5-48d3-8807-dd1937a0298b" xlink:to="loc_us-gaap_StockholdersEquity_301bd8de-58f1-4cc2-ba19-9c826e296a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0b9662c5-8593-44cc-bdf7-dc4192a318ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_09f4bc6f-b2f9-4c99-854b-c0333a495259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0b9662c5-8593-44cc-bdf7-dc4192a318ce" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_09f4bc6f-b2f9-4c99-854b-c0333a495259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_21d27684-df2e-4d23-adc1-074484aa83d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_21d27684-df2e-4d23-adc1-074484aa83d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6749935f-fde0-4989-b2b5-ae09a79a569f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_NetIncomeLoss_6749935f-fde0-4989-b2b5-ae09a79a569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bf863a01-bd72-446b-8ad3-2355c17e8853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bf863a01-bd72-446b-8ad3-2355c17e8853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bcbfd731-325b-47a8-a3f7-bcdf960f4c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_ShareBasedCompensation_bcbfd731-325b-47a8-a3f7-bcdf960f4c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_2dc75e69-227d-433d-9d7e-88af8356d1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_2dc75e69-227d-433d-9d7e-88af8356d1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_64a36626-6f68-4976-9341-95a4f9854df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_64a36626-6f68-4976-9341-95a4f9854df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b3795498-0a3c-48e9-8500-82b8eb1a61ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b3795498-0a3c-48e9-8500-82b8eb1a61ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d5e452dc-5f96-4c44-8df2-9df7384f7b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d5e452dc-5f96-4c44-8df2-9df7384f7b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf7dcc06-43f0-4549-a0f7-a480b52cc262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf7dcc06-43f0-4549-a0f7-a480b52cc262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_84dd35b2-c06e-4394-887c-40cde0933bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_84dd35b2-c06e-4394-887c-40cde0933bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_31af9395-47c1-4b7d-8436-cff224ea3e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_31af9395-47c1-4b7d-8436-cff224ea3e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_582bb42e-f141-4ed8-ac2d-18487a462259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_582bb42e-f141-4ed8-ac2d-18487a462259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_3827c025-3b1a-483a-bb05-f027965b8176" xlink:href="amgn-20211231.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_3827c025-3b1a-483a-bb05-f027965b8176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7b5a7594-df9d-4988-997d-0a11f4728417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_24680f76-d02c-4ed0-8ce0-1e3b9b53ce69" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7b5a7594-df9d-4988-997d-0a11f4728417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d99b30a-92b7-4b88-bbcf-c4847f0ba058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5c1f5bde-0f4f-4964-8cfb-1d8786bf84bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d99b30a-92b7-4b88-bbcf-c4847f0ba058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_21d27684-df2e-4d23-adc1-074484aa83d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fa70c8ca-ff79-4abe-baa1-aa66f599b4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fa70c8ca-ff79-4abe-baa1-aa66f599b4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_67bfa509-5520-45ce-a794-3f82617c2803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_67bfa509-5520-45ce-a794-3f82617c2803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_810718a2-2352-4c06-ada0-a5122e3fecb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_810718a2-2352-4c06-ada0-a5122e3fecb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f29df37b-35c8-4bb9-95b3-3820dcc99ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f29df37b-35c8-4bb9-95b3-3820dcc99ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7fab556d-d40b-489f-aff7-6d582d711523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7fab556d-d40b-489f-aff7-6d582d711523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e3b18688-62f4-4781-8db8-3af56e9f6f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e3b18688-62f4-4781-8db8-3af56e9f6f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1a80f611-712d-4d88-b083-27b47c502bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1a80f611-712d-4d88-b083-27b47c502bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8cc4dda-fb84-4c99-85a5-9660ce2cb6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f9f3d70-197f-4a9a-b859-3651232b5af4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8cc4dda-fb84-4c99-85a5-9660ce2cb6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_21d27684-df2e-4d23-adc1-074484aa83d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c0c59a01-20a4-45aa-851b-17d5d49b8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c0c59a01-20a4-45aa-851b-17d5d49b8a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_56b96756-7e9f-46ad-97af-aaa212882c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_56b96756-7e9f-46ad-97af-aaa212882c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b66bb966-3e38-4b94-b656-a9a7a3cfd0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b66bb966-3e38-4b94-b656-a9a7a3cfd0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_99ff8bc4-9cc5-4908-a0e6-e0196901f8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_99ff8bc4-9cc5-4908-a0e6-e0196901f8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_73d204b6-909c-4433-aa8d-e7c63329ad73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_73d204b6-909c-4433-aa8d-e7c63329ad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b33aeb12-f953-4ce4-9ec6-6ab4e3fb0082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0cd6c06a-86b9-4d1a-8a00-059fbb9538dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b33aeb12-f953-4ce4-9ec6-6ab4e3fb0082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70bc0d29-c7d3-4b51-809a-ebbe0beef621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_21d27684-df2e-4d23-adc1-074484aa83d8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70bc0d29-c7d3-4b51-809a-ebbe0beef621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9de5c1c9-2873-46d9-998e-146e2516ab0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_21d27684-df2e-4d23-adc1-074484aa83d8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9de5c1c9-2873-46d9-998e-146e2516ab0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0457d4a5-f999-4f91-b493-c9f3b4bed6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_21d27684-df2e-4d23-adc1-074484aa83d8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0457d4a5-f999-4f91-b493-c9f3b4bed6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="amgn-20211231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ffca06d1-33b5-4131-9e83-07c2e0646bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6d1075e6-6362-45fe-ac5f-75ec7df521cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffca06d1-33b5-4131-9e83-07c2e0646bc2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6d1075e6-6362-45fe-ac5f-75ec7df521cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="amgn-20211231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock_ab3e3c33-6e66-4505-80a3-d660f0143d9b" xlink:href="amgn-20211231.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_amgn_NatureOfOperationsPolicyTextBlock_ab3e3c33-6e66-4505-80a3-d660f0143d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_37261267-6ace-44fd-be7f-93870eb4f6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_37261267-6ace-44fd-be7f-93870eb4f6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_16721146-04e8-481b-9970-2875d40afed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_UseOfEstimates_16721146-04e8-481b-9970-2875d40afed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_36e0ca0d-7425-4b61-87aa-152d0ae8a5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_36e0ca0d-7425-4b61-87aa-152d0ae8a5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_336290d3-d3e6-4262-8809-66fce911ae7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_336290d3-d3e6-4262-8809-66fce911ae7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_a9e23894-b61a-45ce-b5a1-d4787eff857e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_a9e23894-b61a-45ce-b5a1-d4787eff857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_91a6ba29-36ee-408f-ad25-61d6ee0c1eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_91a6ba29-36ee-408f-ad25-61d6ee0c1eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3942bd8e-a47b-47ee-8f2e-8fbf2a0a6975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3942bd8e-a47b-47ee-8f2e-8fbf2a0a6975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_022ceb9e-ef37-4227-a413-0857198c3fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_022ceb9e-ef37-4227-a413-0857198c3fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_8b5c860b-8135-4de3-8daa-e2587b832375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_8b5c860b-8135-4de3-8daa-e2587b832375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6f832b0c-2332-4841-ba4c-e6a7b644cc32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6f832b0c-2332-4841-ba4c-e6a7b644cc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_0166760d-94f1-483e-a670-a1a5fc6346ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_0166760d-94f1-483e-a670-a1a5fc6346ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c7a7d6d3-9b93-4785-a508-9189db71803d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c7a7d6d3-9b93-4785-a508-9189db71803d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_024a8804-55f2-4d52-a540-5362e3d013fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_024a8804-55f2-4d52-a540-5362e3d013fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b4555e3-5fa8-483b-9d2a-976df42ce386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b4555e3-5fa8-483b-9d2a-976df42ce386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4c88511b-9cc1-43e8-a464-eab6b5f32a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4c88511b-9cc1-43e8-a464-eab6b5f32a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4d883e13-1f42-4581-9031-b183ca1b0c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4d883e13-1f42-4581-9031-b183ca1b0c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e4b04ab4-dfbc-4046-855f-de8f8baf5709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e4b04ab4-dfbc-4046-855f-de8f8baf5709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock_c9e492c4-1632-48a1-82e6-9e34cacbb242" xlink:href="amgn-20211231.xsd#amgn_EquityInvestmentsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_amgn_EquityInvestmentsPolicyPolicyTextBlock_c9e492c4-1632-48a1-82e6-9e34cacbb242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_a9d2888d-dbcc-410a-b027-462523aa12a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_a9d2888d-dbcc-410a-b027-462523aa12a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_81ec4cad-e03d-4480-9ab4-41d0d97d0d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15af6f5d-cb7f-4cd5-9724-0e206d9fff40" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_81ec4cad-e03d-4480-9ab4-41d0d97d0d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_81526414-f2cb-4ccc-9fe6-70df43847823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45b70f7a-a165-4594-af36-142db9e808ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81526414-f2cb-4ccc-9fe6-70df43847823" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45b70f7a-a165-4594-af36-142db9e808ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3eb272a0-8a15-4160-b4a0-d720df797c47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45b70f7a-a165-4594-af36-142db9e808ed" xlink:to="loc_srt_RangeAxis_3eb272a0-8a15-4160-b4a0-d720df797c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3eb272a0-8a15-4160-b4a0-d720df797c47" xlink:to="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5576656a-c627-4b57-8c10-ffc72b6a17d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:to="loc_srt_MinimumMember_5576656a-c627-4b57-8c10-ffc72b6a17d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbd213d5-43a4-42c4-9c65-f66916c57fdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c272c8da-2362-4e95-a653-57cb5a27989e" xlink:to="loc_srt_MaximumMember_fbd213d5-43a4-42c4-9c65-f66916c57fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45b70f7a-a165-4594-af36-142db9e808ed" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_23060f5f-86bb-4c2e-b948-9d32d1a7f3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_us-gaap_NumberOfOperatingSegments_23060f5f-86bb-4c2e-b948-9d32d1a7f3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_65fea0cd-02fe-45fc-b305-cd3172e0db4c" xlink:href="amgn-20211231.xsd#amgn_SalesReturnProvisionsAsPercentageOfProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_amgn_SalesReturnProvisionsAsPercentageOfProductSales_65fea0cd-02fe-45fc-b305-cd3172e0db4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenuePaymentArrangementTerm_1ab10d31-dcf4-4894-9f46-54b8e14a95eb" xlink:href="amgn-20211231.xsd#amgn_RevenuePaymentArrangementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_amgn_RevenuePaymentArrangementTerm_1ab10d31-dcf4-4894-9f46-54b8e14a95eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_cdd56914-8432-41bb-aa0d-94b4dfeaf802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8acafcc9-f7a2-4915-a44b-fc771d7fbe19" xlink:to="loc_us-gaap_AdvertisingExpense_cdd56914-8432-41bb-aa0d-94b4dfeaf802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Acquisitions" xlink:type="simple" xlink:href="amgn-20211231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7cf2ab31-42f3-454d-9d8d-2d71824b1099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0c012506-7687-4d9e-b6c6-681c4296dcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7cf2ab31-42f3-454d-9d8d-2d71824b1099" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0c012506-7687-4d9e-b6c6-681c4296dcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7877beb9-18ed-48bd-b23b-ce15bcd0ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ecb0241b-048c-4efe-a142-c9123e1551f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7877beb9-18ed-48bd-b23b-ce15bcd0ffb2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ecb0241b-048c-4efe-a142-c9123e1551f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_74aee120-3b6b-45de-88cf-2a5c234e611e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_74aee120-3b6b-45de-88cf-2a5c234e611e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_958f5282-5c7d-40fd-9a4d-39f7c2d3c8c5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_e7d6b49b-48e2-4620-a248-67f97f727f0d" xlink:href="amgn-20211231.xsd#amgn_TeneobioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:to="loc_amgn_TeneobioMember_e7d6b49b-48e2-4620-a248-67f97f727f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_1ffe858a-8c55-4897-b6fc-efdb627ef3b0" xlink:href="amgn-20211231.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ccb2bb9-2dee-4d2a-8cc3-43e0391bae21" xlink:to="loc_amgn_OtezlaMember_1ffe858a-8c55-4897-b6fc-efdb627ef3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_825299fd-6ef6-4ba0-933a-06f2c579b279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_825299fd-6ef6-4ba0-933a-06f2c579b279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd289ea4-03d4-4f15-baf9-d2e79002e448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_825299fd-6ef6-4ba0-933a-06f2c579b279" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd289ea4-03d4-4f15-baf9-d2e79002e448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0fefce19-4aca-4bdf-8468-f07ccb872456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dd289ea4-03d4-4f15-baf9-d2e79002e448" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0fefce19-4aca-4bdf-8468-f07ccb872456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4437cb4-3595-4ab3-9225-db7d063c7de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4437cb4-3595-4ab3-9225-db7d063c7de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4437cb4-3595-4ab3-9225-db7d063c7de7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_7ee3c158-be78-47fa-8efe-2f4297875c06" xlink:href="amgn-20211231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_amgn_RDTechnologyrightsMember_7ee3c158-be78-47fa-8efe-2f4297875c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b6e36a4c-d894-4701-a810-9dd1d733ac9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_us-gaap_LicensingAgreementsMember_b6e36a4c-d894-4701-a810-9dd1d733ac9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_d0320043-9667-4577-b8b3-42a15c3cab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_d0320043-9667-4577-b8b3-42a15c3cab2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_afbc85e1-008e-413c-9d9d-4dfcb861c8d8" xlink:href="amgn-20211231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e6a4ba7-1438-4534-9416-2044d27c52e3" xlink:to="loc_amgn_MarketingRelatedRightsMember_afbc85e1-008e-413c-9d9d-4dfcb861c8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_90b0d65b-7b99-4987-8a0e-78c503249afa" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9bd37995-b597-47d7-82ca-0213350402f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9bd37995-b597-47d7-82ca-0213350402f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_856f2ce0-6157-40b9-a0d9-3ec9e72f802e" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_856f2ce0-6157-40b9-a0d9-3ec9e72f802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Transactioncostsassetacquisition_0c93cf72-61d0-4989-8871-98a48c9ed920" xlink:href="amgn-20211231.xsd#amgn_Transactioncostsassetacquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_Transactioncostsassetacquisition_0c93cf72-61d0-4989-8871-98a48c9ed920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_26b5b03c-5de6-4e2e-b4fc-f9d48bdc131f" xlink:href="amgn-20211231.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_26b5b03c-5de6-4e2e-b4fc-f9d48bdc131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_32f5cd4a-6328-4868-9401-5f0357431170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_32f5cd4a-6328-4868-9401-5f0357431170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_191b72a1-de10-4545-b8c0-8975764a12e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_191b72a1-de10-4545-b8c0-8975764a12e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_695dc5a7-fd53-48f9-bb31-b32100f7a7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_695dc5a7-fd53-48f9-bb31-b32100f7a7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_388de26a-53e0-406d-92f7-ed206e8a3214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_Goodwill_388de26a-53e0-406d-92f7-ed206e8a3214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_465087cb-523a-40d8-beba-d3341d26f4ab" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_465087cb-523a-40d8-beba-d3341d26f4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_84c32d6f-9134-44fe-a1d4-4257fd90f4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_84c32d6f-9134-44fe-a1d4-4257fd90f4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_2d29d183-61a4-4fdb-a772-5cb91d09f0d0" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionDeferredCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionDeferredCredit_2d29d183-61a4-4fdb-a772-5cb91d09f0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_d80278f3-3fc4-4f7c-941a-13271108bf85" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther_d80278f3-3fc4-4f7c-941a-13271108bf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_8c32b966-a807-4540-baed-e4919aeef0fa" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionInventoryacquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionInventoryacquired_8c32b966-a807-4540-baed-e4919aeef0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_4bde8d99-951d-4eff-a591-ec1501bf0803" xlink:href="amgn-20211231.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_667cdef0-7e64-483d-9312-b2e790146599" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_4bde8d99-951d-4eff-a591-ec1501bf0803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_39621d12-682f-4083-8d11-1fa554a44422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_39621d12-682f-4083-8d11-1fa554a44422" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b77dcbe-7ba4-4182-8bb6-af53a1d25b5e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_9ffd71b6-1cf4-4a26-adf4-930d8299208f" xlink:href="amgn-20211231.xsd#amgn_TeneobioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_TeneobioMember_9ffd71b6-1cf4-4a26-adf4-930d8299208f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember_7033396b-ae94-4079-87e9-c2fd6249f461" xlink:href="amgn-20211231.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_FivePrimeTherapeuticsIncMember_7033396b-ae94-4079-87e9-c2fd6249f461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_c54dffa4-a3dd-4733-90d2-eee3bdae9802" xlink:href="amgn-20211231.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_OtezlaMember_c54dffa4-a3dd-4733-90d2-eee3bdae9802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NuevolutionMember_a0f84e42-a700-410e-a2d9-cc3532fa00cf" xlink:href="amgn-20211231.xsd#amgn_NuevolutionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a45eb6e-76e6-460b-80e7-d3493c98fdce" xlink:to="loc_amgn_NuevolutionMember_a0f84e42-a700-410e-a2d9-cc3532fa00cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96234b72-3910-46c2-baa1-05c620b3e64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96234b72-3910-46c2-baa1-05c620b3e64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_625d4056-f1b0-44df-8b5d-5ec073d16c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96234b72-3910-46c2-baa1-05c620b3e64a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_625d4056-f1b0-44df-8b5d-5ec073d16c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3319732-b3fd-4f20-8faa-b10e1c15f62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_625d4056-f1b0-44df-8b5d-5ec073d16c0f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3319732-b3fd-4f20-8faa-b10e1c15f62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis_919017e7-1418-4d39-9787-79e452870524" xlink:href="amgn-20211231.xsd#amgn_MoleculeTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_amgn_MoleculeTypeAxis_919017e7-1418-4d39-9787-79e452870524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_884df7d5-fc1a-4fc0-b01f-ae3565227b61" xlink:href="amgn-20211231.xsd#amgn_MoleculeTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_MoleculeTypeAxis_919017e7-1418-4d39-9787-79e452870524" xlink:to="loc_amgn_MoleculeTypeDomain_884df7d5-fc1a-4fc0-b01f-ae3565227b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member_24a77ace-9c1c-4d9e-8f33-7751ea3e43c3" xlink:href="amgn-20211231.xsd#amgn_AMG340Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_MoleculeTypeDomain_884df7d5-fc1a-4fc0-b01f-ae3565227b61" xlink:to="loc_amgn_AMG340Member_24a77ace-9c1c-4d9e-8f33-7751ea3e43c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04c53c5f-aa86-4bce-af30-ef1f3c6e8179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04c53c5f-aa86-4bce-af30-ef1f3c6e8179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04c53c5f-aa86-4bce-af30-ef1f3c6e8179" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_18a03502-6ea2-4f3f-83e8-b5395ed2b72c" xlink:href="amgn-20211231.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_amgn_RDTechnologyrightsMember_18a03502-6ea2-4f3f-83e8-b5395ed2b72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3a052e9e-9bc4-4f0b-9dac-01367a77915d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_us-gaap_LicensingAgreementsMember_3a052e9e-9bc4-4f0b-9dac-01367a77915d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_63694db5-0f1d-4dfc-b3a3-469a4e816036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_63694db5-0f1d-4dfc-b3a3-469a4e816036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MarketingRelatedRightsMember_925c340c-5841-4915-9d52-ad68f0511a64" xlink:href="amgn-20211231.xsd#amgn_MarketingRelatedRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_816c1509-0f87-4543-83ee-dfe260931b45" xlink:to="loc_amgn_MarketingRelatedRightsMember_925c340c-5841-4915-9d52-ad68f0511a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_f7a9b651-9e73-44b1-a782-6d31e9be87b5" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_amgn_AssetsByDescriptionAxis_f7a9b651-9e73-44b1-a782-6d31e9be87b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionAxis_f7a9b651-9e73-44b1-a782-6d31e9be87b5" xlink:to="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssembledWorkforceMember_e3479d21-35ac-45c7-873a-595b1b3adddc" xlink:href="amgn-20211231.xsd#amgn_AssembledWorkforceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:to="loc_amgn_AssembledWorkforceMember_e3479d21-35ac-45c7-873a-595b1b3adddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_19442935-043c-4471-993d-da014523b650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionDomain_94793383-3022-427c-b1c7-e4c44afc7a93" xlink:to="loc_us-gaap_InventoriesMember_19442935-043c-4471-993d-da014523b650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e93c7c1-9b7b-4238-a01f-261ddf9513d3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_950accb5-fc23-4ea1-b534-104c5c01a8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_950accb5-fc23-4ea1-b534-104c5c01a8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bd00b660-82ab-4ec3-8705-6bc2fd8d8dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bd00b660-82ab-4ec3-8705-6bc2fd8d8dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_bb79c51e-2e8d-481e-b410-6cedef41e2c0" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_bb79c51e-2e8d-481e-b410-6cedef41e2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_86d0944f-2091-42df-bdb3-02cf7e150e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_86d0944f-2091-42df-bdb3-02cf7e150e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7e997cf1-b89b-4c77-ae7b-78ec62a14cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7e997cf1-b89b-4c77-ae7b-78ec62a14cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_29e5020f-7f44-4b0e-9156-a9fd7cfef572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_29e5020f-7f44-4b0e-9156-a9fd7cfef572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2f78205-89e4-4a58-af8c-37b225b15f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2f78205-89e4-4a58-af8c-37b225b15f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b7c8de2e-4339-4eec-9e3c-35745fac1c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_Goodwill_b7c8de2e-4339-4eec-9e3c-35745fac1c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b6fd535-dbb6-4b21-b8e9-57588906138f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b6fd535-dbb6-4b21-b8e9-57588906138f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_81edfdb5-f219-496c-90e1-eee75cbfe88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_81edfdb5-f219-496c-90e1-eee75cbfe88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_488d8dcb-3374-45a3-83fd-7ee509911c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_488d8dcb-3374-45a3-83fd-7ee509911c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_4a53793e-66c6-48c7-a6ab-9d1485a92560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_4a53793e-66c6-48c7-a6ab-9d1485a92560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ApprovedMarkets_3b66f2bb-d7be-4ee6-8530-8032e07b6651" xlink:href="amgn-20211231.xsd#amgn_ApprovedMarkets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_ApprovedMarkets_3b66f2bb-d7be-4ee6-8530-8032e07b6651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_22232115-6a68-4da1-b35a-4c9723a9af92" xlink:href="amgn-20211231.xsd#amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife_22232115-6a68-4da1-b35a-4c9723a9af92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_cd3016b7-c897-407f-93af-f1cc47bc8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_cd3016b7-c897-407f-93af-f1cc47bc8eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_e101e4d5-3bc3-485a-a3a3-2cc753ee31d0" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities_e101e4d5-3bc3-485a-a3a3-2cc753ee31d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_7affa31f-f37f-43e3-afbd-72a751c26198" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits_7affa31f-f37f-43e3-afbd-72a751c26198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_e5cfe5e0-1737-406c-8074-996587f973b3" xlink:href="amgn-20211231.xsd#amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate_e5cfe5e0-1737-406c-8074-996587f973b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0bbaf718-619c-4679-a5ef-6960865f7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0bbaf718-619c-4679-a5ef-6960865f7df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_bbf73ed2-8c9c-4c42-ab4b-9a57ebef60c7" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7e9f91dd-1563-41c0-a5ef-3fecbe36e5c4" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_bbf73ed2-8c9c-4c42-ab4b-9a57ebef60c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Revenues" xlink:type="simple" xlink:href="amgn-20211231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8980bbf5-7e46-4872-ac6c-11ea86dbf203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_64828935-2d08-409a-ae0b-1a8665832de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8980bbf5-7e46-4872-ac6c-11ea86dbf203" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_64828935-2d08-409a-ae0b-1a8665832de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9349f452-2663-4ebf-9fd5-77d971628ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_edff245b-5eaa-4218-a89e-99905ef9a972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9349f452-2663-4ebf-9fd5-77d971628ac8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_edff245b-5eaa-4218-a89e-99905ef9a972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bca831a7-4289-4cba-ac36-4ad19f03571e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9349f452-2663-4ebf-9fd5-77d971628ac8" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bca831a7-4289-4cba-ac36-4ad19f03571e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_517bbe86-de1f-4381-9696-3b5e214a6069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_60b7daf7-ef26-4bc7-8a16-bb03f4f6516b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_517bbe86-de1f-4381-9696-3b5e214a6069" xlink:to="loc_us-gaap_NumberOfOperatingSegments_60b7daf7-ef26-4bc7-8a16-bb03f4f6516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_517bbe86-de1f-4381-9696-3b5e214a6069" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4f56de6f-0f6a-4003-be79-a9ded87130d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:to="loc_srt_MajorCustomersAxis_4f56de6f-0f6a-4003-be79-a9ded87130d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4f56de6f-0f6a-4003-be79-a9ded87130d2" xlink:to="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_f63ab857-24ea-46b2-a073-041bfd340ed5" xlink:href="amgn-20211231.xsd#amgn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:to="loc_amgn_CustomerOneMember_f63ab857-24ea-46b2-a073-041bfd340ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_c0062283-ade8-4ab2-b01b-da4d9fb66cb7" xlink:href="amgn-20211231.xsd#amgn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:to="loc_amgn_CustomerTwoMember_c0062283-ade8-4ab2-b01b-da4d9fb66cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_3a3e7490-739a-4b06-a6a9-52fd784ca328" xlink:href="amgn-20211231.xsd#amgn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_28efc4b2-0c71-4514-ba44-36e92121afb3" xlink:to="loc_amgn_CustomerThreeMember_3a3e7490-739a-4b06-a6a9-52fd784ca328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a3f9974-0386-4316-9cf7-912bb91e73ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:to="loc_srt_ProductOrServiceAxis_1a3f9974-0386-4316-9cf7-912bb91e73ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1a3f9974-0386-4316-9cf7-912bb91e73ae" xlink:to="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:to="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_3a64cfac-72e9-4b4c-b740-5b4f3cb3b4d1" xlink:href="amgn-20211231.xsd#amgn_EnbrelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_EnbrelMember_3a64cfac-72e9-4b4c-b740-5b4f3cb3b4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_8be05774-0373-4098-b257-93403d42a535" xlink:href="amgn-20211231.xsd#amgn_ProliaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_ProliaMember_8be05774-0373-4098-b257-93403d42a535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_6b805a0f-d3b8-4d2b-8ff3-cab7f303735e" xlink:href="amgn-20211231.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_OtezlaMember_6b805a0f-d3b8-4d2b-8ff3-cab7f303735e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_850b1251-5d0c-4446-8831-3fa23880eed8" xlink:href="amgn-20211231.xsd#amgn_XgevaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_XgevaMember_850b1251-5d0c-4446-8831-3fa23880eed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_a2847be8-c160-4d58-8998-c02481abc0c9" xlink:href="amgn-20211231.xsd#amgn_NeulastaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_NeulastaMember_a2847be8-c160-4d58-8998-c02481abc0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_2a13b2c4-23f8-4dae-87b4-7fe3870b4828" xlink:href="amgn-20211231.xsd#amgn_AranespMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_AranespMember_2a13b2c4-23f8-4dae-87b4-7fe3870b4828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_aa3c8190-49ff-456d-9d50-4255f8c70e47" xlink:href="amgn-20211231.xsd#amgn_RepathaevolocumabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_RepathaevolocumabMember_aa3c8190-49ff-456d-9d50-4255f8c70e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_6d3e0193-20a6-4c40-a699-78bc9dbf6437" xlink:href="amgn-20211231.xsd#amgn_KyprolisMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_KyprolisMember_6d3e0193-20a6-4c40-a699-78bc9dbf6437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_1441729e-7f8c-44da-84b6-f8e1dd736f64" xlink:href="amgn-20211231.xsd#amgn_NplateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_NplateMember_1441729e-7f8c-44da-84b6-f8e1dd736f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_da386c16-c9cc-4b94-a055-df26359b9ca5" xlink:href="amgn-20211231.xsd#amgn_OtherProductsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_758de1c9-ce67-4037-b8d9-965a1b0f6ad0" xlink:to="loc_amgn_OtherProductsMember_da386c16-c9cc-4b94-a055-df26359b9ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d17ce085-1a7c-4b11-9c0c-10d0a12f2d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_57b5753b-5b22-46ca-bf14-1819222024cf" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d17ce085-1a7c-4b11-9c0c-10d0a12f2d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9f4df996-2371-485d-90bf-35818e33c45c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:to="loc_srt_StatementGeographicalAxis_9f4df996-2371-485d-90bf-35818e33c45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9f4df996-2371-485d-90bf-35818e33c45c" xlink:to="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac9ffc00-981a-487d-bf84-1f09cbe0e5c4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:to="loc_country_US_ac9ffc00-981a-487d-bf84-1f09cbe0e5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_78fe2300-9e8d-4010-8741-b1f1a360e052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0036587a-4244-423b-9943-f50feee36a17" xlink:to="loc_us-gaap_NonUsMember_78fe2300-9e8d-4010-8741-b1f1a360e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0f91218d-d963-408b-8166-00024d333e56" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b4052cd7-d2dc-453c-a504-0a4ac91e4a2e" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b4052cd7-d2dc-453c-a504-0a4ac91e4a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_07b9f994-0f23-46f7-885b-4c5e34be3cea" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_07b9f994-0f23-46f7-885b-4c5e34be3cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_3398c5f2-584b-4b85-be62-892dc43b29f2" xlink:href="amgn-20211231.xsd#amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers_3398c5f2-584b-4b85-be62-892dc43b29f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_cdb33512-b6b7-4014-910d-366b5df13355" xlink:href="amgn-20211231.xsd#amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers_cdb33512-b6b7-4014-910d-366b5df13355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9a94551b-e03d-41a4-b0e5-0631f3fded22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9a94551b-e03d-41a4-b0e5-0631f3fded22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_479bd1bc-391c-4856-833f-5e0b8990ff8c" xlink:href="amgn-20211231.xsd#amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_71b6b631-63f7-4248-ada2-b88658963aa0" xlink:to="loc_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation_479bd1bc-391c-4856-833f-5e0b8990ff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#RevenuesCustomerConcentrationProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6325a3d6-40fd-4dcc-a09d-4eb2d3f52500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6325a3d6-40fd-4dcc-a09d-4eb2d3f52500" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1ead18b0-f4ce-44f4-a971-590b122dbd1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:to="loc_srt_ProductOrServiceAxis_1ead18b0-f4ce-44f4-a971-590b122dbd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61395aac-b89b-4085-af03-eec225afed5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1ead18b0-f4ce-44f4-a971-590b122dbd1a" xlink:to="loc_srt_ProductsAndServicesDomain_61395aac-b89b-4085-af03-eec225afed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6b8554f2-bbcd-43c0-850c-aea3b7a52cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61395aac-b89b-4085-af03-eec225afed5a" xlink:to="loc_us-gaap_ProductMember_6b8554f2-bbcd-43c0-850c-aea3b7a52cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:to="loc_srt_MajorCustomersAxis_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2baf73c2-3a9f-4b1d-aaed-544b8a9930a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerOneMember_5aafa2e3-c5cb-4ad8-a6bc-5fe174a078cb" xlink:href="amgn-20211231.xsd#amgn_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:to="loc_amgn_CustomerOneMember_5aafa2e3-c5cb-4ad8-a6bc-5fe174a078cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerTwoMember_dc7a7d4f-4c8f-4ddf-afd3-443e911495be" xlink:href="amgn-20211231.xsd#amgn_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:to="loc_amgn_CustomerTwoMember_dc7a7d4f-4c8f-4ddf-afd3-443e911495be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CustomerThreeMember_dc609934-f855-46a9-a8af-fa5ae6ef2c2f" xlink:href="amgn-20211231.xsd#amgn_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aed4299e-d940-4896-bd44-1268a521d068" xlink:to="loc_amgn_CustomerThreeMember_dc609934-f855-46a9-a8af-fa5ae6ef2c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_aa25a48a-58b8-4318-9aff-e96f45445212" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b83d6802-3c65-4de3-a9e9-67fec5d5ef9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b83d6802-3c65-4de3-a9e9-67fec5d5ef9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfGrossRevenues_64b81272-63bd-428a-a757-cca247322429" xlink:href="amgn-20211231.xsd#amgn_PercentageOfGrossRevenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_amgn_PercentageOfGrossRevenues_64b81272-63bd-428a-a757-cca247322429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b7c01119-9feb-4331-bc00-6cb456837cc1" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue_b7c01119-9feb-4331-bc00-6cb456837cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_ff0b974c-a7ba-4e14-8ed3-03b508af74d3" xlink:href="amgn-20211231.xsd#amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_4f523870-d25e-4264-bf43-a0b9ab84eea9" xlink:to="loc_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables_ff0b974c-a7ba-4e14-8ed3-03b508af74d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="amgn-20211231.xsd#Stockbasedcompensation"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Stockbasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72911dff-5fe8-4517-9443-5dd4b0d4de4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_db10636c-e587-4ed8-b5d9-868f6f1051ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72911dff-5fe8-4517-9443-5dd4b0d4de4c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_db10636c-e587-4ed8-b5d9-868f6f1051ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73007718-fdef-418e-9ebf-e2cc842233b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_5395c676-ed6d-499d-8e91-425157eb0e76" xlink:href="amgn-20211231.xsd#amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73007718-fdef-418e-9ebf-e2cc842233b7" xlink:to="loc_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock_5395c676-ed6d-499d-8e91-425157eb0e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a8e260fb-a3be-4ba2-a524-a179384d0534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73007718-fdef-418e-9ebf-e2cc842233b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a8e260fb-a3be-4ba2-a524-a179384d0534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a0840626-a489-4153-9626-c25dbc3f5356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73007718-fdef-418e-9ebf-e2cc842233b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a0840626-a489-4153-9626-c25dbc3f5356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8c65667d-977e-4095-8abf-87c17a087693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73007718-fdef-418e-9ebf-e2cc842233b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8c65667d-977e-4095-8abf-87c17a087693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_9dd70818-752b-4dc5-81a7-982629fcfd3b" xlink:href="amgn-20211231.xsd#amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73007718-fdef-418e-9ebf-e2cc842233b7" xlink:to="loc_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock_9dd70818-752b-4dc5-81a7-982629fcfd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eeb2a6b-b522-4028-b140-2397eb177448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5d370d4-b3f8-4dd5-855e-839ccd5a67cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eeb2a6b-b522-4028-b140-2397eb177448" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5d370d4-b3f8-4dd5-855e-839ccd5a67cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5d370d4-b3f8-4dd5-855e-839ccd5a67cc" xlink:to="loc_us-gaap_AwardTypeAxis_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a9b25ff5-0de4-486e-8d54-66ee7f0dcf2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f69bee19-aa66-416a-890e-f389b6831638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f69bee19-aa66-416a-890e-f389b6831638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dd9aa7d8-42d9-4bcc-ae91-4d8e2f5b4bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dd9aa7d8-42d9-4bcc-ae91-4d8e2f5b4bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_9eec2245-b5e7-4cf3-848f-d13e8ef1433b" xlink:href="amgn-20211231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50946c49-e99d-4550-8e26-cddc0c2f1cdd" xlink:to="loc_amgn_PerformanceUnitsMember_9eec2245-b5e7-4cf3-848f-d13e8ef1433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5d370d4-b3f8-4dd5-855e-839ccd5a67cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_6acc1674-f2ab-43a6-ba8c-e01cca3810f9" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted_6acc1674-f2ab-43a6-ba8c-e01cca3810f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_cf9a6d31-cd38-419d-aa83-1312bdc3fecc" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted_cf9a6d31-cd38-419d-aa83-1312bdc3fecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d4375c1e-299b-42b0-b5e3-aa1fe07d1534" xlink:href="amgn-20211231.xsd#amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards_d4375c1e-299b-42b0-b5e3-aa1fe07d1534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_54b791fb-68ea-4e64-92c6-65054ce9003c" xlink:href="amgn-20211231.xsd#amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances_54b791fb-68ea-4e64-92c6-65054ce9003c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_73c953e0-254d-41fc-97dc-3a69a8dee715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_73c953e0-254d-41fc-97dc-3a69a8dee715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa8c306c-09f9-4572-bded-2c96640dd12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa8c306c-09f9-4572-bded-2c96640dd12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b2e32776-cc8d-4439-9748-bfdef392f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b2e32776-cc8d-4439-9748-bfdef392f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ab822bd9-bc68-41f3-be42-712d5de961aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ab822bd9-bc68-41f3-be42-712d5de961aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_92b266c2-1c8e-4e07-aa4f-8daa76eb3521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_92b266c2-1c8e-4e07-aa4f-8daa76eb3521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdb5217d-270d-4405-91ba-ddcd8689672e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cdb5217d-270d-4405-91ba-ddcd8689672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95523337-6756-4a66-ac71-ff32eea25387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95523337-6756-4a66-ac71-ff32eea25387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_577dcbe3-4c69-465f-bc06-f483c3222bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_577dcbe3-4c69-465f-bc06-f483c3222bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3b742fc4-346b-4330-b441-d6240eda68da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_3b742fc4-346b-4330-b441-d6240eda68da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_56d8945f-633c-4f79-82c6-fa0b9a5eab4e" xlink:href="amgn-20211231.xsd#amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned_56d8945f-633c-4f79-82c6-fa0b9a5eab4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f63b0bc-40f6-4685-850d-f59686011410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f63b0bc-40f6-4685-850d-f59686011410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59c1cb6e-0a0d-4fbe-a382-b8b83cd896ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59c1cb6e-0a0d-4fbe-a382-b8b83cd896ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d27b8181-c5c3-41d9-b376-d28d40b72d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d27b8181-c5c3-41d9-b376-d28d40b72d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94b6ce54-f216-4247-8fcf-e2294891c996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94b6ce54-f216-4247-8fcf-e2294891c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d3250d7c-f65e-41d8-a6de-2d4d20345623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21bd01ed-a6f6-4cca-96e6-d719d4caee97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d3250d7c-f65e-41d8-a6de-2d4d20345623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_addce3da-3367-467d-af0c-03a32dc21ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eeaa51c-b8fd-40c0-83ba-0bcb67b3b0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_addce3da-3367-467d-af0c-03a32dc21ae0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eeaa51c-b8fd-40c0-83ba-0bcb67b3b0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5dcfcafb-e1be-4236-88dd-b8426ddb0795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eeaa51c-b8fd-40c0-83ba-0bcb67b3b0da" xlink:to="loc_us-gaap_AwardTypeAxis_5dcfcafb-e1be-4236-88dd-b8426ddb0795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5dcfcafb-e1be-4236-88dd-b8426ddb0795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5aead4c5-63d0-41e3-8233-4152ed895b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5aead4c5-63d0-41e3-8233-4152ed895b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_90903059-9601-4921-8f02-3773aecc1b63" xlink:href="amgn-20211231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:to="loc_amgn_PerformanceUnitsMember_90903059-9601-4921-8f02-3773aecc1b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7040162d-873a-44fa-96f0-245446b16255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138172be-9800-4a74-a9f8-90fcc89a619e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7040162d-873a-44fa-96f0-245446b16255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edfeba1a-7f44-4f0b-a625-3ca7bea84648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0eeaa51c-b8fd-40c0-83ba-0bcb67b3b0da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edfeba1a-7f44-4f0b-a625-3ca7bea84648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edfeba1a-7f44-4f0b-a625-3ca7bea84648" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b6b30304-7a79-4db9-a86f-234b1421dadf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:to="loc_us-gaap_ShareBasedCompensation_b6b30304-7a79-4db9-a86f-234b1421dadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_16a95cfc-a093-4d5d-9ee8-0ac6883bd8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_16a95cfc-a093-4d5d-9ee8-0ac6883bd8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockBasedCompensationExpenseNetOfTax_9819981b-6ca4-448b-be55-4fab9b4f028f" xlink:href="amgn-20211231.xsd#amgn_StockBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d163370f-d80b-4bc1-b825-99b3e962a5c4" xlink:to="loc_amgn_StockBasedCompensationExpenseNetOfTax_9819981b-6ca4-448b-be55-4fab9b4f028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationSummaryofRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7c3eb0-82f9-4c06-92bf-ec140363c788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45e2da3b-9772-4348-b48e-2b69f3311574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7c3eb0-82f9-4c06-92bf-ec140363c788" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45e2da3b-9772-4348-b48e-2b69f3311574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_02078987-2948-4e6d-8802-0fe5688fe329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45e2da3b-9772-4348-b48e-2b69f3311574" xlink:to="loc_us-gaap_AwardTypeAxis_02078987-2948-4e6d-8802-0fe5688fe329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d563fd2d-e012-4491-9681-c9544afd5171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_02078987-2948-4e6d-8802-0fe5688fe329" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d563fd2d-e012-4491-9681-c9544afd5171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_feb18a45-9186-4ebc-ac88-de19e52ab2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d563fd2d-e012-4491-9681-c9544afd5171" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_feb18a45-9186-4ebc-ac88-de19e52ab2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45e2da3b-9772-4348-b48e-2b69f3311574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_81d8653c-3aac-40b1-93c9-e6f6ac2a9e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_81d8653c-3aac-40b1-93c9-e6f6ac2a9e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99d7f50e-441f-432a-b8f0-3f34353c5583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99d7f50e-441f-432a-b8f0-3f34353c5583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87c0e380-fb0b-4777-9461-60eedc8804dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87c0e380-fb0b-4777-9461-60eedc8804dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1547ee34-de5b-44fb-bb35-e85f1c47e6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1547ee34-de5b-44fb-bb35-e85f1c47e6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b7a07b1-0a6c-4d8c-9a70-9303258152ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a3058629-47ba-4188-a51a-383cbeb6bf8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b7a07b1-0a6c-4d8c-9a70-9303258152ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48046af-ccc6-4551-81cd-dee93bc618f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39295040-87e2-4085-9310-6fb62e726478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39295040-87e2-4085-9310-6fb62e726478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_01bac566-e965-45a9-9874-3d272b9e37a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_01bac566-e965-45a9-9874-3d272b9e37a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e74142-7417-4229-a90b-7c13e831ba84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e74142-7417-4229-a90b-7c13e831ba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3bfabecc-e5c0-4ba2-8f73-dfe93cc5640c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3bfabecc-e5c0-4ba2-8f73-dfe93cc5640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6d75693-0437-4982-b0b7-4e00abc5cf42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_321d02ff-b474-4e62-8f48-105e8d7d2b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6d75693-0437-4982-b0b7-4e00abc5cf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32d88a78-2a50-4a6d-8bea-e13c157e8df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2575be-9734-4f8d-b365-d4437ec656b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32d88a78-2a50-4a6d-8bea-e13c157e8df2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2575be-9734-4f8d-b365-d4437ec656b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2e12f869-6d5c-48b3-b1bb-686a327a7d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2575be-9734-4f8d-b365-d4437ec656b6" xlink:to="loc_us-gaap_AwardTypeAxis_2e12f869-6d5c-48b3-b1bb-686a327a7d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_756ea60c-c29d-4b28-aad4-f874195762f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2e12f869-6d5c-48b3-b1bb-686a327a7d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_756ea60c-c29d-4b28-aad4-f874195762f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_50874317-ba5f-452e-b1cd-62a582e1850f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_756ea60c-c29d-4b28-aad4-f874195762f1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_50874317-ba5f-452e-b1cd-62a582e1850f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff2575be-9734-4f8d-b365-d4437ec656b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_937f2537-45af-4d86-b920-03a1ff950fd3" xlink:href="amgn-20211231.xsd#amgn_CommonStockFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_amgn_CommonStockFairValue_937f2537-45af-4d86-b920-03a1ff950fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6969758c-262c-4be8-89d0-31632c914204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6969758c-262c-4be8-89d0-31632c914204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90cfe353-7692-4c6f-8b42-fd0f6c849935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90cfe353-7692-4c6f-8b42-fd0f6c849935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93033cb7-da78-46f2-b57f-61da5f4a5992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_93033cb7-da78-46f2-b57f-61da5f4a5992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f65b3b9a-4a3a-486a-b676-4c7c53a721a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f65b3b9a-4a3a-486a-b676-4c7c53a721a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d1ea90-63f5-4b49-8831-68a400ae11c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09b36453-d46d-4f2f-9726-8603285d6e5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d1ea90-63f5-4b49-8831-68a400ae11c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834a6597-0b66-4e17-8151-67ade4a331a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3ea8038-ccce-4e4a-af1c-d4c383a4e571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834a6597-0b66-4e17-8151-67ade4a331a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3ea8038-ccce-4e4a-af1c-d4c383a4e571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6fc3538c-f361-46c5-a60c-e019468b191b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3ea8038-ccce-4e4a-af1c-d4c383a4e571" xlink:to="loc_us-gaap_AwardTypeAxis_6fc3538c-f361-46c5-a60c-e019468b191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04de7794-ea64-4689-ab66-7e07f88001ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6fc3538c-f361-46c5-a60c-e019468b191b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04de7794-ea64-4689-ab66-7e07f88001ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_55ac2351-0e8c-4b1b-adbd-b78f65d627db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04de7794-ea64-4689-ab66-7e07f88001ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_55ac2351-0e8c-4b1b-adbd-b78f65d627db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3ea8038-ccce-4e4a-af1c-d4c383a4e571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_066bed7d-c9fc-4b19-8988-171495014d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_066bed7d-c9fc-4b19-8988-171495014d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_818105c2-cdac-4a82-8078-55bc8a491225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_818105c2-cdac-4a82-8078-55bc8a491225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f75bd878-3ae8-48df-95c0-a2284a43b840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f75bd878-3ae8-48df-95c0-a2284a43b840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c7b068ba-dfdd-4805-8ae6-44297a1ab9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c7b068ba-dfdd-4805-8ae6-44297a1ab9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45fb5f5a-61ed-49d2-a27b-5b58b226d8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ad26989c-b0dc-44c7-9c18-fd10c0a12798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45fb5f5a-61ed-49d2-a27b-5b58b226d8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c1ad767b-45c4-49f2-a645-497d5c0cf6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c1ad767b-45c4-49f2-a645-497d5c0cf6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aab7a3d3-0f2b-4157-99e3-64121eb1f8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aab7a3d3-0f2b-4157-99e3-64121eb1f8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cf60b86-b50c-4b3f-966f-54a5d54647dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6cf60b86-b50c-4b3f-966f-54a5d54647dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_804fbe00-05fb-4e61-86db-e0d4ae720e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_804fbe00-05fb-4e61-86db-e0d4ae720e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6465ff0b-57bc-4a4a-a702-2b7ddcfc361b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6465ff0b-57bc-4a4a-a702-2b7ddcfc361b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ed7e8e7c-0aca-46dd-8ae5-f5f872bfe507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ed7e8e7c-0aca-46dd-8ae5-f5f872bfe507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d910ca7e-0c15-418a-8530-23a9c76d9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_06fc4a43-138b-481b-a651-daf94e451813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d910ca7e-0c15-418a-8530-23a9c76d9ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e61e3671-85c1-48d0-8ea9-6ee9f9ceab8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e61e3671-85c1-48d0-8ea9-6ee9f9ceab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2af4942e-dd21-4c31-95c5-b0763a9e194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2af4942e-dd21-4c31-95c5-b0763a9e194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c631bc2e-4112-40ee-84ef-c765c3e370b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5a7a70e2-c376-40ac-92a6-30c73c308609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5a7a70e2-c376-40ac-92a6-30c73c308609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6959bdff-6e94-46dd-89e4-cda64424a31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6959bdff-6e94-46dd-89e4-cda64424a31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f9a61898-3c52-45cd-b750-9433b4abbec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f9a61898-3c52-45cd-b750-9433b4abbec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0b83fe0-683b-4632-b647-ef92b0d6aacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0b83fe0-683b-4632-b647-ef92b0d6aacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1c076272-1edc-4118-8abd-30feb6023129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1c076272-1edc-4118-8abd-30feb6023129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a0789d70-b1dd-4cec-8974-2d2cb6290381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9e0d86bd-d1c3-4ad7-8dce-7695da9a62d9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a0789d70-b1dd-4cec-8974-2d2cb6290381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockbasedcompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d334f471-9ee6-4012-b921-a9c2d1fe84dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40c2d965-6f5b-4df6-aa09-eddbabd02f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d334f471-9ee6-4012-b921-a9c2d1fe84dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40c2d965-6f5b-4df6-aa09-eddbabd02f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d91a1de-33a7-48d2-a459-84e00e8ddc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40c2d965-6f5b-4df6-aa09-eddbabd02f01" xlink:to="loc_us-gaap_AwardTypeAxis_8d91a1de-33a7-48d2-a459-84e00e8ddc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2734b98a-661b-48d5-a954-d73773b627fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8d91a1de-33a7-48d2-a459-84e00e8ddc06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2734b98a-661b-48d5-a954-d73773b627fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PerformanceUnitsMember_220f6864-7977-41f6-bc9b-89b74fda70a2" xlink:href="amgn-20211231.xsd#amgn_PerformanceUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2734b98a-661b-48d5-a954-d73773b627fb" xlink:to="loc_amgn_PerformanceUnitsMember_220f6864-7977-41f6-bc9b-89b74fda70a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81b64b4f-a748-47f4-a24d-c4022fc0e686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40c2d965-6f5b-4df6-aa09-eddbabd02f01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81b64b4f-a748-47f4-a24d-c4022fc0e686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81b64b4f-a748-47f4-a24d-c4022fc0e686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CommonStockFairValue_c37566f2-f796-4726-9767-4b7a7f99e401" xlink:href="amgn-20211231.xsd#amgn_CommonStockFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_amgn_CommonStockFairValue_c37566f2-f796-4726-9767-4b7a7f99e401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_440d1ca2-3599-4c68-a00b-e53accc00d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_440d1ca2-3599-4c68-a00b-e53accc00d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9e889c4-59c9-440f-a556-3b5936b52b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9e889c4-59c9-440f-a556-3b5936b52b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2657210f-afec-42e4-a1a2-d40cdb4d5f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1223fec-cecd-4480-9f1e-315aed85744d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2657210f-afec-42e4-a1a2-d40cdb4d5f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Definedcontributionplan" xlink:type="simple" xlink:href="amgn-20211231.xsd#Definedcontributionplan"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Definedcontributionplan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6062f743-de3c-4976-aae2-e5367d838d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_30d40f57-b7dc-4f03-80a6-f153cb0f7c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6062f743-de3c-4976-aae2-e5367d838d02" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_30d40f57-b7dc-4f03-80a6-f153cb0f7c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DefinedcontributionplanDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DefinedcontributionplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c75b0cda-493c-459b-a6ce-5c780ea47298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_9696268d-5407-483b-842c-47182f35d82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c75b0cda-493c-459b-a6ce-5c780ea47298" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_9696268d-5407-483b-842c-47182f35d82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Incometaxes" xlink:type="simple" xlink:href="amgn-20211231.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ce3920eb-98ef-4728-b89d-95ac34dd38c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_45a1808a-a249-49db-a6b5-f2be159c18e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce3920eb-98ef-4728-b89d-95ac34dd38c0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_45a1808a-a249-49db-a6b5-f2be159c18e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a22b510b-42d1-43bd-8916-0fdc56c8d77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9970fd3d-2189-4382-9d5a-621f4b4c214a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22b510b-42d1-43bd-8916-0fdc56c8d77f" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9970fd3d-2189-4382-9d5a-621f4b4c214a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b4e9ab6a-1033-4dd9-82e3-1fd9846a32b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22b510b-42d1-43bd-8916-0fdc56c8d77f" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b4e9ab6a-1033-4dd9-82e3-1fd9846a32b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a5c0b64c-78af-4254-bf5f-d0f831ed47b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22b510b-42d1-43bd-8916-0fdc56c8d77f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a5c0b64c-78af-4254-bf5f-d0f831ed47b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_1b8282b8-7a6d-472d-b445-3e2f53711a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22b510b-42d1-43bd-8916-0fdc56c8d77f" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_1b8282b8-7a6d-472d-b445-3e2f53711a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6f61d988-750a-48e4-9769-9e845ad5b896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a22b510b-42d1-43bd-8916-0fdc56c8d77f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6f61d988-750a-48e4-9769-9e845ad5b896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesIncomeBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1e3a737e-4085-4532-9832-2f94a57613d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_f77609c4-918d-49e6-ae3f-7023205b7e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1e3a737e-4085-4532-9832-2f94a57613d6" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_f77609c4-918d-49e6-ae3f-7023205b7e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a2898d83-3240-4522-97ac-1f4197d67283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_f77609c4-918d-49e6-ae3f-7023205b7e85" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a2898d83-3240-4522-97ac-1f4197d67283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a2898d83-3240-4522-97ac-1f4197d67283" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6b896f61-d846-4edc-ad96-e054c0c114f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:to="loc_us-gaap_DomesticCountryMember_6b896f61-d846-4edc-ad96-e054c0c114f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_f96eee7f-bfc1-4d7a-9f45-db001255b2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_02d4a1dc-9a20-4ef5-b69c-dab7d0968ed4" xlink:to="loc_us-gaap_ForeignCountryMember_f96eee7f-bfc1-4d7a-9f45-db001255b2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_bcedd4f9-bfdb-4dc2-aa09-afdb4bd75ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_f77609c4-918d-49e6-ae3f-7023205b7e85" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_bcedd4f9-bfdb-4dc2-aa09-afdb4bd75ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6a807bc2-a712-4058-99a0-6e027517db81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_bcedd4f9-bfdb-4dc2-aa09-afdb4bd75ed3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6a807bc2-a712-4058-99a0-6e027517db81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d1219fa9-8287-48dc-ab7c-2561f737e0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aeedba2f-6b3f-475f-a03d-aebd3d7b6a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1219fa9-8287-48dc-ab7c-2561f737e0a5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aeedba2f-6b3f-475f-a03d-aebd3d7b6a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0eb7f066-a2c2-4b27-8f33-36c7e9939281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aeedba2f-6b3f-475f-a03d-aebd3d7b6a8f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0eb7f066-a2c2-4b27-8f33-36c7e9939281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6aa8119d-d619-491e-925f-cbf0945cd35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aeedba2f-6b3f-475f-a03d-aebd3d7b6a8f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6aa8119d-d619-491e-925f-cbf0945cd35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bcc8e1bc-7f0a-4d88-ae51-345c0da9ca94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aeedba2f-6b3f-475f-a03d-aebd3d7b6a8f" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bcc8e1bc-7f0a-4d88-ae51-345c0da9ca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ac4d82ed-b5a6-4032-bdcf-3a342a7815e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_aeedba2f-6b3f-475f-a03d-aebd3d7b6a8f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ac4d82ed-b5a6-4032-bdcf-3a342a7815e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3ed57062-e681-418b-ae3e-0d0f7d2508db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1219fa9-8287-48dc-ab7c-2561f737e0a5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3ed57062-e681-418b-ae3e-0d0f7d2508db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_398d80c9-b5b9-4a87-b1e7-73c5cc82b096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3ed57062-e681-418b-ae3e-0d0f7d2508db" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_398d80c9-b5b9-4a87-b1e7-73c5cc82b096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e2bb7a40-3d88-4c8b-87b4-232343357c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3ed57062-e681-418b-ae3e-0d0f7d2508db" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e2bb7a40-3d88-4c8b-87b4-232343357c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cb948d61-53a2-4776-a1bf-a0c23ff360fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3ed57062-e681-418b-ae3e-0d0f7d2508db" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cb948d61-53a2-4776-a1bf-a0c23ff360fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9329ee78-3e29-4572-872e-ed60a6ca2f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3ed57062-e681-418b-ae3e-0d0f7d2508db" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9329ee78-3e29-4572-872e-ed60a6ca2f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5db360d5-4d0b-457b-a0ff-3cf6b972fe07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1219fa9-8287-48dc-ab7c-2561f737e0a5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5db360d5-4d0b-457b-a0ff-3cf6b972fe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c5098800-487c-4186-b1d3-a6bae9c1070e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1e703020-a5e2-491a-bd26-8e20112dc3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5098800-487c-4186-b1d3-a6bae9c1070e" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1e703020-a5e2-491a-bd26-8e20112dc3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1e703020-a5e2-491a-bd26-8e20112dc3ea" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_2f536c7e-3ff7-458e-9f8f-4c7ac4dc0f56" xlink:href="amgn-20211231.xsd#amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_2f536c7e-3ff7-458e-9f8f-4c7ac4dc0f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_aa3a61e1-dd63-4520-ac56-5895529b9937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_aa3a61e1-dd63-4520-ac56-5895529b9937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_12bb1562-1f93-40e6-8fef-623b7e479bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_12bb1562-1f93-40e6-8fef-623b7e479bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_477886ce-1f6c-409a-bb4f-91e9dcc66eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_477886ce-1f6c-409a-bb4f-91e9dcc66eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ccb5ec35-facb-4b49-8e56-7efb9dbcc88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ccb5ec35-facb-4b49-8e56-7efb9dbcc88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_671aa559-0b5c-41bd-8710-78e5fdbb472a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_671aa559-0b5c-41bd-8710-78e5fdbb472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8239cf71-f8f7-4620-af02-11166ca916a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8239cf71-f8f7-4620-af02-11166ca916a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7fbc5190-eb86-4560-9fd3-319f3915a758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd6b364e-9bd6-436d-bb0f-cc1803bf529f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7fbc5190-eb86-4560-9fd3-319f3915a758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1e703020-a5e2-491a-bd26-8e20112dc3ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_affeed7d-d671-474e-b51a-34c6430d53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_affeed7d-d671-474e-b51a-34c6430d53f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_14c5e880-47ae-4a2c-845c-b92e89bd5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_14c5e880-47ae-4a2c-845c-b92e89bd5f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6bfb6667-2b8f-4553-a2af-8497b3819654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6bfb6667-2b8f-4553-a2af-8497b3819654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_9cd03ec2-4bb1-4598-85a5-e98a2ff3344d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_9cd03ec2-4bb1-4598-85a5-e98a2ff3344d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9f7b08fa-0951-4d31-8ecf-337f53032a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_9f7b08fa-0951-4d31-8ecf-337f53032a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_20e71900-dd83-4110-bc9c-7a8b663f01ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_20e71900-dd83-4110-bc9c-7a8b663f01ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5486ff7a-fdfa-4c85-94fe-930bd784340a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_aa36e45a-88b4-42e0-86a3-6ca15ebd549c" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5486ff7a-fdfa-4c85-94fe-930bd784340a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2ee2f59a-363b-4de3-8d9b-5d4cd9d6877c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ee2f59a-363b-4de3-8d9b-5d4cd9d6877c" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_82cb5f12-a51e-43b3-a6cd-3ce5932f3474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_82cb5f12-a51e-43b3-a6cd-3ce5932f3474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82cb5f12-a51e-43b3-a6cd-3ce5932f3474" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bbfb830f-24e0-4052-bc7e-3feac748d289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:to="loc_us-gaap_DomesticCountryMember_bbfb830f-24e0-4052-bc7e-3feac748d289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a37e651c-10bd-4ba6-9f81-0d8af42f6e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a37e651c-10bd-4ba6-9f81-0d8af42f6e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e7db11ea-c89f-4969-94b0-860c5672e471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8ec0ba2e-12fc-4b4e-93cb-25053f3849a7" xlink:to="loc_us-gaap_ForeignCountryMember_e7db11ea-c89f-4969-94b0-860c5672e471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_a1761395-92cd-4e51-a4ee-92f5e08b33cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:to="loc_us-gaap_TaxPeriodAxis_a1761395-92cd-4e51-a4ee-92f5e08b33cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_a1761395-92cd-4e51-a4ee-92f5e08b33cd" xlink:to="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ExpirationInTaxYearsBetween2023And2040Member_70580d4d-fcfe-4d7d-a096-b266741e08c0" xlink:href="amgn-20211231.xsd#amgn_ExpirationInTaxYearsBetween2023And2040Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:to="loc_amgn_ExpirationInTaxYearsBetween2023And2040Member_70580d4d-fcfe-4d7d-a096-b266741e08c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2037Member_421459f9-37ab-4e1a-97a3-4369d6e6a614" xlink:href="amgn-20211231.xsd#amgn_OperatingLossesThatExpireBetween2022And2037Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2022And2037Member_421459f9-37ab-4e1a-97a3-4369d6e6a614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_600ba3f4-3117-4b7c-ac87-e983f8787bd7" xlink:href="amgn-20211231.xsd#amgn_OperatingLossesThatExpireBetween2022And2031Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7f495f1b-13d6-466f-9e9e-aaa1bd2873d6" xlink:to="loc_amgn_OperatingLossesThatExpireBetween2022And2031Member_600ba3f4-3117-4b7c-ac87-e983f8787bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_8cba6485-fbc2-482f-ae4e-effcc4a968ff" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e190fb7b-571f-4f40-a817-c74355aa9f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_e190fb7b-571f-4f40-a817-c74355aa9f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_e676f55e-ba2f-44eb-bc78-ee0f67db8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_e676f55e-ba2f-44eb-bc78-ee0f67db8b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a166ef72-b038-4bb4-a64d-72bbdbc9c798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a166ef72-b038-4bb4-a64d-72bbdbc9c798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_39042a48-3941-45fa-9bf6-e869e6143102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_39042a48-3941-45fa-9bf6-e869e6143102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_921baba6-3bbb-4670-89fb-aaa64e1f282a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_921baba6-3bbb-4670-89fb-aaa64e1f282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b27a9531-e3c8-4a6d-8ee3-81df9127b3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b27a9531-e3c8-4a6d-8ee3-81df9127b3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d26521b3-ae4d-464f-bb95-d8c384214681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d26521b3-ae4d-464f-bb95-d8c384214681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_6e6061bb-d609-4a14-9aa7-fa9d4157d5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_us-gaap_IncomeTaxesPaid_6e6061bb-d609-4a14-9aa7-fa9d4157d5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax_efb18714-16e9-4e2e-ba3a-68fee162130b" xlink:href="amgn-20211231.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_amgn_ProposedAdditionalIncomeTax_efb18714-16e9-4e2e-ba3a-68fee162130b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax_709e0a30-a033-44aa-a8f7-3322c53fc0c2" xlink:href="amgn-20211231.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax_709e0a30-a033-44aa-a8f7-3322c53fc0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_caadd6c4-5ba1-4141-ac7f-c151e96ddb8a" xlink:href="amgn-20211231.xsd#amgn_NumberOfNoticesOnProposedAdditionalTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_705ae5ce-dd4c-4b63-b3a0-f3356dfa906c" xlink:to="loc_amgn_NumberOfNoticesOnProposedAdditionalTax_caadd6c4-5ba1-4141-ac7f-c151e96ddb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f1d96707-e57d-47bd-a64d-b0208febbbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f1d96707-e57d-47bd-a64d-b0208febbbc9" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f04289ac-dd98-4c01-9e89-d1fcb5bf4cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f04289ac-dd98-4c01-9e89-d1fcb5bf4cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c4b60c12-befc-457f-a610-c643872b3c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c4b60c12-befc-457f-a610-c643872b3c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_10a58650-c72f-4c1d-9bc1-afd3d4f0463d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_10a58650-c72f-4c1d-9bc1-afd3d4f0463d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3ecc5bc9-6d21-41e6-8747-017542c00684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3ecc5bc9-6d21-41e6-8747-017542c00684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_91851f99-18be-4f26-93b2-cfff1040d421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_91851f99-18be-4f26-93b2-cfff1040d421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_dfedd1b3-42b6-4df8-84ed-93f2f618b34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6aacf590-8773-43bb-9357-db7174257f67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_dfedd1b3-42b6-4df8-84ed-93f2f618b34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#IncometaxesReconciliationofFederalStatutoryTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0a4bea1-fe5c-41b7-84c1-8636921c6ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c0a4bea1-fe5c-41b7-84c1-8636921c6ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cc7db805-90af-4097-accf-31f7b68b2bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cc7db805-90af-4097-accf-31f7b68b2bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_95437702-6ef0-46c6-84a3-031e9cd0c04c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_95437702-6ef0-46c6-84a3-031e9cd0c04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_3cf288c6-d646-4829-ac31-b7fe37576e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_3cf288c6-d646-4829-ac31-b7fe37576e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_a9888971-d963-40b8-aa06-817259258bf4" xlink:href="amgn-20211231.xsd#amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent_a9888971-d963-40b8-aa06-817259258bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a04ca2c0-eb5d-40ca-9032-5aa88e1e7bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a04ca2c0-eb5d-40ca-9032-5aa88e1e7bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_1e51c348-ce2c-44cf-aefe-dcfb268a25f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_1e51c348-ce2c-44cf-aefe-dcfb268a25f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_58654a9a-2271-46fd-a4e4-675b61933fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_58654a9a-2271-46fd-a4e4-675b61933fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2bb7e12f-e0ff-49fb-aa5b-aaf542d262ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2bb7e12f-e0ff-49fb-aa5b-aaf542d262ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8f8b92a8-1858-4882-bc05-98ecc6d9b9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fe51115c-47b4-4316-931d-d99ec424fc8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8f8b92a8-1858-4882-bc05-98ecc6d9b9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Earningspershare" xlink:type="simple" xlink:href="amgn-20211231.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3bf3320b-b100-4265-a39a-ae403500dd44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ca27a3ed-c86d-454a-bb89-2867ce99deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3bf3320b-b100-4265-a39a-ae403500dd44" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ca27a3ed-c86d-454a-bb89-2867ce99deb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7774f254-3548-4165-9a9c-1c782164255c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4bfb3a07-e756-4ce7-8426-4cdd3721a065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7774f254-3548-4165-9a9c-1c782164255c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4bfb3a07-e756-4ce7-8426-4cdd3721a065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#EarningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_12338c75-ce44-4fdb-89b6-6e936f2713a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract_5157e08a-2e23-4786-bcc1-e4f74e054422" xlink:href="amgn-20211231.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_12338c75-ce44-4fdb-89b6-6e936f2713a1" xlink:to="loc_amgn_BasicAndDilutedEarningPerShareAbstract_5157e08a-2e23-4786-bcc1-e4f74e054422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_2945fcbd-8353-4562-9c58-29e03361d561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_5157e08a-2e23-4786-bcc1-e4f74e054422" xlink:to="loc_us-gaap_NetIncomeLossAbstract_2945fcbd-8353-4562-9c58-29e03361d561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2385a43-0596-44ad-a969-e2fe322d4bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_2945fcbd-8353-4562-9c58-29e03361d561" xlink:to="loc_us-gaap_NetIncomeLoss_c2385a43-0596-44ad-a969-e2fe322d4bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4eab30d7-bea3-4283-9c6b-4fc950d2a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_5157e08a-2e23-4786-bcc1-e4f74e054422" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4eab30d7-bea3-4283-9c6b-4fc950d2a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ab45a6f-9d21-4ae4-bd03-7006e8c1c66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4eab30d7-bea3-4283-9c6b-4fc950d2a1e8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ab45a6f-9d21-4ae4-bd03-7006e8c1c66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5fc9cf37-e7ac-4ad2-8585-3c08ffb7240f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4eab30d7-bea3-4283-9c6b-4fc950d2a1e8" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5fc9cf37-e7ac-4ad2-8585-3c08ffb7240f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f12fb7a-7148-44de-889b-998d7d07fd93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4eab30d7-bea3-4283-9c6b-4fc950d2a1e8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f12fb7a-7148-44de-889b-998d7d07fd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a9129ecd-a342-4d4a-a5aa-c45671eb4ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_5157e08a-2e23-4786-bcc1-e4f74e054422" xlink:to="loc_us-gaap_EarningsPerShareBasic_a9129ecd-a342-4d4a-a5aa-c45671eb4ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eb0e3b55-750c-47d2-ab32-53243ce59170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_5157e08a-2e23-4786-bcc1-e4f74e054422" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eb0e3b55-750c-47d2-ab32-53243ce59170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Collaborations" xlink:type="simple" xlink:href="amgn-20211231.xsd#Collaborations"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Collaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_310a9597-5b5a-423f-a485-bec6672304f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_40bce970-b4a6-4c81-b5f8-3e43eb45d39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_310a9597-5b5a-423f-a485-bec6672304f7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_40bce970-b4a6-4c81-b5f8-3e43eb45d39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#CollaborationsNovartisAGDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsNovartisAGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d10821e-1e11-4b88-9a4c-08592bef31e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d10821e-1e11-4b88-9a4c-08592bef31e0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_56b4e9fc-eb1a-4996-bae1-aec967ce3cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_56b4e9fc-eb1a-4996-bae1-aec967ce3cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57b0f8a4-c961-42f0-a2b8-9f5e37d17aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_56b4e9fc-eb1a-4996-bae1-aec967ce3cac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57b0f8a4-c961-42f0-a2b8-9f5e37d17aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f13149bf-0903-4820-a8cb-42f628e36102" xlink:href="amgn-20211231.xsd#amgn_CollaborativeArrangementwithNovartisPharmaAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57b0f8a4-c961-42f0-a2b8-9f5e37d17aed" xlink:to="loc_amgn_CollaborativeArrangementwithNovartisPharmaAGMember_f13149bf-0903-4820-a8cb-42f628e36102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_44ab3564-cbf9-43a1-8683-ef20372a0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_44ab3564-cbf9-43a1-8683-ef20372a0e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44ab3564-cbf9-43a1-8683-ef20372a0e29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8bc16f6-df2e-46e6-b174-51e3a4a089d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8bc16f6-df2e-46e6-b174-51e3a4a089d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f0884ae1-a524-4fbe-ba6d-7e3e29d6adcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d94e2b5d-a4d9-4f43-a727-9c9ddd374677" xlink:to="loc_us-gaap_CostOfSalesMember_f0884ae1-a524-4fbe-ba6d-7e3e29d6adcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:to="loc_srt_ProductOrServiceAxis_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0155410b-969f-4060-8c62-c97e2c404506" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3a0a4aaa-ef3c-45eb-93c7-ea9c20c306d2" xlink:to="loc_srt_ProductsAndServicesDomain_0155410b-969f-4060-8c62-c97e2c404506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d7e55a29-e640-43ca-9393-cda08b965b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0155410b-969f-4060-8c62-c97e2c404506" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d7e55a29-e640-43ca-9393-cda08b965b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_521d8caf-9fb7-4085-8588-196f99b9786c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_b1e81e05-0d59-4fcb-a3f3-7c0e1d97e3f8" xlink:href="amgn-20211231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment_b1e81e05-0d59-4fcb-a3f3-7c0e1d97e3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_d15c2a8b-875e-4a4e-a559-9ada089d7668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_d15c2a8b-875e-4a4e-a559-9ada089d7668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_ac8df0a0-01a4-44ee-80c1-512fc1225452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6ac439e4-e96d-415c-9196-5564e64a5eba" xlink:to="loc_us-gaap_RoyaltyExpense_ac8df0a0-01a4-44ee-80c1-512fc1225452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#CollaborationsBeiGeneDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsBeiGeneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6f18517-df53-4caa-8977-add66fdbff2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6f18517-df53-4caa-8977-add66fdbff2f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7acee467-375b-4806-9028-0e36efb102c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7acee467-375b-4806-9028-0e36efb102c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f726af8d-8e98-45a4-86bf-2d65edb19c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7acee467-375b-4806-9028-0e36efb102c9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f726af8d-8e98-45a4-86bf-2d65edb19c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_47047eaa-57cc-4158-b45f-b68a95168a0f" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f726af8d-8e98-45a4-86bf-2d65edb19c09" xlink:to="loc_amgn_BeiGeneMember_47047eaa-57cc-4158-b45f-b68a95168a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_srt_CounterpartyNameAxis_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5e1bd44-6998-4e54-b168-084c21e523c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ba12ca6e-cdaf-4ee4-ba2d-058d0245c927" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5e1bd44-6998-4e54-b168-084c21e523c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7749fc5-1e53-45a1-888e-e47e63da7ef2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_srt_ProductOrServiceAxis_a7749fc5-1e53-45a1-888e-e47e63da7ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_71fbe8a6-baee-482b-96c1-e97464643912" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a7749fc5-1e53-45a1-888e-e47e63da7ef2" xlink:to="loc_srt_ProductsAndServicesDomain_71fbe8a6-baee-482b-96c1-e97464643912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_1f3d439f-a753-419e-9552-aab8704cecc0" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_71fbe8a6-baee-482b-96c1-e97464643912" xlink:to="loc_amgn_BeiGeneMember_1f3d439f-a753-419e-9552-aab8704cecc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1cd11090-e918-4932-affa-ccdee58d5aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1cd11090-e918-4932-affa-ccdee58d5aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1cd11090-e918-4932-affa-ccdee58d5aa4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bbac84c6-2d2e-4fb7-baa9-4ed233886aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bbac84c6-2d2e-4fb7-baa9-4ed233886aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f823824-1b47-477a-8801-bc186b4afb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ed1782b8-2e72-4f0e-a7c2-e2ea797cf7e9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f823824-1b47-477a-8801-bc186b4afb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0a0df75-b3f9-4dae-a641-6bfa1ddb9c96" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_8d4a8b59-ef9a-49a2-ac7b-91175906d034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_8d4a8b59-ef9a-49a2-ac7b-91175906d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_3a8b8437-5693-46c0-8017-24f3e77e173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1804526c-a84d-47c9-99f6-ceac03a7d99a" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_3a8b8437-5693-46c0-8017-24f3e77e173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bb53c651-562b-4127-9d9d-622f2068134e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bb53c651-562b-4127-9d9d-622f2068134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4645d489-d897-4958-8db5-23df986afdde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb53c651-562b-4127-9d9d-622f2068134e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4645d489-d897-4958-8db5-23df986afdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_0f97d888-702c-4557-9a63-0db3d140bcb1" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4645d489-d897-4958-8db5-23df986afdde" xlink:to="loc_amgn_BeiGeneMember_0f97d888-702c-4557-9a63-0db3d140bcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5dac4d6d-3b69-4708-8447-eca30f05aec9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_4c025bb8-2975-45e3-bfd2-762e012d85a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_4c025bb8-2975-45e3-bfd2-762e012d85a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_49676ab4-8794-4e84-8c93-8cfaf3a719bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_49676ab4-8794-4e84-8c93-8cfaf3a719bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f745ff30-3be1-4e25-a3c2-340d9ea5d08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f745ff30-3be1-4e25-a3c2-340d9ea5d08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_ad6ba28c-339f-49cd-9db6-1614ce69e1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_ad6ba28c-339f-49cd-9db6-1614ce69e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10a1439f-cc5d-4153-9003-468cd5b0f2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10a1439f-cc5d-4153-9003-468cd5b0f2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProfitAndLossShareOfExpenses_a3797652-a1a0-447f-a7aa-3c2944c58628" xlink:href="amgn-20211231.xsd#amgn_ProfitAndLossShareOfExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_amgn_ProfitAndLossShareOfExpenses_a3797652-a1a0-447f-a7aa-3c2944c58628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_17af0675-98ad-4cd5-9ab2-41b86fa53740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_931f11c4-692d-40f4-8c74-294187565071" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_17af0675-98ad-4cd5-9ab2-41b86fa53740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#CollaborationsKyowaKirinDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CollaborationsKyowaKirinDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d2f6a653-5284-4c1b-b70b-21a2d1231ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_509e706a-511d-4951-af48-4a172adbe560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d2f6a653-5284-4c1b-b70b-21a2d1231ce5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_509e706a-511d-4951-af48-4a172adbe560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b0bf06e9-f64c-4a40-9b61-9ab08904c359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_509e706a-511d-4951-af48-4a172adbe560" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b0bf06e9-f64c-4a40-9b61-9ab08904c359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d5a2175-7ac8-4f64-8c31-d6c43a472d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b0bf06e9-f64c-4a40-9b61-9ab08904c359" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d5a2175-7ac8-4f64-8c31-d6c43a472d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyowaKirinCoLtdMember_f1df9bfd-2c35-439a-b9c9-621dd0dcd3e3" xlink:href="amgn-20211231.xsd#amgn_KyowaKirinCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d5a2175-7ac8-4f64-8c31-d6c43a472d94" xlink:to="loc_amgn_KyowaKirinCoLtdMember_f1df9bfd-2c35-439a-b9c9-621dd0dcd3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_509e706a-511d-4951-af48-4a172adbe560" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_UpFrontPayment_175c3e2f-0354-46a4-9f8e-ac426a9f9d9e" xlink:href="amgn-20211231.xsd#amgn_UpFrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:to="loc_amgn_UpFrontPayment_175c3e2f-0354-46a4-9f8e-ac426a9f9d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_8aa59652-d95d-4005-9648-f13b79bf3833" xlink:href="amgn-20211231.xsd#amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb4f329a-6630-4d75-b8e6-a55ac33b2dc9" xlink:to="loc_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments_8aa59652-d95d-4005-9648-f13b79bf3833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Investments" xlink:type="simple" xlink:href="amgn-20211231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_569ace62-771c-4591-94eb-58fe449f7383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c812ff83-d4bc-4c22-a6f9-325b2fb589b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_569ace62-771c-4591-94eb-58fe449f7383" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c812ff83-d4bc-4c22-a6f9-325b2fb589b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_832316ac-fcbf-4df1-b090-42169a3310f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6c8e5688-6140-4fc4-b9e6-9e6ff5af07ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_832316ac-fcbf-4df1-b090-42169a3310f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6c8e5688-6140-4fc4-b9e6-9e6ff5af07ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_91d8d7d8-26e2-4678-ab9e-293180e2468a" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_832316ac-fcbf-4df1-b090-42169a3310f5" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_91d8d7d8-26e2-4678-ab9e-293180e2468a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e62a5634-e14d-49f8-9945-5cd95caa92cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_832316ac-fcbf-4df1-b090-42169a3310f5" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e62a5634-e14d-49f8-9945-5cd95caa92cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_88c3b87a-1ff1-4f7b-b089-7fd2ea836155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6637b54b-49ee-4e45-8876-9cd31c3fb1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_88c3b87a-1ff1-4f7b-b089-7fd2ea836155" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6637b54b-49ee-4e45-8876-9cd31c3fb1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b9403533-ffbd-463b-8ded-440d99a796f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6637b54b-49ee-4e45-8876-9cd31c3fb1ff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b9403533-ffbd-463b-8ded-440d99a796f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9403533-ffbd-463b-8ded-440d99a796f3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5130f6f1-8bd6-4d34-822c-479cb31ab5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5130f6f1-8bd6-4d34-822c-479cb31ab5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_17e0d6f6-4411-449e-a21f-dbd94377bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_17e0d6f6-4411-449e-a21f-dbd94377bbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cc6d8d27-9950-4c5d-901b-e474f516b2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cc6d8d27-9950-4c5d-901b-e474f516b2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_913136c6-a9a0-4387-8def-9d1d1ad51872" xlink:href="amgn-20211231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a973946e-a4df-43e9-b04f-f6193b72bc64" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_913136c6-a9a0-4387-8def-9d1d1ad51872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b9f3348c-1dca-4978-8552-b4855d2554ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6637b54b-49ee-4e45-8876-9cd31c3fb1ff" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b9f3348c-1dca-4978-8552-b4855d2554ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b9f3348c-1dca-4978-8552-b4855d2554ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d957840c-ac4d-46c5-8da3-c21f1a49fc77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d957840c-ac4d-46c5-8da3-c21f1a49fc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba379571-39c6-4a2d-ae24-94fed0cece32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba379571-39c6-4a2d-ae24-94fed0cece32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcdbf0f3-1b2b-4013-8298-28ae4420bc27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fcdbf0f3-1b2b-4013-8298-28ae4420bc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f931c92c-f0a8-4fe3-9ebe-2c64d3e27d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e27ffd44-19ea-43df-b540-f2ca21ab939e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f931c92c-f0a8-4fe3-9ebe-2c64d3e27d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dc558bc9-c73d-488c-8350-a737a53ee5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2a4d902c-e8a8-437a-a66d-718ea0006b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dc558bc9-c73d-488c-8350-a737a53ee5fc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2a4d902c-e8a8-437a-a66d-718ea0006b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2a4d902c-e8a8-437a-a66d-718ea0006b08" xlink:to="loc_us-gaap_FinancialInstrumentAxis_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4221636-55a3-4b03-b881-7f57a067c6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_46b5651c-32b4-41cc-aa88-1aa4fee4d9b0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4221636-55a3-4b03-b881-7f57a067c6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_6ea5b9d4-8050-4313-895d-955fc793e2df" xlink:href="amgn-20211231.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4221636-55a3-4b03-b881-7f57a067c6a5" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_6ea5b9d4-8050-4313-895d-955fc793e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5c8e6c9f-debe-46c1-b65d-ea56d0eb9d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2a4d902c-e8a8-437a-a66d-718ea0006b08" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5c8e6c9f-debe-46c1-b65d-ea56d0eb9d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5c8e6c9f-debe-46c1-b65d-ea56d0eb9d53" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10119148-274b-410f-8b9a-ba00fa086ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10119148-274b-410f-8b9a-ba00fa086ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e48f66b4-cbf0-4815-85eb-c03ffe17afe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e48f66b4-cbf0-4815-85eb-c03ffe17afe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ff7bc6e-c69a-43bd-8914-9fc81f5b2308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_5ede9fff-f1f6-4ffb-9b65-489cc38eea82" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ff7bc6e-c69a-43bd-8914-9fc81f5b2308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d1a8523-8b78-4bbc-9ace-ebb203fa0431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_739954f2-27b5-495a-8a86-412d845bd30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d1a8523-8b78-4bbc-9ace-ebb203fa0431" xlink:to="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_739954f2-27b5-495a-8a86-412d845bd30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_739954f2-27b5-495a-8a86-412d845bd30b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_380a139d-8f5c-4da2-b0c4-6211320e7d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4b31d607-9eb4-4b93-a80c-cd8b6f0397d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_380a139d-8f5c-4da2-b0c4-6211320e7d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_2092abf2-ed10-4462-b9f4-65d3e8342fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_380a139d-8f5c-4da2-b0c4-6211320e7d7a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_2092abf2-ed10-4462-b9f4-65d3e8342fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsTable_739954f2-27b5-495a-8a86-412d845bd30b" xlink:to="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_6b4e890a-06c9-4aa4-a8c0-96e1cd1366a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:to="loc_us-gaap_Cash_6b4e890a-06c9-4aa4-a8c0-96e1cd1366a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_d802d3b8-6c38-4f9a-a007-27861868fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems_4ef1e95f-d7e8-4a09-ae05-6f6133cf2ec9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_d802d3b8-6c38-4f9a-a007-27861868fc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82350380-ee2a-4bfb-a0d2-60cbd24a5086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_86d07650-846e-47e3-8b96-3f523092eb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82350380-ee2a-4bfb-a0d2-60cbd24a5086" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_86d07650-846e-47e3-8b96-3f523092eb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_8278a678-846b-4a1b-ae74-da5b9befd982" xlink:href="amgn-20211231.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82350380-ee2a-4bfb-a0d2-60cbd24a5086" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_8278a678-846b-4a1b-ae74-da5b9befd982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4086a794-b414-4a38-88c0-5439817e588b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82350380-ee2a-4bfb-a0d2-60cbd24a5086" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4086a794-b414-4a38-88c0-5439817e588b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2fd22534-9a3c-4212-985d-54b6cc0ceb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f8f1ae4b-14f1-4d1b-a8e2-178ec9c01211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2fd22534-9a3c-4212-985d-54b6cc0ceb28" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f8f1ae4b-14f1-4d1b-a8e2-178ec9c01211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5d5500c-faf6-480e-8add-c9971098efe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f8f1ae4b-14f1-4d1b-a8e2-178ec9c01211" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5d5500c-faf6-480e-8add-c9971098efe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ad231624-6146-42cf-8823-29c53f74510b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5d5500c-faf6-480e-8add-c9971098efe0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ad231624-6146-42cf-8823-29c53f74510b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_00084333-e7e3-4958-b77d-e5ec5db77a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ad231624-6146-42cf-8823-29c53f74510b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_00084333-e7e3-4958-b77d-e5ec5db77a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f8f1ae4b-14f1-4d1b-a8e2-178ec9c01211" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cc4d7709-b759-435d-a685-e79fc330cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cc4d7709-b759-435d-a685-e79fc330cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b5794782-7d6b-4952-aa97-cae74fe8af30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b5794782-7d6b-4952-aa97-cae74fe8af30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2603fbc-e6f2-4f80-a1fc-3e88435fe122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f2603fbc-e6f2-4f80-a1fc-3e88435fe122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_45cfbe75-67be-4f8d-99a4-fc14cba8f995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_45cfbe75-67be-4f8d-99a4-fc14cba8f995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_9b77f8e0-c909-4c53-8106-9068a9420069" xlink:href="amgn-20211231.xsd#amgn_EquitySecuritiesRealizedGainLossOnDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_35987429-e547-4652-9469-f366c379f81e" xlink:to="loc_amgn_EquitySecuritiesRealizedGainLossOnDisposal_9b77f8e0-c909-4c53-8106-9068a9420069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7f3971d-3709-46af-b101-4086d1f23e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7f3971d-3709-46af-b101-4086d1f23e10" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_60b840d6-3f43-42f7-a462-92a376e82dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:to="loc_us-gaap_InvestmentTypeAxis_60b840d6-3f43-42f7-a462-92a376e82dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cdf7636e-59a6-4b1a-9d37-ce6f8664e722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_60b840d6-3f43-42f7-a462-92a376e82dcf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cdf7636e-59a6-4b1a-9d37-ce6f8664e722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_9ab0ac45-e027-4597-a0b7-7b12ca4c342a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cdf7636e-59a6-4b1a-9d37-ce6f8664e722" xlink:to="loc_srt_PartnershipInterestMember_9ab0ac45-e027-4597-a0b7-7b12ca4c342a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da3733f0-fd21-4bd9-836e-b96d09ff1a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da3733f0-fd21-4bd9-836e-b96d09ff1a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5f97076-b1bb-4ed8-8d06-cf9f1934a785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da3733f0-fd21-4bd9-836e-b96d09ff1a4b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5f97076-b1bb-4ed8-8d06-cf9f1934a785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6e68bab2-2a26-4ca4-98a5-81449d072087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5f97076-b1bb-4ed8-8d06-cf9f1934a785" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_6e68bab2-2a26-4ca4-98a5-81449d072087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_2a9f31cc-e879-46f6-add4-d37a155bc9cf" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_74d94a89-6c12-4857-8b47-e2b168311f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:to="loc_us-gaap_AlternativeInvestment_74d94a89-6c12-4857-8b47-e2b168311f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_961d4d08-3331-4d98-aba3-12c6f557c56c" xlink:href="amgn-20211231.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_961d4d08-3331-4d98-aba3-12c6f557c56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_b503ecc5-3af2-4235-8ada-c67592bf450e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_e828f1e2-aed4-49d6-afbd-5a47d0052090" xlink:to="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_b503ecc5-3af2-4235-8ada-c67592bf450e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsBeiGeneDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_98faafea-04ad-405e-b440-8377df25d94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_98faafea-04ad-405e-b440-8377df25d94a" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e1ed18bb-5c01-40f7-a29f-f70e2b51514d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e1ed18bb-5c01-40f7-a29f-f70e2b51514d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e1ed18bb-5c01-40f7-a29f-f70e2b51514d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_ae8ae3a3-cb3a-4836-b161-27e889ef1f81" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:to="loc_amgn_BeiGeneMember_ae8ae3a3-cb3a-4836-b161-27e889ef1f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_7367596f-35f3-4f46-8c9f-507b8457a875" xlink:href="amgn-20211231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6e2f53e-433d-40d4-a397-6b9dd18cafe2" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_7367596f-35f3-4f46-8c9f-507b8457a875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05c73e7f-f314-4b80-8424-0967c277bf8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:to="loc_srt_RangeAxis_05c73e7f-f314-4b80-8424-0967c277bf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_05c73e7f-f314-4b80-8424-0967c277bf8a" xlink:to="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5fa2303d-a887-41fb-906b-927216c7f16d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:to="loc_srt_MinimumMember_5fa2303d-a887-41fb-906b-927216c7f16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_78cbe23b-d6df-4999-94fb-64932a1c8ca2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7702086-8f9d-4079-b447-1407d87994e6" xlink:to="loc_srt_MaximumMember_78cbe23b-d6df-4999-94fb-64932a1c8ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_ceecfa5c-2d56-4589-a1a8-7dbfb8cabc7c" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5d05da86-6f92-4fd0-b36a-ed533fe25130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5d05da86-6f92-4fd0-b36a-ed533fe25130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e994b31e-215f-4b50-b11b-d573cb392451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e994b31e-215f-4b50-b11b-d573cb392451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bceeba58-0bb3-4365-bb12-f4a778688402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bceeba58-0bb3-4365-bb12-f4a778688402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_737e15af-1850-49e8-93ae-6e7fd88a0b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_737e15af-1850-49e8-93ae-6e7fd88a0b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_63dde000-92e6-41d4-bd5a-f0f3674bebdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_63dde000-92e6-41d4-bd5a-f0f3674bebdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_3db9def9-8c30-45af-9ff7-4d593c164549" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_3db9def9-8c30-45af-9ff7-4d593c164549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_472d306b-cadb-4bc0-9a87-9cb5313f6044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_472d306b-cadb-4bc0-9a87-9cb5313f6044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_f802744d-6a96-4835-a7cd-4f39c8b0795a" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentChangeInCarryingValueOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValueOther_f802744d-6a96-4835-a7cd-4f39c8b0795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_02b8db2c-e056-40f1-9832-198efc9e17b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_02b8db2c-e056-40f1-9832-198efc9e17b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_f668524f-0713-4a0b-9203-f6d0709e97eb" xlink:href="amgn-20211231.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_f668524f-0713-4a0b-9203-f6d0709e97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7155cab7-0f9f-44df-85e4-5eda1bef5056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_adc3580a-0bc2-48a3-b5f3-b789a97ea030" xlink:to="loc_us-gaap_EquityMethodInvestments_7155cab7-0f9f-44df-85e4-5eda1bef5056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b0bb30a-b603-4404-93e6-5509db0a2bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_98faafea-04ad-405e-b440-8377df25d94a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b0bb30a-b603-4404-93e6-5509db0a2bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9b2974ff-c383-47a6-922f-46758fb633b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b0bb30a-b603-4404-93e6-5509db0a2bd0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9b2974ff-c383-47a6-922f-46758fb633b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ddccd2a7-7f26-4ca1-b790-0cbb0fa28907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_bf7caaff-0b9e-4fd2-b951-1f912bcba8cf" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93522826-dbcf-4cde-bfdf-6ac6d79ad2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4b0bb30a-b603-4404-93e6-5509db0a2bd0" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93522826-dbcf-4cde-bfdf-6ac6d79ad2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_7b063259-db16-4118-838b-a8547efbe2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_93522826-dbcf-4cde-bfdf-6ac6d79ad2b1" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_7b063259-db16-4118-838b-a8547efbe2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InvestmentsNeumoraTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc985261-94e8-4f0d-9a1f-c4cb962e08db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7954dfb6-de72-4437-b93a-95d7e01e8f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc985261-94e8-4f0d-9a1f-c4cb962e08db" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7954dfb6-de72-4437-b93a-95d7e01e8f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee32099a-069d-4790-b2f1-adb8b19d87d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7954dfb6-de72-4437-b93a-95d7e01e8f2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee32099a-069d-4790-b2f1-adb8b19d87d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb1deebc-20a4-4192-af5f-fce337b43f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee32099a-069d-4790-b2f1-adb8b19d87d8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb1deebc-20a4-4192-af5f-fce337b43f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_0782491b-2ec3-4f07-835c-86062ce79813" xlink:href="amgn-20211231.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb1deebc-20a4-4192-af5f-fce337b43f7d" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_0782491b-2ec3-4f07-835c-86062ce79813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_7954dfb6-de72-4437-b93a-95d7e01e8f2c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d259d321-0416-4705-b28c-f226863940ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d259d321-0416-4705-b28c-f226863940ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_db274654-5c90-4a62-afbd-511097ebef02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_db274654-5c90-4a62-afbd-511097ebef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_cbe15c19-43c5-43c6-9bfb-555d22732b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_cbe15c19-43c5-43c6-9bfb-555d22732b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_a93d8fad-dc4b-49d3-b396-dced0be4410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_a93d8fad-dc4b-49d3-b396-dced0be4410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_e1e0951c-8051-4c63-b48b-7ab303e9b4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d4712c17-8e0b-418f-85aa-8f119f330275" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_e1e0951c-8051-4c63-b48b-7ab303e9b4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Inventories" xlink:type="simple" xlink:href="amgn-20211231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3303ac8b-3a29-4820-b105-21b4d97dbf04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_b436fdb9-87b4-4412-af81-b1c4a0208061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3303ac8b-3a29-4820-b105-21b4d97dbf04" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_b436fdb9-87b4-4412-af81-b1c4a0208061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b383779e-d77d-42dc-a0fe-b1151667524c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9919e7de-b131-4bca-b495-7501557b5b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b383779e-d77d-42dc-a0fe-b1151667524c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9919e7de-b131-4bca-b495-7501557b5b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ae54eb67-fa57-4e2a-852f-c806e2ab791c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5db50e12-357f-4e2b-bdfb-8360ab05ac96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae54eb67-fa57-4e2a-852f-c806e2ab791c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5db50e12-357f-4e2b-bdfb-8360ab05ac96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8901ea0f-2efb-4c1c-9bf6-9fb6cda238c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae54eb67-fa57-4e2a-852f-c806e2ab791c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8901ea0f-2efb-4c1c-9bf6-9fb6cda238c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ceea9b91-0c98-4cdf-8d2a-fb99cad260e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae54eb67-fa57-4e2a-852f-c806e2ab791c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ceea9b91-0c98-4cdf-8d2a-fb99cad260e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fa2219d5-382d-4451-8efd-b5a66318d561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae54eb67-fa57-4e2a-852f-c806e2ab791c" xlink:to="loc_us-gaap_InventoryNet_fa2219d5-382d-4451-8efd-b5a66318d561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="amgn-20211231.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e9d78b05-ed5b-463a-90c2-3ffdde0e235a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e3bddd29-69c5-4691-9faa-b087e203606d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e9d78b05-ed5b-463a-90c2-3ffdde0e235a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e3bddd29-69c5-4691-9faa-b087e203606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_93f13762-7d83-489b-ac5c-eca6e39975fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_69c97636-6b60-42bd-996a-d2c188fb9e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_93f13762-7d83-489b-ac5c-eca6e39975fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_69c97636-6b60-42bd-996a-d2c188fb9e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_cdfc1347-526e-4598-a8c2-af803cfd403a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_93f13762-7d83-489b-ac5c-eca6e39975fa" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_cdfc1347-526e-4598-a8c2-af803cfd403a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#PropertyplantandequipmentScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2022dad5-4c6c-4e14-9a5f-9e1dc9e0585b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2022dad5-4c6c-4e14-9a5f-9e1dc9e0585b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1062cd-76c4-4722-9f26-19caf6a1787b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1062cd-76c4-4722-9f26-19caf6a1787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1062cd-76c4-4722-9f26-19caf6a1787b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_b8a3187d-d6f2-44b8-acf5-033fc7ed40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_b8a3187d-d6f2-44b8-acf5-033fc7ed40f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ManufacturingEquipmentMember_a3cc945d-6b05-4c5c-bf27-6a3a17785ca6" xlink:href="amgn-20211231.xsd#amgn_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_amgn_ManufacturingEquipmentMember_a3cc945d-6b05-4c5c-bf27-6a3a17785ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipmentMember_556d1243-b677-4716-a0c6-99624f4a7d63" xlink:href="amgn-20211231.xsd#amgn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_amgn_LaboratoryEquipmentMember_556d1243-b677-4716-a0c6-99624f4a7d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipmentMember_b2f08dcd-3ca4-4b2d-8ba1-86ec5d943728" xlink:href="amgn-20211231.xsd#amgn_FixedEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_amgn_FixedEquipmentMember_b2f08dcd-3ca4-4b2d-8ba1-86ec5d943728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b39b8d27-b54a-45a7-9bad-a02c5ceeb8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b39b8d27-b54a-45a7-9bad-a02c5ceeb8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_730b2dc8-4005-44a7-af05-3e48a38c1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16b1c921-eb73-4078-9e2d-c576652d73db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_730b2dc8-4005-44a7-af05-3e48a38c1b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1820272-932c-4c97-8548-bd48bb8ce47e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:to="loc_srt_RangeAxis_d1820272-932c-4c97-8548-bd48bb8ce47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d1820272-932c-4c97-8548-bd48bb8ce47e" xlink:to="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbd2af4b-afc1-4bf9-bae1-5709a0e62ec4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:to="loc_srt_MinimumMember_dbd2af4b-afc1-4bf9-bae1-5709a0e62ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f0de0ac9-03de-4a95-bed9-6d6017565653" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd9a8514-0c12-4e0c-ace6-43430f3ff283" xlink:to="loc_srt_MaximumMember_f0de0ac9-03de-4a95-bed9-6d6017565653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2717fd8e-974d-453f-8c1d-d443ea6d18b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5ce8aa12-5696-4d5f-933b-97bf2832db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5ce8aa12-5696-4d5f-933b-97bf2832db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_ad8fed99-dafd-4a59-9329-f4f6d921da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_Land_ad8fed99-dafd-4a59-9329-f4f6d921da1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_23cce58f-1571-4601-898d-45aa81623f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_23cce58f-1571-4601-898d-45aa81623f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_b478aa32-9c5d-45cf-8bcc-bee7fbc8a929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_b478aa32-9c5d-45cf-8bcc-bee7fbc8a929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LaboratoryEquipment_fffa20bc-360b-4e0b-b5de-682ecdd87fe4" xlink:href="amgn-20211231.xsd#amgn_LaboratoryEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_amgn_LaboratoryEquipment_fffa20bc-360b-4e0b-b5de-682ecdd87fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FixedEquipment_1eddd2d6-00c9-4091-9a21-d5a30288b4d5" xlink:href="amgn-20211231.xsd#amgn_FixedEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_amgn_FixedEquipment_1eddd2d6-00c9-4091-9a21-d5a30288b4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_ebfbcc9a-95c7-47d5-90aa-ed9cfa7b2f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_ebfbcc9a-95c7-47d5-90aa-ed9cfa7b2f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_4ed52be4-3d70-4cb6-bd4f-fee65aa21b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_4ed52be4-3d70-4cb6-bd4f-fee65aa21b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_8593fb1d-9eb8-4871-ba8c-f2fcdb983e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_ConstructionInProgressGross_8593fb1d-9eb8-4871-ba8c-f2fcdb983e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_32012c24-9242-4793-a589-bb3c7a4a6a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_32012c24-9242-4793-a589-bb3c7a4a6a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9ae850-8e9e-4178-a086-70480e805973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9ae850-8e9e-4178-a086-70480e805973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e694078a-9b88-4a92-b4fc-6eb9f232e07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e694078a-9b88-4a92-b4fc-6eb9f232e07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3cdd6a7a-de78-43c5-a58c-b1b220dcfde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4649199-20aa-41a2-a916-e4ed77391444" xlink:to="loc_us-gaap_Depreciation_3cdd6a7a-de78-43c5-a58c-b1b220dcfde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#PropertyplantandequipmentGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_21f9e881-b09f-4af0-85f0-13ca2366cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6b2da032-b135-4f3d-9b01-0e0e576afb34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_21f9e881-b09f-4af0-85f0-13ca2366cd84" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6b2da032-b135-4f3d-9b01-0e0e576afb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_25bd98de-da61-4b53-a59e-8a1e836c4fbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6b2da032-b135-4f3d-9b01-0e0e576afb34" xlink:to="loc_srt_StatementGeographicalAxis_25bd98de-da61-4b53-a59e-8a1e836c4fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_25bd98de-da61-4b53-a59e-8a1e836c4fbe" xlink:to="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a406f876-70c9-40ea-89e3-4fae0ae6be31" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:to="loc_country_US_a406f876-70c9-40ea-89e3-4fae0ae6be31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_fe6f308b-8496-48a1-ad8e-2e45d7bdffbf" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:to="loc_country_PR_fe6f308b-8496-48a1-ad8e-2e45d7bdffbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RestOfWorldMember_d46ea67d-743f-4a66-b147-8dc0a392e926" xlink:href="amgn-20211231.xsd#amgn_RestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0f3f3a95-39a0-42e3-8c1f-8f635167bc6d" xlink:to="loc_amgn_RestOfWorldMember_d46ea67d-743f-4a66-b147-8dc0a392e926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3290467-1ad8-4780-a46c-2dc087ea6a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6b2da032-b135-4f3d-9b01-0e0e576afb34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3290467-1ad8-4780-a46c-2dc087ea6a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8017e2b7-2dff-4747-afa7-b9d202f3ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3290467-1ad8-4780-a46c-2dc087ea6a01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8017e2b7-2dff-4747-afa7-b9d202f3ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="simple" xlink:href="amgn-20211231.xsd#Goodwillandintangibleassets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Goodwillandintangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_896597fa-77c6-47c2-9527-b4e7a8f9d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5480a133-b7ed-4274-992d-f6cf1bfb1e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_896597fa-77c6-47c2-9527-b4e7a8f9d6d3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5480a133-b7ed-4274-992d-f6cf1bfb1e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f96a9d1d-37e1-4fcf-8986-8756c31b9d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_c01f5dd4-2c87-418f-8401-f6038f0aa59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f96a9d1d-37e1-4fcf-8986-8756c31b9d83" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_c01f5dd4-2c87-418f-8401-f6038f0aa59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_f4c9fd81-6eab-4f73-a1f2-b87c8ed99c15" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f96a9d1d-37e1-4fcf-8986-8756c31b9d83" xlink:to="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_f4c9fd81-6eab-4f73-a1f2-b87c8ed99c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#GoodwillandotherintangibleassetsGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f0ec61-2fe1-43c1-84a8-3a1e81bda9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d4eb9cfb-a154-42a8-a33f-7b3efaf8e435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62f0ec61-2fe1-43c1-84a8-3a1e81bda9f2" xlink:to="loc_us-gaap_GoodwillRollForward_d4eb9cfb-a154-42a8-a33f-7b3efaf8e435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9b74a8f-7e1e-460d-85a8-083579d192ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d4eb9cfb-a154-42a8-a33f-7b3efaf8e435" xlink:to="loc_us-gaap_Goodwill_f9b74a8f-7e1e-460d-85a8-083579d192ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_04532cda-1afe-4def-b080-336a23625d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d4eb9cfb-a154-42a8-a33f-7b3efaf8e435" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_04532cda-1afe-4def-b080-336a23625d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_21ba69e5-16fd-4398-a622-18c77d4518c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d4eb9cfb-a154-42a8-a33f-7b3efaf8e435" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_21ba69e5-16fd-4398-a622-18c77d4518c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_885dd718-e83d-4781-a31f-d647df6b5ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d4eb9cfb-a154-42a8-a33f-7b3efaf8e435" xlink:to="loc_us-gaap_Goodwill_885dd718-e83d-4781-a31f-d647df6b5ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf0a392b-0236-41cb-8bd9-197a27b43e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf0a392b-0236-41cb-8bd9-197a27b43e1b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_96d44622-ab2f-40f7-a4cb-6c1244e4e217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_96d44622-ab2f-40f7-a4cb-6c1244e4e217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_96d44622-ab2f-40f7-a4cb-6c1244e4e217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_550eedd9-395d-4c64-9cf8-5c572a675a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_550eedd9-395d-4c64-9cf8-5c572a675a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_de2f7a9b-bf20-4417-b391-027fedd52335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_us-gaap_LicensingAgreementsMember_de2f7a9b-bf20-4417-b391-027fedd52335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_b8d28d4f-ff0d-49b3-a028-bb7589de8d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_b8d28d4f-ff0d-49b3-a028-bb7589de8d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_00530d1e-df8a-4f35-bd9b-a6108e5bbe53" xlink:href="amgn-20211231.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_599fa798-4432-4955-b55a-ee5b07744750" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_00530d1e-df8a-4f35-bd9b-a6108e5bbe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_86c46844-cec6-4334-ad1a-96c773252d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_86c46844-cec6-4334-ad1a-96c773252d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e50473d-0e9c-41a8-b29a-1d9254110109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_86c46844-cec6-4334-ad1a-96c773252d44" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e50473d-0e9c-41a8-b29a-1d9254110109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d6ab0f32-f028-4c84-a96c-6dacd0511a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9e50473d-0e9c-41a8-b29a-1d9254110109" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d6ab0f32-f028-4c84-a96c-6dacd0511a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c12c1dc-358c-43f9-a3d5-5b2144816ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f490fc1-cbf6-4187-9695-74c3149ff503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f490fc1-cbf6-4187-9695-74c3149ff503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24a50cd0-3a33-4ffa-bf68-17e202921222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24a50cd0-3a33-4ffa-bf68-17e202921222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_353160fd-d108-45ed-bbb9-2b277a623a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0290d8b8-7740-4124-a42c-5f177fca7e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_353160fd-d108-45ed-bbb9-2b277a623a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c71959c4-ce13-42ec-bd2d-f02829799778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c71959c4-ce13-42ec-bd2d-f02829799778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a5e96ff-801d-4d97-ae15-4124d961dae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c71959c4-ce13-42ec-bd2d-f02829799778" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a5e96ff-801d-4d97-ae15-4124d961dae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_5a22f668-bb0a-431b-9f12-41bed5535b5e" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_5a22f668-bb0a-431b-9f12-41bed5535b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_e3f5b2fa-f4e8-4f9a-bc5d-b8a5be001875" xlink:href="amgn-20211231.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_e3f5b2fa-f4e8-4f9a-bc5d-b8a5be001875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_953dc30b-effd-476a-919b-c8e46a57568d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_311b183e-8f29-436d-a4e5-e78554f76c92" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_953dc30b-effd-476a-919b-c8e46a57568d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#GoodwillandotherintangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_200cd9b6-f406-4f02-b028-41027073d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_200cd9b6-f406-4f02-b028-41027073d93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_88282f68-d190-4d13-b4f7-9099c7eec823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_88282f68-d190-4d13-b4f7-9099c7eec823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ee40ac2b-fbea-453a-a11c-62efa99e0e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ee40ac2b-fbea-453a-a11c-62efa99e0e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_68855670-ccc4-4467-8f86-1795ffc1f469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_68855670-ccc4-4467-8f86-1795ffc1f469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_837c9782-47d3-460d-9200-a51dd2f56129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_837c9782-47d3-460d-9200-a51dd2f56129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_92655db3-139a-48e5-af26-4401ab40704a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_92655db3-139a-48e5-af26-4401ab40704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50522695-8c7c-48df-b33d-ac7700ba2b89" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5372ba03-863b-47f0-a924-ec9563b45e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5372ba03-863b-47f0-a924-ec9563b45e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b243d21f-6dd9-4431-9269-308067205c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5372ba03-863b-47f0-a924-ec9563b45e2d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b243d21f-6dd9-4431-9269-308067205c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_8f1b1fd2-9be6-4f73-8ee3-5d1f04c652d2" xlink:href="amgn-20211231.xsd#amgn_TeneobioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b243d21f-6dd9-4431-9269-308067205c2c" xlink:to="loc_amgn_TeneobioIncMember_8f1b1fd2-9be6-4f73-8ee3-5d1f04c652d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_852eefee-c416-4792-a6f1-cb3f16f7cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_852eefee-c416-4792-a6f1-cb3f16f7cfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_852eefee-c416-4792-a6f1-cb3f16f7cfa2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b8268272-87a4-455c-b99e-b6a143aab99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b8268272-87a4-455c-b99e-b6a143aab99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_fcf61b0b-4ad5-4b58-92fa-506c8235687b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_fcf61b0b-4ad5-4b58-92fa-506c8235687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FavorableContractMember_41b12c86-dac1-4d55-969f-7a8eb8075b2b" xlink:href="amgn-20211231.xsd#amgn_FavorableContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_91624634-9f8d-41df-b1c1-2ab3a0bb54e2" xlink:to="loc_amgn_FavorableContractMember_41b12c86-dac1-4d55-969f-7a8eb8075b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b716697a-35a6-4f14-909d-01f5e01b3827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b0550403-79de-4b54-9ff8-debc7461c515" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b716697a-35a6-4f14-909d-01f5e01b3827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7307705a-38b3-42a8-8b82-fe17418319bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b716697a-35a6-4f14-909d-01f5e01b3827" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7307705a-38b3-42a8-8b82-fe17418319bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Leases" xlink:type="simple" xlink:href="amgn-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a3d7adac-4d51-4e1a-8cfe-78284c1b3e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e13ef84e-ef54-40e2-86b8-e2768b9d0941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3d7adac-4d51-4e1a-8cfe-78284c1b3e4d" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e13ef84e-ef54-40e2-86b8-e2768b9d0941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_65c69b55-a677-4ad1-baef-364d577b6c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_cd4f5653-0fd3-4436-a1ec-2a7df3fdb764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_65c69b55-a677-4ad1-baef-364d577b6c88" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_cd4f5653-0fd3-4436-a1ec-2a7df3fdb764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_45c8385d-bcd0-42ca-be2a-5959d07eaab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_65c69b55-a677-4ad1-baef-364d577b6c88" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_45c8385d-bcd0-42ca-be2a-5959d07eaab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c24b9b66-e5eb-400e-afa8-433e84e5af92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_89767b20-41e7-4e18-b29e-4f86a4ee87b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c24b9b66-e5eb-400e-afa8-433e84e5af92" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_89767b20-41e7-4e18-b29e-4f86a4ee87b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89767b20-41e7-4e18-b29e-4f86a4ee87b5" xlink:to="loc_srt_RangeAxis_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dd6cc01d-28f6-4f77-9a1b-84b3e676b6fd" xlink:to="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bab3a76-711c-40f2-8246-7c6447514885" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:to="loc_srt_MinimumMember_3bab3a76-711c-40f2-8246-7c6447514885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4045583-68c8-46d9-a2f5-656893ef699b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_892d7417-fa82-42c3-bec5-0db023a0e248" xlink:to="loc_srt_MaximumMember_d4045583-68c8-46d9-a2f5-656893ef699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89767b20-41e7-4e18-b29e-4f86a4ee87b5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b912aedc-1deb-41a1-bdd8-9735cd6341b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b912aedc-1deb-41a1-bdd8-9735cd6341b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b3fa4fb-532c-4d61-b985-d972be67a791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6b3fa4fb-532c-4d61-b985-d972be67a791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4fbc81c-3458-4955-8042-1d5236c87cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f4fbc81c-3458-4955-8042-1d5236c87cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_fa248297-0203-494b-a15f-d6276295544e" xlink:href="amgn-20211231.xsd#amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount_fa248297-0203-494b-a15f-d6276295544e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_9eb2c749-b6a4-4432-a44d-4583d3463148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_9eb2c749-b6a4-4432-a44d-4583d3463148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bdfc79c9-d30e-4b29-830e-ca130bcf52e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1b077e09-cf4f-46e5-819a-95cc2270a3f9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bdfc79c9-d30e-4b29-830e-ca130bcf52e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesSummaryofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesSummaryofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8f9b5508-255c-4412-a96c-48917e33c57c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0e79f936-60d5-4356-bab1-2a293190aa80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f9b5508-255c-4412-a96c-48917e33c57c" xlink:to="loc_us-gaap_AssetsAbstract_0e79f936-60d5-4356-bab1-2a293190aa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_defa0be4-23e6-4ecd-8ad5-41043bcf2968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e79f936-60d5-4356-bab1-2a293190aa80" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_defa0be4-23e6-4ecd-8ad5-41043bcf2968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b31b856b-acde-4e07-8ec9-d00c2c71a136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e79f936-60d5-4356-bab1-2a293190aa80" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b31b856b-acde-4e07-8ec9-d00c2c71a136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1b20e338-41a6-452c-b2f8-247035dd4218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e79f936-60d5-4356-bab1-2a293190aa80" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1b20e338-41a6-452c-b2f8-247035dd4218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_71ca43e4-3b33-4a52-8b5b-fc9817e628ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f9b5508-255c-4412-a96c-48917e33c57c" xlink:to="loc_us-gaap_LiabilitiesAbstract_71ca43e4-3b33-4a52-8b5b-fc9817e628ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7776b245-229c-4f5d-93ef-2bdddc0ae6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_71ca43e4-3b33-4a52-8b5b-fc9817e628ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7776b245-229c-4f5d-93ef-2bdddc0ae6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ab0424fb-7410-4938-83e3-0ec415bad43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_71ca43e4-3b33-4a52-8b5b-fc9817e628ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ab0424fb-7410-4938-83e3-0ec415bad43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_062c57ed-119b-4a58-92c2-858ed5bd06c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_71ca43e4-3b33-4a52-8b5b-fc9817e628ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_062c57ed-119b-4a58-92c2-858ed5bd06c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_63269ea5-520d-457e-9143-2814f7d869cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_71ca43e4-3b33-4a52-8b5b-fc9817e628ba" xlink:to="loc_us-gaap_OperatingLeaseLiability_63269ea5-520d-457e-9143-2814f7d869cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_130c676e-1f1a-4067-8153-6aba2c452646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c119413d-33b1-4c62-a83e-b09105b38f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_130c676e-1f1a-4067-8153-6aba2c452646" xlink:to="loc_us-gaap_OperatingLeaseCost_c119413d-33b1-4c62-a83e-b09105b38f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_532f4348-589b-4e20-b8de-aefbc99d63e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_130c676e-1f1a-4067-8153-6aba2c452646" xlink:to="loc_us-gaap_SubleaseIncome_532f4348-589b-4e20-b8de-aefbc99d63e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_282b1965-c5b2-41b0-84da-1acdb673b566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_130c676e-1f1a-4067-8153-6aba2c452646" xlink:to="loc_us-gaap_LeaseCost_282b1965-c5b2-41b0-84da-1acdb673b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_248212b9-cdb0-4fbb-8068-61d798afe013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2ad0f3a0-7906-4dc9-8f15-b4d0096c9822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_248212b9-cdb0-4fbb-8068-61d798afe013" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2ad0f3a0-7906-4dc9-8f15-b4d0096c9822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e5a80fd-af09-45c1-8273-c5830af1ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2ad0f3a0-7906-4dc9-8f15-b4d0096c9822" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e5a80fd-af09-45c1-8273-c5830af1ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6836da90-2bb3-4179-b4fb-14a1f9c972af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e5a80fd-af09-45c1-8273-c5830af1ad44" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6836da90-2bb3-4179-b4fb-14a1f9c972af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AbandonedLeasesMember_d90b9e9e-2aac-448e-a852-f7d834924e1d" xlink:href="amgn-20211231.xsd#amgn_AbandonedLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6836da90-2bb3-4179-b4fb-14a1f9c972af" xlink:to="loc_amgn_AbandonedLeasesMember_d90b9e9e-2aac-448e-a852-f7d834924e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2ad0f3a0-7906-4dc9-8f15-b4d0096c9822" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3df0393b-df32-4319-b0e9-86c5a8bb2905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3df0393b-df32-4319-b0e9-86c5a8bb2905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8a2b9e02-7edf-4364-a73e-046dc9c3cbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8a2b9e02-7edf-4364-a73e-046dc9c3cbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fd1a7106-fb24-4ebc-9684-a02fbe02b874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fd1a7106-fb24-4ebc-9684-a02fbe02b874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_52db231d-3bfe-464c-a8d6-1999ab9bd7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_52db231d-3bfe-464c-a8d6-1999ab9bd7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9ca1282c-6ee4-4193-8ae9-41b1f7066e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9ca1282c-6ee4-4193-8ae9-41b1f7066e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8fd3609c-4c67-47af-9e7a-53164fecc556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8fd3609c-4c67-47af-9e7a-53164fecc556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_246ca671-dfee-463c-b93b-87187035888b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_246ca671-dfee-463c-b93b-87187035888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22ecb262-5054-404c-96d7-1a27f823b3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22ecb262-5054-404c-96d7-1a27f823b3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_14aa855a-797b-435c-ab3c-fcf267358124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_OperatingLeaseLiability_14aa855a-797b-435c-ab3c-fcf267358124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_36ee0e36-7a7b-43eb-97c9-9264754d59d5" xlink:href="amgn-20211231.xsd#amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases_36ee0e36-7a7b-43eb-97c9-9264754d59d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a6831a4b-95a4-464c-8b2b-1e26137a1c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_78861a50-4205-4e4c-918f-145b05e5e701" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a6831a4b-95a4-464c-8b2b-1e26137a1c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#LeasesCashandNoncashInformationofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1c2bd074-5e76-4e06-92f7-43c46e925715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_508f8925-320f-40ca-b926-c32bcf1a715e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c2bd074-5e76-4e06-92f7-43c46e925715" xlink:to="loc_us-gaap_OperatingLeasePayments_508f8925-320f-40ca-b926-c32bcf1a715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f4f7f102-998d-487d-a4ef-feb3d0d733e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1c2bd074-5e76-4e06-92f7-43c46e925715" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f4f7f102-998d-487d-a4ef-feb3d0d733e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="simple" xlink:href="amgn-20211231.xsd#Othercurrentassetsandaccruedliabilities"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e43a2a6b-4a23-473e-a330-69faa9bccabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesDisclosureTextBlock_1c2e86ec-5436-4ecb-92b8-d85e986bf53e" xlink:href="amgn-20211231.xsd#amgn_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e43a2a6b-4a23-473e-a330-69faa9bccabd" xlink:to="loc_amgn_AccruedLiabilitiesDisclosureTextBlock_1c2e86ec-5436-4ecb-92b8-d85e986bf53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#OthercurrentassetsandaccruedliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d7dbf2b1-3e45-4eca-a96e-b4b0628ffa66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_188bc071-fc46-4539-ab7d-54e35e2a3f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d7dbf2b1-3e45-4eca-a96e-b4b0628ffa66" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_188bc071-fc46-4539-ab7d-54e35e2a3f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b739ba9b-5618-453d-8f2a-9e6ba2b838fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d7dbf2b1-3e45-4eca-a96e-b4b0628ffa66" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b739ba9b-5618-453d-8f2a-9e6ba2b838fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d1b4bb05-89e2-48ca-ae7e-dd99f9967e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_33a3cda8-74af-4cb9-9b8f-81f7da883695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d1b4bb05-89e2-48ca-ae7e-dd99f9967e5c" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_33a3cda8-74af-4cb9-9b8f-81f7da883695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_169eda1a-70c0-4288-a9d0-6bd316cb1208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d1b4bb05-89e2-48ca-ae7e-dd99f9967e5c" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_169eda1a-70c0-4288-a9d0-6bd316cb1208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_04f7b23c-d8fb-40f5-92b5-f49dbecf353e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d1b4bb05-89e2-48ca-ae7e-dd99f9967e5c" xlink:to="loc_us-gaap_InterestReceivableCurrent_04f7b23c-d8fb-40f5-92b5-f49dbecf353e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_40538c98-01dc-4b11-97f6-40c4f086769f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d1b4bb05-89e2-48ca-ae7e-dd99f9967e5c" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_40538c98-01dc-4b11-97f6-40c4f086769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_abd5bc14-d93e-423b-93b2-4710cb9a03ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d1b4bb05-89e2-48ca-ae7e-dd99f9967e5c" xlink:to="loc_us-gaap_OtherAssetsCurrent_abd5bc14-d93e-423b-93b2-4710cb9a03ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesDeductionsCurrent_3e5dc26f-c3fa-4259-b35d-6bfbcec5cbcf" xlink:href="amgn-20211231.xsd#amgn_AccruedSalesDeductionsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:to="loc_amgn_AccruedSalesDeductionsCurrent_3e5dc26f-c3fa-4259-b35d-6bfbcec5cbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_aca6bd00-7fd3-426b-9918-62bc29b6b28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:to="loc_us-gaap_DividendsPayableCurrent_aca6bd00-7fd3-426b-9918-62bc29b6b28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2c1bbec8-fc4a-4de1-b893-2b2a58b2c7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2c1bbec8-fc4a-4de1-b893-2b2a58b2c7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_af3b2dee-4216-4b77-bc2a-50319daac56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_af3b2dee-4216-4b77-bc2a-50319daac56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedSalesReturnReserveCurrent_97149969-4b3e-48de-b812-c8af480b5e32" xlink:href="amgn-20211231.xsd#amgn_AccruedSalesReturnReserveCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:to="loc_amgn_AccruedSalesReturnReserveCurrent_97149969-4b3e-48de-b812-c8af480b5e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bea3919f-ff26-4038-af76-bbc7740a03a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bea3919f-ff26-4038-af76-bbc7740a03a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ba0f235a-d1ed-4c59-87cd-06e854ede88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a422aebc-5833-42c8-ab6c-62e7d86ba35f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ba0f235a-d1ed-4c59-87cd-06e854ede88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Financingarrangements" xlink:type="simple" xlink:href="amgn-20211231.xsd#Financingarrangements"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Financingarrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_604d435c-9c5f-40e7-9462-1fcba5021bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_04876c94-ffbb-4a0d-a080-7f54d9de71be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_604d435c-9c5f-40e7-9462-1fcba5021bf5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_04876c94-ffbb-4a0d-a080-7f54d9de71be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_022c7121-6736-4164-931a-b18a5e75ce87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4e711c1c-c117-4cff-ac7c-6c77de84c9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_022c7121-6736-4164-931a-b18a5e75ce87" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4e711c1c-c117-4cff-ac7c-6c77de84c9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_86354348-21e6-4c4d-a1df-f308f056b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_022c7121-6736-4164-931a-b18a5e75ce87" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_86354348-21e6-4c4d-a1df-f308f056b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_5de3daf5-9abe-4934-a374-f4180cf9049e" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_022c7121-6736-4164-931a-b18a5e75ce87" xlink:to="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_5de3daf5-9abe-4934-a374-f4180cf9049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_89aac1e5-14ca-4432-a9b0-367e4a43ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_022c7121-6736-4164-931a-b18a5e75ce87" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_89aac1e5-14ca-4432-a9b0-367e4a43ca52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e59f9ee7-1db0-4ef2-b89a-9080e54180c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e59f9ee7-1db0-4ef2-b89a-9080e54180c0" xlink:to="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_57aa52f5-24d1-4c3a-985d-adeee05de3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_57aa52f5-24d1-4c3a-985d-adeee05de3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_57aa52f5-24d1-4c3a-985d-adeee05de3d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_40972c52-5607-4135-b3a7-01ad0fc895ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:to="loc_us-gaap_NotesPayableToBanksMember_40972c52-5607-4135-b3a7-01ad0fc895ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_508a348a-6c97-4497-a3bc-810f0e96c8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5c4b2b34-361c-443d-8acb-87322b2c228a" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_508a348a-6c97-4497-a3bc-810f0e96c8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_18d90b3e-5ba3-47f9-b722-07f5d4558ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:to="loc_us-gaap_DebtInstrumentAxis_18d90b3e-5ba3-47f9-b722-07f5d4558ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_18d90b3e-5ba3-47f9-b722-07f5d4558ebc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_4d8b5e4a-50ea-48bf-bf2a-621db2a5aa07" xlink:href="amgn-20211231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_4d8b5e4a-50ea-48bf-bf2a-621db2a5aa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_63f86d51-f3f0-4c1d-9af8-31a81eda1dd8" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_63f86d51-f3f0-4c1d-9af8-31a81eda1dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member_9b457af4-85ae-486e-a158-d6976eeee02f" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSixFiveNotesDue2022Member_9b457af4-85ae-486e-a158-d6976eeee02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_4ac16374-1bc7-46f5-a9ce-c36a650efd20" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_4ac16374-1bc7-46f5-a9ce-c36a650efd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_3a80998a-3434-4b40-a7da-0fe600c6245e" xlink:href="amgn-20211231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_3a80998a-3434-4b40-a7da-0fe600c6245e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_52f035d9-166e-45d4-8196-0aefe035ce1e" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_52f035d9-166e-45d4-8196-0aefe035ce1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_0822a846-e761-4f9c-8709-9f51ac4447d9" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_0822a846-e761-4f9c-8709-9f51ac4447d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_59712cfc-838c-4b8b-ac66-286a6c07e382" xlink:href="amgn-20211231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_59712cfc-838c-4b8b-ac66-286a6c07e382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_cbef15c7-30ad-465f-8137-ce1bc54da8af" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_cbef15c7-30ad-465f-8137-ce1bc54da8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_79f7d6f9-42d2-4970-aa53-51123ec55054" xlink:href="amgn-20211231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_79f7d6f9-42d2-4970-aa53-51123ec55054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_1f5248ec-01e7-4c55-887d-86bce22478a5" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_1f5248ec-01e7-4c55-887d-86bce22478a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_4b630978-d81a-4a71-ac5f-58d5974350a9" xlink:href="amgn-20211231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_4b630978-d81a-4a71-ac5f-58d5974350a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_51aacb7c-d6bd-4914-828b-ffd5ebc9aa11" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_51aacb7c-d6bd-4914-828b-ffd5ebc9aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b022413d-27aa-4422-9ec1-5defb91bc524" xlink:href="amgn-20211231.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_b022413d-27aa-4422-9ec1-5defb91bc524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_203988db-2a69-4703-99f3-afc08b06fbdd" xlink:href="amgn-20211231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_203988db-2a69-4703-99f3-afc08b06fbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_2c1a2bed-9537-4b00-b307-19fb495c4512" xlink:href="amgn-20211231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_2c1a2bed-9537-4b00-b307-19fb495c4512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eee3f527-b7d5-40d2-946d-e3fd0697f76e" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_eee3f527-b7d5-40d2-946d-e3fd0697f76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_8549264c-1a1d-4055-833c-df29f80c02f1" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_8549264c-1a1d-4055-833c-df29f80c02f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_7812a62c-ac11-4932-bdc5-2a8bb8f3fb78" xlink:href="amgn-20211231.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_7812a62c-ac11-4932-bdc5-2a8bb8f3fb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dae43093-34dd-44b4-90a3-3120dd10b467" xlink:href="amgn-20211231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_dae43093-34dd-44b4-90a3-3120dd10b467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_35c8fcc7-d392-4378-b5e0-5a56aa5207e9" xlink:href="amgn-20211231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_35c8fcc7-d392-4378-b5e0-5a56aa5207e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_8c436d91-8b68-4264-9262-a615095acd64" xlink:href="amgn-20211231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_8c436d91-8b68-4264-9262-a615095acd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_401a4d7f-ab5c-4635-a2f0-8c6c729b034c" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_401a4d7f-ab5c-4635-a2f0-8c6c729b034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_9efab306-23bb-4b04-bcd9-21abf3de8e79" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_9efab306-23bb-4b04-bcd9-21abf3de8e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_56b7fa78-e7aa-448d-beab-364c307d940d" xlink:href="amgn-20211231.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_56b7fa78-e7aa-448d-beab-364c307d940d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_226b5041-e56f-4fe6-9345-e642060b09b6" xlink:href="amgn-20211231.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_226b5041-e56f-4fe6-9345-e642060b09b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_03d3a948-9453-4da1-b0ae-399ac7b78b0b" xlink:href="amgn-20211231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_03d3a948-9453-4da1-b0ae-399ac7b78b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_74a586da-8d7e-4a53-a8d6-e945af2a3431" xlink:href="amgn-20211231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_74a586da-8d7e-4a53-a8d6-e945af2a3431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_750c7ae5-cac9-43d8-992a-77c48b24495d" xlink:href="amgn-20211231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_750c7ae5-cac9-43d8-992a-77c48b24495d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_761fb4e4-7bd2-49e7-8df4-eba9ffff11bb" xlink:href="amgn-20211231.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_761fb4e4-7bd2-49e7-8df4-eba9ffff11bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_dfe421a9-96ca-42f2-bb3f-1d13aad309d5" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_dfe421a9-96ca-42f2-bb3f-1d13aad309d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_bc16463e-16ff-4113-a47b-55d5d7cb48cc" xlink:href="amgn-20211231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_bc16463e-16ff-4113-a47b-55d5d7cb48cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_9c4d32ef-3116-4b2f-bb56-7b93e5455f80" xlink:href="amgn-20211231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_9c4d32ef-3116-4b2f-bb56-7b93e5455f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_0f52eecd-ece1-4ba8-a29b-ff5c38016763" xlink:href="amgn-20211231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_0f52eecd-ece1-4ba8-a29b-ff5c38016763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_ae9c4d91-51a8-4add-aa6d-0cf7ff56b81b" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_ae9c4d91-51a8-4add-aa6d-0cf7ff56b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_bd1ee74e-1dda-48a5-864f-977d6acb9cd9" xlink:href="amgn-20211231.xsd#amgn_OtherNotesDue2097Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_OtherNotesDue2097Member_bd1ee74e-1dda-48a5-864f-977d6acb9cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_c2b9c62b-80fe-4954-b141-4008a7fbad89" xlink:href="amgn-20211231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_c2b9c62b-80fe-4954-b141-4008a7fbad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_3e6686d8-3502-4d28-92cc-f0f92612ef7b" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_3e6686d8-3502-4d28-92cc-f0f92612ef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1880d77-88bd-4636-bd87-e60e9d8436c0" xlink:href="amgn-20211231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_a1880d77-88bd-4636-bd87-e60e9d8436c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_9eb5c2f5-95f9-4597-b366-795ab0188928" xlink:href="amgn-20211231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_9eb5c2f5-95f9-4597-b366-795ab0188928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_b9a3ad85-b50a-4795-b33a-afce163c8b0b" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_b9a3ad85-b50a-4795-b33a-afce163c8b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_b9435b33-dd3c-437a-b931-5bed3d64f3d2" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_b9435b33-dd3c-437a-b931-5bed3d64f3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_773d1a78-56ae-4e26-95d6-f2e226a52157" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_773d1a78-56ae-4e26-95d6-f2e226a52157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_35d58d3d-374b-4e7a-ad7b-744138605d1e" xlink:href="amgn-20211231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cf674b97-55c1-47d7-918d-7ff0adc95eb8" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_35d58d3d-374b-4e7a-ad7b-744138605d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dad4748-a9a9-4198-9e8d-916b95f65ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:to="loc_srt_RangeAxis_3dad4748-a9a9-4198-9e8d-916b95f65ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3dad4748-a9a9-4198-9e8d-916b95f65ad7" xlink:to="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_307bf1ca-efe7-450b-b278-ebee2a4228bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:to="loc_srt_MinimumMember_307bf1ca-efe7-450b-b278-ebee2a4228bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86387999-af88-42d0-93ca-d1b1413ba09e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_634b5aa1-f352-4c44-81ff-3dc29b93c238" xlink:to="loc_srt_MaximumMember_86387999-af88-42d0-93ca-d1b1413ba09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_52ba545b-83c8-4559-9467-bd5cea42643a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0eff85-9ab5-4981-99a2-3894fb789217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0eff85-9ab5-4981-99a2-3894fb789217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3564737d-796d-4a0a-860a-51643af6def8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3564737d-796d-4a0a-860a-51643af6def8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0654392-5d6f-4f77-a567-5628d4be5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b0654392-5d6f-4f77-a567-5628d4be5ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b2765729-cbd3-4210-9d3a-a7db9e3cb472" xlink:href="amgn-20211231.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b2765729-cbd3-4210-9d3a-a7db9e3cb472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_2a60d625-2e1d-44bd-afbe-fb6021ff936e" xlink:href="amgn-20211231.xsd#amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount_2a60d625-2e1d-44bd-afbe-fb6021ff936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_661dd420-f798-4243-b3c6-fed56f4890a1" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_63a84605-de2c-4d61-99d5-a4b118a18c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_63a84605-de2c-4d61-99d5-a4b118a18c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f4c5041f-28eb-4e09-80a9-c28abcd9c436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f4c5041f-28eb-4e09-80a9-c28abcd9c436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0cd0fc2d-4d8d-4664-84ea-c011f3f912e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0cd0fc2d-4d8d-4664-84ea-c011f3f912e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_7d8a0b71-3b16-45fd-99a0-875502f138c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_OtherLongTermDebt_7d8a0b71-3b16-45fd-99a0-875502f138c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c77d2948-1f54-4951-8deb-5521dc3b9dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_LongTermDebt_c77d2948-1f54-4951-8deb-5521dc3b9dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ecc7d3cc-4c80-453b-bd21-da27ed42ac63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_LongTermDebtCurrent_ecc7d3cc-4c80-453b-bd21-da27ed42ac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3bc2d908-16d8-4f19-a2f0-a8eaecce3d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_691041dc-8257-4a3b-8a34-1e1bc588dd42" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3bc2d908-16d8-4f19-a2f0-a8eaecce3d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsDebtIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6d779dc2-531d-4bc9-9f38-e7ad6a3f99c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d779dc2-531d-4bc9-9f38-e7ad6a3f99c2" xlink:to="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e2876735-6b4b-4a31-9ed9-8d64d5e77c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e2876735-6b4b-4a31-9ed9-8d64d5e77c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b8fe3698-d6c4-449a-bf8f-d6e107cde8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e2876735-6b4b-4a31-9ed9-8d64d5e77c22" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b8fe3698-d6c4-449a-bf8f-d6e107cde8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_987e6e4a-885e-4faf-b62a-c014c169abbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8fe3698-d6c4-449a-bf8f-d6e107cde8c9" xlink:to="loc_us-gaap_NotesPayableToBanksMember_987e6e4a-885e-4faf-b62a-c014c169abbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_881910ed-2c0b-49f2-aa92-1c947d9533b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:to="loc_us-gaap_DebtInstrumentAxis_881910ed-2c0b-49f2-aa92-1c947d9533b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_881910ed-2c0b-49f2-aa92-1c947d9533b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A165NotesDue20281652028NotesMember_1c385b6c-e60c-42ad-a17b-da7f02687934" xlink:href="amgn-20211231.xsd#amgn_A165NotesDue20281652028NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A165NotesDue20281652028NotesMember_1c385b6c-e60c-42ad-a17b-da7f02687934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A200NotesDue20322002032NotesMember_978388a7-6ac0-4d37-aaeb-0b2ddc249071" xlink:href="amgn-20211231.xsd#amgn_A200NotesDue20322002032NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A200NotesDue20322002032NotesMember_978388a7-6ac0-4d37-aaeb-0b2ddc249071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A280NotesDue2041Member_f18ac3c2-0cd1-48f1-b6ca-72191612e2f8" xlink:href="amgn-20211231.xsd#amgn_A280NotesDue2041Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A280NotesDue2041Member_f18ac3c2-0cd1-48f1-b6ca-72191612e2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_08837202-16c7-4abe-9d64-e4e315f764db" xlink:href="amgn-20211231.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_08837202-16c7-4abe-9d64-e4e315f764db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A190NotesDue20251902025NotesMember_5e7e2c84-eec9-45d2-9f95-c79c7e5a1d98" xlink:href="amgn-20211231.xsd#amgn_A190NotesDue20251902025NotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_A190NotesDue20251902025NotesMember_5e7e2c84-eec9-45d2-9f95-c79c7e5a1d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_1f05d1d0-8705-49e3-afdf-2158d3889be2" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_1f05d1d0-8705-49e3-afdf-2158d3889be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_08bc0d2f-5f85-497e-a9b6-e6691ceab60d" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_08bc0d2f-5f85-497e-a9b6-e6691ceab60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7f0082c-6005-4d67-b8d2-61943db1821d" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_f7f0082c-6005-4d67-b8d2-61943db1821d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_5cfca7a3-870f-4d87-8fb2-a65bfc5bad65" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_5cfca7a3-870f-4d87-8fb2-a65bfc5bad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_b8d16ceb-f472-4e70-8adf-f53427348648" xlink:href="amgn-20211231.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_27fc011d-60f8-469f-8589-226f5f895758" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_b8d16ceb-f472-4e70-8adf-f53427348648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionAxis_8968cf11-ca52-41ed-bc0c-3e682392ff7e" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:to="loc_amgn_AssetsByDescriptionAxis_8968cf11-ca52-41ed-bc0c-3e682392ff7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AssetsByDescriptionDomain_b37c99d4-fcdf-4f37-87b3-dc6492189e06" xlink:href="amgn-20211231.xsd#amgn_AssetsByDescriptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_AssetsByDescriptionAxis_8968cf11-ca52-41ed-bc0c-3e682392ff7e" xlink:to="loc_amgn_AssetsByDescriptionDomain_b37c99d4-fcdf-4f37-87b3-dc6492189e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6013142b-b314-4579-9f05-e2ce077f3ed5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11191f2b-99eb-4207-81ab-c0e0ba012feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11191f2b-99eb-4207-81ab-c0e0ba012feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f684c9da-dc5d-443e-8796-27cadc3e8aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f684c9da-dc5d-443e-8796-27cadc3e8aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_b94273c8-7163-4119-9cdc-975023913e62" xlink:href="amgn-20211231.xsd#amgn_MaximumBorrowingCapacityUnderCommercialPaper"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ec51db4c-9e10-4e6b-99b2-44720066fbaa" xlink:to="loc_amgn_MaximumBorrowingCapacityUnderCommercialPaper_b94273c8-7163-4119-9cdc-975023913e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsDebtRepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_54548189-f55c-48d5-8bb2-347b69689206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_54548189-f55c-48d5-8bb2-347b69689206" xlink:to="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_891fcb65-cbfe-4150-83c6-332e6adf9862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d546839b-2a15-4ac9-bb8c-654ca8b4e3dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_891fcb65-cbfe-4150-83c6-332e6adf9862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_e76727ce-bbc1-448f-b745-6f388c2afbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_891fcb65-cbfe-4150-83c6-332e6adf9862" xlink:to="loc_us-gaap_NotesPayableToBanksMember_e76727ce-bbc1-448f-b745-6f388c2afbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e043b189-0bfc-4bea-a3e3-52ed76f389ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:to="loc_us-gaap_DebtInstrumentAxis_e043b189-0bfc-4bea-a3e3-52ed76f389ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e043b189-0bfc-4bea-a3e3-52ed76f389ec" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_16f061d9-7897-425f-9115-11ec65119e20" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_16f061d9-7897-425f-9115-11ec65119e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_17e2dc60-287a-42de-9cd4-eb11f252d9e5" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenZeroPercentNotesDue2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FivePointSevenZeroPercentNotesDue2019Member_17e2dc60-287a-42de-9cd4-eb11f252d9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f3a74f46-6a72-4ede-8ef3-a84e6cdfc3f5" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f3a74f46-6a72-4ede-8ef3-a84e6cdfc3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroNotesDue2019Member_a8f5f258-90fa-4bd5-a2de-b58d444b7750" xlink:href="amgn-20211231.xsd#amgn_OnePointNineZeroNotesDue2019Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_OnePointNineZeroNotesDue2019Member_a8f5f258-90fa-4bd5-a2de-b58d444b7750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2019Member_41b470da-203b-40d8-93ea-be1ee5bc71cb" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2019Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FloatingRateNotesDue2019Member_41b470da-203b-40d8-93ea-be1ee5bc71cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_c7bd046c-f524-4999-89ac-a29d0137e655" xlink:href="amgn-20211231.xsd#amgn_FourPointFiveZeroPercentNotesDue2020Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FourPointFiveZeroPercentNotesDue2020Member_c7bd046c-f524-4999-89ac-a29d0137e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_6ebd012d-9984-44be-91a0-7129fa8c0425" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_6ebd012d-9984-44be-91a0-7129fa8c0425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7231446e-f3e9-4561-8be6-5feab62d8ffb" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_7231446e-f3e9-4561-8be6-5feab62d8ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e075d606-02d2-401a-bcd6-9f2027e0d8dd" xlink:href="amgn-20211231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_e075d606-02d2-401a-bcd6-9f2027e0d8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FloatingRateNotesDue2020Member_ab8ee464-67bf-4a55-a220-48ded87505a1" xlink:href="amgn-20211231.xsd#amgn_FloatingRateNotesDue2020Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FloatingRateNotesDue2020Member_ab8ee464-67bf-4a55-a220-48ded87505a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b1259ff8-c1d0-4b12-aa13-1ad594321c82" xlink:href="amgn-20211231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_b1259ff8-c1d0-4b12-aa13-1ad594321c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_bd55ed00-2d2e-43cd-b9ca-d2c2dbe686c3" xlink:href="amgn-20211231.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_bd55ed00-2d2e-43cd-b9ca-d2c2dbe686c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_8aea02f9-68a1-49ef-a1c1-20477ff9c794" xlink:href="amgn-20211231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_8aea02f9-68a1-49ef-a1c1-20477ff9c794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_b9a2f80a-cd5b-4b2e-a7ef-a74d747a1e62" xlink:href="amgn-20211231.xsd#amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember_b9a2f80a-cd5b-4b2e-a7ef-a74d747a1e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_126972d7-2b97-4303-aad6-81a8c548400c" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenZeroPercentNotesDue2022Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDue2022Member_126972d7-2b97-4303-aad6-81a8c548400c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_facc7fd3-d5dd-468b-9438-6e736ca39467" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember_facc7fd3-d5dd-468b-9438-6e736ca39467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_3aa49e3f-7d9a-4827-8592-d0a96336d51f" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_3aa49e3f-7d9a-4827-8592-d0a96336d51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_8a31fcb2-321c-49d4-b2f3-b4e7a0a24896" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_8a31fcb2-321c-49d4-b2f3-b4e7a0a24896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_de851134-0bfd-4a32-a55b-c291877cb7b4" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cd1ba4a-b70f-4ee3-9d10-12f71090b51f" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_de851134-0bfd-4a32-a55b-c291877cb7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e26f849d-2fc8-4eba-967e-d4a4a51376c6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a31ced24-096e-4c1b-b891-857286b9876c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a31ced24-096e-4c1b-b891-857286b9876c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b8cd1dd-af82-493a-99ca-f00d2570a5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b8cd1dd-af82-493a-99ca-f00d2570a5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1454edd9-27ae-489b-b8e4-da5adb2c28ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5922ac6a-d4c8-4b7f-b7ec-785de8aa4dce" xlink:to="loc_us-gaap_InterestExpenseDebt_1454edd9-27ae-489b-b8e4-da5adb2c28ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0380fd37-6f63-47dd-ad13-7096eccbc189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0380fd37-6f63-47dd-ad13-7096eccbc189" xlink:to="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408b6e4b-6685-445a-ad41-4f903564e97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408b6e4b-6685-445a-ad41-4f903564e97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408b6e4b-6685-445a-ad41-4f903564e97a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_59daf2ba-6912-4e1a-809a-4424b9bc16a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_59daf2ba-6912-4e1a-809a-4424b9bc16a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_75fc05e5-eae8-4374-8608-fd0da8228fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2577fd81-e3b4-4ff0-814c-64eb69c84d8c" xlink:to="loc_us-gaap_NotesPayableToBanksMember_75fc05e5-eae8-4374-8608-fd0da8228fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a6c0fde2-7379-4025-b750-5e654996bb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_DebtInstrumentAxis_a6c0fde2-7379-4025-b750-5e654996bb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a6c0fde2-7379-4025-b750-5e654996bb1e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_edfe87f7-bbe8-4bf3-8bfa-3c535b6e2a86" xlink:href="amgn-20211231.xsd#amgn_TwoPointTwoZeroPercentNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDue2019Member_edfe87f7-bbe8-4bf3-8bfa-3c535b6e2a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_bbf68f5a-6b58-4e80-8e2b-e5d4cfdd131f" xlink:href="amgn-20211231.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_bbf68f5a-6b58-4e80-8e2b-e5d4cfdd131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_cecb2259-34dc-4157-a357-253389c66877" xlink:href="amgn-20211231.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_cecb2259-34dc-4157-a357-253389c66877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_a11edbd2-d3f2-44c3-82e8-05284db691dc" xlink:href="amgn-20211231.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_a11edbd2-d3f2-44c3-82e8-05284db691dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_8e1d38e0-6ea9-4a21-927d-8adab8909ab9" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_8e1d38e0-6ea9-4a21-927d-8adab8909ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_15171216-285d-4eba-9998-f1e0228380c2" xlink:href="amgn-20211231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_15171216-285d-4eba-9998-f1e0228380c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_d98f5531-fd79-47e7-a2d0-90f071eec03d" xlink:href="amgn-20211231.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_d98f5531-fd79-47e7-a2d0-90f071eec03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b3f75859-d3da-4e05-bfa4-5c025527bcd3" xlink:href="amgn-20211231.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_b3f75859-d3da-4e05-bfa4-5c025527bcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_b1308dfc-2cd2-4e17-bca3-39141fb26511" xlink:href="amgn-20211231.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_b1308dfc-2cd2-4e17-bca3-39141fb26511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_336ae34c-7276-4f2e-830d-c477989fb2f7" xlink:href="amgn-20211231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_336ae34c-7276-4f2e-830d-c477989fb2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_74e34b48-11ef-48cd-88d8-86b8269d39c8" xlink:href="amgn-20211231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_74e34b48-11ef-48cd-88d8-86b8269d39c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_384793bf-50e0-422f-9a87-dfa99b6baaaf" xlink:href="amgn-20211231.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_384793bf-50e0-422f-9a87-dfa99b6baaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_489ccd1e-a0f8-4c24-bf5b-0e1c65ca5f27" xlink:href="amgn-20211231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_489ccd1e-a0f8-4c24-bf5b-0e1c65ca5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_239c6470-c939-4b52-bfca-4aa5f08c7327" xlink:href="amgn-20211231.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_239c6470-c939-4b52-bfca-4aa5f08c7327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_09b4ce50-c825-402c-88d5-473d4655cc9c" xlink:href="amgn-20211231.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_09b4ce50-c825-402c-88d5-473d4655cc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_9d0222ac-e888-494e-a19c-392b26b2ffda" xlink:href="amgn-20211231.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_9d0222ac-e888-494e-a19c-392b26b2ffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_524ea6c5-5242-496b-af4c-ac93322d329a" xlink:href="amgn-20211231.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_524ea6c5-5242-496b-af4c-ac93322d329a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_5ebe8595-ecf3-4d05-a0ec-48c584f8452c" xlink:href="amgn-20211231.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_5ebe8595-ecf3-4d05-a0ec-48c584f8452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b3bd5e64-1c62-43bc-9929-aea262674cee" xlink:href="amgn-20211231.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_b3bd5e64-1c62-43bc-9929-aea262674cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_58f09654-2d16-4036-9fd6-f21498026bff" xlink:href="amgn-20211231.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_58f09654-2d16-4036-9fd6-f21498026bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_bbae9707-c856-4280-b664-20047b32576b" xlink:href="amgn-20211231.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_bbae9707-c856-4280-b664-20047b32576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_be10d960-d5de-44b6-8987-e0eac73e58da" xlink:href="amgn-20211231.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_be10d960-d5de-44b6-8987-e0eac73e58da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_0310a46d-cad7-4999-be5f-e8ebb471327c" xlink:href="amgn-20211231.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_0310a46d-cad7-4999-be5f-e8ebb471327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_07183d7c-5590-4aa7-b3d6-cbe132f39eed" xlink:href="amgn-20211231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_07183d7c-5590-4aa7-b3d6-cbe132f39eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_98fa42d1-3f56-4cf0-90f7-1351a85ea5cf" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4d33554-0170-462b-bd7b-2342eb887a37" xlink:to="loc_amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember_98fa42d1-3f56-4cf0-90f7-1351a85ea5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6065a9cf-c08c-450e-99ae-07bf5c1647d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_VariableRateAxis_6065a9cf-c08c-450e-99ae-07bf5c1647d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ade08c89-0469-4a71-b6df-ba6e417ea64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6065a9cf-c08c-450e-99ae-07bf5c1647d1" xlink:to="loc_us-gaap_VariableRateDomain_ade08c89-0469-4a71-b6df-ba6e417ea64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_8b113af1-29dd-4285-bfef-4bd4dfec2c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ade08c89-0469-4a71-b6df-ba6e417ea64c" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_8b113af1-29dd-4285-bfef-4bd4dfec2c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_6541f5db-21c4-4306-a721-82b33b1e826c" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_amgn_InterestRateSwapAxis_6541f5db-21c4-4306-a721-82b33b1e826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapAxis_6541f5db-21c4-4306-a721-82b33b1e826c" xlink:to="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapOneMember_72a145bc-39fd-4b70-99a5-ebc617acb309" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:to="loc_amgn_InterestRateSwapOneMember_72a145bc-39fd-4b70-99a5-ebc617acb309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_c35dd8d5-4fd9-4dd6-a3fb-015a7a11cc22" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_5bed535d-c530-4a63-8995-0b87abe32826" xlink:to="loc_amgn_InterestRateSwapTwoMember_c35dd8d5-4fd9-4dd6-a3fb-015a7a11cc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0d129bd9-b921-4fed-8929-06fc60c6d330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0d129bd9-b921-4fed-8929-06fc60c6d330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0d129bd9-b921-4fed-8929-06fc60c6d330" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_9349ed51-6ed2-46d3-a20c-0cc6360cf0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:to="loc_us-gaap_InterestRateSwapMember_9349ed51-6ed2-46d3-a20c-0cc6360cf0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_f5486f6e-392c-43ce-8e8e-269699493a4d" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_037290f3-931b-4282-8058-68e808bf98ea" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_f5486f6e-392c-43ce-8e8e-269699493a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_956ba971-e4c9-4292-8b76-7f823d8acbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_HedgingDesignationAxis_956ba971-e4c9-4292-8b76-7f823d8acbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b712b203-c71e-495f-a211-ac89dbc38839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_956ba971-e4c9-4292-8b76-7f823d8acbcc" xlink:to="loc_us-gaap_HedgingDesignationDomain_b712b203-c71e-495f-a211-ac89dbc38839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62372e42-dc62-4cc8-aa06-4b41ca75e991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b712b203-c71e-495f-a211-ac89dbc38839" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62372e42-dc62-4cc8-aa06-4b41ca75e991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3a936b0d-f136-4a7f-94be-540af91e14e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3a936b0d-f136-4a7f-94be-540af91e14e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a765cf6e-2215-43ee-ac90-7aeeac38f5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3a936b0d-f136-4a7f-94be-540af91e14e7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a765cf6e-2215-43ee-ac90-7aeeac38f5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_512553ce-30dc-45b6-8e76-7d796cc673fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a765cf6e-2215-43ee-ac90-7aeeac38f5f5" xlink:to="loc_us-gaap_CashFlowHedgingMember_512553ce-30dc-45b6-8e76-7d796cc673fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0b5a4c9-aa3a-43ac-862b-67da48daf368" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb642a66-af62-48e6-82cd-363220878c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb642a66-af62-48e6-82cd-363220878c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_4058727e-dcb7-429c-949a-b12dfc769407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeBasisSpreadOnVariableRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DerivativeBasisSpreadOnVariableRate_4058727e-dcb7-429c-949a-b12dfc769407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8a041887-d57d-482c-8abd-f25e6a118550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8a041887-d57d-482c-8abd-f25e6a118550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_08017425-dc4b-4821-ab19-42bd2a6db186" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_08017425-dc4b-4821-ab19-42bd2a6db186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a2a3f59-0d0e-407a-8fe1-7bfa12ad085d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a2a3f59-0d0e-407a-8fe1-7bfa12ad085d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15e44146-cb14-4999-bf86-9a886af80dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15e44146-cb14-4999-bf86-9a886af80dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ebc27597-6996-4483-b598-d9d5677544e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ebc27597-6996-4483-b598-d9d5677544e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration_9ab2e41d-4dd5-430a-bb81-3fc2f4d7d029" xlink:href="amgn-20211231.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_amgn_DebtExchangeAdditionalCashConsideration_9ab2e41d-4dd5-430a-bb81-3fc2f4d7d029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6112d237-ac80-4647-b5e9-65cc9cc3677b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6112d237-ac80-4647-b5e9-65cc9cc3677b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_70397161-4458-499b-837f-8c657ce2dbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aad0505e-0bf7-4d87-af00-6d28db6acae6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_70397161-4458-499b-837f-8c657ce2dbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_964b1aed-fda4-4397-a5bd-beee79a4d5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_964b1aed-fda4-4397-a5bd-beee79a4d5f6" xlink:to="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_655577fd-aafc-4f52-ae42-df08f396235c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_655577fd-aafc-4f52-ae42-df08f396235c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01536a3e-00e7-4e25-81c3-eec2032724e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_655577fd-aafc-4f52-ae42-df08f396235c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01536a3e-00e7-4e25-81c3-eec2032724e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cbcb0bfa-fd22-4ed8-abe6-9f93f63a7e31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01536a3e-00e7-4e25-81c3-eec2032724e5" xlink:to="loc_us-gaap_LineOfCreditMember_cbcb0bfa-fd22-4ed8-abe6-9f93f63a7e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:to="loc_us-gaap_VariableRateAxis_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_ac8d9614-7c3b-4b80-9c28-598d89c5a8b8" xlink:to="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_da496d14-4491-44aa-8294-7796557ce374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_da496d14-4491-44aa-8294-7796557ce374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3ce34193-42aa-45bd-8093-30014fb581d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_afd29787-a561-4ebb-8a42-6e4e1723ac55" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3ce34193-42aa-45bd-8093-30014fb581d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_211311f6-8ffd-4eba-8370-562fc7b83759" xlink:to="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96e345ff-a2b0-4261-b47e-1a2f793a9f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96e345ff-a2b0-4261-b47e-1a2f793a9f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_58e64694-9a0a-40fd-a596-ae13ffbea6c5" xlink:href="amgn-20211231.xsd#amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks_58e64694-9a0a-40fd-a596-ae13ffbea6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_46a6c3d2-ec84-4c83-aaa7-464484d1dd95" xlink:href="amgn-20211231.xsd#amgn_LineOfCreditFacilityInitialCommitmentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_LineOfCreditFacilityInitialCommitmentTerm_46a6c3d2-ec84-4c83-aaa7-464484d1dd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8ec3ad25-1fb3-4be1-ba39-619add8fbd81" xlink:href="amgn-20211231.xsd#amgn_LineofCreditFacilityNumberOfRenewalOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_LineofCreditFacilityNumberOfRenewalOptions_8ec3ad25-1fb3-4be1-ba39-619add8fbd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_e322601e-5950-4e40-97e0-8e319becb4d1" xlink:href="amgn-20211231.xsd#amgn_LineOfCreditFacilityExtensionOfCommitmentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm_e322601e-5950-4e40-97e0-8e319becb4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_a7ae05ce-c5e6-47d1-bcd2-039ed23f2ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_a7ae05ce-c5e6-47d1-bcd2-039ed23f2ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bc48a514-2ccb-44a1-9025-f11b61522342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bc48a514-2ccb-44a1-9025-f11b61522342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d9b7494e-e3b0-4594-b600-d36960029d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d9b7494e-e3b0-4594-b600-d36960029d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_658d20e4-3657-49a6-9922-f3c0b1d05d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_51626e7a-84b5-467e-98b8-3403d4182c56" xlink:to="loc_us-gaap_LineOfCredit_658d20e4-3657-49a6-9922-f3c0b1d05d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cb9a7585-2dd5-4ab9-a653-d2c2f5bd438b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cb9a7585-2dd5-4ab9-a653-d2c2f5bd438b" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6d8697c6-c3b4-436b-87c0-ef42950a3a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6d8697c6-c3b4-436b-87c0-ef42950a3a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5cfab927-de78-4208-93a3-3eb60b7c2ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5cfab927-de78-4208-93a3-3eb60b7c2ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a22d0776-f453-4e2f-a5df-24028f88d598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a22d0776-f453-4e2f-a5df-24028f88d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d2ebd108-3ab9-429a-8412-068e3505c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d2ebd108-3ab9-429a-8412-068e3505c56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0cda312d-b1f5-4af9-a160-58581880f96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0cda312d-b1f5-4af9-a160-58581880f96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1c373659-083f-4aa2-9230-ed2a2c8d2181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1c373659-083f-4aa2-9230-ed2a2c8d2181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_b3768e19-eaa6-475c-a9e8-eb0cf9ab8b8b" xlink:href="amgn-20211231.xsd#amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_5c8b50cd-806a-4a09-b40c-43d84c69d8a0" xlink:to="loc_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet_b3768e19-eaa6-475c-a9e8-eb0cf9ab8b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FinancingarrangementsInterestCostsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_70c55d12-7e33-4a62-99a1-13708e61aa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_5f5bf138-2c45-43a1-a4aa-0d5379241686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_70c55d12-7e33-4a62-99a1-13708e61aa60" xlink:to="loc_us-gaap_InterestPaid_5f5bf138-2c45-43a1-a4aa-0d5379241686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockholdersequity" xlink:type="simple" xlink:href="amgn-20211231.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6f9c6ffe-92c0-4981-8a8b-4fd733ae137d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_010bd1f6-cc15-4e8e-ab65-7bb451b9fced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6f9c6ffe-92c0-4981-8a8b-4fd733ae137d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_010bd1f6-cc15-4e8e-ab65-7bb451b9fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cd1a7880-f0a2-46bc-88ff-d9f24d7ec5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock_b65523ed-b15f-4c2f-8b1d-e323554097c2" xlink:href="amgn-20211231.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cd1a7880-f0a2-46bc-88ff-d9f24d7ec5bb" xlink:to="loc_amgn_StockRepurchaseProgramTableTextBlock_b65523ed-b15f-4c2f-8b1d-e323554097c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2b880ebf-bb48-4b70-8f91-493fe15c900e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cd1a7880-f0a2-46bc-88ff-d9f24d7ec5bb" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2b880ebf-bb48-4b70-8f91-493fe15c900e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f01b6396-d1f8-488e-b6bf-da6f3be8c749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cd1a7880-f0a2-46bc-88ff-d9f24d7ec5bb" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f01b6396-d1f8-488e-b6bf-da6f3be8c749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityStockRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ab9ef6a7-7e4e-44ae-a0aa-2f1677991f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_8a2ce2ca-c257-4a2b-a09c-d10bca05935f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab9ef6a7-7e4e-44ae-a0aa-2f1677991f28" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_8a2ce2ca-c257-4a2b-a09c-d10bca05935f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_575e4c4e-1629-49a2-9f2c-9892edd8d52a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab9ef6a7-7e4e-44ae-a0aa-2f1677991f28" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_575e4c4e-1629-49a2-9f2c-9892edd8d52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3471d565-8bc2-47bd-abe6-831c6849ec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab9ef6a7-7e4e-44ae-a0aa-2f1677991f28" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3471d565-8bc2-47bd-abe6-831c6849ec4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_15d4a2b8-d571-40eb-a706-9d7d9042a763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab9ef6a7-7e4e-44ae-a0aa-2f1677991f28" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_15d4a2b8-d571-40eb-a706-9d7d9042a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9d7ec9c8-a594-4a83-b98f-45d0168b6bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_913735b6-1bf5-4ef6-976a-98d84e84f1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9d7ec9c8-a594-4a83-b98f-45d0168b6bb1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_913735b6-1bf5-4ef6-976a-98d84e84f1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_570c00bd-97d4-45bd-913c-64cb316214fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_913735b6-1bf5-4ef6-976a-98d84e84f1ab" xlink:to="loc_srt_StatementScenarioAxis_570c00bd-97d4-45bd-913c-64cb316214fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_660b24eb-6572-4ee7-841d-a930ed359f80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_570c00bd-97d4-45bd-913c-64cb316214fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_660b24eb-6572-4ee7-841d-a930ed359f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8103c579-dda8-4ead-b94c-b67c966c4156" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_660b24eb-6572-4ee7-841d-a930ed359f80" xlink:to="loc_srt_ScenarioForecastMember_8103c579-dda8-4ead-b94c-b67c966c4156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_913735b6-1bf5-4ef6-976a-98d84e84f1ab" xlink:to="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_911ce317-e796-41e5-bdd0-f367aceaa9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_911ce317-e796-41e5-bdd0-f367aceaa9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_12bf96fd-71a8-4458-a070-1ad40b822555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2db91136-1bcb-45c3-987c-9e1e78195244" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_12bf96fd-71a8-4458-a070-1ad40b822555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f23a4f4c-c1ea-4fbc-b199-f62ecc968373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f23a4f4c-c1ea-4fbc-b199-f62ecc968373" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e23cdf5c-91db-464a-9407-713539f3e1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e23cdf5c-91db-464a-9407-713539f3e1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e23cdf5c-91db-464a-9407-713539f3e1bc" xlink:to="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d1688776-b885-4d6e-9b2f-bcdf1fb53599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d1688776-b885-4d6e-9b2f-bcdf1fb53599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_49ce40e0-cdda-4b7a-ac29-3f5ef64daa18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_49ce40e0-cdda-4b7a-ac29-3f5ef64daa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cfaeed03-9d54-4705-a732-21cd9c3f3bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_cfaeed03-9d54-4705-a732-21cd9c3f3bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_283236c8-4f8b-4c02-8cfa-1a6f7357bd12" xlink:href="amgn-20211231.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_283236c8-4f8b-4c02-8cfa-1a6f7357bd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61d65b66-be3d-4c0d-a1d3-733af7c02924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fba53742-2d52-46e2-9ba8-d5dd93bf4e3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61d65b66-be3d-4c0d-a1d3-733af7c02924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9f2272c-f776-42ce-a4ce-bfe87a5ceb39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_630f7dc3-dbe3-4e5a-9656-0b4ed64edb46" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9f2272c-f776-42ce-a4ce-bfe87a5ceb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_040a4ee9-31a3-4457-9f70-d16ea66a44ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9f2272c-f776-42ce-a4ce-bfe87a5ceb39" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_040a4ee9-31a3-4457-9f70-d16ea66a44ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9260a9ee-87dc-4b3a-80fe-f50c3edead12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a8e2bb6c-5d5e-48cb-bbce-4b816a6f144e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9260a9ee-87dc-4b3a-80fe-f50c3edead12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9260a9ee-87dc-4b3a-80fe-f50c3edead12" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8074648f-093a-4df8-924e-b6fc59344d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_StockholdersEquity_8074648f-093a-4df8-924e-b6fc59344d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a68b54dd-9b99-493e-a425-1c217d54f132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a68b54dd-9b99-493e-a425-1c217d54f132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_42b5bb68-185b-414f-af71-f8c158db51b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_42b5bb68-185b-414f-af71-f8c158db51b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4f0c3420-cd69-4fbc-9a75-7475b67734f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4f0c3420-cd69-4fbc-9a75-7475b67734f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_9da45e39-6317-4cd5-8087-d3166c1b245f" xlink:href="amgn-20211231.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_9da45e39-6317-4cd5-8087-d3166c1b245f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_83ac021b-b3b7-4d1f-a8bd-6a74d33849db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_83ac021b-b3b7-4d1f-a8bd-6a74d33849db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8f63235-6418-47b2-a3c1-73e833b04e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d1e71d59-1fe4-4032-90b9-2ce38a362e1f" xlink:to="loc_us-gaap_StockholdersEquity_a8f63235-6418-47b2-a3c1-73e833b04e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0b484912-da6d-4068-96c5-cf79517fd7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b29eb0ee-deec-4996-913d-8d7884d89f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0b484912-da6d-4068-96c5-cf79517fd7c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b29eb0ee-deec-4996-913d-8d7884d89f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_260b8051-a10c-4878-9dec-9240e694bcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0b484912-da6d-4068-96c5-cf79517fd7c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_260b8051-a10c-4878-9dec-9240e694bcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_4b86b1df-c3fb-43fc-a412-0a09b3be904c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0b484912-da6d-4068-96c5-cf79517fd7c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_4b86b1df-c3fb-43fc-a412-0a09b3be904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_079b3fa0-4161-47db-9829-cab11064e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0b484912-da6d-4068-96c5-cf79517fd7c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_079b3fa0-4161-47db-9829-cab11064e1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29675679-f9be-4207-a5be-4e6be461b1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_29675679-f9be-4207-a5be-4e6be461b1c7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f634eb0d-fa1d-43eb-b416-18a8fc0f2228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f634eb0d-fa1d-43eb-b416-18a8fc0f2228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da4f28b8-5406-4c5c-ac44-c889c1ee50a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f634eb0d-fa1d-43eb-b416-18a8fc0f2228" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da4f28b8-5406-4c5c-ac44-c889c1ee50a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_06733936-3250-44ff-b7ca-a3ce15559c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da4f28b8-5406-4c5c-ac44-c889c1ee50a2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_06733936-3250-44ff-b7ca-a3ce15559c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0d0ff9a8-0954-4dcb-9882-50c5cc3a1a97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d58c9844-fadf-444a-9b24-f74fd83930a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d58c9844-fadf-444a-9b24-f74fd83930a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_b620a936-6e10-4398-a3ba-d003805a076c" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_88ae3ffe-6b82-4c20-829e-e317c76e7493" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_b620a936-6e10-4398-a3ba-d003805a076c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_srt_ProductOrServiceAxis_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_878125d7-7335-4bfe-8d0e-baadb357a078" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fceb1d75-15d3-4f6b-8eb0-2356ff05a9cd" xlink:to="loc_srt_ProductsAndServicesDomain_878125d7-7335-4bfe-8d0e-baadb357a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0da965be-26c3-4968-8a8f-649804de9a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_878125d7-7335-4bfe-8d0e-baadb357a078" xlink:to="loc_us-gaap_ProductMember_0da965be-26c3-4968-8a8f-649804de9a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15c6dab9-1b55-4d6f-a003-303c4e7e6fdd" xlink:to="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_dc53befb-2b10-40b5-a831-e41b282b2ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_dc53befb-2b10-40b5-a831-e41b282b2ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0f4485f0-fade-435d-aea7-a7d08ea345cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a037e769-0918-4a78-a1e7-46a8ab5e2dd9" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0f4485f0-fade-435d-aea7-a7d08ea345cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ca79e62a-b1bd-4ac8-b9f2-eb74487f1eae" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd0cd6dd-ab2f-4c14-a24f-af711ec56bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cd0cd6dd-ab2f-4c14-a24f-af711ec56bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_071e3bff-1997-4540-8b70-6d6ed61b607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_071e3bff-1997-4540-8b70-6d6ed61b607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_850bbfac-dfad-496b-bfd3-26f3369e012e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_InterestExpenseDebt_850bbfac-dfad-496b-bfd3-26f3369e012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_45c4cc98-1ad8-4abd-a40e-2f62b2537a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_45c4cc98-1ad8-4abd-a40e-2f62b2537a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3cb4f67d-32c6-41e6-ad00-62d0cec3fc68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3cb4f67d-32c6-41e6-ad00-62d0cec3fc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e49efa7-c6d2-49be-8c45-acbec489a006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ebea8445-5e62-488e-82b5-54c431b2e342" xlink:to="loc_us-gaap_NetIncomeLoss_3e49efa7-c6d2-49be-8c45-acbec489a006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#StockholdersequityOtherDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d76b7c5b-ea66-45c4-9635-14fc5f0ece24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c4f11b58-6001-4278-870d-bb770e724cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d76b7c5b-ea66-45c4-9635-14fc5f0ece24" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c4f11b58-6001-4278-870d-bb770e724cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3478cf6e-b345-4e1b-86cd-ef4e18be83e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d76b7c5b-ea66-45c4-9635-14fc5f0ece24" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3478cf6e-b345-4e1b-86cd-ef4e18be83e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4b6489a5-3271-4ad0-8e64-cde1a4b53cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d76b7c5b-ea66-45c4-9635-14fc5f0ece24" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4b6489a5-3271-4ad0-8e64-cde1a4b53cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_746c676f-b294-4c00-83b4-a1ac29a1aa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d76b7c5b-ea66-45c4-9635-14fc5f0ece24" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_746c676f-b294-4c00-83b4-a1ac29a1aa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="simple" xlink:href="amgn-20211231.xsd#Fairvaluemeasurement"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_30e2bdae-4de1-4c91-ac74-633b041bd14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_041bc9bb-bba1-42fa-95c3-ca4ed29f06da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30e2bdae-4de1-4c91-ac74-633b041bd14b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_041bc9bb-bba1-42fa-95c3-ca4ed29f06da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e11ad7d1-6879-4b5a-8233-d9439ccbc7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_75a2363d-d930-48d9-812d-7f879524989c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e11ad7d1-6879-4b5a-8233-d9439ccbc7c2" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_75a2363d-d930-48d9-812d-7f879524989c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b5ae3f95-2028-4975-be6c-0c4fa44865fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e11ad7d1-6879-4b5a-8233-d9439ccbc7c2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b5ae3f95-2028-4975-be6c-0c4fa44865fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8b19d40f-3d15-4d56-b6ca-4302f126f952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8b19d40f-3d15-4d56-b6ca-4302f126f952" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8604d7-186e-442b-b310-58fa60800dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8604d7-186e-442b-b310-58fa60800dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a8604d7-186e-442b-b310-58fa60800dc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0608739f-278a-4fb0-979d-4349a6e52b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0608739f-278a-4fb0-979d-4349a6e52b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0693b42b-9ff4-4bd8-aac7-25d71efa6afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0693b42b-9ff4-4bd8-aac7-25d71efa6afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1c50dabf-1f34-4fd9-bc57-36bee0fa45b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17c87e02-20be-4f92-928b-ce4f5b3c0587" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1c50dabf-1f34-4fd9-bc57-36bee0fa45b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_64b79d57-819f-4699-8999-1c172fe31038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_64b79d57-819f-4699-8999-1c172fe31038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64b79d57-819f-4699-8999-1c172fe31038" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a0546740-4969-482b-b942-7c2bec17f93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a0546740-4969-482b-b942-7c2bec17f93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_5d058d8b-fd33-4314-a5a2-a760910949d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_5d058d8b-fd33-4314-a5a2-a760910949d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5e3f97f0-ff3f-4ff8-a44c-9a5c49bbb0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5e3f97f0-ff3f-4ff8-a44c-9a5c49bbb0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f29d1542-99cd-4050-9d65-1debc27bf145" xlink:href="amgn-20211231.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcbd6e39-3259-4984-a962-a35ca5e1e6ba" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_f29d1542-99cd-4050-9d65-1debc27bf145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6c317898-79ed-4b7c-a70a-797a7bac1324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6c317898-79ed-4b7c-a70a-797a7bac1324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6c317898-79ed-4b7c-a70a-797a7bac1324" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_828c1ee0-48c2-4101-8a4b-52f8fc1a65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_828c1ee0-48c2-4101-8a4b-52f8fc1a65f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_4acb6fab-f664-4342-8f72-476d8ac4ae88" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_4acb6fab-f664-4342-8f72-476d8ac4ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_16b9a491-7c8f-407e-a921-f160a8a1950d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f28b6d-f280-43fd-b89d-db76044a8da3" xlink:to="loc_us-gaap_InterestRateSwapMember_16b9a491-7c8f-407e-a921-f160a8a1950d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b43b90f-f22b-4789-8067-7b80722de9c2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c2cb4155-ec45-4e5e-b416-6eb3a11ecbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c2cb4155-ec45-4e5e-b416-6eb3a11ecbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_63c9577f-f14b-49b0-9a9c-e631912337c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_63c9577f-f14b-49b0-9a9c-e631912337c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:href="amgn-20211231.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_226a1d01-03fa-4ee8-94e1-5bf0be8d9b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_226a1d01-03fa-4ee8-94e1-5bf0be8d9b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_36908aa9-d6cc-4905-9060-ff7deee8a534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_9248e5c0-f4ed-4cfb-b326-b65b790d59ad" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_36908aa9-d6cc-4905-9060-ff7deee8a534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_15f8b587-1690-46b8-bf2b-3c2ca40d4dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8574ca2e-6907-491e-9656-1272d6120341" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_15f8b587-1690-46b8-bf2b-3c2ca40d4dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98ba8d82-68ec-44a5-9f44-cfffff3e6611" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:href="amgn-20211231.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2838bd3c-ec08-40a3-8551-ae3089f59aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_2838bd3c-ec08-40a3-8551-ae3089f59aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_2a96713f-62f4-4736-9047-0f97bc16db32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_0e9ca60b-abfc-42a5-a327-1e8a031190c4" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_2a96713f-62f4-4736-9047-0f97bc16db32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c28f7cd4-b2ff-478a-b158-c6c4253a57d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c28f7cd4-b2ff-478a-b158-c6c4253a57d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8213e982-b278-4a8e-bbcd-7b6e9a7e83c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1147f4ce-e5c5-4983-a2d2-f49c88d1903e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8213e982-b278-4a8e-bbcd-7b6e9a7e83c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_500f6c72-8977-4fa3-a21a-aad0548403f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_500f6c72-8977-4fa3-a21a-aad0548403f7" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4c9839c-1ee5-4e1d-9317-6a229bdcbc81" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_11afe727-7866-44d8-bb3a-ed239f0c74cc" xlink:href="amgn-20211231.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:to="loc_amgn_BeiGeneMember_11afe727-7866-44d8-bb3a-ed239f0c74cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_66b2f463-8055-4f92-9e53-6d3d7d77345c" xlink:href="amgn-20211231.xsd#amgn_TeneobioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a8fcd-02f8-4c17-852d-914f2f5c422e" xlink:to="loc_amgn_TeneobioIncMember_66b2f463-8055-4f92-9e53-6d3d7d77345c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a4cd7d07-57f4-4770-abd5-9c20e537ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a4cd7d07-57f4-4770-abd5-9c20e537ac55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ef09a074-168e-4ac9-854a-cebc439eb330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a4cd7d07-57f4-4770-abd5-9c20e537ac55" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ef09a074-168e-4ac9-854a-cebc439eb330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8faafb6f-945f-4a7b-92dd-94de028d89d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ef09a074-168e-4ac9-854a-cebc439eb330" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8faafb6f-945f-4a7b-92dd-94de028d89d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5649a30c-1474-4cbb-a14e-0b63b2a7a80f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_11dc5259-680c-49b7-9d1d-7f3241c5860f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_11dc5259-680c-49b7-9d1d-7f3241c5860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_6e1f0679-c85a-41cc-9e3a-f6e11a56065d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_6e1f0679-c85a-41cc-9e3a-f6e11a56065d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_14750b32-18b3-488f-82b6-33605e41f1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_LongTermDebt_14750b32-18b3-488f-82b6-33605e41f1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8f5bee7e-feee-4011-b215-ed1f02036d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_8f5bee7e-feee-4011-b215-ed1f02036d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f9293a3b-9420-49fc-91a3-7a739598d58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_EquityMethodInvestments_f9293a3b-9420-49fc-91a3-7a739598d58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8f3139b1-d007-483c-b5e5-3598dfa78dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0223bf5b-dca7-4ae3-b3be-0082c1c82164" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8f3139b1-d007-483c-b5e5-3598dfa78dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#FairvaluemeasurementContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_07449321-1fc6-47cb-82aa-e0d531f2fef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e3bdd5c4-e956-4f11-b40c-303a015f962e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07449321-1fc6-47cb-82aa-e0d531f2fef3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e3bdd5c4-e956-4f11-b40c-303a015f962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_df50ac71-d0fa-4cfc-ae4b-776a4579cdec" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07449321-1fc6-47cb-82aa-e0d531f2fef3" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_df50ac71-d0fa-4cfc-ae4b-776a4579cdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_c453f162-e85a-4c04-8147-7b84cef40863" xlink:href="amgn-20211231.xsd#amgn_BusinessCombinationContingentConsiderationArrangementsPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07449321-1fc6-47cb-82aa-e0d531f2fef3" xlink:to="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_c453f162-e85a-4c04-8147-7b84cef40863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_51ad0abc-3ba7-4e6e-9c59-423007b2ed7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07449321-1fc6-47cb-82aa-e0d531f2fef3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_51ad0abc-3ba7-4e6e-9c59-423007b2ed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_beb8c665-0898-4b40-a366-395cb4dcf6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07449321-1fc6-47cb-82aa-e0d531f2fef3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_beb8c665-0898-4b40-a366-395cb4dcf6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_895099c0-fb99-456b-a47b-8cd8959a265e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07449321-1fc6-47cb-82aa-e0d531f2fef3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_895099c0-fb99-456b-a47b-8cd8959a265e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71087b45-4697-4a51-aa0e-87ca268f77af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_895099c0-fb99-456b-a47b-8cd8959a265e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71087b45-4697-4a51-aa0e-87ca268f77af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5622958-1190-4057-8c3d-339722cbe16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71087b45-4697-4a51-aa0e-87ca268f77af" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5622958-1190-4057-8c3d-339722cbe16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_b7afb634-b304-4df6-b523-bec1e26d6807" xlink:href="amgn-20211231.xsd#amgn_TeneobioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5622958-1190-4057-8c3d-339722cbe16b" xlink:to="loc_amgn_TeneobioIncMember_b7afb634-b304-4df6-b523-bec1e26d6807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db97b44a-3b02-4036-9bf1-6c9572ec5727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_895099c0-fb99-456b-a47b-8cd8959a265e" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db97b44a-3b02-4036-9bf1-6c9572ec5727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_88133a55-4e0c-4535-862d-0bb1b7517086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db97b44a-3b02-4036-9bf1-6c9572ec5727" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_88133a55-4e0c-4535-862d-0bb1b7517086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Derivativeinstruments" xlink:type="simple" xlink:href="amgn-20211231.xsd#Derivativeinstruments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Derivativeinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_825fcd43-69c1-4b32-ae5f-d3cf034b17ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_8248dabc-1e14-4ae8-a08e-c6bbdb972880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_825fcd43-69c1-4b32-ae5f-d3cf034b17ce" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_8248dabc-1e14-4ae8-a08e-c6bbdb972880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_474b44d8-0fd2-41f0-a964-a86aed085bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_c728efec-79e8-4a22-a21c-1d27c506af20" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_474b44d8-0fd2-41f0-a964-a86aed085bb6" xlink:to="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_c728efec-79e8-4a22-a21c-1d27c506af20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_ac08c905-6efe-46cc-b971-a001f7f3b168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_474b44d8-0fd2-41f0-a964-a86aed085bb6" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_ac08c905-6efe-46cc-b971-a001f7f3b168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_233a8586-59a8-406d-b8ba-94e5ba537a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_474b44d8-0fd2-41f0-a964-a86aed085bb6" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_233a8586-59a8-406d-b8ba-94e5ba537a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_9ae93cf0-894e-4612-bf21-102531724294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_474b44d8-0fd2-41f0-a964-a86aed085bb6" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_9ae93cf0-894e-4612-bf21-102531724294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_03d7cc06-06ba-4352-8d95-3fc1c44e8fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_474b44d8-0fd2-41f0-a964-a86aed085bb6" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_03d7cc06-06ba-4352-8d95-3fc1c44e8fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_da9d4ee3-0286-41fb-a903-42313200dda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_da9d4ee3-0286-41fb-a903-42313200dda4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a0193924-f427-4606-b2fd-ccc0c32b4b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a0193924-f427-4606-b2fd-ccc0c32b4b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ad85cb64-3266-4f34-98a4-b3f592887988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a0193924-f427-4606-b2fd-ccc0c32b4b68" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ad85cb64-3266-4f34-98a4-b3f592887988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_d9352adc-c66e-47f3-abe4-1af39695f95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ad85cb64-3266-4f34-98a4-b3f592887988" xlink:to="loc_us-gaap_NotesPayableToBanksMember_d9352adc-c66e-47f3-abe4-1af39695f95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a47871ad-481d-4b26-afd5-ee9884676486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_DebtInstrumentAxis_a47871ad-481d-4b26-afd5-ee9884676486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42ed0962-b74d-4eac-9aef-060a00997ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a47871ad-481d-4b26-afd5-ee9884676486" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42ed0962-b74d-4eac-9aef-060a00997ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f6091609-10e2-4ff4-b6e6-e2860953a7ce" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42ed0962-b74d-4eac-9aef-060a00997ca1" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_f6091609-10e2-4ff4-b6e6-e2860953a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8cadb993-775a-4081-8d23-5b1a0a3c97f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_HedgingDesignationAxis_8cadb993-775a-4081-8d23-5b1a0a3c97f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8cadb993-775a-4081-8d23-5b1a0a3c97f6" xlink:to="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a40f1ccc-dd36-4fbb-92b4-431714206f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a40f1ccc-dd36-4fbb-92b4-431714206f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8e673d99-da07-4e44-87e9-97619481b990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f6f6c24f-7f77-4d03-9f0c-6190576e5ccf" xlink:to="loc_us-gaap_NondesignatedMember_8e673d99-da07-4e44-87e9-97619481b990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a5da5674-4e95-4791-82cc-1abdcb285c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a5da5674-4e95-4791-82cc-1abdcb285c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a5da5674-4e95-4791-82cc-1abdcb285c17" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_225841f5-e895-4c55-9509-5a1169383ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_us-gaap_ForwardContractsMember_225841f5-e895-4c55-9509-5a1169383ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_bfe331c7-9d1d-4a7c-abd4-22e7d96aae21" xlink:href="amgn-20211231.xsd#amgn_ForeignCurrencyAndCrossCurrencySwapsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_amgn_ForeignCurrencyAndCrossCurrencySwapsMember_bfe331c7-9d1d-4a7c-abd4-22e7d96aae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1f243086-477b-4bea-b02a-825efa17ae4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_us-gaap_InterestRateSwapMember_1f243086-477b-4bea-b02a-825efa17ae4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_cbb67774-f244-413f-b8ad-2248728789d6" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAtThenCurrentInterestRatesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0aeb2552-fab4-4bcc-86d6-e41ca2d824ed" xlink:to="loc_amgn_InterestRateSwapAtThenCurrentInterestRatesMember_cbb67774-f244-413f-b8ad-2248728789d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapAxis_683d9dfc-55b4-4ba4-9d5c-b467d67a6836" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_amgn_InterestRateSwapAxis_683d9dfc-55b4-4ba4-9d5c-b467d67a6836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapDomain_66923091-8b39-4643-ba02-28b7b9104ae4" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapAxis_683d9dfc-55b4-4ba4-9d5c-b467d67a6836" xlink:to="loc_amgn_InterestRateSwapDomain_66923091-8b39-4643-ba02-28b7b9104ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_InterestRateSwapTwoMember_69194502-a3c3-46fd-9bd0-f0fb092fc6fc" xlink:href="amgn-20211231.xsd#amgn_InterestRateSwapTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_InterestRateSwapDomain_66923091-8b39-4643-ba02-28b7b9104ae4" xlink:to="loc_amgn_InterestRateSwapTwoMember_69194502-a3c3-46fd-9bd0-f0fb092fc6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1da01a6e-2544-49fc-b607-70337774cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1da01a6e-2544-49fc-b607-70337774cb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b43f238-b4aa-4516-a179-39f4320da46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1da01a6e-2544-49fc-b607-70337774cb14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b43f238-b4aa-4516-a179-39f4320da46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_f2d2325a-62b7-4e2d-b170-ad8f546d80f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b43f238-b4aa-4516-a179-39f4320da46f" xlink:to="loc_us-gaap_InterestExpenseMember_f2d2325a-62b7-4e2d-b170-ad8f546d80f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e95996f6-1745-4214-934c-50b99e75a4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e95996f6-1745-4214-934c-50b99e75a4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c222d634-f10c-436d-9207-1755f5aada88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e95996f6-1745-4214-934c-50b99e75a4af" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c222d634-f10c-436d-9207-1755f5aada88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_a98187cf-88d7-47f5-b115-1394f5c31c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c222d634-f10c-436d-9207-1755f5aada88" xlink:to="loc_us-gaap_LongTermDebtMember_a98187cf-88d7-47f5-b115-1394f5c31c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d1cc84c6-33fc-4c36-a211-09f6d6658aa3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeInstrumentTerm_385eabe0-5b41-43b4-85db-751a0cfdd6bf" xlink:href="amgn-20211231.xsd#amgn_DerivativeInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeInstrumentTerm_385eabe0-5b41-43b4-85db-751a0cfdd6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_74e5e26c-656d-4c2f-ab41-c38054c1682a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_DerivativeNotionalAmount_74e5e26c-656d-4c2f-ab41-c38054c1682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_205ad3df-7ac4-4d22-8d59-71854b2310bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_205ad3df-7ac4-4d22-8d59-71854b2310bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminated_64a558d7-e94e-460e-8fac-8a9a60552d44" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminated_64a558d7-e94e-460e-8fac-8a9a60552d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c10a61f-95d2-4d34-8eb1-02c06eda0b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c10a61f-95d2-4d34-8eb1-02c06eda0b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments_0494a79f-745f-4cd0-89f5-e12f66acf3f0" xlink:href="amgn-20211231.xsd#amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments_0494a79f-745f-4cd0-89f5-e12f66acf3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_7ef242ea-ce51-4c77-b3fa-e08c09278fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainOnDerivative"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_7ef242ea-ce51-4c77-b3fa-e08c09278fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_6ff20f7f-d099-419e-bf6a-b5b8b74de644" xlink:href="amgn-20211231.xsd#amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities_6ff20f7f-d099-419e-bf6a-b5b8b74de644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_1dc4ef3f-542c-443e-9cd9-8538f21ec0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_1dc4ef3f-542c-443e-9cd9-8538f21ec0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_ca847e54-a14d-4976-be79-ef61675dd464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_589b08f9-85d8-4da9-9c10-4d9a09fa28b4" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_ca847e54-a14d-4976-be79-ef61675dd464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_52f8c3c5-809f-4a82-887b-e780d8cf90ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_52f8c3c5-809f-4a82-887b-e780d8cf90ac" xlink:to="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ab42c1d3-d0e8-4f1e-9822-893c55f9dedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f3f8259-2bcd-4b35-bca9-f96115dc5f7a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ab42c1d3-d0e8-4f1e-9822-893c55f9dedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_43802e0a-964d-43e4-a670-6031f0c68bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ab42c1d3-d0e8-4f1e-9822-893c55f9dedb" xlink:to="loc_us-gaap_CashFlowHedgingMember_43802e0a-964d-43e4-a670-6031f0c68bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2d471a71-8241-4c14-9b99-bbf3928804a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2d471a71-8241-4c14-9b99-bbf3928804a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_124f6a81-af99-427e-a3bd-5ef6bb1c2cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d471a71-8241-4c14-9b99-bbf3928804a9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_124f6a81-af99-427e-a3bd-5ef6bb1c2cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_415b3cab-33a3-4023-b4ae-b963caf91e06" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_124f6a81-af99-427e-a3bd-5ef6bb1c2cea" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_415b3cab-33a3-4023-b4ae-b963caf91e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_162d9be6-b11b-4a92-9921-9e9345d65d94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_srt_CurrencyAxis_162d9be6-b11b-4a92-9921-9e9345d65d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_162d9be6-b11b-4a92-9921-9e9345d65d94" xlink:to="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_5e719616-97e2-44c3-80eb-faaae6fbb6a5" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_EUR_5e719616-97e2-44c3-80eb-faaae6fbb6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_36e18a2b-5c40-44f9-850f-c98b6790a779" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_CHF_36e18a2b-5c40-44f9-850f-c98b6790a779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_c1251770-566a-4a3d-9617-8c7f4a4dd688" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_GBP_c1251770-566a-4a3d-9617-8c7f4a4dd688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_bf620947-3604-4c33-9254-88d4c6612fe6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_402a7e9d-6f8c-4629-91c2-3dbb2ef762f8" xlink:to="loc_currency_USD_bf620947-3604-4c33-9254-88d4c6612fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e0b5ba5-1eed-436d-b3b7-9d91cb8cbbed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_0cf85b58-f61e-44be-92cd-a4cdd8b4e8d0" xlink:href="amgn-20211231.xsd#amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member_0cf85b58-f61e-44be-92cd-a4cdd8b4e8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ee33e834-a857-4ead-899b-075f7294e12f" xlink:href="amgn-20211231.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_ee33e834-a857-4ead-899b-075f7294e12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_87232e89-175a-4688-a12a-4945e125703a" xlink:href="amgn-20211231.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_87232e89-175a-4688-a12a-4945e125703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_a372faba-aeb4-4dc6-b04b-99ab5874c0ad" xlink:href="amgn-20211231.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_a372faba-aeb4-4dc6-b04b-99ab5874c0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d954dd02-97ae-4c03-91a8-2370115c2d42" xlink:href="amgn-20211231.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d954dd02-97ae-4c03-91a8-2370115c2d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_0fe6d3b0-f558-4c2d-88bf-7b4524b01282" xlink:href="amgn-20211231.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70525bf4-e232-4c36-aad5-d6ca25071365" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_0fe6d3b0-f558-4c2d-88bf-7b4524b01282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f9b5a13-9757-437c-a77b-cbad22e113f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f9b5a13-9757-437c-a77b-cbad22e113f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9d29c07d-7d11-4cd7-9504-061200efd6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f9b5a13-9757-437c-a77b-cbad22e113f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9d29c07d-7d11-4cd7-9504-061200efd6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_deadb642-0d68-4cc1-8b0d-76dfbf4486a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9d29c07d-7d11-4cd7-9504-061200efd6fc" xlink:to="loc_us-gaap_NotesPayableToBanksMember_deadb642-0d68-4cc1-8b0d-76dfbf4486a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5cd455b8-fbf8-4aeb-8690-57567275bfd1" xlink:to="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e57029e6-cd6f-4df4-bfc7-b20bcd963e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e57029e6-cd6f-4df4-bfc7-b20bcd963e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_7164173a-1686-492d-a1f0-8a9108fbc68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_7164173a-1686-492d-a1f0-8a9108fbc68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02840255-e739-4a9c-b5f0-ed33a5f63de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_163d4f28-3d48-43ce-ae08-77282d05dea8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02840255-e739-4a9c-b5f0-ed33a5f63de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1cfa27d7-e4fd-459c-bf6f-a10ea767a530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1cfa27d7-e4fd-459c-bf6f-a10ea767a530" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_94acfa77-cfc8-4c26-b8e4-0471862c7237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_94acfa77-cfc8-4c26-b8e4-0471862c7237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_db6fbe43-f9ee-461b-8258-3c11e476ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_94acfa77-cfc8-4c26-b8e4-0471862c7237" xlink:to="loc_us-gaap_HedgingRelationshipDomain_db6fbe43-f9ee-461b-8258-3c11e476ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e12cf5fd-f061-4388-8760-d272871e270c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_db6fbe43-f9ee-461b-8258-3c11e476ba9b" xlink:to="loc_us-gaap_CashFlowHedgingMember_e12cf5fd-f061-4388-8760-d272871e270c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9c1f4cf-9e62-4407-90d6-27fd0a6e5517" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7100d5ca-41cf-4305-993e-ba6677b9682e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7100d5ca-41cf-4305-993e-ba6677b9682e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_104651ce-368e-42ef-ba50-ce733c2804d4" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_382272ac-23e0-4273-86f3-3c4590eea637" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_104651ce-368e-42ef-ba50-ce733c2804d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f99bde30-ea77-4365-950a-d18e1d6b36fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_9c662ecc-db8f-449e-804d-284cf134705b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f99bde30-ea77-4365-950a-d18e1d6b36fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_9e95733d-9351-49fc-a452-02f06d708b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f99bde30-ea77-4365-950a-d18e1d6b36fe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_9e95733d-9351-49fc-a452-02f06d708b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c989b757-af0e-4763-9f20-b57b46cb85e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_d6b2337f-3c74-444a-b0c0-1e82e5efbae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c989b757-af0e-4763-9f20-b57b46cb85e5" xlink:to="loc_us-gaap_DerivativeTable_d6b2337f-3c74-444a-b0c0-1e82e5efbae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0c8a5a24-b467-489b-a42f-e3d84c5875b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_d6b2337f-3c74-444a-b0c0-1e82e5efbae9" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0c8a5a24-b467-489b-a42f-e3d84c5875b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0c8a5a24-b467-489b-a42f-e3d84c5875b1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_e003a21c-ed9b-4f8e-9291-265636684d85" xlink:href="amgn-20211231.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_e003a21c-ed9b-4f8e-9291-265636684d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_613d28ae-db29-4cd4-87fb-8115dae10fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4ffda666-7bf6-4d2e-bc7a-ce7e3888c85b" xlink:to="loc_us-gaap_LongTermDebtMember_613d28ae-db29-4cd4-87fb-8115dae10fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_d6b2337f-3c74-444a-b0c0-1e82e5efbae9" xlink:to="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_3fdd4158-3a1f-418a-9ad5-926209cfd98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_3fdd4158-3a1f-418a-9ad5-926209cfd98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e2a13b9d-0cc9-4a87-a8bc-eaa969d6d100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e2a13b9d-0cc9-4a87-a8bc-eaa969d6d100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_631db59b-8e33-468d-aad3-c00673a937cf" xlink:href="amgn-20211231.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_631db59b-8e33-468d-aad3-c00673a937cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_e3f6bd61-a350-48d8-b9a3-a61796d3d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_47751d70-7a32-43ff-8383-85026959792d" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_e3f6bd61-a350-48d8-b9a3-a61796d3d27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f725cd98-e7d0-4a25-800a-3b025f29991c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f725cd98-e7d0-4a25-800a-3b025f29991c" xlink:to="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fbd35f3-6c03-46c7-9a76-8c47137ef522" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_srt_ProductOrServiceAxis_0fbd35f3-6c03-46c7-9a76-8c47137ef522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_769965ba-0ba3-4456-9ab5-37a3f6574516" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0fbd35f3-6c03-46c7-9a76-8c47137ef522" xlink:to="loc_srt_ProductsAndServicesDomain_769965ba-0ba3-4456-9ab5-37a3f6574516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7f3b042c-2dd0-4061-b77b-d141df2ab084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_769965ba-0ba3-4456-9ab5-37a3f6574516" xlink:to="loc_us-gaap_ProductMember_7f3b042c-2dd0-4061-b77b-d141df2ab084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b4e62311-0197-4d5a-9a5c-90f193c994a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b4e62311-0197-4d5a-9a5c-90f193c994a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ff6ff8cd-95a5-4857-ba58-34885c5bad9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b4e62311-0197-4d5a-9a5c-90f193c994a3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ff6ff8cd-95a5-4857-ba58-34885c5bad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b8d069-1f2a-4aa9-8923-a371295675c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_ff6ff8cd-95a5-4857-ba58-34885c5bad9c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_28b8d069-1f2a-4aa9-8923-a371295675c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b2c3c9d-3503-4ce9-8267-4217c1734dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b2c3c9d-3503-4ce9-8267-4217c1734dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e542134-17e1-45e3-8369-d74b531d2a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b2c3c9d-3503-4ce9-8267-4217c1734dc4" xlink:to="loc_us-gaap_EquityComponentDomain_2e542134-17e1-45e3-8369-d74b531d2a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a12bc0c3-9510-4ee7-abc9-21e792e00319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e542134-17e1-45e3-8369-d74b531d2a1b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a12bc0c3-9510-4ee7-abc9-21e792e00319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b9568646-7235-442d-be2a-7666fec64d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b9568646-7235-442d-be2a-7666fec64d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b9568646-7235-442d-be2a-7666fec64d27" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_18c5536a-593a-4e28-84df-ec1c97802847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_18c5536a-593a-4e28-84df-ec1c97802847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_11541b93-bb61-4a63-bbb2-4b177d7c90f0" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_11541b93-bb61-4a63-bbb2-4b177d7c90f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bc5a1097-135a-4371-8d55-ea746a7e1927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_83b3aa38-0211-4fd1-a0a3-421ae9b79d3f" xlink:to="loc_us-gaap_InterestRateSwapMember_bc5a1097-135a-4371-8d55-ea746a7e1927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_dcb0e845-390a-407e-84b8-6127d52cd7d0" xlink:to="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_eac36226-ece4-48eb-a1ed-13d8f965d706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_eac36226-ece4-48eb-a1ed-13d8f965d706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a95ca2af-6f0c-4bd9-be3b-17cbf4790cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a95ca2af-6f0c-4bd9-be3b-17cbf4790cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c60c2e93-01eb-497f-9554-17638b962853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_InterestExpenseDebt_c60c2e93-01eb-497f-9554-17638b962853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bad2197c-0ca0-43d6-bfab-9dc69e4a8756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_bad2197c-0ca0-43d6-bfab-9dc69e4a8756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e87c09da-6635-459c-94e2-1da7bf61a4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7d022ad0-fa64-424b-b069-67446b2e9816" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e87c09da-6635-459c-94e2-1da7bf61a4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8720dff-95f3-408a-9ef6-5cd905ef177f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8720dff-95f3-408a-9ef6-5cd905ef177f" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:to="loc_us-gaap_HedgingDesignationAxis_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_46c9b618-a5e4-4c17-94aa-29d0e1f3e30b" xlink:to="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09e9c0e9-d401-4901-bb07-106074bb6d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_09e9c0e9-d401-4901-bb07-106074bb6d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_25104b3d-d2d4-415f-bfc5-d65caac4ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_cacacf17-f301-4987-a210-e9b2ce8efa57" xlink:to="loc_us-gaap_NondesignatedMember_25104b3d-d2d4-415f-bfc5-d65caac4ef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a494c4d0-377d-4d82-ae97-f576c11e7a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a494c4d0-377d-4d82-ae97-f576c11e7a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a494c4d0-377d-4d82-ae97-f576c11e7a63" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_51af9a5c-61e5-4183-a49a-0efd31682b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:to="loc_us-gaap_ForeignExchangeContractMember_51af9a5c-61e5-4183-a49a-0efd31682b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_63765309-1d75-4ff8-8aed-6cae6e689b83" xlink:href="amgn-20211231.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_63765309-1d75-4ff8-8aed-6cae6e689b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b2d14f8a-3de1-417c-808d-f6dd7a3c2e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c286e3fe-7fbf-4ebd-a450-4e5c24b44217" xlink:to="loc_us-gaap_InterestRateSwapMember_b2d14f8a-3de1-417c-808d-f6dd7a3c2e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_219e04d3-49ca-44f2-b501-8f6813f58e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_219e04d3-49ca-44f2-b501-8f6813f58e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_219e04d3-49ca-44f2-b501-8f6813f58e23" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_a4aa27de-f6ad-44e6-9e8b-b7b1f8012133" xlink:href="amgn-20211231.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_a4aa27de-f6ad-44e6-9e8b-b7b1f8012133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_680c5d03-28d9-4bba-835a-1fdb68a4b17f" xlink:href="amgn-20211231.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_680c5d03-28d9-4bba-835a-1fdb68a4b17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_253f1a21-c96b-4bdc-9ffc-56301112a006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b0a9ca6-88e9-43e5-9b5d-efd7b0c5adb4" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_253f1a21-c96b-4bdc-9ffc-56301112a006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_562ea31b-a852-4a81-bb3f-c57eddec67af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_403948bf-5fc6-4be9-80f1-33fbdc17795a" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_562ea31b-a852-4a81-bb3f-c57eddec67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:href="amgn-20211231.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_562ea31b-a852-4a81-bb3f-c57eddec67af" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_11ba6361-2913-4ff0-bb02-d287ae08c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_11ba6361-2913-4ff0-bb02-d287ae08c28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1a752aad-1f54-498b-858d-0b636a3551f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_11ba6361-2913-4ff0-bb02-d287ae08c28e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1a752aad-1f54-498b-858d-0b636a3551f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_25a1eac0-9e4c-4f03-a028-e524bad1fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_855f1841-f3f9-472a-a2a5-e51119625129" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_25a1eac0-9e4c-4f03-a028-e524bad1fc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a2c3908a-37da-42cd-9209-9809f90052fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_25a1eac0-9e4c-4f03-a028-e524bad1fc95" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a2c3908a-37da-42cd-9209-9809f90052fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="amgn-20211231.xsd#Contingenciesandcommitments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01d16ac2-9cc9-425f-9783-587f53e5e55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62a86f53-0c4f-4ed0-b34f-3a971ff23df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01d16ac2-9cc9-425f-9783-587f53e5e55e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_62a86f53-0c4f-4ed0-b34f-3a971ff23df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ba779d9-0a8c-44f8-bf86-a7cfeea9ec42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_91f6f4c9-1640-4308-b35c-0a4d545d4fa5" xlink:href="amgn-20211231.xsd#amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ba779d9-0a8c-44f8-bf86-a7cfeea9ec42" xlink:to="loc_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock_91f6f4c9-1640-4308-b35c-0a4d545d4fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsSandozPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bfde8dc-a84f-496a-bffc-2410f98ae56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_d594fcc8-cb91-401c-b9c1-c5d7025072cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bfde8dc-a84f-496a-bffc-2410f98ae56a" xlink:to="loc_us-gaap_GainContingenciesTable_d594fcc8-cb91-401c-b9c1-c5d7025072cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_77ae53df-1421-488b-b79b-93c4d997c637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d594fcc8-cb91-401c-b9c1-c5d7025072cd" xlink:to="loc_srt_LitigationCaseAxis_77ae53df-1421-488b-b79b-93c4d997c637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e0eb71c8-9734-4651-82bb-09b559bc3f3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_77ae53df-1421-488b-b79b-93c4d997c637" xlink:to="loc_srt_LitigationCaseTypeDomain_e0eb71c8-9734-4651-82bb-09b559bc3f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SandozIncMember_a9cbf08a-02d1-4f3f-8a13-11be6d5e99d0" xlink:href="amgn-20211231.xsd#amgn_SandozIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e0eb71c8-9734-4651-82bb-09b559bc3f3d" xlink:to="loc_amgn_SandozIncMember_a9cbf08a-02d1-4f3f-8a13-11be6d5e99d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_6cf8362f-96f6-48fb-af18-9ac9295c25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_d594fcc8-cb91-401c-b9c1-c5d7025072cd" xlink:to="loc_us-gaap_GainContingenciesLineItems_6cf8362f-96f6-48fb-af18-9ac9295c25a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofLawsuitsFiled_a153319d-c941-44a5-908b-3628e61d762c" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberofLawsuitsFiled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_6cf8362f-96f6-48fb-af18-9ac9295c25a3" xlink:to="loc_amgn_GainContingencyNumberofLawsuitsFiled_a153319d-c941-44a5-908b-3628e61d762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsImmunexandSandozLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1dfe09c8-b1e4-479f-9921-bf8a854d6c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_33be480b-64bf-41ec-ac9f-f27dad1156ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1dfe09c8-b1e4-479f-9921-bf8a854d6c83" xlink:to="loc_us-gaap_OtherCommitmentsTable_33be480b-64bf-41ec-ac9f-f27dad1156ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_33be480b-64bf-41ec-ac9f-f27dad1156ac" xlink:to="loc_srt_LitigationCaseAxis_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_799f6a79-6ee2-4846-a686-f451059cfcb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3168ec5e-ea7f-451e-a7ab-df013f5ddfa6" xlink:to="loc_srt_LitigationCaseTypeDomain_799f6a79-6ee2-4846-a686-f451059cfcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ImmunexAndSamsungBioepisCoMember_6f56470b-f59f-4096-93d9-9d35957f68ef" xlink:href="amgn-20211231.xsd#amgn_ImmunexAndSamsungBioepisCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_799f6a79-6ee2-4846-a686-f451059cfcb3" xlink:to="loc_amgn_ImmunexAndSamsungBioepisCoMember_6f56470b-f59f-4096-93d9-9d35957f68ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_33be480b-64bf-41ec-ac9f-f27dad1156ac" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberofAffiliates_d0e79db2-682b-484f-920c-4f3d2563e83a" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberofAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:to="loc_amgn_GainContingencyNumberofAffiliates_d0e79db2-682b-484f-920c-4f3d2563e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7775be11-8c90-4ea0-9087-6c04918e670c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_58c377c9-d682-438b-abe1-dfacedfd5682" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_7775be11-8c90-4ea0-9087-6c04918e670c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsRepathaPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6426a90a-81b4-4402-aa35-55e3c664df37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_51afdf5f-bbf9-45ca-9c7a-bf0db530874e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6426a90a-81b4-4402-aa35-55e3c664df37" xlink:to="loc_us-gaap_OtherCommitmentsTable_51afdf5f-bbf9-45ca-9c7a-bf0db530874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_594f0c68-adf2-4a5d-9121-402875616801" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_51afdf5f-bbf9-45ca-9c7a-bf0db530874e" xlink:to="loc_srt_LitigationCaseAxis_594f0c68-adf2-4a5d-9121-402875616801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_56c46e9b-3e11-4c41-83c0-e118db64b660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_594f0c68-adf2-4a5d-9121-402875616801" xlink:to="loc_srt_LitigationCaseTypeDomain_56c46e9b-3e11-4c41-83c0-e118db64b660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SanofiRegeneronPatentLitigationMember_7acdc28f-25c3-40c8-bbc9-000527e7d903" xlink:href="amgn-20211231.xsd#amgn_SanofiRegeneronPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_56c46e9b-3e11-4c41-83c0-e118db64b660" xlink:to="loc_amgn_SanofiRegeneronPatentLitigationMember_7acdc28f-25c3-40c8-bbc9-000527e7d903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_51afdf5f-bbf9-45ca-9c7a-bf0db530874e" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_dace2ce0-ec06-41ef-8490-932a0c8bde4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_dace2ce0-ec06-41ef-8490-932a0c8bde4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementLengthofTrial_3b77fa7e-5dc0-4a06-9aba-819b724d0fff" xlink:href="amgn-20211231.xsd#amgn_LitigationSettlementLengthofTrial"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:to="loc_amgn_LitigationSettlementLengthofTrial_3b77fa7e-5dc0-4a06-9aba-819b724d0fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfChallenges_65d28b5e-2a5d-474a-8912-da418560960d" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberOfChallenges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4c2662f1-b795-40a6-9744-2f007518aebd" xlink:to="loc_amgn_GainContingencyNumberOfChallenges_65d28b5e-2a5d-474a-8912-da418560960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b781025a-c101-4d22-a44c-c12261ed073d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ad3ef4df-1ea3-49d2-bd53-337298efe140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b781025a-c101-4d22-a44c-c12261ed073d" xlink:to="loc_us-gaap_LossContingenciesTable_ad3ef4df-1ea3-49d2-bd53-337298efe140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ad3ef4df-1ea3-49d2-bd53-337298efe140" xlink:to="loc_srt_LitigationCaseAxis_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4d1b1b57-5b12-4ad0-bbd1-5fbfabe3459c" xlink:to="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisBreachOfContractActionMember_33c86be8-4c4c-4409-82fc-902e6a4e704c" xlink:href="amgn-20211231.xsd#amgn_NovartisBreachOfContractActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:to="loc_amgn_NovartisBreachOfContractActionMember_33c86be8-4c4c-4409-82fc-902e6a4e704c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_bb0ebb46-bb7f-498a-a361-aedf9572696e" xlink:href="amgn-20211231.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_bb0ebb46-bb7f-498a-a361-aedf9572696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_846e74c1-2882-4724-8f7f-0a419343e54e" xlink:href="amgn-20211231.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_fcdafbd1-495e-4417-a759-19cb629f752e" xlink:to="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_846e74c1-2882-4724-8f7f-0a419343e54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ad3ef4df-1ea3-49d2-bd53-337298efe140" xlink:to="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b640bb36-6917-4038-a543-999aa18ea5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b640bb36-6917-4038-a543-999aa18ea5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_e636a550-969c-4a03-8b3e-a5a3a20a675b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_e636a550-969c-4a03-8b3e-a5a3a20a675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GainContingencyNumberOfAgreementsBreached_f23bc4ca-da7f-4491-9a4e-46a42fefd76e" xlink:href="amgn-20211231.xsd#amgn_GainContingencyNumberOfAgreementsBreached"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_amgn_GainContingencyNumberOfAgreementsBreached_f23bc4ca-da7f-4491-9a4e-46a42fefd76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ec23d3a6-e5e0-46cd-8a2e-81b7439d7df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ec23d3a6-e5e0-46cd-8a2e-81b7439d7df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_77150012-14e0-49b6-8d64-c856e1d01006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_77150012-14e0-49b6-8d64-c856e1d01006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuitsFiled_fb9a9a24-6a6d-4c0f-bff8-57cd8226f6ac" xlink:href="amgn-20211231.xsd#amgn_LossContingencyNumberOfLawsuitsFiled"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_amgn_LossContingencyNumberOfLawsuitsFiled_fb9a9a24-6a6d-4c0f-bff8-57cd8226f6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_dc199464-0726-4299-bdda-cb7f962ef1c6" xlink:href="amgn-20211231.xsd#amgn_LossContingencyNumberOfComplaintsStayedByTheCourt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2e6278b0-8512-4be6-912d-beca7105b197" xlink:to="loc_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt_dc199464-0726-4299-bdda-cb7f962ef1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085a6506-4fd8-45b5-accb-a758410afe07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_91fb1788-4405-4548-9b82-63ef9ad265c5" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085a6506-4fd8-45b5-accb-a758410afe07" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments_91fb1788-4405-4548-9b82-63ef9ad265c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_db7d6310-59bc-4f08-a91d-09e9c0d2bdd1" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085a6506-4fd8-45b5-accb-a758410afe07" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths_db7d6310-59bc-4f08-a91d-09e9c0d2bdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_698cd145-0ff7-4365-b689-a886a2a1b69f" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085a6506-4fd8-45b5-accb-a758410afe07" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears_698cd145-0ff7-4365-b689-a886a2a1b69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_9c474246-bc7f-47d5-a5b0-c3779ede327d" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085a6506-4fd8-45b5-accb-a758410afe07" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears_9c474246-bc7f-47d5-a5b0-c3779ede327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_84cb6e37-2682-41c6-866c-31836c0c485a" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085a6506-4fd8-45b5-accb-a758410afe07" xlink:to="loc_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears_84cb6e37-2682-41c6-866c-31836c0c485a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_34958b9b-8dc8-4b72-ad7e-3e530dc2a5da" xlink:href="amgn-20211231.xsd#amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085a6506-4fd8-45b5-accb-a758410afe07" xlink:to="loc_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1_34958b9b-8dc8-4b72-ad7e-3e530dc2a5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="amgn-20211231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_510151d8-1250-43fb-a42a-4e807c3d83e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_4cb9c0c9-a1b4-49e1-bbda-cd4f91ae56dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_510151d8-1250-43fb-a42a-4e807c3d83e8" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_4cb9c0c9-a1b4-49e1-bbda-cd4f91ae56dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="amgn-20211231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_d21da1d0-a8f6-42d8-b28c-6fbedf4bfcec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7f32501d-5f83-4021-bfa5-e2298f1c7216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_d21da1d0-a8f6-42d8-b28c-6fbedf4bfcec" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7f32501d-5f83-4021-bfa5-e2298f1c7216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9951be8b-e377-447a-8071-3f8e5b9b509e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7f32501d-5f83-4021-bfa5-e2298f1c7216" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9951be8b-e377-447a-8071-3f8e5b9b509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_554de677-7a6c-42f2-b461-d1200fb1d211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7f32501d-5f83-4021-bfa5-e2298f1c7216" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_554de677-7a6c-42f2-b461-d1200fb1d211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_384b8896-e638-48d5-ae8a-8f9c6fd190b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7f32501d-5f83-4021-bfa5-e2298f1c7216" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_384b8896-e638-48d5-ae8a-8f9c6fd190b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1491af6b-f1c2-4222-a277-95ad69b65352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7f32501d-5f83-4021-bfa5-e2298f1c7216" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1491af6b-f1c2-4222-a277-95ad69b65352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3dc2cf0c-16fb-488a-9fd2-eebbb8d2198f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7f32501d-5f83-4021-bfa5-e2298f1c7216" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_3dc2cf0c-16fb-488a-9fd2-eebbb8d2198f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>warninglabel.jpg
<DESCRIPTION>GRAPHC
<TEXT>
begin 644 warninglabel.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M!^$NG^+/B3=:ELUN]_L[2=/TZV\^[U*XQDH@R%&!R2Q %0_M[_\ !4#X7?\
M!.#]G+3_ (D_$F\U"UT_6BD.E:?:6WG7NI3O'Y@A1<A0P7))9@HQUK\>/^#S
M3X+>./\ A./A7X^/CZ2[^'VNSKI.E>&@\ABTZ^2,O)>KSL/F(R#(Y^6O!/\
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MCLFE0F/SGB@,BPE'FFE*.Y+.%0 @#H#Z]_P1F_X*&?M!? '_ (*+?$?]C/\
M:#\6OX[U'1=-O;C0=?FE,US%-! )P%F8!WAE@)=0_P R,N,X- '[=UD^/O%L
M?@'P+K6NS123PZ+83W\D49 :18HV<J,\9(7%?S:_\$HU_;,_X+%:C\7_  9I
MO[5'BWP3X:\&W8U"XO;J::]O;FX=I4@MD971XX,1L6P^ 0ORL>GU]_P;!?MI
M_%W]IWPW^T)\%?BYXJOO'<_@#-K97^H3&YG02&>VFA\UOF>/=&"N[D9/TH ^
MPO\ @CM_P6[\+_\ !823QROASP1K_@\^!S;>=_:5U#-]I\_S,;?+Z8\LYSZB
MO5O^"G7_  4%M_\ @FM^S</B)<^"?$GCV(ZG!IO]FZ( ;@&7=^\.0?E&W]17
MYI?\&9'PA?P%X$_:-O+A=MS!XLM]#/'3[.DVX?FPK]L[BUCO(]DL:2IUVNH8
M?K0!^+%S_P 'G/@VS\1QZ/+^SO\ %.+5IL>78O<0+<R9Y&(R-QS]*]F\,?\
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M_A1J[']E'X^6?[4W[-'@3XC6$!M;7QIHEKJZP$Y\@RQJS)GOM8D9[XK\4_\
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M;\!OC%K_ (*TSXC>&])_LR)KESI<'VN&=GNG@P0S"/YQQG<JXP>:Q_A1X_\
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MK\=OV>]4_;B;QI\-/$/AU?B)X;O;+PV;L1@:Q,[WQ5(L,<Y$D?7 ^85^[=%
M'Y _\&W?["/Q>_90_P"":GQV\)?$;P%K?A'Q)XGNKM]+T^_5%FO VGF)2H#'
MJ_'-7?\ @U&_8,^)_P"Q_P#LP_&3PW\9/A_J_@^7Q/KUN]O9ZM&G^GVWV0QR
M8 8Y7G:?K7ZXT4 ?S4_#'_@VQ^+NA?\ !8N#P;?^%=;;]FO2?&3>(XM9:0'3
M;BR3]]%%MW9\TC; >.S=J^[?^#F3_@D1\0?VTX/AC\6/@_H5AXK\6_"HM:W7
MAB<)_P 3>Q,J2HL:/A7V.K!HR1N60XY&#^M-% 'X"_LZ_LY?M%?MF?MD_#D6
MO[%GPL_9W^'WA^1'\6WNM>%8)HK\I(K2O%YJA_,PNV)$&%+$L^.1Z1_P5A^$
MO[4NF?MP:YJOC;]G?PM^UQ^S]J4$L7A_2[+3(8-0T%'*%%:>)/M*2QG<N?F1
MPY/!Z?ME10!^%/\ P;P_\$B/B_\ "7]O[QU\=/$_PVG^ WP]U+2+W2M'\(75
M\]Q=-]I,15<,2YBC"$[I,$L1@8!KE/\ @B#^R_\ M5?\$SO^"C7Q \ ZO\#-
M5OO GQ+U*:UU;Q:58V=A:Q?:'BN8)5.Q@Y=!@\C=TR*_H!HH _&G_@VA_8!^
M,G[(?PZ_:@L_B5\/]=\'W/C"6'^Q4OU0?VCB*\!\O:QR 9$Y_P!H57_X-SO^
M"?WQF_93_9$_:NT+XB?#[7O">K>-3C0K6^5%?4_]#O$_=X8_Q2(.<?>K]GJ*
M /YXO^"=?_!!7XU_%C_@C5^T#\(/'/A34/AOXWUWQ7IWB+PM'K96**^FM(,;
M7*%MJ-ETSC@L#T%>9?#?]EO]K+PS\ ?#7P+TG]A/P;:_$/1;]+>3XBZKH5M<
MQW5H';_7/(#"<Y&9=YRJ\+DU_3510!^'W_!<K_@EO\<?BE^R1^R5X/\ !GP^
ML?%VO> +N9_$\7@W3H[+2["63R69HX<J%CW!QD#G:3@9Q7KW_!UE^Q'\5_VU
M/V2/A3H?PK\#:UXWU;1?$;W5];:<J,]M$;1D#MN8<;N*_6.B@#\1?^#AK]@C
MX\?$"\_9/^)?PP^'FH^.KKX1Z?;PZKI5DOG7-M<QM:S('C!W&,M$RDKG!_.O
MU=_83^,'Q#^//[+/A;Q5\5/ K?#;QWJL4CZGX>9B?L!$C*GWB6^9 K8)R-U>
MNT4 ?D9_P4J_8:^+?Q9_X.*OV9?BMX;\":WK'P[\)1:<NL:[;JAM=.,=U<N_
MF98$85U/3O7A'_!8[]@3XY>%_P#@M;IG[0$7P(F_:>^&%U9P06OA[<98;1EM
MS#Y$J#)CV2GS5.UD8GGG-?O510!^"/\ P3;_ &'?VD_!G_!>S1/CEX]_9Y'P
MT\&>+-,N%^R>'U@;2_#,4EIY4,,NQAMD'EKOXSN?./3I/^"1?_!-SXY? S]J
MO]N+6?%WPWU_0M+^(GAW7++PU<W(C$>L33W,[Q+$0QSN5E(SCK7[E44 ?A'_
M ,$:/^">7[7_ .R]_P $I_V@O#7ACPZGPR^+FN^([2^T*W\46D$L.KVJ6X6>
M$*^] 77*JSC&[&<#)'R=^T+^PE\?/VO?A%I7P^N/V F\)?&M+B"._P#B-I?_
M !++2]59!OEEA3%J"X/S,&P,DJ!T']1M% '@G_!+_P#9=U_]BW]@7X7_  P\
M4ZK%K/B#PCHL=G?7,+L\0E)9S&C-R43=M![A:_.[_@NI_P $N_CQ9?M^_#_]
ML/\ 9KTFW\6>,?!Z6T6I^'QC[5,T.Y%D1&($L;Q.T;J&#@<@'M^QE% 'X ?$
M_P#9@_;%_P"#A3]K[X6/\:_@[_PI#X0?#FY%SJ*78>/[6"Z-.(UD/F22R",1
MK@!44DDGOWO_  6 _8D_:'_9H_X+3^!/VL_@E\,;OXL:+;6%G;7&E6&7EMYH
M(&M7AE1?G5'B*%9%! ;=G&!G]PJ* /P)^'/[)?[8G[3?_!?;X/\ [2'Q8^"-
MUX,\/S26LTD5C<I<0>'+&&.6-(KE]V1-G+L,9_>#@= ?M2?LL?M2?L,?\'#G
MB+]H;X7_  /U3XK:!XKDD:QEMPSVFRZM5@F$C(0T3QG<<-@' YP:_?:B@#\*
M?^"C'PF_:PLOVO?$&H?%W]F;PQ^US\'=9M2- BTW3(K6_P!"1R&C0SP+]HCF
MCR8VW;E8#(-'_!!#_@D/\9_@7\5_CQ\6_$OP]N?@[X9\9^%]1T3PYX%EOS<7
M4C3_ #QJP8EMD>T*K2$,2YX K]UJ* /P%_X)6_\ !#KXP>/O^"/W[3'P7^(W
MA34OAMXJ\;:W9:GX:_MD*D<\]M%N0ML+'RRXV$]MV><5Q?P3\-?\%$_!7_!.
MCQ3^Q?:?L\3)8Q6E[90^+KN41);Z?([RRV\4FXQ3,Y+K&P.<28QT(_HNHH _
MGT^!'_!!WXT?'G_@WJUCX4:YX2N/!OQ9\._$&?Q=H&E:TZ0&^001PO'O!(3S
M$,FTD@;D7) YK@/"/[._[5OQ/^'W@#X1^'?V#?AUX%\;:!/;VNN>/]<\/6\E
MGJ4$:%-TWF Q@-P[LA=F*C:!G%?TE44 <9\$_ <OP6^ WAOP]+!ICW7AW1X;
M::+1K(6EI)+'&-XMX1PB%@=J]@17X3?LU?\ !"OXC?\ !5G_ (*?_&;XJ?M9
M> O&W@7P1JLLUSH]K)=K:W%TQD$=K$C*6.R*!!NZ DBOZ#** /P&_P""NW_!
MJGHOP/\ @%HOB[]D_0_&VL^/=%UJ%KO3&U3[5<3VYSME@W;=KQ2!6R#T)]*U
M_P#@K+^R3^TO_P % ]6_84\<_P#"G/%O_"3^%K)3XZM1%&#HEVE[9>8TGSX"
MOY,DJ\GY2.]?O%10 V/(C&>N.:_(7]M;]@WXM?$K_@YG^"GQ;TGP%K.I?##0
M]/M(=4U^-4^QVNV&Z5U<[L_QJ.G\0K]?** /YT_^"=O_  01^+/P0_X. H/$
M?B#X>:O:?!OP7XIU77M,UYPHLKF-5F>P"$-DD220\8_Y9M7UM_P;B_L.?%O]
ME']L+]JC7/B-X#USPEI'C+6S<:)=WR*L>I1_;;I]T9#'(VNI^C"OUVHH ^=_
M^"I?@KXW^/?V-/$MC^SWJ6@V/Q&^1X(=7M89[?4K<9$UL!,K1AW4_*7&,C!Q
MG-?S]?M!_L"?'S]L_P"&6C> S^P(/ _QF2Y@CU3XAZ<QTNQO55OGEE@7%JN\
M?>8,1U*CM7]1M% 'X:_\%D/^")_QNUS_ ()@?LM:5X'M6^)/C_\ 9ZM?L>L6
M=I(9)[U95@)>W5\&58I(57;G<4.0.,5XG_P56^'W[>__  6+^#_PMOM:_9FO
MO!^A>"-0,0TRVG#:EJ-U)%'YEZ\,A5H[<"/:N>A8\MU']&U% '\Y'_!R]I_C
M;1/^"J7[)]MX(1(?B%9^'-)CT6.9@J+J*7V(D8GC'F  YXZUU?[3?[/W[;/_
M  7M_:M^%'A/XL_ ]_@OX ^'%Z)];U"?=]DE8LGVB5'9CYKNB;8TCR!NR6QS
M7Z9_MX_\$4?#'[=W[<_PH^..K>-->T+4_A4]J]MIEI;Q/!??9[K[2N]F^9<M
MP<=J^V: /P._X*D_\$A?BM^S+_P5>F_:3^''P2T?]HCX;>)U235O"$T*SM:R
M_9D@E5H2,X.Q9$D4-@D@CCGV;_@BW^R?\>_%W[9/B?XM^/?@%\-/@%\.+:UN
M$\/: GARVBUR.66#RT6"8 2I& 6,COC>3M"X)Q^Q=% 'Y _\&O?[!OQ:_8Y^
M*O[26I?$_P  :SX,A\6:M:/H\VH(B_;XTFO&8IM8G:!(A_X$*L?\'2G_  2J
M^(7[7_A[X=?%;X)Z!J>M_$OP7<OI5W;:4P2]GL)<LDB'(R8I-P/.<2GTK]=J
M* /SN_X(?_\ !-#6OV!?^"1M_P"%-;T9K/XE>/+"_P!6UNS.WSHKF:!HX+9B
M.,H@0=>"S5\9?\$/_P#@GC^UW^RK_P $V_VC_#_A_P -_P#"KOBSX@UC3[OP
MXGBBSAEMM5ACAD6>(!MZ#<#M#,, D9XR1^[U% '\N_[0?[$/[0?[4GP:@^'N
MM_L!?V5\;VN52?XE:0!IEO=*)B6EEABQ:DLORE]P7'(%?5'_  4^_P""/'QW
MTG_@BQ^RU\&/#?A[4_B;XU^'OB$W>NQZ0PF33HY(9VV*S%<Q1F18P?;IBOW@
MHH _%[_@LI_P27^.^H?&CX$_M2_L^Z7#K?Q(^%FB:5:ZKX;E*FYDEM &CDB1
MB%E'S-')'N!P 5SSCQ[]H+]GC]M;_@XC^/?PT\._%KX/'X!_";P'>-=:K<70
MDC\YV*B=XUD)DEE*ILC4#:NXDMU-?T!44 ?CA^U#_P $[OBKJ?\ P<R? WXH
M>&?A[K-Q\(_"&D:=97&O0A/L5@L%I=1;&);=\NZ,=.XJS_P4Z_8,^,'QA_X.
M(/V>/BIX9\!:YK/P]\,0Z<NJZ[;JAM; Q3SM)O)8$8#*>G>OV&HH ^&O!?[1
M/[7&H?\ !8O7/ NJ_#BVM_V8K>!S8>)_L2AY6%HCJ?.\S))G+IC9VK[EHHH
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MKT_X;?M+2? S]GCX72_'?XCV-ZUA/(L4D]BEZ@(>&WCA#27#(-P9QM5=K<D
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M[_13?2W,<4%W=FTN(-SLTC1.@W .S889!X&.,^$G_!/'P/\ \%*_^#G#X^>
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MLEO)G!1_FPK \$$C'>OQ>_X))>$=9\??\%K?^"@VA^&]271?$.KZ?XKLM,U
MML%E<2:FZQR;OX<,1SVZ]J^&=._9_D_83^'WC+P?^TE^R9K7C"+5;Z;;\2-'
MU>Z%[I+#"EK:XC,EE* 59L2 $ECN]  ?U[:%KUEXHT:UU'3;RUU#3[V)9K>Y
MMI5EAG1AE61U)# CH0:R_B9\4_#7P8\&7?B+Q=K^C^&=!L &N=0U2[2UMH<]
M-SN0HSVYYKXO_P"#=#XD?!WQS_P38T.P^"FL^.]3\+^&]0N+&XM_%\T<NI:7
M=-ME>WS& @B D#(%X :O&/\ @Z?U?X$7WP!^'FA?&KQ;\2;$SZQ+>:+X:\&Q
MPRW&OS(BJ?.67Y0JAMJOGAI#@$T ?=GP3_X*.? ;]I#QJGAOP)\7? /BG7Y5
M9XM.T_6(9+F8*,MLCSN; Y. <"NR^._[2WP^_9@\*IK?Q$\9^&_!6E2R>3%<
MZQ?QVJ3/_=3>06/L,U_+%^T;X7T[X$_\%"OV8?%'PZ_9P\:?LNZ9>Z[IO]GC
M6]9GNKWQ$$OH$:Y9)&+1':^Q@,!M_2OL/]J_X8Z?_P %7O\ @ZMF^#/QAN]2
MN?AMX'L##I^BI>/;Q3QPZ<EV4!4J5,TLA+,A#%0 &X& #]N_AW^W/\'?B]\,
M]<\8>%?B9X)\0>&_#4+SZK?V6L020Z<BC),QW?NQ@=6Q7PI_P27_ .#A:R_X
M*4_MH?%'P9J:^$/ GAS1TMK7P397.I*VI^(K@RSK(P8D++E41@D:\!NIS7%?
M"[_@@!^SI^SK^WE\0[#PM\8I-&T;QIX9N=*U'X01:FAN+BQN;;YD>1Y3</'N
M FCRI92!\Q KX<_X-2OV'?A[\7/^"@'Q=\1ZWIU]<:G\$;R"]\*.MXZ):RFX
MNHLR*.)?EC7[W<$T ?I7_P $R/V]_B\_Q?\ CEJ'[27Q<^!S_#CP?,D>DSZ1
MX@TYFTDO>R0H+LQ/F+(\M!YF"7XZU^A'@CXT^$/B5\-$\9^'_$^A:UX2D@DN
M5UFROHYK$Q1Y\Q_.4E-J[6R<\8.:_G@_X-^?V8M'_;.^-G[?'PNUV.-M/\;:
M;<:;O9<_9Y3J-T89A_M1RA''H4%>-_!+_@I_X@_8/_X(\?M+?LI^);J33?B1
MI/B5O#VD6S%@\5K=2/%J(0\':ODOCMBY!'6@#]OO^"FO[?\ JVM?L.:EXM_9
M7^+WP<F\2:3X@LK&\U;4O$%@=,MHI!(6A:65_*65L*54G) ;%>(_\%(O^"]?
MB'_@FS^Q+\%TN9/ ?CCXY?$+2;.;5)+74XI=-TX-&IDOA'"V9(7;<(R"$.#R
M<5\2?MS?L(G]@S_@U%\&Z3J5F+7Q9XU\7:5XKUX,@$B37*2F*)CU_=P>6I!Z
M-O\ 6O*_^"YO[-?A.T_X)[_L,_$B.RG7Q7XG\):=X<U"X$[>7-9P6L;QJ$Z!
M@97^8>M ']"?PM_X*0_ _P"(-AX2M(?C!\-+S7_%4$(L[.V\06S2WL[?*R1)
MORQ\P,N!SD$=17?_ !M_:4^'W[-FF6-[\0?&OA?P5::I,;>SFUK4HK)+J0#)
M1#(PW$#G K\+/^"\O_!)'PG^P;_P3N^!?Q<^".EWFCR_!_68KN_DFO'GN#'?
MR13I(TA^8A+M5 ' 43MBL7]L3X_V?_!PG_P5E_9+^&7AJ87_ (*T'P[9^)_%
M*QM^[MII42[U%&P< I'%%" >0[$=Z /Z'=-U*WUG3K>\M)HKFUNHUFAFB8,D
MJ, 592.""""#[U/4=K:QV-K'##&D4,*A(T1<*B@8  [ "I* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IL
MTRV\+2.P1$!9F)P% ZDUQWCK]HSX?_"_7/[,\2^./"/A_4M@E^R:EK%O:S;#
MT;8[AL'UQ7!_%_\ :G^%7CSX3>*-#T_XM_#FVO\ 6=(N[&VF/B2T BEEA=$;
M/F=F8'\* /Y=/^#B;_@J_<_\%-/VU;RVT.YE7X9?#F6;2/#D.[Y+U@^)[XCU
ME9?E]$5?4TS_ ((4?LK>&KSQSXK_ &E_BS:AO@U^SK;KK=W'*.-=U?K96$>>
M&8R;7([87/6OA3QMX2O/ /C+5=#U'ROM^CW<ME<>5*)8S)&Y1MKKD,,@X(."
M.:[[X9_&7XH>-OA7%\!O#_B/43X,\6>((=3/ATW"0V5SJ.!&DSLV , +DE@H
MV@GH#0 _]MG]KGQ1^W5^U%XP^*7B^X:;6/%=\UP(MQ*64 ^6&WC]$CC"J![>
M]>55^RWQ._X(_?!?]@;_ ((J_%7Q1XC^('P[\>?M :W966R/3M:M;U/#R&ZB
M+VUHJN2\A7(DE R0"%PN2WXTT %%%% !7] 7_!DW^UC<3P_%GX*WURSVT A\
M5Z3&S'$1)$%R%'O^Y/X&OY_:_1G_ (-9OV@=,_9__P""MWAF?7-6L=&T7Q!H
M^H:5=7-[=+;6Z%HO,3>[D*/FC&,GK0!_59^TO?ZMI7[.GCVYT'=_;=OX>OY+
M#;][SQ;R%,>^[&*_G$_X-V+'P38_LB_M;^-Y+_4;?XV:1H#*U[:7$T>JZ9I$
MK?Z5<VS)"[QR%P0SH&;A00 <G^B5OVT/@ZRD'XJ?#D@\$'Q'9\_^1*_$O]M/
M_@D7+\"/VSK[X]?L2?M'?"GP?K&KSS7-UX>O?%EE:"U>8YGCB=V:*6WD.28I
M5XR ,X! !^/'[??C?PYXU^+5D_A/Q?XE\8Z-!8(JW.LZS=:I)%*6)=5>X1&
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MCLJ /T(HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>)_V(?C]\0_V@/C)\3X_B9\7/%>DWEHTUE;M#:0B<*TTK%@"\C>6JC"JJC.
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M_P""[=U^UM_PFFA-X;N+)K?^P?LTOVY6-D+;._[F,C=7Z'44 ?F5^R+_ ,$
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M?\$POVH?C7X]UWQMH/B>R^*,Q>SM;"UEBELE^U33_O"_!.) ..X->7?MP?\
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M\/\ _P %MW_A7]'U% '\X7_$$3\4_P#HMG@#_P %EW_A0/\ @R*^*BGCXV>
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M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8KTC]A#_@CEX:_88_:.
M\1?%./XF?%+XC^+O$VC)H5U=>+]2AO66W202*%98D;((P,D@ GBBB@#[#HHH
$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>warninglabela.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 warninglabela.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M!^$NG^+/B3=:ELUN]_L[2=/TZV\^[U*XQDH@R%&!R2Q %0_M[_\ !4#X7?\
M!.#]G+3_ (D_$F\U"UT_6BD.E:?:6WG7NI3O'Y@A1<A0P7))9@HQUK\>/^#S
M3X+>./\ A./A7X^/CZ2[^'VNSKI.E>&@\ABTZ^2,O)>KSL/F(R#(Y^6O!/\
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MCLFE0F/SGB@,BPE'FFE*.Y+.%0 @#H#Z]_P1F_X*&?M!? '_ (*+?$?]C/\
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M?K0!^+%S_P 'G/@VS\1QZ/+^SO\ %.+5IL>78O<0+<R9Y&(R-QS]*]F\,?\
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M_A1J[']E'X^6?[4W[-'@3XC6$!M;7QIHEKJZP$Y\@RQJS)GOM8D9[XK\4_\
M@[*_::@_:$_:G^"G[*EAX@L-$L)]1M]7\3WUW<K!:V+7#^5"TSDX41Q>;(<_
MWA0!^CO_  1Z_P""UO@7_@L'X7\77/AG0-7\):OX-N(8[O2]2GBEEDAE4E)T
M*<%<JRGT('K7/_\ !8?_ (+K>&/^"0'C3P%HNO\ @'Q'XTG\>VMW<VQTNZBB
M\CR)(D*D/R2QE&,>E?DO^PSX^\!_\$C/^#CZ'PI\//&>A:[\%OBDD.D6]WIN
MI)>VT4=VH\A)'0D;X[M-N.H5P>]>K?\ !Y5XBO?"'[7?[*>K:;8_VGJ.EI?W
M=K9[2WVN6.]L72+ Y.Y@!QSS0![CI_\ P=[Z/?W\$'_#,7QF7SY%C!*)QN('
M]WWKUO\ X*:?\',?@K_@F;\>-*\!Z]\,/%WB&]U/0+/7O/M+RWA6%;@$B(J_
M.Y<8->/_ ++W_!<S]K;XQ?M'>!_"?B;]B^3PUX>\1:S:Z?J.K-I^H+_9UO(X
M5YLN@0;5);YN.*^0/^#E[X!S_M._\%V-%\#V?_'_ *UX!7[&!GF>*UO)HQQU
MRT8&/>@#]K?VC?\ @K#X&_9Y_P""8EO^U#+IVH:OX7O]*T[4K'2[>:-;NY>\
MDBC2 ,3LWH9#NYZ1/C.*\\_X(Z?\%S_"_P#P6&UKQO9^'/ OB#P>?!,-M-,^
MI7<,XN1,S@!?+Z8V'KZU^#NO_MM7W[7O_!'#]FK]D_2=0>;Q?>?$=](N;7<6
M:*U$BI9;@!G;ONWX_P"F5?=/_!H!X&M_A?\ M8_M9^&K/_CT\.ZE#ID&6W?)
M#>7<:\]^%% '[R45\:_\%\OVI?B1^QS_ ,$PO'GCCX5+-'XLLVMK9;Z*#SGT
MJWEE"2W2J01E%/!((&<]J_!#]EW]L?XA_$S3?"?B/PM_P4!\1^&OC+<WT;ZG
MX>^(2W=CH*[F^8"]WSPS+G VO&FX$_=H _JYHK\1/^#E_P#;.^-?[-UI^R1_
MPC?Q(U#PQJOBG[0?$<GA'4Y(=.U>9389=",%XLO(5R/NO7I7_!V#^U;\2?V6
MOV9O@KJ?PY\<>)/!6H:OXH>WOKC2+Y[62[C%L&".5(+#/.* /UQHK\&O^"]O
M[97[17PR_P""B7[,W@SX,?$GQ#X;U/QSX8T^*.S6\9=/N[ZYN#")KB/E7^\"
M2P/"]*\^_:O\1_M?_P#!O5^U=\)?'/C?]H/5OC5X)\?ZAY&NV5Y).MK(P*&Y
M@,4K.!A'+1RH5/R\JO0@']$U%?SV?\%=_P#@KAXW_:C_ ."JLG[/GA[X^0_L
MV_"#PDL<.K>*Q(Z&\N#;K/([M&RNXRZQQQ;T7*DD\\=A_P $(O\ @J=\1/"O
M_!2?Q)^R]XH^--M^T-X&U73KNY\*>,XI6E*306QN1MDD_>;6C5T:-BVV11M)
M&20#]XZ*_F$_X)WO^V]_P5\^-/Q:\!^#_P!I;Q+X7T/P-JG]JW5UJVL76[<;
MB:*&")HE9P-JN2N0GR+P3BOJS]@_]J;XT_\ !.?_ (+\ZG^SE\:_BQXP^(/@
MCQAI#1Z'J'B/4'GC#_9_M4%PN_A23'-$<=R,]* /V]\9>(QX/\'ZKJS02W0T
MNSFO##%]^81H7VK[G&!]:^5O^"27_!6;3_\ @JYX+\9ZSI_P]\5?#Y?!U_;V
M+PZV5+WAEC9]R;0.!MP?J*_.G_@FS^VE\9?^"F/_  5)_:1^*.F?$3QC8_ S
MX9:3JBZ)H<5\ZZ;/(8)8+,^6#M)VQO<'()W%?2O*_P#@DO\ \%-?VAK;_@C/
M^UW\2K?Q3XA\=^//!M]IT6C7.I$W[Z3%*C+-,B$'.Q27Y!&5!(P* /Z):^5/
M^"K?_!4:Q_X)9_#'PGXEO_ 7B?Q\GBK6?['2VT7:)+1O*:3S'W _+\N/J:_G
M@_9R_;7^(/QG\*Z/XDL_V_O&/@OXW3:DK3:%XS2[L] "&0@G^T%>6$C;M.UX
M5!R5P,9K]*?^#C7]K3XS_ '_ ()J_LW:]I_Q%MM,\;Z]KUO!K^L>"[YAIVL'
M[%([/"^ 6B9@&' '- '['>#/$8\8^#]*U=8);5=4LX;P0R_?A$B!]K>XS@_2
MM.OQ._X+.?\ !3OXY:[\;_@#^R7\!/$4OA/QS\3=&TFYUKQ,9##<>9=JJQQI
M, 6C0!7DD=1N.0!T.?$OVC?%G[8G_!MK\=OAAXS\;?'"_P#CK\+/&MZ;+6-/
MO)9WC+)M:>().SF.38Q:*56&2A#*!D$ _H>HK\"O^"N/[7_[1/C?_@O!\-?A
M;\!OC%K_ (*TSXC>&])_LR)KESI<'VN&=GNG@P0S"/YQQG<JXP>:Q_A1X_\
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MK\=OV>]4_;B;QI\-/$/AU?B)X;O;+PV;L1@:Q,[WQ5(L,<Y$D?7 ^85^[=%
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M/[7&H?\ !8O7/ NJ_#BVM_V8K>!S8>)_L2AY6%HCJ?.\S))G+IC9VK[EHHH
M**** "OY_O\ @[__ ."M,5S]G_9:\$WX<QM#JGCFYA?[C</;V&1WZ2R#WC'<
MX_6#_@K]_P %(=%_X)>?L3>)/B+>FWN/$4B'3?#.G2-SJ&HR*1&".IC3F1_]
ME",@D5_&'\1OB%K_ ,;?B7K/B?Q#?7>N>)?%&H2W]_=RDO->7,SEG8^I+-T'
MT% 'T'_P2*_X)H:[_P %4?VO;'X<Z9<S:5I,%E/J>M:LL>]=-MXU.TGMEY#&
M@]V]J\2_:+^ OB/]E_XX^*/A_P"+-/GTSQ!X4U&73[N"9<$,C$!AZJPPP/<$
M&OTH_:'O9?\ @AI_P2IT;X0:7>S:3^TE^T6MMXG\9WEE.8;WPKHD;;K2Q#J=
MR.Y!W $<F7T6N?M/^"@G[.?_  5D^&VA^'?VN8M9^'7QAT&TCTVP^+OAVQ%T
MFJP(,1KJELOS.0!C>H)Y_AH _,*O</\ @F_^QWKG[>7[:O@#X9:';23'7M4B
M;49@I*6-A&P>YG<@?*JQ*W)ZL5'4BOK&W_X(X_LRV>M?;[_]OGX/GPHIWDVN
MEW+ZHT?H(,YW>V*T_BQ_P4V^!'_!/O\ 9S\2_";]B_3/$=WXC\:VO]G>*OBU
MX@B%OJE[;'[\%A$/F@C;D9(4C)^4G#  _IJ_9=_;>^#W[6$FM:7\,/'_ (=\
M6W7@^Y?3=3M+*YS<63Q,8SNC;#%,J<. 5;L37KU?PH?LA?M<>-_V(/V@_#WQ
M*\ ZM/I?B'P_<B9<.?*O(\_O()EZ/&ZY#*?7/4 U_:+_ ,$\_P!M?P[_ ,%"
M_P!D#P9\6/#6(K7Q+9@W=IN#/IMXAV7%NWND@8>XVGO0![57Y<_\'=WQ$U_P
ME_P24FT30HKZ0>-/%FG:3J'V:)G)ME$UT5..0#);Q_4 CO7ZC5^1?_!2+_@Y
MKT_X;?M+2? S]GCX72_'?XCV-ZUA/(L4D]BEZ@(>&WCA#27#(-P9QM5=K<D
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M[_13?2W,<4%W=FTN(-SLTC1.@W .S889!X&.,^$G_!/'P/\ \%*_^#G#X^>
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MLEO)G!1_FPK \$$C'>OQ>_X))>$=9\??\%K?^"@VA^&]271?$.KZ?XKLM,U
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M5XR ,X! !^/'[??C?PYXU^+5D_A/Q?XE\8Z-!8(JW.LZS=:I)%*6)=5>X1&
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MCLJ /T(HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>)_V(?C]\0_V@/C)\3X_B9\7/%>DWEHTUE;M#:0B<*TTK%@"\C>6JC"JJC.
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M_P""[=U^UM_PFFA-X;N+)K?^P?LTOVY6-D+;._[F,C=7Z'44 ?F5^R+_ ,$
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M?\$POVH?C7X]UWQMH/B>R^*,Q>SM;"UEBELE^U33_O"_!.) ..X->7?MP?\
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M\/\ _P %MW_A7]'U% '\X7_$$3\4_P#HMG@#_P %EW_A0/\ @R*^*BGCXV>
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M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8KTC]A#_@CEX:_88_:.
M\1?%./XF?%+XC^+O$VC)H5U=>+]2AO66W202*%98D;((P,D@ GBBB@#[#HHH
$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>warninglabelb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 warninglabelb.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M!^$NG^+/B3=:ELUN]_L[2=/TZV\^[U*XQDH@R%&!R2Q %0_M[_\ !4#X7?\
M!.#]G+3_ (D_$F\U"UT_6BD.E:?:6WG7NI3O'Y@A1<A0P7))9@HQUK\>/^#S
M3X+>./\ A./A7X^/CZ2[^'VNSKI.E>&@\ABTZ^2,O)>KSL/F(R#(Y^6O!/\
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MCLFE0F/SGB@,BPE'FFE*.Y+.%0 @#H#Z]_P1F_X*&?M!? '_ (*+?$?]C/\
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M?K0!^+%S_P 'G/@VS\1QZ/+^SO\ %.+5IL>78O<0+<R9Y&(R-QS]*]F\,?\
M!SCX=U?]B7XD_&O4?@G\1-!TWX=:OI>DR:;J$D4,^HM?.RJ\;, ,)M^8?[0K
MY0_;<M(HO^#QSX/1K%&L?D:/\@0!?^/2;M7U_P#\':%C#8_\$6_&(AABA#>(
M=%)V(%S_ *6OI0!]M_L+?M9:?^W/^R9X)^+&E:3>Z%I_C:P^W0V%Y(KS6PWL
MFUF7Y3]W/'K7G/\ P57_ ."F-C_P2W^!.D^.+_P-XD\>Q:KJR:4++1BHEA+(
M[^8Q8'Y?DQ]37X*7'P3_ &LOV?/^")'P[_::TC]I77O#WA?P\MM:>'_!6D&6
MUCL;"2Y:))#*KA'D,F6*M&<J?O\ :OJ+_@J)_P %/?B]XZ_X-W_V>/C%I?B[
M5O"OCOQ7K$=IK.H:1+]F:^:);F)F.W@!S$'('&2: /W,^%WCA?B=\-/#WB1+
M2XT]-?TVWU);6X_UML)HED"/_M+NP?<5NU^ ?_!?O_@I)\:O@YI'[,'@JS\?
M>,/AG\./&O@K3M8\1^+]#MFFU#4+EXT$R[@Z%S&N',8==QER3P*Z/_@A9\:?
M'VN_M]V.G^!?VTM$^.GPHO[%I-3\.>-7O-.\1O\ (=QMK*82?O(FV'>DNUE)
MR.* /W5NI_LMK))@MY:EL#J<#-?&O_!,?_@L5IW_  4J^,7Q+\(V7PS\9>!I
M/ANR++>:SL\K4-TTL6(\#@CRB?HPK[&U:1H=*N64E66)R".QP:_ [_@AO^W%
M\7_C%JW[=W_"4?$;Q5KG_"%^&+ZZT(W=Z7.E3*]^%DA_NL-B8(_NB@#]^:*_
MF:_X)L:%^VO_ ,%8OV'?B3XDM_VJ/$_A7P[\*9+F[MHY[B>?4-=O1;^>8I;A
M'5TA5%PI)<!F/R=Z]%_8T_;*_:9_X*!_\$!?C-J>F_$[QC!\2O@-KT6I6&NV
M.H21:GJ^FB#S9[6>1.9-B;V4GD[0">!0!_1!17X'>-O^"^/B;4O^#:'2/$]E
MXQU&V^.-QK"?#RXU1+K_ (F37$6)FO _W@[VFP[N[%_2N6_;W_X*)?M _P#!
M.W_@FW^SE\&[CXHZ_9_&+XVVC^*/%?C37+]Y;KP_8SS*L5LDK M$JA@&8#<H
MB?'+4 ?T-45_,[\(?^"FOCG_ ()8_MQ_"@:;^V#9?M4?#/QO<Q6?BZQ2XGE7
M2=TB1R$+,SE67S-\<BL-_EL&4#KT7_!9O_@I)\3]2_X+$>+?A7\0?CA\1?V=
M_A#X71(M'N?#&F27?VD-$C1W4D44L3RK(6<[]S;0H4+UP ?T?2R"&-G8[54$
MDGL*^:/V(_\ @K#\*/\ @H3\:/B+X/\ AC=:GK*_#4PIJ&K/;>58W;R,Z[8"
M3O;:4.6*@'MFOSE_X)'3?'O]IO\ 9D^/G@/1?VQ/!GQ.T&_T22+PCK\.H7;>
M*/#5QO!2>:!XUFAB>,,"A=BK?=/7/QQ_P:H_L\_$[Q=^VGXY\4>'?B7<^'/#
M7PZE\[Q;H\3R@>+%9;E(U8#Y2%D&_P"?\* /Z>J*_F+_ ."9]U^VA_P5B\*?
M'+3M-_:B\:^%?#/P[5M4FEN;B:[NK^Z G,%HCJZ/%$PC8L0V.%^1L5=_X)W>
M,/VV?^"N/[)/Q&LD_:7UCP;X;_9\LI;O[1^\;5/$%T\<LL=M/<1LDC1(EN^'
M=FV[U&QNJ@'],]%?SZ_L%_\ !P+\7OAK_P $%/BWX\\4ZE-XS^(7@+Q-;>$_
M#6LZGB>7-]$'CDN2>9?(Q*03RV$!SS7R0W[=_P ;OA=^S9HO[1%A^WDGB#XL
M7&H1W5[\,I+R:6:*W>3;AT8^0Y'!>$1A0AX;C% ']8-%?@'_ ,%NO^"PGQ5\
M4_\ !/7]C_XS_##Q9KW@'5/B"UU=:Q9:/>O%#<W4 B5XG"GYX_-5\*?X7P:\
M\_X*D6/[;/\ P1T?X5_'SQ)^U!K'CK5_&FI[=5T&$20Z78SA!.;18F8Q2VY3
M<F1'&1CA>X /VP_;K_X*E_"S_@GSXI\!^'?&UYJ-QXH^).IQ:9H.D:=;^;<7
M)>9(FF8DA4C1I%R2<\\ FOH^OYFO^#E/X/\ Q'\;_P#!3;X&^*1\0YUT_P",
M$&FW'@NS=I?^*+<BSCD*]ANG;S?DYX]:_H._8?\ @YXU_9__ &5O!W@_XB^-
M)OB'XTT.S,&J>(96D9]3EWLV\ER7. 0.>>* /E?_ (*Z?\%Z-"_X)@?&#P=\
M--+^''B3XI_$CQK;)>V6DZ;,($6)YFA12^UW:5V1MJ)&>G)&17U-^Q!^T=K/
M[67[,WAOQ[X@\":Y\-=6UQ)&G\/:N<W=B4D9/F^53SMR,J#@CBOYW_\ @K-^
MQK\;;?\ X.%?A_X5_P"%U7;>,?B/J4-_X*\0F2X\SP=;374XMX%YW#RBK$>6
M<?-Q7V)_P56\%_M(?"'2/@KX!\;?MD>"_@]\.M$\/P6WB3Q9)K4Z^(O$>HJ'
M,US]E&)[A,A$11(!G);!H _;6O@3]C7_ (+X^$?VR/B[\>_"6F^ ?$NCS_ ;
M3-0U.^GN;J!TU1;262)EB"G*EC&2-W'/-?G/_P &^O\ P44^)A_X*_ZI\$%^
M/>N?'SX2ZEIU[)9ZOJT$T7GR0Q+(L\*3EI8>=R%=Q5ASZ5S/_!#3_D]'_@HK
M_P!BIXD_]++F@#]>/^"/G_!7WP[_ ,%?OACXO\3>'?"&M^$(?"&J1Z7-#J5Q
M%,UPSQ>8&4Q\  <<U]@U_,S_ ,$4OVF?B)^R%_P06_:X\>?"VTDG\8:3XCT^
M.WN$A\YM,BEB2.:["X()BC9G&1@8R>E>3?LV_MD^/?BGX:\->)- _P""@7BO
MPM\:[C4$?4- \>)>6.@HI;G%\'FAD P,J\2A@2,+CD _J_HKD?@%JNOZY\$O
M"EYXJOO#VJ>)+G2K>34KS09&DTR[G,8+R6[$ F)CRO'0U^2G_!=__@HK\<?B
M3_P4*^'7[&/[.OB5O OB/Q8()M9U^*8P3@S*[K&)0"T<4<*/(^P;FX ]" ?L
MS17\]'Q@^)_[67_!MY^UO\*]2^)7QQOOC=\(/B#=_9M6@O99F5%4HMQM28NT
M<L:N)$='P^W# 9Q7N?Q/_;/^*$/_  =?^%/AI8?$'Q3%\,]0TZRF;PXE^XTV
M4/I1E),.=O+X;IUH _:2OF:U_P""L7PEUO\ X*)6O[,>CWVHZU\2/LEU=:D+
M6V_T+1_(A\XQS2L1F0KT"!L9&<5\%?MX?M;_ !0\(?\ !T%\$/A?HGQ \3Z5
MX"U[0[!K[0;:^=;"XDD^W!G>(':2=J'G^Z*_-GX%_L7?&_Q9_P '&'BKX9Z1
M\;;S2/BCI^JZA=WOC=9+CSKR".(32QY!WY>$^7@G'X4 ?U:5F>-?$H\&>#=6
MUAK>:Z72K*:\,$0_>3"-&?:ON<8'UK^:O_@IA_P4G^*7C/\ X*V_$'X;?%C]
MH'XE_L[?#CPA=/IVBGPWI,UVFU%413RQ12Q/()02YER_4  #I]^_\$)?C#\7
MM>_9?^-9\1_M'^!_CWX3T;2[F;PSJ6GZE//XBTAUBEVFZCEC5XD= C*CLQ1@
M0"10!]:_\$F/^"K-A_P58^'OB[Q!I_P^\5_#]/">I1:<T&N;=]V7C+[TV@<#
M&#]:]U_:J^/UI^RM^S?XU^(]_I]SJMEX*TB?5YK.W=4EN5B4L44MP"<=Z_"/
M_@E#_P %BOBQ\$?^",O[4'Q>\4>*=7\>>+O"^O6&E^')-;F^TI93W,6Q6(/\
M"L=Y7N5 KS_PO^R_^VI^TA_P21\>?M5ZO^TMKM]IWB31[^XNO!-^\L\&KZ0'
M>*X));RHF^5BD:QX 4?,I.* /V]_X).?\%.=#_X*O_LT77Q*T#PQJWA.SM=8
MGTAK/4)XYI&:)48N&3C!WC\C7T_7\U/[ 7_!27Q'_P $R_\ @VAU_P 3^"I(
M+?QQXN^)5WX<T6ZE02#3W>VBDEN IX9DC1MN<C<RD@@5Y5JW[>_QB_8J^%'@
M+XZ>&/V[++XL_$#5+R"7Q+\-Y;NXNQ:12AI"C^8QCE5=NR3"1E"XV$XR #^J
MNO#?^"C?[>'AK_@FU^R1XD^+7BFRO-5L-!:"&+3K-T2XU">:58TC0N0H/)8Y
M_A1J[']E'X^6?[4W[-'@3XC6$!M;7QIHEKJZP$Y\@RQJS)GOM8D9[XK\4_\
M@[*_::@_:$_:G^"G[*EAX@L-$L)]1M]7\3WUW<K!:V+7#^5"TSDX41Q>;(<_
MWA0!^CO_  1Z_P""UO@7_@L'X7\77/AG0-7\):OX-N(8[O2]2GBEEDAE4E)T
M*<%<JRGT('K7/_\ !8?_ (+K>&/^"0'C3P%HNO\ @'Q'XTG\>VMW<VQTNZBB
M\CR)(D*D/R2QE&,>E?DO^PSX^\!_\$C/^#CZ'PI\//&>A:[\%OBDD.D6]WIN
MI)>VT4=VH\A)'0D;X[M-N.H5P>]>K?\ !Y5XBO?"'[7?[*>K:;8_VGJ.EI?W
M=K9[2WVN6.]L72+ Y.Y@!QSS0![CI_\ P=[Z/?W\$'_#,7QF7SY%C!*)QN('
M]WWKUO\ X*:?\',?@K_@F;\>-*\!Z]\,/%WB&]U/0+/7O/M+RWA6%;@$B(J_
M.Y<8->/_ ++W_!<S]K;XQ?M'>!_"?B;]B^3PUX>\1:S:Z?J.K-I^H+_9UO(X
M5YLN@0;5);YN.*^0/^#E[X!S_M._\%V-%\#V?_'_ *UX!7[&!GF>*UO)HQQU
MRT8&/>@#]K?VC?\ @K#X&_9Y_P""8EO^U#+IVH:OX7O]*T[4K'2[>:-;NY>\
MDBC2 ,3LWH9#NYZ1/C.*\\_X(Z?\%S_"_P#P6&UKQO9^'/ OB#P>?!,-M-,^
MI7<,XN1,S@!?+Z8V'KZU^#NO_MM7W[7O_!'#]FK]D_2=0>;Q?>?$=](N;7<6
M:*U$BI9;@!G;ONWX_P"F5?=/_!H!X&M_A?\ M8_M9^&K/_CT\.ZE#ID&6W?)
M#>7<:\]^%% '[R45\:_\%\OVI?B1^QS_ ,$PO'GCCX5+-'XLLVMK9;Z*#SGT
MJWEE"2W2J01E%/!((&<]J_!#]EW]L?XA_$S3?"?B/PM_P4!\1^&OC+<WT;ZG
MX>^(2W=CH*[F^8"]WSPS+G VO&FX$_=H _JYHK\1/^#E_P#;.^-?[-UI^R1_
MPC?Q(U#PQJOBG[0?$<GA'4Y(=.U>9389=",%XLO(5R/NO7I7_!V#^U;\2?V6
MOV9O@KJ?PY\<>)/!6H:OXH>WOKC2+Y[62[C%L&".5(+#/.* /UQHK\&O^"]O
M[97[17PR_P""B7[,W@SX,?$GQ#X;U/QSX8T^*.S6\9=/N[ZYN#")KB/E7^\"
M2P/"]*\^_:O\1_M?_P#!O5^U=\)?'/C?]H/5OC5X)\?ZAY&NV5Y).MK(P*&Y
M@,4K.!A'+1RH5/R\JO0@']$U%?SV?\%=_P#@KAXW_:C_ ."JLG[/GA[X^0_L
MV_"#PDL<.K>*Q(Z&\N#;K/([M&RNXRZQQQ;T7*DD\\=A_P $(O\ @J=\1/"O
M_!2?Q)^R]XH^--M^T-X&U73KNY\*>,XI6E*306QN1MDD_>;6C5T:-BVV11M)
M&20#]XZ*_F$_X)WO^V]_P5\^-/Q:\!^#_P!I;Q+X7T/P-JG]JW5UJVL76[<;
MB:*&")HE9P-JN2N0GR+P3BOJS]@_]J;XT_\ !.?_ (+\ZG^SE\:_BQXP^(/@
MCQAI#1Z'J'B/4'GC#_9_M4%PN_A23'-$<=R,]* /V]\9>(QX/\'ZKJS02W0T
MNSFO##%]^81H7VK[G&!]:^5O^"27_!6;3_\ @JYX+\9ZSI_P]\5?#Y?!U_;V
M+PZV5+WAEC9]R;0.!MP?J*_.G_@FS^VE\9?^"F/_  5)_:1^*.F?$3QC8_ S
MX9:3JBZ)H<5\ZZ;/(8)8+,^6#M)VQO<'()W%?2O*_P#@DO\ \%-?VAK;_@C/
M^UW\2K?Q3XA\=^//!M]IT6C7.I$W[Z3%*C+-,B$'.Q27Y!&5!(P* /Z):^5/
M^"K?_!4:Q_X)9_#'PGXEO_ 7B?Q\GBK6?['2VT7:)+1O*:3S'W _+\N/J:_G
M@_9R_;7^(/QG\*Z/XDL_V_O&/@OXW3:DK3:%XS2[L] "&0@G^T%>6$C;M.UX
M5!R5P,9K]*?^#C7]K3XS_ '_ ()J_LW:]I_Q%MM,\;Z]KUO!K^L>"[YAIVL'
M[%([/"^ 6B9@&' '- '['>#/$8\8^#]*U=8);5=4LX;P0R_?A$B!]K>XS@_2
MM.OQ._X+.?\ !3OXY:[\;_@#^R7\!/$4OA/QS\3=&TFYUKQ,9##<>9=JJQQI
M, 6C0!7DD=1N.0!T.?$OVC?%G[8G_!MK\=OAAXS\;?'"_P#CK\+/&MZ;+6-/
MO)9WC+)M:>().SF.38Q:*56&2A#*!D$ _H>HK\"O^"N/[7_[1/C?_@O!\-?A
M;\!OC%K_ (*TSXC>&])_LR)KESI<'VN&=GNG@P0S"/YQQG<JXP>:Q_A1X_\
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MK\=OV>]4_;B;QI\-/$/AU?B)X;O;+PV;L1@:Q,[WQ5(L,<Y$D?7 ^85^[=%
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M/[7&H?\ !8O7/ NJ_#BVM_V8K>!S8>)_L2AY6%HCJ?.\S))G+IC9VK[EHHH
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MKT_X;?M+2? S]GCX72_'?XCV-ZUA/(L4D]BEZ@(>&WCA#27#(-P9QM5=K<D
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M[_13?2W,<4%W=FTN(-SLTC1.@W .S889!X&.,^$G_!/'P/\ \%*_^#G#X^>
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MLEO)G!1_FPK \$$C'>OQ>_X))>$=9\??\%K?^"@VA^&]271?$.KZ?XKLM,U
MML%E<2:FZQR;OX<,1SVZ]J^&=._9_D_83^'WC+P?^TE^R9K7C"+5;Z;;\2-'
MU>Z%[I+#"EK:XC,EE* 59L2 $ECN]  ?U[:%KUEXHT:UU'3;RUU#3[V)9K>Y
MMI5EAG1AE61U)# CH0:R_B9\4_#7P8\&7?B+Q=K^C^&=!L &N=0U2[2UMH<]
M-SN0HSVYYKXO_P"#=#XD?!WQS_P38T.P^"FL^.]3\+^&]0N+&XM_%\T<NI:7
M=-ME>WS& @B D#(%X :O&/\ @Z?U?X$7WP!^'FA?&KQ;\2;$SZQ+>:+X:\&Q
MPRW&OS(BJ?.67Y0JAMJOGAI#@$T ?=GP3_X*.? ;]I#QJGAOP)\7? /BG7Y5
M9XM.T_6(9+F8*,MLCSN; Y. <"NR^._[2WP^_9@\*IK?Q$\9^&_!6E2R>3%<
MZQ?QVJ3/_=3>06/L,U_+%^T;X7T[X$_\%"OV8?%'PZ_9P\:?LNZ9>Z[IO]GC
M6]9GNKWQ$$OH$:Y9)&+1':^Q@,!M_2OL/]J_X8Z?_P %7O\ @ZMF^#/QAN]2
MN?AMX'L##I^BI>/;Q3QPZ<EV4!4J5,TLA+,A#%0 &X& #]N_AW^W/\'?B]\,
M]<\8>%?B9X)\0>&_#4+SZK?V6L020Z<BC),QW?NQ@=6Q7PI_P27_ .#A:R_X
M*4_MH?%'P9J:^$/ GAS1TMK7P397.I*VI^(K@RSK(P8D++E41@D:\!NIS7%?
M"[_@@!^SI^SK^WE\0[#PM\8I-&T;QIX9N=*U'X01:FAN+BQN;;YD>1Y3</'N
M FCRI92!\Q KX<_X-2OV'?A[\7/^"@'Q=\1ZWIU]<:G\$;R"]\*.MXZ):RFX
MNHLR*.)?EC7[W<$T ?I7_P $R/V]_B\_Q?\ CEJ'[27Q<^!S_#CP?,D>DSZ1
MX@TYFTDO>R0H+LQ/F+(\M!YF"7XZU^A'@CXT^$/B5\-$\9^'_$^A:UX2D@DN
M5UFROHYK$Q1Y\Q_.4E-J[6R<\8.:_G@_X-^?V8M'_;.^-G[?'PNUV.-M/\;:
M;<:;O9<_9Y3J-T89A_M1RA''H4%>-_!+_@I_X@_8/_X(\?M+?LI^);J33?B1
MI/B5O#VD6S%@\5K=2/%J(0\':ODOCMBY!'6@#]OO^"FO[?\ JVM?L.:EXM_9
M7^+WP<F\2:3X@LK&\U;4O$%@=,MHI!(6A:65_*65L*54G) ;%>(_\%(O^"]?
MB'_@FS^Q+\%TN9/ ?CCXY?$+2;.;5)+74XI=-TX-&IDOA'"V9(7;<(R"$.#R
M<5\2?MS?L(G]@S_@U%\&Z3J5F+7Q9XU\7:5XKUX,@$B37*2F*)CU_=P>6I!Z
M-O\ 6O*_^"YO[-?A.T_X)[_L,_$B.RG7Q7XG\):=X<U"X$[>7-9P6L;QJ$Z!
M@97^8>M ']"?PM_X*0_ _P"(-AX2M(?C!\-+S7_%4$(L[.V\06S2WL[?*R1)
MORQ\P,N!SD$=17?_ !M_:4^'W[-FF6-[\0?&OA?P5::I,;>SFUK4HK)+J0#)
M1#(PW$#G K\+/^"\O_!)'PG^P;_P3N^!?Q<^".EWFCR_!_68KN_DFO'GN#'?
MR13I(TA^8A+M5 ' 43MBL7]L3X_V?_!PG_P5E_9+^&7AJ87_ (*T'P[9^)_%
M*QM^[MII42[U%&P< I'%%" >0[$=Z /Z'=-U*WUG3K>\M)HKFUNHUFAFB8,D
MJ, 592.""""#[U/4=K:QV-K'##&D4,*A(T1<*B@8  [ "I* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IL
MTRV\+2.P1$!9F)P% ZDUQWCK]HSX?_"_7/[,\2^./"/A_4M@E^R:EK%O:S;#
MT;8[AL'UQ7!_%_\ :G^%7CSX3>*-#T_XM_#FVO\ 6=(N[&VF/B2T BEEA=$;
M/F=F8'\* /Y=/^#B;_@J_<_\%-/VU;RVT.YE7X9?#F6;2/#D.[Y+U@^)[XCU
ME9?E]$5?4TS_ ((4?LK>&KSQSXK_ &E_BS:AO@U^SK;KK=W'*.-=U?K96$>>
M&8R;7([87/6OA3QMX2O/ /C+5=#U'ROM^CW<ME<>5*)8S)&Y1MKKD,,@X(."
M.:[[X9_&7XH>-OA7%\!O#_B/43X,\6>((=3/ATW"0V5SJ.!&DSLV , +DE@H
MV@GH#0 _]MG]KGQ1^W5^U%XP^*7B^X:;6/%=\UP(MQ*64 ^6&WC]$CC"J![>
M]>55^RWQ._X(_?!?]@;_ ((J_%7Q1XC^('P[\>?M :W966R/3M:M;U/#R&ZB
M+VUHJN2\A7(DE R0"%PN2WXTT %%%% !7] 7_!DW^UC<3P_%GX*WURSVT A\
M5Z3&S'$1)$%R%'O^Y/X&OY_:_1G_ (-9OV@=,_9__P""MWAF?7-6L=&T7Q!H
M^H:5=7-[=+;6Z%HO,3>[D*/FC&,GK0!_59^TO?ZMI7[.GCVYT'=_;=OX>OY+
M#;][SQ;R%,>^[&*_G$_X-V+'P38_LB_M;^-Y+_4;?XV:1H#*U[:7$T>JZ9I$
MK?Z5<VS)"[QR%P0SH&;A00 <G^B5OVT/@ZRD'XJ?#D@\$'Q'9\_^1*_$O]M/
M_@D7+\"/VSK[X]?L2?M'?"GP?K&KSS7-UX>O?%EE:"U>8YGCB=V:*6WD.28I
M5XR ,X! !^/'[??C?PYXU^+5D_A/Q?XE\8Z-!8(JW.LZS=:I)%*6)=5>X1&
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MCLJ /T(HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>)_V(?C]\0_V@/C)\3X_B9\7/%>DWEHTUE;M#:0B<*TTK%@"\C>6JC"JJC.
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M_P""[=U^UM_PFFA-X;N+)K?^P?LTOVY6-D+;._[F,C=7Z'44 ?F5^R+_ ,$
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M?\$POVH?C7X]UWQMH/B>R^*,Q>SM;"UEBELE^U33_O"_!.) ..X->7?MP?\
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M\/\ _P %MW_A7]'U% '\X7_$$3\4_P#HMG@#_P %EW_A0/\ @R*^*BGCXV>
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M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60
M_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH
M/^'!-S_T=S^UA_X5D/\ \8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S
M^UA_X5D/_P 8H_X<$W/_ $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\
M\8H_X<$W/_1W/[6'_A60_P#QBBB@ _X<$W/_ $=S^UA_X5D/_P 8H_X<$W/_
M $=S^UA_X5D/_P 8HHH /^'!-S_T=S^UA_X5D/\ \8KTC]A#_@CEX:_88_:.
M\1?%./XF?%+XC^+O$VC)H5U=>+]2AO66W202*%98D;((P,D@ GBBB@#[#HHH
$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>amgn-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgn-20211231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZA\.OA-XK@M?#WA6^7?9M=0:.VISW<D+91Y'N55=Q!S'!$.U-_X*,_'K7_\
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M?M-?M,_MG> ]&^*/BOQ/KFGZ=J>H^-],BU%WCN4N;B[($RL%,SF+<1C @0#
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MIGQ?\4W:>//'?A<E-5TS0;&2Q%W'92 9BGD6]#"1/G AV@C?7NFB_P#!-O\
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M\?:3+:;9!;R JPDMW1)UAEWO%&)50RH7>+]GZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA>']1TRUD,KP2!&DDU&[MHECW[5)#,PW9"D UZ%10!^#/_!MC_P2^_X*C_\
M!+']K+QAX_\ VHOV$-?3PYXP\%C1XM2T#QWX7NVLKA;R"97EB_M56,11),E
MS A?E()(_>:BB@#\,_VT?^";?_!3GXL?\'$GAC_@I3\/OV$?$&H?##PEXO\
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M0-#>ZB:%[Z;4(M0F2X2WW&:/[.LDCM''A4)ROW?10!^4?QJ_X(I?M/?L]?\
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MUO\ P;/_ .2/:?\ AX;^V%_T5_\ \M_3_P#Y'H_X>&_MA?\ 17__ "W]/_\
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MA?\ 17__ "W]/_\ D>O%J*/]5N&/^@&C_P""H?\ R(?ZU\4_]!];_P &S_\
MDCVG_AX;^V%_T5__ ,M_3_\ Y'H_X>&_MA?]%?\ _+?T_P#^1Z\6HH_U6X8_
MZ :/_@J'_P B'^M?%/\ T'UO_!L__DCVG_AX;^V%_P!%?_\ +?T__P"1Z/\
MAX;^V%_T5_\ \M_3_P#Y'KQ:BC_5;AC_ * :/_@J'_R(?ZU\4_\ 0?6_\&S_
M /DC[U_X)U_M*_&SX[>+?$NF?%7QI_:L&GZ=!+:)_9MM!Y;M(P)S#&A/ [YK
MZOKX6_X)'_\ (^>,?^P1;?\ HUJ^Z:_FGQ'PF$P/%M:CAJ<802A:,4HI7BKZ
M*R/Z=\-<9B\?PA1K8FI*I-N=Y2;DW:;2U=V%%%%?#'W@4444 %%%% !1110
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M_P#Y(]I_X>&_MA?]%?\ _+?T_P#^1Z/^'AO[87_17_\ RW]/_P#D>O%J*/\
M5;AC_H!H_P#@J'_R(?ZU\4_]!];_ ,&S_P#DCVG_ (>&_MA?]%?_ /+?T_\
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MA?\ 17__ "W]/_\ D>O%J*/]5N&/^@&C_P""H?\ R(?ZU\4_]!];_P &S_\
MDCVG_AX;^V%_T5__ ,M_3_\ Y'H_X>&_MA?]%?\ _+?T_P#^1Z\6HH_U6X8_
MZ :/_@J'_P B'^M?%/\ T'UO_!L__DCVG_AX;^V%_P!%?_\ +?T__P"1Z/\
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M_P"1Z/\ AX;^V%_T5_\ \M_3_P#Y'KQ:BC_5;AC_ * :/_@J'_R(?ZU\4_\
M0?6_\&S_ /DCVG_AX;^V%_T5_P#\M_3_ /Y'H_X>&_MA?]%?_P#+?T__ .1Z
M\6HH_P!5N&/^@&C_ ."H?_(A_K7Q3_T'UO\ P;/_ .2/:?\ AX;^V%_T5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB/2'_I$0HHHK]!/SL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6M>OX:Q/^\S]7^9_>.%_W:'HOR"BBBL#<**** "BBB@ HHHH **** "BBB@
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MY^HHHK^FC^70HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _8WX?\ _(AZ)_V"+;_T4M:]9'P__P"1#T3_ +!%
MM_Z*6M>OX:Q/^\S]7^9_>.%_W:'HOR"BBBL#<**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR[]
MM;_DU;QM_P!@<_\ HQ*]1KR[]M;_ )-6\;?]@<_^C$KU^'_^1]A/^OM/_P!+
M1X_$/_(@Q?\ UZJ?^D,_*RBBBO[5/X?"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z[_ ."1_P#R/GC'_L$6
MW_HUJ^Z:^%O^"1__ "/GC'_L$6W_ *-:ONFOY5\4?^2SK^D/_2$?UGX5?\D3
M0]9_^ER"BBBOST_10HHHH **** "BBB@ HHHH **** "BBB@#Y%_X*X?\B#X
M/_[#%S_Z*6OA6ONK_@KA_P B#X/_ .PQ<_\ HI:^%:_JOPN_Y(RAZS_]+9_)
M?BK_ ,EMB/2'_I$0HHHK]!/SL**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *_23_@F=_R:M8?]A>]_]&5^;=?I)_P3
M._Y-6L/^PO>_^C*_+?%[_DE8_P#7V/\ Z3(_5O!S_DK)?]>I?^E0/H"BBBOY
ME/ZB"BBB@ HHHH **** "BBB@ HHHH **** "OS<_P""F7_)U-__ -@>R_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KR[]M;_DU;QM_P!@<_\ HQ*]1KR[]M;_ )-6\;?]@<_^C$KU^'_^1]A/
M^OM/_P!+1X_$/_(@Q?\ UZJ?^D,_*RBBBO[5/X?"BBB@ HHHH **** "BBB@
M HI'#%2$(#8X)&0#7Y[?''XE_M$>'/\ @K=\,O@MXK^.NHZKX<NI;34H]%LK
M86%FAD6X4HT4;'S@&B+*TK.P#8SQD^+G>=4\DI4ISIN2J3C#2VCD[)N[O;T3
M^1[F1Y)4SRK5A"HHNG"536]VHJ[2LK7]6OF?H517QE_P5Y_:6^(/PDM_AK\&
M? 7B>\T.+Q]X@>/7M7TVX:"X2QADMD>&.5<-'O-QDLI#8CQG#$'EOB?\5_$W
M[$G_  5'\$?"SP-KE_\ \(!\3-/T^#4?#%U?RSVUK=W%S+9K/ )6;R6#QPNQ
M7&X,X/4$>;CN+<)@<?4P\H-QISI0G*^SJIN+2ZI:<SNK7T3L>G@.#\9C\OIX
MB,TI5859PC;XE2:4DWT;UY59WMJU<^]J*_/7]HCQ_P"._B3^W'\=OAMX_P!=
MU&UT#P!\!=3U3P38Q7DD$5M>+:V<JZ@FP@-,KS38DY*A0O\ ":]?_8^_:U\5
M:/\ \$W/#W[0?Q_EOM5UA(I[/3U(+7NOS"[DM[.)!C,DTI")NY+$%SQDT\)Q
M9@\3F-;#2@XJFJCYGM:E)1G==-7>.]UV>A.,X1QF%RVCBH34Y5'37*M[U8N<
M+.^NBM+:S[K4^JZ*\T_9@^%?C/X?^#KSQ5\6M6^W>./%]\=5\5RI,7AM9F4"
M.RM\D[8+>,+$N/O%6?JYKTNOI,+5J5\/&I.'(WK9[KM?SMNNCTN]SYK%4:>'
MQ$J=.?.EIS+9][>5]GU6ME>P4445N<X4444 %%%% !1110 4444 ?7?_  2/
M_P"1\\8_]@BV_P#1K5]TU\+?\$C_ /D?/&/_ &"+;_T:U?=-?RKXH_\ )9U_
M2'_I"/ZS\*O^2)H>L_\ TN04445^>GZ*%%%% !1110 4444 %%%% !1110 4
M444 ?(O_  5P_P"1!\'_ /88N?\ T4M?"M?=7_!7#_D0?!__ &&+G_T4M?"M
M?U7X7?\ )&4/6?\ Z6S^2_%7_DML1Z0_](B%%%%?H)^=A1110 4444 %%%%
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M10 4444 %%%% !1110 5^=/[5S ?\%QOA+S_ ,PG3A_X_>U^BQ&1BO&O$G[
M7[+'B_XI6WQL\2^"-9O/%EE)$]GKTOCG6?M$!B_U>QA=_*%[ 8')XY-?-<3Y
M3C<XPU&GAN6\*L)OF;6D'>RM&6K^1]/PMF^!R;%5ZN)YK3I5*:Y4GK-6N[RC
MHOF-_;5_8D^&O[;?@&Q\*>-M4O=)U'1KMKG0M=TX*TMH[ !U*MP\;!5RN0<H
MI##'/Q]X(^#GQ#_:F_X*A:'J.J?%2[\>^'/@E!9Q:UXWETN"UAFO[9WGCMHQ
M"-KR?:'7=DLW[N4YQM%?H'XU^%7AKX@>'X?"7B/4=;.F1P^5-:6>OW5LUTF
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M?RKXH_\ )9U_2'_I"/ZS\*O^2)H>L_\ TN04445^>GZ*%%%% !1110 4444
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MH>B_(****P-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 5^;G_!3+_DZF__ .P/9?\ HNOTCK\W/^"F7_)U-_\
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M+1X_$/\ R(,7_P!>JG_I#/RLHHHK^U3^'PHHHH **** "BBB@ HHHH ****
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M /=%'_$:/#3_ *#_ /RE6_\ E8?\0WXT_P"@7_R>G_\ )GR[17U%_P .V?\
MJL__ );O_P!T4?\ #MG_ *K/_P"6[_\ =%'_ !&CPT_Z#_\ RE6_^5A_Q#?C
M3_H%_P#)Z?\ \F?+M%?47_#MG_JL_P#Y;O\ ]T4?\.V?^JS_ /EN_P#W11_Q
M&CPT_P"@_P#\I5O_ )6'_$-^-/\ H%_\GI__ "9\NT5]1?\ #MG_ *K/_P"6
M[_\ =%'_  [9_P"JS_\ EN__ '11_P 1H\-/^@__ ,I5O_E8?\0WXT_Z!?\
MR>G_ /)GR[17U%_P[9_ZK/\ ^6[_ /=%'_#MG_JL_P#Y;O\ ]T4?\1H\-/\
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M_DE8_P#7V/\ Z3(_5O!S_DK)?]>I?^E0/H"BBBOYE/ZB"BBB@ HHHH ****
M"BBB@ HHHH **** "OS<_P""F7_)U-__ -@>R_\ 1=?I'7YN?\%,O^3J;_\
M[ ]E_P"BZ_4O"'_DJI?]>I?^E1/RGQB_Y)./_7V/_I,CY^HHHK^FC^70HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_0SP_\ X.I__)!_JQQ+_P! 5;_P7/\ ^1/+J*]1_P"&+_VEO^B;?^5BS_\
MCU'_  Q?^TM_T3;_ ,K%G_\ 'J/]>."O^AGA_P#P=3_^2#_5CB7_ * JW_@N
M?_R)Y=17J/\ PQ?^TM_T3;_RL6?_ ,>H_P"&+_VEO^B;?^5BS_\ CU'^O'!7
M_0SP_P#X.I__ "0?ZL<2_P#0%6_\%S_^1/+J*]1_X8O_ &EO^B;?^5BS_P#C
MU'_#%_[2W_1-O_*Q9_\ QZC_ %XX*_Z&>'_\'4__ )(/]6.)?^@*M_X+G_\
M(GEU%>H_\,7_ +2W_1-O_*Q9_P#QZC_AB_\ :6_Z)M_Y6+/_ ./4?Z\<%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "LSQE_R+%Y_UR_J*TZS/&7_ "+%Y_UR_J*YL9_NE3_"_P B*GP/
MT/,J***_,#R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ZOX5_\ '[=_]<E_F:[6N*^%?_'[=_\ 7)?YFNUK
M[_(?^19#U?YL]'#?PD%%%%>R;A1110 4444 %%%% !1110 4444 %%%% '*?
M%3_CRM/^NK?R%<57:_%3_CRM/^NK?R%<57Y_GW_(SGZ+\D>;B/XK"BBBO',0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KT/X=?\ (L1_]=7_ )UYY7H?PZ_Y%B/_ *ZO_.O>X<_Y&#_PO\T=&%_B
M?(W:***^Z/0"BBB@ HHHH **** "BBB@ HHHH **** "OS<_X*9?\G4W_P#V
M![+_ -%U^D=?FY_P4R_Y.IO_ /L#V7_HNOU+PA_Y*J7_ %ZE_P"E1/RGQB_Y
M)./_ %]C_P"DR/GZBBBOZ:/Y="BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#]C?A__P B'HG_ &"+;_T4M:]9
M'P__ .1#T3_L$6W_ **6M>OX:Q/^\S]7^9_>.%_W:'HOR"BBBL#<**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -FG_HFW_E8O/_CU'_#%_P"S3_T3;_RL7G_QZO4:*/\ 7CC7_H9XC_P=4_\
MD@_U8X:_Z J/_@N'_P B>7?\,7_LT_\ 1-O_ "L7G_QZC_AB_P#9I_Z)M_Y6
M+S_X]7J-%'^O'&O_ $,\1_X.J?\ R0?ZL<-?] 5'_P %P_\ D3R[_AB_]FG_
M *)M_P"5B\_^/4?\,7_LT_\ 1-O_ "L7G_QZO4:*/]>.-?\ H9XC_P '5/\
MY(/]6.&O^@*C_P""X?\ R)Y=_P ,7_LT_P#1-O\ RL7G_P >H_X8O_9I_P"B
M;?\ E8O/_CU>HT4?Z\<:_P#0SQ'_ (.J?_)!_JQPU_T!4?\ P7#_ .1/+O\
MAB_]FG_HFW_E8O/_ (]1_P ,7_LT_P#1-O\ RL7G_P >KU&BC_7CC7_H9XC_
M ,'5/_D@_P!6.&O^@*C_ ."X?_(GEW_#%_[-/_1-O_*Q>?\ QZC_ (8O_9I_
MZ)M_Y6+S_P"/5ZC11_KQQK_T,\1_X.J?_)!_JQPU_P! 5'_P7#_Y$\N_X8O_
M &:?^B;?^5B\_P#CU'_#%_[-/_1-O_*Q>?\ QZO4:*/]>.-?^AGB/_!U3_Y(
M/]6.&O\ H"H_^"X?_(GEW_#%_P"S3_T3;_RL7G_QZC_AB_\ 9I_Z)M_Y6+S_
M ./5ZC11_KQQK_T,\1_X.J?_ "0?ZL<-?] 5'_P7#_Y$]7T6SM]/T:TL+./9
M%!:QQQ)DG:JJ !D\G@59J*Q_X\H?^N2_RJ6OKXRE**;=VS[**2BD@HHHIE!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %9GC+_D6+S_ *Y?U%:=9GC+_D6+S_KE_45S8S_=*G^%
M_D14^!^AYE1117Y@>4%%%% !1110 4444 %%%% "221Q1M+*X55!+,QP !W-
M?'OBK_@MY^Q?8_MK>#/V#/A[>ZWXL\:^+=9BL9;O3--:'3--1XVD65[B;;]H
M#( 5-NLB,&^^*^PZ_%3_ (*%*J_\'7?[.I50"WAS1BQ ZGS-5%=^ H4L1.:G
MTBVO5(TI14F[]C]6_P!K+]K#P)^R)\-5\>>*_"GBCQ1J5]=?8_#?@OP+H,NJ
M:UKUWL9_(M+6+ER$1G9B51%4EF' /S5_P3H_X+M? 3]O_P#:#US]E"_^#'C3
MX9?$71K>>X3PWXTM41[E("!/%\I#13QYW-%(BG:"06VL!]H>*8CI]C<>,-(\
M&IK&M:=IMPNEV\;11W$VX*[6T<TI"QB1XH@<L%RB%ONC'XI?L+_M2Z>G_!R?
MX^UO]NG]DG6?AU\5/B%9)HO@"VDU6.>VT1(K!(T\SRTVW;W5O:JJW<<C(&9D
M"%7WQZ8/#T:^'JWC>48WO?7[NW=CA&,HO38_0C]I[_@KO\+_ ($?M!^,_P!F
M+X??"W5_'OBSX9_"^]^('Q&M]/U"&TAT;1K:.*5T5Y<F>[:.>%UA 52LJ9D4
MG ]U_9/_ &I/A%^VC^SUX9_::^!FL37GAGQ39-/9-=P^5/ Z2-%-!,F2$ECE
M1XV )&4."P()^%?VH_\ @E-^TOI7[?/Q\_;!_9SL-(\4Z=^T)^S]JW@.]TG4
M-86RF\/ZM<VEE;17;&0;9K3%E&[;"907<",@*2WX5?LQ^/?V6/V4_AC_ ,$)
M_@E\3WNO'/B?2;S6?C1X]T,LB^%O#5Q=R/?36[,,I/<O(;"T)4,0)9RJ&/BI
MX?!SH1]G+WM+^EO>;[6>W?S!Q@XJSU_JY]K_ +*/[5VC_M=6?BSQM\/O!US#
MX)T;Q3/HOA;Q=/=*T7BG[-^[NKRU0#BU6X$D*2[CYIB=@ N,^M5\B?"S_@J+
M_P $T_A;8:#\"_A?XS&C^!M#\6Q?#3P]XGM=%F7PW%K<%LC)I*7I&TN(MI\T
M_N6Z^:2:^NZX:].5.?PN*>U_Z^\B2:>P4445@2%%%% !1110 4444 %%%% '
M5_"O_C]N_P#KDO\ ,UVM<5\*_P#C]N_^N2_S-=K7W^0_\BR'J_S9Z.&_A(**
M**]DW"BBB@ HHHH **** "BBB@ HHHH **** .4^*G_'E:?]=6_D*XJNU^*G
M_'E:?]=6_D*XJOS_ #[_ )&<_1?DCS<1_%84445XYB%%%% !1110 4444 %%
M%)))'%&TLKA54$LS'  '<T +17QYXJ_X+>?L7V/[:W@S]@SX>WNM^+/&OBW6
M8K&6[TS36ATS34>-I%E>XFV_: R %3;K(C!OOBOI/XY_'WX1_LV?#V]^*7QJ
M\91:+HMC$\DUP;:6>5PB-(PCAA1Y9F"([E45B%5CC )K:>'KTW%2BTY;>93C
M);H["BOFO_@G+_P5#^!'_!3S2_''BS]GGP]K]OH/@S7H=*74M?MD@?4G>'S#
M+'$K,R1XX&\ACW5>E<S^T]_P5W^%_P "/V@_&?[,7P^^%NK^/?%GPS^%][\0
M/B-;Z?J$-I#HVC6T<4KHKRY,]VT<\+K" JE94S(I.!2PN(=5TN7WENNP<DKV
ML?75%>=?LG_M2?"+]M']GKPS^TU\#-8FO/#/BFR:>R:[A\J>!TD:*:"9,D)+
M'*CQL 2,H<%@03E?LH_M7:/^UU9^+/&WP^\'7,/@G1O%,^B^%O%T]TK1>*?L
MW[NZO+5 .+5;@20I+N/FF)V "XSFZ52/-=?#OY"LSUJBBBLQ!1110 4444 %
M%%% !1110 5Z'\.O^18C_P"NK_SKSRO0_AU_R+$?_75_YU[W#G_(P?\ A?YH
MZ,+_ !/D;M%%%?='H!1110 4444 %%%% !1110 4444 %%%% !7GGQ%_Y&>3
M_KDG\J]#KSSXB_\ (SR?]<D_E7@<1_\ (O7^)?DSFQ7\/YF%1117PQP!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!ZW8_P#'E#_UR7^52U%8_P#'E#_UR7^52U^JT_@7H>NM@HHHJQA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %9GC+_D6+S_ *Y?U%:=9GC+_D6+S_KE_45S8S_=*G^%_D14
M^!^AYE1117Y@>4%%%% !1110 4444 %%%%  20"0,^PK\COVOOV-/^"@GQ@_
MX+M_"S_@H-X%_8@\2S_#SP):Z58ZE+/XQ\,Q7DZ1/=--+% =5Y"_:N Q4MY9
MXY&?UQHKIPV*GA92E%)W36M]GZ-%0FX/0^5_VX?VD?\ @I)\#?'GPY\4?LI?
ML067Q/\  .H0R'XF:0-;@M_$.F2-L\M+;-R("5!<L0)U=D*[HP5D;C9_V+_$
MO[9O_!2?X8_\%%OBS\%=5^'6E?";P?/9Z#H'B>YL9-9UK4IVE*/<+8W%Q%!:
MVRS2,@,QD>9VRB(N9/MJBB.)=.%H12=FKZW:?SMY; I66ARWQN^)&H_"#X1^
M(OB;HWP]UOQ;>Z+I4MS8^&/#=FUQ?:K.!^[MH44$[G<JNXC:H)9B%4D>/_L2
M_LG^-_AC\*/%/C_X_:U'<?&/XP3-J_Q,US3VW+8SO"8[73+1LDBUL("L$0R0
M2LDG64U]$T5E&HXTW%==_P#+]?N["O96/Y_8O^"/'[>>H?\ !/O3_P#@DS/\
M$]2M_$]M^UD_BNX\?>2#X?3PW_8ALQJ:WF=K,7<D6P_TC"8,8)Q7[^V%J;&Q
MALC<22F&)4\V5LL^!C<3W)ZFI:*Z,7C:N,MSI*UWIW=K_D5.HY[A1117&0%%
M%% !1110 4444 %%%% '5_"O_C]N_P#KDO\ ,UVM<5\*_P#C]N_^N2_S-=K7
MW^0_\BR'J_S9Z.&_A(****]DW"BBB@ HHHH **** "BBB@ HHHH **** .4^
M*G_'E:?]=6_D*XJNU^*G_'E:?]=6_D*XJOS_ #[_ )&<_1?DCS<1_%84445X
MYB%%%% !1110 4444 %%%!) ) S["@#\5/\ @H4JK_P==_LZE5 +>'-&+$#J
M?,U45^R'Q+57^'/B!'4%3HEV""."/):ORI_:^_8T_P""@GQ@_P""[?PL_P""
M@W@7]B#Q+/\ #SP):Z58ZE+/XQ\,Q7DZ1/=--+% =5Y"_:N Q4MY9XY&?TX^
M-'B;QS:?!74M1\&_!?7_ !'K6H:--'!X8T^^TV&ZCFDMW(222YNXK<8?",5E
M89.1N7+5ZN.<)PH*,D[12>JT=WOV-JC34?0_*C_@S<_Y->^,?_8_67_I$*]A
M_:C_ ."4W[2^E?M\_'S]L']G.PTCQ3IW[0G[/VK> [W2=0UA;*;P_JUS:65M
M%=L9!MFM,64;ML)E!=P(R I.-_P;7_L3?MM_\$]/ 7Q!^$/[6O[+VJ^&AXH\
M0VVIZ7KL'B?1+^T5([9XW246M_),K;E0#$; [QD@ D?H_P#&[XD:C\(/A'XB
M^)NC?#W6_%M[HNE2W-CX8\-V;7%]JLX'[NVA103N=RJ[B-J@EF(521KC<5*G
MFE2=%IJ5EW3V_5#J3:K-QZGY[_"K]F/Q[^RQ^RG\,?\ @A/\$OB>]UXY\3Z3
M>:S\:/'NAED7PMX:N+N1[Z:W9AE)[EY#86A*AB!+.50Q\>[?"S_@J+_P33^%
MMAH/P+^%_C,:/X&T/Q;%\-/#WB>UT69?#<6MP6R,FDI>D;2XBVGS3^Y;KYI)
MKLOV)?V3_&_PQ^%'BGQ_\?M:CN/C'\8)FU?XF:YI[;EL9WA,=KIEHV21:V$!
M6"(9()623K*:_(:+_@CQ^WGJ'_!/O3_^"3,_P3U*W\3VW[63^*[CQ]Y(/A]/
M#?\ 8ALQJ:WF=K,7<D6P_P!(PF#&"<4Z<<-BYR56=K.[>UV[\TO1:)+MZ@E&
M;=W_ %W/Z J*BL+4V-C#9&XDE,,2IYLK99\#&XGN3U-2UXA@%%%% !1110 4
M444 %%%% !7H?PZ_Y%B/_KJ_\Z\\KT/X=?\ (L1_]=7_ )U[W#G_ ",'_A?Y
MHZ,+_$^1NT445]T>@%%%% !1110 4444 %%%% !1110 4444 %>>?$7_ )&>
M3_KDG\J]#KSSXB_\C/)_UR3^5>!Q'_R+U_B7Y,YL5_#^9A4445\,< 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >MV/_ !Y0_P#7)?Y5+45C_P >4/\ UR7^52U^JT_@7H>NM@HHHJQA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %9GC+_ )%B\_ZY?U%:=9GC+_D6+S_KE_45S8S_ '2I_A?Y
M$5/@?H>94445^8'E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!U?PK_X_;O_ *Y+_,UVM<5\*_\ C]N_^N2_
MS-=K7W^0_P#(LAZO\V>CAOX2"BBBO9-PHHHH **** "BBB@ HHHH **** "B
MBB@#E/BI_P >5I_UU;^0KBJ[7XJ?\>5I_P!=6_D*XJOS_/O^1G/T7Y(\W$?Q
M6%%%%>.8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7H?PZ_Y%B/_ *ZO_.O/*]#^'7_(L1_]=7_G7O<.?\C!_P"%
M_FCHPO\ $^1NT445]T>@%%%% !1110 4444 %%%% !1110 4444 %>>?$7_D
M9Y/^N2?RKT.O//B+_P C/)_UR3^5>!Q'_P B]?XE^3.;%?P_F85%%%?#' %%
M%% !1110 4444 %%%% $.I:EIVCZ?/JVKW\-K:VT32W-S<RA(XHU&6=F8@*H
M ))/ %<W\'_CE\'OV@O"TWCGX'_$K1O%FB0:E/8-K&@7R7-JUQ"VV5$E0E)-
MI."5)&>]?./_  7#^"GPW^+'_!,GXR:QX^T2:_F\-?#O5-3T5/[2N(XH+N&'
MSHIS$D@CD=7C7#.K$ LHP'8'QK_@U:_Y1':%C_H=M;_]'K78L-!X!U[ZJ25O
ME<OD7L^8^LOC3_P4?_8,_9T^)T'P9^.7[6O@7POXHG\O.BZOK\44UN) "AGY
MQ;A@0092@((/3FO7-2\4^&-'\,S^-=7\1V%KHUK8M>W.K7-XB6L5LJ;VG:5B
M$6,("Q<G: ,YQ7Y+_P#!>+_@E#^P1\%O^"97C_\ :)3P4X^*6G:G9:@GQ$OM
M2EEU;Q!JUYJ,,=P;G+;9O.$TS>6JA(L HJ*F*['QY^QK^V?K_P#P:^Z?^RGI
M%AJ]]\45^'>GW$V@;F%])9KJ<=\=+"_>\U+$"W\GJQB\K!SBM_J>%G1ISA-J
M\N5WMY7:\E?J5R0<4T^MC[V^"'[:?[*W[2/B&;PE\$?CCH?B#5(M+35%TZVF
M9)[C3W<HE["DBJ;BU9P5%Q&&B)X#9(KJ/B[\:?A=\!O"<?C?XN>,K;1--GU.
MTTVUFN%=VN;RYF6&WMXHXU9Y99)'551%+'DXP"1^/W[&_P &/C)\:O\ @I?^
MQ3\4_@_X.UO3_#_P8_9-T/1/BUK=SILUK!IE_%9ZE;3:/.9%4-=&:5,P<LJO
MYA&%R/MCX8:]H7[>?[4-Q^VKXZUJTMO@5\$]2N].^$<FHW*QV6OZ^A:WU#Q,
M[.0C00'?9VCDD;OM$RD%DI8C!4J-31^[:[[WNTEZNWW:] E!19]HT55T76]&
M\2:5!KOAW5[6_L;J,26UY97"RQ3(>C*ZDAA[@U:KS=C(**** "BBB@ HHHH
M**** "BBB@#UNQ_X\H?^N2_RJ6HK'_CRA_ZY+_*I:_5:?P+T/76P44458PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "LSQE_R+%Y_UR_J*TZS/&7_(L7G_ %R_J*YL9_NE3_"_
MR(J? _0\RHHHK\P/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTMX(%SG:D<8"J,DG  ZU?K+%5_K-=U+6O;\%84Y<TKA1117.2%%%% !1110
M4444 %%%% 'K=C_QY0_]<E_E4M16/_'E#_UR7^52U^JT_@7H>NM@HHHJQA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9GC+_D6+S_KE_45IUYS^US_ ,FW>+O^P7_[42M:.#_M
M"M'"\W+[1J-[7MS:7MI>U]KH:A[1\G?0Q:*_/>BOJ?\ B W_ %,?_*/_ -U-
M_P"PO^GGX?\ !/T(HK\]Z*/^(#?]3'_RC_\ =0_L+_IY^'_!/T(HK\]Z*/\
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MW8ROR\EOBB[6N]K;ZGVE_P /??\ JWG_ ,NW_P"Y*/\ A[[_ -6\_P#EV_\
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MS%'M-S(#(L9W!%PJY./T+H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\Y_:Y_Y-N\7?]@O_ -J)7HU><_M<_P#)
MMWB[_L%_^U$KTLG_ .1OA_\ KY#_ -*1I1_BQ]4?F[1117]1'T@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?4'_  3$_P"1T\5?]@N#_P!&-7V17QO_ ,$Q/^1T\5?]@N#_ -&-7V17\^\?
M?\E/5](_^DH\+'?[R_E^04445\:<@4444 %%%% !1110 4444 %%%% !1110
M!\O_ /!3S_D3/"O_ &%+C_T6M?&]?9'_  4\_P"1,\*_]A2X_P#1:U\;U_07
M /\ R3%+UE_Z4SW<#_NZ^84445]D=84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5]]?\ !/G_ )-NLO\ L*7?_H=?
M M??7_!/G_DVZR_["EW_ .AU\#XC_P#)/Q_Z^1_*1Q9A_ ^9[=1117X2>(%%
M%% !1110 4444 %%%% !1110 4444 %>>?$7_D9Y/^N2?RKT.O//B+_R,\G_
M %R3^5>!Q'_R+U_B7Y,YL5_#^9A4445\,< 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >MV/_'E#_P!<E_E4
MM16/_'E#_P!<E_E4M?JM/X%Z'KK8****L84444 %%%% !1110 4444 %?BW7
M[25^8G_#O+]L+_HD'_EP:?\ _)%?L_A#FF699]=^N5X4^;V=N>48WM[2]KM7
MM=7MW1^)>,64YIFGU'ZG0G5Y?:WY(RE:_L[7Y4[7L[7WLSQ:BO:?^'>7[87_
M $2#_P N#3__ )(H_P"'>7[87_1(/_+@T_\ ^2*_:/\ 6GAC_H.H_P#@V'_R
M1^)_ZJ<4_P#0!6_\%3_^1/%J*]I_X=Y?MA?]$@_\N#3_ /Y(H_X=Y?MA?]$@
M_P#+@T__ .2*/]:>&/\ H.H_^#8?_)!_JIQ3_P! %;_P5/\ ^1/T[K\O_P#@
MZFM=1O?V6?V=K+2-4^PW<W[7WA)+6]\@2_9Y#8ZL%DV-P^TX.T\'&*_4"OCO
M_@K/_P $R?C#_P %-_#G@+P1X=_:IT+X=Z-X!^(5AXTT])OAI+K%U<:G9Q3Q
MPAY?[4MD$.+B4E!'N)V_.,<_Q@?VR;7CW]EC]O+4_B#\-?$FI?MM?\)9X<\.
M_$.QU/Q9X3_X0#3],_M*R19 #]HCDW#R96BGV#._RL<G K4_;?33-<_:*_9)
M@D6"\M+GX\:K'(C!9(Y4/@'Q:&4CD,",@BH?B9\!?^"KWQ$\!:KX'TK_ (*&
M?![PG/JED]LGB+PM^S9J2ZC8;A@RV[77BR>)9 "<,T3X/.,@5+\7/V&_B[K_
M (D^!"_ OX_^&O"/ACX#:O%?Z'H>M_#RXUBXU IHEYHPCFN5U6V"K]EOK@Y$
M9;>48DA2& /ACQ)IWB/_ (-JOVU7\?\ ARSO;K]B+XY>)5'B#3;>-Y5^%GB*
M;A;B-!DBRD QA1DQKLP7@A$WUE^P]K.D>(O^"1_BOQ!X?U2WOK"_O?BA<6-[
M9S+)%<0OXDUUDD1U)#*RD$,"00017T[\:/@;\-?VD/@OKOP$^/GA.P\2>&_%
M&D/I_B'3+B K#<HZC<RC<6B8, Z,&WQLJLK;E#5X7^S[_P $[_%G[*G_  35
MM/\ @GC\!_CI8VHTS3]=TO3/%_B;PD^HM'8W]W?31[K:&\M@\\:7<:E_,",T
M3'8 X"@'Q9_P;^?!;]N[Q]_P0L^&3?LX_MP:#\/X]0@\1KX?AU#X30ZO)I<@
MU_4T8F62\02AI TGS1G;N PP7YM[_@VX\<>$_A'\0OVA_P#@GA\2/AC<:=\=
MO ?CF36?BMX\EU]]37Q[<7,KK_::R/'&T SM98"O"W ?)=Y<>Y?L(?\ !-3]
MOG_@GM^R%H'[&'P6_;]^%UYX<\,_;AH^L:[^SM?2ZG#]KO9[R4ET\3I"Y$MQ
M)LS"0!@,'QSW/[!G_!+3PY^P;_PLOXIZ#\9=0\<_&7XN:N-4\=?%'QMI*2?;
M)U9V2*.RMI(5@ME,DA$*2 Y8#?M2-$ /S,_9"\:_\%*OA+\+O^"BGQB_X)U7
MW@K4-8\._M6>*[J[\+:WX-N+[5KJ-+F1IY]/N%O5@$T<.62WEM9O,9" 265#
M^@O_  02^$7[%'A?]AZU^/W[&WC37?%K?%W4Y?$GQ \8^,+V.?6]0UUR1=0W
MOE*J120RF5/+1=HW,X+^89'U/^"8W_!,?XU?\$]?B)\7/%_B?]J_P]X]L/C'
M\1;WQKX@T^W^&$VD36>I732-*MO,=6N5$.YTPKQLP"8W?-D0? 3_ ()6_$S]
MC3]L3X@_'?\ 8O\ VI]*\(_#/XH:FFK^*_@EK_PZDU33K?5B,3WVGW$.I6K6
M3RXY01N@S@JRI"L0!\Q^%_!/Q?\ '7_!T5^T#IWP;^-__""7\/[/VA276H_\
M(U;ZI]HAW::/*\N=@J?,5;<.?EQWK[G_ &7?@=^TY\'_ -H?XG>/?VD/VA4^
M(&E>)M$\,VOA+5I-"M=)%A]GDU-9[#R('(8B2YCE$S8+FZ"#/E<>*Z-_P2R_
M;-\$?\%(_'O_  4M^'O[=7PX@\2^/?!]MX9O/#6M? .^N].M;&#[*8V0Q>)8
M93-NM5)<OM/F/\@^7;Z]HW[+?[:?C/X\^#OBC^TQ^V/X*U_PSX)DN[[3_ ?@
M3X/W6@VU_JLEO);V]Y>376N:A),MNLTK) NQ/,*2'YXD( /EC]DK_E:3_:M_
M[(?X7_\ 1.F5^F%[J.GZ9$DVI7T-NDDR0QO/*$#2.P1$!/5F8A0.I) '6O@[
M1_\ @E'^VQX&_P""C?Q'_P""DGPR_P""@G@'3_$GQ)\-V>@ZGX;U3X W5YIU
MM96L=LD/E[?$44IE'V527+X)D?Y0-H7V+P/^RA^VMK?[1?A'XQ?M4?MO>&/%
MWAGP6MY=:3X \$_"&3P[;7&JS6[VT=]<SS:O?R3>3#-<!(?E3?*LGWHU- 'T
MK1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7G/[7/_ ";=XN_[!?\ [42O1J\Y_:Y_Y-N\7?\ 8+_]J)7I9/\ \C?#
M_P#7R'_I2-*/\6/JC\W:***_J(^D"BBB@ HHHH **** "BBB@ HHHH **\YU
M7]KO]F+0_%X\"ZO\<_#=OJ7]J?V8T<NI*(TOL9^R--_JTGQ_RQ+!^1\M=CXW
M\<^#?AKX4O?'/Q!\46&BZ-IL/FW^IZG=+#! F0,L[$ 9)  ZDD <FL8XG#S4
MG&::COJM/7L+FB^IJT5R?PP^.?PD^,QOXOAGXZLM5GTJ2--4LHRT=S9F1=\?
MFPR!9(PZ_,I90&'()%7_ !=\2_ O@35]"\/^+/$D%G?>)M2_L_0;-@S2WMQL
M:0JBJ"<*B,S,?E4#+$4U7H2I^T4ER][JV]M_73U#F5KW-VBBBM1A1110 444
M4 %%%% !1110 4444 ?4'_!,3_D=/%7_ &"X/_1C5]D5\;_\$Q/^1T\5?]@N
M#_T8U?9%?S[Q]_R4]7TC_P"DH\+'?[R_E^04445\:<@4444 %%%% !1110 4
M444 %%%% !1110!\O_\ !3S_ )$SPK_V%+C_ -%K7QO7V1_P4\_Y$SPK_P!A
M2X_]%K7QO7]!< _\DQ2]9?\ I3/=P/\ NZ^84445]D=84444 %%%% !1110
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M?'-%'_$#^$_^?]?_ ,"I_P#RL/[$PO\ -+[U_D?8W_#5/P%_Z'O_ ,I=U_\
M&J/^&J?@+_T/?_E+NO\ XU7QS11_Q _A/_G_ %__  *G_P#*P_L3"_S2^]?Y
M'V-_PU3\!?\ H>__ "EW7_QJC_AJGX"_]#W_ .4NZ_\ C5?'-%'_ ! _A/\
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M^A[_ /*7=?\ QJC_ (:I^ O_ $/?_E+NO_C5?'-%>Q_Q _A/_G_7_P# J?\
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M17QIR!1110 4444 %%%% !1110 4444 %%%% 'R__P %//\ D3/"O_84N/\
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MI'%F'\#YGMU%%%?A)X@4444 %%%% !1110 4444 %%%% !1110 5Y_\ $/\
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M])2A*FWII;EF[+9-+I=/&I@Z51KI96^5T_S04445\T=84444 %%%% !1110
M4444 %%%% 'J]C_QY0_]<E_E4M16/_'E#_UR7^52U_:V'_W>'HOR/@9?$PHH
MHK8D**** "BBB@ HHHH **** "O'Z]@KC_\ A5'_ %'_ /R5_P#LJ^>S[ XK
M&^S]C&]KWU2WMW:['-B*<ZEN5''T5V'_  JC_J/_ /DK_P#94?\ "J/^H_\
M^2O_ -E7SW]AYI_S[_&/^9S?5ZW8X^BNP_X51_U'_P#R5_\ LJ/^%4?]1_\
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M4?V$/B+^R3\,O^#3;1I/VSOA3=^.O VJ>)M2TW_A"K#59+!]9U!_%D[V-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU?9%?S[Q]_R4]7TC_P"DH\+'?[R_E^04445\:<@4444 %%%% !1110 4444
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M\F!IH98U9@)(8G7'S*,T ?1-%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5YS^US_P FW>+O^P7_ .U$
MKT:O.?VN?^3;O%W_ &"__:B5Z63_ /(WP_\ U\A_Z4C2C_%CZH_-VBBBOZB/
MI HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/$"BBB@ HHHH **** "BBB@ HHHH **** "O/_B'_P C*_\ UR3^5>@5Y_\
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MS?%__(M7G_7+^HKR<^_Y$>*_Z]S_ /26;X;_ 'F'JOS/-:***_CD^Y"BBB@
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M^<3R<Y_W/YK]3<HHHK^D#Y4**** "BBB@ HHHH **** "BBB@ HHHH *\_\
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M\>4/_7)?Y5+45C_QY0_]<E_E4M?VMA_]WAZ+\CX&7Q,****V)"BBB@ HHHH
M**** "BBB@ KR.O7*\CK\1\9/^8'_N+_ .XSZ#(O^7GR_4****_$3Z ****
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M 4444 =3\+O^/V[_ .N2_P Z[.N,^%W_ !^W?_7)?YUV=?T_X:?\D?0]9_\
MI;/D<V_WZ7R_(****^]/-"BBB@ HHHH **** "BBB@ HHHH **** .6^*/\
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M^AAT445_.!]2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'J]C_QY0_\ 7)?Y5+45C_QY0_\ 7)?Y5+7]K8?_
M '>'HOR/@9?$PHHHK8D**** "BBB@ HHHH **** "O(Z]<KX?_X?+?\ 5N'_
M )>'_P!QU^;^(.18#.OJWUG%>QY.>WN.?-?DOLU:UEZW\C[C@SAKB7B'V_\
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M?^"8N@?M!_\ !,W3O@)^RE\ ]3'CCX9R65_\#H?">J6%A>>'M3ML&-S=7MU
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M^AZS_P#2V?(YM_OTOE^04445]Z>:%%%% !1110 4444 %%%% !1110 4444
M<M\4?^/*T_ZZM_*N,KL_BC_QY6G_ %U;^5<97\P>)?\ R6%?TA_Z0CZ[*?\
M<8_/\PHHHKX(](**** "BBB@ HHHH **** /B/\ X.$OVF?VDOV3_P#@F9XH
M^*7[+VHW>EZY+K-AIFI>(]/3-QHNGW$A26ZB;!\MRWE0B3JAGW*0P5A\!ZW^
MUIX<\0? 7]COXM?\$H_BWXGU+XZ:SXPLM"^(WA#_ (2R]O[S7-EHCZK_ &W;
M32OYT0GVN+F10JQS&1&0*-GWC_P<-_MO^.OV%O\ @G3J7B_X=^!-(US4O&WB
M"'PC_P 5!I:7UC90W5M=2RSS6\@,<X\NW:-4D!0O*I97 *-^6G[>/[!?Q&_X
M((?&#X#?MR_L$?%?6+Y?%:6FEZQHT\H<W^H^3#)/;;8U FL[T!SY)4F)URI_
MU>S]8X/PV%K912IU(J-2<ZOL[_#5M3LX5--(JZ<?G9)ZOQL=.<:S:>B2OW6N
MZ\S[X_;]^)_Q-^*'_!?W]F[]A'XAZEJ,?P8UGP/JFN:EX?BNY8+/Q!J0L=9(
M^T&-E$PA:TM2D;$[&8MC]X*J?\&\7[=/Q%O?^"7/C_XR?MG_ !4O[[PE\*O%
MVI6NE>-_$ER\T\FCV]I;SF-I7R]P8WD9$.68[UB7.Q5K]"?C-^S1\"/VBQHM
MW\9_A?I^LWGA^X>YT#49=T5[I4LB;)#;W,+++!O7Y7V. X #9 %?*NG_  G^
M&?[6/[1.G?L=?!+P%I.@_LV_LX:S!/XOTG0[%(-.\2^+XB)[;152,!)+>Q9E
MN[H'.^Z>%'!*.:^>I9GE^/R98.5+E4(PYI:67)*HW*/7GJ<\8;=-6TM.F5*K
M3K^T4KW;LO5+1^2LV>F?\$^OA[\6O'-YXC_;R_:2L-0TOQA\5(H?^$;\&7LS
M;?!OA:(EK#3C'G"W4@<W-TV 3-*$P!"!7TU7X??&7_@JY^W#X^\%?MO_ +4_
M@SXVZGX0E_9M^(?AK0_AIX1L;6#[ MK+K\^G7?V^&2-C=R3QQJQ\PGRVW"/:
M,8_7O]D#XVZE^TK^RC\-?VA]9T!=*O/'/@32=>N]-CSLMI;NTBG>-"W)0,Y"
MD\E<&N#B')LPP?\ M5?ELVH<L;^Y^[A.,==TH2BKZZIW?5Z86O3J>Y&_?UU:
MO]Z/1J***^7.P**** "BBB@ HHHH **** "O0/AY_P BTG_75_YUY_7H'P\_
MY%I/^NK_ ,Z_3/"C_DIY?]>Y?G$\G.?]S^:_4W****_I ^5"BBB@ HHHH **
M** "BBB@ HHHH **** "O ?VA/VG_@;\+/B3/X1\>>./L&HQVL4CV_\ 9ES+
MA67*G='$R\CWKWZOS(_X*C?\G:ZA_P!@:R_]%U\-X@X*EC\A5.HVESQ>GI+R
M9^G>$W#6 XKXHE@L7*48JG*5X-)W3BNJDK:]CZ"_X;D_9:_Z*A_Y1+[_ .,T
M?\-R?LM?]%0_\HE]_P#&:_/2BOQ/_5K _P TOO7^1_27_$%.%?\ G]6_\"A_
M\K/T+_X;D_9:_P"BH?\ E$OO_C-'_#<G[+7_ $5#_P HE]_\9K\]**/]6L#_
M #2^]?Y!_P 04X5_Y_5O_ H?_*S]"_\ AN3]EK_HJ'_E$OO_ (S1_P -R?LM
M?]%0_P#*)??_ !FOSTHH_P!6L#_-+[U_D'_$%.%?^?U;_P "A_\ *S]"_P#A
MN3]EK_HJ'_E$OO\ XS1_PW)^RU_T5#_RB7W_ ,9K\]**/]6L#_-+[U_D'_$%
M.%?^?U;_ ,"A_P#*S]"_^&Y/V6O^BH?^42^_^,T?\-R?LM?]%0_\HE]_\9K\
M]**/]6L#_-+[U_D'_$%.%?\ G]6_\"A_\K/T+_X;D_9:_P"BH?\ E$OO_C-'
M_#<G[+7_ $5#_P HE]_\9K\]**/]6L#_ #2^]?Y!_P 04X5_Y_5O_ H?_*S]
M"_\ AN3]EK_HJ'_E$OO_ (S1_P -R?LM?]%0_P#*)??_ !FOSTHH_P!6L#_-
M+[U_D'_$%.%?^?U;_P "A_\ *S]"_P#AN3]EK_HJ'_E$OO\ XS1_PW)^RU_T
M5#_RB7W_ ,9K\]**/]6L#_-+[U_D'_$%.%?^?U;_ ,"A_P#*S]"_^&Y/V6O^
MBH?^42^_^,T?\-R?LM?]%0_\HE]_\9K\]**/]6L#_-+[U_D'_$%.%?\ G]6_
M\"A_\K/T+_X;D_9:_P"BH?\ E$OO_C-'_#<G[+7_ $5#_P HE]_\9K\]**/]
M6L#_ #2^]?Y!_P 04X5_Y_5O_ H?_*S]"_\ AN3]EK_HJ'_E$OO_ (S1_P -
MR?LM?]%0_P#*)??_ !FOSTHH_P!6L#_-+[U_D'_$%.%?^?U;_P "A_\ *S]"
M_P#AN3]EK_HJ'_E$OO\ XS1_PW)^RU_T5#_RB7W_ ,9K\]**/]6L#_-+[U_D
M'_$%.%?^?U;_ ,"A_P#*S]"_^&Y/V6O^BH?^42^_^,T?\-R?LM?]%0_\HE]_
M\9K\]**/]6L#_-+[U_D'_$%.%?\ G]6_\"A_\K/T+_X;D_9:_P"BH?\ E$OO
M_C-'_#<G[+7_ $5#_P HE]_\9K\]**/]6L#_ #2^]?Y!_P 04X5_Y_5O_ H?
M_*S]MM$O;;4=%L]0LI-\,]K')$^"-RLH(.#R.#5JL?X=_P#)/]"_[ UK_P"B
MEK8K^H*"M1BO)?D?Q+B(*GB)P6R;7XA1116IB%%%% !1110 4444 %%%% !7
MX?U^X%?A_7Y[QY_S#_\ ;_\ [:?U!]&[_F:?]P/_ ',%%%%?GI_4 4444 ?N
M!7Y^_P#!:O\ ;J_;K_X)CZ;X$_:>^"L7AOQ_X U3QTFD^+?AO/X3F_M@6::?
M>:C<3VE]#/M4):Z?=,QDA;9A7.Y0P'Z!5\W?M\6\%W\9?V5+6Z@26*7]HQTD
MCD4,KJ?!7BH$$'@@CM7]"'^7YZ%^SU^TG\,/VX/V9=#_ &B/V7/B5%/H7B_2
MUN=&UD6JRO:29Q)#-"QPLT3AHY(R<JZL.V:X3_@FK\3_ -I+XW_ [4?BE^T?
M\1= UG4/^$[\4Z!:6OASPP=.@ABTC7[_ $E93OGF9WE%CYIY 7S-H!V[C\&>
M/M$\2_\ !MA^VI-\:_ VF7MU^Q/\;_$B+XVT*RA>5?A?XAF(5;V&-<E;.3 &
M%'*#RL%X;<2=I\0/VQ_$/[,G_! 3QW^T=\"/&MK#=ZK\9?&FGZ!XLLKY?)M+
M?5?B;JEJVH13JLBKLM[AY8Y0K@,$;:PX(!^I-%?FU\8O^"7'[3%W\6?A1^T1
M^R-\-O@Q\!?%/P\\4V]]XL\8Z#\3=6U*?QGH('^EZ?JN[1K8Z@90 YN;J660
M$.<Y<N+?[&?AK0?#O_!?[]K;X7Z'I4-KX8?X6>$+G_A&X4QIZ2W$'[]UM_\
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M,3P HPJJH]%HHK&M6JXBK*K5DY2D[MMW;;ZME1BHJRV"BBBLQA1110 4444
M%%%% !1110!U/PN_X_;O_KDO\Z[.N,^%W_'[=_\ 7)?YUV=?T_X:?\D?0]9_
M^EL^1S;_ 'Z7R_(****^]/-"BBB@ HHHH **** "BBB@ HHHH **** .6^*/
M_'E:?]=6_E7&5V?Q1_X\K3_KJW\JXROY@\2_^2PK^D/_ $A'UV4_[C'Y_F%%
M%%?!'I!1110 4444 %%%% !1110!R'QX^ 7P;_:>^%6K?!'X^_#S3O%/A76X
M1'J6CZG&3')M8,K*RD-&ZL RR(5=6 *D$9KRKP1_P3!_9)\'^*/!7BW5O#WB
M/Q9<?#2,)\.;?QUXSU'6;;PT %56M(+J9XUD41QA975I4$:!7&T8^A**ZZ./
MQN'I.E2J2C%WT3:6JL_O6C[K1Z$2ITY.[2;*NN:;-K.B7FD6^KW6GR7=K)"E
M_8E!/;%E*B6,NK+O7.X;E89 R".*Y#]FW]G;X9?LI_!G1O@7\(]/N(=&T:)R
M)[^X,]W?7$LC2SW=S*0#-<32N\LDA^\SDX P!W-%8*K45)TD_=;3:[M7L_E=
MV]65RJ]^I\L?&'_@CC^Q'\:_'GC;QEXF\+:W8V7Q/U'3+_XH>%=$UMK72_%M
MU83--:S7D2KO#+([,QA>+S&)9]S$D_3VC:-I'AS1[3P]X?TNWL;"PMH[>RLK
M2%8XK>%%"I&B* %55   X   JS16^(QV,Q<(PK5')1V3=[:)?DDO1);)$QIT
MX-N*M<****Y"PHHHH **** "BBB@ HHHH *] ^'G_(M)_P!=7_G7G]>@?#S_
M )%I/^NK_P Z_3/"C_DIY?\ 7N7YQ/)SG_<_FOU-RBBBOZ0/E0HHHH ****
M"BBB@ HHHH **** "BBB@ K\R/\ @J-_R=KJ'_8&LO\ T77Z;U^9'_!4;_D[
M74/^P-9?^BZ^1XT_Y$Z_QK\F?N'@!_R7,_\ KS/_ -*@?.U%%%?E)_: 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=:G9R _,GVFV:: B3;M>2W#[ K;!]<44 ? G['__  2H_;V^#:Z#\&?VF_\
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M_P#*E+_Y,^LJ*^3?^'H?_5#O_+F_^YJ/^'H?_5#O_+F_^YJ/[#S3_GW^,?\
M,/\ B%O'?_0'_P"5*7_R9]945\F_\/0_^J'?^7-_]S4?\/0_^J'?^7-_]S4?
MV'FG_/O\8_YA_P 0MX[_ .@/_P J4O\ Y,^LJ*^3?^'H?_5#O_+F_P#N:C_A
MZ'_U0[_RYO\ [FH_L/-/^??XQ_S#_B%O'?\ T!_^5*7_ ,F?65%?)O\ P]#_
M .J'?^7-_P#<U'_#T/\ ZH=_Y<W_ -S4?V'FG_/O\8_YA_Q"WCO_ * __*E+
M_P"3/MOX7?\ '[=_]<E_G79U\T_L)?M9_P##1OB?7](_X0#^QO[,L(9O,_M7
M[1YFYRN,>4F,8Z\U]+5_1_AWAZV%X4HTZJLTY_\ I3['Y%Q9E&89'GE3!XZ'
M)4BHW5T]XIK6+:V?<****^W/G HHHH **** "BBB@ HHHH **** "BBB@#EO
MBC_QY6G_ %U;^5<96'^W;^TA_P ,Y>&- U?_ (0W^V?[3OYH?+_M'[/Y>U V
M<^6^<YZ<5\T_\/0_^J'?^7-_]S5_.'B)E>/Q7%=:I2A=-0ZK^5=V?KG"? G%
M>>9'3QF"P_/3DY6?/36S:>DI)[KL?65%?)O_  ]#_P"J'?\ ES?_ '-1_P /
M0_\ JAW_ )<W_P!S5\1_8>:?\^_QC_F?2?\ $+>._P#H#_\ *E+_ .3/K*BO
MDW_AZ'_U0[_RYO\ [FH_X>A_]4._\N;_ .YJ/[#S3_GW^,?\P_XA;QW_ - ?
M_E2E_P#)GUE17R;_ ,/0_P#JAW_ES?\ W-1_P]#_ .J'?^7-_P#<U']AYI_S
M[_&/^8?\0MX[_P"@/_RI2_\ DSZRHKY-_P"'H?\ U0[_ ,N;_P"YJ/\ AZ'_
M -4._P#+F_\ N:C^P\T_Y]_C'_,/^(6\=_\ 0'_Y4I?_ "9]945\F_\ #T/_
M *H=_P"7-_\ <U'_  ]#_P"J'?\ ES?_ '-1_8>:?\^_QC_F'_$+>._^@/\
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M_H#_ /*E+_Y,^LJ] ^'G_(M)_P!=7_G7P;_P]#_ZH=_Y<W_W-7UY^QW\8O\
MA>OP2M?B#_PCG]E>=?W$/V3[9Y^-CXSOV)U],5^B^&&6XW"<1RG5A9>SDMT^
ML>S/D^,^">)^'LH6*S##\E-R4;\\):M-I6C)OH^AZE1117] GY6%%%% !111
M0 4444 %%%% !1110 4444 %?F1_P5&_Y.UU#_L#67_HNOTWK\R/^"HW_)VN
MH?\ 8&LO_1=?(\:?\B=?XU^3/W#P _Y+F?\ UYG_ .E0/G:BBBORD_M ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(8Y?+7"C[*AX"T ?IO1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y1^W-_R:5XY_[ W_ +42O5Z\H_;F_P"3
M2O'/_8&_]J)7%F/_ "+ZW^"7Y,^@X3_Y*G ?]?J7_I<3\EJ***_"#_2 ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG7^-?DS]P\ /^2YG_P!>9_\ I4#YVHHHK\I/[0"BBB@ HHHH **** "BBB@
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MH[D 2(A3J=V 2/:Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<?\ !+G_ )-*T_\ [#-[_P"C*_,>OTX_X)<_\FE:?_V&;W_T97UW!7_(X?\
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M3A\90C6H34X2V:=T_F@HHHJ#<**** "BBB@ HHHH **** /VH^'?_)/]"_[
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MSWNIZLED[1I;Q*%+W<N/,1FB8R!@J_LI0 4444 %%%% !1110 4444 %%%%
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M#6W_ *-:OOBO@?\ X([?\E \:?\ 8&MO_1K5]\5^O\)?\B.GZR_-G\,>-O\
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M5\,[NWTB7Q+I-SJFM^));-;B6")(+J2.*&-_DR3:MN9@W#KC!R:N_P#!.O\
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MO\/3/_9_@B#[,!+JHA=A/J;.?F$4CY2)1@%(RY'SBO5:^._$'_!1^V\"Z/\
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M]$4445^K'\7!1110 4444 %%%% !1110 4444 %%%% !7YD?\%1O^3M=0_[
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M /B=;Q4_Z \%_P""Z_\ \TGTW]H_X)V?W_TU>C[1_P $[/[_ .FKU\R44?\
M$-\C_P"?E3[X_P#R ?\ $ZWBI_T!X+_P77_^:3],***^6/\ @H__ ,%/]/\
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M?K+\V?PQXV_\G%Q7^&G_ .FXA1117TI^3!1110 4444 %%%% !1110 4444
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M_P#1=?IO7YD?\%1O^3M=0_[ UE_Z+KY'C3_D3K_&OR9^X> '_)<S_P"O,_\
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M **** "BBB@ HHHH **** "BBB@ K]./^"7/_)I6G_\ 89O?_1E?F/7Z<?\
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ME:W,]K;ZGW/!>3Y;FWM_K<.;EY;:M6OS7V:[(]T_X;2_ZIK_ .5G_P"TT?\
M#:7_ %37_P K/_VFO"Z*_'/^(J\>_P#09_Y3I?\ R!]S_J=PY_SX_P#)I_\
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MG?\ VROT!_X)Y>%/^$,_9JL="^W_ &G9JEV_F^5LSF3.,9/\Z^3*^R_V*_\
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M#_B(OA]_T-\+_P"%%+_Y,YBBNG_X4W\2/^A<_P#)R'_XNC_A3?Q(_P"A<_\
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M0GQ+_P!@_P#]G6O&XC_Y)[&?]>JG_I#.?%?[K4_PO\CX4HHHK^&#\["BBB@
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M% !1110 4444 %%%% !1110 5\:?MJ?\EVN_^P?;?^@5]EU\:?MJ?\EVN_\
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MA'XIO;S4/"%[#9^*-+U3P[?Z7=Z5<2Q^;'#/;WT$,L;F/#[2N=K*>C*3Z%0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#?M+?\D)\2_]@_\
M]G6NYKAOVEO^2$^)?^P?_P"SK7GYMA:F/RNOAJ;2E4A**OM>46E??37L95X.
MI1E!;M-?@?"E%%%?S?\ \04XJ_Y_4?\ P*?_ ,K/E/\ 5_&?S1^]_P"04444
M?\04XJ_Y_4?_  *?_P K#_5_&?S1^]_Y!1111_Q!3BK_ )_4?_ I_P#RL/\
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MU_ZG#_RG_P#VRO/^HXK^7\5_F?4?ZQY-_P _?_)9?Y'F=%>F?\,Z_P#4X?\
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M#\'_ !_\):9\'WT2R2">UGFG:-;&V$8&R/$:2^6N%!M4;'R5MZ?X/\)^(O\
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MHHH **** "BBB@ HHHH **** /H+_@G_ /\ (U>(O^P?#_Z&:^HJ^7?^"?\
M_P C5XB_[!\/_H9KZBH **** "BBB@ HHHH **** "BBB@ HHHH **** /GW
M_@H!_P BKX=_["$W_H KY=KZB_X* ?\ (J^'?^PA-_Z *^7:_EWQ-X?S['\8
M5ZV%PE6I!J%I1ISDG:"3U2:T9\?F^%Q-7'2E"#:TV3?0****^!_U3XJ_Z *W
M_@J?_P B>9]2QG_/N7W/_(****/]4^*O^@"M_P""I_\ R(?4L9_S[E]S_P @
MHHHH_P!4^*O^@"M_X*G_ /(A]2QG_/N7W/\ R"BBBC_5/BK_ * *W_@J?_R(
M?4L9_P ^Y?<_\@HHHH_U3XJ_Z *W_@J?_P B'U+&?\^Y?<_\@HHHH_U3XJ_Z
M *W_ (*G_P#(A]2QG_/N7W/_ ""BBBC_ %3XJ_Z *W_@J?\ \B'U+&?\^Y?<
M_P#(****/]4^*O\ H K?^"I__(A]2QG_ #[E]S_R"BBBC_5/BK_H K?^"I__
M "(?4L9_S[E]S_R"BBBC_5/BK_H K?\ @J?_ ,B'U+&?\^Y?<_\ (****/\
M5/BK_H K?^"I_P#R(?4L9_S[E]S_ ,@HHHH_U3XJ_P"@"M_X*G_\B'U+&?\
M/N7W/_(****/]4^*O^@"M_X*G_\ (A]2QG_/N7W/_(*^R_V*_P#DA-I_V$+G
M_P!#KXTK[+_8K_Y(3:?]A"Y_]#K].\)LBSO+>*)5<7A:E./LY*\X2BKWCI=I
M*Y[&2X;$4L8Y3@TK/=-=CUFBBBOZ2/JPHHHH **** "BBB@ HHHH **** "B
MBB@ KXT_;4_Y+M=_]@^V_P#0*^RZ^-/VU/\ DNUW_P!@^V_] K\F\9O^21C_
M -?8_P#I,SQ,^_W%?XE^3/)J***_E@^."BBB@ HHHH **** "BBB@ K\R_\
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M$&]@"<!U4\J17V#0 4444 %%%% !1110 4444 %%%% 'T%_P3_\ ^1J\1?\
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MJZ9_V#X?_0!6A7]\X7_=H>B_(_2:?P+T"BBBMRPHHHH **** "BBB@ HHHH
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M4?:)O[_Z4?\ $-\\_P"?E/[Y?_(!_P 3K>%?_0'C?_!=#_YI+-%5OM$W]_\
M2C[1-_?_ $H_XAOGG_/RG]\O_D _XG6\*_\ H#QO_@NA_P#-)9HJM]HF_O\
MZ4?:)O[_ .E'_$-\\_Y^4_OE_P#(!_Q.MX5_] >-_P#!=#_YI/HO_@G_ /\
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M.^+'_!0KP+^W;%\5H=,B\%Z3#9-X.7PP)5OC&UV=YN?M"B//VKIY3?ZOKSP
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M?^)I/';_ *&__EOA?_E!-]K_ .F?ZT?:_P#IG^M0T4?ZD<+_ /0/_P"3S_\
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M_P"2#_B:3QV_Z&__ );X7_Y03?:_^F?ZT?:_^F?ZU#11_J1PO_T#_P#D\_\
MY(/^)I/';_H;_P#EOA?_ )03?:_^F?ZT?:_^F?ZU#11_J1PO_P! _P#Y//\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ?\ )=KO_L'VW_H%?9=?&G[:G_)=KO\ [!]M_P"@4 >34444 %%%% !1110
M4444 %%%% !7Q/\ \%2_A3_P4V\??%7P%X[_ &!ETRUC\$Z=?7)NKB^L!//?
M70\ED6&]5HOE@0J'..+F09ZU]L5\Y?M=_'#]O_X,?&+PS>?LZ_LIZ3\2OAQ/
M8 >*4M-76VUJWNS*X/E>;,L8C$?EL/W<FYMX9HQM) /!O^":W_!4/]I?Q_\
MM(W/["/[?7PL&@?$)+*:?1M233C:/>&*,RO'-""8R6B621)HL1LL9 '(8X'Q
M0_X)1?M':2_[37PQ^$C:)J>@_M$:[H^J:9KVHZIY'_"//!JDM[=1W46TO(N)
MY%C,6\G:NX*2<?3OAWX":I\=_P!KSPC^VU\1OA/>^"I_!/A&\TKP_HVM7-I+
MJEQ<79(DFN#9S30QQ11-*D:"5V9KF1F$>T!_2_VE_B#\2_AO\(=0UCX,?#NZ
M\4>+KQX]/\-:7#"S0K>3L(XY[EQQ%;1$^;*Y( 1" =S+0!\T:E\./#_B/2?"
MO_!-/0O%?F?#+X/>%=.NOCKXHN9!!%>Q00K);:.SYQ']H,9NKD9PENJIN_>U
MZW\)?^"C/[)7Q4\3>%O!/@SQ9=VD/C3[;%\/]0U'1I;2Q\0_8I?)N$LY'4 E
M'&T*X0MQL#52N_V'YM)_8*\:_LL>&_&+7/BKQMX;U7_A(?%]^"'U?7;Z%O/O
M9RO.QY"%V\[(E5!D**^(_A#^P?\ M4^/X?V0/@YK_P )-8\*S? /Q-KFJ?$#
M6]2C6.TB1M9@O+>.TF5BMVTL=N #%O"F0%B #0!^L5%%% !1110 4444 %%%
M% !1110 4444 ?HIX2_Y%73/^P?#_P"@"M"L_P )?\BKIG_8/A_] %:% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7"?M.?\D$\3_\ 8._]G6N[KCOV@+:"\^#?B"UN
M4W(]CAER1GYE]*<<RH9,UF%9-PH_O))6NU#WFE=I7LM+M*_5'B\29)B^)N'<
M9D^%E&-7$TJE*#DVHJ52#A%R:4FHIR5VDW;9/8^ **[;_A$?#W_0/_\ (K_X
MT?\ "(^'O^@?_P"17_QKH_XFW\./^@3%_P#@NC_\O/X2_P"*=/C9_P!##+O_
M  ;B?_F0XFBNV_X1'P]_T#__ "*_^-'_  B/A[_H'_\ D5_\:/\ B;?PX_Z!
M,7_X+H__ "\/^*=/C9_T,,N_\&XG_P"9#B:*[;_A$?#W_0/_ /(K_P"-'_"(
M^'O^@?\ ^17_ ,:/^)M_#C_H$Q?_ (+H_P#R\/\ BG3XV?\ 0PR[_P &XG_Y
MD.)HKMO^$1\/?] __P BO_C1_P (CX>_Z!__ )%?_&C_ (FW\./^@3%_^"Z/
M_P O#_BG3XV?]##+O_!N)_\ F0XFBNV_X1'P]_T#_P#R*_\ C1_PB/A[_H'_
M /D5_P#&C_B;?PX_Z!,7_P""Z/\ \O#_ (IT^-G_ $,,N_\ !N)_^9#B:*[;
M_A$?#W_0/_\ (K_XT?\ "(^'O^@?_P"17_QH_P")M_#C_H$Q?_@NC_\ +P_X
MIT^-G_0PR[_P;B?_ )D.)HKMO^$1\/?] _\ \BO_ (T?\(CX>_Z!_P#Y%?\
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M_P""Z/\ \O#_ (IT^-G_ $,,N_\ !N)_^9#B:*[;_A$?#W_0/_\ (K_XT?\
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M_P (CX>_Z!__ )%?_&C_ (FW\./^@3%_^"Z/_P O#_BG3XV?]##+O_!N)_\
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M4E&4N:2DT[3G!6M%W]Z^VAY915;[1-_?_2C[1-_?_2OJO^(;YY_S\I_?+_Y
M_ O^)UO"O_H#QO\ X+H?_-)9HJM]HF_O_I1]HF_O_I1_Q#?//^?E/[Y?_(!_
MQ.MX5_\ 0'C?_!=#_P":2S15;[1-_?\ TH^T3?W_ -*/^(;YY_S\I_?+_P"0
M#_B=;PK_ .@/&_\ @NA_\TEFBJWVB;^_^E'VB;^_^E'_ !#?//\ GY3^^7_R
M ?\ $ZWA7_T!XW_P70_^:2S15;[1-_?_ $H^T3?W_P!*/^(;YY_S\I_?+_Y
M/^)UO"O_ * \;_X+H?\ S26:*K?:)O[_ .E'VB;^_P#I1_Q#?//^?E/[Y?\
MR ?\3K>%?_0'C?\ P70_^:2S15;[1-_?_2C[1-_?_2C_ (AOGG_/RG]\O_D
M_P")UO"O_H#QO_@NA_\ -)9HJM]HF_O_ *4?:)O[_P"E'_$-\\_Y^4_OE_\
M(!_Q.MX5_P#0'C?_  70_P#FDLT56^T3?W_TH^T3?W_TH_XAOGG_ #\I_?+_
M .0#_B=;PK_Z \;_ ."Z'_S26:*K?:)O[_Z4?:)O[_Z4?\0WSS_GY3^^7_R
M?\3K>%?_ $!XW_P70_\ FDLT56^T3?W_ -*/M$W]_P#2C_B&^>?\_*?WR_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M2^.W_)(M>_Z\O_9EKK:Y+X[?\DBU[_KR_P#9EKQ>(_\ DGL9_P!>JG_I#._*
MO^1I0_QQ_P#2D?(E%%%?PB?T2%%%% !1110 4444 %%%% !1110 45^7W_!P
MY^W#\5_!W[/MW\(OV?+^>QT5O%=KH/Q \765RT;K=R6TMXFDV[KR6$4*R7#
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M+:'^"/\ Z2@HHHK([@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ^\)/^2&P_\ BJ?^ER/Q'C3_ )*&KZ1_])04445^E'RH4444 %%%% !1110
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA]8K_P [^]F7_P (9X:_Z!O_ )&?_&C_ (0SPU_T#?\ R,_^-:E%'^K/#?\
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M?] W_P C/_C6I11_JSPW_P! 5'_P7#_Y$/K%?^=_>S+_ .$,\-?] W_R,_\
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MW\*7HSKP'^_4O\4?S1X)1117RY^PA1110 4444 %%%% !1110 4444 %%%%
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M\J;;O>-[OKLEILM-DCY;O/V#9M'_ .">WCK]DOPQXU:Z\6^.O#&K?\)'XTU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#]/\CYKBO_D6+_$OR9UU%%%>Z?G 4444 %%%% !1110 4444 %%%% !1110
M5XM\;_\ D?9?^O:+^5>TUXM\;_\ D?9?^O:+^5<&8_[O\SZ;A3_D9O\ PO\
M-'(4445X1^C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!](:3_R"K;_KW3_T$58JOI/_ ""K;_KW3_T$58KZ
MJ/PH_%JG\1^H44451 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_E7M->+?&_\ Y'V7_KVB_E7!F/\ N_S/IN%/^1F_\+_-'(4445X1^C!1110
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MK%5])_Y!5M_U[I_Z"*L5]5'X4?BU3^(_4****H@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"
M^)W_ "(6J?\ 7M_45NUA?$[_ )$+5/\ KV_J*SK?PI>C.O ?[]2_Q1_-'@E%
M%%?+G["%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'HG[/7_(5U+_ *]T_P#0C7JE>5_L]?\ (5U+_KW3_P!"
M->J5[^ _W9?,_,>)?^1O/T7Y(****[3P0HHHH **** "BBB@ HHHH **** "
MBBB@#SS]H7_D$Z;_ -?+_P#H(KRJO5?VA?\ D$Z;_P!?+_\ H(KRJOG\?_O3
M^7Y'Z=PU_P BB'J_S84445QGO!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7M7P1_Y$&'_KXE_P#0J\5KVKX(_P#(
M@P_]?$O_ *%7?EO^\/T_R/FN*_\ D6+_ !+\F==1117NGYP%%%% !1110 44
M44 %%%% !1110 4444 %>+?&_P#Y'V7_ *]HOY5[37BWQO\ ^1]E_P"O:+^5
M<&8_[O\ ,^FX4_Y&;_PO\T<A1117A'Z,%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TAI/\ R"K;_KW3_P!!
M%6*KZ3_R"K;_ *]T_P#015BOJH_"C\6J?Q'ZA1115$!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %87Q._Y$+5/^O;^HK=K"^)W_(A:I_U[?U%9UOX4O1G7@/\ ?J7^*/YH\$HH
MHKY<_80HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,W_A?YHY"BBBO"/T8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5A?$[_D0M4_Z]OZBMVL+XG?\ (A:I_P!>
MW]16=;^%+T9UX#_?J7^*/YH\$HHHKY<_80HHHH **** "BBB@ HHHH ****
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M)?DSKJ***]T_. HHHH **** "BBB@ HHHH **** "BBB@ KQ;XW_ /(^R_\
M7M%_*O::\6^-_P#R/LO_ %[1?RK@S'_=_F?3<*?\C-_X7^:.0HHHKPC]&"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#Z0TG_ )!5M_U[I_Z"*L57TG_D%6W_ %[I_P"@BK%?51^%'XM4_B/U
M"BBBJ("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)_ 5KIAFU&3P4I&IZ[J+NZB*>3>GEVD*(C>6I/G-.V[;Y2D_$O\ P;T_$?\
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M +-__!,SXH_%WX 7UU9>)[#3K2"UU2R7,VGPW%];V\]S'CE72&61@XY0X?\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"^)W_ "(6J?\
M7M_45NUA?$[_ )$+5/\ KV_J*SK?PI>C.O ?[]2_Q1_-'@E%%%?+G["%%%%
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M114FH4444 %%%% !1110 4444 >B?L]?\A74O^O=/_0C7JE>5_L]?\A74O\
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MWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\
MH;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_ .%E
M<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C7NE%
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M_P"AM\=_^%E<_P"->Z44 >%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\
MX65S_C7NE% 'A?\ P[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^->Z
M44 >%_\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XU[I10!X
M7_P[W^"?_0V^._\ PLKG_&C_ (=[_!/_ *&WQW_X65S_ (U[I10!X7_P[W^"
M?_0V^.__  LKG_&C_AWO\$_^AM\=_P#A97/^->Z44 >%_P##O?X)_P#0V^._
M_"RN?\:/^'>_P3_Z&WQW_P"%E<_XU[I10!X7_P .]_@G_P!#;X[_ /"RN?\
M&C_AWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\
M$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_
M .%E<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C7
MNE% 'A?_  [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H;?'?_A97/^->Z44
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MN?\ &C_AWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\
MAWO\$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&
MWQW_ .%E<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65
MS_C7NE% 'A?_  [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H;?'?_A97/^->
MZ44 >%_\.]_@G_T-OCO_ ,+*Y_QH_P"'>_P3_P"AM\=_^%E<_P"->Z44 >%_
M\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C7NE% 'A?\ P[W^"?\
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MFA>,]2M5L]$\0:O:^?!I#2R)')?>3TG>")I)DA8A99(T1F56+  [2BOYR?\
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M+!0@'[RT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAMW[*4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+\/]6O=4\":1-I7PZ_X2GQ;J.L0^#[";_66VEQ7D\B6:LN$W(-_E@1A@@VT
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>amgn-20211231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgn-20211231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_BG_ &7!K%O<)"+6^26T9W=X/+E,8*[&%PY#J5&[\YO@K^SI^SYJ?_!XM?\
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M6]<FT]M12Y,=[<06\L@,EK&!-(JJD4@7F1@_O?P7_9Q_X*':/_P<-ZI^VO\
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M^,=5FO\ 5]>^"GA74=5OKF0O)<7,^D6LLLCL>69G9B2>I- 'M=%%% !1110
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M"M<U6UNM3OYHM/33+)I4MI'6%(8(UF9F8$S*@0.FYAT7_!(__@AI_P %#O\
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M'[>^C^'(A\,+O3/^$E^(RI(BJWB#3%2&V@*9&Y+K=9NZ[2'6VN]Y^<9^[/\
M@IE^Q/HO_!1/]ACXB?L>ZQK::7)XOT=5TG59(RR66H6\T=U:3.!R46XABW@<
ME-X'6O=J* /PT_X(U>$/^#A3_@E-H&L_L%ZE_P $UM+^(GA*?Q!-=>%_%.H?
M$VSTS3-!DFP)K@W*+.T]FQ43>0(DG#-)@;GV#]D_AS\*]53X<:)IG[0-_I'C
M7Q7;VC-K6N2Z'#'#)<R.TDB6\1!,5NC,4B1BSB-$WO(^YV[BB@#-T/P9X/\
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M_!*SPYJ_[!&I_P#!-72_B%X3E\03W7A;Q5J7Q-L],TS09)B/.G-Q&L[7%FS
M3>0L23AGDQ\S[!Z]_P '&W_!-W_@J'^VU^PY\)?A3^SYXA'Q(UC0/$%S?_%+
M1;"]M=(36+J9%-O<013RQQ_9K5VN(XX7D:14EB+&5D>2OUKHH _GH_X*W?\
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M> _VO/V.]=T>3Q'<66L^';G2_%WAV_2_>VAFC>R'DZD3'.Y="C2!83\V^2/
MSYG_ ,$-O^"9_P#P4T_8O_X+"_$O]L']H[]B'6M$\$?$[2_$%A!J%OXY\-7D
MFD-?ZS::A%+<Q0:FTC(J6S(WE+(VYAA6&37[D44 ?A;^R/\ \$X_^"[W[,G_
M  7%^+G[7FG_  ;\!^*=.\?76L6$?Q0^(?B:.;3[;2KJ]BGMY[>WMI_MJR11
M6\,*VPC10BM%OC0K*-3_ (-]?^"4_P#P5!_X)L?\%)OBGX@^-_[/.BR>!/%&
MGW.G3_$/_A,;1()HUO1<17%G9PM-/*9@N/*E$/E!B7?<HC?]OJ* /Q'^.O\
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MVZ6>VN;E9(UEF7SA+%YKX,:[F:)17[944 ?@[\5/^"5/_!9[3O\ @X&\*?\
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MCXD:4^K:C-#IT=JVIN9YX(+2V/E!4MP\LY:1B^Q44R?:_P"U1^S?^VM\5?\
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M^"-RJ>*]WHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVZ@W#2/(ZI*P(38HC.YE)0, ?5E%>'_LL_MW> OVL/%WQ \(>$_A-X[\.O\
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M&--1GFN(K6UDE,9>.$S&9XRC^6%=20#]'Z*^>'_X*9?L]:__ ,$^_P#AX_\
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MT?5++Q?I4-K<B7RDE251#-,C1NK\'?N&T[E7C(!]+$@#). .IKYMA_X+#?\
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MNGDGGP\S -*[OM RS'D@'].=<C\:/C_\#/V</![_ !!_:!^,7ACP3H:/Y?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _,;_ (.Y?&7Q \)_\$<-
M>L/!%Q<16FN^.M$T[Q,]N2/^)>9))MK$=%:XAME/8[L'KBOF[PUIFC67_!D5
M+;F&,POX+NIB,#!F;QE(X/U\PC\17[%?M4_LQ?"#]LS]GKQ7^S#\>?#QU/PI
MXPTMK+5+>.39+'\RO'/$^#LEBE2.5&P=KQJ<'&*_/6+_ (((_M9VW_!/6;_@
MD/;_ +>7AG_A0\OB3[8NL/\ #:8^*4TPZC_:9TP2"_%K@W?S>?Y><$C9M.R@
M#QG_ ((*^+O'OB;_ (-=?CAI?C*XGDL="T7XA6'A?SR2%L#H_P!H94S_  BZ
MGNNG&<UF_P#!D'_R;'\=/^Q\TS_TB>OTKU+_ ()Q^'_AM_P3:N/^";7[&OC#
M2_A[X?G\&WWAG^V]>\-2:W*+:]@GCN[HQQW=INO)))WF\UG*!RW[HJ0%\8_X
M(F_\$5/B-_P1MLO%_@[3_P!K_2/B'X8\9W]O?:A83_#"32[RWN88I(U:*Y&J
MSH$(=2RM"Q.SAER30!]_5^)_[(WAO]E/X+_\%0OVA/@__P $8_[?\;>/O$>G
M:C/\8_'GQ&UWS_!G@2#[6TD\%E;VR17.KW1N6,:(TR@8.+@JLQK]L*_)?]D3
M_@UM'[)'[7?B_P".'@G_ (*.?$;3O OBM[F&_P#!7A*U;2;_ %#3YIO-^PW>
MII<.SHIPIEABBF(R4>%CF@#Y1_X,<)9!X_\ VCX YV-H_A=F7/!(EU3!_4_G
M7]"U?FM_P1R_X-\==_X)$_M$>-/BGX0_;@U?Q+X2\41)"O@I/!MM9FY2(S?9
MC>W3R3/(81<28$ @#OM9OE'EU^E- 'Y#?\'#W_!+3]AK]N/]C&__ ."D/PCL
M;;3_ (ALNA?V/XUT%O)MO$-O>ZE9V$?]HQ%,R[$N<B3"SKY:HS%5\L?.W_!M
M=\?_ -NW]A?_ (*;^+O^"(G[5NI7=_HNEZ7?S:=I$]XUU%H-Y!%'=QW%E*W*
MV5U;2&01X +2Q.%1C(&^K_C/_P $F/\ @IA\!?V*?&/[)?[,/[5WAOXJ_#[5
M?%NGZMX=\%>-O!+6^M:&O]OVNH206NH1ZC'#) C+),RRQ@E0Z1["5KZ<_8M_
MX)6Z/^SW^UG\0_\ @H;\?_BJGQ(^.GQ+MX[/5?$EKH TK3-&TZ..&-+'3K,S
M3O$@2W@1I9)I)'6%>5+2;P#X"_X/=/\ DS[X+_\ 92KO_P!-\E?H_P#\$A;2
M/4/^"27[.EA,S!)_@7X:C<J<$ Z7 #C\Z\(_X++?\$3_ (Y_\%B;#PUX*\9_
MMO\ ASP-X4\(ZS>:CHVEZ3\'YKR[EDF41I]HN9-:59"D0V@I%$"7=B.55?I?
M_@GG^RW\:?V,/V9O"7[,7Q.^/7A_Q_IG@;PY::)X<U32_ 4VB7/V6W4QQ_:-
MVHW:2L(Q&F46/[F3DG@ _$/_ (,WO >O?"'_ (*-_M#?"#QE;&WUKPWX,DTO
M4[9U*M'<6NKQP3*0>1AUQBLK_@WE^%FM?$?_ (..OV@/&EO;RC3/#;^.I]2N
MDR%4W.L"UCCS_>;S78#TB8]J_6+QA_P21\9_!_\ X*'>(_\ @I=_P3W^+'A;
MP7XQ^('ARXTCXC^$_''A>XU+1=7>22&7^T(A:W5O+;W/F6\3.,LLA+GY&=RW
M:?\ !*?_ ().?"K_ ()?^!?%4NF>-+KQK\1/B-K;:Q\1_B!J%@EK)JMT7D=8
MXH%9A;VZ--,RQ[W.Z5R6.5"@'X_?\&;W@/7OA#_P4;_:&^$'C*V-OK7AOP9)
MI>IVSJ5:.XM=7C@F4@\C#KC%9_\ P;K?#?7_ !O_ ,'(_P >OB'8VTG]G^%+
MCQQ=W]R!\@:XUD6T49/]YO-=@.XB8]J_5WQA_P $D?&?P?\ ^"AWB/\ X*7?
M\$]_BQX6\%^,?B!X<N-(^(_A/QQX7N-2T75WDDAE_M"(6MU;RV]SYEO$SC++
M(2Y^1G<MVG_!*?\ X).?"K_@E_X%\52Z9XTNO&OQ$^(VMMK'Q'^(&H6"6LFJ
MW1>1UCB@5F%O;HTTS+'O<[I7)8Y4* ?6%?R[?\' 7_*S7H'_ &,'@'^5G7]0
M>I1ZC+IUQ%H]U!!=M XM9[FW,L<<F#M9T5T+J#@E0RDCC<.H_(_]MO\ X-C/
MC=^W%^WA<?\ !0#QO_P4ET+1/%(U#2[K3=,T;X%R&RL_[/2);=0)==9W_P!2
MK,2WS,S8"C"@ ]B_X.K_ /E!_P#%7_L+>'/_ $^65?GY\/=,TVW_ .#'OQ=/
M;Z?#&]SK/G7+I$ 99!XZM$#L1]Y@J(N3SA%'0"OU:_X*9?\ !.7X_P#_  4O
M_8<N/V-?&W[5?A+PM)K>IVMSXJ\2:1\*;F9;N.VN(KB"*VMI=9S;'S8E+L\L
MVY> $ZGPC1_^" 'QHT;_ ((ZZI_P1WA_;TT!O#6I>(%O#XP/P:E^VQV8U%-3
M:U$7]M["YNXT/FYXC+)L)(D4 J?\&GND:5XO_P""(FA^%/%&GPW^FWOBKQ'9
MWEC=H'BFMY+EA)$RG@JP=@1T.XU^:_["7QLU;_@V_P#^"WWQC_9/^(.F:OJ7
MP[\3Z?=VVBV%I&\L^J*(I+[P])&%!,L\F_[#QD"6[DS]PX_;7_@CI_P35\;_
M /!*;]ER;]E+7/VBM.^(VBV^N3ZEH5_;^!GT6YM3<'=/'-F_NEG4L%*%1&5^
M8'?D;:_[6_\ P2)^"?[6W_!1;X%?\%!_%UU#%JGP=%R+[2FLPXUS83-I99\C
MR_LEV\DXX.XOC@"@#R#_ (**?#SXJ_L8_P#!O!\8]/M=3\SXB:IX+O-4^(>K
MZ<2#=:QK=^DFMS(P.?+!O+I8^?DACC4'""OBW_@A#^S3^T+_ ,%"_P#@@GXJ
M_8_^&O[1/PQ\+^#M:\2:UH/B>#4/AI?:EK=G/*\%UYOVB/6((22DD)3-OPH
M)8C-?N7\5_A=X$^-_P ,/$/P;^*/AZ'5O#?BK1;G2==TR?.RZM+B)HI8R1@C
M*,1D$$=0017Y-?LI_P#!M7^VQ_P3U^.GB'6_V ?^"OFJ_#_P#XIN$&KZ7=?#
MJTU.^>U1F,<;I<N]I)<(K,JW0BC8;V(0 E2 8G[=W_!O/\:?%'_!&;X8_L"?
M"[]IO2_'/Q+^#7B?5M9\$)J$2Z2OB*TFDGFGTV-)+B7RYHA.OENS[!L"-Y:O
MN3R3_@A)_P %BOVA=>_;<\"_\$R?^"KGPRU+4?B#X1O[^Q^&GCGQ+:S6WB#0
M-0.GS1RV&H;MINHYK;<BRN"Q?RF?S<I+%^HW[0?_  3/\;^*/AS\'/"W[*7[
M4^K?#;Q%\(O&]SXEC\;:OI(UV\UZYN+.]BNS?H\L(N3=S7;R7!++N#.$"$H4
MXKX>_P#!(SQ]\0/^"G.A?\%4?VW_ (L>#/$/C3P3X270O!7ASX=>#)]*TZ)@
M+E?[0NWNKNYEN)PMW.J+D+&/+(9C&* /R\_:G_Y77/#7_8W^%O\ U&+2OK/_
M (/3_P#E%;X'_P"R]Z5_Z9M;KUC]OO\ X-_=3_:=_P""DGA3_@J%^S/^U_/\
M*/B'HL^GRZJ+WP7'KEM=36<8AAN(XWN(0C>0JQ/&V]&"@C8<[NK_ ."JW_!%
MWXD_\%./V3? O[(FH_MO3Z#I/A7Q(OB+6_$OB'P*=;U;7=5$5W'YID34+2&V
MA/VVX(MXXMB?NTC\N.-4H ^!OV^]*TO3_P#@S8^$$-AIT$"?8?"T^R&(*/-D
MO7:1\ ?>9G=B>I+$GDFG>'-*TNV_X,;KJ6VTZ"-KK3YY[EHX0IFE'Q *AV('
MS,%1!D\X11V%?9GQM_X(2?&WXW?\$E/!/_!)W6?VZO#UIHWA"^@\[QC!\')F
MNK^RM6\RSM_(.M;(G1R^^7<PD7RP$C*LTC;;_@A)\<[3_@C8_P#P1OB_;N\.
M?\(VVH$CQF?@U-]N%@VK'5FMO*_MO9YANSCSLX$64\O=B0 'Q'^P;X_\?^ O
M^#-KXQ^(? %]<Q:C'<:]IZR6[$/%9W6H6MO=X(Y \B><DCIDFM?_ ((5?LS?
MM"_\%#_^"!GB7]C[X;_M%?##POX-UGQ'K.@^)H+_ .&E]J.MV=Q)-#=^;]H3
M6((2Q22$IFWX4 '<1FOT0_X)D?\ !'B+]A+]A+Q;_P $\?C9\;-(^+GP_P#%
M,NH!XO\ A!9-%G6WOXC'=V\S?VA<B56&"C((F0EN6RNWY4_90_X-K?VVO^">
MGQQ\0ZO^P+_P5^U;P!\/_%-P@UC2[GX=6FIWTEJC,4C9+EWM)+A%9D6Z$4;#
M>Q" $J0#"_X*P?L4>)_^"=O_  :P^(?V.O%'QM3X@R>#=?TN*T\1)I!L<P3>
M)H;E8/*,TQ7R_.*#YSPH    'A/@S3--M_\ @QS\3W%OI\,<ESK(FN)$B :6
M0>/;5 [$?>8(B+D\[5 Z 5^HO_!0+_@D1>?MA_\ !/6#_@G;\+/VC!X'\/W6
MI0WWBKQ1XC\*R>(M6UNX2[6^>YDE^W6@%Q/=AIII6#[RY"K&*\=TW_@@!\:-
M,_X(YW__  1UB_;TT!O#-_X@6\;Q>?@U+]M2S&I)JAM1%_;>S>;Q%/G9XCW)
ML)(D !YU_P &^$\TW_!L[XHCDD+"+1O'BQ@G[HVW)P/Q)/XUXI_P8X_\D[_:
M._[#7AC_ -$ZG7Z1_P#!*7_@E=K7_!.3]BW6/V&?B+\?--^)_A*_NKY[*>#P
M3)HES%!>JXNX)C_:%T)@Q;Y&41% 6!WY!7PS_@E[_P &]GQ _P""7GQN\6ZG
M\*_^"A7B"Z^%?BK6=/U&_P# EMX/@M-1OC82RRV<-QJ8F=A&IE99A!'#]I0E
M&V*2I /TTK^=G_@C9XC\:?$G_@[*^/?BKXM2S2:Y::CXZAC6Z)+0);ZA':01
M+GG9';*L:_["CM7]$U?"'QU_X(RWEG_P4ITW_@K!^P_\7='\"?$R2SEL_&WA
MWQ1X<DU'0O$\4EO]G>5U@G@FM9S&$)=&97>&-BH/F&0 _,:P\5^,?"'_  >T
MW\'PSEE0:MXJ6QUBVMR=EQ9R>$HWNA(!]X+L,O/1HE;J :J?M^V%CJ7_  >6
M_#RTU&RAN(O^$S\$OY4\8==RZ=;,IP>,A@"#V(![5^J'[ __  1AT']FK]LW
MXA?\%*/VD?BK:_$;XX?$2[N';4M-T$Z=I/ARVFVJUM86[S32$^6B0^?)(7\I
M-H W2&3Q_P"/G_!O-\:OC?\ \%8;+_@K(G[?OA_2O$ND>)M+U/1O"@^"TT]C
M%#8110PVTLG]N+)+NCB DD79N9V*J@PH /A;_@JV[6G_  =\_ Z:V.QI/%WP
M]#LO!8&YC4Y_X#Q]*_HLK\OOVMO^#>?XQ?M1_P#!4_1O^"I<?[?.A:#KGA;Q
M)HVI>&/"G_"FI;JT@ATR6.2WM[B7^VXWG+;/WCJ(MV]MJQ\ ?I[9K=I:1)J$
M\<MP(U$\L,1C1WQ\Q52S%03G +''3)ZT ?C3_P 'LW_*/OX5_P#99(__ $TW
M]?5?_!LO_P H.?@1_P!@_6__ $_ZC4'_  6B_P""-_QB_P""P_A'P_\ "?6?
MVR- \ >#O#/B$ZSI^GVGPHFU&_EN?LS0#SKIM7B1E423$!(4^^,D[<G%_9I_
MX)!?\%!?V7/V+-*_8'^&?_!6C2](\$:3;WMK:ZUH/P%6V\10VUW<RW$T<-[+
MK,T<+;YY=LH@,B;@58%5( /Q=\)>!=4_;P_X.P;J?X,Q-?Z=I_[2S:[>:C9C
M=$FFZ)?K-<7.\<!'6S(1CPS2Q@9+ 'Z+^.GQ;^,EW_P><0VMKXY\/:#K&FW4
M'ASP3?>.-$N-2TW3X[CPD?(C^S0W5K(_GRW4FS;,N);O=AN5/Z^_\$Q_^"./
M[%W_  2D\*:A8_LZ>%[_ %#Q-KD*Q^(_'GBBY2YU;44#;O*WJB)##NPWE1(H
M)52^]E#5X#_P68_X-W/!O_!3?XS^'_VMO@K\?+KX3_%K08+:"77K?36N+?4E
MMGWVLK>5+%)!<PD_)<(S':J*5^164 V?@A_P1M_:#^'?_!8K4?\ @KO\3_VP
M_"VHZQXFT1])\1^!?"?P[N=*M-1B728K*%$EN-4NG7#6EM.P8/EH3C:,;?SP
M_P"#/KXX0?%']MG]J'PI\>[A+[QO\2]$AUS5(]47,EZ8[^Z&HHP?DYDU",LO
MH#Z5^N?["?["?[4GP>U.P^*'[?G[=FK_ !Z\;:)8R6?A-Y?#-IH^E^'HI%V2
MRQ6]LH-U>2)F-KR<M*(W>--HDE,GQO\ M7_\&P?BB^_;QF_X*!_\$U?VVKOX
M&>*M2UF;5K_3AH!NH;2^GW?:9;5TE3$,Q=R]K(CQGS'&0A$8 .H_X*!_\$]/
MV=O^"0'_  1"_:GMOV O"&K:!/XRT6.37)KG6Y[R;[-/<PV<L2/(Q*11VEQ<
M@#[V'8LS'FOF+_@AE^S%^T+_ ,%%/^" WB#]CWX<_M%_##POX+UCQ#K.A>)8
M;[X:7VHZW97#W$5YYAN4UB"$L4D@9,V_"X!W$9K]7?@=_P $_P#^QO@!XR^%
M'[8_QY\0?';7_B9H9TGXB^*/%%M%8Q7UD898EL[.QM<0Z?;HL\S*L>7,DSR-
M(S%=OP/^R;_P;7_MN_\ !/3XW>(=3_8*_P""P&K> ?A]XIN4_MC2[CX=6FI7
MTELC,41DNG>T>X169%NEBC8;F(0#*$ R_P#@JO\ L6>)O^">/_!JOXJ_8[\4
M?&Q/B!)X,U72H;7Q&FDFRWP3>*[:X2#RC-,5\KSC&/G/"@8   \F_9/TK2[?
M_@RO^(,]OIT$;W=CKT]T\<0!FE7Q"$5W('S,%CC4$\X11T K](_V_O\ @DC=
M_M??\$\$_P""='PJ_:('@?P]?7\%WXI\4>(_"TGB+5M9GCO5OWN7E^W6@%S/
M>*TTTK!]YD8*J=O*OAO_ ,$)/C;\-O\ @D#XD_X)$Z=^W5X>N-"UZ_E,/C*7
MX.3"[M+&>[^V7%OY UK8\C3 ;9=P"(74QN2KH ?&?_!#[2M+C_X-3/VLKZ/3
M8%GN=(^(IN)EA4/*4\,P;"QQEMO;/3M7H_\ P9)3S-^PY\7K5I"8T^*Z,J9X
M#'3+8$_CM'Y5]!_LC?\ !"3XY_L@_P#!,GXL?\$S?"/[=WAS4]%^*!U)/^$H
MO_@U,MUI<.HV4=E?1K$NM[)MT,8\MB5\MV<GS 55>W_X(C?\$;/''_!'#P?X
MS^&)_:OT[XC^&_%VI1ZH+<_#I](N[.^2-(BXG_M*Y22(QJ 8S$&W88/C*D _
M,/\ X,O0O_#;'[1)P,_\(I:X/_<2DK._9%L?$'A[_@]#\6Z?\+(GAL+CQYXK
MD\1QVHQ$UO+HEU-.9<=C=%&Y_P"6FSO7WE_P3W_X-]?C9_P2J\8W/QU_9!_;
M'T75?&_BG2;K3_B#I7Q"\$R3Z%?1R3K/;O:+:74-S;20.N-SR2B4._RQ9 'N
M/_!,K_@C5X,_84^-GQ&_;+^+7Q3;XE?'+XKZG=W?BGQD=&&GV=C%<W/VF:TL
M+7S)6AB:79N9I&++#$ $"E2 ?E!_P2R^*O[1?C7_ (.A/VG1X9^)?@_P_P".
M]>N_&FC:==?$/PO=ZQ"UO9:U;>7900V]_9NLB6EDNU_,8"*V<;#N#+^F_P#P
M32_X(Y?%C]A'_@H#\:/VW?'O[6NB^*W^."W]]KW@O0/ \VDVMOJ,^I+>BYC:
M6_N69(O,N(PK9;%SDO\ WO+/^"D'_!MC>_M(?MQ6W_!1K]AG]KB[^"?Q.?4(
M=0U>1-&:YMYM0C01_;H&CEC:"1T4++&5D2;+$@;GW_8G[(W[&_[0?P1\.ZM\
M1/VC?VP[KXP_&G5M#;38/'OB'PE;V6F:/;CYTM;32K%X$CA,HCDG*R)+=&*/
M?(HCB$8!^'?_  ;2?"'P3\3O^#@;XY>(?&FB6]^?!^E^+=6T:*ZB#K%>MKMM
M:";:P(RL-S< 'J"^17]$7P7_ &?/@/\ LX^'KSPC^S[\&?"W@C2M1U274K_3
M?">@V^GP7%Y(%#SO' BJTC!5!8C.%4=  /ST_P""7?\ P;V_%G_@F?\ MP>)
MOVT]+_;RT7QG<^-["^L?%V@7GP>ELEG@N[Z"]E-M,FLO]GD$L"A69)5"LP*,
M<$?IW0 5^'G_  = ?\$(/@;J_P"S_P",_P#@IM^SU_:FD^./#4B:EX\TJ[UF
MXO+77+&298Y9HQ<.YMIH?,$@6-EB,:. F[::_0S_ (+#_P#!,[QW_P %._@%
MH'PS^&/[5_B+X2Z_X5\41Z[I.LZ,LLD%S,D;HJ3QQ30OE2VY)%?,; G:V:X?
MP]_P3;_X*#_'W]FA/V._^"D?[>_AOQQX G^SP>)9/!/@";3/$/BBSAD206EY
MJ<EXT<<3F-%E:&T6>1=P\]2S%@#?_P"#>;XC_&3XL?\ !&SX'>-_CQJU[?\
MB";0+VV%_J3LUQ<6-OJ5W;V+NS<L3:16^&))888DDU^1?CW_ )78X/\ LHVF
M_P#J+05_0_9> $\ ?"NS^&/P(MM#\+0:)I,&G>&;:;16N+#3;>%5CBB%M%-
M6C6-0H59$Q@<\8/YA:S_ ,&WO[16M?\ !40?\%89_P#@I1X<7Q^OB^'74TA?
M@/+_ &8/*@6V6U*?V_YAB^SH(R?,W]6W \T ?J;XU\<^"?AKX7N_&_Q%\8:5
MH&BZ>@>_U?6]0CM;6V4D*&DEE9409(&21R0*L>&_$WASQEH%GXK\(>(+'5=+
MU"W6>PU+3;M)[>YB8962.1"5=2.0P)!KY*_X*]?\$RM0_P""I7[!T?[,_P 2
MOVCK?P5JFE:_:^(I_%^EZ RZ=)+:QSHRSV<EV6%N8YW;!N#L>.-\G9M/G/\
MP;-? +Q[^SG_ ,$V)_ _B/QI>^(?"]Q\4?$-Y\+=9OK)K4ZAX8,Z16EZENSN
M8(KIXI[Q$W,-MT&#,&#$ _0=F5%+NP  R23TK\OO'_P8\)_\%T/V\_#7QF^)
M5Y9']E;]GS5KE/!]M>7""/XG>)Q(JW-XJDXDTJW:%85D(*SM'*$+1ROM^RO^
M"C_[*OQS_;5_97US]FKX%_M3GX03^*!]D\0>*K?PFVK74FF,K">T@47EMY#2
MY56EW,?++J%!<.OX\_\ $#'_ -91?_,)_P#WZH ^DO\ @ZHU+PI^U;_P14U3
MXK? WQ'!X@T+P'\8+&;5-3TW<\!:VGN]'N0C@;9%CN[GRBZY7<C $XKYW\87
MD4G_  8TV1B8$/:VL>1ZK\0ES^JFOUE_9E_X)I_!GX'?\$T-#_X)B_$.2'QO
MX/L_!MQH'B"XGT\V0U87+RRW$XB620V[-+,\B[9&9&P0^0#7R4/^#?GXWS?L
M50?\$H+W]MK33^S9;>-3K2"/P.X\7/IYOFU :2UV;LV@7[4QE^TBVW%@/W8'
MRT 6?^#17X9:_P##_P#X(X:'XAUNVDBC\8^/-<UK3A(""UN)([(, >Q>SD(]
M1SWK\]O'O_*['!_V4;3?_46@K^@WP%\%-#^ _P !-&^ G[--EI'A73?"VAV^
ME>%8;[3);VULH(55%$D23PR3':#D^:K,S%F8DG/YJ:S_ ,&WO[16M?\ !40?
M\%89_P#@I1X<7Q^OB^'74TA?@/+_ &8/*@6V6U*?V_YAB^SH(R?,W]6W \T
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M5WD=@ -SG 50%'I= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!@?$GX6_#OXQ>%G\#_ !4\'6'B
M#19IHY;G1]5@$UK<E&W*LL3?),F0#L<,I(&0<"MV""&VA2VMH5CCC4+'&B@*
MJ@8  '04ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBO$O NJ:G+^WIX[TB749VM(?!&EO%:M,QC1C(V6"
MYP">YH ]MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOP#_R
MD$\?_P#8B:5_Z,:O=*\+\ _\I!/'_P#V(FE?^C&H ]THHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+IOQ)TGQ5JGACPS\1M<_LFY:TN1-+]GM?MP2QNG VI=0[7A.&4< 5],_!?\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%0:IJ>GZ+IEQK.K7:6]K:0/-<SRMA8XU4LS$]@ "?PJ>L+XH^$4^('PS\1>
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MLV28C$XO*:-;$+WY13?^?S6OS"BBBO?/4"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KPOP#_P I!/'_ /V(FE?^C&KW2O"_ /\ RD$\?_\ 8B:5_P"C
M&H ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK@_VBOVE/A%^R
MS\.KCXE_&'Q,EC9QY2TM8\/<W\V,B&"/(,CG\ HY8JH)&.(Q%#"4)5JTE&$5
M=MNR2\V9U:M*A3=2I)**U;>R.I\9^-/"?PZ\+7WC?QUXBM-)TC3;<S7^HWTP
MCBA0=RQ_  =22 ,DU^9W[1G[:_[17_!33XD3?LI?L1:%?6/A"4E-9UF3= ]]
M;YVM-<R8_P!&M/2/[\G0@EA$,>2?]KS_ (+7?%7R8%F\&_"/1+_DG<UM 1Z_
M=^VWA4].$C#?P!LO^CO[.'[,OP@_94^'4'PU^#_AI+*U7#WM[+A[K4)L8,T\
MF 7<_@JCA0H %?G<\1FG'DW3PKE0P&TI[3K=U"_PP[OKMWBODI5L;Q/)PH-T
M\+UEM*IY1[1\^OWH_.'XR?\ !K;\.O$&AV/Q$_9W_:PU_P"'GQ:-N!XG\0C1
MXM0T;Q 0.$FT]W39MQM259"P!8LKG&W@/!/_  ; ?M;^,M72P_:1_P""G$%E
MX;WXO;#X:> 4M+^]BZ$+>7$I^RL1SN$<@R2,=Z_9RBOKH\,\/KV;>%A)TTHQ
M<HJ32BK)7=V[=+L]Y9-E2Y+T8MQ22;2;26VKN]#R/]BK]AO]FG_@GU\$+3X
M?LN?#V+0M#@F:YOIY)3->:I=L )+N[G;YYYFP!N/"@*JA455'KE%%>YL>F%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X7X!_Y2">/_P#L1-*_
M]&-7NE>%^ ?^4@GC_P#[$32O_1C4 >Z4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :51WM[9Z=9RZAJ%W%!;P1-)//-(%2-%&69F/
M   ))/2N7^(7QT^$?PI\(7OCWXA>/+#2M)T^(R75Y<R'"CLH !+L3P%4%F)
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M?$?Q# Y\O3!+8P2+'IMHZDS,6#3S86-=L8F'Z$?\$ZO^"JW[)W_!1_Q?XO\
M!O[$<-UJ?@CX;Z+I,=UXFDT:?3+8W5V;I8["VM9XHWVPPVFYFVJH\V-5!Y(\
MJ/\ P:Y?\$*"<G]AK_S)OB?_ .6=>^?LM_\ !++]A7]BGX.^,?@+^RU\%[GP
M;X9\>[SXIMM.\8ZN]S=%H# 62\ENWN;=A&2%:&6,H264AN: /S0_X*C?\%>_
M^"7O[7'[:$7[$_[5O[4HT7X _"36X=0\>:=HV@:EJ+?$?Q# Y\O3!+8P2+'I
MMHZDS,6#3S86-=L8F'V[^S!_P4(_9#_X+&?#_P",/[,W[&;W5[X T7X=0Z#J
M/BR71I],MEN-5M[VV2RMK6>*.3;##!N9MJJ/,C50>2.5/_!KE_P0H)R?V&O_
M #)OB?\ ^6=?2/[$7_!.7]C+_@G'X1UOP)^QE\&$\&Z7XBU)+_6H!KVH:@US
M<)&(U8R7UQ,Z@*,!58+R3C))(!^1'_!F9X<\0? 3QG^U_P#!;XLZ<VB>(_".
MJ>&X-<TZ]^1[:6U?6X;@-GLCJ 3T^8>M<Q_P9&_LT>*AXI^-/[86K:5-!HW]
MFV7A'1+QXR$O+AI?MEXJGOY2QV>?^NX]#7Z^?'K_ ()2?L<?M!?%O6OCMKGA
MOQ+X9\6>*]"_L3QMK/P^\;:CH$GB?3<!?LNHBQFC6Z7: FYQYFT!=^U0![!\
M!?@#\&/V7OA/H_P,_9]^'&F>$_"6@6_DZ5HFD0;(H5)+,Q))9W9B6:1RSNS%
MF)))H ["BBB@#$E^&GPXGE:>?X?Z([NQ9W?2H26)ZDG;R:\9^&/AWP_I/[?/
MCVPTK0K.V@3P-I92&WM41%)D;)  P,X'Y5] UX7X!_Y2">/_ /L1-*_]&-0!
M[=_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/
MC#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/
MC#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/
MC#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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M?Y8+O)_IO^"?+^$/AM^U?_P6=^*B>/\ X@RR>#?A/I-ZPM(K5#Y$:@X,5LI
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M=I__ #XP_P#?H5)'%%"NR&-47T5<"G44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>%^ ?^4@GC_P#[$32O_1C5[I7A?@'_ )2">/\
M_L1-*_\ 1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%5=<US1?#.CW7B'Q'JUM86%E T]Y>WD
MZQQ01J,L[NQ 50!DDG I-J*N]A-I*[+5?#'[?W_!6&+P!K$O[.?['T8\2>/+
MN?[%<:O8P?:H=.G8[?)@101<W.3C !1#P=S95?-OVL?^"BWQI_;6^(+?LB?\
M$^M)U&6QOV:#5/$MJ##/?Q9VN4<X^R6@S\TK%6<$#Y0=K_2?[ /_  3-^&'[
M&>CQ>+=<^S^(?']S!B]U]XOW5B&&&AM%891>2#(<._.=JG8/SS%YWF7%.)E@
M,BER48NU3$=%WC2_FE_>V6Z:T9\G7S+&9W6>%RQ\M-:3J]/2'=^?3IT9Y9^P
M/_P2?E\-:['^TI^VE(?$GC>]N/MUMH>HS_:H[*9CN\^Z=B1<7&><9*(>?F;!
M7[PHHKZS),BR[(,']7PD;+=MZRD^\GU?X+I9'NY=EF$RK#^RH1MW?5ONWU?]
M(****]@] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O"_ /_*03Q_\ ]B)I7_HQJ]TKPOP#_P I!/'_ /V(
MFE?^C&H ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQIGA/PEH%OY.E:)I$&R*%22S,226=V8EFD<L[LQ9B22: /Q*_P"#,SPYX@^
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M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
MY\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_
M .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B
M@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\
M8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"
M'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J
M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
MY\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_
M .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B
M@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\
M8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"
M'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J
M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
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MU% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\
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M;5F]5KL]=3\HQL,-3Q<XX>7-"_NNS5UTW2?J%%%%>B<H4444 %%%% !1110
M4444 %%%% !1110 4444 %>%^ ?^4@GC_P#[$32O_1C5[I7A?@'_ )2">/\
M_L1-*_\ 1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8?
MQ(^)?@/X0>"[_P"(GQ,\4VFC:+ID)DO+^]DVH@[ #JS$X"JH+,2  20*BI4I
MTH.<VE%:MO1)=VR9SC"+E)V2W;-B[N[6PM9;Z^N8X8(8VDFFE<*D: 9+,3P
M!R2:_.O]M'_@J)\0?C?XU_X9+_X)YVE[JNIZG,UG>>+-*4F6<\ATLFX$<8&=
MUTQ  !*E0!(>(^-?[47[4'_!6KXFS_LX_LHZ%>:'\/()1_;&H7+&(7$.[ GO
MI%SLC."4MER6(R=Y V?<?[%O["7P<_8J\%?V1X)LQJ/B"]A4:[XIO(0+F\;J
M44<^3"#TC4]@6+-\U?G5;,\TXTK2PN4R=+")VG7V<^\:7ZR_X:7R53&XWB*H
MZ& ;A06DJO67=0_67]/S#_@GM_P2Q\$?LKQ6_P 5OBTUMXD^(LR^9]K8>9;:
M.S=5M]PR\O)W3D9[*%&XM]=T45]ME.49?DF"CA<'!1@OO;[M[MON_P CZ/ 8
M#"9;AU0P\>6*^]ONWU84445Z1V!1110 4444 %%%% !1110 4444 %%%% !1
M5;5]9TK0-/DU76M1AM;:(9DFGD"J/Q/\J\;\:_M+ZYXGU'_A$?@KHLUQ/*2H
MOV@+.WO&AZ#_ &G_ "'6OG<_XIR;ARFGBY^_+X817-.3[1BM?F[+S/3RW*,=
MFDG[&/NK>3TBO5_TSTWQ[\3_  ;\.+'[5XFU54D9<PV<7S32_P"ZOI[G ]Z\
M>O\ QU\9?VA[R31/ ^G/I>B[MD\PD*J5_P"FDN,GC^!/7D'K6WX"_9@N+^^_
MX2KXPZM)?WDK;WL5G+9/_323.6^B\<=2.*]@T_3[#2K./3M,LHK>WB7;%##&
M%5!Z #@5\I_9_%G&7O9C)X/"/_EU!_O9K_IY+[*?6*UW374]GZUDV1:85*O6
M7VVO<B_[JZOS?JGT.$^&'[.W@SX?>7J5]&-4U-<'[5<1C9$W_3-.0/J<GZ=*
M]!HHK[K*LGRS(\(L-@:2IP71=?-O=OS;;/GL9CL7F%9U<1-REY_HMDO)!111
M7IG(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%^ ?\
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M6U6NUF_TJ^!/P#^%7[-OP\M/AA\(/"L.EZ7:C<^WYI;J4@!III#S)(V!ECV
M P  .QK\^_"?_!Q_^P_K(6+Q+\/OB+HTA^\\FD6D\0^C1W18_P#?%>F>%/\
M@N5_P3/\4!4G^/EQI,K](=6\+:BF/JZ0,@_%J_2<)FN0TZ,:5"K",8JR5U%)
M=DM#Z.MX;\:Y;34'EE51CI:--R27_;B:/KBBO%/"G_!2']@?QH%_L/\ :^^'
MZL_W(]0\2P6;GVVW#(<^V*]+\*?%CX6>.PK>!_B7X?UD/]PZ5K,%QN^GEN<U
MZ=/$X:M_#FGZ-,\#%93FN!_WFA.'^*,H_FD=!1116YYX4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBL7Q]\2/A[\*O#DOB_XG>.M(\.Z5!_
MKM2UO4HK6!/8O(P&?;.:4I1BKMV1=.G4K34*:;D]DM6_1&U17P9^TC_P<'_L
M9_"+[1H_P<L=7^)&JQ956TR,V6G!QV:YG7<1_M1Q2*?6OGS_ (:D_P""Y/\
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M;/\ A./^$D_X1O[;_P 3K^S/L?VC[1>SW7^I\V79M\_9]\YVYXS@?)?[*O\
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MM,?MLRMXC\:7UQ]NMM U*?[2EG,QW>==LQ(N)\\A<E$ZG<V-GJ?_  3_ /\
M@F3\,OV-M)B\8^)#;>(OB!<08N]=>+,5@&'S0VBL,J.H,I =QG[JG97U#6&6
M\.X_.,9'-.(+.2UIT5K"GYO^:?=O1?=;\ZP>48K,,0L;FNLEK"GO&'K_ #2\
M_P#@6.G2LKQ+X%\$>,X?LWC#P=I6K1XQY>IZ?%.N/HZFM6BOO6E)69]7"<Z<
MN:#L_(\A\6?\$_\ ]ASQON;Q)^R/\.YI'^_/#X1M(93]9(HU;]:\S\6?\$3O
M^"9_BW=)+^S;#83-TFTGQ%J-OM^B+<;/_':^JJ*Y*F79?6^.C%^L5_D>YA>*
MN)\#_N^.K0_PU)K\F?!'BS_@W0_8*U\L^A>(OB#H;?P+8:_;RH/J)[:0D?\
M A]:\T\5_P#!LE\,KLL? W[6.O:?_<&K>&(;S'U,<T-?J%17!4X<R2KO07RN
MOR:/H\+XJ^(6#_AYA-_XE&?_ *7&1^3I_P"""W[=WPX/_%CO^"@"VXC_ -1_
MI^J:5CT_X]WEV_AFC_ABG_@X5^%9_P"*1_:S;Q)Y7W/^*^>\W_\ @SA7/XU^
ML5%8_P"K.7Q_A2G#_#-_K<[_ /B+?$];_?*6'K_]?*$'?_P%1/R=_P"%J_\
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MI\2?B3XHO-:U[6KQ[O5=5U"8R37,S')9B?R '      %?7__  21_P""Q?Q
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MY/\ %[>6QI45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5;' :5%9O_"8^&/\
MH-0?]]5XY^T5_P %(/V2/V9[>:V\;?$N+4-8B!V^'= 3[5>LW]UE!"0G_KJR
M>V:Y,;C\%EM!UL54C""ZR:2_'KY;F&)Q6&P=)U*\U&*ZMV/'O^#A7]IKQ_\
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MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
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M\,=.UBZ\,^)M/U_1[R2,QS0WUE*);=C(A#.BN 3$Q*-T92.*]!5510B*  ,
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M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J
M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
MY\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_
M .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B
M@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\
M8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"
M'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
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M /P4*_X1W3;-?,FO_$'@J$0PCL6D^WQ!>W/Z5\<_$_\ 9AT_X+^+D\*_ ?\
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M/K'C;]AB*^M+&%I;RZG^&&H2QI&@RSLUI<* H"L2>  2>!BOS8_;0_;>^/\
M^WI\7I?C'\?O$,,]VL(@TO2--C>*PTJ#KY-M$[N44GYB69G8\LQXQ^D91P-4
MQ-=1KS@Z*WY))W\M-K_D=F;\;8;"X-PP]*2J/1*<>5+S\[=C]F_^"-'[ ?\
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M/F,G_"I-93(],R7.._UKS/\ 5/,5O4IK_M]'J_ZW9:]J=1_]PV?L-_9VG_\
M/C#_ -^A1_9VG_\ /C#_ -^A7X\_\-_?\'*&J_O[/]BC[,K_ "JG_"MYTVGI
MG$L^?SXH_P"&K_\ @Y[U7]S:?LU?9F7YB_\ PAUBF1Z9EEQ^7-'^JN*6^(HK
M_N(O\@_ULPK^'#UG_P!PW_F?L-_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5^//\
MPNG_ (.HM6_>6?PF^RB;Y47^P?#R;#TS^]<D<\_-Q^%']M_\'9NK?)9Z1]F*
M<L?L_@I-W_?TX/X4?ZL36^+H+_N)_P  /]:8/;!XA_\ </\ X)^PW]G:?_SX
MP_\ ?H4?V=I__/C#_P!^A7X\_P#"(_\ !V%J_P UYXG^R^?Q(/MO@]/+SQ_R
MR!Q_P&C_ (4+_P '3&K?\?GQH^S>7]W_ (J+0TW9_P"N49ST[^O'>C_5NFM\
M;0_\#O\ H'^LU1[8&O\ ^ 6_4_8;^SM/_P"?&'_OT*/[.T__ )\8?^_0K\>?
M^&._^#F_5N+S]J?[-YW,A_X3BW3R\_\ 7*'C_@-8/B?]DG_@OYX9U*"T^(?_
M  4.&E$NH>*V^(EY+,(R>6\N"#GCIO*@],UQYAE^393A)8G&YE0ITX[MR=OR
MU?9+5]#HPN<9ICJRI8?+JTI/9<J_ST7F]$?M&UCIJ*7>S@  R28Q@"O+?B9^
MT=X+\,.^B^"=,MM8U'.P2)&#;QM]1S(?9>/?M7S/^RS^S%^T]8>![FSU#]H3
MQ]\0]1NH&%YK/C_QG>C3I9 ,B..#,J1)N&,K'*ZYY)'%>-_'C_@EO_P6G^-W
MBC^U]"_:S^''P]TZVE)TW2O!'BW6K9T4\9EN8[&.69L=<X3C(5:_*Z&/SOC?
M%2H9%4CAL'UQ5:+3DO\ IS2?O/RE*R[\K/N,1'!\.86-7,:,JV(?_+BFT^7_
M *^5-EZ1OY71]L>&_@7\1_BWJ2>*OBSJDMA:,=T=FJ!92OHJ8VQ#ZC/J.]>R
M^%_ /@_P;IJZ5X>T"W@B &YO+#/(?5F/+'ZU^18_X(/?\%==2_=:Y_P4TW1O
MS(/^$XU^7YNO1E&>>]'_ !#R_P#!1K4?W^M?\%)MTH^53_:VKR_+]6<'KGBO
MM\@\-N$.'Y.M''JI7E\56<92J2?75[+R5O.Y\OF7&W$^9I4WE\HTUM",HQBO
MEU^?X'[#?V=I_P#SXP_]^A1_9VG_ //C#_WZ%?CS_P 0T'[5VHCR-:_X*+;H
MNN/[,OI?F^C70'XT?\0LWQ4U']]K?_!0C=*>&/\ PA4\OR_5K\$_2OJ?[(R!
M;Y@O_!<W^IX_]L<0O;+G_P"#8+]#]@;N/0[",2WR6D*%L!I0J@GTR:S;OQ=\
M-+!VCO\ Q/H4#(,NLU["I48SDY/'%?DK:?\ !II9I(3??MZRR)MX6+X8!#GZ
MG4V_E6E:?\&GW@1$47W[;.KR,#\YA\"Q(",]@;ML<?6C^S.&EOF#?_<*7^8?
MVIQ.]LN2_P"XT/\ (_46[^,OP L%#WWQ6\'PACA3+KMJH)_%ZS;S]I?]E'3R
MZW_[0'P]@,0S()O%=BNP8SDYDXXK\X+7_@U)^"",3??M<^*Y%Q\HB\.VR$'\
M9&K2M/\ @U3_ &8$5/M_[3OCV4@_O##962;AGMF-L<?6CZAPNM\;)_\ <-_Y
MA_:'%3VP45_W$7^1]\W?[9O[#VGA3?\ [5WPI@WYV^=XZTQ<_3,U9EY_P4!_
MX)X6&\7?[:GP:1H_OI_PL32BP]MHGSGVQ7Q9:?\ !J[^Q<A;[?\ '[XH29QM
M\FZTY,?7-HV?TK3L_P#@UJ_8 AV-=_%[XOS,OWQ_;VEJK?@-.R!^-'U3A1;X
MFH_^W ^N<6O;"TU_V^?5MW_P4O\ ^";%D5$W[:'PI;=G'D^+[*3\]KG'XUF7
MG_!5S_@F'8J[3?MC?#QO+.&\G5$DSSCC8#N_#-?/%I_P;#?\$Z+8,)O%GQ0N
M,XQYWB6S&WZ;;,?K6I:?\&TG_!-.V*&:T\>7&P883>*P-_'4[(5^O&*/8<(K
M>M5?_;L0^L<8/:C27_;TCV&Z_P""P_\ P2PLV"3?M>>#B2,CRHIY!^:Q'%9=
MW_P6V_X)-62-)-^UCH3!#@^3X>U&0]<<!;4D_A7"6G_!N#_P2_ME*S> O%5P
M2>&E\87 (_[YQ6G:?\&\'_!*JV=6F^!FKW 48*S>-=2 ;CJ=LX^O&*/9\'+>
M=9_* >TXS>T*"^<S6N_^"\'_  2'LY!%-^U/:$E<YB\"ZW(/S6Q(_"LJZ_X.
M!/\ @DG;QEX?CQ=3D'&R+P'JH)]_FM0*T;3_ (-_/^"2UO&4F_9:EG);.^7Q
MUK@(]OEO0*U;7_@A3_P2BLY!+#^R)IY(& )?$NK2#\FNR*+\&KI7?_@L+<:O
M_H'7_@P^ _\ @K;_ ,%_?"OQ?^'[_L^_L$:A?VNFZS:E?%7CF;3WL[AX6&#9
MVBN!)'N'$DI"G!VIP2U?GY^P[^W%\;OV!OC=9_&?X+ZQ_=AUW0KF1OLFLVF[
M+6\RC\U<?,C<CN#^BO\ P6-_X(%:!\//"4_[2W[ W@FXBTW2K0OXL^']M/-<
MO'$@RU[9F5GD? YDAR2 -R< K7YU?L._L._&[]OGXW6?P8^"^C_W9M=UVYC;
M[)HUINPUQ,P_)4'S.W [D?H^1_ZMO(I>PM[*SY^:U_\ M[]+:=C\USW_ %F6
M?P]O?VUUR<E[?]N_K?7N?TI?L._MQ?!']OGX(V?QG^"^L?W8==T*YD7[7HUW
MMRUO,H_-7'RNO([@>QUXY^P[^P[\$?V!O@C9_!CX+Z/_ '9M=UVYC7[7K-WM
MPUQ,P_)4'RHO [D^QU^-XWZI];G]5O[._NWWL?M.!^M_5(?6K>TLN:VUPHHH
MKE.H**** "BBB@ HHHH **** "BBB@ HHHH **** "O"_ /_ "D$\?\ _8B:
M5_Z,:O=*\+\ _P#*03Q__P!B)I7_ *,:@#W2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBL[Q;XO\*> ?#5[XS\<^);#1M(TVW:?4-4U2[2W
MM[:(=7DD<A44>I(%-)R=EN)M15WL:->*_MG?\% _V7/V#/!7_"6_M!?$.*TN
M[B%GTCPW88GU/4R.,0P @[<\&1RL:GAG&17P5^VS_P '"GB+QUXP_P"&9O\
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M.R_/T"BBBOGCZ(**** "BBB@ HHHH **"0!DG '4FOG+]I'_ (*O_L*?LO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME7K5DMO\$>GJ_P 4>0LKS7/7SYG+V=+I2B]_\<EOZ+\&>&_L3?\ !.G]E?\
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M'[,_VC1M0\;CQ/X@ARO]@>%F6YD1Q_#++D10X/4,V\?W#7R3??M?_P#!4/\
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M1110 5X7X!_Y2">/_P#L1-*_]&-7NE>%^ ?^4@GC_P#[$32O_1C4 >Z4444
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M&Q6>9I2AB8\]J49)J-Z<D_:U&U"#2;M'K*R39^=E%?6'_#CS_@J+_P!&P_\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BB
ML?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$
MEU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^
M$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU
M?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275
M_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"
M]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+
MW_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_O
MI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_
M +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8
MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M^G16+P6K1'H;"Q=@T[%3@74[$88[6<#97T. R"K6H?6L9-4:/\TMY>48[O\
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M*M*4KZIO?KTMN;:(D:".- JJ,*H& !Z4M8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+7[_ +'YL;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;
M%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM
M'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_
M  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;
M%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM
M'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_
M  DNK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;
M%%8__"2ZO_T*%[_WTM:&FWD]]:B>XL)+9BQ'E2D9^O% %BBBB@ HHHH ****
M "L#XKZOX@\/_"WQ+KWA-';5;+0+RXTQ4A\QC<) [1@)@[SN ^7!STK?HH _
M'_X]_P#!6']A3_@HM^PE\!H/C%\4_!.G^)$^.O@./XU?#/QW>6UE/IABOE35
M/M-I=%=UB/WC&4J8O+8;RIW*O"_\&T7["+?#;_@I'^TG^V/^SWH>J:?^SI??
MVEX7^$E_J4<J1>(;>358;F.XM#*-\]M!':^6L[9W"<#<S"3;^O'QL_95_9^_
M:)N]!U'XP_#'3M8NO#/B;3]?T>\DC,<T-]92B6W8R(0SHK@$Q,2C=&4CBO05
M544(B@ #  ' % '\X'_!Z9^T-\#/C%\5?@/X)^$WQ<\.>)M2\,:5XC?Q#;:!
MK,-X=.^T3:>L*S&)F$;L;:;Y6PV$SCD5^W?[,GC+]GG]N3_@GWI/@?X>_%70
MO$^@>)/A5;:'KLOA[5H;I[-;K3!!+%*$8F&4!G!1P&#*00"#7T+10!_/Q_P;
MA2S?\$7?V^OVB/V%_P#@H-XBTOX<W6NZ%8ZEX?\ $?BJ\2PTO7(=*GNQY]I<
MSE8Y4E@OFF4!LXAD5@&C91TW_!KC_P $]?&'CGXY?M$_M]_$7P-?Z9\-/B=I
M6K^$_ \>I6C6YU_3=0U 75S<Q(X!,"I!;QK)C:S22!23&V/W.\3>"?!GC6&&
MV\9>$M,U>.WD\RWCU.PCN%B?^\H=3M/N*TD1(T$<:!54850, #TH _!G_@@5
M:>%_^"%'[2O[7O[+7[?OC_2O TMMIFD:[X-UCQ)>QV5OXJTFP;50UU8-*0+E
MG2YMR(HRT@<O&5WHRCT/_@SL_P""</Q6_9P^"'CO]M#XX>"[S0;SXGI8V'@K
M3M4MFAN3H]N9)7O"C ,L=Q+)'LW %EM@X!61&/[)>(?!OA#Q:UL_BKPKINIF
MRF\VS.H6,<Q@DX^=-X.UN!R,'BM*@ HHHH *\+\ _P#*03Q__P!B)I7_ *,:
MO=*\+\ _\I!/'_\ V(FE?^C&H ]THHHH **** "BBB@ HHHH **** "BBB@
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MRS/9_%;]I6>T^)OQ!5A./ML!;2-,GZYAAD&;F0'/[Z8=0&6.-AFOT* "@*H
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M110 444$A068X ZDT %%8.M_%'X=>'-PUCQIIT3K]Z(72NX_X"N6_2N/UO\
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MNB/?Y H%>I:)\(OAEX=P=*\$:>K+]V26 2N/^!/D_K711QI$@CB0*JC"JHP
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M1J !^ I]%%?2)**LCRVVW=A1113$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$32O\ T8U
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MG[).A_VU\?/B[I6AN\1>UTQI3-?70_Z96T8:5QGC<%V@]2*_-GQ%_P %.?\
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MHQ75Z'M3ND:EW8*JC)). !7QO^V+_P %D?@9\!7N? WP42'Q[XM0F+_0I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M &5O@NUMXJ^/^I7/Q,\0(1(T%]&;;2HGZ\6ZL6FP<@^:[*W7RQ7WNJJJA54
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M*;!M_P"NTG4_[@!KTGP=\ _AAX+V36?AY+NY7_EZU$B9\^H!&U3[@"NR  &
M, =!7W"X=XRSM?\ "KCE0I_\^\.N5V[.I+WO)I)H^G699#ERM@L-[22^U5U7
MR@M/3J>*^'/V2I+^Y_M?XF^,9[VX<YEBM')+'_:EDR6_(?6ND\8_LX^&-8\-
M1>&/!TMMH40F#W4ZV/GRW  ^52[.&P#SC)YQTQ7HU%>KAO#_ (1PV#GAXX9-
M35I2;DYOO[]^97ZJ+2>UK')5XESJM7C5=5KEV22Y5V]VUG;I=,\+_P"&+?\
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M+_\ ([__ !594>+N%N"LWJX7-:-2I7A9>XH2@N:*EHW45W9V>FCNEW/N<O\
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MP#;ZE\6?B!X>\%:'9VXATVRD98MT:  16UM&-\FT  )$AP!TQ7Y^?'O_ (.
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M]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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MQ(_;%\0:_J]WJ7CE]5^'6M>'I#%]A_LP)93M(OR>9YK&5E.6*[?X<\U^[%%
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M_P#X6M_P<M_]$V_\H^@?_%4?\+6_X.6_^B;?^4?0/_BJ_6"BC^P:G_076_\
M _\ @!_Q$K#?]"/ _P#@E_\ R9^3_P#PGO\ P<TZG^]M?!?V<+P5_L[PRF3Z
M_O&S^5'_  E?_!SG_P!"U_Y)^%?\:_6"BC^P)?\ 076_\#_X ?\ $3**VR3
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M+/S3_P"%6?\ !R[+^]?XC;2W)7^U_#XP?3A<?E1_PJG_ (.6_P#HI/\ Y6-
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MC_@G!\$_(U'QCX,UGXB:G%AOM/C'5F, ?OBVMA%$R_[,@D^IZUL^#N%\$O\
M:<RKU9=J4M/_  *2L_D8+QBXOQK_ -FR#+Z4>]6AK_X#&5U\S\N_ /\ P5J_
MX*A_%;Q!'X2^%WQ[\?\ B359O]5IN@^'DO+A_I'%;LQ_*OH27]F;_@X2_:C\
M*I_PFGB;QWI>DW<)#6FJ^.+?1C,AZK+;03))^$B5^QOPY^%/PO\ @_X?3PG\
M)OAQH7AC2X\;-.\/Z3#9P#'&=D*JN??%;]>/B<DRQ3OA*M>%NKK7?X1C;\3V
ML-XF9XX6QF7X"=^BPB2_&<K_ ('X W'_  ;P_P#!02[G>ZNOA;X=EEE<O)))
MXOMV9V)R227Y)/>O1?@M_P $B?\ @KI^S]>17OP:\*^"O#=ZGRIK%G/H_P!M
MC'K]I,33#UX:OVYHK.IEV*K0Y:F.Q#79U9-%T_$&%&?/3R;+XONL+!/\S^>_
M_@I_\*?^"BWPQ_X0?_AOSXD_\)#]N_M/_A$_^)Q'=_9]GV3[5]Q5V;M]OUSG
M;[5\GU^W'_!=_P#8=_:C_;,_X57_ ,,V?##_ (23_A&_[<_MK_B=65G]G^T?
MV?Y/_'U-%OW>1+]W.-O.,C/Y[_\ #CS_ (*B_P#1L/\ Y>NB?_)M?FN=Y+CJ
M>9U(T:=2<=+2:E*_NKK;6ST_ _J/P_X_X<Q/".&J8_%8;#U7S\U-3ITE']Y-
M+W'*\;JTO.]^I\GU_5/X"^'G@+X6>%[;P3\-/!>EZ!H]FN+;3-&L([:"/Z)&
M ,GN<9/>OP(_X<>?\%1?^C8?_+UT3_Y-K^A"OI."\%B<*Z[KTW%OEMS)K^:]
MKKTO\C\H\?N(,ISB&70R[%PK*/M7)4ZD9I/]WR\RBW;[5K^=NH4445]V?S@%
M%%% !1110 4444 %%%% !17/>+_BM\/_  *K+XC\2V\4RC_CUC;S)3_P!<D?
M4X%>9:[^U;K6O7AT;X5^!Y[B=^(Y;F,R.?<11_S+'Z5\MG'&G#>1S]GB:Z=3
M^2/OS;[<L;M?.Q[&!R'-<P7-2IM1_F?NQ^]_I<]MDD2)#+*X55&69C@ >M<-
MXQ_:+^%WA#?!_;?]HW*\?9]- DY]WR$'YY]J\_C^#OQ\^*[BZ^)'BMM/M'.?
MLTKAB![0QX0?B0:\#_:7_;?_ &+OV/?M'A7P;:+\3O'$&4:S2[5K"REZ?OY5
M!3(/6-0[@C#%,YKY#-.-.)9X5UZ&&C@Z'2IB7[S_ ,-&-Y.79:IFN-7"?#M#
MVV:8OG:^S3VOVYGOZ15SVWQG^U-\0-3T2]UW0-/M/#^BV49>]UJ_F01VZ=,R
M3S;8H_QYST-?"WQS_P""@?C3XF>,T^&O[-=CJ?C3Q%>RF"WU;[)+<[W]+: C
M=)CGYF4*,9VLO-=)X,_9)_;\_P""H6M67Q!_:<\53^"/ "2";2])-F8$6,]/
ML=AD8RIP)YCD@@@R 8K[\_9E_8V_9^_9(\.?V'\'/!$5M=2Q!+_7;S$U_>X_
MYZ3$ XR,[%"H#T45\E0X0XEXXJJMC\14]AOS5/=YO.G1CI%><F[JS78^:J<6
M9[FT'2R6@L#AW_R\:O6DO)OX4^^_5,^*OV8?^"+WCCXDZW%\8/V]/&EY/<7!
M64^$[*_WSR#J$N;E21&HZ>7"> 1AUQBOT-^'WPX\!?"?PI:^!OAKX0T_0](L
MUQ;Z?IMLL4:^K$#[S'J6.23R236U17['D'"V2\-4/9X*G9]9/63]7V\E9>1R
MX#*<'EUY4TW.6LIR=Y2?5N3UU^X****^B/2"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O"_ /_*03Q__ -B)I7_HQJ]T
MKPOP#_RD$\?_ /8B:5_Z,:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BN)^/7[1GP2_9B\"3?$CX[?$73O#ND
MQ9$<M[+^\N7 SY<,2Y>:3'\"*QQSC%?F1\;/^"L?[:G_  4.\=W'[.G_  3-
M^%VMZ-IDOR7OB5%5=2:$DCS9)\^5IL1Y^;<9"0-KJ3LKR\PS?"9?:,WS3>T8
MZR?R_P S[#AG@C/.*%*M1BJ>'A\=:H^6G%=;R>[797?>RU/M;]N/_@JK^RY^
MPW93Z+XL\0?\)%XR$6;7P7H,RO<@D94W#\K:H<@Y?YR#E4>O@:U\-_\ !43_
M (+C:VFI>)+P_#KX.&Y#0H8Y8=.= W!CCR)=4E&/OL1$K X,1.VOHS]AS_@@
MS\(/@[?0?%?]KK58/B/XSDE^TOIL^Y])M)R=Q9ED&Z]?.26E 0Y_U9(#5^@-
MM;6UE;1V=G;I%#$@2**) JHH& H X  XQ7F_4<RSA\V.?LZ7_/N+U?\ BE^B
M_!GUCXCX3X%7L^'::Q.+6^*JQ]V+_P"G--[>4I:_XDSY_P#V*/\ @F=^R[^P
MQI$<_P ,_"?]I>)W@V7_ (RUM5EOYLCYEC.-MO&?[D8&1C<7(S7T'117T&'P
M]#"TE3HQ48KHC\RS+-,QSG&2Q>.JRJ5);RD[OT\DNB6BZ!1116QP!1110 44
M44 %%%% !1110 4444 %%%% !16'\0/B;\-_A-X>D\6_%/X@:)X:TJ+_ %NI
M:_JL-G GUDE95'YU\:_M"?\ !P[_ ,$W?@?Y^G>%O'VK?$+4X<K]D\%Z4TD(
M?MFYN#%"R_[4;2<=CTKMPF78_'RMAZ4I>B=OF]D<6,S++\OC?$U8P]6K_);O
MY'W-2,RHI=V  &22>E?C;K/_  7S_P""D7[7^J3^%/\ @GM^P])!$SF(ZK_9
MMSKMQ!Z.TBI%;6_8GS5=1G&3UJLO_!)S_@N#^WJPOOVX/VM6\)Z)=G-SH5]K
MQN=H/==.TTK9YQV,BD=*]M<,5,,KYA7A1\F^:7_@,?\ ,\)\4T\2^7+\/.MY
MI<L?_ I;?<?HK^T)_P %7/\ @GQ^S%Y]K\4?VG_#;:C!D/HN@7!U2]#_ -QH
MK02&(G_IIM'J0*^(OC3_ ,'1/A;4M6_X0S]C?]E#7_%&I7+F*QO/%$X@\Q^V
MRSM/-DF![#S(VQV'2O3OV>_^#9W]@SX6^1J7QEUGQ/\ $G4(\&6+4;\Z=8,P
M[K!:E90,]FF<'ICKG[>^"W[,W[//[.>D_P!B_ CX)^&/"4!0)*=!T6&WDF'K
M)(JAY3[N2?>G[7A3 _!">(E_>?)'[E[WR8O9<6X_XYPP\?[JYY?>_=^:/R;^
MV_\ !RS_ ,%"ABWM[OX/^&;WN%7PRD(;W;?J9&/3<,?7GM/@W_P:\Z3KNL_\
M)M^VA^UOKOB;4[EQ)?V?A>#8TC_[=[>>;)*#T/[I#COZ?K1143XJS"$'#!PA
M1C_<BD_FW=_/0NGPGE\Y*>,G.O+^_)M?)*RMY:GSE^SW_P $E?\ @GC^S+Y%
MW\-?V8/#T^I08*:UXD@.JW@<?\M%DNS)Y3?]<P@] *^C(XXXHUBB0*J@!548
M  ["EHKP,1BL3BY\]:;D^[;?YGT.'PN&PD.2A!179)+\@HHHK W"BBB@ HHH
MH **** "BBB@ HHHH **** "BH[JZM;*W>[O;F.&*,9>65PJJ/4D\"O/_&/[
M3GPQ\+[[?3[Z35KA>!'8+E,^\APN/==U>5FF>91DE+VF.KQIK^\[-^BW?R3.
MS!Y?C<?/EP]-R?DOS>R^9Z)5#7_%'ASPK:?;O$>MVUE%V:XF"[O8 \D^PKQ-
MOBU^T%\6G,'P\\,-IMDYQ]IB0=/>:3"_]\@&K^@?LGZEK-W_ &S\4O&T]U._
M,D5K(78_663)_ +^-?'?Z[YCG#Y>'\!.LG_R]J?NZ7JF_>EZ*S/<_P!7\+@=
M<RQ,8/\ DC[\_1VT7KJC0\7?M<>$]/=K+P7H]QJLY.U)I 8HB>V,@LWTP/K6
M!Y7[4'QCYD9]"TZ7L<VJ;3[<RN,?45ZYX1^%_@+P,@_X1KPU;02@8^TLN^4_
M\#;+?@#BD^)OQ4^''P9\(7/CWXJ>--/T'2+0?OK[4;@1KGLBCJ[G'"*"Q/ !
MJ*G#'$&:TW5X@S)QI[NG0_=P2Z\TW[TEWO;U)GGF3Y9%RP.'6GVZKYGZV^&/
MJ<+X0_9(\&Z6RW?C#5+C5ILY:)288L^^#N/UW#Z51_:'_:X_99_8<\+;O'6M
M6=C>20[[#PSHL*27][Z$1 C .#^\D*KD8W9XKY$^/'_!73XV_M&>+V^ W_!.
MKX::I<75V6C_ .$DEL!)>2)T,D,+92VC'_/:8Y .2(R,UT7[+?\ P1;AN]='
MQD_;J\9W'B[Q%>2BYN/#\>H22PF0\YN[DG?<-TRJD)D8W2*:\S+JV6T)O"<'
M8*,I+25>2?)'_M]WG4?DG;JKH^!S/C3.N(JKHX%NK;><M*4?1*R;]%YZH\Q\
M1?M$_P#!0[_@K!KEUX#_ &>_"\W@GX=F8P:A>QW3PP-&>"+J]"AIC@\P0KT;
MYE8#=7U1^QO_ ,$F_P!G?]EG[+XN\26B>-/&,.UQK6KVP\BSD'>VMR2J$'H[
M%G!&0RYQ7TUX=\.>'_".AVOAGPIH=GIFFV4(BL["PMEAA@0=%1$ 51[ 5=KZ
MG*^#L-0Q2QV9U'B<3_-/X8^4(;12Z=>JL<V"X?HTZWUG&3=:M_-+9?X8[+^M
M@HHHK[,^A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+3_@J+_P7(UH37;_ /"NO@VUSE1B6'3716[#B75)ACJ<0JR_\LB:_0?]B/\
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MFBBO#;;=V>XDDK(****!A1110 4444 %%%% !1110 4444 %%%87C?XA>'_
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M2HQ48QT22LDO)(^GI4J5"FJ=.*45LEHD%%%%;&@4444 %%%% !1110 4444
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M!!1110 445^3'_!=3_@K'^T-X1^/T/\ P3:_87\>?\(CKUMH,.K_ !8^)%M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-?&;XEZ?\
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MSQ/>:?:^$H+]M3V7<4=K*BM?JEE;LURV7+L^,+M1?6?^#4/_ (*P_&?]O?\
M9_\ &7[._P"T_P"-KGQ)XW^%DME)IWB;4Y2][JVCW0D5!<.>9IH)865IF^9U
MFBW;F#.WSQ_P8U%%\/?M,L3S]L\(9^FS6?\ Z]>._P#!DO8:W/\ MT?%_6;9
M'_LR'X4K%=$?=$\FIVK0@^^V.;'T- ']*E%%% !7A?@'_E()X_\ ^Q$TK_T8
MU3ZI^U+\9;#4[FPMOV+?&]U'!.\<=S%<VVV90Q <9;H0,CZUPWP"^)?B[QA^
MVSXX\0Z[\']9T&ZF\%Z>DFE:A)&98@DI"L2IQALDC_=- 'U-16/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%
M[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]
M"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H
M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM &Q17G7QH_:;^&W[.W@>X^)'QMU.'PWHU
MMPUYJ5TB^8^"1'&@RTLAP<(@9CC@5^;GQX_X+$?M<_MS>-)OV<_^"8_PEUNP
MBN 4NO$J0*VI/$3M,H8_NM.BYQYKL7Y4AHVXKS,PS;!Y=:,W>;VBM9/Y?YGU
MW#/!6><4N53#Q4*$/CK5'RTH+K>3WMV5WWLM3[?_ &V_^"GG[+G[#.ERV7Q#
M\4_VOXK:'?9>"]#=9;Z3(RK2\[;:,\'?(02,E%<C%?GO)??\%1O^"Y&M&"QB
M_P"%=?!MKG#',L.FNBMT+<2ZI,,=!B%77I$3FO:/V*?^"&_@SX>ZNGQ@_;6L
MKOXC^+KB?[5)HTLQDTR&9CN+3M(=]])GDE\1G)!1^&K]"]/U6XTFPATO2O 4
M]M:VT2Q6]M;JB1Q(HPJJHX4    < "O,^I9GG'O8U^SI?\^XO5_XI?HOP9]>
M^(.$>!%[/((+%XQ;XFI'W(/_ *<TWU724ODY1=CPW]A__@EK^RY^PSI\.J^"
M?#?]N^+S#MN_&FNQ+)=DD898%^[:H<D;4^8@X9WQFOI"L?\ X275_P#H4+W_
M +Z6C_A)=7_Z%"]_[Z6O?P^&P^$I*E1BHQ71'YEFF;9EG>-EB\?5E4J2WE)W
M?HNR71*R71&Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;GGFQ16/_
M ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+7E'Q[
M_P""@W[,W[,K/9?&;X@V&EZBB;AH4-R+K46!Z$6D >;:?[VS:.Y%#TBY/9:O
MR7F95J]'#TW.K)1BNK=E][/;Z*_,SXY?\'!EY*DVE?LR_ #:W(BU[QY=X4'^
M\ME:MN=3U!:>)AW7T\7O/!__  5W_P""C"&3Q5=^,)O#5Z/^/:;_ (D6AM$>
MWDH(_MB?[_GM[\5\GB^-N'Z%9T,/.6(J_P E"/M'_P"!*T+=_>NNQ\QB.+\O
M]I[+!PE7GV@G;[_U29^CO[07_!3W]B;]FZ>XT?QI\:K'5-;MB5D\.>%%.IWR
MR#_EG(L&Y;=O^N[1CWK\ ?&'QVTO]H[_ (*0_M*_&*#2=0T^7Q'XKTN]M++6
M#']JCT\6"Q6ROY;NGRHF,*S!<@9K]2?@%_P0>\/:!';WG[0'BW4[\1@$Z'X1
MMTM;=2/X3/*"SJ?]F.,^]<7_ ,%.?^""=YXUN/#_ .T7_P $R?!5EX2^(OAG
M2WTW6O"^O7\K:?XRT[=YBQ33N[-%=(V=DI^5@P5V544CPL[PG%/%^35\+/"P
MP].44XJ4^:HY1E&2ORI046DTT]4VM;)G%B\+Q-GV JTL13A2C)>[&]Y<R::N
M]5LFNFZT/@ZO(OVN/"NH>.K?X=>"O"WAQ=8\2:M\5M#M/#.D"/>][=R3E%A"
MY!8,&*D>]>UP_LF_\%@+OQ+_ ,*[M?\ @E/XK7Q&(]S17'C;24L57<5\S[49
M?+9-P/(.#QSR*^Z?^"4?_!#_ .,'P7^/.E?MQ_\ !0RXT_7O'GA^&0?#[P!X
M8)DT?PJ\JE7NY)9,&[O-AVA@-D9RRM(?+,?YWP7X?<24,^I8O$Q]C"E*]U*+
ME==%RMZWW;MIWV/G,AX.SBGF4*N*A[.$==TV_)6;W[O2Q)\(/C)_P4T_9$T3
M_A'OAG_P3@\-Z18J@$\?A_X37$7F@=Y&T^1=Y[[FR<\G-=A_P^A_;)\&_P#)
M3_V)!#L_UG^AZC88/_;5),5^BO\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?
M2U^J3X7XB4G*EG%:_><8U/OO:Y]G#A_,</%1P^.G%+9.,9?Y'Y]:)_P<)^'6
M?R?%G[+%_:,IQ(;+Q6DQSW^5[:/'TS7::#_P7W_94O2J>(?A=X]L&)Y:"SLY
MT7ZG[2I_)37V!K=OI?B5=GB/X4QZ@N,8O;2&4?\ CP-<7KW[-'[-/B@-_P )
M!^QSX.NV88,DWA.Q+CZ-Y>X?@:G^R./:/P9G"I_BHJ/_ *2ROJ'%%/X<9&7^
M*FE^3/*-!_X+8?L%:QM_M#QIKVE9'/V_PU.VWZ^0)*[70?\ @J5^P'XCV_V?
M^TII$>[&/M]E=VO7U\^%,5E>)/\ @G=^PUKB/+K'['VF0*?O-9W,MF!_WYE3
M%>8^+O\ @F/_ ,$V&+*? =_HK<_)9>.)&9?H)I9#7-B,7Q]ET>:O5PCC_>=2
M#_%V-:5#C>3M3C2J>BJ7_#0^F- _;*_9'\3E5T+]ISP#<.WW81XMLUD/_ &D
M#?I7:Z#X[\$>*0#X8\9:5J0897[!J,4V1_P!C7YR>*_^"6W[ +[FT'XD?$2T
MEQPD=]:7$8_.U!/_ 'W7F_BO_@EC\&FW?\(1\=?$L1!^3^TO#5O*/S2X0_I7
MSN*\3\=EO\>GAZEO^?>(B_TD>I1RSQ$G_P ROF])\O\ Z6D?KQ17XYZ/^P#^
MTWH<OE_"K]I'5 5/[L6;WML?;B&1\5V&B?LO?\%F_#^T^$_C]XLNXUYC2X\5
MZB5^FVZ0*/Y5>7^+M/'NT,OJR_P>_P#^VHG$QXKP'^]Y7./I.$OR9^KE%?EW
M=>"_^"_>AP%;?7M8OHU&#Y6K:0[$?\#(?\N:YC6_$O\ P68TG/\ PF'P-\1:
MWC[_ )FB/>;O_ >0Y_"O2QOB+F.&AS4\HQ#_ ,47#_VV1RX?B++^:V,HUZ7G
M['F7WJ:/U9U+QCX2T;/]K^*-.M<=?M%[&G\S6!J7Q_\ @_I6?M'C>VD([6T;
MRY_[X4BORK_X:G_;7\&/GXF_L;:U$B<R ^&]2L3CZRH^*VM!_P""L/P\\+SK
M8_$3]BJ^DG4?.S^.9H6S_P!<S:K_ #KY:?BIG]:?+[&CAO\ K[[:7_I$#V(<
M4>'%%?[1B:U^WLG'\[_F?HUJ7[6_POLP196VJ79[&*U51^;L#^E85[^V1'-)
MY&@?#V:9F^Z9KW!_[Y5#G\Z^2_"7_!:;]C6Q*'6/V3-;M"",M;BSO2OT,KH:
M],\,_P#!</\ 8A>-8D\/^)]&4]5GT*,!?KY$CUUT>(\WS+^)G]"C?^2E?\:M
MCKI\:>'$?X47/_'4<?R1[#_PO7]H?Q#\OASX7^6C=)!I<[X_X$Q"_I1Y/[8O
MB3[\IL(FZ?-;18_++UR.B?\ !8?]A37,+#\5S;N1RE[I5W#C_@30A?R-=CH?
M_!1;]D3Q"0NG?';PBI8X5;OQ/:VY)],2NIKU:.2X#,?]XXAJ5/*G6IP3^4;G
M=3XVR/\ YA*.'^;4W^+&?\* ^/GB#GQ/\4]J-UC.I7$N/^ X"_D:LV'[&MB6
M\W7/'UQ,S'+"WL@A_-F;/Y5UV@?M'?#/Q5M_X1?Q3HVI;_N_8/$%K-GZ;'-=
M(GBC5)4$D?A*[96&5974@CUZUZU#PVX,K/VE2$J[[SJSE^4DOP.Q<89Q.-J%
M2,5_<C'_ "9Q>F_LF?"JRP;QM2O#W$]V%!_[X5:Z#3?@-\(=*Q]F\"V;X_Y^
M2TW_ *,)K6_X275_^A0O?^^EH_X275_^A0O?^^EKZ'"\'\*X+^#@J2??DBW]
M[3?XG!6SS.*_QXB?_@32^Y:%K3?"_AG1L?V1X=L+3'3[-:)'C_OD"KU8_P#P
MDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM>_2HTJ$.6G%179*R_ \V<YU'>3N_,V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:T)-BBL?_A)=7_Z%"]_[Z6C_ (27
M5_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6OG;XM?\ !93_ ()N_ KQU/\
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MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^
MA0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_
M^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X2
M75_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X
M275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A
M0O?^^EK0TV\GOK43W%A);,6(\J4C/UXH L4444 %%%% !1110 5@?%?P[JWB
M_P"%OB7PGH$B)?ZIH%Y:6322%%$TD#HA+#H-S#GM6_10!^/OQ8_:0_X*#_#_
M /96_9T^ G[=_P#P3]\>0^.O ?Q[^'\/_"8>$-:T75-*\8"RU"-(3%)]O1X+
MVX55'ES*D9D)8R1J=J^O_P#!'3_@E'\5_P!GS]MGX]_\%/?VCO FF^!?%/QH
MU:_3PW\--+U*&];P[I5S?+>3?;+BW)@DNI98H&*PLR+L8[B9-J?I!-;P7 43
MPHX1PZ[U!PPZ$9[CUI] 'XA_\'-'_!//_@II_P %6_B7\++?]E7]@SQ')H_P
M[T[6([[5_$'CGPM9B]FO9;7 AC_M9GV*MH#N<(29,;>#7ZH_LS^./CEH_P"R
M#I#^/?V3?%F@^,O"G@>TMW\$WNO:'+/JM];V:JT%K<VVH2VP5Y$V+)/)"/G4
ML%&['M=% '\\'Q$^ 7_!X7XA_;$\<?MF_#+X!0>#?$'C*&/3H8;3Q5X&O_[(
MT:&1GM]+MI;VZE>*!2V]PA032YE<%L$?H9_P0H^ G_!6?0[GXK?&W_@LQ=7E
MYXY\1)I.A^%;34=4T>ZB@T>U6ZEE\N/27:WB$LUWAP0'<P*6R IK]$Z* /R#
M_8/_ & /VJ/^"$7[3_[1MC\"OV6/%'QA^&'Q=T^SOOA9=>"[_3A/I-]:/?&W
MTO4H[VZ@:%!]N*&Z3>A2)7(#,R)[/_P;E_\ !&_Q7_P2<_9GU^_^.5W83_%+
MXDWMK=^*8-,G$T&DVMND@M;!91Q*Z&:=Y'3Y"\NU2RQJ[?HK10 4444 %>%^
M ?\ E()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$32O\ T8U 'NE%%% !1110
M 4444 %%%% !1110 445\^_MK_\ !2_]EW]AG2)(?B;XM&I>)GAWV'@W1&6:
M_FR,JT@SMMXS_?D(R,[0Y&*QKXBAA:3J5I*,5U9WY;E>8YQC(X3 TI5*DMHQ
M5WZ^275O1=6>_P!S<V]G;R7EY<)%%$A>661PJHH&2Q)X  YS7Y__ +<?_!>;
MX/?!N]G^%/[(^EP?$?QG)+]F348"SZ3:3D[0JM&=UZ^< +$0AS_K,@K7SE=^
M*/\ @J+_ ,%QM:DTOPQ9?\*[^#C7)29Q)+#ISH&Y627 EU.48^XH$2L!D1$[
MJ^^/V&_^"5'[+G[#=E!K?A70/^$C\9"+%SXTUV%7N5)&&%LG*VJ')&$^<@X9
MWKY_Z_F6<>[@5[.G_P _)+5_X8_J_P &?IRX<X3X&7M.(JBQ.+6V%I2]V+_Z
M?5%MYQCK_B3/BKX*?\$GOVU?^"B/CJV_:+_X*8_%+6]%TN7]Y8^&G*KJ30D@
M^5'!CRM-B/'&TR$@[D!.^OTW^ G[.7P2_9A\"0_#?X$_#K3O#NE18,D=G%F2
MY<#'F32MEYGQ_&[,<<9P,5VU%>EE^483+[R@N:;WE+63^?\ D?)<3<;YWQ.H
MT:S5/#P^"C37+3BNEHK=KN[OM9:!1117J'QX445S_P 2OBS\+O@WX<?Q=\6O
MB)HGAK2T.TW^NZG%:Q%O[H:1@&8]E&2>@%-)O8F4HPBY2=DCH**^&_CS_P %
MX?V8_ 'G:5\#O".M_$#4$R$NO+;2]-W#@@S3H9C[%(&0]FZ&OF75/VY/^"L'
M[>M_-X>^ NBZIHND2N8GA^'VF-:I&#T$VIS,7B<?WDE@!_NU\OF'&7#V75?8
MNM[2K_)27M)ORM'1/RDXGS>+XLRC#S]G1;JS_E@N;\=ON;/U%^-?[3'[/_[.
M>E+J_P </B]H/AI)4+6UOJ5^JW%T!U$, S+.?:-6/'2OB[X\_P#!?_X5:#YV
MD?LU_"#5?%,XRL>M^))#I=C[.D6U[B7W21(#_M5YU\%O^""OQ?\ &NJMXT_:
M>^,5MI,]ZXEU"WTQVU+4KD]Q-<RD('_VLS?X?9WP'_X)@_L7_L_B&]\/?".V
MUO5(<$:SXK(OY]PZ,JN/*C;WCC4UY_\ :?&6;:8+"QPT']NL^:=NZIQTB_*;
M:.3V_%N:?PJ<<-!]9>]/[MEZ-+U/STE^,'_!8+_@HP[6W@^?Q'8^';LX,/@^
MW.@:2JGA@;QG$LHQUC:XD!'\'.#ZI\ ?^#?B['EZM^T7\8(+-9'\RXT;P;;[
MI').26NIU #>N(FR<_-W/Z;QQI$@BB0*J@!548 'I2TUP52QTE/.<34Q36O+
M)\E-/NJ<+17XFE'A'!SJ*KCZDJ\_[S=ODD_PNT>.? C]@']D?]G+R;OX:_!C
M2QJ4."NMZJAO;W</XEEFW&(GTCVCVKV.LKQ!XX\'>%%+>(_$UE9D#/ESW"AS
M]%SD_@*X/Q'^UI\-M)W1Z)!>ZI(/NM%#Y49^K/@_^.FN_$9UPEPM1]E4K4J"
M7V59/_P".K^X^WRS(,75IJ&!P[Y?[L;1^_1?B>HU'=75O96LE[=S+'%#&7ED
M8X"J!DD^P%>&'X^_'+QZ3%\._A_Y$3_=N$MFF*_]M&Q&/Q%<3\75^,>D+;0?
M$WQ5*\M\K.NFK?;@J@XW,D?[L G@8]#Z5\EFOBIE^&P,\5@<+5K0C]MQ<*>N
MB]Z6NKZ<MSZ?!\'8FKB(T<16A"3^S?FGYZ+3\2;_ (7CJ'_"[O\ A9FZ3[)Y
M_D_9_P#IS^[MQZX^;_>KV'4OVI_A#8Y^S:G>7F.UM8N,_P#?S;7R[7MO[+VA
M?#/QEI-WI7B#PG97.JV,GF>9<*7\V%NAVDX^4\'CH5K\JX XMXKQ6:5<NPM>
MFIXB4JEZJD_?M>2CRO=K6S5O=TMU^PXDR7)J.#ABJU.3C22C:#2TV5[]NZUU
M-;4OVRO#,6?[(\&7\_I]IG2+/_?.^L__ (:<^*VO<>$?A6'W?=_T>>Y_] "U
M[-IOA3POHV/['\-V%ICI]FLT3'_?(%7Z_9O]7..,5_O.<<J[4Z,%_P"3-W/A
M/[4X?H_PL#?SE.3_  6AX4?$W[7_ (CXT_P^; -_TZ0Q8_[_ !)H_P"%4_M1
M^(O^0Q\0_L:M]]/[5=?TA7!KW6BC_B'M"O\ [[F&)J^3JM1^Z*7YA_K-4I_P
M,-2AYJ%W][9X9#^R%KFIN)_%'Q+,C=PEJTI/_ G<?RK:TW]C_P"'MMAM2US5
M;EAU59(XU/X!2?UKUFBNG#^&O!6'ES?5%)]YRG*__@4FOP,ZO%>?U5;VS2\E
M%?DCAM-_9N^#FFX8>$Q.P_BN;N5\_ANQ^E;^F_#GP!I&#IG@K2H2.CI81[OS
MQFMJBOHL+P]D.!_W?"4X>D(K\4CRZV9YCB/XM:<O63?ZB1QQPH(XHU50.%48
M I:**]A))61P[A1110 5#?:?8:G;FUU*RAN(B<F.>(.I_ \5-12:35F#29QF
MO?LX?L\^*L_\)1\!O!FI;L[OM_A>TFSGK]^,UQ6O_P#!.K]AOQ)N_M']E_PC
M'NZ_8--%I^7D%,?A7M%%<-;*LKQ'\6A"7K&+_-'+4P."K?'2B_6*?Z'S%KW_
M  1V_P""?.MEG@^"<^GNQR7L/$NH+^2O.RC\!7%:]_P0A_8MU;)TS7_'6EGG
M:+/6[=P#]);=R1^-?:5%>56X.X5K_%@J?R@E^21PU.'\CJ_%AH?**7Y6/SXU
M[_@WS^#]QN_X1?\ :%\2V>?N_;]*M[G'UV&+-<T__!!;XJ^$W,OPU_;)\DYR
MN[09[(_G%=/^>*_2RBO+J>''!LWS+#<K[QG-?E*QQ3X0X>D[JC9^4I+]3\TO
M^'8W_!5WP5\_P_\ VX_,C3D0#QYK$&[T^0Q,A_$T?\*0_P""]O@/_D7OBZ=9
M\O[O_%0:?<;O_ U!G\:_2VBH_P"(?973_@8G$4_\-62_.Y/^JF"C_"K58?X:
MC_6Y^:7_  N+_@OKX$X\0?"XZSLX;_B1Z7<;O_ )AG\*/^'EW_!6GP1QX\_8
M?\^%.7G/@'6(<CO^\64I^E?I;11_J=F=+^!FV(7^)QG^:0?ZOXRG_"QU5?XF
MI?FC\TU_X+O_ !F\'D)\3OV,Q"5XDQK-Q8\_26VDQ70Z#_P<&_"BXQ_PD_[.
MGB&SZ;OL&LP7./7[ZQ9K]"F564JP!!&"#WKGM>^$'PF\4DGQ/\+_  [J6XY;
M[?HD$V3_ ,#0T?V#QM1_A9LI+M*A#\T[A_9G$=/X,??_ !4X_FF?)F@_\%XO
MV,M5VKJGACQWIC$X9KK1;9U'OF*Y8D?A^%=IH/\ P60_X)]:UM6Z^,EWIKMT
M2_\ #-_U]"8X74?G7I.O?L)?L8>) ?[3_9:\" L/F>T\,V]NQ]\Q(IS[UQ>O
M_P#!)?\ X)]>(=S7/[/-K;N>CV&MW]OM^BQSA?S%'U?Q'H_!6PU3_%&I'_TD
M/9<7T_AJ49>JDOR/A?\ X+S?\%;M%\:_"3P/^Q=^P?\ 'K9KOQ@U2[B\8>*=
M ,L-UHOAZTB62Z2-F56AFN#(L:N/X$F7@L"/SH\&_L\_!+P'X=C\+^'?ACHJ
MVR( [7&GQS23' RTCN"SL<=237U!_P %ZOV"/A3^P7^TG^S_ /M%_"30+^Q\
M%^(IM9\)^([N^OWN(M/U&:*.:P7?(25\X+<#D]("2:\2K\I\3<TXEIXK#8?&
M24/<YFJ;ER.7-)75]79*.^U_,^&XSQN<QKT:6(?+[MVH-\KES/YNRMOM\SS[
M1/%OQY_X)R:YJ?[57_!/7QI=>#=3M[-F\7>$+$*^D^(+%5;?OM'#1+/&I9XW
M"Y4@X&2<_K%^P!_P3(TC]L'P+X7_ &Y/VL?BQ>>,;7Q]HEGX@TK2(-1D=[FW
MN(EEB^V7)._(5@##'C81C?P5K\J/VB?'V@?#CX,^(-?\03@"339;6SMAR]U<
MRHR1PHO5F9B!@=LGH#7]!'_!)?X(>.?V</\ @FA\#O@G\3;*:T\0Z#\-],BU
MJQN,^99W+PB62W;/1HF<QD=BE?0^'F!_UMR[VF<*5:.'E:GS-N+NDVFMI<O2
M]])6=TDEZW">&_MW"<V8)U%2E:',VT[K6ZZ\O2_>VUK>Y^#?!7A#X>>&K3P=
MX#\,V.CZ58Q^79Z=IMJL,,2^BJH 'J3W/)K3HHK]NA"%.*C%62V2/TF,8QBE
M%62"BBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X7X!_Y2
M">/_ /L1-*_]&-7NE>%^ ?\ E()X_P#^Q$TK_P!&-0![I1110 4444 %%%%
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MFM31_:"_X+)?M2_MI^.Y?V;/^"7?PKUJ$768YO%1M%.HRQ9VF5 Q\K3X>?\
M72MO&5.8FXKT?]BC_@@GX(\(:O'\:/VZO$W_  L+Q==3_:YM!:YDETZ*9CN+
M7,C_ +R^DSR=VV,G(*R##5]O_L^_LT? S]EGP)%\.?@/\.=/\/:8F#.+6/,U
MVX&/,GF;+S/_ +3L2!P,# KNJ6'R25:JJ^8S]K/HOL1]%U]7]QIF7B%# X.6
M6\+4/JF'>DIWO7J><ZF\?\,7IJD[.Q!I>EZ9H>FP:-HNG06=G:PK%:VEK"L<
M<,:C"HJJ %4   #@5/13+FYMK*WDO+RX2*&)"\LLKA510,DDG@ #O7T"71'Y
MBVV[L?17S-\>/^"N7[$/P+$UC'\3#XRU6(?\@OP/&M_DYP0;C<MLI!ZJ90P_
MNU\@_$7_ (+4?MB?M :ZW@']D3X*1Z'-<!A;M9:>^NZNP!XD1?+$,?'56AE
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M6YO!?[+'PV?PY;NP#0>$-(;5+^)&XQ->3QF.-?\ ;6&$KR=WI=^&_P#P1/\
MVN_CWXB3XB?M9?%]=(NIUQ//JNI2:YK!7.=A<R%%7T_?-M_N\8K]2]!\/>"O
MASX=BT/PQH>EZ#I-HN(;.PMH[6WA'LB!54?05SWB/]H7X2^&]R2^*H[R5?\
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MTU3@FFNJ:C=/T.FIFV:UH.%3$3<7NG.33]5<****]P\\**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML****LD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\+\ _P#*03Q_
M_P!B)I7_ *,:O:]9UG2/#NDW6O\ B#5;:QL+*W>>\O;R=8H8(D!9I'=B%10
M222  ,FOA+X<_P#!5[_@FA=?\%$/&EI%^W=\*]FH>%M.L+"]?QI:+:7-TDC;
MH8[DN(78=,!SDD =10!][45':7=K?VL5]8W,<T$T:R0S1.&21",AE(X((.01
M7AW[9G_!1;]F#]AO0&NOB]XT6?79H/,TWPCHY6?4KOT/EY AC//[R0JO! )/
M%95Z]'#4G4JR48KJSMR[+<?FV+CA<%2E4J2VC%7?_#=WLNI[I))'#&TLLBJB
MJ2S,<  =237P7^W5_P %V_@5^S[/<_#/]FJUMOB1XVWF 3VDI;2;&;. 'EC.
M;IP<?NX3@\@R*1BOD?XN_M6?MZ_\%8!<11>(](^#7P0:[-M>:GK.M#3],F R
M3%/=OM?4I\#_ (]X5VYVY1?OUU/P+^,__!+W_@G!!%JOP*\!:Q\:OB- BE_'
M&M6@TZSA?D.+43JSVN.<%(79@2#,1@5\5F?%5)0O&K&A2_Y^3W?_ %[AO+[O
MN/O\9EW GAM#VW%V)C6Q2U6$IRV?_3Z:NUYQBF]OB3+_ ,(_^"87[>/_  4V
M\<6G[07_  4<^)NL>&O#K'S-.\/21B._,#$'R[>T(\O3T(ZM(ID. 61L[Z_0
M'PSI7["/_!,WX81^$].U'PK\/M,:'SG2YN@=0U5DX,I!+7%Y(,GH'('   P/
MSX\8_M]_\%0?VP5>P^&-K-X.T&X79YGA:U-@K)NR&-].QEW@8!,+ID?P<UD_
M#K_@F+XO\=Z[)KOQB^(6H:MJ5[(TMY;Z$CW-S/(W\;W$REF;/7Y#G^]WKX*O
MXE\.Y34<<LHRQ%:6\YW5WY:.;]+1]3X_.>/./O$.G&AE>!E#!Q^"-E1P\5T:
MO;GMWO?>R6Q](_'K_@OE\'O#)GT?]G?X8:GXJN5+I'K&MO\ V?9=/EE2/#3R
MKGJCK ?>O"]:^+7_  5V_;FB6Y&K7O@?PI>['26UE'AS33$X*EDFD<75Y&1G
M**\X_P!FOIKX%?\ !.NW^',D-_X ^$FF:%<QLKQZUJK"2]C<#&Y)7WS1$]PF
MU>>E>XZ)^Q_:33?;?&WC:YNY7.9$LX]I)]W?<3^0KG^O>)7%.U"I"F^BMAX_
M^!2O4DGV5M#YW_4JK6USW-U%=:>'3?R<_P#-/U/@?X5_\$J_@!X4":I^T#\;
M=4\37GWI=%\#V7V>V$F[)#7=TN^5".NV*-N>#7U)\%?#'P\^$BBS_9/_ &5-
M&T6=5:,ZPME)?W^UNH:ZDS)C_99BH]*^CO#GP(^%/AC:]EX/MIY%_P"6U]F=
MB?7#Y /T KK888K>)88(E1%&%1%P /8"O;RKP\S^D^>IB:>&OO[&'--_]Q:M
MYI^FAZ^ P/ N0V>7X#GFOMU97?W*_P"AX3_PK']IOXB?-XO\7G3K=_OP/=A0
M1_US@&T_1B*VO#O['_@VQ*R^)O$-[J#CDI"!!&?K]YOU%>O45]/AO#?AF%55
ML9&>)J?S5IRF_NTC]Z/2J\4YM*')0<:4>T(J/XZO\3GO#GPH^''A/:VA>#K*
M*1?NS/%YD@_X&^6_6NAHHK[3"8+!X"E[+#4XTX]HI17W))'@UL17Q$^>K-R?
M=MM_B%%%%=)D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC[]0N)HF5E>!+=69]RD;5;@@$5_3%X;^']SX.LTT_P )V>B:;#&@1([+2UC
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%
M%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%
M%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O"_ /_ "D$\?\ _8B:5_Z,:O=*\+\ _P#*
M03Q__P!B)I7_ *,:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "O"_ /_*03Q__ -B)I7_HQJ]TKPOP#_RD$\?_ /8B:5_Z,:@#W2BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KFOC-\2]/^#'P?\5_&'5]-GO+3PGX:OM9NK.V_P!9/':V[SM&
MG^TP0@>YKI:BO["QU2QFTS4[.*XMKF)HKBWGC#I*C AE93PP()!!X(- '\_/
M[-?[;^J_\%?_ (.>'/C#^T-^V%XPM?B5=_M>>$-&7X5>"/'-WX>L_"OAJYOX
M$AFM+>RDBDN')DE7[=,TLD;HH4QL 7_3K]D[PK^W)^QK\;/CK\.?CK\;O%WQ
MA^$WA[P3IWBCX/ZUXIM(I-60M_: O=(GOHXD-W/&UM 0S[FV3Q-P68#\?_\
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M%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWH ]ZHKP7_ (5]_P %#_\
MHX+P)_X2[T?\*^_X*'_]'!>!/_"7>@#WJBO!?^%??\%#_P#HX+P)_P"$N]'_
M  K[_@H?_P!'!>!/_"7>@#WJBO!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\
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MA_\ T<%X$_\ "7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\
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M+P)_X2[T >]45X+_ ,*^_P""A_\ T<%X$_\ "7>C_A7W_!0__HX+P)_X2[T
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MT >]45X+_P *^_X*'_\ 1P7@3_PEWH_X5]_P4/\ ^C@O G_A+O0![U17@O\
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M<(DGA=MRAT# ''&>>U7O^%??\%#_ /HX+P)_X2[T >]45X+_ ,*^_P""A_\
MT<%X$_\ "7>C_A7W_!0__HX+P)_X2[T >]45X+_PK[_@H?\ ]'!>!/\ PEWH
M_P"%??\ !0__ *."\"?^$N] 'O5%>"_\*^_X*'_]'!>!/_"7>C_A7W_!0_\
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MA_\ T<%X$_\ "7>C_A7W_!0__HX+P)_X2[T >]45X+_PK[_@H?\ ]'!>!/\
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MC_#ZQN]+\ Z'IFH6[13V^CVT4\3]4=8E#*?<$$5L444 %%%% !1110 4444
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MQ-([7DGBKXB;ED.3$J7LL21CV1 J#V44 ?IM_P $SO\ @KS\0OB[^W[\8/\
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MBWPO:R6ECXKBL)&$H-M([F&<PK]I7:VQXM_RQF/]Y^G5?S*?L]>.?#?[4?\
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MQ/)&L<DP0;W12Q52>I +L0.VX^IH _ K]BK_ (.4?^"E_P #/^"C6E?L,?\
M!7;X.Z1I\>O>)K30]1:'0!IVH^'+B[=$M;A3$[0W5H3+&20&)C;S$D;;M?\
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M8JEO8_9]4EFTW3XY&"[C)81K#YTF,O<LY*KP/U$HH _G0NOC]X$OO^#31/\
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M*;NZ=L[55?LJ *,,6^#/^"5GQ'\,_P#!-7_@DG^W)^P3^VKXCTWP#\4]';Q
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M&U:.V^S1ZHUHAN5AR3Y8DQN"9).W.,DT 7P !@"BBB@ HHHH **** "BBB@
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M$7 4#@  =!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45C?$+XA>"/A/X(U3XD_$GQ19Z+H.BV;W>JZKJ$PC
MAMH5&2S$_D .22  20*^:_V O^"P/[+/_!0CQOXE^&WPVGO-%U[1;R9M*TK7
M2L<VM:<IP+V #\WB/SQ@@G()(ZJ6"Q=?#SKTX-PA\3Z*YRU<=A*&(A0J32G/
MX4WJ['U;1117*=0445\__P#!43]N72O^"<W[#GCG]K"ZT:#5=2T*RCM_#.AW
M#L!J>K7,J06EN0GS,IED5G"_-Y:.1C&: /H"BOE7_@D;_P %"_%O_!0?X >(
MM;^,WPYL?!7Q0^'?C[5/!_Q+\&6,[O'IFHVDQV[-Y+E&B9/F)(+I* 2%KZJH
M **** "BBB@ HHHH **** "BO!/^"D/[;%M^PE^S1<_%'1O"Z^)/&NOZS9^&
M/AAX.\S:WB'Q)?R>3968(((3=F20@@B**3'. ?8/!$_C/3_AWI-S\7M0T;_A
M((='@?Q-=:-%)!IXNQ$#<- LSNZ0;]Y4.[,%QDDY- &W17YL?\$N?^"\WB#]
MOG]MC7?V=_'GP9TWPMX/\4:-J^O? #Q5!<2F3Q9I>G:M<6$YE#DJ)BL#2[$
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MPDSS\DH)4G!:-XV(&[%>XT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%87C?XA>'_ /]G?V[/L_M*_6VBP?NYZN?\ 97C)]Q7/B\7A
ML#AY5\1-1@K7;T2N[+\78UHT:N(J*G2C>3V2-VBBBN@R"BBB@ HK\U?V@?\
M@O?K'P7_ ."L5E^QK9_"'2KSX.:/XQ\/>"/B)\3Y+J42Z1XFUJTO+BRMUP?*
M\I?(19"P)3RY\D$**_2J@ HHHH **** "BBB@ HK(\?^(KCPAX#UOQ;:6Z2R
MZ7I%S=Q12$[7:.)G"G'."5Q7Y3?L:?\ !5S_ (. OV]?V>=%_:A_9R_X)X_
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M3L_'-S+=2/;7MW;-:VE[,7GM$G>"$RO&PD>-Y8RVTIM]9_8_^#>G_P#!+_\
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M#3P9;Z^L/B[6)8O,O;[4)=%MY)"(&!C1'>/AXS&1B</V'_!)O]N;]G3X;_\
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M<K]VK[=K^I[AX._:YM-'\,66D^(O#=U=WEM (I;F*=0)=O 8YYSC&??-:?\
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MP[U_6_A#>VOB+3((;/Q3?Z7+!+I2VTERDENLLER8A*Z"%4L8<NH)QU&)X?\
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M_P"%7BW3_"$?AC5_B]JOQ!TC_A'H9%@^SR:Z8++S+J^N)/FG,0!)ED)9R,Y
M/G+XU_MG_M._%3_@T1\"_M,>)_BYKEU\0X/%UE8R>*AJ$BWMX+/Q-/:P--*&
MW2L888E=F),A!+9+&O:OV]_^"8>B_P#!-K_@D]^T?^TIX7_:?^+?BCXJ>*_A
MY81>-/$WB+QQ+)%<ZB=4LY;B\MX8U3R':3<JG<Q2+Y >6+<==?\ !)W_ (*(
M3_\ !LYIO_!-]OV=B?BSH/Q'^TQ>'E\6Z1Y=Y8?V_)?_ &M+DW?D!?*F/R/(
MLF4(V9QG]#/^"T7[.WQC_:S_ ."7_P 7_P!G;]G[P?\ V_XQ\4:!!;:%H_\
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M+Y[,1G4K1KIC:S2I(RYP6.;2(KD'S(\O]LKX*?\ !8/_ (*!_M"_LQ_M$O\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\3?\
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MGK.BW) #/;7,*RQ[@"=K@, R]58$'D4 =51110 4444 %%%% !1110 4444
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MH_L(R?LOV7Q OO'VKVFL_LW^/K311%-XQ66]@MI-)U.> +(\UO%*[(HR4D)
M'EW$)'TM_P '+EK\9?%?PW_8OLM&U33?"GQ"U+]I7PVEI>B(7UGHVLR0D+)M
M8#[1%%<$'! WJF".:ZGXE_\ !N=XK_;>36_'_P#P5._X*$^,/BQX^.AR6'P[
MU'PWHD/A[2O TK.D@NK6Q@<I/,6B0.SE0Z9# NL<J>P_''_@D9\4/VD_@5^R
M_P##KXT_MK:AKGBK]GOXC:-XOUOQKJOA%)Y_%TUBQ8V[*EQ%]FW#""9C,^$#
M.)7+,0#S[Q7^P!_P<'?$[0KCP)XP_P""VWA+0](U.)K?4]1\)_ ^SAU!(&!#
M^1*&1HWP>'1T=3R&!KZR_P""=_[!?P<_X)L?LI^'OV4?@E->7>FZ.9;G4=9U
M,J;K5K^9M\]W-M  9FP HX5$11G;D^W44 ?)/_!7C]D#]EC]N_X8?#G]FO\
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MPPS0![A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<K>_!#X2ZA\9K']HBZ\!:>?'&G>'YM
M"M/$Z1E;L:9+*LSVC.I&^$RHL@1LA6&X8))/544 %%%% !1110 4444 <KX\
M^!_PE^*'C#PIX]^(?@+3]9U;P-J<NH^$KN_C,G]EWDD+0M<1*3M$OELRAR"R
M[CM())KJJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124386232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,531,019,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,029,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified portions of the registrant&#8217;s Proxy Statement with respect to the 2022 Annual Meeting of Stockholders to be held May 17, 2022, are incorporated by reference into Part&#160;III of this annual report.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | The NASDAQ Global Select Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">2.00% Senior Notes Due 2026 | New York Stock Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.00% Senior Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124295256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los Angeles, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124518520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">6,454<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">4,819<span></span>
</td>
<td class="nump">4,207<span></span>
</td>
<td class="nump">4,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,368<span></span>
</td>
<td class="nump">5,730<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,340<span></span>
</td>
<td class="nump">16,285<span></span>
</td>
<td class="nump">13,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">7,639<span></span>
</td>
<td class="nump">9,139<span></span>
</td>
<td class="nump">9,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">6,701<span></span>
</td>
<td class="nump">8,133<span></span>
</td>
<td class="nump">9,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 10.34<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 12.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in the calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 24,297<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
<td class="nump">$ 22,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124195336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of reclassification adjustments and taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">(Losses) gains on foreign currency translation</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Gains (losses) on cash flow hedges</a></td>
<td class="nump">324<span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">(Losses) gains on available-for-sale securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">189<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 6,082<span></span>
</td>
<td class="nump">$ 6,807<span></span>
</td>
<td class="nump">$ 8,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124241112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,989<span></span>
</td>
<td class="nump">$ 6,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">4,895<span></span>
</td>
<td class="nump">4,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">4,086<span></span>
</td>
<td class="nump">3,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">2,079<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,385<span></span>
</td>
<td class="nump">21,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,184<span></span>
</td>
<td class="nump">4,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">15,182<span></span>
</td>
<td class="nump">16,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,890<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="nump">5,639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">61,165<span></span>
</td>
<td class="nump">62,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">10,731<span></span>
</td>
<td class="nump">10,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,184<span></span>
</td>
<td class="nump">11,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">33,222<span></span>
</td>
<td class="nump">32,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Long-term tax liabilities</a></td>
<td class="nump">6,594<span></span>
</td>
<td class="nump">6,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">2,465<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies and commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding&#8212;558.3 shares in 2021 and 578.3 shares in 2020</a></td>
<td class="nump">32,096<span></span>
</td>
<td class="nump">31,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(24,600)<span></span>
</td>
<td class="num">(21,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">9,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 61,165<span></span>
</td>
<td class="nump">$ 62,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129820120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock and additional paid-in capital, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock and additional paid-in capital, shares authorized</a></td>
<td class="nump">2,750.0<span></span>
</td>
<td class="nump">2,750.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock and additional paid-in capital, shares outstanding</a></td>
<td class="nump">558.3<span></span>
</td>
<td class="nump">578.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123783256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect of changes in accounting principles, net of taxes</div></th>
<th class="th"><div>Number of shares of common stock</div></th>
<th class="th"><div>Common stock and additional paid-in&#160;capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Cumulative effect of changes in accounting principles, net of taxes</div>
</th>
<th class="th"><div>Accumulated other comprehensive (loss) income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,246<span></span>
</td>
<td class="num">$ (17,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">7,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(3,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(7,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">9,673<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,531<span></span>
</td>
<td class="num">(21,330)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">7,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(3,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,843)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">$ (3,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">578.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 9,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,802<span></span>
</td>
<td class="num">(21,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">5,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(4,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">$ (4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">558.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,096<span></span>
</td>
<td class="num">$ (24,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (796)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124496440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122594488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and other</a></td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(453)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(237)<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Accrued income taxes, net</a></td>
<td class="num">(854)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="num">(585)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability', window );">Long-term tax liabilities</a></td>
<td class="nump">204<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">9,261<span></span>
</td>
<td class="nump">10,497<span></span>
</td>
<td class="nump">9,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(8,900)<span></span>
</td>
<td class="num">(8,477)<span></span>
</td>
<td class="num">(9,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">8,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">8,831<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
<td class="nump">20,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(880)<span></span>
</td>
<td class="num">(608)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="num">(2,529)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of equity method investments</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(3,219)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">733<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
<td class="nump">5,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of debt</a></td>
<td class="nump">4,945<span></span>
</td>
<td class="nump">8,914<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(4,150)<span></span>
</td>
<td class="num">(6,450)<span></span>
</td>
<td class="num">(4,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(4,975)<span></span>
</td>
<td class="num">(3,486)<span></span>
</td>
<td class="num">(7,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(4,013)<span></span>
</td>
<td class="num">(3,755)<span></span>
</td>
<td class="num">(3,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(8,271)<span></span>
</td>
<td class="num">(4,867)<span></span>
</td>
<td class="num">(15,767)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="num">(908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">6,266<span></span>
</td>
<td class="nump">6,037<span></span>
</td>
<td class="nump">6,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 7,989<span></span>
</td>
<td class="nump">$ 6,266<span></span>
</td>
<td class="nump">$ 6,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Noncurrent Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IncreaseDecreaseInNoncurrentTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129239672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;A expense in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the R&amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $843 million, $962 million and $789 million during the years ended December 31, 2021, 2020 and 2019, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;D projects with no alternative future use are recorded in R&amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#8217; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars by using average exchange rates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and nonmarketable equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other Income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other Income, net, in the Consolidated Statements of Income.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Equity method investments</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129238216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business combinations</a></td>
<td class="text">Acquisitions <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teneobio, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#8217;s existing antibody capabilities and BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#8217;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; R&amp;D technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for this transaction were (i) an upfront cash payment of $994&#160;million, which included a working-capital adjustment and (ii) future contingent milestone payments to Teneobio&#8217;s former equity holders of up to $1.6&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair value of the contingent consideration obligations aggregated $309&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pre-tax cost of debt. See Note 17, Fair value measurement, for information regarding the estimated fair value of these obligations as of December 31, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D assets totaled $1.1&#160;billion, of which $784&#160;million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of mCRPC, and the balance relates to four separate preclinical oncology programs. The R&amp;D technology rights of $94&#160;million relate to Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies and will be amortized over ten years using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred tax liability of $253&#160;million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $251 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Five Prime Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, Amgen acquired the outstanding stock of Five Prime for total consideration of $1.6&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. The operations of Five Prime have been included in our consolidated financial statements commencing after the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Five Prime to the bemarituzumab IPR&amp;D program of $1.5&#160;billion, which was expensed immediately in Acquired IPR&amp;D expense in the Consolidated Statements of Income; deferred tax assets of $177&#160;million; and other net liabilities of $47&#160;million. The acquired IPR&amp;D expense was not tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2019, we acquired worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene. Otezla is primarily used for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla. The operations of Otezla have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated cost (consideration transferred)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of 8.5 years by using the straight-line method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce is being amortized over a period of 5 years by using the straight-line method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#8217;s effort are applied. Inventory fair value adjustments is being amortized as inventory turns over, which we estimate to approximate 2.5 years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119&#160;million, a net deferred tax liability of $24&#160;million and a deferred credit of $96&#160;million. The tax effects of the acquisition are based on Amgen&#8217;s estimated blended statutory tax rate of 20%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuevolution AB</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2019, we acquired all of the outstanding stock of Nuevolution, a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution&#8217;s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129277240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of ROW revenues relates to products sold in Europe. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla was acquired on November 21, 2019.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2021, 2020 and 2019. For the year ended December 31, 2021, on a combined basis, these customers accounted for 82% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>As of December 31, 2021 and 2020, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 73% and 74%, respectively, of net trade receivables on a combined basis. As of December 31, 2021 and 2020, 27% and 28%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2021 and 2020, was not material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129239672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text">Stock-based compensation<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2021, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 19 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units and stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#8217;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2021, 2020 and 2019, were $233.10, $235.63 and $182.12, respectively. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair values of RSUs that vested during the years ended December 31, 2021, 2020 and 2019, were $166 million, $161 million and $160 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black&#8211;Scholes option valuation model to estimate the grant date fair value of stock options. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.64&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised during the years ended December 31, 2021, 2020 and 2019, were $56 million, $98 million and $68 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2021, 2020 and 2019, were $12 million, $21 million and $15 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, $346 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2021, 2020 and 2019, which are accounted for as equity awards, are based on (i) Amgen&#8217;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#8217;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, 1.6 million and 1.8 million performance units were outstanding, with weighted-average grant date fair values per unit of $229.39 and $207.52 per unit, respectively. During the year ended December 31, 2021, 0.6 million performance units with a weighted-average grant date fair value per unit of $254.68 were granted, and 0.2 million performance units with a weighted-average grant date fair value per unit of $226.32 were forfeited.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair values of performance units paid during the years ended December 31, 2021, 2020 and 2019, were $149 million, $230 million and $176 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.</span></div>As of December 31, 2021, $130 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129343096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined contribution plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined contribution plan</a></td>
<td class="text">Defined contribution planThe Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $279&#160;million, $231 million and $220 million for the years ended December 31, 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129224488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. Significant components of our deferred tax assets and liabilities were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,522)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased in 2021, primarily driven by the Company&#8217;s expectation that some state R&amp;D credits will not be utilized and certain foreign and acquired net operating losses will expire unused.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $75 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided no valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2040. We had $798 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $709 million of those state tax credit carryforwards.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $606 million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6 million of those federal NOL carryforwards. For the federal NOL carryforwards for which no valuation allowance has been provided, $426&#160;million have no expiration; the remainder begin to expire between 2022 and 2037. We had $391 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $330&#160;million of those state NOL carryforwards. We had $2.0 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $561 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $800 million has no expiry; and the remainder will expire between 2022 and 2031.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the UTBs as of December 31, 2021, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2021, 2020 and 2019, we recognized $98 million, $116 million and $198 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2021, was primarily due to lower interest rates during 2021 and settlement of a prior year audit. As of December 31, 2021 and 2020, accrued interest and penalties associated with UTBs were $881 million and $783 million, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the years ended December 31, 2021, 2020 and 2019, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#8217;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2035. Additionally, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing site in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes in 2021, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid during the years ended December 31, 2021, 2020 and 2019, were $1.9 billion, $1.4 billion and $1.9 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities (including the IRS) are becoming more aggressive and are particularly focused on such matters. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021, which seek to increase our U.S. taxable income. The Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $3.6&#160;billion plus interest. Any additional tax that could be imposed would be reduced by up to approximately $900&#160;million of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS&#8217;s positions set forth in the Notices are without merit, and we are contesting the Notices through the judicial process. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office. We were unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a statutory notice of deficiency for these years as well. We expect to contest any such notice related to 2013&#8211;15 through the judicial process. We are also currently under examination by the IRS for the years 2016, 2017 and 2018 and by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125998920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129338584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">Collaborations<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into collaborative arrangements for the R&amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8&#160;billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;D costs by providing cash and development services of up to $1.25&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $220&#160;million and $225&#160;million, respectively, and were recorded as an offset to R&amp;D expense in the Consolidated Statements of Income. During the year ended December 31, 2021, product sales from Amgen to BeiGene under the collaboration were $72&#160;million and were recorded in Product sales in the Consolidated Statements of Income. During the year ended December 31, 2021, profit and loss share expenses related to the initial product-specific commercialization period were $64&#160;million and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $21&#160;million and $22&#160;million as of December 31, 2021 and 2020, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $61&#160;million and $99&#160;million as of December 31, 2021 and 2020, respectively, which are included in Other current assets in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Note 19, Contingencies and commitments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangement through December 31, 2021</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal, recognized product sales of Aimovig in the United States, shared U.S. commercialization costs with Novartis and paid Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;D expenses. In addition, Novartis was required to make a payment to Amgen of up to $100&#160;million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangement after January 1, 2022</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the amendment effective January 1, 2022, Novartis retains the ex-U.S. Novartis Rights and will continue to pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide. In the United States, Novartis will no longer collaborate with Amgen or share Aimovig commercialization costs and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen manufactures and supplies Aimovig worldwide. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, net costs recovered from Novartis for migraine products were $160 million, $192 million and $187 million, respectively, and were recorded primarily in SG&amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due to Novartis for Aimovig were $116&#160;million, $139 million and $115 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due from Novartis for Aimovig were not material. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kyowa Kirin Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize an anti-OX40 fully human monoclonal antibody (AMG 451) worldwide, except in Japan. AMG 451 is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we will lead the global development, manufacture and commercialization of AMG 451, except in Japan. KKC will co-promote AMG 451 with Amgen in the United States and have opt-in rights to co-promote AMG 451 in various other markets outside the United States, including in Europe and Asia. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made an upfront payment of $400&#160;million to KKC that was recognized in R&amp;D expense in the third quarter of 2021. Amgen and KKC will share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850&#160;million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan. Net costs due to KKC were not material during the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417130799528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $733 million and $802 million as of December 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by contractual maturity were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual maturities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through three years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, realized gains and losses on interest-bearing securities were not material. For the year ended December 31, 2019, realized gains on interest-bearing securities were $92 million and realized losses were not material. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $611 million and $477 million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2021, 2020 and 2019, net unrealized gains on publicly traded securities were $161&#160;million, $174&#160;million and $112&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2021, 2020 and 2019, were not material. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $262 million and $203 million in equity securities without readily determinable fair values as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ets in the Consolidated Balance Sheets. For the year ended December 31, 2021, gains due to upward adjustments on these securities were $152&#160;million, and gains realized on the dispositions of these securities were $41&#160;million; for the years ended December 31, 2020 and 2019, gains due to upward adjustments and gains realized upon dispositions of these securities were not material. For the years ended December 31, 2021, 2020 and 2019, downward adjustments to the carrying values of these securities were not material. Adjustments were based on observable price transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8&#160;billion, of which $2.6&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;D. Our equity investment in BeiGene is included in Other noncurrent assets in the Consolidated Balance Sheets.</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our equity investment is accounted for under the equity method of accounting due to our ability to exert significant influence over BeiGene. See Note 1, Summary of significant accounting policies, for factors in concluding our ability to exert significant influence over BeiGene. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sets of BeiGene by approximately $2.4&#160;billion. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity method of accounting requires us to identify and allocate amounts to items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Other income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the carrying value of the investment was reduced by our share of BeiGene&#8217;s net losses of $265 million and $229&#160;million, respectively, and amortization of the basis difference of $172&#160;million and $109&#160;million, respectively. During the years ended December 31, 2021 and 2020, we increased the carrying value by $50 million and $569&#160;million, respectively, as a result of our purchase of additional shares of BeiGene. In addition, during the years ended December 31, 2021 and 2020, the carrying value increased by $265&#160;million and $34&#160;million, respectively, from the impact of other BeiGene ownership transactions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, our ownership interest in BeiGene was approximately 18.4% and 20.5%, respectively. As of December 31, 2021 and 2020, the carrying value of our investment in BeiGene was $2.8 billion and $2.9 billion, respectively. As of December 31, 2021 and 2020, the fair value of our investment in BeiGene was $5.1 billion and $4.9 billion, respectively. We believe that as of December 31, 2021, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257&#160;million, which is included in Other noncurrent assets in the Consolidated Balance Sheets, in exchange for a $100&#160;million cash payment and $157&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of December 31, 2021, our ownership interest in Neumora remained at approximately 25.9%, and the fair value of our investment was $220&#160;million. Accordingly, during the fourth quarter of 2021, we recognized a loss of $37&#160;million for the reduction in the fair value in Other income, net, in the Consolidated Statements of Income. For information on determination of fair values, see Note 17, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnerships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $573 million and $496 million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. These investments, which are primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2021, unfunded additional commitments to be made for these investments during the next several years were $185&#160;million. For the years ended December 31, 2021, 2020 and 2019, net gains recognized from our limited partnership investments were $143 million, $241&#160;million and $27 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129338584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129229400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, we recognized depreciation and amortization expense associated with our property, plant and equipment of $644 million, $640 million and $635 million, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geographic information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129345208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and other intangible assets</a></td>
<td class="text">Goodwill and other intangible assets<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition from acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;D projects may vary from their estimated fair values. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we acquired certain finite-lived and indefinite-lived intangible assets as a result of the Teneobio acquisition, including IPR&amp;D of $1.1&#160;billion, R&amp;D technology rights of $94&#160;million and licensing rights of $41&#160;million. See Note 2, Acquisitions.</span></div>During the years ended December 31, 2021, 2020 and 2019, we recognized amortization associated with our finite-lived intangible assets of $2.6 billion, $2.8 billion and $1.4 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2022, 2023, 2024, 2025 and 2026, are $2.5 billion, $2.5 billion, $2.4 billion, $2.2 billion and $1.8 billion, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417130796744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain facilities and equipment related primarily to administrative, R&amp;D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;D and administrative space.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_8e72894d-153e-4a5c-a949-14e5e6efb449"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_aa058334-0aaf-49a3-8af4-aa023d961fb9">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_425f51cf-a3fa-4258-bdbe-9af1266d73f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_ea705079-dbdc-4ad1-8743-a06d3d2376ba">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_b89a7ea2-fc91-480e-bd31-38a43ceb270a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_f7f1087e-27ba-483f-bdb7-bd0cc9f4c25f">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2021, 2020 and 2019.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2021, were as follows (in millions): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes future rental commitments for abandoned leases of $138&#160;million. We expect to receive total future rental income of $108&#160;million related to noncancelable subleases for abandoned facilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $35&#160;million. These leases will commence in 2022 with lease terms from 4 to 6 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129175304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets and accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AccruedLiabilitiesDisclosureTextBlock', window );">Other current assets and accrued liabilities</a></td>
<td class="text">Other current assets and accrued liabilities<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124452472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financing arrangements</a></td>
<td class="text">Financing arrangements<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% &#8364;1,250 million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due in 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#8212;except our 0.41% 2023 Swiss franc Bonds and Other notes due 2097&#8212;may be redeemed at any time at our option&#8212;in whole or in part&#8212;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt issuances</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, we issued debt securities in the following offerings:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we issued $5.0&#160;billion of debt consisting of $1.25&#160;billion of the 1.65% 2028 Notes, $1.25&#160;billion of the 2.00% 2032 Notes, $1.15&#160;billion of the 2.80% 2041 Notes and $1.35&#160;billion of the 3.00% 2052 Notes. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we issued $9.0&#160;billion of debt consisting of $500&#160;million of the 1.90% 2025 Notes, $1.75&#160;billion of the 2.20% 2027 Notes, $1.25&#160;billion of the 2.45% 2030 Notes, $1.25&#160;billion of the 2.30% 2031 Notes, $2.0&#160;billion of the 3.15% 2040 Notes and $2.25&#160;billion of the 3.375% 2050 Notes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any debt or debt securities during the year ended December 31, 2019. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt repayments/redemptions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made debt repayments/redemptions during the years ended December 31, 2021, 2020 and 2019, as follows:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2021, we redeemed $4.2&#160;billion of debt, including the &#8364;1.25&#160;billion aggregate principal amount ($1.4&#160;billion upon settlement of the related cross-currency swap) of the 1.25% 2022 euro Notes, the $500&#160;million aggregate principal amount of the 2.70% 2022 Notes, the $1.5&#160;billion aggregate principal amount of the 2.65% 2022 Notes and the $750&#160;million aggregate principal amount of the 3.625% 2022 Notes. In connection with the redemption of these notes, we paid a total of $24&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2020, we repaid/redeemed $6.5&#160;billion of debt, including the repayment at maturity of the $300&#160;million aggregate principal amount of the 4.50% 2020 Notes, the $750&#160;million aggregate principal amount of the 2.125% 2020 Notes, the $300&#160;million Floating Rate Notes due 2020 and the $700&#160;million aggregate principal amount of the 2.20% 2020 Notes. In connection with the redemption of the $900&#160;million aggregate principal amount of the 3.45% 2020 Notes, the $1.0&#160;billion aggregate principal balance of the 4.10% 2021 Notes, the $750&#160;million aggregate principal balance of the 1.85% 2021 Notes and the $1.75&#160;billion aggregate principal balance of the 3.875% 2021 Notes, we paid a total of $96&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">In 2019, we repaid $4.5 billion of debt, including the $1.4 billion aggregate principal amount of the 2.20% 2019 Notes, the $1.0 billion aggregate principal amount of the 5.70% 2019 Notes, the &#8364;675 million aggregate principal amount ($864&#160;million upon settlement of the related cross-currency swap) of the 2.125% 2019 euro Notes, the $700 million aggregate principal amount of the 1.90% 2019 Notes and the $550 million Floating Rate Notes due 2019.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.0&#160;billion with respect to the 2.45% 2030 Notes and an aggregate notional amount of $500&#160;million with respect to the 2.30% 2031 Notes. In connection with the redemption of the 3.625% 2022 Notes, discussed above, associated interest rate swap contracts with an aggregate notional amount of $750&#160;million were terminated.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of certain of the notes during the year ended December 31, 2020, discussed above, associated interest rate swap contracts with an aggregate notional value of $3.65&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2&#160;billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and the 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2022 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2024 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% 2025 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% 2026 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% 2030 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% 2031 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% 2051 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR +4.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 4.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A = not applicable</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt exchange</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $940&#160;million principal amount of the newly issued 2.77% 2053 Notes (the Exchange Offer).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% 2038 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% 2039 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% 2040 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% 2041 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% 2042 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% 2043 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2.77% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the 2.77% 2053 Notes. In connection with the Exchange Offer, $85 million was paid to holders of the Old Notes (the cash consideration).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $264 million discount associated with the 2.77% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cross-currency swaps</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the redemption of the 1.25% 2022 euro Notes, discussed above, associated cross-currency swap contracts with an aggregate notional amount of &#8364;1.25 billion were terminated. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf registration statement and other facilities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2021 and 2020, we had no amounts outstanding under our commercial paper program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1%. The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2021 and 2020, no amounts were outstanding under this facility.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual maturities of debt obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2021, are as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2021, 2020 and 2019, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2021, 2020 and 2019, were $1.2 billion, $1.2 billion and $1.3 billion, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129196072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text">Stockholders&#8217; equity<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Total shares do not add due to rounding.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, October 2021 and December 2021, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $3.4 billion, $4.5&#160;billion and $5.0&#160;billion, respectively. As of December 31, 2021, $10.9 billion remained available under our stock repurchase program. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors declared quarterly dividends per share of $1.76, $1.60 and $1.45, which were paid in each of the four quarters of 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 3, 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share of common stock, which will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $33 million expense and a $55 million expense in 2021, a $14 million benefit and a $110 million benefit in 2020 and a $28 million expense and a $46 million benefit in 2019, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $1 million expense and a $7 million benefit in 2020 and a $22 million expense and a $14 million benefit in 2019, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract (losses) gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2021 and 2020, no shares of preferred stock were issued or outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129268088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text">Fair value measurement<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair values of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available information for similar companies that have actively traded equity securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Teneobio in 2021, we are obligated to pay its former shareholders up to $1.6&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;D programs. See Note 2, Acquisitions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of BioVex Group Inc. in 2011, we were obligated to pay its former shareholders upon achieving separate sales-related milestones with regard to IMLYGIC if certain sales thresholds were met. During the year ended December 31, 2020, we determined that the likelihood of achieving these milestones was no longer probable, and accordingly, the obligations were written off.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2021 and 2020, the aggregate fair values of our borrowings were $37.9 billion and $39.4 billion, respectively, and the carrying values were $33.3 billion and $33.0 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2021 and 2020, the fair values were $5.1&#160;billion and $4.9&#160;billion, and the carrying values were $2.8&#160;billion and $2.9&#160;billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129308616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative instruments</a></td>
<td class="text">Derivative instruments<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.7 billion, $5.1 billion and $5.0 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The notional amounts and interest rates of our cross-currency swaps as of December 31, 2021, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, our 1.25% euro Notes were redeemed, and the related cross-currency swaps were settled, resulting in an immaterial loss. During the year ended December 31, 2019, our 2.125% 2019 euro Notes matured, and the related cross-currency swaps were settled. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts to hedge variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2021, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2021 and 2020, we had interest rate swap contracts with aggregate notional amounts of $6.7&#160;billion and $5.9 billion, respectively, that hedge certain portions of our long-term debt issuances. See Note 15, Financing arrangements, for information on our interest rate swaps.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.5&#160;billion. Interest rate swaps with an aggregate notional value of $750&#160;million were terminated in connection with the redemption of certain of our notes. The resulting gain on these terminations was immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, interest rate swaps with an aggregate notional value of $3.7&#160;billion were terminated in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $40&#160;million, recognized in Interest expense, net, in the Consolidated Statements of Income. Additionally, we terminated $5.2&#160;billion aggregate notional amount of interest rate swaps, which resulted in receipt of $576&#160;million from the counterparties and which was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2020. This amount is being recognized as a reduction in Interest expense, net, in the Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2&#160;billion principal amount of notes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $85 million and $89 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $440 million and $525 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $85 million and $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $340 million and $425 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2021, we expected to reclassify $19 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2021, 2020 and 2019, the total notional amounts of these foreign currency forward contracts were $680 million, $1.0 billion and $1.2 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2021, 2020 and 2019. </span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative contracts that were in liability positions as of December 31, 2021, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our, or the surviving entity&#8217;s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129248504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and commitments</a></td>
<td class="text">Contingencies and commitments <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Sandoz Inc., et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC (Amneal); Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited (MSN); Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc. (Sandoz); Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc. (Zydus), each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#8217;940 Patent), 7,208,516 (the &#8217;516 Patent), 7,427,638 (the &#8217;638 Patent), 7,659,302 (the &#8217;302 Patent), 7,893,101 (the &#8217;101 Patent), 8,455,536 (the &#8217;536 Patent), 8,802,717 (the &#8217;717 Patent), 9,018,243 (the &#8217;243 Patent) and 9,872,854 (the &#8217;854 Patent), which are listed in the Orange Book for Otezla. Each of these lawsuits was based on each defendant&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Celgene filed amended complaints against Alkem, Amneal, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz, Actavis, Unichem and Zydus additionally asserting U.S. Patent No. 9,724,330 (the &#8217;330 Patent), which is listed in the Orange Book for Otezla. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN, Pharmascience, Prinston, Sandoz, Actavis, Torrent, Unichem and Zydus additionally asserting U.S. Patent No. 10,092,541 (the &#8217;541 Patent), which is listed in the Orange Book for Otezla. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#8217;940, &#8217;302, &#8217;536, &#8217;243 and &#8217;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#8217;283 Patent) and 8,629,173, which are not listed in the Orange Book for Otezla. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene Corp. v. Sandoz Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz, Shilpa, Actavis, Torrent, Unichem and Zydus filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Amgen&#8217;s acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;854 and &#8217;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the &#8217;717, &#8217;516 and &#8217;854 Patents, leaving the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#8217;s apremilast product during the term of the &#8217;940, &#8217;302, &#8217;536, &#8217;243, &#8217;330, &#8217;638, &#8217;101 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#8217; apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal&#8217;s apremilast product during the term of the &#8217;101, &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;243, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#8217;s apremilast product during the term of the &#8217;638, &#8217;101 and &#8217;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#8217; apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;536, &#8217;717, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston&#8217;s apremilast product during the term of the &#8217;638 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo&#8217;s apremilast product during the term of the &#8217;940, &#8217;516, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;717, &#8217;243, &#8217;330, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent&#8217;s apremilast product during the term of the &#8217;101, &#8217;638, &#8217;854 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN&#8217;s apremilast product during the term of the &#8217;940, &#8217;638, &#8217;302, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience&#8217;s apremilast product during the term of the &#8217;243, &#8217;940, &#8217;638, &#8217;302, &#8217;101, &#8217;536, &#8217;330 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL&#8217;s apremilast product during the term of the &#8217;638, &#8217;101, &#8217;536 and &#8217;541 Patents, unless authorized pursuant to a confidential settlement agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 2 and 27 of the &#8217;283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the &#8217;101 Patent and claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus&#8217;s ANDA must be after expiration of the three infringed patents (the &#8217;638, &#8217;536 and &#8217;283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus&#8217;s generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the &#8217;638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the &#8217;638 Patent, claim 6 of the &#8217;536 Patent and claims 1 and 15 of the &#8217;101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the &#8217;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz&#8217;s ANDA must be after expiration of the three infringed patents (the &#8217;638, &#8217;536 and &#8217;101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz&#8217;s generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the &#8216;638 and &#8216;101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis&#8217; submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#8217;s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the &#8217;522 Patent), 7,915,225, 8,119,605 and 8,722,631. By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis&#8217; etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court&#8217;s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche&#8217;s &#8217;522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties&#8217; submission.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Sanofi, et al. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Amgen initiated a series of lawsuits that were consolidated by the U.S. District Court for the District of Delaware (Delaware District Court) in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#8217;165 Patent); 8,859,741 (the &#8217;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to PCSK9. By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#8217;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#8217;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#8217;s infringement of Amgen&#8217;s patents is willful.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT infringe certain of Amgen&#8217;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a five-day jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#8217;s post-trial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#8217;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#8217;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron&#8217;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#8217;s conclusion that the judgment affirming the validity of Amgen&#8217;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#8217;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#8217;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#8217;s claim of willful infringement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, a jury of the Delaware District Court again unanimously upheld the validity of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent. The jury also found that claims 7 and 15 of the &#8217;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse the jury verdict against them or for a new trial, and Amgen filed a motion for a permanent injunction. On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron&#8217;s request for a new trial and their request to reverse the jury verdict that the &#8217;165 Patent and the &#8217;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court and based on the subsequent hearing, on February 11, 2021 the Federal Circuit Court issued a decision affirming the Delaware District Court&#8217;s ruling. Amgen filed a petition for rehearing en banc which was denied on June 21, 2021. On November 18, 2021, Amgen filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the invalidation of claims 19 and 29 of the &#8217;165 Patent and claim 7 of the &#8217;741 Patent as lacking an enabling disclosure of the invention. On January 11, 2022, the U.S. Supreme Court requested that Sanofi and Regeneron file a response to Amgen&#8217;s petition, which is due March 14, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany, Spain and Japan. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#8217;s patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#8217;s patent. In November 2018, the EPO confirmed the validity of Amgen&#8217;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA&#8217;s decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA&#8217;s October 29, 2020 ruling.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#8217;s appeals making final the Japanese High Court&#8217;s decisions that PRALUENT infringes Amgen&#8217;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#8217;s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. The Japanese Patent Office dismissed Regeneron&#8217;s invalidity trials and Regeneron has appealed the decisions to the Japanese High Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEUPOGEN (filgrastim)/Neulasta Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc., et al. v. Hospira Inc. et al.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Hospira Inc. and Pfizer Inc. (collectively, Pfizer). This lawsuit stems from Pfizer&#8217;s submission of an application for FDA licensure of a pegfilgrastim product as biosimilar to Amgen&#8217;s Neulasta. Amgen has asserted infringement of U.S. Patent No. 8,273,707 (the &#8217;707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#8217;707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the &#8217;707 Patent. In June 2020, the FDA approved Pfizer&#8217;s NYVEPRIA, a biosimilar to Amgen&#8217;s Neulasta. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2021, the Delaware District Court stayed further proceedings in the matter pending claim construction of the patent claims and, based on a subsequent hearing, determined on June 11, 2021 that the term at issue required no construction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently pending before the Delaware District Court is Pfizer&#8217;s motion for summary judgment of noninfringement, which has been fully briefed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No date has been set for argument on the motion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Trial and Appeal Board (PTAB) Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Apotex PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the PTAB of the USPTO granted Apotex&#8217;s petition to institute inter partes review (IPR) proceeding of U.S. Patent No. 8,952,138 (the &#8217;138 Patent), challenging claims of the &#8217;138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the &#8217;138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2019, the PTAB issued a decision denying Apotex&#8217;s request for rehearing on the PTAB&#8217;s finding and sua sponte amending the final decision with a finding that the one remaining claim in Amgen&#8217;s &#8217;138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court&#8217;s decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inc. v. Smith &amp; Nephew, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., 941 F.3d 1320 (Fed. Cir. 2019). </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the &#8217;138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the &#8217;138 Patent, for proceedings consistent with its decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex Inc. v. Smith &amp; Nephew, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requesting that such remanded cases be held pending the U.S. Supreme Court&#8217;s disposition of the petition for writ of certiorari in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Arthrex, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government&#8217;s petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2021, the U.S. Supreme Court decided</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> United States v. Arthrex, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 28, 2021, the U.S. Supreme Court granted the government&#8217;s pending certiorari petition and vacated and remanded the Federal Circuit Court&#8217;s judgment for further consideration under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2021, the Federal Circuit Court issued a remand to permit Amgen to request rehearing of the PTAB&#8217;s final written decision holding that all claims of the &#8217;138 Patent as unpatentable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2021, Amgen filed a request for the USPTO Director for a rehearing and review of the Final Written Decision pursuant to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arthrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On November 22, 2021, the Director denied this request. On December 6, 2021, Amgen filed the Notice of Director review with the patent office.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer PTAB Challenge</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2021, Pfizer filed a petition to institute IPR proceeding at the USPTO of U.S. Patent No. 8,273,707 (the &#8217;707 Patent), challenging claims of the &#8217;707 Patent as unpatentable. Amgen&#8217;s preliminary response was filed on May 18, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the PTAB of the USPTO granted Pfizer&#8217;s petition to institute IPR of the &#8217;707 Patent. On August 23, 2021, the PTAB issued the schedule for the proceeding, including oral argument (if requested) on May 18, 2022. On November 17, 2021, Amgen filed its Patent Owner&#8217;s Response.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breach of Contract Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharma AG v. Amgen Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York (the New York Southern District Court) against Novartis seeking a declaratory judgment that Novartis materially breached two collaboration agreements Amgen and Novartis entered into in 2015 and 2017 (the 2015 Agreement and the 2017 Agreement, respectively) related to the development and commercialization of Aimovig due to Novartis&#8217; affiliate Sandoz GmbH entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig and entrant in the CGRP-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis&#8217; complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz GmbH entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. On July 16, 2019, Novartis filed an amended complaint adding a claim for breach of contract alleging Novartis is owed amounts associated with 2018 budget overruns, and Amgen responded with a counterclaim alleging additional breaches by Novartis of the collaboration agreements. On September 17, 2019 and October 8, 2019, Novartis and Amgen, respectively, each filed its motion for judgment on the pleadings. On February 3, 2020, Amgen was granted leave to file its amended counterclaims. On February 4, 2020, Amgen filed its amended answer to Novartis&#8217; first amended complaint and second amended counterclaims for affirmative relief to add a fraudulent inducement claim. On February 18, 2020, Novartis filed its answer and affirmative defenses to Amgen&#8217;s second amended counterclaims. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, the New York Southern District Court entered an order granting Novartis&#8217; motion for judgment on the pleadings that Novartis did not breach the 2017 Agreement, and denying Amgen&#8217;s motions for judgment on the pleadings seeking dismissal of Novartis&#8217; amended complaint that Novartis did not breach the 2015 Agreement or the 2017 Agreement, and Novartis timely cured any breach. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the June 9, 2020 order, which was denied on September 14, 2020. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, the parties executed agreements to settle two claims in the litigation, relating to the 2018 budget overrun dispute and certain counterclaims alleging breaches by Novartis of the 2015 and 2017 Agreements related to the development and commercialization of Aimovig, and to amend and restate the 2017 collaboration agreement. As part of the agreement, Amgen paid $48&#160;million to Novartis to resolve the 2018 budget dispute.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the New York Southern District Court held a status conference with the parties and set the dates for Novartis&#8217; opening brief for its motion for partial summary judgment on two claims, fraudulent inducement and negligent misrepresentation.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the parties resolved all claims in the litigation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Class Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From February to April 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceuticals USA, Inc. (Teva) alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. Two of those actions were brought in the Delaware District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 21, 2019) (Local 1500) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cesar Castillo, Inc. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar and alleges that the plaintiffs have overpaid for Sensipar as a result of Amgen&#8217;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson Laboratories, Inc. (Watson) and Teva of the parties&#8217; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#8217; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cipla Ltd. v. Amgen Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consolidated and designated as an MDL in the Delaware District Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#8217; consolidated class action complaint and the indirect purchaser end payor plaintiffs&#8217; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#8217;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims v. Amgen Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Delaware District Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#8217;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#8217; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#8217;s recommendation in part and denied it in part, denying Amgen&#8217;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#8217;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#8217; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#8217;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the plaintiffs in the antitrust class action lawsuit brought on behalf of putative classes of direct or indirect purchasers of Sensipar filed their amended complaints. On March 4, 2021, a stipulation and order regarding the filing of a second amended complaint were filed to add another plaintiff: Teamsters Western Region &amp; Local 177 Health Care Fund. On March 17, 2021, a defendant, MSP Recovery Claims, Series LLC, filed its notice of voluntary dismissal. On March 30, 2021, the remaining defendants, including Amgen, filed their motions to dismiss the second amended complaint.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2021, plaintiffs filed their oppositions to defendants&#8217; (including Amgen&#8217;s) motion to dismiss, and defendants&#8217; reply was filed on May 25, 2021. A hearing on defendants&#8217; motion to dismiss was held in the Delaware District Court on July 13, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humira Biosimilar Antitrust Class Actions </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From March to May 2019, twelve purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie), were filed in the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court). The cases are captioned: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UFCW Local 1500 Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 18, 2019) (Local 1500); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (March 20, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mayor and City Council of Baltimore v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 22, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pipe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trades Services MN Welfare Fund v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">St. Paul Electrical Workers&#8217; Health Plan v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(March 29, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C and 137R v. AbbVie Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 1, </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 9, 2019) (Law Enforcement); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(April 16, 2019); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sheet Metal Workers&#8217; Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 19, 2019) (Sheet Metal Workers&#8217;); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Locals 302 &amp; 612 of The International Union of Operating Engineers-Employers Construction Industry Health And Security Trust Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 25, 2019) (Construction Industry); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Louisiana Health Service &amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (April 30, 2019) (Louisiana Health); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (May 10, 2019) (Cleveland Bakers) (collectively, Humira Antitrust Class Actions).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the Humira Antitrust Class Actions, the plaintiffs bring federal antitrust claims along with various state law claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully monopolized the alleged market for Humira and biosimilars of Humira, including by creating an allegedly unlawful so-called patent thicket around Humira. In the Local 1500, Sheet Metal Workers&#8217; and Construction Industry cases, the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira biosimilars, including Bioepis, Mylan, Sandoz, Fresenius Kabi USA, LLC (Fresenius), Pfizer Inc. and Momenta Pharmaceuticals, Inc., in connection with the settlement of patent litigation relating to Humira, whereby Amgen and the other defendants that have developed Humira biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA, its Humira biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira biosimilar in that market for five months, beginning in January 2023. In each of the Humira Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney&#8217;s fees on behalf of a putative class of third-party payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira in the United States. Defendants&#8217; responses to the first six complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the twelve purported class action cases for pre-trial purposes. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz and Fresenius. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual motions), challenging the legal sufficiency of the plaintiffs&#8217; allegations to state any claim for relief under the law. On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support of the motion to dismiss. On June 8, 2020, the Illinois Northern District Court issued an order granting the motion by the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the FTC and one on behalf of 20 states, each filed on October 13, 2020. On December 21, 2020, the defendants-appellees filed their opposition brief. Defendants-appellees amicus briefs, including one by the DoJ, were filed on December 28, 2020. On February 25, 2021, oral argument was held by the U.S. Court of Appeals for the Seventh Circuit on the appeal by plaintiffs-appellants of the lower court&#8217;s dismissal of the consolidated complaint with prejudice. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6, Income taxes, for discussion of the IRS tax dispute and the Company&#8217;s petition in the U.S. Tax Court.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments &#8211; U.S. repatriation tax</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2021 (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129140040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31, 2021, 2020 and 2019 </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at beginning<br/>of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>charged&#160;to<br/>costs and<br/>expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance<br/>at end<br/>of period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124447256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NatureOfOperationsPolicyTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues and Arrangements with multiple performance obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales and sales deductions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#8217;s products, primarily in Europe, are excluded from revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;A expense in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements with multiple-performance obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into arrangements for the R&amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#8217; costs; and amortization of acquired technology used in R&amp;D with alternative future uses. R&amp;D expenses also include costs and cost recoveries associated with third-party R&amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, general and administrative costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative costs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $843 million, $962 million and $789 million during the years ended December 31, 2021, 2020 and 2019, respectively. SG&amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.</span></div>We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#8217;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;D projects with no alternative future use are recorded in R&amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Interest-bearing securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#8217; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and other intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#8217; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of IPR&amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#8217; earnings are translated into U.S. dollars by using average exchange rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityInvestmentsPolicyPolicyTextBlock', window );">Equity investments, policy</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and nonmarketable equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other Income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other Income, net, in the Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity method investments</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Equity method investments</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#8217; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income, net, in the Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income, net, in the Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the policy for investments in equity securities that are publicly traded and that do not have a readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129197512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; R&amp;D technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated cost (consideration transferred)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122384008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue by product and by geographic area</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Otezla was acquired on November 21, 2019.</span></div>(2)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenues earned from major customers</a></td>
<td class="text">Certain information with respect to these customers was as follows (dollar amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total gross revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124296952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock', window );">Components of stock-based compensation expense recognized in the Consolidated Statements of Income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit from stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSUs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our RSUs:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant&#160;date<br/>fair&#160;value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance nonvested as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (average of implied and historical volatility)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our stock options:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>(in&#160;millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise&#160;price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value<br/>(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance unexercised as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.64&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock', window );">Weighted average assumptions used and the resulting weighted average grant date fair value of performance units</a></td>
<td class="text">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing price of our common stock on grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of units granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124266328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income before income tax, domestic and foreign</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes included the following (in millions):</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes included the following (in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred benefit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant components of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses capitalized for tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,522)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the total gross amounts of UTBs were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, Puerto Rico excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits, primarily federal R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129212920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation for basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126233336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock', window );">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair values of available-for-sale interest-bearing security investments by contractual maturity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of available-for-sale investments by contractual maturity were as follows (in millions):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual maturities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through three years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129219128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125406232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;life&#160;(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-40</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-12</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Property, plant and equipment by geographic information</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126141976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill were as follows (in millions):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition from acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock', window );">Schedule of identifiable intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417130763096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary information, components of lease costs, cash and noncash information on leases and other lease information</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_8e72894d-153e-4a5c-a949-14e5e6efb449"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_aa058334-0aaf-49a3-8af4-aa023d961fb9">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_425f51cf-a3fa-4258-bdbe-9af1266d73f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_ea705079-dbdc-4ad1-8743-a06d3d2376ba">Accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_b89a7ea2-fc91-480e-bd31-38a43ceb270a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_f7f1087e-27ba-483f-bdb7-bd0cc9f4c25f">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net lease costs were as follows (in millions): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2021, 2020 and 2019.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and weighted-average discount rates were as follows:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and noncash information related to our leases was as follows (in millions): </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2021, were as follows (in millions): </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.810%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div>(1)&#160;&#160;&#160;&#160;Includes future rental commitments for abandoned leases of $138&#160;million. We expect to receive total future rental income of $108&#160;million related to noncancelable subleases for abandoned facilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122817304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets and accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate partner receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales deductions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,141&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122385256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Carrying values and the fixed contractual coupon rates of long-term borrowings</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% &#8364;1,250 million notes due 2022 (1.25% 2022 euro Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70% notes due 2022 (2.70% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65% notes due 2022 (2.65% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2022 (3.625% 2022 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due in 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of interest rate derivatives</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective interest rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2022 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 2.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% 2024 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 3.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% 2025 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% 2026 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% 2030 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 1.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% 2031 Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 0.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% 2051 Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR +4.1%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR + 4.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notional amounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A = not applicable</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock', window );">Schedule of Long-term Debt Instruments Exchanged</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal amount exchanged</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% 2037 Notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% 2038 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% 2039 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% 2040 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% 2041 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% 2042 Notes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% 2043 Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate contractual maturities of long-term debt obligations</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December 31, 2021, are as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Long-term Debt Instruments Exchanged [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126172552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_StockRepurchaseProgramTableTextBlock', window );">Summary of activity under our stock repurchase program</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.304%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Total shares do not add due to rounding.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of accumulated other comprehensive income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassifications out of accumulated other comprehensive income</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings were as follows (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract (losses) gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_StockRepurchaseProgramTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_StockRepurchaseProgramTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124249384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Changes in contingent consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126590296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock', window );">Schedule of notional amounts and interest rates for cross-currency swaps</a></td>
<td class="text">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2021, were as follows (notional amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock', window );">Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivatives in fair value hedging relationships</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $85 million and $89 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $440 million and $525 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt">Current portion of long-term debt includes $85 million and $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $340 million and $425 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Summary of amounts of income and expense line items</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div>(1)&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair values of derivatives included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance&#160;Sheets&#160;locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;current&#160;assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129155880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock', window );">U.S. repatriation tax commitments</a></td>
<td class="text">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2021 (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining U.S. repatriation tax commitments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122613336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_SalesReturnProvisionsAsPercentageOfProductSales', window );">Sales return provisions as a percentage of gross product sales (less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising cost | $</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RevenuePaymentArrangementTerm', window );">Revenue payment term</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RevenuePaymentArrangementTerm', window );">Revenue payment term</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RevenuePaymentArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Payment Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RevenuePaymentArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_SalesReturnProvisionsAsPercentageOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Return Provisions As Percentage Of Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_SalesReturnProvisionsAsPercentageOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417118817048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Aggregate Consideration Paid (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 19, 2021</div></th>
<th class="th"><div>Nov. 21, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
<td class="nump">$ 14,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Additions</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_Businessassetacquisitionconsiderationtransferred', window );">Business asset acquisition, consideration transferred</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Other assets, net</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet', window );">Total assets acquired, net</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_Transactioncostsassetacquisition', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_Businessassetacquisitionconsiderationtransferred', window );">Business asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionDeferredCredit', window );">Deferred credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther', window );">Other liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionInventoryacquired', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla | Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla | Marketing-Related Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionDeferredCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Deferred Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionDeferredCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionInventoryacquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Inventory acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionInventoryacquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Noncurrent Liabilities Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Businessassetacquisitionconsiderationtransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business asset acquisition, consideration transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Businessassetacquisitionconsiderationtransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Transactioncostsassetacquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs, asset acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Transactioncostsassetacquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417117448248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 21, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>market</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Estimated fair values of contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,890<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">14,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate', window );">Estimated blended statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum additional consideration due contingent on certain milestones</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Estimated fair values of contingent consideration obligations</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Fair value of liabilities assumed, deferred tax liabilities</a></td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Fair value of assets acquired and liabilities assumed, net other assets and liabilities</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired in-process research and development</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | IPR&amp;D | AMG 340</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember', window );">Five Prime Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Fair value of liabilities assumed, deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ApprovedMarkets', window );">Approved markets | market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Adjustments to carrying value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities', window );">Adjustments to deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits', window );">Adjustments to deferred credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla | Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife', window );">Acquired assets, weighted useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla | Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember', window );">Otezla | Marketing-Related Rights | Assembled Workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember', window );">Nuevolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Fair value of liabilities assumed, deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Fair value of assets acquired and liabilities assumed, net other assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember', window );">Nuevolution | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Assets, Weighted Average Useful Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ApprovedMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Approved Markets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ApprovedMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_MoleculeTypeAxis=amgn_AMG340Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_MoleculeTypeAxis=amgn_AMG340Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AssetsByDescriptionAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AssetsByDescriptionAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_MarketingRelatedRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AssetsByDescriptionAxis=amgn_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AssetsByDescriptionAxis=amgn_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_NuevolutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116840920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue', window );">Number of major customers (as defined) accounting for more than 10% of total revenue | customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables', window );">Major customers (as defined) accounting for more than 10% of gross trade receivables | customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers', window );">Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers', window );">Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation', window );">Percentage of net trade receivables due from customers located outside the United States, primarily in Europe</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 18,194<span></span>
</td>
<td class="nump">$ 18,496<span></span>
</td>
<td class="nump">17,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">7,785<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
<td class="nump">6,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">24,297<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">17,286<span></span>
</td>
<td class="nump">17,985<span></span>
</td>
<td class="nump">16,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">7,011<span></span>
</td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">4,465<span></span>
</td>
<td class="nump">4,996<span></span>
</td>
<td class="nump">5,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">4,352<span></span>
</td>
<td class="nump">4,855<span></span>
</td>
<td class="nump">5,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
<td class="nump">2,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">Kyprolis [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">5,851<span></span>
</td>
<td class="nump">5,724<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">3,636<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerOneMember', window );">AmerisourceBergen Corporation [Member] | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">14,783<span></span>
</td>
<td class="nump">14,743<span></span>
</td>
<td class="nump">12,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember', window );">McKesson Corporation [Member] | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">15,187<span></span>
</td>
<td class="nump">13,779<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember', window );">Cardinal Health, Inc. [Member] | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 7,681<span></span>
</td>
<td class="nump">$ 7,332<span></span>
</td>
<td class="nump">$ 6,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Major customers (as defined) accounting for more than 10% of gross trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers (as defined) accounting for more than 10% of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_ProliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_ProliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_XgevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_XgevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_AranespMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_AranespMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_KyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_KyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NplateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NplateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122216776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Customer Concentration, Product Sales (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue', window );">Number of major customers (as defined) accounting for more than 10% of total revenue | customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables', window );">Major customers (as defined) accounting for more than 10% of gross trade receivables | customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 24,297<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
<td class="nump">$ 22,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | AmerisourceBergen Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 14,783<span></span>
</td>
<td class="nump">$ 14,743<span></span>
</td>
<td class="nump">$ 12,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 15,187<span></span>
</td>
<td class="nump">$ 13,779<span></span>
</td>
<td class="nump">$ 11,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Cardinal Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 7,681<span></span>
</td>
<td class="nump">$ 7,332<span></span>
</td>
<td class="nump">$ 6,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfGrossRevenues', window );">Gross product sales to major customer (as defined) as a percentage of total gross revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Major customers (as defined) accounting for more than 10% of gross trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers (as defined) accounting for more than 10% of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfGrossRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross product sales to major customer (as defined) as a percentage of total gross revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfGrossRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=amgn_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=amgn_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116695656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Textual) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted', window );">Amount by which the pool of available shares will be reduced for each stock option granted</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances', window );">The amount of common stock available under the plan for future grants and/or issuances (in shares)</a></td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Description of vesting of restricted stock units and stock options</a></td>
<td class="text">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to nonvested awards</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period over which the grants of equity instruments vest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned', window );">Number of common shares issued for each performance unit earned</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted', window );">The number of shares by which the pool of available shares will be reduced for other types of awards granted</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards', window );">Number of shares added back for tax withholding on full value awards</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 233.10<span></span>
</td>
<td class="nump">$ 235.63<span></span>
</td>
<td class="nump">$ 182.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of units that vested during the year</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 217.95<span></span>
</td>
<td class="nump">$ 198.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Units, forfeited (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in usd per share)</a></td>
<td class="nump">$ 213.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of stock options from date of grant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised during the year</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Actual tax benefits realized from tax deductions from option exercises</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember', window );">Performance units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted', window );">The number of shares by which the pool of available shares will be reduced for other types of awards granted</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards', window );">Number of shares added back for tax withholding on full value awards</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 254.68<span></span>
</td>
<td class="nump">$ 249.07<span></span>
</td>
<td class="nump">$ 188.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of units that vested during the year</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to nonvested awards</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 229.39<span></span>
</td>
<td class="nump">$ 207.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Units, forfeited (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in usd per share)</a></td>
<td class="nump">$ 226.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock available under the plan for future grants and/or issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued for each performance unit earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the pool of available shares will be reduced for each stock option granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the pool of available shares will be reduced for other types of awards granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Added Back for Tax Withholding on Full Value Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122621576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Components of Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit from stock-based compensation expense</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_StockBasedCompensationExpenseNetOfTax', window );">Total stock-based compensation expense, net of tax</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember', window );">Performance units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Components of stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense, pretax</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_StockBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total stock-based compensation expense, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_StockBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417118805784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Summary of RSUs) (Details) - RSUs [Member] - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance nonvested at beginning of period (in shares)</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance nonvested at end of period (in shares)</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant&#160;date fair&#160;value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance nonvested at beginning of period (in usd per share)</a></td>
<td class="nump">$ 198.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">233.10<span></span>
</td>
<td class="nump">$ 235.63<span></span>
</td>
<td class="nump">$ 182.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="nump">177.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">213.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance nonvested at end of period (in usd per share)</a></td>
<td class="nump">$ 217.95<span></span>
</td>
<td class="nump">$ 198.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123389400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_CommonStockFairValue', window );">Closing price of our common stock on grant date (in usd per share)</a></td>
<td class="nump">$ 237.17<span></span>
</td>
<td class="nump">$ 236.36<span></span>
</td>
<td class="nump">$ 177.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">28.10%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">$ 40.43<span></span>
</td>
<td class="nump">$ 42.34<span></span>
</td>
<td class="nump">$ 30.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123824392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Summary of Stock Options) (Details) - Stock options [Member]<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance unexercised at beginning of period (in shares) | shares</a></td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired/forfeited (in shares) | shares</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance unexercised at end of period (in shares) | shares</a></td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest (in shares) | shares</a></td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise&#160;price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance unexercised at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 179.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">237.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">137.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">208.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance unexercised at end of period (in shares) | $ / shares</a></td>
<td class="nump">197.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested or expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">195.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 165.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock options information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years), unexercised</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (years), vested or expected to vest</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (years), exercisable</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, unexercised | $</a></td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested or expected to vest | $</a></td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable | $</a></td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123745880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Weighted-average Assumptions) (Details) - Performance units [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_CommonStockFairValue', window );">Closing price of our common stock on grant date (in usd per share)</a></td>
<td class="nump">$ 239.64<span></span>
</td>
<td class="nump">$ 236.36<span></span>
</td>
<td class="nump">$ 177.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">29.30%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="nump">22.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of unit (in usd per share)</a></td>
<td class="nump">$ 254.68<span></span>
</td>
<td class="nump">$ 249.07<span></span>
</td>
<td class="nump">$ 188.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_CommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_CommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amgn_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123383368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined contribution plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense attributed to Retirement and Savings Plan</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124142616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Income Before Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 6,701<span></span>
</td>
<td class="nump">$ 8,133<span></span>
</td>
<td class="nump">$ 9,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 4,851<span></span>
</td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="nump">$ 4,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125394120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Provision for Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 1,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(308)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit</a></td>
<td class="num">(434)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129474072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes (Components of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards', window );">NOL and credit carryforwards</a></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses capitalized for tax</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(663)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangible assets</a></td>
<td class="num">(824)<span></span>
</td>
<td class="num">(903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Debt</a></td>
<td class="num">(275)<span></span>
</td>
<td class="num">(282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Deferred Tax Liabilities, Property, Plant and Equipment</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(1,522)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred income taxes, net</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (201)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123998680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Textual) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties related to unrecognized tax benefits recognized in income tax provision</a></td>
<td class="nump">$ 98,000,000<span></span>
</td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="nump">$ 198,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties associated with unrecognized tax benefits</a></td>
<td class="nump">881,000,000<span></span>
</td>
<td class="nump">783,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce income taxes</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">606,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs with no valuation allowance and no expiration</a></td>
<td class="nump">426,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ProposedAdditionalIncomeTax', window );">Proposed additional income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RepatriationTaxOnProposedAdditionalTax', window );">Repatriation tax on proposed additional tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfNoticesOnProposedAdditionalTax', window );">Number of notices on proposed additional tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Expiration in tax years between 2023 and 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards, valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Operating Losses That Expire Between 2022 and 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce income taxes</a></td>
<td class="nump">798,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards, valuation allowance</a></td>
<td class="nump">709,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">391,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards available to reduce income taxes</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">561,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs with no valuation allowance and no expiration</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member] | Operating Losses That Expire Between 2022 and 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">NOL carryforwards, valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfNoticesOnProposedAdditionalTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of notices on proposed additional tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfNoticesOnProposedAdditionalTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProposedAdditionalIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed additional income tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProposedAdditionalIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RepatriationTaxOnProposedAdditionalTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repatriation tax on proposed additional tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RepatriationTaxOnProposedAdditionalTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_ExpirationInTaxYearsBetween2023And2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_ExpirationInTaxYearsBetween2023And2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2022And2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2022And2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2022And2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amgn_OperatingLossesThatExpireBetween2022And2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125824072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="nump">$ 3,287<span></span>
</td>
<td class="nump">$ 3,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior years</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 3,546<span></span>
</td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="nump">$ 3,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417117430488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(7.80%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Foreign-derived intangible income</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Credits, Puerto Rico excise tax</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent', window );">Interest on uncertain tax positions</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Credits, primarily federal R&amp;D</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquisition IPR&amp;D</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Audit settlements</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126163432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Income (Numerator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">$ 5,893<span></span>
</td>
<td class="nump">$ 7,264<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares (Denominator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares for basic EPS</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares for diluted EPS</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (in usd per share)</a></td>
<td class="nump">$ 10.34<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (in usd per share)</a></td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 12.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124529816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Novartis AG (Details) - Collaborative Arrangement with Novartis AG [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment', window );">Potential future milestone payment</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember', window );">Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember', window );">Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties due</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Future Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amgn_CollaborativeArrangementwithNovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124014392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - BeiGene (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,979,000,000<span></span>
</td>
<td class="nump">$ 25,424,000,000<span></span>
</td>
<td class="nump">$ 23,362,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene | Other current assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related Party Transaction, Due from (to) Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000,000<span></span>
</td>
<td class="nump">$ 99,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene | Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related Party Transaction, Due from (to) Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cost recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene | Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ProfitAndLossShareOfExpenses', window );">Profit and loss share of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember', window );">BeiGene | BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProfitAndLossShareOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit and loss share of expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProfitAndLossShareOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124484392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Kyowa Kirin (Details) - Kyowa Kirin Co. Ltd. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_UpFrontPayment', window );">Up-front payment</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments', window );">Revenue Recognition, Milestone Method, Potential Future Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amgn_KyowaKirinCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amgn_KyowaKirinCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116674040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 7,304<span></span>
</td>
<td class="nump">$ 9,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">7,304<span></span>
</td>
<td class="nump">9,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">4,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">4,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">4,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">4,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417130616728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Fair Values by Classification (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets locations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 4,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">7,304<span></span>
</td>
<td class="nump">9,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember', window );">Available-for-sale investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets locations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">7,256<span></span>
</td>
<td class="nump">5,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">$ 7,304<span></span>
</td>
<td class="nump">$ 9,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125395624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Available-for-sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems', window );"><strong>Gain (Loss) on Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems', window );"><strong>Gain (Loss) on Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Total realized gains</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125165912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Fair Values by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 7,304<span></span>
</td>
<td class="nump">$ 9,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue', window );">Maturing after one year through three years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale investments</a></td>
<td class="nump">$ 7,304<span></span>
</td>
<td class="nump">$ 9,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116665768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity Securities, FV-NI, Unrealized Gain (Loss)</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquitySecuritiesRealizedGainLossOnDisposal', window );">Equity Securities, Realized Gain (Loss) on Disposal</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value</a></td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquitySecuritiesRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Realized Gain (Loss) on Disposal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquitySecuritiesRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124140952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Limited Partnership Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount', window );">Investment Company, Financial Support to Investee Contractually Required, Amount</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember', window );">Limited Partnership [Member] | Fair Value Measured at Net Asset Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Investments</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AlternativeInvestmentNetGainLoss', window );">Alternative Investment, Net Gain (Loss)</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AlternativeInvestmentNetGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Net Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AlternativeInvestmentNetGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL6742756-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 35<br> -Paragraph 54B<br> -URI http://asc.fasb.org/extlink&amp;oid=122636397&amp;loc=SL7495116-110257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of financial support committed by investment company to investee that is contractually required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66023616&amp;loc=SL35737432-115832<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125182072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - BeiGene (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investment, Quoted Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentChangeInCarryingValueOther', window );">Equity Method Investment, Change In Carrying Value, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Company's share of profits (losses) of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Approximate carrying value of the company's equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investment, Quoted Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember', window );">Neumora Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">25.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentChangeInCarryingValue', window );">Equity method investment, change in carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentChangeInCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, change in carrying value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentChangeInCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentChangeInCarryingValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Change In Carrying Value, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentChangeInCarryingValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417117340520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Neumora Therapeutics, Inc. (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember', window );">Neumora Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">25.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1', window );">Noncash or Part Noncash Acquisition, Investments Acquired</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity Method Investments, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125513658&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123786680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 4,086<span></span>
</td>
<td class="nump">$ 3,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125255496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Schedule) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and improvements</a></td>
<td class="nump">4,028<span></span>
</td>
<td class="nump">3,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Manufacturing equipment</a></td>
<td class="nump">3,080<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LaboratoryEquipment', window );">Laboratory equipment</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FixedEquipment', window );">Fixed equipment</a></td>
<td class="nump">2,402<span></span>
</td>
<td class="nump">2,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized software</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Other</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">987<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">13,982<span></span>
</td>
<td class="nump">13,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(8,798)<span></span>
</td>
<td class="num">(8,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,184<span></span>
</td>
<td class="nump">4,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization charges associated with property, plant and equipment</a></td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember', window );">Manufacturing equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember', window );">Manufacturing equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember', window );">Fixed equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;life&#160;(in&#160;years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FixedEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FixedEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of laboratory equipment, gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_FixedEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116664808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment (Geographic Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 5,184<span></span>
</td>
<td class="nump">$ 4,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,801<span></span>
</td>
<td class="nump">2,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PR', window );">Puerto Rico [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=amgn_RestOfWorldMember', window );">ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amgn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amgn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125660936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Goodwill Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 14,689<span></span>
</td>
<td class="nump">$ 14,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Addition from acquisitions</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 14,890<span></span>
</td>
<td class="nump">$ 14,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116713656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Identifiable Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">$ 32,099<span></span>
</td>
<td class="nump">$ 32,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(17,987)<span></span>
</td>
<td class="num">(15,461)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">14,112<span></span>
</td>
<td class="nump">16,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsGross', window );">Identifiable intangible assets</a></td>
<td class="nump">33,169<span></span>
</td>
<td class="nump">32,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(17,987)<span></span>
</td>
<td class="num">(15,461)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets, net</a></td>
<td class="nump">15,182<span></span>
</td>
<td class="nump">16,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">25,561<span></span>
</td>
<td class="nump">25,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(12,769)<span></span>
</td>
<td class="num">(10,564)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">12,792<span></span>
</td>
<td class="nump">15,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(2,973)<span></span>
</td>
<td class="num">(2,791)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing-related rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,112)<span></span>
</td>
<td class="num">(1,041)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember', window );">R&amp;D technology rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,133)<span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123758648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization charges associated with finite-lived intangible assets</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Total estimated amortization of finite-lived intangible assets for 2022</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Total estimated amortization of finite-lived intangible assets for 2023</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Total estimated amortization of finite-lived intangible assets for 2024</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Total estimated amortization of finite-lived intangible assets for 2025</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Total estimated amortization of finite-lived intangible assets for 2026</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember', window );">Teneobio, Inc. | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember', window );">Teneobio, Inc. | Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember', window );">Teneobio, Inc. | Favorable Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_FavorableContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_FavorableContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125774200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount', window );">Total undiscounted future lease payment</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Leases not yet commenced lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Leases not yet commenced lease term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417117418936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other assets</a></td>
<td class="nump">$ 566<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 670<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126215384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total net lease costs</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125254824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember', window );">Abandoned Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases', window );">Future rental commitments for abandoned leases</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Expected total future rental income to be received</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amgn_AbandonedLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124526360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cash and Noncash Information of Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 340<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417130803848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets and accrued liabilities - Schedule of Other Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,223<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Corporate partner receivables</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Tax receivables</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 2,367<span></span>
</td>
<td class="nump">$ 2,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125798840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AccruedSalesDeductionsCurrent', window );">Sales deductions</a></td>
<td class="nump">$ 5,174<span></span>
</td>
<td class="nump">$ 4,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">701<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AccruedSalesReturnReserveCurrent', window );">Sales returns reserve</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 10,731<span></span>
</td>
<td class="nump">$ 10,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedSalesDeductionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedSalesDeductionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AccruedSalesReturnReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AccruedSalesReturnReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417110497672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized bond discounts, premiums and issuance costs, net</a></td>
<td class="num">$ (1,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other Long-term Debt</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt</a></td>
<td class="nump">33,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 33,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.25% 2022 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.60% notes due 2026 (2.60% 2026 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.65% notes due in 2028 (1.65% 2028 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% notes due 2032 (2.00% 2032 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.80% notes due 2041 (2.80% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.00% notes due 2052 (3.00% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.77% notes due 2053 (2.77% 2053 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on note</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Other notes due 2097</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Carrying values of long-term borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Floating Rate Notes Due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent', window );">Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember', window );">Debt securities payable [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount', window );">Redemption period without payment of make whole amount</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember', window );">Debt securities payable [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount', window );">Redemption period without payment of make whole amount</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Period without Payment of Make Whole Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFiveNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFiveNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointZeroPercent2032NotesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointZeroPercent2032NotesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125199752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing arrangements (Debt Issuances) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_MaximumBorrowingCapacityUnderCommercialPaper', window );">Commercial paper, maximum borrowing capacity</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="nump">$ 9,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.65% notes due in 2028 (1.65% 2028 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% notes due 2032 (2.00% 2032 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.80% notes due 2041 (2.80% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.00% notes due 2052 (3.00% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 1,350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_MaximumBorrowingCapacityUnderCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Borrowing Capacity Under Commercial Paper Program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_MaximumBorrowingCapacityUnderCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A165NotesDue20281652028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A200NotesDue20322002032NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A200NotesDue20322002032NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A280NotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A280NotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A190NotesDue20251902025NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417118102504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Debt Repayments) (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,450<span></span>
</td>
<td class="nump">$ 4,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Make-whole payments recognized in interest expense</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Make-whole payments recognized in interest expense</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.70% notes due 2019 (5.70% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% 2019 Euro Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.90% notes due 2019 (1.90% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Floating Rate Notes Due 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Floating Rate Notes Due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.25% notes due 2022 (1.25% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.65%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenZeroPercentNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenZeroPercentNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveZeroPercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FloatingRateNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenZeroPercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417111799592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="3"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="nump">$ 10,497<span></span>
</td>
<td class="nump">$ 9,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">6,450<span></span>
</td>
<td class="nump">4,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapOneMember', window );">Interest Rate Swap, One [Member] | Interest rate swap contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember', window );">Interest Rate Swap, Two [Member] | Interest rate swap contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds) | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember', window );">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes) | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member', window );">5.50% 2026 pound sterling Notes [Member] | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member', window );">4.00% 2029 pound sterling Notes [Member] | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember', window );">1.25% 2022 euro Notes [Member] | Cross-currency swap contract [Member] | Cash flow hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 6,650<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2022 (3.625% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.663% notes due 2051 (4.663% 2051 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeBasisSpreadOnVariableRate', window );">Derivative, effective interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.77% notes due 2053 (2.77% 2053 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtExchangeAdditionalCashConsideration', window );">Debt exchange additional cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.25% 2022 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DebtExchangeAdditionalCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt exchange additional cash consideration paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DebtExchangeAdditionalCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeNotionalAmountAmountTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Amount Terminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeNotionalAmountAmountTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointFourFivePercentNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointOneZeroPercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointEightSevenFivePercentNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125480248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Shelf Registration Statements and Other Facilities) (Details) - Line of credit [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks', window );">Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LineOfCreditFacilityInitialCommitmentTerm', window );">Initial commitment term of each bank which is a party to the agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LineofCreditFacilityNumberOfRenewalOptions', window );">Number of additional term extension options | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm', window );">Additional period for extension of commitment term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Annual commitment fees for syndicated, unsecured, revolving credit agreement</a></td>
<td class="nump">0.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under syndicated, unsecured, revolving credit facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">one-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineOfCreditFacilityExtensionOfCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Extension of Commitment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineOfCreditFacilityExtensionOfCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineOfCreditFacilityInitialCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Initial Commitment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineOfCreditFacilityInitialCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LineofCreditFacilityNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LineofCreditFacilityNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124482936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing arrangements (Contractual Maturities of Long-term Debt) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">2,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">27,075<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet', window );">Total</a></td>
<td class="nump">$ 34,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417117349560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Interest Costs) (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid, net of interest rate and cross currency swaps</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116728040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Stock Repurchase Program) (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchases, Shares</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchases</a></td>
<td class="nump">$ 1,461,000,000<span></span>
</td>
<td class="nump">$ 1,069,000,000<span></span>
</td>
<td class="nump">$ 1,592,000,000<span></span>
</td>
<td class="nump">$ 865,000,000<span></span>
</td>
<td class="nump">$ 1,221,000,000<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="nump">$ 591,000,000<span></span>
</td>
<td class="nump">$ 933,000,000<span></span>
</td>
<td class="nump">$ 1,090,000,000<span></span>
</td>
<td class="nump">$ 1,170,000,000<span></span>
</td>
<td class="nump">$ 2,349,000,000<span></span>
</td>
<td class="nump">$ 3,031,000,000<span></span>
</td>
<td class="nump">$ 4,987,000,000<span></span>
</td>
<td class="nump">$ 3,497,000,000<span></span>
</td>
<td class="nump">$ 7,640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, additional authorized amount</a></td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available for stock repurchases under a board approved stock repurchase plan</a></td>
<td class="nump">$ 10,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417125532440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Dividends) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">1 Months Ended</th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2022</div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends paid per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends paid per share (in usd per share)</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417118004472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Components of AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">$ 9,409<span></span>
</td>
<td class="nump">$ 9,673<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">9,409<span></span>
</td>
<td class="nump">9,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative effect of changes in accounting principles, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(709)<span></span>
</td>
<td class="num">(718)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
<td class="num">(718)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(263)<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">159<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax', window );">Other gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(985)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="num">(769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">158<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">253<span></span>
</td>
<td class="num">(534)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax', window );">Other gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">$ (796)<span></span>
</td>
<td class="num">$ (985)<span></span>
</td>
<td class="num">$ (528)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Other Adjustment, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123807512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122363096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">6,701<span></span>
</td>
<td class="nump">8,133<span></span>
</td>
<td class="nump">9,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(808)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
<td class="num">(1,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">5,893<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
<td class="nump">7,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">24,297<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Foreign currency contract [Member] | Product sales | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of AOCI [Member] | Cross-currency swap contract [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">$ (245)<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417117347640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity (Other) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417110921352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">$ 7,304<span></span>
</td>
<td class="nump">$ 9,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">10,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember', window );">Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">4,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">4,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">7,914<span></span>
</td>
<td class="nump">10,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">4,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">4,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeAssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeAssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments liabilities fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129891416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Length of time hedged in foreign currency contracts</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Aggregate fair value of long-term debt, including current portion</a></td>
<td class="nump">$ 37,900<span></span>
</td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of long-term debt, including current portion</a></td>
<td class="nump">33,309<span></span>
</td>
<td class="nump">32,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">BeiGene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investment, Quoted Market Value</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Approximate carrying value of the company's equity method investment</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417124355944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Additions</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationContingentConsiderationArrangementsPayments', window );">Payments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net changes in valuations</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember', window );">Teneobio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationContingentConsiderationArrangementsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationContingentConsiderationArrangementsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417123986712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeInstrumentTerm', window );">Derivative Instrument, Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="nump">$ 10,497<span></span>
</td>
<td class="nump">$ 9,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">6,729<span></span>
</td>
<td class="nump">6,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember', window );">Foreign currency and cross currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_InterestRateSwapAtThenCurrentInterestRatesMember', window );">Interest Rate Swap, At-Then Current Interest Rates [Member] | Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency forward contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminated', window );">Derivative, Notional Amount, Amount Terminated</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments', window );">Derivative Instrument, Aggregate Notional Amount of New Instruments</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities', window );">Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap [Member] | Interest Rate Swap, Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments [Member] | Foreign currency forward contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 680<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.125% 2019 Euro Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Aggregate Notional Amount of New Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeNotionalAmountAmountTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Amount Terminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeNotionalAmountAmountTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_ForeignCurrencyAndCrossCurrencySwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_InterestRateSwapAtThenCurrentInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_InterestRateSwapAtThenCurrentInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_InterestRateSwapAxis=amgn_InterestRateSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417118922312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Cross-currency Swaps) (Details)<br> &#8364; in Millions, &#163; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member', window );">2.125% 2019 Euro Notes | Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember', window );">1.25% 2022 euro Notes [Member] | Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember', window );">0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds) | Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember', window );">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes) | Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member', window );">5.50% 2026 pound sterling Notes [Member] | Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member', window );">4.00% 2029 pound sterling Notes [Member] | Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | 1.25% 2022 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">SFr 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | Euro Member Countries, Euro [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | Switzerland, Francs [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | United Kingdom, Pounds [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | United Kingdom, Pounds [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | United States of America, Dollars [Member] | 0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | United States of America, Dollars [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | United States of America, Dollars [Member] | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedge [Member] | Cross-currency swap contracts [Member] | United States of America, Dollars [Member] | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417116657928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="nump">373<span></span>
</td>
<td class="num">(251)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments Gain Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="num">$ (214)<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417117339768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying amounts of hedged liabilities</a></td>
<td class="nump">6,729<span></span>
</td>
<td class="nump">6,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">$ 340<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hedged Liability, Discontinued Fair Value Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_HedgedLiabilityDiscontinuedFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417130651864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments - (Summary of Income and Expense Line Items) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 25,979<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">$ 23,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Gains (losses) on fair value hedging relationships, Hedged Items</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="num">(349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">24,297<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122625080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments - (Fair Value of Derivatives) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedging instruments [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129153912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Sandoz Patent Litigation) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>lawsuit</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_SandozIncMember', window );">Sandoz Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberofLawsuitsFiled', window );">Number of lawsuits filed</a></td>
<td class="nump">19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberofLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberofLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SandozIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SandozIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417129150984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Immunex and Sandoz Litigation) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2019 </div>
<div>affiliate</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_ImmunexAndSamsungBioepisCoMember', window );">Immunex/Samsung Bioepis Co.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberofAffiliates', window );">Gain contingency, number of affiliates</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberofAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Affiliates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberofAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_ImmunexAndSamsungBioepisCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_ImmunexAndSamsungBioepisCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126090712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Repatha Patent Litigation) (Details) - Sanofi/Regeneron Patent Litigation - patent<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2016</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LitigationSettlementLengthofTrial', window );">Length of trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberOfChallenges', window );">Number of challenges</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberOfChallenges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Challenges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberOfChallenges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LitigationSettlementLengthofTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Length of Trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LitigationSettlementLengthofTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SanofiRegeneronPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SanofiRegeneronPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417110469496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments (Additional Information) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 02, 2021 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>claim</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>agreement</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>complaints</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>plaintiffs </div>
<div>lawsuit </div>
<div>claim</div>
</th>
<th class="th">
<div>Oct. 26, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 04, 2019 </div>
<div>claim</div>
</th>
<th class="th">
<div>May 20, 2019 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_NovartisBreachOfContractActionMember', window );">Novartis Breach Of Contract Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss Contingency, Damages Paid, Value | $</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_GainContingencyNumberOfAgreementsBreached', window );">Agreements breached | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember', window );">Sensipar Antitrust Class Actions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | plaintiffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, number of lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LossContingencyNumberOfLawsuitsFiled', window );">Loss contingency, number of lawsuits filed | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amgn_HumiraBiosimilarAntitrustClassActionsMember', window );">Humira Biosimilar Antitrust Class Actions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt', window );">Number of complaints stayed | complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_GainContingencyNumberOfAgreementsBreached">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Agreements Breached</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_GainContingencyNumberOfAgreementsBreached</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfComplaintsStayedByTheCourt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Complaints Stayed By The Court</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfComplaintsStayedByTheCourt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LossContingencyNumberOfLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LossContingencyNumberOfLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_NovartisBreachOfContractActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_NovartisBreachOfContractActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amgn_HumiraBiosimilarAntitrustClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amgn_HumiraBiosimilarAntitrustClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417122000568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments', window );">U.S. repatriation tax commitments, number of annual installments | installment</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths', window );">U.S. repatriation tax commitments, 2022</a></td>
<td class="nump">$ 587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears', window );">U.S. repatriation tax commitments, 2023</a></td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears', window );">U.S. repatriation tax commitments, 2024</a></td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears', window );">U.S. repatriation tax commitments, 2025</a></td>
<td class="nump">1,834<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1', window );">Total remaining U.S. repatriation tax commitments</a></td>
<td class="nump">$ 4,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140417126620776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Allowance for doubtful accounts [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions charged&#160;to costs and expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Other additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>amgn-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20211231"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:exch="http://xbrl.sec.gov/exch/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amgn-20211231.xsd" xlink:type="simple"/>
    <context id="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i387dbf98d1b24d5f83cd817582c5b3af_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if9cbde08232d47f1b1397109661d89c3_I20220211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8aa4009b79ae4a1aaa88901012cdc38c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c9dfed05d2a4cc7b238e87a2395d611_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5666794b15d1495f894c2e5fa67e1ff5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide4e5e657f16482091a0d8f7d0722737_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8dfa3d2f9c9049c0a19ece84de2ff2ff_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie07c6d9499a1435a873c87b9197752bb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i883c7889246b4351952e694e54ad42f3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if37f4705aa9b489a9965276d6b9e48de_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib936adc316344e80a16bdf77c98d380b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1a8de5ba86f046cdb69fc0f4c708fc92_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i59abc98712f3458ba5b91a6534b6a125_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iace73d6c035d4a77a2cbffa4ce90f25e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i661e28e3d2d84263805b3d206b050c22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea207d0ec0394b108fc793525231d205_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia86993e4e7394c7c9f663f9dc7533e39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf1a1b1a0dce4a0f9ea205178fdca9c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i719c98f9ce454a51b25b0be7d1e61269_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i490a73e325c3475f986e675f73de9c08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69699f22fd2341d793a1b05ac851fe93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d2ab0ebd9f7498a91b623bb412e8f34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i810c9e939c3947a6b2840daa5f56ecbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdc2047b094b4f3391b29249a580f128_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2766f3376fe7415ab521166b30e8525e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3d57a8001b04306923d18707df004a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71b12895707c4d109b2ebe044f17363e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i198f13e9ae764a128ee94408e59bd0e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64483c0647e5467db4e1fb64385c92da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ac218800d9e4f97b70805d4885f19de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5a12fd9b94548e0a6d019cff9050821_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43850937751e42548fbb66e789879cef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie61e545057e747e8b5917b8708e7bbf0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-19</startDate>
            <endDate>2021-10-19</endDate>
        </period>
    </context>
    <context id="i7d48e8621c0c4e169bae7f879ff2d533_I20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-19</instant>
        </period>
    </context>
    <context id="icd31e4ab273d40649861d236ae32fc27_I20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-19</instant>
        </period>
    </context>
    <context id="id8c5cd2aa30845ed99aa434901b0d817_I20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-19</instant>
        </period>
    </context>
    <context id="i478925270fe1447f980033f781c7fe54_I20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-19</instant>
        </period>
    </context>
    <context id="id3f3a35884aa4230bf0c3a5ae22cbc37_I20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:MoleculeTypeAxis">amgn:AMG340Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-19</instant>
        </period>
    </context>
    <context id="i0d7b6973dd21459c98dd74519c04349f_D20211019-20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-19</startDate>
            <endDate>2021-10-19</endDate>
        </period>
    </context>
    <context id="iab0cb85e7f8b470988475352b8970a11_D20211019-20211019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-19</startDate>
            <endDate>2021-10-19</endDate>
        </period>
    </context>
    <context id="i87696c073dc9445795bb552e00095165_D20210416-20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="i0a658c14aef44e0cbf1c161341c595a2_I20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="i1f6477d9cdaa4150a5f594b11b70839a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iece52d145d314403bfe12e67331edc59_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="ie30125d0ac2b49b99dedfab8ab62d268_I20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-21</instant>
        </period>
    </context>
    <context id="i57b09ca2dd3744c7ace9c82038d6088e_I20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-21</instant>
        </period>
    </context>
    <context id="ieb825857cbe9452cb4d3fdead6eadad7_I20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-21</instant>
        </period>
    </context>
    <context id="iae11cd746d46413ea3fdec017bcaa8da_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="ie16d2f30b24a4021ae737b2878c082c2_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:MarketingRelatedRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">amgn:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="i71cdf38101c24a728fe566e9c8f95072_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:AssetsByDescriptionAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21358fdcfee142efb4e3f013e87d4e7c_D20191121-20191121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="i312f9fef123d41a09674e4d6ef7b0632_D20190715-20190715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-15</startDate>
            <endDate>2019-07-15</endDate>
        </period>
    </context>
    <context id="i8f809eda07244ef59df9c01c24fcb962_D20190715-20190715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-15</startDate>
            <endDate>2019-07-15</endDate>
        </period>
    </context>
    <context id="i6d08f130fae446808d4e5f6792b4477d_I20190715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NuevolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-15</instant>
        </period>
    </context>
    <context id="ic9859eb8505743f1b3da7314c2873003_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i122e8f06671c4fd2959f297cfb936b40_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24b29f9a84bd403788979c7c9655c7f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic461d7a3b3e14e9d9f9edf67703a28a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e2ec1c2699c4f75baab1192500e0ea8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30ef6be9e72c458d8eb025c1d314c9a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9352d3542ba4641b31259a6145356d4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice6338b51a744e2ba61b90799c71483a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib39684b43bb94026ba38cc4efb929d6f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f12f30e019c442caffd84baf0cf6f58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id824580714f14645861336df6b9234d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87d377423aea4783859ef42175fb0740_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica0d3e2283c44651a1eb8f9a780b8dbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i967209b4b4c84e76b9b0f7a497310bce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie54c41e6f0b54a38a252ee5e94de98a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i989b6283d29a4b4c851c78cd48583e8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b813a299ccd4e28afe5bbb0576b487d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e5c8a7d9df04367a21590c9c29fd269_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i40878748d11247a087bb8456c38f461b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6eb6c05be38b46a0a66d8019c30f41f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20b1aeb912604f64a39deebff1f224b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied8dfc99854e4c9a8e28f37c644909fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35fd136605f54042b5bff6d375c0e5a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i165ce47df9044130bc2739fba82a949b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b0c0fc9a5c549fe95bfb0a1d9f0cff5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie2ac36e2ce074ccd9ae5750b82cd3469_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i512f3b69b8d744cba5ed5ccf09f3f93e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb9e422d984343799da5efa61983dbc4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1dcdb5108a874cfcbdd8b792226e2b87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31c0360db44649d0a20ab30019d4726f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5084637c7a7340da84829b4511548a9b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6556904df3ab4367ad18978f9b68d5ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68f620dbefa34330a378e5ed07d62563_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbaf8798276a40dfb14013a2f2c650ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i983f5a9292ac40f4a3da11e27da9ebb9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida0d758076054681926e066e61927847_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i823d72e733d04847bac4115a76bc88d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i927d3e095b5f4aa59c0a266db71e1970_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i068d095d40cd4db2974af05b034cdc53_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i183bf5775ef447918eb6b6e9ba438bf6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0446449664249d586f43b4ab973920a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb5db1424a06489da055b9a4d4e9586a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5bd4a1f6b184369845ffe664e69f8c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36247d9eda1441289af859ad6b549ad5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdcea96c498b412ea276b523469efb7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9bd7649ab404e7b84591d36bb2baa43_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibdbb2a2df8dd4a688aa35f134c78985b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i866795ca32e048e8bf0d0a64e1e48428_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic529e4ce045d4f18bf4eb6e91d16750e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i961bb9f5333e4fb7a4343811368337f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e1cedc1286e435db02a41c255e0aea4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e0d7fa648b44bf4b5f6ab3d243b3379_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaf1a44c568f248928074918ec2942de6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i31ae78b9ba034a46abf7a36f2b0f0200_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i122ba16c86614e1c968b2254fd76300f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3cb60fa2c2944183bf45dfb60666df8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d943ea15f1a4586994e9ac4e411be31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8467a81094b048fb8b342e412bd92615_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77cef9372919476794b87f18a0ccd73c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2dbf9c7559f438aa4cb0fd8e3bd05df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc140436757d4c8b8b0f16f5c3d24f73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1be7cae3f58843ba99977a2b0ef10946_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74c266403b0e40b8a06f2641ca3a0a6d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7946d27038d14bb2aa1d01148f309fce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f835d6c583e4df99d995013745f7e0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4dbe0c7d5d6b4242b1252f5fcb8be12f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4708f4aef9e64cb5ad424e50c8dc709d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a458f529ef74a5e96517e593dec14f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f4010fa4de94f1f9c1f6362f8ec685e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70cba4592c834e3e8d094a23a2fcaa5b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib066bf92577d482b9105bb3d4d131f35_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11c7e88092ac49d78f2b821816062d7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i73e280126ffb45dd8d20fc69bcf08ce6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia437ec7f284c49d6a65b54737b247969_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i794fd5a1ff8d49928a90b66d34aae6b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie08cb03dda2a4cbeace3bd8fec2bf082_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3aa8459da664468b847514e8360e549b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0e82165e6ed4ce0870f8f592e298c7f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafe308e8cce24a29bfe153c46d6eed91_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c2a9a63cb37432fa884cace4bab4206_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iae5877faf81e455bb0d9482eb25bd1ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idb6b177906644a8ba787927952e1e6ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5cedf86849344ad185dd0473b29aa1f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i64ee7a4be4a741f49a25afd921009f06_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f9fd64f276d4139aea96a0883ba58ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2365d4e32b64cd087bbb41137067445_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2dda7d1128174280bf5cb5fd5f91bc58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if35d3d6d4b644346b1122b986aa9fe50_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4abfdddf9be24f51a5a6754cc8ad2888_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i69f26fd68cfa4c65a24d973779fd0e1a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0795e4a54f5843d393051071fa6d5f9b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee2014a7861a48b799fb3652e82edcd5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i676e864b987849b3b20c91a321c3dda8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i116d123386f643908f969672fc7551ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0adce9b11c444f0992f20820cf3828f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0a71c3bfd064ff09a900ad9f82e3ff4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8d8aa15dac8a479aa274d63cceb3e3cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice1f469a4b2e4de98ca61b255d39fffb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3dbe8a4fa56d4704aacdf9825e608952_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9d6910ca4184832834d336a96a65391_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16a1575152424f7d8ace591bcbc21966_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f0b7b5c89644713988c1ec6f68bb082_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99cd8f4d101d41ada52bea1b7f7707dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie389e5de5a4d478db22bca7314e7c2e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b16e7fedb4e4c24ae45b97df7a610b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ef86d4467f84eb1bb360dfad6d77585_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e2955a78f1c41a08c3ed208c99513da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ef9644ae27a4c1a8fe31454e5457a11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i293bc5a8ad2541879fe865ae5d2417d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44fe8e6898034d56a3a0bdcfc063bc2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5aee82520bc437a8e545732608e5e33_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie45ea7d90fd9496098876205bd24f226_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d011b83be41426c8583d49144da9518_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i127aa134bb05481bae71c4068800e12a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6de6025ba0e4e2690eec1546e065897_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37f412791f92490e9d982b4d75831aeb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbf19b5b37714e80a93f4933d02ef7d6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">amgn:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bb8e713474c47ff83f089068a521247_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie689ea75a1044f2d984398ed617833af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id620434bf9034620994881cbe32601bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c5f3303e39f4bc0b7b331b548b22fd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie439637f4a754340a91825cf8855bd2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafb155843fbb43a4845a41a3a8dd1ff1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c176348e21b4ba1a3156259d8a42916_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f3ff89fdeeb41748a0d6033b1bd4fa9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amgn:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3022ab55cbe34d28a3a4a40e97b0e2f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i378c1ff5055142c89725880372cbf969_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07aa01d299e2400ca85cb51dfeac2827_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f5e991692b349cf9019705e77e8295a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if882d889ea614a7891f8c06a940d0411_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13da767a4eec472cacf227f166d68782_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9cc399ea0ce04799a09de06e546eceb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19cf357e0ed44f0a9240d63f761e319f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:ExpirationInTaxYearsBetween2023And2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i876ecb33b93d407bbf54fbff636fcbcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ea7e54e88b146f383ed2ca43d4cc454_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2022And2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id46afb35127d450e9e5b64faa1484510_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14e3f4af542345b1913d9608046945a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amgn:OperatingLossesThatExpireBetween2022And2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1607fbba52af401f822b87f6c9ca7b4d_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ib69e5cff7c72466aa64106c866eef4f2_I20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="ib96fb2589f6d4eb6be9dc2329f9e3e9a_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="i0f3e83663ab7448f9d89322ae4c89d53_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27f3367e2504432e9241fb90f97792c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5cbd73363fbf4d9f8ecace3f93987d50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e5fbb50886445c0a5885afd85d45f80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81e3c18d48c546e08d8c78658032b099_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19738ccb7dec4ff194a1f820e6610a46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i558ccb32284541ab8aa7100457c3f800_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03daed3f241a433a99f8a3e456d25e18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47ecb19fa54443e6a1c8180a5b4978c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic20c274ca8254d83931002497f749d6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22383ad8ad98490387eb40c5fefbfaa1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5ded1767e5544259a8f3222f3f0b097_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83cee794a408414492622e90651c37e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida0758ef280b4ca39e8e5f8ec2aab3e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1f36a12191440cbbf96604a76e7170e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:CollaborativeArrangementwithNovartisPharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4c8816fa7e9c49cba0ab2b9df683b53e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8bdd4a592dc14b00a7340e260c55ac4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amgn:KyowaKirinCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40d3a97a52f545c186e429329ac5c396_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd76882af6a14d589b489655ffae4b5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i746af9fdf7bf446bb8052c84b495b30a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27c8bf716a3045cab5d5c381fde23d68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id95f26b95bbc46e58dd92512a74406b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i811e98c080a8445ab332e5093987caf0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4b2c07d94924b70a99e1b31e4959623_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6bedbb0fb8544608b6b4b38788612de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id775784f91834b37bd5778c4af33ff82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0685790a88a441c3b4731096daf74bcb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc49ed11c95a425c91f0d42a0e3a802b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i356b9dbd15c04f05b6aa947471d7ecc0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife9d7263c2934799ad99b2e304ed9c06_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie26bf44881b14ed4b71997783873d549_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8bdea1c8311e41d9a8dd2e5681a38379_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id2bdf24151064c60a96102ab1941f91f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05cf3220a1054a8f8f5e45eba0b0f1b1_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3795b0430f51414baeabe5e24d635ce9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5e3474cb0114feba5cd13cc8ae2c916_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaf2649fff4c4de298cd836c69f79d22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96eda76077d241f081c28bb4ab52763e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfa8066544024fa19ebe0b52eeaba353_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a675d05a0804539a7d21138c1722b7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6a6e2eaf0994cebafac018b5e3fe2b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a0a9ca1a0cd4f579495b0fabf37ebe5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieccfdc26f7e24e8784d8e7068a04a895_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3cf9f313b68c4865a53543614de8354e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8902072edc954d06a4fa32d21142b284_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5451fcd71feb4721a719c87aa7225d50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:FixedEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice11863ea1f641c982d327a9700952dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaaff719184b24d3c8e81d58f99addf22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie80ef32cb43043a09a41633946a002ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ac8514d57744567b3fefdd3b73af1a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if24c03a5fa36492bb701fd1cf35c078e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf9b0d86322746389e6bcdfa6dca160c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i873c3b8314524d3fad876f18c5598ab3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87470154c5964bf885e913dea7bf3103_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i697e8dd993f14956a1d252e84ed707d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39392b4b995449a590f6320c08ce61e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amgn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idafcf86294d042a097451c547386436c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9afda65b678547869ef5990f59bf488a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2b135991cad418282667c91fa819593_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i641193dfa12140ac8063f9a64824a74f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf6fec59b238425ea04b200b698f4eaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ae35a0ac1214710b7c190312232e3a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6c22c6a79774622a0b10ce923ca150e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5d95d8ba10643ef98491d2fb2c2e0c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa636f63d01f499bbc23a8871f6dac49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff6483f2d4ab4e57a98ea68547e64b32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0c996cd5afc4b66986324061c0fd03b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibaa9036d3707491ba2a27c213ba7af11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:FavorableContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a62dfd4c2d440e88628b7259f5b5158_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amgn:AbandonedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied090dfe9b534fd38d657521d8581f48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i201a72549edc46dd976f10480c16db04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e359c669dcf409083123e716b593d81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3115a2e5d2b648bb866394e00f7e6265_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib927e41cd49b4bcda2eea7a252c62906_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d4ded6128cc4111af96fa1184ea3cdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56cb2b9855fe4608b5d0321fa7ba2bc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf3d349c123746008f444a2b21e4dc29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ac644eb4ce441cab9fe07e3d012948e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9030955f37e9430a99c50565728d5f24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf619b21445f463d85928fc668c93d2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99b857ada0494363b1816eed0b185516_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28d5c7dae0c9470d9de4d136b31872a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05c9361f0899452b92a78f57514f9339_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddb35d257f424b58b378b933e22c6e16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i059fdacf21234e8ea4393764e3826ae1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3ece76323354edab6344395cebe3bba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i728c44682ed441d0ac7d57d3f4f20961_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50a9f89f55144c7383b92a1e2a084413_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaab56d58779141ceb2afcc0c4b3c034e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb12c286c5b04cdda990afcad1d3f906_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia09e03b111064a778c3c0f67fa5ceca5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0fc0421471445c09ad2091231e1ebd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cb361ad83d5412a809267468ed87948_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4474d10ca0a044769c40e2e8fe8ba5c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64fa2b6c75f84ce9b2d6f2c73986f8c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaaf325c2ad564616a25134ef5af769ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec40a5633cc44bf78f5770c8d2eca6e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7db5be88f2184c5c83f07cb2e96fa2ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A165NotesDue20281652028NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18b66dea34d04457952516f934bfa710_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i365214c0e6504d3fba7ccd3e791c85e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib57500a573714861937e2948abb1c417_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if39aebc177504df78daf24169177353e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic86def4b22434c24861ce1aea3a31420_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i932124c0f7a5410abab4ba175c13bfb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i193e18f2a5ad4e6d9490bcfe10dacd22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4283cce94284118a0034337aac219b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0205d38f0748461e9cefc43080126f92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d7a63a419144cf0aca9c1b14bf3aff1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f57518a37364ab085186556dc6f209b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29d7e93cc83149e6bd46d9c7b5b95be3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfdd983a38394043a29f22f15239cdb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08afea356a38453090c19b18d61b4a71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93bbfe5fa69940c08425fb453c4429a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c53473bc8014e44b15542181f09808a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id612d8d410b345cf9c48f162584e09ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34f197c292c0446c9383e5222324d6c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2169d5c603a14255b95c241f6c3323ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i689ad4255db545eda69e365f169f332a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee3977d9de514e63894403ca1ca898f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29adc72b130b479ea45a8aaa03b088d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i965cc877b8694f78b1c2b606c84f7f38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i364ca273078a47eca7c0fe7c36707bf5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idea96f4e89df43b18b9bd6729d02ad77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b2eb0ad81574e8e8c6e79ecedad6dd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66cf2c987b9f46568650effba9da5361_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c13c24eff8b47b6b20d9d46230a1c57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e6253005b2a4664a03ad8f8f5898630_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if17bac99f15a4fd08c57b8d625475683_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b860697a584413f99229019ccec2aa9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f42705f67d145a8bcd98e79844df3dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccec61d10cf24b1f9a049d503b7a1dad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5fe83762b5347d3b5b16cc99dd81437_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i102f385c304b406995d8b7e6800cb786_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c06f986336b4293934da0346e70a8ef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i062455b6853247eba1cd91fb4b7af879_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e3042dc4e974d1bb2015139dbedb73e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37fc7e470e2e4805af580456ed7f0010_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A190NotesDue20251902025NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6540ef5c27054d6e9c7985f2b141767a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48f26a3a0d594e26854ea76bb3c6743d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1863ab64829b4fabbec539235c0ac7d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd810185a212412e83638c36004bad29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53e1283c932d4edcbb8cc22fd4ab8960_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88ae1c03870043a08889cc2ff6ed20b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8710c24c464449b8fa26275c77a6e58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie10a62100d1e4b0e9d7ab8a2ba247c8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia850706d72994599bff9431d2e8b1a5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f2a64b79a0c404dba15ff2230fc371d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7fefa5369ca248188f3e2d24acec7468_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55ba559d13f24efc9fdf4abebc7c8924_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaeaf9de7e4f74c20b1108870b6ea1974_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic44afd752e7745c885bb3c653ec2d9f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5edec977c0494db1989203785b65a079_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i832afb5f09ff42f8972ccf47b59012a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7991c3b6e9984fe98b17e71a271b7557_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d0d27fa96204770aed6605e64628c8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFiveNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04bf222f1adc48dbad767adfdca6631f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6bc114e2ad04b349cc3973ecba76b7f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9278d061be544509ac7ccfcae7335101_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i581122c175be46309a19781a1813a543_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i787a1f1611f040bdb13bd41c6d2e7221_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac386b55791042908ad00f98e5e6a2ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29bd0ebc2ef643d89e8a4df0e1f5a0a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34aa68b41c90434093ba0c86e0923545_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04b1b2aa03f54c1aac5954067859bd2b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42b1c907d2284f46b65c2993a8518ee2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i880cd534575949e3abab9e8a7d2a0235_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11b4dae7d4c14e8d81c11fcee49b8148_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae894d8f94e84e9eb8cc52ce4c1e5efd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3dc259e1f874437e8de85f6ffd31abd9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie151d775f0614294815a86857329b491_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50e0eaf522434115aef33c9b0f4b32fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1502d4ddb0b4ea78f2bfbbf53ace156_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie619fdd6365143709fe3ef8c6e3e1cb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32f3ef7ef219414d9621fb4cbdaf429d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic29f8a9193ed4db1ad73321b122e4e45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71d7cd08a4ec4828acd8e3620f7b4d78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A200NotesDue20322002032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ba4ba7693a5434e9b35ca55c38722ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A280NotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd12628ec78f4499a7e276a61e90e99b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0cbb29ec00d4533a3e1155ce9550ede_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55367f6c3ff34f7cb01d46d89ee2c379_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf9c596023174e558d6631c3ca855b65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b742eeadacf4b658c093123bb55c0fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i070b4afa879f4c5fb36fc518fe1cfec4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b11859028a1422083400b2109fb068f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenZeroPercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf4f6ca5c74d48349c15921ae8a0933a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide87aaebcc2a4447a457f81d1aa31c9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebfd131a231b493da0babaf4c3b5395f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9a1311f688d45e5a1f460915c39e581_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54c22a3e15e54b178cf491b39cbfbbd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveZeroPercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5477a7c207054d569f2eca1cdcac36a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab353bc1f2344a55b1479a0f118d799c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id97511afa493447da0eb4625d1fbf9ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if97696feb118453eb13e08998850ad56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf411ca29d03476a953c14fc1769501d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9e3b5bf697b4cf0bfb5716a830f11db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id189fc4607ae4a208ed0437205c4c7f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointFourFivePercentNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb3ed5ae8257400c9ca750016aa502ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0682f6237def4973ae5a5cc46f9d59e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointOneZeroPercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3291bf95ec2416b94e22bd933d142ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1b2177f702640cd8b47f293f2ad22a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointEightFivePercentNotesDueTwoZeroTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3d97e7f0efe4261b956189daec4c902_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b8269488a684ef385c1e94d4f756b8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointEightSevenFivePercentNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie46f97dcfd2c4ee5b216081269ea57b0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i84d8db7b345b4458ae3f758755659354_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if87fc1146c544c828abfcec0fe2987c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f2c8de012264cf89c56a2b6158356f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e964a7c87d14059977b9c5c2746d0d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenZeroPercentNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfd842d4f03947599d399bf5eba13005_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09a6ccbf40d94c65aaafe7871e4a210a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id608276fe2a6484594c7c005d1cd220d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29b52d16bd6d4af083d152823f4b96ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i104a960196594625971a4b192145a8c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i82257eb313254ec0ab7249ac84b173fd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FloatingRateNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f6bff492829406da23ff2efa25558e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i165f3ecafa0a4de4b1c4b6db200d90b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib46494b393a34b9f8c60e96025f45f23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i845d5c989f794e06bd6777c9e801b93b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:InterestRateSwapAxis">amgn:InterestRateSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff27566615ea4d2bb9437ebad4ab002f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if93f0a53c32847ae98f3c48eb087f0d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2ae88e4533c4b4cb0927518f3740856_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fec9853ccc64441ade8c731c993d7bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5344d1029ee4871879edd955c41939b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d68f7e07a094edd9e2461d6c0fdd4fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3894bb298da842feac52ee9f09993b0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib38c6961bd484a1aaeb68b6dd42b1548_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i034a224066ae4802b5005e8a780dcba3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if99e95ece1544f458f56a09770d012f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c48563bcda143618f52c18180794c29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16fe501f4d234ba3bc01f6fd307e4f03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b1708fe50d04fdb89f763085b73c7a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie53460a2e2c54b1eb6ba01dd799c1956_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85ecb4c22c6d4edd9158a292a2b738c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77e71d687a124355ab2c2f4d216034fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27fb3b4b36f14d56bd098848256071d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf7b496d1968423ca0b81cb87f205866_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10d539e441f54f7987471e03eeb9fc39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d56a45dc3ab43509ef66161e0e3fa63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib05b839f30d040bebcd89a0c1fb92f5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i367d9d22b1c34ce1b4cdcd7cc2620446_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b46f3feeb0e47c0a2c7e9a4c6f05a7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec7fdb2956cb4333b6f9bcb209040ea5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35713b5b6ffa49349b004817c7c9da42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie614baae5549413b95d0a5b95b79a24b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie558eaebb0734ac988923b72ab5749e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33af7431531e4906871dc1c72260a8f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c65ad1961624e6fb50c1eb26eb83dcd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if03447162cb44ded9a9e6203334836ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d0f0acd616746d5b35dd8a2dbf392d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie320a4dc28964d3e945ea0199a471f76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5e84ea875e544c9937c0c203818dead_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85976d51465e4619a93074b54175b619_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i304433386dd64f7b8b7c9d12385a8ff0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f3f69cfacea4717a178488113e7724c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0423efbfc4c49a3a0c6e8782283b9e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if751ec72d1334a0aa3244e35632460fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd3e56f17777422db7fd7146740984bf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5da70484870944a2be74c9435a52ba12_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5cae36825a8244718a036f07b201a220_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if1d25f0b06be4a2ca6927d47f49abd4e_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i893df3cf158b4ab2a0c0d1c82a28c1bd_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i5154a4b4a2bd4af983bf6185d3daba74_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="icfca6c2819ef49179fc85b016ce6016f_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f7cba5195f24f829ec32f1b71cfd77c_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4eaa406cdfdd4c51b6756655cc712766_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i7254d1d0af7c46758551512b7d50361d_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i8fabc5abd9df4b559effd9eb67abea89_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b33af0508754ca28e72f99a484d9cf0_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i39b8f49d86e9448ab5f6101aa9d1fc57_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8a8d1cde152d418a976984815e041aa2_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i323451cad3a2466080975105981c98c8_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i8a85ddddc43a4b40bf86ad5da75e8de4_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i5a63a090508f49fdaacb88df082eb50b_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i67c13f8bb98d4f9b86238d8564507387_D20220308-20220308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-08</startDate>
            <endDate>2022-03-08</endDate>
        </period>
    </context>
    <context id="i309108b032084722a376b8a102fdb202_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifeb9c001d530444d809bab4daa3b3248_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib4494701f92e4c3497b69ce57bf3c5db_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i22a6854354df440da13fa35f04216a12_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4295abe2e530430ca537010e380381f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if79b493edfda4614928afa72235cd218_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ab69b9f5c1b4692a5c95f9a65dc9566_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98c41d891d134edd86170c260149c788_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3e3518c83274b19a2f3f3b2116e682d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9cfb6c5904e48c7bbfba692c97f5afb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b2c015276b143d1902156c9b84463e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b69b0fa4326426ba338b1b8a382b779_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieef7a11bc8b34811a438f59e60dba040_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53d33d7ade654ad299e31d14b471a5bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbbfb42202ea4564988889ffa1175789_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04a925f891f9422095e83c9bfcfb8e7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac308cc20ed14c5cace71b3353e328da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i258fcbb2c8764cbb987b87e8e1c787ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i000812ada76e42979388c4d128fa90de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0914f3d7dcd6426aa7c1a21fa7f2d1fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34745a1b911c4d30a56546635c8aa0de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99bd951fd41947b592b8c02d8f1c27c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fd5e2c85c274498bad48e922806e3ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b2f149e177b4bc3b630018b36f6e49c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifad2966682ec4e37bbcfa6626b7183ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e4dd663b9fc4f028f2085d56886e460_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i35372b79111c40a58a07694440d9622c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd31886569fd4668bfb1bce453953983_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8a842d09a06449083eeab3521739d0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35320f15f6674855866c5c06e985c83d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3749d6c99c044fd49a6d259f74ef6c99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe1e6522010e42beb2d5a512da981242_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69f61d55abb54285bdf1fa8615440956_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfaf46a638094fa5b126a5684fbeec50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6203c3d089a640c88db71d0303989c08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d32c14a32b146d491c15b7db4b291f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91b247dc676e4516bae8242fab1601e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bae52b8579846bf94e3c6a5aedc9878_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ed17b422b8a4a51b6f39304fe4350a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18b00e4e2c4742499d53a470e0343c3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf2471fcfa074988acc387470355b7a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if844eb33233f407fab5a2d1540261d05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1100eb5cd384e00b09db36c3d0a2866_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61f18fc869d74053929c46a2c61d88f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieac281d4e27f4175b82ae37df330c749_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c953f5c148c48d182cf8f1587a75aaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb66166118bd4add9f632ee3b805827f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ddf499ee3f344b5b42a90e01e741b82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb7d6eb6e0ea47e19bdbc24585673349_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d6231133c44412abb1a5cee2a4babf6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie81fa5de4d71466aad60dae129ee4fb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bea7ddb5d2b4c51a7e8fcffe813ebfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ff7bb5325c6416cae92c622ff045f13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03d6fad6c8dd462eaf5fde3ea0c3ff70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i004a939dc0024ba59fe2c2766322fdd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f15e114d3c64fe7946425ca3fc21f73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbe1823365054cc481d757a51d3eb3f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7a924c3505e43a9b71b7be707de1ac1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7eafc754316345619b018dfaaebc87f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5354f3fcd8644c87860ba3a5544fad9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iceba7ccd82584acda921d0e558528e50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d1ed82dd0d54655985037c85ddd3ede_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d3b3a83ca454eaabd5077059293ed84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ad26877e4a04bd7bb26b8a8c7c28eb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46082d9efffb4b3c95fe13c8f220bd0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9405eeed0ae040f5a34607effb78d146_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96b00be27f6e4944a30922c5c0fe6670_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1180ce65c8843b4991f543dc49f55be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5662300e135747438ae3581b6b70a657_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33c59ef250904a0c8c3737d73fef0bc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i607d4a85aba9437d83f47c041399a92e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5dc42b4f17b2415db5b78c0f90591e04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie630eb784ad2416794c05aa8a219fd58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62f25224e2b54616985641a3771ed55c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0614eede5b234c61be2259d587e7b43a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99958e30da4d4cbfa5e3d682930d68fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88f2b4195bd34883bf7b39bc3b2efe92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b26de6dcae348c4a7d727d21d2b83ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2c7782342094a07a4240eb1534d6ac4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03f94e6a78404c5c928e7256392dfe2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i089ac98960b04b439f83de38bd8c51dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefb49b4259114419a84f22f50981dca8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5427fc4b2ce14c1f83b6ee82f6be8aec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a08253dadcd44d2b7a7f73f8fb62ba6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2b282aad63a4bcaaf14002bae397df0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7211fd50bd2642b3aca55c89862f86d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a63aa87c0224ee98ac2fd8fd67ddaee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68179a299576480aa8d41a7687749389_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5c684a9063940959ca5882be53b9b80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71ec6c587d9b4e62aee06a72a1f73f9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5da09ffb67c742d795348bf45a166d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fe2830b43b44d79b43091fb7f32ea57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8359101653f44adbb212efe4e4294a95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibec9d656079e405f82e3bf12e4d8c37a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i665816818e0a44d58309ed1a320f177a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifaabba1893af44ce9e672215ac116ce8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i730ee854cf6c432ab6aaa706614c8632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fdabb7d166a4746adca1c02c5f92d88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bb0ddc693254332b142eabe8b6a28aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ecb51f1a572468b8e76872013008be7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc0cdd08ffa245b5b14a99b5ae9342c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointOneTwoFivePercentEuroNotesDue2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c071ab35a1441a7ab265cde48d713e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1dafda6691b84625923472fe59fa12bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i632df15458d646f08f1906bc1e27b8fa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2cce474dbbd049c4984d8bf485ab3a19_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29069e42d7524b4db8c509bf319d9680_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2c56acaf30d4dce85c3d989ea151652_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i665b76a3b3b3476c84386f9224fe17a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3eba7e66fb7849818cac30465266bf74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc742c16678e447d8a1223755190162f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i806e9dc1988340d9b23b17a31bc072d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16d30d400605402ca45a9146fa90bd76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:InterestRateSwapAtThenCurrentInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52186ecfa5c2464a9932151770b9a053_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc4882cfbc084ea5ae95c042bf24548e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b50391be4bb48db8dc8f419683a2218_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i739fe173b25a47189a34271891a4159b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7da02963523c4db1b9d260cbec5d9af3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied61ab999fde4db3b59917ff3e2febd4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2aae7469fe64dcd8bac1076dd7692d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:ForeignCurrencyAndCrossCurrencySwapsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i760d8f96eac94b7f88f95302db5dd2d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a34b1b31c7e425a8ee9baab7f3c59db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71e6675ffd9f4a3998395c7c583d88f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i089ec9cec29f4c7ca63544d5e4b387da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32f066d29e5c45d0ba4c511e73c8df4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i794004d7dfa741ea84b274eb42d3ec54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3d0846cbb0548819c01c3db53240ca0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3377db1e364448a198a868926553f9b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i050bfd34fd664c4086976b07e6af5cdc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e65e212078b47438c294f4cc92afbe1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a6728c58d4145b3887b604065653c19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfc161492cc64bd983de97ee811b16fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic268132426814d8eb399e70d427d8801_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie510af3eca8f4a73a86d9d56fbd815f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i479675435c2d49f99965cf557ed29fbf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44666b59eba54e9a95bb28abe178e8f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9952aa6a3b134df69afed008d9e67bf4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i19d673199032476d834451d22f3f5dc6_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:ImmunexAndSamsungBioepisCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i1d65a5d55e5642be9bee7decb061fd66_D20141001-20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="id07a2cf432c24ff9a1f851f3d46e53b5_D20160201-20160228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-28</endDate>
        </period>
    </context>
    <context id="i3b4cd2176c02454e86da12e52b785bfb_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SanofiRegeneronPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i5a349ce4f68f4e62ac77c54575a7b956_I20190520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2019-05-20</instant>
        </period>
    </context>
    <context id="iaf846f658f5942ce82b4f681a169e2fa_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i84504b4b6730469e9a42aebe34756f62_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="i42713d0e16f04d26a1b1ce71cf3aecd4_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i7c633c2c74b0432094a5ea889bbccf99_I20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:NovartisBreachOfContractActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-26</instant>
        </period>
    </context>
    <context id="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i1ab8018abbdc4ab1bcbc87cc2571878a_D20190430-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i3ac324416a7c4f1f83e593ede6d076bd_D20190731-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:SensiparAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ibba78d537ea54a03a6bd4d13b80aea70_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i7e56044cea924d89ae341cd4198e2725_D20190301-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="id63608bd810a4daabb58c50a1d92c7fc_I20190604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amgn:HumiraBiosimilarAntitrustClassActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-04</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>amgn:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="market">
        <measure>amgn:market</measure>
    </unit>
    <unit id="customer">
        <measure>amgn:customer</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="renewal_option">
        <measure>amgn:renewal_option</measure>
    </unit>
    <unit id="lawsuit">
        <measure>amgn:lawsuit</measure>
    </unit>
    <unit id="affiliate">
        <measure>amgn:affiliate</measure>
    </unit>
    <unit id="patent">
        <measure>amgn:patent</measure>
    </unit>
    <unit id="claim">
        <measure>amgn:claim</measure>
    </unit>
    <unit id="agreement">
        <measure>amgn:agreement</measure>
    </unit>
    <unit id="plaintiffs">
        <measure>amgn:plaintiffs</measure>
    </unit>
    <unit id="complaints">
        <measure>amgn:complaints</measure>
    </unit>
    <unit id="installment">
        <measure>amgn:installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8wLTEtMS0xLTU1NTU0_2acfe96f-9f78-4c9a-9b5d-b457633e8448">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8xLTEtMS0xLTU1NTU0_f6c09dbc-bf27-424b-90b6-8f76b0f4e4a4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8yLTEtMS0xLTU1NTU0_8587aee8-1720-40a2-9914-499c7ccc4e2a">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl80L2ZyYWc6NTljYTNkYTFjNDY1NDJlMjliMDVjNThmOGUxM2M1MjMvdGFibGU6ZjY1YTUwNjgyNTNhNGUxNTgxMDk3Y2ZiNTJlMWY5ZjAvdGFibGVyYW5nZTpmNjVhNTA2ODI1M2E0ZTE1ODEwOTdjZmI1MmUxZjlmMF8zLTEtMS0xLTU1NTU0_ad94484f-e797-41e5-8bd2-e498ff176540">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_8e72894d-153e-4a5c-a949-14e5e6efb449">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_aa058334-0aaf-49a3-8af4-aa023d961fb9">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_425f51cf-a3fa-4258-bdbe-9af1266d73f5">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_ea705079-dbdc-4ad1-8743-a06d3d2376ba">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_b89a7ea2-fc91-480e-bd31-38a43ceb270a">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_f7f1087e-27ba-483f-bdb7-bd0cc9f4c25f">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE1_b1ab2310-7a8a-428e-83ff-d927724f577c">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6NTQ5YTk1N2VjOWM2NGNlYWFhNzgxOWU0MmIwNmIxNTkvdGFibGVyYW5nZTo1NDlhOTU3ZWM5YzY0Y2VhYWE3ODE5ZTQyYjA2YjE1OV8wLTAtMS0xLTU1NTU0_e4aea066-54eb-424b-a79d-2cab8aea2dff">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8xMjc_0b635e0a-0541-4c70-a7ec-bd1e16a640e6">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8xMjc_9701eba6-ee42-4e25-aacf-1fc69969e96f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6NjM0MmEzZTExNWIzNGQ3NWEyNDA4MThlOTEyOWQ3NTUvdGFibGVyYW5nZTo2MzQyYTNlMTE1YjM0ZDc1YTI0MDgxOGU5MTI5ZDc1NV8wLTAtMS0xLTU1NTU0_fb2c12f6-4bfb-4220-b8c6-bdf9773e6314">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDA4_24fc1dff-b524-479d-b471-9290e7e7d935">001-37702</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDA5_53e7c2b5-f174-42ce-a1b6-92b8766c41a4">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8wLTAtMS0xLTU1NTU0_1e0e13b8-7459-4c28-9175-9d0d14a59322">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8wLTItMS0xLTU1NTU0_bf6e8dd2-29ce-4f3d-b77f-baf34c9a9207">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8yLTAtMS0xLTU1NTU0_a144d91b-c810-4f83-ad07-64748e21fc28">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8yLTItMS0xLTU1NTU0_10d6a9e0-fc15-4372-9af0-30d317065d1b">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF8zLTAtMS0xLTU1NTU0_e5da8ed3-56d4-4990-905f-9d26f278eb52">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6OTkzNDM2MmU3ZWIwNDNiZDgxODI4ZWMxZjYxY2QzMTQvdGFibGVyYW5nZTo5OTM0MzYyZTdlYjA0M2JkODE4MjhlYzFmNjFjZDMxNF80LTAtMS0xLTU1NTU0_06fabe7d-8b4e-45ad-bb6a-06b17d022bc7">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEw_fc6a4378-a6e9-44f3-b515-c77663c64b99">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEx_4ef63034-5e17-4b02-9e6b-7ca35547c147">447-1000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8xLTAtMS0xLTU1NTU0_25b2b998-d05e-477a-a559-e20b809ac420">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8xLTEtMS0xLTU1NTU0_643b6945-28ae-4b7e-aaaf-5e35bda9be68">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i200d4e6ebc4e4bea86b08c2930450960_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8xLTItMS0xLTU1NTU0_87422197-b414-4870-9890-bd76831f2bde">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8zLTAtMS0xLTU1NTU0_648908b5-d9c1-44a6-9de4-1fc39417eb7e">2.00% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8zLTEtMS0xLTU1NTU0_b28f44ad-fcfd-4446-9340-15b03d462e87">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ife8cce51ad7f4210bbb1ea29766edce3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6YmY5NjUxZjkxNDE1NDBhMDg3NzA0MWYyNzAzODBlZDIvdGFibGVyYW5nZTpiZjk2NTFmOTE0MTU0MGEwODc3MDQxZjI3MDM4MGVkMl8zLTItMS0xLTU1NTU0_2e6d7377-0d20-41c7-b21e-0d2b382f214b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8xMTU0NDg3MjA5NTI0Mw_35fc6abb-73d5-477b-9ec4-e7aef54c27cd">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEy_035d09b8-9ba0-4d9f-9202-30d54e577cde">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE3_91667049-a7f4-4762-9bac-f908a6ca7ea3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDEz_70a47703-751a-46a2-972e-7f9914ced498">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6MzJkMjAyY2RkNDE3NGIxNTk0MzM2ODllZjFjMzg4ZTEvdGFibGVyYW5nZTozMmQyMDJjZGQ0MTc0YjE1OTQzMzY4OWVmMWMzODhlMV8wLTAtMS0xLTU1NTU0_e0d72b2d-5178-4bd1-8628-440aadcc855d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6MzJkMjAyY2RkNDE3NGIxNTk0MzM2ODllZjFjMzg4ZTEvdGFibGVyYW5nZTozMmQyMDJjZGQ0MTc0YjE1OTQzMzY4OWVmMWMzODhlMV8xLTMtMS0xLTU1NTU0_ac31c0ee-d856-42df-97b4-547f46488b48">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGFibGU6MzJkMjAyY2RkNDE3NGIxNTk0MzM2ODllZjFjMzg4ZTEvdGFibGVyYW5nZTozMmQyMDJjZGQ0MTc0YjE1OTQzMzY4OWVmMWMzODhlMV8xLTQtMS0xLTU1NTU0_8bea7e12-fe14-4ad4-a032-99fb85811cfd">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE4_a3d445f4-d0f5-4497-857a-f7d8dfbacc03">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE5_1c4d23ae-e104-4f8a-b893-88ed43cf3eaf">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i387dbf98d1b24d5f83cd817582c5b3af_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8yNjAy_0c0a3319-0290-4edb-b164-311462dcdd5d"
      unitRef="usd">137531019585</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if9cbde08232d47f1b1397109661d89c3_I20220211"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zMTEw_77118236-ac7a-41b6-808c-d420f1fb95aa"
      unitRef="shares">557029370</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xL2ZyYWc6OTYxMGVjYjdhODIyNDdjYzhlYTkzMjk5Mjg5YzcwZGYvdGV4dHJlZ2lvbjo5NjEwZWNiN2E4MjI0N2NjOGVhOTMyOTkyODljNzBkZl8zNDE0_597f332e-d8df-4363-a812-53ba43263a81">&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specified portions of the registrant&#x2019;s Proxy Statement with respect to the 2022 Annual Meeting of Stockholders to be held May 17, 2022, are incorporated by reference into Part&#160;III of this annual report.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xMjQvZnJhZzpjNGQyNjU5YTE5ZGI0OWIwOTdhMjExMDE2ODU2ZmM3Mi90ZXh0cmVnaW9uOmM0ZDI2NTlhMTlkYjQ5YjA5N2EyMTEwMTY4NTZmYzcyXzEwOTk1MTE2MjgyMDUz_4b944334-039e-480a-b24b-47ba56c129e2">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xMjQvZnJhZzpjNGQyNjU5YTE5ZGI0OWIwOTdhMjExMDE2ODU2ZmM3Mi90ZXh0cmVnaW9uOmM0ZDI2NTlhMTlkYjQ5YjA5N2EyMTEwMTY4NTZmYzcyXzEwOTk1MTE2MjgyMDU0_516bffeb-710f-4acc-87cf-1631c5bfa97c">Los Angeles, California</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNjAvZnJhZzoyOTdkODRlZjkzODM0YzI3OGUwZDdlZTczM2UxNmE2ZC90YWJsZTo5MTNkMjgxMDEzNTA0MzM3OTc0YTVlY2NlY2ViYTQyYy90YWJsZXJhbmdlOjkxM2QyODEwMTM1MDQzMzc5NzRhNWVjY2VjZWJhNDJjXzEtMC0xLTEtODg1NDUvdGV4dHJlZ2lvbjo1ODEyMzE3ZjdmZjk0MGU2YTJlYWQyYmZhYzI2NGNkNV84Nzk2MDkzMDIyMjg0_c3697f78-d5c5-40c1-9ee7-3b228158d31e">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzUvZnJhZzo5ZTQ5OWIxODMwYjE0ZjUyYTk2OGE0ODFjZmExNjMxYy90YWJsZTo0YmNlZmI0Y2Y0Zjk0NDQ4YjRkOTA1M2U1ZTQ4MDMzMC90YWJsZXJhbmdlOjRiY2VmYjRjZjRmOTQ0NDhiNGQ5MDUzZTVlNDgwMzMwXzUtMi0xLTEtNzg4MTEvdGV4dHJlZ2lvbjo2YmY1ODAwYWViNzU0MzVkOWJkMzQ3YzA4NGNkOGMzZV84Nzk2MDkzMDIyMjUx_5a50214e-8b27-4672-a471-e634ab978a4e">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzUvZnJhZzo5ZTQ5OWIxODMwYjE0ZjUyYTk2OGE0ODFjZmExNjMxYy90ZXh0cmVnaW9uOjllNDk5YjE4MzBiMTRmNTJhOTY4YTQ4MWNmYTE2MzFjXzEwOTk1MTE2Mjg4ODY1_84f2765a-075e-4297-b450-f307adc1f746">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzItMS0xLTEtNTU1NTQ_7227de08-8cc8-47fe-85bc-f1ec1c7e0784"
      unitRef="usd">24297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzItMy0xLTEtNTU1NTQ_4c4cbf07-21e8-474d-b95e-d677dcaece6c"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzItNS0xLTEtNTU1NTQ_8606d566-e1c5-4286-9699-15eaeb9e810f"
      unitRef="usd">22204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aa4009b79ae4a1aaa88901012cdc38c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMtMS0xLTEtNTU1NTQ_34511cd8-70d9-438b-8580-daf651422474"
      unitRef="usd">1682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c9dfed05d2a4cc7b238e87a2395d611_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMtMy0xLTEtNTU1NTQ_2f9f8186-65c7-4b02-a291-efee68e136e8"
      unitRef="usd">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5666794b15d1495f894c2e5fa67e1ff5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMtNS0xLTEtNTU1NTQ_05b37d21-8e14-47ec-8b4c-533c319b7454"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzQtMS0xLTEtNTU1NTQ_f27e77bf-d4c8-42e1-8a9b-df6354b8d2a4"
      unitRef="usd">25979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzQtMy0xLTEtNTU1NTQ_02b2841e-d29b-4ecf-82d1-fb86473acb2b"
      unitRef="usd">25424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzQtNS0xLTEtNTU1NTQ_7fbb289f-6cec-465e-8cc8-bed6febcd00c"
      unitRef="usd">23362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzctMS0xLTEtNTU1NTQ_bc0adb6a-7301-4f63-be9e-8db0e6d33b84"
      unitRef="usd">6454000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzctMy0xLTEtNTU1NTQ_e0f22518-e7f6-4aaa-9236-4883b2f45c60"
      unitRef="usd">6159000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzctNS0xLTEtNTU1NTQ_05d77ddd-c993-4b42-aa86-004aabf05aaf"
      unitRef="usd">4356000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzgtMS0xLTEtNTU1NTQ_89a0cbc0-e06a-4604-8c46-229b1b4347f6"
      unitRef="usd">4819000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzgtMy0xLTEtNTU1NTQ_8d0dc1f9-cb44-4161-8473-484b1847549e"
      unitRef="usd">4207000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzgtNS0xLTEtNTU1NTQ_5d1c9172-c22e-4f06-aeca-102970b9f233"
      unitRef="usd">4116000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMS0xLTEtNzg0MDc_8cf94d6f-660e-4c08-889b-911fa7d383c8"
      unitRef="usd">1505000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMy0xLTEtNzg0MTA_2a1472a3-f40f-48ea-af29-ad9ed60cbc16"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktNS0xLTEtNzg0MTI_ac643572-75c0-4847-9951-413bf63ba0db"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMS0xLTEtNTU1NTQ_ac19a5fe-f6d6-4718-b48c-fb81550b12c8"
      unitRef="usd">5368000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktMy0xLTEtNTU1NTQ_551ab1e3-f84f-469b-8967-47e839fdba63"
      unitRef="usd">5730000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzktNS0xLTEtNTU1NTQ_cbbf0012-ee39-4e90-b20c-7340681f649f"
      unitRef="usd">5150000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEwLTEtMS0xLTU1NTU0_8b8aa5f5-75d5-4f6b-9bf1-b0afed728347"
      unitRef="usd">194000000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEwLTMtMS0xLTU1NTU0_89856fa2-a585-4636-aab3-ef1ca972be32"
      unitRef="usd">189000000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEwLTUtMS0xLTU1NTU0_e751f1fc-b65b-4324-9b97-187d389c4820"
      unitRef="usd">66000000</us-gaap:OtherGeneralExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzExLTEtMS0xLTU1NTU0_fa40a75f-34c1-4535-a15c-be9749890015"
      unitRef="usd">18340000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzExLTMtMS0xLTU1NTU0_0d4c7bf1-abd9-4143-a8e1-b59d61682a1d"
      unitRef="usd">16285000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzExLTUtMS0xLTU1NTU0_aa657aad-9614-4d8d-a576-1882ac7899e0"
      unitRef="usd">13688000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEzLTEtMS0xLTU1NTU0_9dc28e7c-323f-4c8d-9944-8b3d6e82e751"
      unitRef="usd">7639000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEzLTMtMS0xLTU1NTU0_d92b9965-0724-48f1-95af-6d92396e39ff"
      unitRef="usd">9139000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzEzLTUtMS0xLTU1NTU0_937f4b6f-b60d-4287-83f0-eb816ece56ce"
      unitRef="usd">9674000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE2LTEtMS0xLTU1NTU0_179644f7-8ab2-4cd0-913f-7ca22d1169d7"
      unitRef="usd">1197000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE2LTMtMS0xLTU1NTU0_7399d86d-22cf-4479-a7e3-8e55a19d3a21"
      unitRef="usd">1262000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE2LTUtMS0xLTU1NTU0_0d1ed789-b0d4-413f-9004-ad29802a08f7"
      unitRef="usd">1289000000</us-gaap:InterestExpenseDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE3LTEtMS0xLTU1NTU0_c5035f41-97c4-4b56-9814-5ce5d60ec548"
      unitRef="usd">259000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE3LTMtMS0xLTU1NTU0_16cdc567-9efd-4fbc-a353-74734c04e39d"
      unitRef="usd">256000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE3LTUtMS0xLTU1NTU0_600b23d6-0189-46ac-ab01-28227a146fe1"
      unitRef="usd">753000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE5LTEtMS0xLTU1NTU0_58baacb7-1419-4fd1-b775-0bb542ca95e2"
      unitRef="usd">6701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE5LTMtMS0xLTU1NTU0_61eda238-fb4f-484b-a703-1845fa7e95c6"
      unitRef="usd">8133000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzE5LTUtMS0xLTU1NTU0_54a055cd-de00-4e52-8dce-f16a1062262f"
      unitRef="usd">9138000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIxLTEtMS0xLTU1NTU0_299d0eac-2523-4115-93e0-11437c55268c"
      unitRef="usd">808000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIxLTMtMS0xLTU1NTU0_c8b86c66-4c5d-41c2-85f8-e30cf5cc349d"
      unitRef="usd">869000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIxLTUtMS0xLTU1NTU0_0e6477fd-4a4f-4228-8211-5aff9b9fc9de"
      unitRef="usd">1296000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIzLTEtMS0xLTU1NTU0_da1a388d-a634-4b45-ab99-61edc358abf9"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIzLTMtMS0xLTU1NTU0_8bcce490-5beb-4ced-acfc-32645677e6d3"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzIzLTUtMS0xLTU1NTU0_49f2e5f1-c55e-4ba1-87e4-8ccf1852e398"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI2LTEtMS0xLTU1NTU0_7e0d204b-d80f-496e-9b61-4a5994ed79c0"
      unitRef="usdPerShare">10.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI2LTMtMS0xLTU1NTU0_a1a34e62-ab49-4b66-b356-22bf85314a40"
      unitRef="usdPerShare">12.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI2LTUtMS0xLTU1NTU0_0236bf44-0cf2-479d-9c46-7c772b7b5a8d"
      unitRef="usdPerShare">12.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI3LTEtMS0xLTU1NTU0_8b124835-8cb3-452c-8523-9106b91fd949"
      unitRef="usdPerShare">10.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI3LTMtMS0xLTU1NTU0_7370c7a8-58ee-4586-a527-fbeb1a18dbc4"
      unitRef="usdPerShare">12.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzI3LTUtMS0xLTU1NTU0_e93d53c2-3af0-4400-9a63-f0e8d9318345"
      unitRef="usdPerShare">12.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMwLTEtMS0xLTU1NTU0_97200bcc-2442-4f14-abc0-308681eb0ef7"
      unitRef="shares">570000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMwLTMtMS0xLTU1NTU0_cbfffef2-1b9e-47f1-aad9-a7c6e826fb86"
      unitRef="shares">586000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMwLTUtMS0xLTU1NTU0_b0df7951-e203-4d72-9d29-5c57eabfbce9"
      unitRef="shares">605000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMxLTEtMS0xLTU1NTU0_f8c1437a-ca8c-4804-86cd-710209a850ec"
      unitRef="shares">573000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMxLTMtMS0xLTU1NTU0_b726ec00-aca0-4afb-be88-3cc413dc1d4e"
      unitRef="shares">590000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xNzgvZnJhZzo4NmQxNmRkMzg0YTA0ZjA1ODM2ZDNjNzkwOGQwMmEyNy90YWJsZTphNjc4OTEzZDcyMTg0ODBiYWYxMGMxODQ3MTdjYmJmMi90YWJsZXJhbmdlOmE2Nzg5MTNkNzIxODQ4MGJhZjEwYzE4NDcxN2NiYmYyXzMxLTUtMS0xLTU1NTU0_038782c6-5bf3-4e3e-869a-7e11e374ef50"
      unitRef="shares">609000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzEtMS0xLTEtNTU1NTQ_9f6ba638-3cc7-4ed9-9504-e3f7f706d317"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzEtMy0xLTEtNTU1NTQ_6f6a5c04-9ed0-4201-88a1-9c9b9468ccff"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzEtNS0xLTEtNTU1NTQ_14ab7bad-a871-4ae0-8b9b-224a8337f3e3"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzMtMS0xLTEtNTU1NTQ_d7c0d144-e124-4326-bfe2-f18ff797536b"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzMtMy0xLTEtNTU1NTQ_18e6da07-a794-464d-8a94-56fe93d4db3b"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzMtNS0xLTEtNTU1NTQ_a181bb12-8c3e-4ea3-902a-e9236ed3a267"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzQtMS0xLTEtNTU1NTQ_561ed24b-ce24-448e-bcd2-1bc397915577"
      unitRef="usd">324000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzQtMy0xLTEtNTU1NTQ_960652cb-1c5c-4812-aba8-37d3095e2fc5"
      unitRef="usd">-438000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzQtNS0xLTEtNTU1NTQ_492b0f71-5a44-4a3d-97e5-d131cd192c4b"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzUtMS0xLTEtNTU1NTQ_28767772-181d-421c-bb37-051447ecf3bb"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzUtMy0xLTEtNTU1NTQ_bf4bcc22-38b6-49a7-8c0c-fa192241250b"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzUtNS0xLTEtNTU1NTQ_626ba57c-0b68-4e7c-8534-ca3542a30c5a"
      unitRef="usd">360000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzYtMS0xLTEtNTU1NTQ_e368f3fa-8d80-4401-81c0-180e81e74966"
      unitRef="usd">1000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzYtMy0xLTEtNTU1NTQ_357d77ce-9ade-43c5-93c0-b67783827ecd"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzYtNS0xLTEtNTU1NTQ_f1c669ee-88ad-45c2-ad5c-fcc223bec4f3"
      unitRef="usd">-5000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzctMS0xLTEtNTU1NTQ_426c5fa2-c342-468f-ba47-342ebce885ae"
      unitRef="usd">189000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzctMy0xLTEtNTU1NTQ_99711c90-1059-42ce-9ca4-4a5b8df321c8"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzctNS0xLTEtNTU1NTQ_6cce17d0-e6f2-4e25-ae30-49948c6dba7f"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzgtMS0xLTEtNTU1NTQ_8c8d5f13-6965-458b-b097-f2092ac4fd35"
      unitRef="usd">6082000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzgtMy0xLTEtNTU1NTQ_d48f1215-c614-460f-9c42-464b93ba11d2"
      unitRef="usd">6807000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODEvZnJhZzo0MGVkMGZlYmFhZWM0OGFjYmVlZjhmNmI5NGEzMDdkZS90YWJsZTpiYmQyYWZhMjBmMGY0MThjODkzMTViNmYwYjM4NzQwYi90YWJsZXJhbmdlOmJiZDJhZmEyMGYwZjQxOGM4OTMxNWI2ZjBiMzg3NDBiXzgtNS0xLTEtNTU1NTQ_5022aa5d-befe-4a01-a997-3e8d1c34a64f"
      unitRef="usd">8083000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMtMS0xLTEtNTU1NTQ_6f5e0670-2be9-4fa7-bda5-b325d7a4a4a7"
      unitRef="usd">7989000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMtMy0xLTEtNTU1NTQ_327d62c0-30d3-40ff-b27b-07fa740f6a8c"
      unitRef="usd">6266000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzQtMS0xLTEtNTU1NTQ_cc16f07e-d5b0-4ac3-92a9-cd64bf936550"
      unitRef="usd">48000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzQtMy0xLTEtNTU1NTQ_bb547790-d41c-4c71-92bf-a34305467e7f"
      unitRef="usd">4381000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzUtMS0xLTEtNTU1NTQ_28e1c057-b1fd-46b5-8b6c-34929a7e62b4"
      unitRef="usd">4895000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzUtMy0xLTEtNTU1NTQ_59e35f46-e18b-467c-b219-91d01b04b11d"
      unitRef="usd">4525000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzYtMS0xLTEtNTU1NTQ_8ac1f156-dc03-4dcc-829d-29052bcf7828"
      unitRef="usd">4086000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzYtMy0xLTEtNTU1NTQ_8ee9f433-1279-441f-b44b-1bdccd69980a"
      unitRef="usd">3893000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzctMS0xLTEtNTU1NTQ_07a04e09-2883-4f0c-a5fc-26ba26bebf7c"
      unitRef="usd">2367000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzctMy0xLTEtNTU1NTQ_8b42243e-a5a0-4689-9c22-6e00dae0c0ff"
      unitRef="usd">2079000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzgtMS0xLTEtNTU1NTQ_e7712d53-5000-4fd9-8e4c-0425f5682829"
      unitRef="usd">19385000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzgtMy0xLTEtNTU1NTQ_d50cb2ce-7361-4e25-a250-ec12472f140b"
      unitRef="usd">21144000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEwLTEtMS0xLTU1NTU0_f9e6b26e-875e-498d-923b-30288a2baac2"
      unitRef="usd">5184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEwLTMtMS0xLTU1NTU0_d3e32e46-5355-4922-bfe9-7b04b85c67fc"
      unitRef="usd">4889000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzExLTEtMS0xLTU1NTU0_3af9470d-d3e6-4201-a672-aa26196a591c"
      unitRef="usd">15182000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzExLTMtMS0xLTU1NTU0_3b316478-f4a0-41e5-ae60-53e353e337ad"
      unitRef="usd">16587000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEyLTEtMS0xLTU1NTU0_d25676a5-1acf-4046-afe3-3bf28d54ccbc"
      unitRef="usd">14890000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEyLTMtMS0xLTU1NTU0_0a0ee5b1-0c1a-4f64-b8ff-cb95b1be58f7"
      unitRef="usd">14689000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEzLTEtMS0xLTU1NTU0_2a0d5b19-dfa9-4d4b-a19e-fb4437208fad"
      unitRef="usd">6524000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzEzLTMtMS0xLTU1NTU0_8e2be61f-c48a-4c2e-bbe3-c97432393948"
      unitRef="usd">5639000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE0LTEtMS0xLTU1NTU0_c7b481b3-d454-4494-824b-502886aeac91"
      unitRef="usd">61165000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE0LTMtMS0xLTU1NTU0_d39a4bfd-6ce9-4a42-97a2-3351d351f829"
      unitRef="usd">62948000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE4LTEtMS0xLTU1NTU0_153bbf31-f95e-44aa-b61a-0637d2f553dd"
      unitRef="usd">1366000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE4LTMtMS0xLTU1NTU0_801dc95a-8b3b-419f-be24-c4c7100e657a"
      unitRef="usd">1421000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE5LTEtMS0xLTU1NTU0_6a444282-57fe-408f-b25a-750af46b2812"
      unitRef="usd">10731000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzE5LTMtMS0xLTU1NTU0_8b5216bd-92ad-453f-a624-91dadd72b938"
      unitRef="usd">10141000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIwLTEtMS0xLTU1NTU0_31d4bddc-f2db-4e0b-91eb-9e3dabb143db"
      unitRef="usd">87000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIwLTMtMS0xLTU1NTU0_b2fd9d93-9e13-4382-b743-027ee99421a5"
      unitRef="usd">91000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIxLTEtMS0xLTU1NTU0_ca34269e-b446-4130-adc3-b7426e36fc51"
      unitRef="usd">12184000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIxLTMtMS0xLTU1NTU0_bfdb6d0c-faac-4cf2-b9b0-6fdd9cc1b138"
      unitRef="usd">11653000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIzLTEtMS0xLTU1NTU0_ec15eaab-f857-4597-a4be-f8769b2f8766"
      unitRef="usd">33222000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzIzLTMtMS0xLTU1NTU0_92d463e8-201e-4f12-8c8d-a713b5749686"
      unitRef="usd">32895000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI1LTEtMS0xLTU1NTU0_90b5f1bc-4ca0-411b-b778-772359168a10"
      unitRef="usd">6594000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI1LTMtMS0xLTU1NTU0_f97f9af1-88ec-4055-b2e8-78285b20ff14"
      unitRef="usd">6968000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI2LTEtMS0xLTU1NTU0_e04fa956-1209-4446-812a-3783677d3ddf"
      unitRef="usd">2465000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI2LTMtMS0xLTU1NTU0_e614863e-900b-4ac7-9ad9-e06fe2e58224"
      unitRef="usd">2023000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI4LTEtMS0xLTU1NTU0_66fc0b8f-ac44-4c29-979c-98d59751286d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzI4LTMtMS0xLTU1NTU0_3e31997c-b046-4924-a69e-58bd2eb3f07d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNDk_23c071fa-bfc9-4229-a985-02bf1960e4fb"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNDk_4092ff15-305e-4a0e-8104-b8dcabdc2a03"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNzM_8e593125-9e6d-4a9e-a215-5330268c3a88"
      unitRef="shares">2750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfNzM_f7a75665-3bba-4f58-88e7-297142de6791"
      unitRef="shares">2750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfMTA4_59335bb2-9e73-4f96-8fda-bdebc0181354"
      unitRef="shares">558300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZGI0MTkzNmUzNjQ1NDgyZjgyMDE3Mzk3NGI1OTg4MjlfMTMw_699f2105-3b38-451d-95a1-41549573c639"
      unitRef="shares">578300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTEtMS0xLTU1NTU0_d2036425-8a6a-46e1-8977-cdb5bb207b65"
      unitRef="usd">32096000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMxLTMtMS0xLTU1NTU0_fb1a26f1-d9a6-486e-9424-9749a0ab53fe"
      unitRef="usd">31802000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMyLTEtMS0xLTU1NTU0_42540228-ac7c-4035-a46c-d01af3b4b132"
      unitRef="usd">-24600000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMyLTMtMS0xLTU1NTU0_7453bddd-7e06-4c0f-80ed-ca5b0e291d98"
      unitRef="usd">-21408000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMzLTEtMS0xLTU1NTU0_935aab3b-66a3-40d8-882b-7f19972f1641"
      unitRef="usd">-796000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzMzLTMtMS0xLTU1NTU0_fc857877-7b95-4229-81d8-f9be58f82e1f"
      unitRef="usd">-985000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM0LTEtMS0xLTU1NTU0_d268dc95-10c0-4a27-abad-423ac0c6f0fc"
      unitRef="usd">6700000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM0LTMtMS0xLTU1NTU0_5b38871f-d452-4839-bdf8-8c0ddced8b03"
      unitRef="usd">9409000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM1LTEtMS0xLTU1NTU0_777f29e7-50de-4417-a521-cccafa25410e"
      unitRef="usd">61165000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODQvZnJhZzpmNjA2ZTVlYzk3ZGE0ZTMwOGU1YWY3NGMwNzA3OWU3ZC90YWJsZTo5ODBhMmNlODk0MzI0MjA2YmQxOWM3YTJhZThkMDBiMC90YWJsZXJhbmdlOjk4MGEyY2U4OTQzMjQyMDZiZDE5YzdhMmFlOGQwMGIwXzM1LTMtMS0xLTU1NTU0_99d40b08-833b-486b-b2d9-8694769a747a"
      unitRef="usd">62948000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8dfa3d2f9c9049c0a19ece84de2ff2ff_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtMS0xLTEtNTU1NTQ_32dcc8a5-c1bc-4b7e-85e6-d9e406e96895"
      unitRef="shares">629600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie07c6d9499a1435a873c87b9197752bb_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtMy0xLTEtNTU1NTQ_dfe5a2eb-8242-4eda-8cc1-a08295591c2d"
      unitRef="usd">31246000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i883c7889246b4351952e694e54ad42f3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtNS0xLTEtNTU1NTQ_f3d00d7b-bd9f-4da1-a1d1-77c12402851f"
      unitRef="usd">-17977000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if37f4705aa9b489a9965276d6b9e48de_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtNy0xLTEtNTU1NTQ_a4ae3580-fdf6-4ac7-8981-8873b1108b0a"
      unitRef="usd">-769000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEtOS0xLTEtNTU1NTQ_f615c16a-00de-4616-af70-83bda6dd1865"
      unitRef="usd">12500000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzMtNS0xLTEtNTU1NTQ_be324798-1ae2-4370-b552-d91d851a4f42"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzMtOS0xLTEtNTU1NTQ_27056b99-1b7d-4082-866b-d25466b7d20d"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzQtNy0xLTEtNTU1NTQ_63a87a68-9634-4ef4-a273-b97913102207"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzQtOS0xLTEtNTU1NTQ_33d05379-2d75-4626-9c7c-da7d7e9dfd29"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzUtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0NzUwMTkxZmU3ZWU0NWRkOGE5MjE1ODI0OGVmMTM5NF84Nzk2MDkzMDIyMjc5_1c65bb51-df28-4d5e-a52a-cbb3d6d67614"
      unitRef="usdPerShare">5.95</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzUtNS0xLTEtNTU1NTQ_9b969393-3d84-4935-b471-a2c0426d5975"
      unitRef="usd">3555000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzUtOS0xLTEtNTU1NTQ_51ae1f25-f28f-4427-a38f-f674bd32f8ff"
      unitRef="usd">3555000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1a8de5ba86f046cdb69fc0f4c708fc92_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzYtMS0xLTEtNTU1NTQ_e928d9f5-9f86-4b85-a8e2-d4639ac84fd0"
      unitRef="shares">2000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzYtMy0xLTEtNTU1NTQ_44bba085-2db7-4acc-a2f6-16d9eb589e3f"
      unitRef="usd">97000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzYtOS0xLTEtNTU1NTQ_58657854-e836-4a4f-843f-973744002597"
      unitRef="usd">97000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzctMy0xLTEtNTU1NTQ_32b0ebb4-8429-4685-8868-d7220bec1c23"
      unitRef="usd">323000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzctOS0xLTEtNTU1NTQ_d94ebf84-6c40-44da-be17-7c4e37d83267"
      unitRef="usd">323000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="i1a9eb62a9d6b46f5be2122281af6b439_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzgtMy0xLTEtNTU1NTQ_c0f301e7-0375-4c2d-8df3-b945bc6b6535"
      unitRef="usd">-135000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzgtOS0xLTEtNTU1NTQ_975fd2a8-d6ac-498e-a19d-6266d11ea718"
      unitRef="usd">-135000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i1a8de5ba86f046cdb69fc0f4c708fc92_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzktMS0xLTEtNTU1NTQ_631c15aa-c45f-4185-aeb3-9e3321ad7764"
      unitRef="shares">40200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="if1958d1df77e41b39ff0871492b8228c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzktNS0xLTEtNTU1NTQ_9f426de0-2b56-4780-a6c4-714197bbe206"
      unitRef="usd">7640000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzktOS0xLTEtNTU1NTQ_69dfc282-44f2-474a-bce7-999dca3c8d64"
      unitRef="usd">7640000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i59abc98712f3458ba5b91a6534b6a125_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTEtMS0xLTU1NTU0_c8ab1917-cfb5-4a5d-ac92-11c7340a87bc"
      unitRef="shares">591400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iace73d6c035d4a77a2cbffa4ce90f25e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTMtMS0xLTU1NTU0_2ae02194-b4b3-42eb-9ace-f2d5c2ebf084"
      unitRef="usd">31531000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i661e28e3d2d84263805b3d206b050c22_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTUtMS0xLTU1NTU0_9d2fd1c2-4809-4d78-9512-a388aff8ffeb"
      unitRef="usd">-21330000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea207d0ec0394b108fc793525231d205_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTctMS0xLTU1NTU0_be5b828a-8b5b-4957-97ed-3cf3e1e2b6d0"
      unitRef="usd">-528000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEwLTktMS0xLTU1NTU0_280545d2-2046-45c1-84f2-93479df4c46f"
      unitRef="usd">9673000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf1a1b1a0dce4a0f9ea205178fdca9c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzExLTUtMS0xLTc0NjQ0_f2851f60-4fdf-4153-a78d-53ce3c6772dc"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i719c98f9ce454a51b25b0be7d1e61269_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzExLTktMS0xLTU1NTU0_b125439d-5b44-433d-bd9f-38f88cbe79f8"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEyLTUtMS0xLTU1NTU0_dd4607f3-bb52-4c40-8eb3-e017a3743434"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEyLTktMS0xLTU1NTU0_be674299-2a8e-4da8-a04a-e24087fe0669"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEzLTctMS0xLTU1NTU0_592782cd-f461-4d0b-9703-ac85320dee41"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzEzLTktMS0xLTU1NTU0_617c2977-9d5c-4186-8bdb-a3f2755ef369"
      unitRef="usd">-457000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246NmNhM2QxNjZiM2YxNDQ0MWJlZjBkYzg1OWY4ZTAyMmZfODc5NjA5MzAyMjI4NQ_afc6a6f8-906e-4b2d-9c6b-f80e1e02b46f"
      unitRef="usdPerShare">6.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE0LTUtMS0xLTU1NTU0_e1ed8585-815c-4969-9670-87dc853ca7f6"
      unitRef="usd">3843000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE0LTktMS0xLTU1NTU0_f758cb48-cfc6-48d9-9238-f0ba7bb7388c"
      unitRef="usd">3843000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i69699f22fd2341d793a1b05ac851fe93_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE1LTEtMS0xLTU1NTU0_25104f3b-ecf3-42ff-8906-b1238b05a827"
      unitRef="shares">2100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE1LTMtMS0xLTU1NTU0_36b0926f-43a1-4e54-a073-d2ba3cb270cc"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE1LTktMS0xLTU1NTU0_88f61614-b059-4c72-8153-a5e1893294cb"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE2LTMtMS0xLTU1NTU0_b30dc13d-4bbf-4adf-a03d-58057f7bc07f"
      unitRef="usd">349000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE2LTktMS0xLTU1NTU0_7077a374-19ed-4ffe-ab4f-e6e18035c984"
      unitRef="usd">349000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="i36ca2920c2774f3488f1d7dddf1bdaf5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE3LTMtMS0xLTU1NTU0_01a7239b-0099-4b5a-a377-a295397930b3"
      unitRef="usd">-169000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE3LTktMS0xLTU1NTU0_21f7327f-9a9f-4779-8fa8-ea56fa3e2b5c"
      unitRef="usd">-169000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i69699f22fd2341d793a1b05ac851fe93_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE4LTEtMS0xLTU1NTU0_48cc3420-8bfc-434d-8a80-faddf7a5cac9"
      unitRef="shares">15200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ic3596ccc578c4dec99cd5e340cbc7df5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE4LTUtMS0xLTU1NTU0_3842de9a-fec6-4eb5-a504-c56567b3ca18"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE4LTktMS0xLTU1NTU0_e5086e29-a9de-4b4a-923b-62058fe2bc7e"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2d2ab0ebd9f7498a91b623bb412e8f34_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTEtMS0xLTU1NTU0_eb951c49-f2e0-42f0-9b23-6fe8a1fc4059"
      unitRef="shares">578300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i810c9e939c3947a6b2840daa5f56ecbb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTMtMS0xLTU1NTU0_b535863b-b05a-43a0-8912-d70f3f859a4f"
      unitRef="usd">31802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifdc2047b094b4f3391b29249a580f128_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTUtMS0xLTU1NTU0_d9def424-3108-4020-bdc8-24c6280cc43e"
      unitRef="usd">-21408000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2766f3376fe7415ab521166b30e8525e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTctMS0xLTU1NTU0_f8df43d0-5b76-434f-99c4-1e836031615e"
      unitRef="usd">-985000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzE5LTktMS0xLTU1NTU0_b0ef75a1-e071-4915-aa6e-bc262c5f9da4"
      unitRef="usd">9409000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIxLTUtMS0xLTU1NTU0_0b50ba35-6a2b-44fd-b546-d7382b64b8c2"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIxLTktMS0xLTU1NTU0_368bf1fd-2a16-4ba7-8cfd-d052e76feca3"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIyLTctMS0xLTU1NTU0_ca8a907e-bf2e-4f7c-8c0a-26df14e3e342"
      unitRef="usd">189000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIyLTktMS0xLTU1NTU0_069f6f3b-9b4f-49e7-8f84-9efc636be0e1"
      unitRef="usd">189000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NjY3MDRkYzA1NTYzNGY0MjliMWZmM2FiYmUzZDFiOTZfODc5NjA5MzAyMjI2OA_3836fada-ecd2-44e9-9afb-95e88c171aad"
      unitRef="usdPerShare">7.22</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIzLTUtMS0xLTU1NTU0_86222be2-294e-44d2-9817-d3cd3d4c6518"
      unitRef="usd">4098000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzIzLTktMS0xLTU1NTU0_f77e37ff-5b19-4420-845c-66dcdc2c771c"
      unitRef="usd">4098000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i71b12895707c4d109b2ebe044f17363e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI0LTEtMS0xLTU1NTU0_97b90921-9909-4021-9c75-ab309f95da4c"
      unitRef="shares">1700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI0LTMtMS0xLTU1NTU0_4219e5d1-7205-4e7b-ab4e-035c3dad7e9d"
      unitRef="usd">82000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI0LTktMS0xLTU1NTU0_ba8442c7-cca7-4d61-8d94-8f5bb3998936"
      unitRef="usd">82000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI1LTMtMS0xLTU1NTU0_fb99e447-0ec5-420b-ab2b-6b433364692f"
      unitRef="usd">361000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI1LTktMS0xLTU1NTU0_29b473a1-46f2-463d-8d5a-474177bd51c0"
      unitRef="usd">361000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="i7478783dbb9c4540befa22a6829498a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI2LTMtMS0xLTU1NTU0_02fd1a89-385a-4991-a01c-20244038764b"
      unitRef="usd">-149000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI2LTktMS0xLTU1NTU0_8ea67ca8-cf44-462d-beb3-ed7e7a3c0827"
      unitRef="usd">-149000000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i71b12895707c4d109b2ebe044f17363e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI3LTEtMS0xLTU1NTU0_77587b66-0ac1-42fc-891b-995c4b25ae4b"
      unitRef="shares">21700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="icac26cc6c2014b83a312462ec730b0c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI3LTUtMS0xLTU1NTU0_32530f0d-686a-431a-9e6b-f80a08c42d8f"
      unitRef="usd">4987000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI3LTktMS0xLTU1NTU0_1b60e4d9-0928-46ca-adbf-fc1687169ca9"
      unitRef="usd">4987000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i198f13e9ae764a128ee94408e59bd0e9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTEtMS0xLTU1NTU0_33f9beec-44a4-440e-9d0a-13ea0255364c"
      unitRef="shares">558300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i64483c0647e5467db4e1fb64385c92da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTMtMS0xLTU1NTU0_559514d6-0620-40e1-a168-a07f4482ec51"
      unitRef="usd">32096000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ac218800d9e4f97b70805d4885f19de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTUtMS0xLTU1NTU0_6a04a603-ff19-498c-9f1d-0f7041259413"
      unitRef="usd">-24600000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5a12fd9b94548e0a6d019cff9050821_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTctMS0xLTU1NTU0_6e7a97f3-a6ac-4904-8c93-d264425ce415"
      unitRef="usd">-796000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xODcvZnJhZzphY2VkNjRjNzljNzY0Y2E4YjNlMmZiMTNjYjEyMzNkOS90YWJsZTpiOWMxNTcxNjdiMGQ0ZGU1YTUwODkyNzJjNmRkOGYwZC90YWJsZXJhbmdlOmI5YzE1NzE2N2IwZDRkZTVhNTA4OTI3MmM2ZGQ4ZjBkXzI5LTktMS0xLTU1NTU0_685268c3-575c-48f8-962d-64497b7ae20a"
      unitRef="usd">6700000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzItMS0xLTEtNTU1NTQ_1909a243-dfdf-4297-ae75-342bf7b364de"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzItMy0xLTEtNTU1NTQ_15366c96-b798-48ca-a0a5-2add32de0df5"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzItNS0xLTEtNTU1NTQ_d365c01b-bf96-4517-bc07-290c16351600"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMtMS0xLTEtNTU1NTQ_915b00fe-f408-43fc-82e6-546b8f40d75f"
      unitRef="usd">3398000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMtMy0xLTEtNTU1NTQ_7bad2fc2-a89f-4fea-83e6-ae59ded63965"
      unitRef="usd">3601000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMtNS0xLTEtNTU1NTQ_d7e17b01-5ba1-4515-929b-df40d1f431c7"
      unitRef="usd">2206000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzQtMS0xLTEtNTU1NTQ_25c6684e-d8a9-468a-ae2c-40b88cc07c58"
      unitRef="usd">341000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzQtMy0xLTEtNTU1NTQ_ff80ed2c-580a-4ffd-bcbc-83a6057cb514"
      unitRef="usd">330000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzQtNS0xLTEtNTU1NTQ_77c00d07-0d4d-4542-a3d9-0de6b4f6b1ab"
      unitRef="usd">308000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzUtMS0xLTEtNTU1NTQ_a08e9ad1-08b2-424e-ac51-f06a9d132325"
      unitRef="usd">-453000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzUtMy0xLTEtNTU1NTQ_be29b857-fbfc-4162-940a-0b77577a8bc5"
      unitRef="usd">-287000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzUtNS0xLTEtNTU1NTQ_3ccea856-040f-4837-a49d-098da374c059"
      unitRef="usd">-289000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMS0xLTEtNjE5NzM_92d29478-9c5b-4d91-b150-89c6ae2dbfbc"
      unitRef="usd">1505000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMy0xLTEtNjE5ODA_bbc8b4f7-f612-4e05-8e1c-3094388ba855"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtNS0xLTEtNjE5ODM_1e3574f6-e9df-4cfa-bcee-1de7ab014ddf"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMS0xLTEtNTU1NTQ_941e612b-5375-4c0b-8e5f-766b4d69707f"
      unitRef="usd">229000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtMy0xLTEtNTU1NTQ_f397b279-2ac4-467b-8723-8aee1cefbec6"
      unitRef="usd">195000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzYtNS0xLTEtNTU1NTQ_91ed6d7c-8424-4da6-a0bf-a794efceace8"
      unitRef="usd">186000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzgtMS0xLTEtNTU1NTQ_f5a4e0e0-e3e7-4656-9981-da13d873c44a"
      unitRef="usd">429000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzgtMy0xLTEtNTU1NTQ_3b43e4f4-5310-42ae-b596-6244083ad888"
      unitRef="usd">427000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzgtNS0xLTEtNTU1NTQ_4f0e4cc9-af7a-48f2-8bee-1360afbcb8da"
      unitRef="usd">504000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzktMS0xLTEtNTU1NTQ_b2640c87-569b-4ac4-b476-c46b8556c1fc"
      unitRef="usd">165000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzktMy0xLTEtNTU1NTQ_4d4073d7-da69-4263-81eb-bf353f7faad3"
      unitRef="usd">215000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzktNS0xLTEtNTU1NTQ_409207a8-67e1-408f-8f9d-8217079e428b"
      unitRef="usd">66000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEwLTEtMS0xLTU1NTU0_e2216991-9723-4b99-9bd2-60f655f2e5c8"
      unitRef="usd">237000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEwLTMtMS0xLTU1NTU0_2f5d8920-80a9-491b-80d2-98d4a07a0e65"
      unitRef="usd">-129000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEwLTUtMS0xLTU1NTU0_5c641afa-ba15-482b-98a9-ae08dca190e2"
      unitRef="usd">-10000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzExLTEtMS0xLTU1NTU0_36608f55-7395-4474-9b6d-5bea63614453"
      unitRef="usd">-69000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzExLTMtMS0xLTU1NTU0_99b04bfd-bbcc-4dba-845f-7cc079a2930a"
      unitRef="usd">45000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzExLTUtMS0xLTU1NTU0_e84fcbcd-6db9-4178-8632-369fd298b495"
      unitRef="usd">164000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEyLTEtMS0xLTU1NTU0_8ca13632-5a3d-4ced-98fd-ef09ecfc5d56"
      unitRef="usd">-854000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEyLTMtMS0xLTU1NTU0_64bb12b0-4212-4ad1-8541-cd47279b6bbc"
      unitRef="usd">-249000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEyLTUtMS0xLTU1NTU0_4270e590-147e-4169-9520-fe2cec68f687"
      unitRef="usd">-585000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEzLTEtMS0xLTU1NTU0_e52798cd-85e2-4e52-84b6-05cf51a0caff"
      unitRef="usd">204000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEzLTMtMS0xLTU1NTU0_ffb8300f-d5a4-46e9-ba67-bbef58f008ce"
      unitRef="usd">-482000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzEzLTUtMS0xLTU1NTU0_44ca753a-cf91-4771-a16a-22c0cb2437bd"
      unitRef="usd">-146000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE0LTEtMS0xLTU1NTU0_e3a1bec3-b49a-4491-a99e-915054170e73"
      unitRef="usd">356000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE0LTMtMS0xLTU1NTU0_11116f21-962c-44d5-aecc-b73048f540e9"
      unitRef="usd">983000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE0LTUtMS0xLTU1NTU0_7d4477e7-f707-4654-9d02-5ebd9e53ed55"
      unitRef="usd">396000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE1LTEtMS0xLTU1NTU0_fac21cb6-2b37-4912-b03e-f348dcca6513"
      unitRef="usd">9261000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE1LTMtMS0xLTU1NTU0_f3a5aa7b-5406-4e48-994b-d891131d4183"
      unitRef="usd">10497000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE1LTUtMS0xLTU1NTU0_b0737e4d-258c-407b-9a2e-9fa884e09fbd"
      unitRef="usd">9150000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE3LTEtMS0xLTU1NTU0_6232a027-6510-4db5-b0c6-1000e4f3e6ae"
      unitRef="usd">8900000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE3LTMtMS0xLTU1NTU0_87a2b7ff-921c-4124-b890-f9b6f78c5fef"
      unitRef="usd">8477000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE3LTUtMS0xLTU1NTU0_654c14e8-230b-4279-84fb-2b17ad42d61c"
      unitRef="usd">9394000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE4LTEtMS0xLTU1NTU0_4c86f2d3-c7ce-4ea6-8245-33314b3a8c7d"
      unitRef="usd">4403000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE4LTMtMS0xLTU1NTU0_0ada219b-451d-4b20-a533-22b095824dfe"
      unitRef="usd">2597000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE4LTUtMS0xLTU1NTU0_69b244fb-ff2a-46b0-a292-dda4a8b96c27"
      unitRef="usd">8842000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE5LTEtMS0xLTU1NTU0_875aa772-3bb1-46e3-ab01-80f29196151a"
      unitRef="usd">8831000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE5LTMtMS0xLTU1NTU0_a7af7b36-921c-464c-8389-52ca1ad0d44a"
      unitRef="usd">4381000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzE5LTUtMS0xLTU1NTU0_7b1fb365-49eb-4d0c-a03e-63f37e9289df"
      unitRef="usd">20548000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIwLTEtMS0xLTU1NTU0_bbc26e2b-c018-4f37-9d46-7fc418cca85b"
      unitRef="usd">880000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIwLTMtMS0xLTU1NTU0_38430467-594c-48a4-b734-7d4fb7d42aec"
      unitRef="usd">608000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIwLTUtMS0xLTU1NTU0_085c4193-6862-4d19-a610-21aa0d4b039b"
      unitRef="usd">618000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIxLTEtMS0xLTU1NTU0_6acb17e6-3115-4dba-8831-c5ea676ac022"
      unitRef="usd">2529000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIxLTMtMS0xLTU1NTU0_6b63f3bf-ef50-44d8-9c3f-53491b0ef0ec"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIxLTUtMS0xLTU1NTU0_6e7a6b0f-6d9b-4d07-a8c4-7d447f803ac0"
      unitRef="usd">13617000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIyLTEtMS0xLTU1NTU0_58aa8041-4880-4a25-88c0-773d52a4ee6b"
      unitRef="usd">157000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIyLTMtMS0xLTU1NTU0_bb4c793b-2c2f-4e69-b53a-33de1deef3ad"
      unitRef="usd">3219000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIyLTUtMS0xLTU1NTU0_bb89f7f1-f905-407e-9b1d-f79d0ac131c3"
      unitRef="usd">24000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIzLTEtMS0xLTU1NTU0_686b5a6f-0a22-423a-aa25-da317beae134"
      unitRef="usd">35000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIzLTMtMS0xLTU1NTU0_5127af6e-f211-40bf-a0a4-5009256d1764"
      unitRef="usd">75000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzIzLTUtMS0xLTU1NTU0_57572866-16b2-4dd5-b358-eb0c316f8373"
      unitRef="usd">28000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI0LTEtMS0xLTU1NTU0_b2812c39-7251-4051-81b6-490569f8228f"
      unitRef="usd">733000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI0LTMtMS0xLTU1NTU0_020782a8-ac58-40b8-afac-d6f9f41d3ca2"
      unitRef="usd">-5401000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI0LTUtMS0xLTU1NTU0_02c73839-72da-4121-abdd-17f56b45ade9"
      unitRef="usd">5709000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI2LTEtMS0xLTU1NTU0_7183a8d6-9ca5-4218-a895-2a40ae278d43"
      unitRef="usd">4945000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI2LTMtMS0xLTU1NTU0_f80a46df-9e07-4e32-92ae-9ed1612be967"
      unitRef="usd">8914000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI2LTUtMS0xLTU1NTU0_8a04b431-93ea-4996-8507-911ada909942"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI3LTEtMS0xLTU1NTU0_8f5ffced-02d9-4f01-8f27-de04cf9566f1"
      unitRef="usd">4150000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI3LTMtMS0xLTU1NTU0_dd9b8591-63d1-4856-a500-4246388e9bc9"
      unitRef="usd">6450000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI3LTUtMS0xLTU1NTU0_570e566d-c297-44d3-97c2-b0c6b6a1bcad"
      unitRef="usd">4514000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI4LTEtMS0xLTU1NTU0_18c5c0cc-072c-4c57-a959-f08029c59128"
      unitRef="usd">4975000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI4LTMtMS0xLTU1NTU0_e85cdb60-371c-4b2a-92bc-7b48881a2024"
      unitRef="usd">3486000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI4LTUtMS0xLTU1NTU0_1d9b9282-dcce-4b7b-8918-4d99ea2f182d"
      unitRef="usd">7702000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI5LTEtMS0xLTU1NTU0_57068e28-9f38-4b68-80b3-1198ce090414"
      unitRef="usd">4013000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI5LTMtMS0xLTU1NTU0_0c7f1f68-5bf9-46ed-ab05-e9673f4fb2b7"
      unitRef="usd">3755000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzI5LTUtMS0xLTU1NTU0_ba80112f-c58b-4677-b4c0-5bab0729093d"
      unitRef="usd">3509000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMxLTEtMS0xLTU1NTU0_d3b472f4-793c-4cc7-87e8-c8dc416aaae3"
      unitRef="usd">-78000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMxLTMtMS0xLTU1NTU0_c34de9ce-82c5-4405-825c-bf5540291fb7"
      unitRef="usd">-90000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMxLTUtMS0xLTU1NTU0_2973f4fc-d57a-4add-8ffd-413c3eb86126"
      unitRef="usd">-42000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMyLTEtMS0xLTU1NTU0_c3adb482-dd93-4b21-8ac7-da67c1b8a62e"
      unitRef="usd">-8271000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMyLTMtMS0xLTU1NTU0_021fd17a-261b-4f97-bf42-db65469e8331"
      unitRef="usd">-4867000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMyLTUtMS0xLTU1NTU0_4f96ef8f-94d4-4472-838d-77379779e0b4"
      unitRef="usd">-15767000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMzLTEtMS0xLTU1NTU0_e9038253-7548-488e-a1b2-924acb4bae12"
      unitRef="usd">1723000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMzLTMtMS0xLTU1NTU0_60f99738-d283-46ce-b1e6-cbc4b096f36c"
      unitRef="usd">229000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzMzLTUtMS0xLTU1NTU0_61738c50-ecff-47f5-944d-56ee6e49375a"
      unitRef="usd">-908000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM0LTEtMS0xLTU1NTU0_75613c29-652b-4142-8d9e-e825ee22a88b"
      unitRef="usd">6266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM0LTMtMS0xLTU1NTU0_c45263cd-b512-4420-854d-3ee62da29bb4"
      unitRef="usd">6037000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM0LTUtMS0xLTU1NTU0_ddda603f-22df-458f-9893-b33e394dbe75"
      unitRef="usd">6945000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM1LTEtMS0xLTU1NTU0_53fff926-2253-4700-a83a-3cbb82539d1b"
      unitRef="usd">7989000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM1LTMtMS0xLTU1NTU0_aee81569-3597-4564-a4e0-290547d2fcc9"
      unitRef="usd">6266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTAvZnJhZzo4ZjFkM2NhNTYyYWI0YmRjYjcxNTk5MWEzOTQ0NDUwMi90YWJsZTpiMWQyOGM4MTlkMmY0MmRlYjRkZDQ3OTcyYzFkNDNhYi90YWJsZXJhbmdlOmIxZDI4YzgxOWQyZjQyZGViNGRkNDc5NzJjMWQ0M2FiXzM1LTUtMS0xLTU1NTU0_dd9b821b-e547-48da-9c7b-01d785a1db5d"
      unitRef="usd">6037000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzEwOTk1MTE2NjY3NDY_b80923a1-74ec-429d-81f6-2c28d7c5273f">Summary of significant accounting policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales and sales deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#x2019;s products, primarily in Europe, are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;amp;A expense in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with multiple-performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into arrangements for the R&amp;amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#x2019; costs; and amortization of acquired technology used in R&amp;amp;D with alternative future uses. R&amp;amp;D expenses also include costs and cost recoveries associated with third-party R&amp;amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $843 million, $962 million and $789 million during the years ended December 31, 2021, 2020 and 2019, respectively. SG&amp;amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#x2019;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;amp;D projects with no alternative future use are recorded in R&amp;amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#x2019; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#x2019; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of IPR&amp;amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#x2019; earnings are translated into U.S. dollars by using average exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and nonmarketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other Income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other Income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#x2019; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <amgn:NatureOfOperationsPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTI3_a1ea30e6-e135-4682-afa0-f81859e845cc">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;</amgn:NatureOfOperationsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI5MQ_83832797-5079-4ffc-959f-6848fdebbf1c"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTM3_ff7b06a3-881c-4c0a-a10a-41a8b25b7b98">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDQy_b7c22537-b63e-43d3-a479-aa519fd55174">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDA3_a4a5fa5b-e414-440a-b35e-d900d5ad3096">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales and sales deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Returns are estimated through comparison of historical return data with their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indirect taxes collected from customers and remitted to government authorities that are related to sales of the Company&#x2019;s products, primarily in Europe, are excluded from revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in SG&amp;amp;A expense in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty income is estimated based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements with multiple-performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into arrangements for the R&amp;amp;D, manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&amp;amp;D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial-performance milestone payments; royalty payments; and/or profit sharing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <amgn:SalesReturnProvisionsAsPercentageOfProductSales
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI3MTU_93994400-7d56-493f-8245-c6fffc7021ef"
      unitRef="number">0.01</amgn:SalesReturnProvisionsAsPercentageOfProductSales>
    <amgn:RevenuePaymentArrangementTerm
      contextRef="i43850937751e42548fbb66e789879cef_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzMwNDQ_a366eba3-f016-4114-af14-46a342c41421">P30D</amgn:RevenuePaymentArrangementTerm>
    <amgn:RevenuePaymentArrangementTerm
      contextRef="ie61e545057e747e8b5917b8708e7bbf0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzMwNTA_b0d5dd94-12ab-4b1f-b1c1-d21a599d0de0">P120D</amgn:RevenuePaymentArrangementTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0Mzkw_4f91b904-1778-499f-8771-4cf956ac1efb">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred and primarily include salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems&#x2019; costs; and amortization of acquired technology used in R&amp;amp;D with alternative future uses. R&amp;amp;D expenses also include costs and cost recoveries associated with third-party R&amp;amp;D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&amp;amp;D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDE1_468ea368-626d-47f9-ad28-7eb5abcca1f5">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A costs are primarily composed of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $843 million, $962 million and $789 million during the years ended December 31, 2021, 2020 and 2019, respectively. SG&amp;amp;A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&amp;amp;A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzc3MDc_a604c471-4478-4a01-8dcd-f0201b188a09"
      unitRef="usd">843000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzc3MTE_b8179449-d28a-4563-9d1e-7b1c1374601c"
      unitRef="usd">962000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzc3MTg_b5089898-4175-4a22-bf46-52b575d31279"
      unitRef="usd">789000000</us-gaap:AdvertisingExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDU5_32605fb4-12e9-4a0f-af83-528c7282129e">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other noncurrent assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate a lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date less lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDYw_5df305c0-f837-41cc-842f-b2a93d90df2b">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have stock-based compensation plans under which various types of equity-based awards are granted, including RSUs, performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDMw_26bb8756-e5bb-4e6f-8ab5-65eea1309250">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of UTBs is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, when appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTMz_390c7ad5-2dfd-4aed-880e-5a01ba65328d">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree&#x2019;s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&amp;amp;D projects with no alternative future use are recorded in R&amp;amp;D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDc2_df9323b1-14cc-4125-b9a0-c6b6a823247b">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider cash equivalents to be only those investments that are highly liquid, that are readily convertible to cash and that mature within three months from the date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDc1_acaeec2d-b7cc-4481-a527-0737d4ea2029">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider our interest-bearing securities investment portfolio as available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in AOCI. Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTAx_a18106eb-93c1-4aaa-8461-13220d184f9d">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDYx_4081de6d-5dcd-46f5-980b-cb319023c6cd">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0Mzk4_db5e063a-8eef-4299-8470-ea37a795d816">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is recorded over the assets&#x2019; useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTEy_0d1a4f89-130f-44a5-b31f-7e177c1068cb">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recorded over the assets&#x2019; estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of IPR&amp;amp;D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&amp;amp;D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDUx_5784774e-ac79-428f-8ac7-02d97782c553">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NDk0_318a3ef2-4504-4339-afd7-415bc3596d00">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries whose functional currencies are not in U.S. dollars are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translation of the net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries&#x2019; earnings are translated into U.S. dollars by using average exchange rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <amgn:EquityInvestmentsPolicyPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2Xzg3OTYwOTMwNzA0MjQ_99a44415-4175-4fe1-b4b4-50ebfa93da55">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and nonmarketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in Other Income, net, in the Consolidated Statements of Income. Investments in equity securities without readily determinable fair values are recorded at cost minus impairment, if any, adjusted for changes resulting from observable price changes in orderly transactions for identical or similar securities. Such adjustments are recorded in Other Income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</amgn:EquityInvestmentsPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzI0NTI2_640ddca5-c2e5-4110-8393-618ca7780b0f">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that give us the ability to exert significant influence, but not control, over an investee for which we have not elected the fair value option are accounted for under the equity method of accounting. In concluding whether we have the ability to exercise significant influence over an investee, we consider factors such as our ownership percentage, voting and other shareholder rights, board of directors representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of investees&#x2019; earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Other income, net, in the Consolidated Statements of Income. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments for which we have elected the fair value option, changes in fair value are recorded in Other income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we hold investments in limited partnerships, which primarily invest in early-stage biotechnology companies. As a practical expedient, such limited partnership investments are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships, with such changes included in Other income, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTYvZnJhZzo2MTU5ZTJiYjIzZmQ0MjQ5YTdlNmQ3OWYwZWIzYmZkNi90ZXh0cmVnaW9uOjYxNTllMmJiMjNmZDQyNDlhN2U2ZDc5ZjBlYjNiZmQ2XzEwOTk1MTE2NjY3NDE_7575bfdd-58b2-4c22-8b3d-4308bd03dce8">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from the LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard to expand the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzczNzc_2d02c882-74a0-48ae-ac28-f9f931bd5708">Acquisitions &lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Teneobio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#x2019;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#x2019;s existing antibody capabilities and BiTE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#x2019;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset &#x2013; R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for this transaction were (i) an upfront cash payment of $994&#160;million, which included a working-capital adjustment and (ii) future contingent milestone payments to Teneobio&#x2019;s former equity holders of up to $1.6&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair value of the contingent consideration obligations aggregated $309&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pre-tax cost of debt. See Note 17, Fair value measurement, for information regarding the estimated fair value of these obligations as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of acquired IPR&amp;amp;D assets totaled $1.1&#160;billion, of which $784&#160;million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of mCRPC, and the balance relates to four separate preclinical oncology programs. The R&amp;amp;D technology rights of $94&#160;million relate to Teneobio&#x2019;s proprietary bispecific and multispecific antibody technologies and will be amortized over ten years using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A deferred tax liability of $253&#160;million was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $251 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, liabilities assumed and tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Five Prime Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 16, 2021, Amgen acquired the outstanding stock of Five Prime for total consideration of $1.6&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. The operations of Five Prime have been included in our consolidated financial statements commencing after the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the consideration to acquire Five Prime to the bemarituzumab IPR&amp;amp;D program of $1.5&#160;billion, which was expensed immediately in Acquired IPR&amp;amp;D expense in the Consolidated Statements of Income; deferred tax assets of $177&#160;million; and other net liabilities of $47&#160;million. The acquired IPR&amp;amp;D expense was not tax deductible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 21, 2019, we acquired worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene. Otezla is primarily used for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all of the value of the assets acquired was concentrated in the global intellectual property rights of Otezla. The operations of Otezla have been included in our consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated cost (consideration transferred)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The developed-product-technology rights acquired relate to Otezla. The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights is being amortized over a weighted-average period of 8.5 years by using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce is being amortized over a period of 5 years by using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer&#x2019;s effort are applied. Inventory fair value adjustments is being amortized as inventory turns over, which we estimate to approximate 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing, we had a difference between the book basis and tax basis of the assets acquired. The Company used the simultaneous equations method to determine the assigned value of the net assets acquired and the related deferred tax assets or liabilities. Use of this methodology resulted in an increase to the carrying value of the intangible assets of $119&#160;million, a net deferred tax liability of $24&#160;million and a deferred credit of $96&#160;million. The tax effects of the acquisition are based on Amgen&#x2019;s estimated blended statutory tax rate of 20%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nuevolution AB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2019, we acquired all of the outstanding stock of Nuevolution, a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution&#x2019;s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $150 million, primarily comprised of technology rights for a drug discovery platform with an estimated useful life of 10 years; goodwill of $26 million, which is not tax deductible; deferred tax liabilities of $22 million; and other net assets of $29 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2Mjk5ODAy_ad7c05ff-5ece-47f4-b16d-3f56dd53dc7a">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset &#x2013; R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated cost (consideration transferred)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzEtMi0xLTEtOTQ1MzU_f6a308e5-c332-48a9-a2a1-2ccc773b30b8"
      unitRef="usd">994000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzItMi0xLTEtOTQ1NTA_aa92eec1-2df0-4f03-ac93-1ec6bf2e936a"
      unitRef="usd">309000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:Businessassetacquisitionconsiderationtransferred
      contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzMtMi0xLTEtOTQ2MDQ_f2c7150f-8869-46be-b00e-260a140e6288"
      unitRef="usd">1303000000</amgn:Businessassetacquisitionconsiderationtransferred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzUtMi0xLTEtNzg2ODU_cfe6ba2e-a4b4-4b4b-b155-3bdcde8cb783"
      unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="icd31e4ab273d40649861d236ae32fc27_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzYtMi0xLTEtNzg2ODM_f1387254-e8ed-43bd-840a-411563149997"
      unitRef="usd">1054000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id8c5cd2aa30845ed99aa434901b0d817_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzctMi0xLTEtNzg2ODc_0d9b924e-5b16-4fb8-b0fe-31300f0870be"
      unitRef="usd">94000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i478925270fe1447f980033f781c7fe54_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzgtMi0xLTEtNzg2ODc_d4d4cc7f-4e3b-43b4-ad52-a50b13fef5c9"
      unitRef="usd">41000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzktMi0xLTEtNzg2ODc_d515d540-2c19-4ebc-84b7-969d79bfdd57"
      unitRef="usd">251000000</us-gaap:Goodwill>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzEwLTItMS0xLTk0NjYy_7dc3b393-f656-442d-99af-a4959c3c11c4"
      unitRef="usd">16000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzExLTItMS0xLTc4Njg3_111f126e-d10d-46e6-b479-f1a463c8288d"
      unitRef="usd">253000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTpjMDgxODc2NThlMmU0NTczOWY5NmIyZWI1NmViOWVjNS90YWJsZXJhbmdlOmMwODE4NzY1OGUyZTQ1NzM5Zjk2YjJlYjU2ZWI5ZWM1XzEyLTItMS0xLTc4Njg3_14131882-28b4-4ddc-8626-95df157ad96a"
      unitRef="usd">1303000000</amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NzE1ODQ_2204e386-2d07-4bf7-982f-ab22b33cded4"
      unitRef="usd">994000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3MDc_98d80930-ab15-41eb-b5e5-5a277ba75d4f"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3MjI_4c391530-40f9-4eff-a1ec-ee6a3dc0d87c"
      unitRef="usd">309000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="icd31e4ab273d40649861d236ae32fc27_I20211019"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNDc1MTg_1dd191be-e46d-4758-bb3f-33a55fe5663a"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="id3f3a35884aa4230bf0c3a5ae22cbc37_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNDc1NDQ_ca75170d-df1b-4d14-b196-cd41c359662c"
      unitRef="usd">784000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i0d7b6973dd21459c98dd74519c04349f_D20211019-20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNjYwNDg_0c0ac9ea-1146-4695-8e3d-1d9429d5e3c5"
      unitRef="usd">94000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0d7b6973dd21459c98dd74519c04349f_D20211019-20211019"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NzE2MzE_911bede6-0cb5-4be3-a46e-c3b8422f78a5">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="iab0cb85e7f8b470988475352b8970a11_D20211019-20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1Xzg3OTYwOTMwNjYwMDM_15796452-52ae-4170-a298-43e88d0c5278"
      unitRef="usd">41000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NzE2MDI_b46b9eb1-6dd9-4684-828f-9e72000153e9"
      unitRef="usd">253000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:Goodwill
      contextRef="i7d48e8621c0c4e169bae7f879ff2d533_I20211019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3OTM_f8993095-8dd1-4767-b957-11d12a64f053"
      unitRef="usd">251000000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i87696c073dc9445795bb552e00095165_D20210416-20210416"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3NDA_caa9aad0-52d5-47e4-aa55-9c59c5db1a08"
      unitRef="usd">1600000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i87696c073dc9445795bb552e00095165_D20210416-20210416"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2NDk3NTQ_2a130bca-6d80-4682-809d-219f25f86c54"
      unitRef="usd">1500000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i0a658c14aef44e0cbf1c161341c595a2_I20210416"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2Mjk5ODA0_b734bfc1-ee89-4c46-a77f-ba311564734d"
      unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i0a658c14aef44e0cbf1c161341c595a2_I20210416"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzEwOTk1MTE2Mjk5ODE4_295873ff-89b7-4220-9a0a-be3e5ba8fde5"
      unitRef="usd">47000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <amgn:ApprovedMarkets
      contextRef="i1f6477d9cdaa4150a5f594b11b70839a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQ1NA_6577c4e3-f74a-4422-9061-89acd2707df8"
      unitRef="market">50</amgn:ApprovedMarkets>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzEtMi0xLTEtNTU1NTQ_e2b99003-0c1f-4e85-8a12-c1d65c987316"
      unitRef="usd">13400000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:Transactioncostsassetacquisition
      contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzItMi0xLTEtNTU1NTQ_c3227ec7-e10a-4e45-a75f-74323df339ec"
      unitRef="usd">40000000</amgn:Transactioncostsassetacquisition>
    <amgn:Businessassetacquisitionconsiderationtransferred
      contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzMtMi0xLTEtNTU1NTQ_9111a2fc-006b-4ebd-adac-416ab596b3c5"
      unitRef="usd">13440000000</amgn:Businessassetacquisitionconsiderationtransferred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie30125d0ac2b49b99dedfab8ab62d268_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzYtMi0xLTEtNTU1NTQ_bcce589c-d289-43c6-aef8-e74715ea47a5"
      unitRef="usd">13007000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i57b09ca2dd3744c7ace9c82038d6088e_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzctMi0xLTEtNTU1NTQ_ed197e45-c857-4972-8a33-3ac1dac7fe78"
      unitRef="usd">195000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <amgn:BusinessacquiredassetacquisitionInventoryacquired
      contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzgtMi0xLTEtNTU1NTQ_f9b343ba-f701-4982-8cbd-24afacd2ee9d"
      unitRef="usd">367000000</amgn:BusinessacquiredassetacquisitionInventoryacquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzktMi0xLTEtNTU1NTQ_f42e61ca-c48b-49f3-a486-85772bf11261"
      unitRef="usd">24000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessacquiredassetacquisitionDeferredCredit
      contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzEwLTItMS0xLTU1NTU0_7af4697c-6f47-48b1-90ea-7fc90bb7095c"
      unitRef="usd">96000000</amgn:BusinessacquiredassetacquisitionDeferredCredit>
    <amgn:BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther
      contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzExLTItMS0xLTU1NTU0_29899974-a11c-49a9-80c3-1df8852041d4"
      unitRef="usd">9000000</amgn:BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther>
    <amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet
      contextRef="ieb825857cbe9452cb4d3fdead6eadad7_I20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90YWJsZTo1ZWQ4ZmIzYWMzY2Y0ZmE4YjI2NDkzZjExNzAxZmNkOS90YWJsZXJhbmdlOjVlZDhmYjNhYzNjZjRmYThiMjY0OTNmMTE3MDFmY2Q5XzEyLTItMS0xLTU1NTU0_ea436662-94f4-4d69-85bc-9e91b570129d"
      unitRef="usd">13440000000</amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iae11cd746d46413ea3fdec017bcaa8da_D20191121-20191121"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzE4NzQ_336da0f0-4f9c-4b54-a023-030ca134b0b4">P8Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie16d2f30b24a4021ae737b2878c082c2_D20191121-20191121"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzIyNjE_29abb4e8-bce1-418a-97ff-b9c4eedbaef1">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <amgn:AcquiredFinitelivedAssetsWeightedAverageUsefulLife
      contextRef="i71cdf38101c24a728fe566e9c8f95072_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzI2NzY_a8912623-c823-4a50-86fb-62f6abe27353">P2Y6M</amgn:AcquiredFinitelivedAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMwMzY_37f8752b-811d-42dd-b9b7-76ac479866dd"
      unitRef="usd">119000000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities
      contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMwNzI_172b9e14-a7d3-4b6f-8004-b22e4752dad9"
      unitRef="usd">24000000</amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities>
    <amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits
      contextRef="iece52d145d314403bfe12e67331edc59_D20191121-20191121"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMxMDA_1987cc0f-aca1-4a75-b239-3375a468d02b"
      unitRef="usd">96000000</amgn:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits>
    <amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate
      contextRef="i21358fdcfee142efb4e3f013e87d4e7c_D20191121-20191121"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzMyMDA_54363b13-97e2-4e03-8509-cce3ecce4c3b"
      unitRef="number">0.20</amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i312f9fef123d41a09674e4d6ef7b0632_D20190715-20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzM0NDk_86fca1b3-1dd8-412d-9e70-99ea9062c034"
      unitRef="usd">183000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i8f809eda07244ef59df9c01c24fcb962_D20190715-20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzM4OTM_611b6df2-40a7-44d3-b9ef-e47e11f136c7"
      unitRef="usd">150000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8f809eda07244ef59df9c01c24fcb962_D20190715-20190715"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQwMDE_d1f05bb4-14fc-4843-975e-3ea16f768ae9">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="i6d08f130fae446808d4e5f6792b4477d_I20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQwMTc_de91e012-02b4-4c87-9fce-6e45280ed89a"
      unitRef="usd">26000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i6d08f130fae446808d4e5f6792b4477d_I20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQwNzg_aade8d4c-d8fc-44d6-b0b5-5f7e6096c81e"
      unitRef="usd">22000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i6d08f130fae446808d4e5f6792b4477d_I20190715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8xOTkvZnJhZzo2Yzk0NTVjNDk2MzY0Yjc3OTJiZTM1ODg1NDM0ZmY5NS90ZXh0cmVnaW9uOjZjOTQ1NWM0OTYzNjRiNzc5MmJlMzU4ODU0MzRmZjk1XzQxMDY_c8f77830-bf7e-4b50-8d60-138f55ce1533"
      unitRef="usd">29000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE5OTA_86540549-5504-47fb-bcae-bff4db64c644">Revenues&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#x2019; locations, are presented below. The majority of ROW revenues relates to products sold in Europe. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enbrel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Otezla was acquired on November 21, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2021, 2020 and 2019. For the year ended December 31, 2021, on a combined basis, these customers accounted for 82% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of December 31, 2021 and 2020, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 73% and 74%, respectively, of net trade receivables on a combined basis. As of December 31, 2021 and 2020, 27% and 28%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2021 and 2020, was not material.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzMx_f278539a-f2af-4135-8dbf-5a23da735009"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE5ODY_1234c6d2-a95c-47c2-b7f3-f188244a5081">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enbrel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Otezla was acquired on November 21, 2019.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic9859eb8505743f1b3da7314c2873003_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMi0xLTEtNTU1NTQ_216deec3-c028-4a7d-8736-6ade34166cf5"
      unitRef="usd">4352000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i122e8f06671c4fd2959f297cfb936b40_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItNC0xLTEtNTU1NTQ_53f0836f-a478-49f9-ad6e-045230bd3496"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i24b29f9a84bd403788979c7c9655c7f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItNi0xLTEtNTU1NTQ_ea27ca72-c794-4ab2-b14c-6ec693e80bc3"
      unitRef="usd">4465000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic461d7a3b3e14e9d9f9edf67703a28a5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItOC0xLTEtNTU1NTQ_88cd232d-d311-4295-93b4-9e90c03b8d06"
      unitRef="usd">4855000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1e2ec1c2699c4f75baab1192500e0ea8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTAtMS0xLTU1NTU0_159b1633-6ed9-4191-aaa5-60308ef226fb"
      unitRef="usd">141000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i30ef6be9e72c458d8eb025c1d314c9a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTItMS0xLTU1NTU0_4ed67078-d0d8-4a5b-bdd3-a729383a2624"
      unitRef="usd">4996000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib9352d3542ba4641b31259a6145356d4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTQtMS0xLTU1NTU0_cf58c0ea-95b0-4a09-9783-6020c7afdcd9"
      unitRef="usd">5050000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ice6338b51a744e2ba61b90799c71483a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTYtMS0xLTU1NTU0_a135760e-a31d-4ab1-ac44-a15a19ffeeb4"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib39684b43bb94026ba38cc4efb929d6f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzItMTgtMS0xLTU1NTU0_f304297f-f34f-4ed3-a9ff-a9b3d8fa54f8"
      unitRef="usd">5226000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7f12f30e019c442caffd84baf0cf6f58_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMi0xLTEtNTU1NTQ_5392fe44-0606-4ac9-9ce6-971eae8570c9"
      unitRef="usd">2150000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id824580714f14645861336df6b9234d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtNC0xLTEtNTU1NTQ_7aff1d3d-89f9-444c-a569-a9c56d4831e3"
      unitRef="usd">1098000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i87d377423aea4783859ef42175fb0740_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtNi0xLTEtNTU1NTQ_72cbd0ca-706b-46ad-acdf-08d01bc4c97b"
      unitRef="usd">3248000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ica0d3e2283c44651a1eb8f9a780b8dbb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtOC0xLTEtNTU1NTQ_5ea765a0-95d7-4957-9376-3dfd34a6a530"
      unitRef="usd">1830000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i967209b4b4c84e76b9b0f7a497310bce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTAtMS0xLTU1NTU0_d2139ba3-33cc-4185-be85-73beae80a6dd"
      unitRef="usd">933000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie54c41e6f0b54a38a252ee5e94de98a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTItMS0xLTU1NTU0_1d2c5545-99f3-4e91-b752-ea49652f3a93"
      unitRef="usd">2763000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i989b6283d29a4b4c851c78cd48583e8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTQtMS0xLTU1NTU0_2b4f1682-4e68-42f3-8fff-08259637d3a9"
      unitRef="usd">1772000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5b813a299ccd4e28afe5bbb0576b487d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTYtMS0xLTU1NTU0_9792d916-fdbe-497c-a91a-9677481804c7"
      unitRef="usd">900000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7e5c8a7d9df04367a21590c9c29fd269_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzMtMTgtMS0xLTU1NTU0_a426eb32-8530-4345-bd34-34ac0d5acb87"
      unitRef="usd">2672000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i40878748d11247a087bb8456c38f461b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMi0xLTEtNjAxNjk_f4b681ea-ff5f-481d-88c8-a41a132a86fb"
      unitRef="usd">1804000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6eb6c05be38b46a0a66d8019c30f41f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNC0xLTEtNjAxNjk_51734c6c-970a-426a-aebc-9a317c2c3ea1"
      unitRef="usd">445000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i20b1aeb912604f64a39deebff1f224b4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNi0xLTEtNjAxNjk_bd40cbc2-b7c1-4fbb-b933-2f3c8cf6648c"
      unitRef="usd">2249000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ied8dfc99854e4c9a8e28f37c644909fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtOC0xLTEtNjAxNjk_69fe478e-772c-495c-8e6a-5b70d16e8b97"
      unitRef="usd">1790000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i35fd136605f54042b5bff6d375c0e5a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTAtMS0xLTYwMTY5_082fc07e-b778-40d2-9a6b-71d5da4f2f18"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i165ce47df9044130bc2739fba82a949b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTItMS0xLTYwMTY5_b79a5390-695f-4ea8-af15-cebbd1c1be7c"
      unitRef="usd">2195000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3b0c0fc9a5c549fe95bfb0a1d9f0cff5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTQtMS0xLTYwMTY5_e4c9b225-2c13-4d6a-9299-6d5ad3d78f8a"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie2ac36e2ce074ccd9ae5750b82cd3469_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTYtMS0xLTYwMTY5_1c90d904-2dab-4384-9bf9-72784d1a34c6"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i512f3b69b8d744cba5ed5ccf09f3f93e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTgtMS0xLTYwMTY5_18cc9277-d295-446d-897e-8c1e1e568ace"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifb9e422d984343799da5efa61983dbc4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMi0xLTEtNjAxNzc_0dd55be8-87ed-4087-b7ac-2d5b54ac6fd2"
      unitRef="usd">1434000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1dcdb5108a874cfcbdd8b792226e2b87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtNC0xLTEtNjAxNzc_b374e0ab-3925-444c-9276-06a529982ce0"
      unitRef="usd">584000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i31c0360db44649d0a20ab30019d4726f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtNi0xLTEtNjAxNzc_2e4c45c3-4cbb-4e84-bd32-868bb10cc418"
      unitRef="usd">2018000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5084637c7a7340da84829b4511548a9b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtOC0xLTEtNjAxNzc_0674a415-73a2-46fb-8eeb-9085d197efea"
      unitRef="usd">1405000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6556904df3ab4367ad18978f9b68d5ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTAtMS0xLTYwMTc3_74c7c799-e706-476d-9952-47e637d93998"
      unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i68f620dbefa34330a378e5ed07d62563_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTItMS0xLTYwMTc3_038c09c3-2f14-46ad-8431-847e4d4b8dc2"
      unitRef="usd">1899000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icbaf8798276a40dfb14013a2f2c650ad_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTQtMS0xLTYwMTc3_dd0f1e43-5bca-42d4-b987-03b0fa08c0fd"
      unitRef="usd">1457000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i983f5a9292ac40f4a3da11e27da9ebb9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTYtMS0xLTYwMTc3_e9cb37a5-b6fa-42c3-b65e-01c88b2cbcf9"
      unitRef="usd">478000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ida0d758076054681926e066e61927847_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzUtMTgtMS0xLTYwMTc3_bd60fdd1-479a-4597-8460-a85b940003be"
      unitRef="usd">1935000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i823d72e733d04847bac4115a76bc88d4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMi0xLTEtNTU1NTQ_64666179-ffdf-41e2-8cd0-7e221eb6ea0f"
      unitRef="usd">1514000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i927d3e095b5f4aa59c0a266db71e1970_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNC0xLTEtNTU1NTQ_08e4227f-a8fb-457a-a4e9-b605e66d99d5"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i068d095d40cd4db2974af05b034cdc53_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtNi0xLTEtNTU1NTQ_378e29da-c099-404f-a595-633a88546656"
      unitRef="usd">1734000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i183bf5775ef447918eb6b6e9ba438bf6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtOC0xLTEtNTU1NTQ_37a2ef9e-8333-41d3-bf01-bc128f0b672f"
      unitRef="usd">2001000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id0446449664249d586f43b4ab973920a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTAtMS0xLTU1NTU0_dfde9a93-ebd9-44ff-8181-f5a421af7950"
      unitRef="usd">292000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ieb5db1424a06489da055b9a4d4e9586a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTItMS0xLTU1NTU0_7243b737-846f-4f68-8832-4f7837870825"
      unitRef="usd">2293000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib5bd4a1f6b184369845ffe664e69f8c8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTQtMS0xLTU1NTU0_ad1f6197-d376-4369-8747-a294a5019c2b"
      unitRef="usd">2814000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i36247d9eda1441289af859ad6b549ad5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTYtMS0xLTU1NTU0_d634c879-84e1-4f18-9b68-85ec8b839cfe"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibdcea96c498b412ea276b523469efb7d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzQtMTgtMS0xLTU1NTU0_798301fb-9c40-41b7-bab4-246e0d26bc2d"
      unitRef="usd">3221000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id9bd7649ab404e7b84591d36bb2baa43_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMi0xLTEtNTU1NTQ_37bb221e-4624-418a-9511-72c987091ce0"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibdbb2a2df8dd4a688aa35f134c78985b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctNC0xLTEtNTU1NTQ_8918f2df-979d-49ac-9cd5-a42297d3291b"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i866795ca32e048e8bf0d0a64e1e48428_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctNi0xLTEtNTU1NTQ_fa507041-e5c2-4d90-ab77-2853a58ba7d6"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic529e4ce045d4f18bf4eb6e91d16750e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctOC0xLTEtNTU1NTQ_f67b510f-e7ce-4e9f-a5d5-5dc27d8d1578"
      unitRef="usd">629000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i961bb9f5333e4fb7a4343811368337f0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTAtMS0xLTU1NTU0_c3648728-22f9-41fd-9223-19537a3d4379"
      unitRef="usd">939000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5e1cedc1286e435db02a41c255e0aea4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTItMS0xLTU1NTU0_be37d8cd-28db-4841-b074-2ea6afb32e51"
      unitRef="usd">1568000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3e0d7fa648b44bf4b5f6ab3d243b3379_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTQtMS0xLTU1NTU0_9a0eaafa-c08a-4c1c-950f-34ab1bc9ca81"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iaf1a44c568f248928074918ec2942de6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTYtMS0xLTU1NTU0_c0a0507a-798f-4978-9a39-be63e0e0ac43"
      unitRef="usd">971000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i31ae78b9ba034a46abf7a36f2b0f0200_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzctMTgtMS0xLTU1NTU0_e38cdd82-1b98-4690-9d6a-5f8e53293bce"
      unitRef="usd">1729000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i122ba16c86614e1c968b2254fd76300f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMi0xLTEtNjAxODg_1d5a11e0-a79c-42a1-9f9e-0fd405ab0690"
      unitRef="usd">557000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3cb60fa2c2944183bf45dfb60666df8b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktNC0xLTEtNjAxODg_601bd0db-7469-463f-91e8-5230084dce63"
      unitRef="usd">560000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1d943ea15f1a4586994e9ac4e411be31_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktNi0xLTEtNjAxODg_addda7a9-514c-45d3-8f1e-bb869897c72d"
      unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8467a81094b048fb8b342e412bd92615_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktOC0xLTEtNjAxODg_0c0e337f-9cce-46f6-be91-a6ab6039f688"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i77cef9372919476794b87f18a0ccd73c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTAtMS0xLTYwMTg4_14e6abcc-0f2e-4a23-98c2-abc9e665a7bf"
      unitRef="usd">428000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia2dbf9c7559f438aa4cb0fd8e3bd05df_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTItMS0xLTYwMTg4_02621444-2c2e-4d7d-9c55-c13c20f733f6"
      unitRef="usd">887000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icc140436757d4c8b8b0f16f5c3d24f73_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTQtMS0xLTYwMTg4_f7c1a94a-4376-4c2d-a513-7ad17392c6f6"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1be7cae3f58843ba99977a2b0ef10946_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTYtMS0xLTYwMTg4_63135597-38a3-479c-afbc-809ba6c045a4"
      unitRef="usd">285000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i74c266403b0e40b8a06f2641ca3a0a6d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzktMTgtMS0xLTYwMTg4_8e157141-5b12-44a9-931d-05f1b996aa8b"
      unitRef="usd">661000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7946d27038d14bb2aa1d01148f309fce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMi0xLTEtNTU1NTQ_e8f64ab5-54e9-481e-a098-84602953e644"
      unitRef="usd">736000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4f835d6c583e4df99d995013745f7e0c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtNC0xLTEtNTU1NTQ_1c70b43c-9ea8-4da8-9fcb-6efb3e66f502"
      unitRef="usd">372000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4dbe0c7d5d6b4242b1252f5fcb8be12f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtNi0xLTEtNTU1NTQ_f01f3141-b562-441e-a1e2-e996979a135f"
      unitRef="usd">1108000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4708f4aef9e64cb5ad424e50c8dc709d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtOC0xLTEtNTU1NTQ_834a0278-1011-4568-b879-d715a9eaea9d"
      unitRef="usd">710000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7a458f529ef74a5e96517e593dec14f8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTAtMS0xLTU1NTU0_d0d8f9dc-a51e-4c90-a381-07a080ebff92"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9f4010fa4de94f1f9c1f6362f8ec685e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTItMS0xLTU1NTU0_67e07de1-196e-41e9-94d9-b57f7ba6110b"
      unitRef="usd">1065000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i70cba4592c834e3e8d094a23a2fcaa5b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTQtMS0xLTU1NTU0_78f1dfe5-ada2-4cf4-9eb5-bbb7e1a6b65f"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib066bf92577d482b9105bb3d4d131f35_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTYtMS0xLTU1NTU0_b44c21ea-9e0d-405a-827d-0c5723bdc3dd"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i11c7e88092ac49d78f2b821816062d7d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzgtMTgtMS0xLTU1NTU0_4fefcbc8-80e4-4a73-aa05-e9f4049f7a84"
      unitRef="usd">1044000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i73e280126ffb45dd8d20fc69bcf08ce6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTItMS0xLTkyMjAx_40d31ff6-527c-46ae-9397-fdceff1df2a3"
      unitRef="usd">566000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia437ec7f284c49d6a65b54737b247969_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTQtMS0xLTkyMjA1_89262a17-566a-43b5-a1c9-c81e9e6f54fe"
      unitRef="usd">461000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i794fd5a1ff8d49928a90b66d34aae6b2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTYtMS0xLTkyMjIw_9edad57b-1f3e-4481-9409-0eeb1064ca4e"
      unitRef="usd">1027000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie08cb03dda2a4cbeace3bd8fec2bf082_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTgtMS0xLTkyMjA4_d5851b69-becd-4b16-af6f-570858540292"
      unitRef="usd">485000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3aa8459da664468b847514e8360e549b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEwLTEtMS05MjIxMQ_08149f75-f7ea-48fb-929a-f2ed5909bdec"
      unitRef="usd">365000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic0e82165e6ed4ce0870f8f592e298c7f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEyLTEtMS05NDQ5Mw_cb9de1eb-0c5f-4df1-a2d0-5df5e2140831"
      unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iafe308e8cce24a29bfe153c46d6eed91_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE0LTEtMS05MjIxNA_bdaecac5-dc6d-44ec-954c-cc696d24884e"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2c2a9a63cb37432fa884cace4bab4206_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE2LTEtMS05MjIxNw_2e492137-7990-433a-9a02-8e8c01500df6"
      unitRef="usd">315000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iae5877faf81e455bb0d9482eb25bd1ca_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE4LTEtMS05NDQ5Nw_dbbcb2d6-ecf6-41ec-af0e-4b31908e78cf"
      unitRef="usd">795000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idb6b177906644a8ba787927952e1e6ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTItMS0xLTU1NTU0_cd7a235d-5859-4625-ae37-20ebb6c9a997"
      unitRef="usd">3636000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5cedf86849344ad185dd0473b29aa1f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTQtMS0xLTU1NTU0_9badce48-5106-484d-89b0-c8f538c3fe31"
      unitRef="usd">2215000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i64ee7a4be4a741f49a25afd921009f06_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTYtMS0xLTU1NTU0_9c654a1e-1bdc-4ed2-8f70-a0818759484c"
      unitRef="usd">5851000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3f9fd64f276d4139aea96a0883ba58ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTgtMS0xLTU1NTU0_2406bdde-5a3a-4267-9da2-c8f3deb3c9a4"
      unitRef="usd">3821000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic2365d4e32b64cd087bbb41137067445_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEwLTEtMS01NTU1NA_af933f24-e568-4c40-977d-488d99b2bc35"
      unitRef="usd">1903000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2dda7d1128174280bf5cb5fd5f91bc58_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTEyLTEtMS01NTU1NA_bc745110-f605-4587-85ab-ea14e7d7dbd0"
      unitRef="usd">5724000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if35d3d6d4b644346b1122b986aa9fe50_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE0LTEtMS01NTU1NA_43641b76-8523-4333-afff-5841f1d4002c"
      unitRef="usd">3031000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4abfdddf9be24f51a5a6754cc8ad2888_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE2LTEtMS01NTU1NA_91c231ef-92c9-487d-a1ea-0108049295e7"
      unitRef="usd">1712000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i69f26fd68cfa4c65a24d973779fd0e1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEwLTE4LTEtMS01NTU1NA_9bc33338-f159-4fb7-bef5-16ee902a0c8a"
      unitRef="usd">4743000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0795e4a54f5843d393051071fa6d5f9b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTItMS0xLTU1NTU0_b6f6ff06-1311-4cd5-97b1-6e1619ff1604"
      unitRef="usd">17286000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iee2014a7861a48b799fb3652e82edcd5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTQtMS0xLTU1NTU0_d97a4ef6-7946-4f1f-a531-6692ff2270f2"
      unitRef="usd">7011000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTYtMS0xLTU1NTU0_f745bc97-5607-4fff-8d57-a5dcd9f5682f"
      unitRef="usd">24297000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i676e864b987849b3b20c91a321c3dda8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTgtMS0xLTU1NTU0_4c4d347c-6583-45b4-a7f9-95a1ba8f7fad"
      unitRef="usd">17985000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i116d123386f643908f969672fc7551ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTEwLTEtMS01NTU1NA_08398191-4b8d-4310-ba86-34378c79d1b9"
      unitRef="usd">6255000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTEyLTEtMS01NTU1NA_291352f2-f050-44cd-9da6-05886b44ada6"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie0adce9b11c444f0992f20820cf3828f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTE0LTEtMS01NTU1NA_28e4bd56-bb06-4ec0-9094-486deeaba330"
      unitRef="usd">16531000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if0a71c3bfd064ff09a900ad9f82e3ff4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTE2LTEtMS01NTU1NA_606ce058-9de2-4e4b-83bb-4d10c25f3efc"
      unitRef="usd">5673000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzExLTE4LTEtMS01NTU1NA_b3632c68-6586-4dd5-a369-71cd02754467"
      unitRef="usd">22204000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8d8aa15dac8a479aa274d63cceb3e3cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTItMS0xLTU1NTU0_a72e05ca-dccf-42d4-880e-34858cb95a57"
      unitRef="usd">908000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ice1f469a4b2e4de98ca61b255d39fffb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTQtMS0xLTU1NTU0_c56affa3-6c76-4881-8389-91ba1800ff4f"
      unitRef="usd">774000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8aa4009b79ae4a1aaa88901012cdc38c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTYtMS0xLTU1NTU0_a0bcad92-ac70-4ae1-9b63-0ca0e20a97fd"
      unitRef="usd">1682000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3dbe8a4fa56d4704aacdf9825e608952_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTgtMS0xLTU1NTU0_708f683f-1f3c-4600-94bc-734be97c6ddb"
      unitRef="usd">511000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib9d6910ca4184832834d336a96a65391_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTEwLTEtMS01NTU1NA_2b800e97-0b30-4448-af95-fcfba5cd8126"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6c9dfed05d2a4cc7b238e87a2395d611_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTEyLTEtMS01NTU1NA_af1a0f36-07b3-4a6f-8cb3-a6ac4d2e603f"
      unitRef="usd">1184000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i16a1575152424f7d8ace591bcbc21966_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTE0LTEtMS01NTU1NA_60412d0a-0f77-492e-897c-efe8208144e5"
      unitRef="usd">693000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6f0b7b5c89644713988c1ec6f68bb082_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTE2LTEtMS01NTU1NA_53862b8e-f4e8-4d68-94c3-d6906f804f47"
      unitRef="usd">465000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5666794b15d1495f894c2e5fa67e1ff5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEyLTE4LTEtMS01NTU1NA_760085e5-e082-4036-a6f6-eb32337bb0c5"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i99cd8f4d101d41ada52bea1b7f7707dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTItMS0xLTU1NTU0_b8801cae-7ca0-4558-a41a-9f0db5af9868"
      unitRef="usd">18194000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie389e5de5a4d478db22bca7314e7c2e6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTQtMS0xLTU1NTU0_fb33ebf9-704b-4091-8325-00b60ddaa761"
      unitRef="usd">7785000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTYtMS0xLTU1NTU0_c7400ab4-da1f-4f1d-8d88-c48b090ed03c"
      unitRef="usd">25979000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6b16e7fedb4e4c24ae45b97df7a610b3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTgtMS0xLTU1NTU0_3770c813-5271-46d0-ba48-ce79da0ce6ed"
      unitRef="usd">18496000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1ef86d4467f84eb1bb360dfad6d77585_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTEwLTEtMS01NTU1NA_f4fd40b4-be79-45a5-b4e1-100a425dcbb5"
      unitRef="usd">6928000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTEyLTEtMS01NTU1NA_848c5915-e7d4-4764-81ef-a69df2c4a181"
      unitRef="usd">25424000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9e2955a78f1c41a08c3ed208c99513da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTE0LTEtMS01NTU1NA_e40a886e-95c9-4197-bbbb-6136072d7de8"
      unitRef="usd">17224000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6ef9644ae27a4c1a8fe31454e5457a11_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTE2LTEtMS01NTU1NA_d43a969c-7d1d-4547-956b-201e5e035c5c"
      unitRef="usd">6138000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTo1NDFiMGI5NTVjMjQ0NzM2OGQwYWRjYjY2MzY2MTc2Yi90YWJsZXJhbmdlOjU0MWIwYjk1NWMyNDQ3MzY4ZDBhZGNiNjYzNjYxNzZiXzEzLTE4LTEtMS01NTU1NA_5fd92b5b-69a2-4885-9658-e80a1c3f85f5"
      unitRef="usd">23362000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEyMDc_10f44b59-cd13-43ff-9b68-7ca74be05ee9"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEyMDc_4498db88-87fe-41e9-8ae2-0abcee6e05b4"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEyMDc_8e56425e-d4b9-4267-8888-baf3e95f569b"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue>
    <amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzEzOTg_d804264f-6173-42bb-b0ec-6b3abb635603"
      unitRef="number">0.82</amgn:PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE5ODg_5636de42-117a-49bf-8eaf-7e9e4660fbb7">Certain information with respect to these customers was as follows (dollar amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;% of total gross revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i293bc5a8ad2541879fe865ae5d2417d1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMS0xLTEtOTA5NTQ_13238b35-cdaf-4ced-8fc7-2838bc9df3af"
      unitRef="usd">15187000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i44fe8e6898034d56a3a0bdcfc063bc2b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMy0xLTEtOTA5NTQ_ae798d2c-b51c-4e20-b2a3-9959a8f01086"
      unitRef="usd">13779000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia5aee82520bc437a8e545732608e5e33_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtNS0xLTEtOTA5NTQ_f85cbf84-3023-487b-9620-519ec311d3ca"
      unitRef="usd">11795000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="i293bc5a8ad2541879fe865ae5d2417d1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMS0xLTEtOTA5NTQ_b4e97a9e-47c4-4e22-875a-5d538f2ee740"
      unitRef="number">0.33</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i44fe8e6898034d56a3a0bdcfc063bc2b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMy0xLTEtOTA5NTQ_85cdd7d9-aef7-4b0b-9bbc-bbc5d4bde07f"
      unitRef="number">0.32</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="ia5aee82520bc437a8e545732608e5e33_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtNS0xLTEtOTA5NTQ_84a2c949-a673-4963-917f-71761462930b"
      unitRef="number">0.31</amgn:PercentageOfGrossRevenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie45ea7d90fd9496098876205bd24f226_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMS0xLTEtNTU1NTQ_5f3a1bff-748a-4324-be10-b7a11546f587"
      unitRef="usd">14783000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7d011b83be41426c8583d49144da9518_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtMy0xLTEtNTU1NTQ_58c07aed-ede9-417c-8042-139ac8ba9cf9"
      unitRef="usd">14743000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i127aa134bb05481bae71c4068800e12a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzMtNS0xLTEtNTU1NTQ_1c67e7a8-78b1-4baa-b27d-e4760a9aa84d"
      unitRef="usd">12301000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="ie45ea7d90fd9496098876205bd24f226_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMS0xLTEtNTU1NTQ_c39fd090-9b7e-404b-b58c-2b8c30d0314f"
      unitRef="number">0.32</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i7d011b83be41426c8583d49144da9518_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtMy0xLTEtNTU1NTQ_590098ca-1531-40ca-bbd6-9e1e85eff879"
      unitRef="number">0.34</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i127aa134bb05481bae71c4068800e12a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzQtNS0xLTEtNTU1NTQ_6dd41616-a019-4744-aef6-eb2e0c9ba015"
      unitRef="number">0.33</amgn:PercentageOfGrossRevenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib6de6025ba0e4e2690eec1546e065897_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzktMS0xLTEtNTU1NTQ_f37b58a0-f1a8-4b90-b386-d32f4baa38e1"
      unitRef="usd">7681000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i37f412791f92490e9d982b4d75831aeb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzktMy0xLTEtNTU1NTQ_16fc845d-56e9-4a06-916c-4a5154604163"
      unitRef="usd">7332000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icbf19b5b37714e80a93f4933d02ef7d6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzktNS0xLTEtNTU1NTQ_4e692a75-db2d-4385-b9f3-e19779d54a7f"
      unitRef="usd">6538000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:PercentageOfGrossRevenues
      contextRef="ib6de6025ba0e4e2690eec1546e065897_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzEwLTEtMS0xLTU1NTU0_302378e8-f268-4667-aea4-4f7595a44897"
      unitRef="number">0.17</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="i37f412791f92490e9d982b4d75831aeb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzEwLTMtMS0xLTU1NTU0_b0f84194-e685-46a3-b542-c0263949a06a"
      unitRef="number">0.17</amgn:PercentageOfGrossRevenues>
    <amgn:PercentageOfGrossRevenues
      contextRef="icbf19b5b37714e80a93f4933d02ef7d6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90YWJsZTozOTFhNWI1ZTIzMzA0Njg5YWJiMjdjM2EwOTI3ZTJhOS90YWJsZXJhbmdlOjM5MWE1YjVlMjMzMDQ2ODlhYmIyN2MzYTA5MjdlMmE5XzEwLTUtMS0xLTU1NTU0_cf417114-b499-481a-92b9-cc8fbc4fa87d"
      unitRef="number">0.17</amgn:PercentageOfGrossRevenues>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE1OTc_4e77bddd-d658-493a-924d-d9bd20b886c8"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables>
    <amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE1OTc_6d730040-18cc-4ddc-8493-93e5fb403212"
      unitRef="customer">3</amgn:NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables>
    <amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE2NzM_5d1feb59-0fb5-425b-b411-e88c6df60075"
      unitRef="number">0.73</amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers>
    <amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE2ODA_7f8cd217-fab8-4df6-8369-6de01c4bb02c"
      unitRef="number">0.74</amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers>
    <amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE3NjE_e28ec069-969f-4bc0-b0a0-dbccbcf02cfa"
      unitRef="number">0.27</amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation>
    <amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDIvZnJhZzplNDhhMmUyMmIyNWM0ZTNiODc4YzZiNjU1ZjM0MzAxOS90ZXh0cmVnaW9uOmU0OGEyZTIyYjI1YzRlM2I4NzhjNmI2NTVmMzQzMDE5XzE3Njg_4aa4b35a-c6d7-4abb-8f49-5200806b4c8a"
      unitRef="number">0.28</amgn:PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MjQ_fbae9268-c2a9-4268-958a-284ce9128956">Stock-based compensation&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Amended 2009 Plan authorizes for issuance to employees of Amgen and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including full-value awards. In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2021, the Amended 2009 Plan provides for future grants and/or issuances of up to approximately 19 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units and stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee&#x2019;s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares only when and to the extent the underlying RSUs vest and are issued to the recipient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values per unit of RSUs granted during the years ended December 31, 2021, 2020 and 2019, were $233.10, $235.63 and $182.12, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;grant&#160;date&lt;br/&gt;fair&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant date fair values of RSUs that vested during the years ended December 31, 2021, 2020 and 2019, were $166 million, $161 million and $160 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black&#x2013;Scholes option valuation model to estimate the grant date fair value of stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (average of implied and historical volatility)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic values of options exercised during the years ended December 31, 2021, 2020 and 2019, were $56 million, $98 million and $68 million, respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2021, 2020 and 2019, were $12 million, $21 million and $15 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, $346 million of unrecognized compensation cost was related to nonvested RSUs and unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years. The performance goals for the units granted during the years ended December 31, 2021, 2020 and 2019, which are accounted for as equity awards, are based on (i) Amgen&#x2019;s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen&#x2019;s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of units granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, 1.6 million and 1.8 million performance units were outstanding, with weighted-average grant date fair values per unit of $229.39 and $207.52 per unit, respectively. During the year ended December 31, 2021, 0.6 million performance units with a weighted-average grant date fair value per unit of $254.68 were granted, and 0.2 million performance units with a weighted-average grant date fair value per unit of $226.32 were forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair values of performance units paid during the years ended December 31, 2021, 2020 and 2019, were $149 million, $230 million and $176 million, respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period.&lt;/span&gt;&lt;/div&gt;As of December 31, 2021, $130 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM5OQ_e35828f4-d796-463f-87ab-c76e8b302d5a"
      unitRef="shares">1</amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted>
    <amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQ0NQ_4089222c-4ba2-44ce-abe2-63f05b4787aa"
      unitRef="shares">1.9</amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted>
    <amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQ0NQ_690ef843-c212-4242-bbf4-0fb305133c7e"
      unitRef="shares">1.9</amgn:NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted>
    <amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzEwMjI_a412567f-9c3b-4a29-8c9c-f542db06af7f"
      unitRef="shares">1.9</amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards>
    <amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzEwMjI_be646eca-2d93-4c05-b316-637f79344f06"
      unitRef="shares">1.9</amgn:NumberofSharesAddedBackforTaxWithholdingonFullValueAwards>
    <amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzExMzI_c8c18c26-ce76-4120-ba64-42ac2c1713a4"
      unitRef="shares">19000000</amgn:AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances>
    <amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MDU_726df507-f632-4629-8ce9-09e81a94c453">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit from stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzItMS0xLTEtNTU1NTQ_8b55b02a-9e36-43a1-8756-687f4d3be9a5"
      unitRef="usd">183000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie689ea75a1044f2d984398ed617833af_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzItMy0xLTEtNTU1NTQ_c209e7b1-7a1a-4795-80a1-7635263041f4"
      unitRef="usd">178000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzItNS0xLTEtNTU1NTQ_ae5e1260-8896-4faa-85ff-57567cf11671"
      unitRef="usd">168000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzMtMS0xLTEtNTU1NTQ_12db82a9-f199-446d-96dd-9d7e2243458a"
      unitRef="usd">121000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzMtMy0xLTEtNTU1NTQ_be079cf3-d803-4fb9-bea9-0bf034606ba8"
      unitRef="usd">118000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzMtNS0xLTEtNTU1NTQ_04e23aa8-9056-463c-8648-2f1f28d8e4b3"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzQtMS0xLTEtNTU1NTQ_4ac6f0c2-b6cf-49c9-a9dc-828af73b3906"
      unitRef="usd">37000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzQtMy0xLTEtNTU1NTQ_1b5096b1-8565-47b5-9d2d-64aeb447f3d3"
      unitRef="usd">34000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzQtNS0xLTEtNTU1NTQ_74136c1f-f749-4f6a-a5f1-8b95e25e49a0"
      unitRef="usd">35000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzUtMS0xLTEtNTU1NTQ_fd6e7680-fa70-450c-8ded-a737c8ab66c0"
      unitRef="usd">341000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzUtMy0xLTEtNTU1NTQ_ab68707e-0ac0-4a89-a43c-4879a1acbf29"
      unitRef="usd">330000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzUtNS0xLTEtNTU1NTQ_08dec69f-12c0-4fb3-9365-24cb3ecff839"
      unitRef="usd">308000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzYtMS0xLTEtNTU1NTQ_c7afd424-c627-4b66-81de-2939e76322d6"
      unitRef="usd">74000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzYtMy0xLTEtNTU1NTQ_f493a082-18dd-4622-bf30-a0cf12ac5008"
      unitRef="usd">72000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzYtNS0xLTEtNTU1NTQ_6e01dbeb-b12d-4580-b324-7bba449c025f"
      unitRef="usd">67000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzctMS0xLTEtNTU1NTQ_4b49600e-6ee5-40c5-803e-1489c622d470"
      unitRef="usd">267000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzctMy0xLTEtNTU1NTQ_f6404a76-1fe9-4278-8ab0-858b277db0a2"
      unitRef="usd">258000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <amgn:StockBasedCompensationExpenseNetOfTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTplYTUxMmQ5ZTZjODU0MGNlOTc1OTY2NjUwMDUxNTQ2YS90YWJsZXJhbmdlOmVhNTEyZDllNmM4NTQwY2U5NzU5NjY2NTAwNTE1NDZhXzctNS0xLTEtNTU1NTQ_a5ad8692-edee-4541-9a57-c340ff913fe2"
      unitRef="usd">241000000</amgn:StockBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MTk_15bd2116-ead1-4806-b7a7-8d0d3c8b627b">RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzI4MTA_29703698-e73d-4ad7-aeae-58ea6d171ebb"
      unitRef="usdPerShare">233.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie689ea75a1044f2d984398ed617833af_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzI4MTQ_f590cdb7-7241-41d5-8453-667d41d1a638"
      unitRef="usdPerShare">235.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzI4MjE_23681d0d-856a-4945-bd95-9d3c9a5c0eab"
      unitRef="usdPerShare">182.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MzA_fb07d07a-8743-4739-8bac-f2b8d9383c14">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;grant&#160;date&lt;br/&gt;fair&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance nonvested as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5c5f3303e39f4bc0b7b331b548b22fd1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzItMS0xLTEtNTU1NTQ_5dc70c62-a3f0-483d-9e58-1eed5e2a99a9"
      unitRef="shares">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5c5f3303e39f4bc0b7b331b548b22fd1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzItMy0xLTEtNTU1NTQ_f8e54861-05ce-46eb-be87-e486349fb320"
      unitRef="usdPerShare">198.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzMtMS0xLTEtNTU1NTQ_a7725ed7-5165-4bd1-9786-92f7dfed0e5f"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzMtMy0xLTEtNTU1NTQ_08718a93-6345-4510-b24c-0d9711ee093d"
      unitRef="usdPerShare">233.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzQtMS0xLTEtNTU1NTQ_90ea0a1b-9b98-421f-9e12-0d769fb5a56f"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzQtMy0xLTEtNTU1NTQ_979580bb-4905-4ae9-abac-c26658cc726b"
      unitRef="usdPerShare">177.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzUtMS0xLTEtNTU1NTQ_9d64e957-5086-4953-a979-f61aa67823c6"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzUtMy0xLTEtNTU1NTQ_932a7c96-5435-4239-a826-4e772555626f"
      unitRef="usdPerShare">213.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie439637f4a754340a91825cf8855bd2e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzYtMS0xLTEtNTU1NTQ_8cf3889c-90b4-4f96-aa92-d03ddb3ea1ef"
      unitRef="shares">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie439637f4a754340a91825cf8855bd2e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3OWRkYzc4MGUwODU0ZjViODZmNzNhYWU0MDFlZWFkNi90YWJsZXJhbmdlOjc5ZGRjNzgwZTA4NTRmNWI4NmY3M2FhZTQwMWVlYWQ2XzYtMy0xLTEtNTU1NTQ_ca730bcd-92dd-4480-bc62-8a9c42848f48"
      unitRef="usdPerShare">217.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i8bb8e713474c47ff83f089068a521247_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMwMTQ_3a5b574a-d516-45e7-bd36-a8e50c5be49a"
      unitRef="usd">166000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ie689ea75a1044f2d984398ed617833af_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMwMTg_94371469-dc93-4075-8687-0d8157acfb33"
      unitRef="usd">161000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7f6345e802c94552b499a21a83bc4811_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMwMjU_09517306-8863-433f-8abe-ca77c3e02f95"
      unitRef="usd">160000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzMyNDc_48f04975-e206-4d16-8b71-528b62cb0786">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzc0MDg_1fbe0f00-93ed-4947-aa3e-ca3a329798c8">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (average of implied and historical volatility)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <amgn:CommonStockFairValue
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzItMS0xLTEtNTU1NTQ_259e4d14-a3db-4944-91f5-d1a12c5039bc"
      unitRef="usdPerShare">237.17</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzItMy0xLTEtNTU1NTQ_0f0c42a8-cdd2-4f3a-a6dd-edde0d786d2f"
      unitRef="usdPerShare">236.36</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzItNS0xLTEtNTU1NTQ_4b95014e-5dce-43c2-afaa-ecf17fe50c02"
      unitRef="usdPerShare">177.31</amgn:CommonStockFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzMtMS0xLTEtNTU1NTQ_b685dba9-e915-45a2-bfd2-89e7f0a5f652"
      unitRef="number">0.256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzMtMy0xLTEtNTU1NTQ_a541840e-e0e3-49af-ba38-80313752108d"
      unitRef="number">0.281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzMtNS0xLTEtNTU1NTQ_646d6492-da80-42b6-89b1-6d2bf9c5bcf8"
      unitRef="number">0.235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzQtMS0xLTEtNTU1NTQ_75e1d74c-0235-4969-b784-223ea4b63d44">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzQtMy0xLTEtNTU1NTQ_ae4c758d-8cdd-41f8-8900-3740be130a4d">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzQtNS0xLTEtNTU1NTQ_48df24f7-3d90-4df2-b0ff-53a33aad7f43">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzUtMS0xLTEtNTU1NTQ_06b7dc0c-e71b-4f70-8632-40e3b86dec3a"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzUtMy0xLTEtNTU1NTQ_54e67161-da85-4879-a12a-7082fe7e4541"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzUtNS0xLTEtNTU1NTQ_b1826e6f-4455-4f88-a327-dc7d063c3c91"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzYtMS0xLTEtNTU1NTQ_87b5b5f9-ecc5-4353-9857-6e538ab704fe"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzYtMy0xLTEtNTU1NTQ_dbfced6d-a714-449e-a207-170ef3ae2ad6"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzYtNS0xLTEtNTU1NTQ_3be56844-c5e2-447f-9edf-13786fafa61f"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzctMS0xLTEtNTU1NTQ_fb7e62f1-5459-48be-8105-6b157ad79eae"
      unitRef="usdPerShare">40.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzctMy0xLTEtNTU1NTQ_da532166-123f-42f8-bd3c-ccbc0f6d7ed3"
      unitRef="usdPerShare">42.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpiMmUyZWU5ZmUyNmI0ZjU3YjQ0ZjFiNjliZGU2MDkxNy90YWJsZXJhbmdlOmIyZTJlZTlmZTI2YjRmNTdiNDRmMWI2OWJkZTYwOTE3XzctNS0xLTEtNTU1NTQ_f3ba1578-83ba-4aef-8d50-c128b3acf112"
      unitRef="usdPerShare">30.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzczOTA_46c652c9-a47c-4ba0-8f43-fbc727373bd3">&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information regarding our stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance unexercised as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iafb155843fbb43a4845a41a3a8dd1ff1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzItMS0xLTEtNTU1NTQ_5180df7f-488f-4c4e-b32d-6a4e27ff9b76"
      unitRef="shares">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iafb155843fbb43a4845a41a3a8dd1ff1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzItMy0xLTEtNTU1NTQ_d2f260d8-4e39-4cf4-8010-6cae41509394"
      unitRef="usdPerShare">179.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzMtMS0xLTEtNTU1NTQ_69085da1-f56d-4e33-b2e0-56143b8c340c"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzMtMy0xLTEtNTU1NTQ_850fd72a-1975-4dea-878a-997f462ff41f"
      unitRef="usdPerShare">237.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzQtMS0xLTEtNTU1NTQ_d8bd9e39-66a1-409f-8a39-bdba556c26b5"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzQtMy0xLTEtNTU1NTQ_9de34e0c-0037-405d-89d1-e662658eda29"
      unitRef="usdPerShare">137.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzUtMS0xLTEtNTU1NTQ_71643d59-c9ed-4c47-b364-b1d9ed29df92"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzUtMy0xLTEtNTU1NTQ_46382b02-b019-4df6-badf-dc1568589a44"
      unitRef="usdPerShare">208.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtMS0xLTEtNTU1NTQ_51384953-36c0-4dc8-803f-b5b3ade3ac21"
      unitRef="shares">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtMy0xLTEtNTU1NTQ_c76ba95c-ef7c-4028-a69c-fa840fc844c1"
      unitRef="usdPerShare">197.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtNS0xLTEtNTU1NTQ_d77aa471-db68-4165-b559-d79e27b74a48">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzYtNy0xLTEtNTU1NTQ_3900956b-6dc7-4ed8-be52-bf49adb428ce"
      unitRef="usd">168000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctMS0xLTEtNTU1NTQ_0366d634-afb6-4c8a-b4d2-00d00a385c34"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctMy0xLTEtNTU1NTQ_e81e6f83-3e55-46cf-a86f-1ee04c740874"
      unitRef="usdPerShare">195.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctNS0xLTEtNTU1NTQ_7710316d-57cc-4fda-8219-e8fc5c5f5290">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzctNy0xLTEtNTU1NTQ_3ee1d57f-1052-4be5-829e-ed967f763f1e"
      unitRef="usd">167000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtMS0xLTEtNTU1NTQ_9c540729-e10e-491d-ba92-2642a1b37c7b"
      unitRef="shares">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtMy0xLTEtNTU1NTQ_5df5dcfb-3512-47df-b125-d71ca1892e18"
      unitRef="usdPerShare">165.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtNS0xLTEtNTU1NTQ_66ce01f7-78ec-427d-97da-b873ff8fcf6b">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i225e1eeec4fe4106a01db4e50bc8ae4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTo3YjFlNGU4MTQ4OTg0NDA3OWM4ZGM2ODUwZjk0NzE4MS90YWJsZXJhbmdlOjdiMWU0ZTgxNDg5ODQ0MDc5YzhkYzY4NTBmOTQ3MTgxXzgtNy0xLTEtNTU1NTQ_5e85fa54-edaa-4605-bf4e-d6acdae2283a"
      unitRef="usd">120000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM3MTQ_ff260f0d-f098-402e-a128-c2c51ce4258c"
      unitRef="usd">56000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM3MTg_797fe0c4-bc35-4f5f-95dd-ddd649477dd5"
      unitRef="usd">98000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM3MjU_5b2e07fc-c745-4c6f-bfde-0316b51866bd"
      unitRef="usd">68000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM4NjE_3755eb16-47f8-4473-b770-70e9d2ebc5f6"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="id620434bf9034620994881cbe32601bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM4NjU_3b9b0c78-2e90-4e55-a0e5-5a56a873f53b"
      unitRef="usd">21000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="id3ec5388b3cc4a5bba8d14104f6fbe1c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM4NzI_a14e8ae0-5ce9-4dd5-a648-79285f659c10"
      unitRef="usd">15000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzM5MDA_a8a2e8e6-a99d-4894-9c7e-be27b1fbe599"
      unitRef="usd">346000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQwNjQ_ec83bae3-eb90-4c26-9dd4-16ecaf540277">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzQzNTM_40a3b5f0-d43b-44a1-b26b-54176d6ddbdc">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzUyMTg_72c1b835-a366-4597-88db-beda86844cbf"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzUyMTg_9bc726c2-977a-4391-b71d-1f39112a7083"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzUyMTg_c7ed7429-373e-4fa7-8cdb-f01c848991a9"
      unitRef="shares">1</amgn:NumberOfCommonSharesIssuedForEachPerformanceUnitEarned>
    <amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzczOTE_a9a97ae2-f4fe-4cdd-b36a-8c47f8badd96">The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Closing price of our common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of units granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock>
    <amgn:CommonStockFairValue
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzItMS0xLTEtNTU1NTQ_59e8b046-416a-41d1-81d5-29c604e9cdc1"
      unitRef="usdPerShare">239.64</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzItMy0xLTEtNTU1NTQ_de39b4db-a206-464d-ba92-af63b0fc7c73"
      unitRef="usdPerShare">236.36</amgn:CommonStockFairValue>
    <amgn:CommonStockFairValue
      contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzItNS0xLTEtNTU1NTQ_e1de37b4-8480-465c-aebc-7e0326f25ddf"
      unitRef="usdPerShare">177.31</amgn:CommonStockFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzMtMS0xLTEtNTU1NTQ_1088140e-8011-4332-ba4d-48879a743e9e"
      unitRef="number">0.293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzMtMy0xLTEtNTU1NTQ_ce01ffa1-15c1-4f71-8c4a-1ccf7ea0747a"
      unitRef="number">0.275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzMtNS0xLTEtNTU1NTQ_347f35c7-9fd1-4168-966e-7b8deec2bce5"
      unitRef="number">0.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzQtMS0xLTEtNTU1NTQ_fe19b0db-f8f0-4b1b-9e80-e0ffb5e637d3"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzQtMy0xLTEtNTU1NTQ_8abacb8e-9d5b-44e3-a12b-5be704e19b0d"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzQtNS0xLTEtNTU1NTQ_e8b66fe9-29a7-4e36-995f-ddf871a6a45a"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzUtMS0xLTEtNTU1NTQ_53673ea9-95ac-4715-8d21-13c93f95837b"
      unitRef="usdPerShare">254.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzUtMy0xLTEtNTU1NTQ_badc74ee-e805-44f7-8dec-a7fdd5deea20"
      unitRef="usdPerShare">249.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90YWJsZTpjMTZkYzU3MzRkNDk0NzQ2OGYyOTM1MjQwOTA2YzI1YS90YWJsZXJhbmdlOmMxNmRjNTczNGQ0OTQ3NDY4ZjI5MzUyNDA5MDZjMjVhXzUtNS0xLTEtNTU1NTQ_9ec0ad67-a8d8-4e98-9bc5-924c96bc56a4"
      unitRef="usdPerShare">188.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5c176348e21b4ba1a3156259d8a42916_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY1ODI_a345d215-b167-479c-84a7-8fbd53e2ea8c"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7f3ff89fdeeb41748a0d6033b1bd4fa9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY1ODk_01bc3934-ef7d-4079-96e0-3e4a1304c2ba"
      unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5c176348e21b4ba1a3156259d8a42916_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY2ODQ_6a4d41e8-a172-44e1-8da9-8362923bad4a"
      unitRef="usdPerShare">229.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7f3ff89fdeeb41748a0d6033b1bd4fa9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY2OTE_4a18cfec-18db-40b0-a2dc-63d71d337362"
      unitRef="usdPerShare">207.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY3NDQ_79110f87-e318-418c-b3d0-8e242f31b883"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY4MjM_d4ef60cf-339a-4968-b614-2ffe7df5cab4"
      unitRef="usdPerShare">254.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY4NDQ_9616840c-0d9a-429e-9a81-7c459e197a77"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzY5MjM_66cba7b1-d9d4-4bcd-a183-b1b88e1453ea"
      unitRef="usdPerShare">226.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcwNDU_d8214e4e-829a-4e0e-a106-194472179aff"
      unitRef="usd">149000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iae8799bfe61f4dfeb96c2f87793c1d0d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcwNDk_ef39d9af-9051-4a99-a1ce-7705069cc744"
      unitRef="usd">230000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i6a2c0a337619447e8a7d7b99c209e8b9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcwNTY_3c33bbd2-f0e8-463c-8bf7-05402b015922"
      unitRef="usd">176000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5c176348e21b4ba1a3156259d8a42916_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzcyMzM_836edff4-5e86-4674-8e8b-801de9d6803f"
      unitRef="usd">130000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDUvZnJhZzo3OGIzYzAwYzBkMTg0YmZlYmEzYzczNDEwMWNjZDYzZC90ZXh0cmVnaW9uOjc4YjNjMDBjMGQxODRiZmViYTNjNzM0MTAxY2NkNjNkXzczODM_735c55eb-ccbb-4718-a82a-593061fa7b97">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0XzQzNQ_90fe9ed9-83cc-44ee-acff-f1aaed795d9d">Defined contribution planThe Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $279&#160;million, $231 million and $220 million for the years ended December 31, 2021, 2020 and 2019, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0Xzc2OTY1ODEzOTUwMTk_e0bae4af-6875-47c0-bde6-59e0e331573e"
      unitRef="usd">279000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0XzM3Ng_a30a8815-3572-4a36-abaf-b14198528803"
      unitRef="usd">231000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMDgvZnJhZzphZTQxZjZmZTU5MDA0ZmYzYmVkMDlhZWFlNGNkN2VlNC90ZXh0cmVnaW9uOmFlNDFmNmZlNTkwMDRmZjNiZWQwOWFlYWU0Y2Q3ZWU0XzM4Mw_cedbf985-9f1f-4d3d-a194-4a75a32483f4"
      unitRef="usd">220000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNjA_c46fe30f-dd99-4d24-8466-b1f7b08497d0">Income taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of NOL carryforwards. Significant components of our deferred tax assets and liabilities were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance increased in 2021, primarily driven by the Company&#x2019;s expectation that some state R&amp;amp;D credits will not be utilized and certain foreign and acquired net operating losses will expire unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we had $75 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided no valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2040. We had $798 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $709 million of those state tax credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we had $606 million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6 million of those federal NOL carryforwards. For the federal NOL carryforwards for which no valuation allowance has been provided, $426&#160;million have no expiration; the remainder begin to expire between 2022 and 2037. We had $391 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $330&#160;million of those state NOL carryforwards. We had $2.0 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $561 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $800 million has no expiry; and the remainder will expire between 2022 and 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the total gross amounts of UTBs were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the UTBs as of December 31, 2021, if recognized, would affect our effective tax rate. During the year ended December 31, 2020, we effectively settled certain issues with the IRS. As a result, we remeasured our UTBs accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2021, 2020 and 2019, we recognized $98 million, $116 million and $198 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. The decrease in interest expense for the year ended December 31, 2021, was primarily due to lower interest rates during 2021 and settlement of a prior year audit. As of December 31, 2021 and 2020, accrued interest and penalties associated with UTBs were $881 million and $783 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, primarily federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Audit settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the years ended December 31, 2021, 2020 and 2019, differ from the federal statutory rate primarily due to impacts of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from the Company&#x2019;s operations in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to tax incentive grants through 2035. Additionally, the Company&#x2019;s operations conducted in Singapore are subject to a tax incentive grant through 2034. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing site in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes in 2021, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes paid during the years ended December 31, 2021, 2020 and 2019, were $1.9 billion, $1.4 billion and $1.9 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities (including the IRS) are becoming more aggressive and are particularly focused on such matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021, which seek to increase our U.S. taxable income. The Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $3.6&#160;billion plus interest. Any additional tax that could be imposed would be reduced by up to approximately $900&#160;million of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS&#x2019;s positions set forth in the Notices are without merit, and we are contesting the Notices through the judicial process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office. We were unable to reach resolution at the administrative appeals level, and we anticipate that we will receive a statutory notice of deficiency for these years as well. We expect to contest any such notice related to 2013&#x2013;15 through the judicial process. We are also currently under examination by the IRS for the years 2016, 2017 and 2018 and by a number of state and foreign tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNjE_a768658d-bb4e-4965-93fc-7a35a1c60677">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i3022ab55cbe34d28a3a4a40e97b0e2f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzItMS0xLTEtNTU1NTQ_025feaa4-779f-4d98-8ebc-e03737a46951"
      unitRef="usd">1850000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i378c1ff5055142c89725880372cbf969_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzItMy0xLTEtNTU1NTQ_3bc13665-c656-493e-a575-bbaf8f01266a"
      unitRef="usd">4087000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i07aa01d299e2400ca85cb51dfeac2827_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzItNS0xLTEtNTU1NTQ_328f485c-c349-4619-bf25-8a671054b2f1"
      unitRef="usd">4371000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4f5e991692b349cf9019705e77e8295a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzMtMS0xLTEtNTU1NTQ_13b381a0-aca5-4d6e-9f51-ca26eff5f554"
      unitRef="usd">4851000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if882d889ea614a7891f8c06a940d0411_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzMtMy0xLTEtNTU1NTQ_180a756d-130b-418c-be01-dbb798e5c389"
      unitRef="usd">4046000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i13da767a4eec472cacf227f166d68782_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzMtNS0xLTEtNTU1NTQ_8b25cc47-ad37-4130-92c5-69332b3dd0c6"
      unitRef="usd">4767000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzQtMS0xLTEtNTU1NTQ_82c86379-6601-441c-ac0a-ead54c4885b3"
      unitRef="usd">6701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzQtMy0xLTEtNTU1NTQ_86fa78e2-2e63-424f-92a1-9408be9eb8c3"
      unitRef="usd">8133000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo3MmIzZmU0YTVjMzM0YjQyYTJhMmYzNmJlY2M4MDViMC90YWJsZXJhbmdlOjcyYjNmZTRhNWMzMzRiNDJhMmEyZjM2YmVjYzgwNWIwXzQtNS0xLTEtNTU1NTQ_ae0f1e50-f9c8-4266-a92f-91332c67d41a"
      unitRef="usd">9138000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNzg_56319dbd-b4fa-46e5-a5d8-3891b342450b">&lt;div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes included the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzMtMS0xLTEtNTU1NTQ_ad66fc72-205a-478c-962a-815b07e55c99"
      unitRef="usd">865000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzMtMy0xLTEtNTU1NTQ_21d1a4ef-13d0-488b-9fb4-71c18187c3cc"
      unitRef="usd">921000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzMtNS0xLTEtNTU1NTQ_93622c7d-57ba-4da1-a064-5073e82e99eb"
      unitRef="usd">1284000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzQtMS0xLTEtNTU1NTQ_7cbd6b40-b2c7-4387-b727-e380d6e99039"
      unitRef="usd">18000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzQtMy0xLTEtNTU1NTQ_72385df0-b1c1-4651-8db4-eca16cb4fcc7"
      unitRef="usd">34000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzQtNS0xLTEtNTU1NTQ_4acdea9e-327a-4711-81f6-0bb637c041fa"
      unitRef="usd">39000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzUtMS0xLTEtNTU1NTQ_d3938043-cd7e-4af7-98f1-7a02ee2bfc04"
      unitRef="usd">359000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzUtMy0xLTEtNTU1NTQ_a29238d0-347d-42fe-98e0-270386639f85"
      unitRef="usd">277000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzUtNS0xLTEtNTU1NTQ_4e288745-85ea-438d-ad73-607435663420"
      unitRef="usd">277000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzYtMS0xLTEtNTU1NTQ_a324cfc0-7246-45b2-be4f-111d84643b02"
      unitRef="usd">1242000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzYtMy0xLTEtNTU1NTQ_dd62a83b-e0c0-4dda-aff9-af0b377f6f78"
      unitRef="usd">1232000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzYtNS0xLTEtNTU1NTQ_d1dba5bc-b6c1-4b10-9527-7a49132cfa51"
      unitRef="usd">1600000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzgtMS0xLTEtNTU1NTQ_fc5b7d37-2bcc-45a5-ad45-f62b381274e8"
      unitRef="usd">-308000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzgtMy0xLTEtNTU1NTQ_69beef0b-cb7d-4b5c-9600-5867d8005277"
      unitRef="usd">-321000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzgtNS0xLTEtNTU1NTQ_bd60ce12-6091-4cd7-8c4f-060b3427b9d2"
      unitRef="usd">-276000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzktMS0xLTEtNTU1NTQ_b58517f3-54f4-4258-bcaf-54719c9bcde2"
      unitRef="usd">-9000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzktMy0xLTEtNTU1NTQ_fb885bea-094b-4aac-952d-b0dc75591832"
      unitRef="usd">9000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzktNS0xLTEtNTU1NTQ_371b70be-ce45-406c-9a77-efc972590cc9"
      unitRef="usd">-22000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEwLTEtMS0xLTU1NTU0_36d24bd7-c4f1-4f49-8e04-9aa58756e5b2"
      unitRef="usd">-117000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEwLTMtMS0xLTU1NTU0_047b3446-944e-4cc4-9b1d-abde31f8c4c1"
      unitRef="usd">-51000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEwLTUtMS0xLTU1NTU0_8e9961b0-690b-4b03-bacc-ed4628444381"
      unitRef="usd">-6000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzExLTEtMS0xLTU1NTU0_44157af4-7d2d-4502-ac26-5b7549888b65"
      unitRef="usd">-434000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzExLTMtMS0xLTU1NTU0_1ef9cd7e-5440-43d5-add3-7e146e6c8cc4"
      unitRef="usd">-363000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzExLTUtMS0xLTU1NTU0_25e5da62-825f-4ca5-bad1-d083a3cad1b4"
      unitRef="usd">-304000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEyLTEtMS0xLTU1NTU0_b48445fb-ec42-49b2-8f08-987de66b7fca"
      unitRef="usd">808000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEyLTMtMS0xLTU1NTU0_df3fc5e1-556b-4c4f-9285-d92eb9afcb4f"
      unitRef="usd">869000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiODE2NTg2ZDljNjc0NTIxYWJkM2YxOWI2NGE0MmRjNS90YWJsZXJhbmdlOmI4MTY1ODZkOWM2NzQ1MjFhYmQzZjE5YjY0YTQyZGM1XzEyLTUtMS0xLTU1NTU0_c7e0383e-2be9-4779-8cd1-b669e9746bf9"
      unitRef="usd">1296000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNDY_0bb6b117-99ec-4fa5-b5ef-ca2238f25b8d">Significant components of our deferred tax assets and liabilities were as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzMtMS0xLTEtNTU1NTQ_8034a0d7-6344-4f55-a0c6-80ee36914542"
      unitRef="usd">1065000000</amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzMtMy0xLTEtNTU1NTQ_28e67c8b-9eeb-4759-9854-c51af96cb287"
      unitRef="usd">794000000</amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzQtMS0xLTEtNTU1NTQ_942412bc-ac45-4ce8-b380-a6c4b62b2b00"
      unitRef="usd">600000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzQtMy0xLTEtNTU1NTQ_4a40e5a4-8477-4b65-8b8f-d2ed2dabda10"
      unitRef="usd">561000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzUtMS0xLTEtNTU1NTQ_d0dade87-d383-4727-b0cf-465c6a0b78e6"
      unitRef="usd">244000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzUtMy0xLTEtNTU1NTQ_0b175019-1adc-4ec2-a946-aca460921831"
      unitRef="usd">144000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzYtMS0xLTEtNTU1NTQ_6d247dc4-f9d9-4b31-b81f-d99cd9d0c3fa"
      unitRef="usd">96000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzYtMy0xLTEtNTU1NTQ_0793e80a-eb21-48c8-9692-2ca227735da3"
      unitRef="usd">92000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzgtMS0xLTEtNTU1NTQ_0d4d0187-600b-4df7-988b-f84fec2675e8"
      unitRef="usd">326000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzgtMy0xLTEtNTU1NTQ_55aeca39-34a1-4679-82c8-ac9c1b400cfc"
      unitRef="usd">301000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzktMS0xLTEtNTU1NTQ_b846340a-5c59-4fe2-a193-260ee5a30426"
      unitRef="usd">2331000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzktMy0xLTEtNTU1NTQ_d02f2e16-8a04-4d15-9537-210c0cd0d91e"
      unitRef="usd">1892000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzEwLTEtMS0xLTU1NTU0_f3198738-86e9-4f6a-8aa8-4bae4f531421"
      unitRef="usd">663000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzEwLTMtMS0xLTU1NTU0_37bab24a-2e63-48ff-bc5d-9243116c9502"
      unitRef="usd">571000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzExLTEtMS0xLTU1NTU0_fdd552b5-685c-4222-a1da-ac63599a0bdb"
      unitRef="usd">1668000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzExLTMtMS0xLTU1NTU0_d33785af-a1e0-4c76-9481-d109ba682984"
      unitRef="usd">1321000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE0LTEtMS0xLTU1NTU0_c7ddb40d-f1bc-4256-aded-0b4339d0f8bc"
      unitRef="usd">824000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE0LTMtMS0xLTU1NTU0_0b4a829b-f295-45eb-b70b-1246bcb25c97"
      unitRef="usd">903000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE1LTEtMS0xLTU1NTU0_bdab623d-05f8-4d34-9fda-382cf8a36a5a"
      unitRef="usd">275000000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE1LTMtMS0xLTU1NTU0_bc32b066-eded-4d9f-91a8-f71ac1dd5575"
      unitRef="usd">282000000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE2LTEtMS0xLTU1NTU0_5ab0379f-3ba4-47c5-b9f0-23751618d3d9"
      unitRef="usd">129000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE2LTMtMS0xLTU1NTU0_26ddceca-0cc1-4ace-9c73-b30b9f8584d4"
      unitRef="usd">148000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE3LTEtMS0xLTU1NTU0_ce9fd0c0-994c-47de-9364-7f8ebc3390ab"
      unitRef="usd">221000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE3LTMtMS0xLTU1NTU0_2e8d6a6d-ca26-40e0-adef-00dc81cd6090"
      unitRef="usd">189000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE4LTEtMS0xLTU1NTU0_6e3af493-167e-4e9e-ae7f-a40a6b048652"
      unitRef="usd">1449000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE4LTMtMS0xLTU1NTU0_d0d0f5e2-b4d1-49b4-ada5-d955b0c1cef5"
      unitRef="usd">1522000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE5LTEtMS0xLTU1NTU0_061f7d12-16ab-4566-a91c-c01083a77f15"
      unitRef="usd">219000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTo0YWE4OGZjNjAwMzE0NDE4YmY5ZTExYzgzYTYwOTgyMC90YWJsZXJhbmdlOjRhYTg4ZmM2MDAzMTQ0MThiZjllMTFjODNhNjA5ODIwXzE5LTMtMS0xLTU1NTU0_9d677367-d701-43fd-88fc-d52fba94b239"
      unitRef="usd">201000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEwNjI_4f0896a6-c33b-4b32-9c3b-fc9fbca07272"
      unitRef="usd">75000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i19cf357e0ed44f0a9240d63f761e319f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzExNjc_deb512cb-5326-412f-94c9-8cc7b398bed6"
      unitRef="usd">0</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEzMDg_a4e3e308-d1e5-48c9-91a1-c6e88d9e9d00"
      unitRef="usd">798000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE0MzU_c8d3f37c-4d70-4d98-8102-a75307f24612"
      unitRef="usd">709000000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE0OTY_de1d5384-51e5-4b35-97fd-9b4081e658c5"
      unitRef="usd">606000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE2MjA_1447f6be-4938-4e91-a967-fce07fb9e4c9"
      unitRef="usd">6000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i7ea7e54e88b146f383ed2ca43d4cc454_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE3MDA_699104a8-6aab-4f3e-a8b1-a3cd115d1705"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i9cc399ea0ce04799a09de06e546eceb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3Xzg3OTYwOTMwNDQzMTQ_dc162291-dfd0-4087-8b39-c329bf603c91"
      unitRef="usd">426000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE3Nzk_7d6b74bb-f8b4-4db5-bda3-674f460786f0"
      unitRef="usd">391000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i876ecb33b93d407bbf54fbff636fcbcc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3Xzg3OTYwOTMwNDQzMzE_19f5e86f-a5fd-4309-b0e9-645ee8bc5406"
      unitRef="usd">330000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id46afb35127d450e9e5b64faa1484510_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzE5NDI_3fcb5178-225c-4d29-8838-c46e6cbfae48"
      unitRef="usd">2000000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="id46afb35127d450e9e5b64faa1484510_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzIwNjY_900be28d-fb50-4559-be4c-f9c5747e5472"
      unitRef="usd">561000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i14e3f4af542345b1913d9608046945a8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzIxMzE_3eab7172-91a7-41ee-8a08-44bf563a357a"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="id46afb35127d450e9e5b64faa1484510_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzIxNjQ_3cc6c1ca-8941-4d32-88e4-584e26e83918"
      unitRef="usd">800000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNjg_517cc09a-38cf-4107-a249-12dbaf4bcc0d">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the total gross amounts of UTBs were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzItMS0xLTEtNTU1NTQ_db42c626-c43a-472f-98c9-3faa80e1255d"
      unitRef="usd">3352000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzItMy0xLTEtNTU1NTQ_eee64919-dbfb-4497-97a3-49a9f3639805"
      unitRef="usd">3287000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzItNS0xLTEtNTU1NTQ_c2cf3ced-d8e4-41c4-a304-009cfa6f7fba"
      unitRef="usd">3061000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzMtMS0xLTEtNTU1NTQ_97097023-05d5-4c8d-8a97-87855e0200e1"
      unitRef="usd">171000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzMtMy0xLTEtNTU1NTQ_632d0fb6-ff69-47c1-8a5b-e5332503fb75"
      unitRef="usd">165000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzMtNS0xLTEtNTU1NTQ_e9d086c5-7299-423d-af09-4f4d90bf9b23"
      unitRef="usd">215000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzQtMS0xLTEtNTU1NTQ_1eaea427-4b71-4723-b1fd-89ec550c211f"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzQtMy0xLTEtNTU1NTQ_c7928666-cd73-4de7-81ac-2e9e7f3d5cef"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzQtNS0xLTEtNTU1NTQ_8e7202e3-f257-44f0-9d83-b7dac9d347fa"
      unitRef="usd">22000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzUtMS0xLTEtNTU1NTQ_9f18faf2-84e1-484f-9242-132ef27a3e8e"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzUtMy0xLTEtNTU1NTQ_7ffec5b3-1195-4d97-a682-254645555beb"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzUtNS0xLTEtNTU1NTQ_76ed95e3-6f5d-4ee9-baea-4dc474fd8111"
      unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzctMS0xLTEtNTU1NTQ_d154ec71-0d37-4432-a611-dcd955777d03"
      unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzctMy0xLTEtNTU1NTQ_03b6e3fb-2017-4ee5-9a68-c985d49eece0"
      unitRef="usd">68000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzctNS0xLTEtNTU1NTQ_f98a2cf1-494a-40d4-bab5-50b0a05c06fa"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzgtMS0xLTEtNTU1NTQ_83663934-6ff1-44f3-8c28-b889b534d8b2"
      unitRef="usd">3546000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzgtMy0xLTEtNTU1NTQ_13cef463-88ae-46d1-a726-7c380171d18f"
      unitRef="usd">3352000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTpiNmRmZTRjYjQzYzY0MGFmYmYyMzY1YWQ2MWExN2NhYy90YWJsZXJhbmdlOmI2ZGZlNGNiNDNjNjQwYWZiZjIzNjVhZDYxYTE3Y2FjXzgtNS0xLTEtNTU1NTQ_d3a94da8-069f-4b6f-bf31-090f2a83c8e4"
      unitRef="usd">3287000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzI3MTE_9ae1c881-49e8-44f3-bcb8-bccffbc92b70"
      unitRef="usd">98000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzI3MTU_6e371402-4f62-440a-8410-69d79b2055bc"
      unitRef="usd">116000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzI3MjI_4eedcf1d-2be6-4a78-ad17-afabce5e53dd"
      unitRef="usd">198000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzMwNDA_40b4f0ab-e842-4d9c-bab9-f5b8ad628716"
      unitRef="usd">881000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzMwNDc_6b7d0873-1d01-467b-9f6c-f3d94140da1f"
      unitRef="usd">783000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzcxNzA_f54bc673-92b5-41ab-953b-b99691c4341c">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, Puerto Rico excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits, primarily federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Audit settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzItMS0xLTEtNTU1NTQ_6995032d-172e-4a61-9a51-c332c30faff0"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzItMy0xLTEtNTU1NTQ_45b3f948-c4a0-4669-9074-32bcc753aac7"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzItNS0xLTEtNTU1NTQ_e293cc8b-5145-4cd0-b3f0-5700b8ddf5d8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzMtMS0xLTEtNTU1NTQ_f2ce497f-22ee-4818-8014-fe2893ea0061"
      unitRef="number">0.078</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzMtMy0xLTEtNTU1NTQ_d1a4f7aa-8bd2-4367-bf98-13801e62484c"
      unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzMtNS0xLTEtNTU1NTQ_3553e147-2ee6-4589-881f-3143ab8c94f6"
      unitRef="number">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzQtMS0xLTEtNTU1NTQ_8ce21228-e989-4391-868b-e2b3e456080d"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzQtMy0xLTEtNTU1NTQ_d806336d-9ad6-458c-bc6e-b136c897ab29"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzQtNS0xLTEtNTU1NTQ_d177ca96-96f5-4f01-95a4-631cd8e917ce"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzUtMS0xLTEtNTU1NTQ_3dea4780-3e1b-4d57-b23c-252b63f0b64f"
      unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzUtMy0xLTEtNTU1NTQ_3a23b40f-6ad5-4f1e-b902-46cb9321814d"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzUtNS0xLTEtNTU1NTQ_d1499823-6a64-4fef-812c-7c07f8d600c2"
      unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzctMS0xLTEtNTU1NTQ_65f644d2-7caa-4aa2-b117-576b1822baf1"
      unitRef="number">0.011</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzctMy0xLTEtNTU1NTQ_e4e00ee5-647b-4175-be30-b2b6c1cfb6f6"
      unitRef="number">0.011</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzctNS0xLTEtNTU1NTQ_ac2b53e3-1e33-400f-894b-7b5e809f09de"
      unitRef="number">0.016</amgn:EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzgtMS0xLTEtNTU1NTQ_42b65d52-00e6-44a7-993e-8e6acc4af8fb"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzgtMy0xLTEtNTU1NTQ_36bad039-8a0d-45dc-8aba-f6aaa7d73243"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzgtNS0xLTEtNTU1NTQ_62f5873c-1b99-4be2-9af3-0893bb3c89f1"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMS0xLTEtOTQ0Njg_61e1f2c4-deae-44a8-872f-bd4a5aeca27a"
      unitRef="number">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMy0xLTEtOTQ4ODE_6b76cbdf-f6c1-47ef-a77e-c7e19fff645b"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktNS0xLTEtOTQ4ODk_fb81ef3b-c939-48bc-aa20-5ecc8776ffe7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMS0xLTEtNTU1NTQ_3b93776c-9e90-4aa2-98ae-bf9e38345eec"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktMy0xLTEtNTU1NTQ_dc614636-d34b-43c9-b5fe-93cb0ad3b293"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzktNS0xLTEtNTU1NTQ_33537be4-c75d-4323-b36f-bb5a356f5e10"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzEwLTEtMS0xLTU1NTU0_9b790add-8de9-440c-b9c7-c905915102c2"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzEwLTMtMS0xLTU1NTU0_2af173d0-753a-4beb-999b-fb1789869376"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzEwLTUtMS0xLTU1NTU0_5471149e-ee19-4e04-8d4b-cfcf47395fec"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzExLTEtMS0xLTU1NTU0_69329ffe-ef1f-4922-8f2e-8276c5a8ba3b"
      unitRef="number">0.121</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzExLTMtMS0xLTU1NTU0_9208c3bb-a0a7-4734-badb-8e24d5223c9a"
      unitRef="number">0.107</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90YWJsZTphNzdmMDljZDNmMTI0NjE5YmU5MzQ2OTU0YTE3MjYxYy90YWJsZXJhbmdlOmE3N2YwOWNkM2YxMjQ2MTliZTkzNDY5NTRhMTcyNjFjXzExLTUtMS0xLTU1NTU0_567875ea-6a64-41f4-bf80-56101374d287"
      unitRef="number">0.142</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzQ0OTM_7820dd21-877f-4952-b747-f1421abacba1"
      unitRef="usd">1900000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzQ0OTc_e6c0ef39-9da6-4b5d-af54-b7ed8b841682"
      unitRef="usd">1400000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzQ1MDQ_e3568364-d4b8-483c-bbdf-f5038e90cc0b"
      unitRef="usd">1900000000</us-gaap:IncomeTaxesPaid>
    <amgn:NumberOfNoticesOnProposedAdditionalTax
      contextRef="i1607fbba52af401f822b87f6c9ca7b4d_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3Xzg3OTYwOTMwNDQzMTI_53801ddc-c53a-4abb-9de6-fdda7d4adbc6"
      unitRef="usd">2</amgn:NumberOfNoticesOnProposedAdditionalTax>
    <amgn:ProposedAdditionalIncomeTax
      contextRef="i1607fbba52af401f822b87f6c9ca7b4d_I20210531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEwOTk1MTE2NDk4ODI_86467cbe-7e86-4804-b124-68c282c1bd6f"
      unitRef="usd">3600000000</amgn:ProposedAdditionalIncomeTax>
    <amgn:RepatriationTaxOnProposedAdditionalTax
      contextRef="i1607fbba52af401f822b87f6c9ca7b4d_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTEvZnJhZzoxNWYzYTViMTE1MzU0MGZlYmJjMmExYWJmNDFmYjhhNy90ZXh0cmVnaW9uOjE1ZjNhNWIxMTUzNTQwZmViYmMyYTFhYmY0MWZiOGE3XzEwOTk1MTE2NDk4OTY_36c5a19c-3b0b-474c-a9ce-180522e3bc96"
      unitRef="usd">900000000</amgn:RepatriationTaxOnProposedAdditionalTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90ZXh0cmVnaW9uOjE4ODZiYzBhZDdjYTRiMjJiOTc5OGIxOTE5NzY3ZDNlXzc2OQ_e163bbd3-815a-44e5-a194-904ffea970f5">Earnings per share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the three years ended December 31, 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90ZXh0cmVnaW9uOjE4ODZiYzBhZDdjYTRiMjJiOTc5OGIxOTE5NzY3ZDNlXzc3Nw_d2922cf7-de9e-4699-a166-a55efc05830c">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzMtMS0xLTEtNTU1NTQ_9f6ba638-3cc7-4ed9-9504-e3f7f706d317"
      unitRef="usd">5893000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzMtMy0xLTEtNTU1NTQ_6f6a5c04-9ed0-4201-88a1-9c9b9468ccff"
      unitRef="usd">7264000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzMtNS0xLTEtNTU1NTQ_14ab7bad-a871-4ae0-8b9b-224a8337f3e3"
      unitRef="usd">7842000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzYtMS0xLTEtNTU1NTQ_97200bcc-2442-4f14-abc0-308681eb0ef7"
      unitRef="shares">570000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzYtMy0xLTEtNTU1NTQ_cbfffef2-1b9e-47f1-aad9-a7c6e826fb86"
      unitRef="shares">586000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzYtNS0xLTEtNTU1NTQ_b0df7951-e203-4d72-9d29-5c57eabfbce9"
      unitRef="shares">605000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzctMS0xLTEtNTU1NTQ_31802af7-00eb-47c8-afde-4aeb24c9a65a"
      unitRef="shares">3000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzctMy0xLTEtNTU1NTQ_a49ac65c-7eac-4217-aba1-19f078eed05f"
      unitRef="shares">4000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzctNS0xLTEtNTU1NTQ_7f9b8de6-8dc4-4c9d-9a9a-2876dfa064b2"
      unitRef="shares">4000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzgtMS0xLTEtNTU1NTQ_20e78705-4988-4dc6-8ccc-d83397db202a"
      unitRef="shares">573000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzgtMy0xLTEtNTU1NTQ_c98cea95-3ba4-4c9e-a2ec-13312e09ba33"
      unitRef="shares">590000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzgtNS0xLTEtNTU1NTQ_bc0f3d43-a459-4df0-af3c-b887f2eb6ab3"
      unitRef="shares">609000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzEwLTEtMS0xLTU1NTU0_e587c2e9-85fe-4eab-af7c-cff409ce283e"
      unitRef="usdPerShare">10.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzEwLTMtMS0xLTU1NTU0_2084c95d-eb56-49e8-b166-bb6d3264f9d6"
      unitRef="usdPerShare">12.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzEwLTUtMS0xLTU1NTU0_f47c7c7d-c31a-45c9-a00b-5af092b41722"
      unitRef="usdPerShare">12.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzExLTEtMS0xLTU1NTU0_9a524d7c-8e53-4256-8cdd-08be269c712e"
      unitRef="usdPerShare">10.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzExLTMtMS0xLTU1NTU0_54f2857c-a07c-4340-93c3-2dbe1d1e02d9"
      unitRef="usdPerShare">12.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTQvZnJhZzoxODg2YmMwYWQ3Y2E0YjIyYjk3OThiMTkxOTc2N2QzZS90YWJsZTo1OTVhZTIzODllY2M0NmMxOTZkNzJiZTJlYTUwNWU2Mi90YWJsZXJhbmdlOjU5NWFlMjM4OWVjYzQ2YzE5NmQ3MmJlMmVhNTA1ZTYyXzExLTUtMS0xLTU1NTU0_112402f4-07d0-4bfe-be88-e31762d8ab6e"
      unitRef="usdPerShare">12.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzgxNTc_4f153580-99a0-4c4e-8292-84b377e1e32f">Collaborations&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i)&#160;active participants in the activity and (ii)&#160;exposed to significant risks and rewards dependent on the commercial success of the activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into collaborative arrangements for the R&amp;amp;D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized under these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2020, we acquired a 20.5% stake in BeiGene for approximately $2.8&#160;billion in cash as part of a collaboration to expand our oncology presence in China. For additional information regarding our equity investment in BeiGene, see Note 9, Investments. Under the collaboration, BeiGene began selling XGEVA in 2020, BLINCYTO in 2021 and KYPROLIS in early 2022 in China, and Amgen shares profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we jointly develop a portion of our oncology portfolio with BeiGene, which shares in global R&amp;amp;D costs by providing cash and development services of up to $1.25&#160;billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside China, Amgen will also pay royalties to BeiGene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, net costs recovered from BeiGene for oncology product candidates were $220&#160;million and $225&#160;million, respectively, and were recorded as an offset to R&amp;amp;D expense in the Consolidated Statements of Income. During the year ended December 31, 2021, product sales from Amgen to BeiGene under the collaboration were $72&#160;million and were recorded in Product sales in the Consolidated Statements of Income. During the year ended December 31, 2021, profit and loss share expenses related to the initial product-specific commercialization period were $64&#160;million and were recorded primarily in SG&amp;amp;A expense in the Consolidated Statements of Income. Product sales from Amgen to BeiGene and profit and loss share expenses were not material during the year ended December 31, 2020. Amounts owed from BeiGene for product sales were $21&#160;million and $22&#160;million as of December 31, 2021 and 2020, respectively, which are included in Trade receivables, net, in the Consolidated Balance Sheets. Net amounts owed from BeiGene for cost recoveries and profit and loss share payments were $61&#160;million and $99&#160;million as of December 31, 2021 and 2020, respectively, which are included in Other current assets in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis Pharma AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are in a collaboration with Novartis to jointly develop and commercialize Aimovig. On January 31, 2022, concurrent with the settlement of the previously disclosed litigation between Amgen and Novartis we modified the terms of the collaboration. See Note 19, Contingencies and commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangement through December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, Amgen and Novartis jointly developed and collaborated on the commercialization of Aimovig. Amgen, as the principal, recognized product sales of Aimovig in the United States, shared U.S. commercialization costs with Novartis and paid Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig (the ex-U.S. Novartis Rights). Novartis paid Amgen double-digit royalties on net sales of the product in the ex-U.S. Novartis Rights territories and funded a portion of global R&amp;amp;D expenses. In addition, Novartis was required to make a payment to Amgen of up to $100&#160;million if certain commercial and expenditure thresholds were achieved with respect to Aimovig in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangement after January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the amendment effective January 1, 2022, Novartis retains the ex-U.S. Novartis Rights and will continue to pay double-digit royalties on net sales in the ex-U.S. Novartis Rights territories. In the United States, Novartis will no longer collaborate with Amgen, share Aimovig commercialization costs or pay milestones and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide. In the United States, Novartis will no longer collaborate with Amgen or share Aimovig commercialization costs and Amgen will no longer pay royalties to Novartis on sales of Aimovig. Amgen and Novartis will continue to share development expenses worldwide&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen manufactures and supplies Aimovig worldwide. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021, 2020 and 2019, net costs recovered from Novartis for migraine products were $160 million, $192 million and $187 million, respectively, and were recorded primarily in SG&amp;amp;A expense in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due to Novartis for Aimovig were $116&#160;million, $139 million and $115 million, respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2021, 2020 and 2019, royalties due from Novartis for Aimovig were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kyowa Kirin Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2021, we closed our collaboration and licensing agreement with KKC to jointly develop and commercialize an anti-OX40 fully human monoclonal antibody (AMG 451) worldwide, except in Japan. AMG 451 is for the treatment of atopic dermatitis, with potential for treatment of other autoimmune diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we will lead the global development, manufacture and commercialization of AMG 451, except in Japan. KKC will co-promote AMG 451 with Amgen in the United States and have opt-in rights to co-promote AMG 451 in various other markets outside the United States, including in Europe and Asia. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We made an upfront payment of $400&#160;million to KKC that was recognized in R&amp;amp;D expense in the third quarter of 2021. Amgen and KKC will share equally the global development costs, except in Japan, and the U.S. commercialization costs. Outside the United States and Japan, any commercialization costs incurred by KKC will be reimbursed by Amgen. We may also be required to make milestone payments of up to $850&#160;million contingent upon the achievement of certain regulatory events and commercial thresholds. We will also pay KKC significant double-digit royalties on global sales, except in Japan. Net costs due to KKC were not material during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones that in the aggregate could be significant. We may also incur or have reimbursed to us significant R&amp;amp;D costs if a related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payments of these amounts, however, are contingent upon the occurrence of various future events that have high degrees of uncertainty of occurrence.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEzODk_0735a70d-9c22-45bb-98fb-08e2e0372e4d"
      unitRef="number">0.205</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzE0NDQ_e6c1da8e-303c-4bb5-b56b-769ac508495f"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="ib96fb2589f6d4eb6be9dc2329f9e3e9a_D20200102-20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzIwNzU_2cb9450e-ab17-43c0-abcb-b02a499f8a76"
      unitRef="usd">1250000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i0f3e83663ab7448f9d89322ae4c89d53_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzkzNDU4NDg4NzMzMjM_5ba56690-2b08-454d-9d28-ca50dca58e28"
      unitRef="usd">220000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i27f3367e2504432e9241fb90f97792c4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzI1NzE_eb90a917-adc2-457a-887a-bd033a2a17dc"
      unitRef="usd">225000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5cbd73363fbf4d9f8ecace3f93987d50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzAxMzE_18ce9359-92c7-4511-ada2-6c21460c9d19"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <amgn:ProfitAndLossShareOfExpenses
      contextRef="i4e5fbb50886445c0a5885afd85d45f80_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NjkzMjI_a6508401-7a58-47b3-8909-62bf35f2af3b"
      unitRef="usd">64000000</amgn:ProfitAndLossShareOfExpenses>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i81e3c18d48c546e08d8c78658032b099_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3NTA_8bed0b27-86ff-4934-8fbf-670f13425f36"
      unitRef="usd">21000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i19738ccb7dec4ff194a1f820e6610a46_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3NjM_e8328b45-0127-45d1-b4d1-364f91ded1e3"
      unitRef="usd">22000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i558ccb32284541ab8aa7100457c3f800_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3NzY_e3c29f60-8ecd-466b-9e16-754f11a9ddba"
      unitRef="usd">61000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="i03daed3f241a433a99f8a3e456d25e18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0Xzk4OTU2MDQ2NzI3ODk_756b07d7-3a4d-425f-ac87-3561062aea5f"
      unitRef="usd">99000000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment
      contextRef="i47ecb19fa54443e6a1c8180a5b4978c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEwOTk1MTE2NTk2NDQ_5befbc0b-b03d-4f21-b0d6-e48c05649141"
      unitRef="usd">100000000</amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="ic20c274ca8254d83931002497f749d6a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzE2NDkyNjc0NTU3NTk_7654101a-aa4f-41a2-a101-1a4ce9d50e79"
      unitRef="usd">160000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i22383ad8ad98490387eb40c5fefbfaa1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ0MDY_69816b01-c9fe-4607-838a-4b4a668cec61"
      unitRef="usd">192000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="id5ded1767e5544259a8f3222f3f0b097_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ0MTM_ed7edfac-9b5d-4da4-ae2e-c1ccb28df5e5"
      unitRef="usd">187000000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RoyaltyExpense
      contextRef="i83cee794a408414492622e90651c37e8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ3ODI_41d68a12-3359-4974-aa13-18a06d20ebc1"
      unitRef="usd">116000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ida0758ef280b4ca39e8e5f8ec2aab3e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ3ODY_1830f9ba-0d04-48b9-ac7e-8f0540d32649"
      unitRef="usd">139000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="id1f36a12191440cbbf96604a76e7170e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzQ3OTM_7bccdea9-3e82-475d-8e8c-fc49b5765205"
      unitRef="usd">115000000</us-gaap:RoyaltyExpense>
    <amgn:UpFrontPayment
      contextRef="i4c8816fa7e9c49cba0ab2b9df683b53e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEwOTk1MTE2NDIwNzY_80ac00f7-fb5d-4637-9d79-53896447daaa"
      unitRef="usd">400000000</amgn:UpFrontPayment>
    <amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments
      contextRef="i8bdd4a592dc14b00a7340e260c55ac4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMTcvZnJhZzpiNjRlZWQwNTZhZjY0ODhlYWVkMDRjNjZiNDQ2MjljNC90ZXh0cmVnaW9uOmI2NGVlZDA1NmFmNjQ4OGVhZWQwNGM2NmI0NDYyOWM0XzEwOTk1MTE2NDIxMjI_0321ce7d-5fd8-45a2-ac30-6a58c2c0f643"
      unitRef="usd">850000000</amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxNDE_153a4d1e-8bad-4e3f-9812-dbb812ac40c0">Investments&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents in the above table excludes bank account cash of $733 million and $802 million as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by contractual maturity were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021 and 2020, realized gains and losses on interest-bearing securities were not material. For the year ended December 31, 2019, realized gains on interest-bearing securities were $92 million and realized losses were not material. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments in equity securities with readily determinable fair values &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $611 million and $477 million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2021, 2020 and 2019, net unrealized gains on publicly traded securities were $161&#160;million, $174&#160;million and $112&#160;million, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2021, 2020 and 2019, were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments of $262 million and $203 million in equity securities without readily determinable fair values as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent ass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ets in the Consolidated Balance Sheets. For the year ended December 31, 2021, gains due to upward adjustments on these securities were $152&#160;million, and gains realized on the dispositions of these securities were $41&#160;million; for the years ended December 31, 2020 and 2019, gains due to upward adjustments and gains realized upon dispositions of these securities were not material. For the years ended December 31, 2021, 2020 and 2019, downward adjustments to the carrying values of these securities were not material. Adjustments were based on observable price transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2020, we acquired a 20.5% ownership interest in BeiGene for $2.8&#160;billion, of which $2.6&#160;billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&amp;amp;D. Our equity investment in BeiGene is included in Other noncurrent assets in the Consolidated Balance Sheets.&lt;/span&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our equity investment is accounted for under the equity method of accounting due to our ability to exert significant influence over BeiGene. See Note 1, Summary of significant accounting policies, for factors in concluding our ability to exert significant influence over BeiGene. The fair value of equity securities acquired exceeded our proportionate share of the carrying value of the underlying net as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sets of BeiGene by approximately $2.4&#160;billion. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity method of accounting requires us to identify and allocate amounts to items that give rise to the basis difference and to amortize these items over their useful lives. This amortization, along with our share of the results of operations of BeiGene, is included in Other income, net, in our Consolidated Statements of Income. Recognition occurs one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, the carrying value of the investment was reduced by our share of BeiGene&#x2019;s net losses of $265 million and $229&#160;million, respectively, and amortization of the basis difference of $172&#160;million and $109&#160;million, respectively. During the years ended December 31, 2021 and 2020, we increased the carrying value by $50 million and $569&#160;million, respectively, as a result of our purchase of additional shares of BeiGene. In addition, during the years ended December 31, 2021 and 2020, the carrying value increased by $265&#160;million and $34&#160;million, respectively, from the impact of other BeiGene ownership transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, our ownership interest in BeiGene was approximately 18.4% and 20.5%, respectively. As of December 31, 2021 and 2020, the carrying value of our investment in BeiGene was $2.8 billion and $2.9 billion, respectively. As of December 31, 2021 and 2020, the fair value of our investment in BeiGene was $5.1 billion and $4.9 billion, respectively. We believe that as of December 31, 2021, the carrying value of our equity investment in BeiGene is fully recoverable. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 8, Collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neumora Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257&#160;million, which is included in Other noncurrent assets in the Consolidated Balance Sheets, in exchange for a $100&#160;million cash payment and $157&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of December 31, 2021, our ownership interest in Neumora remained at approximately 25.9%, and the fair value of our investment was $220&#160;million. Accordingly, during the fourth quarter of 2021, we recognized a loss of $37&#160;million for the reduction in the fair value in Other income, net, in the Consolidated Statements of Income. For information on determination of fair values, see Note 17, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Limited partnerships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held limited partnership investments of $573 million and $496 million as of December 31, 2021 and 2020, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. These investments, which are primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2021, unfunded additional commitments to be made for these investments during the next several years were $185&#160;million. For the years ended December 31, 2021, 2020 and 2019, net gains recognized from our limited partnership investments were $143 million, $241&#160;million and $27 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxNTA_fa6a0e7e-da14-4d7a-a922-47e4aa6b0593">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtMi0xLTEtNTU1NTQ_17cf73ed-9a2e-476f-8d3b-181b16a80d3e"
      unitRef="usd">47000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtNC0xLTEtNTU1NTQ_f0c8b686-51f7-4bde-bfe8-ebfec447b1f7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtNi0xLTEtNTU1NTQ_761740f8-2bc3-49d9-8d5b-765858908283"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEtOC0xLTEtNTU1NTQ_41930ac8-8959-4169-bacb-d8e2ca594f0e"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItMi0xLTEtNTU1NTQ_6e7e0bf2-be88-4718-86da-e18796e7de4a"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItNC0xLTEtNTU1NTQ_06df8371-0044-46a1-a74f-afbdadb7e790"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItNi0xLTEtNTU1NTQ_6cbca5f9-c70d-4ce7-a390-f7d643754bf2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzItOC0xLTEtNTU1NTQ_9e00b630-22a7-4438-ad79-c1187653823e"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktMi0xLTEtNTU1NTQ_5d907719-08b4-4820-b7f1-17dd9b38278c"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktNC0xLTEtNTU1NTQ_80e74373-63e8-4651-a858-97acc7f7567d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktNi0xLTEtNTU1NTQ_836c3e38-2605-4e71-8da5-c229106348d7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzktOC0xLTEtNTU1NTQ_8d608975-f968-4102-ac5d-592f479bc608"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTItMS0xLTU1NTU0_702c270a-668e-4431-bc89-33eae90bb100"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTQtMS0xLTU1NTU0_38f21fc2-fed4-4333-8776-79c729f5f62f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTYtMS0xLTU1NTU0_ec10c2f0-65a8-48aa-bde9-4e97b60a619b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzEwLTgtMS0xLTU1NTU0_3a5ba063-26d5-4767-9aa4-1e77b53a2ee7"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTItMS0xLTU1NTU0_3ae9d687-c754-4ecb-a033-013797aebaff"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTQtMS0xLTU1NTU0_5e4f9ce8-7025-47bb-abb6-711398d5762c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTYtMS0xLTU1NTU0_da50eb9c-0c0e-46d4-b9c6-84b8caca3533"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTphMjZlNjA5Zjc5YTM0OWUxYWE5NmY1ZjA0Yjk5ZTVmOC90YWJsZXJhbmdlOmEyNmU2MDlmNzlhMzQ5ZTFhYTk2ZjVmMDRiOTllNWY4XzExLTgtMS0xLTU1NTU0_b806429f-6289-4c88-af99-36f60ce1aa22"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtMi0xLTEtNTU1NTQ_cf910fce-39f1-440c-9f58-0155aa12629d"
      unitRef="usd">129000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtNC0xLTEtNTU1NTQ_fcd3becd-75a4-4771-ac39-aadcc6a94a1a"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtNi0xLTEtNTU1NTQ_66ce7809-55a6-4c78-be3b-38eba67491c0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEtOC0xLTEtNTU1NTQ_121c137d-d6e8-4e30-8dc3-43c0424ceb4f"
      unitRef="usd">130000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItMi0xLTEtNTU1NTQ_11714b60-1f54-4d54-ae8b-5631ad6de043"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItNC0xLTEtNTU1NTQ_d775bf79-cd24-44fe-9c38-4a1339a44b77"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItNi0xLTEtNTU1NTQ_10c8c52b-1b53-4506-8402-a429b101595a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzItOC0xLTEtNTU1NTQ_d576bb46-bd06-4d5a-bb70-de2cc79e8d6e"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktMi0xLTEtNTU1NTQ_7037222f-d30e-488f-8116-01db283a8422"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktNC0xLTEtNTU1NTQ_b3452e55-ea6b-4977-87de-51502744d498"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktNi0xLTEtNTU1NTQ_a8c81482-2a5e-4c16-9d3d-6da386fb0465"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzktOC0xLTEtNTU1NTQ_126d1bd2-afa7-4f7b-93b2-09dfbd27f6b5"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i811e98c080a8445ab332e5093987caf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTItMS0xLTU1NTU0_f87b91d5-9f3b-4547-8a7f-7c2f1a7ac152"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i811e98c080a8445ab332e5093987caf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTQtMS0xLTU1NTU0_a9e9e270-cf32-463d-8eda-1049df300133"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i811e98c080a8445ab332e5093987caf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTYtMS0xLTU1NTU0_b0849009-fa0d-4297-94fb-7018649515c3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i811e98c080a8445ab332e5093987caf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEwLTgtMS0xLTU1NTU0_ac3f679e-cff5-43ff-8f8e-69ce38b10db3"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTItMS0xLTU1NTU0_a49e6463-93e4-47ee-a2bb-06c85f65f2be"
      unitRef="usd">9844000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTQtMS0xLTU1NTU0_8f3cd67f-0ae1-498c-80a3-cf913b028e19"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTYtMS0xLTU1NTU0_3dd02012-aab6-4741-b1ea-47282450781c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTo1ZDQxOGViMDBkM2U0Y2VhYmMzNmE0YTFjYzIxY2FjMy90YWJsZXJhbmdlOjVkNDE4ZWIwMGQzZTRjZWFiYzM2YTRhMWNjMjFjYWMzXzEzLTgtMS0xLTU1NTU0_9464426e-863c-4c34-a330-b7405d4adf6f"
      unitRef="usd">9845000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxMzA_63947dfd-5e69-48f3-82ae-fed3a93a8c34">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if4b2c07d94924b70a99e1b31e4959623_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzItMi0xLTEtNTU1NTQ_b2c18254-56e0-4ade-8b59-38ac358e249f"
      unitRef="usd">7256000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzItNC0xLTEtNTU1NTQ_0226f139-50e5-4270-8192-fdad6a741d0c"
      unitRef="usd">5464000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if4b2c07d94924b70a99e1b31e4959623_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzMtMi0xLTEtNTU1NTQ_66bceca9-3b9c-448c-8b89-ee10f2d917fc"
      unitRef="usd">48000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzMtNC0xLTEtNTU1NTQ_a353fb02-1352-4900-8a4a-ab146f14a702"
      unitRef="usd">4381000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if4b2c07d94924b70a99e1b31e4959623_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzUtMi0xLTEtNTU1NTQ_9e1a9d99-5edf-4b92-8626-86a62e863e0f"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1028f88f96fe4c0e9e936d5aa4799bcf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZToxYTFiMjU5MTJlNDA0NjljYmY0YjgxOWRjYmI3MDRhYi90YWJsZXJhbmdlOjFhMWIyNTkxMmU0MDQ2OWNiZjRiODE5ZGNiYjcwNGFiXzUtNC0xLTEtNTU1NTQ_08c0b8aa-724b-4235-b63b-94c20e05167d"
      unitRef="usd">9845000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:Cash
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQ3NQ_766af9e5-9e9e-40c1-934c-b9a87abef4d6"
      unitRef="usd">733000000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQ4Mg_6f456231-5e0e-4ed5-9242-94fef0d988af"
      unitRef="usd">802000000</us-gaap:Cash>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzYxMzU_e7d45af0-416f-4f11-9b9a-680409cc9f93">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of available-for-sale investments by contractual maturity were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzItMi0xLTEtNTU1NTQ_0cac917d-d147-4167-84e2-f21a206e97bc"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzItNC0xLTEtNTU1NTQ_cf0346e4-c6a2-4224-93cb-b6d0627f72c0"
      unitRef="usd">9795000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzMtMi0xLTEtNTU1NTQ_ebfbed0c-7e91-47b2-b2cd-0158f9eefb7f"
      unitRef="usd">0</amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
    <amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzMtNC0xLTEtNTU1NTQ_1b41d623-9059-4eca-b095-a79895fa3a69"
      unitRef="usd">50000000</amgn:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzgtMi0xLTEtNTU1NTQ_990d5ff3-3d59-4ac5-9142-bda567410e3f"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90YWJsZTplODk1MmI2YTE5MzE0ZTJjYjA1ZGI2ZDVjOGI2ODgwNy90YWJsZXJhbmdlOmU4OTUyYjZhMTkzMTRlMmNiMDVkYjZkNWM4YjY4ODA3XzgtNC0xLTEtNTU1NTQ_03b64c65-28b3-48f7-a2f2-1c2fa3f9adb0"
      unitRef="usd">9845000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ic6bedbb0fb8544608b6b4b38788612de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzgxMQ_f5c47ff2-e51e-4e08-801c-62021f51af3b"
      unitRef="usd">92000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id775784f91834b37bd5778c4af33ff82_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI0NTA_24b15fef-1079-4102-a4d7-df34ede09af6"
      unitRef="usd">611000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0685790a88a441c3b4731096daf74bcb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI0NTc_eac96ac7-cafa-4ec3-8dda-cacea59b2b78"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNDAzODY_1d85c37b-fae2-4d5a-b284-e5248eb10aca"
      unitRef="usd">161000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI2NzI_8e1c1464-dcde-4f0b-8ec2-538eb3181758"
      unitRef="usd">174000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI2NzY_75ad99db-b0bb-427b-8ff0-163bfebc28bc"
      unitRef="usd">112000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="id775784f91834b37bd5778c4af33ff82_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI4NTQ_86061f95-005c-4c61-959e-4f9fae474cc4"
      unitRef="usd">262000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i0685790a88a441c3b4731096daf74bcb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzI4NjE_73fe75ba-806e-4932-b19f-246f727851d6"
      unitRef="usd">203000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4NjIyMTg_1cd66b31-6c66-47a2-9c26-b77892d03f06"
      unitRef="usd">152000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <amgn:EquitySecuritiesRealizedGainLossOnDisposal
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4NjIyMzI_829f9b79-b1c9-4311-8fda-f85600e1006e"
      unitRef="usd">41000000</amgn:EquitySecuritiesRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQxMjY_6044e9b1-fa6e-4b49-985d-964bbc987044"
      unitRef="number">0.205</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQxNjM_199c2f2c-67c0-41b5-af24-64808826c6d6"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQxNzY_167e00ff-7867-496d-9b91-c218f9aee533"
      unitRef="usd">2600000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="ib69e5cff7c72466aa64106c866eef4f2_I20200102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzQ1NDc_b87d1ef5-7aaf-408b-bb27-53586ae62b0a"
      unitRef="usd">2400000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icc49ed11c95a425c91f0d42a0e3a802b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzUyNDk_ff92e33c-93d5-4b46-9b5a-75e54e71b0a5">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i356b9dbd15c04f05b6aa947471d7ecc0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzUyNTU_89a42988-b5e3-413d-9cec-fb7f9c786a43">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczNDA_7f34f84a-3e66-439d-bc85-27321fc71900"
      unitRef="usd">-265000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczMjc_cdd4d582-886b-4fac-b183-a72a41bec832"
      unitRef="usd">-229000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4Njg5NjM_97f52f07-cddb-4d03-b01c-dc37860bc3c0"
      unitRef="usd">172000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczNjE_427dc9d4-a35a-4b1a-b3e7-dc53339f1263"
      unitRef="usd">109000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0MDU_8853ed36-1ad7-4db4-a8f2-c2a0d01c826d"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDczODk_64033b27-ac36-48fd-94c8-6c840ee2dd18"
      unitRef="usd">569000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <amgn:EquityMethodInvestmentChangeInCarryingValueOther
      contextRef="ic1ebbd7db4a1454cac5a273742c33741_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTQ4NTc_e49aef8d-2532-4636-afc7-b7838d627aa7"
      unitRef="usd">265000000</amgn:EquityMethodInvestmentChangeInCarryingValueOther>
    <amgn:EquityMethodInvestmentChangeInCarryingValueOther
      contextRef="i0ae9a734c43c437dabf279b6614b575b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4Njg5NDg_f2bb85a0-3208-4951-942b-a0a8bd6d7bf0"
      unitRef="usd">34000000</amgn:EquityMethodInvestmentChangeInCarryingValueOther>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkwMjI_da3bfb21-ec8c-475d-8c9c-16205a85b24c"
      unitRef="number">0.184</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkzMTQ_c374f9df-9d6f-4dc0-b13c-43b0c1585ae1"
      unitRef="number">0.205</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzU4NDU_bf19de0a-795f-42e4-8436-37b7b4cd35c4"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkyODE_f16d13aa-dc71-488b-a74e-844dacb70270"
      unitRef="usd">2900000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkyODk_7cc6b98b-b781-43b6-bce5-01ed27a89690"
      unitRef="usd">5100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzE2NDkyNjc0NDkyOTQ_8d936709-5a1f-42ee-b65d-22eac2ceff25"
      unitRef="usd">4900000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie26bf44881b14ed4b71997783873d549_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0MjY_56d74636-2dbb-45cb-b6eb-246a5e59d85b"
      unitRef="number">0.259</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ie26bf44881b14ed4b71997783873d549_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0MzQ_62d21149-c351-4b9f-88a7-f2dd00d23665"
      unitRef="usd">257000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i8bdea1c8311e41d9a8dd2e5681a38379_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0NDc_e0e76844-3cab-4a68-b715-a71a39a0405f"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
      contextRef="i8bdea1c8311e41d9a8dd2e5681a38379_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0NDk_b4e9396c-f648-44a4-a4bc-28fbec4121e8"
      unitRef="usd">157000000</us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id2bdf24151064c60a96102ab1941f91f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTQ5MjE_2d97655c-5be2-4bfd-bb3c-ec4b29c6d00f"
      unitRef="number">0.259</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="id2bdf24151064c60a96102ab1941f91f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTUwMzc_6a965b3e-e4bc-43e5-a2f0-5cdfcac5ef24"
      unitRef="usd">220000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <amgn:EquityMethodInvestmentChangeInCarryingValue
      contextRef="i05cf3220a1054a8f8f5e45eba0b0f1b1_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzkzNDU4NDg4NjI5NDc_7c266b91-670e-480b-addd-fed48ac5d517"
      unitRef="usd">37000000</amgn:EquityMethodInvestmentChangeInCarryingValue>
    <us-gaap:AlternativeInvestment
      contextRef="i3795b0430f51414baeabe5e24d635ce9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDI5NDg_00654ddf-b986-44ab-a374-d144a9868c0c"
      unitRef="usd">573000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment
      contextRef="ic5e3474cb0114feba5cd13cc8ae2c916_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDI5NTY_622de112-cc9e-4072-aa1a-c59b8be1f500"
      unitRef="usd">496000000</us-gaap:AlternativeInvestment>
    <us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0Xzg3OTYwOTMwNTE5Mzk_33d4bf0a-0c6d-4455-b17b-8c45cc39cbbe"
      unitRef="usd">185000000</us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="idaf2649fff4c4de298cd836c69f79d22_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDc0ODg_41089115-e487-41c8-917f-b57ff8b43d56"
      unitRef="usd">143000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i96eda76077d241f081c28bb4ab52763e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDM3MjU_e4746730-c205-4b21-a2da-b09583821dba"
      unitRef="usd">241000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="idfa8066544024fa19ebe0b52eeaba353_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjAvZnJhZzowOTkxYjYwZmY5Mzk0ZWNjOTU4NjQ5MWYyZGI5MGE4NC90ZXh0cmVnaW9uOjA5OTFiNjBmZjkzOTRlY2M5NTg2NDkxZjJkYjkwYTg0XzEwOTk1MTE2NDM3MzA_d7b32b17-4004-4d1f-a488-8702891b4bee"
      unitRef="usd">27000000</amgn:AlternativeInvestmentNetGainLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90ZXh0cmVnaW9uOjc4MGExNTNlYjM1MDQ2NTU5MDVjMjc4YWUyMTk1Nzk5Xzgy_787af64a-4b92-42a0-93fd-a17e13693200">Inventories&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90ZXh0cmVnaW9uOjc4MGExNTNlYjM1MDQ2NTU5MDVjMjc4YWUyMTk1Nzk5Xzgx_8e9ff5ed-395a-4287-af7e-cbd8802fe96c">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzItMS0xLTEtNTU1NTQ_6dd1fa9a-86df-479f-8dbd-ae4280255cbf"
      unitRef="usd">647000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzItMy0xLTEtNTU1NTQ_f409a983-b7b6-4bf3-89cb-641b2b20570e"
      unitRef="usd">486000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzMtMS0xLTEtNTU1NTQ_7e51d5e5-f782-44da-9b0c-8ccb5dd83715"
      unitRef="usd">2367000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzMtMy0xLTEtNTU1NTQ_cbe90735-bb3a-4105-95f6-1676fd9b5f49"
      unitRef="usd">2437000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzQtMS0xLTEtNTU1NTQ_0b3da261-5595-436b-9f0e-9ebd6249d28e"
      unitRef="usd">1072000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzQtMy0xLTEtNTU1NTQ_1993acb7-c7d6-4df9-8cd8-a84c4d78bf06"
      unitRef="usd">970000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzUtMS0xLTEtNTU1NTQ_d2d5748f-1824-4b72-b5db-07d62e6cccb9"
      unitRef="usd">4086000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjMvZnJhZzo3ODBhMTUzZWIzNTA0NjU1OTA1YzI3OGFlMjE5NTc5OS90YWJsZTpiOTVkODc3NmJmNWY0NTMwYmE3ODA5MWQ4MGY2MTRlOS90YWJsZXJhbmdlOmI5NWQ4Nzc2YmY1ZjQ1MzBiYTc4MDkxZDgwZjYxNGU5XzUtMy0xLTEtNTU1NTQ_ca3db049-e875-43aa-a623-0f832abcc200"
      unitRef="usd">3893000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzQ3NA_b4e0d5c9-de21-4dff-8043-180b5ad20e63">Property, plant and equipment&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;life&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021, 2020 and 2019, we recognized depreciation and amortization expense associated with our property, plant and equipment of $644 million, $640 million and $635 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Geographic information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzQ2NA_b6424a38-5ee4-4b98-8c7f-e17579efb3b0">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;life&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8-12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzItMy0xLTEtNTU1NTQ_13cad7e8-dd0e-403c-9aff-d3ccc7898efe"
      unitRef="usd">279000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzItNS0xLTEtNTU1NTQ_5471489c-f502-4583-ab01-401d2e6c71b0"
      unitRef="usd">259000000</us-gaap:Land>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9a675d05a0804539a7d21138c1722b7c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiYzA3ZWY2MGY4NTc0NzBmOGY3Mzc2MzYzMWNkMDBmN180_dda30299-cd98-4087-a7e4-e9ad3dc9cbf2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if6a6e2eaf0994cebafac018b5e3fe2b3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiYzA3ZWY2MGY4NTc0NzBmOGY3Mzc2MzYzMWNkMDBmN183_385b1c4b-51c7-4e8c-8236-58e8347f7c96">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtMy0xLTEtNTU1NTQ_f84bae1a-1798-4b10-b59b-266f56883a79"
      unitRef="usd">4028000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzMtNS0xLTEtNTU1NTQ_a2f526bf-96c2-41e9-8be6-48652d6808d4"
      unitRef="usd">3857000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9a0a9ca1a0cd4f579495b0fabf37ebe5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2YzRhN2ZlY2Y3ZjU0NWUzYmZmY2NiZjQ1MjE4NjA4MF80_8fe72b11-4fad-413e-a285-f4cc27d2abce">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ieccfdc26f7e24e8784d8e7068a04a895_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2YzRhN2ZlY2Y3ZjU0NWUzYmZmY2NiZjQ1MjE4NjA4MF83_b74b31af-314f-4cd3-9679-77eb605dbc14">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtMy0xLTEtNTU1NTQ_0df83310-b863-4fa4-a283-af1f38b1ad05"
      unitRef="usd">3080000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzQtNS0xLTEtNTU1NTQ_d6e2ead3-9a43-41fb-bb0f-d09972da38fe"
      unitRef="usd">2865000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3cf9f313b68c4865a53543614de8354e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiOWQwYjI1MzhhZDQ0Mjc5YjA1MGJkZjIyOThkNDM4NF80_26cf4178-54fa-43f9-8e80-bb0ad4e36284">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8902072edc954d06a4fa32d21142b284_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiOWQwYjI1MzhhZDQ0Mjc5YjA1MGJkZjIyOThkNDM4NF83_fcebd41e-3374-4692-8a9b-eb5d65ead25a">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <amgn:LaboratoryEquipment
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtMy0xLTEtNTU1NTQ_707cc371-c7c7-41e7-a611-af3953ecb6e8"
      unitRef="usd">1193000000</amgn:LaboratoryEquipment>
    <amgn:LaboratoryEquipment
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzUtNS0xLTEtNTU1NTQ_fa986fe4-94ce-4724-a5d7-c063628b71f0"
      unitRef="usd">1257000000</amgn:LaboratoryEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5451fcd71feb4721a719c87aa7225d50_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzYtMS0xLTEtNTU1NTQ_1675a3f6-5bfb-4342-8832-ce903318809d">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <amgn:FixedEquipment
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzYtMy0xLTEtNTU1NTQ_6ab1ab2d-7f6c-4eee-8a01-c3d5692e6906"
      unitRef="usd">2402000000</amgn:FixedEquipment>
    <amgn:FixedEquipment
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzYtNS0xLTEtNTU1NTQ_c9dc1f26-ed6c-44bf-ab33-1b860098e6af"
      unitRef="usd">2406000000</amgn:FixedEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ice11863ea1f641c982d327a9700952dc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2ODdlODE2YTU5MTc0ZmI5YmRjNTg0OTczM2Y5NjhmOV80_5b18dd9e-c29c-4b24-b6ba-a5f3d3d58ef7">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iaaff719184b24d3c8e81d58f99addf22_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2ODdlODE2YTU5MTc0ZmI5YmRjNTg0OTczM2Y5NjhmOV83_906af8b7-26c4-4869-bc4a-1db6a5598fb9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctMy0xLTEtNTU1NTQ_38333e52-4f9b-498e-bfe7-7eff05349dbe"
      unitRef="usd">1151000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzctNS0xLTEtNTU1NTQ_4be13fa8-8e22-468d-ae61-797ff87918b7"
      unitRef="usd">1216000000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie80ef32cb43043a09a41633946a002ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjoyYTAwOGMxMDhiZWM0OGRlYjNhMGM3OGE2OTAwY2EyNF80_0b6f89b3-1d68-4bac-b0ee-ca137a97351f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2ac8514d57744567b3fefdd3b73af1a4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtMS0xLTEtNTU1NTQvdGV4dHJlZ2lvbjoyYTAwOGMxMDhiZWM0OGRlYjNhMGM3OGE2OTAwY2EyNF83_7979d1b7-62f9-4155-8f4b-63e31d2db98e">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtMy0xLTEtNTU1NTQ_fcc6ebe6-d37c-4ec5-9c8c-03fff49a1662"
      unitRef="usd">862000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzgtNS0xLTEtNTU1NTQ_a3ae27d3-7882-411a-8092-16b4079e4234"
      unitRef="usd">1091000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzktMy0xLTEtNTU1NTQ_282dc28e-442a-4fd6-815c-4e97bd794481"
      unitRef="usd">987000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzktNS0xLTEtNTU1NTQ_029ea2f1-3276-49f0-a5df-10dfd4687f91"
      unitRef="usd">915000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEwLTMtMS0xLTU1NTU0_f570686a-5218-4099-84d9-8820de352f79"
      unitRef="usd">13982000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEwLTUtMS0xLTU1NTU0_26aca78a-2085-4b84-b70f-dc28cd769a99"
      unitRef="usd">13866000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzExLTMtMS0xLTU1NTU0_346ec80a-906d-4df3-84aa-8585ddfd4565"
      unitRef="usd">8798000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzExLTUtMS0xLTU1NTU0_21d28b73-c8e8-401c-94d6-e346ef49c4b1"
      unitRef="usd">8977000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEyLTMtMS0xLTU1NTU0_b5bdc160-fc53-4989-854b-244377b9dc4d"
      unitRef="usd">5184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZTphYWUzOTU5MzZjMmE0YzY4YTUwNDY3M2NlYWM4ZmU0Yi90YWJsZXJhbmdlOmFhZTM5NTkzNmMyYTRjNjhhNTA0NjczY2VhYzhmZTRiXzEyLTUtMS0xLTU1NTU0_ca9d73c9-e360-4bbc-952d-6e2cd778aba5"
      unitRef="usd">4889000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzI3Mg_c529b6d1-2cc2-4ff1-a3d3-d1b12ba53b35"
      unitRef="usd">644000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzI3Ng_41fa86c1-c4db-468c-9058-d925acab6769"
      unitRef="usd">640000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzI4Mw_88d7a941-2628-4ee2-9304-49c5d0050d30"
      unitRef="usd">635000000</us-gaap:Depreciation>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90ZXh0cmVnaW9uOmQyZWJhYjMwODBmZTQ1ZDA4OTU2OGZmZTRiM2ZjODI2XzQ3OA_c09bc52e-e0fc-4e5f-8ee0-5e3b699aceef">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if24c03a5fa36492bb701fd1cf35c078e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzItMS0xLTEtNTU1NTQ_315dd3be-7c33-4fc9-b7ac-446ea88aba5e"
      unitRef="usd">2801000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icf9b0d86322746389e6bcdfa6dca160c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzItMy0xLTEtNTU1NTQ_8e7d1ff7-eeb1-40c4-8114-729e6242de8a"
      unitRef="usd">2473000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i873c3b8314524d3fad876f18c5598ab3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzMtMS0xLTEtNTU1NTQ_5435f5af-b547-4f5c-859c-4dce602d8683"
      unitRef="usd">1311000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i87470154c5964bf885e913dea7bf3103_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzMtMy0xLTEtNTU1NTQ_d868c0b2-708f-4dfa-8adf-bcbad68306b0"
      unitRef="usd">1331000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i697e8dd993f14956a1d252e84ed707d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzQtMS0xLTEtNTU1NTQ_06651446-d6d2-4791-918b-37b71d3fc787"
      unitRef="usd">1072000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i39392b4b995449a590f6320c08ce61e5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzQtMy0xLTEtNTU1NTQ_6f441adb-4425-435d-8a8b-2518bcf2aa77"
      unitRef="usd">1085000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzUtMS0xLTEtNTU1NTQ_174ec3db-4b61-49a1-bc87-adb0f0b95c58"
      unitRef="usd">5184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjYvZnJhZzpkMmViYWIzMDgwZmU0NWQwODk1NjhmZmU0YjNmYzgyNi90YWJsZToyM2QxOGIwZTQyYmM0N2U1YWNlMmJkYmI1MzczZTg0Ny90YWJsZXJhbmdlOjIzZDE4YjBlNDJiYzQ3ZTVhY2UyYmRiYjUzNzNlODQ3XzUtMy0xLTEtNTU1NTQ_dc0b5ea4-3124-41c9-999c-a8318e59da92"
      unitRef="usd">4889000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3NjI_1cda1802-ddf2-4188-a08c-9eb222d0b6c2">Goodwill and other intangible assets&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&amp;amp;D technology rights pertains to technologies used in R&amp;amp;D that have alternative future uses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D consists of R&amp;amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&amp;amp;D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&amp;amp;D projects may vary from their estimated fair values. We review IPR&amp;amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we acquired certain finite-lived and indefinite-lived intangible assets as a result of the Teneobio acquisition, including IPR&amp;amp;D of $1.1&#160;billion, R&amp;amp;D technology rights of $94&#160;million and licensing rights of $41&#160;million. See Note 2, Acquisitions.&lt;/span&gt;&lt;/div&gt;During the years ended December 31, 2021, 2020 and 2019, we recognized amortization associated with our finite-lived intangible assets of $2.6 billion, $2.8 billion and $1.4 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2022, 2023, 2024, 2025 and 2026, are $2.5 billion, $2.5 billion, $2.4 billion, $2.2 billion and $1.8 billion, respectively.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3NTk_5cdd2cbc-079e-4fb5-ab6f-923e7b894e0a">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzItMS0xLTEtNTU1NTQ_53963025-e8d1-4a37-a856-a71d69965875"
      unitRef="usd">14689000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzItMy0xLTEtNTU1NTQ_97f2adf6-f2c8-4194-905a-f2328c8503a0"
      unitRef="usd">14703000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzMtMS0xLTEtNTU1NTQ_d9d4ec6d-f69d-4943-a320-eedb174227bb"
      unitRef="usd">251000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzMtMy0xLTEtNTU1NTQ_bb45de70-c32a-4503-a90c-4696d83a9faf"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzQtMS0xLTEtNTU1NTQ_0cf9eef6-351e-4088-96a5-d5656b40058b"
      unitRef="usd">-50000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzQtMy0xLTEtNTU1NTQ_df36ac3f-3b37-4753-bd8f-af605c1b85dc"
      unitRef="usd">-14000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzUtMS0xLTEtNTU1NTQ_0052af8c-133d-408e-800f-32408b8ff2e2"
      unitRef="usd">14890000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTo0NTg2MThiZjJlNWQ0YmU5YTlkODlhOGM0NzEyNmQ5OS90YWJsZXJhbmdlOjQ1ODYxOGJmMmU1ZDRiZTlhOWQ4OWE4YzQ3MTI2ZDk5XzUtMy0xLTEtNTU1NTQ_47d27b8a-751d-4994-b86d-3c173c010c4b"
      unitRef="usd">14689000000</us-gaap:Goodwill>
    <amgn:ScheduleOfIntangibleAssetsTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3NTg_7e84fbff-4739-47a8-9f0d-b5a8b8eb0b46">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idafcf86294d042a097451c547386436c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtMS0xLTEtNTU1NTQ_13540bfa-74b0-4953-9973-fa15677ee146"
      unitRef="usd">25561000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idafcf86294d042a097451c547386436c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtMy0xLTEtNTU1NTQ_d4662484-9681-4cb3-8dd0-e0c6d72ba645"
      unitRef="usd">12769000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idafcf86294d042a097451c547386436c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtNS0xLTEtNTU1NTQ_191c29d2-c4cb-481d-806f-fe03fa96a954"
      unitRef="usd">12792000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtNy0xLTEtNTU1NTQ_c409665f-4f6b-4cc7-9c0d-900e97d4d018"
      unitRef="usd">25591000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtOS0xLTEtNTU1NTQ_066e28b7-9066-47d9-a077-2a8c9d3dff81"
      unitRef="usd">10564000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icfece266d0ce4c84ad286bdfa9f4e6ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzQtMTEtMS0xLTU1NTU0_52ce625c-71c4-40cd-a143-07b7c193df43"
      unitRef="usd">15027000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9afda65b678547869ef5990f59bf488a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtMS0xLTEtNTU1NTQ_de8a8a1e-7c02-455d-ad9e-a46e8d392b6e"
      unitRef="usd">3807000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9afda65b678547869ef5990f59bf488a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtMy0xLTEtNTU1NTQ_702e89bb-493e-4617-b8cc-939bb27cffdc"
      unitRef="usd">2973000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9afda65b678547869ef5990f59bf488a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtNS0xLTEtNTU1NTQ_91b1d3aa-a29b-4308-906d-32ec9c2c2f76"
      unitRef="usd">834000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id2b135991cad418282667c91fa819593_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtNy0xLTEtNTU1NTQ_54abfd87-c27f-455b-96fe-005f17af4f3f"
      unitRef="usd">3743000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id2b135991cad418282667c91fa819593_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtOS0xLTEtNTU1NTQ_83325d38-6ebf-40d6-908c-1d77c5c250f9"
      unitRef="usd">2791000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id2b135991cad418282667c91fa819593_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzUtMTEtMS0xLTU1NTU0_45a1b4ff-f493-46fd-a662-68f1e5751db1"
      unitRef="usd">952000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i641193dfa12140ac8063f9a64824a74f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtMS0xLTEtNTU1NTQ_697224da-b8b1-410b-9761-08cc5f75b21e"
      unitRef="usd">1354000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i641193dfa12140ac8063f9a64824a74f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtMy0xLTEtNTU1NTQ_ecafb192-3d46-4ca7-8cdc-c36cffaf5c9f"
      unitRef="usd">1112000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i641193dfa12140ac8063f9a64824a74f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtNS0xLTEtNTU1NTQ_8df61f6a-7a01-4495-aff8-0428e4c1a6e5"
      unitRef="usd">242000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaf6fec59b238425ea04b200b698f4eaf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtNy0xLTEtNTU1NTQ_90ca41f0-23e4-4294-8dc1-251e4feaf59c"
      unitRef="usd">1367000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaf6fec59b238425ea04b200b698f4eaf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtOS0xLTEtNTU1NTQ_ce1d98cf-50f5-414d-9fde-4505e5b979e9"
      unitRef="usd">1041000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaf6fec59b238425ea04b200b698f4eaf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzYtMTEtMS0xLTU1NTU0_db026349-73fa-4c17-b036-321becf0a350"
      unitRef="usd">326000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9ae35a0ac1214710b7c190312232e3a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctMS0xLTEtNTU1NTQ_020e6275-15dd-465a-9b9f-dc2e1bbd0f55"
      unitRef="usd">1377000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9ae35a0ac1214710b7c190312232e3a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctMy0xLTEtNTU1NTQ_bdf8a6d9-f741-4d9c-87c5-cf171c2e26c9"
      unitRef="usd">1133000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9ae35a0ac1214710b7c190312232e3a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctNS0xLTEtNTU1NTQ_b583aeb3-bc02-4482-a270-543e2973dfe3"
      unitRef="usd">244000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia6c22c6a79774622a0b10ce923ca150e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctNy0xLTEtNTU1NTQ_5149da3d-ee18-4cf1-b7ea-f2d887e870fc"
      unitRef="usd">1317000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia6c22c6a79774622a0b10ce923ca150e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctOS0xLTEtNTU1NTQ_2698662a-4c0a-4392-8245-2d6a5883a42d"
      unitRef="usd">1065000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia6c22c6a79774622a0b10ce923ca150e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzctMTEtMS0xLTU1NTU0_57c57d4b-ecdc-4eec-bf15-6e7f815b279e"
      unitRef="usd">252000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtMS0xLTEtNTU1NTQ_c914741c-4a99-4c4c-b1d6-77dbdcbe7193"
      unitRef="usd">32099000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtMy0xLTEtNTU1NTQ_4c83d606-27b4-4944-a0a3-363d0b9c36d6"
      unitRef="usd">17987000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtNS0xLTEtNTU1NTQ_fd47561a-42ad-492d-95e2-5fc530e7c284"
      unitRef="usd">14112000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtNy0xLTEtNTU1NTQ_33a04e49-869f-4033-a349-fa93da493b41"
      unitRef="usd">32018000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtOS0xLTEtNTU1NTQ_9a38773b-bffd-45fb-949b-30dd658bdad4"
      unitRef="usd">15461000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzgtMTEtMS0xLTU1NTU0_4de1e0cf-3423-4c23-82cb-ab10c514b7a6"
      unitRef="usd">16557000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia5d95d8ba10643ef98491d2fb2c2e0c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTEtMS0xLTU1NTU0_40c3cae1-b3ce-4e9f-aae6-992d37ca102f"
      unitRef="usd">1070000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia5d95d8ba10643ef98491d2fb2c2e0c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTUtMS0xLTU1NTU0_d2b2362f-0db7-44a7-9d63-b4e4aa93e832"
      unitRef="usd">1070000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ifa636f63d01f499bbc23a8871f6dac49_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTctMS0xLTU1NTU0_c8fdeb27-293a-4f83-a2b4-0e8c2cd57bf0"
      unitRef="usd">30000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ifa636f63d01f499bbc23a8871f6dac49_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzEwLTExLTEtMS01NTU1NA_9455773b-e637-42ed-a36e-64b4f3020cbe"
      unitRef="usd">30000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTEtMS0xLTU1NTU0_00a1b799-d368-4f02-810d-f7fda9ac5e8d"
      unitRef="usd">33169000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTMtMS0xLTU1NTU0_96cae39d-57eb-45d4-9c6c-95f087318ff1"
      unitRef="usd">17987000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTUtMS0xLTU1NTU0_7c02c86e-cd90-432a-a660-5cd64c2c27f3"
      unitRef="usd">15182000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTctMS0xLTU1NTU0_62c9d4bb-5ff6-49b6-8425-9b8d5c621f21"
      unitRef="usd">32048000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTktMS0xLTU1NTU0_ee0166b9-7c81-4b24-96c2-b5ba3eba3385"
      unitRef="usd">15461000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90YWJsZTozMWIwZWU5OTFlOTk0YjZmOWI4MGNmYTU4YTVmZjk2Mi90YWJsZXJhbmdlOjMxYjBlZTk5MWU5OTRiNmY5YjgwY2ZhNThhNWZmOTYyXzExLTExLTEtMS01NTU1NA_dcc604b6-b7ae-48a2-82ac-865ffa5ff747"
      unitRef="usd">16587000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iff6483f2d4ab4e57a98ea68547e64b32_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzEwOTk1MTE2MzEwNDQ_bf1eb55d-6b19-4bca-88f7-c64190efecc2"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="if0c996cd5afc4b66986324061c0fd03b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzEwOTk1MTE2MzEwNTY_32f4b447-7ef5-4066-98b5-87059a3ab74c"
      unitRef="usd">94000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ibaa9036d3707491ba2a27c213ba7af11_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzEwOTk1MTE2MzEwNjg_a5160a64-2195-4235-a211-0098dd50db56"
      unitRef="usd">41000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI0MjY_837ca2d5-39c5-4f0a-8073-4d47f67159e7"
      unitRef="usd">2600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI0MzA_b69b3aaa-7b72-4557-bd6f-3567a4994fcb"
      unitRef="usd">2800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI0Mzc_45071a86-884c-4513-bec9-26df9cf1a072"
      unitRef="usd">1400000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MTM_007ed592-c66e-48ea-abde-d7e4d09973fb"
      unitRef="usd">2500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MTc_d02fb988-8ff6-4bf7-97d0-9a10c38c9f4a"
      unitRef="usd">2500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MjE_4721d818-ec15-46c6-a03b-e69fef7f2ea5"
      unitRef="usd">2400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MjU_e3bd2246-6c29-43ad-9c14-76f69b57e5d4"
      unitRef="usd">2200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMjkvZnJhZzpmZDRmODc4ZDA4NWM0NDcwYTE5MTI5OGQyZTI2Njk4ZS90ZXh0cmVnaW9uOmZkNGY4NzhkMDg1YzQ0NzBhMTkxMjk4ZDJlMjY2OThlXzI3MzI_67259113-1cdb-4a60-b711-7d2f4ca8ae6b"
      unitRef="usd">1800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIyMjY_af19ce16-98b2-49e9-953d-688659737a4f">Leases&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain facilities and equipment related primarily to administrative, R&amp;amp;D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years. The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&amp;amp;D and administrative space.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_8e72894d-153e-4a5c-a949-14e5e6efb449"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_aa058334-0aaf-49a3-8af4-aa023d961fb9"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_425f51cf-a3fa-4258-bdbe-9af1266d73f5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_ea705079-dbdc-4ad1-8743-a06d3d2376ba"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_b89a7ea2-fc91-480e-bd31-38a43ceb270a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_f7f1087e-27ba-483f-bdb7-bd0cc9f4c25f"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net lease costs were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2021, were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes future rental commitments for abandoned leases of $138&#160;million. We expect to receive total future rental income of $108&#160;million related to noncancelable subleases for abandoned facilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease terms and weighted-average discount rates were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and noncash information related to our leases was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $35&#160;million. These leases will commence in 2022 with lease terms from 4 to 6 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzY4Mw_e09957a4-ba59-47a0-8ea2-abbec0d57b4d">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIyMjc_1dd22e8f-24b9-4cef-b6a1-a19a42ddebf3">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_8e72894d-153e-4a5c-a949-14e5e6efb449"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMC0xLTEtOTU0MTQ_aa058334-0aaf-49a3-8af4-aa023d961fb9"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_425f51cf-a3fa-4258-bdbe-9af1266d73f5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMC0xLTEtNTU1NTQ_ea705079-dbdc-4ad1-8743-a06d3d2376ba"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_b89a7ea2-fc91-480e-bd31-38a43ceb270a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMC0xLTEtNTU1NTQ_f7f1087e-27ba-483f-bdb7-bd0cc9f4c25f"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net lease costs were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease terms and weighted-average discount rates were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and noncash information related to our leases was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtMi0xLTEtNTU1NTQ_924c35ad-9712-475b-9e1d-3091dddd2cdd"
      unitRef="usd">566000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzMtNC0xLTEtNTU1NTQ_7c34bfb1-ecc4-45a2-99f4-e54e794978c5"
      unitRef="usd">408000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtMi0xLTEtNTU1NTQ_55263ecb-ad0c-4559-969c-22bc9bd12103"
      unitRef="usd">145000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzUtNC0xLTEtNTU1NTQ_cf0dce57-ef24-4652-85c4-99060bc75308"
      unitRef="usd">153000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtMi0xLTEtNTU1NTQ_3d6e973d-dcbf-42a5-846b-c5931e615486"
      unitRef="usd">525000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzYtNC0xLTEtNTU1NTQ_2e82cdd0-5fb3-4926-9f8e-b102e057bd85"
      unitRef="usd">306000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzctMi0xLTEtNTU1NTQ_449ff219-0b71-4b69-8580-23618b2a7ec1"
      unitRef="usd">670000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo1NDJlMjUwMTM2MTc0YzUzYjYzODRhNDllNjJkYmQzYS90YWJsZXJhbmdlOjU0MmUyNTAxMzYxNzRjNTNiNjM4NGE0OWU2MmRiZDNhXzctNC0xLTEtNTU1NTQ_bcebdb8c-2708-40a6-93ad-c4fd72cb6012"
      unitRef="usd">459000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzItNC0xLTEtNTU1NTQ_559c4d7f-94f3-4d0d-bb41-eee18b6f1aca"
      unitRef="usd">237000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzItNi0xLTEtNTU1NTQ_33eba411-a671-4a13-a131-64571c33a6d9"
      unitRef="usd">223000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzItOC0xLTEtNjExMjA_12e25332-dff6-4b23-89b1-d01c6dbbfd81"
      unitRef="usd">204000000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzktNC0xLTEtNTU1NTQ_aa14f2cf-5109-44e6-8286-922b5683b77b"
      unitRef="usd">38000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzktNi0xLTEtNTU1NTQ_57f1c0cb-e464-45d9-9b3e-27f811a41ec5"
      unitRef="usd">34000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzktOC0xLTEtNjExMjc_0f45f71a-0c87-4042-ac91-e83947cf6671"
      unitRef="usd">33000000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzEwLTQtMS0xLTU1NTU0_fc450106-38fb-4066-b2d1-dfc5581e596f"
      unitRef="usd">199000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzEwLTYtMS0xLTU1NTU0_7c0357f9-c300-4bd7-85f7-0a060d6bc3e7"
      unitRef="usd">189000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToyYTUxYmU2ZDkzNzk0NDJkYWFiZTQ5MmNhNjBiNWZkZi90YWJsZXJhbmdlOjJhNTFiZTZkOTM3OTQ0MmRhYWJlNDkyY2E2MGI1ZmRmXzEwLTYtMS0xLTc1MzY3_09b07446-e184-45cb-b8ed-583b99db1a28"
      unitRef="usd">171000000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIyMjg_2052f8d1-5661-49f5-ac36-37331929cec2">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2021, were as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Includes future rental commitments for abandoned leases of $138&#160;million. We expect to receive total future rental income of $108&#160;million related to noncancelable subleases for abandoned facilities.</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzEtMi0xLTEtNTU1NTQ_d5770dc9-ec8a-4dc6-ab47-b0c6e3131e91"
      unitRef="usd">148000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzItMi0xLTEtNTU1NTQ_eef5e43b-00f1-4616-880e-e0accfaf8f41"
      unitRef="usd">148000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzMtMi0xLTEtNTU1NTQ_5f339eae-b974-4d03-913b-e91b488122d4"
      unitRef="usd">75000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzQtMi0xLTEtNTU1NTQ_5b940321-1022-4908-9e35-8c9018f38a5e"
      unitRef="usd">49000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzUtMi0xLTEtNTU1NTQ_8fbc31ca-157d-426d-be08-043ac15bf320"
      unitRef="usd">44000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzYtMi0xLTEtNTU1NTQ_81fdbb80-c6a6-418c-943c-037fb22d1dcf"
      unitRef="usd">289000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzctMi0xLTEtNTU1NTQ_87d26419-8a28-4e00-9a2b-59a04cf00ed8"
      unitRef="usd">753000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzgtMi0xLTEtNTU1NTQ_2df67009-23f3-4fbb-a289-f753ee052c5b"
      unitRef="usd">83000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTo0NDBmODI2MmZlNDg0MmRiODY0YTMxOTAwYTkyMjEzZS90YWJsZXJhbmdlOjQ0MGY4MjYyZmU0ODQyZGI4NjRhMzE5MDBhOTIyMTNlXzktMi0xLTEtNTU1NTQ_46874589-7d58-4a4a-86c5-6c9b6bbd2a2f"
      unitRef="usd">670000000</us-gaap:OperatingLeaseLiability>
    <amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases
      contextRef="i6a62dfd4c2d440e88628b7259f5b5158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzE2MjY_7938aab0-333b-4ac4-84db-6f8eada23db5"
      unitRef="usd">138000000</amgn:LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i6a62dfd4c2d440e88628b7259f5b5158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzE2ODE_8ff1dc29-196a-4f1c-a5ac-cfee4a35910b"
      unitRef="usd">108000000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzItNC0xLTEtNTU1NTQ_cda5d874-191c-4955-bda4-6681365d52ae">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzItNi0xLTEtNTU1NTQ_b0994e49-1364-4680-ba14-3f9753d4cf40">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzMtNC0xLTEtNTU1NTQ_e148d498-9f2e-4648-89e9-9a4627a75754"
      unitRef="number">0.025</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZToxZjhlODNmMjI4Yzk0ZTI5YmNiNTRjYTVjNWM1NWI5Mi90YWJsZXJhbmdlOjFmOGU4M2YyMjhjOTRlMjliY2I1NGNhNWM1YzU1YjkyXzMtNi0xLTEtNTU1NTQ_23cb0555-9e76-43e8-926d-56889d523b09"
      unitRef="number">0.031</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzMtNC0xLTEtNTU1NTQ_8a81f9d5-07d6-4a74-9dfa-f67911c381b1"
      unitRef="usd">190000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzMtNi0xLTEtNTU1NTQ_afe646bf-f24e-44ae-86a4-1c02e4f03f81"
      unitRef="usd">177000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzMtOC0xLTEtNjE4MzA_28412e6d-1865-4ab9-b4ab-03cc848d84d8"
      unitRef="usd">148000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzctNC0xLTEtNTU1NTQ_0000059f-9e0c-40ce-959b-61f465f2cadd"
      unitRef="usd">340000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzctNi0xLTEtNTU1NTQ_2d8b171c-f8a2-4970-842c-a9224fcc2df0"
      unitRef="usd">101000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90YWJsZTpkMjhlOTUyZDdhZGE0ZTMzYTVlODJhODczZDY4ZmY5OC90YWJsZXJhbmdlOmQyOGU5NTJkN2FkYTRlMzNhNWU4MmE4NzNkNjhmZjk4XzctOC0xLTEtNjE4MzY_544ce419-e97a-4f3c-9a6b-d87ca0f92b6f"
      unitRef="usd">163000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <amgn:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIwNDQ_6da40f7e-b61e-4582-8742-a34684aefa97"
      unitRef="usd">35000000</amgn:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="ied090dfe9b534fd38d657521d8581f48_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIxMDU_32bb58b7-1090-4565-9c8b-46009f152d3a">P4Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i201a72549edc46dd976f10480c16db04_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzIvZnJhZzo1Zjk3YTAxYzk4ZDg0YzRhOTExOTQ4ZjA4OGFlZTE0Yi90ZXh0cmVnaW9uOjVmOTdhMDFjOThkODRjNGE5MTE5NDhmMDg4YWVlMTRiXzIxMTE_ac3263b4-9458-4631-a576-6039639771b4">P6Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <amgn:AccruedLiabilitiesDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90ZXh0cmVnaW9uOmE4YzAyZDhiZjI4ODQ1MzRhNmQ3NGU3Y2ZmYzFmZGE4XzE4Mw_1a6341db-298e-4b24-8845-ad4d56b470f3">Other current assets and accrued liabilities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate partner receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:AccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90ZXh0cmVnaW9uOmE4YzAyZDhiZjI4ODQ1MzRhNmQ3NGU3Y2ZmYzFmZGE4XzE4Mg_2ae3c5ff-bb2e-41fd-8def-442d0958f8df">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate partner receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzItMS0xLTEtNTU1NTQ_aa6b901d-a3c3-488a-8f10-0eda9da54fec"
      unitRef="usd">1223000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzItMy0xLTEtNTU1NTQ_8c9f121b-8c34-4339-81f9-9f4b70dfa281"
      unitRef="usd">1156000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzMtMS0xLTEtNTU1NTQ_e9668e34-b580-4316-85ef-f8f8c5de0485"
      unitRef="usd">780000000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzMtMy0xLTEtNTU1NTQ_38fae02c-1f2a-41b7-b20a-ac9b908f53dc"
      unitRef="usd">583000000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzQtMS0xLTEtNTU1NTQ_42f28ca8-e078-4eb7-93cf-1b4b0204b03a"
      unitRef="usd">164000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzQtMy0xLTEtNTU1NTQ_0a997cd9-686f-4578-b35b-d5b8cb4e02e7"
      unitRef="usd">216000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzUtMS0xLTEtNTU1NTQ_7190c880-9227-411e-bf0c-94a29c2918b3"
      unitRef="usd">200000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzUtMy0xLTEtNTU1NTQ_8bfc112b-a8c4-4114-8e8a-d233cb1b41cf"
      unitRef="usd">124000000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzYtMS0xLTEtNTU1NTQ_ca5a527b-0941-424b-958a-d7d909894864"
      unitRef="usd">2367000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo2ZTI3MTNjZTNmMzU0MTMxOTc3YmM3NDgwNmJkN2ZjZS90YWJsZXJhbmdlOjZlMjcxM2NlM2YzNTQxMzE5NzdiYzc0ODA2YmQ3ZmNlXzYtMy0xLTEtNTU1NTQ_dcfc39a3-ff6b-4a97-80de-38a3a6fd84de"
      unitRef="usd">2079000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90ZXh0cmVnaW9uOmE4YzAyZDhiZjI4ODQ1MzRhNmQ3NGU3Y2ZmYzFmZGE4XzE5Mg_0b8bf714-c243-492d-920d-f9e78d528293">&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales deductions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <amgn:AccruedSalesDeductionsCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzItMS0xLTEtNTU1NTQ_85dd3467-9f99-44ae-b288-d8babca29cb4"
      unitRef="usd">5174000000</amgn:AccruedSalesDeductionsCurrent>
    <amgn:AccruedSalesDeductionsCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzItMy0xLTEtNTU1NTQ_55c59ec2-921a-4b1e-a7e6-911c6d228e7a"
      unitRef="usd">4801000000</amgn:AccruedSalesDeductionsCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMS0xLTEtODc1ODE_853b290e-b36d-4e32-b37e-5c7917b918ca"
      unitRef="usd">1083000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMy0xLTEtODc1ODE_60248b9d-48b4-4701-beb1-75ab960a4f26"
      unitRef="usd">1018000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMS0xLTEtNTU1NTQ_27003ec1-ede0-4830-b494-7291c5ce8aed"
      unitRef="usd">1081000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzMtMy0xLTEtNTU1NTQ_a529776b-37f0-4cd1-a1e8-3ff15adf7a10"
      unitRef="usd">1098000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzUtMS0xLTEtNTU1NTQ_008c507a-8ebc-47e1-bf12-573d3dd57eaa"
      unitRef="usd">701000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzUtMy0xLTEtNTU1NTQ_46becf79-2105-4e4c-aaf5-e73aa70ad180"
      unitRef="usd">828000000</us-gaap:AccruedIncomeTaxesCurrent>
    <amgn:AccruedSalesReturnReserveCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzYtMS0xLTEtNTU1NTQ_765c1a95-8f54-4e0c-bb30-618cc9c8c019"
      unitRef="usd">542000000</amgn:AccruedSalesReturnReserveCurrent>
    <amgn:AccruedSalesReturnReserveCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzYtMy0xLTEtNTU1NTQ_5bb9bb38-9a43-4416-aa9d-94bd68364339"
      unitRef="usd">474000000</amgn:AccruedSalesReturnReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzctMS0xLTEtNTU1NTQ_cee3d998-2302-423f-bbc2-8347ebe8dba5"
      unitRef="usd">2150000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzctMy0xLTEtNTU1NTQ_abdd905e-24f8-4ef3-a24d-f9e5364d14d7"
      unitRef="usd">1922000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzgtMS0xLTEtNTU1NTQ_ca585e62-d886-46ad-a529-346506b77a76"
      unitRef="usd">10731000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzUvZnJhZzphOGMwMmQ4YmYyODg0NTM0YTZkNzRlN2NmZmMxZmRhOC90YWJsZTo1NDhkMzk3NmE2NDM0ZTg1YmFmZTU1OWI2NzNlYTdlOC90YWJsZXJhbmdlOjU0OGQzOTc2YTY0MzRlODViYWZlNTU5YjY3M2VhN2U4XzgtMy0xLTEtNTU1NTQ_93bdea35-d2d7-45ac-896b-cff9d237e590"
      unitRef="usd">10141000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcyNTY3NzY3NDU1MTg5_28372b5b-f486-4573-8130-c7faa2c9c6ca">Financing arrangements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% &#x20ac;1,250 million notes due 2022 (1.25% 2022 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70% notes due 2022 (2.70% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65% notes due 2022 (2.65% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2022 (3.625% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% notes due in 2028 (1.65% 2028 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% notes due 2032 (2.00% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2041 (2.80% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2052 (3.00% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes&#x2014;except our 0.41% 2023 Swiss franc Bonds and Other notes due 2097&#x2014;may be redeemed at any time at our option&#x2014;in whole or in part&#x2014;at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, we issued debt securities in the following offerings:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2021, we issued $5.0&#160;billion of debt consisting of $1.25&#160;billion of the 1.65% 2028 Notes, $1.25&#160;billion of the 2.00% 2032 Notes, $1.15&#160;billion of the 2.80% 2041 Notes and $1.35&#160;billion of the 3.00% 2052 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2020, we issued $9.0&#160;billion of debt consisting of $500&#160;million of the 1.90% 2025 Notes, $1.75&#160;billion of the 2.20% 2027 Notes, $1.25&#160;billion of the 2.45% 2030 Notes, $1.25&#160;billion of the 2.30% 2031 Notes, $2.0&#160;billion of the 3.15% 2040 Notes and $2.25&#160;billion of the 3.375% 2050 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not issue any debt or debt securities during the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt repayments/redemptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We made debt repayments/redemptions during the years ended December 31, 2021, 2020 and 2019, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2021, we redeemed $4.2&#160;billion of debt, including the &#x20ac;1.25&#160;billion aggregate principal amount ($1.4&#160;billion upon settlement of the related cross-currency swap) of the 1.25% 2022 euro Notes, the $500&#160;million aggregate principal amount of the 2.70% 2022 Notes, the $1.5&#160;billion aggregate principal amount of the 2.65% 2022 Notes and the $750&#160;million aggregate principal amount of the 3.625% 2022 Notes. In connection with the redemption of these notes, we paid a total of $24&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2020, we repaid/redeemed $6.5&#160;billion of debt, including the repayment at maturity of the $300&#160;million aggregate principal amount of the 4.50% 2020 Notes, the $750&#160;million aggregate principal amount of the 2.125% 2020 Notes, the $300&#160;million Floating Rate Notes due 2020 and the $700&#160;million aggregate principal amount of the 2.20% 2020 Notes. In connection with the redemption of the $900&#160;million aggregate principal amount of the 3.45% 2020 Notes, the $1.0&#160;billion aggregate principal balance of the 4.10% 2021 Notes, the $750&#160;million aggregate principal balance of the 1.85% 2021 Notes and the $1.75&#160;billion aggregate principal balance of the 3.875% 2021 Notes, we paid a total of $96&#160;million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;In 2019, we repaid $4.5 billion of debt, including the $1.4 billion aggregate principal amount of the 2.20% 2019 Notes, the $1.0 billion aggregate principal amount of the 5.70% 2019 Notes, the &#x20ac;675 million aggregate principal amount ($864&#160;million upon settlement of the related cross-currency swap) of the 2.125% 2019 euro Notes, the $700 million aggregate principal amount of the 1.90% 2019 Notes and the $550 million Floating Rate Notes due 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating LIBOR-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.0&#160;billion with respect to the 2.45% 2030 Notes and an aggregate notional amount of $500&#160;million with respect to the 2.30% 2031 Notes. In connection with the redemption of the 3.625% 2022 Notes, discussed above, associated interest rate swap contracts with an aggregate notional amount of $750&#160;million were terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the redemption of certain of the notes during the year ended December 31, 2020, discussed above, associated interest rate swap contracts with an aggregate notional value of $3.65&#160;billion were terminated. In addition, because of historically low interest rates, during the year ended December 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2&#160;billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and the 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2022 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% 2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% 2026 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% 2030 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% 2031 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% 2051 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR +4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A = not applicable&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt exchange&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we completed a private offering to exchange portions of certain outstanding senior notes due 2037 through 2043 (collectively, Old Notes), listed below, for the $940&#160;million principal amount of the newly issued 2.77% 2053 Notes (the Exchange Offer).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal amount exchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% 2037 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% 2038 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% 2039 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% 2040 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% 2041 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% 2042 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% 2043 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2.77% 2053 Notes bear interest at a lower fixed coupon rate while requiring higher principal repayment at a later maturity date as compared to those of the Old Notes that were exchanged. There were no other significant changes to the terms between the Old Notes and the 2.77% 2053 Notes. In connection with the Exchange Offer, $85 million was paid to holders of the Old Notes (the cash consideration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Exchange Offer was accounted for as a debt modification, and accordingly, deferred financing costs and discounts associated with the Old Notes, the cash consideration and the $264 million discount associated with the 2.77% 2053 Notes are being accreted over the term of these newly issued notes and recorded as Interest expense, net, in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the redemption of the 1.25% 2022 euro Notes, discussed above, associated cross-currency swap contracts with an aggregate notional amount of &#x20ac;1.25 billion were terminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shelf registration statement and other facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. As of December 31, 2021 and 2020, we had no amounts outstanding under our commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1%. The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2021 and 2020, no amounts were outstanding under this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual maturities of debt obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December 31, 2021, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2021, 2020 and 2019, were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2021, 2020 and 2019, were $1.2 billion, $1.2 billion and $1.3 billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5OTI_9f82b7bd-a178-431c-88ba-0b9ab173d440">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% &#x20ac;1,250 million notes due 2022 (1.25% 2022 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70% notes due 2022 (2.70% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65% notes due 2022 (2.65% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2022 (3.625% 2022 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% notes due in 2028 (1.65% 2028 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% notes due 2032 (2.00% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2041 (2.80% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2052 (3.00% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e359c669dcf409083123e716b593d81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NDQyZmMxNzNkNjU1NDczYzgzNzMyZWJhYzJhMjNlYzZfNA_f81c28ee-95da-4777-aebc-2ee761e01a8b"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3115a2e5d2b648bb866394e00f7e6265_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NDQyZmMxNzNkNjU1NDczYzgzNzMyZWJhYzJhMjNlYzZfNw_d507f740-d481-44ec-a893-396a0b5d9ba5"
      unitRef="eur">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib927e41cd49b4bcda2eea7a252c62906_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEwLTMtMS0xLTU1NTU0_74360d52-bcc0-46bf-ace1-33860d8a7429"
      unitRef="usd">1527000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d4ded6128cc4111af96fa1184ea3cdb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzExLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NmQzOTI5ZjkzYTc1NDBjMmExODU5ZWRhN2ZmODNiNzJfNA_7b821a46-6846-4850-b78c-20fd37f9722f"
      unitRef="number">0.0270</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3d4ded6128cc4111af96fa1184ea3cdb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzExLTEtMS0xLTU1NTU0_fe43ee69-9a57-407d-8672-dc3668fdcd66"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i56cb2b9855fe4608b5d0321fa7ba2bc5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzExLTMtMS0xLTU1NTU0_9cf64149-9661-4d53-8ccc-44cfb934dcf8"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaf3d349c123746008f444a2b21e4dc29_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEyLTAtMS0xLTU1NTU0L3RleHRyZWdpb246YmZiNjNjNzU1MDg2NDQ4NGI5N2VjNDEwMzI1YWVkNjJfNA_57623e00-d86d-402b-8af1-57c6c4e8856d"
      unitRef="number">0.0265</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaf3d349c123746008f444a2b21e4dc29_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEyLTEtMS0xLTU1NTU0_2e889caf-8f2b-4c6f-80e3-92fae883f1b8"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5ac644eb4ce441cab9fe07e3d012948e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEyLTMtMS0xLTU1NTU0_976ca674-dfac-4b52-b800-d1e96d7b0294"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9030955f37e9430a99c50565728d5f24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NDQ2MDJkNjE2ODY0NDc5OGI2YzA0NzBjMTI2OTdiMDZfNA_afb15aa5-5eeb-4cf5-a579-e5d561282175"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idf619b21445f463d85928fc668c93d2b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzEzLTMtMS0xLTU1NTU0_7eac9573-1bf6-4807-b14c-0665903957a5"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99b857ada0494363b1816eed0b185516_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246OTZiOWFhOGFhNWQwNGFjYjk5YTg1OGRlNTAwYzU4YThfNA_5b263fd5-8301-44d8-88ff-a538d50d3f1f"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i99b857ada0494363b1816eed0b185516_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246OTZiOWFhOGFhNWQwNGFjYjk5YTg1OGRlNTAwYzU4YThfNw_252a5a0f-a38d-4e25-9f4c-ea62fcb94889"
      unitRef="chf">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i99b857ada0494363b1816eed0b185516_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTEtMS0xLTU1NTU0_42c606b4-8212-4acf-b50b-22f3f497b04b"
      unitRef="usd">767000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i28d5c7dae0c9470d9de4d136b31872a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE0LTMtMS0xLTU1NTU0_0ea73d86-1cb3-4c31-99e0-af28fc6a9650"
      unitRef="usd">791000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05c9361f0899452b92a78f57514f9339_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE1LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzcyZTUyNTg3NzQ0NDM2NGFmNWU2ZWJlMTNhMWJkNDZfNA_28669c0e-2579-4b05-a1de-405ca598b387"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i05c9361f0899452b92a78f57514f9339_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE1LTEtMS0xLTU1NTU0_c794a914-e516-40ea-9b4d-fec9cd97f517"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iddb35d257f424b58b378b933e22c6e16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE1LTMtMS0xLTU1NTU0_ba1af27b-7ac6-40d4-bd4a-31aefc69ff8c"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i059fdacf21234e8ea4393764e3826ae1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YWIxYzc1N2VmMDc1NDU3MGE5M2Y3YzYzYzMzYzNkZjJfNA_de87c254-f298-4963-a69d-e9f32b4ac657"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i059fdacf21234e8ea4393764e3826ae1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTEtMS0xLTU1NTU0_d43bf291-f5fc-450f-ae79-8403252e6337"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia3ece76323354edab6344395cebe3bba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTMtMS0xLTU1NTU0_4f1a0269-bbd6-4873-aa96-90ccf70caa94"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i728c44682ed441d0ac7d57d3f4f20961_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE3LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MDU3MTdkMjg4MDk1NDEzY2EyMjYwMmUxODBkYjg3YWZfNA_4fa79c87-b2f1-4caa-8464-b4bf733adcf4"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i728c44682ed441d0ac7d57d3f4f20961_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE3LTEtMS0xLTU1NTU0_a0348edb-6a30-41e7-af5f-978a3792b104"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i50a9f89f55144c7383b92a1e2a084413_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE3LTMtMS0xLTU1NTU0_58957b81-4d24-4aac-8a4a-eac01e075412"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaab56d58779141ceb2afcc0c4b3c034e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE4LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzU1ZTdlYTFlNmIzNGQ5MWFjOGExYzRkYjhkODc2NTZfNA_87b4a973-a5f1-48c8-ad7b-12e20db8d41c"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaab56d58779141ceb2afcc0c4b3c034e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE4LTEtMS0xLTU1NTU0_e7e3996b-8759-4804-9b28-29f6a9a8b650"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibb12c286c5b04cdda990afcad1d3f906_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE4LTMtMS0xLTU1NTU0_2f46b905-1755-4942-8e29-0d991e472af8"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzM3YzU5ZmQ5ZTFhNGY0ZDkzYTQyZjAzZDU1NjA1YzNfNA_947e354e-21a9-4e11-a903-6b231bc4620d"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzM3YzU5ZmQ5ZTFhNGY0ZDkzYTQyZjAzZDU1NjA1YzNfNw_ab42fafe-8206-429c-b2e4-4d0665836959"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5fd0d814bbbb4be198dc33b5a661ee6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTEtMS0xLTU1NTU0_a2781f7b-670d-4852-adfa-1cb062f65f08"
      unitRef="usd">853000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia09e03b111064a778c3c0f67fa5ceca5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE5LTMtMS0xLTU1NTU0_9bddcdf8-94dd-4121-a840-f57f705e288f"
      unitRef="usd">916000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if0fc0421471445c09ad2091231e1ebd5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246YzFjZjVjY2FlZWZmNDhmYzk2YzNjMmY4N2I4MjU3Y2NfNA_4d368655-854b-43b1-8048-29c83580dc11"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if0fc0421471445c09ad2091231e1ebd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTEtMS0xLTU1NTU0_13e83ee7-6fb7-4534-b95d-1d9b5ef88749"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2cb361ad83d5412a809267468ed87948_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTMtMS0xLTU1NTU0_c93ff6fb-0b5b-4d14-a168-cac2adcafe28"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NTZlMWI0MTkyZmVmNGYwZThmMjI5OTUyOTg3NjhmYmRfNA_a4ab4139-d584-4248-b096-d4e2be934153"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246NTZlMWI0MTkyZmVmNGYwZThmMjI5OTUyOTg3NjhmYmRfNw_63980570-3dc7-48b7-af77-4dafeb0d9552"
      unitRef="gbp">475000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTEtMS0xLTU1NTU0_8de405a7-519f-4f2c-b1ae-92cbc3b8416c"
      unitRef="usd">643000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4474d10ca0a044769c40e2e8fe8ba5c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIxLTMtMS0xLTU1NTU0_dd98879e-1f28-4013-85b1-1fde20abece7"
      unitRef="usd">649000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i64fa2b6c75f84ce9b2d6f2c73986f8c9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIyLTAtMS0xLTU1NTU0L3RleHRyZWdpb246YzA3ZDI2YjA5Mzk2NDZiZDk3NjViN2Q5MmFjYzNlMWRfNA_210e3148-8f48-4231-b51d-c094d10e9fc2"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i64fa2b6c75f84ce9b2d6f2c73986f8c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIyLTEtMS0xLTU1NTU0_0ee67563-272b-480b-991f-2b102b932191"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaaf325c2ad564616a25134ef5af769ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIyLTMtMS0xLTU1NTU0_e072c22a-1912-43e2-ab05-d49f4a834530"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iec40a5633cc44bf78f5770c8d2eca6e9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZjJkMzgxY2ZiMTQwNGUxMThlNjAzODY2Mjc3NGE5NDVfNA_74f5c7a6-6e33-4c14-89c6-d32fb3218289"
      unitRef="number">0.0320</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iec40a5633cc44bf78f5770c8d2eca6e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIzLTEtMS0xLTU1NTU0_86e97e33-62cd-4351-ab7a-9f43b2cc46b3"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7db5be88f2184c5c83f07cb2e96fa2ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIzLTMtMS0xLTU1NTU0_030adcee-6fbb-4f65-8e2f-79a0662545f5"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTAtMS0xLTYxNTkyL3RleHRyZWdpb246Yjg0NWE2ZGY1NmU4NDYzYTg4MGE1N2UwNzU3YmIyZDNfNjU5NzA2OTc2NjcwOQ_d2c523da-f3c0-45da-be4c-f1bc4f22d650"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzE2LTEtMS0xLTYxNjEx_180b1d31-c1e3-4029-838f-2ee189c2651a"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzU2ZDNmMDYyMDlhNDg3OTk3Mzg0ODc2MzdlMzY5Y2NfNA_9faa9e6b-0136-4fac-8a0c-489012c85905"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzU2ZDNmMDYyMDlhNDg3OTk3Mzg0ODc2MzdlMzY5Y2NfNw_31448696-f740-4247-937b-c3a92cf59e53"
      unitRef="gbp">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTEtMS0xLTU1NTU0_e6c288ac-e554-4266-b856-ee8d1b7674e2"
      unitRef="usd">947000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i18b66dea34d04457952516f934bfa710_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI0LTMtMS0xLTU1NTU0_a3540e47-fa50-4c3c-9efc-8f4ec15f9731"
      unitRef="usd">957000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI1LTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZTc4MjgwZTE5OTI5NDk1NmE4MTM5N2MxNjU3MjQ0NWJfNA_a94753c9-0232-46f9-9e5a-ad2a9f77ae91"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI1LTEtMS0xLTU1NTU0_20f66b08-4d6a-4e4d-a4ba-1ec62baffb45"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib57500a573714861937e2948abb1c417_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI1LTMtMS0xLTU1NTU0_fab280a5-65e1-4cfd-9472-cb592f6bcafa"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if39aebc177504df78daf24169177353e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YTU5MGFhYjE5YzQ0NDdhMzgxMDQ3YTczMWFjZGMwNTRfNA_4584d362-e736-41ec-8e28-f1a35d2373a2"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if39aebc177504df78daf24169177353e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTEtMS0xLTU1NTU0_508169a4-2fb3-4e3d-97a0-79ee3a5b95e8"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic86def4b22434c24861ce1aea3a31420_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTMtMS0xLTU1NTU0_9a7a60eb-ed4c-4ace-b8c8-9976ab0533cc"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i932124c0f7a5410abab4ba175c13bfb4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTAtMS0xLTYxNzY1L3RleHRyZWdpb246ZWVkYWQ4NjIzY2UwNDhlOWJhMThhNDQ3YzUxZTRkNTFfNjU5NzA2OTc2NjcwNA_732ae6db-6287-499f-b392-09f377ff483c"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i932124c0f7a5410abab4ba175c13bfb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzIwLTEtMS0xLTYxNjM0_a74055ea-cae9-4506-ad44-95668fbdc9dd"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i193e18f2a5ad4e6d9490bcfe10dacd22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI3LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MDEwMmEzNTFlMTlhNDIxYmI3NzliMzEyMDgwMzFlN2RfNA_7f130a4c-89b4-4ed2-b2d0-ebf0a052e4e0"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i193e18f2a5ad4e6d9490bcfe10dacd22_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI3LTEtMS0xLTU1NTU0_e2a159f1-a806-4d6b-aea9-a477ffb21e1b"
      unitRef="usd">478000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib4283cce94284118a0034337aac219b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI3LTMtMS0xLTU1NTU0_fe381adb-05ca-4da9-952b-7596d4cdf892"
      unitRef="usd">478000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0205d38f0748461e9cefc43080126f92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI4LTAtMS0xLTU1NTU0L3RleHRyZWdpb246NzdkMTRiMDRkNzQ0NGMxZGI3MTdlMWQzYjNiNGUyYjhfNA_2aed1166-6fc3-4906-a66c-0d9892104c4f"
      unitRef="number">0.0690</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0205d38f0748461e9cefc43080126f92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI4LTEtMS0xLTU1NTU0_90896628-92f2-40ca-8c32-8517646302d6"
      unitRef="usd">254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5d7a63a419144cf0aca9c1b14bf3aff1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI4LTMtMS0xLTU1NTU0_c71a6fec-0fe6-405a-b7fe-6ea34b60857e"
      unitRef="usd">254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0f57518a37364ab085186556dc6f209b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MWQ1ZjFlZDNiODdkNGM1M2E5MzUzMThmNjYwN2M0ZGNfNA_7108598d-9232-461c-9c07-defa399ab060"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0f57518a37364ab085186556dc6f209b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI5LTEtMS0xLTU1NTU0_02d94791-5298-4cc7-a4b8-718f724a9c2f"
      unitRef="usd">333000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i29d7e93cc83149e6bd46d9c7b5b95be3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI5LTMtMS0xLTU1NTU0_a97a505b-faa6-4606-8965-7a8ed9161723"
      unitRef="usd">333000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibfdd983a38394043a29f22f15239cdb1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246OWM0ZjUxNjNiODcxNGYxYjkwOTYyNzVhMTU0NzBhYzFfNA_a2c56bf6-3570-405d-97f1-5f464c78909f"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibfdd983a38394043a29f22f15239cdb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMwLTEtMS0xLTU1NTU0_fd3dd1b8-2865-4e07-a591-70e4b76150bf"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMwLTMtMS0xLTU1NTU0_b09ab538-d9b4-4143-a4c9-4f318485b627"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i08afea356a38453090c19b18d61b4a71_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMxLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZjFmNmE2MWNiMDAyNDk0NDkzZTZkNjU2MDk5MzlmZmRfNA_3832d2fe-5952-49d7-8a61-996fd4f6276e"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i08afea356a38453090c19b18d61b4a71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMxLTEtMS0xLTU1NTU0_9df4862a-bbfe-410c-a0d3-6d3a70847e44"
      unitRef="usd">373000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93bbfe5fa69940c08425fb453c4429a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMxLTMtMS0xLTU1NTU0_25d35563-7c6d-4895-a2ea-785ad9d5b025"
      unitRef="usd">373000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4c53473bc8014e44b15542181f09808a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTAtMS0xLTYxNzY3L3RleHRyZWdpb246M2ZkMzNjNmRjNGQwNGNmZjkwYzEyMzNkMGNjNzk4OTdfNjU5NzA2OTc2NjcwMw_a9bc1cbb-f31d-49bd-b81c-9b68687662c7"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4c53473bc8014e44b15542181f09808a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzI2LTEtMS0xLTYxNjQ4_5aad2390-bdef-4316-97c8-07a33df3b3d1"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id612d8d410b345cf9c48f162584e09ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMyLTAtMS0xLTU1NTU0L3RleHRyZWdpb246ZDU0NmNkZWY1MmQxNDkyZmIxY2UwZWIxYmU3ZGZhNjdfNA_139d20ac-2d1c-4040-93ac-b22c456e7a17"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id612d8d410b345cf9c48f162584e09ec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMyLTEtMS0xLTU1NTU0_a56f0c6b-e1db-4609-9bf0-2c5ef7385aa7"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i34f197c292c0446c9383e5222324d6c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMyLTMtMS0xLTU1NTU0_53248082-9522-40bf-8f4d-3a104ae0584c"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2169d5c603a14255b95c241f6c3323ed_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMzLTAtMS0xLTU1NTU0L3RleHRyZWdpb246Y2I1ZDRlOTRjYzI0NDA3YjkyNjkzNjUyYjQ1NDM0MDBfNA_ff4a666c-10b1-4043-acc4-beda653bb1f2"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2169d5c603a14255b95c241f6c3323ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMzLTEtMS0xLTU1NTU0_a8a1b71c-2f1e-4e5c-8a3b-0bd14b274e79"
      unitRef="usd">729000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i689ad4255db545eda69e365f169f332a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzMzLTMtMS0xLTU1NTU0_28adfc03-3344-4bde-b9ac-57adf34b81e8"
      unitRef="usd">729000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iee3977d9de514e63894403ca1ca898f2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM0LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YmI4Njk1Y2Q0MjhkNDczZWEzYTc5OWNhZDRhMGQ4MDJfNA_a8c66533-e929-46b0-b417-22258a4b217f"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iee3977d9de514e63894403ca1ca898f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM0LTEtMS0xLTU1NTU0_c42600bf-e9a4-438c-b74e-857105f3b99e"
      unitRef="usd">415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i29adc72b130b479ea45a8aaa03b088d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM0LTMtMS0xLTU1NTU0_cd6f8c8c-4e35-44c1-9716-4be19eb090fc"
      unitRef="usd">415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i965cc877b8694f78b1c2b606c84f7f38_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTAtMS0xLTU1NTU0L3RleHRyZWdpb246YmU1N2U5YzMxMzUxNGM2NjgwYzU1ODRiYzZhNzJjY2ZfNA_17b9c944-0281-48ad-bff8-343630e4427b"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i965cc877b8694f78b1c2b606c84f7f38_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTEtMS0xLTU1NTU0_9d40cc6d-3d49-4d03-ab3a-3931ec87a788"
      unitRef="usd">185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i364ca273078a47eca7c0fe7c36707bf5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTMtMS0xLTU1NTU0_6d0f75e0-0d80-4522-ba93-81b43ab8b417"
      unitRef="usd">185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idea96f4e89df43b18b9bd6729d02ad77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM2LTAtMS0xLTU1NTU0L3RleHRyZWdpb246N2EwMzRjMjY4NmY2NDk3ZGE4ZGZkYmIzNzUyMTg3NDhfNA_38c2e7a2-c035-4166-a1c9-24d45847842f"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idea96f4e89df43b18b9bd6729d02ad77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM2LTEtMS0xLTU1NTU0_a140a5d3-3a51-41bc-ad40-9d3620316259"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3b2eb0ad81574e8e8c6e79ecedad6dd7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM2LTMtMS0xLTU1NTU0_e734e72f-1218-4f0b-9fd6-fc73e39ec43f"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM3LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MWQzODE1YTI1MmQyNDI3MGJkMDZlNTJhNDI0YWY4NTRfNA_d10be45d-18d7-43fe-9a02-5be20fc53692"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM3LTEtMS0xLTU1NTU0_d87e0234-d762-48e9-9c4b-80c2cc328676"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i66cf2c987b9f46568650effba9da5361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM3LTMtMS0xLTU1NTU0_3aa6c3b6-9156-49c3-8985-354ef99147ab"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c13c24eff8b47b6b20d9d46230a1c57_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM4LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MTczMmE4MjFkMzQ0NGQyYWJkNDI0NzYzNGFlYTg4YzRfNA_ddaaeb9f-df0a-4ee1-9866-75d9d6a7ea92"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6c13c24eff8b47b6b20d9d46230a1c57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM4LTEtMS0xLTU1NTU0_4a107195-3f90-474c-8182-ede2414050f7"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5e6253005b2a4664a03ad8f8f5898630_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM4LTMtMS0xLTU1NTU0_11d36814-c28b-43b1-beed-70b375dfb0e6"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM5LTAtMS0xLTU1NTU0L3RleHRyZWdpb246MDI3YjUzZWM0NzZlNDNkNGJlMDI3ZmEyMTg3OTZkZjBfNA_43592d16-7332-46e3-97bf-db79122656ff"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM5LTEtMS0xLTU1NTU0_0f8b706e-61c5-4c85-bf99-831d29f349d5"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9b860697a584413f99229019ccec2aa9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM5LTMtMS0xLTU1NTU0_82ab52be-c5a8-4ea6-9fc4-00f4aeee7ec6"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTAtMS0xLTYzNDI2L3RleHRyZWdpb246Njc2ZWNjMzMzODgxNDM0Y2IxODAwMzU0Mjg4Njk2MGVfMTA5OTUxMTYyNzgyNA_297bb2e9-e0d8-428c-b413-d1eeabb208e9"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzM1LTEtMS0xLTYzNDE5_876b94d3-8656-4e81-86c4-40c858216b73"
      unitRef="usd">1350000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQwLTAtMS0xLTU1NTU0L3RleHRyZWdpb246MzEwNjcwYTc4OWNiNGM5MGI3ZDc3NTk2ZjlkNzVlMDNfNA_0286a533-a17c-484a-a0c4-a8acd1f31a30"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQwLTEtMS0xLTU1NTU0_368048fc-de44-443a-ba09-99251766e64d"
      unitRef="usd">940000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQwLTMtMS0xLTU1NTU0_aff28902-3172-4190-b958-261eee98dff4"
      unitRef="usd">940000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iccec61d10cf24b1f9a049d503b7a1dad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQxLTEtMS0xLTU1NTU0_0308dbff-4b1e-4faa-85c9-c586e2685206"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic5fe83762b5347d3b5b16cc99dd81437_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQxLTMtMS0xLTU1NTU0_075a938b-dc85-463d-a00a-96b1e7d3ea37"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQyLTEtMS0xLTU1NTU0_9cf983ba-8c47-4ed0-8ebf-7534af514d71"
      unitRef="usd">1213000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQyLTMtMS0xLTU1NTU0_3195a356-c99b-4af9-886b-954f75dc829a"
      unitRef="usd">1188000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQzLTEtMS0xLTU1NTU0_4c743830-4b99-4e97-87c9-08b64c9998fd"
      unitRef="usd">284000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQzLTMtMS0xLTU1NTU0_cc33b58e-77d6-4bb9-8b01-f05b50171ca5"
      unitRef="usd">566000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:OtherLongTermDebt
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ0LTEtMS0xLTU1NTU0_49871025-7a72-4618-b3c1-4405d3ea0310"
      unitRef="usd">15000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ0LTMtMS0xLTU1NTU0_f95b0eb1-05f5-49ea-ae56-ffb61c36cb81"
      unitRef="usd">5000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ1LTEtMS0xLTU1NTU0_199455c7-6b85-4e10-9c39-f6a708c9781e"
      unitRef="usd">33309000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ1LTMtMS0xLTU1NTU0_a5b614a7-316d-4708-afda-762fbdc64106"
      unitRef="usd">32986000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ2LTEtMS0xLTU1NTU0_5706c878-6fa8-40b4-8bdc-af4a9f23dfa9"
      unitRef="usd">87000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ2LTMtMS0xLTU1NTU0_75a591e7-48d2-4a92-8306-e4091dce2bd9"
      unitRef="usd">91000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ3LTEtMS0xLTU1NTU0_a09efa87-ddaa-44ce-980a-f5c53f82274c"
      unitRef="usd">33222000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTowMWE5ZTNhZDE5NTM0MWQ2OTc0NTdiYTJhNmMzMTE4YS90YWJsZXJhbmdlOjAxYTllM2FkMTk1MzQxZDY5NzQ1N2JhMmE2YzMxMThhXzQ3LTMtMS0xLTU1NTU0_ca6ac939-3a9c-44f5-a43d-21eeee9a23e1"
      unitRef="usd">32895000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIyNA_c4684f35-7c52-42f1-9f97-af9f431572be"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0Mw_947ef470-1574-4790-b999-9577a075fed7"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI2NQ_6e458cf0-2af8-4c94-ac76-5526a126996e"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i93ec0b38ff0e4a3fb17d61c5a8707c3e_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMxOQ_b853162d-0b2c-4f00-984b-3c9a2a507171"
      unitRef="number">0.063</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if17bac99f15a4fd08c57b8d625475683_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMyMw_a94bbb86-5337-4dde-888c-4c6113a14d9e"
      unitRef="number">0.056</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5ccfecc72eba40d8aceaacfb322cf5c5_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMzMA_d0e5e441-379c-4896-81d4-a53633673556"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i102f385c304b406995d8b7e6800cb786_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_014bf800-b926-49de-8a88-eb1c6bfff35e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i1c06f986336b4293934da0346e70a8ef_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_0b6ce5c5-6094-4580-b692-769f3000fb70"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i062455b6853247eba1cd91fb4b7af879_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_11e8948e-7225-4932-bd06-da45f018685d"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i7e3042dc4e974d1bb2015139dbedb73e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_1b43c38f-69c4-497e-bb36-ae7a1e68c664"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i37fc7e470e2e4805af580456ed7f0010_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_1ea86725-fb93-4541-b104-7162f6819708"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i6540ef5c27054d6e9c7985f2b141767a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_26c71c28-f172-405a-8a71-006cce24e22b"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i48f26a3a0d594e26854ea76bb3c6743d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_302a3502-230d-4173-8421-2dcf8011de13"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i1863ab64829b4fabbec539235c0ac7d1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_302cd1ac-09fc-4189-99f3-2a90206de7ae"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ifd810185a212412e83638c36004bad29_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_34efd3c9-585d-4371-ad96-d9effba80642"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i53e1283c932d4edcbb8cc22fd4ab8960_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_35312396-9841-471b-8e01-234bf6a39a9d"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i88ae1c03870043a08889cc2ff6ed20b1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_35399fd1-f7d1-4f65-9aab-a7319614bf3e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ib8710c24c464449b8fa26275c77a6e58_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_3cdbc11e-2bd3-4831-9d0d-5eedf251d332"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ie10a62100d1e4b0e9d7ab8a2ba247c8a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_41d99db7-bd43-4498-96a9-a777b7c2c0e7"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ia850706d72994599bff9431d2e8b1a5a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_48a80050-22b5-4732-9072-29ff4d905c5e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i9f2a64b79a0c404dba15ff2230fc371d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_54cbe8d0-541b-4aa9-8b55-be9b291e61fb"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i7fefa5369ca248188f3e2d24acec7468_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_5aaf3834-7baa-44fc-92c0-e0da1ab0926c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i55ba559d13f24efc9fdf4abebc7c8924_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_6be46848-74bb-47dd-8cd3-de51b93b5494"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iaeaf9de7e4f74c20b1108870b6ea1974_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_6ce77e1a-3ae3-4a1c-acdc-de1c7f25fcba"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ic44afd752e7745c885bb3c653ec2d9f4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_6fed14fd-8142-468f-a520-e0a85dee9353"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i5edec977c0494db1989203785b65a079_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_7121936d-5263-40bd-be26-da882dfd9a26"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i832afb5f09ff42f8972ccf47b59012a5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_72b1964c-1f96-4c4a-8e40-5b50313874bb"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i7991c3b6e9984fe98b17e71a271b7557_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_754ef522-a879-42f3-b98f-1068ce9d0951"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i6d0d27fa96204770aed6605e64628c8a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_8465c54d-a682-4cfa-a8ef-c6c02c01a70e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i04bf222f1adc48dbad767adfdca6631f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_8f8563ab-d241-4021-ba5e-06fa7b962231"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ic6bc114e2ad04b349cc3973ecba76b7f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_8fce14f9-02be-414f-984c-6177fdb022e5"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i9278d061be544509ac7ccfcae7335101_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_a3ce6a93-1fef-4b63-8766-6c1891c4e1b1"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i581122c175be46309a19781a1813a543_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_a719a18c-52db-44b5-ac83-ee156353352c"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i787a1f1611f040bdb13bd41c6d2e7221_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_b998db18-5954-487c-87d0-10879eddd776"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iac386b55791042908ad00f98e5e6a2ea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_b9cab92e-1c96-4a52-94ea-f39daf1fdd42"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i29bd0ebc2ef643d89e8a4df0e1f5a0a9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_c0ba5ed9-27b0-4221-a35d-43e710304d34"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i34aa68b41c90434093ba0c86e0923545_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_c162bed6-ffff-496c-a6e6-580ca36e6932"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i04b1b2aa03f54c1aac5954067859bd2b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_c3e79286-eb6c-4912-bed9-ac4584e91e8e"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i42b1c907d2284f46b65c2993a8518ee2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_d6ff7ab0-2043-4e22-998b-c014e617dd48"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i880cd534575949e3abab9e8a7d2a0235_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_d7c62120-76e3-4338-9441-c5d31388a4f5"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i11b4dae7d4c14e8d81c11fcee49b8148_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_d9e7ccdf-3137-42e4-85c3-29c79a393c03"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="iae894d8f94e84e9eb8cc52ce4c1e5efd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_da9aa2e0-8f44-454b-869e-6640a3110387"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i3dc259e1f874437e8de85f6ffd31abd9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_e2aed8ca-c739-4753-91c1-6c5caa9ab017"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="ie151d775f0614294815a86857329b491_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_e8209e12-78e3-435f-b0d6-ed5c8f67991f"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent
      contextRef="i50e0eaf522434115aef33c9b0f4b32fd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU3NQ_eb6773c3-a6e5-4a64-a8ea-4ec72a410885"
      unitRef="number">1.01</amgn:PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib1502d4ddb0b4ea78f2bfbbf53ace156_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcwMw_b19f24b7-93b7-4e10-bf40-d200662644e6"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount
      contextRef="ie619fdd6365143709fe3ef8c6e3e1cb8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzExNzU_2b46b9b1-b4e3-4dfc-b362-465a8eca26bc">P1M</amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount>
    <amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount
      contextRef="i32f3ef7ef219414d9621fb4cbdaf429d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzExODE_d70e799e-07ae-4bf3-a809-b3fa169c02d4">P6M</amgn:DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic29f8a9193ed4db1ad73321b122e4e45_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU4NzM_2563e143-fdd9-4258-9de0-d7007a3e4fed"
      unitRef="usd">5000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU4ODc_b08fe1aa-dae5-4088-adaf-eddf9156ca2e"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifb7c6d5f0cd6496fb9c92580ae627060_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU5MzI_71aeaf6f-3cbd-4148-8620-23cd352ef593"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i71d7cd08a4ec4828acd8e3620f7b4d78_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDU5MTE_6428e37c-b544-46f2-9c3b-b80fd691f69a"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i71d7cd08a4ec4828acd8e3620f7b4d78_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2NjQ_b8c8bbc9-2f09-4c37-ab60-e7ea265b73ba"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3ba4ba7693a5434e9b35ca55c38722ec_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2NzE_71de60bf-6691-464d-a248-126886f0fe3d"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3ba4ba7693a5434e9b35ca55c38722ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2ODY_0cc7f29c-fc36-4512-b704-ab48c2a67630"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk2OTM_23329b71-00d4-4c9e-ba48-a8b42f94f93e"
      unitRef="usd">1350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f42705f67d145a8bcd98e79844df3dc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDk3MTA_6dcc4b83-067b-4f0d-a1d4-37e07f50b8bb"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifd12628ec78f4499a7e276a61e90e99b_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI5NTc_340e39f0-f9cc-4d0e-a099-a4a36cfab379"
      unitRef="usd">9000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i50a9f89f55144c7383b92a1e2a084413_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEzNjY_87ed8929-60fd-4483-ba82-6df782071129"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50a9f89f55144c7383b92a1e2a084413_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEzNzY_3497d4d0-6929-4423-95c3-7cdd80a84086"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaaf325c2ad564616a25134ef5af769ea_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMwMTc_8f35a86e-96a2-4b09-827d-58d63c30c6ed"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaaf325c2ad564616a25134ef5af769ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0MDE_61c24d2b-8268-4588-8ea6-5b8e282e07cd"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib57500a573714861937e2948abb1c417_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0MTY_c9b1a73a-f4d4-467f-a9a1-99e486e4d494"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib57500a573714861937e2948abb1c417_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0MjY_ad25239c-899d-4032-a6a3-925024d0a800"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic86def4b22434c24861ce1aea3a31420_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMwOTg_cc40693b-9fce-4794-9a2f-c78408ea6bee"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic86def4b22434c24861ce1aea3a31420_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMxMTk_ae7a7320-6f89-49ca-9ad6-546100925bf0"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMxNzY_dd2653aa-9d96-4239-ac34-63723cbde5ea"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d189bfb68b7475ab9ca69a1712f9f77_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0NTE_7e03645e-a574-46e0-874a-2dc0cd1d8b3b"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5e6253005b2a4664a03ad8f8f5898630_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDMyMDY_74ce8e81-60b2-4e03-b0ad-9c3ac0f8f825"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5e6253005b2a4664a03ad8f8f5898630_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzE0Nzk_440ee6b0-8ce9-452e-a821-766bb773091a"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie0cbb29ec00d4533a3e1155ce9550ede_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2ODc_ac5dc7f7-5f91-49ab-9772-12a300b300ce"
      unitRef="usd">4200000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i55367f6c3ff34f7cb01d46d89ee2c379_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMDA_35937f2d-6bc3-448e-ae84-b5abe2753bb3"
      unitRef="eur">1250000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icf9c596023174e558d6631c3ca855b65_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2NTE_dfef1af6-db47-4b3c-90f9-0b29fd42dcc6"
      unitRef="usd">1400000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7b742eeadacf4b658c093123bb55c0fe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMTY_778fca82-4eb0-48a2-81f7-6b9fbf5ae010"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i070b4afa879f4c5fb36fc518fe1cfec4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMjM_68da7150-5f70-4653-9d99-2f9a287b9689"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b11859028a1422083400b2109fb068f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxMzc_7d7869b5-26ed-43b0-945c-eff64ab90c81"
      unitRef="number">0.0270</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibf4f6ca5c74d48349c15921ae8a0933a_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxNDQ_aecf8950-c194-4cf0-a27e-c7c41209ec2f"
      unitRef="usd">1500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ide87aaebcc2a4447a457f81d1aa31c9a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxODM_6eed520a-14f5-41aa-8026-b88d87e14dbc"
      unitRef="number">0.0265</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1863ab64829b4fabbec539235c0ac7d1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxNjA_21d186f9-6289-407a-acdb-b6973c2b1363"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9030955f37e9430a99c50565728d5f24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxNzQ_375901ce-e8a9-4cc7-ab0f-5793b4217b3e"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="ie0cbb29ec00d4533a3e1155ce9550ede_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAxOTA_95c770d6-5a2d-4825-9961-99c9011d48ca"
      unitRef="usd">24000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iebfd131a231b493da0babaf4c3b5395f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIwMzI_f64b3093-3721-4705-acc8-99171a389ae9"
      unitRef="usd">6500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie9a1311f688d45e5a1f460915c39e581_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIwODc_ecbe84a5-e5bb-490f-a31e-f7f8cf16029b"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i54c22a3e15e54b178cf491b39cbfbbd5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxMjQ_2acd5e01-ab56-44dd-9a8f-434751a0d1d3"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5477a7c207054d569f2eca1cdcac36a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxNDM_87a455cb-2724-48f5-b6e5-cec8f8b489ad"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iab353bc1f2344a55b1479a0f118d799c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxODA_3e5679da-082e-4170-978d-83b278cb5fd4"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id97511afa493447da0eb4625d1fbf9ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIxOTk_e151c83a-dc2b-4b3d-85e1-06e8e485e256"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if97696feb118453eb13e08998850ad56_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIyMzk_28d28b2a-709b-451a-b7db-cd4d37a76c64"
      unitRef="usd">700000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf411ca29d03476a953c14fc1769501d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIyNzY_4cf7dfdb-f664-4e7f-af71-4b34c9b123bf"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id9e3b5bf697b4cf0bfb5716a830f11db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIzMzI_e33c40d1-9530-4604-b252-8e49ba301e39"
      unitRef="usd">900000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id189fc4607ae4a208ed0437205c4c7f4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIzNjk_22c28039-3b44-4a93-84d5-fc717e2a61c5"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifb3ed5ae8257400c9ca750016aa502ef_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzIzODg_34799c3d-89f6-4fad-8a21-df86c2c8efcc"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0682f6237def4973ae5a5cc46f9d59e2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0MjY_c585cca2-83b8-4834-a2aa-e2e1c21c595f"
      unitRef="number">0.0410</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia3291bf95ec2416b94e22bd933d142ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0NDU_e9077c6b-079d-4a96-b0cd-4a9f6b4567c0"
      unitRef="usd">750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie1b2177f702640cd8b47f293f2ad22a1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI0ODM_f8d18506-7776-40ca-888e-942e2377e5a4"
      unitRef="number">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if3d97e7f0efe4261b956189daec4c902_D20200101-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI1MDU_e907dd8c-b150-45dd-9aa3-be527a13ed78"
      unitRef="usd">1750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4b8269488a684ef385c1e94d4f756b8b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI1NDM_38f83a33-71ee-4124-aa7e-a0ca9e0d8eae"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="iebfd131a231b493da0babaf4c3b5395f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI1Nzc_30a4d1df-67d5-4c8a-a057-b96c70c03b15"
      unitRef="usd">96000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie46f97dcfd2c4ee5b216081269ea57b0_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2NDQwMzE_f86bcc15-9874-44de-b1e5-90b38a736e97"
      unitRef="usd">4500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i84d8db7b345b4458ae3f758755659354_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI3ODk_ca85052a-41d9-4ba5-81ff-b3af30b2587e"
      unitRef="usd">1400000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if87fc1146c544c828abfcec0fe2987c9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI4MjY_93d90277-0efb-4491-9d2b-d766f698248e"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3f2c8de012264cf89c56a2b6158356f6_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI4NDU_68759696-4e81-4c3b-b5d1-3c74bd17e543"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0e964a7c87d14059977b9c5c2746d0d2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI4ODI_ab791b8e-0363-42de-aeb3-a6a78740df7d"
      unitRef="number">0.0570</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icfd842d4f03947599d399bf5eba13005_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI5MDE_35c31f20-95a0-41e7-982b-b546f2146abf"
      unitRef="eur">675000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i09a6ccbf40d94c65aaafe7871e4a210a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDAwNzQ_45e54436-1430-40d3-a4dc-f4222b95b52f"
      unitRef="usd">864000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id608276fe2a6484594c7c005d1cd220d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzI5OTQ_671d3229-45e5-4abc-90b2-cba3395605d4"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i29b52d16bd6d4af083d152823f4b96ca_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMwMTg_53fec4a5-31f5-4e21-9b84-c09d2ae3df41"
      unitRef="usd">700000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i104a960196594625971a4b192145a8c8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMwNTU_1abb17c0-c8a5-454d-bbd8-6d9a0a921e0e"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i82257eb313254ec0ab7249ac84b173fd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzMwNzc_4420f7bb-8efa-4abb-897d-24ea157c2ca8"
      unitRef="usd">550000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgwOTQ_fbdab0ce-509a-4d1b-88a4-2ea9518c0483"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i365214c0e6504d3fba7ccd3e791c85e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgwODA_de7ab43e-27ac-4758-ae23-be5aa76769d5"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if39aebc177504df78daf24169177353e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwOTk1MTE2Mjk5NzA2_99ecf30e-85dc-48e9-9886-9edc397860d8"
      unitRef="usd">500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if39aebc177504df78daf24169177353e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgwODc_10e08214-dfe5-4b15-b03d-8cf565904dfb"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf619b21445f463d85928fc668c93d2b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzg3NjA_dabdfa74-3631-4985-93ee-d6428b654215"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzg3Njg_dbedd088-d2b0-495f-b65b-e618de4c259e"
      unitRef="usd">750000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzM4MjM_7856c55b-c380-4d4c-935f-8a74cda5f08c"
      unitRef="usd">3650000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i165f3ecafa0a4de4b1c4b6db200d90b9_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwMTI_8bd7d83d-cc7a-43e7-aa53-6f9f3e5fbf2e"
      unitRef="usd">5200000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia3ece76323354edab6344395cebe3bba_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwMzE_54973948-e23d-462a-9435-3e17b25d48d3"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2cb361ad83d5412a809267468ed87948_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwNTA_9fdd30a6-6252-4783-ab63-8d2819df086e"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9b860697a584413f99229019ccec2aa9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQwNjk_f59e6cfe-08f6-4a08-9ac5-5e45e667627d"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf619b21445f463d85928fc668c93d2b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQxMDM_0475bd2d-7067-445e-8f8d-631e176887d0"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibb12c286c5b04cdda990afcad1d3f906_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQxMjU_e46f681f-af27-4022-8402-f05008caea37"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib46494b393a34b9f8c60e96025f45f23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQxNzM_9733cd63-c6c8-4866-9e6c-995deb26a3a6"
      unitRef="usd">576000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i845d5c989f794e06bd6777c9e801b93b_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzQzNzQ_8991f516-aa63-4a8a-a9ca-92d5233a2a46"
      unitRef="usd">5200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDE3_e4d914b5-f84c-48d8-a3e9-859922c66a5c">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2022 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 3.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% 2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% 2026 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% 2030 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 1.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% 2031 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 0.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% 2051 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR +4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LIBOR + 4.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A = not applicable&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff27566615ea4d2bb9437ebad4ab002f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjozM2EwNmZkNTA0MGQ0MmNiYTc5YmRjMGY4NjU1NjJhNl80_acdaebff-f215-498f-bc13-1b9576cbe648"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iff27566615ea4d2bb9437ebad4ab002f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtMi0xLTEtNTU1NTQ_ad1ca5d3-6835-4bc1-9974-33a2be9504c7"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if93f0a53c32847ae98f3c48eb087f0d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtNS0xLTEtNTU1NTQ_4b9aa1c1-a8b3-4f25-8fcd-c08781826b87"
      unitRef="usd">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ib2ae88e4533c4b4cb0927518f3740856_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzUtNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjowMGFmMWI0MjA0OTc0MjI5YWU1ZjlmNGQ1Njk5YjJlNF8xMg_e43af0f7-610f-4214-9e27-be5657e7b673"
      unitRef="number">0.027</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5fec9853ccc64441ade8c731c993d7bd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1N2E1YmNiMmQyMmE0MDYzOWExNWFhOTZlY2Q5ZDFkMV80_863e7a43-8f03-4305-875b-baf4f6b38917"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5fec9853ccc64441ade8c731c993d7bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMi0xLTEtNTU1NTQ_b173cde6-dd04-49ee-a311-79e9ebc3aaf9"
      unitRef="usd">1400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="ic5344d1029ee4871879edd955c41939b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1NmE0N2E1NTNjN2I0NzBhYWEwMDkxMjBjNThjZDNiZl8xMg_658cba63-8930-4e02-a909-0815e17e25d3"
      unitRef="number">0.032</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5d68f7e07a094edd9e2461d6c0fdd4fc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtNS0xLTEtNTU1NTQ_82a95a5e-4ba9-46aa-b345-f20d5515a213"
      unitRef="usd">1400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i3894bb298da842feac52ee9f09993b0a_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo5MzYzYWY4MjRmOTk0NWMwOGI3ZGE1MGVhZGMwYjhkOV8xMg_c89607f1-63e5-4be6-8f5c-f14198376c87"
      unitRef="number">0.032</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib38c6961bd484a1aaeb68b6dd42b1548_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0YzM1NGY5ZjdmYjI0ODNiOTM4OTIyMWMwMDg3Mjg3MF80_6079228a-c38b-41fb-8094-fe032bd5c584"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib38c6961bd484a1aaeb68b6dd42b1548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMi0xLTEtNTU1NTQ_412c9a4b-1e1c-4f37-9fad-d880f4a61753"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i034a224066ae4802b5005e8a780dcba3_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjozZmI0ZmQ2NzQ3ZGE0MGNhODNlMDhjMDRmYzIzNjRkMF8xMg_c7bcc352-5e36-40c0-9803-e7e39c38b791"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if99e95ece1544f458f56a09770d012f6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctNS0xLTEtNTU1NTQ_1544db97-7a6e-4024-94ca-cead7184a621"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i4c48563bcda143618f52c18180794c29_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1NzJkNWEzNWVhYmI0ZDU3OTY4NDA3ZTg5NzIyZTRlYl8xMg_736dbc04-d9a0-430e-83b8-538dd4f36c49"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i16fe501f4d234ba3bc01f6fd307e4f03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0ZjZkNzNkN2M2ODg0YzNmODAxODFhODViYzRmNzgyZV80_e3485ce5-5b8a-4691-b4b7-c4dc9cb93f95"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i16fe501f4d234ba3bc01f6fd307e4f03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtMi0xLTEtNTU1NTQ_74167e81-c0bf-4fce-801a-fbcfe36d6727"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i7b1708fe50d04fdb89f763085b73c7a2_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo4N2JjY2ExNDU1ZWM0NWUwYTkwY2QzOGRhNWYwNzY2OF8xMg_9b4c2fdf-14b7-4722-923c-55277baecedb"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie53460a2e2c54b1eb6ba01dd799c1956_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtNS0xLTEtNTU1NTQ_55992813-6ad1-4e83-8a55-98639b3a943c"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i85ecb4c22c6d4edd9158a292a2b738c1_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzgtNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo0MWJkYzY0NDNlODU0ZWE3OTZjM2E1OTk3MjFjMWE5OV8xMg_bc944c53-1e49-42c1-8a84-36c9e60a49a6"
      unitRef="number">0.018</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i77e71d687a124355ab2c2f4d216034fb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMC0xLTEtNjg1NDcvdGV4dHJlZ2lvbjozMTRlNGFhNmIxOWQ0NzZkYmU1MDBiY2Y4MmEzY2UyN184Nzk2MDkzMDIyMjMz_71d547ac-c708-48ac-b1cb-315f3e0cfab3"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i77e71d687a124355ab2c2f4d216034fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMi0xLTEtNjg1MzM_30702e08-8b5e-4652-90f8-de81e11f9798"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i27fb3b4b36f14d56bd098848256071d3_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtMy0xLTEtNjgyODQvdGV4dHJlZ2lvbjpmNDJiN2IxY2Q4ZDE0NzczOGNmYTdiNzE2ZWJiMDRiMV84Nzk2MDkzMDIyMjI4_8ebe0fe4-ca5f-4220-b136-889542894745"
      unitRef="number">0.010</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibf7b496d1968423ca0b81cb87f205866_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzYtNS0xLTEtOTU1ODM_704379cc-3718-4e00-89fd-7bffdc1277eb"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10d539e441f54f7987471e03eeb9fc39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMC0xLTEtNjg1NTMvdGV4dHJlZ2lvbjpkYTVjNjA4ZjkzYTU0OGY3YWRiMTlkYmY5OTNmMjU3OF84Nzk2MDkzMDIyMjMz_42715a68-68a7-4fbf-9194-fd6899703cf0"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i10d539e441f54f7987471e03eeb9fc39_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMi0xLTEtNjg1MzM_a8e452c7-ed63-4a18-9836-c1e272c0031d"
      unitRef="usd">500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i9d56a45dc3ab43509ef66161e0e3fa63_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctMy0xLTEtNjgyODIvdGV4dHJlZ2lvbjoyNjVhNWUzZDA3OGY0Mjc2ODhlOGYyYzIzNTUwMjQ2Yl84Nzk2MDkzMDIyMjI4_de017450-75b0-4144-a285-342938ab7d53"
      unitRef="number">0.008</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib05b839f30d040bebcd89a0c1fb92f5a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzctNS0xLTEtOTU1ODU_0c37fded-6749-4375-84ce-cf8ec1024321"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i367d9d22b1c34ce1b4cdcd7cc2620446_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo2ZjAzYTFkZWYzZTI0NGUxOTdhMGZhMTc0YzVkMDAzMV80_049a6ba5-534a-4a4a-ac35-7de53f30518e"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i367d9d22b1c34ce1b4cdcd7cc2620446_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktMi0xLTEtNTU1NTQ_992413df-2b11-481e-b7d3-73f8fe891451"
      unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i3b46f3feeb0e47c0a2c7e9a4c6f05a7d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktMy0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpkNGMyYTAyN2YyMzE0NDUzYjhlMDBhYjk0NmZlZjlhYV84Nzk2MDkzMDIyMjM3_85fd230c-07a8-4c5f-b062-9f921edf0c86"
      unitRef="number">0.041</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iec7fdb2956cb4333b6f9bcb209040ea5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktNS0xLTEtNTU1NTQ_eaebf3cf-090c-49ba-b9c9-6196c5ef6062"
      unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeBasisSpreadOnVariableRate
      contextRef="i3b46f3feeb0e47c0a2c7e9a4c6f05a7d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzktNi0xLTEtNTU1NTQvdGV4dHJlZ2lvbjozNWZiMzMzYWQyZjQ0MzVjODliYTE2YTIwNzM5NmIwNF84Nzk2MDkzMDIyMjM2_85fd230c-07a8-4c5f-b062-9f921edf0c86"
      unitRef="number">0.041</us-gaap:DerivativeBasisSpreadOnVariableRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i35713b5b6ffa49349b004817c7c9da42_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzEwLTItMS0xLTU1NTU0_0d08513a-704c-4edc-b7c1-49af1804c93b"
      unitRef="usd">6650000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie614baae5549413b95d0a5b95b79a24b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZToxZjVjZjA3MDdmOTM0MzFjYmFiYjhkYjM2M2ZlMDA2NS90YWJsZXJhbmdlOjFmNWNmMDcwN2Y5MzQzMWNiYWJiOGRiMzYzZmUwMDY1XzEwLTUtMS0xLTU1NTU0_28d2ceef-d364-4cb4-a4de-ee3b693e0809"
      unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgxMTQ_6790987d-26f7-47e4-a5f1-a46c91ee7d2b"
      unitRef="usd">940000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwMzgxMjg_b760409c-9c2b-4766-b66c-dbde0c51263e"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDI3_4bcbfe82-c378-4b4a-a4eb-83471f35addc">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following principal amounts of each series of Old Notes were validly tendered and subsequently canceled in connection with the Exchange Offer (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal amount exchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% 2037 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% 2038 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% 2039 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% 2040 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% 2041 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% 2042 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% 2043 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib4283cce94284118a0034337aac219b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzEtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo1MjgwZTQ0NjMyNDU0ZTc5YjY3OGJlNDMwNDk0ZTZhOV80_553de637-27ba-461b-b5d3-86133fd5aa66"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ie558eaebb0734ac988923b72ab5749e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzEtMS0xLTEtNTU1NTQ_a8ef1ebb-f8fc-477c-aa3d-9db4bf484da3"
      unitRef="usd">74000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5d7a63a419144cf0aca9c1b14bf3aff1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzItMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjphOWNkMWIzZDlkN2U0MjIwODc4ZDM5MzYxZTg2MmFlOV80_6a4dc4da-0224-4347-b62d-2def74e747fa"
      unitRef="number">0.0690</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i33af7431531e4906871dc1c72260a8f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzItMS0xLTEtNTU1NTQ_6940e88f-fb29-4087-a6bc-a4e80e26a897"
      unitRef="usd">37000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i29d7e93cc83149e6bd46d9c7b5b95be3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzMtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo5YjRkZmViMTg5OWM0NmU2ODRmOGE3MjU0Yzk2MWJhYV80_b3dbd208-0d53-4446-9737-18f3a19173c0"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i5c65ad1961624e6fb50c1eb26eb83dcd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzMtMS0xLTEtNTU1NTQ_5b0bfc86-b40f-4ee4-896b-85afa3c328b7"
      unitRef="usd">133000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i93bbfe5fa69940c08425fb453c4429a2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzQtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjpiN2Y2MDhlNzY3Y2U0NGFlODM5NDBhZTEzMzJlMjdkMl80_33b5b776-f656-4d8e-bba3-1e85c240c938"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="if03447162cb44ded9a9e6203334836ae_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzQtMS0xLTEtNTU1NTQ_d401647c-3b5e-45ea-8aac-880813f662bd"
      unitRef="usd">39000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i689ad4255db545eda69e365f169f332a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzUtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjplZmExYjFkMDQ2ZGQ0MWI4YWQzYmEwNjllYWU5YjdkY180_79288eed-1425-47b8-a5f0-c91164fb37b5"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i9d0f0acd616746d5b35dd8a2dbf392d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzUtMS0xLTEtNTU1NTQ_4ee60c54-b8a3-4e3b-b708-95a86ec449a3"
      unitRef="usd">245000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i29adc72b130b479ea45a8aaa03b088d5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzYtMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjo4ODZmNzllNTUyZjI0NWQ2YmI0YTRlOGU3MTA1YmZkMF80_94d84804-8e34-4867-9f23-bef1a7c9b2ca"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ie320a4dc28964d3e945ea0199a471f76_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzYtMS0xLTEtNTU1NTQ_d12eb813-99a6-46f1-a900-66a486c5dbd9"
      unitRef="usd">72000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i364ca273078a47eca7c0fe7c36707bf5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzctMC0xLTEtNTU1NTQvdGV4dHJlZ2lvbjoxNzc5ZmI0NTYzZWI0NTYzYjhmMDgzNmYxZmE0MjBiNF80_795f6e91-4626-464e-b18e-539ebd31da70"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ic5e84ea875e544c9937c0c203818dead_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo3N2VmZGI4ZDViODI0MTg4ODM1OTA1OWIyYWU2MDAwNy90YWJsZXJhbmdlOjc3ZWZkYjhkNWI4MjQxODg4MzU5MDU5YjJhZTYwMDA3XzctMS0xLTEtNTU1NTQ_630478e3-8595-4ede-80a5-3cc02a6895d7"
      unitRef="usd">76000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzUyNjk_a97ca2c3-906a-4da9-8bef-51c3dc84d795"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU1MzY_0a7cd5ff-1d7a-4f83-881d-bc17558869c8"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:DebtExchangeAdditionalCashConsideration
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU1OTA_f7a96d04-0266-4f28-b2d0-c23da181eafa"
      unitRef="usd">85000000</amgn:DebtExchangeAdditionalCashConsideration>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU4MzU_b1d80c94-82c0-4e8b-9dcf-6bb28d3c8148"
      unitRef="usd">264000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65aa6303a58f433a9f8c30fcfafcc35e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzU4Njc_c07e03b4-0a70-4693-bd40-c5f8a7422082"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85976d51465e4619a93074b54175b619_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzYzNjY_25260897-f8e5-4dd5-a47e-107c7dfd753a"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i304433386dd64f7b8b7c9d12385a8ff0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzYzOTM_8e06de45-df3f-4a96-9378-3c0d894aa341"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98a4dd44308e488e8ca8ea8c340c9dec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzY0MTM_4081980a-0bc4-42d5-89bd-2e76dde579ca"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iac7cfc1d53e24fd78daf8dd8e35119d4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzY0NDY_1b35ed9c-8ee1-4765-87da-81a6d39b84ce"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3115a2e5d2b648bb866394e00f7e6265_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2NjU_0fb0d36b-47a7-47af-b315-11adff808d9d"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3115a2e5d2b648bb866394e00f7e6265_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzg3OTYwOTMwNDI2MTM_d507f740-d481-44ec-a893-396a0b5d9ba5"
      unitRef="eur">1250000000</us-gaap:DerivativeNotionalAmount>
    <amgn:MaximumBorrowingCapacityUnderCommercialPaper
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzY4MzM_39475a59-96ba-40ec-ba6b-8f401e06cfbe"
      unitRef="usd">2500000000</amgn:MaximumBorrowingCapacityUnderCommercialPaper>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3f3f69cfacea4717a178488113e7724c_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcwMzg_99e4a8d7-36c4-4fbe-970e-b9c311f72b30"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks
      contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzcyODE_c4ee5265-3247-4f6b-8693-edee0de45ba9"
      unitRef="usd">750000000</amgn:AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks>
    <amgn:LineOfCreditFacilityInitialCommitmentTerm
      contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzczOTQ_c8131925-6a5b-4146-ba12-e933180a9765">P5Y</amgn:LineOfCreditFacilityInitialCommitmentTerm>
    <amgn:LineofCreditFacilityNumberOfRenewalOptions
      contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc0MzQ_51da4eb9-b6ad-4d74-9ad2-d4c41fbee822"
      unitRef="renewal_option">2</amgn:LineofCreditFacilityNumberOfRenewalOptions>
    <amgn:LineOfCreditFacilityExtensionOfCommitmentTerm
      contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDAx_4fae9202-38a0-4b0b-8458-574441c50319">P1Y</amgn:LineOfCreditFacilityExtensionOfCommitmentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i7d423a8369fd46a5b5605a028723f14a_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc1NDM_678d1e36-82e2-4535-bfed-9a8437aed3af"
      unitRef="number">0.0009</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc3NjA_d9c73842-403d-4acd-bb74-69ffa70e019c"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib0423efbfc4c49a3a0c6e8782283b9e4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc4ODk_05997eb6-58ee-458a-a33d-25337fff1404"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5OTU_c7ccd4b3-d705-490a-a4a6-8826f612e9f1">one-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i96b009c3cd61481292dc6c534b741eec_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzc5MjA_18c062f8-59ce-42a2-8e53-0d797e976899"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCredit
      contextRef="i3f3f69cfacea4717a178488113e7724c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzgxMDc_3031d9d8-8707-49b8-bc1e-e4d17983ca62"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="if751ec72d1334a0aa3244e35632460fc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzgxMDc_ef3a1381-86bc-4d86-a4eb-83e4e824bfcc"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4XzEwMDIw_485946bb-f829-4051-ab20-276cb65f8eb6">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December 31, 2021, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzEtMi0xLTEtNTU1NTQ_47b4c6b4-e1f5-4c6f-8da0-f9adea8e824a"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzItMi0xLTEtNTU1NTQ_fecd8146-5e1c-4478-a086-9cb44a89bbf2"
      unitRef="usd">1517000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzMtMi0xLTEtNTU1NTQ_bd76eb4c-6bf2-4700-8aab-99cc3ff235bd"
      unitRef="usd">1400000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzQtMi0xLTEtNTU1NTQ_4f6cad3d-9cf3-4f63-b0de-d80047dff907"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzUtMi0xLTEtNTU1NTQ_c707aaea-b841-467b-8fc5-4af6bce1cc17"
      unitRef="usd">2746000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzYtMi0xLTEtNTU1NTQ_9a786abe-1b7e-4568-84e1-c358df3e9309"
      unitRef="usd">27075000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90YWJsZTo0OWQ1YTk2YTg3NTg0NTNhYjQ3YjdjN2Q5ZGM0MGU3Mi90YWJsZXJhbmdlOjQ5ZDVhOTZhODc1ODQ1M2FiNDdiN2M3ZDlkYzQwZTcyXzctMi0xLTEtNTU1NTQ_c8410799-0ea0-4c54-8ce1-55fd34d311f3"
      unitRef="usd">34238000000</amgn:LongTermDebtMaturitiesRepaymentsOfPrincipalNet>
    <us-gaap:InterestPaid
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5NjU_531408fe-f09b-4ba7-97f9-dad573c0525d"
      unitRef="usd">1200000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5Njk_fc2eca58-4ce7-4733-ab76-333c7907001b"
      unitRef="usd">1200000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yMzgvZnJhZzo2NDk5YmZiNTBiZjU0YzliOWViYzBkNTBmYTVlNTc2OC90ZXh0cmVnaW9uOjY0OTliZmI1MGJmNTRjOWI5ZWJjMGQ1MGZhNWU1NzY4Xzk5NzY_5a6fdfe3-379d-479c-bd97-fbad874b12b1"
      unitRef="usd">1300000000</us-gaap:InterestPaid>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMzE_ba2d221d-225a-46d9-b8cf-5fb495d3a76d">Stockholders&#x2019; equity&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock repurchase program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Total shares do not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, October 2021 and December 2021, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $3.4 billion, $4.5&#160;billion and $5.0&#160;billion, respectively. As of December 31, 2021, $10.9 billion remained available under our stock repurchase program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors declared quarterly dividends per share of $1.76, $1.60 and $1.45, which were paid in each of the four quarters of 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 3, 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share of common stock, which will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $33 million expense and a $55 million expense in 2021, a $14 million benefit and a $110 million benefit in 2020 and a $28 million expense and a $46 million benefit in 2019, respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $1 million expense and a $7 million benefit in 2020 and a $22 million expense and a $14 million benefit in 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2021 and 2020, no shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <amgn:StockRepurchaseProgramTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMjI_ccbb7948-bcc3-467c-b9f9-74eb363341f5">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Total shares do not add due to rounding.&lt;/span&gt;&lt;/div&gt;</amgn:StockRepurchaseProgramTableTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtMS0xLTEtNTU1NTQ_43ce3e45-af96-4f4f-95ed-4a8f23141eab"
      unitRef="shares">3700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtMy0xLTEtNTU1NTQ_2fd7ccfe-694f-4261-b5c5-04594b6e96e1"
      unitRef="usd">865000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtNS0xLTEtNTU1NTQ_4130e974-04d2-4c8e-a1ad-20f9a83c66ee"
      unitRef="shares">4300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtNy0xLTEtNTU1NTQ_38235627-d334-4588-ad9b-78d043c911ae"
      unitRef="usd">933000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtOS0xLTEtNTU1NTQ_c5817b05-261c-474f-ab0e-ffb522f46b40"
      unitRef="shares">15900000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzMtMTEtMS0xLTU1NTU0_2c9de23f-91e7-4d4b-8b34-022dad98d63b"
      unitRef="usd">3031000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtMS0xLTEtNTU1NTQ_bcbc7591-e5ac-40e9-a314-637c0976cca4"
      unitRef="shares">6500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtMy0xLTEtNTU1NTQ_efe32a7f-674e-4425-94a1-ba28e25803ef"
      unitRef="usd">1592000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtNS0xLTEtNTU1NTQ_9d03f421-c48b-40a2-a77b-fa6af9bc30bb"
      unitRef="shares">2600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtNy0xLTEtNTU1NTQ_d22a17e1-26e6-4e99-909c-827293cf973c"
      unitRef="usd">591000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtOS0xLTEtNTU1NTQ_8e65bdde-f157-43a2-9798-38668502455e"
      unitRef="shares">13100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzQtMTEtMS0xLTU1NTU0_68ceedbb-7aa4-4e55-8858-4ca3b0b59358"
      unitRef="usd">2349000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtMS0xLTEtNTU1NTQ_4cf2e996-bc50-4b66-bdac-f03e8331b5a2"
      unitRef="shares">4600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtMy0xLTEtNTU1NTQ_0d1faf3e-1a21-4892-a2c1-c82943d53661"
      unitRef="usd">1069000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtNS0xLTEtNTU1NTQ_79722a40-a2fb-400a-b875-995f60ed988d"
      unitRef="shares">3000000.0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtNy0xLTEtNTU1NTQ_4b0572de-362f-423c-9b03-82f29b4c409b"
      unitRef="usd">752000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="icd3e56f17777422db7fd7146740984bf_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtOS0xLTEtNTU1NTQ_9b40e469-cf89-40cd-9001-dbf00dd928fc"
      unitRef="shares">6200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icd3e56f17777422db7fd7146740984bf_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzUtMTEtMS0xLTU1NTU0_cf497197-895f-453a-8e43-1ecccd0d5f3b"
      unitRef="usd">1170000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtMS0xLTEtNTU1NTQ_b2da0214-edd3-4358-86e9-5951380a2400"
      unitRef="shares">6900000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtMy0xLTEtNTU1NTQ_d3d4f900-21ff-4b15-ad51-a9432b7c1be6"
      unitRef="usd">1461000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i5da70484870944a2be74c9435a52ba12_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtNS0xLTEtNTU1NTQ_9a7e2527-60b0-4c5f-830e-c8a13cb5a268"
      unitRef="shares">5300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5da70484870944a2be74c9435a52ba12_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtNy0xLTEtNTU1NTQ_1f8ab06e-6d84-4575-aade-267836cfc8b5"
      unitRef="usd">1221000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtOS0xLTEtNTU1NTQ_7e27fd9d-4d76-4f2b-ab14-33dfccfbd08f"
      unitRef="shares">5100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzYtMTEtMS0xLTU1NTU0_862ebf61-e8a1-4753-9f09-75ffbdf61c79"
      unitRef="usd">1090000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctMS0xLTEtNTU1NTQ_948b9c71-6387-4e45-9e81-b402b6ddcd71"
      unitRef="shares">21700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctMy0xLTEtNTU1NTQ_fabaa075-5430-444b-bbb3-ad9eac324dfe"
      unitRef="usd">4987000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctNS0xLTEtNTU1NTQ_0e1b95b7-9b0e-445c-a849-9643b6950280"
      unitRef="shares">15200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctNy0xLTEtNTU1NTQ_2a215277-d574-4c7a-970d-06a3fa31372b"
      unitRef="usd">3497000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctOS0xLTEtNTU1NTQ_c4252065-50bc-4da8-b149-b0a81923c62c"
      unitRef="shares">40200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTo3ZGRmMjc0MzdmMWE0MTE2ODZkNWIwNGFjYjU0ZGJkYy90YWJsZXJhbmdlOjdkZGYyNzQzN2YxYTQxMTY4NmQ1YjA0YWNiNTRkYmRjXzctMTEtMS0xLTU1NTU0_fa1635ba-ef08-4c3e-9dbf-2a92ccefcd25"
      unitRef="usd">7640000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5cae36825a8244718a036f07b201a220_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzMyMw_8822b562-97b4-4b83-8957-043aaf00ff2a"
      unitRef="usd">3400000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if1d25f0b06be4a2ca6927d47f49abd4e_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEwOTk1MTE2MzEwNjc_d880accd-e79e-4616-9ae7-9a9677647511"
      unitRef="usd">4500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1Xzg3OTYwOTMwMjU4MTI_54707672-ca4f-456d-ad63-e9bd7d2227b9"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzMzNw_992fa5a1-64d2-46ff-93e6-754fa53ce7e2"
      unitRef="usd">10900000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i893df3cf158b4ab2a0c0d1c82a28c1bd_D20211001-20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_2ac64e40-5260-49cf-afdc-57c1b7550228"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5154a4b4a2bd4af983bf6185d3daba74_D20210701-20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_37b9f524-9fc6-4fa3-8f1c-5664b4c761cd"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i84b80cae33f14e50bf2db19c64a6b9b3_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_45a47744-5d2c-4cd0-b732-c40fd344e758"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_52d52d8c-59c8-41fe-849e-923b9ade4145"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="icfca6c2819ef49179fc85b016ce6016f_D20201201-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_722cce9c-2975-4438-b26d-85e2a8a1d974"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="id0da8ff0a4ea42e5bde711755c1becc7_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_b0640032-3f6f-4345-a8f8-7696bb67543f"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2f7cba5195f24f829ec32f1b71cfd77c_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_babe7c61-3728-41eb-b024-05d71dec1047"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="iea5b5d1d715a4d60bf920b423703f939_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3MQ_f7a20ca3-96fb-4cc6-929e-2fe45d1b8ced"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i79d67c476fb84742aaa3dd181c473b11_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_03cd5030-96f9-4f45-9071-d85d7a782f11"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i5da70484870944a2be74c9435a52ba12_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_04bd71e4-d126-4973-88fd-b1c2a515e8e2"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4eaa406cdfdd4c51b6756655cc712766_D20200701-20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_71eac9d8-8c94-434b-881f-5b70db93b1e2"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ie0525317a3854d51a1e9bfd978e4a25e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_b8686433-06cf-459b-b63a-0d2496174ab8"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i057e903f7a944a79a5b3a683153318e4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_cb360cd7-c636-4cd9-85df-359c430c2076"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i7254d1d0af7c46758551512b7d50361d_D20201001-20201031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_d0b36cd3-91c0-4d82-8d41-e95b02e72070"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8fabc5abd9df4b559effd9eb67abea89_D20191201-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_e24c8796-532f-4af0-b268-77f650a2c336"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i3b33af0508754ca28e72f99a484d9cf0_D20200301-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ3NQ_e87adaa3-d05a-41f4-9cca-d43951897c2d"
      unitRef="usdPerShare">1.60</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i39b8f49d86e9448ab5f6101aa9d1fc57_D20190301-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_065fe602-8579-436f-a948-c397b4b71ee8"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ic5d469256f014ad1b7014a15666552cd_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_075be703-a8a6-4929-b222-b2eb6569a12b"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ic9606f64c78d4da69fb515f527a9d162_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_2b64cc56-6e60-4d73-bc94-f27507a8d94c"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8a8d1cde152d418a976984815e041aa2_D20181201-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_4defe74a-35c5-4f1a-956e-b166443f3497"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i323451cad3a2466080975105981c98c8_D20190701-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_57034503-b948-4a2d-8733-3762e67d1ac5"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i3bfd777b57744211bfc870b0e16e1e64_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_7270c19d-6488-4df6-8a34-86bbe0b9533a"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8a85ddddc43a4b40bf86ad5da75e8de4_D20191001-20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_839140d3-4c9a-4f92-85b8-961aeec35ad1"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="icd3e56f17777422db7fd7146740984bf_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzQ4Mg_cfe148f0-8a4b-4b4e-96a2-7c16915945e4"
      unitRef="usdPerShare">1.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5a63a090508f49fdaacb88df082eb50b_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzkyMA_57ee4ea1-c400-4003-ba7c-e0dbf4c3654e"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i67c13f8bb98d4f9b86238d8564507387_D20220308-20220308"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzkyMA_80f99692-de30-4eb4-b716-4443b97d9f15"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMTc_3cf36598-a208-4247-b5b7-b8ed0efca809">&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i309108b032084722a376b8a102fdb202_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtMS0xLTEtNTU1NTQ_dd7e343d-f9b2-4504-b799-b466935ca82a"
      unitRef="usd">-670000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifeb9c001d530444d809bab4daa3b3248_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtMy0xLTEtNTU1NTQ_b505650e-d37a-4571-9e6c-37751a766c61"
      unitRef="usd">241000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4494701f92e4c3497b69ce57bf3c5db_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtNS0xLTEtNTU1NTQ_b6347297-2a1f-46db-8aed-22f7a45b2a3f"
      unitRef="usd">-338000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i22a6854354df440da13fa35f04216a12_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtNy0xLTEtNTU1NTQ_5df4dc43-269a-4988-bfc3-86666251f9e2"
      unitRef="usd">-2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if37f4705aa9b489a9965276d6b9e48de_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEtOS0xLTEtNTU1NTQ_728ff407-da1d-4315-bcc3-81ca5b062151"
      unitRef="usd">-769000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4295abe2e530430ca537010e380381f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzMtMS0xLTEtNTU1NTQ_45ae5c4d-d094-42b3-8192-580c69487e0f"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzMtOS0xLTEtNTU1NTQ_9f3a0a97-677d-4186-9730-ea7adf965e3e"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="if79b493edfda4614928afa72235cd218_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzQtMy0xLTEtNTU1NTQ_cbc0c18b-7bc7-4306-9511-4baa2ab8c5f6"
      unitRef="usd">127000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzQtNS0xLTEtNTU1NTQ_eb8e7d6b-0dfc-49d7-a5aa-8d28ecfaf7ff"
      unitRef="usd">424000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzQtOS0xLTEtNTU1NTQ_26d5f496-da91-406e-9808-0c0a7b118364"
      unitRef="usd">551000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="if79b493edfda4614928afa72235cd218_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzUtMy0xLTEtNTU1NTQ_8da60dd5-a776-4cda-bfaa-8caf2ac80462"
      unitRef="usd">211000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzUtNS0xLTEtNTU1NTQ_10bf1ba1-a277-4009-acfe-432bb48ab5a0"
      unitRef="usd">56000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzUtOS0xLTEtNTU1NTQ_4223f7be-ef37-42a1-97b9-0885981e143d"
      unitRef="usd">267000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i8ab69b9f5c1b4692a5c95f9a65dc9566_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzYtNy0xLTEtNTU1NTQ_eca08c65-3d4f-4ba8-a4f3-70601fb1d8a2"
      unitRef="usd">-5000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzYtOS0xLTEtNTU1NTQ_0d5fa5fe-37e8-4077-a5eb-ae6fc6a8d1df"
      unitRef="usd">-5000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i4295abe2e530430ca537010e380381f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctMS0xLTEtNTU1NTQ_2dd581c4-95e5-40ba-afa6-ac7511d49138"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="if79b493edfda4614928afa72235cd218_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctMy0xLTEtNTU1NTQ_7ba11eff-e80b-443b-b094-7f7bc286b114"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ie8d1f8dc121b44b98a69b572780b1482_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctNS0xLTEtNTU1NTQ_86fbf402-549e-4f26-b447-691819968b47"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ifa3b6399dc8a464da15f6f8b77ed1bfc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzctOS0xLTEtNTU1NTQ_7fd5475e-832c-4916-9970-0df886c06a73"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i98c41d891d134edd86170c260149c788_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtMS0xLTEtNTU1NTQ_30593eec-fdf6-4579-9108-810579aca7f7"
      unitRef="usd">-718000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3e3518c83274b19a2f3f3b2116e682d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtMy0xLTEtNTU1NTQ_4b33dd22-c40d-4cee-94ac-f05696815917"
      unitRef="usd">175000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9cfb6c5904e48c7bbfba692c97f5afb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtNS0xLTEtNTU1NTQ_c56eb19f-55bf-4fce-9ee3-da4b2f7a6ef3"
      unitRef="usd">22000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b2c015276b143d1902156c9b84463e2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtNy0xLTEtNTU1NTQ_219c198d-cb21-4784-b071-e8c03095049b"
      unitRef="usd">-7000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea207d0ec0394b108fc793525231d205_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzgtOS0xLTEtNTU1NTQ_861f6b62-4790-4ee8-a89d-4ba29a5aab16"
      unitRef="usd">-528000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4b69b0fa4326426ba338b1b8a382b779_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEwLTEtMS0xLTU1NTU0_104c6c64-ab09-4c6a-a844-19fc3af825b4"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEwLTktMS0xLTU1NTU0_de520191-54bc-4a85-88e9-d0bc4f16ffa3"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzExLTMtMS0xLTU1NTU0_672dff8e-773b-414c-8038-d1211b4f71cf"
      unitRef="usd">-61000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzExLTUtMS0xLTU1NTU0_97acb0a7-d7b3-403d-bd5f-69c4b75064dc"
      unitRef="usd">6000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzExLTktMS0xLTU1NTU0_f98dfa48-7fa3-4db0-ad1f-14463cc9fa84"
      unitRef="usd">-55000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEyLTMtMS0xLTU1NTU0_e33d3d53-58b4-4bec-bd62-e974888aed67"
      unitRef="usd">-501000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEyLTUtMS0xLTU1NTU0_6349301b-1f83-4c2d-83ac-f206b7118b70"
      unitRef="usd">-33000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEyLTktMS0xLTU1NTU0_5111b0ef-9b9d-40a5-b379-3d73be041066"
      unitRef="usd">534000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ieef7a11bc8b34811a438f59e60dba040_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEzLTctMS0xLTU1NTU0_c696b537-8bdd-47b7-bb0e-536b9facb8f8"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzEzLTktMS0xLTU1NTU0_dbd334ac-54e2-4cec-ac98-b27e03644a04"
      unitRef="usd">-7000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i4b69b0fa4326426ba338b1b8a382b779_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTEtMS0xLTU1NTU0_bc3a8c9e-2b36-4ce7-890d-b5c71c336e7b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i00eaf3897a2d4ba8adf1408857ad7499_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTMtMS0xLTU1NTU0_6c187673-a4d2-4a46-bdc4-e126e0c73521"
      unitRef="usd">-124000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="icf7fe3490bfd4458a9e8f52a72daf794_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTUtMS0xLTU1NTU0_bb37250a-99ab-48e8-8c17-5cc0aa10c8a5"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i490a73e325c3475f986e675f73de9c08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE0LTktMS0xLTU1NTU0_3aa59c9d-c25f-4d58-a5ea-ec6c7c131153"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i53d33d7ade654ad299e31d14b471a5bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTEtMS0xLTU1NTU0_ff50ba09-a09b-4d78-a05a-97420becc34e"
      unitRef="usd">-709000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbbfb42202ea4564988889ffa1175789_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTMtMS0xLTU1NTU0_e3b6ce41-fc5d-423d-a411-1c2e5f3f561b"
      unitRef="usd">-263000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04a925f891f9422095e83c9bfcfb8e7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTUtMS0xLTU1NTU0_e1d3dc90-c680-4779-99ea-0fcf2729624b"
      unitRef="usd">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac308cc20ed14c5cace71b3353e328da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTctMS0xLTU1NTU0_933ce352-0720-4c29-88e8-00f79a7deb20"
      unitRef="usd">-14000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2766f3376fe7415ab521166b30e8525e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE1LTktMS0xLTU1NTU0_1f9ea6d4-7bac-4247-ab72-410b47d8cde7"
      unitRef="usd">-985000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i258fcbb2c8764cbb987b87e8e1c787ea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE3LTEtMS0xLTU1NTU0_05f81bdc-df83-4151-b57b-32a24d9a235d"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE3LTktMS0xLTU1NTU0_af57340f-dbe2-4458-8984-88e690eb3262"
      unitRef="usd">-135000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE4LTMtMS0xLTU1NTU0_48987d63-d94a-4bf1-a504-b041296f9a07"
      unitRef="usd">159000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE4LTUtMS0xLTU1NTU0_6e863f8c-fd4e-4ad7-a95f-d089f2caf35e"
      unitRef="usd">-1000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE4LTktMS0xLTU1NTU0_33a9bcac-2f67-4b11-8f3e-6458fde879f0"
      unitRef="usd">158000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE5LTMtMS0xLTU1NTU0_661d0972-477d-415a-976b-fa9b0ad1d858"
      unitRef="usd">253000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE5LTUtMS0xLTU1NTU0_31af02b4-1512-4ddd-a644-caa0a64ffe1f"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzE5LTktMS0xLTU1NTU0_862555ea-a416-4877-885a-158bd8037b1c"
      unitRef="usd">-253000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="i000812ada76e42979388c4d128fa90de_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIwLTctMS0xLTU1NTU0_86edff0a-4b97-4c4e-89db-9496eef09ecf"
      unitRef="usd">1000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax
      contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIwLTktMS0xLTU1NTU0_01d14e19-a374-41c3-9f0b-2317ad18e34f"
      unitRef="usd">1000000</amgn:OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i258fcbb2c8764cbb987b87e8e1c787ea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTEtMS0xLTU1NTU0_f5717ba7-4f8e-44d1-acc7-37f1ce345afa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i0d0053beb691413d8368603d9e5b44c4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTMtMS0xLTU1NTU0_565c8d98-1920-4407-88fc-7d62e1262bd6"
      unitRef="usd">88000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="iab60cfd2287642e4bbec1374ffc6a6df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTUtMS0xLTU1NTU0_eae993d0-f55e-4162-a968-eedf81ad61ae"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia3d57a8001b04306923d18707df004a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIxLTktMS0xLTU1NTU0_4235f375-3021-4369-9f72-5785aee884c4"
      unitRef="usd">88000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i0914f3d7dcd6426aa7c1a21fa7f2d1fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTEtMS0xLTU1NTU0_7dcfcfb2-c6b5-4c9e-a339-cea76035a3d3"
      unitRef="usd">-844000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34745a1b911c4d30a56546635c8aa0de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTMtMS0xLTU1NTU0_3eb274e1-8545-4f28-a182-1109a8df6c00"
      unitRef="usd">61000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99bd951fd41947b592b8c02d8f1c27c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTUtMS0xLTU1NTU0_c7a5c0ec-35fc-4272-877d-34de9e980abf"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2fd5e2c85c274498bad48e922806e3ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTctMS0xLTU1NTU0_0fb49484-ab61-491b-b74b-383c6ce8b5fb"
      unitRef="usd">-13000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5a12fd9b94548e0a6d019cff9050821_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTphNjgxZGQzMGNiZWI0OTQwODY1M2VkZDFmMDIxMzMxOC90YWJsZXJhbmdlOmE2ODFkZDMwY2JlYjQ5NDA4NjUzZWRkMWYwMjEzMzE4XzIyLTktMS0xLTU1NTU0_95f64898-c5eb-4d7c-a358-d1906afd34a0"
      unitRef="usd">-796000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzNDA_72707def-51bf-4482-a7cd-95fe90fef467"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzNTc_32b92e7e-2f2d-4431-9086-8f5eecc2158b"
      unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzNzc_35c5adb5-3b24-4091-b0a7-185613a489f1"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzEzOTQ_39f02b13-95d2-4041-947c-3ace2b163689"
      unitRef="usd">-110000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE0MTc_edc0e859-7f17-41c9-882c-574c39e8c50a"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE0MzQ_a52047e0-4e42-4411-9470-6b7a9a72f6f1"
      unitRef="usd">-46000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE2NjM_510cdb74-cf41-40e9-9bb7-85f5ebcac65a"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE2ODA_a5154d33-4e64-4179-a659-3664ca8a51ab"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE3MDM_0b1a15d3-1ecf-4481-9990-7bcc963e5054"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE3MjA_8ed581aa-c653-4832-9a61-290badc573f3"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzIwMjU_17973fef-ca36-4a24-ab7d-f44885596b18">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3b2f149e177b4bc3b630018b36f6e49c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzMtMi0xLTEtNTU1NTQ_c7ddbdf6-1398-4864-b9b4-09d0ad47243f"
      unitRef="usd">-8000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifad2966682ec4e37bbcfa6626b7183ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzMtNC0xLTEtNTU1NTQ_97d94ec5-44dd-48d8-afd9-5e129ef9a591"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7e4dd663b9fc4f028f2085d56886e460_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzMtNi0xLTEtNTU1NTQ_0ceb126f-a6cd-4e5b-8c14-7af8263cb4c5"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i35372b79111c40a58a07694440d9622c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzQtMi0xLTEtNTU1NTQ_21545584-9072-4211-bc8b-9799527d201f"
      unitRef="usd">-245000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icd31886569fd4668bfb1bce453953983_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzQtNC0xLTEtNTU1NTQ_97771b98-602c-4b26-9713-06e7e1e0f50b"
      unitRef="usd">323000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if8a842d09a06449083eeab3521739d0d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzQtNi0xLTEtNTU1NTQ_1a23efcc-70c0-4b57-b659-da7f06bb343b"
      unitRef="usd">110000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzYtMi0xLTEtNTU1NTQ_685c68cc-d9e1-4b4a-b5b9-17e2c7d61261"
      unitRef="usd">-253000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzYtNC0xLTEtNTU1NTQ_9984dd83-ba07-41e9-b153-c6b52c4e2605"
      unitRef="usd">501000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzYtNi0xLTEtNTU1NTQ_c0f97ff3-fc18-4941-b00c-81d78b5ebf41"
      unitRef="usd">211000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzctMi0xLTEtNTU1NTQ_cace139b-504f-473a-9a04-690e322a5d99"
      unitRef="usd">-55000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzctNC0xLTEtNTU1NTQ_06a0efc9-32e8-48ba-a6d8-f7ec9d66a35a"
      unitRef="usd">110000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzctNi0xLTEtNTU1NTQ_d79b8afc-1ad8-4786-90c4-3355572e61fd"
      unitRef="usd">46000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzgtMi0xLTEtNTU1NTQ_5b570fe1-6802-4eb7-8cab-35e8deccb6f9"
      unitRef="usd">-198000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e0d29723ee24231b1b0e874971b3727_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzgtNC0xLTEtNTU1NTQ_ec3337e5-cef9-4c6f-84cb-b6c8bbfded20"
      unitRef="usd">391000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i36d1a16080a04f809bc12fc05812b14e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzgtNi0xLTEtNTU1NTQ_228394a0-8aba-4359-b32e-dcc8c646a836"
      unitRef="usd">165000000</us-gaap:NetIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEwLTItMS0xLTU1NTU0_b9b8014c-2d7c-4f43-8cd2-12d5cac62af8"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEwLTQtMS0xLTU1NTU0_4d6f8bb7-a3f4-442e-8112-88e31d8d862a"
      unitRef="usd">33000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i35320f15f6674855866c5c06e985c83d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEwLTYtMS0xLTU1NTU0_e8014c68-b951-4abe-b3f8-11ca38b77781"
      unitRef="usd">56000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzExLTItMS0xLTU1NTU0_7fb395c0-7a39-463e-908e-c4e95ab5b85d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzExLTQtMS0xLTU1NTU0_f6316a4c-af65-4f03-8a5e-827f5af4a3d2"
      unitRef="usd">7000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i35320f15f6674855866c5c06e985c83d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzExLTYtMS0xLTU1NTU0_878e1b42-840b-4cd9-9b52-0b451b805fc0"
      unitRef="usd">14000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i57c7076358b7434dafa9839f9bfdc051_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEyLTItMS0xLTU1NTU0_5f9eea10-5455-470d-8782-fe3348d588ac"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i59bb5d06d0bc47f0909fdd7008d8a786_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEyLTQtMS0xLTU1NTU0_a6c79d98-5963-4db4-b607-f80de4d7ed72"
      unitRef="usd">26000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i35320f15f6674855866c5c06e985c83d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90YWJsZTozNDExZjZmOWRkMGU0ZmRhYWFjY2EyZWIzN2E5ZmU1My90YWJsZXJhbmdlOjM0MTFmNmY5ZGQwZTRmZGFhYWNjYTJlYjM3YTlmZTUzXzEyLTYtMS0xLTU1NTU0_ad805297-8dc3-429e-b185-d6b15ad018e6"
      unitRef="usd">42000000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5MDA_f482fe9c-412a-449d-bb7c-f7b37cee1f49"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5MzA_ae3ecc1c-9f22-4b0b-983e-169920217d29"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_2fc625a6-b1dc-4855-a27c-708ef1450106"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_97432e8c-06d6-4b8b-8931-578eeb6466f5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_b0b915e4-9deb-4fe8-8ac4-6429029c80c6"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDEvZnJhZzo1MWFhMmY2NTk1MTc0YmZkOTljNTJhYWU0ZGU5OWJiNS90ZXh0cmVnaW9uOjUxYWEyZjY1OTUxNzRiZmQ5OWM1MmFhZTRkZTk5YmI1XzE5NjE_c2b139f5-9cc3-4150-98f8-1a721d4e6c8f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyNzY_be58fc97-9d4e-473c-a5e9-7f8ed0d5ffa1">Fair value measurement&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations for which all significant inputs are observable either directly or indirectly&#x2014;other than Level 1 inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair values of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available information for similar companies that have actively traded equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net changes in valuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Teneobio in 2021, we are obligated to pay its former shareholders up to $1.6&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;amp;D programs. See Note 2, Acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of BioVex Group Inc. in 2011, we were obligated to pay its former shareholders upon achieving separate sales-related milestones with regard to IMLYGIC if certain sales thresholds were met. During the year ended December 31, 2020, we determined that the likelihood of achieving these milestones was no longer probable, and accordingly, the obligations were written off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of the fair values of other financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2021 and 2020, the aggregate fair values of our borrowings were $37.9 billion and $39.4 billion, respectively, and the carrying values were $33.3 billion and $33.0 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in BeiGene&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of December 31, 2021 and 2020, the fair values were $5.1&#160;billion and $4.9&#160;billion, and the carrying values were $2.8&#160;billion and $2.9&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyNzM_4095b313-aa24-465f-a428-8ec3590389a2">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2021, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurement&#160;as&#160;of December 31, 2020, using:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3749d6c99c044fd49a6d259f74ef6c99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtMi0xLTEtNTU1NTQ_ab1c4c58-da3d-4459-9f9c-db274e78353f"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe1e6522010e42beb2d5a512da981242_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtNC0xLTEtNTU1NTQ_06be2146-0147-4e30-8efb-43bdbc06d2ac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69f61d55abb54285bdf1fa8615440956_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtNi0xLTEtNTU1NTQ_90b38d6d-80a4-4fc4-a1dd-e79ff5fe3574"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1139b7c0e41848a5a7f99ae9f9cd45da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzMtOC0xLTEtNTU1NTQ_16be45f0-6a0d-4092-b80b-a36b0ba5f821"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfaf46a638094fa5b126a5684fbeec50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtMi0xLTEtNTU1NTQ_e74ef756-507e-4147-abcf-455138fed28e"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6203c3d089a640c88db71d0303989c08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtNC0xLTEtNTU1NTQ_c45b0d3c-0d1a-4abc-9676-8b8a408e58b9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d32c14a32b146d491c15b7db4b291f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtNi0xLTEtNTU1NTQ_caf2db4f-3eb4-44da-815d-0ce9c19fb47c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40d3a97a52f545c186e429329ac5c396_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzQtOC0xLTEtNTU1NTQ_2bbb2a9f-c105-4a71-b8a7-942bb1ef2cee"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91b247dc676e4516bae8242fab1601e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTItMS0xLTU1NTU0_0339ae60-c548-492e-9c07-7dd0fa8f6059"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bae52b8579846bf94e3c6a5aedc9878_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTQtMS0xLTU1NTU0_c7c0c210-49be-44f5-9671-68d1183af9e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ed17b422b8a4a51b6f39304fe4350a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTYtMS0xLTU1NTU0_a2016a7f-42a6-4f6f-8a2e-46371b801203"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd76882af6a14d589b489655ffae4b5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzExLTgtMS0xLTU1NTU0_6f4eb004-2818-45c8-abad-beae5cf45a95"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18b00e4e2c4742499d53a470e0343c3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTItMS0xLTU1NTU0_c35e37bb-4d16-4025-9e99-b094caa381b6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf2471fcfa074988acc387470355b7a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTQtMS0xLTU1NTU0_78a00093-7f58-40ee-9eb8-d18366187246"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if844eb33233f407fab5a2d1540261d05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTYtMS0xLTU1NTU0_654414cc-69a9-474e-96bd-37cb2d7d2467"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i746af9fdf7bf446bb8052c84b495b30a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEyLTgtMS0xLTU1NTU0_63caa8dc-6a06-43b6-9529-a46225c28486"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTItMS0xLTU1NTU0_6cded592-40f3-4487-a4b4-c41af5a7e5e6"
      unitRef="usd">611000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTQtMS0xLTU1NTU0_21297f52-a5e7-4f66-97a5-2c0d03706a94"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTYtMS0xLTU1NTU0_f21877b9-fb2f-4eb4-849d-5d1d416511e3"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzEzLTgtMS0xLTU1NTU0_3f16fcc0-0b35-4e7e-8a9e-c1eb44724f40"
      unitRef="usd">831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i5c953f5c148c48d182cf8f1587a75aaf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTItMS0xLTU1NTU0_5dc92dc9-b0da-46f2-b624-c7753f9806eb"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ifb66166118bd4add9f632ee3b805827f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTQtMS0xLTU1NTU0_d1ee22c2-185b-4e02-a7b0-467b8f4310e6"
      unitRef="usd">183000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6ddf499ee3f344b5b42a90e01e741b82_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTYtMS0xLTU1NTU0_12f2ea9f-9959-42e8-9a3f-df283c034d25"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ifb7d6eb6e0ea47e19bdbc24585673349_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE1LTgtMS0xLTU1NTU0_fb20fd0e-aa04-48ff-938d-6c82a99ba35a"
      unitRef="usd">183000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8d6231133c44412abb1a5cee2a4babf6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTItMS0xLTU1NTU0_56212184-31f9-4003-b2a6-4227894e376b"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie81fa5de4d71466aad60dae129ee4fb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTQtMS0xLTU1NTU0_daabe189-5e49-4448-a867-24f8bc821edd"
      unitRef="usd">66000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0bea7ddb5d2b4c51a7e8fcffe813ebfb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTYtMS0xLTU1NTU0_4124cdf9-b238-49a1-98e1-6d365aa264c7"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2ff7bb5325c6416cae92c622ff045f13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE2LTgtMS0xLTU1NTU0_7c08e3c3-8376-47d9-ad01-677807f34ad6"
      unitRef="usd">66000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i03d6fad6c8dd462eaf5fde3ea0c3ff70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTItMS0xLTU1NTU0_5c50bb00-3b0f-4765-a123-b302ff77d4d8"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i004a939dc0024ba59fe2c2766322fdd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTQtMS0xLTU1NTU0_ad6bcd41-9fbb-4050-8bb2-8b5cacbecfd8"
      unitRef="usd">16000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i1f15e114d3c64fe7946425ca3fc21f73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTYtMS0xLTU1NTU0_68a935c8-372c-4c53-8cf5-d51471b23770"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="idbe1823365054cc481d757a51d3eb3f8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE3LTgtMS0xLTU1NTU0_b453caec-a4f6-47e4-9bc5-9c0af544a332"
      unitRef="usd">16000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTItMS0xLTU1NTU0_a7649abb-962b-4e93-90f4-2091cfa7a5f3"
      unitRef="usd">7914000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTQtMS0xLTU1NTU0_25e64b77-8ee8-4acd-a67f-3cec2dd44b03"
      unitRef="usd">266000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTYtMS0xLTU1NTU0_e7e7c42a-dac1-4496-bdc9-ee8e1f6647f4"
      unitRef="usd">220000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzE4LTgtMS0xLTU1NTU0_15f31e1c-c067-47f8-871c-2b1c4425fa22"
      unitRef="usd">8400000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i5c953f5c148c48d182cf8f1587a75aaf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTItMS0xLTU1NTU0_a1b8c00d-0357-4340-b475-a3d8e4efe3e6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ifb66166118bd4add9f632ee3b805827f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTQtMS0xLTU1NTU0_260b3a8d-55dd-44f7-80fa-70b10efd2972"
      unitRef="usd">39000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6ddf499ee3f344b5b42a90e01e741b82_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTYtMS0xLTU1NTU0_ba4d86d1-587f-4037-ab16-3e6300aa299e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ifb7d6eb6e0ea47e19bdbc24585673349_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIxLTgtMS0xLTU1NTU0_9f2ca49d-baf1-42d4-adb4-6ce053814c60"
      unitRef="usd">39000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i8d6231133c44412abb1a5cee2a4babf6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTItMS0xLTU1NTU0_038415de-3e1f-457c-bfc4-5f72369ab67c"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie81fa5de4d71466aad60dae129ee4fb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTQtMS0xLTU1NTU0_a92c81b9-ccba-496f-9168-4f2e104631c1"
      unitRef="usd">339000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0bea7ddb5d2b4c51a7e8fcffe813ebfb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTYtMS0xLTU1NTU0_aedcc644-9cf8-4f93-96e9-dbaef33b7da2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2ff7bb5325c6416cae92c622ff045f13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIyLTgtMS0xLTU1NTU0_7c4ba9e6-6f56-492b-b6d5-4ad8838695fe"
      unitRef="usd">339000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i03d6fad6c8dd462eaf5fde3ea0c3ff70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTItMS0xLTU1NTU0_86ce378c-bb61-4636-acce-8bc2214082fa"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i004a939dc0024ba59fe2c2766322fdd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTQtMS0xLTU1NTU0_9dad2f5a-fdcc-4c01-ab01-b281ee929a8a"
      unitRef="usd">156000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i1f15e114d3c64fe7946425ca3fc21f73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTYtMS0xLTU1NTU0_dabcc686-0bf0-42ac-abef-8d41fc32e9a8"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="idbe1823365054cc481d757a51d3eb3f8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzIzLTgtMS0xLTU1NTU0_7abe8644-96cd-4fa8-afaa-fb0ac281903a"
      unitRef="usd">156000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTItMS0xLTU1NTU0_6994f6d7-a299-4eb5-88fa-e86e03f9ea0a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTQtMS0xLTU1NTU0_7e9c8442-b13e-4bd5-8a09-e3bff9a5d1b6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTYtMS0xLTU1NTU0_6b8c04e6-a38a-455f-9dc7-72218db5cdd5"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI0LTgtMS0xLTU1NTU0_b2778885-48eb-49e1-934b-59ec44caa8ad"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic1100eb5cd384e00b09db36c3d0a2866_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTItMS0xLTU1NTU0_375214d0-1c35-4169-becf-e43c7c594993"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i61f18fc869d74053929c46a2c61d88f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTQtMS0xLTU1NTU0_40f49fec-5923-4125-ab9c-016d9533a5df"
      unitRef="usd">534000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ieac281d4e27f4175b82ae37df330c749_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTYtMS0xLTU1NTU0_16d5f034-fe00-4232-a5be-82d594200a7f"
      unitRef="usd">342000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo2ZDMxYzVhMDAxODI0MDkyOGYwMDdiYWQxZjhkYmY2MS90YWJsZXJhbmdlOjZkMzFjNWEwMDE4MjQwOTI4ZjAwN2JhZDFmOGRiZjYxXzI1LTgtMS0xLTU1NTU0_2a0c9259-ca3f-43e1-9eaf-aff6a2d92c04"
      unitRef="usd">876000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7a924c3505e43a9b71b7be707de1ac1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtMi0xLTEtNTU1NTQ_0290619d-b2ef-4384-a31b-7c5055be3a4d"
      unitRef="usd">130000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7eafc754316345619b018dfaaebc87f3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtNC0xLTEtNTU1NTQ_1c6bf370-ea28-4ab6-b598-cde448da37a5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5354f3fcd8644c87860ba3a5544fad9d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtNi0xLTEtNTU1NTQ_94398aee-658d-4252-9e9d-5bf95a9be89c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47de02220b2b4d2ba01a1708f7a2d39f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzMtOC0xLTEtNTU1NTQ_6c2cb14f-45b1-4206-b0e8-6439672513fc"
      unitRef="usd">130000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iceba7ccd82584acda921d0e558528e50_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtMi0xLTEtNTU1NTQ_56abaaf1-1f99-457c-8e25-4a52f7d861d5"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d1ed82dd0d54655985037c85ddd3ede_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtNC0xLTEtNTU1NTQ_7b45571f-9c37-43c7-af2c-f56b82c6e204"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d3b3a83ca454eaabd5077059293ed84_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtNi0xLTEtNTU1NTQ_3a6b0fad-d611-4ed3-8c8e-6dba5bc0146a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27c8bf716a3045cab5d5c381fde23d68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzQtOC0xLTEtNTU1NTQ_fac2eb69-0381-49ef-ac05-c2f8f0903cbe"
      unitRef="usd">4948000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ad26877e4a04bd7bb26b8a8c7c28eb4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTItMS0xLTU1NTU0_1928fdf0-e5be-4ae6-a7aa-004e210b0885"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46082d9efffb4b3c95fe13c8f220bd0c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTQtMS0xLTU1NTU0_fe2c147e-040b-4d38-98b0-73a740faab9f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9405eeed0ae040f5a34607effb78d146_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTYtMS0xLTU1NTU0_cf0cf29f-1e7b-441f-857c-e9d5415d5b7a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id95f26b95bbc46e58dd92512a74406b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzExLTgtMS0xLTU1NTU0_0ec7a49a-f612-4f2a-b599-9973eec5347d"
      unitRef="usd">4765000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96b00be27f6e4944a30922c5c0fe6670_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTItMS0xLTU1NTU0_0a84a53f-8f0f-4d69-bbaa-ca60947ed8ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1180ce65c8843b4991f543dc49f55be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTQtMS0xLTU1NTU0_79670d8c-3286-4c59-a058-24585b0bb6a9"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5662300e135747438ae3581b6b70a657_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTYtMS0xLTU1NTU0_4968ddd6-7957-49d0-b461-83d925975c71"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i811e98c080a8445ab332e5093987caf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEyLTgtMS0xLTU1NTU0_35449109-3cc0-4250-a7e1-2a66a7e67f87"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTItMS0xLTU1NTU0_65b47d57-2848-48f6-bfd9-54a71f027182"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTQtMS0xLTU1NTU0_dac64837-bd84-4c2e-b749-b51a3ac8a809"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTYtMS0xLTU1NTU0_9a19844f-7833-4965-9b88-a65e811a7f7d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzEzLTgtMS0xLTU1NTU0_8d9a9115-0641-44ab-aab4-6f14b376cae0"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie630eb784ad2416794c05aa8a219fd58_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTItMS0xLTU1NTU0_d0ceeb1b-f862-4066-921e-1d7e5e0ee020"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i62f25224e2b54616985641a3771ed55c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTQtMS0xLTU1NTU0_fcc33044-3611-4950-9a71-08f277c2d1e2"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0614eede5b234c61be2259d587e7b43a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTYtMS0xLTU1NTU0_9f93384c-ef5a-4775-8ff4-7095edeb769e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i99958e30da4d4cbfa5e3d682930d68fe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE1LTgtMS0xLTU1NTU0_ac738d81-64e2-496a-80d8-79dab5d016b3"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i88f2b4195bd34883bf7b39bc3b2efe92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTItMS0xLTU1NTU0_defe7110-e016-4906-9e76-4cb8fca5e112"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6b26de6dcae348c4a7d727d21d2b83ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTQtMS0xLTU1NTU0_9f3ab852-bb11-4911-b0d7-b73205968a1f"
      unitRef="usd">255000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie2c7782342094a07a4240eb1534d6ac4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTYtMS0xLTU1NTU0_d7a776e0-0796-4f16-880b-a9f73d960e47"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i03f94e6a78404c5c928e7256392dfe2f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE2LTgtMS0xLTU1NTU0_3b0d7b22-9cf4-4216-85d7-53fcc11df723"
      unitRef="usd">255000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i089ac98960b04b439f83de38bd8c51dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTItMS0xLTU1NTU0_a519cde0-8da7-4c6b-b869-8be991c83478"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="iefb49b4259114419a84f22f50981dca8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTQtMS0xLTU1NTU0_2ab4ae52-36bc-4272-aa99-1bc8cba3ab3c"
      unitRef="usd">66000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i5427fc4b2ce14c1f83b6ee82f6be8aec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTYtMS0xLTU1NTU0_68db29db-b6a1-4828-ab61-4526b2b7e0ea"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i0a08253dadcd44d2b7a7f73f8fb62ba6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE3LTgtMS0xLTU1NTU0_94db9afb-791f-4f73-95a9-676da460f5c3"
      unitRef="usd">66000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTItMS0xLTU1NTU0_5f2daec4-38c6-474a-a16f-218fd9dd9884"
      unitRef="usd">10320000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTQtMS0xLTU1NTU0_a1b4d8a2-8079-4ba2-8251-d8f1a54a400b"
      unitRef="usd">351000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTYtMS0xLTU1NTU0_7496ca7c-ceda-42f9-b355-81a702f1a7c9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzE4LTgtMS0xLTU1NTU0_89d55e6a-6116-4c0d-991b-bf4f7912c5bb"
      unitRef="usd">10671000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie630eb784ad2416794c05aa8a219fd58_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTItMS0xLTU1NTU0_f0d9be30-0278-452a-9653-90af67aacfef"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i62f25224e2b54616985641a3771ed55c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTQtMS0xLTU1NTU0_1b635eb0-e1ff-44a3-9be6-eed678c45fe1"
      unitRef="usd">237000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0614eede5b234c61be2259d587e7b43a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTYtMS0xLTU1NTU0_657b6eef-14df-4636-8e80-f845f38415ea"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i99958e30da4d4cbfa5e3d682930d68fe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIxLTgtMS0xLTU1NTU0_85d1b694-fa2c-4982-ac40-92c485f529d6"
      unitRef="usd">237000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i88f2b4195bd34883bf7b39bc3b2efe92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTItMS0xLTU1NTU0_9dd8835d-3c69-4d7c-b287-d057fd3a7ad6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6b26de6dcae348c4a7d727d21d2b83ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTQtMS0xLTU1NTU0_9fb3a10d-e119-4a80-ba74-a345f7555093"
      unitRef="usd">318000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie2c7782342094a07a4240eb1534d6ac4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTYtMS0xLTU1NTU0_18e90218-dc54-44e1-990e-1403898b0d9e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i03f94e6a78404c5c928e7256392dfe2f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIyLTgtMS0xLTU1NTU0_3b444f12-ae04-4495-9db4-34f07124dae0"
      unitRef="usd">318000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i089ac98960b04b439f83de38bd8c51dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTItMS0xLTU1NTU0_127b4dae-4eb5-49d7-aad3-72c1c0234f7b"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="iefb49b4259114419a84f22f50981dca8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTQtMS0xLTU1NTU0_a7716be3-90f9-4af8-a0ea-cdd8ba920873"
      unitRef="usd">15000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i5427fc4b2ce14c1f83b6ee82f6be8aec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTYtMS0xLTU1NTU0_33d48217-1ddf-4c68-acda-ec352b62b49b"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i0a08253dadcd44d2b7a7f73f8fb62ba6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzIzLTgtMS0xLTU1NTU0_38319454-4c71-468b-a463-fe6f522185d6"
      unitRef="usd">15000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTItMS0xLTU1NTU0_0003aea6-419f-42a0-aaa5-519fbe6753b0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTQtMS0xLTU1NTU0_9432dd1e-a0fd-4cc9-8867-b7780ada9a37"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTYtMS0xLTU1NTU0_e75ad618-bd13-4030-bd1e-f9ae9e57993c"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI0LTgtMS0xLTU1NTU0_e67a5299-1387-4924-9700-e2f76e421ae8"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i33c59ef250904a0c8c3737d73fef0bc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTItMS0xLTU1NTU0_14ba2d17-878b-4aa6-ad2f-decd98eef7a2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i607d4a85aba9437d83f47c041399a92e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTQtMS0xLTU1NTU0_11b70b19-442f-4442-89f2-ec0444d93a4c"
      unitRef="usd">570000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5dc42b4f17b2415db5b78c0f90591e04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTYtMS0xLTU1NTU0_7812a10e-e0cf-4faa-9851-263ad07889c5"
      unitRef="usd">33000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZTo4NDE0ZjA1ZjU0MDE0OTRhYjdjNjE3ODU0MGI0ZGVhNi90YWJsZXJhbmdlOjg0MTRmMDVmNTQwMTQ5NGFiN2M2MTc4NTQwYjRkZWE2XzI1LTgtMS0xLTU1NTU0_c882aff1-eb56-473f-ac38-bed69d2d1698"
      unitRef="usd">603000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzMyMTk_57bc4d1c-f656-45ec-8ae4-da217cfd1600">P3Y</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzExNTQ0ODcyMTEzNjk5_d60bdbd0-ba44-47cb-b2c5-166ab341e407">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net changes in valuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzItMi0xLTEtODMxMzA_64ec987a-d56f-4a1e-9608-9c4b1bd4677c"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzItNC0xLTEtODMyMjc_0309b5d5-2ffb-4adb-9477-ceabdb9ddc89"
      unitRef="usd">61000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzItNi0xLTEtODMyNDU_6a1a8e03-9746-4947-9f16-5d31235cf9cc"
      unitRef="usd">72000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzMtMi0xLTEtODMyMDg_a01174dc-1abd-43eb-8296-92c2785abc24"
      unitRef="usd">309000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzMtNC0xLTEtODMyMjc_abcbf730-80cc-4d58-8f5e-90390371fcef"
      unitRef="usd">0</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzMtNi0xLTEtODMyNDU_2c420d55-e183-46a9-a9e7-da9f5f0a7fab"
      unitRef="usd">0</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzQtMi0xLTEtODMyMTU_a22cc3b1-4d3a-4d57-8737-7338496da793"
      unitRef="usd">7000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzQtNC0xLTEtODMyMjc_98c73f51-ce17-44ac-8352-abcf7926266d"
      unitRef="usd">6000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzQtNi0xLTEtODMyNDU_d60fc8e5-5f6c-4f86-a5f5-60901090c386"
      unitRef="usd">0</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzUtMi0xLTEtODMyMjE_e5313912-d92f-4e9b-b643-28b69e4d17ac"
      unitRef="usd">7000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzUtNC0xLTEtODMyMjc_d226c3f8-db0a-4cfa-ada9-1c305d07002d"
      unitRef="usd">-22000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzUtNi0xLTEtODMyNDU_9beaa545-ea19-4459-a995-5de21aa56051"
      unitRef="usd">-11000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzYtMi0xLTEtODMyMzM_16c0ef1e-30b6-472c-9b6f-9e75bf8517ae"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzYtNC0xLTEtODMyMzQ_e10ea60b-576c-4ecb-90b3-46a240d14211"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90YWJsZToxYzIyMGRjOWU2MDE0NGU4ODdmODQ0NjcwY2Y3YjkzMi90YWJsZXJhbmdlOjFjMjIwZGM5ZTYwMTQ0ZTg4N2Y4NDQ2NzBjZjdiOTMyXzYtNi0xLTEtOTQ1NTY_59a4f6eb-e8b6-4967-ae79-ea9bbb568e77"
      unitRef="usd">61000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ic2b282aad63a4bcaaf14002bae397df0_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzEwOTk1MTE2NDc1NTU_1c54af8f-1df5-4bed-9272-776b2ea067b1"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzU5OTI_04b50bc3-6d31-4a81-a33b-b78e2225f9b0"
      unitRef="usd">37900000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzU5OTk_15ecbfc8-09af-492a-aec2-31160858c7af"
      unitRef="usd">39400000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LongTermDebt
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYwNDY_5f5aadcf-1587-4413-8e71-59b7f00c70c0"
      unitRef="usd">33300000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYwNTM_e0e81b06-c01f-406a-854b-9a616a2785ed"
      unitRef="usd">33000000000</us-gaap:LongTermDebt>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyMzk_b4fa6c7d-17ed-4c87-9bcf-0068bf5b5f31"
      unitRef="usd">5100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzEwOTk1MTE2NDk3OTQ_e5ac3ba3-1554-4b15-a734-f35a3a623a97"
      unitRef="usd">4900000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestments
      contextRef="i057bcd2df3a24e23bc9926a0bf3b7154_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzYyNDY_4e3e02dd-0bc6-42e0-98a6-230e95e3a409"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ife9d7263c2934799ad99b2e304ed9c06_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDQvZnJhZzozMmVhZTU3MTkwY2M0MTI1YmM0OWZhMTA2OTQ5YTgyMS90ZXh0cmVnaW9uOjMyZWFlNTcxOTBjYzQxMjViYzQ5ZmExMDY5NDlhODIxXzEwOTk1MTE2NDk4MDg_c25d72c6-32d2-434d-9007-0eaf7f76b646"
      unitRef="usd">2900000000</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzA4_f8082475-d573-4495-95e6-07b6cb805cb3">Derivative instruments&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, 2020 and 2019, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.7 billion, $5.1 billion and $5.0 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The notional amounts and interest rates of our cross-currency swaps as of December 31, 2021, were as follows (notional amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, our 1.25% euro Notes were redeemed, and the related cross-currency swaps were settled, resulting in an immaterial loss. During the year ended December 31, 2019, our 2.125% 2019 euro Notes matured, and the related cross-currency swaps were settled. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts to hedge variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2021, and amounts expected to be recognized during the subsequent 12 months are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2021 and 2020, we had interest rate swap contracts with aggregate notional amounts of $6.7&#160;billion and $5.9 billion, respectively, that hedge certain portions of our long-term debt issuances. See Note 15, Financing arrangements, for information on our interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we entered into interest rate swap contracts with an aggregate notional amount of $1.5&#160;billion. Interest rate swaps with an aggregate notional value of $750&#160;million were terminated in connection with the redemption of certain of our notes. The resulting gain on these terminations was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, interest rate swaps with an aggregate notional value of $3.7&#160;billion were terminated in connection with the redemption of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $40&#160;million, recognized in Interest expense, net, in the Consolidated Statements of Income. Additionally, we terminated $5.2&#160;billion aggregate notional amount of interest rate swaps, which resulted in receipt of $576&#160;million from the counterparties and which was included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2020. This amount is being recognized as a reduction in Interest expense, net, in the Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2&#160;billion principal amount of notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $85 million and $89 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $440 million and $525 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $85 million and $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $340 million and $425 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impact of hedging transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2021, we expected to reclassify $19 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2021, 2020 and 2019, the total notional amounts of these foreign currency forward contracts were $680 million, $1.0 billion and $1.2 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2021, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:7pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative contracts that were in liability positions as of December 31, 2021, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our, or the surviving entity&#x2019;s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts in the Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <amgn:DerivativeInstrumentTerm
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzExNTQ0ODcyMTExNjcy_0da98a90-7f26-42ee-906c-5fc205c39535">P3Y</amgn:DerivativeInstrumentTerm>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7211fd50bd2642b3aca55c89862f86d3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE1NjA_3f6e12de-6b3c-4c01-880e-d03a9c8bb90a"
      unitRef="usd">5700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i4a63aa87c0224ee98ac2fd8fd67ddaee_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE1NjQ_8faec7b8-e11e-405a-8aaa-04c5aaad81a9"
      unitRef="usd">5100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i68179a299576480aa8d41a7687749389_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE1NzE_29210174-14cb-4cf0-84b9-badd2790cee4"
      unitRef="usd">5000000000</us-gaap:DerivativeNotionalAmount>
    <amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzI0_8d19b7cc-440c-438e-96ca-611f51a06921">The notional amounts and interest rates of our cross-currency swaps as of December 31, 2021, were as follows (notional amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id5c684a9063940959ca5882be53b9b80_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtMi0xLTEtNTU1NTQ_0c8b8cc6-6115-48db-97ba-0d31b249d5f3"
      unitRef="chf">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i71ec6c587d9b4e62aee06a72a1f73f9e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtNC0xLTEtNTU1NTQ_1d367342-a34b-4ab0-9fd8-a2df8d0e55d2"
      unitRef="number">0.004</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id5c684a9063940959ca5882be53b9b80_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtNi0xLTEtNTU1NTQ_a1cc878a-c436-4fce-a5dc-b26c04bc24ba"
      unitRef="usd">704000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i5da09ffb67c742d795348bf45a166d74_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzQtOC0xLTEtNTU1NTQ_46ec8f83-a26a-45f6-b9e7-ad4b8ba890af"
      unitRef="number">0.034</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5fe2830b43b44d79b43091fb7f32ea57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtMi0xLTEtNTU1NTQ_b4b46a90-81f0-404d-af19-45ed1c3c04d7"
      unitRef="eur">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i8359101653f44adbb212efe4e4294a95_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtNC0xLTEtNTU1NTQ_fea7147f-9a8b-4cab-9822-edf010a2cc09"
      unitRef="number">0.020</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5fe2830b43b44d79b43091fb7f32ea57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtNi0xLTEtNTU1NTQ_f9723f94-a644-488e-824b-8e5977f95a4c"
      unitRef="usd">833000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ibec9d656079e405f82e3bf12e4d8c37a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzUtOC0xLTEtNTU1NTQ_f572adcf-a4d4-4cd0-99b2-5bd860748ff9"
      unitRef="number">0.039</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i665816818e0a44d58309ed1a320f177a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtMi0xLTEtNTU1NTQ_990615b9-90d7-4cd3-87eb-658b0d2a1153"
      unitRef="gbp">475000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ifaabba1893af44ce9e672215ac116ce8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtNC0xLTEtNTU1NTQ_5283192a-3e43-41de-aa85-f7fdac556fe0"
      unitRef="number">0.055</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i665816818e0a44d58309ed1a320f177a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtNi0xLTEtNTU1NTQ_2fa161dc-2db3-4b6d-9521-1df81317bdf2"
      unitRef="usd">747000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i730ee854cf6c432ab6aaa706614c8632_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzYtOC0xLTEtNTU1NTQ_81d02151-4ebc-4cca-9bd9-9787877cad81"
      unitRef="number">0.060</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8fdabb7d166a4746adca1c02c5f92d88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctMi0xLTEtNTU1NTQ_6d732f6c-9a98-46a3-ad35-599225d426da"
      unitRef="gbp">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i1bb0ddc693254332b142eabe8b6a28aa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctNC0xLTEtNTU1NTQ_83c86aa1-359b-4052-be6b-75e3b03669f9"
      unitRef="number">0.040</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8fdabb7d166a4746adca1c02c5f92d88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctNi0xLTEtNTU1NTQ_555ed936-9379-4697-ab78-b5991691925f"
      unitRef="usd">1111000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i8ecb51f1a572468b8e76872013008be7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTpjNDRlYzU3OWQxYTg0OWFlYWVjOTRlMDY1NjRmNTQ0ZC90YWJsZXJhbmdlOmM0NGVjNTc5ZDFhODQ5YWVhZWM5NGUwNjU2NGY1NDRkXzctOC0xLTEtNTU1NTQ_60f68c1d-64fc-4b97-ab35-1f9ff85b4e44"
      unitRef="number">0.045</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib927e41cd49b4bcda2eea7a252c62906_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzg3OTYwOTMwNDIyNTE_522801f9-ba66-4202-aafb-ed19757bab3b"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc0cdd08ffa245b5b14a99b5ae9342c3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzM2NDI_0b948c74-5fd0-4dda-b5e1-495b6fc5ca4f"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzQ0_16979273-79b3-4629-a57f-66a08caf8a8b">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i6c071ab35a1441a7ab265cde48d713e8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzItNC0xLTEtNTU1NTQ_514b2ce7-a642-4e71-922a-10b438a7e514"
      unitRef="usd">373000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i1dafda6691b84625923472fe59fa12bf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzItNi0xLTEtNTU1NTQ_7226f545-e7f1-4a13-be4e-7aa35de4d6b7"
      unitRef="usd">-251000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i632df15458d646f08f1906bc1e27b8fa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzItOC0xLTEtNTU1NTQ_a7e7ef59-b915-46b4-8277-6876b9aeacd5"
      unitRef="usd">148000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i2cce474dbbd049c4984d8bf485ab3a19_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzMtNC0xLTEtNTU1NTQ_fbbc8e94-f980-4d3d-a2c0-6a0c62901554"
      unitRef="usd">-214000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i29069e42d7524b4db8c509bf319d9680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzMtNi0xLTEtNTU1NTQ_b57d0817-c027-40fb-95a3-3a0c02002f45"
      unitRef="usd">190000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ia2c56acaf30d4dce85c3d989ea151652_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzMtOC0xLTEtNTU1NTQ_a45fef1b-efc8-4cde-9e7f-aa22fe31a0fd"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i665b76a3b3b3476c84386f9224fe17a9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzUtNC0xLTEtNTU1NTQ_a738ec2c-0d62-442c-86f2-34a7b34f86f8"
      unitRef="usd">159000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i3eba7e66fb7849818cac30465266bf74_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzUtNi0xLTEtNTU1NTQ_4264aee5-acd3-427b-bc23-a2158661834d"
      unitRef="usd">-61000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ifc742c16678e447d8a1223755190162f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo0ODVhODcyOTIyNzA0N2EyOTBkMjY0NWU1ZDk4ZTU3Ny90YWJsZXJhbmdlOjQ4NWE4NzI5MjI3MDQ3YTI5MGQyNjQ1ZTVkOThlNTc3XzUtOC0xLTEtNTU1NTQ_9f4977c6-19cb-4a94-aecb-e267f4a0ec26"
      unitRef="usd">127000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzM1MTg0MzcyMTA3NjMx_2447a531-fb00-4559-b972-39ef3859962f"
      unitRef="usd">6700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzUwOTk_05cd413c-0ae9-4e92-b288-7b430909a1f3"
      unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <amgn:DerivativeInstrumentAggregateNotionalAmountOfNewInstruments
      contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzg3OTYwOTMwMzY5MzM_a4abb069-2293-41ab-9e65-db06f5127c39"
      unitRef="usd">1500000000</amgn:DerivativeInstrumentAggregateNotionalAmountOfNewInstruments>
    <amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities
      contextRef="i2f6200ee75c5469ebd46c5795d8d7a3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwOTk1MTE2NDc3ODY_220ad18c-0e03-49de-9e82-f513865bd82d"
      unitRef="usd">750000000</amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities>
    <amgn:DerivativeNotionalAmountAmountTerminated
      contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzUyMzQ_31294d24-4335-478f-9112-5fc533be1912"
      unitRef="usd">3700000000</amgn:DerivativeNotionalAmountAmountTerminated>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="i806e9dc1988340d9b23b17a31bc072d3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzU0MjE_e89e2d14-7cb2-480d-86e4-6a1879294a79"
      unitRef="usd">40000000</us-gaap:DerivativeGainOnDerivative>
    <amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities
      contextRef="i7f6bff492829406da23ff2efa25558e6_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzU1MzI_a92ca46f-47b0-47e3-9f0e-23f8be83c775"
      unitRef="usd">5200000000</amgn:DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib46494b393a34b9f8c60e96025f45f23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzU2MTg_d5a6196f-d2c1-4a68-acb2-20eabae9d8c0"
      unitRef="usd">576000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i16d30d400605402ca45a9146fa90bd76_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzYxMjQ_c9015ea5-c7fb-4f20-a55a-dc1042808dd2"
      unitRef="usd">5200000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzI3_49162cb9-3f37-4576-9343-72ab50341217">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $85 million and $89 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $440 million and $525 million of carrying value with discontinued hedging relationships as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.93pt"&gt;Current portion of long-term debt includes $85 million and $89 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively. Long-term debt includes $340 million and $425 million of hedging adjustments on discontinued hedging relationships as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtMi0xLTEtNTU1NTQ_5f1b66da-c5be-45bc-beea-0d6137d60147"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtNC0xLTEtNTU1NTQ_acedc978-9c20-426c-bcc1-aee960f69769"
      unitRef="usd">89000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtNi0xLTEtNTU1NTQ_a46645eb-a0f3-4c0c-821e-c6c5d9ae0374"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzMtOC0xLTEtNTU1NTQ_1e7f041f-0da1-47a3-9809-dc49c778bdfc"
      unitRef="usd">89000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtMi0xLTEtNTU1NTQ_677028e7-b2eb-445f-b15a-40c68df02205"
      unitRef="usd">6729000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtNC0xLTEtNTU1NTQ_570458ca-1c45-472d-b7d4-793a9d5e7c84"
      unitRef="usd">6258000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtNi0xLTEtNTU1NTQ_b6053d8e-2fac-4f51-8f21-6a532e6bcf88"
      unitRef="usd">199000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZToxNjFlYmU0ZDgyYmQ0YTYwODQ4ZThhYjRmMmRjNzJjMi90YWJsZXJhbmdlOjE2MWViZTRkODJiZDRhNjA4NDhlOGFiNGYyZGM3MmMyXzQtOC0xLTEtNTU1NTQ_5eb18f91-701c-4812-8eef-9e4c0b87a766"
      unitRef="usd">477000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzcyMDQ_7d6a43bc-f2bb-4db1-a39e-b8447d15ec95"
      unitRef="usd">85000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE2NDkyNjc0NTQ3NDA_6d4ebd26-c394-48e2-b2b4-3118d0c77063"
      unitRef="usd">89000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzczMTQ_923f4dd5-31b4-4d37-a6e7-a82dcdbc4542"
      unitRef="usd">440000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzczMjE_062bf57a-1f90-471c-9980-e91ac02e577a"
      unitRef="usd">525000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i52186ecfa5c2464a9932151770b9a053_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzc0NzA_2689f3a8-9f87-47c2-bbe3-6e3cf4df2562"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ifc4882cfbc084ea5ae95c042bf24548e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzE2NDkyNjc0NTQ4MDA_3afde7af-c738-4a31-8eac-b89f3bbd9dd1"
      unitRef="usd">89000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i8b50391be4bb48db8dc8f419683a2218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzc1ODM_52c4ac36-89d6-4d89-92f4-676416adf712"
      unitRef="usd">340000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ie7e2a30bb5ae4acfab18f3b65fe1302b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzc1OTA_aa5ab670-ac2a-472d-8254-ff964759bf62"
      unitRef="usd">425000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzI4_97c4220a-fa46-4984-a50e-3bb374e68644">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Losses on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Gains on hedged items do not completely offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i89707ff1787c4959b80ff3a5710eb27b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzItMi0xLTEtNTU1NTQ_c7cdc7fc-110f-4f3c-82d0-01f63f77fecf"
      unitRef="usd">24297000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzItNC0xLTEtNTU1NTQ_a32af547-8f3a-4a5e-bba0-d9dcc2a8b188"
      unitRef="usd">259000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzItNi0xLTEtNTU1NTQ_21de69c3-edc9-4842-8fe8-b5d92aa81c6d"
      unitRef="usd">1197000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3b2f149e177b4bc3b630018b36f6e49c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzUtMi0xLTEtNTU1NTQ_f00838c4-c613-4cea-9b82-a189641de36b"
      unitRef="usd">-8000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i35372b79111c40a58a07694440d9622c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzYtNC0xLTEtNTU1NTQ_7c30c0f4-b56d-4f3b-8451-9acbd890d8b0"
      unitRef="usd">-245000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i739fe173b25a47189a34271891a4159b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzgtNi0xLTEtNTU1NTQ_19b31399-ff01-4a2c-ad2c-1dcc6a118537"
      unitRef="usd">281000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i739fe173b25a47189a34271891a4159b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTozZjlkZjdmZGQyOWY0NTlhOGZhODBmMGVjZGRhNDlhYy90YWJsZXJhbmdlOjNmOWRmN2ZkZDI5ZjQ1OWE4ZmE4MGYwZWNkZGE0OWFjXzktNi0xLTEtNTU1NTQ_0b625db2-d731-496c-9619-226b0ed94eb4"
      unitRef="usd">-192000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iff09705dc60d4d10b9a1fb4e532ba42f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzItMi0xLTEtNTU1NTQ_da9a7d3d-8e66-4fa1-a835-a38eae40cd25"
      unitRef="usd">24240000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzItNC0xLTEtNTU1NTQ_3a09f168-a082-488f-8470-2bea5be6d52b"
      unitRef="usd">256000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzItNi0xLTEtNTU1NTQ_30b7ae8c-7f45-4fe4-8488-96f202dfc642"
      unitRef="usd">1262000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ifad2966682ec4e37bbcfa6626b7183ec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzUtMi0xLTEtNTU1NTQ_2acc082d-216c-4bbf-aa3f-7bdad634c2de"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icd31886569fd4668bfb1bce453953983_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzYtNC0xLTEtNTU1NTQ_1d2a092d-204c-41c8-a1bf-8365b6a0d129"
      unitRef="usd">323000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i7da02963523c4db1b9d260cbec5d9af3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzgtNi0xLTEtNTU1NTQ_3255ecc7-ee99-4135-bf75-8768e17acd4c"
      unitRef="usd">315000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i7da02963523c4db1b9d260cbec5d9af3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTo1M2JmYmVlYzc0ZGM0OWVhYjQ4Y2JiZjVhM2U3YWJjMC90YWJsZXJhbmdlOjUzYmZiZWVjNzRkYzQ5ZWFiNDhjYmJmNWEzZTdhYmMwXzktNi0xLTEtNTU1NTQ_c735cb19-95f6-4852-ba9c-47413f1e155f"
      unitRef="usd">-204000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9342d5d8779b4c4ea2f6879b7021ac9f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzItMi0xLTEtNTU1NTQ_ab01c394-4556-45a2-8faf-ab0a0d0f6d67"
      unitRef="usd">22204000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzItNC0xLTEtNTU1NTQ_c43e6f80-07a2-4d85-81fa-674872d05b00"
      unitRef="usd">753000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzItNi0xLTEtNTU1NTQ_7e6ff3d7-9a19-44b4-b999-c492549d5e19"
      unitRef="usd">1289000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7e4dd663b9fc4f028f2085d56886e460_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzUtMi0xLTEtNTU1NTQ_71fa0f1d-f8df-4f41-a0df-abd1da5c99f4"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if8a842d09a06449083eeab3521739d0d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzYtNC0xLTEtNTU1NTQ_4d9f4305-fef2-4120-9f9e-1bf9f41a63a9"
      unitRef="usd">110000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ied61ab999fde4db3b59917ff3e2febd4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzktNi0xLTEtNTU1NTQ_0276d3c5-371e-4fc2-a5c4-b8f492020efc"
      unitRef="usd">-349000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ied61ab999fde4db3b59917ff3e2febd4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTphYjQzYjFjNzA3Yjg0NmNjYmQ0NmUxMDJiZWFiNjYxNy90YWJsZXJhbmdlOmFiNDNiMWM3MDdiODQ2Y2NiZDQ2ZTEwMmJlYWI2NjE3XzEwLTYtMS0xLTU1NTU0_864c7fb9-5bef-4f8b-9937-15f86a50d67d"
      unitRef="usd">352000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="ic2aae7469fe64dcd8bac1076dd7692d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzg0OTk_93a3da01-f7a8-478b-b40b-a3fe0fbe325b"
      unitRef="usd">19000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i760d8f96eac94b7f88f95302db5dd2d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzkwNTE_b4bc3d13-1831-4985-ab1c-3d83d309d641"
      unitRef="usd">680000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3a34b1b31c7e425a8ee9baab7f3c59db_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzkwNTU_b8d76710-669f-4680-a0f7-fe086521bb70"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i71e6675ffd9f4a3998395c7c583d88f3_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzkwNjI_9b7d5179-904d-4cf6-952a-6305ecd09ef2"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90ZXh0cmVnaW9uOmFkODVkZGRkZGEzNjRmMjU5OTYzMGU4M2NkOTJiZTllXzEwNzE0_bbb8f059-6f37-434d-b8d4-a4ee3dd45d2d">&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance&#160;Sheets&#160;locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;current&#160;assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i089ec9cec29f4c7ca63544d5e4b387da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzMtNC0xLTEtNTU1NTQ_7445131c-5b3f-4f31-9bbb-2731bba5cb5b"
      unitRef="usd">183000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i32f066d29e5c45d0ba4c511e73c8df4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzMtOC0xLTEtNTU1NTQ_217e60d8-b041-4d28-87d5-5df88c59d150"
      unitRef="usd">39000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i794004d7dfa741ea84b274eb42d3ec54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzQtNC0xLTEtNTU1NTQ_47251c71-4de9-470f-b54b-fadc79eb3874"
      unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia3d0846cbb0548819c01c3db53240ca0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzQtOC0xLTEtNTU1NTQ_d967a971-ec15-4741-b692-cfd1d2548319"
      unitRef="usd">339000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i3377db1e364448a198a868926553f9b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzUtNC0xLTEtNTU1NTQ_04c07122-1fca-4a45-8dda-f0c85840900d"
      unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i050bfd34fd664c4086976b07e6af5cdc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzUtOC0xLTEtNTU1NTQ_1f2e15db-8869-4284-afdd-a8a7447d0b7a"
      unitRef="usd">156000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8e65e212078b47438c294f4cc92afbe1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzYtNC0xLTEtNTU1NTQ_bf6b9fcf-3e30-41f6-9163-7b1aa3c4d733"
      unitRef="usd">265000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8e65e212078b47438c294f4cc92afbe1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzYtOC0xLTEtNTU1NTQ_aa4f2e34-dd90-44a5-bc27-f2a0f330acaf"
      unitRef="usd">534000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzEwLTQtMS0xLTU1NTU0_c6a71076-39a3-411d-bd14-12b724f4ebf5"
      unitRef="usd">265000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzEwLTgtMS0xLTU1NTU0_357ef686-9aaf-4201-bb8f-020cb94355dc"
      unitRef="usd">534000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2a6728c58d4145b3887b604065653c19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE1LTQtMS0xLTU1NTU0_13f1bde4-372f-420d-bfc5-a4eb66016409"
      unitRef="usd">28000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibfc161492cc64bd983de97ee811b16fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE1LTgtMS0xLTU1NTU0_a581d3ca-1fcf-4182-9eea-c3db0cfd507f"
      unitRef="usd">237000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic268132426814d8eb399e70d427d8801_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE2LTQtMS0xLTU1NTU0_a8d6fa97-a44d-42f9-bf97-e1b218ba0e1a"
      unitRef="usd">255000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie510af3eca8f4a73a86d9d56fbd815f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE2LTgtMS0xLTU1NTU0_60fa5e88-9583-4b2a-a62c-332634036dad"
      unitRef="usd">318000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i479675435c2d49f99965cf557ed29fbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE3LTQtMS0xLTU1NTU0_b58ad7cb-9d63-4d78-a515-7a5128eddd2e"
      unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i44666b59eba54e9a95bb28abe178e8f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE3LTgtMS0xLTU1NTU0_c66d74d1-6c37-44ea-a095-edcf5970cd94"
      unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i9952aa6a3b134df69afed008d9e67bf4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE4LTQtMS0xLTU1NTU0_59e8c290-4fdc-420f-883f-d935010453db"
      unitRef="usd">349000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9952aa6a3b134df69afed008d9e67bf4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzE4LTgtMS0xLTU1NTU0_1a76f0f9-8a48-4269-b746-c379c7cca92c"
      unitRef="usd">570000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzIyLTQtMS0xLTU1NTU0_0b9aadd3-4772-473e-b101-932cb2cc7cce"
      unitRef="usd">349000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNDcvZnJhZzphZDg1ZGRkZGRhMzY0ZjI1OTk2MzBlODNjZDkyYmU5ZS90YWJsZTowZTEzYjU0ZDc4YzU0OTQzODg2ZWE5MmQwMDgwMDU2MS90YWJsZXJhbmdlOjBlMTNiNTRkNzhjNTQ5NDM4ODZlYTkyZDAwODAwNTYxXzIyLTgtMS0xLTU1NTU0_d8676477-02d7-4b47-8628-a40e74c7c189"
      unitRef="usd">570000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2Mjgy_445a4883-d7c3-4dad-9c10-dea705ee675f">Contingencies and commitments &lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our business may be affected by litigation and government investigations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain recent developments concerning our legal proceedings and other matters are discussed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otezla ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Sandoz Inc., et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC (Amneal); Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited (MSN); Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc. (Sandoz); Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc. (Zydus), each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the &#x2019;940 Patent), 7,208,516 (the &#x2019;516 Patent), 7,427,638 (the &#x2019;638 Patent), 7,659,302 (the &#x2019;302 Patent), 7,893,101 (the &#x2019;101 Patent), 8,455,536 (the &#x2019;536 Patent), 8,802,717 (the &#x2019;717 Patent), 9,018,243 (the &#x2019;243 Patent) and 9,872,854 (the &#x2019;854 Patent), which are listed in the Orange Book for Otezla. Each of these lawsuits was based on each defendant&#x2019;s submission of an ANDA seeking FDA approval to market a generic version of Otezla. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene Corp. v. Sandoz Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant&#x2019;s ANDA effective no earlier than the expiration of the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, Celgene filed amended complaints against Alkem, Amneal, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz, Actavis, Unichem and Zydus additionally asserting U.S. Patent No. 9,724,330 (the &#x2019;330 Patent), which is listed in the Orange Book for Otezla. Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN, Pharmascience, Prinston, Sandoz, Actavis, Torrent, Unichem and Zydus additionally asserting U.S. Patent No. 10,092,541 (the &#x2019;541 Patent), which is listed in the Orange Book for Otezla. Between March 1 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243 and &#x2019;330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the &#x2019;283 Patent) and 8,629,173, which are not listed in the Orange Book for Otezla. On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene Corp. v. Sandoz Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz, Shilpa, Actavis, Torrent, Unichem and Zydus filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following Amgen&#x2019;s acquisition of the patents-in-suit and the new drug application for Otezla, on February 14, 2020, the New Jersey District Court issued an order substituting Amgen for Celgene as plaintiff in the consolidated action and all related actions, terminating Celgene as plaintiff in the consolidated action and all related actions, and amending the case caption in the consolidated action and all related actions to reflect Amgen as the sole plaintiff.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2020, based on a joint request by Amgen and Unichem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Unichem&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 3, 2020, based on a joint request by Amgen and Hetero, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Hetero&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;717, &#x2019;243, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 28, 2020, based on a joint request by Amgen and Emcure, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101, &#x2019;854 and &#x2019;541 Patents unless authorized pursuant to a confidential settlement agreement. On July 7, 2020, the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen and Sandoz with respect to the &#x2019;717, &#x2019;516 and &#x2019;854 Patents, leaving the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330, &#x2019;638, &#x2019;101 and &#x2019;541 Patents asserted by Amgen against Sandoz in the litigation. On August 6, 2020, based on a joint request by Amgen and Mankind, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Mankind&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330, &#x2019;638, &#x2019;101 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On August 14, 2020, based on a joint request by Amgen and Macleods, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Macleods&#x2019; apremilast product during the term of the &#x2019;638 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On October 7, 2020, based on a joint request by Amgen and Amneal, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Amneal&#x2019;s apremilast product during the term of the &#x2019;101, &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;243, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 30, 2020, based on a joint request by Amgen and Shilpa, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Shilpa&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101 and &#x2019;854 Patents, unless authorized pursuant to a confidential settlement agreement. On January 26, 2021, based on a joint request by Amgen and Actavis, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Actavis&#x2019; apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;717, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On March 24, 2021, based on a joint request by Amgen and Prinston, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Prinston&#x2019;s apremilast product during the term of the &#x2019;638 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On April 6, 2021, based on a joint request by Amgen and Aurobindo, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Aurobindo&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;516, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;717, &#x2019;243, &#x2019;330, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2021, based on a joint request by Amgen and Cipla, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Cipla&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent&#x2019;s apremilast product during the term of the &#x2019;101, &#x2019;638, &#x2019;854 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN&#x2019;s apremilast product during the term of the &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience, the New Jersey District Court entered a consent judgment and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience&#x2019;s apremilast product during the term of the &#x2019;243, &#x2019;940, &#x2019;638, &#x2019;302, &#x2019;101, &#x2019;536, &#x2019;330 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and DRL, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL&#x2019;s apremilast product during the term of the &#x2019;638, &#x2019;101, &#x2019;536 and &#x2019;541 Patents, unless authorized pursuant to a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trial on the consolidated patent infringement action against Sandoz and Zydus was held at the New Jersey District Court from June 14 to 25, 2021, with closing arguments on July 28, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2021, consistent with its September 20, 2021 opinion and order, the New Jersey District Court entered final judgment in favor of Amgen and against Zydus with respect to claims 3 and 6 of the &#x2019;638 Patent, claim 6 of the &#x2019;536 Patent and claims 2 and 27 of the &#x2019;283 Patent; and final judgment in favor of Zydus and against Amgen with respect to claims 1 and 15 of the &#x2019;101 Patent and claims 2, 19 and 21 of the &#x2019;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Zydus&#x2019;s ANDA must be after expiration of the three infringed patents (the &#x2019;638, &#x2019;536 and &#x2019;283 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Zydus from making, using, offering to sell, or selling in the United States, or importing into the United States, Zydus&#x2019;s generic apremilast products during the term of the three infringed patents. On October 27, 2021, Zydus filed a notice of appeal to the Federal Circuit Court with respect to the &#x2019;638 Patent. On October 28, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 12, 2021, the New Jersey District Court also entered final judgment in favor of Amgen and against Sandoz with respect to claims 3 and 6 of the &#x2019;638 Patent, claim 6 of the &#x2019;536 Patent and claims 1 and 15 of the &#x2019;101 Patent; and final judgment in favor of Sandoz and against Amgen with respect to claims 2, 19 and 21 of the &#x2019;541 Patent. The final judgment ordered that the effective date of any final approval by the FDA of Sandoz&#x2019;s ANDA must be after expiration of the three infringed patents (the &#x2019;638, &#x2019;536 and &#x2019;101 Patents) and any regulatory exclusivity to which Amgen may become entitled. The final judgment also includes an injunction prohibiting Sandoz from making, using, offering to sell, or selling in the United States, or importing into the United States, Sandoz&#x2019;s generic apremilast products during the term of the three infringed patents. On November 9, 2021, Sandoz filed a notice of appeal to the Federal Circuit Court with respect to the &#x2018;638 and &#x2018;101 Patents. On November 10, 2021, Amgen filed a notice of appeal to the Federal Circuit Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ENBREL Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis&#x2019; submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen&#x2019;s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182, 8,163,522 (the &#x2019;522 Patent), 7,915,225, 8,119,605 and 8,722,631. By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis&#x2019; etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court&#x2019;s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 2, 2021, Amgen and Bioepis, with the consent of Roche, jointly submitted to the New Jersey District Court a confidential stipulation and a form of final judgment and order of permanent injunction resolving the dispute between the parties and enjoining Bioepis from making, using, offering to sell, or selling within the United States, or importing into the United States, any product containing etanercept until the April 24, 2029 expiry of Roche&#x2019;s &#x2019;522 Patent. On November 3, 2021, the New Jersey District Court entered final judgment and ordered a permanent injunction against Bioepis in conformity with the parties&#x2019; submission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Repatha Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc., et al. v. Sanofi, et al. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2014, Amgen initiated a series of lawsuits that were consolidated by the U.S. District Court for the District of Delaware (Delaware District Court) in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the &#x2019;165 Patent); 8,859,741 (the &#x2019;741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to PCSK9. By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron&#x2019;s alirocumab, a monoclonal antibody targeting PCSK9. In January 2016, the Delaware District Court granted Amgen&#x2019;s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron&#x2019;s infringement of Amgen&#x2019;s patents is willful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT infringe certain of Amgen&#x2019;s patents, including claims 2, 7, 9, 15, 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent. In March 2016, the Delaware District Court entered judgment in favor of Amgen following a five-day jury trial and a unanimous jury verdict that these patent claims are all valid. In January 2017, the Delaware District Court denied Sanofi and Regeneron&#x2019;s post-trial motions seeking a new trial and for judgment as a matter of law, and granted Amgen&#x2019;s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. In February 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. In October 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court&#x2019;s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Federal Circuit Court issued a mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron&#x2019;s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. In July 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court&#x2019;s conclusion that the judgment affirming the validity of Amgen&#x2019;s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen&#x2019;s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron&#x2019;s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen&#x2019;s claim of willful infringement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2019, a jury of the Delaware District Court again unanimously upheld the validity of claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent. The jury also found that claims 7 and 15 of the &#x2019;165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse the jury verdict against them or for a new trial, and Amgen filed a motion for a permanent injunction. On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron&#x2019;s request for a new trial and their request to reverse the jury verdict that the &#x2019;165 Patent and the &#x2019;741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court and based on the subsequent hearing, on February 11, 2021 the Federal Circuit Court issued a decision affirming the Delaware District Court&#x2019;s ruling. Amgen filed a petition for rehearing en banc which was denied on June 21, 2021. On November 18, 2021, Amgen filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the invalidation of claims 19 and 29 of the &#x2019;165 Patent and claim 7 of the &#x2019;741 Patent as lacking an enabling disclosure of the invention. On January 11, 2022, the U.S. Supreme Court requested that Sanofi and Regeneron file a response to Amgen&#x2019;s petition, which is due March 14, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Disputes in the International Region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in Germany, Spain and Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment and Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen&#x2019;s patent, and each of Lilly, Regeneron and Strawman Ltd. also filed oppositions to Amgen&#x2019;s patent. In November 2018, the EPO confirmed the validity of Amgen&#x2019;s EP 2,215,124, which was appealed to the Technical Board of Appeal (TBA). On October 29, 2020, the TBA upheld the validity of certain claims, including claims that protect Repatha, but ruled that broader claims encompassing PRALUENT were invalid. As a result of the TBA&#x2019;s decision, national litigations regarding PRALUENT in Europe are in the process of being resolved. In Germany, Sanofi-Aventis Deutschland GmbH and Regeneron have filed actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT that was lifted after the TBA&#x2019;s October 29, 2020 ruling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2020, the Supreme Court of Japan declined to hear Sanofi K.K.&#x2019;s appeals making final the Japanese High Court&#x2019;s decisions that PRALUENT infringes Amgen&#x2019;s valid patent rights in Japan. On June 24, 2020, Amgen filed written answers to the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen&#x2019;s Japanese patents that were previously held infringed by PRALUENT and valid over challenges filed by Sanofi K.K. The Japanese Patent Office dismissed Regeneron&#x2019;s invalidity trials and Regeneron has appealed the decisions to the Japanese High Court. Damages proceedings against Sanofi K.K. are ongoing before the Tokyo District Court, where Sanofi K.K. has initiated new validity challenges to Amgen patents in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NEUPOGEN (filgrastim)/Neulasta Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc., et al. v. Hospira Inc. et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2020, Amgen Inc. and its wholly owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the Delaware District Court against Hospira Inc. and Pfizer Inc. (collectively, Pfizer). This lawsuit stems from Pfizer&#x2019;s submission of an application for FDA licensure of a pegfilgrastim product as biosimilar to Amgen&#x2019;s Neulasta. Amgen has asserted infringement of U.S. Patent No. 8,273,707 (the &#x2019;707 Patent) and seeks, among other remedies, injunctive relief to prohibit Pfizer from infringing the &#x2019;707 Patent. On March 4, 2020, Pfizer filed a motion requesting the Delaware District Court to dismiss the complaint by Amgen alleging noninfringement of the &#x2019;707 Patent. In June 2020, the FDA approved Pfizer&#x2019;s NYVEPRIA, a biosimilar to Amgen&#x2019;s Neulasta. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2021, the Delaware District Court stayed further proceedings in the matter pending claim construction of the patent claims and, based on a subsequent hearing, determined on June 11, 2021 that the term at issue required no construction.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currently pending before the Delaware District Court is Pfizer&#x2019;s motion for summary judgment of noninfringement, which has been fully briefed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No date has been set for argument on the motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Trial and Appeal Board (PTAB) Challenge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Apotex PTAB Challenge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2017, the PTAB of the USPTO granted Apotex&#x2019;s petition to institute inter partes review (IPR) proceeding of U.S. Patent No. 8,952,138 (the &#x2019;138 Patent), challenging claims of the &#x2019;138 Patent as unpatentable. In May 2017, Amgen filed its response. In February 2018, the PTAB issued a final decision holding all but one claim of the &#x2019;138 Patent as unpatentable and Apotex filed a request for rehearing in March 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2019, the PTAB issued a decision denying Apotex&#x2019;s request for rehearing on the PTAB&#x2019;s finding and sua sponte amending the final decision with a finding that the one remaining claim in Amgen&#x2019;s &#x2019;138 Patent is unpatentable. On July 22, 2019, Amgen filed a notice of appeal to the Federal Circuit Court with respect to all claims held to be unpatentable. On August 5, 2019, Apotex provided notice that it would not participate in the appeal. On September 16, 2019, the USPTO filed a notice of intervention on the appeal. On March 24, 2020, the Federal Circuit Court vacated the decision by the PTAB and remanded the case to the PTAB for proceeding consistent with the Federal Circuit Court&#x2019;s decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arthrex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inc. v. Smith &amp;amp; Nephew, Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., 941 F.3d 1320 (Fed. Cir. 2019). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 14, 2020, Amgen and Apotex filed a joint motion to terminate the IPR proceedings stating that there is no current dispute between the parties with respect to the &#x2019;138 Patent. On July 29, 2020, the U.S. government filed a petition for writ of certiorari with respect to the cases that the Federal Circuit Court remanded to the PTAB, including the case regarding the &#x2019;138 Patent, for proceedings consistent with its decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arthrex Inc. v. Smith &amp;amp; Nephew, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requesting that such remanded cases be held pending the U.S. Supreme Court&#x2019;s disposition of the petition for writ of certiorari in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States v. Arthrex, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 19-1434. On August 25, 2020, Amgen filed its response to the U.S. government&#x2019;s petition for writ of certiorari indicating that Amgen did not intend to respond unless requested by the U.S. Supreme Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 21, 2021, the U.S. Supreme Court decided&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; United States v. Arthrex, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On June 28, 2021, the U.S. Supreme Court granted the government&#x2019;s pending certiorari petition and vacated and remanded the Federal Circuit Court&#x2019;s judgment for further consideration under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arthrex.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 2, 2021, the Federal Circuit Court issued a remand to permit Amgen to request rehearing of the PTAB&#x2019;s final written decision holding that all claims of the &#x2019;138 Patent as unpatentable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 4, 2021, Amgen filed a request for the USPTO Director for a rehearing and review of the Final Written Decision pursuant to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arthrex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On November 22, 2021, the Director denied this request. On December 6, 2021, Amgen filed the Notice of Director review with the patent office.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pfizer PTAB Challenge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2021, Pfizer filed a petition to institute IPR proceeding at the USPTO of U.S. Patent No. 8,273,707 (the &#x2019;707 Patent), challenging claims of the &#x2019;707 Patent as unpatentable. Amgen&#x2019;s preliminary response was filed on May 18, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2021, the PTAB of the USPTO granted Pfizer&#x2019;s petition to institute IPR of the &#x2019;707 Patent. On August 23, 2021, the PTAB issued the schedule for the proceeding, including oral argument (if requested) on May 18, 2022. On November 17, 2021, Amgen filed its Patent Owner&#x2019;s Response.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Breach of Contract Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis Pharma AG v. Amgen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 4, 2019, Amgen filed a lawsuit in the U.S. District Court for the Southern District of New York (the New York Southern District Court) against Novartis seeking a declaratory judgment that Novartis materially breached two collaboration agreements Amgen and Novartis entered into in 2015 and 2017 (the 2015 Agreement and the 2017 Agreement, respectively) related to the development and commercialization of Aimovig due to Novartis&#x2019; affiliate Sandoz GmbH entering into a contract manufacturing agreement with Alder BioPharmaceuticals, Inc. (Alder) related to eptinezumab, an expected direct competitor to Aimovig and entrant in the CGRP-related migraine therapy market. Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. Also on April 4, 2019, Novartis initiated a separate lawsuit against Amgen in the same court seeking declaratory judgment that Novartis, alternatively, did not materially breach the collaboration agreements or, even if it did breach the collaboration agreements, such breach was not material and has been cured, and that Amgen may not terminate the collaboration agreements. On April 8, 2019, Amgen answered Novartis&#x2019; complaint and filed counterclaims seeking a declaratory judgment that Novartis materially breached the collaboration agreements due to its affiliate Sandoz GmbH entering into the contract manufacturing agreement with Alder. In its counterclaim, Amgen seeks to terminate its collaboration agreements with Novartis and also seeks damages from Novartis for breach of contract and negligent misrepresentation. On July 16, 2019, Novartis filed an amended complaint adding a claim for breach of contract alleging Novartis is owed amounts associated with 2018 budget overruns, and Amgen responded with a counterclaim alleging additional breaches by Novartis of the collaboration agreements. On September 17, 2019 and October 8, 2019, Novartis and Amgen, respectively, each filed its motion for judgment on the pleadings. On February 3, 2020, Amgen was granted leave to file its amended counterclaims. On February 4, 2020, Amgen filed its amended answer to Novartis&#x2019; first amended complaint and second amended counterclaims for affirmative relief to add a fraudulent inducement claim. On February 18, 2020, Novartis filed its answer and affirmative defenses to Amgen&#x2019;s second amended counterclaims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2020, the New York Southern District Court entered an order granting Novartis&#x2019; motion for judgment on the pleadings that Novartis did not breach the 2017 Agreement, and denying Amgen&#x2019;s motions for judgment on the pleadings seeking dismissal of Novartis&#x2019; amended complaint that Novartis did not breach the 2015 Agreement or the 2017 Agreement, and Novartis timely cured any breach. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the June 9, 2020 order, which was denied on September 14, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, the parties executed agreements to settle two claims in the litigation, relating to the 2018 budget overrun dispute and certain counterclaims alleging breaches by Novartis of the 2015 and 2017 Agreements related to the development and commercialization of Aimovig, and to amend and restate the 2017 collaboration agreement. As part of the agreement, Amgen paid $48&#160;million to Novartis to resolve the 2018 budget dispute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2021, the New York Southern District Court held a status conference with the parties and set the dates for Novartis&#x2019; opening brief for its motion for partial summary judgment on two claims, fraudulent inducement and negligent misrepresentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2022, the parties resolved all claims in the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sensipar Antitrust Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From February to April 2019, four plaintiffs filed putative class action lawsuits against Amgen and various entities affiliated with Teva Pharmaceuticals USA, Inc. (Teva) alleging anticompetitive conduct in connection with settlements between Amgen and manufacturers of generic cinacalcet product. Two of those actions were brought in the Delaware District Court, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UFCW Local 1500 Welfare Fund v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (February 21, 2019) (Local 1500) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cesar Castillo, Inc. v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (February 26, 2019) (Castillo). The third action was brought in the New Jersey District Court, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Teamsters Local 237 Welfare Fund, et al. v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (March 14, 2019) (Local 237) and the fourth action was brought in the U.S. District Court for the Eastern District of Pennsylvania (the Eastern Pennsylvania District Court), captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Amgen Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 10, 2019) (KPH). Each of the lawsuits is brought on behalf of a putative class of direct or indirect purchasers of Sensipar and alleges that the plaintiffs have overpaid for Sensipar as a result of Amgen&#x2019;s conduct that allegedly improperly delayed market entry by manufacturers of generic cinacalcet products. The lawsuits focus predominantly on the settlement among Amgen, Watson Laboratories, Inc. (Watson) and Teva of the parties&#x2019; patent infringement litigation. Each of the lawsuits seeks, among other things, treble damages, equitable relief and attorneys&#x2019; fees and costs. On April 10, 2019, the plaintiff in the KPH lawsuit filed a motion seeking to have the four lawsuits consolidated and designated as a multidistrict litigation (MDL) in the Eastern Pennsylvania District Court, and the plaintiff in the Local 1500 lawsuit filed a motion seeking to have the four lawsuits, along with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cipla Ltd. v. Amgen Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, consolidated and designated as an MDL in the Delaware District Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2019, the MDL panel entered an order consolidating in the Delaware District Court the four class action lawsuits. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs&#x2019; consolidated class action complaint and the indirect purchaser end payor plaintiffs&#x2019; complaint. On December 6, 2019, the plaintiffs responded to Amgen&#x2019;s motion to dismiss and, on January 10, 2020, Amgen filed its response. On February 6, 2020, the motions in the class action lawsuits were transferred to the U.S. Magistrate Judge for the District of Delaware (Magistrate Judge) for a recommendation. The MDL panel certified its conditional transfer order on February 6, 2020 transferring the additional class action lawsuit brought in the U.S. District Court for the Southern District of Florida, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims v. Amgen Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the Delaware District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On July 22, 2020, the Magistrate Judge issued a recommendation to the Delaware District Court that the claims against Amgen be dismissed but leave be given to plaintiffs to amend their complaints. On August 5, 2020, the plaintiffs filed objections to the Magistrate Judge&#x2019;s report and recommendation. On August 19, 2020, Amgen filed a response to the plaintiffs&#x2019; objections. On November 30, 2020, the District Court adopted the Magistrate Judge&#x2019;s recommendation in part and denied it in part, denying Amgen&#x2019;s motion to dismiss on the grounds that plaintiffs adequately alleged reverse payment claims but granted Amgen&#x2019;s motion to dismiss with respect to the other Federal antitrust claims. On December 23, 2020, Teva, Watson and Actavis filed a motion for interlocutory appeal and for a stay pending appeal and Amgen filed its joinder (the 1292 Motion). On January 5, 2021, a joint status report was filed advising the Delaware District Court that the defendants are still considering whether to withdraw the 1292 Motion and plaintiffs&#x2019; offer to stay discovery, pending further rulings on motions to dismiss the amended complaints. On January 19, 2021, a joint status report was filed pursuant to the Delaware District Court&#x2019;s January 6, 2021 order along with a stipulation to defer the 1292 Motion until after rulings on the amended complaints.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 16, 2021, the plaintiffs in the antitrust class action lawsuit brought on behalf of putative classes of direct or indirect purchasers of Sensipar filed their amended complaints. On March 4, 2021, a stipulation and order regarding the filing of a second amended complaint were filed to add another plaintiff: Teamsters Western Region &amp;amp; Local 177 Health Care Fund. On March 17, 2021, a defendant, MSP Recovery Claims, Series LLC, filed its notice of voluntary dismissal. On March 30, 2021, the remaining defendants, including Amgen, filed their motions to dismiss the second amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 27, 2021, plaintiffs filed their oppositions to defendants&#x2019; (including Amgen&#x2019;s) motion to dismiss, and defendants&#x2019; reply was filed on May 25, 2021. A hearing on defendants&#x2019; motion to dismiss was held in the Delaware District Court on July 13, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Humira Biosimilar Antitrust Class Actions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From March to May 2019, twelve purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie), were filed in the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court). The cases are captioned: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UFCW Local 1500 Welfare Fund v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 18, 2019) (Local 1500); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (March 20, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mayor and City Council of Baltimore v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 22, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pipe&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trades Services MN Welfare Fund v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 29, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;St. Paul Electrical Workers&#x2019; Health Plan v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(March 29, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Welfare Plan of the International Union of Operating Engineers Locals 137, 137A, 137B, 137C and 137R v. AbbVie Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(April 1, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Law Enforcement Health Benefits, Inc. v. AbbVie, Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(April 9, 2019) (Law Enforcement); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky Laborers District Council Health and Welfare Fund v. AbbVie, Inc., et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(April 16, 2019); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sheet Metal Workers&#x2019; Local Union No. 28 Welfare Fund v. AbbVie, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 19, 2019) (Sheet Metal Workers&#x2019;); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Locals 302 &amp;amp; 612 of The International Union of Operating Engineers-Employers Construction Industry Health And Security Trust Fund v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 25, 2019) (Construction Industry); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Louisiana Health Service &amp;amp; Indemnity Co., d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc. v. AbbVie Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (April 30, 2019) (Louisiana Health); and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cleveland Bakers and Teamsters Health and Welfare Fund v. AbbVie Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (May 10, 2019) (Cleveland Bakers) (collectively, Humira Antitrust Class Actions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of the Humira Antitrust Class Actions, the plaintiffs bring federal antitrust claims along with various state law claims under common law and antitrust, consumer protection and unfair competition statutes. In each case, the plaintiffs specifically allege that AbbVie has unlawfully monopolized the alleged market for Humira and biosimilars of Humira, including by creating an allegedly unlawful so-called patent thicket around Humira. In the Local 1500, Sheet Metal Workers&#x2019; and Construction Industry cases, the plaintiffs further allege that AbbVie entered into allegedly unlawful market division agreements with Amgen and other companies that had developed Humira biosimilars, including Bioepis, Mylan, Sandoz, Fresenius Kabi USA, LLC (Fresenius), Pfizer Inc. and Momenta Pharmaceuticals, Inc., in connection with the settlement of patent litigation relating to Humira, whereby Amgen and the other defendants that have developed Humira biosimilars were permitted to market those products in Europe as early as October 2018, while remaining off the market in the United States until 2023. In each of the Humira Antitrust Class Actions other than the Local 1500 and Construction Industry cases, the plaintiffs allege that AbbVie and Amgen entered into an allegedly unlawful settlement agreement under which Amgen allegedly agreed to delay its entry into the U.S. market with AMGEVITA, its Humira biosimilar, in exchange for an alleged promise of exclusivity as the sole Humira biosimilar in that market for five months, beginning in January 2023. In each of the Humira Antitrust Class Actions, plaintiffs seek injunctive relief, treble damages and attorney&#x2019;s fees on behalf of a putative class of third-party payers and/or consumers that have indirectly purchased, paid for or provided reimbursement for Humira in the United States. Defendants&#x2019; responses to the first six complaints were stayed by the court. On June 4, 2019, the Illinois Northern District Court entered an order consolidating the twelve purported class action cases for pre-trial purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2019, the plaintiffs filed their consolidated complaint, naming as defendants Amgen, along with AbbVie, Bioepis, Sandoz and Fresenius. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual motions), challenging the legal sufficiency of the plaintiffs&#x2019; allegations to state any claim for relief under the law. On November 19, 2019, plaintiffs filed their opposition to the motion to dismiss. On December 20, 2019, defendants filed their reply in support of the motion to dismiss. On June 8, 2020, the Illinois Northern District Court issued an order granting the motion by the defendants to dismiss the consolidated class action complaint. On June 29, 2020, the plaintiffs filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion. On July 28, 2020, the plaintiffs filed a notice of appeal. On October 5, 2020, the plaintiffs-appellants filed their opening brief to the U.S. Court of Appeals for the Seventh Circuit. Plaintiffs-appellants amicus briefs were filed in October 2020, including one by the FTC and one on behalf of 20 states, each filed on October 13, 2020. On December 21, 2020, the defendants-appellees filed their opposition brief. Defendants-appellees amicus briefs, including one by the DoJ, were filed on December 28, 2020. On February 25, 2021, oral argument was held by the U.S. Court of Appeals for the Seventh Circuit on the appeal by plaintiffs-appellants of the lower court&#x2019;s dismissal of the consolidated complaint with prejudice. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Tax Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. &amp;amp; Subsidiaries v. Commissioner of Internal Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6, Income taxes, for discussion of the IRS tax dispute and the Company&#x2019;s petition in the U.S. Tax Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments &#x2013; U.S. repatriation tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2017 Tax Act, we elected to pay in eight annual installments the repatriation tax related primarily to prior indefinitely invested earnings of our foreign operations. The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining U.S. repatriation tax commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzkzMTE_6dd6f615-2357-4b74-baef-48307e78888b"
      unitRef="lawsuit">19</amgn:GainContingencyNumberofLawsuitsFiled>
    <amgn:GainContingencyNumberofLawsuitsFiled
      contextRef="ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwNzc1_f5bf0bc5-4a1d-444a-becd-a261f5478976"
      unitRef="lawsuit">19</amgn:GainContingencyNumberofLawsuitsFiled>
    <amgn:GainContingencyNumberofAffiliates
      contextRef="i19d673199032476d834451d22f3f5dc6_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzI5MTY1_dab93ba1-4ff0-4a8a-b520-cca0a78e2a06"
      unitRef="affiliate">2</amgn:GainContingencyNumberofAffiliates>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i1d65a5d55e5642be9bee7decb061fd66_D20141001-20141031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzMxMDEz_16071788-3969-4b6a-b6e1-8f016a72971f"
      unitRef="patent">7</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <amgn:LitigationSettlementLengthofTrial
      contextRef="id07a2cf432c24ff9a1f851f3d46e53b5_D20160201-20160228"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2MjY1_30add478-8894-4672-8c95-fdc7aee476ac">P5D</amgn:LitigationSettlementLengthofTrial>
    <amgn:GainContingencyNumberOfChallenges
      contextRef="i3b4cd2176c02454e86da12e52b785bfb_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzMzNDM3_527f661e-1c97-4199-a01d-3917766dc3f4"
      unitRef="patent">2</amgn:GainContingencyNumberOfChallenges>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5a349ce4f68f4e62ac77c54575a7b956_I20190520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQxMzg3_fec627e2-776e-43cf-a32a-192b6c5cda34"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5a349ce4f68f4e62ac77c54575a7b956_I20190520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQxNjYw_23553a13-f88c-42ef-9786-46c8ca96a019"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <amgn:GainContingencyNumberOfAgreementsBreached
      contextRef="iaf846f658f5942ce82b4f681a169e2fa_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQzNDQ5_f4728cdf-0045-44b7-8ec8-d288fcc2b2b6"
      unitRef="agreement">2</amgn:GainContingencyNumberOfAgreementsBreached>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i84504b4b6730469e9a42aebe34756f62_I20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MjA_e5c7486f-d6c0-4420-a278-1bcae781d94e"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="i42713d0e16f04d26a1b1ce71cf3aecd4_D20210602-20210602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MjI_06a73ee5-0955-4732-816e-3659d6802b79"
      unitRef="usd">48000000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i7c633c2c74b0432094a5ea889bbccf99_I20211026"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MzQ_2da86a16-ffed-4fb3-aa2c-95713502689e"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ2MzMw_fb3ddb33-45f6-400c-bea2-6588af9d4da8"
      unitRef="plaintiffs">4</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ2NTY0_203942d3-009f-4397-8bb4-f93415731ef9"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i1ab8018abbdc4ab1bcbc87cc2571878a_D20190430-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODQ3Mjg_54a0e7e4-8150-4a44-9316-a945613b6461"
      unitRef="claim">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <amgn:LossContingencyNumberOfLawsuitsFiled
      contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ3ODQ0_956480cb-7b16-4e74-9f44-9ffc75c4b369"
      unitRef="lawsuit">4</amgn:LossContingencyNumberOfLawsuitsFiled>
    <amgn:LossContingencyNumberOfLawsuitsFiled
      contextRef="i05f08ac1682f47d19a53c5b391ca8380_D20190201-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzQ4MDQz_82ae9f09-d884-4aac-80a2-3a39497e4194"
      unitRef="lawsuit">4</amgn:LossContingencyNumberOfLawsuitsFiled>
    <amgn:LossContingencyNumberOfLawsuitsFiled
      contextRef="i3ac324416a7c4f1f83e593ede6d076bd_D20190731-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzEwOTk1MTE3ODM4MzY_5ec911a1-bf75-437e-b8e5-1abd9741fd57"
      unitRef="lawsuit">4</amgn:LossContingencyNumberOfLawsuitsFiled>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ibba78d537ea54a03a6bd4d13b80aea70_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzUwNTQ4_b6c361a8-029e-4ceb-b92e-1f46b09add12"
      unitRef="claim">12</us-gaap:LossContingencyPendingClaimsNumber>
    <amgn:LossContingencyNumberOfComplaintsStayedByTheCourt
      contextRef="i7e56044cea924d89ae341cd4198e2725_D20190301-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU0MTE5_ed0a5c6f-a895-419e-bcaa-2f9599dc1f23"
      unitRef="complaints">6</amgn:LossContingencyNumberOfComplaintsStayedByTheCourt>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id63608bd810a4daabb58c50a1d92c7fc_I20190604"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU0MjQ4_806c16ed-2cc3-420c-a857-7aab3409f376"
      unitRef="claim">12</us-gaap:LossContingencyPendingClaimsNumber>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2MDI4_c01a038b-6158-48a1-bb5a-dd57809fd16e"
      unitRef="installment">8</amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments>
    <amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90ZXh0cmVnaW9uOjVmOWI2MTFkYjRjYzRkMjZhYzgzOGJkOWJiYTYxMGVjXzU2Mjgx_f8ad8b79-44e2-4342-9bdd-4ef864c366d9">The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2021 (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining U.S. repatriation tax commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzItMS0xLTEtNTU1NTQ_67372e55-1e64-4e42-bcbd-787b6dc8ba47"
      unitRef="usd">587000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzMtMS0xLTEtNTU1NTQ_a0ad568b-6fdd-403b-b49f-16abaa3381f5"
      unitRef="usd">1100000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzQtMS0xLTEtNTU1NTQ_ca1629c5-38a1-4375-8809-6d894c3c53f7"
      unitRef="usd">1467000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears>
    <amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzUtMS0xLTEtNTU1NTQ_7a981e6e-56b3-45ce-8c6a-848c49843a95"
      unitRef="usd">1834000000</amgn:TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears>
    <amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNTAvZnJhZzo1ZjliNjExZGI0Y2M0ZDI2YWM4MzhiZDliYmE2MTBlYy90YWJsZTpkYWY4ZDQxNDFmNmQ0NmY5YjdjMmQ3ZDVhMWRlYTY1OC90YWJsZXJhbmdlOmRhZjhkNDE0MWY2ZDQ2ZjliN2MyZDdkNWExZGVhNjU4XzYtMS0xLTEtNTU1NTQ_ba35a7ce-551f-4baa-9b22-e41c11994fbd"
      unitRef="usd">4988000000</amgn:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90ZXh0cmVnaW9uOjMyZWU0MjliMzhhYTRhMzE4MzUyMDdlMWJhODY1OWUyXzEwOQ_a8968493-5464-42d8-878c-77e574249a6e">&lt;div style="margin-bottom:8pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AMGEN INC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ended December 31, 2021, 2020 and 2019 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at beginning&lt;br/&gt;of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;br/&gt;charged&#160;to&lt;br/&gt;costs and&lt;br/&gt;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&lt;br/&gt;at end&lt;br/&gt;of period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtMi0xLTEtNTU1NTQ_7b5e5eb6-6e39-476b-a3ff-5949c5aac16e"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtNC0xLTEtNTU1NTQ_60bc209c-6163-455d-9c9b-87a189bd5c1d"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtNi0xLTEtNTU1NTQ_d7fc4a0e-85ab-4a5c-8055-b3e5f1e6f0dd"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtOC0xLTEtNTU1NTQ_2ba0e377-b17a-455e-a6e8-1c6e5148db7b"
      unitRef="usd">6000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7b1dfb5d9a21406fb43a36399d97dd92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzEtMTAtMS0xLTU1NTU0_d1623324-d87c-4948-9789-229cca7a9897"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItMi0xLTEtNTU1NTQ_da5fbbdd-31b9-428f-b6d5-1024f5f7ee4d"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItNC0xLTEtNTU1NTQ_d3f528df-f1ed-49a0-819e-75a319edf466"
      unitRef="usd">8000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItNi0xLTEtNTU1NTQ_a409fe56-ca73-4dda-9d73-73e2c8c5ffac"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItOC0xLTEtNTU1NTQ_3e1f6bdf-f308-46a2-a9ad-b18d0c18d470"
      unitRef="usd">2000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ide4e5e657f16482091a0d8f7d0722737_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzItMTAtMS0xLTU1NTU0_ba136f75-b2ba-4c8f-b5b9-4e1e1cdb2c21"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib936adc316344e80a16bdf77c98d380b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtMi0xLTEtNTU1NTQ_de0a77cb-6477-4612-8301-33cb315bb055"
      unitRef="usd">48000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtNC0xLTEtNTU1NTQ_56fd499c-730d-4dfa-b1e6-2fa0bd984a39"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtNi0xLTEtNTU1NTQ_f2dea520-8c1f-4172-94de-4b67737e2ced"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ifd4301c23f864819a9e99c46e427bf1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtOC0xLTEtNTU1NTQ_a4837839-e7d9-4b3f-bb73-a7f3ef4adb1d"
      unitRef="usd">22000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia86993e4e7394c7c9f663f9dc7533e39_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhOTcxY2ZhZWY5ODQyNGY5NjkyMDQxZDZlZDNhMjIyL3NlYzoyYTk3MWNmYWVmOTg0MjRmOTY5MjA0MWQ2ZWQzYTIyMl8yNjIvZnJhZzozMmVlNDI5YjM4YWE0YTMxODM1MjA3ZTFiYTg2NTllMi90YWJsZTo1MDZiZGVlZWExOWU0OTM2OWRmYTk4OTEyZWFmOTk1OC90YWJsZXJhbmdlOjUwNmJkZWVlYTE5ZTQ5MzY5ZGZhOTg5MTJlYWY5OTU4XzMtMTAtMS0xLTU1NTU0_e7e84dd0-f92d-4af6-969b-efa11fea46c6"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>141
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1?Z6+K]0?&O>6RVY4CPQ'S>,0K.D;X#?5QRFL[C0 QS>E=[\!U!+ P04
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MWL.;U^B!ZIQ)0S@<K'0X^&B/3S<5W@Q0E;ZJ]@IMC?IN81]%T"[ KA^4PN/
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MS+AH8G,37QN/)C="N5M<H:%303A,%UI9+47.$7)VRR57&;"5H[/L;,D-*"P
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MTR).UQD58 O:&')R2TU83^V+?MGDU[2L W2%J-=D>2[.8U47SA#Q;"2-/6]
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MT.DY**8SLN3Z4:PO:!E/Q]J+!%?Y+UH7VC!T4+146J0E;':0LJRXDM?R?]@
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M!J#_OQ%"_?QB!CC<WU_^#U!+ P04    " #UA%!4]+--O! ?   [80  &0
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M:T8M$I;XS'TN$6RPN>)*<VXG!.V6>2RSJ)5U/!E 0F>+0SCZK>:V((M>U?5
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MM"^&219P72"[3:,L RD[R!Q>D5)-Q_(0;SN]O46RB.TQ>5I7T.;:TX3OJM*
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M)!AI.5IF#^9L5?-O50T'^ZW5^@%[-'D!8F%TCR((_F"1G)L][@N<'0,E\8M
M]+@ZF>:(_W_,X^^.LO]IIOD:TJ]QR9FO(!&S.7T<@0DW"!A2*8[ ;BQJ] $R
M\MMMS7Y@QX<XAS.<#?9JW<%Q5W,TVF%ZT7#@PR4&]XD=G@J3$Q^K#_WCZ#[0
M8 ";5,^@'/WG]>!))TT^"N?]V_H'W.J@_<K@LC5=T4[H^V#.X["BX65HI04/
M4AS#H3GR(9O1TX[ P?V"4L$_"7XN8$CKD+^UOM3([Z]3BP.D3.>!# ,1I7'R
MG-J@4?(/ [A2%K4*LM>A\",TMWKYE+H"IT<2OFDJ0G?/T-V?UH6#^<7#S^_=
MWU='#Z.>S>;GGYN:PO1&.JP>7I@7T\/J@7QZGKY%5^!CH=.W8(V71;8@.SWY
MIHDWN_#,6AN/M E#=#LT."; _JTQ_G[""@[O[O-_ 5!+ P04    " #UA%!4
M)ABQ%JX,  #")P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6S%6EMS
MV\85_BL[JM*Q9BB( .^I[1GYDC8/:3RVDTRGTX<EL"2W!K (%A#%_OI^Y^P"
M!"^0%,N=/H@B@-VSY_J="_AR:\HO=J-4)>ZS-+>O+C9557Q_<V/CC<JD#4RA
M<CQ9F3*3%2[+]8TM2B43WI2E-]%P.+W)I,XO7K_D>Q_*UR]-7:4Z5Q]*8>LL
MD^7NC4K-]M5%>-'<^*C7FXINW+Q^6<BU^J2J7XH/):YN6BJ)SE1NM<E%J5:O
M+F[#[]^,:3TO^%6KK>U\%R3)TI@O=/%C\NIB2 RI5,4549#X=Z?>JC0E0F#C
M=T_SHCV2-G:_-]1_8-DARU):]=:DO^FDVKRZF%^(1*UDG58?S?9ORLLS(7JQ
M22U_BJU;.QY=B+BVE<G\9G"0Z=S]E_=>#YT-\V'/ALAOB)AO=Q!S^4Y6\O7+
MTFQ%2:M!C;ZPJ+P;S.F<C/*I*O%48U_U^E-EXB_7)%<B8I/!UE:2NE[>5*!.
M:VYB3^F-HQ3U4 HC\9/)JXT5[_-$)8<$;L!6RUO4\/8F>I#B.Q4'8A0.1#2,
MP@?HC5I91TQOU"?K1I;*R_I![N!:E;@M2YFO%7__Y^W25B7\Y%\/'#9N#QOS
M8>-OH-BOHR1^KDMQ"\ZA;:AHN! ?4@D_KZN-*?5_E!6(6:&MK64>*U$9H;(B
M-3N%)V:%G6N%U7DB<I,W3T2FLJ4J>8$!^3=&E@E=O-,EXLC@B24MM@O 4 96
M+/$HBKJDPRHZ:PV]5KQ,_5[K:N<%D%L0M .A\SBM$YVOQ<=/O^#:$3 %"6:9
MJT*5C#G$>YUK0(_XO%&B,(@14/5LR#NI4[E,:4VB2E%AR:E.M 6 )'6,F\N=
M@+AN.RM(R7AS<+QCG7C->7D8+)K3:+W!$3AG5S@E.(&:/5W!5G6:7M_)M%9^
M42!^!'&5JU*F6(B]^:ZA;.OEOZ%@TAS9D-:W?#PDF;HO8!D!OI8*MF"15DHS
M*Y4J@1B22.!Y3)I,\7VKX2!UQ01;[V@U.N#[IUS9&FKRPI+J9$*,+"74IG,\
MIUVMZR7>3+DC)L$7S \K5!O)!^_$5H%(J3)SIQ)6# AJ4O_@(7D'#6<DQ$:E
M";%6R!U;!L+JK,Y@3%G5\-6=J.2],,M4KZ7S*]J%0VWAA3HQT1\5S4D%Y>V=
M)!"W? ?HQ;'4(MB@QX1%:>YTXKUK55<U6/#1 P^\Z<0PTZT+=I("V^XUTI)*
MX:(+")^FY+S]X1F(+I)X>9VN:6D+ 0<84X!#IY5,)LHI,%=;G$E,@8X_#W^J
MA"E9B&H#I0 ,"F.5B]J529'^*2HJ#E:D7LK+EE5"!R(F/5S8/KB#J^,[[8W-
M.F=3Z)Q9?PO;FE0G[.J?8'W&<Z;V8\Y1\0(KO8;LU??B'TH"R9PA3NQ$'T-\
M0*F$3>)2A/,1?<[F]#F=BP_'T"1"; O#N0B'$Z?E%LI&,S$:B]%$?#:53!^5
M;@!W4.2VHW$H1J.A& WGXC.NE\"-E:[$JC39XSIZ,1M?X2/"QW1V]>2S<U2!
M4!J=?RFBZ8P^)R1U!&X^*F1''9..'5PZT0DE#]'[/0).DY7W^<:C'MP&UE.H
MPQCE\KP&6^SK="QK&^0&[$2Q*BL4E6!.Q365;M>INE/IGNA1TA@XYV3 @7,P
M7X32+4AWF$B4PT:7#VA+0_7/?YI'X>PO@#Z9HD@EYA)UDH^8DT"\]2SBIO0U
M!*\LS4I9*EME>LPTL:3C TU [";>:\0!QZS"*4R/\B?OI:M _/T/I6J96O.8
MP@,N(XB'8T,V3'E\8J/(F')(V>84%'PZ)QBX@W-0>$,;C>%B7<9U!C!FY)*6
MBF56N7;8Z:$%IY8J98J.,;DNE0O@;C9EU21*5IN!2+252YVBJM@G.6*8#C5Y
M[@M^=@<IX@T5>/Y950*[V3,V!"055'6H9C+1=F.@7(1"(PE!FXY5 \>P-?:B
MJG&;H<+&<X\"8>]PI!YB ;M@ )F9FO')YT< &GD]8+-T5<<*!B7F\QR6*ZTL
MM8-T6NV41%C7G!O')1)8HLE*V$R<(:<Y!6XWFO(V\'OO>,B7#,)ZGRURW-YN
M?#WH4YZZKT@U])6S1+IKRC4G#BTEPCX1^%UP-UUH=M8>P/A\((1825T*EX,I
M4G/V1=:3SPZIL71P46I7IYR4G5Z->YH#\K;'=".2NN2$M%'$@/=?1+DVB4M:
M6V[I5'(M800R^EFN+>UAT5H,:PJW_0EB]U#&&;B40PJEM#-PQ=%E-!H%X7!
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MW)']Y+9N*F=IE[16X3]9%:+4<JE+[32V$8<K7<DJU^#<*%!VM'/7F%UME=]
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M(M("_+ZJ@:_P@0YHW]E]^6]02P,$%     @ ]8105(_6QG.U P  C@@  !D
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MB8F#[>D82?,A#E)"N> S!D"9+34\%@\L(J#Q5C?$7C_+N/?H("0BB+CJ]_C
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MRW&*-LH'/B:GH]2JY*3:A=,/WL3Q64EXV]!!UBUY@T>/U(LR)[]0 F[ *MP
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)U7:V_;-A3]*Q=&-R2
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MMK>" H5R03\'72P13O U;7(''6_&\:()AV]W?-0E+APPB>2VX[P_#Z%K?GF
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M<6GHW3E/IF8!9  +H^@!2[V$#U+3352*'I7[> I4$:SGA+"K2A@RF%ELA*P
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M?2GOGMM*K-TH>\>;$/X0L\X[U]U\V04YTY.JW?WWSA[8&1I>A"B+;8G/<G\
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M])Q#MT9SXC2!MX&(3_WL*[4-B#2MB+2-RM05<#KENN)CVRE7;J2=B/6=1F;
MSL)@KU5*),36M7EZ7 G*&C GIB;!X>$NQ!O:(/J"$1H\XW"6'I^&2)G)^'<D
M3GSZ4AKZ0QBPI:HSH$*-Z%JAR7(Z6D5, )!6%<R!<<1<>M^N,80V,@)]5TDW
MV"8=<5K,=307,DF$T[-,3\$T*T*W")Q%(1*5!686OI$L22@X6O6IHF]X">3+
M&EPJ8O[C\%Z80B\BYJT8);\(A62+0< [V!/R3W>D)T+%>XB'9FN6 $'LM7"^
MU'#H4S*RVI009ID#<>QZ*(UU*1723O6U(,Z-D59I30>ZIB8F/V,0VUHG9+=
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MM".A0WX2'I-UD,>!8745'US[HOJ$KH 0IM*0D1K77$5 B^SN;T9(O@XTF)6
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MXSX ^5<(S(?5AA4I@N 8\&1<Q+@XWV9"L+W@F39HH"C610[D/R4Y\9RA]]N
M"2:P*[Q# H-,8@"0MA"E@0 03 "D0-J!,!. )K(+P"-V$&NB MYT)5!N1!#P
M"YB*@,&[!> 0T> !J%0A2.DE&2H$,!&O8+,RB-&_(T+2'WE+XN>6A\"/7.<\
M.>C>'*:2U/AF@X(#B8(K,JSCL2I0_V'KT^EPSE8RBLC_P9577M'N<&-4/T:-
M%Y0<17OR;^260Z$!#^/#^Y6T@QD0M)7@Z\FZ*M^!?H(2)W#17-=68WT@<"L
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M7FK_)DIX;,2.;EVJ/#DD,I_<@<R6KNCU<1X3QMS2(X$CO)2/#-1.2]X'@C
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MQ_=6[.R]DPV66-[^#/UG76'U*Q_HFJ_?=^-X)[JNH3NUU[[0V'-77Z$NXHX
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MKP)F!:H5S]=[UAP^Z]_0UU;BA2K!6O8(!)T?S7&CV@L ;R^"UY_X0R2\L"=
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M IDDX*2B2*)F&]TF.21]#)_,4A9I0AJPW3@O2DYIHB/">#XAN<QPG3V2E3_
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M,;E!#8NC/UQ0#I0K_.<2TN[2">4&C\\NB["HY_S/]B8^/N/Y+4<.2NDI[]4
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MM+,GM.!LQ05AR(3VJX+6>UQ2IPKAXNU/8%&H2A+NBID<RDJG.1TB*#5/$3[
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MC=<@$'F\]]W',T\VUGWT2V,"?>G:WI^.EB&LCL=C/UV:3OLCNS(].'/K.AU
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MUL_,[)\&QHAG'Q3?!77!#UI\:J9')%A&/.?L@#VQ3U(D>^)PDC1WMJ-+Q.H
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M\P#JGREEMP]LH/W+8?(/4$L#!!0    ( /6$4%3XN>X$2@8  #81   9
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M[ BP/E?*-@,GH/VKY.0?4$L#!!0    ( /6$4%0"H) [W@(  $,&   9
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M9!KUSK, E!]9?F-DX\;$0AH:.FY9TI1'917H?BFEV6ZL@^Y_8_H74$L#!!0
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M-/ZZSYS^-U!9!MK/)+7ZY<(::/Y@1O\!4$L#!!0    ( /6$4%28YRIT9P(
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M;RMZM5 [![HOE+)[PP7HW\'%?U!+ P04    " #UA%!424WYCL<#  "M"
M&0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R-5MMNVS@0_96!MEC8@!+=
M+%O.V@9BMT47:% C:;8/BWV@I9%-E!)5DHJ3?OT.*4?)+A*E+[R)<^9R9CA:
M'*7ZK@^(!NXK4>NE=S"FN0@"G1^P8OI<-EC3EU*JBAG:JGV@&X6L<$*5".(P
MG 85X[6W6KBSK5HM9&L$KW&K0+=5Q=3#&H4\+KW(>SRXYON#L0?!:M&P/=Z@
MN6VVBG9!CU+P"FO-90T*RZ5W&5VL4WO?7?B+XU$_6X/U9"?E=[OYLUAZH34(
M!>;&(C":[G"#0E@@,N/'"=/K55K!Y^M'](_.=_)EQS1NI/C&"W-8>ID'!9:L
M%>9:'C_AR1]G8"Z%=B,<N[OIU(.\U496)V&RH.)U-[/[4QR>"63A*P+Q22!V
M=G>*G)7OF6&KA9)'4/8VH=F%<]5)DW&\MJ3<&$5?.<F9U581O\H\^- (5AM@
M=0'XH^4-!=[ Z"O;"=3C16!(EY4(\A/NNL.-7\&-8KB2M3EH^% 76/P7(" C
M>TOC1TO7\2#B>\S/(8E\B,,X&L!+>L\3AY>\Z?FV]_Q#[_G?ESMM%.7,/P.J
M)KVJB5,U>4751E:-K E6@RRA&0KY2Y$>!+=5>Z$;EN/2H[+4J.[0>X/67%)1
M:8.%-<<<$$HIJ#IYO8=104NF@%6RM?;RFK).""H@/;X X@"K'2K'PZW&LA4@
M>(DPHGL/R)0>.WKL$,)GJ_7WW[(XBO^ =Q#/YG9,Y[!NN2A(FW9V\8HB<H>5
MBT\4GDU"F/AAG$'B9^D,KEC=ED1$JZQ]3TYD9Y1CB1]F(<1^-DU)W4XJ9J1Z
M^/^MR(_F"8TQP7WD]_@\%O0Y]B=A-TYAPQINF. _Z9*6I3DRA9"<I18CC2Q&
M-(4O%#,%Z5D40C:U\.$\@@V%R*BV>VPH'.34GOC0?03FV0SF40J#W/BP5Y*$
MHL2?9[&=LND4/EL<EN=MU0IF>2N0N,XYZUXV B"^E.$_NX-1YL_FV=C.\]EL
M_);&FM[^=Y#Z43:A>>)GV1P&LC[MLSX=S/KA'-P]P!XI0JPY\)SBU?47LOZE
M"AA4]'(%;$@U]:17E- K:P[45'1#W0&,'"[*+D0C(>O]F: F0N'6&HT>^W!D
M1(P^%9!V=?!:O3P5QFW-+8DWAKC4MB;\+(S</)DEL&W)$ G7/)>46DEDLRY)
M(KC^\LVFVLPE7);"5TF)^BN&_PJWP;,64J':NT:IZ:6@5Z#K)OUIWXLONQ;T
M=+UKY%=,[7FM06!)HN'YC-A377/L-D8VKB'MI*'VYI8'^I] 92_0]U)*\[BQ
M"OH_E-6_4$L#!!0    ( /6$4%2$[_0O[@,   <)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;(U6;6_C-@S^*X17'!+ K=]CNY<$2-O=78$-*]IN
M^S#L@V(SB59;RDER<_WWHV0G[= VZY=$HD@^#TE1]'0GU8/>(!KXT39"S[R-
M,=OS(-#5!ENFS^06!9VLI&J9H:U:!WJKD-7.J&V". PG0<NX\.93)[M1\ZGL
M3,,%WBC07=LR]72!C=S-O,C;"V[Y>F.L()A/MVR-=VA^W]XHV@4'+S5O46@N
M!2A<S;Q%='Z167VG\ ?'G7ZQ!AO)4LH'N[FN9UYH"6&#E;$>&/T]XB4VC75$
M-+X//KT#I#5\N=Y[_^)BIUB63..E;/[DM=G,O,*#&E>L:\RMW'W#(1Y'L)*-
M=K^PZW6SQ(.JTT:V@S$Q:+GH_]F/(0\O#(KP'8-X,(@=[Q[(L;QBALVG2NY
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MZ[K,S72K)"86 >#_=8D!UGX0@_X2\_YO4$L#!!0    ( /6$4%3)JN,<:P4
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M&[J6;3O4;?G]BCW((@#C>;M10O4T[ Q+KYBH=F=(-J !9Q<\@8R7I+]E*<Z
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M4>#WB# ?+\V#XFO]P?"**\53/5PQ"FAQ <PO.%?E QJHOB ?_P-02P,$%
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MC0\@_UIKMUOX!/UKF_\%4$L#!!0    ( /6$4%10OT"X10,  #@*   9
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MZ0_%=A5J93#+=&7=R%P]94HG)Z?1CS433.^R 'UPNECD=$$D!:&ZP6*:DZ(
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M >KYG'/Y=*'?3=:OQR?_ E!+ P04    " #UA%!4^3H9Q4X'  #^)   &0
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M@S ;]/<EY^HP,01EOSW^ U!+ P04    " #UA%!4(8[UQGP#  !>"P  &0
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MYSQ21^)5^ZPFDFU,0UDPJ=J3&:[5)P=P':#VEXS)PT0G:#YBDO]02P,$%
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M78_:.!2&_XH5]6(JE4GL?!!&@#2%KK92NQUUVNZU"0:L<6+JF('97[_'229
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M%3#?%T+HIP?KH#YHG_T/4$L#!!0    ( /6$4%3XFKR[<0,  (H*   9
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;*U6VW+B.!#]%95K'I*J3'P# U-
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M4I$K^TMVAW='@4?24J$H*K">0<'XX9_N*R-. .&P!1!5@.AW0-P"&%2 P:6
MN +$UIF#%.M#0I%.QU+LB#1O:S;3L&9:M);/N%GW1Y3Z*=,XG#[P5!1 D.Y!
MD=X"4L%3EC-J%T6LR"?(0-*</"+%$H5\(O_0/5E0A/>DEP!2EJOW8Q_U5 RA
MGU9A[P]AHY:P842^"(X;13[R#+)S E]KJ(5$1R'WD9,Q@;1/!N$5B8(H;)C0
M[')XT !/+H:'MPXU@WI9!I9OX%X6XW7"5)H+54H@W^Z6"J4^*O\[0L1UB-B&
MB%M"'%=6U2NK-P&1>F6;EM/-%87]('C7Y/H;<<GK<6<F7-<F7+M-$%)G!DZ
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MI_Z'4FX'ZE6=\8B4CIZU)9N6QD[KG;V4\JC?/+SB24K!6;NTM&XZN!1IRR)
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M)1'_.%[F<9U^?"-Y3.J,DS?*8V*5*1J=5-*&0#3I+B0,C 4&-U)'E<CU G9
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M[0K"87:CEF"1K@4M.V+77!CVR&4-EN5K-M(*#1E=<\EN.=9&X)KMCP&YD/:
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M?!"XSPQC0I4UP/65E.9Y8#=HGHW3_P!02P,$%     @ ]8105"0H)8;Y @
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MQPE"AJEQ#,1^MGB%C#DB*^.AY@R:(QUP?_S$?NU]M[ZLB,8KR;[1S.3C8!A
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M*(R!?K_F7.TW9H*6=[+Q3U!+ P04    " #UA%!4C0V"<5P"   H!@  &0
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MS0+?+5#6 .=74II=QR[0OH3I7U!+ P04    " #UA%!4TL;12V $  #3%
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M/*L.UY0D5)0!ZOZ2<_EZ4G[7:K]CSOX%4$L#!!0    ( /6$4%3=R<ULU ,
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M1 AB%$(O0U"$IO*5GOWP&**7+UZA%]H&W6DO6DDY=97&9;R[T0G#,L?@MV#
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M*]UVV,=$MY(@S +]?L.Y>AJ8 $5S.O\?4$L#!!0    ( /6$4%25ALSB_P(
M /0)   9    >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;+5676_:,!3]*U;4
M2:W4DB\"M *D%31M4IFJ=ET?JCV8Y )6XYC9#I1_OVLG!-A"QB;U!6S'YYQ[
MKNUK]]="OJH%@"9O/,W4P%EHO;QQ714O@%/5$DO(\,M,2$XU=N7<54L)-+$@
MGKJ!YW5<3EGF#/MV[%X.^R+7*<O@7A*5<T[EYA92L1XXOK,=>&#SA38#[K"_
MI'-X!/VTO)?8<RN6A''(%!,9D3 ;.!_]FY$?&H"=\9W!6NVUB;$R%>+5=+XD
M \<S$4$*L384%/]6,((T-4P8Q\^2U*DT#7"_O67_9,VCF2E5,!+I,TOT8N#T
M')+ C.:I?A#KSU :B@Q?+%)E?\FZF!N%#HESI04OP1@!9UGQ3]_*1.P!@N@(
M("@!P:F L 38S+E%9-;6F&HZ[$NQ)M+,1C;3L+FQ:'3#,K.,CUKB5X8X/;P#
MS($B5^0KE9*:E)+S,6C*4G6!HT^/8W)^=D'.",O(A*4IIE[U78W*!N_&I<IM
MH1(<41E#W"*A?TD"+_!KX*/3X=XAW$6_E>F@,AU8OO"H::4 +HDU?TG&H&+)
MEG9;O=SA7/)% U<_&I3"2BFT2NTC2@^0P9JF1(/D=6EK1G?)!JA4#7&TJSC:
MC4S/=CM#<D57(/%XX@DT9YQE<Y*:)-@ R3DNLE6\J(NU6:%7($E(N,CT0A&_
M1Q*ZJ=LLHV:FL&3J54Q!#=-!&J(J#=&_I2%A*A9YI@GN?:@SW<P7M"+O0YW#
M9EC8\G^''=CI5'8ZC3S?A,:]E6=;%Y"06:YS">6B+ND&*ZZN\U401Y;8E/K5
M,(SZ[JHFF&X53/>$8 Z$:RM%]P_E;A362_<JZ5ZC] 1W,L\Y>9D GX)L.KC7
M%>7U.Y<(W]N58*\Q_+(&9T+CSM<D%AR3%^-B[HYF;<EM9FW_M7CX>Y>$WYQ@
M^G9J@OU=$?;?NPK[NS+L-U?2_TUQ,VOG>(K=O2O9O(<F5,Y9IE!OAE1>JXL'
M0!9/C**CQ=+>TE.A\<ZWS04^RT":"?A])H3>=LS%7SWTAK\ 4$L#!!0    (
M /6$4%3C,RE(\P(  "@*   9    >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM
M;*U6VV[B,!#]%2OJ0RO1)B0D0 5(+;3:E=I=5+:[#ZM],&$ JX[-V@;:OU_;
M25TNX=(5+XDO<\Z<F?$D;BVY>)%3 (5>,\IDVYLJ-;OV?9E.(</RBL^ Z9TQ
M%QE6>BHFOIP)P",+RJ@?!D'B9Y@PK].R:WW1:?&YHH1!7R YSS(LWFZ!\F7;
MJWKO"T]D,E5FP>^T9G@" U#/L[[0,]^QC$@&3!+.D(!QV[NI7G>K@0%8BY\$
MEG)EC$PH0\Y?S.3KJ.T%1A%02)6AP/JU@"Y0:IBTCK\%J>=\&N#J^)W]W@:O
M@QEB"5U.?Y&1FK:]AH=&,,9SJI[X\@L4 <6&+^54VB=:%K:!A]*Y5#PKP%I!
M1EC^QJ]%(E8 T2Y 6 #"8P%1 8ALH+DR&U8/*]QI";Y$PEAK-C.PN;%H'0UA
MIHP#)?0NT3C5>0"= XDNT2"O(^)C5*R=]T!A0N6%WGT>]-#YV04Z0X2A1T*I
M+H%L^4HK,#Q^6GB[S;V%.[SU(+U"4;6"PB"LEL"[Q\.#=;BOXW;!AR[XT/)%
M._ANI 0EK_<P18XILDRU'4S?9R"P(FR2)Z^";#]<\O'ELP1D_5300&$%N@64
M2?(]89BE!%/4YY+8(_W[[E69!AE20'=LGEE*SOZ4Y?F '#4%D;N5%?2-LW0N
MA'9<EO)3,*WEK.9R5CN"&EOJLA!S=&S1YFNTZ,1)TO(7J^*W;6I!P]FLR8J=
MK/ASI7P@>$@H46\5U,V#_UPI'XA4I37<K^,F3<4<1LX] >D$E-7Q5&QK24M<
MTI*]G;1"NZ^=ZHZN?I1:^D%;EL#Z5O6KM7CCA)38Q%'Y"6DX=8W_/B$?'7*B
M0W) BNVAM:+N[_:3T:UEKNDRUSR"GSG*0P5N;G\"PLT";]M$05)>X&KP\5<,
M]@K]P96N%#7E/:2Q8%H5D-2##9$E1K6XN:'27_F-FSO4(Q83PJ26,=:HX*JN
MX2*_EN03Q6?VSS[D2M\3['"JKW(@C('>'W.NWB?FLN NAYU_4$L#!!0    (
M /6$4%0!X+L,D (  !0'   9    >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM
M;(U576_:,!3]*U:TAU9:FT_24D&D0C9MTJI59=T>ICV8Y$*L.G9FF]+]^UT[
M(:,LH+X0^^:<XW-L?#/92O6D*P!#7FHN]-2KC&EN?%\7%=147\H&!+Y92553
M@U.U]G6C@):.5',_"H+4KRD37C9QM7N53>3&<";@7A&]J6NJ_LR R^W4"[U=
MX8&M*V,+?C9IZ!H68!Z;>X4SOU<I60U",RF(@M74NPUO\M3B'> [@ZW>&Q.;
M9"GEDYU\+J=>8 T!A\)8!8J/9Y@#YU8(;?SN-+U^24O<'^_4/[KLF&5)-<PE
M_\%*4TV]:X^4L*(;;A[D]A-T>496KY!<NU^R;;'IV"/%1AM9=V1T4#/1/NE+
MMP][A# ]0H@Z0G1(2(X0XHX0OY60=(3$[4P;Q>U#3@W-)DINB;)H5+,#MYF.
MC?&9L,>^, K?,N29[ O@IFER0>:R;J0 8321*^+*6-,X/<O!4,;U.:(>%SDY
M>W=.WA$FR!WC',].3WR#3JR>7W2KSMI5HR.KAA&YD\)4FGP0)92O!7R,T.>(
M=CEFT4G%'(I+$H?O211$X8"A^=OIP0 ]?S,]')]($_>G$CN]^/2I_+Q=:J/P
M:OPZH9GTFHG33(YH?FU 4</$>NBX6NK(46VG>,ZB^&KB/^_OX  FBE]C\@%,
MD/285[Y'O>_12=^+S9*[?R,3A:QAR'TKD.ZM>A%?'[@?PB0'[H<P\;#[M'>?
MGG3_31K*B<#^W88H[)4:RI#^MW/A>'R080!S?8#)!S!7X4$&?Z]?U*#6KN]J
M]+81IKUR?;5O[;>NHQW49]CRVP[]3Z;]7MQ1M69"8^H52@:75^A(M3VXG1C9
MN*ZTE 9[G!M6^-D"90'X?B6EV4WL OV',/L+4$L#!!0    ( /6$4%3MW3P1
M)@,  ! *   9    >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;+6634_C,!"&
M_XH5<0 )2)R/MJ"V$M!%BP02@F7W@/;@IE-JX<19VZ7P[W?LA+1LW<!E+VW\
M,?/,C.,W,UQ)]:P7 (:\%J+4HV!A3'4:ACI?0,'TL:R@Q)6Y5 4S.%1/H:X4
ML)DS*D081U$O+!@O@_'0S=VJ\5 NC> EW"JBET7!U-LY"+D:!31XG[CC3PMC
M)\+QL&)/< _FH;I5. I;+S->0*FY+(F"^2@XHZ<7-+,&;L=/#BN]\4QL*E,I
MG^W@:C8*(AL1",B-=<'P[P4N0 CK">/XTS@-6J8UW'Q^]W[IDL=DIDS#A12_
M^,PL1L$@(#.8LZ4P=W+U'9J$7("Y%-K]DE6]MY\%)%]J(XO&&",H>%G_L]>F
M$!L&--UA$#<&\5<-DL8@<8G6D;FT)LRP\5#)%5%V-WJS#ZXVSAJSX:4]QGNC
M<)6CG1E? ]9 DR-RP\Q2<<-Q(.?$39-KSJ9<U)/[$S","WV >Q_N)V1_[X#L
M$5Z2&RX$'H@>A@;CL5[#O&&?U^QX!WL"^3%)Z"&)HYAZS"^^;AY]- ^Q"FTI
MXK84L?.7["R%U@"'=>Z'9 (Z5[QR+]OC->XE5P8*_;N#E+2DQ)'2'20,./:5
MJ[;*G)6]?R]CF@Z&X8L'E;:H]#-4XD/55KVOH+(6E7V&2GVH; O5S_RD7DOJ
M?4;*?*3>%BD]\9/Z+:G_&:GG(_6W2:F?-&A)@T[2CP6@#,\-*!]OL,6+!SM2
M.VF!)]U :9@@PEWTBKVA-!OO'3[Q'%_B1]-HK3I1)]S>-<*+:FE@AB*"68,V
M7@6)MO!'@UWX#=&CG?A;Q&&^Y(6))5B]J\L@UGKGC85NQ=+K1VTLC6;1K4N<
M9CN.BJZEB<:= 9]-63F3)1:K$>S'&RBFH+K4B*[EB";_6?GH6H]HMR!=+O$[
M ]@!E/;URV51<./>/8(]"6%MGNY$_,?@T:YDAW;1M7C1;O7Z]EIA9X%@X^[%
M_$.8O,1  9?(U,[E@*W'S!M;MBWAT;^QA1N?:]LKW3#UQ$N-*<_1*CJVS86J
MVX]Z8&3EON!3:; ?<(\+;-E V0VX/I?2O ]L4] V@>._4$L#!!0    ( /6$
M4%1"OF7,I (  , &   9    >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;(U5
M76^;,!3]*Q;J0RMMY3/]4H+4A$VKM&Y5JVX/TQX,W(!58S/;:;I_OVM#6)J2
MJ"]@FW..[[G7ODS74CWI&L"0EX8+/?-J8]HKW]=%#0W5I[(%@5^64C74X%15
MOFX5T-*1&NY'07#F-Y0)+YVZM3N53N7*<";@3A&]:AJJ_LZ!R_7,"[W-PCVK
M:F,7_'3:T@H>P#RV=PIG_J!2L@:$9E(0!<N9=QU>91.+=X ?#-9Z:TRLDUS*
M)SNY*6=>8 ,"#H6Q"A1?S[  SJT0AO&GU_2&+2UQ>[Q1_^R\HY><:EA(_I.5
MIIYY%QXI84E7W-S+]1?H_;@ "\FU>Y)UCPT\4JRTD4U/Q@@:)KHW?>GSL$4(
MS_80HIX0[1*2/82X)\3O)20](7&9Z:RX/&34T'2JY)HHBT8U.W#)=&RTSX0M
M^X-1^)4ASZ1? 9.FR4>RH+HF5)3DFQ2%'=^([E#9ZL@EZ8''&1C*N#Y!RN-#
M1HZ/3L@188+<,LX1JJ>^P;"LN%_T(<R[$*(](801N97"U)I\$B64KP5\]#.8
MBC:FYM%!Q0R*4Q*''T@41.%(0(OWTX,1>O9N>GAYP$T\E"AV>O'A$OVZSK51
M>$]^']!,!LW$:29[-%VU6\I*@D4FM)$K8326L> K+(&MIZF!-+CS2@'><F./
M +>!$,YHSC@S#$9KW>T[<?O:GO.<AI>8Q.?M](]@SL]?8[(13'(Q8%Z9G@RF
M)P=-WW]_)%1K0*<RQU,L.J?P4M145.!2T7F4.6>5._JC'B=O8HN378]O,6$0
M[G@<P9S%.Q[]K;O=@*I<C]2DL!7K;L2P.K3A:]=]=M;GV)Z[;OI?INOMMU15
M3&CTOD3)X/0<(U)=O^PF1K:N@^328#]RPQI_,: L +\OI32;B=U@^&FE_P!0
M2P,$%     @ ]8105+N$]T&; @  #P<  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#@N>&ULC95=;YLP%(;_BH5VT4I;^0K0500I331M%]6B9MTNIETX<!*L
M&LSLDX_^^]F&HC0A66_ '^<]YSDO8-*=D,^J!$"RKWBMQDZ)V-RYKLI+J*BZ
M$0W4>F<E9$513^7:58T$6EA1Q=W \V*WHJQVLM2NS666B@UR5L-<$K6I*BI?
M[H&+W=CQG=>%1[8NT2RX6=K0-2P GYJYU#.WSU*P"FK%1$TDK,;.Q+^;)B;>
M!OQDL%,'8V(Z60KQ;";?BK'C&2#@D*/)0/5M"U/@W"32&'^[G$Y?T@@/QZ_9
MO]C>=2]+JF J^"]68#EV;AU2P(IN.#Z*W5?H^HE,OEQP9:]DU\5Z#LDW"D75
MB35!Q>KV3O>=#P<"?W1&$'2"X+V"L!.$MM&6S+8UHTBS5(H=D29:9S,#ZXU5
MZVY8;9[B J7>95J'V7<L0>I"4D*-A"H%J BM"^UO+C=0$,[HDG&&#!3Y1!;Z
M+2HV'(A8D58Z:257,T#*N+K604^+&;GZ<$T^$%:3!\:Y?EXJ=5'CFJ)NWJ'=
MMVC!&;09Y#<D]#^2P O\ ?GT_7+OK=S5)O5.!;U3@<T7GLDWIR]TR:%U9V+<
MH5R1WY.E0JE?QC\72H1]B="6&)TK(:&AK""PUQ^I@D'/V@R1S6 ^T6WF!T&8
MNMM#9P:"_"CN@][ C7JXT46XJ9"-D!2!-%1BK1^]A!S8UIHR1-JFBP\@DEOO
M"/0T)KH-ASFCGC.ZR/F#[O]'%IU4]>/1$=EI3."?<3#NR>*+9/:#&>*)3VMY
MQTZ=QOC!:)@GZ7F2RTX)I)R(@1-@"#(Y>:>",$Z.* >"O.3S$:9[<%R97\4#
ME6M6*\)AI67>3:+ULCU^VPF*QIY@2X'Z/+3#4O^Q0)H O;\2 E\GYE#L_X'9
M/U!+ P04    " #UA%!49H]_".,"  !C"   &0   'AL+W=O<FMS:&5E=',O
M<VAE970X.2YX;6R-EEUOFS 4AO^*A7K12EOY3DA%(K7)IE5:M:A9MXMI%P9.
M$JO&9K:3M/]^MJ&(!A+U!FQXSWL>'QN;],#%L]P"*/124B:GSE:IZL9U9;Z%
M$LMK7@'3;]9<E%CIKMBXLA* "QM44C?PO)%;8L*<66J?+<4LY3M%"8.E0')7
MEEB\W@'EAZGC.V\/'LEFJ\P#=Y96> ,K4$_54NB>V[H4I 0F"6=(P'KJW/HW
M\XG16\$O @?9:2,SDHSS9].Y+Z:.9X" 0JZ, ]:W/<R!4F.D,?XUGDZ;T@1V
MVV_N7^W8]5@R+&'.Z6]2J.W421Q4P!KOJ'KDAV_0C"<V?CFGTE[1H=%Z#LIW
M4O&R"=8$)6'U';\T=>@$^-&)@* )"#X:$#8!H1UH36:'M< *SU+!#T@8M78S
M#5L;&ZU'0YB9Q942^BW1<6KV0VU!Z$1" %,(2PE*(LP*7=]<[*! E.",4*((
M2/09K?0J*G84$%^CVT;QO:.X7(#"A,HKK7U:+=#EQ16Z0(2A!T*IGC:9NDI3
MF]QNWA#>U83!"<(%Y-<H]#^AP O\@?#YQ\.]]^&NKE5;L* M6&#]PA-^2_R*
M,PIUD6P),)7HSVTFE=!K\N^9%&&;(K0IHA,I5MCX%[K0=JD/UJQVB*V#^5+W
ML]@?1ZF[[U:F+XH2SV]%[^"B%BXZ"[<@>U( *R2JZDH,T=46HTYBWTO"([HA
MD9\,T\4M77R6[DM94?X*@')>ZHU.XGJOT%.5 8,U48/%C(=P_2/<(='D!.ZH
MQ1V=Q;UGFA.0PB]PMIZC7NZQ=\S7UR3!";QQBS?^P$(4H':"F;L$L1_D&_=R
MQU%PQ-?71)T%^XXO:?F2LWQV\QKB27JY C_VCH#Z(G\2!,-$DY9H<I;H)U>8
M#NV=0Y23WN?I>^/P>%Z'5'YT_!6[G2/ '+\/6&R(GC0*:QWG78^U@:B/M+JC
M>&5/A8PK?<;8YE;_!8 P OU^S;EZZYB#IOVOF/T'4$L#!!0    ( /6$4%0+
M/"XMRA0  .;!   9    >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;,U=:V_<
M.);]*X+G 0_0;8NDGCU.@$XD[330V0F2[=D/@_U0<<EV3=?#HY+C[L7^^-7+
MQ2N*XJ6N):3FPW2YPG-UBR+/(2GRZ.;Y4/QZ?,CSTOEMM]T?WUP\E.7C#]?7
MQ]N'?+<Z7AT>\WWU+W>'8K<JJS^+^^OC8Y&OU@UHM[WFKAM<[U:;_<7;F^:[
MC\7;F\-3N=WL\X^%<WS:[5;%[^_R[>'YS06[>/GBT^;^H:R_N'Y[\[BZSS_G
MY2^/'XOJK^M3E/5FE^^/F\/>*?*[-Q<_LA\R'H8UHBGRCTW^? 2?G?JW?#D<
M?JW_^&G]YL*M4\JW^6U9QUA5__F:O\^WVSI4E<B_NZ@7IXO60/CY)7K6_/KJ
MUWQ9'?/WA^U_;];EPYN+Z,)9YW>KIVWYZ?#\M[S[17X=[_:P/3;_[SQW9=T+
MY_;I6!YV';C*8+?9M_]=_=;5! !P-@+@'8"K #$"$!U V%[!ZP">+<#O +XM
M(.@ 05/W;64U-9VLRM7;F^+P[!1UZ2I:_:&Y70VZJN#-OFY:G\NB^M=-A2O?
M9IO]:G^[V=\[JZ)8[>_SJMF41^?R8[&IOGY<;9T?=X>G^JO5?NV\KPK]7A?^
MQVK[E#N'.^?GP_[^^S(O=LZ[0U%=N_K'XU^<RR0O5YMM]>F/SF;O?-ALMU4S
M.MY<EU7*]86O;[OTWK7I\9'T&'<^'/;EP]%)]^M\W0]P75WO](/YRP]^QXT1
MD_SVRA'L.X>[G/WR.7$N__@735[O)T1Y_[?,N?R<%;HXR80XZ2^?G,L__R$2
M@?=77:QT0JS_>/>QCL4"H0V5V8=RM974JWMQ:FRB"2M&PIZ:S]>Z^1SK]K,]
MM9\OI_9CN))WNI+77,D;N=(O^]7N4)2;_\W75>"JY:XWQ]NF'7_G5!2\VSSM
MVA:].1Z?J@Z0.[>'8_V/^[S4M=+V:GYSM9JMO[[]GG$F;JZ_PDK5E6)1="K5
M^RG^Z:?XQI^2K39%6V'.:OVOBA&:'JI+LHT3@,OSR%-2');Q@T"?8'!*,# F
M^/?R(2\ $23Y%VT=!H-+,U_);EC$U^<6GG(+C;G]UZ&L*.RVU^[J9K<>R3$<
M)""$<&,E34TI'D<CU1B=4HV,J?Z<'X\5XQ=%=7N=Q[KQ'O:Z%*/!Q;^/0B5!
M39F8Z=.+3^G%%C4IN^M8#<:#/B $YUQ),-;48!2/W&SF2C%SC4FZ5Q[[D_/Y
MN>K53E;)V6VE2OOUT4FJNUY1F7 NVQ+-Y[;8G2QFHC@&!)492:YN_LY/^V-9
M/-4]U?GGSU4!YZ<RWQW_QW0!+B_ C3_RIWUU _)CZ12K,O_..9;5?];.8U[<
M5I>KAH-:E36';&I%IX)$7$+$I=-Q_4J42L2$,=)_'LI*@/[Y(=]]R0OC?9&2
MP[Q%;KP4 H8I0:53JV8XIKW'_J#K^:[K*CU/4RJ&I?JY20U@9A'HUZ?S?PZ[
MXG[3T;B3/Q4'Q[[");>S<)$*EXS,S)1,ZFGFD$VU:'L:#9<0<2D1ETW']2M?
MZ@TS"\['4S77@OUXFH^T':#^;M\TJ?)A558SHM^=+[GSN-JLG:?':L9ZN&VE
M]+9!WS[44YMZ*G);S2:*:I95%IO[^[RH!P7YUWRD0YD39"Z[<EW3C^52N+B[
M\,B82X'BS#S0Z&GX=\Y]<3CJQI-9%P=2!?-YJ*<*+O6+FTE\0!7\*G3_U-W-
M=:O4W+ELOVT^-PB3.G/)^]P\!2%R!I<JP,TS#PIG("&;FM#.46FXA(A+I^/Z
ME2B5CIN5[MOW?21!B[XOI9,'2_=]*9G</!^R[?OONCBP[ZLC"3Z<!OEC PDN
M-9>;!43##H&O8X? MV8'J3D\7H(=A.1Y89Z@4-@!"=G4A(X=B+B$B$NGX_J5
M* 5,F 7LV[,#DB#.#D*JI> +LX, RW/F29$U.W1Q3.R@*<)&Z4%(>15FC1G0
M@[@*N(8?NJ_M"$)(81+^(@0AQ4"8YU$D@C"';*M"RQ!$8$(%IE1@1@#V[X"4
M2&&6R#-@%W."%NPBU59$2[.+%%=AGB]9SSO$< TQ]$>8PY/2ZYGU9\ <RRT6
M>E+*O$46"STI'][\BX5(R-'%0B(N(>+2Z;A^)4I=],RZ"!;>JG;S.2NTO[Z-
MP1ALMF[WOY'&"QYGF67OVY,2DB!.2IX46<\LLC,\)I1ZZYF%PWK(T\7ID5*@
M/G?QA@^PPK$'+YY4),],^)HIT6#((^HI43?B$?B(QY,*X9D5@LI04A8\LRR0
M&,H<DH\MLA)Q"1&73L?U'Q%+<?/-XO;M^0%)$.<'7XJF;Q;-U_.#+_73-XN(
M-3]T<<8&+=W3=W.A?HY2GOPIS[)&YD0>G!-Y.$/X4IO\19Y[^6 #A'FQC<(0
M2,CQ.1$5F%"!*168$8#].R!5TC>KY!G0BSE!"WJ1<NN;'RO.0"]277UDTX<U
MO43#Y11O\' 7*]7/4DJT;]8IS</=6'UBXSN7[;?-9Y1> BEM@?G1&)%> BDG
M@7FUCD(O2,BF)G3L0L0E1%Q*Q&73<?W*E_H:F/75O*<A"X:".;J(&$C!#,R"
M^>WI#$D0I[- RG-@EN?7TUD@E3HP2XXUG07:O2KJ;D!SH7Z.8+?BQ)TJXHH-
M1DM^/5IBW6C)ALZDN@2+;%H)I*0$\V]:04*V5:'E,R(PH0)3*C C /MW0,IE
M<.X[5Y $<7H)I3R'2^]<":52A_/L7'D7:G:N#+?"8:7Z64I)"R?O;ZDJV^DV
M]E?S/6?7GH?H4TY0K^"X[0 J 'OF3+032LD+%]GW$DJ9">??]X*$Y,-&VK(.
M$9<0<>ET7+\2I7Z&UCL\JW;3M1CM+VGC,-Y?23 M-H=2(<-SG^TA"5KP%S@@
ML/1L+Y32',XTVPN'\[C(5T^;: K%;.000BC%*YPXU^-7@3K7:Z@J>*$JE*4B
M*2;1(G.]2"I(-/]<#PG9U(2.I8BXA(A+B;AL.JY?^5(8([,P?GM>01+$>262
M@ALM?=8MDMH;F07(FE>Z.+T1#Q^L4F.E^EE*<8O,XC9@%O_*;\9%]2%%+_1'
MAT5MN>;S8]52UE6WS8MM7;<X]4C1B\R[,*G4(X4F,C_%(U&/.613,5KJH>$2
M(BZ=CNM7(C@C9U90=8!4-QUM0FT8)D ;]EX&2",-64ID=.[S.R1!G,=B*<GQ
MTO.[6*IS/-/\+A[.W )/'1]I"\4CIR"EB,639W=<'1^%S</XEK-"G*1B*2KQ
M(K.X6"I)//\L#@G9U(2.I(BXA(A+B;AL.JY?^5(@X]><[\OBX7(H&WUZ'$OA
MB\]]MH<D:,%F4H3CI6=[L=2J>*;97JQY:C?<.Q /#W4;;C\XUCUQOB>T?"8F
M\!ESX8'M169\59L EYA_SH?%%&.D1@4F5&!* "I5R4%5GOL,#LL0)POF@D/B
M[M*3..:"\^/N3-.XET#(^O9+L6"LF)(I.(CN3IS*,>605G57*ZZ(ZCT!W3FM
MR(8WP'%S=Y'I&G/!Z7)W_@D;%I.-'=:B A,J,"4 E:H$Y^A=ZVF;OM8T"CBZ
MXL!<<(;<-1_HFZ$#0_<1Q'[$O@-W@2Q_<,]\Q,SV@Y[I=0^?ZIERZ(X\>XJ=
M2^_EV5,\>9&%0>\29C[.1NVWT-D#L?8@]5LDIC?V*(H*3*C E !4JA(H$C,K
MDNURRTN<WGH+<OB!0>,3Q/GD#,8=2(86XPYHIL*6/A+.H(T*F^E0^$N@WB,G
M3ST$H2WEC]A&,.C&@GB+:)9>/&7CCG#KI1>O&7)4GRVH"V@)6^1P. ,N((S/
M?SP<B]E4AY:ZB,"$"DRIP(P 5.X!4%#$'@59A6$Z5Y1QZ0:V* SQ13D#DD,R
MM" YX,3"$"N6&4@.V+(PQ)S$GN2XU4,RM)B2*1 [Q%M$0W-"69$1K*8YT0S8
MJL\XS0$W$H;8D9!I#@@.XD)"HSESS*8Z]#1' R948$H%9@2@<@^ F"(^*RC-
M39J2 8L5QL_]Z1F6H07- <<7)I9^@,: -0I#K$?L:4X@.M:U ZR8DBF0.T':
M)MFC.2[W1 H+'P\FH/_C(H_2&+ J88A7"8GFD)BC>R*IP(0*3 E I2J!)B*^
M*W-T(B"!B)O(A$XT/!5NZAU (A&3CT'O"*Y$J$YV0N>R^[KYPZ)_ 'U G$'(
M_0,H 6((0NL?YIAM?>@["!&9D)$I&9E1D(IO+9 HQ!KE#"09R=!"DH'I"D-<
M5V9@$^# PA ?$GLV\8:GW;PP4A49*:7D"101<3G14(YZRE-$->.TISR%S1,=
M#[HG>XL0#O 58=[\!\FQF,'844\J,*$"4RHP(P"5>P"T%3%<.0>N>>U^$P:\
M6YBW](X3!LQ:F#?3GI.70)!%N*^^+0(KI>0)I!]Q/M%PC:=R35QSC==R36S!
M-< MA?G+[#H!'B7,7V#7"1*SJ0XMUQ"!"1684H$9 :C< Z"\B'G+&7 -DJ$%
MUP ?&.8OOJ(*;%^8/]>*JC]<*A5"W:Z+E5+RA&]-F+B>*JZ8,I/RW.:\=S.1
M\FP>&P'K%.8OLYX*#$N8O\!Z*A*SJ0X]U]" "1684H$9 :C< Z"\B),+MIZJ
ML6;AX\_&@3<+0\Q9SH'D7KV>"NQ@&.(',P/) 6\8ACB=V)-<,%PHY9H]>5@Q
M)5,@=L'$]53_2ETPJFFN_=:2YH"E"@N664\%1B8L6& ]%8G95(>6YHC A I,
MJ<", %3N 1!3Q.'E#-@&R="&;>!KC1;?B0.\85@PUTZ<8+C'1H2#(1522LD3
MB!UBEJ)Y=A,ITS>O>40=-=,WS^81-?!78<$R.W& JPD+%]B)@\1LJD/+-41@
M0@6F!*!2E4!"P\576X'Y"D/<5^R[4#A<1V5L]-D-L%IAX<2%5.\J5I68U3MN
M8]^Z=P C%A8NLY *;$H8XE-"ZQWFF$UUZ'L'#9A0@2D!J%0E$)BS-UO!,K00
MU!"^LV_Q]5!@N,+F<EQA&C>58#AZ1THI>0)%F^JZX@_7*%@]>&?VE %L5]@R
MOBL,&*^P!9Q7L)C^Z!H%$9A0@2D5F!& RCT VGCV!BQ8AA9< RQ8V.(>+ R8
ML+"Y7%B8QF EY.I+IK%22IY O*?[L*AO6/-XS37MR3W/9N,5\%EARQBM,."T
MPA:P6L%B^J,G]XC A I,J<", %3N 7QUKEEYSX%KD%?56G -4/!H\9.&P)2%
MQ7.=-(R')PT]YJM<@Y12\@2JCSBZ:+AFL(W-$S79=-O8/(N7ES#@UL+B9<X;
M D\6%B]PWA")Z8]O8Z,B$S(R)2,S"E*Y$4" $2>6,Z <)$,+R@%V,2Q>?%,L
ML(EAB W+!,K1;(J-AI1C+J7D"<0_GKASUAML+?'\>O6EW5KB6;A[,V#ZPN)E
M]LW&\,7H"^R;16)ZHUM+B,"$"DP)P%Y5<A>^=OW<=[YB&=J\91Z\^MU=>BV6
M [L8CIBQV+]MVAVNQ?+A89278L%8,253\%9X=_*2K1\(A36BFC6:KYL_\/=.
M ^\7[BZR:,N!:0M'3%M(;Z9'8K;UH>,-,C(A(U,*4JE.\-9VUZR'Z=U=?EMN
MOM8]'E2LTWEKZ&O3'#(8.\-(!2948$H *C4)WDF/.,V< PF_]I6['+CA<'?I
ME^YR8('#W7E>N_ON)5#_[5&#N2):K)\IL,_AB'V.9J/>8++H-SOUNLFB;[&'
MA0/S',X6>1LO!_XWG,W_/EXLIAB=+)*1"1F9DI$9!:G<"*#XB$T.LE_O!3XZ
M(E$N#)0>\=0Y [9#,K1@.^#=P]G2LU0.G',XFVF6^A((&W)BQ91,@>HAKCN:
M(6>@#CG]9IM T XY?8N'?AS8Z7"VR$R5 \L<SN:?J6(QV_K0LQT1F9"1*1F9
M49#]&P&,A3ABD$,9K"(A_;'W7E"!"168$H!*38(Q F(/= ;TC61H0=_ E8AS
M\P+Z#/0-/($X-ZNR/7WSH3X+WV,J?6/%E$R!C"-^0IK!JFI?X?-ZK-K:5_@6
M3U$Y, GBW*RJ5/(&1D"<FZ641-Y(3#%F7T$%)E1@2@ J50FT'C'N0?Q/7^"]
M*948'60 EQ_.%Y]J FL?CACG3.B]FCGD^ \&;CM<3)Q#\JLP5+JEJ'<FU]\V
MG_%N">QWN%AF!@E\<SCBFT/JEDC,ICJTW9((3*C E K,"$#E'@"9$J^;/(JA
MZL3>:.L&HH-8ZE"&<4A(?\S)G@I,J,"4 %1J$NBG./=S+%B&%L,X8&G$Q=+G
M6#AP+^*(>Y&]$ B=H^Q@$MZ5"NSZ$Y!',?$<R]_+A[SHJ44<&NL$B*-8>H,0
M!Y8^'#',L;\#GL:*?+#Q&2NEY D$TYOL5\[4UX\TBR"L=2>W60,!WCS<6V1[
M$ >V.ARQU2'H=8;%;*K#F!_0%._LUR.1#"V8$)@ <<3,1C-"'+[_O;&1?GG_
MN\U3!N" P[U%-L!R8#K#O=DWP&983(Z]()T#GQJ.^-2<0Z-[[>Y0#OQN^%2_
M&S&P+N?-DRW/OLD!OQN^C-\-!WXW?'Z_FPR+*1!;;PZ\8/C9>\%@&5JT.. %
MP_V).UK85:2V.%:_GR?RK845F,-P?YG]+,#7A2.^+K06APRZZ^HPY@=XWC_W
MDWU8AC8M#H@.XJ:BVT.E#N7<9@N5:\]Q0%+\91YG :L5CAB9T%H<]IC'_&Y<
M#JQ1>'#VNQF1#"U:'#!GX8@YRZ#%9=O#JJP3_%2OBK3_G'0MSWA-H"/!,C,&
M8*7" S-UG\-M-&=H<QN!5B#^)#:OU'7!*W5MB -8FO!@F4<IP$6$![,_2LFP
MF-A[9SGP'>&([\@YM+A7[\ #_B5\JG^)N(K4G6;UZ*C[VG)X!!Q,^#(.)APX
MF/#Y'4PR+&9;'\8$ 7N'9_\D'<G0HM$!9Q*..),T]_R85VEORDWUNQY7OZ^^
M;'/8##]L]IO=T^[TE?'*0%#"1;RY.# =X:&9PS_EZWSW6-9O%JR:V.:P=IXW
MY</AJ:Q_9G/1ZB[M5K_FSO/#86M\&(I<B3F[ZA8_&/,&Y(]8>=C<E-5O]C<%
M:$*XS#(0\-K@H9DTY[PIYBL%[4W1KEY?'Q_RO$Q6Y>KMS2XO[O/W^79[K#IJ
M=:WJ]UR ;YTBOZL/0/WP([^X'GS_GOV0LOK[:QGF[<UC12 ?5L7]9G]TMOE=
M%=*]JF]ZU?\?3G^4A\<W%U5G_W(HR\.N^?B0K]9Y41>H_OWN4%%-]T=]@>=#
M\6N3]MO_!U!+ P04    " #UA%!4TO[_$]0$    '   &0   'AL+W=O<FMS
M:&5E=',O<VAE970Y,2YX;6RU65MOVS88_2N$L0$)T%GB1;X4CH'60;$ ZQ T
MZ/90[(&6:5NH)&HD';? ?OQ(2A5]42BKL?(04Y?OB.?C\=&1-=MS\55N&5/@
M6Y;F\FZP5:IX&P0RWK*,RB$O6*Z/K+G(J-*;8A/(0C"ZLD59&J P' 493?+!
M?&;W/8KYC.]4FN3L40"YRS(JOK]G*=_?#>#@QXY/R6:KS(Y@/BOHACTQ];EX
M%'HKJ%%62<9RF? <"+:^&[R#;Q=D9 KL&7\E;"\/QL!067+^U6P\K.X&H9D1
M2UFL# 35'\]LP=+4(.EY_%N!#NIKFL+#\0_T#Y:\)K.DDBUX^G>R4MN[P60
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M<T3YNJG<4+RP;VR67"F>V>&6T143Y@1]?,UUTZL-\Q*H?NDW_Q]02P,$%
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M\#IKD7X0JJL?OO,H=WY"083N@C!4_$C?H%?5V\N)5$/+'C!9%<.8Y\,@#</
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MJQ^0? G8:M9XD1()V K6>"4VA[;:+ZC %1484($A =CR 9:7/UEE^&!BZ&1
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M!&#+!XCE)6H?IX>_VUUI-2Q[Z%>GT.!@E'I((_Z==OP;9?P[^_@?L^45R8:
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MD0%!;]O0<\>&D'> J&& H=ZWH:X-7OZAC;1'H.9C&SDR30CY!"6JR%,#^@Q
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M]:R6'?J4J#RF /7]AC%9GJ07J-XM3?X#4$L#!!0    ( /6$4%2)$=3<_@,
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MNJW!/S-NE7.G+N?.+Y5S3N/_7,K3#J!L/D)$UQ#1#"+Z9!,]T]P -+< S1U
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M;8(9!6%?L>EB4--EO]@#H+YG=Y  R/-:&A-F%(5]JZ:+N9V2VW,!H+Y';6J
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MCI!.L*>U(20,F\4.:K&#9\6><*>G3*?PEKH"O,=DB6?PCO36JW,D?0BW>X>
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M^<2[]D@&*U8+O)>[3]#Z&5F^5 KM?LFNB1V%'DEKC;)HP49!P<OFS1[;.AP
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M*+X3J(ZTR7Y8FSC:)KOR=C-U@Y.46RMK@YG!8M';%?Q%'$V3>I[.RWIOBOZ
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MI1' ]S.!VR![, [R_T/T_P-02P,$%     @ ]H105''CC6J<!@  >#$  !H
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M^4+.I/DEZ]+6L4BXE(IG)1@CR-*\^*?/92&V &[K", K =X^(#@"\$N _UY
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M9EQADS3#!!\^(+0![L><J\U$.ZB>4H._4$L#!!0    ( /:$4%0 Y6N?/0,
M ,4,   :    >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6S-5UU/VS 4_2M7
M$0\@#?+1IA^HK01%$T@@(1#;P[0'MW$;#R?N;*>%?[]K)TT#3=IJ8A,OC9W<
M<WW.N;VQ,U@)^:QB2C6\)#Q50R?6>G'NNFH:TX2H,[&@*3Z9"9D0C5,Y=]5"
M4A)94,+=P/,Z;D)8ZHP&]MZ]' U$ICE+Z;T$E24)D:^7E(O5T/&=]8T'-H^U
MN>&.!@LRIX]4/RWN)<[<,DO$$IHJ)E*0=#9T+OSSL1\:@(WXQNA*5<9@I$R$
M>#:3FVCH>(81Y72J30J"ER4=4\Y-)N3QNTCJE&L:8'6\SO[5BD<Q$Z+H6/#O
M+-+QT.DY$-$9R;A^$*MK6@BR!*>"*_L+JR+6<V":*2V2 HP,$I;F5_)2&%$!
M^.T&0%  @D,!K0+0LD)S9E;6%=%D-)!B!=)$8S8SL-Y8-*IAJ2GCHY;XE"%.
MCZZH9$MBK 26*BTS+)%6< K'US2:TPAN&9DPSC2C"D@:P3A+,IX#+A*1I?H$
MCJ^H)HRKZN@4GAZOX/CH!(XP,=PQSK%J:N!J)&V6=J<%P<N<8-!(<'H&+?\+
M!%[@U\#'A\.]MW 7K2K]"DJ_ INOM=^O'[?X#&XT3=3/'9E;9>:6S=QNR%PQ
MEEAC%8@9S B3L"0\HQ!C05@Z!Q+]PO]%7B=)$8)5T@)T3&%*I'RU,9L,YGZ<
MUY)O:EE7B)Q?:/F9]E^.@EY[X"ZK;F_'A)U.&?-&>+L4WMXC7$H4 PLA;6<C
M9R[2^:FF,L&.G.@=YH;E&N$'EZU39N[L9E]C^6%VYWD[%2M[X3NW:T+Z]69W
M2[K=3_XOZ^Z771/2(+M7RNX=5J5<Y(KI&"*FIB+5+,V0]%JVE6K>5#%;U-+O
M[:=?$]) OU_2[^^D?UU3%.R4OU/0WZ^@)J1!@>]M-AIOIX;;0WO:K^Q=_@=W
MM;]YS_O!/^KK(G'5O4XWZ+^SN"XJ"'L-+F\V$?^S[R(%P:HPO[^E?CNHW>TV
MB-]L)/Z>G>3#NKQ8Z V_MO=>Q'90&(0-(C8[E1_^OUXOUJKNUZUM'=M![2T=
M;N6,:0[X=T0B!06<SA#EG741+O,S<S[18F&/G1.A\1!KAS%^9U!I O#Y3 B]
MGIB3;/GE,OH#4$L#!!0    ( /:$4%3;BO9O6@0   X0   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$Q,"YX;6R]6&UOHT80_BLC]U0E4ARS@-^NCJ7$ONM%
M:M0HZ;4?3OVP@;%!!ZR[N]@YJ3^^LX#!!LREJE7)LF&9F9UG7O9A/-L)^54%
MB!I>XRA1-[U Z\W[P4!Y <9<78L-)O1D)63,-=W*]4!M)'(_4XJC@6U9HT',
MPZ0WGV5KCW(^$ZF.P@0?):@TCKG\=H>1V-WT6&^_\!2N VT6!O/9AJ_Q&?7G
MS:.DNT%IQ0]C3%0H$I"XNNG=LO=+-C4*F<3O(>[4P348*"]"?#4W]_Y-SS(>
M882>-B8X_6QQ@5%D+)$??Q5&>^6>1O'P>F_]8P:>P+QPA0L1_1'Z.KCI37K@
MXXJGD7X2NT]8 !H:>YZ(5/8-NT+6ZH&7*BWB0ID\B,,D_^6O12 .%-CHA()=
M*-AU!?>$@E,H.&]5< L%-XM,#B6+PY)K/I])L0-II,F:N<B"F6D3_# Q>7_6
MDIZ&I*?G2Y3AEIO80Y@H+5/*J5;0AXOGO!) K. ^\42,P!,?/KQ2Q2F$7\@.
MW&N,U25<+%'S,**K/GQ^7L+%NTMX1^;@(8PB2JZ:#32Y:C8<>(5;=[E;]@FW
MF T/(M&!@@^)C_ZQ@0%A+(':>Z!W=J?%)7K7X+ KL"V;M3BT>+NZU:*^?+,Z
MFW:@<<JT.9D]Y_MI^U*EXL\.RVYIV<TLNR<L/^$6DQ1A)44,"\J!I-:DHM0!
M++)R1'EE"B)*_3!9PZU22!\??N.O;6G.-QMFFYDS:#NWA],QA6![&/LV*==V
MCZ66+5*.,[)+J2.\PQ+OL!/OKSI 2<5J*OP*$M1M*'(3HV,4-0QM,J,:@J;,
M>.BT^S\J_1]U^G^?:)2H-&#>F2<QC!I[]QF;CFLHVJ3L@QCG.%JE)M-V).,2
MR?AM2"37"&K'-\#7$C$_D;X\8/R"LJO$)^5&DS,WS[2T/.V$\#,1K8*+2)BN
MN 3BM14/)6QY1!T5H+\V+2,QXH;S5!!NU!5\HF7JG\R'MKQ-FW4U8;6L-64<
M-JSEK"G3=]P3*6-611_6V1%7\5=$T2I<)Y1P'[@J%0ZHJ)4[K);ZF]:*=-$F
M95OU0Z5%RAF>.%/8 :NR[YRB7L25"E>AER$'>N4R3'KK>6F<1AG>_.19B)A>
MV +S)D7U6##MOMCA;UAP%?SX QM9/ZWH'2V+$*HC 4FQ[WNIE)AXW_*^\8IS
M^TUMP^P*E7WFQF$5H3'GOY_#A8WCE+K#>N*;4H[MU//>%&+,.I'WBCQ9-WL^
M2N&GQ)>*1ZBZXE+1$QN>.^85=;!N[C@SU[,F+=BNW:"8=C'7JB>H1<P^[-]C
MT!7+L&Z:.4H1]<__V*HTJ= <DD#9K/^N3RM^8^<F.%8Q'.NFN'/7S+3Q4M>?
MU NF*</&DWJYM A9K%8L@X-!B1Q=9P.GHC2DB<Y'B7*U'&IOLU&NMGYGAMUL
M *O,Y)/R Y=K0XD1KLBD=3TFCV0^?.8W6FRR<>Q%:(I6=AG0P([2"-#SE1!Z
M?V,V*/\"F/\#4$L#!!0    ( /:$4%3V/P!?RP,   (3   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$Q,2YX;6S%6%N/VC@4_BM6U(>IU)G$#H%0 =*44;65
M=K2CSK;[L.J#"0:L.C:U#;32_OBUDTP<R*70F:@O$"?G?#GG?.?B>'(0\JO:
M$*+!]Y1Q-?4V6F_?^KY*-B3%ZD9L"3=/5D*F6)NE7/MJ*PE>9DHI\U$0#/T4
M4^[-)MF]!SF;B)UFE),'"=0N3;'\\8XP<9AZT'NZ\9&N-]K>\&>3+5Z31Z(_
M;1^D6?DERI*FA"LJ.)!D-?5NX=LYBJU")O&9DH.J7 /KRD*(KW;Q83GU FL1
M8231%@*;OSV9$\8LDK'C6P'JE>^TBM7K)_3WF?/&F0569"[8/W2I-U,O]L"2
MK/".Z8_B\ <I'(HL7B*8RG[!H9 -/)#LE!9IH6PL2"G/__'W(A 5!3AH44"%
M CI7(2P4PLS1W++,K3NL\6PBQ0%(*VW0[$46FTS;>$.YI?%12_.4&CT]NR.2
M[K$-):!<:;DS%&D%KL'5>TPE^(S9C@"Q DY.O097=T1CRLS5-?CT> >N7KT&
MKXP^N*>,&7+4Q-?&-OL&/RGL>)?;@5KM2&Y "-\ %"#8H#X_7STX5O=-1,JP
MH#(L*,,+6_!NE2):=0"%)5"8 0U:@/X6&C.35V64<8;\!JQL>/<VO$W!RD&C
M#-16XGZ&AM'$WU<C4I<)!^-2YLC:06GMH-/M/RE>4$8U)5V^1R5:=)GOS,'_
M+  Y\K#B7!0.3@+0(#,*F@,P+$T>=II<27-CN*)KCC59&M+ ABS7E*^/JN3?
M>Y(NB/S2$:M1^>+1\Q(N+H'B/A(NKL6RGG!UF=:$&Y?6CE\@X6#@NEG06\H5
MT-TYUR34EG2PTH1A#VD'_@-FE)E!Q<VDD)+PY =(!-?2S,8CJ;_TALA"1A<)
MX><W\\4YF0Q=[X3/;)[0=4_82_LL4*LLP3@\I;(NA.(6)ET#A8/?R>1MDLB=
MP:ND=4$D%_R)X,K#LXAU_1Q&+U&MKMG"[F[[K&H=UKO1^)3AN@P*1RT4NTX-
M1_U0/)="J>N28'7 VS[KU4T,&#^S7ET[A^->ZG5<(VHX/"6S+H.BJ)E,Y 8&
MZAX8_9/91\DB-UD0?(&2195],>JM9 OHHY*MU6R3$&QIR\C-$=0]1WZ9Y@]<
M$TF4!M(H]%VRR(T9U+U1_VG)(M?4T86[]/-*%M5WW_"T9!MD*F5];*\;&JB/
M+?H%5/92L&ZZH.X/@3,+UC5W=.'WP"4%&]<^,6%4([E)Z(1DOW) 84^'[K$T
M3"G R,HH!3<CHRWS Y=\H<4V.[-8"*U%FEUN"#9>6 'S?"6$?EK88Y#RV&OV
M/U!+ P04    " #VA%!4FH0Y2RL"  # !   &@   'AL+W=O<FMS:&5E=',O
M<VAE970Q,3(N>&UL?53;;MLP#/T5P4\M,,2.T]L*QT"3[M*A'8(&VQZ&/2@V
M;0O5)9/HNMW7CY(=+QV0O-@B19YS2)/..F.?7 . [$5)[>91@[B]CF-7-*"X
MFY@M:+JIC%4<R;1U[+86>!F2E(S3)+F(%1<ZRK/@6]D\,RU*H6%EF6N5XO9U
M =)T\V@:[1R/HF[0.^(\V_(:UH#?MBM+5CRBE$*!=L)H9J&:1S?3Z\6YCP\!
MWP5T;N_,?"4;8YZ\<5?.H\0+ @D%>@1.KV=8@I0>B&3\'C"CD=(G[I]WZ!]#
M[53+ACM8&OE#E-C,HZN(E5#Q5N*CZ3[#4$\06!CIPI-U?>S%9<2*UJ%10S(I
M4$+W;_XR]&$O(9T>2$B'A#3H[HF"REN./,^LZ9CUT83F#Z'4D$WBA/8?98V6
M;@7E8;XT&H6N01<"'..Z9(512B#U'1T[69/'_&$KCF2S>X&BYKZ;I^SD%I +
MZ4ZS&$F'1XN+@7/1<Z8'.*?L@5@;QS[H$LJW^3'I'XM(=T4LTJ. 7UH]8;/D
M'4N3Z97DG6L%'H&=C;V9!=BS [!#\7>ZF!Q!.QO1S@+:[ #:)]H0]K;=/^\I
MAMTA*/?K",/YR'!^5._75FW ,E.QH0>.54+^W^&^H3W214#RB_N<3]]G\?,^
M>[PW50IL'7;'T7RT&OL!&[WC>M[T4_DOO-_M!VYKH1V34%%J,KDD>MOO2V^@
MV889W1BDB0_'AGXQ8'T W5?&X,[P!.-/*_\+4$L#!!0    ( /:$4%1Q%R7J
M/0(  .,$   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q]5%M/VS 4
M_BM6GD!"=9L"VU :B99=D$!#5-L>ICVXR4EBX4MFGU#8K]^QDX9.6ON2^'*^
MRSGV<;:U[LDW ,A>M#)^D32([17GOFA "S^Q+1C:J:S3 FGJ:NY;!Z*,(*UX
M.IU><BVD2?(LKCVX/+,=*FG@P3'?:2W<ZQ*4W2Z26;);>)1U@V&!YUDK:E@#
M?FL?',WXR%)*#<9+:YB#:I%<SZZ6%R$^!GR7L/5[8Q8RV5C[%":WY2*9!D.@
MH,# (.CW#"M0*A"1C=\#9S)*!N#^>,?^*>9.N6R$AY55/V2)S2)YG[ 2*M$I
M?+3;+S#D$PT65OGX9=L^]EV:L*+S:/4 )@=:FOXO7H8Z[ '2^0% .@#2Z+L7
MBBYO!(H\<W;+7(@FMC"(J48TF9,F',H:'>U*PF&^L@:EJ<$4$CP3IF2%U5HB
MU1T].[G5NC/P$C?6]+%_V)U$68M0TE-V<@,HI/*G&4<R$RAY,0@O>^'T@/",
MW9-TX]E'4T+Y+YY3$F,FZ2Z397J4\+IU$S:?GK%T.OL@JDHJ*1".$,_'$LTC
M\?D!XJ$&?"VT[TS-EM)"*SU;V<D1]O.1_3RRSP^P?\4&''&]%?WG'86P6P3M
M?QT1N!@%+H[:_TR=28>Z.^;7,V8ZO2%-6[&Q3/Y_!]CS7D;>T-S/>9KQYWTK
M?._B:7!U;"]/:IW!_@Z.JV,'7_<7]RV\;_][X6II/%-0$70Z>4?JKF^I?H*V
MC==X8Y&:(@X;>H7 A0#:KZS%W20(C.]:_A=02P,$%     @ ]H105,D]T+27
M @  H 8  !H   !X;"]W;W)K<VAE971S+W-H965T,3$T+GAM;(U5VV[;, S]
M%<%/+;#5B7-I420!FF3%"G1;D&+;P[ 'Q:9MH;IX$M.T?S]*=KRL38R^V!+%
M<WA(RO1D9^RC*P&0/2NIW30J$:OK.'9I"8J["U.!II/<6,61MK:(766!9P&D
M9)ST>N-8<:&CV2385G8V,5N40L/*,K=5BMN7.4BSFT;]:&]8BZ)$;XAGDXH7
M\ #XO5I9VL4M2R84:">,9A;R:733OUZ.O7]P^"%@YP[6S&>R,>;1;^ZR:=3S
M@D!"BIZ!T^L)%B"E)R(9?QK.J WI@8?K/?MMR)URV7 '"R-_B@S+:705L0QR
MOI6X-KO/T.0S\GRID2X\V:[Q[44LW3HTJ@&3 B5T_>;/31T. ,1S') T@.0U
M8'@",&@ @_<"A@U@&"I3IQ+JL.3(9Q-K=LQZ;V+SBU#,@*;TA?9M?T!+IX)P
M.%L8C4(7H%,!CG&=L=0H)9 ZBXZ=K:'B6'*VXD@&=B]0%-PW[)R=+0&YD.Z<
M?60/7)M<Q&L@(K#4SC?^Y%0%VR1&DNV#QVDC<5Y+3$Y([+,O)+)T[)/.(/L?
M'U.Z;<[)/N=YTDGXA=L+-NA_8$FO?W5$SZ(;?@N;"Y9<!?CX"'S9#?^68AM]
MV)'-H.W@(/ -3O%A"98M#KKVZYY<V!V"<K\[ @S; ,,08'@BP->MVE $DS<=
MI&LB)74ZDR],Z-SZZY,=JT--.PZT?OP\S2XG\=,1):-6R:A3R3WH DNO!*W@
M\ECKN@E&+.,OKJ,FXU;)^)TU24M?#2J!.W:SQV]*D+PJ07SP[2JP19B!CK["
MK<;Z2K?6=LS>A.GRRCZG\5M/RW\T]>RF^UX([9B$G"A[%Y=4)%O/PWJ#I@H3
M8F.0YDU8EO0+ >L=Z#PW!O<;'Z#]*<W^ E!+ P04    " #VA%!4AG+7<^T#
M  !I#P  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&ULM5==;^(X%/TK
M5U$?6JDB<8  (T#B8[JEG>Y44\WLPVH?3.* -4[,VDZ92OOCUTY"H)"XS(SZ
M G'B<^ZY'[ZVAULNOLLU(0I^)"R5(V>MU.:#Z\IP31(L6WQ#4OTEYB+!2@_%
MRI4;07"4@Q+F^IX7N FFJ3,>YN\>Q7C(,\5H2AX%R"Q)L'B9$L:W(P<YNQ=?
MZ&JMS MW/-S@%7DBZNOF4>B16[%$-"&II#P%0>*1,T$?[E'/ /(9WRC9RH-G
M,*XL.?]N!HMHY'A&$6$D5(8"Z[]G,B.,&2:MX]^2U*EL&N#A\X[])G=>.[/$
MDLPX^XM&:CUR^@Y$),894U_X]I:4#G4-7\B9S']A6\SM#1P(,ZEX4H*U@H2F
MQ3_^40;B . '#0"_!/C' -0 :)> ]A$ -4GJE(#.L85V Z!; KKG H(2$!P!
MVDU.]TI [UP?^B6@?PSH-P &)6!PK@7D[3+GG6L#5<DNBJZHDKS$YECA\5#P
M+0@S7_.9A[Q.<[RN+)J:)?6DA/Y*-4Z-9SQ5-%V1-*1$ DXC"'F24*57C9)P
M.8DB:DH?,UBDQ0+6HRNXG!.%*9-7< $TA0?*F'XOAZ[2F@RS&Y;VIX5]O\'^
M79:VP/.OP?=\]/5I#I<75R'#-*FAFKU%Q5K01H8*#1C>RHRJ&I:YG66R$9K%
M*UB:E'S\"0Z\$H28<-;PW-AY'O!+Y9!.RT:KT5FIX?GC)_04+#2.91FC)B=O
M[:2?0]4"/R@RU\2Q.-=!WVNBN#NG@#KV?-V_+<-O3KFKUU2UL/QJ8?DY9[N!
M\Q.7$EZOKK\_Z3FP4"21_U@LM"L+[=Q"I\'"GUFR) )X#+GFNKJX+QB"G,'L
MKL]C-'2?:XQV*J,=NU'^C(6B$J9Z P_7\#G.G11Z:X1)ODM:/.M61KKO%+N@
MLA#\;NRFP4GL_"IVQ0*QS7@EJU?)ZEEE'3G^<@USG.B3C81'3*-K^(991N _
MN*C36U!W#]1T^O5R^I6<OE7.9->Z)"SS=)-(&[<UM(_]<T,RJ#0,K!J>S/%M
M@P5,=%24T'LBS!C682JJ35J* 7G[3=![IX)#!QLM>CNWX6%NTZH(]SU9QW<_
MJ.WTZ"3"G?H(HWVK0OXO2RLWB3HM\Y*V7DLI]W1*0T&@?=]#]L9WCER(*<NK
MM?D@,$.GW?%$OFW*:_G[#HKL+?0V2ZC ,*5<TH2R7ROM?2M%[]5+T;Z9HM_N
MI@MTVBS143^]L\]Y+6[?4I&]IQZ(JXY0(!5^R<O#>JRZ*:D/!05'>MR#L[>Y
MA#Y@L:*I!$9BC?%:/9T>4=SKBH'BF_PXON1*'^_SQ[6^"Q-A)NCO,>=J-S G
M_.IV/?X?4$L#!!0    ( /:$4%1)2S@$B0(  "4'   :    >&PO=V]R:W-H
M965T<R]S:&5E=#$Q-BYX;6RME5M/VS 4Q[^*%?$ $FK27-H,I9&@U;0]("$*
MV\.T!S<];2T<.[,=RB0^_(Z=$,*:LH?Q$M_.Y?<_\27;2_6@=P"&/)5<Z)FW
M,Z:Z\'U=[*"D>B0K$+BRD:JD!H=JZ^M* 5T[IY+[81!,_)(RX>69F[M1>29K
MPYF &T5T7994_;X"+O<S;^R]3-RR[<[8"3_/*KJ%)9C[ZD;AR.^BK%D)0C,I
MB(+-S+L<7UREUMX9?&.PU[T^L4I64C[8P=?US LL$' HC(U L7F$.7!N R'&
MKS:FUZ6TCOW^2_3/3CMJ65$-<\F_L[79S;S4(VO8T)J;6[G_ JV>Q,8K)-?N
M2_:M;>"1HM9&EJTS$I1,-"U]:NO0<XC"(PYAZQ Z[B:1HUQ00_-,R3U1UAJC
MV8Z3ZKP1C@G[4Y9&X2I#/Y//I3!,;$$4##2A8DT*69;,8-V-)J?WH^6(W$)%
MC6+4E?&./I'YJ\D9.5V H8QC[X0P0:X9YVBG,]\@GDWB%RW*58,2'D%90#$B
MT?B<A$$XOE\NR.G)&1/:4,YMJK<!?=39B0T[L:'+$!T5^RK-2GTK?L%TP:6N
M%9 ?ERMM%.Z8G^]DC;JLD<L:'\GJ:JCZ-318PUZ9SXFHRQ4H(C>()6K*24^W
M)L_D:!F:NC;Y)RZ_/86/>9KYCP/(<8<<_R\R_J1PB*4)G/18DG0Z3)-T-,D'
MT$1#-,E!9<;C(!C&F70XDP_ B8=P)H<X\>1(=:8=SO0#<)(AG.DA3AK%PSAI
MAY.^BW,G<:<BCWT0\&R1?^(-@:4'FRC^E/Z]I_W>K6<?D&NJMGA0"(<-N@6C
M*?JKYE)N!D96[B)<28/7JNON\!T#90UP?2.E>1G8N[5[&?,_4$L#!!0    (
M /:$4%2,4QSX#0,  -8(   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q-RYX
M;6R-5FMOVC 4_2M7635UTMJ$\"CK "F0=D7J:Z5TFJ9],,F%6'5L9IO2_?O9
M2<AXIOT"MG/NN><XOK[I+(5\5@FBAM>4<=5U$JWGYZZKH@13HD[%'+EY,A4R
M)=I,Y<Q5<XDDSH)2YOJ>UW)30KG3ZV1K][+7$0O-*,=["6J1ID3^[2,3RZY3
M<U8+#W26:+O@]CIS,L,1ZO'\7IJ96[+$-$6NJ. @<=IU@MIYV+;X#/!$<:G6
MQF"=3(1XMI-AW'4\*P@91MHR$//W@@-DS!(9&7\*3J=,:0/7QROVR\R[\3(A
M"@>"_:"Q3KI.VX$8IV3!](-87F'AIVGY(L%4]@O+ NLY$"V4%FD1;!2DE.?_
MY+78A[6 6NM @%\$^-L!C0,!]2*@_MZ 1A'0R'8FMY+M0T@TZ76D6(*T:,-F
M!]EF9M'&/N7VM8^T-$^IB=.]T>#J(AQ?7\!P""?P%%R/@\?AW2T$MR%\'P?7
MP\N?P]MO$ P&=^/;QQ$<AZ@)9>J308]'(1P??8(CH!QN*&/F1:J.JXTL2^Y&
MA81^+L$_(*'FPXW@.E%PP6.,-PE<XZ<TY:],]?U*QA"C4ZC7/H/O^;4]@@;O
M#_?VA(?O#J]]J7!3+U]1/>.K'^ +F*E-PB,$4^40B\5$3Q?,5$PD%EPK^/4@
M& -3!4LBX]\5"1MEPD:6L'$@89^P+!W1,,$9Y9SR&8@IS%%2$>][P3E?,^.S
M%\U+K^YWW)?U+=^%^*U-2+@+:;1+R(:39NFD6>DDB&-JKQ<%44+D#../'VHM
M[ZL6$ EEMH[P&/#57*$*]Q[<G+VUILC;LK6+:&^YJN+8,-4J3;4J3=WI!"60
ME;5]NEMOZGX3$58A-G2?E;K/*G6'&"^B@Y+/=M*=;)V/P1[(UBD+]T'\_;+;
MI>SV>ZL!S7&IK(/VFX=\L O9+I6PDB7WX*[=^"F:DVT[ISGE]D;([\ERM6S.
M0=:3MM;[IFGG/?8_3=[Q;TS!4%,Y#*>&TCL],X)DWD7SB1;SK*],A#9=*ALF
MYL,#I068YU,A]&IB$Y2?,KU_4$L#!!0    ( /:$4%2L#F'!9P,   86   -
M    >&PO<W1Y;&5S+GAM;-U8T6[:,!3]E2B=IE::&D)&("L@;4A(D[:I4ONP
MM\H0!RPY3N:8#OJX7]GKOF*?LB^9;QP2H+Z(]F&%!='8]_B>>WQ]G;CT"[7B
M]&9.J7*6*1?%P)TKE;_SO&(ZIRDI+K.<"HTDF4R)TETY\XI<4A(7X)1RK]UJ
MA5Y*F'"'?;%(QZDJG&FV$&K@]FJ38VX?XX'KAV]=Q]"-LI@.W+OSU]\6F;IZ
MY9C[V9NSL];=Q=6N_;P$+ES/2MHY@/2RA?-J#*,.#Z/>3X[3=[?I*P?-M?;%
M''MV73=CB62R0?;G,K(3__GQ"R%ND+W$W9:=^/=/A+<&]M/Z!RW0GM4IB;VJ
M>H?])!--$0>N,>C()*7./>$#=T0XFT@&7@E)&5\9<QL,TXQGTE%Z]V@I/EB*
M!P/[I@<;J^))F<AD&=M$,'\GU? =8-T#@8SS6F#;-89A/R=*42G&NE,.+HV/
M(*=JWZYRK7 FR<IO=]S&H;SI()-,QE3687QW;1KV.4U CF2S.=Q5EGL *I6E
MNA$S,LL$*36L/:J&IIU2SF_@J?,UV>)>)AMK6A:*J)M:4-4T-*8#_)MLAGN3
MMO,L7B=G]YGZL-#3$64?:H5>2YJP9=E?)K4 C-W'V4F>\]5[SF8BI6;R!P<<
M]LG:SYEGDCWH:% J4VV@TG7NJ51LNFGY+DE^2Y=J74[+!-?</D'-_S;/,RJH
M)'Q3M*[]8\[RLQ57K^F7T%P^5G856T4&W>/76!U-CEUD> HB3V"Y@^CX-59'
MQV,7>0J9[+[8D_TI(OVC%.E5Q[6-,^'6B;"V.G#R'KA?X(S/FZ#.9,&X8J+J
MS5D<4_'H8*CI%9GH?W*W^/7XF"9DP=5M#0[<IOV9QFR11O6H:TA$-:II?X+I
M^6%][->QF(CIDL:CJBMGD[+IZ(:.6EW@L(N,R\N.8#X&LR. 87$P!9B/\<+B
M_$_SZ:'S,1BFK6=%>JA/#_4Q7C9D5'ZP.':?2%_VF491$(0AEM'1R*I@A.4M
M#.%K9\.T@0<6!R(]+=?X:N,5LK\.L#7=5R'83/%*Q&:*YQH0>][ (XKLJXW%
M 0]L%;#:@?CV.%!3=I\@@%7%M&$[&$>B"$.@%NTU&H9(=D+XV-<'VR5!$$5V
M!#"[@B# $-B-.((I  T8$@3E>W#G?>2MWU->\\OO\"]02P,$%     @ ]H10
M5)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(
M,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5
MN %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;
M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%
MR=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M    " #VA%!4_/6IR3P(  "H3   #P   'AL+W=O<FMB;V]K+GAM;,6<77/:
M/!: _XJ&FTUG-AMC_($[36=H2%OFS9MF0]N]W!&V $W]P4HR:=Y?OT>F224P
M9_?FP%6"#>9!MLYS]/GNJ5$_%DWS@_VLREI?#];&;-Y>7>E\+2JN_]%L1 UG
MEHVJN(&7:G6E-TKP0J^%,%5Y%09!<E5Q60_>OWNYUH.Z<E\T1N1&-C4<M >^
M2_&D?Y^W+]E6:KF0I33/UX/N_U(,6"5K6<F_1'$]" 9,KYNGSXV2?S6UX>4\
M5TU97@^&NQ/?A3(R/S@\MY!?^4)W1PQ?/'( N1XD 5QP*94VW3NZZW-@W IX
M\^Y5:YJ/LC1"3;D1GU33;F2]LI>!7W'E_(RN'%[^[@KQK?I_BK%9+F4NIDW>
M5J(VNW)4HK2 M5[+C1ZPFE?B>G#3;(5B&[X2]D?!M\R*W0\T0.84EWHKX82:
M%1TC'<^D+:1ALWKW83CK8(4(5DB+=0.OFU(6\.T%FUL(^P'-FB6PYHT#.4(@
M1V>#O&FJC0,9(9#1"2$_\)+7N6!=1=$.8(P QF<#9!</W(%,$,CD;+=Z;IK<
M@4P1R/2,D/\.'<@Q CD^7Z7A>NU 9@AD1@LY;ZN*JV<+I>6JEO Q7ANP2MZT
MM9%NZ ZPV!T0!^_\/RU\:7?<94)]0BR41[$5=2L\'DPD0V*3V.KYXW+!-3QN
M.41E4>M]SPTQAPR))3(52UEW;+51<M':-[ -1$$7$//'D%@@UK>5@'SKIW]3
M,64,B9UQRU4-&9QF&TBF])HK+YO"/#$D%T59\D6C^$&EQ,0P)#;#K-X*;;I
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M5[P]0.^@>@> WD'U#@"]@_FR#= [J-X!H'=0O0- [Z!Z!X#>0?4. +V#ZAT
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MY[]??CQI$7KG>O@Z8[KY"U!+ P04    " #VA%!41K1.*H\"  #M00  $P
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M4$L! A0#%     @ ]8105 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #UA%!4D5LUX.X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #UA%!4F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( /6$4%27<YN*  <  #<=   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #UA%!4D7+>0"$"  !R!0  &               @(%##P  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ]8105 /.%M9,!0  0A8  !@
M             ("!FA$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( /6$4%3,K*CX@ ,  #,+   8              " @1P7  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #UA%!4+Q)EQED%
M%0  &               @('2&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ ]8105!R+=-YZ @  6 8  !@              ("!82
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /6$4%2PRG&=
MJ08  ",B   8              " @1$C  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " #UA%!4ASS",1 #  #D#   &
M@('P*0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ]810
M5/IJT"DS!P  RQ\  !@              ("!-BT  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( /6$4%3TLTV\$!\  #MA   9
M      " @9\T  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ ]8105(8"Z3 9#P  62P  !D              ("!YE,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #UA%!4XJ( B0L'  "##P
M&0              @($V8P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( /6$4%0F&+$6K@P  ,(G   9              " @7AJ  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ]8105&.E!*K!
M @  ,08  !D              ("!77<  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " #UA%!4/JK?0<X.  "_*P  &0
M@(%5>@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /6$
M4%2/UL9SM0,  (X(   9              " @5J)  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ ]8105#:R-2I]#   5B8  !D
M         ("!1HT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " #UA%!46%6L!_<+   K)P  &0              @('ZF0  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /6$4%3-O(^;80(  !8%
M   9              " @2BF  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ ]8105'>PM&CQ P  YP@  !D              ("!P*@
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #UA%!4<+&.
M,U '  #C$0  &0              @('HK   >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( /6$4%3ND&.Q5 8  #D/   9
M  " @6^T  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M]8105-3,Q:,# P  Y@8  !D              ("!^KH  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " #UA%!4&S$0U]P2   Q/0  &0
M            @($TO@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( /6$4%0!MAI$G <  ,T4   9              " @4?1  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ]8105!L)A8KC#
MBBH  !D              ("!&MD  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " #UA%!4D#@R'^@0  !L00  &0              @($T
MY@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /6$4%3%
M$O+JP2$  *"*   9              " @5/W  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ ]8105+)AAW'" @  ,P8  !D
M     ("!2QD! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /6$4%3XN>X$2@8  #81   9              "
M@>%* 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ]810
M5 *@D#O> @  0P8  !D              ("!8E$! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " #UA%!4( V 8Q\$  #-#   &0
M        @(%W5 $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( /6$4%28YRIT9P(  !,%   9              " @<U8 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ]8105$E-^8[' P  K0@
M !D              ("!:UL! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " #UA%!4A._T+^X#   '"0  &0              @(%I7P$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( /6$4%3T<+X'
MD@0  'X+   9              " @8YC 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ ]8105&6(H+PP P  7P<  !D
M ("!5V@! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #U
MA%!4#'I ,&,'  #0%   &0              @(&^:P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /6$4%3)JN,<:P4  +$.   9
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M970T-RYX;6Q02P$"% ,4    " #UA%!4"<+:J!@%   J%P  &0
M    @(&)BP$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M /6$4%3Y.AG%3@<  /XD   9              " @=B0 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ ]8105!#YG(R%"P  &T\  !D
M             ("!79@! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " #UA%!4"1 HQUL$   %$P  &0              @($9I $ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /6$4%3@N>]#!P<
M &8?   9              " @:NH 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ ]8105)E;7@A) P  Z P  !D              ("!
MZ:\! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #UA%!4
M);W@FUT#  !["P  &0              @(%ILP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( /6$4%0ACO7&? ,  %X+   9
M      " @?VV 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ ]8105#!A7?]^!   _A$  !D              ("!L+H! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #UA%!4H^=&A",#   7"0
M&0              @(%EOP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( /6$4%0 ?!- 70(  +X%   9              " @;_" 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ ]8105#"_9YC#
M @  T @  !D              ("!4\4! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " #UA%!47+J!VT@#  #J"P  &0
M@(%-R $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( /6$
M4%1O?<?TU0,  -4-   9              " @<S+ 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ ]8105"^H=1#\!   =!<  !D
M         ("!V,\! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
M    " #UA%!4^)J\NW$#  "*"@  &0              @($+U0$ >&PO=V]R
M:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( /6$4%3> _6)O@,  "0/
M   9              " @;/8 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL
M4$L! A0#%     @ ]8105 2M6=XZ P  2 H  !D              ("!J-P!
M 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #UA%!4T>2(
M]OX"   ]"0  &0              @($9X $ >&PO=V]R:W-H965T<R]S:&5E
M=#8V+GAM;%!+ 0(4 Q0    ( /6$4%2^;X7M5 0  &H2   9
M  " @4[C 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
M]8105 >2[FB  @  R 4  !D              ("!V><! 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    " #UA%!41O_)90$$  #W$@  &0
M            @(&0Z@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( /6$4%3PGU!9K (  /P'   9              " @<CN 0!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ ]8105 ,#D4&, @
MIP8  !D              ("!J_$! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    " #UA%!4UMY8#'$"   "!@  &0              @(%N
M] $ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( /6$4%0&
M8?M=9 ,  $(*   9              " @1;W 0!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ ]8105"0H)8;Y @  & @  !D
M     ("!L?H! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /6$4%3O/6X8G0(  /((   9              "
M@:$. @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ ]810
M5$@.#4&K @  %0<  !D              ("!=1$" 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    " #UA%!4TL;12V $  #3%   &0
M        @(%7% ( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( /6$4%3=R<ULU ,  *@.   9              " @>X8 @!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ ]8105)6&S.+_ @  ] D
M !D              ("!^1P" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    " #UA%!4XS,I2/,"   H"@  &0              @($O( (
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( /6$4%0!X+L,
MD (  !0'   9              " @5DC @!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ ]8105.W=/!$F P  $ H  !D
M ("!("8" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " #U
MA%!40KYES*0"  # !@  &0              @(%]*0( >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( /6$4%2[A/=!FP(   \'   9
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M970Y,BYX;6Q02P$"% ,4    " #UA%!4-2;1/A00  !FB@  &0
M    @('+4P( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M /6$4%0_F,\-- 0  (L-   9              " @19D @!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ ]8105/RMS+IC @  @08  !D
M             ("!@6@" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"
M% ,4    " #UA%!4\N!YQV8"  #6!0  &0              @($;:P( >&PO
M=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( /6$4%2EQ!2H2P0
M &<2   9              " @;AM @!X;"]W;W)K<VAE971S+W-H965T.3<N
M>&UL4$L! A0#%     @ ]8105(D1U-S^ P  #Q8  !D              ("!
M.G(" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " #UA%!4
MJPVR"RH&  !F(   &0              @(%O=@( >&PO=V]R:W-H965T<R]S
M:&5E=#DY+GAM;%!+ 0(4 Q0    ( /6$4%2^TI7Q-@,  /4(   :
M      " @=!\ @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0
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M965T,3 T+GAM;%!+ 0(4 Q0    ( /6$4%3!FPTX9@,  %0*   :
M      " @0"6 @!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0
M   ( /6$4%34EL$N704  ),8   :              " @9Z9 @!X;"]W;W)K
M<VAE971S+W-H965T,3 V+GAM;%!+ 0(4 Q0    ( /:$4%1QXXUJG 8  '@Q
M   :              " @3.? @!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM
M;%!+ 0(4 Q0    ( /:$4%2<+0Z4  ,  %8)   :              " @0>F
M @!X;"]W;W)K<VAE971S+W-H965T,3 X+GAM;%!+ 0(4 Q0    ( /:$4%0
MY6N?/0,  ,4,   :              " @3^I @!X;"]W;W)K<VAE971S+W-H
M965T,3 Y+GAM;%!+ 0(4 Q0    ( /:$4%3;BO9O6@0   X0   :
M      " @;2L @!X;"]W;W)K<VAE971S+W-H965T,3$P+GAM;%!+ 0(4 Q0
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M965T,3$T+GAM;%!+ 0(4 Q0    ( /:$4%2&<M=S[0,  &D/   :
M      " @?"\ @!X;"]W;W)K<VAE971S+W-H965T,3$U+GAM;%!+ 0(4 Q0
M   ( /:$4%1)2S@$B0(  "4'   :              " @17! @!X;"]W;W)K
M<VAE971S+W-H965T,3$V+GAM;%!+ 0(4 Q0    ( /:$4%2,4QSX#0,  -8(
M   :              " @=;# @!X;"]W;W)K<VAE971S+W-H965T,3$W+GAM
M;%!+ 0(4 Q0    ( /:$4%2L#F'!9P,   86   -              "  1O'
M @!X;"]S='EL97,N>&UL4$L! A0#%     @ ]H105)>*NQS     $P(   L
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64$L%!@    !] 'T ="(  #+: @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>682</ContextCount>
  <ElementCount>627</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>178</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>19</UnitCount>
  <MyReports>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100010003 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100020004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100030005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100040006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100050007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100060008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100070009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210041002 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210081003 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210121004 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Stockbasedcompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210201005 - Disclosure - Defined contribution plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Definedcontributionplan</Role>
      <ShortName>Defined contribution plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210221006 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210301007 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210331008 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Collaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210371009 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210471010 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210501011 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210541012 - Disclosure - Goodwill and intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Goodwillandintangibleassets</Role>
      <ShortName>Goodwill and intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210591013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210661014 - Disclosure - Other current assets and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities</Role>
      <ShortName>Other current assets and accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210701015 - Disclosure - Financing arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Financingarrangements</Role>
      <ShortName>Financing arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210791016 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Stockholdersequity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210871017 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Fairvaluemeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210921018 - Disclosure - Derivative instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Derivativeinstruments</Role>
      <ShortName>Derivative instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>211001019 - Disclosure - Contingencies and commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Contingenciesandcommitments</Role>
      <ShortName>Contingencies and commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>211071020 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>220022001 - Disclosure - Summary of significant accounting policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>230053001 - Disclosure - Acquisitions - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Acquisitions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230093002 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Revenues</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230133003 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Stockbasedcompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230233004 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Incometaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230313005 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Earningspershare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230383006 - Disclosure - Investments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsTables</Role>
      <ShortName>Investments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Investments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230483007 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Inventories</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230513008 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Propertyplantandequipment</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230553009 - Disclosure - Goodwill and other intangible assets - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsTables</Role>
      <ShortName>Goodwill and other intangible assets - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230603010 - Disclosure - Leases - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesTables</Role>
      <ShortName>Leases - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230673011 - Disclosure - Other current assets and accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables</Role>
      <ShortName>Other current assets and accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230713012 - Disclosure - Financing arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsTables</Role>
      <ShortName>Financing arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Financingarrangements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230803013 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Stockholdersequity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230883014 - Disclosure - Fair value measurement - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementTables</Role>
      <ShortName>Fair value measurement - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Fairvaluemeasurement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230933015 - Disclosure - Derivative instruments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsTables</Role>
      <ShortName>Derivative instruments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Derivativeinstruments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>231013016 - Disclosure - Contingencies and commitments - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsTables</Role>
      <ShortName>Contingencies and commitments - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Contingenciesandcommitments</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>240034001 - Disclosure - Summary of significant accounting policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails</Role>
      <ShortName>Summary of significant accounting policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>240064002 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails</Role>
      <ShortName>Acquisitions - Aggregate Consideration Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240104004 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240114005 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails</Role>
      <ShortName>Revenues - Customer Concentration, Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240144006 - Disclosure - Stock-based compensation (Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationTextualDetails</Role>
      <ShortName>Stock-based compensation (Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240154007 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based compensation (Components of Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240164008 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails</Role>
      <ShortName>Stock-based compensation (Summary of RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240174009 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails</Role>
      <ShortName>Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240184010 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails</Role>
      <ShortName>Stock-based compensation (Summary of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240194011 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Stock-based compensation (Weighted-average Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockbasedcompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240214012 - Disclosure - Defined contribution plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DefinedcontributionplanDetails</Role>
      <ShortName>Defined contribution plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Definedcontributionplan</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240244013 - Disclosure - Income taxes (Income Before Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Income Before Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240254014 - Disclosure - Income taxes (Provision for Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Provision for Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240264015 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240274016 - Disclosure - Income taxes (Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesTextualDetails</Role>
      <ShortName>Income taxes (Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240284017 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails</Role>
      <ShortName>Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240294018 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/IncometaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240324019 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/EarningspershareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240344020 - Disclosure - Collaborations - Novartis AG (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsNovartisAGDetails</Role>
      <ShortName>Collaborations - Novartis AG (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240354021 - Disclosure - Collaborations - BeiGene (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsBeiGeneDetails</Role>
      <ShortName>Collaborations - BeiGene (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240364022 - Disclosure - Collaborations - Kyowa Kirin (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CollaborationsKyowaKirinDetails</Role>
      <ShortName>Collaborations - Kyowa Kirin (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240394023 - Disclosure - Investments - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsScheduleDetails</Role>
      <ShortName>Investments - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240404024 - Disclosure - Investments - Fair Values by Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails</Role>
      <ShortName>Investments - Fair Values by Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240414025 - Disclosure - Investments - Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsAvailableforsaleDetails</Role>
      <ShortName>Investments - Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240424026 - Disclosure - Investments - Fair Values by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails</Role>
      <ShortName>Investments - Fair Values by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240434027 - Disclosure - Investments - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails</Role>
      <ShortName>Investments - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240444028 - Disclosure - Investments - Limited Partnership Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails</Role>
      <ShortName>Investments - Limited Partnership Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240454029 - Disclosure - Investments - BeiGene (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsBeiGeneDetails</Role>
      <ShortName>Investments - BeiGene (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240464030 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails</Role>
      <ShortName>Investments - Neumora Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240494031 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InventoriesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240524032 - Disclosure - Property, plant and equipment (Schedule) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails</Role>
      <ShortName>Property, plant and equipment (Schedule) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/PropertyplantandequipmentTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240534033 - Disclosure - Property, plant and equipment (Geographic Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails</Role>
      <ShortName>Property, plant and equipment (Geographic Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/PropertyplantandequipmentTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240564034 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails</Role>
      <ShortName>Goodwill and other intangible assets - Goodwill Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240574035 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and other intangible assets - Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240584036 - Disclosure - Goodwill and other intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails</Role>
      <ShortName>Goodwill and other intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240614037 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240624038 - Disclosure - Leases - Summary of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesSummaryofLeasesDetails</Role>
      <ShortName>Leases - Summary of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240634039 - Disclosure - Leases - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails</Role>
      <ShortName>Leases - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240654041 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails</Role>
      <ShortName>Leases - Cash and Noncash Information of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240684042 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails</Role>
      <ShortName>Other current assets and accrued liabilities - Schedule of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240694043 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240724044 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails</Role>
      <ShortName>Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240734045 - Disclosure - Financing arrangements (Debt Issuances) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails</Role>
      <ShortName>Financing arrangements (Debt Issuances) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240744046 - Disclosure - Financing arrangements (Debt Repayments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails</Role>
      <ShortName>Financing arrangements (Debt Repayments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240754047 - Disclosure - Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails</Role>
      <ShortName>Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240764048 - Disclosure - Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails</Role>
      <ShortName>Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240774049 - Disclosure - Financing arrangements (Contractual Maturities of Long-term Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Financing arrangements (Contractual Maturities of Long-term Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240784050 - Disclosure - Financing arrangements (Interest Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails</Role>
      <ShortName>Financing arrangements (Interest Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240814051 - Disclosure - Stockholders' equity (Stock Repurchase Program) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails</Role>
      <ShortName>Stockholders' equity (Stock Repurchase Program) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240824052 - Disclosure - Stockholders' equity (Dividends) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityDividendsDetails</Role>
      <ShortName>Stockholders' equity (Dividends) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240834053 - Disclosure - Stockholders' equity (Components of AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails</Role>
      <ShortName>Stockholders' equity (Components of AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240844054 - Disclosure - Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails</Role>
      <ShortName>Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240854055 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails</Role>
      <ShortName>Stockholders' equity (Reclassifications out of AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240864056 - Disclosure - Stockholders' equity (Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityOtherDetails</Role>
      <ShortName>Stockholders' equity (Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240894057 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FairvaluemeasurementTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240904058 - Disclosure - Fair value measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails</Role>
      <ShortName>Fair value measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240914059 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails</Role>
      <ShortName>Fair value measurement - Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240944060 - Disclosure - Derivative instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails</Role>
      <ShortName>Derivative instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240954061 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails</Role>
      <ShortName>Derivative instruments - (Cross-currency Swaps) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240964062 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails</Role>
      <ShortName>Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240974063 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails</Role>
      <ShortName>Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240984064 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails</Role>
      <ShortName>Derivative instruments - (Summary of Income and Expense Line Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240994065 - Disclosure - Derivative instruments - (Fair Value of Derivatives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails</Role>
      <ShortName>Derivative instruments - (Fair Value of Derivatives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>241024066 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Sandoz Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>241034067 - Disclosure - Contingencies and commitments (Immunex and Sandoz Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Immunex and Sandoz Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>241044068 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails</Role>
      <ShortName>Contingencies and commitments (Repatha Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>241054069 - Disclosure - Contingencies and commitments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails</Role>
      <ShortName>Contingencies and commitments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>241064070 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails</Role>
      <ShortName>Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/ContingenciesandcommitmentsTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="amgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>241084071 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</ParentRole>
      <Position>117</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="amgn-20211231.htm">amgn-20211231.htm</File>
    <File>amgn-1051_20211231xq4.htm</File>
    <File>amgn-20211231.xsd</File>
    <File>amgn-20211231_cal.xml</File>
    <File>amgn-20211231_def.xml</File>
    <File>amgn-20211231_lab.xml</File>
    <File>amgn-20211231_pre.xml</File>
    <File>amgn-ex1015_20211231xq4.htm</File>
    <File>amgn-ex1023_20211231xq4.htm</File>
    <File>amgn-ex1025_20211231xq4.htm</File>
    <File>amgn-ex104_20211231xq4.htm</File>
    <File>amgn-ex105_20211231xq4.htm</File>
    <File>amgn-ex107_20211231xq4.htm</File>
    <File>amgn-ex21_20211231xq4.htm</File>
    <File>amgn-ex31_20211231xq4.htm</File>
    <File>amgn-ex32_20211231xq4.htm</File>
    <File>amgn-ex432_202131xq4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amgn-20211231_g1.jpg</File>
    <File>amgn-20211231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="1725">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>146
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amgn-20211231.htm": {
   "axisCustom": 3,
   "axisStandard": 32,
   "contextCount": 682,
   "dts": {
    "calculationLink": {
     "local": [
      "amgn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "amgn-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd"
     ]
    }
   },
   "elementCount": 918,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 10
   },
   "keyCustom": 93,
   "keyStandard": 534,
   "memberCustom": 108,
   "memberStandard": 65,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover page",
     "role": "http://www.amgen.com/role/Coverpage",
     "shortName": "Cover page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844054 - Disclosure - Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails",
     "shortName": "Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854055 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
     "shortName": "Stockholders' equity (Reclassifications out of AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7eddf836edaa42b799954c8ea6198ffd_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864056 - Disclosure - Stockholders' equity (Other) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityOtherDetails",
     "shortName": "Stockholders' equity (Other) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894057 - Disclosure - Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240904058 - Disclosure - Fair value measurement - Narrative (Details)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
     "shortName": "Fair value measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ide4e5e657f16482091a0d8f7d0722737_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914059 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
     "shortName": "Fair value measurement - Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:BusinessCombinationContingentConsiderationArrangementsPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:DerivativeInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240944060 - Disclosure - Derivative instruments - Narrative (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
     "shortName": "Derivative instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:DerivativeInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ibc0cdd08ffa245b5b14a99b5ae9342c3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954061 - Disclosure - Derivative instruments - (Cross-currency Swaps) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
     "shortName": "Derivative instruments - (Cross-currency Swaps) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i665b76a3b3b3476c84386f9224fe17a9_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240964062 - Disclosure - Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
     "shortName": "Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i665b76a3b3b3476c84386f9224fe17a9_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240974063 - Disclosure - Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
     "shortName": "Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i52186ecfa5c2464a9932151770b9a053_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210041002 - Disclosure - Acquisitions",
     "role": "http://www.amgen.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984064 - Disclosure - Derivative instruments - (Summary of Income and Expense Line Items) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
     "shortName": "Derivative instruments - (Summary of Income and Expense Line Items) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i739fe173b25a47189a34271891a4159b_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994065 - Disclosure - Derivative instruments - (Fair Value of Derivatives) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
     "shortName": "Derivative instruments - (Fair Value of Derivatives) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024066 - Disclosure - Contingencies and commitments (Sandoz Patent Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails",
     "shortName": "Contingencies and commitments (Sandoz Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ibd8306676c13410b97176dcf42d9df6f_D20180601-20180630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofLawsuitsFiled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i19d673199032476d834451d22f3f5dc6_D20190401-20190430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "affiliate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034067 - Disclosure - Contingencies and commitments (Immunex and Sandoz Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
     "shortName": "Contingencies and commitments (Immunex and Sandoz Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i19d673199032476d834451d22f3f5dc6_D20190401-20190430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:GainContingencyNumberofAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "affiliate",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i1d65a5d55e5642be9bee7decb061fd66_D20141001-20141031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044068 - Disclosure - Contingencies and commitments (Repatha Patent Litigation) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
     "shortName": "Contingencies and commitments (Repatha Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i1d65a5d55e5642be9bee7decb061fd66_D20141001-20141031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i5a349ce4f68f4e62ac77c54575a7b956_I20190520",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241054069 - Disclosure - Contingencies and commitments (Additional Information) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
     "shortName": "Contingencies and commitments (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i5a349ce4f68f4e62ac77c54575a7b956_I20190520",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241064070 - Disclosure - Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails",
     "shortName": "Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ide4e5e657f16482091a0d8f7d0722737_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084071 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "role": "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib936adc316344e80a16bdf77c98d380b_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210081003 - Disclosure - Revenues",
     "role": "http://www.amgen.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210121004 - Disclosure - Stock-based compensation",
     "role": "http://www.amgen.com/role/Stockbasedcompensation",
     "shortName": "Stock-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210201005 - Disclosure - Defined contribution plan",
     "role": "http://www.amgen.com/role/Definedcontributionplan",
     "shortName": "Defined contribution plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210221006 - Disclosure - Income taxes",
     "role": "http://www.amgen.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210301007 - Disclosure - Earnings per share",
     "role": "http://www.amgen.com/role/Earningspershare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210331008 - Disclosure - Collaborations",
     "role": "http://www.amgen.com/role/Collaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210371009 - Disclosure - Investments",
     "role": "http://www.amgen.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210471010 - Disclosure - Inventories",
     "role": "http://www.amgen.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "000020002 - Document - Audit Information",
     "role": "http://www.amgen.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210501011 - Disclosure - Property, plant and equipment",
     "role": "http://www.amgen.com/role/Propertyplantandequipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210541012 - Disclosure - Goodwill and intangible assets",
     "role": "http://www.amgen.com/role/Goodwillandintangibleassets",
     "shortName": "Goodwill and intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210591013 - Disclosure - Leases",
     "role": "http://www.amgen.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210661014 - Disclosure - Other current assets and accrued liabilities",
     "role": "http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities",
     "shortName": "Other current assets and accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210701015 - Disclosure - Financing arrangements",
     "role": "http://www.amgen.com/role/Financingarrangements",
     "shortName": "Financing arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210791016 - Disclosure - Stockholders' equity",
     "role": "http://www.amgen.com/role/Stockholdersequity",
     "shortName": "Stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210871017 - Disclosure - Fair value measurement",
     "role": "http://www.amgen.com/role/Fairvaluemeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210921018 - Disclosure - Derivative instruments",
     "role": "http://www.amgen.com/role/Derivativeinstruments",
     "shortName": "Derivative instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211001019 - Disclosure - Contingencies and commitments",
     "role": "http://www.amgen.com/role/Contingenciesandcommitments",
     "shortName": "Contingencies and commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211071020 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "role": "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i9963b4918c704c66b6ec451aa47770c2_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010003 - Statement - Consolidated Statements of Income",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220022001 - Disclosure - Summary of significant accounting policies - (Policies)",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230053001 - Disclosure - Acquisitions - (Tables)",
     "role": "http://www.amgen.com/role/AcquisitionsTables",
     "shortName": "Acquisitions - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230093002 - Disclosure - Revenues (Tables)",
     "role": "http://www.amgen.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230133003 - Disclosure - Stock-based compensation (Tables)",
     "role": "http://www.amgen.com/role/StockbasedcompensationTables",
     "shortName": "Stock-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230233004 - Disclosure - Income taxes (Tables)",
     "role": "http://www.amgen.com/role/IncometaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230313005 - Disclosure - Earnings per share (Tables)",
     "role": "http://www.amgen.com/role/EarningspershareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230383006 - Disclosure - Investments - (Tables)",
     "role": "http://www.amgen.com/role/InvestmentsTables",
     "shortName": "Investments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230483007 - Disclosure - Inventories (Tables)",
     "role": "http://www.amgen.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230513008 - Disclosure - Property, plant and equipment (Tables)",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230553009 - Disclosure - Goodwill and other intangible assets - (Tables)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables",
     "shortName": "Goodwill and other intangible assets - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020004 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230603010 - Disclosure - Leases - (Tables)",
     "role": "http://www.amgen.com/role/LeasesTables",
     "shortName": "Leases - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230673011 - Disclosure - Other current assets and accrued liabilities (Tables)",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables",
     "shortName": "Other current assets and accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230713012 - Disclosure - Financing arrangements (Tables)",
     "role": "http://www.amgen.com/role/FinancingarrangementsTables",
     "shortName": "Financing arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230803013 - Disclosure - Stockholders' equity (Tables)",
     "role": "http://www.amgen.com/role/StockholdersequityTables",
     "shortName": "Stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230883014 - Disclosure - Fair value measurement - (Tables)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementTables",
     "shortName": "Fair value measurement - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230933015 - Disclosure - Derivative instruments - (Tables)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsTables",
     "shortName": "Derivative instruments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231013016 - Disclosure - Contingencies and commitments - (Tables)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsTables",
     "shortName": "Contingencies and commitments - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240034001 - Disclosure - Summary of significant accounting policies - Narrative (Details)",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
     "shortName": "Summary of significant accounting policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:SalesReturnProvisionsAsPercentageOfProductSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064002 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)",
     "role": "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
     "shortName": "Acquisitions - Aggregate Consideration Paid (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i53ec49e1c08447c4a475e13c41bf649a_D20211019-20211019",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:Businessassetacquisitionconsiderationtransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i21358fdcfee142efb4e3f013e87d4e7c_D20191121-20191121",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030005 - Statement - Consolidated Balance Sheets",
     "role": "http://www.amgen.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104004 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.amgen.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:PercentageOfCombinedNetTradeReceivablesFromMajorCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240114005 - Disclosure - Revenues - Customer Concentration, Product Sales (Details)",
     "role": "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
     "shortName": "Revenues - Customer Concentration, Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ie45ea7d90fd9496098876205bd24f226_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "amgn:PercentageOfGrossRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144006 - Disclosure - Stock-based compensation (Textual) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
     "shortName": "Stock-based compensation (Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154007 - Disclosure - Stock-based compensation (Components of Stock-based Compensation Expense) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based compensation (Components of Stock-based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ComponentsOfStockBasedCompensationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i5c5f3303e39f4bc0b7b331b548b22fd1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164008 - Disclosure - Stock-based compensation (Summary of RSUs) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
     "shortName": "Stock-based compensation (Summary of RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i8bb8e713474c47ff83f089068a521247_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174009 - Disclosure - Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
     "shortName": "Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i6ddf6a81f52142b289af6c28c4643c6f_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "iafb155843fbb43a4845a41a3a8dd1ff1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184010 - Disclosure - Stock-based compensation (Summary of Stock Options) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
     "shortName": "Stock-based compensation (Summary of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "iafb155843fbb43a4845a41a3a8dd1ff1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194011 - Disclosure - Stock-based compensation (Weighted-average Assumptions) (Details)",
     "role": "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails",
     "shortName": "Stock-based compensation (Weighted-average Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i34b7dbb1d5fb4d9093e75f971d74d54e_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amgn:CommonStockFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214012 - Disclosure - Defined contribution plan (Details)",
     "role": "http://www.amgen.com/role/DefinedcontributionplanDetails",
     "shortName": "Defined contribution plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240244013 - Disclosure - Income taxes (Income Before Income Taxes) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
     "shortName": "Income taxes (Income Before Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i3022ab55cbe34d28a3a4a40e97b0e2f6_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254014 - Disclosure - Income taxes (Provision for Income Taxes) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income taxes (Provision for Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264015 - Disclosure - Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240274016 - Disclosure - Income taxes (Textual) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesTextualDetails",
     "shortName": "Income taxes (Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ide4e5e657f16482091a0d8f7d0722737_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284017 - Disclosure - Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails",
     "shortName": "Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib936adc316344e80a16bdf77c98d380b_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294018 - Disclosure - Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)",
     "role": "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails",
     "shortName": "Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324019 - Disclosure - Earnings per share (Details)",
     "role": "http://www.amgen.com/role/EarningspershareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i47ecb19fa54443e6a1c8180a5b4978c1_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344020 - Disclosure - Collaborations - Novartis AG (Details)",
     "role": "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
     "shortName": "Collaborations - Novartis AG (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i47ecb19fa54443e6a1c8180a5b4978c1_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354021 - Disclosure - Collaborations - BeiGene (Details)",
     "role": "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
     "shortName": "Collaborations - BeiGene (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib96fb2589f6d4eb6be9dc2329f9e3e9a_D20200102-20200102",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i4c8816fa7e9c49cba0ab2b9df683b53e_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:UpFrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364022 - Disclosure - Collaborations - Kyowa Kirin (Details)",
     "role": "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
     "shortName": "Collaborations - Kyowa Kirin (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i4c8816fa7e9c49cba0ab2b9df683b53e_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:UpFrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394023 - Disclosure - Investments - Schedule (Details)",
     "role": "http://www.amgen.com/role/InvestmentsScheduleDetails",
     "shortName": "Investments - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i8dfa3d2f9c9049c0a19ece84de2ff2ff_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i8dfa3d2f9c9049c0a19ece84de2ff2ff_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404024 - Disclosure - Investments - Fair Values by Classification (Details)",
     "role": "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
     "shortName": "Investments - Fair Values by Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "if4b2c07d94924b70a99e1b31e4959623_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414025 - Disclosure - Investments - Available-for-sale (Details)",
     "role": "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails",
     "shortName": "Investments - Available-for-sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424026 - Disclosure - Investments - Fair Values by Contractual Maturity (Details)",
     "role": "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails",
     "shortName": "Investments - Fair Values by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240434027 - Disclosure - Investments - Equity Securities (Details)",
     "role": "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails",
     "shortName": "Investments - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444028 - Disclosure - Investments - Limited Partnership Investments (Details)",
     "role": "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails",
     "shortName": "Investments - Limited Partnership Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454029 - Disclosure - Investments - BeiGene (Details)",
     "role": "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
     "shortName": "Investments - BeiGene (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib69e5cff7c72466aa64106c866eef4f2_I20200102",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464030 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details)",
     "role": "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails",
     "shortName": "Investments - Neumora Therapeutics, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i8bdea1c8311e41d9a8dd2e5681a38379_D20210930-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494031 - Disclosure - Inventories (Details)",
     "role": "http://www.amgen.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524032 - Disclosure - Property, plant and equipment (Schedule) (Details)",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
     "shortName": "Property, plant and equipment (Schedule) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534033 - Disclosure - Property, plant and equipment (Geographic Information) (Details)",
     "role": "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
     "shortName": "Property, plant and equipment (Geographic Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "if24c03a5fa36492bb701fd1cf35c078e_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i5a63a090508f49fdaacb88df082eb50b_D20211203-20211203",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ide4e5e657f16482091a0d8f7d0722737_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240564034 - Disclosure - Goodwill and other intangible assets - Goodwill Roll Forward (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails",
     "shortName": "Goodwill and other intangible assets - Goodwill Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574035 - Disclosure - Goodwill and other intangible assets - Identifiable Intangible Assets (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
     "shortName": "Goodwill and other intangible assets - Identifiable Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584036 - Disclosure - Goodwill and other intangible assets - Narrative (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails",
     "shortName": "Goodwill and other intangible assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614037 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.amgen.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624038 - Disclosure - Leases - Summary of Leases (Details)",
     "role": "http://www.amgen.com/role/LeasesSummaryofLeasesDetails",
     "shortName": "Leases - Summary of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634039 - Disclosure - Leases - Components of Lease Costs (Details)",
     "role": "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails",
     "shortName": "Leases - Components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644040 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "role": "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654041 - Disclosure - Leases - Cash and Noncash Information of Leases (Details)",
     "role": "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails",
     "shortName": "Leases - Cash and Noncash Information of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684042 - Disclosure - Other current assets and accrued liabilities - Schedule of Other Assets (Details)",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails",
     "shortName": "Other current assets and accrued liabilities - Schedule of Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedSalesDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694043 - Disclosure - Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails",
     "shortName": "Other current assets and accrued liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "amgn:AccruedSalesDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724044 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
     "shortName": "Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:MaximumBorrowingCapacityUnderCommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734045 - Disclosure - Financing arrangements (Debt Issuances) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
     "shortName": "Financing arrangements (Debt Issuances) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:MaximumBorrowingCapacityUnderCommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744046 - Disclosure - Financing arrangements (Debt Repayments) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
     "shortName": "Financing arrangements (Debt Repayments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ie0cbb29ec00d4533a3e1155ce9550ede_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754047 - Disclosure - Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
     "shortName": "Financing arrangements (Interest Rate and Cross-currency Swaps) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i165f3ecafa0a4de4b1c4b6db200d90b9_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "amgn:DerivativeNotionalAmountAmountTerminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i3f3f69cfacea4717a178488113e7724c_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764048 - Disclosure - Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails",
     "shortName": "Financing arrangements (Shelf Registration Statements and Other Facilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i3f3f69cfacea4717a178488113e7724c_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774049 - Disclosure - Financing arrangements (Contractual Maturities of Long-term Debt) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails",
     "shortName": "Financing arrangements (Contractual Maturities of Long-term Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i7b1dfb5d9a21406fb43a36399d97dd92_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784050 - Disclosure - Financing arrangements (Interest Costs) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails",
     "shortName": "Financing arrangements (Interest Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib32a5da7a4f04365b91a6d2fcf854d0f_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814051 - Disclosure - Stockholders' equity (Stock Repurchase Program) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails",
     "shortName": "Stockholders' equity (Stock Repurchase Program) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i5a63a090508f49fdaacb88df082eb50b_D20211203-20211203",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824052 - Disclosure - Stockholders' equity (Dividends) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityDividendsDetails",
     "shortName": "Stockholders' equity (Dividends) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ib7382715dfdf4662b65ce30d8d3fec73_D20211001-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "ide4e5e657f16482091a0d8f7d0722737_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834053 - Disclosure - Stockholders' equity (Components of AOCI) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
     "shortName": "Stockholders' equity (Components of AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20211231.htm",
      "contextRef": "i309108b032084722a376b8a102fdb202_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 178,
   "tag": {
    "amgn_A165NotesDue20281652028NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% notes due 2028 (1.65% 2028 Notes)",
        "label": "1.65% notes due 2028 (1.65% 2028 Notes) [Member]",
        "terseLabel": "1.65% notes due in 2028 (1.65% 2028 Notes)"
       }
      }
     },
     "localname": "A165NotesDue20281652028NotesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A190NotesDue20251902025NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.90% notes due 2025 (1.90% 2025 Notes)",
        "label": "1.90% notes due 2025 (1.90% 2025 Notes) [Member]",
        "terseLabel": "1.90% notes due 2025 (1.90% 2025 Notes)"
       }
      }
     },
     "localname": "A190NotesDue20251902025NotesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "terseLabel": "2.00% Senior Notes Due 2026"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A200NotesDue20322002032NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.00% notes due 2032 (2.00% 2032 Notes)",
        "label": "2.00% notes due 2032 (2.00% 2032 Notes) [Member]",
        "terseLabel": "2.00% notes due 2032 (2.00% 2032 Notes)"
       }
      }
     },
     "localname": "A200NotesDue20322002032NotesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A280NotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% notes due 2041",
        "label": "2.80% notes due 2041 [Member]",
        "terseLabel": "2.80% notes due 2041 (2.80% 2041 Notes)"
       }
      }
     },
     "localname": "A280NotesDue2041Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A300NotesDue20523002052NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.00% notes due 2052 (3.00% 2052 Notes)",
        "label": "3.00% notes due 2052 (3.00% 2052 Notes) [Member]",
        "terseLabel": "3.00% notes due 2052 (3.00% 2052 Notes)"
       }
      }
     },
     "localname": "A300NotesDue20523002052NotesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AMG340Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG 340",
        "label": "AMG 340 [Member]",
        "terseLabel": "AMG 340"
       }
      }
     },
     "localname": "AMG340Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AbandonedLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abandoned Leases [Member]",
        "label": "Abandoned Leases [Member]",
        "terseLabel": "Abandoned Leases [Member]"
       }
      }
     },
     "localname": "AbandonedLeasesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying values as of the balance sheet of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulated over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Other current assets and accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/Othercurrentassetsandaccruedliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities/other non-current liabilities.",
        "label": "Accrued Liabilities Other Non Current Liabilities [Member]",
        "verboseLabel": "Accrued liabilities/Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesOtherNonCurrentLiabilitiesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccruedSalesDeductionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales deductions, current.",
        "label": "Accrued Sales Deductions Current",
        "terseLabel": "Sales deductions"
       }
      }
     },
     "localname": "AccruedSalesDeductionsCurrent",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AccruedSalesReturnReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued sales return reserve, current.",
        "label": "Accrued Sales Return Reserve Current",
        "terseLabel": "Sales returns reserve"
       }
      }
     },
     "localname": "AccruedSalesReturnReserveCurrent",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AccumulatedOtherAdjustmentAttributabletoParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "label": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherAdjustmentAttributabletoParentMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AcquiredFinitelivedAssetsWeightedAverageUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Finite-lived Assets, Weighted Average Useful Life",
        "label": "Acquired Finite-lived Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired assets, weighted useful life"
       }
      }
     },
     "localname": "AcquiredFinitelivedAssetsWeightedAverageUsefulLife",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired research and development technology rights.",
        "label": "Acquired Research And Development Technology Rights [Member]",
        "terseLabel": "R&amp;D technology rights [Member]"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentTechnologyRightsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AlternativeInvestmentNetGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Net Gain (Loss)",
        "label": "Alternative Investment, Net Gain (Loss)",
        "terseLabel": "Alternative Investment, Net Gain (Loss)"
       }
      }
     },
     "localname": "AlternativeInvestmentNetGainLoss",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks.",
        "label": "Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks",
        "terseLabel": "Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks"
       }
      }
     },
     "localname": "AmountByWhichBorrowingCapacityUnderSyndicatedUnsecuredRevolvingCreditAgreementMayBeIncreasedUponOurRequestAtDiscretionOfBanks",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of common stock available under the plan for future grants and/or issuances.",
        "label": "Amount Of Common Stock Available Under Plan For Future Grants And Or Issuances",
        "terseLabel": "The amount of common stock available under the plan for future grants and/or issuances (in shares)"
       }
      }
     },
     "localname": "AmountOfCommonStockAvailableUnderPlanForFutureGrantsAndOrIssuances",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_ApprovedMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Approved Markets",
        "label": "Approved Markets",
        "terseLabel": "Approved markets"
       }
      }
     },
     "localname": "ApprovedMarkets",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_AranespMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aranesp.",
        "label": "Aranesp [Member]",
        "terseLabel": "Aranesp\u00ae (darbepoetin alfa) [Member]"
       }
      }
     },
     "localname": "AranespMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assembled Workforce [Member]",
        "label": "Assembled Workforce [Member]",
        "terseLabel": "Assembled Workforce"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AssetsByDescriptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets by description.",
        "label": "Assets By Description [Axis]",
        "terseLabel": "Assets By Description [Axis]"
       }
      }
     },
     "localname": "AssetsByDescriptionAxis",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_AssetsByDescriptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets by description.",
        "label": "Assets By Description [Domain]",
        "terseLabel": "Assets By Description [Domain]"
       }
      }
     },
     "localname": "AssetsByDescriptionDomain",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.amgen.com/20211231",
     "xbrltype": "stringItemType"
    },
    "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value",
        "label": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value",
        "terseLabel": "Maturing after one year through three years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AvailableForSalesInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sales investments.",
        "label": "Available For Sales Investments [Member]",
        "verboseLabel": "Available-for-sale investments [Member]"
       }
      }
     },
     "localname": "AvailableForSalesInvestmentsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BasicAndDilutedEarningPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earning per share.",
        "label": "Basic And Diluted Earning Per Share [Abstract]",
        "verboseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningPerShareAbstract",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_BeiGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BeiGene [Member]",
        "label": "BeiGene [Member]",
        "terseLabel": "BeiGene"
       }
      }
     },
     "localname": "BeiGeneMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BusinessCombinationContingentConsiderationArrangementsPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Payments",
        "label": "Business Combination, Contingent Consideration Arrangements, Payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsPayments",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 3.0,
       "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "label": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "terseLabel": "Additions",
        "verboseLabel": "Estimated fair values of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Credits",
        "terseLabel": "Adjustments to deferred credit"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredCredits",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities",
        "terseLabel": "Adjustments to deferred tax liability"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 1.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "terseLabel": "Fair value of assets acquired and liabilities assumed, net other assets and liabilities",
        "verboseLabel": "Other assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "label": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "totalLabel": "Total assets acquired, net"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionDeferredCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 4.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Deferred Credit",
        "label": "Business acquired asset acquisition, Deferred Credit",
        "negatedLabel": "Deferred credit"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionDeferredCredit",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionInventoryacquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 5.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Inventory acquired",
        "label": "Business acquired asset acquisition, Inventory acquired",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionInventoryacquired",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 6.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Noncurrent Liabilities Other",
        "label": "Business acquired asset acquisition, Noncurrent Liabilities Other",
        "negatedLabel": "Other liabilities, net"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionNoncurrentLiabilitiesOther",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_Businessassetacquisitionconsiderationtransferred": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business asset acquisition, consideration transferred",
        "label": "Business asset acquisition, consideration transferred",
        "totalLabel": "Business asset acquisition, consideration transferred"
       }
      }
     },
     "localname": "Businessassetacquisitionconsiderationtransferred",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_CollaborativeArrangementwithNovartisPharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Novartis Pharma AG [Member]",
        "label": "Collaborative Arrangement with Novartis Pharma AG [Member]",
        "terseLabel": "Collaborative Arrangement with Novartis AG [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementwithNovartisPharmaAGMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CommonStockFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The closing price of our common stock on grant date used to estimate the grant date fair value of our stock-based compensation.",
        "label": "Common Stock Fair Value",
        "terseLabel": "Closing price of our common stock on grant date (in usd per share)"
       }
      }
     },
     "localname": "CommonStockFairValue",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amgn_ComponentsOfStockBasedCompensationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of stock-based compensation expense recognized in the Consolidated Statements of Income.",
        "label": "Components of Stock based Compensation Expense [Table Text Block]",
        "terseLabel": "Components of stock-based compensation expense recognized in the Consolidated Statements of Income"
       }
      }
     },
     "localname": "ComponentsOfStockBasedCompensationExpenseTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_CrossCurrencySwapContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross currency swap contracts.",
        "label": "Cross Currency Swap Contracts [Member]",
        "terseLabel": "Cross-currency swap contract [Member]",
        "verboseLabel": "Cross-currency swap contracts [Member]"
       }
      }
     },
     "localname": "CrossCurrencySwapContractsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "AmerisourceBergen Corporation [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer three.",
        "label": "Customer Three [Member]",
        "terseLabel": "Cardinal Health, Inc. [Member]"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two [Member]",
        "terseLabel": "McKesson Corporation [Member]"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_DebtExchangeAdditionalCashConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt exchange additional cash consideration paid",
        "label": "Debt exchange additional cash consideration",
        "terseLabel": "Debt exchange additional cash consideration"
       }
      }
     },
     "localname": "DebtExchangeAdditionalCashConsideration",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "label": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "terseLabel": "Redemption period without payment of make whole amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodwithoutPaymentofMakeWholeAmount",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from acquired net operating loss and credit carryforwards and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.",
        "label": "Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards",
        "terseLabel": "NOL and credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DerivativeAssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative assets.",
        "label": "Derivative Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeAssetsFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial instruments liabilities fair value disclosure.",
        "label": "Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]",
        "verboseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DerivativeInstrumentAggregateNotionalAmountOfNewInstruments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Aggregate Notional Amount of New Instruments",
        "label": "Derivative Instrument, Aggregate Notional Amount of New Instruments",
        "terseLabel": "Derivative Instrument, Aggregate Notional Amount of New Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentAggregateNotionalAmountOfNewInstruments",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DerivativeInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Term",
        "label": "Derivative Instrument, Term",
        "terseLabel": "Derivative Instrument, Term"
       }
      }
     },
     "localname": "DerivativeInstrumentTerm",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_DerivativeNotionalAmountAmountTerminated": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Notional Amount, Amount Terminated",
        "label": "Derivative, Notional Amount, Amount Terminated",
        "terseLabel": "Derivative, Notional Amount, Amount Terminated"
       }
      }
     },
     "localname": "DerivativeNotionalAmountAmountTerminated",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities",
        "label": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities",
        "terseLabel": "Derivative, Notional Amount, Amount Terminated Resulting In Net Cash Provided By Operating Activities"
       }
      }
     },
     "localname": "DerivativeNotionalAmountAmountTerminatedResultingInNetCashProvidedByOperatingActivities",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate",
        "label": "Effective Income Tax Rate Reconciliation, Estimated Blended Statutory Rate",
        "terseLabel": "Estimated blended statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEstimatedBlendedStatutoryRate",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Interest On Uncertain Tax Positions, Percent",
        "terseLabel": "Interest on uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInterestOnUncertainTaxPositionsPercent",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ENBREL.",
        "label": "ENBREL [Member]",
        "terseLabel": "Enbrel\u00ae (etanercept) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_EquityInvestmentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the policy for investments in equity securities that are publicly traded and that do not have a readily determinable fair value.",
        "label": "Equity investments, policy [Policy Text Block]",
        "terseLabel": "Equity investments, policy"
       }
      }
     },
     "localname": "EquityInvestmentsPolicyPolicyTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "label": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquityMethodInvestmentChangeInCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, change in carrying value",
        "label": "Equity method investment, change in carrying value",
        "terseLabel": "Equity method investment, change in carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestmentChangeInCarryingValue",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquityMethodInvestmentChangeInCarryingValueOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Change In Carrying Value, Other",
        "label": "Equity Method Investment, Change In Carrying Value, Other",
        "terseLabel": "Equity Method Investment, Change In Carrying Value, Other"
       }
      }
     },
     "localname": "EquityMethodInvestmentChangeInCarryingValueOther",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquitySecuritiesRealizedGainLossOnDisposal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Realized Gain (Loss) on Disposal",
        "label": "Equity Securities, Realized Gain (Loss) on Disposal",
        "terseLabel": "Equity Securities, Realized Gain (Loss) on Disposal"
       }
      }
     },
     "localname": "EquitySecuritiesRealizedGainLossOnDisposal",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ExpirationInTaxYearsBetween2023And2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration in tax years between 2023 and 2040",
        "label": "Expiration in tax years between 2023 and 2040 [Member]",
        "terseLabel": "Expiration in tax years between 2023 and 2040"
       }
      }
     },
     "localname": "ExpirationInTaxYearsBetween2023And2040Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.",
        "label": "Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Consolidated Balance Sheets locations"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.",
        "label": "Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]",
        "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.",
        "label": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FavorableContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Favorable Contract",
        "label": "Favorable Contract [Member]",
        "terseLabel": "Favorable Contract"
       }
      }
     },
     "localname": "FavorableContractMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "label": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "terseLabel": "5.50% \u00a3475 million notes due 2026 (5.50% 2026 pound sterling Notes)",
        "verboseLabel": "5.50% 2026 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FivePointFiveZeroPercentPoundSterlingNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointOneFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point One Five Percent Notes Due 2041 [Member]",
        "label": "Five Point One Five Percent Notes Due 2041 [Member]",
        "terseLabel": "5.15% notes due 2041 (5.15% 2041 Notes)"
       }
      }
     },
     "localname": "FivePointOneFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSevenFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "label": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "terseLabel": "5.75% notes due 2040 (5.75% 2040 Notes)"
       }
      }
     },
     "localname": "FivePointSevenFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSevenZeroPercentNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Seven Zero Percent Notes Due 2019 [Member]",
        "label": "Five Point Seven Zero Percent Notes Due 2019 [Member]",
        "terseLabel": "5.70% notes due 2019 (5.70% 2019 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointSevenZeroPercentNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSixFivePercentNotesDue2042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "label": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "terseLabel": "5.65% notes due 2042 (5.65% 2042 Notes)"
       }
      }
     },
     "localname": "FivePointSixFivePercentNotesDue2042Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointThreeSevenFivePercentNotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "label": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "terseLabel": "5.375% notes due 2043 (5.375% 2043 Notes)"
       }
      }
     },
     "localname": "FivePointThreeSevenFivePercentNotesDue2043Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePrimeTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Prime Therapeutics, Inc.",
        "label": "Five Prime Therapeutics, Inc. [Member]",
        "terseLabel": "Five Prime Therapeutics, Inc."
       }
      }
     },
     "localname": "FivePrimeTherapeuticsIncMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FixedEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed equipment",
        "label": "Fixed equipment",
        "terseLabel": "Fixed equipment"
       }
      }
     },
     "localname": "FixedEquipment",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_FixedEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed equipment",
        "label": "Fixed equipment [Member]",
        "verboseLabel": "Fixed equipment [Member]"
       }
      }
     },
     "localname": "FixedEquipmentMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FloatingRateNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes Due 2019 [Member]",
        "label": "Floating Rate Notes Due 2019 [Member]",
        "terseLabel": "Floating Rate Notes Due 2019 [Member]"
       }
      }
     },
     "localname": "FloatingRateNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FloatingRateNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes Due 2020 [Member]",
        "label": "Floating Rate Notes Due 2020 [Member]",
        "terseLabel": "Floating Rate Notes Due 2020"
       }
      }
     },
     "localname": "FloatingRateNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ForeignCurrencyAndCrossCurrencySwapsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency and cross currency swaps.",
        "label": "Foreign Currency and Cross Currency Swaps [Member]",
        "verboseLabel": "Foreign currency and cross currency swap contracts [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyAndCrossCurrencySwapsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPercentPoundSterlingNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "label": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "terseLabel": "4.00% \u00a3700 million notes due 2029 (4.00% 2029 pound sterling Notes)",
        "verboseLabel": "4.00% 2029 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FourPercentPoundSterlingNotesDue2029Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "label": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "terseLabel": "4.563% notes due 2048 (4.563% 2048 Notes)"
       }
      }
     },
     "localname": "FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFiveZeroPercentNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Zero Percent Notes Due 2020 [Member]",
        "label": "Four Point Five Zero Percent Notes Due 2020 [Member]",
        "terseLabel": "4.50% notes due 2020 (4.50% 2020 Notes)"
       }
      }
     },
     "localname": "FourPointFiveZeroPercentNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "label": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "terseLabel": "4.40% notes due 2045 (4.40% 2045 Notes)"
       }
      }
     },
     "localname": "FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointNineFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "label": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "verboseLabel": "4.95% notes due 2041 (4.95% 2041 Notes)"
       }
      }
     },
     "localname": "FourPointNineFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointOneZeroPercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "label": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "terseLabel": "4.10% notes due 2021 (4.10% 2021 Notes)"
       }
      }
     },
     "localname": "FourPointOneZeroPercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "label": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "terseLabel": "4.663% notes due 2051 (4.663% 2051 Notes)"
       }
      }
     },
     "localname": "FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_GainContingencyNumberOfAgreementsBreached": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Agreements Breached",
        "label": "Gain Contingency, Number Of Agreements Breached",
        "terseLabel": "Agreements breached"
       }
      }
     },
     "localname": "GainContingencyNumberOfAgreementsBreached",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberOfChallenges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Challenges",
        "label": "Gain Contingency, Number Of Challenges",
        "terseLabel": "Number of challenges"
       }
      }
     },
     "localname": "GainContingencyNumberOfChallenges",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberofAffiliates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Affiliates",
        "label": "Gain Contingency, Number of Affiliates",
        "terseLabel": "Gain contingency, number of affiliates"
       }
      }
     },
     "localname": "GainContingencyNumberofAffiliates",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_GainContingencyNumberofLawsuitsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Lawsuits Filed",
        "label": "Gain Contingency, Number of Lawsuits Filed",
        "terseLabel": "Number of lawsuits filed"
       }
      }
     },
     "localname": "GainContingencyNumberofLawsuitsFiled",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_HedgedLiabilityDiscontinuedFairValueHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Liability, Discontinued Fair Value Hedge",
        "label": "Hedged Liability, Discontinued Fair Value Hedge",
        "terseLabel": "Carrying value with discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedge",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_HumiraBiosimilarAntitrustClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humira Biosimilar Antitrust Class Actions [Member]",
        "label": "Humira Biosimilar Antitrust Class Actions [Member]",
        "terseLabel": "Humira Biosimilar Antitrust Class Actions"
       }
      }
     },
     "localname": "HumiraBiosimilarAntitrustClassActionsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_IdentifiableIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets accumulated amortization.",
        "label": "Identifiable Intangible Assets Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_IdentifiableIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets gross.",
        "label": "Identifiable Intangible Assets Gross",
        "totalLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsGross",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ImmunexAndSamsungBioepisCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunex And Samsung Bioepis Co.",
        "label": "Immunex And Samsung Bioepis Co. [Member]",
        "terseLabel": "Immunex/Samsung Bioepis Co."
       }
      }
     },
     "localname": "ImmunexAndSamsungBioepisCoMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_IncreaseDecreaseInNoncurrentTaxLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Noncurrent Tax Liability",
        "label": "Increase (Decrease) In Noncurrent Tax Liability",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentTaxLiability",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_InterestRateSwapAtThenCurrentInterestRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, At-Then Current Interest Rates [Member]",
        "label": "Interest Rate Swap, At-Then Current Interest Rates [Member]",
        "terseLabel": "Interest Rate Swap, At-Then Current Interest Rates [Member]"
       }
      }
     },
     "localname": "InterestRateSwapAtThenCurrentInterestRatesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap [Axis]",
        "label": "Interest Rate Swap [Axis]",
        "terseLabel": "Interest Rate Swap [Axis]"
       }
      }
     },
     "localname": "InterestRateSwapAxis",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_InterestRateSwapDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap",
        "label": "Interest Rate Swap [Domain]",
        "terseLabel": "Interest Rate Swap [Domain]"
       }
      }
     },
     "localname": "InterestRateSwapDomain",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, One [Member]",
        "label": "Interest Rate Swap, One [Member]",
        "terseLabel": "Interest Rate Swap, One [Member]"
       }
      }
     },
     "localname": "InterestRateSwapOneMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_InterestRateSwapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap, Two [Member]",
        "label": "Interest Rate Swap, Two [Member]",
        "terseLabel": "Interest Rate Swap, Two [Member]"
       }
      }
     },
     "localname": "InterestRateSwapTwoMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KyowaKirinCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin Co. Ltd.",
        "label": "Kyowa Kirin Co. Ltd. [Member]",
        "terseLabel": "Kyowa Kirin Co. Ltd."
       }
      }
     },
     "localname": "KyowaKirinCoLtdMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KyprolisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyprolis [Member]",
        "label": "Kyprolis [Member]",
        "terseLabel": "Kyprolis [Member]"
       }
      }
     },
     "localname": "KyprolisMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LaboratoryEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of laboratory equipment, gross.",
        "label": "Laboratory Equipment",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipment",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount",
        "terseLabel": "Total undiscounted future lease payment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Abandoned Leases",
        "terseLabel": "Future rental commitments for abandoned leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAbandonedLeases",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LineOfCreditFacilityExtensionOfCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Extension of Commitment Term",
        "label": "Line of Credit Facility, Extension of Commitment Term",
        "terseLabel": "Additional period for extension of commitment term"
       }
      }
     },
     "localname": "LineOfCreditFacilityExtensionOfCommitmentTerm",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LineOfCreditFacilityInitialCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Initial Commitment Term",
        "label": "Line of Credit Facility, Initial Commitment Term",
        "terseLabel": "Initial commitment term of each bank which is a party to the agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityInitialCommitmentTerm",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LineofCreditFacilityNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number Of Renewal Options",
        "label": "Line of Credit Facility, Number Of Renewal Options",
        "terseLabel": "Number of additional term extension options"
       }
      }
     },
     "localname": "LineofCreditFacilityNumberOfRenewalOptions",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LitigationSettlementLengthofTrial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Length of Trial",
        "label": "Litigation Settlement, Length of Trial",
        "terseLabel": "Length of trial"
       }
      }
     },
     "localname": "LitigationSettlementLengthofTrial",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Current Maturities [Member]",
        "label": "Long-Term Debt, Current Maturities [Member]",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of long-term debt following the date of the latest balance sheet presented in the financial statements which may include maturities of long-term debt, sinking fund requirements and other securities redeemable of fixed or determinable prices and dates.",
        "label": "Long Term Debt Maturities Repayments Of Principal Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LossContingencyNumberOfComplaintsStayedByTheCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Complaints Stayed By The Court",
        "label": "Loss Contingency, Number Of Complaints Stayed By The Court",
        "terseLabel": "Number of complaints stayed"
       }
      }
     },
     "localname": "LossContingencyNumberOfComplaintsStayedByTheCourt",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LossContingencyNumberOfLawsuitsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Lawsuits Filed",
        "label": "Loss Contingency, Number of Lawsuits Filed",
        "terseLabel": "Loss contingency, number of lawsuits filed"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuitsFiled",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing equipment.",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_MarketingRelatedRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-Related Rights [Member]",
        "label": "Marketing-Related Rights [Member]",
        "terseLabel": "Marketing-Related Rights"
       }
      }
     },
     "localname": "MarketingRelatedRightsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_MaximumBorrowingCapacityUnderCommercialPaper": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Borrowing Capacity Under Commercial Paper Program.",
        "label": "Maximum Borrowing Capacity Under Commercial Paper",
        "terseLabel": "Commercial paper, maximum borrowing capacity"
       }
      }
     },
     "localname": "MaximumBorrowingCapacityUnderCommercialPaper",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_MoleculeTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecule, Type",
        "label": "Molecule, Type [Axis]",
        "terseLabel": "Molecule, Type [Axis]"
       }
      }
     },
     "localname": "MoleculeTypeAxis",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_MoleculeTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecule, Type [Domain]",
        "label": "Molecule, Type [Domain]",
        "terseLabel": "Molecule, Type [Domain]"
       }
      }
     },
     "localname": "MoleculeTypeDomain",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as \"predominately\", \"about equally\", or \"major and other\". This element is also referred to as \"Business Description\".",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "Business"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta\u00ae (pegfilgrastim) [Member]"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NeumoraTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neumora Therapeutics, Inc.",
        "label": "Neumora Therapeutics, Inc. [Member]",
        "terseLabel": "Neumora Therapeutics, Inc."
       }
      }
     },
     "localname": "NeumoraTherapeuticsIncMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NovartisBreachOfContractActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Breach Of Contract Action [Member]",
        "label": "Novartis Breach Of Contract Action [Member]",
        "terseLabel": "Novartis Breach Of Contract Action"
       }
      }
     },
     "localname": "NovartisBreachOfContractActionMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NplateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nplate",
        "label": "Nplate [Member]",
        "terseLabel": "Nplate"
       }
      }
     },
     "localname": "NplateMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NuevolutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuevolution [Member]",
        "label": "Nuevolution [Member]",
        "terseLabel": "Nuevolution"
       }
      }
     },
     "localname": "NuevolutionMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NumberOfCommonSharesIssuedForEachPerformanceUnitEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issued for each performance unit earned.",
        "label": "Number of Common Shares Issued for Each Performance Unit Earned",
        "terseLabel": "Number of common shares issued for each performance unit earned"
       }
      }
     },
     "localname": "NumberOfCommonSharesIssuedForEachPerformanceUnitEarned",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCommonSharesToBeReducedForEachStockOptionGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the pool of available shares will be reduced for each stock option granted.",
        "label": "Number Of Common Shares To Be Reduced For Each Stock Option Granted",
        "terseLabel": "Amount by which the pool of available shares will be reduced for each stock option granted"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReducedForEachStockOptionGranted",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the pool of available shares will be reduced for other types of awards granted.",
        "label": "Number of Common Shares to be Reduced For Other Types Of Awards Granted",
        "terseLabel": "The number of shares by which the pool of available shares will be reduced for other types of awards granted"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReducedForOtherTypesOfAwardsGranted",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major customers (as defined) accounting for more than 10% of gross trade receivables.",
        "label": "Number of Customers Accounting for More Than Ten Percent of Gross Trade Receivables",
        "terseLabel": "Major customers (as defined) accounting for more than 10% of gross trade receivables"
       }
      }
     },
     "localname": "NumberOfCustomersAccountingForMoreThanTenPercentOfGrossTradeReceivables",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major customers (as defined) accounting for more than 10% of total revenue.",
        "label": "Number of Customers Accounting for More Than Ten Percent of Revenue",
        "terseLabel": "Number of major customers (as defined) accounting for more than 10% of total revenue"
       }
      }
     },
     "localname": "NumberOfCustomersAccountingForMoreThanTenPercentOfRevenue",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfNoticesOnProposedAdditionalTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of notices on proposed additional tax",
        "label": "Number of notices on proposed additional tax",
        "terseLabel": "Number of notices on proposed additional tax"
       }
      }
     },
     "localname": "NumberOfNoticesOnProposedAdditionalTax",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberofSharesAddedBackforTaxWithholdingonFullValueAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Shares Added Back for Tax Withholding on Full Value Awards",
        "label": "Number of Shares Added Back for Tax Withholding on Full Value Awards",
        "terseLabel": "Number of shares added back for tax withholding on full value awards"
       }
      }
     },
     "localname": "NumberofSharesAddedBackforTaxWithholdingonFullValueAwards",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "label": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "terseLabel": "1.85% notes due 2021 (1.85% 2021 Notes)"
       }
      }
     },
     "localname": "OnePointEightFivePercentNotesDueTwoZeroTwoOneMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointNineZeroNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Nine Zero Notes Due 2019 [Member]",
        "label": "One Point Nine Zero Notes Due 2019 [Member]",
        "terseLabel": "1.90% notes due 2019 (1.90% 2019 Notes) [Member]"
       }
      }
     },
     "localname": "OnePointNineZeroNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "label": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "terseLabel": "1.25% 2022 euro Notes [Member]"
       }
      }
     },
     "localname": "OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five Percent Notes Due Two Zero Two Two",
        "label": "One Point Two Five Percent Notes Due Two Zero Two Two [Member]",
        "terseLabel": "1.25% notes due 2022 (1.25% 2022 Notes)"
       }
      }
     },
     "localname": "OnePointTwoFivePercentNotesDueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OperatingLossesThatExpireBetween2022And2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Losses That Expire Between 2022 and 2031",
        "label": "Operating Losses That Expire Between 2022 and 2031 [Member]",
        "terseLabel": "Operating Losses That Expire Between 2022 and 2031"
       }
      }
     },
     "localname": "OperatingLossesThatExpireBetween2022And2031Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OperatingLossesThatExpireBetween2022And2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Losses That Expire Between 2022 and 2037",
        "label": "Operating Losses That Expire Between 2022 and 2037 [Member]",
        "terseLabel": "Operating Losses That Expire Between 2022 and 2037"
       }
      }
     },
     "localname": "OperatingLossesThatExpireBetween2022And2037Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtezlaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otezla [Member]",
        "label": "Otezla [Member]",
        "terseLabel": "Otezla",
        "verboseLabel": "Otezla [Member]"
       }
      }
     },
     "localname": "OtezlaMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "label": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "terseLabel": "Other gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "label": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherCurrentNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current assets/other non-current assets.",
        "label": "Other Current Noncurrent Assets [Member]",
        "verboseLabel": "Other current assets/Other assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentNoncurrentAssetsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherNotesDue2097Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Notes Due 2097 [Member]",
        "label": "Other Notes Due 2097 [Member]",
        "terseLabel": "Other notes due 2097"
       }
      }
     },
     "localname": "OtherNotesDue2097Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other products [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherShortTermInterestBearingSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term interest bearing securities.",
        "label": "Other Short Term Interest Bearing Securities [Member]",
        "terseLabel": "Other short-term interest-bearing securities [Member]"
       }
      }
     },
     "localname": "OtherShortTermInterestBearingSecuritiesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_PercentageOfCombinedNetTradeReceivablesFromMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables.",
        "label": "Percentage of Combined Net Trade Receivables from Major Customers",
        "terseLabel": "Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables"
       }
      }
     },
     "localname": "PercentageOfCombinedNetTradeReceivablesFromMajorCustomers",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis.",
        "label": "Percentage Of Combined Worldwide Gross Revenues From Major Customers",
        "terseLabel": "Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis"
       }
      }
     },
     "localname": "PercentageOfCombinedWorldwideGrossRevenuesFromMajorCustomers",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfGrossRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross product sales to major customer (as defined) as a percentage of total gross revenues.",
        "label": "Percentage of Gross Revenues",
        "terseLabel": "Gross product sales to major customer (as defined) as a percentage of total gross revenues"
       }
      }
     },
     "localname": "PercentageOfGrossRevenues",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net trade receivables due from customers located outside the United States, primarily in Europe.",
        "label": "Percentage of Net Amount Due from Customers Located Outside Domestic Location",
        "terseLabel": "Percentage of net trade receivables due from customers located outside the United States, primarily in Europe"
       }
      }
     },
     "localname": "PercentageOfNetAmountDueFromCustomersLocatedOutsideDomesticLocation",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "label": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "terseLabel": "Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event"
       }
      }
     },
     "localname": "PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PerformanceUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Units.",
        "label": "Performance Units [Member]",
        "verboseLabel": "Performance units [Member]"
       }
      }
     },
     "localname": "PerformanceUnitsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ProfitAndLossShareOfExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit and loss share of expenses",
        "label": "Profit and loss share of expenses",
        "terseLabel": "Profit and loss share of expenses"
       }
      }
     },
     "localname": "ProfitAndLossShareOfExpenses",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ProliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prolia.",
        "label": "Prolia [Member]",
        "terseLabel": "Prolia\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "ProliaMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ProposedAdditionalIncomeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proposed additional income tax",
        "label": "Proposed additional income tax",
        "terseLabel": "Proposed additional income tax"
       }
      }
     },
     "localname": "ProposedAdditionalIncomeTax",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RDTechnologyrightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R &amp; D Technology rights [Member]",
        "label": "R &amp; D Technology rights [Member]",
        "terseLabel": "R &amp; D Technology rights"
       }
      }
     },
     "localname": "RDTechnologyrightsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RepathaevolocumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatha (evolocumab) [Member]",
        "label": "Repatha (evolocumab) [Member]",
        "terseLabel": "Repatha (evolocumab) [Member]"
       }
      }
     },
     "localname": "RepathaevolocumabMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RepatriationTaxOnProposedAdditionalTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatriation tax on proposed additional tax",
        "label": "Repatriation tax on proposed additional tax",
        "terseLabel": "Repatriation tax on proposed additional tax"
       }
      }
     },
     "localname": "RepatriationTaxOnProposedAdditionalTax",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest Of World [Member]",
        "label": "Rest Of World [Member]",
        "terseLabel": "ROW [Member]"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RevenuePaymentArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Payment Arrangement, Term",
        "label": "Revenue Payment Arrangement, Term",
        "terseLabel": "Revenue payment term"
       }
      }
     },
     "localname": "RevenuePaymentArrangementTerm",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Future Milestone Payment",
        "label": "Revenue Recognition, Milestone Method, Potential Future Milestone Payment",
        "terseLabel": "Potential future milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayment",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Future Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Future Milestone payments",
        "terseLabel": "Revenue Recognition, Milestone Method, Potential Future Milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialFutureMilestonePayments",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_SalesReturnProvisionsAsPercentageOfProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Return Provisions As Percentage Of Product Sales",
        "label": "Sales Return Provisions As Percentage Of Product Sales",
        "terseLabel": "Sales return provisions as a percentage of gross product sales (less than)"
       }
      }
     },
     "localname": "SalesReturnProvisionsAsPercentageOfProductSales",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_SandozIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sandoz Inc.",
        "label": "Sandoz Inc. [Member]",
        "terseLabel": "Sandoz Inc."
       }
      }
     },
     "localname": "SandozIncMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SanofiRegeneronPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi/Regeneron Patent Litigation [Member]",
        "label": "Sanofi/Regeneron Patent Litigation [Member]",
        "terseLabel": "Sanofi/Regeneron Patent Litigation"
       }
      }
     },
     "localname": "SanofiRegeneronPatentLitigationMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.",
        "label": "Schedule Of Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of identifiable intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Long-term Debt Instruments Exchanged [Table]",
        "label": "Schedule of Long-term Debt Instruments Exchanged [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments Exchanged"
       }
      }
     },
     "localname": "ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps",
        "label": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]",
        "terseLabel": "Schedule of notional amounts and interest rates for cross-currency swaps"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]",
        "label": "Schedule Of U.S. Repatriation Tax Commitments [Table Text Block]",
        "terseLabel": "U.S. repatriation tax commitments"
       }
      }
     },
     "localname": "ScheduleOfUSRepatriationTaxCommitmentsTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_SensiparAntitrustClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensipar Antitrust Class Actions [Member]",
        "label": "Sensipar Antitrust Class Actions [Member]",
        "terseLabel": "Sensipar Antitrust Class Actions"
       }
      }
     },
     "localname": "SensiparAntitrustClassActionsMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted-average assumptions used and the resulting weighted-average grant date fair value of performance units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Performance Units Fair Value Assumptions [Table Text Block]",
        "terseLabel": "Weighted average assumptions used and the resulting weighted average grant date fair value of performance units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceUnitsFairValueAssumptionsTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_SixPointFourZeroPercentNotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "label": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "terseLabel": "6.40% notes due 2039 (6.40% 2039 Notes)"
       }
      }
     },
     "localname": "SixPointFourZeroPercentNotesDue2039Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointNineZeroPercentNotesDue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "label": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "terseLabel": "6.90% notes due 2038 (6.90% 2038 Notes)"
       }
      }
     },
     "localname": "SixPointNineZeroPercentNotesDue2038Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointThreeSevenFivePercentNotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "label": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "terseLabel": "6.375% notes due 2037 (6.375% 2037 Notes)"
       }
      }
     },
     "localname": "SixPointThreeSevenFivePercentNotesDue2037Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_StockBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total stock-based compensation expense, net of tax.",
        "label": "Stock Based Compensation Expense Net of Tax",
        "totalLabel": "Total stock-based compensation expense, net of tax"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseNetOfTax",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_StockRepurchaseProgramTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchase Program [Table Text Block]",
        "label": "Stock Repurchase Program [Table Text Block]",
        "verboseLabel": "Summary of activity under our stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramTableTextBlock",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability, Total",
        "label": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
        "totalLabel": "Total remaining U.S. repatriation tax commitments"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Number of Annual Installments",
        "terseLabel": "U.S. repatriation tax commitments, number of annual installments"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingNumberofAnnualInstallments",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Four Years",
        "terseLabel": "U.S. repatriation tax commitments, 2025"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInFourYears",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Three Years",
        "terseLabel": "U.S. repatriation tax commitments, 2024"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInThreeYears",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, In Two Years",
        "terseLabel": "U.S. repatriation tax commitments, 2023"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityInTwoYears",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "amgn_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months",
        "terseLabel": "U.S. repatriation tax commitments, 2022"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsUSRepatriationTaxCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TeneobioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teneobio, Inc.",
        "label": "Teneobio, Inc. [Member]",
        "terseLabel": "Teneobio, Inc."
       }
      }
     },
     "localname": "TeneobioIncMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TeneobioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teneobio",
        "label": "Teneobio [Member]",
        "terseLabel": "Teneobio"
       }
      }
     },
     "localname": "TeneobioMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointEightSevenFivePercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "label": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "terseLabel": "3.875% notes due 2021 (3.875% 2021 Notes)"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointFourFivePercentNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "label": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "terseLabel": "3.45% notes due 2020 (3.45% 2020 Notes)"
       }
      }
     },
     "localname": "ThreePointFourFivePercentNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Five Percent Notes Due 2040 [Member]",
        "label": "Three Point One Five Percent Notes Due 2040 [Member]",
        "terseLabel": "3.15% notes due 2040 (3.15% 2040 Notes)"
       }
      }
     },
     "localname": "ThreePointOneFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "label": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "terseLabel": "3.125% notes due 2025 (3.125% 2025 Notes)"
       }
      }
     },
     "localname": "ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "terseLabel": "3.625% notes due 2022 (3.625% 2022 Notes)"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "terseLabel": "3.625% notes due 2024 (3.625% 2024 Notes)"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2024Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointThreeSevenFivePercentNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "label": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "terseLabel": "3.375% notes due 2050 (3.375% 2050 Notes)"
       }
      }
     },
     "localname": "ThreePointThreeSevenFivePercentNotesDue2050Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointTwoZeroNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Two Zero Notes Due 2027 [Member]",
        "label": "Three Point Two Zero Notes Due 2027 [Member]",
        "terseLabel": "3.20% notes due 2027 (3.20% 2027 Notes)"
       }
      }
     },
     "localname": "ThreePointTwoZeroNotesDue2027Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_Transactioncostsassetacquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 2.0,
       "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs, asset acquisition",
        "label": "Transaction costs, asset acquisition",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "Transactioncostsassetacquisition",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "label": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "terseLabel": "2.00% \u20ac750 million notes due 2026 (2.00% 2026 euro Notes)"
       }
      }
     },
     "localname": "TwoPercentEuroNotesDueTwoThousandTwentySixMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointEightZeroPercent2041NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two point eight zero percent 2041 Notes",
        "label": "Two point eight zero percent 2041 Notes [Member]",
        "terseLabel": "2.80% notes due 2041 (2.80% 2041 Notes)"
       }
      }
     },
     "localname": "TwoPointEightZeroPercent2041NotesMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointFourFivePercentNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "label": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "terseLabel": "2.45% notes due 2030 (2.45% 2030 Notes)"
       }
      }
     },
     "localname": "TwoPointFourFivePercentNotesDue2030Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointOneTwoFivePercentEuroNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Two Five Percent Euro Notes Due 2019 [Member]",
        "label": "Two Point One Two Five Percent Euro Notes Due 2019 [Member]",
        "terseLabel": "2.125% 2019 Euro Notes"
       }
      }
     },
     "localname": "TwoPointOneTwoFivePercentEuroNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]",
        "label": "Two Point One Two Five Percent Notes Due Two Zero Two Zero [Member]",
        "terseLabel": "2.125% notes due 2020 (2.125% 2020 Notes)"
       }
      }
     },
     "localname": "TwoPointOneTwoFivePercentNotesDueTwoZeroTwoZeroMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Seven Percent Notes Due Two Zero Five Three",
        "label": "Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]",
        "terseLabel": "2.77% notes due 2053 (2.77% 2053 Notes)"
       }
      }
     },
     "localname": "TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenZeroPercentNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Percent Notes Due Two Zero Two Two",
        "label": "Two Point Seven Zero Percent Notes Due 2022 [Member]",
        "terseLabel": "2.70% notes due 2022 (2.70% 2022 Notes)"
       }
      }
     },
     "localname": "TwoPointSevenZeroPercentNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]",
        "label": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]",
        "terseLabel": "2.70% notes due 2022 (2.70% 2022 Notes)"
       }
      }
     },
     "localname": "TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixFiveNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Five Notes Due 2022 [Member]",
        "label": "Two Point Six Five Notes Due 2022 [Member]",
        "terseLabel": "2.65% notes due 2022 (2.65% 2022 Notes)"
       }
      }
     },
     "localname": "TwoPointSixFiveNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Five Percent Notes Due Two Zero Two Two",
        "label": "Two Point Six Five Percent Notes Due Two Zero Two Two [Member]",
        "terseLabel": "2.65% notes due 2022 (2.65% 2022 Notes)"
       }
      }
     },
     "localname": "TwoPointSixFivePercentNotesDueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "label": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "terseLabel": "2.60% notes due 2026 (2.60% 2026 Notes)",
        "verboseLabel": "2.600% notes due 2026 (2.60% 2026 notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSixZeroNotesDueTwoZeroTwoSixMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointThreeZeroPercentNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Three Zero Percent Notes Due 2031",
        "label": "Two Point Three Zero Percent Notes Due 2031 [Member]",
        "terseLabel": "2.30% notes due 2031 (2.30% 2031 Notes)"
       }
      }
     },
     "localname": "TwoPointThreeZeroPercentNotesDue2031Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "label": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "terseLabel": "2.25% notes due 2023 (2.25% 2023 Notes)"
       }
      }
     },
     "localname": "TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Notes Due 2020 [Member]",
        "label": "Two Point Two Zero Notes Due 2020 [Member]",
        "terseLabel": "2.20% notes due 2020 (2.20% 2020 Notes)"
       }
      }
     },
     "localname": "TwoPointTwoZeroNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroPercentNotesDue2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Notes Due 2019 [Member]",
        "label": "Two Point Two Zero Percent Notes Due 2019 [Member]",
        "terseLabel": "2.20% notes due 2019 (2.20% 2019 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentNotesDue2019Member",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "label": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "terseLabel": "2.20% notes due 2027 (2.20% 2027 Notes)"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointZeroPercent2032NotesMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two point zero percent 2032 Notes Member",
        "label": "Two point zero percent 2032 Notes Member [Member]",
        "terseLabel": "2.00% notes due 2032 (2.00% 2032 Notes)"
       }
      }
     },
     "localname": "TwoPointZeroPercent2032NotesMemberMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front payment",
        "label": "Up-front payment",
        "terseLabel": "Up-front payment"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_XgevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XGEVA.",
        "label": "XGEVA [Member]",
        "terseLabel": "XGEVA\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "XgevaMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "label": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "terseLabel": "0.41% Swiss Franc Bonds Due 2023 (0.41% 2023 Swiss franc Bonds)"
       }
      }
     },
     "localname": "ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember",
     "nsuri": "http://www.amgen.com/20211231",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PUERTO RICO",
        "verboseLabel": "Puerto Rico [Member]"
       }
      }
     },
     "localname": "PR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US [Member]",
        "verboseLabel": "US [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "verboseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Switzerland, Francs [Member]"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "United Kingdom, Pounds [Member]"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "United States of America, Dollars [Member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XNGS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "terseLabel": "The NASDAQ Global Select Market"
       }
      }
     },
     "localname": "XNGS",
     "nsuri": "http://xbrl.sec.gov/exch/2021",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "New York Stock Exchange"
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2021",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r67",
      "r69",
      "r145",
      "r146",
      "r352",
      "r392",
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r159",
      "r167",
      "r173",
      "r267",
      "r502",
      "r503",
      "r504",
      "r548",
      "r549",
      "r633",
      "r636",
      "r638",
      "r639",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect of changes in accounting principles, net of taxes"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r159",
      "r167",
      "r173",
      "r267",
      "r502",
      "r503",
      "r504",
      "r548",
      "r549",
      "r633",
      "r636",
      "r638",
      "r639",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r159",
      "r167",
      "r173",
      "r267",
      "r502",
      "r503",
      "r504",
      "r548",
      "r549",
      "r633",
      "r636",
      "r638",
      "r639",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]",
        "verboseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r226",
      "r431",
      "r435",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r351",
      "r391",
      "r457",
      "r460",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r735",
      "r785",
      "r789",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r351",
      "r391",
      "r457",
      "r460",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r735",
      "r785",
      "r789",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r226",
      "r431",
      "r435",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PartnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A general or limited ownership interest in a partnership or unincorporated joint venture.",
        "label": "Partnership Interest [Member]",
        "terseLabel": "Limited Partnership [Member]"
       }
      }
     },
     "localname": "PartnershipInterestMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r222",
      "r431",
      "r433",
      "r737",
      "r784",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r222",
      "r431",
      "r433",
      "r737",
      "r784",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r351",
      "r391",
      "r437",
      "r457",
      "r460",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r735",
      "r785",
      "r789",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r351",
      "r391",
      "r437",
      "r457",
      "r460",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r735",
      "r785",
      "r789",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r145",
      "r146",
      "r352",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r168",
      "r458",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r168",
      "r173",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r431",
      "r434",
      "r787",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r857",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r431",
      "r434",
      "r787",
      "r821",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r168",
      "r173",
      "r319",
      "r458",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r702"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r30",
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r23",
      "r747",
      "r768"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r310"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r80",
      "r88",
      "r89",
      "r90",
      "r91",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Cash\u00a0flow hedges [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r80",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Available-for-sale securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r77",
      "r79",
      "r80",
      "r770",
      "r797",
      "r801"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r76",
      "r80",
      "r88",
      "r89",
      "r90",
      "r156",
      "r157",
      "r158",
      "r590",
      "r792",
      "r793",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "verboseLabel": "AOCI [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r71",
      "r80",
      "r88",
      "r89",
      "r90",
      "r590",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average period of amortization"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).",
        "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net",
        "terseLabel": "Tax impact related to employee stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r462",
      "r464",
      "r507",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising cost"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestment": {
     "auth_ref": [
      "r642",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.",
        "label": "Alternative Investment",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AlternativeInvestment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r122",
      "r292",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization charges associated with finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r139",
      "r211",
      "r215",
      "r220",
      "r263",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r586",
      "r591",
      "r656",
      "r700",
      "r702",
      "r745",
      "r767"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets:",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r65",
      "r139",
      "r263",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r586",
      "r591",
      "r656",
      "r700",
      "r702"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r235",
      "r275"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r239",
      "r241",
      "r761"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r232",
      "r236",
      "r275",
      "r751"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/InvestmentsScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair values",
        "totalLabel": "Total available-for-sale investments",
        "verboseLabel": "Interest-bearing securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r234",
      "r275"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r466",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r600",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r14",
      "r309"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r456",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r456",
      "r459",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r571",
      "r572",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r121",
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Net changes in valuations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "verboseLabel": "Maximum additional consideration due contingent on certain milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r570",
      "r573",
      "r576"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Business combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "terseLabel": "Adjustments to carrying value of intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 9.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 2.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "verboseLabel": "Fair value of liabilities assumed, deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 3.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r564",
      "r565"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 7.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r838"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r43",
      "r702",
      "r803",
      "r804"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r43",
      "r124"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r19",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r118",
      "r124",
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r118",
      "r665"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedge [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Hedged Items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r136",
      "r139",
      "r176",
      "r177",
      "r178",
      "r180",
      "r182",
      "r191",
      "r192",
      "r193",
      "r263",
      "r335",
      "r340",
      "r341",
      "r342",
      "r346",
      "r347",
      "r389",
      "r390",
      "r394",
      "r398",
      "r656",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r580",
      "r581",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Collaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r318",
      "r752",
      "r774"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r328",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Contingenciesandcommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r331",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, dividends paid per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "terseLabel": "Common stock and additional paid-in\u00a0capital"
       }
      }
     },
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r156",
      "r157",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Number of shares of common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock and additional paid-in capital, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock and additional paid-in capital, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "verboseLabel": "Common stock and additional paid-in capital, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r29",
      "r31",
      "r412"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "verboseLabel": "Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding\u2014558.3 shares in 2021 and 578.3 shares in 2020"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r83",
      "r85",
      "r86",
      "r95",
      "r756",
      "r778"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r98",
      "r737"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r543",
      "r552"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r543"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r543",
      "r552",
      "r554"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current provision:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r543",
      "r552"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r127",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt Conversion, Converted Instrument, Amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r365",
      "r372",
      "r373",
      "r375",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Financing arrangements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Financingarrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r138",
      "r148",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r381",
      "r382",
      "r383",
      "r384",
      "r677",
      "r746",
      "r749",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r24",
      "r376",
      "r749",
      "r766"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r348",
      "r381",
      "r382",
      "r675",
      "r677",
      "r678"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Aggregate principal amount of notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r55",
      "r379",
      "r675",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate on note"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r56",
      "r138",
      "r148",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r381",
      "r382",
      "r383",
      "r384",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r56",
      "r138",
      "r148",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r381",
      "r382",
      "r383",
      "r384",
      "r406",
      "r409",
      "r410",
      "r411",
      "r674",
      "r675",
      "r677",
      "r678",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r361",
      "r674",
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt Instrument, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r361",
      "r377",
      "r381",
      "r382",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized bond discounts, premiums and issuance costs, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Total realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "verboseLabel": "Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial obligations in a security form.",
        "label": "Debt Securities Payable [Member]",
        "terseLabel": "Debt securities payable [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r544",
      "r552"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r544",
      "r552"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r140",
      "r544",
      "r552",
      "r553",
      "r554"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred benefit:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r25",
      "r26",
      "r533",
      "r748",
      "r765"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r140",
      "r544",
      "r552"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "NOLs with no valuation allowance and no expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Expenses capitalized for tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r518",
      "r536"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred income taxes, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedTerseLabel": "Debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Acquired intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Deferred Tax Liabilities, Property, Plant and Equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense attributed to Retirement and Savings Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DefinedcontributionplanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r122",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization charges associated with property, plant and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r122",
      "r208"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and other"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative.",
        "label": "Derivative, Basis Spread on Variable Rate",
        "terseLabel": "Derivative, effective interest rate"
       }
      }
     },
     "localname": "DerivativeBasisSpreadOnVariableRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r604",
      "r717"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Total derivative assets, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r604",
      "r717"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Total derivative liabilities, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Interest rates"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative",
        "terseLabel": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r69",
      "r601",
      "r605",
      "r610",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r629",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Derivativeinstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r598",
      "r601",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r598",
      "r601",
      "r610",
      "r615",
      "r616",
      "r623",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments Gain Loss [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Fair Value, Amount Not Offset Against Collateral [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r594",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r593",
      "r595",
      "r596",
      "r598",
      "r599",
      "r607",
      "r610",
      "r620",
      "r622",
      "r626",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]",
        "verboseLabel": "Schedule of Cross-Currency Swaps [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r593",
      "r595",
      "r598",
      "r599",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue by product and by geographic area"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Stockbasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r53"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic [Member]",
        "verboseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r96",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r174",
      "r176",
      "r180",
      "r181",
      "r182",
      "r186",
      "r187",
      "r639",
      "r640",
      "r757",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in usd per share)",
        "verboseLabel": "Basic EPS (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r96",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r176",
      "r180",
      "r181",
      "r182",
      "r186",
      "r187",
      "r639",
      "r640",
      "r757",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in usd per share)",
        "verboseLabel": "Diluted EPS (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Earningspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r520"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r141",
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Acquisition IPR&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "negatedTerseLabel": "Foreign-derived intangible income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "negatedTerseLabel": "Credits, Puerto Rico excise tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Credits, primarily federal R&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r520",
      "r555"
     ],
     "calculation": {
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "negatedTerseLabel": "Audit settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to nonvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": 2.0,
       "parentTag": "amgn_StockBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedTerseLabel": "Tax benefit from stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Actual tax benefits realized from tax deductions from option exercises"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r88",
      "r89",
      "r90",
      "r156",
      "r157",
      "r158",
      "r161",
      "r170",
      "r172",
      "r190",
      "r267",
      "r405",
      "r412",
      "r502",
      "r503",
      "r504",
      "r548",
      "r549",
      "r638",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r792",
      "r793",
      "r794",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity Method Investment, Aggregate Cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Equity Method Investment, Quoted Market Value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r44",
      "r212",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Approximate carrying value of the company's equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity Method Investments, Fair Value Disclosure"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r44",
      "r117",
      "r259",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r651"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r255",
      "r781"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r643",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r452",
      "r644",
      "r707",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Fairvaluemeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r363",
      "r438",
      "r440",
      "r445",
      "r452",
      "r644",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r438",
      "r440",
      "r445",
      "r452",
      "r644",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs (Level 2) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r452",
      "r644",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs (Level 3) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r440",
      "r642",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r363",
      "r381",
      "r382",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r452",
      "r707",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r600",
      "r607",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r252",
      "r253",
      "r254",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r374",
      "r403",
      "r629",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r293",
      "r298",
      "r302",
      "r306",
      "r738",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r302",
      "r742"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "amgn_IdentifiableIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross carrying amounts"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r293",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r302",
      "r738"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "verboseLabel": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "verboseLabel": "Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Foreign currency and cross-currency swap contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Foreign currency and cross-currency swap contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r69",
      "r438",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency contracts [Member]",
        "verboseLabel": "Foreign currency contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "verboseLabel": "Foreign currency forward contracts [Member]"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsSandozPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r285",
      "r286",
      "r702",
      "r744"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 8.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Addition from acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and other intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Goodwillandintangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r289",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and other intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Hedging adjustments on discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying amounts of hedged liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Fair value adjustments",
        "verboseLabel": "Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r598",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r211",
      "r214",
      "r216",
      "r219",
      "r221"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r92",
      "r122",
      "r209",
      "r257",
      "r753",
      "r775"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Company's share of profits (losses) of related party"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails",
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r521",
      "r531",
      "r538",
      "r550",
      "r556",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesIncomeBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r142",
      "r171",
      "r172",
      "r210",
      "r519",
      "r551",
      "r557",
      "r782"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/IncometaxesProvisionforIncomeTaxesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r516",
      "r517",
      "r531",
      "r532",
      "r537",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r119",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Accrued income taxes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r296",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "amgn_IdentifiableIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r296",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r291",
      "r300"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r105",
      "r369",
      "r380",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedTerseLabel": "Interest expense, net",
        "verboseLabel": "Make-whole payments recognized in interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense [Member]"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid, net of interest rate and cross currency swaps"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Asset at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Liability at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "netLabel": "Interest rate swap agreements [Member]",
        "terseLabel": "Interest rate swap contracts [Member]",
        "verboseLabel": "Interest rate swap [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Tax receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r37",
      "r282"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r62",
      "r702"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r63",
      "r133",
      "r189",
      "r280",
      "r281",
      "r283",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r39",
      "r282"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r38",
      "r282"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount": {
     "auth_ref": [
      "r802"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial support committed by investment company to investee that is contractually required.",
        "label": "Investment Company, Financial Support to Investee Contractually Required, Amount",
        "terseLabel": "Investment Company, Financial Support to Investee Contractually Required, Amount"
       }
      }
     },
     "localname": "InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r259",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Interest-bearing securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Fair values of available-for-sale interest-bearing security investments by contractual maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r251",
      "r743",
      "r762",
      "r820",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r13",
      "r46"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r693",
      "r695"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total net lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary information, components of lease costs, cash and noncash information on leases and other lease information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Leases not yet commenced lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r694"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Expected total future rental income to be received"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r139",
      "r263",
      "r656",
      "r702",
      "r750",
      "r772"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r139",
      "r263",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r587",
      "r591",
      "r592",
      "r656",
      "r700",
      "r701",
      "r702"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing rights"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r24",
      "r749",
      "r766"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount outstanding under syndicated, unsecured, revolving credit facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Annual commitment fees for syndicated, unsecured, revolving credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Property, plant and equipment by geographic information"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r362",
      "r378",
      "r381",
      "r382",
      "r749",
      "r769"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Carrying value of long-term debt, including current portion",
        "totalLabel": "Total carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, by Current and Noncurrent [Abstract]",
        "verboseLabel": "Carrying values of long-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtByCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current portion",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r148",
      "r332",
      "r367"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 6.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r148",
      "r332",
      "r367"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r148",
      "r332",
      "r367"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 5.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r148",
      "r332",
      "r367"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 4.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r148",
      "r332",
      "r367"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 3.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r148",
      "r332",
      "r367"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "amgn_LongTermDebtMaturitiesRepaymentsOfPrincipalNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Total long-term debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r56",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r326",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r318",
      "r321",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Paid, Value",
        "terseLabel": "Loss Contingency, Damages Paid, Value"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r14",
      "r309"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Marketing-related rights [Member]"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Maturities of Long-term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsContractualMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Length of time hedged in foreign currency contracts"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market mutual funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Allowance for doubtful accounts [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118",
      "r120",
      "r123"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r81",
      "r84",
      "r90",
      "r93",
      "r123",
      "r139",
      "r160",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r179",
      "r211",
      "r214",
      "r216",
      "r219",
      "r221",
      "r263",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r640",
      "r656",
      "r754",
      "r776"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income for basic and diluted EPS"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/EarningspershareDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Income (Numerator):"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r173",
      "r186",
      "r230",
      "r231",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r334",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r546",
      "r547",
      "r548",
      "r549",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r698",
      "r739",
      "r740",
      "r741",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "ROW [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Investments Acquired",
        "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedging instruments [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "verboseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing nonoperating income (expense).",
        "label": "Nonoperating Income (Expense) [Member]",
        "terseLabel": "Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Aggregate fair value of long-term debt, including current portion"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes payable [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes [Member]"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtIssuancesDetails",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "verboseLabel": "Number of business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Unrealized gains (losses)"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r211",
      "r214",
      "r216",
      "r219",
      "r221"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r687",
      "r695"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r680"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r680"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r680"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r682",
      "r689"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesSummaryofLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r692",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r691",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards available to reduce income taxes"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "NOL carryforwards, valuation allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r53"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64",
      "r702"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "totalLabel": "Total other current assets",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsImmunexandSandozLitigationDetails",
      "http://www.amgen.com/role/ContingenciesandcommitmentsRepathaPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r584",
      "r585",
      "r589"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "(Losses) gains on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r584",
      "r585",
      "r589"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "(Losses) gains on foreign currency translation",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r72",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "verboseLabel": "Total unrealized gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "terseLabel": "Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r82",
      "r85",
      "r88",
      "r89",
      "r91",
      "r94",
      "r405",
      "r666",
      "r671",
      "r672",
      "r755",
      "r777"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r82",
      "r85",
      "r584",
      "r585",
      "r589"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of reclassification adjustments and taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r78",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "terseLabel": "Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r584",
      "r585",
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedTerseLabel": "Income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r74",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityAccumulatedOtherComprehensiveIncomeLossTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r600",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherGeneralExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.",
        "label": "Other General Expense",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r24",
      "r749",
      "r769"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-term Debt",
        "terseLabel": "Other Long-term Debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r284"
     ],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Gross, Current",
        "terseLabel": "Corporate partner receivables"
       }
      }
     },
     "localname": "OtherReceivablesGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesScheduleofOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r109",
      "r575"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 1.0,
       "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired",
        "verboseLabel": "Cash paid for acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchases of equity method investments",
        "terseLabel": "Payments to Acquire Equity Method Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r437",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined contribution plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Definedcontributionplan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r28",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityOtherDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "verboseLabel": "Net proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r106",
      "r107",
      "r233"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "verboseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r113",
      "r116"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r106",
      "r107",
      "r233"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues",
        "verboseLabel": "Other revenues [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]",
        "verboseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r313",
      "r824",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Propertyplantandequipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r309"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r311",
      "r702",
      "r763",
      "r773"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r311",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful\u00a0life\u00a0(in\u00a0years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Reclassification adjustments to income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "verboseLabel": "Reclassification out of AOCI [Member]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassifications out of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.",
        "label": "Recovery of Direct Costs",
        "terseLabel": "Cost recoveries"
       }
      }
     },
     "localname": "RecoveryOfDirectCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r143",
      "r338",
      "r340",
      "r341",
      "r345",
      "r346",
      "r347",
      "r699"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction, Due from (to) Related Party",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/FinancingarrangementsDebtRepaymentsDetails",
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r412",
      "r505",
      "r702",
      "r771",
      "r796",
      "r801"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r156",
      "r157",
      "r158",
      "r161",
      "r170",
      "r172",
      "r267",
      "r502",
      "r503",
      "r504",
      "r548",
      "r549",
      "r638",
      "r792",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r206",
      "r207",
      "r213",
      "r217",
      "r218",
      "r222",
      "r223",
      "r226",
      "r430",
      "r431",
      "r737"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r206",
      "r207",
      "r213",
      "r217",
      "r218",
      "r222",
      "r223",
      "r226",
      "r430",
      "r431",
      "r737"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Total product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails",
      "http://www.amgen.com/role/RevenuesNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues and Arrangements with multiple performance obligations"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r432",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r690",
      "r695"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesCashandNoncashInformationofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalties due"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/OthercurrentassetsandaccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r80",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r240",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Changes in contingent consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r56",
      "r148",
      "r381",
      "r383",
      "r406",
      "r409",
      "r410",
      "r411",
      "r674",
      "r675",
      "r678",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "verboseLabel": "Carrying values and the fixed contractual coupon rates of long-term borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.",
        "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Fair values of derivatives included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Summary of amounts of income and expense line items"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Computation for basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation between the federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesCustomerConcentrationProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r5",
      "r139",
      "r261",
      "r263",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Derivatives in fair value hedging relationships"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r293",
      "r301",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain (Loss) on Securities [Line Items]",
        "terseLabel": "Gain (Loss) on Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGainLossOnInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about realized and unrealized gain (loss) on investment in security.",
        "label": "Schedule of Gain (Loss) on Securities [Table]",
        "terseLabel": "Schedule of Gain (Loss) on Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfGainLossOnInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of income before income tax, domestic and foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of interest rate derivatives"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r18",
      "r40",
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Net Investment Income [Line Items]",
        "terseLabel": "Net Investment Income [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r103",
      "r105",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]",
        "terseLabel": "Investment Income [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Aggregate contractual maturities of long-term debt obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentGeographicInformationDetails",
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r466",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r471",
      "r483",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r59",
      "r136",
      "r191",
      "r192",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r398",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Revenues earned from major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, general and administrative costs"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails": {
       "order": 1.0,
       "parentTag": "amgn_StockBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Total stock-based compensation expense, pretax",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Components of stock-based compensation expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Period over which the grants of equity instruments vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights",
        "terseLabel": "Description of vesting of restricted stock units and stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)",
        "terseLabel": "Units, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, forfeited (in usd per share)",
        "verboseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Units granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "netLabel": "Weighted average grant date fair value, granted (in usd per share)",
        "terseLabel": "Granted (in usd per share)",
        "verboseLabel": "Fair value of unit (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance nonvested at end of period (in shares)",
        "periodStartLabel": "Balance nonvested at beginning of period (in shares)",
        "terseLabel": "Units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance nonvested at end of period (in usd per share)",
        "periodStartLabel": "Balance nonvested at beginning of period (in usd per share)",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant\u00a0date fair\u00a0value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of units that vested during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock options information [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised during the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired/forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, unexercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r473",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance unexercised at end of period (in shares)",
        "periodStartLabel": "Balance unexercised at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance unexercised at end of period (in shares)",
        "periodStartLabel": "Balance unexercised at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average exercise\u00a0price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested or expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r463",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationComponentsofStockbasedCompensationExpenseDetails",
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofRSUsDetails",
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails",
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails",
      "http://www.amgen.com/role/StockbasedcompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r466",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period of stock options from date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r489",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationStockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), unexercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years), vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r131",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/PropertyplantandequipmentScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r136",
      "r139",
      "r176",
      "r177",
      "r178",
      "r180",
      "r182",
      "r191",
      "r192",
      "r193",
      "r263",
      "r335",
      "r340",
      "r341",
      "r342",
      "r346",
      "r347",
      "r389",
      "r390",
      "r394",
      "r398",
      "r405",
      "r656",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r60",
      "r88",
      "r89",
      "r90",
      "r156",
      "r157",
      "r158",
      "r161",
      "r170",
      "r172",
      "r190",
      "r267",
      "r405",
      "r412",
      "r502",
      "r503",
      "r504",
      "r548",
      "r549",
      "r638",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r792",
      "r793",
      "r794",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r190",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r405",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r405",
      "r412",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockbasedcompensationSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r412",
      "r465",
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, additional authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount available for stock repurchases under a board approved stock repurchase plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r28",
      "r29",
      "r405",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchases of common stock, Shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r28",
      "r29",
      "r405",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r28",
      "r29",
      "r405",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchases, Shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r28",
      "r29",
      "r405",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchases"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityStockRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r34",
      "r35",
      "r139",
      "r229",
      "r263",
      "r656",
      "r702"
     ],
     "calculation": {
      "http://www.amgen.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets",
      "http://www.amgen.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/Stockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r688",
      "r695"
     ],
     "calculation": {
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r523",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards available to reduce income taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Tax Credit Carryforward, Valuation Allowance",
        "terseLabel": "Tax credit carryforwards, valuation allowance"
       }
      }
     },
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services  that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r252",
      "r253",
      "r254",
      "r374",
      "r403",
      "r629",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/CollaborationsBeiGeneDetails",
      "http://www.amgen.com/role/CollaborationsKyowaKirinDetails",
      "http://www.amgen.com/role/CollaborationsNovartisAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. Treasury bills [Member]"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r144",
      "r438",
      "r452",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "verboseLabel": "U.S. Treasury notes [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.amgen.com/role/InvestmentsScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r515",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties associated with unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties related to unrecognized tax benefits recognized in income tax provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesReconciliationofTotalGrossAmountsofUTBsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r202",
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r149",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Additions charged\u00a0to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Other additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsInterestRateandCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsShelfRegistrationStatementsandOtherFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "verboseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r175",
      "r182"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares for diluted EPS",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares (Denominator):",
        "verboseLabel": "Shares used in the calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r174",
      "r182"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares for basic EPS",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com/role/ConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 19
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(1),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=122636397&loc=SL7495116-110257"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r839": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r840": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r841": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r842": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r843": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r844": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r845": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r846": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r847": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r848": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r849": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r850": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r851": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r852": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r853": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r854": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r855": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r856": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r857": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r858": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r859": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r860": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r861": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r862": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r863": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r864": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r865": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r866": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r867": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r868": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r869": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>147
<FILENAME>0000318154-22-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-22-000010-xbrl.zip
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MG/U2I/^]Q2N'?3Z2SN3L[UTY$B%KBS'K>"/N_CT?PC8<AB*0?75C*/\2 !3
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MUS,[3%(:J,P;AR N3MXNW;D1#P;2/8P\7WW8MD1RSSO=5N.RR4KLD"7!\A=
MMHN)I<%]&0$@?Z'D$,$H9'%(!AZ+LJ%:I!77BYB'^A>X7C!;]&$YV_ASX1 \
M.26)B-8$=T%F )&%5B![2C"%,=A_ZC7TAJ>0#*N@7]->SXLB;Z10Y7/;!G@/
M'=&/SBK'68+4[U4_@>,*\)X=XDT;VK52H;0YHR2+JG+)H,H6EE8L9Z1P\#E@
M)^O6]<:.L ?/:,8L%M$%]DR1M&6YCZP@Q3#S%#G*PE6"%1VK' =SJW1<? M,
MAZHXC. &S'3?*/T<LE/P!?"A>J%<. &G9E;7YF>MAEQ/+PF\QRT,=7'7$DK1
MZU5AT0KX+KD66A A_'"P8%GD\PL!9K+GDVAH>&&DE,DG 38!:!CU"RB0Q 2A
MKX/GVJ!8.O"L&XOL#4I\] 3^!5U,@(5G/X#U>"A#9:KD+/TIQ@Y)'D=8T\!=
M"F[_^DNU_O9"A,#*9/QWQ"!V>.2!^T(!'Z7DKL"CZ7,KB@-$,SZ7V%D-;S02
M@27AT^CW%.#/%)A?3-%;0\^)7Y8B:")C(>EW0O-TDWQ0 3**E%( 4\6.K0BT
M"Y@M\!II 9H#$0J*%N 6V*G])+JXD!B5!HJ%C?H2>/2X'P=A#(8,+CFEYNJ\
ML;P8"E![S&1;(D&>(-I*L#K<AB1B*&WA9643!]X@X*,E=Z"*1/4'G_G@5Q98
M&KES2,VPQ7+%F:U \3U5@7,6"*!]\'+G:E+,<UHM%J>/\%[H.7$T_\C[=Q'O
M.6+Z9 ""_Q ]:>Z'XLS\Y:TM0]_ADS/I$AW10V^S6K@&,-X!IA Q6NV26E&7
MIV\N%-7;(]#OD6W>K"\7Z-)19,]?.STIG!:77RX62LFU(UH[F,%CJ4;Z/J+
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MV(K*Z"U(O1'%4&>-ZNH"!*9:\+"5Q^0&#N802,[9_9E$Y;\ASD*3&J2JZV[
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M[V#/HU&M8]GB.YGK)&W2;P8_"*PA_=IEI8QHSB72+!MSL64 -YM/3<),-)(
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MW6BJ=9=2)D<]SY[ '\-HY+S_?U!+ P04    " #VA%!4-O9AC*T(!@#J_T$
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M*>X>T%>6'-L,H#$+!PH6P)4"/0)B-UA;:]W7QKMHC[<F.;89P$,+7)W61KT
M(9.O.<1:P0=%(\#5E=),>>!>3HV/=T)F1$DL'"R<:T!PC3GUE%7."DEV#9I-
M)L?6")V%J\%!J8Z@FAF--JK,J@)QPM$\&'<&NJM,CJT1GU!R-EA*[EK )ZXI
M>)]SC4XQG>>==P*?#2?'U@B9L 2+%+,-+ \5(T<?( >5$EUUDB>PD&?KQM;F
MU_-P;*DPFJ*L#J++%&+S6)S%_LX!3[+/PQ:.R,T#77PUOT?)H)6Q#I9JT*H.
MH/L2<]3= _KJ(L7-  H%"\96*PDD<%4[A\ 9 XTX8@='[O9$BAL!W!-V'Y58
M2P:VP:Q*  XU46U.Z>J6G4QYX%[*>I@,@%%<AJ()<FD5U/>:(6(2"HUW$9J-
M1HKK@\Z;K/5H JB10J=2BT.7&B"F[NFLI'TGH+O22'%]^$@R4]<;53(GA^HX
M-^=)>B>7' :_,_AL.E+\*,A>MN Y^_#?]>!9=<XZ/WAQC3_JP?/B@O/3\>/>
MTM/GB3U\GZN]/CEF5ME1+"5YA6"DZK7FK 4)"XENHB7@AU)K3$7??=D:;#R]
M-9O/CDZ/=E'X:/;F5I-+14WT*M9$OE0+4E%+K7T*2O=-@/&S704L114@]>(0
MP,)-AI+41P%?>P;B,\#\J&.X>+!M@%U8Y2]/C\UI'A_?$#/>9\UK7VD%>%_G
MNJBSQ:6#Z-V!I_<$\=53/R:^- VDF(.A*"9G,U4+/+J9R-Y#2S&>.]X]=N]P
MJJ_"\3$ZJ$5S5UQ#B0TLTB#,OH6866/H$LHU@>.]/VWLLM;-)Y[H]Z:?+"RQ
M&_]P=)P^VP?BR^>W^/%BN6KQ^;H.^V[^PW(A]CWOZK'R4A[=L#&D3_5P\>2R
MZ[K62)>&DJ0%YF@V.&DC8H8(-/*\H[_FGBZO?]HW'T*5U3>X>_.^RJ/YXG#Q
M\&S3TDN/J-9$#3"E&U(HKJLW]]S)@M\8>T$OI9O0VE/C(ZAQ\:;O9S*N,W]X
MX^%25]'?5.C18H\<$R*8Q0C1F<"6R(DU!*D2]Y;C_--6%[NU.%0Y/=2Q9>FK
M+:)O?1O![5W96@CI6JF93/:TX"&-.O/6"B1/XH9'Z]<MFIBX3]M\9,/52<4T
MHID*Q9&9NI)B"G7T>N;S'I9[0DW)$VZ>5%@R97%FIH0 4J%4:TI!#79*/J?S
M)!7X?'#Q8)JD^L;@_V%I[[K_2)?\1$]/9G+\W5PN/Y$%!SZ_'ZBOG?H1H#K.
M"<4#:P=0LQK=B\\^@I=$B<\[_>VQ_$!E\!H\'S-WUS.4TDB:256?W*C,'6MM
M_9C$BS2!:=<_AN?.B?YZR!.8]3GBY<_ZEDF?LV,?/$NCHBDT$WPM6I3J8K5H
M-6@N,7IM-OK.NH08N.==0NS!'N0_Z/OA[3Z];]^/5T_]F'F;Z'Q(S;&$"E2)
MFK;.%;GFT$+&\T6ANXW<Y8JK\VA.VTO=?O?2<U&_I<A'6/ T2O2%0VNQ $AA
M41(,+F++#E'W%/FX@.[6ROB:^+ZKJ\J"29%#*X:$J4A5@A2D0HN]*;=L_^=6
MK@4YM@4,5N^E%<@-,OBH/* 0YTL59FQ\O?SQSECU+5 )?NS'&5T-P# V]=$2
M2PU84!P&"1,@UEG.]QS4FWHLR]F3W[!J'#TRZ-N_%LN?^V(I[RKFFCZ;K]0!
M;9['Q<QCC^C'/A+ )6#7E/.0,YV2*V$"54I72:D_'C,O9S">VE=?+&>ZDZNO
M@H]IM%;JJAZ"CGWI8G?F7;$TT"(;L'V3&&O1ATY=NPVB!IX=Y0(*I@N[Q1,Y
M7O2$+3X=7#R8YEB[?:I/%X>GX]5+MYFN'/CT?CB^=NK'),T[.M+&9AX!M"=J
MG61E0+M4RE/"\0HFV_:<>A].Y>;&.BG760$R.C1+FGHN%"J,;/%9U+C-5-H@
M?*^%CJ\A\C&EBX2)+)@?%=P0NZ^Q<8D>Q$1^M!LX 64T"K9?K./X5A</E_SD
MT4SX\ P869S.3Y;//__Q[9MSO]='O'D?NQ7L7\_K4G=S76,8G6Y<SJ:@H;=
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M;<8$#JUC,\&0$9ECZMZB_8*$:2IK"#?.CYU/#&'.A9)P#.H %6MWS;$)2J^
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M*-"Z%#!*C[TC]:9:P1= =BV[&*O);>A,DS-95P_&^HQ5="%P36E$/- "FN<
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MPOWLTJO]%&?SV='IT2Y.UL=D45RKS2=QT%VJF9F@P-C(4$6FL%KK38#QL_<
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MD#%H _#-L6G;5%KLT(.C/&4;<L.3>X4*R8^^JB&M7MI-6JPQC>N8.E*WP!I
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M?%1IEH['4=XH1F(PCI,0=$0:-)]%IOXX:0EM*8!JJ7)""VP]4\S@5$5:*"N
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M!/#T4YI-M69SXR)-LICFN/VRCHB9'ZV FR<BC6 0H<"D0X8X&;1A3D3$C6Q
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M6C3H-,4SBHJQ8"DEE$:&))BXW! /TD5$@$/=9,^HJ=!IBI?D, :%9;GS5+&
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MG_E!)V"LD N".Z48M4RGDA6,>L=TY-PVV1MJ*G2:XAEQ(0A%".P6+IED5)E
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M%B<_9%=="/_><')M1[FCA#$LC'0LXJAHX)H&'X1'4E@_%:BDTXDOF^9+/JY
MY27W\#L"E?/Q)*TU4GE.93"<&40-")%Y3&'>FF#D9(L$0KQA<GPY/LY+\SPO
MAOEQWG\P>5Y9Y0%7=SX[!@,7*)WY;31A7FD##@<&DQ9K%8@D?#KGZ$S9MK+Z
MH;EWVRB.OBK8'U2ZKCB>Z-5O*-V+ZW</X0HJD$I)7,@PG\Z-Y^G@"X.]!FLZ
MNFEP"##5PN0N4SI)'GP;]F-3^ESRU6/]_K<#%)=N^&?9_Y9_?EJ&83$N71A.
M_CP*QE<=]?FG9_^!?V:; '1RA4V(6C'"HA::((:]"#X5H21_)\:X>&8X.NN#
MT(_S0><HY(='HZ>,K$I^,OK]-/>CHZ<8H?^[4MWZ[#_#$S-X]A];_@8OF/P^
M><_7;S/E(;QP5)P\I?"F-#8=T\\3UD-*DIA\D@\2?IY2<9)&)[UP]KPK^D7Y
M]%^H^N_W"*/;B0:0</;T__4 0L-L-YQF^\6Q&?R_)T,S&':&((\XN7&8?PE/
ML8*OK?X\G71*PGOZ^2#,.HE)ZM;KW:U>=R,[Z*WUN@=7^W2I-U\U_Y%:>]!=
M?[V_U=OJ'F1KNQM9]W_77Z[MONAFZWL[.UL'!UM[NX_8!72K+KPUPZ-\<#@J
M!D^RC=7UU8P@SO0WFWT)1^0F'#V2(#:+\OC?_\("_?X?F(>#8K [/H8WN6S*
M _LA)G.+$L.]D89%<'8$MQH;X4ET47'F4;RIJ&4V,(F"?<B?;A2NRD]))VZN
M3-F>OCFS&\6G;;+_Z1W=&?L/W4_O7^@/>Q_^.-KKN<_OR/NC]V_?\;V-O\YV
M7[SCNQ\^GNUL_/7Y_<;[_ON-W:.=#UMGVW2W_^Y+<?:N]Y'NO-T]?O?VS?%>
M[Q#M?-B'G^_XSH<UM//V+_+^[5]?WO6VSG;ZZO,V>7_V[JT3</WSSHLW']Y]
M\$=[&UMGNQO^P[LO1WUXUY>=#Q_AV4/^[HL[??_BW2?_X@WS+__HOR?]3_9#
M 6WIGKY_NYOODBZ#=J!=LOMA[\4;:/?.V5[OX]G>1O_#[I?G']_WU9?=C2[^
MVX)#"4.".M(HTV%$A8ZB,79 LTD)O,:E="O/X/J?%1M>2.%9=DL\/=(<^&7'
ME!^SO4'X]7OMM,5H5!P_Q=^ _B@=N3I[Q!8E:(,.=*)O3H;AZ>R7WWT^!.OB
M#%1-U93JH=^O?D%B^T^A'.7.]*=?4GW?Y/)4$2BURGBE"T:@=$9^]L53-;%:
M7?IMY+^^QE<YQM^\BE:_?>V?WJK)*E'Z5J_]K6KQI-4P+FG0_V>%KLP>.#'>
M RD!)#YGU\:Z'^+70U.<W!XY:V5N^MGK0>X*'[*=@V]!AUR##KL.G8D:OG^Z
M61L,QJ:_'TZ*<K2216 Z,X*WPXB ,?C4%D7?@L%2C&SQN9&LM)G;%Z_%;N\O
M#M?Q+GGS8>_M#ME] =__=O-H]\OAY[VWK]'.\=;I[O'6Y]W>Q^DS;^"[^.!]
MK\"[&WWHUVOZ_NT.O/<=>D?>'+U[VZ5[&UW^OO?7V;L/:^3=AR[>>Z-.MWMK
MHYT#]'F[]QKO]EZCOP,#5QL)T>$L6& U9CM&:M\ASE@%EXB/<>79O_^E)1._
M7R>V<[Z8 OZ!L7Q+%KP.Y:]8L(+RVN[NZ[7M;+_[:F^_E[UZO7_P>FVWE_7V
M,C!S>F#+3!0LIMG>?H;Y+_[7;&\SZ[WL9I?,H',3:&V]ERYC3=F50:IF_F\5
MY]78*@)[(AL=A2SF0Q!-=A9,F8&O&7SV !/^5>7*=">N[949_]3#)YUC^,ZC
M]%C'F[-.:ELG#!HY]7_8(/F\\\']C:R@/"#3 8L5=YB3"&9N<!WK<<#""(:"
MN%>&GJ:W;U8@>0=RN*W,EE)<6B(<K!&=$!CIL$!XQQ@7.S@ZH75:T1= M!O!
M32(3*<ASE6R?9$D(M[<MZT(F1=F:E:U963>SLE="^_(4MUMXT_+##IB/W2_O
M>]W/NV^WONR^^(ONONW"LVMLIW?4W^MUS_;>PF>]U]=-2[+S!<S'WFY_I]?%
M[^ ][S<<AC:AG0TP2U^\YCN]+9X^V[W)M(R6.$RBZ# ;DVE)4,<J)T!!12TE
M#8)B-C4MV4*;EKW]M=V#K61#MN9E&H_UXO@X'Z:P.UB80.V#<:7R[G'6=ZL@
M^R9\V6[U78V<SC\3OUIC?Q,6'09OKF,Y81V6G#S+).YHHE&007I->5I4P1TJ
M9<JB^K$@5FV"HO<.I_UPF ]'H$=&NW!E^2#%_^8T2$<L[T0L 5+$A8[!5@"D
MK))".(8-,/S:\6$89%L#MUIGX_4K2V02&^U^-FY4B3XK8E:>BSPSPVQX$EQ:
M;?19/LCRT3!S1Z:$MMXACOK@YJW6JXK3'S%OF5C5A,[=OF6K G_[Z@^_E:]B
M(>_9:IZN'3Z G?%=O7K?9O.$\=+)NB58R]42>77 [GHQ'HS*LW6P^K^VH(?I
MCI.R^)3>TU"G?V)# _L!X^V0G>,49MTZW=W8S=\G&WACB[U_N_/Y_8=WT.Z_
MONST_KIN0W-@3[3SY=W9^Y[OOTOM(G]\W-M(# O?^67S>/?#YH?W&SN?=S=O
ML*%Q0"$E1'4DX[K#'%$=C27O:(\\9H9K2DB*&O3-J2G#3QC1*)NPT8_9VTLW
M$WKF\]8TV612$*+!=N5#0WSK*L1M%$%Y3SI$@_W (@6[5$HP4TVDS&FC"9(K
MSS3O4,Z0E.(?03YO,I_HSH<W/BH4_U)1;%:469$JBF0?QF4^]'F5;0362)7X
MDE^FY.K6\M ,\B_5W[\^,@$\[NAMK>ZO'JQFW>.3?G$6RFJXKD[:;+=8_?4F
M_,S:>FX+3BRUEA:_0XMKWI=A.)S^V(8&X)82OT>)9U]I?8,9\QK;CE,8 24J
MVC$>R8Y@DJE <'1IY_O>(&03WVJ]PEFV4>:?[LL&*(O3IM#!XV+_59$R*-_G
M)Q.;N 7_=\%_S1[ R NC ^I$AWF'44DZVD34H<A3+)'@'ENP!S!-Q8RDUK>Q
M!Z[S.6OY_"Z87H=?]\I><=KZ<-\%])>O4VQ #"IXVN'"LP[3&G4TXK&3CI^.
M1*I@.?APO:-B#%CPV9[Y.)P7B3\$_)>"U2M+?*]\51:?P.)N8QT_/T_05_,$
MB6ALD+ZC+ -'D!MP!*TP'20LEAX18ATX@NN .AC\06[F/$D:I0^^X?),T9I"
MU2<E #4_,?TL? YNG&I%PL?@^83A8[N%CSA 8)=ER3"[P>NK_;+I+_>9RY6H
MK@RFL4;K3R7WG_X=G3!@:JJ.$4%W&(NT8SF8GTY*(6@Z#T+KE6<*\>ND\^M]
M+ENG:K/]5T?%8%F7K;N?_V8A"HHHZ_" 98=9!.Y $+8CG:&<,^DP ZW F.S
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ML)(3:C?-J%O36 9ZY.N!"K.X:;F\M'=W&FNT;,_!U,4DBE-?K$V4B1H\.',
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MG8ZEC^G1<.3K=&P+G:TUMHJHOGP;;H#0 *$!0@.$!@@-$!H@-$!H@-  84%
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M]SK7.O:]8CDIF'CA%B))5S&7<HB><54 C#L& , M^'0J6#8G$$$I^L5KZ%2
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M=<N1K  #H?Z> 5EN;5HY!4_^I>$'_L2*$EH./4X2Z!% \T/BXKGM73B<F(/
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MY#K#[TGW/J; V+[ H=RA,$FMRL=(N1M3X02B0O7"0YE>Z_C2<4'Y<54ZP?<
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MN]>"+80I_$*&+KKI<'E7!X&BF%C2LEXR>(J<U>0H^PC" 1X7OG.>P@?FR7X
MBSB'H=MQKA)X)2RE?]"_ <=31_B=!K-O22!8%LSNW\DG/.4.-C^!;X.2#]<@
MJ&%XA"O)S4BPCA.2WE2A4;L)2<\$,UKQK0+IJ=P[0!&SPD$25TJ"'W*@"CMA
MIK,@O "!H",9 \%0 ,(9PW?^A)+<Z:!72'Y7*M8A\_>^ \KA &@3A "(#2#1
M^%)68AHL,&RH R,<('$D,"+\1E"<XWJLW+&C@63CXG?P8)XBP:NX60RZ:(I*
MYY50/LW(PFZ_,8994/9$64R!%I![N!>[:1TGP YBG8W&SMD_11"]^^ (%\X"
MYP&^X/2!&?& 3=29$AW(TD_;LR=*X48E!V42 0^#](%G7>1%8Z0/!TZ%[\=^
MQ+1=7V2A.X8E9M<R^R^.!N#PY)7T=<0 OD ^Z!9XAM(917P0P1&,&%:N%=#\
M B<9XZ+F2NR[2-J[)'0S2;R3P.70EN%9%;IX(2S$I0,J1):O$4@/7R(+0*HP
MU%>"JQZ\+#:_4K'CJR&\9N+Z$D0SWZPKD"6[?@8J*RB=L%'[DBHJ('(87"CM
M>PJ#\)A#Q4N$@/2VW (.%(A+R<N"E /1-YG=/AY0QK2(C[J+JQ. .B@-& 0L
MD(*VK(=#>!0@K>-4@)#1$?Z5A?P$8S(^@O*((#$5)@1MR=P':V$9!BJ$<Q+"
MR9Q+E5KPP#^O,%' B<:3!/8)Y$N_*-XWP=,I?#$29G6^(N42P=. ;: ^2> A
MGN/IA*[.OO-91/VSZB?/TROTCDQ0AP5Q>QB'!GP8RX 8E(B 1Y"&XL79J, T
MD8*F'!CTP]^@P)SZ&?XA@3DEXLH2 / ,A0J, &:G(@>3.*SFZVD7^ ]1;>0#
M$.#CG'J)=-ETLV3HR"&@9$J$ +A!(6Y0B\N,$+FWO0Z#\O:?5K?"&_ <#=:\
M"#2LSTP9E+%P!.2<B*%,X2#P*K@U%_Z"2U5BH'R%'QNV;/YECP:;OI(A_(D6
M:@XO8'+*11:![$OB0BH8P*E(J8>E7#(MX"QDO:H #TO-N8B@)$;EN7Z:%<#\
M'/B9S =1W4?S7V:QO ]T@J:\H77Y'<B?))Y)%M"A89G 9E7$F1',/"D+@0 B
MO98UXH;"E<0\\=\EOE^2,RW#L?'C8:P#9Z  Q!ALC=E80ZD'5X?RL_2=H_!;
MQAJXY\0P*(&/^'I$%7-F;R5VS[=*0BQ";@@/H?:/@B9%$3D&"J1,"CU ,*"(
M-W@**WM 8F'.#=,Q4*)*\??DP=E\9U08LT'ZL/O.$IF.%: !O"^6Q,E=:;='
MA&>A!R?%[T#Z>'@JB10@*6.C"IJ*I#:78EZ!@PGLR1/AH^*!ZJ,(E<T5R=6$
MTGH&AB2@#TY//AT<MYSC@Z_T%UU#+E;P'[0,@["R#$NK@^/W9P=?.B" X)1!
MYJ<*Q-1-+Z-DFN$-!YC:<*MR[#$I=62*#16FO8A(>3[QB@1?R@ZG$>IV@"2@
M.C$+@'MT?9+1N%>@RW'I3O!PI8W:;3!"BWPQOA4$_!2DT0U!V42? #(QZ:[.
MF1R9=C[&,U%\,-> -$_U+88"=-X7$ 8R\$$10=6H4!XK5\ ?2]X=\;QK5%Q]
M!>J>@VX[RS&)*9)*8$@M$A/\DS*3*@J<CW2,^&VUM="H E&6"J9BRE6:E/DT
M+<F<?%9%[,,;<W5X'F)K/HED?0O)ELXQLS<?3A6#_4CKCWP]@.4*0L(G/.9A
MF4I \QH!62<I7_L@%J3%3%UZ"<=6A:W_8;"2J(E([3J<A^<,EWE(24#269J@
M.QAND]R#?"\)\T(R+QATR%\MH.?#N,(!JB:4<0B6<.40W<;HR6,'7,Z^CK[U
MSP];S//MPG#?_2N!%\XT^[E__/OA\<6<QWZ3,8YQ4>$[(YWP);LS+^D??3KX
M=GC1G[- %H#TQQ_*[^TR/ J.3D!'\TPAG_SXH5_('3AX_^CWVY=&!D4W42S.
MI[)Z&N]R_H7!A[^+,,/,P=YF;\N L;=)9%0<[]OYR9<Y.SB3 <A03]X6EY"R
M]Z:W_8QHNU#EW"!%"8;=*NC.#OOOC^<@UIE*L^\B)"Q 3@32X7961^IDF3$A
M1=Q .#FEFCL?9FD&A"?<6(,::Q%P1=A6+ND"L)ZG90C[8XRVEQA_"GZ6! )D
M1*!]Z6:^+/&1]](56<*F4X46;8 !I$:@8&6C<J*PS$"%10C'9". =)LXN=5&
MDHWL &.F@$$&"I+1G8W%5-+&0'-D(T>@\L*F&=E:]"U[-9 QLZ_ &B2R#4\D
M&1DFJ+B0:IMBW!$./7^G[%0 S<BZ>,H^&WY/P:FG6?$-X$/#,T!+SM?7Y#Y#
MJVK*$5&D#ON:XS7R.^CV"3H[2 >P9H0'5H)K4I1=4/DXTDB&*SM'$'R@;'ED
MV*EPWL;P-T 4 ;G$SE$+C$3,%(K8(D 1'X64)!V6'%7X!@,(C@3%H"U&FMT\
M,4 +U K.B7;(?$S&8.LB8BCMT>_AA2\1;5H5$KX@2D@9B8R1A@9AH5FS'RWW
M1)8>0)J4[*"5[C@D2H=_#R85)='(2 !;/"*5SRR@0NR-Q&JV&(#J4K)F+4ZC
M,X*M!;SR5^I7:Z1*K\*=41#/]3JW'$09(ZC1&6:2]-DY;-$=L& #GGBEX 6
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M+?3V\1CUN9X_RJ$G@FF%O<[S^QG5V=[!?._A[2[#JI*\R.MJD@+*T-BM1U+
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M80@0.9XOVVB$&//;B*P1!SN&6>C1OW%?)?P :1%;-1]VM452#'U+ C0[N."
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M*Q7P TQ1!06&/#'W34D,I#XBH=CX62GR@[PO@PVDK!H"H$,I/;2&*!Q#9DL
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M[*F4_G'P]LWIC9KP5Y5%OLL-)?'2U&1U7O?(?TP:/+<9F$D<$)F5B,WI1%V
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MR0DD_VS2TE.]XN'TQE%MDG%.RSR:12561!Z=M%K<S])J[+[7"M0T]5R/TW+
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MQ=!Y'<$2R]KSL"5.M8&5LAH7V0!J%:FW9)R:"YLNP=PFQ.BXU16B=Y\:][Y
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MGGZ*MMI*"'?KBL\D'0PR\UDAELZ]^B;V9.N9BU#EQ'5BGJ6+OW/%VB>),?3
M*ZW];2_NMS0 3$GSRD1GHF$W7L7D42]8X(=U_8QUW2\F4T/>XB&:72L@8F#
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MOE07/?(]3$QPBZ?K!3D<!K15S, H[2MYC>&?N,)'HT0KM4&# S+B^M?'W.@
M%#9=CP?^Q-PVB?ILPA@ASBY/UJ62<QRV-'&QI;)80S21?FI!<WE&63KI-V6E
M.?_\(BV+'/^6=).VUZ +&0VI"C:V-T R>60X#>\ A@GM:F9R+9N43:Z]5%)/
MFI;(E V+A LBBL\"[+" S+3:F>8ZT1;CN-(\+RXD(V[)I*J>K<(PJ1JM#@I/
M^8AY>3R\$+L/*2%_/%F;OJ&]JL7H;<&!%D'GR)%<[\/VT][VDR>J"R;\*Y88
M;$CT[(ET^Y3<Y<;GQTC:$A>RI7*Z2E9<6E 5D-+\XU(0278V%A?F%'E*,N16
M7D0G:.)Q)YOGD"86''K-06<$7VY0<]R,CA6XIJ6C+CP/LZE5E.DR63$S1IK4
M2B,]'%K%:G)N,2SD:;G]*$_23%X*RBA%=T?A5*EK8H+2Z9MH5 "ICA<O2KVD
M'+\2^'?2A5(E1.*8?R\R*OGJIKPP,U:6<<3JD:L]_$9@N*E"=1G\3JMI^\=_
M'+[>V-H-3W3/=C/6,^T7K>P8M+X!-H;+LM*YF.:HP?')C1)2N3B"J,U!B:3H
M*'S,:X"3VU0"-Z*%8U)[AZRWK^!R[G[+;>O,JR(N606_3C%:EC;\"Q%L=Z'T
MPO:54RIYY;I]<N-:<%Y[';<F2@=&)RS'V$/%\F)7005-%Z+C-PP,:APE]YST
MT++![8/^!S*^CEQOJ9PP>3XGK63JIEJ?@JLP0X8MT%G+3"R-+.S*I+[$WB[-
M,/9V')>3.#$-.\76P"D^+*Y9'9%!*NANUO,4J%U$ N% $+%8-AQ:DY.R*&.<
MJ2AHQ.4V*5P&)\OZK6EFWS8>C(6$ ;=5#RRZX&2R?([]]Z +:=L"3*-R!V_.
M<6-LFJ:5UL7*0>#03<U8/A6-*$XGO%U.Z$S'JEE[94O@O+"^70%FKM^(_I8_
MIF3$BLPU3Z&1L%(\C.R=M%1\3+.LDHFMF1F,1#Q<=W@+.:RB(# ,"R!CTW5I
MN"O*3IZ@=6$YZ#/:WP%>_B[ZWJ+:9G%%K)!*1^NM'689RVJ4YI)UK#-2\ ;;
M8J108S<G4 1H@ZW.J*!;^4/GVO$=4$:3Q:W#S,73F-,]SF<,NO"%R]*50=4^
MZ@&XZ/;MS^S4"_Q-GTV<TTG\MY!BNEN$N^WB&E(MH]22#6(1F523F\Y5SV"%
M;"L[+@1CN*'@E,Z:^J4(WY@7M+MUWA#R<^F)C6OWN.'!O$? [:O]3QNYV=XT
MI!G2*8^NA"MC_9\6.8&)D;FR!#?2BJUM+HHG4_>*!U2W?MOM3QR2!XB<>$];
M*F;"0NQV*OCMVJSY>>'.$(=3P7*$)X/A<4YG #>6&CD\5E^$-"(PGB28:,</
M+^B_2GYE+6I'R)D+Y+$06R&:5%RNR88;TQ@0/KI<R?YD,64-^P#,;0%SM^\S
M,/?NG 3V"[H>HT]P.2H+LJKQ8 ,>Q,!Z9 YTP[')!7^1C?*&,&QQO\X$K%IH
MO*SB"_Q1!G[5BO?<C*#]K(;C_HAYD^2L43VG'1UU11)@@"3HSH9QZ=Q.O9T^
M1(4!4W2@I*8BMW4.N/>W^6!KC@3P5OP&^9:\]O_%\^S95:^J%/DR=EC1K$5/
M*M^D<QPX&+V .8.<B&R0T/=Z_O;^.L%/W*<5"I[1M"D3YBK#0_2B868^\?I4
MW!OE_63Z998.Z>K>.B=V45QND5P&GN22),Q# N5$7CB_1S6V3H:_ ,6OUOVV
M*]7C3>>+]<.H#<'K!A[ P<LJW0^*-TA8: /8.2D9-^6%+PQZ^'$=]['D2S(*
MQGUW+G:_O?%6_IB(6G.@M*;.>:/EK1M.YX7(XW5R]/>[0>1[#^L+8FDN#2"K
MYXQ<Q>>XPN6L(6P%I"KUTX)">MLM:#?N_C?/<QKB+!X:C2W_M&*-_\"ZHB!;
M@$D*L:;FB]9$;!AO(=FKBE: 7UF.E>0+:><3X[B4-"Y"LGAJ>?;)35<"""P5
MHJ!(FO(Y^QE+V2*2(0:5+#+ZA<N!\USUK]Z/ZD4\6RP I4Z15DBM)L$)'Y7R
MW/ICO98%@SLUIUZR$0*G85'5-@\IO].4'7M\J2./E"( Q1QT N!'ZY=5Y'L<
MMS&HM54QX82@T $(6K4L"K"\-0IYE8N@:WI@></T'3773G%UD;&[J;J6(UC\
MW"9H=,!B44JZA5.C$DW9ED<I' W#=VRI6.[(%=<3UK,4MJPJS GO:5^OJEP7
M1D0<#V1*8L5U!+]#I1NW,&SR1'[N'B (0W@NY-0XD/U;R87O^WY?_VF+]8[S
MN_]LR!$PH/+IR\#/3C)).+6$A$XH?Q!Z(C#G5'C\4<RDY2:2^%O[$S$)A40
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MA[%CP$V'HQW7?ZA[W+:00.,'XT_\-AO7E<+4#1@GT 6.VEWCM)/'CRA0JU
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MPV.*B^^;LTTT2(RVQ0>\P>.F1O^LDFG,G6!W@&5-9*)U+!U8*48<3Q@YJQ/
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MAL25G#.K4@_(HCV$JF(V1C^9&XGS2Z;&;Q/7=)O]0G2N*FTLW-3PZBE^V5[
M#T:7INF -Z+UD1S>5R:%L>K-M;R#;LU<VG=E^\<90,?!IF7_-MS<DKJQ$\G
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M@D.NF?"5E&H+9U,42J/?UL2"N#H(<,G91!_AWJ8?.SN9[;H][YKSU!D75TY
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MO3Q124;,@*Y'J21-54["%\"Y07MR8*:8GKOY(RS?O2A4.N*#:%^O&D6Z7:1
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MG]L"LP#$-(*#,?$]V3!8UC'F;Y%/Q"9PO#P'W@&T+X:5NEOV8H9["BE',PX
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M\44!3CDC':CM7Z+-DTB6)F97II"!G*BS]273?*K4CL>O4UY+0JBX8%X_>3D
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M,AV"BKF8\CNC/V]@1BJ8,4*U>9GJA(9IYHRI'1&LIAO!^_CR^',%%2O3661
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M>G@_<//956\G1@%MK,0M\OD%B]; YUN0$(2GF2M[X37D'LWEPN'.UD,(DLQ
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MK&HG2\/(6= 'AQ5!7)!$4C,NI(=/C(1#P&'=.\ZY0GQ_S5^+ &E4AU!XJE3
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M EWQTD3UCM3=(,94_6O/\E#D][2(S\'><@ZP];I:A:]P@[]EIB@CTQ.II%\
M>#B-$H&[W'::;&C6%3/XO I'U-GB>$M-N67!^Z@10NI*<L#$ZUQ23%RN>JHQ
MQM5AB1'"QXV.2VADJN=LR^Q;B+GJUWB=3893TZ*<V^#F4^,V<@T=M-;<G'/U
MPW8\JU&.I%15?0BV:)!,3F)WI5Q,.X*2'WY%6%YP:FRZ7F%J_*BKDIXH!-\=
M.%1CI)(&WYE*JI.\S=U-W:<ZDL&P4&ZKYW@F*HTQK)2_\_3DIQ?/CA[]98&6
MB*U8..3X8DWYK"H;"&L&)SJ,5$=?4W)7?I0740")S#3]GLG-NSYWC)&R6R^>
M?T!E.RR3DYY29S)S^IA-MWH/A5KJ7[2,%F=V(FMZXJE#G RY+*&XA+?:'LPY
ME71XTF:'1/  ;*8PZV;?C J\,*/5A_ '"#PJ>,^>%A8>5RU #7*X=S09(F3]
M.9<I:VLR//9Z_'+45#J]:=1@',ZPQFQZ@?]?:&(J,5HIR'6]MSD8]G2JT RP
M42L72$$I,"*L+(J&%$@B(,::13;1]N0SATF*F_:K#2IEE<+H# PHE3Z#%ZVH
MDB"Q_F.P0.&-4.ZQL_58%BA=_*L7/QX_4*.E+*8,4*?Q>F_]6-R1LPH^'[&W
MBV2HS>/;X-#];1_^YS650O\_XH+!05)!4'2Q#AXG!%/.4)[+7%O/N(:,V$P^
M@/R@L!J*>W1!@B[XXY>,+OA$@T8Q4+#.!?O5O]"MRX[6[ 06UXZ_&G:8[B5!
M*$[.CH*[):VQU7JJ7(+<#DBI0CFRH%-&53'ZBDS%@=A5"B\'8E=_UAQPA@DQ
M74G.0KUWSY+C^MFIJA U3Y"98F,1GKI1QKQ?*1).J!:G^9+[G-&=B>*SN*C0
M&".ZD9L\MIUWUN!XDRP@13^B"A@V*;P='X_%RG 3OK6^C#M27;K@XSZIPA"V
M+$)$@?.W_%S.W\I<N76U*?FDE<83Q.SAJ?^?/WVS6)*0)F>:J%HK"0+6$2]B
M0N%I.-JY.X0*</R>K]^<O'S^]EC/\XIBA*8>SN3C[TY>/GG]1K0("(J]V-0#
M!8BF71+BG'H,\?.+%R_PS'P]_?J0O(2T;8$K3NKV:";=3.I_](8H/$?!@R(2
MP*&U!\FJ\->G9^6.YN(O:E/QKD_*]CWMB=5E>.UUY=,=4#?'7J [<#G9(1<E
MM+2F'QX!:\^ !TBI""!&D$=@T5N?NGE62V7_:=A7H^',[<_9Y +'?AX<B'8D
M(1[C9V)T^.SXZB4/KQA]4*?E'+^,/IW1$N\>%GN3(#FZ?RO)B"%/ [AHK;9\
M6X/+BR&FODI=MYN^U-D.@?(Q8G]&#Z-5\;0;:U]]77;M6LK^OA1,;KY*HMA$
MH242\[0HPVIGK]-430:"0G!B2;W@<O&Z*3%$QVNR7EO1>*:OQZ''1'),/_-U
M"86'R0"ZZ8%"$Y'W>H8:52+1P:>36IN@")- ;RXD5:(+B$0#EBQ_QN&5:<8G
MF\ RB&:3V#R<M(N3U=@1C]TWP?)PR'$<'NV/OS_B?[QO$>WP"PF%S(\D+AC6
MA%A(M\/2E5<HN0R:WNB5J?WK.SK+7U$80+<-7WT6U@[^.Z9Q>+><550%E#@@
MQ,,],,,I,CSO@I_.26&F_"5U)--F?4[VZFQN_BY8 )X48F-<Q$\3AO1OX>BE
M?4EZP^%AOT%O]])#J3N-R1_]D;]R!:;YRSH^GX?=A*U)'?EA74X,(X59^QUS
MUL^E9>6\(&1<)L6EVB\62".;)LQ^U-<<EH#^7$XS);\4T"UG2JO9^Y; R.I&
M7I4[\K0BJZ(3N/'I($#4JKB=!'"Q/PW^-+VA/2OZIS5!0P"8\>SA H-%;XI1
M8>= #@GJ@F2F4'XAQG&P"<3[44$A:>&<>REU)=#ZJ7=G"/^6\$&[8)6)SC08
MAH>+'X+-/B=$5'9.2&"\ ">7?WM@C.C6DIB@C6F^S813CX^^JU[&XS+=MVF
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M8BD]9)G @1X:ZGG?JY9]W E2_SOVT\:8!](JITSUJ\AO1BWW$EM%!!.?FMZ
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M$8J0GR*B:,Y!5P86H2O00@R0GH$*@>F+J8D[_'\41*])_8ZUD^.O%<S5='/
MHQSH]K<]J!H?_8$N&J_G^?,$NDWG2*N=H'3UR$(7FSV?_T.HYV.Y#<33$1-,
M[;X:(YKW@^<)EJYIN@N&U#A, *PU2$M'PYX=[_JZH>?^<_[<.WI<_#!]]N!Y
M+9;EN#KC!,]/=(8NZP_Y2[R]J,=_5[U3 HAT$JL^N(AXO(K+&OQJ@HF.@["M
M1J@+ .C6,IF_+DI@U["\I9)!?#GA2,($QXVD/D#99K"" \L>JH%CS0M75G?3
M09V=_\HIQK/+@:@B6U9[ ^T(WZT:PLLM*^6IX?*-8F\&>,0$[YO@4.YA9#<V
MH"<31GRI.%>@AKF5 Y%B1C+HZ)61 =,%@ GS=%:H-CY5Y"R(W$3*RK,6AU3)
M_<BSC522_K+"<4EZK8L7,,J+D;A0A*XJ[.QVL2$J% ;;$MO/OFZ"C0[/ NLM
MP#AH^AHE03:08;NJ;3APB_&,J+KL'K! F\OTVJ"(G!UP%#FSH=1-S+L(&NQ5
M]+G JOZ^,M(=87X^L #"*<J:"L)3>:!J5N!#F(,=B6V:>F;UH4:V;=(2K/.!
MAF]:9K5B$>V$GCX6]&+=ACR D?T(YZ.JSF$"$N)25W%^N'B[!_8I>>9,R!*2
M*>14DY]-SV=#=&A']69_T<5"5&<BV"1X,N/LXZ*TS&SAI&#OB*5*,(YS0:JB
MBOLPD\2?L.U:,$%)5MB'J-?(U$4)5;8X=*82-'[X119Q8NVP1^>M$5P2DGJH
MC')* JT;W&S*!'2UT<71>%YWC3AKI]()P*1@EUBRY/>2N5MU?2\\J&6,\W]G
MDL$73,NW:*IQU%B2]I UU='6&PB;R#JPY]W[2DY>ZFEP^8+P'V?!!\*NV LN
M*F/EF(>38QMENH:PD+QE>,*)&=03TC-CS(5Q\%L4<+/QOGJ N=&4X^JP@ZBM
M8H3Z#>%080P^+_IY<@8$PS(+/Y[(PXD6"^FK=PTW183--W> /_RDW#,PS=*&
M8H88)\6$:'@F3M/ )G@<VWH<A>,U.0W)ZRAXP=<BVSV'3!;-L'5->PF@<),R
M=[!GG&+6?.CLT*B;+<&P#,0T+P?US:W2K2Q%YF]YWVHN;1CM&>@[67@F#"#[
M-_7-=A<[DU<ZC6'Z9/F5YV7=\#%)H9R<C<MRJ).C4)RC6YG4:[8X>RM]C.03
M\+H=]+_*"U.]P''EN:95;PZ-PS!\<S]\O+3")&G@/:EK$PBI2M)%Y4+>3'*1
M8OZMJSU,.R2"&VT"0N$\V5*,G03KG-C#Z_W8[>OA/+A15;'X>_CS?O4^ML-E
MI+$<U3\)GG-9!%-$7BN%X$P?]WQ/=1EFIZ3]KK13N6!8%,M3!V7;Q:^$15LU
MZJ(P^^\<\526#[CIO>WQ)\T)LD-D7I,VEE_406 S/)&JIVZ: ?&ZS$(QV1#Q
M*\[DB(SA@0'R8IKRAM)VF)"XN=5BTC/2[>CJ$G4OCEH9W V<&X4MB3SIDR<X
ML":#K]QMIQT0,W2F!W0ZARJ<NYB:,Z(,M>W# %-F@[VSS-GOSBACQ8D:VB<0
M8#(!A?-*Y'^VU)5*7$7T)RJ*=@.Y>$-5O9>0B,CK6Y)=_7=EZBWH!$K]QUF&
MZ*@>,>)(/NW8'T#]%82^LE<\4^[<E;)L9E@UQ_M32F^P"(.H^2E-0;"#\;TH
M'<UJ?F$2,L6ZL$I)MB <9,NNXYAQ'=;<X+K0M!8\#)(:!)5!#;RZLAJ JBY$
M&$)QS^D)DT2MVQW9[I$4,=8J"9$_2+C+\W;@H7QN]WH9[_52[O5T[EY/]5XO
M^%[D6KPDDOK9L525B?2TH,J77Q^Z&(+1HR2"1A"+*-52D:%1 96?*,:B=./Q
M)IRHRIR[V_<A>(8DH/I&M':D;YE7)P= N[.RWY8K9"$Q:*<D4H+D1J)Z1><@
MI4MGE@AS30=#]>NI#,^-G[=R-U$=+D1IY!>(;5^M=WQ04EOIZ8=!"*S@.WOU
M%-4AU9R/.IRQ)"P"))QIHEB'W5!_D=1?EPC66VN>W_8_,#W\"V+$E(\YN@!7
M'WMH=%?$2P=-@%7%-)GVUXUH@FC 7K7G==^)FE$X)CMC[.3I9Y0, I-PI2]I
MV*\C,_9,\P3/$0YY4UV5 ;*IH!)6FXX7#BN15&FD/HD!I+1A*V*\M(U;RAN_
MI>RT"#!YN\$HHG.HL$2WS*F-2M$/B5MBS"5W>@5^5W*S-%UO9 ]>'3C\-[Y[
MCP1(D !_OD<"W'K0:*W1PGS^]OM@KLG"H^/[Q6;Z5XNC4=MGS,W@5K^H!<B2
M=;K%1A"'4XL:OG V+6]08.RKX.U(Y.'-9[$@BH8M0#;\ HBA*8Q=57?%G)W(
M#(1!H-[U>F!9HB1I0Z]^42W#7JU$[H*+OX/-'WGDFB6IHHZ19N=P20E9Z>N2
M[EN3.MR:8^XHUR&!&Z'.B$-!0GWYQY!8PF7)IBQX)OUY=0G;.%**I;I(,VF;
MOMQ69*J%7K[KP]TH=Y[J6CU<'"='7'PU$YBC$N$1><YB>+=6*U_V7;FFU$M'
M,FD,+F#'Z]+H%^04]D6_8)TI_(\T.UQ,H\18 [67RG\8'D&HV/7,B:640B;1
MJBI>[&MF__F@G!Y,MYZ#EI%.Y3#(VI_N0KY@'1.*@^97]6_"SG/>-:K="$4@
M?\KPA\[O%G\>^F-KR\A R[[CJ'+,&)<*DQIG$7)3+^M<UAP945$<MWG5!QE$
M-2;J-K'_2 (=B=9.NP_>/@6'?3V\3PYCO <[NO.$R_&0S\R7\?@F$U3D[#U]
MM>KW]5AHFE\>D9]VL:[9MM$J#VM<I8QE(QNJ-&^':="<RYXX!6(M"$ @5!S&
M$58XV0D3V1JD0=!+KSILLZ(K$113KL*8\+G/GCDFS@G?B\7!8$3 ==033%Z)
MWT)R:PJB%I"E;9;"NH)79;^DP 72E7B9<DR(._"2P0ZTU@8QZP_;$17W%2D
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MCJ5]<#&#QLGNFM:=L#B4%@1F1Z',+K,VCVBR2*]AW6,[%!?M:MTURP/*R;1
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M'X'<8M[8MR07Y-MY@O3NI*E-HM@H<I*V.&'V+?J*PE%R/,^_98)P4B6"?<W
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MP!&,7Z@M@@*?"^S)C.X,K)(7IW7Q%74_ OL$;W&6&)2'\UX7:?Z8 H?ZT\M
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MZ\-0VNF?6?"-1\!ZNO;>":/ &<>1 Z,S>-D-=[D5P:#B1_#'%SDG^?"9/U_
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MHA&9:CS6?!25FJR:K +3*3"= DTI,)WBBT,'TU41<R7S5/4=4WG@!71(MZ,
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MP2Z.XN 0D',&YOK?UW9KP2+LQI=UWPKS[;=R=*]E#Z[&@+Q.08)XN&C.^G;
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M&>*>0<!L/ZLXABPF'IN!<8S"@66E\"W,!K$+DV (2@[.0@PNFOG&*8:?6/)
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MI&"&_ X<X3LAMQ<^AL9DT%XF=LU\BD<#WH K]QDN=A0S<DCZ(2G>KI3#_F3
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M:0])Y15:<#(9<CJ@1J@?^K)1=&FFUVAI03L.S)R'\]L3?:O4-S+]1]5OT;I
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MC8K]2T&ZI%A(B0E4DLDO6U&>E3@D5.NII,G,.-/ #/J<Z !@%I2HF\,C">]
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M-GCYPT^C2)54J3P4Z@W9IEIP 0=:&ZRBA\L&#R/D;TAOJ$+7-"WXO1BVJE/
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MLEZ3"R3C1%7[QVH8],3?@C$L?F^)^^&5^SH-RF["D++K9SOE:@V7"S6,>PR
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M<42SG0U'M,4#?+(>:>._:_5]=W@=PO2<YG^P@JA=A?^Z_UMHDDJ%I(-,+<)
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MIF,+/R]U,\(,Z)6G#Z_1Z\"91,&O!)E>!C]CA@YO+](#^S?+UQ(&65#O@@H
MI<AG<S!?9OQ/C_V/(\?@@N+_VW\/<]/^NZ.^RN'.42M@]9B&]Y#ZQ;MF?7^W
MW=B/XSX@!Q'_<2S[-52_>'_TWXO:Z<[^,:S'[X^^DYVM _B/(!YQ1A7(.76
M(,F!)C0''N=<60,])VQE_6.WGVUTOKLB*+X9S:%NK]-4=R/PQ4[03*F %/Z]
M%O[%\ZEV)2I2[>I.S]%+U;\J@SKU#[5&MMW8_,42%"\Z^,V=QM[.Q^VMC?W:
M5K:W'_ZJUQK[>]G.^SBCG7IM >=T4!3 N;7D32RX,ZJ\ ^4OUCIXT?F]V>YD
M[3(R$A.ESF)]GI@5!OJ'T3B/MN?;>TX+WS*M9\_%X#G_E5P,2M?R7\S%N#/%
M ZU)SN:>XI&O48Q?^6#Q&D0O=8_RA2NPWJ\(:22II2Q >^_IYZ]Z^E ^J/*N
M,L??>\%8MF T0F.<\_ZNJKO/'MJ\,Y YNI[6__T>NW[K;.]5@/@>9^6GR_F8
M9RSI(!]\0GWQS_0)S>+?O+03*GM8KUW@G3ZP#YEPGE7DIOZ=T_W7HZ8XXV6K
MU-Q&'JCW,6$^AB2&G6;I?QKV[<IUAY2003WU/AC#W!!)I1:Y]UA1#G.G$=<W
M.J2L,\VV:O7_=P6PL7MJV ??E3KY?<1Y[WO=]N8H9_]K<W"X.;HU4#L;!7HV
MBE"5L_OJ;"4KKU2$X9P-?N\,V\!V!V#T(0%L857#![ 7]W9]'WN[2*/]^:S1
MWCVN7WS/#_8W\F]'&W!GJX["\X\:%\>G.Q\^G];;M?/&I;?[Y+!Q9,C.?NWB
MVY8YKX?/VMEZUSSX>G!6_U _"V/%]7U[=-#^JUUO3GF[VS44/IO6]QO'C8OH
M8?M,ZA_".(YJIP<7-=+8,F<-U&@>M _._WNQ/:COC;S=^U]@8__S/QPA;ETN
M@#!& ,*] X)J SQT!AKN<BY($,YD%4D^]H>-3\YZ6<#V,5 9T]\#(/,@;I_Z
MR&GYD(AK28G+^SQ0%[6&Y998F&NIH-?$48RT(JCTI.=CXLH3<56?N,ZO$Q<Q
MQ&B?<X"@B\1%+-"2.F 9Y]8H9QPS)7&1/!%7(JX%(2Z)";+4"LZE#D?<*>29
M"%_SH%XI(POB@G)$7% FXJH\<36F-"[!<F8I8\!!0P%!@@')I 20.N6T= +F
M/A 76D4YJ1!QS<D=LQ#&[DYQI61<B.I6]PQZV.QOY.&%)BNA5'A&(">I'%%0
M*25$P4W(6(.%2>;A8I%5?<8\Q(1":*P /+<2$"QT, ]%#JSRC$*"4%"\5M;A
M*A/HL5QU!U\\E9)U7^_AJP<Z,])Z9X-!A10QAFN$A1-<(2RI91 F<VKA@#YE
M3B$OO8!!%V'4<$!TCH!"$@+GG6/"0<R<B$"'XM%*20)Z=8$>]%+&)=&06D@D
M]4(2@QSUBG$'O:?)_%@TH$^;'SG5F%L$00 U 80[ T2P- '%V& 8=#E""XD.
MJ:@0T.<9:H.RRK;'?G=0]+QZA.TQFON]>],N'XW]4B)UHK'*TMCG&</$(^XX
MUQY8$N-6R 5"4U(#ZQFF1(NHJ*ZL([HJN9R3%^4AO9Y?TC><..)^GE;)L"82
M"L-S8AC3S)E@[2I%..>Y0<FF63B.F+)I<J21(- !BP(S$&<\$,A"X+5@A&-E
M--(%1Q T+T]KXHBEX@AO"<ZA0=B'$R.@5-)):0AS! 79 U4RAQ:-(Z;-(>YU
M( GI 3/!$B*,NC(31CO+O-/&YGD,(^-5S![MX7PNCOB%^^,5RZQ,@ZQ8CFIU
M[>6=J]I#9R>NT__5?.K["LSTC-<5"][L]@>7M=13*/C9/"YQW7?\AV[7]C<Z
M=L_U8MV@_EZW99-"-#^%R,PX5K3)E=5, 1XT7T \PT$7DD$KLCIWS&*L8T(P
M6R4T!8*6&,]S]XXD/#\3GJ><("[W"%$H@..> :*4 A+A\)406"-/J&%YQ#.D
MC_:3)CQ7%\]S]V0D/#\/GF?CMY9S:\/IE1(#H@D"2@D&\CQ@6_N<*N57ULDJ
MIJQ">'Y-5R5W7=^I7FR0V;E6K?$QL=SE)J<G"->66Q"8:>MJ VJE@^#*R6J*
MKDQVN_.IK \<.2VQU_S8Z_N,=2&DRDTP,8#+@XE!6$Z "%((("0UU 23H*1$
M]A)P7E';!0VZ+#?@GR#VF@!?#<!/F1_"YK',G@1&$P((9! (PH/B(HB&X2M*
MI(N 1_D27B].@'_"0&H"?"4 /VV?4 N-A!P!@Y #0:%C0#FC ,R1Y+F6'F$<
M 0_AH^V3=+OMEV [!D76[(!Q8XS>/&V65^%0>2:;)2:"#,8[5MQ+W#]4G?VR
M2^J[V/*V8+6V'C45^]IK#@:NL^-]HKGYT=SQE2$3QE;?,O\(XR6QS /&\D!S
M)E90$5(#":%7W&*!37%?AN:T0FZ8Y%9=3$-F7BS@FV?.@@O7ZR8">"@!G$\0
MP/[&/TA!PI'"P)/<!W/&*: \DD!9Z2R+3@[(5M:+@O3HCT0!RTL!SV3:) IX
M<0IH3.H ^]O_*,,(IL'4X=3DT:/!@904 @*Q]D$NJ-SJ*E+ :PK&[+E6J^AC
M^-UUBAZV18=0&[O']@>]H@M"BLL\FXTSVHT/Y5X$@MNXMA,C]TVR7)[$<ADY
M:)0),HIZ!SRS#! .!=!$F'@K!E*::XBBY4)7,7OT!>#DD:TNMN=NN21LOZ!1
M,G:^A@W4T 6C1)!@E#"I@9",QVO^ DMOM6(X8IOC):R)F+#]9"9)PO8+6ALC
M;!NM?>!C!)S#$A G<Z!1;@#')&<">D:DC]B&M$K8?DV!E<(J3Q&39[,FBO4>
M<=(E!266>0#+U$XCPY060F29+_D_0@L5S ,*.+4TWO_00 :9 72NO+,<"4SX
MRCJ4Z?;'$D-U[L9!@NH\H%J?@JH4E'F%@*(B0)5A!I32&#@/C9(<:8=1@*I(
M%SN6&*ISU_435.<!U2_7H>HXA1YZ W30>P#!B 2I*CF (N8*A/T2*-["6M8K
M&XM0<J\[4T@@%=^KAIX?DS;C);,1&_63GV&.7'4V8P%X17+%J0>8& @(Q10H
M2$V\!LZ)%#+H?32J%:MX;IU54MFLI6* )[D\GAC@Z1A@RK#(+3%1>01*QZK_
MD&"@A(- 4VD99 (I: ,#L%4D'IW=F!A@&1G@2:Z;)P9X.@:8LE>48I0K98%D
ML4JX%18HREFP5P+X#1=2NF"O0+S*Q+RR!%)9O.6H.+<0@WQ%9?&:'=-MIR2W
M9PQ+C9=^NUCYC]U^DE;SE%87,Q:KM 8)QPW 0>$ Q 1I)24A0&ALF1,H>M]6
MUODJPZFJP!(C>?Y1JX3DIT;RE.5I)=)A&RG(.0IZIP@VJ*3* Q9^@25S6'J_
MLBY784+R,B-Y_D&MA.2G1O*4!2DQ]T0S#S3+;6QSRX' /@=."QAXV5%F7$0R
MXQ7L<EL9&S$]XQ[/6'YCKNA'7!IRV9M1>/)MJG/^U,]X3<FKVT'\]EQ_,(Y^
MKV8=]]K*?[QY2;?!> -&'NXMIU.EHGFJ*&C&;0"Y9(3XH)@HC0 Q-@<28@^X
M40A9")FTO&B%*6=KD[U-R7/+@.*YNPP2BI\<Q5,N XZEM()9@)#Q@! N@>(.
M ^$H55!:K!",*$8W-'!**%X*%,_=79!0_.0H_C*=<@*=Y4("G=M8)S2(89GG
M!"B+I,B1RH4O9#&Z(9O]15#\FHIH3-J?OVX7O K/Y=S-@D:WT[WNO$Q)^;_$
M.7A&_S<TQ]03""0W@7,T94 *2  UCEJ6.T.)B/UA4ZAAB0$[=PL@ 79^@)U2
M]2$SUE#&@73> N*U 0I3##CAF)B<."QM!&R5*@LGP%8]-I@ .S_ 3FGU+,\U
MPI:!' ;5GC 5 *OCQ@B$N(*$>1<3<RBN$&"K%@)<T@S,A1CDTD<62[[+M//=
MGAM'& ?J['&7'Y=; #U!Y&><D_*^UVUOAL]J=H9A_49)*]U._UVQ/^7K]N/N
MU)N=;J\Y.!\[JC8Z]OI3:O\W#+^NN\%A-_SF1WA)+"*;DE[F*>_HC$5)A5;*
M: X@@4'>>0N!YIR"7&M*D%&2.A2;;?(<5DCB)16UZC9E8HB%98@I$Y9!9Q7"
M G@=*S0*HH'B.090$.H5=Y(:MK(N5B&NDDZ<&*+J1FQBB(5EB"F;F1*54VIL
M6-$\!\11!(0U#GC(%,P90@R-4N"K5)^Y:E9S>D9*G%U9_]3K_FCV(Q<'RDKF
M[4N:MT'DC-RJ[US'^>8@28H'28KMV4(]2$J;.V4 H@@# B$%$KL<0$@P-Y0B
M)DS0)?,JR8FD22Z&K9G@^GBX3IE^1FC!P@X!8J@-<#5!L:-> (=SXZDQF,3H
MI6 IW6")X?I$AM\-<$U&VCRQ/)VNZ%C@UYB$H*(;!R$!1-"% %7>2RV]D=85
MZ8JR2KD(53/2EC1JN!"#7'K;K^$&M]2^>;0$NFFB+RJ _O6H*2Z-<)U_\JT;
MI((!3R)29XOX6 45%K'0',,Q&Y=0H+24($9,#*9":2]C?QLAES RDBAI22EI
M_NG%B9*>CI*F&VSHH%X1F0.JG0YFNPOD9'PL,\8(99P[9G&L*Q:^3924*&E!
M*&G^"=2)DIZ.DJ8<#T1ZY*B'P%#J@I:D(!#<$2",\5!0Y+ 4D9($F;WMG!P/
M-YC+.$S)=H>ZY:ILU"_7*)?>]U!3O4X8:#\[<>'0'ZJ>2\6:GOH9KZE8TSO5
M;YK'W'I?-H7MIBDNKL+VR?7V(FG,U[V%IO6V,4N-/ZXX59<J6IY4M/NH:+-E
MI;C++<J)!E;D'A#)')":04 4E9(XRZ6)O1/R-;R$/503"2TY"3W2H95(Z(E(
M:,IU%9WIQ#$$5-BL8"<R!C2F#""D@[3 D"@220BM/;Z'6R*A1$+/3$*/=&$E
M$GHB$IK.DD&8:4\(R(U'@'!I0=PEP WG2'--E; %"3T^2R95]OHE[&TU6\.!
MLRE#8EE]_R]D2H[.5:+0AU'H;(TRH2$B E,@C,: 4&2 B-G^$N8L;)JWDLC"
MF$1+F.6?:&C):>BIC<E$0[]*0S-%EL-V<"4 %<X%&A(,*(HX\-IIJ*"PVI!"
MD\-+6-@BT="2T]!3FY.)AGZ5AJ8,2B>QI=@@@)7/ 0D' $C%,/"Y$U9B*#"A
M!0W-K2OQ,F8_I&?<XQE+GZ-0,%,_&_:=S9J=;'#HLC L,VP5Y4*RKL]<RF)(
M60S/G<7PB$DOJ%Y2(*O_U%=9OA9C<78CK(GZ[AK#MG:]'5^RP,YPT!^H3ES,
MZZ[OE*=Y'TVE?CK;DIH'NU4; Q A"! /"5#:Y #G@@GH=.YB/PO*9Z-O\P#$
M/*3A$H)J[I<Q$JB>%E33%11TD)O.(P"U=(!P#X%2-O9[,K'-._-:L  J,1M-
M2J!Z,E#-_3I! M73@FK*IM:Y]5Q2"!S*,2"6(R MDH :RIW27ALG5]993N\&
M58J:SLM,7'1">"[5=;0+,[R0*.%AE#!;6,P+$TN(*6"4,("(G #!C 4<!JU(
M*D%S9Z+R.GL1NRK^@26$U7,IKPE6<X/5E/JJ.0I[EN= &94#HKP&V@D!L#$$
M8FN@)2[ 2L[))DRPJI+ZFF U-UA-9QEBP04R#%#M@P+KL O22BK '80.<^(\
MS:,".UM7;U:!_6V@=,N%OVWSQ_J_PQ_CP]M6O>_-#B@/]N\B',313T8EER8A
M85RLJ/W\IQ\5;GWG,F5,MQT^^SR<KZS3';C^VN54IR<V>C-!I<Y]TNTWX]K\
MWG,Q$/##_7':M(/#,;0FWCA:BOSJ+4KWN_&0W_J6JJS1>T"NK\?DGW&\!1"1
MDAP:KYR7@B#B)9,H)] R%WM*(_0/%'!E_*[#R_#>20 ]T#VGCH'R88Z_J]:I
M.N^O_';]/(6C,[7TTZM6KLWZOW7OM_6;AGOGZ7S^I>8W+O5&_4.MD6TW-F\_
M@=4=_.9.8V_GX_;6QGYM*]O;#W_5:XW]O6SG?;:Y4_^T6_NSUMC;_KL6Y[=3
MKRW@# ^<ZO4SU['.9EO.N"BK,@Q7LVB9%7_F69!3611]V0+.[\UV)PN/;<4&
M"&_O.?Y232H$P177%7?<PZA;ZJ3O?A]_\8=M]D]:ZOSW9J?X[.)-?UQ_7(3V
MM.<BKD[YZQ'JI5SC.8_ '[E01A\\XH2U@A.F<A;*WU&ZEE-QZZ_S-7CK[^YZ
M;$S*Y^R7'GOW[RC&KWRP> TB<J_'_L2G]@#-_@X%OL3G\VCPXF>@+81?Y)Y[
M6#Q+//W\54\?RL=YEG\><ZF6._D7*I4^I.SK,J:E/GC^"^JR2#5.;W)5[&S5
MQJZ*O/[A[^/ZAV^M@_;[\%GU?.?#^Z.#]M^M;T>'[49[FS8^U"[J6_;XV]ZE
MJZ)YT/Y\?O#U6_C\=^WZAX.\OG]XM+-U?%'?_[L91G!Z<%0GC8O/IP<SKHJ_
MFM^VPN>V:^?A?:??CCZ?[7RHDYW]^EGCZS;Z=O2N6;_XCAM;[YK_O1@[U6N#
M1N&J^/R/]$PKA@N/'P?$60DDS0EPV'//<V8QY',J<?I0@%3\QG8BNE='=*ER
MZ@(1W?EUHF.>*6H"LTEG<T#"[@ A% 322"T)B\4*_9P*IR:B2T2WV$27ZK$N
M#M$UIC0Z2)3F6EF@!(\5OEP.A)8:($24P)A[[/"<RK$^%]'-,Y&+KMV4QU5\
MW^Q8UQG\#LC:30[2%[/%=P:'KI?%\%G/';I.O_G#C?M&OFD%.+U=S3K!7._Z
MK.=,2_7[31_&74!<V:/AJ$5NX3,O^DRF&S/IQLS\3N>;R.BN_S;[KIJ=?E;V
M-0TOZ&1FV.NYCCG/!KWP_/(.UR_U.+UOB:SJB=PWS^M%Z8<)AZ^FA6]!()N3
M_%'*XO?E1FV.]FD_;E,YSHV.W;_:M(U+%@EB?,?OJ[-/W5[QB\&@U]3#(L2T
MW_VDPF.JTY1Q,>1W?<8C8[G)+20$.(@((!@QH+U#P$/A/9><8J97UB&>37Y^
M^U#!72$C9,F)X"6=# G^E8;_E)\""L>LRCE07 ;X,V*!4.$KRGPL-4"LQ@'^
MCV[(FAB@PJK ',SOI HL(!=,F_(*"J@U1$ 8[ !Q"@.9(P6<1+A,^6-\99W,
M%A9Y$4W@-5VW^E 8.X7Y'6V? &>C^H>9;W5/LT-GO[O^+UDZ]ZW>5#UZ>\EP
M\6VD%BW3S; M[\.N_!DW)>Y:_.%&3(+=G7*61*(+=):8Z^',]7G&B*&Q128B
M&A@7C1@B'-#&QEO2!DLN(:4\,!=&2]BD;LF!_A ]9@ZFS /UF 3YYX/\E.$B
M6<XH,AI 0^,-31@+_2L!,+<XE]0%@J=!6<&/T582VBN,]N>W6A+:GPWMTZ8)
MD4CGGD- %0D"7F$+)'<46(BAL5 B0_3*.ILM>_(B8'_= 1GU0S5;T3 'OML#
M?14OD3@S[#4'S5^T4UZ'&^;Y(S(;XYT*&Q7W:>]RFY+CY>G8[<N,^8($9T%%
M#?:*@!80! W0&G.04T@(=\9C'6,PU?"[)/_KXMLM"?@O!/PI(T9[HHU!"&"A
M&2!2<2!,;L*1#"H-(A#1/  ?)>0O$/)?,N\QX;U:>)\V8QAB6E%N0*Z9 ,3Q
MV,L&$V 4I@0IG!NJ5M8QJU)'PM<49RGPDT(I3QY*4>TPZ[O<+,7OBJA7:5XF
M<IHW.1W,6"$.,^&Q5T!84;26@$! DP>C)'<".DXD8S=9(2F$4FV OZPIDJ!>
M!:A/V1V8<LNY<4 JZP#!A@*) ]0UXUQ@@;@S=F6=5\.;FE!>_=!)0GD%4#YM
M;7@8&%PZ%V^>6D"H04!9:H"/+@>L [-[O++^F,3NBL9,H*R\D7&O"U;%_:G'
M1$P>=Y>V>B17U;2OQ&;S9C,S8YX0Q SU"@&#8S^98*L '=12$+YSVC@AJ'+!
M/!'SRE5?E/OTKYD/JAUE2<SP1,PPG0HF.81&Y@#F5 *"HEUC5$P3H5I8CQ$T
M8F6=T,?8,XD4%H84JAB 253P-%0P$V )9QIRFP/'?% 2'*) .9P#(B41AEFM
MN%]91^317LP%JT5176MH\P8[Z*'VYV@71N6&<5AJVQW&XL7CX;_:FD+S7Z"E
MX?ZY&X@WT/Z8\E,)HOF1_O<9RU 88:F'&##)*"!4:*!SR8%'N43*$&\Q75EG
MJ[EX= FBN>/IA9WBB5D3LU:_I$1BUN=BUBG+VA+A(8(4& 9C=8C<!\NZ\+X1
M+;%6$%H4F57DL[9U8M;$K(E9*^ZO2,SZ3,PZ[:B@.4(JV!] .^\ 46''E PZ
M*W;"0H.)8L2OK(N@LSZZ$'IEF/41_>5XZB^W8/WEZ'SZRY'47^[5])=[M_%Q
MH[%9R_;^K-7V]Q9P-C/]XT:=XU"^Z)WC5C-W9ES@_9,@(8HNLIE5 W7?AG+X
MEFDM2HLYQM=R\6LMU.YLA$;6D*2+TK6-K%%YOP'-KVO;=:7EIVI)U?MZS;NK
MV[(MS_6N;S<>(_C 6X/WFO9SA+]NGO3&WMZDK'L=(;^B[.,@4_V^&RQQ??C7
M5 8DUL4IM)VB,*'[OV'SAVK%1@"/N;*X;)ZMFZ:X-+XIKJ'UFEJI$"0Y\YI@
MA1F6TDINK43_;-\SC!H.T$;'QK]J5\=H8["I>KUH;O^M6D.W*,ZISR/GU$F[
M<;2!ONW_'9YQC+]]J.7?]NNG.Q^^P(.O![CQH7[:N-C .U^_X&^;8^=4-XSG
MW6&]W6CM;!WG]8OM\%D;Z*#]^6SG:QT?[(?G[A\>U[?>->N;4\ZIHV,2K,+S
M _2%[.Q_OJ@??0[S^=;\ME6C!Q<V//-]:^?#Y]/ZA^W3FVK",T]=SG@.D'82
M$*\XT%91H#&BEBL2_N6QIXN<6[)MA5+G$D$M*4%91QQUC'(/&1$HEU#E5GAN
M<XX0Q[P@J/M$(Q-!/3M!3=]?1-PR9'* <XL!R;T'&G$-<AZX*GS+E# Q+HEN
MJ B7*BD\!R[KJG?L1NZ=QQ5_6]PKF2^@/%T6>GG?[>U=*_2RY?3@ZKN1"9:(
MZ$%$-%MXVAC(?,X=L%3G@"B#@41* F,9T5YB1FE^8\G\5#1A:; [+[WBP=A-
M&L8<@3U=F4U3PKG,@270 &(X#,#6'BA,<$X)XRY>)""K6%2I(,IK\CCM]Y1U
ML0>E"RIX0$V_N#;]RNK+OH2*84Q8NT%_]W+E&VZ0.&GNG'13F5@'34XYT-!;
M0)BF0&AF "822<4=0YI$3A)RMJ;#PKME$I#GKF\D(#\7D*>4"RH=IIXPX*#0
M <C< (V@!!+:'.J<: AM!#)%50+R:W)?;'=^!!1T>\EI\0P:Q7BQSP/_).*9
M'_',EG@4RD /*0/6Y!@0:PP02%J 9$Z1-IX+%"LEK.;BT7[3Y+&H+G#GI4$D
MX#X9<*<T!N&<] 1C !&7@!#H@29$ Z@#ABV34N2Q<'10_>=U72"Y(WZIJMNU
MU*;DC'AJU:%8]8UBL9/E,G<>FBW"EG.5$Y=+@(0("H3/#5#4&Q#KVH?_G?;<
MK*RC5<P>?2$TN2"J"]]Y*1 )OD\,WVDU0A.$"'8!M"J/-10ED+']#'-Y;I7+
M3>YC>:35G%<IL6N>CH=JEX;=[PY4:QY*Q/4[GZ^QM-O<PAV)G9Z&G6;K^#C.
M(;(4 QI.45 NK 3"$0-R@JBG3""!Y,HZE*M8/-HO^E" +)#OXA6#?FZAD03Z
M)P/]=(D9FAL=2[9RS."H8B.B.7 &(L*1#^1=M,!;A80L"NA'"LM4 0!("TC/
MVQA9]&<L_76W3[WN21C+^6IVTE)1K>O8XH+42>RZ]^M)*Z_"4STO+6Z\!Y_B
M#FQT;&V\_LES/5=^KYU&;B\5N\CO7_)_O'1,(^: X-0!(H4%$F$-<(Z$4$@K
M9=#*.EV%8E[\OJ!ZVW(C>5ZJ64+R\R&Y?AW)%CN,'&& 8DH#DA$"VCL)>$Q9
M$=0P[DV1?_;X:X'5"T)55[_8[@Q4YWLS7K4I/48I$?:9TE;&ZUZ:BX& :F>F
M-8Q+]Z';M:?-5BLQTAP9Z6Q&M\#*2\)S"P(U,4!0K*+'. )*(08E4U3"P$@P
M*A>/+OV<XE'5A?3\$EH2I)\;TE-*!M8X["$7P),8HH(N=O!@>= Y'([_8ZYL
M@#1;I:)*(>:E]V*,CW_R53RU7I&(Y@F(YGQ&=["(,AY4! "5\8#DP:Y1WF&
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MY?C1?)32'ZJ+XSGJ% G'SX'C:;5"4P29CO>QE06$8@\4"VJ%A#:<6XZTQ*+
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MKQ>!\&LKY]J_-0<T575]T<#+9')NK=B09 K-D:AF^\1;Q$3L=P5@;G) %.)
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M8IL>0J4<2B.%EX%(*5$4:D1UKAVWT#&(V!WV6:+2IZ/2*5M,0T0)EH$[-2&
M8&R!MM(#++P0)NR6]*(R5#K/YM,+<!VC$<R@LM=TZBZ=KOBE;4K;]-0N58.I
M9,88RH4A029+:2QUF.1&&VX]C<F=*!\E=P;I_5/?:J"PJV:GR:TZ1U%^/A,L
MM9:PG,<J!)HB0&)5'1&O,;D<<H4YP>'?F+^)V+QRI1*&$]6F;?HUJI6284TD
M%(;GQ#"FF3.$0J4(YSPW*%%ME:AVVFIRC!,D)4!*.$"L$D#E1 &'2"ZX=SEC
MLGI4.\_;[)#=;#]-!YXJ!<^B$WM1@NRR%7O6"FBY)>+T.EPZR?.6MBEM4]JF
M5[5-#_%C$YDKCAU&U&#"J9>"!?%//<?629.+>VAJMSBT"WFT.2F.KC2XH,[M
M^'UUEI2UAREK%S,9AE0B+I"QP!,&@[*6:R!YCH$R@F*46^<(7%DG=+9'2(H7
M+@6 YV!J)0 _)X"GK"T&N4&2<R M-;$^#P-"6PT4]HA3ZCR.UE9E )R*1-^(
MV,L>V!%:+=5S-NMVKO?S??.ONU#]R?6*&[;S1?=VX_T=5WHO!SW^\*W1V"]1
MG2=4WP?5^<?]C6NH_HAW6^[/W?-O7^V)1H0UVF$-T.<PCC!6='#6V/H<YOI7
M*[[_X.([W/EZ0+[M;YR'N?@PY[!^&[1^$;X_VB:-S_\H;YAB7@"9,P>(1A9(
MPS3P(G?0Y4@7.<5LC;(9DLA.7"\K[HB_?42RZ>(Z+9-O.6U3VJ8723:==[CU
M4EQ-B+!-U3],X8#YBK*IR&N0,%;0V 4,1@55,@DDXSD0W$8;TRCNV<HZ7A5D
M]D)+*@A?62@GQEV(;7IF5T!BW)=@W"F7@.=4&$T$,$'O!T38P+@("^!SK;C6
M' MA*L6XZ8+@C=B-S;*+^F93Y<;CY<  W(XK$7W:'!QF@T.715^;ZIP7S,S_
MZ&>N2 //U*GJV>RDU_W>4^W7>67P8=7/6-!1I$?(6X0)M%QB!75.HTL<>B?Q
MSWCPYH+ELZW/RY)HJ??Y/%@0SE1'0Q3FQ&,-G/&Q1I+W0,B< 1WV2\3M%(BO
MK*.U1Q=(2N&-JJ!Y5J7!S"@D45!>. ^'@0CA Z"MM1YJJW[!B+P%RD4%UH3D
M.2%YJMH99CJ7B'E  A$#XB@!*N<86*05-AH%W33H,S(!>=& G/)!TC:E;5J&
M_.HD%I]!+$Z9^4&789!! H(R*P$Q'$47*P:*.B@D1I(873&Q^,KNJ.[=M[?S
MZ_!%)I?Q0FS32YI75RTI^[?VI"SDB9Z6)[O1V]5O#MR>Z_UH&E<*H%UGNM\[
MQ5-&33*2U'F(U$$SQIC&N3406T"T#A:9LCX88^%;*G+*/=<FYWYE'1-9H;L]
M"?>)GM,VI6VJJ!2=NS66I&CEI.B4[<9S7I0= %"Z($J]=T!IXH%CP7;+,36R
M:.!0*2F:HK0W GU?G67-]DG8GJSG6FH0;+U!-W/MDU;WW+DR8GL?&_ UQ6.3
M1W$AMNDAR4-S, 5ON4=T)<UN%6;EQ:* Q%I12/E]K]N^V>O8<(,DO!XFO/",
M"9A#Q1&6&N2YE,$.I H$6<9!V'^*)9<XUWAE';)9X97N#%86ZXF2TS:E;5K0
MM-LD.2LJ.:>;>T#/,>(>2"7]_\_>FS?%<6QYPU^E@V?>)WPC2-W<JBK3GD<1
M6)(]NF' U\+CD?\A<BMHJ>EF>A%"G_X])[.JNGI! M%  W5GC*"[EMS.[^SG
M$-A?351I% DFRTLC K>9VR+.^<S<=?,^VY/ED-MGYJF[&K[N,6#VFVW/WU5C
MZ5#I)J@D5R)EI7).2$Z)LJ4C4DA/E%$4CA9H;X7)G'$:4"E[<9M*UYT!^E%(
MBMTV;0W4WD-*[/5PMK+Y=SE;F\3@I2Q9H23W01L"4GA.9+ 9,1F5Q&5YEA=6
M.,,4YFQ)?9M"+AUU=R#<;=.#J^L="&\)""^IYR&C*@]<$Z,]ULF1!A-G+<DY
MS50)VKDKPE:!\'V[9!^"-G\V@Y@$:Z)2_CJX<&;#N"?8;@_IZS8%B9]-?^"U
M6COWW%@:L*-1(;4RFMD<3KN5C =5"HDMJ*ZCK+>2^Y-&?CB;3J9FB*O78=+-
M,"E;4<Z#U1ES4I.2!XIIK)1HRP7)RZ ,*YVD&2CGH!&\N'4_X)M2Q2-R(3P;
M2E^55Q2C3@<MM!-:%B:W7$GJC<G*#"07:Z\@\ZX3^+U3_G*D=28R!;(FYO<8
MS'VE1&G&B2]H*4J5:2,QTIKM*KIJF.M(_ZF2_DUTE=([3F5AJ09AMA0"6#S7
M7&J3*5HRKJZF_1MTF>Q 8),@L-RW"C214G))!*.*2-@M8KU3A(/JR15U3@I0
M23C;E53=WFG8T?_3HG]>Y#F0?0'"8B%99FS&&<MS*VA0&<_"1NB_(_$;DOA2
M"?Y2^5(*3TEFBQS=;R71VDG"@A(Y%2QG&9"X5EE'W\^!OF] WC[(D(4\*TJ6
M2\6I9H9Z51:>%IP7HNA$^VTA^>46:3241688";1@1&J6$6/R0*SC.7=9J;V1
M0/+ U&^= ')?E/\-4Z3O3\X'YA)G$KX.%MV5=W_E,POLZGJ%=^[';INZ;;K'
M7N$&.+ESN0/Q2UHEC&!<YCRX0E!+71Z=Q*QV$K.N@>V#26=O/Z_87*C-J#4B
M([GAEDA9>F(SF1-?",5M#OOI^,[+;%?I6[M<.AKNH+;;IEM!K17<9-X41I94
MBCRSH 7GGI>N5)GTM.R@=IN@]N-R:5=E2P8 RPW+B;2F(,K!GYYF/*#9TAFQ
M?5"[R5[ACT!]6M<9/*E376_P+A6SVZ9NF[IM>B[;= /!S B?%491RBP(9C37
M7'BF"EKXDE)IZ(T%LZZA\.9%LLL5=Z0SRFA:!&)+'H@L"P<B&36$Y[YD,H@@
M)&B_3&W*,]'1[A;2[L:5JHYV[X1VE]0I -DRQYXW&HO)21U G2J5)#J4+A>Y
M#32P;:/=;>D(GD=%[(%(\Z[Z?]^2CKO^W_="R%^^V?_[ ZP:/./]ESWX_OT7
M6".8]Z"__]??\*1?^N_/_OSR]^M?^H='*_V_^>'>L5 B+XTW)#C/B91!$VU*
M0(DL*.58P8SQ.R^+%WPUCKCK_]W9B[MMZK;I 8H=;-J%VG6CO1]6MN1-53GG
MW 9.N):@3TK@0%JQ@GCAO/#2Y1E6-I"[5-\F@+TCY0YQNVVZ'>)N7.GO$/=^
M$'>E_W<11%&6)+-, ^)B92^9.9+GWGG'75$PMU6(VU66[_I_;U%AA()9QI7.
M"EHXZ1G5E@<;J)0E*T0NPK=PL.O_??\H2%<*)^C":JHY(QK^P<Q)^,T5&3%6
M4%UJ8'02:ZV^6"WETODQ'BDUKXHTA2Q4H82W5CN926I#:3@WN0)E1*OO\$%V
MC4[O@9*7"B%(SG3(/",%IQF1H;#8+"<0[),CO/%%T'[GI=I4$82.D+=;A^RV
MJ=NF;INVR[W?L<5[8(O+2<1&@6[O"N*<*8CT.2/*:TE4F5DKM%9:Y%O&%I]9
MWFG7_[LS&3^^;7I(]:KK7+I=7(>M*&.EU3I(61 :'"ACG*(RQBW)K11"Y#+7
M'*O2Y6R+\G4ZNN_@N=NF;INVE(MN7!OKN.C6<='E1G#:RD(81F1><O@A/.AN
M6.6UD*PHK,^8H]O&13LO;=?_N[,H/B>+XDV"AS:@"G9=3+>1>?'5_M^\],PH
M381"EJ4U(X8RA_LJ)16JR*7=><GDEG0Q[6B]@^1NF[IMVE;.N0'UK^.<6\HY
ME]0^%4Q>.*.(*Z4$M8][8H,5)/@B%$8XJGBQ19SSF;GKNO[?W]G_^VX"9KO^
MWW>"2F(E4K8H,E78/"?4.(8MQAPV&K)$Z\Q)RS,34)[GZT)ENP2MK:7ASD_P
M*+;I05-BN]:S#X;!R_V_>29H23W)58[-WI@A.N26E(H:JISD7I68LZ55!\*/
MB+H[$'X4V_2@6;(="#\8""^IY\SF-$BO"=5<@7KN##'>EJ1T+%<%R[4S>JM
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MW[_1D*$-EX+XTI=$<ET0$XJ,",EM65B12Q]V7F:[2F\JL/$1.3PZ1-JFN=T
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M*:77GX:SR6YO&+Y/H7D>UI:-:S1Q[0]&0V<FI\G0\B;%CG7(\[W:1YWR(%D
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M\&Q+J/<Y^3QBQM*YZ7M4D7L&26'2QZ5/W6%078A5'TPB$O_,7![;I1[\/)O
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M![:1=YC;86YG4>LP]]N8NZ1FFQ 4RW)-1(;EBK-<$B,#)5S33!88W9(JCV_
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MI <RDXE?PNH$9^)BUMC0L[,H*YV;*=X(\WFW;OE0B9^:6M-L\*D>8J7KPO;
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M7A/Q=</*#V/F>_:B]_.:(515:!?&"XAZ%LQP7C1V_A#X F#6+\JA+WI_SA-
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M#-L$)(9-29@."+101!5C%M+[3H,_287\*H?^:?^\73UT'M#5FD<L9YFB28>
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M*TWI6 %[%*QDF3*2\BS+1 ;_YJ)@3\:*]T=PD>NUZ]BW#]43P5)0$?;-&+
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MHWD(CF%K<4ID204Q3@O"@LMMR8,6N=EY*:B^+3I^!83N' #72[CQW<6U !#
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M+W6RAJNFY_>2[/OAFC 3-;].O>O2.MVHY#<U/!U\KI$ENJ?U<M9X$[E5*7H
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MD%">*;B)'+GF%IGUKC#PUC&/RK.0#7$UN5\1%/G?]L';\ W*BPME)3!;%WQ
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MM5 298F(HP[/;?-NX< \TZ_&NB)2R9IA0HJE8P'F<] LA&"S0!-,C:6-?K!
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M+6@A."N&:P;:6>8T!I910+;)II"J2ON&E8MT@K=A_9&Q7I1.*I'W3F8=%)A
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M0[:O=G_=^KSW^>7'O<\__;5-G]L[^O-P[^@U_2Y^WGGU^B-=\\.?KPC /\]
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M.L<1N4ZTWY!-,-RWMGEA+[L;O]XV'<%N')O%\0DH'W/K=]>!2Z=\\=@"E1I
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M^> &H.Y^N'(3<)6'5WQX>$@Y@D"P5/XM6)S9TGQ]F'-9W_9'X"=A;F 'BQ2
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M9/3%ZZO'^WAV;S7R+*X=^8+:]V'>1R,^]!:]]O#1XI3&HC]MJML=CKW1&>G
MTH [^]ZP.^5@]N""7#H.2#+6>+/H8S7D0HJ=L^ZT_EQE4Z$UZ;MT!T_$H%$L
MQ6\>V1Y3>*(DXSI2XKBSQ#(B)!4F:,NI(?(.R@CQ?#O+=;?^^B!(7E%(3.N]
M=$ ^;N\>6<8%./X".0)[ U?&(\USD[WD@F"11ILY#\GF3R@DLB0]3H94R@S3
M)H&Y[3A17%L<)&;,$1=XLJ:0H4FNIDJ&EE&&OAUAXCPSC*.85$ <*X.,C!BQ
MR"UAF'OJ["T6ATD9FFR.533% BPONC8#T+\IN^T]M.$6W+!LRPC@]U-&G#L,
MZ:?!W#/:S]<2NOZF\PSR2>$9CL"R#9Q$C2Q1-!_.$_#YK4&:26HH<S;P?$B6
MJTC,I(C>RS-VAP0]#>0J"5HZ"=K?.0(<TSY%CTCN,\VQP\C2X)%D09$ [C;+
M/?0H5IMB"K'A$(O&>3FW;[?VO[NS_^-VUQE/?9YSF[T=!*AVV3MD$!S]3T?*
M$(*35B@R @X\""1R+& $6Q2GB1&G=9':^!-+;<HN6_(W/&Q7G7E3K<XCUU X
M^=[IWE'@,4GL$V+,6,2-U,A)PA%-*:J0A+>.WWF>6-IZ@R2%-T_P)U8(\=Z7
MY!HQ5*!WGUQET#.22,VQ1SADN:(F(F,U0<IS82(QRF:"N&EYE17H/54V,_%+
MA7@_D4R1$4]*[ZQR! 43..+.@QP1S9#+&W$D7+!8.!5RDTT1S@+QTA +YAEK
MY 4SWPL&L'N9'?/^YM?GMC$+N=5CZ>1GW2(F*&\7IX;_%$[9<'\HR$9'U*[:
M+:8VDK^H;W\Y"IH2'GE$FN;=(N((.HDE*LY"*5'&IMS^AD_Q\I]$/C]CFDDE
M5,LO5-^.8F(&C(^$#!8$<6L,")6/2"DLL#3>*YY-6S9Y:OIDJOH93_$KN5IZ
MN=H_.&*>,><"10E'\.<E\TB[I!#.M,<.$V$HS;VZ[O;G;\>3WMP^Z;R?668*
MRZ ?]'H>/>2]H^-S_GC3=K.]?/D3DJ-',#2OUKGJ=**-^[F)[SB/?=S&\\1#
MV E<6!C[>:7Z=ZC^Y=[5WI%F,H:4.!)1Y_:CBB,-N)Z;7(5H@M2893OE9UM*
M4=LQ0C;J1Q8$_@"]O+#=:^[/7KO6&J[BW5S*C0E:T9$O*!(SICC-I9[G\?R,
MA.E)YO<SR6JY=8'S.W@I?ZXB/AZC:=K>.U),>"&B0]X[EVL&-+*:6B0,PV
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MC@/FA%2>Y:L!B#'/DFALE9 !$8;=H#]5!#$(SBFCH_!,F\*SY),5K15 K U
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M-0E,G3<^;N_0^OXQ/=QNGM9//:[O[^;/?MNC!S\^?MVE]0\[>._L\VG][['
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M_7A?NMTR'\?L%X(*(N8;S48!%]URR\S&6*Y=.LY,K:-I=5_V_X#-,79RHWE
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M33]LL@2P;A;V!MX/KR_;!PL,ZIGXW_4)ZQ9&_2%CKCHG5M.=IJ'I[04NR50
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M0$8CX*]^[5&HZ"<[%:XB7EFV4HVW4I=?LL[5J@)=RL%/\7SD+Z8/9F;=$;/
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M  SM9H_FNU&.:Y]\^T<UAT;9NR(,\71G]RO9VGU+MW>_TAR2*%Q,SN,<N,!
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M''MDDM ($R&L)512$UZ])M0\E18$#<8U&/>D,>ZFI^(-\"T%? O]]GQ@+OJ
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MAGMBV,B,QQD(=)6B\UQPJ:V3F-& M1$T>(_#J_O*MA@#P512Q3BE(H;?SM[
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MF>M(W$ZGYS.2V$+5U07#> R_'-IAZR!' _?;@S@6C,X. +W#A#?*0^ [N!U
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M.TIP+XSD+FDMHB$L1*M<8@2S4LU8.D&>4C.RI'KL*%)8IYRS9)&V >3:.QM
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MRRXXC%JCB$\V)J,YY<E(0S$G0<; +*7TD%*S\9#$C,N [#S19\W3N"N*KXB
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M06*)J'(<<<,YLM@R!&L;L#.>R2#!$E&;1L^Z&N8. BI18?E18;E H2RDN6
MF#XU2($K(8E%G-H  $ #,B)2))(7#$?EJ<Z]$OBMF36E;E"B0"M$'D640B62
MDW&P(18'G53 BE+%5'GDL)0X,*4(,&8QC]P@+4VNPL$8LCGB,%G#@N6&.4[&
M-@+1)0Z\&1R8JT#/\P-!:2.\ #1,GU88R[12S"&7$J@((CEDN'&(X1"DT"[8
MP(M2V_R6II2EC;"&J+!<H%#:"(MV$LP4_@F11.P38IPRQ#W\T=0[9/.AE2#<
M*9N]!')3B$6E CX[#"PH/V&I3T9VNR'>?R[R[LZ#D1=J\EX^HWS&JSSCK9V2
M[OXY25$J2X'=&90A@A%!.TNPY"PFH[DA@29'/87MCS_4G_D#=F_55SY^]^U1
M)N/G7B^<M=KM4GM9G/;R\>R/&>T%>^9M),@Q'Q&/)B%KHT3&T,"4A]6F1>T@
MK/ 2Y4^6R<X/D>[_^W\T)?37<IF6>YE*$'YS(+P_E<).'662)H2#4XASJY )
MDB''([?6L*@9+4%X[:4[6<EDRL$%)'%CG/.46:T523)8S\U#W4'S2W<IP',*
ML+\IP%ZG$!U5B!IF$4^:(4L=1SAJ3WT0RJ5<@Z*4WE63WE*%6HEE*D%V'4'V
MX_>)N4J*T[;WAX8+41RV1<E 3Z(Q(,MD1)([GA@LFW=QR6#VA3SIP][IJR88
M](;-V/]Y9L'/9CTYV!B3\!T#FH?>*#_N<AY/.RQ<.K_CPYN.+YY :X/H3XVT
MM!V8[&Z(W6$KM2P0LXRP>FYP_S[CA\38$J>,08%)#1HTID@3'%!2*5ACO8@Z
M +2S32*?G(:Q<%EZY<S1$E5+5%V^K):?PFH9K_8B0%N]";1&>AN9"4BHZ! 7
M@2/CI4=&)*P5(SHELH"DEA)C2XQ]FQC["CE"MP3]E4<XSPRK4T<XRF/JM8S(
M!X,19]3F]G\8"1\DSSVU56)%'##1BRJ'4&)KB:TEMCY7;'7I%7@-5)TZ5Y/4
MF\"=0R(EB;AQ$N5:_,@X'827E"0Z2;SB3TZ\*E&U1-6WB:HOF<=6>@66 VA/
M;@)MC)A(Z0Q27A/$'>7(2$^1$\ZR"/]C6BP@C:W$V!)CWR;&OD)68.D5>(53
MK>F0A>"]Q!ST5J=L1%S;7,W4>J0EJ+06_J>X&F<'WN)N754-M@AZ^&68MW?X
M;VC]LWTYM=JH _+CM_\#7UY.I&/[1ZWNY7CU38@['@U 4S@??]7J9L7A':5;
MHH#A%Q9DF@5Y)_X3V[W3&-!IOQ=&?HAFNAIE<1ZT!O"AERZ_ZL="I:D,>Q68
M[TG,GR</&%2L_]]1JU^D((X_#UIY_0=;E3]:/L*SND<SCS[M@XCV87[Y)1D_
M,M.,;/ORPKN>F4?0CSZV_HF5-!J.^K$"5(J#8:\;-RO]WKEM#\\KMEL,+[6
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MC;POS&X6K<'$2BZ<[)>>>C#,?^L-"NLZ^^8+)TK>UK)K*!]Q%?O17T/XS_@
M :[;[?I>)VY5ZMF?6B2R_G#PW-C1L@_G ;M8ONS&3IJWUNFME!9_6?&7%W_%
M9%NE<K-P3,XC#(^,(9^1@?L*2U^CQ,?OIZ"_QQJ\OWX6V__$*@RF6<K(73+"
MJO7J(<8J!F$H6.@R'P)'BZP+$04505DQ1K%48.1L0\O';9"OPQ,-8/KZ6:]D
MA;M9P1\&3),S6B-=1+2ZI!"L"4;&$NR9]B9QNR:LT.S'6#+#G<QP_/&0*TJ"
M)AI%3T!QEEXBBXOR%B;%I!*-5F1FN&_O7 UF^ 2;9\D+=_/"_F%D+E#*)9*>
M&@0+$Y#QA",E$VC80D61&PG0K=GLH4?KT:_(#G!MR0YWLL/%[J%45!@"RC3Q
MP2%N)49.$8)4H(E[JVV4+JO5=YM54VKUK*_K[GB1B6.)TRV5*S>?]L;>LW=%
M! P\[M>S5A@V+R,;K]TX\97A'[=8![KW:'CW+==\:A[4\MA_)?_9)Y3K!MUP
M#E[[FP=<\"&U1A&?;%%[D_)DI*&8DR!C8)92>DASJ<;)7<W^Y2Q.[5%$KA_M
M";())OG.ML_L^6#CEYL>QU873=%^FFQCXFS_Q_7AUEN&>Z__<O)-#OR[W9WY
M[+17M]*>L*W*?VX$""[ VW<3H_Z(@$=Q[S2'"X!1]D>T@SBHPQL^M'O^Y+5!
MYF)W C(]<G!\PAKU]]\;%QD8CG#CXBN\^^/WO?H7?G#\GN]]_M0^J'_$C=84
MR!SG]X1F=>?3,0#)R=[.U^/:YPQ.'T5MI]D!X.$PEG:U_K4%('.>'7<V$>,C
M*4YS*.(F&F0$"TAJ+058)9G@XST#0".&]QFKB1'"\T2 _S7'P/1>P[X1L-1!
M"Q_P!IC0WIYFR>Z/XL;VF-(S\9\W6/=6U_7/7W1S8!+#MY%ZZ9C@ )@F B?(
M&+UE-BJ7-E;8N?\M5MJ9CC\B$*R?G$&-HWK^=]0:1WA=!BG^<(L,>Q4; %E:
M14P1H/>/<]\B6*EPE>1/G<NHR$K>2?XIGKY5&:_?).PL]CN%WX302J>P^W.4
M2#N'W66W11QO\$7XEZWDU^4IH#R='!?6@JMSM$L1O 9/*EYZ&8>5CQ+Z81S-
M-^.T^6#;1?S07\T(.L6ZA*!4L[.J/2;OQ)T%E(N9I* UP7]/KP7L=N/9YB3.
M-7_.,6/%8A3A0#GRIPCL"@7MQJQ2D'ATFF^_#UOG40)_#JE?QX.KP[MOZ'=
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MK4V(&\N0MHDC^)ZR8"1)#DA>Y!14NKVN'_7[11KAS08+-_^SP,XQ3^X6LW2
M\? B-;=-<6W*S"RJ^.R4 S@/9B_M#\8! ,N3W+(JZ- :HT-1/@;0P>3L#9&#
M012AB"OAD(DD((8-"?!_U(>PL2WD;&S]RO>L*I%G39%G406N2N19)/+4?KN)
M/,HS[I(C*'K/$1>6(F- +XF"Q\)7KKW8V.;XR8575Z_;UJL*VK7\TV4RGV^I
M,[:$]O/4*$L#NC2@GX*:^U?6W"5J<BJ2(#XARY)%\"^-7' 1&9L(E3(HED1)
M\H62/%J%!58&!1<\XC80I!5GR&(96*!,26<WMM][WQ_%7(#@"CY+X[E489?*
M>+[<VL]_&SMY2AUV7FB8LIZ%H))%[Y -.">G"H.,-!Y1ZKQQ@5""<U<6/IMM
M55K/)?0L)_0\C_5<0L\3H6?:?/8)!Q^%0C%1,)^EH$@+,*2-P1([KP3#.E?4
M9TL$/0LRGTO#9^WYO3&CA3MMK,K1S,D;@KC&$0P?1A#3EC,?'578EB1?*,D3
M; %8JXBH<F!K:I:RK9GKKV"?$\D]V**WG!PNU@)ZJ)^&S@<CMZHD*[UO/[/)
M4+M:X'+KGE>NIJP&%F0TB@44O$N(4RN0YM(A+PPC41+!M=S8%O3)5L,]V^<K
M-;0IQ?6%U.Q27!\MKM.:-HTZGX)C)))CB!LJD4D:U ^":<1"N9![5S'\Y"/R
M!8KK(H\8"-VBRZYJUXOB6N-<J]OTCQ=T?)0]N5Z.0&NS&SRS\E;N 7/M 7Y&
M9>/<I$2)0=BIW+]0&J2%QH@R2;2C8)EZLK$M%5Z0M^7U>VPM/5J64/EPZJP-
M3CZSUESBY)PX.:TK.Q]=<-HCJK!&'%O0E7.I,<]34-0["6NSL<V%>76<?*Y&
MA"N=MIW[)?6ZE]5KNW%X618F][6JG,5^KD0[2>Z>3JA^:'LXLEH9U0)O:;Q2
M2<IO?K!,/RQ/>^[!/BRQ_@73OXE8S?SOQAV=(-8T%_R/'R!:9GR7&=_/DO%=
MDNSG)"-F>9/DKVIOOK3U=64*7=)FH8.06:/]Z2AN*0&;J8O8UBWJ76X!FQ^P
ML?TO\N^I&J4+/*I:&!>LFV]B[OFOC??AJ5VA?N*&R/75UL4# >_:_][H[-.#
MG9.+VL4)KNW\?M+X]JEU4/\BJIU:LW;\H57[=G!RT)KV0/S>K-7S=0<G>_4J
M@W?@:N=K$ZYIUW9.SAOT(ZU^WB4'G:^=_U[LSG@@A#">!Y60X2FWB,(!.<<)
MBC$2[60BUN<&"$PMZ+1N:1RQSP5G;QK+UA3(GMKAK 2R9P"RZ2@A%IWEA" K
M\Y&3)0S!_PB27"CB&8.=QP"0T2<'^,XE R6*E2BV+"CVU#Y])8HM'L7V+M6Q
MXX_?81Z'A$8J&*,HC/M148:T<00%6#@9G$M!DVR:W]7;>;E0["<>@\OC"IA&
MO!_XWL:5);E*<I7D6I(K2W*5Y'HU<CTTX'BI%?*_+KLYM(JVOL\17/R@_(B'
M9E@OGW+_K]=TMEXNW[@I<ZG9SZ79G\PX6JTE/%&?D"#8(,ZC1)IJB0RE3DC-
MG%)N8YO-EN_Z]PI7/2CE\_E\B*5\/DT^IVN3J$0\]@Y%+G-]O6"0<2PG\R9-
MB.4DYOIZ;-;P+N5S+>1SX=ZQ4CZ?))\W/6/^$"<NDB(68:\5XIA39'-I@ZB9
MX<HG*14!^9QU[[^*?+ZQTAWC?,*I .CGJ%_P0']FF4WX @1:;NQ_3=.I/ ]Y
M'.I_//NC_F58_2LC?];*]O%A B49*"\1T\D![$N)' T$A>2%T"0*(]/&-C%/
MSI!9N'RLQM%OB90E4KZB$5LBY>.1LG$3*97'#(Q8@SS#&'$7%-*@,2-LL<1!
M.L^B J34)5*62%DBY<H%VY1(^72D]*1ZT6"'V#BL.)<H$IU=?=XAIV- 0C-G
M3'#$TEP+5)&U0<IY$Z\G[T09F]Z1<5K)3Y*QT?BR14OF Q)BZ*,38@ZO_=_#
M&UR_%>K\B_Q[S.^S?Y\E]^F!B?>[XQ[F@\J@V>L/T3#V.Y-.Z!7;#95_;+]5
M),M?\T1M3GJC%QGYW=ZPTK%P6\NV*ZG7KPR;L7)^1X9M)1O\Q5]</#UC]=94
M$M48(VJC#CS27^X1DW\NP-$PO0T,!C'>48^C:H>C/ORWG@E0A]=^:/?\R8IN
M$P?_;6+?^;MKOYG1WG%^3VA6=SX=[]6;)WL[7X]KGS^*:OVCJ.TT.]6=(PYC
M:5?K7UO_O8#W'A\=4BQHTH$@(25!W"2!K&<2,<48,=3XZ.EXTVYU1S&\'P*-
MM*$6!^\D]YXSYXQ,CF&K@HZ1"@N;?(3-]Q368]@?Q8T5+E\Q8956+$I7S%2"
MRW4KX/M;1&%UJUH8LZ4%>TQ1"YVK&>AGJ1-!%U]Z@6YI\N Z$>L0+;4405$/
M2ZJ^1.A*;G2_X.H&*Y5=_KX#BO*#SHA6CAW7OUL\[ 3T%4_WWKJCY2WY4195
MZ?->O?E/>][)5;QV1K$&;ZZ?Q?8_L0K#: [6Q=N":SL?.GL[N[3:.6C7X)Y<
MEFYOIX$;]2K<]_X,Q@)J\\>+@YD2=U]P]7.#5X\;YP>=?9SG=?!YE]>.OS:K
M%Z""[WR =\,8Z[7V?R\^SI0"#4(I4*D-BEY;Q(.7R#JND,->1D88B8;DGD]/
M[EOZN@GF:[!+K6"(.<@^*^/*UPE_<ZFS^EFOA-VY8'=W!G8!"T7DS"&,$T%<
M$HET;@(4L?4^V:037PSL/GM0ZQH@ZPJVM0:IYF4#HK5#UF8_KDTH\@MA:W6V
MC6EBS$0;D3.*YYI)#!D"4 N:K.-:$TH#W]A6R]^/: V@=3655E$JK>L&K9]Z
MHWZ)K',AZY=99'6&8T8)(IA2Q W6R$0FD/8&$YV8M@*@@B^J''Z)K&NGM,I2
M:5T[9&W]4^JL\R'K_@RRZN0\(]XB(E1 G,J 7 1XQ;" G@B7&,6 K(NJ*U4B
MZWKIK/5F[$>;AK%?:J[KA*_O\Y*6(/LHD)WM5*Q)"LYIC+RT$G&B/3*<>829
M2H[20()/H*4\/06CU%^?77^]%KIV(]Y7%MG8KYIG/8[6.YU(<=F'X-&Z^M/B
M2<J-9HZ-IMQ;YMI;9ENJ:A6HY,0@;:E&/&*,8.T<$L9B[A/&,>CL='[V^M9E
M',7R!9\^$!^RL%9:G=/1,(9**X>$QL&P5.B?M:[0BP#M?A<XU^>(VA@^?O=P
MZ3B^MD3=N5#W: 9U:4A286P09;D]2G(. ?P:E !H8\2">N$VMO625!U:$TA=
MM^I(?P+,@AI4^<>V1_'6=)NR5-+R1EN7:>W/L)NM>4/Q%]JO3F;V*RZUX@(V
M*!4$6 F66Z2E%TAZXZ1S@5J:-K9A2UN;U/:5VO/*%/R'I^!/YU67U!HC]21C
MV19078#DS[.6;V8Y6Z6=M%J2(!6WCFN1HO/>2DX5)X'^)/5_:@S;KUD,X':"
M_'R"5T4$TF@XZL=*'SC"MH%.G4YK6/BLBM( UMEN "$.EQ4&0'G[GSFV2VDE
M6!"!>QHXQU%K2;535)@DG"!"_VR[M!U8_GLMOWKO0_S3ML+[RY$6/P\V\O [
M-J_V]^&[[JB#0F^()J]8^5WV\:4!/E+860^58=I:AQ%CS,$NZ3G2/#@DDXXV
M6,J"$QO;Y)9B[&,9F.2[;U6^Q4K\?AK]L#+L 0_Y"((,'S,KW62L<0N$EV:?
MZ[Z#7O\F!UWZ9C,#?1V//)1<<Q?7[.U\/-0ID>"I0<1(BW@B'EEA/?(I1FZ9
M, 0[X!K\$ZZI%(@/D (L Q=YV_7P15$(85(Q>AI[DO43.W%K%GTKL[OF372^
MMF].H)/3L<T\NP=-*@B,K8)K-TYV6OSC%NM E1L-[[YE)OO\E0I=?$*,3)'H
MVM]F_X<?]R@BUX_V!!5Q#N]L^\R>#S9^N:EY@-HQ1<5I HRGN?T?U_]E^[87
MW[IC22Q\B-1+QP3G5IH(<BUC]);9J%RZ:Z>CRG"CK 4-P/'$HU.:8AQ=XH)K
MHE>Z1$F]&2OC"V) %G0B6"$0GHYM=0'$)DZ47/YG7/AGYM)+EVBEGVLM3!<N
M>3='P:=9*KUX\1+@KRT\YK%YJY=(N:7U@^N,O*XQ]>!)$;XE.'N6DBP/KITR
MWV#%@Q[[P-.F!Y0#>0T3V*QF,9+K98YN>$!6>S6N.8\?VN9SN=<I:[L/<97_
M=+8/6+#U(1F>AZ77(@_@VT.TAJ)R65'W;^:L;OGD]\E1&FKB7EWZL_7[ZB?.
M<_IPWWG#)7^\'[/'UTON*'ZL V^0&Y8P3,6_"Z-^9I85M7TGYQ+?#XZ;[;V=
M6@?>S^$^?%#?%8U.K56K?SUNU/\^KGVKDMJW75&=J;G[J;/W>9]7:>.\>MP$
MF_EKNWK<;C7H+JE]KC7S?8V+?=* >>9R!-/=[WRP(FC%P78&LYD;(9 +EB,I
M-6%2!$$MB(#>8C-NW^=,YRD%;$K 0N111)E[H4D.EJ0A%@>=5,"*4L54(6"X
M%+ E$+"I@S^'C>&1&P3BQ!&7&B-G"4<L&258X#YQO+'-MM2] O864EEFE(,;
M?H(E5076,X[N3E=X=Y3-L87$'K"YD&IGP@M?@17^C/VLSU_YO1$ML>D!V%2=
MV?PCX3IPHY%)- (V<8VTB089RR555@DE.%@J6T\NF+&84+K7D(3_KXS"?6;T
MF$>U*='C-=%C.@27>8<%& PF*HDXBX C.7U92*T-& X,5)^LV3RY6\>ZH,>\
MD4;+? ;TFQTTB].=XJ04/K>Z8[MAZB"U-^I?AFB<V<'3Z]/K5ZA/_X0C'H&W
M!'YP@?KRB.>9CGA6:K#R#9Q'$;&:!U*-.]K1E(=3R[MFY>'4TP^G2I+]G&3$
MO+GSO$(+/+6P8$5@W+AU2(ZIS#&\.9.UZ.'5 ?UOU(\YJO'6)*MW2^K;6]0I
MQ%...5[LJ&3U!KD@G_BJ)"M>.3@JA;V5"B,JBUWOZH>QH;5<TO1D_];2+<3#
M\Q5OF^)R.RSFB(%_5,_$AZ<>7H;!KWQT^]A-=WI2S6ZZ^O[YP4YH'GS^B _J
M57CVW^V]'1CWCK\XV&GP@PZ,^[<I-UWGR_G>YWU1J_]^4J.?3AK937>1W7/[
MO-KYR&L7M9/:<;,#8^*W.?FUU229(!!602)N%4<F)(N25(80SS1QN>& >7+F
MX;/GR\_M9R^Q9TVQQQC)'#=$>X6YE]+)Z+D@UG*E%/:TP!Y\B3TSAP<E]CP7
M]DP=$=@4)9<NH41Y1)S;B+2T'!&/:81]@R6=L4>I$GM*[%D1[$F!,TP\!=Z5
M7!-C333&<QDY52X1F[$'=M,Q]A!38L\+8<_>I=YS_)%7+]X?4LT)C3(@HJ4
MO<<9Y. OPLQ[S770/-=E6ZY&2S\Q:9>O>,+Z75DNP:M?^18\IU_W]BMV,(C#
M0:7GAK;5';M+XW??M-VC6#AVQH[2GH/1%N?JJ^PH718WXU(_X\UZ-$O'9:G
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MY[K6/QY:SVBVZI'AN?Z_9 19H222F(&U;Y0BCF]LRYEU+>I@;3VDE.RX["B
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MQFLGGZ''JR,K'/5H_&I3[O?'PY%<X^C5CP?CBZ"L32%@T:QL#\5"UEZ1J:Q
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M[96)WBM L"JQ1:4KHF&(HIO3\B%YB*U>R69]J[HF UG^@\P&4RW.94\A&.9
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M%))P@-)(]<1=54+1X@Z:GN8_=U(HY&:M;89J@50SU9X')/:D4 C.#%G!2R4
M+?F>OJ&J[:>!LA]*G'A6.C2*63#<=V=>+Z"7@!A@2U5DP0&6XC"*#Y![7E <
M!&"Y!*"P> &HM,VL0![V@^&B@HFQU:RM93]W*-C&5'4PF3V UT@E"@DLQ-$Y
M+]L^", 2"0"YPH'0"0GD/BI>7($40U"AF"14#MCDN36 3[*IMICH>Y3)B028
MWAB=3#*./+A! )9) **1_4E%W,":%4#VBDIRBMF(:? "63MW*#BF2*:98$S3
MW;',QN4*IH1J.5H[:(!E$H LKIKL4%(>/2A(L8@&J%J\ /$*N-8:X]QQ "HN
MA2S^'AH-%G42+J ;IM[*BRP/7L!R"4"AC):5*3T.0-XJ!";5'%9JIM4Z?TZ@
MQ5PUYV*Y!7 U(2>"VC2;YDG3$ E<)@$HNI/^BLK&K!6(@E;DINFA'(UV&JJ;
MOS((2)S*+$H?>RFX1I=)EQ18]]QP&"*!2R4 )@C]KWW45A,2B*$H"AR43[J0
MDT<X?TJ8^'XF6R+MFH=BB$JW+SK$Y$4WV#P(P#()@" =;0J*L^P]H+$J=X5
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MZFJUP3N23>^S&L6GZYTY'*C@HNT9%NSYXD#U/L"_F!@,X%_8W(\WGNU$UBZ
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M8,11JXG-*J40>#GWO[6C%G/I+RR7;K_9;7^TXIIQ3@LT')@-ALJ@M=<I2,4
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MK1WAKMV)7YFL,MEF,]G:C?O*9%=BLO89'&Z%DT")!0]$"N6(%SR1&((-6FI
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M:&Z R(&S;*X%MU48KPG/[=P<%BFXY 04A@<B@T+[(V1%HF+2,,^%,361[T,
M=2P^82Z$5E3)$*1ET2@#BD61O,A+Y\BJPO@:P=MR&7BI1( 4",A<7 9)$N>#
M*KGUT4"2$H3@&R:,UQEZP-7F'_79'XRAUX&R]*\ETN!']_G!,*8A&0^.'I=A
M&PUZW=B9=_N'C+9QP_FW5=U<R_?_WC#YNG*4-'P]^N$N3DW8?"56EPO^$3!:
M.D#KRFE>(KV=((YF23AU+&1 F9S%UHYYY)A<DR]X:9#<\BY/);M*=M>4[>4[
M9%?Y;$4^:Z=V44E+;PRQ*5DB(40"VF0B0@H\1BE]*2S!U[:S5=FLLMDF=?P6
MDM]4-EL?F[4<9LDD$R0'$B$P(J73Q)>#M<AMB66M)<[<6C+@5#:K;':WV6Q=
M>8*J(7I#5-=R+S(T-%EB@02J#4%BL\0:_)-[%J3D*@/G6SOV$2Z4NT)V:XI8
MVA!J,I<B]-]=\-U>DU'KY[(++;MGLL0SSDVHP"F+@XGOI849O<H;:BOO?"MK
M]J_-RC)5G[&9SWAHX;8WF_WKRMO_&S=^R]LHEW7QWI@AUYS,;#37MT[J@:?K
M,DY>?EG<)6/>!DHCH4*A<2(D)5X:14!$FV3*2:3U%??;O,"ERE;WE*VN.4';
M#]BJLM**K-3>Z]+4"["1*!4CD3(;8FD&8JAG-.7(G>%;.\)50JJ$=$<(Z9IS
MSE7UZ6:(JK6-Y4%&JR,CJ 9G(JDP!#S3!+4F02D QQFOZE-EJXWHV^;DT:OJ
MTWI9J;7CY#(/4.K)>,B,2!XE@>@ET2%1)2R30=,-4Y]J+KV:2^]^Y-*KFM@-
M<-[)@B.+"BN9B@E5+X::F#*!^!PD4=EPH1UX;4+-W/, X'W-"?6JZK)>&+</
MQCL>+/..A."!2*<S<4Q;(C-/C$HM6&"HNEQ==ZD0WEP(7W-:O2JA;P;:+5\)
MI!B"EI*XD N@RX$LG1R)'E(6 BU.X%5"/P!X7W-NO2JAUPOCA01[:":YI(G.
M2J.$YIYX'161$*T55CN5TZ9)Z)N.5XW=S_-GSQY!RO6/.3WGF>CV8^J/'Q/7
MT,3&)N+#OM1D(7<U'=\I%=8L0&NGQJ\+/@BK0Q+&!N*]9@2-%4T %S*Q/O!R
M=L/R#/=X-Z@"^^92\ET.[ K@%0'<\CZX")%G!22CJ4)DH(R Q_]X;EE"+=6!
M+56(U":E JK@O7-Y^:I4OE90OVT7ZO A:*L)]9D2R2$@J%,F-DJ6@^ )45VE
M\@, ]O7GYJM2>2T ;GL<$*ZV<1SJ$(G,8 ED0"'M:9/HP5&Q<5)Y3?$,5_8X
ML//)_6[?XU!\=-@V;$6!YJ@;TQ :V X\]J?Y..I<P?50?; WG-WNU\D(FS$:
M/1T<^FZ_F<"S.7YZ?HI/N;%J.NLA2KK@?]#.R:RC(27NE$B<7F)M!H+LF:C(
M+@%=G_^A[K!L+KK7E<ZMHOLVT=UR3ICD@I62$\]$(M)'1#=01Y+P.3M0D?GU
M'=6KZ-Y<=*\KO=E/H;NB>$44MRL%E/.V,FD"P@*12F7B8C#$<,YL+ I95%L[
M0O**X/N+X'6E]*H(O@D$M\L%<&.LM8I(FSR1+C'BA/1$N12D#  6XJ8A>)TY
M3^Y.O8#>60JOVTAU,LOA-!V(R](X/=ADCNL?H'LC&M;EF#F7OJY&N5Z;=& +
M/AAA%,KT2 D+ D4$TXZ4<FXD21%,4$XZ)]:]V[0^'&WX>>+*J)51;\T9]B-&
MK<RY(G.V_%N29NER"JA(<X',R14![P*A3$>GA  5\]:.$E<NUU)9L[)F9<T;
M<C)6UEPS:[;\B4B.*E,A249C@4@N. 'E$[$\HK+)*063U^*-J*Q96;.RY@TY
M=BMKKIDU6SY<#C0XKAPI8;U$BN+#39 )Y(R6 4Y4H')KQYIUA93=/FLV'N!_
MC@%?>AI9->W:J\DAXB),_P[-]L&DV3.X$%4V0X3D4^?OT6#4+=<\'J9>DX3]
ME^-N'!_,$7/NQEF?Z=DMX+%[D_&W;SG7LY!*L.7- Y\WF;-).<5X(1CMW'\/
MAF<1=Q\2\<,$GW !87,?0^\83D9;_[S0J\-NG[1&L3T TV[N_,L/\=9+7MR:
MH"GX<0EKYF46C%MIN?<EQC7FDN4I.Z/4E*+PGA2?%(<?9\%3K9+B)DF>LX68
MH[=%N3-,*W%Q+@YA^ $;?K9RM[[1#%0VG-"19RNXQ,=Y9AEC)71>Z'+X!>]K
M5M_9NFA6/,YE#XY&Z?'\PR^Q.SKJP<GC;K^9D>:F7RXVHXQ=:[4W:V;Z\VQ8
MG=M6FI61G6U\S%X\&_3M9M!; )[^)MFVX_*;/]-M]I._H?'Z4W=^K[&,;TOJ
M:F-K8R432SWV!YN!5PA!7C--VZ4*]10%:2J5/Q<U:?KQ,$'1E Y1?$R_@-'T
MWT'N/$LA'?HT[ CVJ(/Z&'W4*?OH'QXO'7B\0FV*[XSF5+;=C*J[W%"^G@S&
M*4X'Z@AU@C0;M&Z_$4E%!?J<.LC%G])X]E,>#)O?NB6TO'1C7J6]?/GW?Z?/
MJ==A_UAB^_6^CND;;$ W8V/F*W$P/DC3,1MX?.3G(M^F0]@_FEP<.%X'KAFX
M9DPF_1^.EWC(X]7$/%SH_\]&?:QBC&R(3^/R(9F6/-RD\FW?'L\-JCA6&WG#
MC7Q@I=N>?(9NK] X0>V!C* 8A2E,AE<HMG@7"H_59]1B;E>%SA_;;[8[^\/&
MNCGI]%%=KU7<:F+_%<[ &W!<!J&H2E* \X9YXY.A)B8&@34;%'2)8M)S"G\Q
M&+Y! G]SRM_/DA^?_75?MBKDJV?/Z;N/3]B[CW_07?R\M__[P=N/\>.KC\_%
MWC/\[K>7]-UO?QZ\ZK:W*K!=^[\?[C[[\_#5_NOC77SVJ]]>=%_Q7;Z['V3Y
M[NW'WS^]^^LY_^_7W?%NMVQ3/!^_:K8J7K^GW%'-2BY_GLI.A94$!//$!)Q"
MY9, &;=VF+AR[>C-RUQ12>B>DI!)D(-14C MI,+5[2FS,0,D'ZS)8OTD=+^C
MG6^,G%X]O4A.+&B?A:$D ;=$@M?$*V=)B$E*&T$84/<XM4XEJ'M*4$HHF44.
ML:2=04JRFGH0H)24&:*+E: VE:!:VI.3PEE(B6AE(Y%<<>(2*E/*9Z=0^TW6
MK:\J2"6H2E W1% 2S37*.:>>>QFY!\J &6JS 1Z%R]6,NV4BVFMI2CKPX)DL
ME8E\*<E&45.BR1*-!*4-5PRES::9<0^M)MM%WYKO]GJU$MOUGG5-'DQ +8LK
M*R%$<)Q%FI2RBMNDZ/6J6?W)(8F#,9D]N5+<2A3W>L%3I31X* 4G62[9QTH%
M-IMX*0RA>#:H2K.2V40^<M)N4&:$"NIU.W<B2XCH&&E44BOEK*+"!*MBC"+%
M=..V$ZUX7@K/;>>.\5(IPS)Q01A2CJ\3R#R0K+2W/.C$2XQ\S3=V[Q%-H_ "
MK @@E4P /BIJ#%6..P2TE171FXKHEH06H#W-$$G4#(V0% 6QP2:BHP?E V52
MU_R@#P'1'.6QSX9I$%2J %Y%%81E.28NHK95\=YD6+=]"QD"3UX[0G$*2T*R
M3"!010+/-E-'1?!I\Q3O'W@7YJ> L+'I^SQ0K_S9*^L4W/J5=0IN_<HZ!;=^
M99V"6[^R3L&M7_G08IEWL>\GL].$G</)> *]3L;N74M$\U+&WX,H@\4@<FV-
M21*H]-%XS[6W8(,)W"9_S>Z<:OQ=Q?A[_F4AX2ASW.:8*4DE[9.$DEK> !!*
M9>*,>FIML^UBM-J@O>6*ZG5'A&AJ>43;/V<OO0BE##L3P>82)!)IJ"%K&POH
M5A[,4BN829,(E=03&84ESGI*C  C:0;P+M_CF+4*Z3FDG:0JI10I)%P*68%
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MD8X#@10X$0S-*:ML,)!QXMVV_.;$EUHFI23+M)3P:5F9!:%T:\SP;]0/]U$
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MK(HEI8.3TW.3-X\JW7(S\O'AM;@^R,:!V*< VCZ;\WE6#,XDXA))GVM ;0P
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MZR@B-LNU5QGU"F<&2YF)5#@]5QH%$FO%+8:S6N6$)UZ[\TJKM0L56FH?4&^
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MY\THGL%MN<YP,OTKSFO%,XC%B]G^YUZGZNED W/D!V>=Z8O"2%R<^+(3_<'
M#\_[O;C\ZJ/9N@#O]%QWH"?]BU[5YW.8_K[;6Q2NUNSBOW*Q7[.P,;Z+=;VF
MH![V6^=QOON]-*7]\6#NM)R?YF^V+OS M_S?Y;2&0?\L#9).!SKBI,<FBIN*
MLZ,@,#WX:J_U,K4^Q[:'X>>%3ZQ<-LX5"-_D)-YEZ_]N4NL1:^T%Y2IX3IUU
M$@PCR@5W3G"%G?JT'Y]V/4 JCU:]*O-77\%(O(6!2$&["BH=]W_R?]0.#+X>
M#T"4#J$O"!] ITZ&3_LL^<?_G.3V[*^>?J_&@(N^'+W^ZTMQ[YMOA_"\@]-W
M#)[Y[>#G=_0 'WXY.@9<==SM_N?;YQS:_*2()DX#9@U"RXP*@$*&YB;3)( 2
M-)Y@9IZ]0(N1NQ:(?[=<ZCU0<I/E'H4VS!^*BSK"7I6-7#_HF:[N]$  O1[T
M8#JC-HS3FN2[!W/;0KAUEF9WK[5H]V?M3DT9E&N-XB(/9-&*EM2?A6M0N[%4
M'_GT%FV&_>YXM/J6922W#Z%2WF:4S@U1[>?)8)H!\-EG!CR1+YD.T-T?=?="
M7PZ?_6-6G8(NG1O%^0$H7O/%O\S@'R^6/7BI+<Y9KKD(TA$+T$,)J8G4BH%)
MQEH%QIY=K=3O;FQ3BS]V1C"3=HW1KH=:(QA8#+?6N#<?MZTZCO;!C:U/*Q[,
M1G\X'B3,LK#Z0W=L1\5T1R#2LH!005TD4S4J $2WHTVG"VLKQ:A[_0HQP%5S
MS<$5A:&*BZI0$XL/[ \N],#5U,OH1(]:&OJW?%:2<AG :!3:#=3*07]8@:*A
MG[S>,+51 A407EVHH6S4S](O+4#;G:LL;-P-22\<8P3MI-!&B0H2^@4/KG%"
M3IZ]QMLE*+")B18\=S(H#@!?40,+#_Y@),?.,.>PH^N:Z*F\'Y;]?YFZWQC=
MY4;WR\7A\9M/AAI+'"(9D@1E5$F6:8-L1IPDCN3*<0K>!Y>+R=*5U6UO--M@
MXZE!AB K/,5,2^^5T1KFG=CH]Z797JP,(+<[V^J[G.UWGXP$W"M0GG% Q!F%
M:<UT'D0& $MRAL'C%CE K+TELVU*C!45QD;+&WG.!0LA9N5KHI0DBEEA&<@7
M+'42)WQ)B+*9\-M/^.G^)V6$8TBH3.749=0&GBF&=<9)SKQUN?(!QPE?#"]6
M$]YN1;>X<-FZEWNM(N"0[&012RA][6^%A9S Y.BQ1VOL)O,V$U-8;?OJ5R5C
M$B^%"89VP"3%9J.ENH0'#9=SM2_8MGE@/A./FY560[!F3@M-0TYCD7F%-'<X
MV" 9=7DBCL6HJF!26J590?W3PIN,N_XH3$6V%C/?[TUXD8_"6X 6 "-T][<2
MS$^"[<?0I9^Z??OENQ/<-Q>'W][DGXPQ,N1,93P0D5$"X@O:BV::>D^<HPRP
MP;.6A_5]'EV<P=A? \QW"*Z"_$Y#9 E>N1I8GP^/S9!J_Z2[(#&^]>>)]]4"
MT7&U=;O]BV'K.=Q3VN7A#S^N">^+7</[+7L"3MI>7CAJF]8](7Q/<'8G]3E6
M/_2F]3D0WZ.4/);.YM#9NZE\<@>=%7N4B\?261A9QK=9I^5!M^OGRRNLRJ-8
MMD-YQ3NM/,:B'F<]F2D *.,+S5C$L:@%6&Y256>G)'_5R\XATFU,_%.LP+(,
MVQ1JHP XQ>^ @XN(75/EY@9C''V*8AP+O-G(8B.+.RF+-SUT>M/AV3VKL4%R
M_(-3T&Y-N)M./LU.?@]LZ/=+N7OK$T+YDN&<22542Y+V'G)\4YW#PF 40SPJ
M_BC<J7^TBCJ(O7ZO_'9]/^NFV?1/)VG^:>;&YU)YJZRW6 5JA=6<,$H=\]00
M*9S>?#MY$I.O1_0C5_'HT>\>E]7%+SX>O_GVX?1=_O&UI1^^O<N/CG__=O3Z
M,SSC#3LX^_WBX/5G^/\[?/#G?'7QG[H'QX>=P^,_OAQ^.SD]//Z=';X^H$?P
M/M#_RX^O7UX<P?\/CS_\_9]O!PM478)2A@BR&3,D9K\3E"EC3(8%0<9H9DU*
M^9(;%CO:H3,X]V'X5I&GJ/-%[?Y "_BEM8.8MEL+_93*NYC(F@9?%AW:G+ZD
M4>9/09D3''+.'5:>6<I<;C2U#"$O8K)\H&9+ROS74N0N&X6^H4(_FE/H& D?
M\[DRDU.448=E!D:79<P%*6."#V+YLQ=D,8?WSO7Y]U#)^=Y)EF\QD(U#LK7!
MQYL-_E)#]ZC-A%#0!'7"!2TH\EI2@P7UAF)'O&4W2"%M,/^63,3OB_2\ C-D
M1;0.7F54Y"$SC!H0(F>%\M%+H\]></[TV'GOP^PTOD"C1V^L1S5QN:3<&I,S
M*B52-A99=X813'.K\P9N/[ NG8?;3G&A%>A2;Q$#70J8VW"%,QL<<ACFD,3R
MJ613O/T8**^>DD;<7R1,7H3M6X^!-+L)#[B;L);169>GYU$;'4*$< 9YPBFE
M4B,EM>128<X8"<ILR^@TX'US@_-N ;SGU.8"89RA8'5&-669=$YG(;>229JK
M/'?/7J!;@_?=(]-J3-5.!O(;/3K9^&2Y"8[0X#BGEN:2*\%-+CS7@5EG&_#^
MP+IT'KRC@#UBSF02IBJC6-),!^<R+;6@5+C<" VZE.V2,MV9NA"L5C_EX;7B
M<3HW[S;)W[N'>,:NM+%&7&7M%,ZGI[>EY\QCA',A#7CP1%JL:*#6*JR#\:C!
MOP^FLQ=KRYG 8UGTD!%/\HRB>)X:<9()@[0FECI!R+,7X+ML*>"R26KS8PMM
M-SKGJ>N<!BO>5._,8T6M*:!%0C/G%.@=JEEF+!99P#H/A.3:ZO#L!2/TL>B=
MIO3@@U_93,&#7]E,P8-?N<T*+"3?_0HL"Z[JKAQ4N8LVKKOO=A!PY^9VX_((
MZ[__DX&^X*FY8)A3&B.:\V HT803I9P2 *YPXVX_&.R-Y1%^GRV/8+D6D:\Y
M(TH3\+>1RXQ#-$/8" P>BS>!;<7?WG1!/,+=J$;!-@KVZ2C8)K9P<R7[>5;)
M$B9\X))G2NN049RC+)+O93G.K5&4,.;L5H(+]Z5D2TQ?=:249%SRW-V6\>3!
M+ZV-'X$1<OUQ9.Z[ 6' @U]Z@S=YC"11#3U:0X_6T*.MID?+&TJJAI)J)RFI
M&EEL9'%79+&A1VOHT9I./IE.-O1HN[#KU!QHNJ=(\'<0['V:\5RLN<#2,NDH
MHLP0*87A.<TYXXQ8I%94;&HVS.XAEHL6-LP0"<@X3S,B<(KENLP$RV+9%,-Y
MCCC-U;,76.[0F8*'U_[- :T[9UIK[,)3LPN@5A!'5&%K.35.2>*\$MY+A SB
M06_)+C3[?#>W#7/[?)I)Y(C5\? NV 8D<::\UUFD^,AM<"P7 6P#$3MD'!K:
MMH:V[9$Y2@W=T)H6Q&(N$<$T_D.=](8HY47N*!9.RAPUGL7#60^\X%EHZ<"J
M*P&N1"PEBH,"SP+^],A@)(W./=)@/=BVCKX]\M-MC6O1$+?=FR;U#.4Z$&^U
M#%0+HB5WRC$>C).(A6W%:!HL?G-M.H?%>1XT\U)FBDF248-UICFV&2&8$YH3
M[K1[]H*@6P=J&N:VAKFMP>\-X] =6!TJ%!>,$F:QHRHHI3BS@3'A'5;!A :_
M/YS%(0OXW3"IG; F4XZ#Q7%"9IHAE@GXB:5WSF&_#=[E9F=@1VW5KNT,-(IT
MHD@IY]PPY8UFU"NMF#%8:N.1D%X&T<#W!U>FG^?/)7(GJ$,9MT1DE'J [[EB
MF7=@ )7(K5,T<K?MD#)MJ-L:ZK:&1FFK>ELIAK7FFAA$J M<Z>!=GDNG/!<F
MT 8 /YS.I@L &.QKY+G*,QJ<C:DQ(9.2A,PIPG*44T:<>?:"T&V1Y>_,6?)&
MZ31*IP&+]ZAXYL BTH*'/*A,:BI!\7"5&4%Y!M!166&M5CB>KQ;Y8U$\#6W5
M@U_93,&#7]E,P8-?V9"W[<@QF@?D%BHF9!E_1$,^M+4!>C+HV7GJF>=,!,2I
MQ+E".G<R")<+C 795JBU<=DW1\[P;O,N>VZ4!C$D&14"PP_B,X-RE"F"K<$V
M@F>_%9=]ZROF$6YY-3J\T>&-#F\B(-O0XW,1$">YX*##LQP[D5%#128YEIFF
MN1<4U#B2:BL1D)W1X\DS^<=(PT,G&T7%JQV.ST#$[,P&V9D>?.[TJOY&.HSR
MD]A!,:O33L?#42=<SNR?8;S''F('#:?<K/&@YI),\]]:HQ,]:EWX@6]U>I.4
M@LO6>7_8210Q<7NM'UKS;%#P,[:AX28+0YS^'7C7&66#SO!+-O#=M#<7KX%9
MBND*YX/^U\XP-5D\LS_NNI;QK1',U&?H@&MU0NMYYX="FBY\T:M1'[0,]/QS
MOZ5;]D1#8[&GZ07ZW9;N.;BGNJD_'K1;_0$\P+>&X\'7SM>X*PA/AU?ZG_\C
M,1+_'+;+CE[T!Z,3&*=AW$P<P=#T8WH@?'UQTK$GK<ZP!=WV ]WM7L(% :XL
MMAIUT68G);/ILK&86A@_3F\&MQK?[5] /\'[&\7MR-;G@78^=DVWSG1\6FKW
MPNLOT,I"AW2 2]);++SQ7FL_Q&^&ON6_QHW.R3#UK8VOG^Z"Y08MG.M!S XI
MAQIZ[M.W:66TS'C4ZO5'Z9.^ :E-E$"Q(=OM#WW93B4F:0Y:7@^ZEQFT?-;I
M%9=/9Q4Z!E(]AJ&SG8$=GPU'D7QHN+1#-G5HX/\[CFF9G;,S>/^4F^E'HZY/
M ]:OWG+:AQ"'[RRV5(J0/H?'_]V) YJ> O^O:"Q&K0#FHE4P])2-39M*?8T*
M)+X#2,RJQ:%A9.,8#<?FU-M1'!S=NVR-+L]];/-,#^,\]:#7<?+U8! G*W:_
MG02SZJP;^TI@XCP-6F'0/XNR,QV5RW*$9T?]3%_&%=(/ 4:FI3_KN,'=ZA>B
M=V7C:06 (9U]1K\'0@>K#/1/$I[X$B#;>MP=I64SG=AVE/52[-NS(K8WN[5^
MI8;<995X'(=:#T]:(:Y5'X*/0PXCLE(<8!7&<9TAV?IS!/^DC(-XZZO8WEMH
MKY"=3L]VQRYJMA[T>E0\+BV9^*&!"3GWI>:(IO1K2N9JM_S?UH-)"Y4FFUD5
M((\P/[H[$0#XS"X>3IPHLI7]& ^+#V".8:7.]F%NCJ-5+%3Y.$G'S*R7@TIQ
MD3)268X?DPV  ?SG1<>-3BH$6;NQE)-\>HLV,+#CT>I;%HC!'DAVWF:4S0U1
M[6?L<,*@.-9]MT'[H"3%-"BN<$Z1X]X1C3'^A%G^K+KK9,*%>ZX_@P\] ..0
M)4OPH^Y>Z,OALW_,KC98:G-C/S]LQ>"\^)<9P*U+NKLNNI'WL$@7^,320".U
MU_K7#":;.^!.L&9."TU#3@EG!OP,[G"P03+J\O#I=00K>8Q'3!FM9SV,5_VS
MLTZRTL.7/?>J0BP6EL'KSC :P_' '\,3?^KV[9>']BZ.7Y;>11]]/.UV#D_?
M_/WQY_W\ SX CV$??WA_0 ^^G70^ONYV/IR]P0?'/W4_7*K\XW].<GOV5T^_
M5^.C4WC.^WWX[NV7#Z=_G'[X]L>7@]./)Q^^??YV]/,O7X[>_]+Y %["P<]_
MG?[G&W@:IY\O/U'*-)629$[8F)FL7:8LRC/GM<B9]URP\*S$>V/O7HYBM5NA
M#;-$.&0)-81*Q0.17ENAA67./&MY<-K.X[H>C'UB+YR.?;*@=CHWK05L/B/0
M<QJJF*7K.S#;8:T"SW.)J726YHBKW"GKJ27@NWI-T;/=-G>IQ1\[(^B!74.)
MS0SW$S'J^X6)!L\1K-H@<IF-!\,$ULQXF,!U1#.E4?S:[WXM;.!7#?A_/&QU
M_6>PK&"AK??1O82K/_?!A^PEZUO@^1(I%P):8#% H*"F*U0ZB)CA[+SK_XY-
M YX"_9$N3@B\/Q[!M[YVL>N$T+$1@P'$.H^^@!WMM?[TOO4;H+;6?KNU#Q"C
MA5[NM?X YZKU%NQT?S!,#@V>N-V[(5/1SZQ&NH*O.D&K O#$?/72TX@CLG)P
M0>O?[7M=^1;O?4PPM8-.!-_P1@MB<=7<Q\34#DRH[A6@NG"PHTO8\0E.%GYO
M%(*9:Q.Z[$0WIS\"D.>?"LZ&P1S VP[ 'XJ'&W2W\.3 K@ZG\8&D\4'\X^*%
MCD>!J 8.KDGHM=5)KC7,@HD1FW+ :S&+$QT=;W !.\49"9=F*;980.7*#:R"
M$T4/8$!,_$P/ 54;\(^B%$:7TNVUWD<G&UQ(^ N\1!#9UG_'L"0]>,$MHX<=
M4 \.YK3;/R],5 RAK"LJA1Q8#3 \^F/0Y]B'%"-POOR]=#AFNS]]X=3.Y*UU
M>70$-,C7J,RZET]%@HZ6+L%2?T]TMQZ>USVXB19*GGBZRD<7&+REKNZ<P=0-
MXPJ$OPL_"89M&,6N!RJIVPJ@8\?1R>K&!T_T_3]@=L:]SG_!YRXZ!!/2'T2'
M*484 %B<5+-4S76E1]QT?</D]3ZWX]_%DR\JI9#DMB[216BB?W[>[R7Y&GK_
M)0J+OM"PG.!).KJ#V:4?92"8L)1"Q[N:N#A]!J[$,,6=>M7G58PJ!C:J6-1<
M0 2:':=HW]S+G/N>2XYB&8D8%VXNM =J_+((#X%P%,\LI74Z;\-I<*TWL9#U
M&2UO&?8':>'#',3Y 650J 27],80%MP FKR$I\&POX0NP.H=@OELQ[.E?LL3
MD&PV=/(S/",ZS,-Q--8=F(YN7("#_OCS"5CPH>VG(2AE)':@IAEBGSIGY_!>
M.D6F"MGJ].!]SJ;&L!BJSG X+G2A[R4]-R[^*+52?-L4$H0FP6\>=N(E49.U
MB\#.90J ICA<%2"HHEC3R7Y_TNE6^C1^,VDH!KABC >NA-<KL4BADHK@4!%H
M2\&C^ H3,#,)UY7#WDX"YV!,AGYR<XG,>ZTT3: /^P._<&<5P(O/+\7-3N.7
MT_#II/4B<A/5<UPLMAZ<*>2B4 E%I 6^;5<1CRB79>0A]F82"YJ/?CQ:O?FJ
MC,R#^8U".&.JHE4%Z!6'=UV$4V#5H1VGA9!"W#_>:J1VQA-Z>?CZ)8#M!#M^
MG2#4[4D!(COE^!V-_+>N;MWU6^^8N_OR#' FV#F[U_H*[A7(=_];^K/=BL'U
M[E-9]3]YZ&RO. [7^F4,JA;G2+9;KWPW[FA%\P?+=^56?E=?#,>=T3R1I),D
MYUQPBPA%N5$"">YLH-@I%WB*LR&9\Q1GB[^0O+ZOOW_XM@J[Z3,8M)]!+4W#
M#Y>'"6WTPZ_%LX=O8Q<G._KY=Q=S^_+MX/C-)^X<#QRQ#!,6-^0%S8SV(:,P
M%<(+"?\Q,4*ZL!\/&.E<)[*3<C(G6Q?O]O[<:[WN#$>#:-=?@>:?;C-,/@9K
M&47QEVA=+UO/XW>UOV?O_F&"!5]VO_BSUJ_:Q'W4A(E;OX[ AWJ>OOCAGZV7
M9ST/-N:W$PV@Q_IQVI>'BWY]!=>D[^)%O1[<7U[4^BUMPOBBH6B0_AV11+_U
M[L^7Q4)^#HNJZ^.V!>"5=OEU;&8,7B(LQG[5TJ2%A6]6M36Y$)I[U3D'??EK
MYZP34<7S\L^1@Z]>__'K/UMOSFR,\2R\VK3;@TY$Q0M7+'MPT1@T_7/7]T#U
M?%G>[O/J:[CR0-NN[[OABBNKK].5O2_P4C/#\KS\,'[]Y^'L%$YFH'IWN *N
M*VX?1AP,&+UXBYG/XC6#*!>@6F8[55U=?@L7UE1QZWGQ1_P4,.JY;AU$"!J1
M1]'5XE/X^A@<\X77A;EL%^VDJ;8C_;532MC<Y!9?Q7;ZQ7;Q\I$KOX7KWO7
M4Y@3\'9Y5?D=7!4?^_'2C1=GXCGT[8?R'=,5/[0+?S$N/_ $!IURZSB!U05\
M#)=U 6]%K7Z>+/;PQV(QE_;[L ^^$&\KCMN*YL6B+3,>XM_%5?!(T<:Y;#/$
M9RZ)?]<NH5BT.9$SE\2_:Y=PIMHDQS.7Q+]KETA%VBA',Y?$OR>7R#9EK,W(
M7%\(KU\B<]P&6S-S2?Q[<HEJ1^N&*9FY)/Y=7I(F1;6EP&W)Z,Q5\>])0]/M
MTBZHN,I?]*VCPM_ZJ=__DB:K0$][K3=3;W]8T[07,1ZC(T+NEQ$!YP,X,CK2
M(14I*#&?X S\O.1XI-WX!,6B=Q\G^"W\GE(;OL8 0[\5%WE$*$5"2L=&9[NZ
MM^K,\55*>M8I*OK;V/\=MO]O+@Z_6?0I,!-R8UE&-7(9I51GQEN7:<Q18%1(
M)?AR #"1QBBP,]&)Z.9&7[NG2W5S/AZ %^PC1(C>?VL(<])-F1&^?==!^$TW
MK$H$^ZH_.+\.Q#\$\BY40CGV:3E'-[J5TA@K/;YZD9[IM/IC@M&,!IA$K5-\
M,V:D+"J4I#^*0$B\H-=/L;A.2BC2O3*J?MXI(B!5B_ $&/<48RIMRE-Q@?9!
MHXX_0Z^6NCZ@AGHN)2>> 8[KI!!9'<2V2ZA:PX#MU@3SM2/D:T_ 67L6"[5+
MF9Q C/8$.4RQ015H33F D01OD%* 9NWY'M@L@6F;D%ES'O^>LUF <=8S63_Y
MT47<*CBRHWX,[R*6>G4(VB&%>\'NWW+$"@1^Y<@5^+8^@A4^;5?PM!V!Z,+(
M5I!QR1B7..T6@XWR=JYPF]%9P!+_ONUH'^@!W(8*3'H^Z'1;- VSVF"8JW&-
M #VV4WH<:X)'P*Q??5;VNEKKK:.:(*SH4&^Q3Y,N5:[$LC[,PL]V#2&V:SBO
M74=K\:T61'RVEW)%+Q?\W4D?"Q$HYVFUZEWV"@OH6H* D#:6<T!3S@)-V>98
MM9$@=4 98^SKR0R\[235.KYI\;Y7]WX.W47Y+(=A4^M?V EHO8BZUYI]I'#@
M(=% Z2%,C'7:J9VNJ][PHDC975B@]>7?6ZH5XC'K\:@(\=6DMMQ\ M#0<9UB
MKS,V7B[X4OG%QY>KHS/: _W=AV8N.J.3>&UG4'9LV)[L9I8:OM) A3IO\D.O
MRP_EJ_-#'R#3<VEZW+7I;O/Y?)I8S9EG,@=?Q%!M)7>Y0/!+3BR7FZ?'/=#T
M; A&5B"\(A:U'@HIUCTXQ%V=HD>7K=.Q^YQ6;9FA7V0EU!!*VJ<O<A0&,0]A
M83F7AJ52 :Y:_V5R6]0":5]_"H7!E$Q"$[IUVH_FO#J%82XG9C5V>SH@5QN?
MM,J2$8[V(K[/Y,5B,YW>Z;AGJZ,B)QW3*=_-E_Y.NSI1<Z8=C&U,VH#/AKY;
M[-'WP:<9I#OZZ<-VN8]>?)FL&_3&%,H0!JCJ]L0STN<##Q*DA^D$DAM#Q]UX
M4/4A[DM?@5<XD4NQ"\K1*AS3KH.8&J:9 DD0E'&OFS)3QJ.3_@#DUD4[/(P9
M'&D'/@YEZ$0W*NY1U]+_]>>!3[_MM9Z(I_9V$M9,VW/3:;/_'7>JO?D9N8=N
M9P7&*Y.[>M 3-QA_KOS9=,\44Z7$K;?>#,8Q'Q0EZ(WSZ\0Z96&XJ?<^'!L8
MN5$A9\5.8GS$9,4,6X5M[H100;P9_%1&V9(]AZ5<I: 5'\=#4E6"!#2_M48G
MZ*$2]X3^K#ZO\C V;#$*Y\"'&$<OQT /RXR=&$.H^OI4H@A'E>N&624T5VG/
M<D1@Z$KU?_>J\WIM&1V;2F$FKZ;HVI-7CS!WA:M--INZ"N7NWLP5/=O.Q#'$
M;SR) HE5$SKY/>ZKW.WD'NC+%I:;S6V%]79O;HN>W7QNZW-8G[?5\["E:?AE
MW+ULB?5,:C*D1;AFU#D?%Y8%\%O<"8-G1!>T/XYO[&' .RGU,QFA*EUW!B>7
MQBV$3LJ@K(+B,9)ARK#;=.++N$!R<LLP>N5X+Q'JN!E:&[3I'B$\M.L+L+IY
M?&OI.IF;MU5S-7'<I^)<>O#EFY6F?'JXHE" !>[GFZV2B=>S>\ND[-IV=.#=
MS-76C%<Q=U.XNN[D5<[K+LY>T;=RT&ZDY>YXU*M L]ALU*O-C]T;\Z)G-U\P
M=6.R#O)[.+0W)2C)-YN\*HJS>Y-7]&QKJ&"E4=L2%-"]Y&%C7A'$K+EXJNC9
M[DU V;4;*ZQ-(?<JF'W?T#KYO'2S:9QNSN[>/%9]N]52NA=O==.U,]UEW[U1
MGW2N\5F?3KRV=+W99G*:]@QW4493Q^XV&%:7P[N'07%RT(:J>[)MM7OS4W9M
M.P"V/D/W$Z$J,C@VT.?%5OONS4/JV%-;)WA#+99RTG9O;J!;3VEFTHDUA#9$
MG[,[]+>:I":UY;K4%K'[J2W7IJK,I;8P@(@*4Z8"7.P9T4X&1:T+5CJCJ7XT
MJ2UWXT#5E]?-E4T=>M]F'_&^E)#83 FEA*+=LP_0K>WO+,536G<W!4_$63I.
M/!7])7D612[+7/9FF7LQN[4S32&[2(5.NR[2K5R3SAP98 L1IG'(IT G;8%%
M2L-.XJO]/"Z92\N=O')'%3TE=_5/?SXJ3S?(&G7U,.;:PJBG$8DGI6K7%1%D
MU.J?=WI5.DS:O5QW>4>"D>YT:4>25?VU/R@B\I6ZF,U1G]^<+-,!B[QXOB0<
M52RW=G'APA734Y1%VG?1&DY_8#&OER<Y[,4)UBNZ7YZIJ'6_>*$5W2^"SH@M
M>F7+>M<&AZGH(9I_G8E^*8XZSO6PVEI.*9,IB7UR%"JNM^*0Y65YU^1@E;E,
MU\;#5M6;311E.E!U%K?@$H%=I'E>/$ U.@&%5<N_K#(SGZ]0H'-*<SKLP^+L
M0.SCP'^.6^,Q0]3_;;N@[K\FJJ]^>9R@&.Z"62]1R$4]"AK4+1T8W1WV*_;?
M84$SMM3"E$FJ46_,&9JE]J6T/A-6@5YG0H4\G#- DW,%<Q?-#G=ULG71/@U7
M&:@5@S^SCX<G%KR>A9M(LZH$@_-S7YRR3:+@7>*6>A49S#O5JKXB;V"Z$&>?
M.]$T9:K@39[[5*Q@_9@1KL;E:CV:Q/9&RG1%JL>=:--KE=NUVK1FX]=2IP^K
M(8O>WJN*G([E@ZO(<J[N4T?.#?B6E>3DU.<D2%F]XG:U))_=/>/U29WM",H?
M7&WN#%O5F\.?_GCSZW=$S[5_=@8>R]_I-%]_4!:A*,[T%V?[SH9CD/"?.GU_
MWAG"97L%_<KC&9#KK&29L)Q7ISY74G3$M,=N+)@R1]*!E.."(*5R@JG@3A)*
M&7(8!Q*8LSR1=*B<%B0=\,N-2#I>5D\?/FL5!);P:!C%H;<_]L9G%V!JAK[W
M';-W[+.#XP_HD]-&$:-11D/(,ZJES@S#>6:MSK60'NN</WLQNN@OTG=,)G@X
M13G%J=8EJZ1,0?N<3IKWQHE==)#LTH2T:8[\*%[[0QM6UN3HY[_!A($(][)?
M-0BS/:DXG=+O/[0GFK@Z6'SMB>HI'ENQ;%O/RX]^B%:Y=F89W/*STA4IKZCR
M;Q98<^8/_$2< A_X7JS84%[C1QJL9JJG4D6\(D%/IS_L1!N:3N#.'CTJ-.]>
M#5P6(U+PCU:IN//'Q4.$4JNIF60[YZ2-)(Z<1@A^97B6/"G^72-/4HBU<8S;
MP-6@"WC.RM/E N,V)VBO]=-E>6!W<BZXO=#EBB^X!FD2Q7R!:B:3D@8[EEJ
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M3-V8A/X3[OR]R><YFT#\GT/P=/K<H\Z?&+>C^8GOM<][^G0FOOP8@M/8^-+
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M/IDRTTE9S;M-[E_UMEOX19+P;'C5LH?$8B:(8>35*\VR,'(1(@RG/J))BEF
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M6)Y$B 111-,ZW35.8I0RE*$4>8@RE+H1%S@_(_R;;NA&+WJ,G\P+N*(G<RZ
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M\F?%=";JK8A_L>\7#.J=_,9+=@!YS5*BS.+]OJNQS:BLV/0[+T(-9I@Z+.T
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M,!W(EN$=10X+KT#Q^G/1$J51KE22#/8>_I0'6Y"P"C1Z-.9GW NXRQP\LSY
M)\3I)N"3*SCLSE7EO)5$"QZ#1/B' $)64TA_3C'_(K#XQ(J);@":G/$Y=&Q&
MO8 ]TS6@54=/ AU.I7UUZ$H<^@WD*7'Q$/@PHS0,M&$KUY: -(2?@S:0$FI6
M3&X#2!C<$3@=A3,:,FCGV] IDY) M0\_A^I063^4J/^EI] 5E=A#R.WO,^XZ
MU \N?HM8N'R33JPA)X'P 'Z.U%5BD<&?K9C%!L::<7_;E-2A+0'X$'Z.WP;P
M9MY6-Q\DF%VZ_$5_+:RG(@'Q"'Y.-#8N0-<2A'L$U4,TGQ-_R2<!FWIL I(*
M7;&%[9)YTP4,E0WG=26\%$FU@+8'J T&R2F9!;;+@\BGB&!,&E$J$+=RZE9*
M?@/=RGC?K1_".Q4HX=2 /V^ $@K_D++JD_94 ^&&^#XT])F>TY P=YWX5DBW
MX0R[V>'^6W'..%H_)#S[!/C(A@U#(*BIP5BJ(-&G^X/$$%8$ITB@IP/]2,:N
MHE:LJ=8VZ' 4/QC6S(@B&=1M,:F^"OIH.O7I%/9?N"-CL'$6;;LCS-%1:'H4
M)7KL<%\R5?#/E(E5XF(AF]XKKTYK4BL!"6)'^[%5N0VQ?J\M]_29>I&BHLL*
M2]:4XT'-L*>5>SBX&FO)2A7).G(RK-%(*8D^KB!IWSMIFL;*[5IF@!;;_484
M-AHF'HBS* CYG/JP+MK0FV3U];D3V>$# 3GM I4R40F$@_WX>J0)PI2/56+T
MHY6PL@2O7L(K3)OH2>$ . OJ!>IW]@U5VQ>7@3BT5$Z32&I;T+**Q'H/A,;2
MTTJ@?2$:#(<U*WX3*'U<F!H&E[Z&$7&U3#0JA"3:;G\_OF%412LF_I>-?LL&
M!9T8N%>X2A(ES@HE+E[Q5SWKVWI82< _V(_O)A7!S]EG%UE)N6(3K*0-&QG)
MQR0SIMX_/&EM;C3(2;!&B\6Q.M8%FRPRV8!9&/UV3,37MPMA4U@#U/K,)(*
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M)=, ?Z=, U<>#HVXTE=/>_"'-,;47= E>88]+30L72\DDM=4W 0QJ]PJO[)
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M,&'FB9-'$HR57S?'ND[!5U]2\P_MX4\[T,' GM$Y^?E/_P=02P,$%     @
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MVR0SEGS]:%NO9??($0PQ*F_ SB<5]"%ING;AL=@8)3>08R:(9-[()FER8,C
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M+;/@0?8I]GS< MY])C97@M>_+ET+?B&5E^-%FLP6I_-ZSQF%6J;VD; Y5+_
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MAN)D3@0CLZO4N&,OY):'#ZE7?@<9-YG3-I)]-?Z,E]PPI9,GG\]";;9!04-
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M9B$Q]% E'5Q7&S0OTM<(3]5Z,U.E*A6$4OOO,<V5[5->_"VXKAWHL+/KNHN
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MZ%0&ICT*]"4:V_RP<?W[3][D+:EVA<5;*!=[_Y'"P24 #><I:L9IP:DCU 3
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MZ&FQ%Y.N)UAK9H\.7-[[H^Z)J*5UT8!(B8-2?$:?D4#0HA\TTUG%;JIZUNV
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M3]Z 1,F-+<GK![O8=8VM)[!?=V6M%<AJLSO._?,%R31G.G-(W-9;14&#UR&
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M+_V:<GM1!S19;+;UAOS/].O^@ :'$_K;U27FRCA'?ZC%T)_#8'8@+471*:L
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MP(79YD+["N=!X8?PY>8(G4I29%/ <TG:5P5KUY!Z0E./9#PK*A^_8[EZ;&>
M\R,%0HN,F;<3&\LI>B?!L13Y)?V_/^V)+'SF3H+A]2RQY%@;Q K0*7J>F2_L
M;@. QQ))&[WW#/#4M;;;I+O<2-9?1\-T1<)6DK=O6)XMYKWLF+"N2)"E=H<L
M-H%7/ "7PG+.7"Q.MX*2]3(\%<2T9(4V*2TWDOO-\#/)/!I_77Z@YV@1C-[4
MZXC,UF":00R8 97G/B IKX160'/OU4\%*\UTO@(B+9UBK!%WOJ&&E;YCF&^H
M0YSV5,SHLO?@-:_$DJ5 T)X#)JX9CX4Y)EO!S6;R/!4P=6"=%0AK?!#R/GW$
M?#7 MV6%FB8_?KWQT[P$V;/(LM$1;"2IE7<67& (UB7-I% ^W%V&VJ+BW%+2
M?=T:Z,RS[M0TA[X#\(#V9N6U7KNBA:N^G*5YP0HI+J@,TM,^+;),-*9]E5 =
ME#VG4Q"LB>6:&*,#DK958LW755R0-FPB8*><L(^*>!A^V%8,N@%(FEOC(+"Q
M*441HP>1$4%E$<"E)&=MWZ7GY.J);BH6#P271]AC#X.6;8S0>ET8#G$4^Z-%
M)3C:;*+RD39J%*",8!"$<F!L\;988<O=/NOKJL!N/?<H7-XF6A^UH[*VZTW?
M3O%_!V$A""\%G79U&+HVPO 6HBD)L.1HA,4BXV:9MYM//2O+[:RN#M;F1RH'
M?OSZ2_COT?CE@"*E.:67T,)[6G@,%@,J!D9^M S :DVIMCZ*CAH ;"GHDW 3
MNS1>!Y0*CXA[+>ROX7(YR381N5.'<@>A#^-B=@J&[8#7FB7WO^"M%#UGX3P&
M!4S6TZ["-<10/.19\H )5,J=-_@><5B/'7O;&+ 3S/TV'B7:"][A!.G)M4CU
M%7[&P>C3#1Y"5K DY+0)A!1(*;F 4\9!8=73<%8HW4U3J8W$.T0'MHX-?0]8
M;5NI@\8+/VTQRZ)2TJ:H0&I/KF6($KP0LP:7F1E),21N=)E\:T!M(>23\-.Z
M,EH']S$>$'7EA-M$W$[]LRT%/HQOUAD -@=::];K8'_<5FR.)I#38($KZ4!I
MJ6K!@*G=J"D,MTD+E.<+MD=\L6/%VC9&:YW:\=4'3!^'H\'HXNNX?_%QNNQZ
M8A%EXKJ6;-:&I;8$<%@01%'"6V=U8G=\KG6LCFO>L'^WJ5.[C-I6:@<NTL_]
M5*?*\.+%Q1CG=Z$7@D6#D@:;(%<V265I@@?'*?;(F6=+ 4C:C!UIZW5CK4CG
M"8]V+='!AK-PZS%?(_C=301G\NA8)8+WIE+":VLA.EH<E0A<)YE"O$MST!)0
M'A'LO.'2IE7:OLG^2QC_$ROEPCN<-46Z)5@H,3F-9%#F$!27B8!<FP?G0B&A
MX<EEM]$N\M!;SM/V[2IW;4#4#2M4&TT8'GQ>FYQ/VS548%G%%+QTP:F(P0FC
M;(Z)_,004DZ]!Y_<(:.315\\SQFX-C3S>6(0-!:0!5.D/05UZO8NRF$8G30+
M*44-)0D:-08.L4XOSE0B;XH'U]%%UQ-C=-H&'=LS.FUAA [<VA7W>S9@ 9JQ
M]+TM;Z^FM67?9$8?]/_0\MJ+F;%H# ,G0JQM[B4XRS28F$3)M*9F[*:-8KOC
M.", 'M# ;<?;W9%7Q6A]TIR"273D SA>Z6HH<# )R?B*HTC;W>LZ=P*R71!Y
M1#;LH QAG\0;SF3FE2H$0,\I4,D%8J:0A8E4+'+-T'93I/]T.5E:7H*/ AJ=
M'?0,5HFV'!:ONO0V%7)T7*TL3!1Q![01K,-D*.I6*<=.X+N)=&>$N]:-T0&5
MU5*0![("?V -W&D^?*;MX )_GV"Y&OS<+]@3'C43K( M2H&*#,&3GB#XDFE,
M6+3MJ'5. ZG/"&![,]Z1LT>M(38HHE@GR#EV'FF$03L(Q260-@JA(]?%=9/O
M?7(,%\>R.[< A"[II:)-E0H)04GI*7C#!!XER:&MTB4DGCJJ.#Q2>JDFL-E)
MJ2W22VV08/H5IV_+C+UR>>%=15,9SNI1?*P5DJ)N^^A!6^V<9X9+5SH!P#92
MGA%(.C-.!Y1/J^L39XO>4L09L<:'CV'XX>-X='7Q<<72^<>X/YWB\&TI/8K
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M%+D_J@6U%#,F8K89DB_UE)][J VC@5NNO&9<97=D9X'KAG)"$&\18]W!?@>
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M[Z<_X&+Q8Y7M3*=_+APXJ1-TK2=#YGD2S-1PHY#2Z$:%H/=QO&26[*Z0%C-
M;AHF#R"@JU"FD2+[!&34ED@V)_>&>>,](P&5$&)POE%Y]?!K.51FTLF0\\AT
M.)7\I]J4]&VYLZQE(,_8J#&4Q#"2<ZU#C;@ "@:8@G4)58)&?0/6P3E^B_7C
M4.1AA'1O534X=!\+ ]:O?S5_M0/<II<D/0$?Z1)E?U4_;-1_ #V= KU<Y,63
M>4$H!=.R< 8R>GK=#"J7A0-L<^MZ$K3:=EES?%;U4,_0D=M->_CW\>+S*A[U
M[C/,OL"K?ZQ:* DE=(B%\<!5O:JN[4S($ZZ))-*CLH\J^C?.VNS[[,.[#4UU
M.3V<(IKUS%WF'E6@-?EHJ8OZ^F@-49&]R5(L@6D%@GGK%<-2;RPD<)1M4O^>
M /6WP32HVAHXHQN@75^;= %W@(3S#?".F74^@#*[D60/333+/]\$,@>-,IK,
M0.<:J]6*@9..A11RSLIIZUHFH1^4)ITRT0_-DCX*:#$Q""_H5Y_^@1.<P07M
ML*_R%Q)V';58]]?K^-OJW(X^)F&+9;E(9-HBV7O":68$*M#+0&VCX<Y]8!XK
M3W40%3\,-3733P-;IX;RWY8/<'$#J'#O]=(C,%+3TF,M]+:9.53TQF0+N5$F
MZR,HYT2*_>0\X"XRGRUJG7^^3(NWLP\X^S9.5S.N%'#B&P!MD"HQ;3#6_&S'
M$$*2/"EN<Z<+%'K '9W3=P_UO0G!"S=C!U',@)W,[N"IZ[]&-+]^%[J ZF.S
M]F'-8SB'M5&'T=1CM0\DYC:;Q1IP7!BC!2=(MA9@<,N93U:R%!S*I+DVW2:R
MGJ+N-QB>!U1]'^DVL#*O@=WB6D[/OCZ[LD-C0 :&MHXO4 EHM4&Q5&_^8[ F
M.M[$1G@*U>',A0$5-VTD]0/,^KN?X_<:Q]7B'2SA\<'G#9OM^!38!ZF.Q413
MP'I4#G6,SA>H)8?<916SUCAZ\I-/*,\Q*%&$2)K9(#/1LFBB)3D:,FCAG;&&
M-ZI+/(4\Q]M,ICG22_&9'OT3?L.+Z=?EQ<CM4^LPN!G4#I[7 S=_F<Z6[^!\
MF?1$#L)E[0;ZC]ET/A_IQ*6)T9,,G:F;OJI#PR1S5B(7,GL#;=J&#+J,9YZR
MU(?7CQ/;CD6'@R51ZF"=A4A"<8'<3/15/'1H^%2@*' BQ#;N_#DF4>['M7W5
MT\#*6S^U\NWW"3'\\_@KD3[1]_"I#K73IA3%F8HH:O\_PT ER93F.2"8S#TV
MX5%GB"^86VW4V. B;#W05Y\^S? 3++"^$R/(-H+TB2FUK.M/F84<+1-6Z(0V
MH, VF;P=P/W-L<%4UZ#I_G49Q&JH;SVX_SE>?'YS.5],O^",3NN+RSR>?*J-
MW.E_M;/Q2' 0NJ)-R2R32A4+O&8=6)^RB;S(1KF/.X!]P>QKK=H!&^^O6NF6
M\6+9NF8^__ 99OBVK&Y^:MN:X*R1# 20(Z]=8>  &&W$0>MDO)7=ZJ6>>LH+
M),NPDF_0$_\]7M!6F=_!;/'CSK)_NB+VQ^G=WX^$@\(M>1+! TF *,L"1$E$
MCMX6,,KI-D&V/BA?(,N:*[-!4_P6=UP9DLXVDR5I ]..>^;IA6*80/%26\ZF
M-IEP?U?#[$W=(]/AM*MA'"1$;1U3SD2F/;=D-DC/."I;N^!SV8C89U\-TX<B
MG:IA^JCJ!,H5NL#]NQIF %7O6;>PBYY.@%[%20O%US%/P3-M@$X$&PN3V1K,
M483$VVQ<)T&KG:IA#LFJ/NH9NAKF^EIRU5')<>V0W![C4JJ.L6=1F\*B]1",
MH#]YZ>1_WOO8TZ]AZ:6!Z2#B&_">IV8=+#N@XNQK]2G^@"]7N2<1A$Q@L28"
M%*:)T'6H;F;<^,RE-BG(3@GAG?)PUB%XX3;*((H9,-A>\;S'KY>S]!GF^.K3
M#*_O,N]#O$Y7Z0)R\$R^SO .G]FWOR:GAU+#P)E^W<&"05&S7\CWK!LI&@)+
M^Q[C7B<IT$B5.G7F>0Y<>2(3\$A4Z2/]0V2.@W,ZE&08/5O58U4P[STRI%/2
MJ@P.R]^9XXW/G[T5<[#,\2Z@7ESF>"]-=4H?WD7,!\L<=Z)$]+!L/8"UP+LF
MRR;!,#AMZ;\JB,%WC%/-'!]>]7VDV];1%$7EY0TLN+HV$9 %4V_?('IRHA*F
MCLVRC^1H#BCGS>YD'R$=N-N!2%D('C@M29"E$12A*@582AF1[!D#C1)<7TBW
M@ST"XD.I;<#$AVY5E%W _=WM8$=E]JICWT43!^]V@%DX7QO-2'22Z<*1]LDD
M&4H$%UPJ#@_:<.5$NQVT8TD?!;1H\[HV1?\ZH>=F2!PD\GTMD[G6T->:VPA0
MIY1GJ93W%AJU\.X [M2*V'NILU.YQ.ZZ:#&PKU?S!5V\5%YJ)B(=N]HY(-N;
MU!R3\#9J*%&VL6^>=7.,?2C43C\-]I[7< &3A!\^(][?;2,'GHLS+*K:6R8#
M2<!JP6PL('*.(84V0Z V(?K;*!Y.80WR/M?A6L7].R!K:@YOQG8<6W@8'78@
MQAX*.-!>L[+3/==&VL3 ZTQO1 HLA&)90DA<@<LAM#%O#DV-+?;OH9G11^X-
M&+&L,WU3ZTLGBUK6L%B=BCYK\-$$AB74%JY MGYRD04AG G<9J[:6"V;$!W>
M0!E*:],&(F]@U=(IF?%52O4^</X>$XZ_U;/R&IPB:%XKQXP-M;HE<49&DF-2
M%X7.H7"J4?OVIV"=#2F&$WZ+8^-R/I[@?/XJ_??E>#Z^W1*C4<D:0;!D9%K4
M-F4Y9&:E+));+Y1N4ZZ[ =#?!NI@ZFI0'K(.5OURAC?I*1T MC53MT$\DK4Z
MA$([D&1_;1QH\[D/5%MMLO:!91_(@0^&WI4<#9,JE^ ME)P/MPT=@"[;+-BC
ML*6/$MK>!_,27/;>,\=E[9)F:)U@%>,YJBPTCRD^Z$%T6O?!C62^^6ZXC\ .
MWO+K?_^8?H?_/9Z-)X-U_7K\D<,V_MH"^4'O+V,T-QQ0.IVT%60K2ALT(N2L
M;=%VM.W#3ZC]%T8R2"4Y+]8J7D=KD[?LT=:1?9"4BC(WJFH[A?9?RS?KSZ^_
MS*:3Q6KD)3EN2:$LC"NCR7 'S4+Q2'Z=EA9"H0UX*WG7?.XS+XCN0Y-[^]8>
MTAUZDON^TU#G(P]@0FT3D$/M',&Y8<%JSXI0T858E%>J$S?VAO)2Z718';;H
MTM_ \>0!';? C!"YVA2"0:$5:1!.0HYH;)N&$']7W.],YA.APVE7W$<>"[<8
M6+$ZU4G"G(5H1>V0P7W@.BGS=\5]<XITJKCOHZH3*(GN O?OBOL!5+UG;?0N
M>CH!>JEL0)*IRQPD>JL(//-)"99MT@JTDSFTN8D["5KM5'%_2%;U4<_0@:_;
M8,";Z6^+?#/9,!>R/3.3M$ZF%1D3]7::62ERYCEEA=T<B[4??_H5^+TT,AU4
MG <(C]VVQ9RO#O,](F-/?-J^0;&N0!_$P[CS,9OD8BY%!V<\=\IGAT* TD+#
MZ(G/'<J;>O6-/JX:-[],9W6<T@=,ES-:/]XQU&,H2FF?F,BIWM8[SWRMJ(F:
M_LK2& UM;AUZP=S[L-KXB%=QONR0.4+I2JF5PB(@"4+EPJ*A';?(1*\AQ* >
MQKB&.I^V8CO\7M6.0X_.J6$UTR"AY"'"GS N[J#\,ITMQO^#N3;U?0US.K9S
M,,YKGFH +]<T!\-\!L62%$5 +6!L-'2R+](CG($#:WL+F09550L;^FF\*5U^
MN5PVQEP.3?AS,D.XJ OX!\GZ-9;I#&OOWE@[M1I'= C)DIDH,P.4F@5=,/.$
M"56;)N"#P']I)&R@U ;-YW==1&TD?+N(DC)Y,$4Q$>M=/1>*>1D\DQY0:\EC
MZM9MZ6#,O ?_;V;NK=0&C>LWR^C^<D8E*)&"3*QPJ/X3*A8P(OD_5I.S(UT6
MG1KO#&C0W4=X]OP:1#4-BJZ[6+=706%KE:/E$\U#;5N FNP#[RP+Y"Z+I$H4
MI1S-.SKH[=#A/((VVCF56YU?QA.8I#%<_#JA-^[R-M87-%=&*59*K):HBF2)
M(GU5A\T$<,$6U81I&P =_V9G4.U/A]=" W]@&04L.+MMH#*>?'I;UJ"=UXCQ
M?/VO5HFO'=;2]#YGR-4<Y[)G$)H\+I$XKHY/G;<0G K:8AT=7\@"P< BUX45
M*X**3D8R$EXH7[?<(IT\7?NHM@%-__SPD5R:^>7LQ^U9<GT[8H3BQ1;!?,SD
M;F>ER:FI:<0NI*C([C6-1C]NQG1X]^!XNIXV452#8/ MLM?CBXM'Z(1#GFTA
M8%H(^B/0\J4H+,<<M'(NQAP;TV@=KK^I-(3"&NQ(OT\G^.-WF/T7+GZYG.05
MJI1L]KE6M@3#F:XCV0(7L?8YU,4(&V5NXW:NQ_."Z3. @@:,SBZO]Y>%UQ\^
M3V>+CSC[\FOM>HSSQ6N$&<GH$<&#4$+99!F$.L5->5?/_L)"%EE -L*[!Y<#
M&[(H>CWV!3*FL6XV1E*;I&3\ N/9?\#%)<[CCS<7,)^/R_BZ2'R0)(WMGS]@
MVD;/Q3Q,Y+!<*RVD@)*T P4IIR RO>:^5J>54:\G'3*UPR2/-@4ZS&IL5==V
MJ]'23H5@;.880S9M0DH'2>U8OF^W G_\K#MZ>?U &[].WDPG\^G%.-?;CKN]
M$&X#X08SAE+HI1?5/"#7J2;?&:9]2$EY1/#=-LYV&$\]+Z0/ >]MHR>BU@;^
MPQN8UY: ]:\Z)/H;+>CNOO'3>%Z#T9<S' DN1!#:,^EJC%/P0BY/3=H#S@MP
M;Q.VZ9O6&>+AZ'=2I)@>0J,'2#;9=#MWW=-GA-H7:Z-F*1:R3KPPS!N,+'%5
M"M8AK0_S;P]\?WH-]&\:MM;N ?)+-EX5^U(<F=O(DJW=I%3,S--+Q$))7A03
MI>(OY1;_'.C72Y\-LD>Z7R]*\OU"[22!ON8H* <,K,W,"8^T87,;&Q'OF5_]
M[V+TM=7.J5_]:QN--2(Q)6D_UB(E!N ]$P"Z(-)"8YM:Y6=[]=]+^QVO_OMH
MX=2O4+NLY>^K_YVN_GO1I.5=ZBXZ/G7>HI926&69,:"8CERQZ+U@KA@'W+ID
MP;Q0ONYX]7\R=.VCVJ'K2Q\>)_,[AO)U*-Z2>4*FB6:>UPL=59.::R^48$Q)
M+BA\=..V(=JW_5G/_&ZDER*G[;1PV!K5&_!E.IO#4+6JFSYUP,N/3L ?]G(K
M@?/"L\G":NECY-8F",5*G;S,;M3A\X=RTVI53*T_>#NY\]!?)^GB,A.)KVYF
MZ^/OI+)/\IU_^N]XD5\M:L77@T$=[_'K=$:^\*LORV;%'RZ_?('9CUL_1F,1
M& SY,0YK%Q >&" WS!8KE$I%8J,F<,=?^Q!![I&-&GW@P#AY@R0_T Q\XBQ8
MK .8E+70IO:G/OV8-R//@K'KHMB]5-;@;N1!.=*#X^+]G3*Y4?9<9A4]LTG5
M I) #B#GCDGGK?#6E]1HS$-WC']3L"<%&ZF_:;^ZM8*^BE$X%8+111*H:&H_
M*6 >O*T=B[/7)F;%VZ0"=D%W^-#ALZ3DX(H^E5#D4^,1=50B6WJ; E:7,09%
MIP!/+&4?;>$JN-S&"3_I0;9#$:#':-H^BCCXK-$NX/X>3;NC,GL-'=U%$P>G
MB_(<A J9^6)2'3LE6>1)U^Y30DF.+KLV!MOS&DW;CB5]%-" '7],)U/:=PG1
MY-,5T/NC4"4/$B+MH9@%9UI;@A<*P3-9H5=:EMS&V]X"[-3FB?92X[2=#@X;
M?:N)58L?=W,*AHB^;?K4 :-OG8 _B+Y)ZYT' TX5JYW2,:=27(Y!"Z<=XJC#
MY^]Y4;W*,;F;)_*/V?3R*S'G)C1\0]$W\/5!]V=E@G=:!H:FSJ*MG<6#MH$5
M9<EC<Z%XT::7VK[(]]WF'NKCEV]_C$<IZ>P<^1W1F<"T,IF!]88A"2(IQ1.4
M-F??.C2'W] .RJ:'>][>"FD0YUJ'Z7X;J.IHC*)Q03LOF<NV-CF@90,$QQ*@
MTP4]%-4F+:0;OK^)M*_2&IA9#U'^<[SX/+U<O$?(XXL?=#K@[ L)JH;55L*\
MBIN,BK1<E9@8VE('E7O.0)3$Z.3W](84%+)-$[F=(;]P K91;8-4WQV __GU
M.\SRN]DXX:O\?RZOC)U7D\DE7%RO29M4(CK#K*M9AL5G%@)H5I+0*8(O(;0)
M4K58S=],/BPA!LPK7F8V/%S0^P>GPMO)3^/YU^D<+D8A.E<\<I8"V1\Z&<6\
MX)8%;CT$+3FW89L+T_.9+X1=+371H ?=K8Q^K)/2562Y^"( =61"%T'>OH@,
M/$HFG,<4$A?$BL9^U&9TA[I#.NI>-;B:3N4&:-T \&4(LIAL#.>)%:A5()XC
M\Y SO2;!"1X\%FSC=FQ"=*R[G^%5_W :[1 J:#&J>/-L^"[(VHZVWHCM2#.M
M!]%A!V+LH8##4@0RV2E6:F:%)H0R%>:]5$P&.F*+TT8TRGLX-#6VS:\^,#/Z
MR+T!(Y:=3^K M:OZTE?S.=ZD]7+.R=%4BJ%#=37@F8RO3.<Q)I/I2VA$B2=
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M:FM69O@0Z*M/GV;XB2126^F,,(3:<@"9%*:0D6$(HA"19>-4BBI(;=HDF'<
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MTRDR2^O6&C5*T<9P[@'R^(E0P]*DNV^_E[H.&W:\!?H'?%E5)7:!V[3G4$_
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M]W5:EP\?YH:M]S(>7+K)+$$:[E2@UZE.'%&@G5*R8/(ZISCJ_IBV]W#.>RO
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MNG= H)7,UY!DSUAA[]EL'A"X+(%9#Z)6]!<&(@GB@':NE)!<Z-;GZCG/PAO
M4&@A[S7T&"9DN,VQH?^MV!Q %L^!I6PB;7E$:7 5L]/9:0>B:X/]WH\^!WJT
ME?<:>NP78%PY/ILO1*1<78A(&YS,CLDZ0E(KKN@H)*O7"W)VC?::\]1MV^C\
MS',@1",)KV'",/UX/HS_ZDC< BFYDA7+)M<Q\#XR,HD\L^B43:#JH,E^A.CZ
MZ+/B11-YKZ''GK')FV./ *_?W.XP60'43D&%N1R 7";IF#=!LLPA6*5L?I2Y
MLM7$Z/#8LZ!%,SFOH<0P0<CMW8,\J)K&*5EUF,@"RII%612+=3 P!ZE]Z%;
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MN 2OHR+X!3K+3@?B,SI('O<QP7D2W/6CP9.//"<:U)5O]::/#T<H;CS Y.H
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MG -AAI#]!L+4&G13[N>VS/%^G"]T.UV!&F9%,I$HY6B)L1D21"HMN "!9^$
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MRLF59MA(6Y$#VD'*&\]8C+Q;B>761YR90O<37=-)1G>VPOO1[%^+W8@FQEU
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MFR3JOD@/[Q"ZK*]#;WSQWS_&]W7R^T(G[R=75_C6???3=)G0>&=).<(RR#)
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M=9$^: BIF9J.?>E^Q^R;VZ;?UR++BULGX"*FK-!^82F4]E">.$D-,4PHX;(
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MR>?:"NGG)58=+36(N2\Z:L%L?@.G-/F\M(J&D'TD*?M$I-/HA><D"-=9".V
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MX[$/C'FEJ59M3M0G@/UDK*JII@;FV.O)^%.):I86>I=,&D6#X(39(- =0,/
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M)F(]!V)9,%*X9%)N,X7G26C/GBIME-"@0] Z0/B^/.L6]9FWB8Q,48IK9[)
M=$$3F[0DT2H-+%'6JL*_ [BS9<JABGC,%7G8#=IF)C^LY\W!>>>Y)-KKA.XF
M+7V?LR7*Q&0YU_E1=NFV2[0.3WOVJF\CU\>*5RT4_W*";G+9Q68?YOX'I!<_
M/GZ&EY/KZ?PR1>:<1%Y2]"F)Y,Z1D)(G,9CL-(?,HCZ$!=L??=:4J"3QQ_S0
M=0^1VXI@GP1D64H%H8SK=HDC*B6($(8["QF8;-/"=C.>H:[?!CD@]A+RB5[
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M9R^U\$G(:U$5Z"M3^VUF_]K$0O_4S/['Q/[GO'H  6XN)'C<P@ :8+-2HY6
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M8LE$#N8$-H T7[L(/'8P9K&L?>$N)7G:>,+P?E)0ZFU3&>;]LZ TL.P.KV]
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MO8L>32AR8=Q VK@XB5 K)-CO=85>C:5RI49W3GQ;NO$ZY(KJC:8D-K)H0CW
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MXL#H]QI=]*Y/9$B+Q  A<^;EWI V3$'S]!/*_DV#A&B61:[G\I5,Q/*Q&,O
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M7\]:I]8G$A#A/"-VUL9011)'=A_[S]X+^K^FD2+(;@B649)H'V+O(E*?A,;
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MQ:B:#_A6TQT?_!EK]?/ K3WG/+>O72-WKG;@2YT8UY*N#W,; H4CF8BJ\<Y
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M==9/I=[\;;(NFO(<,QN@B^0'WC=(?@A8?G 3/6OS5VUU:\DB%C-K^C?=-;>
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M2  41\\<N+0A8L)LO@!_1UMKW6+AOUT>NI,&,POE$<H<BY>+H)TB&!(.LXN
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M#7(1Q3J0>!KS*KNB1@ 5GRGBX-;PT?GCR$182CPQI\3!1':SV!G*L'$4\;#
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M]S_'KO%D#_1O&]+9!^H35G;#(,IQ8J5QWA>_C$YGF[7!6.45,N6O]Z%P$9'
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M\WK4^X>\H@(CAK@(Y_'J"A5-'>(F^XR,-*KG<LF0E]='O0<OUQ)\(MJ!WO?
M!'S'X=M PP1Q9A@]3X>]^A&(RC;\A/X!@]='*O HH&["(]7?2%B5@!FL)QIZ
MLJ@DOD"&].PYA0U<A":20\WZ_;-]XV0YHQ:UN(@VT;5B])P=A"C,(OR%MAY@
MY< O@14?CH D0Y(YUR/?K;<.]PGUKB)V21C=2,HNQ,?5J/W(W$-?R@"##5)Z
M'$U?UP7G-NE64!1V&G9**YXY%>VR9PO;Q  PPD?@85)6=P48>_R1CP:CJ@T=
MW37K<6T8Q-(^:D+X+5L,M#FB_DYV6-A41-G1:U+#(XXC^C&BO*H'^!T-76WU
M@T0N^N%Y.+*X+B+= @6J:!2S=L+WNX1VKK:IS53NQZJP8ZC;3Y ;[=27,@N/
M4-M["M+KYWV%ZD]%4YV+7[;L&0_(%6>N957I0*(?.YEKRXCND$PW%W&%BR %
M, /[.6J@4>VG/I0P1Q/:^_[=>YT[1XH/]MV)S_#U%>XHI;\0R3]5<LKB0L"$
M;NL>[%;V8[0'.1:@7XJ9 W>3H_5X9P!DC>S@FEE\@#(K9KS.OJK][.P"C>S.
M.FTW:'YKQWT/A>5Y(V5]-ED7%VJACWI,<JOG(H:(X_V09%8+0+<(!,:>XD6T
MY\)7IVH'L,(Y@%-@>UU[;FM@1:J.(?73A_XK%LA5K:CVB%;+BHTUV?>I+30B
M(X-J<P_B?<YID#L,VH[=?%/-130B9<&?37*2Z2YE%5'?(\Q+R[K\O);]/[S?
M\BKI_;F'*[7"7PJ(IRWTY0)8]IP.' ^[&' UE^6TDT5W"+\$IQIL["[TO-S;
M<:UKQWS1%CG=3Z_X]]S1\O2:G -WH&>-&,O,?>S8PMN=I#G;$"-*:J&:M=WG
MKDMJ]0W&753.ERXM\)6CM!1-7G0S:TY)13$9X_E-'[6+0R:9TV08,53)>LR]
M3 EVHJXY9>Y!ZNB1,H9D$R#BL<JY+Z2S94!A>+J/WRLXMT&+\<Q,;1*_+VR>
M5IZ;]G^Q]^[A4+5]__ JE9"4;;93H41(2$6FDNR24,EV*LDNJ21DFE6$"!/"
ME6+*)GNRKVS&7DA"]C$[FVR&&9NQF-V[7,_]/,]]7]=]O;_?<[_O>SSO\3N>
M/];,K..86;/.<WW/[^?S.<_O^?U^W?-P'E+BG<72&AB/V1$U^U@BY>R4MW39
MS@@]1$#F@#M&KJ0GO]#\1TS,I@_M?@=WI#6I)RJI*S]VGO_.WF (H#UA<],K
M8E=C)#D-3CO82>OYATMN%Q+GQ5FZW8EGB^B;./N[RG3-7<V?/BT9NN7M&K\O
M6C#F4,S&F*UWQCY=8BK_-PKC D^*4;B>"W$^N.8@W:\!)R2(:CQN$UHXKR6K
M^/)#=77$R.C60U7)"\H%O$CM^V4-G!Z4Q"0[!68XL$I$R%'1.OM*U(/08CDS
M75,[B@0?]CV(_;GU%/#"H:7BZ-%.TV$AR?-5\F(/AGIJ*M&M<::JN&!4<1AU
MF5;(> $/$5=,%P;)S@0]$&)VF%XIL::):M*)AY/-%>5205$?!/4%]^R-EX_0
M_DS8EO!A=^U+<:N,!VR8$6ZV9!?AB6E(/I X2G@*[D2[YWC6B$"O*(^,SG7K
M*\PD6):EI+F[*%;/9LTY#_65.!P4KW&7YB\M-@I1+T5'T:49&_I +Q!2? \;
M]&;*]ZI'$J$<S2:*N763U,1KDIEQ:<<1717[\0J!6R\V!P9F1>[[==XQ/3ZY
MJOY;^VYV.'SC#OZ4*_ ;%JR3KY&!TAA#M'VOR:^QDOX/R#U-XG*[NRD)@M=4
M"S/+0Z>-7SV8BU<EX^X WEZMV 0\JG/&Y=7];&>2^7E1^I%LWBJ%=_E'W>(R
MTV*G?&7%,\-#H^RRNV]W-!B-H/PFUU=])QF24!1=G23$DA&C]S"D(.N\:1O$
MEH,<Z2F[(?][]H.W#R[!\#3+5LBC24I6)207[%/+,4KJ]M[]<M,C 1K%M@])
M?(<L?XJ36*+:C6.VLOC["N[/;\TOG?W@W]F\54JZ^@R1['E"3Z(B+*CP7H_Q
MKF<)'T!W[ :8XV^I=&4"G%HYT5):8A,B^A [K7E4NZ>B,\O?I[X\IWSE>%/3
MU[Q%O5Q)\<LJ\D1S]2\7S]17!5*$FE&RO^\O_8 &X-=]G [.GA_ZNUA[BB!'
MWVP/8>AJ^O'0M_0!#_-;0>/QR<[19D?''EA)N<NA#I6A&]_)=#N-!HWCBD;M
M%ZQ#<BZYHT:3WUPOZZ:6I4>7CB >G)]Y3?<V_%7A.C4N1O-C2>-_IXI3ZW*#
M_52-LQO35;'30^X +3%RKNJ8+WF7E_"&W!;9LORO/I_/BHE?4'MPI F8O=Q\
MI7]4F[Z:@GK6YL/_VW'&9'!)^6AN:_(/C^8RQ:.S,/06B/QQ/>?_IU-$0L^X
M )&D/N3*B%TO!4%\E:($93#5/70>.GU2*[GVWL-)OJ='1TH-=W>/R>W46PC5
M]H +X<??X>Z]J+N"YLWG]*7(T'EK40/S9%CD8<F$\&7UZ*3.R(.EZL]&84[T
MM)C!6708=,/F< &O87.5U2X^QL=/,:?S?"1WOE :7,&R9'28WM , R8$0?>G
MG=0A/Z*YO,./*B_R5C0\6L6V)"3V';DP8N]H=G#1_LLV'ZS:2-K%%Z+JR@DV
M0!K&#C.*_(!J](9VAS4+/294J,_NI*.NU*#$,MXGYKGUM,D0IO7/';;P*M?>
MZ*G[7695T22\7QGLG64[!],&[ 8-E7WWIEGYY,[.TWK+=(]>[#'.S40DQS[$
M2\L>:RYQ_Q6+]RV8^<JD,-@0CJY##F-)K#!NLY]B]DS;18);M'$\TTD3&22H
M8#RHLU'J15&?,?-4U,MS>SS-K&**="6?.Z\$Y8!U5:@*BT9[ J38B>4<Q@S"
M;5*?KU*DY38-Q1?$4T!AAZJ>UK3A(?MOSNXH]3O. 9([QG^;OY*H*^:YM)^B
M,]M%DV<\EU(E-(,A:YB2 !(S[--W;4D_P\ ,L[VW7@S_K&\_*-T__BB:YS'/
MC0TH9=B4^3B2G#YDZ?EDIBQ:F"8>]Y;3@2\)+=G$4>^^KRL:?)ZN_IR\-]!+
MS.J0L%F@N$OE9U[=N131.Z;'"E,R7HU#K%=7Q\WB3Q^:2$APB,WZF=:?DJEW
MK<+<WNS\*ZO<\_A2J^KAXF4SH[&\P2D<S:(P#"]>Y1- 1@ZW,V(__-#"[T)?
MC$! 9UF2@9I>-.^05,4\+8K<G0HK7AT=\\?GNI_6[GB",K<AK32C(.5):@-E
M?C,&)I=ER&#](].8'8D,+RB,E"]$RGQZR^LJ<^-0>V%GIB.[1E+>V4^!WIR'
MKD>7_Y0?TL#VXP=Y*+<SF*:<-J0@Z/;(]:2C\F*+_J9NWYGJ(WJSY0ESW0=&
MM51;3WX['=?J($4DR[P^!,NT,IOQ$@^9(OPGYL?S&OWWWRGESN3X/7+ZS6YI
M.C &#SK:X4>Q9V&X&_]6^Z?5T[]7"9/+OQ!"R#$[BW_+.W:.EL8Q#8!E%>:N
MWIM)=N<$WOK>>FDXGO'3?UD'C)?QE)W)V<(Z",4AGZ(#*-@/'AI#3?)P9]QT
M: ]Q:4ON:FS_LE*(*?R*A91U6,D%[[C 5<_UZN^"Y.W\"<@]%Z>/).HYI<0N
MN$Z-BMSIXXF 4J\<=,C8E7-O?3?M>96<V/)J[%L\Z1/2I7!-&;%ZIH8+4+3
MAGN8=M321>1"^",NT.RYV!W!LF#;U?YMC]Q2(NO4>3$N@.O%TY3 A9(E=8YT
M',.."Z3"?__2;)ZC:<32V3];Q@4,8=FAE$A@W<2?4$K[CPN<@@F^=0@XN>S-
MXD>P\M@PZ0P=8R?@?V6!X\),+A#9Q04$6YFJ8-<%F,4KKG !R<).4UCS7?Z
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MJ@X*A>KO0-^D?Z)GUEF$/RP-$A0KN*E6<5RQ=YBL8M]DS=\<6QQ0/Q(Q]OG
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MPS34TYH]T,WYNI3CM)&$PG1"T_BH^U!4<?NV]A<G7:Z>J@."?^S8.G;9B'4
MMQ$1A:#AWQ>E6 @+;><"UQI\%-MWD4H6J\C9B)'+ZJVW;D1K1JOD%+0-/)VR
M"M$M, 29 945*[9HK!!/_(]H3<EG38KJ7@JQ(X%*34I-([YQ;Y*&"6ZK%/)*
M:)4NT=Q4:/ YXWK7[N\L%[H44J=1?T_IB&)?7&K])FM4NV9"S!LU56K#D4W8
M!>*> J&6%'WZ_J=(+UPHDF:!?#J4WQ_,$O B#A;,X8Q49'M[%/,'P\]\%=A\
MN<+F^J$;-Q\U]O?H"T!($G*3_V0C0?A6>F5E'\O&1V3:9F61UY\4?L3 4UQT
M*^G4QY!IV\'?BH[E@<]1)>H-R$BYPUWZBIX"X'O_M(8BB^TQ9'/A,0._39IG
MZ>U\!_,*(HN/-AP8LHV(5X@;-D"$/5WU<#*+GUY&SQVQ\ALQ<AGT*'N@'WB(
M]+6M#.$9XO&&G8=00"DS=F1E*+NGYTW/'*L6?7TA[FZ$:\*ZM%Z7Y>&(,IW9
M062$ODI;HMVW,#)?:7:9,?$*Y^?S;8?S(K,VAFWTRG0#J+S9VDL9]W";:_A8
MVFR<OIPM6@VR('U<ZI!K\5%0GIU7B+RW8#QKIELT;3(+U +;"S[>7;ZS3(]7
MOH ]*/W ,7&YY]V2@T[0UX79,,'0K\I,.UJ0=4H!-: :Y5GM-'\9%GWWY ;^
M& _,,&+M'.:8\D;!:@RF(&EV-5#A$]C911,6+NBYK^LV;[94[TH3!E^/6I#/
MG%'OP#7('8$Y95,3&(KCO%[?N[64.?:GX.!_U\\M"-H5W.I^CL#Z(D0G)\(.
MDJI9A;UJXSHMI:'8H;?!):O^VEZ8P*\7W&-DIH-++T&?]<78?3."'&7<VKU3
ML(3NP.7],9) [ACS/J>7 1:UU.H61C088JU^%*A?[RE5X7N3Y^/XI:#VBY&N
MF'S,%YGDUZ<DO]#GG^'*)YN]!^W)0K"RB%XKQQ;Z&Y ?Q$E/ZSRPLQE4_#ZO
MP1>3MF? Y#;>+9)ZQR&G:"0F> I%LP0']]NRBT#7]U @Z8334*=#][);F:-D
MX94\3=.85NG3LQN4)171,C*''.A)4"*#W 6Z(9^O($I@# B@:Y(R4F(HTF;6
M-^P:'*-7"U*]2X8%RHW[=[P?#E X=I.)_:YFT7?CMW.5$J9O]M\<QIV@^LK9
M-Q646^2L_L*HD+?X-1T[HB-B%W8\TME@FI7]\7Q:3IJ52'')O>?%UK\*$?Y,
M:<HDU9PRC!RVKD46V33H5C[:BQ*>TCG^OH)L<JN/?&6OL5IZM)(S&*<P5#YQ
M]>=Q"N^^ M@NCW,!3S;(^ CM>43N1$R)/Y":#_-]=;_CNMENJR%BGOO>;T_"
M!_AK^,>(V?+ X^/82$2Q=ZB^(NL&+9,J\M8_FG**7A%,G2CK*;M"[2,?H*9'
M7W1S#7\V"B19I1]^<>/6Y-L%61U&( W;<&)[ X>OBWEB^N'C8)N1?+0=_4Q<
ML._VUWNV=B5>$%-38Q5M5$(H') GTEJBD8._1?)G;';/D*[T<E4+T.G5(L?.
MI]H01G,Y%2YH0VL))_22S+22P2L[CPNI6=:1F*]IVI>MDV,M;YN7511A.E&B
M+&_Z<*/3'BC3\ZXLOJ$'R0"#=C,/"4^G2ES3?_\-<TT4^S+\[ ;C]IC%B&4[
M:+X10;-D>F_\Q06$U3$[6+M[WM-TZ@0-3+NT=R4MOTU9,K_7=\-.^9UQ[#XL
M<(0Z$[PPB<W51_A33D*OB2<DR#HAK@%:'8&F%3\.RAD.-4NFV8K<F;W3(%_T
MI4 &L[V:EZJX_4JU^)!;TOF16ST8O.*2GG;*^*>G<N(I^X?Z(N[%E9B,^@3?
MP0]<VG/44&70\'92W ", 1WZ>7^:<ERB</C6TY/'9ZZO+*YP@;,V$R<P;\ Z
M-7"LNY0+,+>-<H%?;6MS_%P@!J9D/*PN* S+!18,##AX RY@\FK)4-02E8MH
M^JN1NN&/^P_PYC.+\AQ^F,OL]\P"!Z3:N8!A_Q=Z)BN\'^H?Z_RI!W"!V EP
M>0)<NRB4G)4:P4KG?/\C;ND5,KY_1X,4<+"RB0L(8J18NGCZ]GPR4FC$G1%C
MYS18^Z(J_(-6E(_>2?6O%NT?69G1KQ9!:!^J#O4<W(R_:8OA8?E#%H]2'?+9
M2X6Z'N4Z.QP,CJ'B[89((_:;PY2!X?X8U'E+Q^\MO:$;2*(V*K'QR]5]R50(
M<<(^E!8/14M^S;$8.OWZ?=K<PKW6D9%[BTXSJ]@PT!,+*>C49M5L]%1G'D#O
M2+&0Y5,%B[I8UOK\[%2D+D=_;A-J&MU9#?E$K!0."#%\GS-<V*^TU#<X09:E
MC^[-:8#DW+-XYGG?_=%'QZ^VS3WV"M^R8Y82_;XZ-:*OQAO;=)63?_FVV>LD
M:CFCK"Q0M;M\4MRQ]J?.2]?.(W47H@Y\QG0F['QZ-5'SMHE2YK?YF_-Y5I?U
M7"D6P7KVS-,P*>%L\ZB1JRJ'_-YMU<9)C/X\;:6^PR%LQ//]60OATWDI]\=N
MR!:U--M5P;2&"6.%(D2AN-:AAGAJ'RI^*\IDG:#?MX:>FQ0YKNP<TNXHC;J[
MS=%%><_5+Y]\%J[*R#PR-W0UT,@-S>8[I6*H?9O5UNW=00 5/LL>2Q0@+CHH
M/KP2WMJ6]T[-2ZWZS<OLIOOCS^U];UL$:([CH?V%LRNP4^ML$HKD K(UN]TJ
MI+0K&K%2'8%O?_7C5.N'!'(_779_(3)>(O!BXY%=MVX]B4%961HZ1S9=;";+
MVN;JN&3>B$4%Z18??"WXPN5%W06O9K7S\P\F]Q]#ODF?_:RZ,4*IP+G_CU:$
M]-#_XS0&XA_G.?!OE;@ O_XS+G!8 S?OBX3AY1 \E Q^^]-(FB@L!>MTD?@U
MC^6E?(QK__ =/T&B?]@P^[J5PYOR<7>T0W]USRQVG ND8Z/0EX@K#!1#6TI;
MOXRZRBYU50E4=VYO;[5*+J0J!A)</#W!]YPNF!3/<KC 5&X7 POM=X5'I[E3
MS8W4FF'.GAHC+H!4?D3G F-"ZVGYD[W%D+^$-L, .,,%%DU@(8DD)N,(;.V'
M^O]YF?ZO+]?KZ1)@#,3%Z\/(N+"!"XCDDS/9&XAXFB/(<4>>4TJM^3V7#NS+
M+9;@"^\;]M_';$&5V#Q'H]ZC3]*C,D/0QT"2H\5YJ[7J-DT#+V7'3J$$Q(W?
M7L0&7_MI$\G9!V;Q_EBR^;*^>A!4A=9GXVHT(6DBCOJ)J<4Z"ZDC&Q^==.?L
MH*/"ATU^: E4DD_:&U7WJ!?H=V@<?,L7JSU63GU;]LCW/R%9['F6_Z)AQ(H=
MC1.<[.KP?>E+80'K1*;#:;4V\\D  6:_<5?&(=.L&_<=LA4?3U2I</B285FZ
MA0N$/6<=IL\WVD"*CX@'T )TU&7:B6]1V3.63C]-M)\^Z%#HUE*2CWK^K74\
MS3BM_4M,Q57@D4C6U!"FT%GM5>X5 U^OXZ))H^3=4WM3WKT<VSGK@0^KTB3A
MMT[EIOE;-_0==TDJ<BGMH0KOJCMA?!%PI>7^^-OF3$_/!Q_MRY]LRXH,/V#Y
MZ=*S@QNF-RA_DF5@31^);DB$Q=8F?\UZZY\C_C;UQYU>J<[,5\59?(@63_XT
MWJ9T,$#OS7*^Z7\A0N./(2ZY_2\Q/PD+[D['8&JDP_EA2OX*CJ'L6<*L5TLR
M^[F XGD>#MZ*"W23,68PR8).<5[\*X4M$#? .EG\V%O_'GBL$-:T<^<C(,0_
MB8.982ER@;W',<6L098&Q9OUQL$&@OG?U,?U:C&FF'-_664(UM:;PV$H (EX
MYK:?Z_&3A4]RYW'_+!(&2_=F83T>PF/"Q&@%&81<N/V!0,[F ID*Z]D,!]>^
M_)&=)I('T*YWT[7Q3[R7VLTF;ZF.YKLK-EZ(1+QNBZ(<EJ&,C^+L%CN#"<6N
M3VMDT,8_.+K^[8TV*>K0DSRC<4<H[7*XR.P'YXVCW9M655,!9QX?N7N3^ZJ=
M(H9V191.M>UX8$6H="RLKBH_JB%Y4T B(O-9OIR[M5_4L(?Z;1?IA45O=_M7
MCH.Y+Z;-L]XGZ[KO-% <"(G*<?AB=22.U^WF!=."N[$;=C\XH1+,3M;G'V7M
MII4MST=J9Y5A=_F_MGQDW7Q\Z6Z\?64+L)4BV%8GO#E"@;+U,5%<^]?%B\UY
M%).Z6U0P<6I\="0F_YPL_\>/U_<5*NU+&_2QFQN9S7_4[:6J,$^?QX+$WT;W
MXKTC.'R0'UWB_ <:KEG6T_Q'66&%W9>5AP;#CM4_PF_G+IPKUJ5_BKL*H =:
MUS))A"?W$2$<H$M?VM].QUSG9'?^$G-S? 4R?INGU-R)8?[#@6_Z.L1ZPK]J
M^'_V$'.Y7[8Z>':^LMAL?'0R_B7MFUGL=5<4KT6"E4-EA=NG;YD'O8LGWV2X
MC XKI<.6V!A(^A-WR$30S'"K6OE(3H,.?NTP7F/FGS"6_CLVK&@$A)C -NJ!
ML,5((9;7$&OG.E-AQ\R^PE'[/WR[Y*OEM6OK+Q6AR$4)+G 'QNY%%A=8NP]V
MG. "/B S#QX%F#P0M]Z]O%,AF*M@75=%OQVJ3F@PS+JHJ\#W0#Y,V[D 7_OV
MY!OT@_WGRH?"=YZ]>3]2=V>IQ'V'F$\O;V![UECPT YB<;Z!Y>I43]B)!<EM
M9<<C;[ #FR=)*RV.(BUV<YE"X4NJ^@.# TUW"C==9UX(M7D555N[4(\.4^U!
MMKFR ;D]3)_I467XQTS,0-)^EG [1ZP7AAIS%:)%9"E!#FT=3#8?SX$2+S\V
M4- P2AN>6O@YW+XAFAH\\BC]K6;MP.IIDQ442]2>T?<#=&G'A>"W5HDI?I53
MAAHHKM]+.\[WU%<DC7TVCZ]^TU_1WS5@VZ+0[Z-PZ!DE\H"EPI3"XQ;IW  A
MEI@!0Y3]5A^)#2/0+#L'S.JZ(7O&&\C@CB*-$UZ LH5Y+9]^],*AS]_5QR-(
M^6W&6/FSS5[/)XPKTPXG8GDX_ B:$(>?AWD/O1%:+_VTD9T\CQ'#="$W5'G!
M/2"T :(T)AE24RIJ>,0XR;*CN("#9X^=[;7=YR:04_SA6<T8T TAF<9PNT]6
MZ<*N;$=WS4;HP0K9KPD9Y'2,%C(63M]/!FM?1VVDU-JQ-"P4+!VT[##Q8LMO
M4K5.ZI7%H;_4W!DR6[68!>F)' %876^6@%3HG_2E.4.$[1PY_S!26 M>Q-_:
MN)\$V6XF]ME;1/=>^[##0OX]SO53\I ?TZ5=.F]C+K"(267#MN6F#AT(HUI3
MS.7MV.^1UV#1XHH3\'=W>6U?_D//SS.? .4LOXT5+0]2\:\M*XD:TQ'4BIK0
M;>+?K73#8]6>L]6'/D,.J\=OQ_0EJ3UA'O#O;Q$OY@S4Z'[\OHS@<YAZK_NZ
MNR^'H?DH9T[$X^25-^<IK7NOZX2>WLKK^7M:3Q,N0$Q%58 LX68"&5D[_S1)
ML*+E$2^YC:4+I9UH3*#;^J/M+808T26B.H?S[FE=CC/<'_/I<<QK@;V9"<-<
MH&22.D)7(W#X5WAG%4F$(1KZ%N1-+@RVP2CVL"RSIJ0N5';YYII1O%6K=!Z:
M9^3GCW_")J!41Q16SP6[6U-P$B Q 55A40N3'<7^L!H$"T%[@*/,2T-AC)=8
M<@55A%9IU$\I*:%C<+[W%@G^&)7P-H4/F\V4DE$;K_%\X-V[;\D3^Q1!NX"7
M .NNU@AP?HJ#'T)PH2Q!3YKG!9H7(]&7SF.^R%+#/MAGZYU >'A[Z$%&-6[H
M8HA#VZMKN[98L'9.UN$1ZGAB.K+<BQ")]_06A9[H:=-!LY+>Z[WWDX_AR\E2
MMX)VC23\E+X88GS&#%0]_7;3_\7>F\=#U;__XZ?MMB65M90I>Q0I:\EH08B)
MRAI3278JA RGR!(QE5#$9(GLV2,9NY E1,@R8RL99BSC,#-G?L=]OS_?W_O>
M/LO[^_D^?H_'[_OYX\QX''->RW6NY7E=K^MUO<3T%["0-.'!>F6:G8&MZ-*I
M<H8$W#.(JBN =-F ,S%\\'5^BDS06+^B2N3WN,&3+N+#,+F[GS/"QM3R<NM9
M)<Y"M1YL(1M )CYT@7X.D<G8P%[;_16LN D:1WWG(S&%GBK+5[YP6^.@ETGN
M38LC1E?I^E*6[4/ZX>,C$F$:/K$"!]Q]8*X0JC"]DY5 M%<<]*DABH#7.H5^
M#+*!!L5'MDHT?'!)#B@ .8_-J":4G)>J$KM^-RMZ5^R3MH>[SLNVON<ONW>L
MX &VK)_RDW$=X06IZLUPSVBQ8E")",Z')F/>[5HM\;/;T&UO>8AR2&7RJ$6_
MV]C[QWKR>O1KM)JF<WXUL\]T+[V!6[#E\0UNAC#/AOS VMT@Q90HJK5[!MS8
M'%V%'I>GR)^+7C3NO?HEY '=9-C)K*PLOFQ2'U2RNQ:]V;Y-8GJ*)4,76S_%
MRI</YFQD* >VWX1;CD6GY3#W(?[^&]QUZ*CG^"$1O?$/&T_H+GP?TKNU9:)L
ML0;W=1=EVG[;L.E)$=ZY!+[:44C6K *1Q5*J,&7(C[%C  )K$N)GYT8V50>-
MD[<E+T"7>1U'A3]8J'$0VB0EA9)Q9TJN=*1]<JQ!ZWW_5XZZ#&6])DX\@.+A
M6L1//];O>5F-<H@-2,HT$.E\;&"@K\H= ?I/_7>Q =ML\,?6Z4:PLI<-\##Q
M(<CCL CZ^+]TN%@00BG$R'[\0E9D<-2S@92$M8AJF[^X2<S'(6CSJ03?3S1+
M06_H.G%!$9^SON&EX'.GQ=]-"AK_JR254?2?@GU$%'ET5:QW"0\_Q<^!F\&)
MX:O$Q@MLP/@LTLQJ\?)_^="1@AX\)-7)3# CL(&KB:.L7=CGRW^5RO+SG3RL
MQ\?D6]0CBZ$1YY&7;XW%QY)V^/R;D17^6\S\_XN-2>NUR+K90#:"%F()<(_M
M#RQ/_WCRH5MF8#W:%&[/FV5EEDRM7)5?8!S'F<3F?:*7K1$\:_VTK!/]P;SZ
MQ/BXP5*71>R-]Q+#:%()<2:!#4PZL(&2]8IFK]G Q?[U<F6LC"J%"*8G++Y^
M=%*7 WP!^<]'E"><>7.:B3BM+0CP:Q'[\?LG\)";XEH&<=62#5!42%Z(F[O#
M' ]^1X#: 62X$YM8QJ3.5<1;CL$@+*F%B!N3A;#L%W@86XYE\J.,J#*4$U0S
M15ZD_9K=F=$Q^C2/>C^FC!J]IMA(:]'D77+WVB[Z&T,;K1_/6WA<ZRJ^I=R#
MF]"\:.TW!8=9R40G="BJG&.V+07^C"J:;GB3V56%?9W7$94;>2F6(MDA&>IH
M0;KQL%Y/\OJDC<6=]IL$JA$6\6U*XIO8P/U!?*/B()JL<#]W!D5-@C*U2TJI
MTZ';DC8K.>UFP4^+DA8_=2Q$HI07-JXF:A_WV<[WJM2WU*GD?;B7_)"_2U](
M2%[C< Y&X+;=I$.4#<^;$Q>/Q<P<Z^\ J<9X2*8#<8,V,PJAARE6N#N)359@
M SY\,#/:^V*OIL;>=/I@(T(3.E[N;(8\_?;^R[H?+?B3H#'6 >P.1 (-T<[X
MP7JZ%ZN,>'T^;)0[4.;[FL_]0'G<)3;PP+_IF")3G-;F[[VS3DJ"XGG\052H
MKD2$QH9=B]MN EK?4B.F P\Q+2 ?J@PI^@,MGMP?05%&;X7L#!)-^I9=?FS4
M<?'8*>0C4U%3LRE.$N#:=YY#1\<3O250Y@=6M)H7,AS7#<GL=+(CLX&M7UW,
M[I2?\7O;Z.VQYSN^Y,F[@_?V[+F^^\>;?^D8H_4K7Y0>AW "/QG+X$!$^Z=-
M^\W1DG+F8\).Q*M Q-K!BO8.#^O/.K#N(@1,/TH0A']>8"HN: FLEVZ^PIS]
MLZ 5X?S'C7A(Q/NE!>')LB\;,QQW&W6DO6E-D]H7)!UWB@,G%W.)TR"]]UK^
M2+B3ZFP$<0<LSU2"3KS""^#,H. T7T^,TQF3$1>K9W=:),/FFD)U1;_1+[6)
MU?0>*V_"A&KMA9S038J"OG5#.M3&O,)W%7W>7UQ$4B./GRX?W+A=Y+&PQ-2W
M]YY/"*VHKX@'L$SM#Z_>ASCGW$F,F\P#M-'P63><0;(8534E];O)R'=X<_G-
M_-8,_9BV)P_>ZDTU/9J8DYRZR?<93;4B\D(]O^[V<7=$;2=>CZ^D!8:/B!?2
MMGRI#N9O.02_H/L_&"G<\.'3[39196L?A2;)3;N:1\S&,H,Z#G_=>OF;G<8;
MX_SDCB-.:IPKS]QCA\S!&X-$74NPN(#;\\[[X@#%H?ZU0CJV#H]G [_ ZGMU
M%4/ [0>]_:/$SO:8%3XJ\3'3/3.*2MI\__JC8WL_6FK?:GTJ?[H)*P"CF%I]
M7GS;H/H&JJ6SV($OZ.*J$]=:.U66.^.ZCXCODPPY<^/&/KD-<>+5NUB)RJ@=
M+D2J^6@4JFPNM.<'EF,,\K%W\B,G?D\8;#[_XJ#RU)60FFW[A!96HX](*%$D
MW:<'T3?:$C&/M#0_('./P'E_"#[=72IJUAVX[4<EL\VUTNS>+%?UK?T;%$I_
MN?2,#>RL>9MA;&&>^/RZR&5!6V]5TBQ)WNE3]L6H+X?RO.8F4TLN?#9HF33G
MY79?Z6Y9'<XC=K9]6KL;X7KTM"?W9>M/17KBH=%GKEQZ]BB(<^; EP6'[7_E
M)RX),Q%S".L6[ "_:J%86_M[+RW,_^D6RY.$9CX1 1'M]^.VUI 4&WB""\"N
M'^40&'WW;Y?0VK#4BQ@ K L8*^!&S(!+0,SLVNOZN07-]H$H72UJ(\Y^?:<\
M&[@0#U\@,NP#$)]O"X T;5Y/I&]/9 /:@@L44,$W,7GJG9A2@6Z(H8ZLD^.'
ML?<9G7I\Y.GPRP?T[2O,U :Z0K.U.I[E3LZ?<# V_5*V'!CVG W4:X"]2-//
MYN$!/>;1>)8Q=M484=VQ/WK7-T[E[9IGPHB6MT,4?R+8 -(\X%#LJAZ":EKQ
M2H@%NLT&LMH0U3[**L)##HIK+XD+20B*E>]YD\9R[ 2G5V!#%'P&349#Y6S@
MM"(S+0RQ,WK_;K<F<(D#<9'!!J00KA1'T5#K>;$I\; )@F86TCZ!I)?$&:3;
M5L22NJ;!N]K@3$5F)DAO79J190-61T=7$7ORM!FA#A^$AQ$8UH6,3Q:AV*K)
M%)K:@5W6 "<15Z_,Y'<DO>LM /[S7,.8>K\N5WY'*/\,\>.9;Q91_S0_V=]/
M_<.Q"'3?HQ48!"<0&#]Q&D;@7B2X= 09I3H(7_3#_],,GX'_-'7;)!W43UT$
MS:")"Q;(]/8CUI(--!+7=H&3>Q#E)Z?9_$\S1/_SU N,4_'+:2?8 &%T]2"X
MNIT-A+,!\BAK*W$A&H5@ C&[WTT0]4]3-\\TT5O[G,P&.N>9<6AF^/^\U_\U
MOR4.F&N2A(%.HV_D[.6AL &G@6P;8N*D:\?U#J48YL^)5H8B77[=7CDAX)2'
MP-I&-*8F'ONTN$TV]J".L2-#X[B5O'5SD9Z63*.6YK@<>+Y#*;GOZ4I%0)(L
MH^W,/*?.[$A\X4]E$QU0_^7?EL7YJX4Z/,Q]@3K=9"O)RO)8-A+66WSE)MU^
MAN 8Y;=CL?ZP"NVE=WA*:(O 3+N.9YZUOBN#4. K\])^EXP(9L=S\OY3A**$
MJ2SU.K7;(;$3W>^+>P)V+0P+(EBZ+A%Z@N#1:=CX-,)X"/KC]B#KL7@(JQH(
M+PAC\:"+/;@(HR !\!.,\'9X)&F%Q4LE0B;KI0XT(N01"!BB1I. 0SJ9+Q$>
MB$R#!48;\&O"Z(7;*%@!3W$M@$'D!6]<+Y-P!LM'_.X1@G0:@66^^&1B@V8>
M(#Y$+2F $Q-HI@V*F@%+@EWK*/\Q&Z!Y_5/7:+(X%( P&DX1%E@OZM!Q+0*!
MG20CYEF$A3S9@ PB..3O?QP*PQIY4P0J B33UNM"[!"NGU\3)8'4U/5*"YX"
MYI@_S%;O]\,9', RV4 8O&6]2D-X-0KL&D5 =X@ <?7H\]1*$+H [D1_OXPP
MUD<0JD3_<3!P7RL;F&:BJ;*_EK_0H3+@4 C+E%TO+O&R\3\FO1Z]S!S1"^N)
M^7K,>EA<,6QT2:T.F;2.(GQN2C:?\'M"_V$TI47$53; Q^1>+Q*Q Z>%C*Q:
M&.EAO8Z&DHX7&_@CK?\P&%9>+*(>('#,Y+<Z'/_SVO\;7COA+?J/D>68,9'K
MY52%R,TY84;2 Q8.*3MD5?*PW0)67G;?\8NC@K*=_!HZPZK_6.O\LZL<\G,N
M8E4/WI4SCF5Q@:LF96Q@/!;"1FGHNB6P3L]8^'V9I)=//'CMPCB.C3UNV]$_
M\HG%=X_V3A/5IU5H>I@H59%@7JY"N7.SQ-P;49Q?: 7P R+SS1!(0ZQ-0K4*
MHF81JL6*>L :V% P6Q-AR5-K; "20QA /#"$51H#=AFAF=O04_^)%O36TAK!
M)<4"!-1E@PO[_^GA !NL6N"H$-6&:<^*/>3^2O]://V1UU,-@2.5A"V^;[:?
M' LZ;MZM,D8HS9PMIZW0@Z!,:DXSN UTQ/! AL80=KR4=O&860YU:MPLT;0"
M;J_N29!)4C&\ND>75W?L7F'<MNUS^PW*5S282X&!$.,,39$I>I7A;$0KJ!FT
MI_3/8FC$AO!JU:[<%#]S$AA^8[\97:1?RG6B1L2DE4]^"ZE\YQV4D.@9V@I3
M%$]K(Z."<7[9C8+)%3076^I4!0DE:&-YD(%S*FC;&F2M<?ZR]LS)KY-D[ZNQ
MFN8_A!L+@E%\1$?%X(3^FE&\F&!/E2%IGM]Q/M,7?^Y=F?R6"?=W =F6"5J!
MU_='IFW97R[K#)G3":P('&+--L^P@>!;U4<"FP-WTJ(ZWJ?[ZI$R'QG'9(UJ
M2R3E>2C.%Z1$:V?R2CIY%1Y]Q.'8MD5[2)OC$[K,G,EO5SNR'DJ36]^,]9!:
M0)[&>Q4,"I,R:T=Y? M.0Z$X!]]S=SY;6A;_>.@T%1 G>NE>[)EHJ1N.7UX[
MG8O9=2*-3H->%^!N0<'(*#Y _>0\C8/+&!&<87?I!X-N%;FWEVV^O^T4!^YN
M<>)L+KW+-TMA\,-=HV6*S)TY8\39#[1I>A#U)U.F#Q:!C#UV2-\GZ5.\*2YZ
MT1U]Y!/[YWB'3@/[Q2.LWXPK*CN33(4"QA$WQQT#2:\TX >+QSUJ,!'HK41'
M#"_$80!QD1OZES#;+N-4XR]8K\;NW,_3)I;I+'[OS&M!4\V@@6\WMP!^*Q0I
M:N*81P,>.H .S]-2&&QAZ#BO$'E<79EJC.-&I!SKO.,U5-$PM=W#P^VSY([V
M? OQW.B<.RVBX6;V1CDTG[H\C6H-L!;Q,7=[%> /$R.D(3?_<5$LEUJX(O9\
MC %CR[>@+LEN9L>5;2VBY7(IVMS IGG#]75Y&<H.$@J2)>+1[AX#X_01S"\6
MN*M=RBY\$<DBB37;9RX8:;UP+2M;L7)=[##]S'QUZN&U=V<<;K?(7LGJ"&P?
MI9ZA6(_US\K0BNF;:/,4[VQ?0AU:4$%3VTM#G%KZ(;=RH[/K)_LG5<W^ U_H
M2M<^Z]ZL$9\;UA;3H5DW)/C,(F!J\Q@+K[4]L$-K>W>5!IK"-\X'0)Y-\:IK
M$VOB,^<QZ0&IOF+PR(&,4O_,T.,WXF0'3^Y9H PV'%XB<H*UJF@G3 A(/5\0
MAD5TTNSB&#Z8N(&YU\[),YV)I2K>8]J!WO;C_I;WK)UV]SH)F?WPV?K(\L:^
MEOVR/$"ZZDH4>NS18#,%0:V;O_2 5SP&&?2\:II9'LG7BP!IXT 2@;LQ#1WJ
M[O5NJY#P>>N'KYVD=\1;)DVQR!]K-6-"]Z)F[1F;X1$4'],\Y2=BEL[S00<.
M33>U'Z]U(]96[RVD2F4\W&3#.2B[S*MK$6D$'M&E3*9'%4J*WUB4NN@%,(3^
MJV44_NUZYS%H#9_%/ 1G$;1<G.>C4A_8/;IP"H>\TBML@)7DTD1&K\H4$I9G
M,N'''3AS1AZ&2OP(F4;(%I""%]_^*8R!IH= #FI-!?=LU2$--UQ9D6]Y[5IR
MU-ZVZ1TJ7W(?<ZC/\DQ3\^LBNJ,LN_)VOQTYI#)3>OK1R^L)WP,5 MO7.I*H
MD3 7+T,/;L3NR3,_!3U,A[*JVTF\9Q]45SV=L&AVH?MBVF^]H'P-?718PF53
M$!=+9'U[%W,;;3UJLAY:@KRIQ>2H1WUW*:4AB-HGW#Q,!UVJDG_LN^)G?N;%
MZ0/?:\.<UWX)X->M["7UY7M%6BH>ZGK]X5O<C/U#S/E<W8LH;><O 3[;;WDM
M5DD9['C],?L2O;L/ <[B(6FI1<,_?;+-N^??\T?[AJN_&5R8"BPK7$13>#41
MR*W7[,L&KA&W?6H? [>*VEB/VS,53@UO/%-FB]IZO.,BYN8O2ANSK_M]+>!B
MY5_[LKY01CVM S6[[&0>Q)/@ E:(QYM7NRVJ=@>F*]P670F\>1)8YID8+PV\
MYY@L3.T,M:4C:N!./<;-8'7>6ZBPY&S4E[9[8DZJ]ZMUN5^]O_YR:[(<2MA7
MM!:[7;DP!5JL7;,MORZU,_($%A,]M6\\S?7)V8\MM4U^^9>)X4Z3RP)VF)7
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M&[[8O..7.U$29M^^#A[9H'&%\Q=AYIXHQ@E?+<S Z;$;I51L[=W &!I?+1M
M,:4R<*B G2W[DOO\,AW[FK[J_O*1MMMP,E] ]*(K+K8\$T+7!8HCO68N,Y+
M^C+S(DNX\7"GLWM>'T;.G+:]W.=\?>CA-LDSRP,2BKKBU6\@/<:NP#:'!K&=
MT"2)Y6!+ZV1*""VHU;^?%_!=8 ,V)5W=%LSXIRWN#D\V9YSXS$I9Z7ACL_F^
MY;,V/B9_(OU<.2O_.NO]?FK80W-R>A_J2GS#.-F,&%:X>&;TJBK1G7&@9!$
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M^RV#)Q$@<!X-3@)KGH-F,\H_W=8^8L&J&&TOB48K G@R_N,>2"78[5@]\&?
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M[^":K0WQB_8T^S75X0 XN @B8U?]M@)OGPMC%RY!Z4%@[I]64#_#)L7J%[U
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M5"JR:S-:7@(N1CMUU$MY'K<XRL46%O>TZLIO"$F_^CC['?:))I<E#:#B:*.
MRZ!L_7;)-VTWZ^;T:6+$&85VL>)>G]0K0T,+UJ'BZY4VEEL4%KZ1C57/+9.V
MK'R0;2#K[CDU?D-.16QKY,.NV8F/GJF&<^\YM88F7:Y_9L$N86X2>' [&*I=
MJ"#Z"?\[= M23(/&N2D041Y-?%%:4'Z#<UORE2W[W-WW;5D/0]O'[!L_93>
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MHC>K/Y%K2+- Q]*1*DNW;Z4*-WR&UR!^RG6'[#3(;C#Y2-KV.,OHB(4F ?
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MP_F.:D=<"G4/KLR=NS-)S@2<0->[N<J Q8(A<!#1/ZP- DZLW?@5&65O/TV
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M&>N:.AKF/E2HK[;WHJI.0;R(7C&$^P$DL;DP:BMYFBO?1ON>R31F1^9T+2Y
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M/T-JS*;%9BK,;O>7F@[Q/V%_YB5H^31R)X:,J!_IU@@[R:3TX,A#-%PJ :I
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M7E#Z]>0ET#HOQO@<;9\]<]B\'C(]=I$+4C 22<WG"8R[<ZC"R]E/P3Z6+B/
MJU$[=&HVY[TTC8O8*S%R11B"/8N5QNQ!R= 7[S*XT<SI'C:Y+S<&UQBJ?.W,
MC876_.WVQ)->!!H.G(^Q]58-7ZR-Z<17TV/',RLS#W)W27$O%9=6T^X<W#^R
MLJ0;[7!F8%P[.6]&*T!2\(J1]Q#N/A?T6&3KZ:$9VI!S= F+GTZQTF;%]?(U
M.MK#PKWX<G !L=Q4W C*U]LNMG8W@1#K(6$O]O###Q=N1^WS>$SN*,("I"W"
MIWC%IC(SVRA\<0_FVDBOYF'@RK^3/V.:-95'"^.6)=P?C?UTK'F>M^-.J<-S
MQ\1"_?H28<6W8%8E1H!K7R4&Y +[GO/W8F=/=F/,2KM)HS:\EFI4DEWBX+S^
M"X.O<R_-I;0'?N:_V66V-^M7@*X@Y(Z'+0J[TLB)04FPW[!B>F1$47":>0X7
MU%22T4LW82JAF@?':L)?4R=WN\:&:Q?O?W0IQN&+3F#NS:L>CMA'4;3YW>#B
M7$Q?:TPBVHLU3L))\_500]3U^'87E51N *NY"Z.!?\O\_NCVJMK.V**\^2\]
MV28V+PB$8J/O99(GJ[2@UT<1,,PDD7FA;H;#AO$>F&#GU.F&/7:3[5!Z44,F
M"<9,G\M<KE. QZCFD]5W=.]]\#7+./O#J__&WGM&-=5%[:)!I(/T(@A!J4I3
MJB(2&R"B@J@@($2EBQ 5D"@A09!>HB"@( 2I*B+204KHB#0I4H*0@H(TV4&,
M&U*XF_?^N-^]]XQS?MQSSG?.'>^/-89CR-Q[SS7GFO-Y5N::2]K:2^X=/@JQ
M3;]C<A#L0K-#S'WH+1@C &P 1FA\"559*Y<LAIJ5T;>&-8LJJN(\TCT;*AOK
M:U(5TL[=_;RF(CZW;X< ;/-F/.L@I$,DKO4!=B](Y@@=!4(9A@"BA1B7Z1UN
MOIME43/*NI)[BK)42(<GEEE4-I7'G ^V[G];D&!XZ(.([H\7SVXGBGX9)&5Q
MA)R8)IQ.0F5M).*6'@E)B>G2$P!=NC:?D?PCEI1X9/Z.R7[ZR^6/TE'+]JI-
M.;-2F&GVQC&65V1 DWO95.MWQBP?2Y%[&ZN!YP$"A*H5_<WA&$^Z=R3F[)=3
M)O&-6@!H7>0SGM+EZ2+4T)L0Z]])293U0WNDGX9%VYW@SF?G$RFS9% #U2+Z
MV-FQ&RDR^4_9G1]32R';]AJ(I-0T5P!@HT6H3[!6R0O_E>5?UR#5+1Y@O^B;
M6)KH'C?_F]<XSKC(+L7R8DG(2GP,[E99.%97'A_9:'/]KW%([2$YU?"NU3U#
MYY(X[\\4))^^<X'K5(2EP$9^!P) EDV,7  0\1PS-()*[EB592D">O%YP-]$
M<Q,HC=1D*.T90;G.GL+KT_7>4RTSE4=(I'ZQWW;1>T>?B-;YE&4C;L/! Z++
M@TPY;.]#O97BV=>L$S14M#S-V=J?1N:^VO[:I5OZRRD_@TA]DPSC/X*+<MY<
M\>G76..S.-#4"LI]5.3D[%EV$<: "D^8T0-^_)EUN55*_6?E%?R>D1NYF.,7
M6^KO\:S+[?"Y+N_$_(T;KM8P-CRO&8T#]V<L_RF#UI#Y%HPZ"ZWE(((TZSAP
MF@//N#121>9#!X3V7Z!T#.[Y8/11]%N5O=6^LVO2R7HZDP2?GG_*C$5PK?[-
M6IP)1+5C-SD)M\=\!\N.+C5SC&X2554F[(PQ!3P'*@M /9O81?%6_Y [SV6&
M\%6&95I<<R8DU3;\,QCVVY %II=IAVMU1'B1)XL9*<#X\HTB,+"3+-%\"/W^
MV[<%HC!'?F%LW#G1N,WDV;=K/2&!_GZW<JY!2[_IQ:[.Z:0"":[UK]*_RY:=
MH$ARDIVQ!0NPW0-V4P;;EY)"VA$2YDHSUOZSJ&CS(R/VW2[#9ZU_&";MN6<C
M3$>U;7RP.;!C(<6D:%49[(34WX7;G@EOY-2.588*.W>D6TF(GD-XW>D79EQ/
M_4FLI%K?=,JK,Q&_=M@G1]W*_M7S5:%:[&58V(@%1F/[Y&IK.^Y#QHHXTU]O
M6=!L+]VF)>=HP[/.5_@X++^IF?R[9L?L/7=54Q5BG:\2'\C512M27L,-#A :
M-+D[_]F8LR#>0$[&="* QYPA9#4JPDS\[=-GY73+>L743SM*)')\%5IVU6N]
M#-C]WJ\= 3ANUS(C$U;S1PSAH":QU5=7[8FJ73]=Y4)4@?L7S13/;[:W@\L&
M5L%C.:1I"#O81LDF[=CM#K:\3DG;2',YVZS-M:[FB/B%/_L7 >Z57>X&1!E0
MDHY\P-G%VLW.:Y;^R=$"&)6O_!CC]YU+4\[8&3>\$=774 G2?W,TY?2!GRWZ
M3XX;<FU:Y/LYF\2N9_GCVDG5U>RD[UI&A2O/EK0-NMH/_%P\XZGRY$1KB1%K
M -)/$N>OET0$K/5 G5W;1]FRZ<0.?QL7\%(IQIX(G#/U*CR"7OXC&00L?$RK
M4-K[@/S)^LJ=][4*SV62#C&'F-=QK99$;]S$8!=6"#PUBUPA2F(LP*370H@=
M&$/ ]9FC\U@%LZ8J/M5&ZN#)XJ/%=>F:T6,;'(<6OJ:+2'-.-Y3B()(.A<IN
M,&.V+#QGSW"C%84<1Q31VZED GK/-FB%AB'/VQ^W><3PG:^M?U2KJQ[A*[GK
M\1/5D]_P*T*0=T6QLYKY6;YTU/("!1&#%#/714]15Z,TZ!H=Q[BI;JG>03.[
M1_*.+_\-=)LFM<ZE7;=HO&=]Y%,')AZVV18/($"-5994Y7;A040&2X# "&<_
MQZ".=:45NU87$8N6[A,]FH?>2^^,/OJ\5_K:*V'%W;,W7AXYT((>C$50B+CR
M' (%*<5Z".#;B7$S.J )!2_=227+8NX Q!@=#6 F>SO;\#7:++V^,A?G'.IG
MG<=>O!$;K,K]ZX#6/&Z*FR,8R#3&=B$J!E*9M\ Y'5P'43@8O:(6TYG#6Q%C
M%Z$9P A+#^'U<)?JLK@2)*Q_W+_^&FN:-@@>V8)Q!$;R./UCQ&J-"!8/'=\U
M(\\\D= A0H&R$-''?'=_NTM;\)$?.4=MU%^,;EPTX_B5J.PD+9[A^]GOB29W
M<21 ?ZK.J>Z<H^,KZTWPLS5^2587&\+*73J:7 <]%0=O@;AN.'"WFR59TKX%
MJ]R5Q;S$,DV@:70DJ:^>X8R.!>G%N F&LJW:C2.\'Q5^;>]1;'Z>YS-ST/O%
MSD(;BSF-?N0IR+\0.$HNH1+'DFIG!%>QBQ!>.O<WYT]EV679CFH;A1Y"A17.
M=(@75-<G.7WU$%!%K36\<9**5O["NWT$!,WI0E3/5+Y!AS#<V,6-DK-+;*6O
MNL$VMH)+P(RUGU#-UP<[;Y]]$\!U;&G,;^,QM$ZNXFZ1=V)["-5ZW=-^3F#(
M+$YN\6-&](V8XX!C.U)@\-VMS2P+G$K/CQ,RTN*2/(5ILW'WWB(#\VI_V;(D
M SE""*8L],UVU7@)M +%E1S7>'06R;^*$F.9TSF)F?<K?25ZOU?-7+[7JY#W
M^32JPM)G\MF9UZXAL#!/"\P2<UO?<QQN%C\[/TAO8JK=39KNV$%,5%(>\1@M
MQ2I@3*LK,SECK6(-KJ[]8<%^OMY*4BN_BRTQ[[_Z]V81RKM94C&,A^R&9AET
M"8UO^:\?3:C)KX64U/5B5B_&N?JQ@YOR4/7AD$AW,XG/^ZR=\H.M?I_3_MS>
M]]G\BR@VCXAHWOZ9O0\.V)3%.Q+$=?0P2!I9 !\ULZ=NS,Q%(]',B('<O[<Q
MXM/4Z3>J>*/>:]<LY-M*TE4W':$(TWH(1RF!5VJPI%.IMK%874X?R3O^G3;&
M@*8^],=&3W;!CO0M#E.0IG91>$3%<I&ER(P>J7=,# _3/L.M2ME5U.P?PQ$2
M@>)'?3TX2JCLKUTA V.VLM88[?R12QWE<J2?-4,!NEQKP@T<6[V^Z88?7>BR
MB^QB+&P2.PKG1S7S@C%='YL3J&SL52K=[DN \\RJ_8C!BV4)JMRQCQ=@\=:2
M\VLY5TXFTDZSQ"$[9V_!*"GP#R;+"Q#1,&DE?D"V)>FU(67,<+2:+RN-TH5^
MYY[>8O >>Q-\8/J<@XQ-I/#)FY_@ V$_&AM?\ZTCKVG@<;=$)Z>HN$ZX,$L,
M?$0O;G_HF,CR#F;@A-#V2U<2;YEF/0Y1U[IS+@IFV9=U7_CZDS/2D8 0Q2H9
M8\*41',S L%!NH)C UT]"5BU&#)SI/D+.662UGZMD8;YWWLE+PA^CK96P<WL
M=SKX/=IA(^9W+\4V BO&SB92Z(H:5+[P/R*WYJU'S#7:=5XV[QM_'VPSN)X-
M<]7O"0Y:LS57\N(J# G+]7R^=AQ1;*J9%ZZ@77Y"TM8L/C;>:7J*Z_BB];+6
MO*C0-M!&4#+<#,$A^/(&%3E52ZW^F^#=R%2LR4+1SB2&R*K5Q.ZK&WRJ7=AL
M%_LCX0Z7F:,?TY_3^Y=<@VP))4[6S-,"WE!1(F#F)K]98' N,0T7EJ\[7_<A
M K5Q/4"P6Q@?R8QY<;QW!P*&H,Q#N6WOWV4;R,C?P+W ;\93=E*5JTU;SSMT
M)4>\"=7V]^&?@5?2O48%?P_-G/Y[8:VKEQ%BI? 9;GSL;=0%BNA"0.,^!+A_
ME24YAXHO 9SU2$NM(C3>L8'X)TDWL'VD(L1W)=TMV.RW:0;S<&K_H$)@)P8.
M!7AQ=@7.%S<IQ!$)!4+P&!0MZ6PWK3O)7!YT;_OM9W"V)PQU%^>_N^XI>;5T
M?"*_CF=-T>MHY5.D%IA!'8^"B'FDDN&*Q\^:+=CMVM&\,0G*:1/V>ULEH]IL
MPNH#";G*<92B)O>FZ'O);F(UW_(*0*3AH['\F./@"+5)JPMK\)&)B&K<'_RV
MRTCQ?-O15.DZ]9/A*E[G&W@/GE$5!']S^+F85N@2CN!N:&*\ 2-R)T'1;Y"F
MN%^W48UV#'=N3*UZ5(,IS+SQQ-7R]!LMDL+UM1(!(8,/USL.LN(!C58$/W:
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MU!$DV9/7.YLM+XH?OZJXP8,QX B$0F]D8(Y#GN&&": '% -E'$%IFE!9%/;
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M*7/36CW\J*!F7KB9S65VA+G(K<WL@=) 6IG"NXQ+C</:;GKU5X3[KH9S43R
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M6_4X)!1;>_?8>L)+C9V%%0':EA?6N&PS:;O4VSSN)JG).HI?.F./[]38M&K
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MX1JGI][/YJDAT;N:><=&H9C[ENNI:NIASSU<R',L678DT1,^.44)J&>:8L1
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M@[HP_ ]+CTN$T3&0#K&["_,,_J^'AKK )49Z'@OHC4)L_C+ZU\/; S=W(_Y
M_D#^0/Y _D#^0/X/A03&+AG1C-%<C+\P8HA8S!G4Q]C3]GT^KG>^X52D+K
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MK-=L+0P=YBUS#?"B&T:%E"\6$ .NMH" ;>]J@T[K>GG*R^9[;Q9L\\C&,2R
M%$]3L";,^#5<'SZ?]RBNY5ML)4X^C&LMV?XG"_A<&D^-8]0BG#PA*61K('B?
M!8QX7L17DK-_Y):55/^2P-=\&4XA70<SQ\"RS1^_=&1GS(99P#L<G0]/A"\:
M$Q_[Y^F)U4S+C#](Z8CPN+N#_."ZZKSWCY:,C\OHG:W$BQLLH +5!!^=IMZ$
M?&$M8"BU>BAIVI5 Z&E:KMK_J"DE\*Q:C=4! 9WF9T?-WOZ=7,A,5:]%P-F6
M!50I!1:.U-2L&J.Z#7UJUCR8[@V*WY.R91C^<'EG:Q8P==8Z$\_^+3+WSY1'
M9J/8R_\+2*#^(]2S4OI5<MCC+*L%,XO6ZTE?*Y\=7(6.GMZ4?+R!4V.D,!7F
MQ<Y0]I80\7S6'AFK_HUEG5..*ZV-'^\^_B7<&*Q <JLY\^5=G;TS9O7#%KJD
MB@6TKL?Z!058Y0E&?C1M:PJN7 (U5CQUBU:UDB).X]YJ?ORCW/EOHMP9QU=P
MT/G%J;\K[;6C$5 +30G3[ND;/,4C2!PX?R"+U.GCO-YM7SOHON(>U_5;NA/O
M=K;I;](=<1..N'/&[#2O#FSBW-_)",.OG8*P+"#)=SUV4?=W*3%&%'XJ#7-H
MB+Z?)H0^@MP[ASDQ$,<"+!ZYCH6]&5;;?R3Z3F>(EU(^YUF!._(2TQ)Q.[8.
ML<_G$.#="M^AZ4A#T0]#%7FJ+TB(??,9(J%6_3B,7G72X$:MQR['\O./D,A7
M0</)8-,;\-T7/*6"V+ND1O%NK7XX&@"V3>X$P[9M<B0<[5MK7G;*+O?'H+-I
M0HB-D2"S);4.''12<M&+G8I9#C5JN&:(4.3#T.:D#UPTOO:QWI85$9?SNS,D
M^Q\(+KY_7I:B\M[ZS:E9,8>O@IA!()CC(^H18B_"?N7I-N)C[^@FL?TU$;'?
MZ3#S1F*F\T&W" &)"@6))'^'DREZ9Y9[S%](I #T:RP@5$GS' GV*$.)@6-R
MH<W[4R]3X$]]D3Q-I<[#>/%Q Y?M[VH[*D9%+TCF]6BYOF(#Q$&'6 $8/]V9
M\:[*7=I)V7-Q7'[?K^18H?V!#_H8Y93;FZM)&IHL8-CKE^O&VO0PG3>>JLYX
MTRB[@!*MZN6!DENTSU!LGC%>3+L[$C>CJT1W(OGF:KFHUI?O?!:>D/O*YQVK
MY,2%=WFD%3HE_Q$>"B_?; Z!3SDNTLC3U\G8IY5<H.2U;\K/574YX\Q?Q1EH
M5/!^%F<_V)G6.$/ [_?:C:T!N9_8NEJY1D=\$YV(U&A,W'\&>>O&I&% ;PO\
M  3J,QK1P?=RG$S]ODH^KBS_:WPL\T2\^/U'>_<^0$AO[_VW7WWY!N;!_-+/
M F;;X;3UT_]Z*.UR>B=\<0G!_%WA#W\Q]E\/<S,?'?\#^0/Y _D#^0/Y _G_
M%B+3Q +<6< X?@I<-"+"-5K_LIQG2G]X5/V":'G%2)EQ(<DX]$?+R^@?]Z>>
M<>MTI(!-%_%316*"C+2<6DB&?.@81;[5?'QQ]4CRE^IOV1[  _Q"J>*#XZ(P
MPJ]##6O4WX5"3:&:#J8<"P@K8?_QJ->[-"#4.,UF##(SC>^QG=UCW]B[^W%T
M=<O,3<!K2(%<5\,[K5 [:F_.:5S:>#X6\OF ,O>+>;\2K(S^HJ'>:JL@ORLQ
M1QKK CI@<8&!8)/>#IH6IAU;Z4@7@)&N(ZH$EZ*+)N:T]\G7Z_6Y_S6>^DGI
M)4^:(T.WQK#_:$-Z).]]5#]L-UJ5#&OQY+P#B7S$P/K72\0-'UVRO^?H5G3T
M*N*UI$1\G+Y$G+Y*!;^19>L['=[,$\\NZWZ\>1[0X/0-HB-:[FB&I>6F%M@$
M?<FN2L#^JC^Y5C^PTE6.UC83E/@^;T!*A;)9@.[H/U6W"*P[EOXWTDG]%R Z
M!9W$B</MAD@S5;\A<JE]QH/"0JW.4A$2N"0^M;(S,,4FJKO(Q37Q;)/D<J8G
M];L_"[A_?YM4ZZY$K&F'QPY_@T))J@6G7N=X3.RIB\)ULX#KI*4.2@UBQ:SY
M9X/GQ0S9F2TMR<@VWRCM?8$#&5T3-8TQ'=_N0ICL_.(;YS'ML?X4 [K"! M
M&BM1GT 3;Z#)4<V34T6V9^RP/>\;%';3=."^M^TT]&R\XF/VGEN+Y0X(OTG&
M/C]#U\_1'EV<-;>;#8TI#'G^2;O]0P9JI$[XBA-3?.E6APL+L)O=U:_MKTR
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M+VE69:Z_E5@$'G#>5N[=)9#PLQ:^F<(7#F6=9CJ+LCVA94; /T8B;_"@MDR
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MJN_ZJ2Y:1(YGPA)8P,LBJC,[_P4CP76M$WAO[3U.PH@(O#UB+X1J597RO5>
MUNHO\2S)_C+Z-JY=V4=]\?9+Z"O'+$CGD_Q=<^_N[[6T1AGZ_4$6X B+T!:
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M8U85.9_K#EVQN# S+?-!2.\M^P3I6/(-> 2A(KP))LH<@Q_5% Q\,XE&&HC
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M7@Z</,("R ]Q3UC CW,TT4M%[@LLX##U'-N(C^)A1OW](\,+X:V$2 (GDRO
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ML!6VD8E!YOQBH>Y($?](6Q*T:$7%V%_>0$>I^,:=WM+#;\,?F<QS)FJ3\UY
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M6'6X7G].])Y9961'7([&]O?IR9:^% FFKDSLC<\<P?4/UY9Q#!9Z9->M48D
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MF]1?,_AD*7E*?T>G)R#1P<8F?>=;Q8.%B)LP@,2,[7\!X27989K!'/5\N?Z
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M67SHR)*=U$Y=+)KQ0\KJ*;V=3RTPQACOC,:2FZFR_B^PBGEEDCU;UMF)#._
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MW8Z+P6H&14$YZ!IN+T<U,8_)DPTA5VVL/06?C.N8G//X04(2,0T0)Z]Q&VH
MXXVZJ0<9T[RB@)&[J-I@4N"1REP9/GQFGVO0CBQ/P][+.F,?!867F^X'Z?UF
M7VO8/XN*'>6)TO4G,5MUO6-MC<O#HS#J\J1R9655BNNFVFH$]XM"TK+6G?+9
M)R-T7-*S9[;_7@4'3*%NZX.HSK\3J[\KFO+\_U8V73G^6OC7PK\6_K7POW)A
M_Y"7(K929/J>T>/VUQNYLA![I;WM__S6]GVX)7FMF.W,7F'ER9DOCLLS\S_8
M6UNI)XB:JK^Y<.S4!?YOYTDVF[>YYM?;49-7F3R";)1*M6!DZ.U%S+#].!0O
M<W4>LX<>#" %Z0HR!T<K[,QN4)Z7#<M>OWDGI%&&=^J5N8QM=_Q[;D>Y1P$8
M##ML.P(AO$6*L4 N?5,N\_@_*#R.K)!&@(G274<P0ZU(?O7&&U*CY+4D7WAU
M8DC9W/0[N;KD>Q\>?"D_ONI8\UXS;VG?*-F64Z0E3JBU9(N+[X)0YOPH^A+X
M-9+L:T@7Z6/R_*F'80.DD,OP5'-&F(ZA HJ\?FM4%CM"OSR/YK6*GL X53:%
M0TC.(5%5S]>\7[X_6QT&*X"40^+TSK-CB#*!-TQ=1B+<Z@/0TY+)55&-W#>[
M,BE=OEP]2GU4S%G<6Y6E\L4R7O-48M>!G>$OIO4R8_H@I Y82&\/LIF(.,8H
MU?&A.=/5 $ZN,/CE>27'H:SPH7;[_3CFUX&L^$R\<54R==DRBE.EL454Q/B]
M[:%F<!::? 7U'$VV"!%8G*ONP .GVD<6%N/@UU)O11!M3 SO#JQEAQE6VN0[
M;<P/VA7/"?<&1NSC\MV;_)7'??-6%(@>Q@AC@>X+3N8P#^C3H,R!*LA>G!-*
M%.X .% "H>58P,J?4,_0AG[$6^M2J@>WE-8]/[C>#JG)JC/Y=4?^"<>YX\$0
MNM2?N]5>%!A=V)?J,K;./&\W#J48SYF0BO%1]X<412Y_G)SZ&#K:["1]XY=S
MQ@^_'=Z>2N-3CTB[RO\9QX;$?J^3V/+!J<I(03ID'+^.4  J'MDK! 6.!VE=
M<TIE/HXIO'ZN:O8<8^? U^_]/QZ48EYGO?JX;)$08VD1N%!K[YCN*/NR:3#I
M1L+D64L$ULC?2W\DDP7ZIP;Q"PLM^J+7[:T>>A=$[3<6#@()^,+0[&@)3!=/
M(VPWUT\P19E?=VW!0G07.9RSB<'>OH^3MV[U%PQDC&'20:4'(R K:CQCWRT1
M2O^4@-OL4YFOCN.S0K;4 ]IC\@H^<E^6OK^HM9)O2C%[Z[BF)*2\)U[H8N$Z
M:MR+R6WZMZRUV^X(L7X(49;R)EI<3WW,P;+VCH&$C:+RHP@Y![TG H=GL<B5
MG62?-8)E>1X+!)&K1!)1["AY/R*]QO<E<#CXUO'/I=J558?>-H[C=D-,/18E
M5IAR?5%8'F2S(LX#!BBAXHIQKCC@!*I=Q4M_<(&Q@ I/+U@VX3ZZ8]J,4C9Y
M3>D8.G9T[=*M7886P$T[#Q=FO(-S"[8B7T $*M8%EDSO=QU)MTI8:.I\KUZ<
M\IY"]_SFT^%]UJY2;,EIQT!$M>%#[:?MMY6).RQ0_(:M2<<.7N3S0-&(CHX>
MC_J8BG9)<M1,R=IZ9?(+?5'+S_ @4WU?%D@8>XI^&M B=E("VS&O4Q7#*RHN
MFC#K\]O=A;S6PN.?.^N^?9CYW,RH,?+_;&KZ(1LK];?GH43&._J>13<81X-L
M,?W2L,BQTPU5@YLSK:%\0UGO:*(OWE ]P[%.(Q!/**#,15I!:D5@]_ZJ^Q3]
M\<9/Q0@B]=UHOH3NOLGT;_:*X%FC^URTRHV=B,/>5#O+\;K90<S&'?M!K^Z!
M <@);;16]-RW'$&(BWY=.?/>::].K]KR+?%Y&.DL#<+\_NP.^Q)(ZZFZZDD:
MW:ZLQ.8B"GW\N$SY.-2^A^18Z/AAHK$Z;&E ,L5<]0+B:1KTHR-P,^WNSF(@
MX6KN..V"?N6:_+:1, =SY.E8LQ=P%/.G(?ER\3QT,GA>K"I1=R72GS?D[-2=
MX1*HC\:WCT>1U'(M("2##&9RA]'$F7US4GA!N&S5Z-9U;X/RN3+5Q>D+:H6H
MDYK;<1H:BRR0&R79XQ,OK[0Z>*IH)\]S.=TO>B/-]0>5;I.*Y$GW[@]Q6H>N
M33Q3;X3V&2'.()OOXP@Y J.S@NBV +TC]=IG +WI7Y(W\HDO&ER$N\^.:M:\
M$:)+$W;SFL" UMSJTV?5)'%***]&/+TG5JJYBO;QR2TC]_QAT&Q-9)GO[T#(
M)TI'_-$H.9X"D+GI<ZY<%8WFNZ6#9M]]-,Z:N/<H=IGH+:>KB &IID1IZ>63
M-;L)&,BZEE<"E%QO& <_P'B.?(B<Z.FJ!]S)CL:2;[65BY<_>WD%"LY9.4\_
M4!S4S9ELC"MKN#R/X@HR-0Y"M8U:/.3;\9U6\MVT_<'<6P,18HZB^2LR!GZ]
ML5].$*P;N+I@@"@"(,!2"=W O\56Q7#B;O&-4)B3%82^]P*NA@8O/]H^\BGK
M12L6MM8Q0-N$12YK'!D9:4PJ2JGV/>5S]?#3AX[/"_8;Z359AH-1..F&9S=A
M DSPCA!DIL;8^1V&4?'8 ")D"VT? 3H_JE2 1>#FRCWPHI5/Q51"@8"6FB'M
M"S?!L7_7LLL9>]()>,Q'N2>M8MV/FO+QSBN)GDVNPZ97ZZ&YFL=3:UX/M%F\
ME&/V[N0M9@]1%-CN=_XSLF7M3U><.FC94R:4C>26^M9(G25Z7MN%X_ZJDV@B
M?QRB-W_6WK&R,CJ&C9M[*S=(P5ZKC5GP<Y3DQ,#<H+"6 ,L+Q3&9+N^]<^GC
M-EF3M_3,FN>SK.F%S[6KHRA6N;;UO/:IF<?OY#\K@.(K?^1T;[O;:'@%&OO3
M!.2ZGCS2UGY0:)88*Y?CJEXQ8<^H+_;7J%2=4FX]RX:2S2F_=T,^^45#MK_O
M]K% X>E ,<:'"'[EL!V"WWRZAMP$5:Y.>KW24<UQI(%; PZ]6Z*ZJ]]$XH^:
M[S+2&+;S,9:T[S[=]68YG"Q0HI8O$5*IC4"1OVC]?ON#K>M91,,V/!N9OP:&
MZ'J/.9!#'\\Z,MG&@^V+7YG13(%HYE7P069'\?80S7QL\Y6W^XQK#O,8B8<%
M6J\-5\ D%@PC?N7N1.SVWD&3SPQG_<P*W*X*>@@I.U2;7X-N!PM_BYV6+[P!
MI7-/(T].#B$=6:"(JG$/8]L1SWO^Y@G:P\P]1@SW4=>2=$AX@UA$BM:(*/II
M]Q,<DU,!QW&AP1(]8D'M5947VY$-'T(ZKX>E>DH$W;S5"I1X+L"94J6[%LPT
M\F*3I(' >T+Q2>$+%^X9UO_N<'\4M7M*5?"A-G@;+J_][(HRY?K&BO/3.%F@
M,D_52FLW4MJG)50[Q_RVMKG$WN0HY7$C^8?>:W_SHOQ4M$/^5)K=C6ZIUY%=
M<4%A^71!,0W15!.K,*-TYT::-J)/[V0?71Z\I^%PON?W]6K ?O#Q(@8?,R;V
M)[ZZ@'/ "7LR!Q@I=%F9-=S](?V\A1^BG43[ 7WOT>ZR!D.*ZQ7[TFCZ0(\9
M1V@Q93!Z*PJ9]?L0.[;<%_ G!7;%*5,PU'=IK5-^5<?XL^H/S$4E.J>/]3;]
M8 159:3,KQ?9:6VUZ%H^2IKFV$R>Z0+'AN3J/S6ON?C*G7[O)%))?D?.>YA(
MC\.TAT=TGT!80/0TU@&M/@*C8QW09X%<8<(3BVL,W(WJVLXQAVB-7@C]H,T<
MYN5T#WF,VK5QZTE]Q>%5U*+8$#,(,]BMW)-/[-S?^_N4EO+ZX5[$G=)VO8/$
MI8L%FH@["0QHKRH0H$47"VR&05I9H"G4M]CS!P5EW ]Z;N[PW8R@J"-;WK Y
MH@*"3/WUZ#RK#>8Z_:YD2,<ZG?\RN@-G[/J9+7,A24/,_8I"4+K&0]S%1&;!
M_1SZR1$'IB1JJW8GEP7BC6;RKA!NZ5PFUZQ<U/8"XI<"I7!D[G D#X2X@"=;
MH/?YS/>-(_M>G7_:]]S_]9.+3(K3B5W+)0]19/Y$ABK!>?P54_$PTXUK%Q>3
M1S_E;\Y4R-W)^6V")-2S0(<;9*[ ;S%BVN2#$B5[VU$0(X^/[7X7!.G24N3L
M>3 YD?D]\UCY4OVJY#=Q[2W:RB'WS1-)5C>^[!,*%7RV6+G^$LS=<,>( FEA
M@026;>)L2+MR(@]9H*;^ 498QS#R5=J)TX-9@KT7(Z@N0D/ V6T62$R;Z896
M<(60[57'>\PGZ_+"=0(_G=5VKAOPR##$/JA]8$@$+-T^L,7H(82 MAX=J0.Z
M C_5^QFS0'SXK4T%;3O#1?M$#*(%5AH1N8<YQ$AN., K^)ZD<\[+LQ-_]G@Z
M;4S\CQ#*LT $M/VQZ3%(>6]Q?2;*H1@_1=H]Y?N*W@ZVI,B@FFWXS>BF^6"&
MG&Z*^!#PR#2E((&.>L5>U<#>5))X!XY;1Y FCFAF@62JW'$2&L8U#0YS&: >
M_M%HXLKU9../L>_-LU()7TL+402CE- FU'?4?F8?9%\#%W&<KDK$AU\X.74<
M1/+)ZU1/E.:KB".4EW;>,0FYS#8WRXQ0/5%F,[("O<H"T?3I<OVJJW#QN1.5
M:&X@;FV7L79\:.MP=IP[)_Z8/)Q0S9$XN-<((XSIAIOT:B=G*O-'=!A=G?[Y
M*"U%-D4]:60KX,9%$O(<L:9/*KVC4?)>1,_:S&>M[H5O3,_N*=)O'=HUBE<G
M&E!4J,UGCL#(4)BD79"6676Y,R7PY:DKV,0Y7C$+/':@]5IY1VZF%F_24<+#
M=&8IH@E,OADK2VTFJ[[Z4WIZLG.N?3'& QZ2;06$W1@\.OPPL+:Z)M(IFI0B
MM_[5 M0JHRD42Q?#=*,F%3LGN5I187I'Q^B7M?>::-K87'3HF;'MCHEOB1YY
M_^[%BRG%#QJ,?<AF>>:!H$6J-UM#7.$"@")%L]L=>O 7A'_S:V6A5,Q.<J#J
M@63C@#Z#R/0.PP=)FWHR]Y&CT_63+CSF.1%)^;\UY]82W8IS>P:W!RT"C>17
MO#.E:('<O>\43>\D97V;NK5B4]+0J#H[93V[2,!S!ETE+H87ZQPA0/C&?^V:
MQR#L,C,^31:=:<-&%8!D/F[KI YE1S'J#K[2_MQNI9( ,8IQE,@5>Q@:I50@
M\5_=%>5_Q_A?JM-GYIPJY6H_-V<>ISU<7E^U]T677&;H\VG_)W@)IA9<GH'6
MX?6G*,]#49MX =?DL.WJR;=$#DUNH>R8BC)IZ>/[G5?YX58T=ES>'(3@@?/5
MU0!VM%/W;.C7*3E&5/^&JH"0X]\?>'.]/SP3M-/9Q3WIBSHC5-6@3%BD"[=2
MV9XZ-"'HYQ@UG/TBD0X=;8!DG_^MSC8]VG>'^?@N;V15=29]Z@CZOJ FK#;P
M8QW#(9*1;QX$WZ=;?*L*<&2>\-BP3T/G+NC)W(CC.8\6MMA-%EM^F[1R=R,/
M&H),-38YDCH\P/CPIUM,I2HI;[X6Z=P'R.-;&A\)^;_[23&M,/O<<RC@_>VS
M&Q7 4Q;(3MGKL-F[M*A-Y#@;]"H24 <>4>BNC+H&$[;1YFT?,V.4>'"6/$RY
M%>5\,=KV*PO4@$W4R9AR5#Q:%,8/\V+VX<H-F_HF7)KBX><!0?(BE$Q]]^Y<
M]+W?&E,O4&I/TU3/L4 5J]>E^?AXUO(=-HPL"@I_GJ.6_TFF$(=9;DLZVQ^[
MRA&6;-,RK)<?\>Q&8..S3-_\!F2K^*?\BQ</NCVS?Y^U],5U\G0&9T9&D;)8
M<6Z1LK1W1PX/6]S-02 0X>ZFV6E/CZ+B'PT--=>S_B1VE?R/Q*Z0O79".]$>
M]:6;EM_P,A!"":Q4L*E4(P8I(AA3>2^"'DH7E,3_6-PG%=OS^*-,@1,?I!YV
ME,YVKJ'#B'%TQ?ZZV3V,>#T>PZQ>;PF;RN3,W;62)ADY_8VVLY01Z\.7F%MP
MJEL[')+8-S&G7(+\$;MPD;H0.[DS 8;$S3U.XSAM=/<G>J-U%I'JBBXT7#:,
M;# CHCA=+?64*"FO5]4SU+[K;C^+RPM*)E_"S3Z5?F6Z9@+/HBS^>;Q\F"YW
M;LE^ST@E^+7UQX<%G<1H[U-)I<WN75$=OY"-7!F;F*0_E5GVL3UKZ&O$N/46
M+I8%<@='B2P=?,\7WS,W8[<E5>_OD."Q.N<HRC&J2YZG56YY-2&!X[A5?W+B
MUV&Z3^ZRS,41V<E>K=>*$ZXE%Y*JHA\E06;>]MA#J(MBSI-.[\!.7%2*8 H+
M=,)@ ^<\@X+0#"/+=<^\\S=0)=W%+\B@U0<V J.0A (TV71]BLLFK1E9UMGJ
M0EZH_\+/]5(]?$1USF!>Q!YZ.$Z#!?)P>(E1#,S%LX6>?(T%FER?Q[].G%,D
M.5%"_*+SQT3Z"I;ON*<VVRXZ^![3AT'QFO@U2A3#N!^N2\!$Z!V)ODKNB,C]
M=<$D>T[J(J\KR8,H\_6%N6&_I>X<9%*<J!J^+8<]&;=AS@(E6S]Y7\X"[86Q
M"9?!0,YT>?ODD;31YWRC:=+=L8H+78?2BP=F5Y=;O U4-3_GQN2;B9SN7N9=
M.(+=#*IN0@%RD%4SLF'7L*H>&!+C?_W+K:QY;OU!%ZQ*2Y%$G\G7;Y"&8,;9
M/+>Z )3#H92/]RZ[N^_=%SHY>32^(R>[X#-(T,'^;"%B+/!94B<5^5QGC^ZW
M8F9QR7@YF.8B8\0"80L^X2?'YK0L0H0G&*-#7K^3:\EPIY:@ PT00:*B'>F1
M>@:&L:2.94#[S]@*GJI*6+Q+'F#^-L(EU'N-F4WYAP1?[5=ACI6L'*KR0?89
MYX^>W2D5:P50U ^ Z8>UN"$S])TD9&C+=#QZ&_T(W92ZX(>>$)B_7</LIZRC
M7&J3<*,JV<*=S$FC!.1ZZAK\/$T/KD >'8MHB;?KQFV,W78\"R$?VD$>L\/9
M4\":+%!@RV#+Y:U\Q3L!:V_5H=V&+B. #1?]QE 1[?*3SO5DG/I3QAC)D&U]
MQ;Z/0OBQTN>JO(\,&B?+T&XKP=KB35F@%GZ:&5U_IT%_SF"P&%WDY7>,,T3S
M$C?$ .-765E9]L*CB)03KBYQ;^Y2@=[SNV^1GR?"'4M\WH\6SYZI5'JFW;%-
MZT<6:=N>?B<M=VQ1^3LL>)S2)XCHQ$J]>-49K6/^-.38^8=5EWD2UV[-(1HL
M@XE]84@^^(G*"M3^B9WH0?>7O]/!MP<?HEK%ADSMURR;X2J)$T3O-W=@;B5N
M2,*=>CH4(HYVD2 I6R3:)9;1DMZ 1#EO@SB>*Z=08,WH<*;6R)0=!1J1NK:4
M<_<W_^;*JR,@'L*>S2-=)=E15$HM@D,M9]7'+^>.>&.>F#R"ZE:8&<)W2Y'7
M+#-F6GY&$ST;)\X\7$C(8W C=TQK6:#YI%PB- S"3Q<J+*DG>@EJY YV=/WD
M79HZ^2ST\%?9Y8L<=OIBB_W$.*F6T=A'VB?/IML-W26DNA<\TH+V+^6G.5=^
M()H):8G7^29"1VR5LJ.V!77^5VI _,9-5E/O H=I[G1."M?J!,T 4#@2W)(I
M6R5D/WGQ;<)AL3!#'3757M&!&DM#^\M'.B[3LRDPNM0>FD.0LE4(+_4/PGFW
MM*TG+&!I$C8'?GYHQ>Q+1$9IY3?A5W7WSVB5&::CW]ZW)/&+-:.Z-Z8'4\/5
M8A[)%_R,"MC$=IY6Y@SK:#<4,C%1*4FLGD5X,YOQ9$_5)J^)\KFJ>-IUQ"A8
M<@L=QP(=A$.T:\G3=6M)AS*R7%- "YXJ%5]G]<_E=\C%3^\M6'Z]7 0Q_)Q=
MYPW ]83_*?=!+L%X0(4__T[NE=2\6R?/VL@5I72Q?;Z-Y'_YX??_7>-?W1>V
M7[(7)X!WKBNB6*#5:X.X3<?;7'7_(V2R[6OOB\'Q,/<",NMST ZHS!)6NG\U
M8GV+_Q;!(/?+]6O@9X;:VOJ<[\A[-'82:?K(9E>(&V22UGD'T8LF&Z-?I?88
M/ZW3HMC<"Q^61UVTOA>/"W04A*S\O/C\/M*OI6&Z5:-YH8MMBH/UW15_H8J(
MF;Q]005/D@_QJ#M01M(6\CA'NJ$F%Y6Q555YTY"J%+HHB@ICA/L9>D7-GA'/
M/)[,OQL85O&@_)'68;"RVL,#LI#?@U<^$$C3!I/TY6'L47;,=9N-;FJL?\R"
MR?O?X@68@E*)1X:SW8X-S>Q9<$;O-;EA.BNW]^B5M7O,K6#4J@W;28J0L:]*
M%#O6I^;;46Q3=6@62JVEZWC)I;8K.-943J_!>R;.#1\I73P:>;D7$>VZJQE/
MG#DY=9G,3/)P='3A:75S<MG;+BKTN27[^/,_B1IGE'MV/[FEKT0CNE,V]&E]
M]#L,<4)?*7.:L,:QK:9]ROFLU^M\\ P;<PT5A%@OG?<?T<Q I2(=V,YE<;6>
M)F@]!41<&8 0E2@%G30V>G6O6AXR:/.EWJLU-E_6L_UZ^=A'!QAT+(4>P*C
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MZ-.R#.4YRE,J+*YPM9SO^Z>34*8M\>@P+/$M0F-%KN\9*MS6Z'WGY*)$A$2
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M:<@+[/$O_6S5QG,!U6V['\)'^YHNA,SF!'O_>!E[*N>IG./8<VX%'"\;C>U
M=R1QSF@:^Q]9H*N#RE2NN9\9)2M@\O5UD249<2LILSI&.L9A*/FH\>&I2_XH
M4."T@1+';UGF 1HE&,;F,QSI!IY$SZN2+.?0(LB6L\1@$U5CX#Q1Y5S;=FH(
MYN4'G ?4:=ITLCMJ;#G98G5,)>5T7\SI81B4O?8>A(!!BR(]P!.H3A9H_Y]<
MZ->)[O9*P'FQRE6$ZJB"JO]G5S.Y&O>4\^>,/:EKDLX[&?+1 3_Y>@FP?S-5
M]BN>_!@:0??!]- <M<+F,AKP$\9MA][LG(3N^DTAONV'1/](.;+;SS7-OL"&
M^.A)%H@N?8YVG<E&%(?9LB(*I#&%4+R3;L]@S7W<;IF*#4,DN#PG[5'PZ;FX
MT;L6N+MEU<ZUCVL#X X!V;M]=,D_G0D=@#Y:,+./J<;(^%N+7RE;(+&##23D
MRQ)O433S3@3/V!C6"9_DC=#I51=NZ1[2^K:B;E-]QL4K$T+HR(XFKD\Z12Z2
M,@_V#3F7LT!CF"/LC9%?U:AE@3Q1T;N]91#J0PB/A7*VWJ],DULC65SXQ[Z.
MOUPY=N]F1REQ[&!8H-"9H/,0-SR@TM>.>567NXHCAP-Z4ZUC>O+5E>_RJ+$_
MZE0BPT<F;EU[5&#U_/Q7V;!0[6CT<S"'YZ8@H%^B=S#H\1)14^7+@,,>@PNA
MXFR87G&^[WQ)#[6VE"+>P@(!IU)(&N3"N<Q&-_\Y74?[P8:KCKX>AV-53^4-
MW?<_( BILY*-C?C\^"'?D/*.5]OCSK,Y[1K>Y/2L ^ISB6[V1C?N# 7\F,0N
M=^L*=NM<FY.FG9T3XS.WDC?(4#*S=%,R$#(M^VT]XU5+1.[96H_Z<Z 2,R72
MFHS<0W_JF^O&/%8ZC"/RX&K;-GY9&HS>*_&8=^. %^_K^X)^=X[O2/<]AACY
M-]43&* L=CP!2H8NC]$]BF'V3ZM32S[$JD'/GU<Y52Y<THFEGM_$J(_!.0K@
M#]F*Y8(,8R.9^S3#V$IDC*2CV^VB*P[[,U&XVS6I"A:6+U1&WF^?D#*O.2H$
M&Q(/9X*G@0N]ZBP0]\2OU,=G/UR+ZS&^UV3:#Z_!%':5R1R=U\D1C-K%E\:F
M)BYXWDE(M%TQ;[AKEC3T)-IS<1FNU6GKG^K=R*=>?O*MF\'I-+]A1VN?.XG&
M*_P7HH3J;YQ<WH:<PHJRS9T4Q T3-33I#CM,U_=W$PT8:)6&GDBX1[A<>5SX
MUB5]T^=[E3]+<$3M#A'0=*%M0DJKJL*V:459YH:.B+^.PL;CW8@4[L/;U]M#
MK*BJ4BQ0OV</"[0'!0S\W;NQD?L-2L0Z,^J[B;MM)NM]"BDS4I#&4B= I_ $
MNJ+%X4.!%TFA,=> ]AOZ7G%13"25C%\=(2>V9EE5[,?%/S/Z_.TA"]2Y7X0%
M.E(R=6MPL_?XN-72!;]#7^+B;5H^YY!O<[J$1+.E?U.*#1J;')GJ?_=.8_M]
M@/%;IX,+S0Y$*/VL$7W2$GFNO]V14C/V;$M>U6*B5-^1\>\L7TH/;Q=#_3OL
M_:V%\U_S?\W_-?_7_%_S?\W_-?_7_/^OYT?#TV1RQ#Z;W)D[[S3]A*(P$#=]
MFS/JG]^W;0(PQ!F;=C9B@1L3=?=>,V:876JH*'.34\IV.^IWY9Z?U#O?R>I?
M'P0[\='@B@BZ*)C( JT6TR[ ]S'J_YQQQ.I$=-IS -MD)ABXJ7.LV+7N4]+\
M'J?/!F_>?:0]TQ&OYBG0J4V251/NN#Y,@K$Q8^@%9+,24YG9AZ[JZ\0!)]9)
M1P@F6DW8$\! (2POG"GI]NRM5C%QYN3/'2\%FE-[[1DC_U.EE]H=G/7'.WW4
M/*"#W,6$&A[%5]*R$7;+ A)^LKJ=Q7K/(0?9U/Q$ 8IHNN@0DZ>:HDITPJT6
MTO8'Q9F B;,9188AA4!8I]ZA<O%R^Q[W%WS(R6\T,8\]TT1N-4>O_;A[+)"C
MA]E<0"5-*\BF!<?>1)?&P*8+L_%$#XC)R";LX+*U^8:)>D"^].S=5/^%;AV;
MM\]M<]3B-P0N;:4J<6P(4@49SR&/4, Q<1*$9C!.YV$DZYA2(H@1[3-ZWVE$
MI['0]4VB7F*(ZW8'WG@XI['N1=9EZESXDE;6]:2O?-\BV<C-,X4NA&Y#DV]X
M32#;[M#A*2;U0!I%<WEVL;TJ0+BXO2K%9>_UJDGOQ+5OW2X9/_QW>(TK XL<
MIC;M_U$RH.#*;$S,AO*A?,SO2/)MF(P[3ES'9G[&I@6K,:QA',P0[T <J>3.
M=Q.^ZN#A?-R([X73B^3Q<]=68NKOY^\4$HI5F?QT!G8=Z1KK2_7IQQ%R9<13
M6Z\,D+SZHOS!KVY4HT2_W=WC6;U?;26L*Y'_Q9 "+G#E7_7%(#_RQEZV?Y($
MUWETWJ@'W[ Z5;^PZ)6DN=XC9?@U?5#4-__*O66?ST2)=BV)&8,3!B>I]65&
M[B%"OUWH(O5,_M^ "HT+[MG/ CU2\9W_U$@!SWF^UUGWGR,AH0?%HVRDT@PJ
MJU_)/ZP,$U<PR0D^=$EK_L6NH+[8TOTO$K;8M%?[!CVI]6ZN24E3"T;RKH7Z
M?@9;RK=R+_A-WE"?[Q%-B+I!FNPZ7;R\Q5; >K[_EEW7_M''_YZN<'^-_\)>
M-7^-O[3@'WDHIP*]%%4H<):,;$=*^(=H!O= N8%'-*NZ\BH6R$HGH&K]H@&:
M=.8*5VU)<C;N2^G(*><AC8O:)2HE#UQ+5!9C+MR(.>#DI'/FZ)O+A+!+X+Z^
MU3&:US*.;,D"A65* ZVTJXAQ^S.50%(@S3[HJ@'LE?T!2B\^HHBN3"Q, X0/
M%ZNL?HPRCE PLB0-J9<9_,JZ^7@/<@@S<;$%5ZVXZDXIG\>THN-P4@UV[*!$
M*Z)!)"\HA\"LG$N[_G'D337U>>.@(C9.3LNW8[3_8%]M%53$V^HYG:VKH=/(
MY@:LYM]JQA@.0+R@@()7G,9UOQ[T:TFXO0Q9,U,AQ.O2Z"(Z)'4))5E:%_W]
MMI"4<-9X;9H<9A9/]L33Q?%M.+(I=$]0)R&/E'(H+1=N ,"(Y<7+V!/A\I65
MHWY![_1]GNI<XJQ*%7>ES]3$ONSNS@^_O>>W(5UJFV8.N#!Y36BWX5YU;!J2
MX/:C=*/YX/J+-NAP)@AV&+:4>BOE8VF->-C-BLI,>>'V-',U^A!GZ]JIA\^H
M?QK?K%!G&#D:^!ADI=9J)*5O_E#]/#X<M[?!Y GV(&4[:GUV8ZW[N_+*%+*\
M)V#G:3RA4N3H@QL'?O!NO"G<2:&X4P^,(+TPT1 I""$/0KZ,C$#(D5$O]$2!
MA!.DHF.C/\I'MO@-'U:+IZ3R'3P:?"\'U9WD80W3>@S$G%#V1+/CW>8&%J@:
M$\;49;]4Q+GVC?.VL$#[*V!\<'UR8(OJP4?4R;$(#QZCN5]KIQ3#2-4/DY^J
M.K[_$#M==>3A:R6[E[>YW-@Q60C0^">MJ!52@2)!*2G40@HT$D>4(#=^2LFE
M2Y.3W\\%]^J-M=R&5>65K2F1G/3=MXR5 ]R3>U)<.L0?J1:QUWY&DBW^/-RJ
MQJVR0/.J$W@JFE+9%ZGC12ZS.:&^+O+H24KC2$5PUO$/-;[?ABZ?.E5\#OZ]
M7+_>=W_ SCR3[Y$25H;QZ5XF8H+(Q]!TAS">4?" FGVK#9KZ"\ 53<FR0,Y7
MR;D/ZF37(G\,DZP/AE [-?7"GT-R;_S;!T3R1G1X:<^,\Z=[/L(#R=<T8R^F
MW<LE-\1T'7:L-)KIX@"E;@CR!AE36].H]11$4B[<AIQNKQ3=,AF\?*'PUVF/
MGU6G9FW=96Z-<B7,_.)8[59N1A)AR.:K+- O0@,W"_2R?H %XJ$Q>=@&T)"3
M *7+SS[778XBPP!+//DV"[2KK;H723R]B6S!L@4K@@4:: X288&X S\(/LMN
M$&>*;=-%(<PXWB8T8-P()F-PA"P6:-/;?A\+U&+WBV/V,X:3!7H5P@YX!=GL
MA)(5F<+KAG3E=4 )R9 6?P$AISP#;1?\1=4_,E6)3*45MD9LMWH=#CK7$HB3
MIA]3SSP].@6M3IAJ/2IW4U:USJ0IH0$IP!^ _^_#U5]4_4-0M=5&-QUC@;S6
MPV?5R"XOUQ'G@2MN.G;%56@O^>KP2]??&<#\TE[(!S&E)4&[+?]-F/J+JG\<
MJA;Z8LW8COT2]B#\Y)B>PB/($;J4S_[8!Y[RX4.MVO%-1QV,0VL7:XIQ_$$V
M3![Q.;" VRX= J8+1(8XB;7(98I[=!_A /ET/"5= E\SM>?]ESRA_@4[>];O
M6H:R2?P73.7\/3^@X!$Q NY?,O6O^+DDLZ4?I/KW3$'^Q2[W<S7^1=8_#EDK
MR< (A"[*2^1J*?:=<\ZAX)NK#[J.*LS=\] Y%RF]=[]HC7)F<!1H-RYJ!]]J
M?XC]"Z^ B-94!$Z0#3DYLF%6^MZ1BJ^FGD1<:I+VR0PV7____);]1=9_/EEH
M*A*(H*PSQ5F@2+T#='>*<WR17BRQWAA8J\C06EVV=[OGF.DMNF>K%Q2<\2_3
MKOY?+OCFP<9N/]D;H1"T-C0?2+*D.3-'$0<K@.!"YI"U,X[(4"7^#,MO?@H)
M]].U<$Y>*/$\JL"M*N? *\2K=B(V;N[A)#K_G$VSMRB41]M0H'Y8^LPO@V"4
M=0@(<179+(QS@4Y5,P^$$/X<G2HS[&"!QEL[P,)T2#Y02S<D0([ 3]0.G295
M!KB[%F=R9]<UA-IH.E6_2.FU^U#QH4K,:A</:,TS#U13O*A'@$0VV!UB%-+/
MY0"^'>A#+K55@TSI)?$!^U9B\?'@UD#YAM_Z[YSBTZ]D.9YZ_4;P?<PKLRVU
M?Y0'#V(_9/C)JM%%$ ^()/Q20[\+2G]8!YQG/?'H%%?*J8%Z\<M]M_F?,?Y#
M-0OV_ !7(%_ [>;ZHL'<&C@!UW,SDZZ(,PDK%ID'>29;[CL)3&_VB:UL_@>2
M I]RD< $F'A0^5QGBXE7:RK?=D J.$:N;B3OY=ZJ+^\.7ZW6/=?^'V5C$5R)
M?Z5C.(^>R.O0$R+'Q:LP<Y$Y%18!WB![R^D\USZ$,@8(<0S,!;BN#FGP!D0%
MA\A,GIA#?%X1#C=;.W"\ZC]R3W*>6D_.>TWWI:D#G2UZ0H/RN&',9D#4]^\@
MWF[:6]+A]?9GNJ)[4.3=CG5CLD#$IT>'2*+47=T*LS:&Z:@\7][T0?W'_Y$C
MR_\9<F*9R)S$5QY@O&&!7&8LYWZ^)^,M*-6OK8/\\/L!J4LQE>NO*Z-3-DB/
MLYL>9+U+2;@I)&W:<VS?,;$5,>G1Y!2UJQKM14]T&\*O'^D7D4IR.O5Q\Z)5
MBFRYT'0_U^].FCFRN0E-]E&DBZ3-CX;-H:>JJ09DK_ &^3FC3(]SS7T?.T8M
MDS^W]H;SWQA=#K!Y:VB['GC2RBKKY!7T!/+/6<*;2!?< ?9?=2ZZF*Q% D5G
M/PLDZ-%@QI_(*?Y$ZN5E_@A%UQKW2.%QW^IOGC4_L5PL4%@!_-B<UU3P'48F
MA)"$+A^-$*BD7.V8A2!%WMU]Z%JG7UG<GC,[<V9?ZV/KGX8J^-5;H%.BDF"R
MKWB+,7@<P^1?(BNN9I"[=Y]6Z'*T8<7(E;T]):,-U965-2G?WW#$#D+=I5_Z
M30^#=G"$+S"RF02.D$!!-OOO+R:($!4IZ&0\!X0HCCSF)TC*R7&A67ZG&4XA
M^CF>UNND2^]H[[AOYE$?,RH1,H@1?"GR%<X#&9IY:$R#)-6. *-N#]$AN:VB
MJ2AT0ZM*LLRUZ-XH_P1%YWC'_9H/B ;+]"<CV==QA/8?-^]+*4E1($+#+- Y
MV&UD<Z:,TI@&"P3('1CT=[,KWH1$6<\DOY,F?U$/2)%3K4[S.;&;>$GZ2 I=
MVHQF"X>RC?@H(,[D3A%<S? BI^G#I/^TG1Z<:J]^LVQ-^H9\^+2?JS*^6"5^
MF&V&Z]QCF_*MOG@C'RPD:\NZ?8HW%3*^6-IT^T)"L.7O8(H+T]*Q@FVQ8[-9
MH&5E=U@>GNP[1K*<!T] F=S<\_4L4$3=QU')OK@M7E6NJ4>'ULQ)Q(;38S;7
M?XA7A,^=,3CP6^V\Z!Z;5C#Y'CB&[7SQDWEMR#(T71C<A)48@4,(1A:JKW$5
MXJB<FAHR,T/VG%+8K;*JA!,:)^Y]S+1YGQW;\,G3<4HV9(B<T@([J'.8*#K(
M5(1;U5(ROVSLI%@W3.I6OKR?9+K0RED7&[\W]WE@T@;I_8%)KM^]-!" 9_*\
M8!MKMGL/0V[" *7.5?\YY,LQF0,XRJNURGG5 ^[VO'4U(YXY'K=_M?QT+_7+
M&K"?Y#S8%B\:&?U>8DV,IL]>_9*]G?& "Y,GCR;T"U)Y*Y[HU.]OT5@SJ&/S
MH?-\LB[D;O6XT_7IC8$Z(]&NS"LW"YY<5M^S2?I_8$NE<1VXZ%D^@(,<W8:6
MTCLV#96))'I(SM\91G3M27XJ&\F[XV-P/MGRZ'&#\X%.IEUB@#D[\F#K32@!
MV?P57Q:0XT S!1:I4OU84?K1X:UKT9<&Z)>S]0O.QFX,7,WOY>]#>US\?#2T
MJB&TH'8_#N%9K**:3=,E%?D:-L(>?I;PM.#+XZJY?T#W]7[<>1QA"1RIR0Z2
MFE4UP!.6K=;[4ED@%%,["'>-W-FZSCO>NFB'G^G\/&7_E7)-[X&8"M536KGO
MH)SG8= V'E"(H(LN$M'LR)O)O?21.;.;B19_Z>&QJHHCGO]24Z.FGSUS;XT&
M6S^C=;7T6O=X7\KQ'_OW"49A.=B_9X_T0@%*F-5VVO4_'4)9H(<LD%@0M$F&
M Y >(Q&@>]UG!9A#-11K-RK7[9H+&5TU!B]R7W9\3I[2J4KD_#%16X551+1C
M%=C[8LK^@B(6B!UUZ \[HMN_T,\..U.*%]ZFY00S[C@9CP]$S,8IY9W9/__D
MBA2H%).*)$P%Y8#)GBFD%\J"C<'S^EX?R+%H(!7$N,'^MAM_,L)UV+:'\R;C
M=1'R41\?8&$G:U%:6S-(=R&ZN_&W+NT6-[C)Q5_SYLN7>Z)_"OZPJ"#OIP4F
M%$)@4T%^HDJ*H,DQ1Y@2C!CL843[.?IY+(7S^_LG.J84M;71W;7?QG7U9[A)
M*J=.RX>>JC!3<G..?V%A&:YI*WB.+;I2#:8E=H J-8%\=Z-VZ+$&E&=V\ACD
M9)^/3*'TQ^"DJ@C(6M0&%+CHR#1S)/,RNSHCD%MR(TH<N_L81<P+;OARP=5Z
MBC@U=B19(:P)>V!$8T@4'V!169G@A(H1MGJCQ)%P;\\HCE-'ZT^[9O;O?=)Q
MRIH*0K> R29'C,V'O(X+3RQ+>JTNSITG9!SX^C!>_F13'&$.EX46![1:,B']
M\F1,;(.N6\%2>0]?XCCLBERX1=3=9-WNH/M'A+X$77R*X6?O80EB[#:S!4>^
MA8^&5= M5[SR@X);SG42.YU7"FWCW1^<G0[YY&K$ 5R5&=ZSL4V70K.)80?N
MH:'(9A.L#!P*--*< ?>6.KUXHI>(#>#;6I4))L^TO^S]W"EEC"B/S'OS4R-Y
MX KAX/>='P]P1H4_\,"QOM5HU54SM@K7 ,;D8.LOKCJ7GQ(7*%S1<")M/G_Y
ME)>"D=$RY6GA_I"C8.O=[O_Y%%*G]O;&C(:40-^/IM=>+20;\'S^\# !"MHS
MBS9)E2@Y[A[\.FG>_^2OE3=-Y,M<GS\(M@D")U3IAUR8O$,?@[PL&"4LT /D
M>+'."9K&K\'#%:@C01&7PED@TS$_\KC=G6 KQ=^DHEQ;(RE>?UZ1"+=;"%@%
MCO"";4'3,(#R^FI[<1!NCBO4C^TJX9?)IXL%,N:E^*6[J%))J>?D&Q?JOGZC
MR+U0,)/Z/]A[[Z"FOK9M-(B*@!!ZAZ#T+DB1(E'YT42,J(" $A5I D9%)$C(
M5D!Z1T!1B J(TGND)=(5! 0$!(04;" EL82M*7R;YWWGF^^;<\Z<]SES9LZ<
MF?>/G>2/[+U7NZ_[NM9:][WVYP7Y?-F3W^G"$][#/H2SY!8 U )  1>UV-_B
M$U*;V)815Q*<H]W'>P*$LCSR*P@#;5X%NGS=>BW[GI$@A(G#(JF/-F%2T%T4
MA@M2#NJ$LB=#Y3A7,/4",@7SRVNQ=]:]20;%+0K4+<Z%7<I[3RTY*_=ZY_XL
M$12DJABGR;-(GE FU)%28!=[#[Z;+(5#,A9?H;?_:E7K8*Y"PD;6IY-IV&!(
M>BN]-_]TBJ+X7M3@6KY]\AFKJ-M: -1Q6M (&("T3-<IGAS8TT61LU%^A@VA
M?^V>=S/=A"DNW=I/_H#QNYF]E]3L)5\D7BR?O:C/EI=:ZTT1^)+(D>=7GR8K
M 4$Q#C\"\P,94[&7\AWT1X;#L<[J/YS5+&M0/!%7ID-S&=!UP]8"O-CM:86O
MI)(E%3\XSL_+=%X<>^WX_.,@G&MJV\2W4<N1#>&)[N26D:GW;WJCXO$2O.Z_
M1<T#J0H_$"(<>S U&L,MN,KJVSZ\([VHYZ/M]OHZMHN/RF'QUQW3WX"5$":R
M#R$/^)'OHN5YJKYVFLUT<D*A3'/U1SNA/L7Y<\$,U'[=#'&7=C$!V#5T.M1Z
M.!0G!S6SR.M'B@-+!]/Q+Z%6L'#;.M_G!F>[XXE!R@Z<_BXUU<R55&\8Z,D3
M7(?:&<\MVX11FX'FZ3X*#/^&+&ECS,BE8;K9+N%/+\N2)!5&R/2 E_G8I^T1
MQ3<2%C[&/'H]5B&+-C<UD>C-/ 0]VG8+AGFF^,E-6'-Y_RBHN;$*T%!P>Z8+
M]=D+7%R?K6A+/N4X4Y00@M<O?30WI)Z.48TDX@1TOR/G[>1%P!*V,\<07(1Z
MS@1ZVF/.8? -]#L/_$BR8GSMH;$RY=/Y75^^#[/1*Y__F,?K9O+]\T,H6>U'
MEP1FIT;XIV./C990'(5HIB3K(/?);Z-T=+.IK\;[VDU8,$4)&[OH#C;OK)>P
MDVXNFE\I$.3>2SD>6NBA<N'BN4L99N<K]AKRL??_WQYS_[]<Z'L XS0!U,GD
MR.2P^XJ-Q\C4+$+]I4)*SR8L@5A@KF((OG@1G+7@^F+9H[3L,ZD@T/3UM/'<
M8,-AM0&IE0F[O344HZ_<LS5^]-K>K:Q3C=/=:''.13"]TOM;L1SC669DY??(
MM]L<,1@)TW'2@2$EXP$/OX^%,,X(9%S7H)XBH\6ASXJV6D@3!ZS/ EU_S1)[
M"8+?0JIG0E24B%B#B*)]KLH=P^JBPY]&I1H/"7I\H%^1-E=>N+/%3+K.X/5Q
M6V=0DD" MVN.+8--=6!,E026?;R,EL)K72[<-ZD^SFG?V>&B*.QQ([EL]CQ<
MOVSRV.<C5](;?XYR%" MO/T7<S0>@]> 'N;!TP?-.!9&_8ZMS6#X8Q?9 G5O
MJ0UR:.&GF@,9P7[$,[?\#5+32I-00PB& USB^U9"D+AZTGXLH7?<VM>97IOT
M,-\N5Z)LI5[=;T9,%^XOQ?=W:TH!JFML!^<(V,[&<\Y#OU'XZ>]/AYE&M(0R
M+$^661QW?LIC07^<EKUS*<S;46;CHLZ%>U57W/)*7Z&U"V:@&Z:APOG9[@.Z
M]$B[/^(<P!@V'$SMERD_G7@4I?C=NZRZ^$YPE*F#4UZ.93%K<2WKVFXW&<5_
MV"1OSC,&.<6L5A#H6K:0)2'R)M=(VO->9W5O8+48/_NTU5[.KN ?JTS^5=R$
M"40#@TIF&+;V+5E>6LYMVSSHO6KX#Q0Y  -Q&L^>VEG*XEPPP,@#V[Z>"W,V
M=9$,"U&8^Q[)JAM0\K]?4;7/@;Q_OW*K>HXKC@%0:P!%\A4D!-4I #4/6?<U
MS13-'X06,3UX_/L 1<H, :^IC8X _/7-QV>]?%SVVBE=FS^K?OR'0*#QFR95
MH>$9H*N:\"-V-!;Y>Z*7\C=G.>^/'UL'S(:&2B+$OA&]RN$L:@A!"*M(MU]/
MIH[CPE]XOPZ]8CI_E(E96;>9/"EO\_I)PLE6<:<1I=MIAP2^$3D2X3SA<&;(
M8N3J-%.1)VC-C@ZR132"1.K!P-.-C*^I.*,0C;+,%'I==OSC.:>U"X^ZR9#.
MJ*=3?O3[<;\N30(FA,;I#)P%>XM8T:8H,L@ 0,RPEO:=DE1P*TUA./Y*MFO@
MSCM[YUU^:N]!7*H0A)DST];D>87?8$]3M/^K%__/#9Y0+?O6UD%[.+/%2LH,
M-*[9;-7:7I3<-X50"[)81UA5DJPKXVMQ\249L=34)+679.S1XV-K@*'.!5N?
M!X=1]Y#4NQ!X7B.N^K./X><PT "$T"@V@V,UH6]SX?G0<^^@6_,927_]/S][
MX:^4,UI.F<VM/_XZ0&BPOJ'C@CP:>XE;*;;T%_NR4]Q.H' AXGW7D?4]V];#
M/]YUES]X3S26+$ZF9A,:C+DD)+4#K0A0FPJ/9QGP)+%^_58U#QE#I\7#4GO_
M9C7SWD9_$'"\<U[RZ*5U@][S_CF''B-\@2X?)+76UX1[CWP9$4MA'#>:N3SP
MST/Z>O^H>/!49BTV97*M"J=5-D\1-B-%7\(.OWW;?=-IJ.+.E;[&O%.C6%F>
M4 ^SA 4QFMAN:)"H;<(@ Y/YQMM7SQRYZ_^<8PP^*?_F4G9.L3(^-^PNM^FZ
MJ;Y*D&:*SL5==E$7\CJZQW@8_,*"QA3'%1KQA:"6X]2EF\1W)#50=-3%TU*0
M;\*4_52 ^-"F?-EUR_T_M'&K!A$\402(6$0)#RZ]"%919OBOQO7B_8L-;OU^
MEQDSJ,W_V^*_N^S_9UWV%_5OV"2L-AN@OD"W3*]&,81=QDC\0)<ETO\+V,@D
M]K6<HG@%;UQ7]T8GWGCMY?9;^,^E?*ES/_:ER!6>X4QY.?E]EL+45)@U-;D0
MR2YG>G\XU+_9=[ASS$7ZY*TLX7K^EL7E('Z&'DL7*O@]@ I1%WXDM<3;<\5X
M*WT%:%T:S/R^H-GT[K=,XB&%FR6TH53B/\TO3TDV67C$#\FK[]0T_RGA,->\
M"7, J.UHQIDP"-GXV?N6(*ZQ$5_5X<R$][>EM47>_B5RU-'G''-O9]]J?W?-
MNR,JJF[R7@M!T]=C1\AP_#MTPUE@:^L::+DVT5^\8T("G8!LE'GP>!9WE/F/
MX,.0^8O]7^A<T[YKO;GR7WVB/"V=5@/>[#AA,0HP;F4F1W2ZL'Z >ZC6+Y26
M;B)%%7Y,F>#=#HZ\, T77_.8W<W= 8OALD\!7>[($"2H]G45Q=@*2^!("=#1
M"?B].&MPWN\@B4Q7-NH.*3F'M3Y-S)DTU$@=>C#^I4MD1;TJ]>MVC_,KGGY<
M>:A-CG);R"'DV[=\TQE05=^PC8A]A'2204/QWR%4>_;>\0[KLM[!S.?HP1_=
M<;BTO0F:^4BS_)-R?^P5?[!Y\$=SGWE#"^T=(9F<Q].K%BO&-<NV9I @%>/8
M,=4/-Q>%TU")ALT^#\2B&IS^WC"I"UB^^L/IZBT9S*E#B%1"O2='J63KR ]P
MJR0*X^0+F: >L6M>#97IRS1[EOB\R0HVT8P0/7NN3:.Z^W[1D[8FS3-O5(V-
MB?=SS.=KV9YL3P[ '%WYSFAA#Z!%@0! CG-J,JSJRI4+C/5XS?H[K.Z',V6%
M+&RVK+*TS1N?K&PG![T?^UFQW)PM-"!OY5FX66S*,+R?PS'FWF\:WCE!]TQ1
M/3;G^UW&PD)VZ9E>AOK]4:NYP=9!QQ!S)]T[Y%"<SR9L;TWY)NS\'_(O_D.(
M C3C4"UH6+ *D:X=\=P7MH;!"'%;)6QX%T^$04@(->08T>81;U^^3/[<FBV_
M=N535Q'K.4+]FA8BW%*]-@E)?0W_<X"2B6"I+R'^>IE)\7$5_L_3!0-=#I"O
M?DS@!Z@/* VD3K8;[L9["Y_@[ZPP ;O8\T2KM6?+_<)R^PD/!NL#NL3[,_?(
MV?E^MX<!1HB&3([R<8A)CO8AE'GC"TCNG:J.*&8X_?AC=.^"#0G,FB(Y%"D"
M3X-E9#9A,S]B,OIW=?/)9<\ZGE+/6"5BEA']J'B@"<V11?-$YDA,K713'V%T
M,B"N^I)9?J=)^.(+C!\KYJ17T[RMI9SAHD9\"+Q(TV1#_U,% ^FF_1C^]<CW
MQ8T[1F3JQ#]0HU\UKX /-#,'06N>U(\7MAI6.> H^[0]]^$F#*'&E0J\^?;*
MG_#V%&X@]%]#WNLM;F" I.85[P =F=^]QSG(JAFOT1J0MW'B_=Z$V7X>*WR_
MG?K;;N-/)3U7?&Y.!5T7W.XYU=-%$D-+(A2,[MX8J[J/*ZD4EN.-^_6;1[VD
M$)4;4\8?PS^OTPM63[&MMG3@0AU^_"99OL-2Z_9>L*1T[LVBZ23=ZN*?6\J=
M:3F*60MGDJ](9[UI/S][_.I^=!.2<8[\810J5^PSZ%X=SJFM!;*KDTV;,(D0
M5J,W6/(J[!FZSXQ4'1ZPVK:KS$-[6!]^34)Y#M=_+,LD9,U*F_\/A5NX"0M%
MQWL[<A1>,%U8$F YW25,DCX:N]Z,$NAAC'K:.G1&1 -5J7/N*5U,F\28CZD_
MGNB&E8Z8*W"W4B0$(B\@4I%U1AR)=4>&XX#KMJ\.S,!TCELTG>O3L_'<(T;[
M;$\89KO$B\\:[(.EAM^NNI5>.B_O5-O^A6$16X-S1:0;VB#*WE3U/MP[24"E
M?7Q*31,\NLZ_/2VP\_)_7>I EX B^P@. )W9^C@IIM:J"'.NWWP6'M^A]>P@
MJ[GB;+%:^E5I=T<CM=8SXV9#UFT5L6>$>&$08X][WH0",8 $[^,F3 QYP8RY
MUABLU&;4O:N9@."FP'<$:26>,9@:C&!'O!DZ>PZC?UCLV>OWB3P"-)R&R:!6
MP:H:$\43%88ZX3(GBHGL7Q<X \KVH,4_3]K J;6B7J.LOO'JB6/)/B="XI3"
MKNFTM]T<F71GZ\)*=OM01T&-P%Y@ZPA1,X": Q"U5B39E\%,5P:\[Z!RQZ$;
MZSN_$YE=T36V)8\-[I8$,UM%8I0FYIX[[]E=ZJ)X26\;\.36\*2-(DTD_$PC
M4[29=L[\QR;L>-ALS._)M.NNH>&/^E>$M6SC3PA\">0H0#IS^T\PE;TU&6G[
MNS:9TF21\(PQFL+3^9Y:,[_DW83_YV] -D:@(*! %S1VBCQ[W+W.3>M0UYE]
MB/L4QHU-V*H1 TZ'U*01#9G&D^'XO+-!E6+M7BF(D),BD*++V6B?F9'"A2<W
M&$U9C8:_$\X\>JY^9^\&G5R^K,U?!**9D314_[I@WR(E#BEI"I<)"F_Y$)$I
M$B)&\;$.\YC5N/L@O/G>HF4/W)NS##7GUUSV1=X,I0'#D7 \A@R>X(0P82";
M'O/TUR8L/M+1\=KNSH[V6,/W@9DFN_X^$N):5$A@T3TF8+(-VB@Q5-$C8VYE
M;#D]*.'SA3>V9W(58R_E$@^\,>7#P7;^.Z0=5E'(ZGR*];'K9"*3FU//(5TG
MPM3;WANM!YYYTA)K9J3>8"WV/.5Q_<5#,(G+\U)\G$G>UN)T^'37)BR%PG K
M0M)#@88AG!>(8N#_$&B:<178^J:'>IUASIY,C?<[Q\.O::/SQ]1G58^,2_^\
M9(M>,N*(3?.$C9B5/&%W)@KR C9V#&M7$&"P:1L)5:8_:=\B,*OFD\T''8(?
M#6OT=(G/2<D<B]4X@1P_TXI[-CK^5YN?$<[;E<>H[$8SCE! W<Q5+;8Y?L;7
M>AS'1XO!=+^IX)@Q(U.;M5>@/A4+EBEHL,'LZ.T[Z94OG/=SS\ESOCH.HMTA
ME9!I'(6<"Y"LHL#<Z(>#.J.]HSLHWVYA>B,?.H/!*I67WWU$+X7[<EN^;/C!
M_C%D>NN'<0(LG:@ZF%F,!-:ZV]:D)66TCR<S$7'F_#V7[=YY:>%55ZQ,$K?S
MKUE6JVZ[7;%/X! $0="(C9O<A 5A[A#$FS!W*$)X9<Y9QA<RW8#?ARDUR\M^
M&K)O'E56,Z1]N]7I0=KN2\Y2>M1<2>:/1_@Z:"3OP^_'67"?DJGYP&Y3HYGI
MQ<#$9H/PXZ#BXZ6"ZTL*39[[@ZP*6$<.588KA?H*JA7K\#G"OLC*4:<G[YT0
MH!(X"FPZ*IY2MU#+/H'O0S).*I\Z!$8RMZU[-+R<OD%(L6!X#=0LO9#^N#];
M8V[7&FVGX_57#6^4WUUK/5.8RA.)X=[%'=XZI.($R18_A]YN<_!%,*5QN!*;
MV(,0;JY\?2D%*3XS6M5G\(1H @M,T MQ#\A]QDJ+6>T";N+<&!NO; ]@T?TD
M@;'?"2VC,R,OGME?O3AZCG2QJ/75DO>['ND.%PQ&HC3HB9OX52E1&.R&%&SY
MWTD&R(M!4DEHQM7U5V1)WJ15Y J:AKZ+9C3SX#C;:?O1WM6]TWU:QQJ9Q<UA
MJD$W_F@Y:9HL34UH!_L)[>A]O7/=4-6?%[L5<@K11[6O'"5+9BU/Z#O[*HAA
M!3!D5UI+<0:,R'B<\0ML:E__4"]R-A,(W*WG'Q+PL%K5)RC_RX^%DZ=E-+>?
M<(^L_!/)V6\"=.F1J4NEW J2\8(W%D.E#)A-UYJB$,L_JUL*@BLI7LX'A].'
MA[*5),T^70_U5+LU*BYO'<O[-GDPLN>O0,J-UAM(R:";M]+O??A9M;Z:$U3:
M]?ICQJX#JBJ.EV$<6P@SO'FOK6I7BR QH8B#E$AL)>C[FH)38:!2S+ V\HMR
MTQ&92;\#(2VT";/+73O;H^3PY92I_SV$VO;U[;>F.2I\;#O<;LA_Q@8LX/@P
MJ<5*N0.R@%B3!VJ7757WWT*'9(V>HZS!_C.+XO?"5IX T0BDU=??Q.,33=R]
MW<I&SG4)4U,+QLJ=S1V'U9)AK]S=8=K\=2^>\_]$\D2.@K\9/GT$AN,Z) ?Y
M.0>9IWHV\":,WH6]"AMW+TP^L4K/(;5'7\W4(*T;G^B+X!>8(VZD#L= CF7'
M-JA F?AA0F-!XAI))0@OE;IHU+^M%+2FDN.:F%7+&Q;</3ET.0^["U>J8S=,
MXH4JYB+KA/"5%5:(!)P%[7X9D4%)7+D!?GWPK$@_3&*/>MKUD2[8D.0;K=Q#
MB <06D&\40W5#Y^1'5"QAMZ5S%L@FD<2$"3#^7,?*4LM$^IO:$/10X3FCR5.
M\25GA\W'V<+ZP0I/ZS_^X=K^F]$YG*UD50\@1;, XSYZA@:UM+KYHFJ79T?S
M-F'"%:[\O@HQ?1FIJKO_VEA<U,&/1D2(]^9$A5Z,/0;S/3'VIYPCF<D3]682
M5]V8/9#Q2NYG'>'&VE@RHNW>X]S*EK(7@DD&5H5+;2(EJ97?SA-#M O>YHP+
MOGN[TBNO<$SV3^+Z.2D^,!IJTS%N)LZ1;0I9;A@Y$ GJ+2Y)&'7/X$)HJ8B4
M8C6G5#M(C[F\C_>=KT.T$:,=T@3A@PHS][)\]UT#@BDSE:[_2=J'>=O!=+;M
MY2G??: ;(^008_YK+THYR-,YLF3@8%Y?_]/"Z_/_>.L\>_ Y5DW!V%]$1S7*
M-7,^>D[OH,/X.>2)II3HJ$7CX>UC"<YB:=+^-F*.VQ5J(0$E@@WO]O8.*I9^
MI]\TI/W&>&:)]6+W4><W>\1@)E%+AQ#I!$:X$4<V^A6B\=X0Y-8_@8>,S+@^
M7C_(M CGQR$]J)?U8Y?X"(X)*_9&,VLU3P_DH S23CC?%AY40$)UCKT&%7W(
MUYQ;87L )[DUW/&OT76.B;;PH%N9*::=)M;#%GWEI\Y9'&ZZ%A&S6V;57^)/
MCO=A*_FB^W%JSK&;L'W<[T]O(^$ M0U9O[Z55HT &A!7OD+MBHO9:P_Z&*7C
MC/V8IWJ#Q8-PEM>";V6ESK7P;WBL!XW=V?/'SL<D1[A?U&C5FFT63/X/;4I^
M11 G!PY[#_4CA&Q%@E04.\#DQ6JA)<-?V*\-+U^^/W7<YWFJO>F$3=T_?@[Z
M3\K4X3KU[-IH_\#GLR[ERS+9*(Q-@.7CPGUO]HK'5I7'[J+&N7.0M%I1K(N+
MJV1WVX[\!_[RFM8';2?W)#M;JN^%[40=U-[V[RQB[\!#>-+5^Z^,='"@R\B6
MWPCR\/%6O9Y(!4YT>1MX:U9>BIC8Q#)0*FQZG,#7H&PP>4=$-W]/ONRIO\Z0
M^#%%-!AQE.5C& AJ0"8;CN^&'N4ZK]6CL- :SB4\!0G>8*YF=41D#<6J/\+G
MLQ7.-29<?:2&760G5F'^M )>#6FN=12H)="/R$##2$KX6>3.#B1 3_>D*<F:
MJUAFC$R\;2\X6C"8'<&OY'<O-JC49#M"=U[VE=/'S-D4B!.<X@G_*</Z\(0;
MV2?QKPF-Z!7^Q6&C@5,NI=\51M,B !'?@9@PVD&MD[E'MRUSZ1IA#R3&KU_,
MJKJ;=T(GT!WI#54?!Y6AWI=O:R6%-]CFN#+ MEGHQ>MC,WNREQ9$)I[D>768
ME3H0 GD3!:JW7^W)F#\C-O[BHOS%"&1IL3(#$V^C2A2D&0DMM9UI?SC<IA"1
M=E6PE,=>X0^/+@XY>AM9""$03S2-!,(9^QVYB>0+ *BYEDM+QYQMY8V.X5#5
M..=<C[;V:4R1GU7UCR);35)K3J!GS,B3)'=%-W>!7WKLPYQH4(^]CR/3R71<
M%682#S%6BUKN7BLZU3O;W)F+MCDAN<?^IIMZ8LWK+LOSL$]"ORH@ @*YBSAC
MTD&<#'B8[<'Q80ST 2G%",;DU^0.V?*!QXZURXR9]"-G:A5Q)QYX_9/#IUN4
MXB*>PR=TU?-7W__WJ1__^_KOZ__UR\.BURC)=Q>(HJ:?HJ-Z"5)>W]I$4P,V
M;M54/C^FEC K+:_?RSLDZJP*<]Y&"N'>)E/KD VC'"FU?IX&&,:8C1Z6]1W#
M:(;I'9T^.F#>7*[SJO,V?)B.M#D?>UU0K2)?6!8-M_I%_;B':9ORU>#L38F$
MO5*ZKCJC--?EE1@?>RE/G?=2;F@D!#ENR"OG]'B"PVQ1[%=67=O8X\D( Z%!
M:V#WMTC15Y=O-;]]L:.L5?"GR8-+'E?)%OD9#L:%L+_;4OYX\@05(7<DS,1P
MI!!4@:1F<AI%-!0GS;2C43*;40(<%X9_VAISJ3"]=.#*\*=6A^3<+^JQ2]K;
M[]96//\_"L$.29Z0'3O4!]^-;K0?[5-6[/Y.1RE\_SM,2+"5PUJ_G5W8P]3@
M%+OFW5>-E;QY*2MV5XJ.\0@?"[X=M7@025O(#6=&GQ@CTU03'>]P7"-*[-45
ML.WB_%??Z8^L96$63ELW[NAWMC3E(]KC0X$N0X#:L:#*)0%AZ9&L2.;7KB*+
M[@4XTR&]\CL%9N.^H_<92B;XULWJ:Q<L[UGJ:NKQN]3#9O<46"HZ;Z!  Q1'
M2HMNQ)%49"F\1UX&[A+@OP#)$!F2QL2-US>*;GJ=G)]:/GDW.3FOP3H\TQOV
M=R3ESQ!/T)X=Z;R5:YJ;R-%CHT)L98B,35@21JMS H>FM0=<-RTZ.?[%23,.
M_M/PB/IMBSW^9W^B3;865B$20#JPM?.8^I@L %R P'03MJO)"*(5W<'/@YC8
M[V<FGST"_ S+GROZ.)7\N*]]?V#'^W:TI9L\O_QK@:6#TC^V)HR_\X3N,#9X
M@F0J8;>W44]8(%VKEYS4-LK:.E+P[H+">>*":N?@SC\L8JZ0O!I<<T!U\+;:
MI<575R#E2 $MAUP9/W'N!)X@EVTY'SS6QWIAJ^2-96WP)-3DY,WIWX98:N8'
M7@_FOE.YQ_?WH#VNA*T,=)W&\;&OXKOP1MQ:O#PHP^[A[6$8%-<'+R(2>>KJ
MYX*LOA!")US\+/E<=/[LNEIQE*R;(2\["%4TCL XBX%O;28@*6%S'9A0G7^1
M!2 ]=_<5P9U!*KJF=CBJ[.BA6-[<L,9@@J;.3A^_4/4[)D(P[K:G)#=N!9GZ
MN/@@"/G1'2;<0N!"I\"K0GM6,K,;+D%JKO9UUFZ;R'CHQ[K/N5TEMGY%\:K-
MC>K.<-8TD] -@#HW<]G2N*L,5F8@#9UB"\\]#>K1*Z7R+3%FUGQ%/HX=%#6]
M$37LVI,;9][W>NT*A&7!2[_]/XFDKQT%YE)YPA#)W1W(=@-+6*&;L 2(J\7G
M\L3)]4#O=YYD9CVW9%7FQ#G@!7MWN_D?MNV?D8_,1W M:-P0R,N0:/RIL0G;
M:.G0_>B2<Z)2UUUWUBT,>=.G&F'W*Q0>3U+]<D;W3(>Y<&&14_\U_'A.QZ7<
MXR-/+R]5*Z#:D&>V"O A\E\%$'D %0#]/PN X4F@6C9A_RI!2PQAA75J?JL$
M/AM1BK9@_\K/-,2[E%]7+1,D34J7:67#4JN-WM_^ELTCC'K/[B^^^LS\P+&I
M@L87VB_*AN6CJYN*:#H&]%^=O^;./TVIKOINY9EX(YHL%C*;9G[3W'S\K._\
M1R>) WOM]=?>8H6D))R_[;BI(AB0PEF 2- _T B(Z/"!NE&:6\YQ9EC3R5W"
M\.W!MS82#'%HAI%;1A1N70*\1?%LG_#/][]'/:ZRP_K$[J0OH6&PZ261_QUR
M/=^0&=ZUH#8J$QI@]Y%U"?5L+XXI0R63[NKI.MTTM^M7YY;ICG^YIFALO"_T
MSNLO'9IL%F0<<?D=.J4NBR(A/,%3C!!T?0/1PD(!XO(ZH:2V= =Z5E3N/A/Q
M1R)5SM1M3MOY?SU-^>/"N@25/NL[F7$"#FK&;,)6*]GB.&4K0@;:X?V%<9(B
M-M<MA1^1%!:I,Q'X,C!E7\*A^*/>^_RRY>+5*[@[&&KGP'HZ(59%E&DQ0."?
M!0,'%#+OKACB_&GMBKTOXXY.^LXK+$]9NLU?<OIBHAIQ<[>4V%M1)P%/>VDJ
M0HJ,&=W%V4IB<)=C!'UBX;#+%FT;O9E"RPM[K#9ALWX9$\>;&C*.R&*,]&N8
M>7/Q[J?:PQ'YMP_R_K5S7>\S .H35S<6R:!FXHI6#7X*(<(1*<6FNH\W#QOV
M&QCYY)PFWFAK=Y)/3H[SMY.P7-;F7_Y7HBV]+H!:BFCI*U]18YO,<]S'<88V
MSHL&X6<:&:,]" %!<W(2SAG0RO6[M$MUU>B!TA:$[_H*XVQ _;NU7)"+GT?4
M=6["5B88=M31+B 1;P.6,-O=6L?,7&*.K"WWN+AZ[ I-9NOLE\F0R:<?BZKI
MU:TY'GX( ;BA"\@RY*VL!><V81^F::P2M@-^FL(X2DZ\5="#$7$P[+APC?&=
M?O'-B^"I/;=SEBYF?_[IL2]23/:V8(#][N^_$E>EV9Z\>;0$"88SX#Y!4G,H
M?!TB3 LG)BNMK8^-9?<:E#UTD5^E%HYE"<J:6#Q0O:&^HI,"^SN8PHEC$#G2
MBSSASXN(.60OI<X\$=*+OT&E39B$C09-SL:E.GATL?TN,1/U@/9/Q*/1^CD+
M<<[C3Y?^>D)M2V&<S@1U/%<$H7NF.[E5R)#1&12-E,J4QNM]  %71DLZ76>]
M:>E&]'V_N9OC WO\"2.RPHTWS9\^@BI>*N69B?^X"2,B5R"(W+[.+38#9E&L
M7.;5B::P U$>,F(7UB-2I[;W^0>+JPY99UTUD3Z]O_6TPX7/F[!ZSX%U4*=V
M%<G>BR4L;L+Z1F<V7A&$;;QJEZ9E 8$.X2INRS)6S;C=V[P%]R%%7C!);E&\
MS= KMOY'%O]W!;T>,K4(:*FYP\;A!_]J#3Q$PDEQ-67#_>F+9,&1/P][%E0;
M <V_W<=^_C@J>/*JMT5ZDF*][^)_40YZR*;S]F"!5\@9RESC"F^<[!-4AU^[
MU;JU#_W-AO1H:A^M[D"49Z^K@] TYI^:%;*LG[?I9;JN[HV2J(,Y%D%/4[Z9
M_&M^3N^G)^L.-+8VOB-V0&9?Y8&NKR9T*^O^I'[)7$3 L6J0%_QC6":QI*(Y
M56UDJ%\]+3#XH^"U?5:=ADWKC\-">K\J_O<)/SVU =[>EXS$V[_),K,^I0U+
MM^R'/[HY'9\.H@<*71L1/.OYV6(E&!K19R'@N$W&H&>^VG.? X%&H%;FJV&[
M;BO.]+5@XJW$S,"FO-F%+R[!X5*Y"6>=)>\4/P[LA.%?NJ%WX7N0# ]R)D*,
M'*9' 36G.5(HEGTF]6O_3D8/-K'[>A!/W=73D6E;7-7M0,QS<'NOGB8;'JMZ
MWS@]]\(O -1 _<MXM07B>?NQB0/%.\=-=6SE.0!3X+;IAU_)&OX=31.+S4%K
M_C_EZ!YLNRO"=_\X[(#%N/U?+OU H$(L6&73$!\\%FDR>70$[+*M:B?8P\RU
M V.>EN6]O=KG;_O$MK^]:$[KTK7$\RFE[3O./M9XST_Y5JL*9C(%6-UCF[!0
MHT0D'*_(V3%N!L2U]>=6N# 1 ],*[XU]@RRN=:_Z[S8?MGIC,JS]3X!3J9!<
MCJ=\+?H_8VG^H'E"86P\=ITEQY1=^5."U7HUZ]!$D",A@WQADQ3W''=SF8*U
MP8U]?RX%N,^]"JU]7EL!,4I2&+=I$Q:&D><H@4Q&-,N:6VR#+/F.EN09@.F4
MP:EQ+_U?\-TS?.:5E6?531Q6/)#SA^5O2+BJ*B8YG/HYL-KWG["4!D+4](XL
M1Q)@"7#S><K8]5-(H?/,T@W;_<SML]%5#FL^4:</9)^XNU<?WA%I40;#IXUM
MG>PH 5!KR Q/U <+1R(X"CU,'WJ8U[=].,T4EIR-ZR(ZWM<ZT^TEX]?U _8O
M"\=F9O_Y>&CDVX0^7Y:Q.R8<^F\=1*"TN$EDZH/Z_]C/'I".Z%DXV/!^S=3+
MQF8V[:>P'EOY<,$E:K_[G_0>O@%?>UC,0WM\I"/;;FOVZ9ET.X*!&IT9N32+
M&,RD^X^W9[0?#GBE]0PEO41AN,!!74P2$@,7X[AP"7@D;]0"$,2;X90F'S<P
MU^^43WK\A1M>_2+<'G+77<*!YW.5'Z9@+OI];S,L)M$>'XV[MK4M#_\>D"=?
M7I?A]0(,)\S,?F>PC(Y(]-0+9AK1T>F_IR8X!K3V<2_7;&.Z2VM>WF2^N8>(
MTAVW;FLCC<5U4'>#([T?4AXUWVRW=GNV\OK1HH[=!A@OXOAO9 J!OYD]=!]G
M9+K:8&D49B3\EBE#;5OA?UIP/?NEP%*S]$^ (Q7(&F%25@XR(GL0S9F)'.-2
M,)66D4>OE.,96MGK$Z=45#HNP"9#O77,R3-?\@75T[,YK[T&F_PC/<<4CE<^
M"YD]U]+Z]++8N1G?N5)6P<WQQ(R@(CNU$E'YHUF'E<2"MO7]%\!*)8;MSGOG
MC5RI9%MCB:PDID!B342(D6"P0<RU<J_!%P;=">ZS51_Y?T;6CF# E"$6?A-6
MXL8LX(E6([O)IR.*9!V9,@7FR701S=F_@Y_-SWHM'&KHT_UKLF]/8KWTT":L
MQQH_2OEUA .IK?B^\DV88BW:L/?3+QVSU)ZV'%*Z:_]0<_;BEP-GOW2>9F#O
M'C>?/*!S;J,=60R NF2.C!V=R)$*/]W,<$S\%4(0X)A/* <0&2])/_W?&SIR
M.N;;[HIZ@FK\ER/^W%^KS<&K<(XPR=V XA(@@5?$/OUI/]WDT]L^WGS.UD]I
M:D+GM;_:#U7&8=5806GN5MR5)Y*: @A 5H9.2*>OWUZ0>L=!,"WL6OQ*/RZQ
MW&:]0XPS\ ,WU$Z8 +&A_H)=@SE;ZZ22_+Q=4<QV5ATX_QRJGC/6SHOA>9LC
M7=5)2,'/\1^.?#[?2SEXM\5Q M>C6^$P[I6 //FF<0V1X:)SZNBC/<S#R[\W
M8>.M[=ROGRT7#O>>&J%76)P,QZ],I:*X6@7$800*)P>![PN.=3G.=+R)DHEL
MM*U^#M;,SER<;$:*+M?9!T?O97[5/VEXT>#],R>! P=>J4RP=8&N?N0.\N7:
M62U(@I(A)QZ(D JV(!E,YO=3W#HFPXKU;NH.M^8Y./V)]IRSE>;F OY;!X)=
M&>BVE8&@13JP/+CE#28P#)$0EI1A)L>O'U__^Z*SEGJ.LUEC"0<.&M#F3RIC
M>B#M9F/D%QW*7EU;X2##I.HM*MH>Z\9TU8X:6R:*N)]B82TUUP-'5@B.&,.!
M;Q]"VY-?'(@^=NE27DUG8?LY=PZ;,_*4C"!3VR@MF2M=U5M[V\D!J ]QK$?@
M:!GV%*V@9_4\S@TLBWSQ0$4XM3WB7A!+-+M2)@#[V3#^?-_-Z@^!K)WD@Y O
MS",S4)1T-582MY2,,0*UR:_"]J.8Z_WPI%39NSC+FG/!LSU!/-GZ)(U8P;"R
M8O4 QS/S=H%<$4'^ [4/;!__B6:Y;RV;\/I(T$B(RX@HX.8 06&2?8 (.00A
M,.M(WS$>/V97!H[W7?*Y/J2K\Y99HJVJ_!/]:#'L%H(CI49S[*7,$GBB^\ H
MML8,?LSV  -]&V?'UC?[FEEE(T\7# V<U+\X]5L@Y%(V:DW!ZVFSL\8A]7WZ
MV0E\P]&!'%DUGF ,'3Y+9%DV3@(7*'?_:CY@UM)JTV^093AF#QT3AHX51@\%
M=W<@@[(&%. &L^X+7<?RF9<RFF4A_1R GM.C(S@RC30+CI0L'?.*GU8K8L]6
M<Z21%>J9*D5(ED7RY_=7#)]-'+&[_N.8V%%CF\N,[$R")8S_TP.H\8HATLI'
MIK;<!!A'@9EI5@W82$/<1DN1! <6"2K@\=$!"Y-Y)]8T\>9P2'"T<=2J1&2L
MI%Y_MV/ZY[26\8<Q@2PD:%&^%20%/8Q40*FCO$(FXXT*J!N0.@F89O9-Q]N<
MHH<4'5?6\XASS_DP>F6BT>J+=>0;]?R?'R2..,A^,U+"OR8TF4.N08 ?W,]:
MF""I_"$(_R+,%"]V%R8F;\*:JP7R*EMJ(ZZV4 ),4A/>GE2+BMV/&$Z?V<[?
M3VE K IL9<IZ11+GMJR05 3Q,DN$1N6!^&:XI++'NUV_;TX9UNRHG4DC!X7V
M[+6XKV;,^3"?90_#E6T=$,--L3& '-H[T(YN!.ILK/YFHNFVE<^QB_W>30AA
MW'X:1842+&.[?=S T'MA/FQO4[;L*M_B]1%V7DNE26-C8SBA#KTJPH9<6I>5
MS99*UV&6]ZVG>V_T(<5P8E/Z%QFD^D7AC9?1B\KI'V^%C^R_/2+RY-$SX;KK
MSGYMG5HL'88C1ZJ2)YA=@NUA8;=$#F^8(DJ^C+CM79L>H8RB1:;<(*3]Q6=;
MQ/$F-)>:OC.UL\ZIFX0GF7S5[XW3*I E0&]&D/T)25 S<=",DZB9 58W,Z,@
MB@Y/0HL!- 032,+I27:F/ZN8FGZ*J4^^.JQ<VN"@YMFU5THDK1#V9YKJ"/$#
M<*] /S SYP*^86/_%61BZ8N?P&N/3;A/V^X-/H&=DL>I5;PM/M\\06ML8"-R
M+[]5X[/K[Y/K'TR[$[V>"3#<UF?]6 \A\SE[!7\06T WAYI76*L+*7-C5'@!
M.]CKXF?>-%68WMZ%'8H_[T\LY%,];U%W_=457=MR[B/>?J K$KA GBEPY":L
M ]3\6: O4QR4M,OL(?&#C4]PIR?"3 V.]N_BI.JE#D7GNR2EN:E?>+\2A2-3
M#=HR06V(TTSPA #V8:CL0G1N'D\-7$"F$Q#-".E@*U*G6?/(P[(YA^3GZNMA
MVW.X^9H9"V*RT;1/YWMW2Y_@^X)DN&^%E"X\9(M!]R,[MF(*Y<! ]CE<P$-6
M!ABYLZB:PD%U@HF16JSA"=^YO@C)6<E/CI>[@VU>JMF[NZ<KWEKSX 9P"9RH
M"MQI4(2:F?SWH_% -!VU:ZFM[-/5M+U#UT*4:J1N\CVB=QCQA%W85IQ+W&HD
MM8 L2PY$SVQT41A9V*$^!>E.TMV235B0SVS,,W=22U[!<&O.@5Q!Q4?MSQ>5
MG:17T8V(.(XCXR<K%(RFPN6"*7Z3OY#\2U;X%\%?U8OMWYI?<]2]<L2];KE'
MU^G :W5(5PGAYV]!UB$/V29M],,&Z\KT_3>T]6V@42]%7*,.\SO2*N[PP;+2
M*NLF$Q\!NP^- ';Z F2':O@Y 98A-!P]L0LH^/?Z#V YW0NU'>OK\/!"^GKV
MU#(NX]10H\LS4=OO?W"Q]M?1C-,'5= S[3QA>;;\5G:;9E-!VCG'TY-X*;";
MVR48:/@"8\1R"_A6,2TQXF(.^S& -'=TA81J+] 4N JAQXZGH#$33A_H/@/0
M'O%V@ Z;,)^)WR*.I^L+$6+8FN_B50[# <&L[J<+]E$73\^':8LDP\[#A]?G
M<EGC4#'1^"%RP_I*(A."4B;;!_3I(TALPB[5BBTQH*]@L?G#%LFFT<^G#EZQ
M>2.T^^/1W6F"<C[)S-B053AHN0FC&\7Q]@%=\!62/N?@E-K[&W!)D-CMW9(,
MR,ZW-KW,"T@XO/)Z&5!@4Q:U5MS9QC@,Z$C/C//5!W5H2;]&I4'\3R=R_F@/
M:VQ8R5.LXQCSY;&2Y]?=$W5?B;^N?0-( UW[D=1JWZTX$< 08L$+-MSBXR\6
M*8D$68,]#/4Q<-3AQ^]UX1[L%;4V+U^&OBWZ@:[^?JFL?^INE\;"!"8HC.-_
MSG.3D-1Z=+/1BG#%VWP5&3!/F=B_GB@^V'W@]+FZEJF\\!^W#?.V/5]2;CTP
M@!H%9F]-+;+N,F3OD*DO9G^)CO/>0>B $"J/_?+ R9^1D"Q3]BS83N">OE]K
M]NU788,??]>^@X,'X#S!/^Q0_+@G>O<F+!@.:GZYLX/2AQ3U!N.ZVNBD^A"_
M]IY;:P_-JGM7-=[65RH&6)>X:TRN6534'X=$09<+DGH?*1LQ^H'-.L+-VX3Y
MH1,6>\T1_*0#H)';U "KK"@[SG["P/#"2S*F:5@N;\BJ7=W_4T!65O6;QZ(^
M=-W#BVC0VO.5MV-OF4<+(W.E.>(Y!TE\B5#M+&0MRW]-4['ID2HX>B:\19P[
M^W>.)R3 #N?X<U/GNET8N2P8^(0YQ),X#' ?XQ5G]<D?R(%LV]$F_^,VZP=9
MP+1 K=F6%(%*N9]GS'MO:PU>8X?Q>LA2IJ/;\>\H.PTU@5W+MSX>F[W27OYV
M%^%HYP=A_2L*AZKX8*XF63:C)D@3#*A=P%'2DLFP529SQ.+L<_M]<+GT#SRK
MX+A#1@-_#]WF,1PI@Q:*S/[P/I@K6QE/H4!2/<SH-J%%-AZ/P'<K)+XB2&.U
M[,D$^O'<JN#\?.+LL^KG9RZ;V&P<F9<N7C1?.?=YB+ O'"V$?[L):QCMH\2A
M&8Z8F1">\ 6VZ#<'= IYNZGR>2R[9^I5!3C119DK3.YHOJ]MO2#W-D/48M=0
MW5#/+D0,T(7<FA@D-V_"7AG% <U:_9C9D@&\+%.V'SU[>3!ZU:?'5XBX+_B6
MZ[B7;Q\F9/?&;M*%@/;9MQ].?["-LLQBPSGB JQ+X#!;#>C2)4GRAA%-!7<*
M#C$3$TV'CXH =C%'9AF' B:-M.Q-YIS537:FG,;D?<!].*!ZFP^B79NP60)-
M=K46LFJ(G\0&\MXCM_T> VBULF#D #'_6&]4RR@WR\,G^+:Z_MC16LF:XRKF
ML.PXWR<0\%A>CD1 ),R/DH!H02=\G ,3J>4#ZR+87)>.S$1C>?78D.O1 UH/
M5'Y_ZX+9>,;CC*$7B/,FT UPCNP0K7R ,C/:(_(</_37H;46+)QZ'S)US9'Z
M</64\\N6MH:,*:_\*+6HQ>8/%](G_8(F6],_L"D<);L2%[9+,+*1P)'TZ7YM
M:#::CE8V7?JM=UH^R,:ZM'_#JFB&O^DH@V@C)A?Q&#[V]]\]9I6SP*SE* $,
M5)>OR21',8)M@7T6=2/].'W0N62R.O;UF-/K,]L.;*\)^970&I)YA[Q][6MT
M96W<@DR^U]F.'&<:.R#PXG5G#4OUC9K=,4K=#9F3EY_[1 \4?IVXNH!,N+K_
M^<\TI7K!LL$2MXG/MQ98QS<FQ@=^%K !_(25[&HJA(9$5@9C.L'P5XB1.#?N
M]03FF9=&X@I+AE4>KB5@P'<AXZW>@-XR&C2PO?,$Z\<3\F/JV3&F4H/+O0YS
MTS]Y?9C3-W9L=ZCW:Q:#F?3FWGFC/CWD#K;X*62_U=/-^'$R;V$Z,O+F4CC[
MY]W+%T*N]N_$!ATX=2/X0!\I4.ZE8[[![V O=,W7>MXK9-/(7<@HIG@2W)(.
M%UIJ9\!0#P'S\]><?+YE -O^;M_SV=%7/<?EOC84<G4V84D/2#N!L09LXR9L
M)XM,0^\&NF1,182W]E6<0B2T(9)O^+@Z# *K!-N1OS,!*:YM9C]%7E/C$F!I
M&;MVDJ,W8;0C' C$GAK1D!PM P!,81M*]WQIOO['QBQBU\^#2J>;FR+('_'P
M1</@KON&6B6[*4;%>TM*9,H4&I[=BUKV-G>>?_:07-2F:"O$-%4Q8US)7M3S
M\8PU0!\C=F;([S)0&%)X>=+Q)/_%K9#]N$= Z+=-F#\2U)3I9+ /,]U;\NB8
MM-DT7X&QM35-[9:6@D-%#I]9L=T:C5Y^ 8B(&C4;!OR;?V>'3)9&=96@E)NJ
MTV+ZD0IM.1C?.[Y9TDYPB0W'CR%:!"!Y\ JA3++B["4B&K^^JDV,S $UOYYZ
MOW+E,5,@Q:A;?21TRJ/0+,/BF.F8ZD_3W[IGK JYTN<,4)]3,D3#^KS0]I_P
M6/P"@DCD2$RSO-XA_3)G^7F"<VQW,+JO6(];$!&-%%F>E<G$7!-9(-.L4R_L
M+'OY1J+2J4^Y#B42K??#$1D,8>8;@C1O[V5TO<7*ST7R#'+18"KN!;:6=9\1
MR=F[H#=6HSATHZW^_:66!_?$M.+K$^P4/RMI;U=@GV)E<..!@,Q9)%4VC<<'
MIM+@":&A'#_:P_F]/FPCN(\Z*P#K;5:L>7K'I?3[5ED.\COP%X(I#!0"U)/=
M6M[(138&KL0P"UC7C1:!VQ#)/7XG6KURT57E= ?#MYB88&"O+OOP9C=1)[1.
MZ?C)[7OWYR8<SH:0YPH$#%'+2,91KAJU8!7-%L!/05P42,4;@M.EH&R?RCXF
M)L,P(KOVV8NP2-+RCP7J_4L1.;"Y;?J I?7UYYXE6_-E^&Z\(O3M@'/>VOL>
M!LR<8MT&ZY'I'79L!S"RBRQ>VX%F[OQY&BT7_#?EH]E89X:']CG26P=Q-X%'
M3B=>W\6W0W=_WE(W%JO)C$1JXEU(BQLEDAG9:- .:CMB"L=>@-5<5CYCFGI@
MW;YOY/L+/R]S^1+NK$PV$5=Q]2J9<18UH\A*X-;AI3C"C.F5)0:;)Z%'$8#(
MN30S,'D/;ZJIB:V2&:C\K;5U^'U]\O]Z,Q_3@B-MS=K@/N 9 EWG.<[LK=WC
M=D"(D0+.E$L@B8/6QU]V,FKO5#<3]@^HJ)*(Q';!://L[8T&51[3.O$:.\$?
MU?FA6T$# /XCI0&^L@G;:EG0CVT*=$&RZ3):&=R@6O0;&)V:@+3')JS?O)"3
MA37R)A*#5]9#-:?"%N\9](_JC)T;D-B?R\XBN_,FT0VCJV-L!-"%,@- W<@5
M$88C"B27<(XR_ F))!.<=D%O7;#"O1ROJN"0%Q\^GKTH>RE!>]'88OCN5?ZH
M)T]7D $HB$Y=0%X&YDX= U>9ZS0[_ B%WT;C\=FY\N[V=.#8U.],Q<LG*W5'
MPTUW=8_L2MY=4:NXE@0O\K]X&Z&*G]N$-9%7]2!,6<._)QU W<WRQ1T&?=C'
MO.9]<0C&>I+-$27L_@&A=[V,W&O:<\^RKRG=/>S69"^G\WD_^1N&(U'+4F6.
MKMBS]P\\P86#]978=7IYFA&E%R%EXU6Q?/UC:I$W4.QDL/'(,4R4GE0A94S1
MG#211N@&(1A.E!0"XS20B50 +AN!^EJ0?K .KOI&M-T%2C(FV#<'>:B=WQ+A
MW.8O,\.F_&[YKC6[;FH/[:V[9*S+5=S*)\W8X$@ITK16UJ/8^Z"N/,R1\)\D
MR2^G/\4:T2]9?2[ZZ&OQKD2_I2!,Z51GKV1IT',Z37SFV#$7RP*8"@12 E>!
M03D<I&[\:NYLPLIB'S"-Z*,<Y9.;L-T8&AC!UN6]%;N,*3>9.1N,U^HL7C,Y
M07OBTIY$-<D0^E/Z[-I+\<)?D$XZ4,*RXI:0KXR"FHY)R,#:&4_:-$?#=E\G
MTS8[,J04")GYL)X@G/6#^##*U$VD<D0X-IK_K!*:B.(H78L*,(W9S]OE1E,V
MI-%^K/XV.,5*&M,B$F->>JFGR,=G/%[4+95\)SYUVX:?90*F,UQZD(Q0XJHX
MXRLKYF&_KS)S$]:#$<$V3- GB2EG?$(\; WW=12<DA2^('E39F^I296UST;2
MIV^<D^!GM@/G&O<ADOJ0P'!9OXM0YCA3'P!!F?%_?<N8R($VF<=CWUU+EDC*
M3>VMQ-BEAK&AJ^0@ Z.%>07^5I5_,$Z@V5;"&VX5?FOM7@L9 A?@.+XW!13P
M8^BF3_@]3(&DIDV8Z+D!3'E->?1NDFN\Y-G[)3!G_:IQRW]$C$\<?7RSD?F0
M)YC,#O;!#U#J+2!FTGYX+ P(JIVQ>#5K7S9P!V=7>22_\)-1R:S7<IO=N=Y5
MB=?'1!2.(@9[AA(5\Y[SCY"IS\AU(UNQZ2;@CJT9%E<(#Q^2)3D [?MZ8K'F
MN"?=(O;WN@IZN0V5_JNR_76U1L:R8JNZL'%.4%*V>?SNE8H:\0(UU@SW+C)@
M=%:/)VH([O&GZW3X<_.8:-K.1KKKC26>Y?NJ+S]IL?9Q*^N[EZ>R5U(.CAUQ
MEUO3%[R(*L%/;\+@2&H%A>&#% 0C689@*WL[>87&2%GL;5$H[Z-(0TI?DU"%
MOGQSJJ&JQW7B2<.G_&SW^)%MG\4^'\G#?]U:[K#FS9-%R-0R-!^96H*HVUA)
M#V06]M V87<B"$+?2=M3!V2\MS/*!E\F^!>O2.VRF=AP'UVK<[?;"4-H\.8H
MQ(&50/9QJ/8^MH:\D:UD&L L94!E!RC/\-83072116SD,;55MH93&JEO.TGO
M-<;"/F4ER<F-*2_2%HVSDWM8"(8S>>XAZP:(@= KM(&;M#7K16D62.=IXJ$'
M2G0(1#T/_@M/7S5[RMO)%,D9LNX*MJW='J[H'/;$KU'?XK5@:/GP.E(<PF[4
MOZ8:!GA"EDP$ZP\WB1P0 J1!;61KNU1XEBQE*]M%'W)5\WK7_% [S6UA=N@Z
M[L'B!?6[V6<:;<:O5B3]7@;J [;4[A7N4R!4V9-5P*WND$>\(L<51B8@&SA:
M#..(:J37>[/4+]>'*RCS78I1<A[GZQV^8=.DN_<?Y?N!YDAZLJP9!(YL.:TV
M#4DM)3!.8)(W86)F;+0TN.Y1#WI2STD.6/P]GD?E*DRA-?FWF^<XMGV]&C;"
MC@OU\ \(,!N$FM(?\%^?K6190[PEQE8+MY/[E!PL"Y8%EG+.CF?V&(E?#G<Q
MKQ9(?'@J;B6_,'[\^<^OF2(_TV[+J5J['6*A9L)IF1RI==ZNIPN6W#P\'_Y5
M.MN.HSB)"P3HB+L*7Q-(>X+_FK'N*B\*A.GR%!<JTDRTTJ0_/RRB'_B#G)/D
M"4)><4<8MQQ)S4)*VT@S"6X/!PB*)#V.]P3'W8\Q,M'O\=6%<3Q/^=?UFMS
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MPI_A-!A]DYR<&=R>]Y^R5;H7W8G^X@];U0[KO3%ZVVHB+M]XQH_[/</I2WI
M@OV-B!U>QP\+/-G9T<,:X6;Q1""H;W1,@7109L9?K3F;@_1.L^I/^68J,6G4
MM=BUG:JKA?+;G!*?>6Z75D<4(:G)OEOQ*CF\8:@<S80//3PA?L:OA0\X$[(5
MIIN2:KZPI[XUM<]*8K^Z^)OMD?"([=E[:WI,@^\_$"=ADZ_"H1K'!EV.1.Q$
M4EL)1.1*24DK6C3$ B\/)I9[&PEB .""_/M+_,^6RHJ$57A'IY>4\5>!+D13
M\/]H[SNCFFK;-:.H((@(@DB-%"E*4420(K$!(F)$I)>(="&@(!(E9BM(;PJO
MH/!"5$!$@2A5*0D=I1@I4D))4U2D[%CBUB2;D[QS9LTZY\^<F;/6K/GQ_7A"
MUB*P=Y[G+M=U[[L H0"DCUD26H'U.^J==9-;[=FS5LR5!./32".N]-IA;)21
MENY*CW9:I&M?OV?@#_8/PO^>YG\GI@'U?AG@:(\,,WYELZ_/Z]ME)1%GGFSW
M']W0IOQT]O,U0SX]E#R\%'P[4S%_UH.]8'M5:5S%O.?<;Q/:0I9CQ2#K<77U
M>^+U_587%2Z>#?]^OK+Y3N.;;U_G/N4"74&X$/C6P"J"+W'B&R63KF!DLQM7
MO#^H(3[<*G2=6_Y;9OJOX -L;?C&-?>7\+MK]&0R$EH;_&(XPN7TF$-C[>X+
M-_.T/MV^Q-]-'ZO&4S!#<SKS,PZWGM1&1%JX.^F_L2M,(DXY/6OBCT\S"<2G
M%_.E=I$4<[J8L^95+M'1E"NDIO _)4S&"FU^U![LR<]C&4O/^LYY']+,G]<?
MVW@%W/[I;[;2KR$A4_P/=RIT\NK&HWA=-B]H ON@ $W1I'WVL5,*F"%X6JCZ
MO\C[['0=O8J0H"0#GWV?KR+:CXGZ%*NO'SPPD1Z=C;<)V6[I=+CW;("^=D'S
M='/;A'OUJ+611E>@A8UY?HWL&_2<DU,Y^>FLX71#)CVY!%4'%3 O<VRSB8;U
M4?MZ->_>M'"9T'R.ND"DJ71@:C&+TVPB+8"E_2!T;@/8-E]W%7E/H>*;9HC'
M%B+[3F=O:8ME]L]9+T_/R:/<>)7C#W,LIN3][0@)9%6AF*T0^BD-?4N?0'/F
MRJ(KSPK2#..KL(EIS0'X",[):Q_O/AG&FX=;1[^VKIQWB%3[H+^K2E]CZ.&F
M#3]UN3/2UKZJ:@?.!U<X:Y=K5Y7]:;E,"6!<DBNU_'97[UM/F\)*$$V [C>^
M1:\7@@M=EG#KMI#8QETY-$?N>_ N:4F1T]5-HW0/G;=@M?!LB6FYGZD57FG'
MCMDIG3MV($)W.ECACR_HPN6W"5J%%GDZ1YTP-EZR,Q^UG4:@JN\>;?6,#;L8
M4#+A]WRXYE'AN?[#666!CF4=_56?8PIYP''!?2#$4-RAX5U]S@WRYH21_MD=
M#3?Q^\-3V;:23TWNMR,D^>.@.'^KBQ!(WL=?X@$$X>&NA\5K'H+F[%]=;8 W
M=#0^G&5H(A'!=P'*!]8UGYEVB,[UKJKUN7>K)D'!<7OTPL8^YS0AXMLLO+V"
M?$ 58"3* AUV!"O"V"I"L0'(LI1I#Z=LPR&[\^E;HK#5?(MM]_VU:=>+&^I/
M:4GZ-Z0Z[=Z0[[ SWY=Y3[;!F+^5[2P@ 8RT. KH2J%%<9]##37XZRF,DH=L
MDC2N#LT9&DJJN<7==F:&YN4UY?U7@FE@4^9)WLD<[=K72I[)-G/089XF_&Y.
M48A_"-Y<C0D"\BI27F:1^A3G LOF+(7;K2+26FFV/:U7Z&&>3A239M+]^:L!
M%@8(G2(P@WM,\%"4C[CA#V7Q< W_X#<;/>14D2OX .SC-I0"W2RL)FO.*JJ^
MZC']?J#M=VNJ0<C.&^O>B0L->M,$7R&&-4X40OIV00I?@2/#S1\G*P_Q'$*Y
MT7@_J(4YO3NM(5Q-N7=\@'?"V[4AZZ-C44IS5E/WK83M"(5L:Q5NIJ 6Q<A#
M/2<EFR)I*;!$!2\"[U+ HB;Q#_OK4!CH+4?94L7[6#KWON_RFZ9GN;WS+BM2
M*I?;;:<8OHC9T^N^1%(#.O0H6*D5D7.+8U$2+2.S'A)&,+5)Y=D/RR'W;J^_
M33P6CG7)7\N^8SC4FJ7\^Y'$C3L8_\F!MKC?:9/XHY"0A*V?%S26@Y1VZBW*
M"R$*J\TTK*'-"'_5PD(B0\D[XG?K%5T>IV'+''1IVK<3MMD[W4)4/[<!UXAZ
M&5Y%*5 "B*HX,5BJ@[<7*G G'@7+[V;E]!FG;%U84JM(Y1M>X]@U[3VRK.G]
MV<OCQHZ@U%MYJ2?(=+YL8N<J0AG KB"A'%C*G7<2JOFSEZ.C7T]/0&TV;.@M
M0H/$).9]EJ=VEFKWK]%:B[C>#X/$N+=[^^IXL7 OIB&$+T_D@J!,.RJ3OKE\
M& C,20Y&;H5*_GSU>9&+3KOV(]Z)7,)]=W*T+V1C!*58-5S#$]Q\[B(%1%,G
MZ=SG(G=#F+5!"8K)\GRS/(S@#KS#P3P=KU1I6S.EQ;<8+S>8L/1H+(Q]F?O6
MS:<B3S4]Z2%5A_E9;"DJB_[-SAJSBCA/?KB**!,RMSC^%EU84I$7CU\G*D;%
MHR ,: Y+_&*3,FR41U<:'C_GC&>P!Z14PKEYKLVYMA[!6<7XIBNI'[X%:%\,
MYWYEY6=5XG*8!:G\@Z7>5R<*_DA_;"NS>H]_XZ?HZO,"$7C;Y+C"-X"O(N#I
M\@%!&HIQER(#!*\B:/'M*# 3-WJ4,O[AO6G4DK<C72-R?WA+:DYQF,$+L\_E
M=K]]V%<V2^Q X"B+<?^$&8Y0L,;0+CA+>'88 1D5(FW%(*2 ]'9%/Q7A3<^A
MMG8\N^!NXGOUZ_[9F7?^AS;&7#2K[9W:NT9=H1@65=:*:C,,18&TCD,_ 1JI
M&UE/[P&0/I"8@Z#*&A/TD'\ G,A8KL^RXIUM:RVP+.Z;\M1^>:][_)*=4J.=
MYNTEG:,Y,^E0 2R1PM,DO*/7RMRDA#HAN6FBXDR)G]1LX ): 4<19>:%>_D*
MFNQ:T]]@:^JP!@D'YY50<3I3BE&#B5H[U(4JN\YW A5*6AM&;P06I1X0WM&2
M&REBA!T^7S#B?&^.^M)/)=-0HVHCY?=&Q:G[#HMUJ?SU^_#@S2,;UA".<J)N
MH1A)^1A)8VMCGB/0<0K>R8\0/-$=72YKA1+!OAZR[G@DT'AJ'K,(5;DNYDO\
M_?3!I:QG8X%K?GY*IC *B(VZF88 HTQ=@C(: )X6E.XOCTKRTR)Z->8;GD#6
M^O3VNC;F.V ?17_=FB:+":PZ8B9119S\_4_;5 FAW*B)P1OI8#R\45QH1Y/\
M#$?Y&LCD_4"&<#_5M&#9SX$>-E2=YG.UWXU(-=J_*_8B'/*/>+Y^>\@F&IK@
MA<"C% 448QBY%AY5UX5>U?CBCR;VC+N9X)Y<D#-<8M1Q3+G/34>29W=O]T_S
MO9>GL:[149E+FJ;#&U,>"<_-C,+(H]<#2_I,@ :PZ.DVNW DYL=;?J8<\]36
M2P9W?!9TS];EL[[-;7]OG1)FOJMX\(SQ;76/)K58X9X7"T4@5>CE-[P-HX!.
M7$%Q&E3W@&_/.^FGCMGV1=WW8PJ77R \.\>\N _KOSU&:;VN#9*8^CODQSY8
MRI9GA0\05(G<AM!1" EXU!2O0PB,X;T<NYOK&__]8;G@L6M;TW]Z6"Z_YG<#
M+P+H,*LABR(XJIK"NZB>A<=1BB14&%:\PT:=D\X_%(7T+3/[/N,0/!(&>I9*
M:-9G6]#TAL\B[SC*26FT"05>I)SX"S9BPA\.(I1Z?8P2+I/ACJF?*V(Z2?5^
M@V"DZDP75N']S'B.85+;K2#LTF*I8T&V7JGM#LU( _/=UT7_!2&X X1&95'
M(\517#/('^3QT"Q;>B=6W*X)_,1M*+-:J89[/MERTX*\+S6]R9LWP5KA=+4,
MA5>] ;\FUJ-Z5R -LP:>,G\/%"^HX.BL,,UNEGH+R:77B-JO\=Z^MQE+<OV-
M[*@\W<% VA7PE-VA TA(/[@Z@#/ Q0I*8%W">PSH+%1<XPYLP,FF<1OCL.;@
M-K.\9]#;L!^?'R>>JBO9.G]5TR[&8&_"8$Y+U85PQJP*^Q-_*_&?I)3;\, ?
M(2J1W<=-@,J-\MCH#*Z-#%1=/C<+I;.[+'NR%E]T).H\?QC\RG>Y7_9O?4EV
MV$EB%0J+GD1RAT 1(YH2YTZ YHL%C_FQHP1)O%%.E\U^R!A@24E=K3(N&;2+
MW6W7'!!N6JEE=-%C?D3SE?A@CC&W']+_]V>(-^%WE#KDDMPJXCFA&/S*_-6!
MSB[<UG0)7/C*VG8WCK5[P/15MG>UFYMG0'W"=HTF6?L+N:V+$YMZCB/T-OSJ
M1JX))X(>5,B@HC=G2H9=T).S/8RXAA),E_Z\9X@A(P'ELAUR>BSG*J.XQ'JZ
M8\2 P9W>9Z87;B9O.M[O?KF(5VW.]8>$![GN$#BQ),9SX"M!GY[@"KBX88+,
MW%=8 ;)G^U[YY=+ZCN\4IM)<7CWX,=VC_ZG"V&N?^@?$G^=J\=<%1:C(G$D7
M6#*&'07IZRY:\*QH_# PI3=G4UAS5$].<CZLUSC\TUO-'IUUKF&LZF-S]S[=
MOUJ\#)8-M5-4D[U1FU#!49!>%%\^AN7>0TW#@*>K9=P@0["HERYA!*M#1QF&
M.5GGWP=B&C9:KR*V8%1BN/Y7UF6^6//]AJN'S$ZO0S)O9:8&V$U\67MN*K0^
MB$.')47)W6;01"4\8F/8<-W%C>.6)I.YE)*P_''GHX81UO-:,T=5R=.;-@88
M5-=)N-I?Y83 DFJ\0_ 8 %Z@]U"0N#X6M^X)1&62>J11'2_XM@T\N^)XELJ!
M_==W>6-M:^7.7L76#*L^W]RSG3(XA'&!^U<1L@#C)1$\A9IJ.2E(7*8P[C4"
M*C6MXA7%6YE-/1AIO//HY=G=9T9+^SV+OH8_]EP:U'^Q'=]R%[%=:RARE$T5
MPE!84H9W#NB0;HWBJ1+&5Q'U?G>%D#F;;!+ZLW[,:T[E^KZ3KQ)/-[8UC6CA
M-)S>)35^RWQ;=?3M)X/T^C4+ .BUBI##98A*JFTI63:ZX%M*?,4%-XKT-F^L
M7>\79HDB76:P5F-31=YKBWF*C=#R/*/7Z78!6<2Z%?Y6>Q:IV]"^>\*2GMF*
M!;LZKOT<5#=H2PH:C<2N&VE^=&*;5>UW"Y[7S0.OUT *"YB&AD]\Q1184E?4
M3H=COVA\7?BF=P16"G>WD7'$*.*H'E!E^6Q/S4"HW.&@<N]C#+M?N9T9\U2]
M9(D/^!:S<=(1D?&$.Y&-E"P4HYCXXAM,Q6PPX+MRS+E1'.)-:Y=J_L$6SL[R
M.Q2L+EIVAF9_9?G<G.[9,QW]?\V]]DER0T0))8RRN"0\Z7%!,BJ8F&QCR)%7
MWSQ*W@:-C(6YPYK-+3ROPX]]KCI%?S\^%+UP2..#P932T$6@EK3(+@<ZKJ+"
M2#1=[BU!([P31W<1VBXJ>W,Y^(F)Z:3*0)V_[$<61T\='Z1E?@W1CC(<?!2*
MN10I95G\6NLLUS>>2Q TKB+"A.@A18@EKN-XW#,%[87VB60UJ(;.(MPQS[H\
M>[C5&(@/NB3=5HG[8-\Z-TAL3=!\@*+6B:L2$VRDA*;;%L6X36E ]U:'<-T%
MF:L(Y@.;C?Q(SFQ?=L1EJ@QN9,#^/7]GC:_,C]>!V6!2R=R1I[*E;[O33 [W
MWQ;R#29ET8H7#7<#M8I+4B"J@RA4').)SH)=D>1UN$\LO]*#LRM=LQ9L%-;[
MZZMV:57]O,CI]&Z7^(L]BM_1W$HTI!%U@Q*$D;] J9O@RQNSD=W&M((N=>F7
M[R-L=''&/7.[QI9)L0/>5^[-4"TWU"8,EQ\E._4'I.9O/I%/JJ&$"F'VBJBH
M1BBT:^"1)GJ]<3<&.L:_SLGQ'(XBJ^/%,<I%LRJ=A7X%IFC!WQ-ZA+=&D=W^
M9;B^OX+2S<^3 Q,.8M)$[<0\41?0DV+=@!"*WJ" QP$9F.I8@T>]?(>W)7VE
M;#%-'L$RPMW2XP^:C'3%#.WLW)"T\Z^R2U=;BM^*G18OAFET)?Y5WC&X&P.>
M6,E&RC=@FJ \(2.I#^ER%,2?UI.?G6U%M=V[>4-I1G$'PJ0/L7DW-Y*B*ZI8
M6_=9\ J/^:<5E!4L"W3>S*7WH-8*S;>5.U1>.L"ZKE>L<G)4_?BGYN]NGWNB
MS=;=UI;1OG5 Q7RM^%=I!"&2T'VMND_4%N9 $Y<,5;)T]P&=)=!5)G(-SC7H
MTV)CP7#CPVA%7DM-]<=(*]1XK2+L1D-Q0P#>O6K2S4)K2BV&KWJ?D]%)UCP<
M7DH8PTC4$[=")[YTR,XL%"I7%[_/5?^6>O+722NMQ!G)#ZA(XYM"5HA,Q(#>
MDQ2&$+R\T%U4"./D=>6 FC(;AM16NMNTCAQ?]H(=T]!_?+[JZSU3Y-?1\&]5
M=MDB"#?@:74D"*13 J(R;%2@Q*AUS0J_NGRCU?R-#NT5W*_2D=M&/??*8BES
M@JG86QS08TGG*Z' Y:\]N0/:+W -AHL?B%9957YZE&Q9:I"M*X;K&KX415,Y
M(>29*:)8Z2I"*E9F2KR77BO>19^*;R?OS>"A^N;VMT)YX2RG$T[Z;XT,ES2?
MW[XQTM=L4H,("L:8[.E)"1<J;Y:HXH)_G-/'EU44-12)!CIL" IO6"IT*323
MYR1F5^196Y<?[VUQ]W&)P_+'Y*U:^!$+ RFK%V)_GQ8G$MX303<B9*RX& ;N
M^LYN$B5\:AO?K,+O+NM!<IM235?2Q=QS3J2E/WGULJE.&I7[:L"R4M)"V_TQ
MT*$,!*ZD*V^X(S+^ YP8-B4!UN&?%I1=YF'=1H#DK_M"E0G$<+'J\JRZD]L\
MMY\_\/?QA[>GJT)BGK40$A9*5(;QSDQ'H@2NSK9QS'3)'AU_$'U*:#&3YS=J
MZ6N?T0KR57(X4[$CP99P52A@.D*DBYI&PQNQ/'^^B^#.94S*A(VF(,_:X;IQ
MFLTVW"N^0^ (=(I[6MG7R-LS<OVT79=^FU:L\:;HBR'W'FPPYBN[^S^8 3JT
ME_" 0GLS!YD.:T,I9SC5_)1],Q=T/M@WNRUX=*B*$U="VHR7_GF<?8<CWMFF
MR\)TT6G>L$0L!^@E2EKK5LUZA_OI3M3O]L[9?(%[)>YE,K]ZT$G%NZ5'?KA@
M773*DZH^03K J$""QS$T799X#QK:&==)W80/A30XJ.YH*,\/4JB&<@\J.H/+
MSXRL?U\>J$Q-Z;_X%($=E-7*Z0]0?CU):= I_1^#!A)>\C7'*0'YPG=QD#DW
M%+K.E@IZSB%EV>S VS5QI#EUWQ4^.!XPR#=SUSBDPMH5<U/[ZLP#Y.4%-WC-
M/S&?^T:-?M*^NEV8[80-:8:F^LXH%B:L\LN:TD2)M8ER@P\4VM>O\3GGGB[<
MXB:B"M^>LP)+=(#H;MBH+9?M//PCGBKC8%J=ZS]*6C982D;[>!]%_$GT2^(=
MPQ5TTD%'$J3%??FG((,P&PY&,0*OZ=Q_ZGM$ WMB>=3)4<K@P7G93R^WZ)T^
M+JVG=#!\'RSAR3/$Y7!%T5DT7A%28_M:.CI=,=Y$)M5XG6H):FP>JPD>4]\H
M'I*QI*EIM?T%U0OQY[\^4U[4_S4A$^BX+*0,U&QB/3(#%2PTLDTYIM04>!VH
M\\(L@X7)R/O\?,']SWC%QMTQ416V!_;T1:D$;>IQM%@SG, POX'3@B6W"K>^
M%%*LTLUL%87!-^3U]8I_C\1K<<P[W6(F+WB\^38([D)';M15=ZGPO[T>7^+?
MIVI\=QYYIILE?\'P1]X) <W)F'*JT=H (_?AI0'F_3/7$]<O8XW=[A9\&8,S
M0TD%*$8>$72AK!6U_ )"BDBI7)LM!9U^^\''3R]C4N?$FU_)O2F]L.OA3?MV
MD^E^BG7TN9#-;<[/%BS_/#FEL*-<\?)/IXCA93OGO\X^6K[G;$OP@=^AY( (
ME! _\A5XK!#^UJ-,^Z4F$H&ZBI A2$+[CH_]?-.Z4=X9RNN9B.."/E=O^[SY
M/CW=V2215/IZTX:/P/Z3E_?]5$[G=[<*2BB,*B3H&$6S9V+2"=+P>XK"*N)"
M5"+!E%-,22'KXJQ8ZQ\M-%.3JS^]W7_/^'34EFZQ.K':/:ZRB5>?#O]!\U7W
M\<[QKPFR*0$R4E^)8C8[G!@>_'".MQU8D4G0F?["6L"(AS8="7XUIG5$8K-U
M^:$/E^:WE ?N?8[@]:?SJP3IL 8_7'!/*+SU?^(6Q<%2+I^SLJ0%MG03-Y1Q
MW#.7;32@=.EKOSHF.JA3C[TAV2/VEO?6ME\TFRV]/65_,(>O&L#)X.9"<4S*
M5)W0RT_Q['!%S+LKW73:UA-@?AT+*>43\=+;JAN7UK>FLTY<\OBZ!_,W+*E;
M@ [)"&LUCE0/K"_(H# >HE1MUH6JHR8^C;>Z,S!BX68C89@HXOUE@UR<9U7@
M[9OY=@=H3UM<G=T_KR(F';F;1,7XZY8A59OU!&HSX3&WP++J3R.%A$L\;5[X
MN*V2VO26W/IWTO?@BZD;)9^NO2%_GHP:!QA9 '@6O3GTUS5Z)PDZL)6]B:S5
MV!1F&MKJS!SPKK9Q3%(Z5F)VYV96*J*X^H8#;9)V/1R6."P43#%(E$BI+$BH
M)AO@KX]$5//CF9AM%VSD.%EOBR1[L$!\R$=S6JGM;Q>\2\]+XS?SXC2%XZ?7
M<+$*' I?D<*M@9Z)&ACLL8[CV#,4TVHNYZ0J)W'O/(1TN&]D'SM^';*;T_J8
MLMXQ==.'0'5[MM]!Q@JT<X*O<&'%,YVV F_>S\'^Y!9KHZL^CU,D?[S9%+*C
MWBECJ%]FA]P#MM"W?'%2 )%\^4_<^X)*PDY1":\$P,A%O0!ZMT'8&F@5T34Q
M9PS=Y>B,GDI?X!T!9^L<Y.R#<Q,R]G</.RK>LSN=^EK+P%Z%F9.*:43RY3)@
M22LPGHN!?O/\H2(VT '0U$@_@,U?45L,L6]?,3%RWG:Y]BH^[6G<5"-\=Y9K
M2K_';<4!G=,R+U$1Q"ES)F:IBV<&E7(#H+ZH2X(L5KB&,MWCI6.UV8*Y)Y:$
MI4.ZR8'99P^:W-AR> >7*,VW8AF+\P^^XXO"[LIHEI.[XXCATG[DEEEO Y.%
M&'OETIDWRO@GW_88=1!.>S#6W,04"]D5O!.>$&4BY$#ZI!Y@LH][35#-=P#1
M3/%%3D78E3E3CN*-:NPJHI'OQ-H-E00F6-T?)E.CUO;MVN-J@<MF=![;^Q,#
M.M&%.*?R'XZ[!KHO%*IT03W9[ W'RAG\E(BUC@&)K%,/'_>$/5F D?E!C86T
MG^?7:!=NG#U]W(3:Z*:[YL@-P@UG6[P0':[[+=QHCBX7$M3!^PGOO>*ZU;QD
M$H'-#95D)?P><"C_ >?+G]F?I=K-C6W6%Z[,[#LY[#UMT5_FH(,(#CB$#!_&
MW%Y%U-80>>% 1RQ9BQ\(O:\1S20C:.)E0/$;-KL7_#:!.:(& G'.885WZ\W\
M]\8]F3W73]6[>&6/5K1#T_D;I3.H\ZN(C:+:$5%C#TC/L&GQ*J>+U90)A*)O
M$/: 2;T53&J&G_;PH3%KK<J.UB(I7O?K^T$>KUTT=A9ZI$=TI[<C'\J[LWM6
M$E"1*Y">#'];%_>IH! OLLZV4 4(=*(D'X!#;V^60@ZYX<"/6:/9LD/9"UKJ
MYT+8%B;*B=SY EA2E"VC!.;< K M%.'AI,$HO&E&[[@EJCLGA2[+MXJH&PB*
MQOP:+SA!U3QNMF7MW2[YX.];3$Z++\8J_)X57BD3(O+"1.#*$(>$)?- XSX;
M/8Y[QXJT@WH!YRN#-7,?2ZDMQR9ZU:51WCMM Y%A8M''!M>J)#\E@L[&D/Y*
M)B54@J $=PA!^BHB=;R9TA.5\T>-W""3<YD^YPTI=LHA1L-=_@[6OV^N'=IN
M^3QRVU')E^*?/^+(*3P%R%)FNLA'T,H/8@T(@.Y1R&RZ<V[S:)2&;3U8<Z\F
MN-G[G$5838C&A_MD[),[F7H[H J^/-!)K\]9S. A0I'U,HM+G+I>/RU.R.)\
MXYP.9]VUY38#(OC<-#ZT_^LV6F%BK<O..O3%K.?W@I*LJQ/(E9 2IZ"=6._>
MD2.)CX<PE8*Z+K()^+.D[M',;;&##8.[#>)OZ(;?:#?YZ;9.W181>_;_45^A
MJP5+63Q=_BY!DV@@B#P\B%$R#,$J=G,UC1L]#SA66WY1"VIJ:P(8)4JY%L[-
MD8<D=MR.-TXFJW"0B02USWZR'""KQMKQZ9=KM@V/2UF[6X*2L6="66?C*V5M
MSEZ5^)_J['WY?Y6'^TSTHM?CBECVG8 <_B 8U6U%W7BA<#XMQC^ E64Y&_1J
M)##?['"LY"O)H)PK'ZAK;FAOV7/-2T^,B@I<F4IDVB\&\"QQCEQ_:&?906(R
M'UE6?C?U?J+3Q=_&^P<'$3*F(_6YKR>5KFYGA"A\OOS?F#?Y?[G4C7D8N(<@
M+:@BP>JX6;XGP(Q2YN_B-%#2\-)L:1WY^ Q]]P_-];&$G0W-3<:;A@,WK#\5
MG=#VGT=3",E#1-0DJ8/>. ))=5*V67L2R$+KD%7=ZE0-6=+D>:AT(\,UX5;A
MO9%.]3%WBQ\BTKQ,I=M)H?_%=C+,54284PR+F@RO@XB^D$+9=4H/MSG YF8(
M]Y)QD0TS:?*X="]NB("'!K@%0BSXXRA3VLW7F&%:&=T<,3_U$"S;V9U@1G/?
M?/7MWHYY"OH)J63HFX%=6%J2%ZZ__JSK*W_MO/%?UPY>NZ9^"F7P+*M:^4[W
MJ>+\X2MHOV9D/V9QIWHAI99XJWS4!U44=6GGV*V/A3$QQH4>/W4)3&KYM8_Q
M0I4+@26^\MQ@H454P[MSNKAZ$/(9_@RDRW8*OG[A5SLL>\NI!F<&7Z%?S&],
ME(X+7G;4/"9E9W-&7N<W(1"LJ>,=QWN,N[>O(M8"YZA9Y)T<TQ&)TI%Y"(CU
MEZY/>=C\ZJ5K.FW/B8\SC$@E4CNN],;+8H["U=,/%CJK/NJ]\9K['CE$MR.%
MQ!NU(/-#?(R+K6EEE2XQF1]HX4-TO_%I;S4J?VL>&[5$XJ& CA/66 9F,K[K
M]-=?Q*TVJK1PF]TCI:.V7;3'17L;DS_^]=PGF/&8G7A_[T_!&4$A; UTG+-V
MX$QW*2OV81(QY\"D\<>5I#F@TTK>[ZS**6]<M/O?,>F)L(0HF%7$H2RJ/<!5
M<#,%E?N=S)VA]QP3%5S#2]/[^&G4IB^G^>^^F'U#_KRUEVZ:\:WEZ?H9+3D4
M/9:G[MGIF8R4NL5]N?#BKE['B2T%+W]?\YKVGHWWW;U,???<<[/1767UT:VF
MS.T5VRFQT^7536A3A=]TGB-!%,&@0(:8)26V9ZL2YV@/60GZ B)=4KKF]#C4
MKHRB:AFO$1V;2\E*ZBP9H^4] ?<,7E=W/G<X4BC80KJ%BJ!"FK_2R3KP^R:@
MB;JXGA<&Y7'CH(ZJ+QQ/J.7,B*E'K*]6]W#WTQ<J QN+93](II8774,:>O3Z
M;$/AKEM\6UDR%/4$%;4FO5Z_(DT8M=DIFLVV@*PGMF_CQ&9GL5$2_!,C[9P-
MQ/4#?WE6D[P<@HK']!'W%>),(I,F#,CEHLP;3D4O4C1M2=X.">V@=Y%4O" M
MYBA^'T:9?YES>(31,O;SH-72Q3*OX)(FR>'.N<#\MR&(YKIEU2-G_/*Z4."Q
M502MCIL"M3"1:4C0C0KIYU<+3PP6F_ ?;S4'J;;@SH(44X?8[='^+]L<73+:
M7D5HV%K?-7*>51D#& \HH,-2%+=$\,@:R;L,OUE%U,^5@F@AM3=]95IDK#3U
M><]"HQ<YOV=R"N-YHC]/S\2AX=M%;0OW:?5VF4%2"J4>W4.$]A=X0Z4\B3<\
MXRG\(3*'2PJK@H=@F_KA8RZXGJ"V!)J3KDL)HM9ZG'-B,=WDS)%#ZK[=VM<-
M5Q'B1E[\( ZF"Y@D#]B]-Z5+XH^,4<(PTN7EGU,QGI]I@[=OUV+/V0S+NZ]3
MW6+^]%QV>"4D5/0-GW D[IQ35)\(>0D! CK3Q@ '?8[VP%N-X<T?'64N[6X?
MJ2M+6!CO%=>W[GET:/'CT<='UWY5K5Q$J0*,.T1Y5!CJ)J96"$E)6:C&QH<U
MN&?<>"BK%$?QYM0\8\J7 (I.YWNR6G;YV'*Q71(Z ?N88@?N#NQ%?%]1@-N1
MX,6X[B5)=GO)'N&!3^,<CX[L/U!(=QG#ZX(V;]4.[SAW]+=<LET6B+M\.=8Z
M>0.Y5L3FX0Y ',4H0M824RA!R 07/]\OS1;YGYS'8TT>?W6CW&^BQIF]0P1'
M($J3CMDJ3><MC9T6?X,"W7.FQ+@>@A9X.]Y"5'IP 4VK02>[31#EZY?0769<
M=>W:41+?L?)0;H\Z\4(D(2S0/_I$U8[7JG;MJN?X#O\>,#I&Z*. )TF316=%
MY>U AZ5IE@MCI8>86)A<\.0+07O$VA6X)&A0I24UE#46/(NS?F;Y6G<F>I^&
M"C+:RI"0)#0=%,;?]$TH1CEF;159 3?1J]QWZZ>HYVSR=+?-&@X]9;O4*F)S
M^+;?WR(?O5&9F-<H[?]P+MG^;.SOKFXD:$>==N2^>M^ZET&'=H7PY0?Y7I W
M\^!YN@N0XJ<(!84S)UN=8]<,&CY%;WH[<DQBX%!I^#9MDRW*-PZ@D]4MWEO[
M"H5%GV\$M;"K=X35X>T%B=C(^@'[UQZ1]+/F+M,ZRW&:5679#U1+&L: CBMW
M&E:FO>&-OQA96I_>5P@JL+''_='DB,6L^H*3XK]<E1ROAW\VAO2:^%LM4=/V
MGM!U3@NCJ<_)D2G3B[D5]WV&;PEE/?KB[)?A47%8K>?N^[+,RMCP77HN2OZ9
MSS_Z'2.8<[U%%;'XJ!&A!SQHSOTCBLT3)C^QW;LQDJ'NRO9=&=+[.L#/7L9)
M&B_/%.SKPJIF![VZ*Z5Q-[VXYFSRM%*FV""*D7Z<)LZ7KX E51C%H8OOV1#]
M\4*._-^HR65&:^[4BXFP0Y=^EDT,MWH*O[O_YUPHYE<&$YCL*>B601[/+!1T
M' .BC<Z=DSF@-=+FSA7UG_;@!W#<EZZ;\^7%X(T\'N8-Z,[*;F)^OHQ2[P.8
M>K%#*CWY%V\T+L6$:Z=]G#GV]&F=?D"CZ6G%><,Q4=4ZA5&H2'E!R2+L((P@
MU581H=+V0BK42T]O,EMA ZF%)7?4B=L;FGP;N=O<[M095M<'B(4&M%RX^%#V
MK-B<\.,8N:]D*6@].V<[Y/%\[ =1?"&N\-+AUR6[/=6MXY>=,8K"B]3F^ZF!
M!?PM?8SEMHB/^0OT;LOL9S&J6*T!<^[\P_F]DE)6B)M[UNB>$],A\\BU=6-5
MCT<;I (+YU@ZV;B@TP.:>[KTQ9_LN)/.YPJ_L,07RYS%%*PHO5Z#_:8LPQ52
MXVQ><08/O2+$HL3#Y?;/$Z^J$^"=X7<+(H\<[W"8[4%<9,,;A:QDW;CPS^NI
M,4+]$+4 OT 81\K!LE!!KW+6)(6STFGH]=7.Z12L1+/XV/+B9;:%VY$%S\9[
MFXIN9;U\[?F$+P<)L<GZ@Z)0+-!A!V\6@OPF\26'"O@=( 5;"[74 Y+I4[RF
M[!'^9[\@4U_+L/-A@$'@D.2+7 <'N15WM&%I9%<W"CQJ3'/D7H*&6*0,%'A<
M2%/<7H%;[3F-=3K5+.-D2U+"$OZH\$)-#G!MN$>DA^&3B#4W59YO=XT]=LSO
MUS]AM8-\6RB>Y^I!F!/E?T]'800/;8Q"E7W^  DKQOB#4:6AL&)Z;&!QM8'A
M5.E6RWT/;T=LO]*_C=8NQI99SQ>-A;V)=Q-Z,"%-RL!,(KGUX$1G$<\*)4Y)
M,VJU9Z3&-HSY8S5GCJ36 D_U.MYHU3"_8(XN * M<KJ VPV5,I9B8,EAX5[L
MS6%5=*TBQ'#9TG%HR)4IDW*E69U823\BD_\KM[NC['#^F<S,$U9/K>.+4 Z$
M(3IX"@6%4" ]2A]]^A>LJ,NE\(U5G#;+0$*'QE3GH;BZW-BGWI^6,*% _>^B
MN(#^C,A+WV-)%:%B\VAH=]32+!C 72_(;+7G2+'Z;E6W^EYG>2"[2K9 ,0;J
M,5"+2TO6HQSTM^>.W>TO"A)3NQ!*Z<\(WD#'5AMUZ#LLL8]W\0NR#KWT"VSJ
MHLG!8^1MHS764AS)OGBCC"K[_+S.42>M/8=J3Z4EG=]$";$JD]N0\X/40P$=
ME6Q,@0[TY2A(+V=I+^<3O-5)B\F]C25OYN]65^09IB09J_CG.><&-__E-[MM
M4\>@,]9_(W)!JT]4<" J.KZ"UQ"^EA#Z+:F+0YPSG!_/[@<Y"MDR5#L^YA3#
MG/7:@<^8+(B.ZIVWSXE>R;;W[3\>A/A)SYQ3?]?J"P(]A*V<$UIAA17)I.K]
M"K?QCS<:SFJ+3X<K0P L'<5!I^)%HUV/0 =U4P-S[9X7^;VH*SR:R^6$QSW;
M_D=/,/E#]B:M&3/=Q\+TTB?%88FI*DB+A>X-L]F-]QUKW4.4:55DJ:BM^])$
MWL794%$DM<';Y9)%^%W/=2/GC\ZK7/59-UL?G\+?ZLVU;Q3< LZM(I(HM8$Q
M/8;41+R^-/G%P5>"&=I?Y37&@6BN\D+89%S7IG?B+_\;P^[_M?[S(*7=\>!1
MIM%#3F$?-[49W%:"OU2!(V E1[N_*'F_>.RX:Y";N6 'G7Q2NRXBR?_EN5RT
MZW]DT]%D:P@)%K!2,JWUV?14PMK1G\7>[;2_FW-NU:RP38"@.0>I(Q.R^E;'
MR-XF*3MJEZV.:Q<N//D_+'3^U_K7^M?Z_WZA5J?^#5!+ P04    " #VA%!4
M\=X4-R+/ 0#SZQ( %0   &%M9VXM,C R,3$R,S%?;&%B+GAM;.2]>W/<.)(O
M^O]^"MR>,WO<$8*;#_ UL[LG9-GN\1VWI;75\]B.&Q5X2MPN%34D2[;FTU\
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M,8I9ZF?8RI*RZ7QJ1-3*!K1P8$/Z,R#E;QQ4K^KB>[!UH1T?60V.&3D-!?G
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M6BRDF;_D;!5[H*^9415%'P4"1C0D$*5>##%/& Q3QE& $<>9$>O;=3LU2K_
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M[_S8^V-=R)5X53?9WWDCNJ6OTVV0S(S$P:$?>F/LW07HHBK/@!] +SL#*Z7
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M-K-4N9*] LN%'">  2G4J3U\?U\6BA5V+P3WLG'+A%/NHVI&R^.,U<"DK)4
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MNQ>8?Z.WL[]]^ON7&<&8!$F((!(1DTLZ@6&*Y;K.9S'S0Q1E'!DYV%<M3LU
M4O7A_EZ4OX(OM31&5ZD>S5[0-4Z'WTDG[0=^#3^]^ROX^^7G/X,OUY<7?P;O
M_G;QI_-//[X[ Q\^71@<GS=^.Y_H?N#D@+JV?1GE)_T2ZM=OW<8H;]P3D;N7
M[.D/CA.C:]EZ=3"I?MPX1GFIRJ5?RT>V+6C_J="U1SEKRMG/PBS"/O,Q#-5I
M<H0"#V+/HS!#7L 3$4<ILRJ[,)KD4^.)GQ>YJA>YK*L:+Y@ZS*Q\P-KW:[I\
M&G_T,\:PGR ?2J).(*(L@%GJ!U"D%"4L89G'Q>Q>;]5^J7%9_X:?@5TMAMP%
MD']2+E<LK;  UX#PFWRA/*\JE7 CRV_B 4$XQO(9D9-Z+.E!^(H>8@(SN=H1
M0H1I%D7M _)N89@U<,*/1Z?#R \'7[#?UF-AN,*8XD /O7A1"D&B- *;6F]E
M<"6/8/.Z5G6@=3\#C?9;.3*T_J"6 ( 6@3.PPD!^U"CTN% :>^#Z78.-)OVX
MR[NQ!^7)RG%T 4XX++MQ3FK'9[6J3BH0XR*$."'2]!$)EY]$!A&ATB+V4Q:8
M&;Y6O4[-:.W?^V^,O\$>P!"H#DS_ZO#DO3YP^4]UGO*^/6JYQA(T(I]RXO4H
MM ['7/N$>,2SK290]WR&U10IHX.K1QL;_[2JJ7[/'E$UOMG-+;)9N.,G7"]+
MG17J,[]O)IOJ4ER5^8+F]WC^8?&)?ZNOO_+Y _^I6-2WU8RGA++01S .$\GX
M:<QAQGT&(TSC0&#,61+;N#I.DF9R,X$7!':KC=,&PVP%,1K$ T\+NG;0=5<[
MZ RTNCR>@;]S7(++18^['+U@UJM!?II$HQK9O8"W:SCWTZB#,:RZD(M&53Y;
MS<F8=.G7DQ2G(0U@2J(8H@ QF!%&((DSDOAA[ MF7@)O3R=3([A63/!J+:A3
M0,8^3 WLV1Z0&IBGA@;)PC+M :R1#%$WT.RLSR-H'#0V]]T[GFUY1/HM4_+8
MM:X%<II#).^^*<<%5TP\\Y&@"5,IW[-(%:&(U=8U3B$F22 M1!+XJ>\0;O),
M5Q.-.5F==>*-J$YU<)[BRHB(4!AR&"14V=E9!@G.?!@1%@@_)HS'EL<_7"$=
M]?#'3_A7#K_>R@Y!-[&K(D/%S2+_)V>J1DZ^@_?I4)M9T2?"-_"<LWH*WW5/
MH1*PS^)!>[7ON5;0TWY&+@VT5]&GE8#V7^I@9WZXNULN^+?S!?N"[ZKEXN9-
M7O#[O+KH$J]1+PW"@*42,U5SF>$,IE[F09I(/0G/L.>9&YS'>IN:Y=G*^T,K
M+6C%!1>%32&.HQ@;&*!](C<T*S2B BDK> 8X%Z/T*((6UFF?2(YDIAY!M"=#
MU128@Q;KT4;&,UU-]=FR88UO<C-F?\3Y0AV9R1<W?$%S7GU<9ZNG+&)A1" 7
M(I)$FTJ;E@D" XQ\'(LH%"*P\7'N[VIJ+*LD!5NBGI":_@#"9B97/[@-S+&N
MD%F;8,?1Z-42.]#=J ;9<;5W[3*#.^PHHRKKC<+G?\'S9;-IOV#_N<3S7#SJ
M^AI-$<AU=8WU45+*L(C21$#L)Y&J&1M"'/,,4C^,6$8BG"&C=$@GRC$ULNE4
M 1\^  A6ZNAB#FN%5D51S<CGU+$ZS$PCCL# M/7EW07H-#D#?@"][&SUA8JC
M.SH>6\6%>CTOW!/*A^A0=K%!A?*O71H\5891.+(GH#H"[:LY>W:]6-XMYSI;
MS3LA.*V;Q%:7XIP5.KCIG/WWLJJ5?=\%'JFRDH)@&/E1"E$8<TAHDL$@9!'W
MA9]D66)*J;:=3XU'U_(#KA50KV]SP*92'C/<#)EZ=^^;+;*N7+>ZL,;?3',H
M.(W4<4(=$O^!670#^D;VLR[OG42VD_\,K#7H<4OC%.A.ID;KCD?C0U=(-DG0
MN0V7[ KW]V7QP%E3M[>:(3^-21 '$",10Y0E*2297(&&B< ,QR2-DL@\E<)V
MXU-CKDX\<-?(9W.D?P<V \?="6 ,3",K''XZ&0>;/ ;N>(SD;3/&Q3([P?.*
M'TY%L'//B'D'GI=V.\G GFM<<X$*7I:<7>-O'W-,\KD.M9EAQF-"/0'#P%=;
MDJF 690)R#".HS",:9R1U59O4>.YF7?L^=Y<=GM7?0[W1.H^ &M%;O,,-#:4
MP\;O'J#-O&,GX#967M 6)94.>$/$,_#I % .64$/X=!S0M!GNQHY%^@A=9^F
M 3UXM1L_Z),GGZ2XN+IM,B"T6Z"S$./,4Q3AIYD'$4[4%J4*D8LQ9X1BFJ:\
MHP@S=MC;EP-!#,P-S?FR7#D:';A@/ZAF=' :4.,P0H-0*V2;F02\:N7L(?>0
M,1:]LL+^WD8EAJ-*[W+#\1M.3B6.\U*YD?BE6']Y7E6\GF4>PG'"?1BEF$&D
M4EGB, U@$OI8!(AEB%#'G.)[.YW:\J<S)E85W;&24I*'D"J !Z6#<\;Q_<B;
M6A?]XCFXK;$"48MV!I38VHG-S\"/95%5S0^#9",_BM!0:<GW=_Q2^<F/0G$@
M4?GQ>UU//%75>D/PL3D?>RFNYCB77PI1S7PO]1(68<A)2%0>#P;3@$;0CVDB
MDDQ$.+3*J7NTQZE1D1(8T+7$TH#1,NN,"BNI;<\V'8/=C(IZ!7-@'M(X7FSB
M^&F%X]5Q'!W.*1EBT_-9I&.]CGS>R!"$IV>*3&_LTY%R51;WO*P?93>+^GRA
M3_;?*V_:# >)C^*00AJR **,2:,H( &,4!IZG'H>CEV"Z2W%<'&]C$!1^]T)
MG29G0.NB-ZQ7VO3AD=D_8J>X:DX;@)?VX;B!WI-WYRAT([A]]LLP 7_048#,
M'$7'F[$C1L;SV3M)K?7C7XKY<E'C\O%]/I?D,1-AF(HD0I!1R7HHCC-E@0DH
M?!^G7A80$OHF%MC>'J9F<35"@I64H!'3C*[VXWB8D'I!9V#*L07&F%*.*G\@
M9Z:\5_/%/Y#Z")N/FB3VMSH*#1Q5JGO1CU_H9N/H!5JU6KNMXX+.2:7K$<Q\
M%+'4U^]R&D&41![,6$IAB%/F$XQ(@&.[HVQ'^[1YG,<YV-:(_ <[:^0XMF;V
M1Z]X#?SZG[<^L+7_9BO0L).XQ\!J8W1Z-2J.]SJJ&6$,PJ[A8'[CZ>EJ9C3E
M210E,8QH[$'D"P333 308QEC'O4RP<2L-M][WFS<RD 8;:N9XK+48;?:':S<
M".S0P<[C$$I;BH:1%TH;2Q7S1#B&)%6(^DFHSA5[?F 47W0RA&-$1CX!;ZYR
MR-0JAPS3.63R!9TO=:)ANI3FKUS'W!>E"FHY 6%3KY8;;H,[L#J ^CU _)RZ
M@^7'>;ET-_L]3<]<XT:(*ZK]L+A?UM5'_L#G?AMLRR/B\S0(8<1I#)%' HBQ
M\* TL[PP#ADA,;4SM0[T-CTCZS^7A4H&?%_FM M]UEM";7@A$$4IX91O>4XE
MM3:[;>"5U@GXMCE:3,;#C IZPGA@9MC<4&L$/0,M=#U&-5M@TBM]'.IO5#8Q
M4'R77$QN<>.:3[R^P-7M55D\R/>&O7G\N5*UA#_H3+/Z-(A\O[2G:+4BB5$<
M^H(1&'./0Y1RN=J+HA **I+,PQGU_,2.@NR%F!XS*06 F!=?JZ;N8MX)WU"4
MEMYR<>@P-F9T-"S> [.4%!YHL#OQ59[P5TH#B?GW8*4$6&LQR*+2'<1>:<U!
MC%'9SAVF71(\H257'_;'7+=<=>6,SK_EE0IL0HQ2 7&BHJ0%"V JY#K5HVF&
M$A'C.#(Z['NXFZFMM%JG;2?JV:K$DWRYI+B&)M41:$U]VZ<"-HZ#VQXK!T_W
M(2A.='<_V_3(/N]#ZCUU?!^\VC4EGHJ;O,;?GO'-)@G'Q,,,AO)6B#BA$/NA
M7);Y2/ H#:/4+L3Q0%]3HX,VM%=M&MLY;ZU!-C-I>H)N8&)P1LTAG=M1/'I.
MZ[:_OY'3NQU5_&F:M^.WN)S[?,"Y_&/.WQ?E%SSG56.IZ)2'K?<@#7#$N9?
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ME=][*>]%L\_;I/205U\55:[KI\V2(/)IEH90$F<$$4TX3#/.(4=9YL=IBI)
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MG#ZNL\FB(.:A1R(H! TARF@*,Y)RB-,HB GR8L\3%AZ\HQU.SX%GMXPTA-7
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M0>1G#!+LI1#+>23R8Y90;%3O^G W4YLD.D&!DA0H4<^ LJD<.&H_M 9S0"^
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M,RPH\4(D8*93D\<D@ZFTC&&8>K$(?"P\QNULN*-]3L]XZP14<3Q*0NOD+$=
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MB<Y599P--$ +!^CP. ,;B( 5)*IYT)S U+!,_GFR.1P[]>=JK .VOX7GR_+
M[DL.[>%#OR\BV8@'AU\2^>W#QR\JB=NJ]YT07#L85T7YU*ZVRH4F5]CS9J)7
M>I6<Y;4J3B#[I+>SD F2!CB#/ D81!@%D(21!R,6I%$:9XBD8K;@-TJA:_/%
MKYLT=A$M.S(-QW*ME&<JG_$=+O/Y(Q!<CHQDH\__BN_N__C6;GGK.%1FR]L!
MD1]IIZ)3H#OVHN8('2*SK<29_J'1XPQTBIQU>Z7]+7-/0[379:ZC**,N<T^#
M:W>9>V)KO5;-ZH+DMTN[?.%UW>3#KOZ:U[?R>E52?5G?%HV_<Y8B%/HT%!!%
M2:PR(:<P2W @_XPPC8B<64+D0+&]"CE1YMT0NY<"68XC:,:\XP_(BY?+ZG3;
M+9>UH1WX*M4#C7Y@0\'!JV:=AOL8Q;,<)9Q"#:W3P#4LI75B)PXNSC\_%E_Q
MG_,R7UP4'VO6)0%B?I1P$D*"0T_:R"F%)$@S&$I:3R*!0]^L?M;^+J;F(M1"
M BTEN"A> RGH_O(-IC :^.M.!F=@*GP.%Y=,/\\#9.& .AFHD1Q$5@^2G:/F
M( 0''2G/WSF>H^.@Y%N.B,-7NAFW:C?^"Z?M;OQNX>C/',\5#?^H3A%&(4Y$
MIBQ7%$K+E>($9B+V(*5!@I(PRP3);+;$S;N>&B$VV^!E*R&XD2):6J06L)N9
MF\. .3"!*J'!6NHSL)(;BJ*$*I)?K>5;F)7P_=F)]H#U:@1:=#^JA6</RZ[Y
MYM""2W;VIL[1XN9C44F;\/H6U^^^W><E?\/KKYPO).S!^8(%7IBLDK5[(DI]
M#F.BJE:G"8-I&B4P9L@7<9P&E!G5J'?K?FH4ME( -!H I0)H= "M$FKC-]#)
MM)0>-DG'K0?'P!H<%/*!B<X>;:=<[]:PVZ1^'Q+^L3+!]_?06R:$=P7O<'YX
MZU9'3!?OJO%V]GCG5MRLX:Y4X45Q1]I2CA>%WMF3#Z?\5.6L+:]W7I;RR6H<
M#Q>WZN.'19.;Z5+LN66US^?/XI00XL<^I"R2<Q'&*505\F 84>1%4>9ASRJ=
MW$AR3VT2^\1K0+42NDSG YXOFTP4=L;X6*-N9LE/<"P'GAU7!4(W5#X#:PW
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MQ1N..IK#]!7@71&TNI T ,H--9H,Q>>7%Q]4O;H"\+8^ RBDB'IW;R%5!'X
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MN%>I@108AI6FQGXVS"SN"8[XT).=4J?EX:W);D-I0![!YG6MXD!K?@9:W<_
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ME!PN/'U-?O#?Y.9N)4Q=IJHN"?%IM2CYXUSPA&:*%;#(,8,XR2-8H$3;+:E
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M<50XT=+IYJ=&/WL)@1'1JS;L&0"[^>1Z6(8^J/!#Q"MV\+SB5\<)GFAZM)C
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MH.N.0F=7#(VK5U-?2(_EX63Y\)61^*<Z,_:Y6^T>;X*\4.K9Y\FEYY']GSS
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M-(C#/(%1A#*(..$P%Q)#G"8,212(7&9NU;-'V;>JU8:H%_BZ3557@.)YJK'
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MS7)F'/:AZ#;1CM;0GN?M#FT FX=@TQFL!8*9YULP[*R8=$WXA=2I<,HKJ-
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M%C*(69ZS*)0\958A,N<&&QLO[;2>WG0/="]9<1;HCHY=3_#Y=MG<D;-WR#I
MTJ^K=6[ 89VH#JH?N$==ON/8XEK'_RJW2SM8GS8I2#&A:<BQ@)G)7Z4,09*'
M$4S2&"$:YAAGL0V#'!UE;-1AA#1GZ&:UZ)[Q=1S3;F1Q-5*>6<(%)/O&UN=
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M0\%#R).00"0B!'$:Q##)\IC)'&4RS9VR%MNCC(W:]C/QZA^ 61C<SEVS%G>
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MR&)W$/N-%K(78]A@(F>8#F*-W._D&+&\F)>+6<&KS9V]FI,QXVG*H@"&21Y
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MK0$P*O3(PJ[H]<JQUD(,RJ"N$.WSH_-]7#>&JW[Q]^1'E:5OIO9IR .<T(C
MA&:Q<H5Y4)5OCT0<9HG $1;$;A/WV#!C8S(CE.W6YU'\NFY37HN*]RW%2D#3
M&Z,2<0+.H^2P@W@.A)YW^XX.-?#.W#EU#W?1SEX]<&F,#Z18FE1?4[2C2A=6
MSMIO8O6XX(O9XN'EAI:FI-U4QE&,:!+K;;0<(BZ0CN?/(8]R3J,LRX2T*G8Z
M@,QC8Z._"]U347!(OHDE>1" ;#4P*S(UV'IF?(+O^Y<^*%Q6@.MR!5(!4)7)
M*,$?C:ZVZ^T!GIB."_!Q/0>^=R2O+W6A]:X*58";O>>GI7N7)V.X>A;VMAI'
MY0H+N?\<-2KL#=%;-0J'H=UFP_=/S[/%BQ!?Q?);P<1Q@3\OYE6)(2-;:>J'
MM_^N@]0^+U;_$*MM!2S=(A*GH:!0Q+EN22N)G@-3&*=Y%'.!DU!:%2_T)NG8
M9KZJ//MZOMP6O6-M]M/QO6KVJ[HRK!9@WN@,B%':;G+S]P!TF])&8=8!)[+-
M!+4E@0G8Z-?,6UHA'8P(7L2J5?UP FZ>].*XOUG*._R]SDW^I!UT1O(.^OX\
MY'_ /C))WHF2+0LSV=W*OY&EJ9[X1=&<$K4HIYRJ:2,,U822J+D$96$*,<49
M)!B%,4Y0Q BWVY7I/OC8YHB6M+I/S[=:7K#4:QZJ);XF]^."(;IN[_B!U_NF
MSUY6QQ[4C>Q "P_>G(7ZRN2-;IAYS-2X(, KIF5T@^9\#D;'>_31#O3EL_C^
M=D:*I_)#,1/\\]I$P&>"!GD8"\@911!)F4$:!0@*%$89C0BGD96'W&',L?&8
M">1E6YDG8&[DU&_:C'POUX7M"5H7X+L16,]P>N:MO6:B+SJM[#NH) 9&9/6)
M$=I7<]&S"'GL-'I\W%=L.WH6B/,]2,]_U8Z*RN5J^D6O,6Y^J$D[R[$($ XA
M"FFHR48G)@0)S&(91[JU0)IT2DS8N>O8Z$3'V!7EJM#%4GX3I%POZXA&+6S'
M7=]=V,Y3A3,8OA><;CAT)H"C>I][Q=476J^W^FW_U=Z]XR O[U$EFM?S^!\=
MDB_K.E+D0=S*7Y?J96\ZB4U3FI,H0PBR.(@@2G ,21(0&"2Q$#Q &8NZYU^>
M'&9LKZ@1;K?YH-[$>B+_O5@"5O>! C^1$G AB[G@/P/U,P'/&P6U;[ R>V0/
MYEY+J]9L%XQR_GWO#VK/!'"W@U:%N5T+NPLX661O]H+70 F<_I[.7WK* [V(
MYME4T-/?'BX;]*(&.PFAEZ]V6Z!]*.;%2GPJO@G^4=U^_E!L6G7H8A88"X2S
M1)$S(H%RERB'- XD1$'"<< 3%J1\:NS<;6UV?C@KDMX,ZCD42/>9J 75A^_"
MJ:C(!9B[K<3Z \\S[5:"0B,IV(JZ"1[JM=)'-U1Z77A=&'+0-5<W]?>76QV_
MY<8IORX6_'LQFTTYSJ,L%!@FC&.UXE)(4L(3G04>B3Q#0<JH7>/IYM8V#_LP
MW:0;R>QX80.5B#,F",I@'F9,><&!(EJF#XS3-$P"D61I:!5/[@+4('[O=3!A
MRD3 )()2$ )13"DD69Y!*FC"48S2* ^GR@LI%EPM_I8=VS*[@+4_B#_(WHB'
M8C[7$5Z4S'0Q'$?LXA"K.5LF,) 1@DC@'.8DSB"309B0. Z$D#5V[^?<-W+-
M$/YP>V_ZE%P)6K>9V04&SW/PQ1?->J+=5[+7*75S\T$GSWV5]J?)@[^[38BW
MSZ8*X?SADR"E^*+#-&_E[V4UX6X28F^EFI75HUJ0V=VB+/0*[_V/E9B7>F[^
M5)2K:9I$(8LC]<HF5*A)@J<0\T#]A+&B/YZ$++<Z^NU)KK'-,1NU@-%K HQF
M<"&ATJUR0B>MHBAJI;I1$#0:@C^V.H+W<[7HKNI(6L;,]F7Y;C3T"O;TS&*O
M8TIK:NP9^%Z9M2_9!B7FG@'=Y_6^;^\8="JE8%4]$UWRY)[\T,?N.JI(C3DK
MS$/Z8;$4Q<-\YXIWA?JBKM.N!)NF,<8LS#"4.%/+!9$$$*<LACS/TBA($BZ"
MW*&*;!^R=>*1X4O)UF(#09;:J[8-%.W#:-WH?# ;#,/E&W6:NF0ZG\R$#^VJ
M- &-A?:O:RLV:9K%]!@$VB/>_<9[]B'8L*&=/4)Y$,79Y[WMF)N9_ACL9?K[
MUW?3*"&<B#B!/$5J/1UCKKSQ5$+)1,;SF*,495V\\?9-Q^9*_ZZW"7GE897:
MO;I1WE/!R 2\TY49EJ5E)=0= ,^SH"LLGEGL(B+7\]$QS<\TH&DNK_BD^<UP
MB6&1G=L-P@+'%&C>XJ-_<SR[:K*#ZM@.?K/Z+%;&AS,?JPG"A'C7E7:3/.%!
MI#RE(),Q1%%,(19<P(#$82AC@7!JM7JV&WYL;W8K);"1'Y"5/IJIEE7UWY02
M56*AY8ON:*..!V'>D/=],-8[Z/;'94[8]7M\9B?"L,=I3O <'*^YW<61!A=+
MG:FBHR=U)F19OTIAEA(<QAF,@TSGB209)!DB$-,XUEGYG'!A=_AV?*#Q'<4U
MRX=FJ@&R$MQ$6!O)7<GL.-(=2>MJ]'R34XW2V^XHV;//61#Z99GC0PW+)F?5
M/6"-\U?;ASU_5>MCLBP6O\_+9\$*60C^;O%$BODTX%$6RD3 D&.U=@DR"M52
M!D&B'"'U="08H4ZE?<Z.,C:7IQ$4_%')9Q$)?1K)\R]_;_AX?O>[0V,5''U1
M]:N#I4^/,%CP]$4EV\'4ER^^MA)N<V:Y+8Z71P&-61+ *"-,O>PLA7E  YC0
M/"%Q(N,LM*KC=6:L\;WRE:AZH?[@%'IR#MAN$W]/<'EG@"U2C9QU)5<_Y00[
MP.*I.NOA>*]49O6DXJ?KI9[^RK6\<;16_\?YN=.PS3*G51<5A4&<!#D45#<U
ME$$*<2(Y)(QF C,<81K8K3IZEG"$RY56;2[U\O&-EB4HYFRVYH*K'\#J49C.
MI8M9P4W-DS=58!/X^BB$;7IHWV:W9<+!33D@>Y[HV*-,>"%08:=.US#4VZL=
M/-%U/S*^$L7W"O#I::'?8?J(<M-E4J9)2/,TR21D4G"(&,*0<A'",&512(5(
M@M3*\SP<8FP.YT;":^+$#';=*/4Z1#RSXD'TEI;/5]156W>/ 51FF%>,A6JK
M>3ZL:>?*:[W#CZ8HDJ:2ZDS]BWA>+'61)%.(JWSS\E8QS<-B^?*IF(N/BG3*
M:1[GC)),0(9Y"I%::4+"&85QG"2"HPAGB=5YVS7"C(TF](G/5HLFT.4/+2\P
M COW0G$PE*WSYA=^SYQT!?)7^%GND'ERJAP$>B4/RAVZT^[2%?=T(](>VIQL
MW]=0YB3D!,&8ZI.]2$8PEVK)C0A*J2 AX:%5BZH^A1L;T?;1SLB9E7NU>C>6
M?BU;>F;MH<QH3?$^\.Z5\GL5<- IP >T^U."ES&N:\*RB5E]_T/7'!5OQ%S(
M8C7-HSR-&,M@3!(!$44<$AJF,(PD2I,PC642V)1BN#">%9$/4(NA*@?-FUXD
MM)+2K4_+*8B[46R/P'EFS4WGEE8@?2TL^*D6]^?^F[A< ,9+-Y=38[Y*6Y<+
M )SJ[W+I:ZZNY]/38OYUM6#__&B.$XKYPPWG9@^0S.Y(H<9]2YX+]7K5\4PL
M3[(XC AD:8HAPK$N^I)F4,8X"#.9BX!;+=RM)1B?$ZD5 *76P#@<9",]>%;B
MPV+^'_\6IL%?6*6%K9=H:Z"NKJ!'V+W[>P9Q(SS82 ^VX@,MOSY3J37P$*OF
MC%_/_INM% ,[:8X@'7IBKC=RJ$9X\XT4,WV^]F&Q_$IFXJM@ZZ4:2I2Z-O)O
M9%7_=B,5O=S.Q?WC<K%^>%3_$>(?@BS+S>')E(B4Q9AQG82/(,KS#.:)6I$+
MR4D0$!(F4=ZY?&%_<HV-0BO9U2M,M.A@H99B+TI@M5 S&NC_BNHCF\)\/=KQ
M/*>^HG4\,^U&*:BT EHML-5+EWVG*[!5;0*,<D!I!VKU@-$/& 7;)]BO8T:+
M@HRO8\Z!*C@.;U:[^HW]@W^VX&./PPU7(;)_C'9*2GJX_16M*.GE]F!TOSW8
M;=41[&]5NY8YU^LFIJL(+/1'M^M5N2*F"%331?&FZHSX1>B(6_5Y$VJ_)K-[
ML7P*IUDBL<B#"#*>4XC2 ,,\B"5$A"5II)ZKB%IMK8]'M;$Y! >-+9>-Y)LT
M'24ZF!52@)^,7_#S!-3=H12CB1H/7996?^K0RG(49K'I>#D*@4?DNO30&+.&
M9P+^5K>.4XO[]ZU'2W^LKMK"- $-4*!&"FR@ BVL@ :KYRZ:H[)__\TVQZ'>
M\#TYQZ'WJ3/S\4GH6&SI7^MB]5)U#MT>__^_]4(-_1M9_K/.S)W&/$,1"@64
M:88A"N(8$I(I#R BDG >9"BS\@ ZCCNVZ;D2N^X.W J8F8!*=%#);K/4L[5$
MMYG1 [Z>IZU^H+6O;F0'5+\%C#J./6R-(CM #LH067[=C;;>K,MB+G1OI"=:
MS WY;MM.?N2ZFI$T'=NJXMTW3$FU-(3[27U<S*H5G.Z>+'ASSG1/?E173WF.
M,6,RA[D(B"[JSR 6-("!S.,H2],X")%=MHY7>6U>XF%R=S8GK"ORH^X.8$>&
M?NW;C4)'8S//Q-OH"5J*MKH*@[:J=:\"T"AK5@8M=4&MK]Y*JQ\!?;I^<_X1
ML";M04S3*]7[E7C0"6(0\/>GE6$&==RHTZ=S7\2S>B$?E;]_MUP\+,G3S5I-
M@4LM7A4^&TZ3#",I*(-2UY1 .<LAI4D(DX@P'N62D3BUVD7K-N[8?.CJ]'JY
MD5LW5-*"3]KQ V2C!2#GFYI?99*.VTS] ^U[#\A@O!49W#48;Z7NO5N\)4S]
M;I5T''O8?0P[0 XV&2R_[L9>?Q7\H9@_O!-E\5 1:UW"A4<1$4P@F(2Z,"#)
M.,0AH3#%69KQ),BE70/B4P.-C9]J.4%+4,O2.!>A[48[?0#FF6><L+(FEDM
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M+6RZY02@I"R886A>S-8ZLNO]W==K .TVOSF#Y'G^JBIOM7QP<+-:+0NZ7IF
MB]4"W)%EKYM)1Y'H=8K:'6'0*>BH<OM3S/&+/'2QUALL$9:QKDRBWGA$"(:$
M"P2#).9A'*-4B-3N93\[WOA>_FH]Z1(#=A[8;B]];V#YWBFYW-!YH+;,7OC@
M_(CC::%\BB^Z?<EAT_93549IL7S1<;//VM6=)D&:YHG0E)&FRC\(E7\0<;66
MSJ6(A(B2 ,>=]V2/## VKVHK(A"-C!9;?\<@[+"U>B4PGOF@A<G[GC"QV.V\
M$IN!-C/?DN7RQ=1.,'$P:H[1]>-U/P!:MP H=0L H-L"Z+_,CCQG$_"P5"[
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MEBG2]^L9BM7))1'"ZHHJM,!3\V3OZZN]6"TS=M==VT!J]>OU  BP4A8][:$
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M+3=)$4]H%E/(25E G C=PI5CJ(B+9WD4R2Q#-B;?\6FF9M/U4H*!F$Y%/$^
M:D9$UT,5F',<4+(FE_,@>.61$U.-2AGGU7W.#A<^[5AZ3:=QO2:-X+K.L#*0
M.M=WD0H>$4D@C9,<8B%36"8R@5F>Y42(!*,4V]DLQR>:GGG2)A-!J@75F6U;
M23=EWBWKJ!V'%W.."$\%I#A/(<Y9 A782 &-XIB5(L<XLBIC=S6XXYV=FPL
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MNGI"E]C GXMA1(O:YYB:=A/8TO]6_>^K^"'J34>W)$<%RPB,4Z$K<^FF"^I
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MHRS*;7C)28JIT=2W[V(IB);0CJG<EL",N((#&YC'.OFU&[K7 +0JW.QZ8-^
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MOAUG!<)T8)(R<#9B@ETYNVJ00:NY78(C=&VWL_V-7>GMDN(GZKY=?,2/5$R
MACEQU41EK.//="T7ZY6VD>6#%/.73PM5F3^)/YZ6B]^?FU/3&(L""P3CE&80
ML9A"DF,""8E3GM,TQTGAPC7N(DR-@AJIS&;/4R.\*?K12*\9IQ7?C6X\QL6.
MA89%>V!RJJ.W=J2_ :W\8*, V&@ GK4*-Z!1(AQO^0,8E,X\Q!B5Y?QA.B2_
M*UKRX\1-;=PF]\KM0NP4F?Y-4I,-7-PMODBSIV LO(7X?;FHNE_?TE6Y:E)"
M<YJIA,4(9E%6:'>?1MHL2U/(TX)%B<JQPDX%#8))-C4&W2T[O9&^KN2V*[]?
M(N]PPVG'L*\R2 ,3;Z#Q<2;;X%@&Y>!PTHU*S<%!/63L\!WXA@VS]:?%:EW5
M84XM)1?FKH;$,,:%@*B0!%(<"?V?!'&.5:Q=9;=HX:,^ID:NNWG[Z^*.NM-'
M8 0'6\E7?N1Z"F([FKP2N($)+Q!F'F'#9U$)'"U\W,_(0<)G%3V.#3[_53]B
MJ N^M)5ZRQ67<SWV<OF\:JOYSE*2(<23""8R+LR5 @HIBR,H!%8H*E1"E).+
M>Z&_J1%&+:X;#UQ"U(X3 N(T,#\TQ;>[^I1[PMYTE<[#L8(E+D$9XE*?H[*%
M)0"'S&'[F,?%@O:F*7V02_596RV\?*+S9DMNJ>K[I^MO=/U(7YC\3,O:.;WC
M[2&T?N3=-_TVR<:QU4#<5^7#@S3&SX?O9KJ@6-(,4PIY(1*(F%"02)7")(LC
MDD6<"V)5_&1X4:?&75MEZ_VX3EU :WW-9TV: J,RT#H#)L&3UKK>+0++C=[F
MF[S6')2+IO+><@[6&^6!N7)L6>=AA!>FGU^G]1H,3,W[;\!&T_8 PWSV^]$;
M8!0&1F-PM_<&O-N\ :W:8*LW^#"I-\#A LEDWH21;J!,Y(UPN\XRRB#UWH<9
M5H+Q+M2,@N3>C9QQ>O1);J3G5)TQPZ3.^%K^K#/YG\[S;[[ZP=PD:B^H<:2]
M(IH@R$S9;811 BE*M8L4\1AK"R57A7VA%W\YIF9OH%^R/-W/?80P>--^7/_B
MG*7VBE&RL /&P7[H#6G=4IN<I\[38_*P-A5%>LJ.U _5^G@E2?(?%9><2:.,
MSE@IE(8>)<>L2E=CVY]DR;_Y$7,N78W!?@JFZYOSV\+[FS1-27'[759ZG6T.
M?N_4UV]4O\!WS^O5FBY$>YC 9TF!<*(B<_)*!$0"48B)=JIQ020OTABK7+E=
M4'7JWV5JCG,GHQ8+O-%F[*J6V')Y\D-?B3CFDA:0B"2%2#()&=>F \[C6!51
M%*/,JKK(X-B/83!TPD/:2-\. %#+"K!Z5#Y\_CKD:-AMQ0Z&\<"&02<W: 4'
MV^"L1G:P(_P-J,4/MU'KA5K0;5LW"4;=Q/4"YW!+UZ\1OS7F ZT6NJF57L_J
M]M^7\V?=]4QI,F,IU]ACAK4KE!)($\6A3!*<Y?I_A#J%]9SI9VK,U8I5KQK/
M*P&>]+2JR<MQ\3@':Y'*/):*P9B;-/LY0Y"HC$$ABP)G,LFXHFZ+= !@QUF.
M.V@U]0\&KQWO!X!L8(;O)#0^1,/I-Z"5,AR17X A*&6?ZVM4<KZ@\"$-7_JZ
M)^'6-[+K)(+FGL8]_?F%KN47:70HYV7MK7Z13W1=-3_?*5/\N'Q8=.+,:%KD
M.<<9)"0R.?EE"FDD,FWM,T58SA+ML<T6\L'DR;EW8.AK!;.:/Z29/T?B#>F@
MUU)JBJVT<N8>FEX^'TIS:::Y*N-(/5>/GR5)C3(<(]%9ITM73,3<P#'J@'U]
M3.#E5B-CS[8Z@4ZIFVY7)2 -A@(Z+&%>+=6XU!H*Q",2#M9PP#V8=B4X,LAO
MQ7\]-WEA9U0*G"6(P$PD%"*9(&T_\PA2FE,A,B+2A 38C;DLR?0,P69(S>P6
M1GI#"RL3%UN'S@;>K[$8J2OV"L*B_TJ[!IU=?KQU +9Z#+Q]8 _D\!L)%K*\
M_I:"/6!6FPL.S?G1J$F0O7/!Z3U]U'VOS,%P'40_RPC'D@D!::H$1)&)5E<H
MAKF,"(^*F*G4*63]0G]3VW8PXNY?^FLEKF,T;IIK*6YT> EQ.]H+B./ ]'8=
MA,XT9@E,4+JZU.>HM&0)P"']V#[FF9/LW5\_SKB4::IB<_+%&$2)++35E6$8
M1SE'D3:](JILN&2WT:D1QM<?Y?I?LM*?Z5?[8T47W#5=\QYD_63@"\3 ,_X$
M!@$3BNWH&B*!F&ENW(1A.PH<)0C;_9MG0K#EXH\NKW>:IKGB>O'.(R0A0IQ
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MU!H!HY*)6@:-4J#1"FBUP%T%-HJ-.U8.:]BX8S;6XC;(W/LET (8#O+>E3%
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M7E:/9N_Y[4M[5*7E^%WCU?["5G4.DUE6)"2+400Q8P@BQA*("Y'#B%*NXJA
M"7.LF6+?^?16A7=[>R/U,C#7ZD!MAC\"MJRJY0]3W\:U*H#U:-AQ]3 (#TS$
MOVYP-&+? /;2'6#7)+R5'?R]DSX@O[I#%KB*@'7W(Q<4<(7EN+: <PL>T=2F
M]4\+W4X=HOI%"OGX5&\WR*HTZ3O7WY;/Z\_TQ?QUJ7ZC_Y!_^Z9A:#.CH21!
M120Y%$@PB!1+(5;8A#"F),DR$N?2JCC!]:),S_7OQ#=E0;7\H%7 '+G7.=4T
M SYJ'< /HT1[H=\ADOFZ@>NGPW&'8XS#^ZTBIBK?9F@^[P_-Y^W0&'U K9!3
MYL$ 0^,0DS[:$(T4PC[T4+D%O@=!MS=._KH>Q@NK#X+$7A1^F!:]@T.?'Y_G
MIF+KG0E..)%JMHUAXC@CN$@RR*BIXY5A!6D:48AE9!("JEQPISI>UCU/;37;
M$;P)Z#!I9W:2*K^9FVS*7EFH[4=#92SF(LT@E44$M<$10VSJCB=YC!!.N&1Q
MYAR]&WX\1@KHO7OWR3-JSQYQ.Z=I$!0'-@IJ^$[G^QX@JL\9H= 1P9:]CQTD
M[ ;*B;AAQP9\$X;S2M*5?"^;?S\M3+Y:O2Z9_ XS)A2)$I9#@9EF)54DD%+"
M])*!"$<H$X3)KGZY'2OU]F<UA_;+D@_,1#O"N6;G[L/5CGNNQVJL7-J-?.!-
M)ZE9+8$-=A[9L2TP"9STNJ_'D7-96RA_G*+:YB'O\B5=<K:C@K2S)).*Y#C5
MY)%QB+A*(<UP#F,N>5S$A-(X=S-I^KJ;GA7S;B]YX4( *D2=+H#.P1,M!=1S
MA-.G<DWG-VUB4+#<*N1<[^3\2.0T$E$L4EB@5--X+#.($=7V/L:%B#C/(Y;,
MFIV<KVM:K<<=C<..!PR'DP_E8M$<S<U-CL";MI1V0*RUK<YX$:>0$!1#5*0Y
MI+E)V4!8A.,H5[E2+=8?%I:+9EBDNVZ'P_E#4Y-\.)#MUL]0L V\?.XFJ>VP
MNMDM[AZT2,]%1$)7Z3G?X=AE>BZJ?J).S^5G_%;.^XHN5DI6YISWJZR^EURW
M>:<VY2.V^T>K>]W#ZO2?VIQ(&8Z5S%(.E4A2S3F%*=>#%<PS(E-*S74=JY.*
M(82;VF[/MLC+CJB>V:J"#J(=I[W6T S,@9ZCXDR 0\ 7E#"#"C@JP0X![2$A
M#]*'K^NS6M\I4P9R*XQ<?5W.Q2S+HPA%F,"\R#0=YS2&I$@ES#41IT@[0GGF
M1,?GNYH:N=;Y09<*K&C?O1!7/&VMO1 H#6[K-0#58M9.82<H,)*&M/0NH1'8
MSCO;W<A6WB6UCVV\BT_X5.72Z+;IB<N?]S^6)_,3)Z@]BJ XD5'*M,%&)((H
M40HR;<#!C&=%4C"1DR2SK\SETO74""3])4\.DL@G"+QI/ZY_<:_/Y306_60S
M+,(#DT\M=Y?5O/P)3"&ILWG--=(^Q;J<L'8IV#44YJ/5-0F,O6/E+A_X^JMW
M.;4X8@4O'TWWJWAYM>"V2 A9MA>&WDE3%E*;IT+^_ _Y,LMQELI"%I!3$W68
MLAC2)-*K HYX@64<*V*5O^=L#U.C_$9(T$H):C&!EM..=<X#V4_D0> 9F*^=
MD;'FA(O:GS .5Y+_\K#\_F?];&T7_A.9'V'S8\T+YUL=9?I?5*J;Y9>_Z.<2
MWO'RK53+RB3_,]?!2E7R>EE9-1_?TY^[41GWRR8F8R;R#.,HYY!'$NN)GDCC
M+S(H"$KB(C=U6[F+O^@IQ]2(X8]%)>F\_)<4X$'[ZZLF$,O:]KMV5.R\SA&P
M'IAE[MY]N@&L%A8<*;'YB];CYDQ,43BG]4HP@WJTOK*,ZNY>"=BA+WQM<QZ.
MLHEK6B[,KMR=J@]:WM*5%.93N5C5?7_X:7Z4!]=3<5Y@C&0$4\X2B)B@D*K4
M%+-&%,N,)'F16+O,GD),C3"W:M1[<$81R(PF=4!KIPJ0C2YU'9^'1<VO99-]
M^IT>Z>6\%'4H[%?M$LG'KK5/#M&O5PVLA?\]PG -?^2[,U)->=)FI':U *T:
M+E>(PPV$@W,^PH",Y:93]CRG%1#EBFMKPY04;<J0#CRQ0A4HO7(D>CU^W[;'
M\_VOU'YO%^#:MOQ<B,_54CSS]78GN@[^;;?+BDQ%U"QW3$0Y1 C'D''$8)'H
M%8_%+$TQ=O$3^CJ;VMI6BZ9G5IU9Q?%HJ1=4B@@M<H$@SK%VOK3#92*W"EC0
MB O]>9K'S"U*,12LXT0I[@/K>>NB%V$[1RH4:@.OW*V8NT=W-Z#!,/S5"AM,
M@CH]O1V.ZMG8J'[HOE@]XYD:PT1.FZ/"698D*D^*!.8DCTSV-P4I)QDL",99
MFB B!)FMEVLZMV.+3<M.C+MI?T!3R/0!%G(-YG5P/^^M9WD!-3L.\,)BX E?
MRW135_,,F%?B4-&P:2,VK8^;%>)0J:.D#T=?\)N,9F.PL[#OZ<^W<B%5N5YU
M%QQ67^3J>6[R17[4,GZNRF75W+S5W_V\;"KVK69IDN<\Q@HF)"<0%5P;4S$G
MD*:(,54D6:10=[7IWMZF"B&;U=N_?PWJ?@03[(LT[&H$!&I9U16HGCJ1C2?S
M9+0!+Y)6CC019#SM&&:TX1F'G';5J:M2=0J9_.KMI:R-2L!,65 KU24<,(]L
M] I';R%1#LJ,000;E51#0GG(QT';]MG[;7-CU@?N75:"%">4T@AB&>>FBI6
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MHMI'@9B7G_".+WF2U?KELQY_<U#ZX9_/Y9.Q>-]O IZV$6#:R,O3-"50$9Y
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M*X-,QC'D1$0I5HE(L6,5Y> R3L_1:'0P&Z]/RZHYK%1UVI?G127;]$D/^@4
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MMALFGDOJ]3BI-@&)&^UEWG\D&:[>7*YK-\)ZSC IB5PJ9A)XS\BK2L27+[R
M=M*78IUWNK<\R1-T= /-\\K ]B;W1BYAK;Y5;V/^Z>N[2@G.$W[ +^N?Z,-_
MU#OO,2;O(.5:95DSB,%J!D(F9Z0JVCA[-)@ZD],-4\\E73N,%MHP4,36,LQ>
MSS-^^3?\.I%2,^D4!VU$!"5KI]=$W_J4$W)EDG1]%;G>>76WVY_/+&E[A'1'
MAL<9 3Y7T&\\=(S$M4,++->>)UPH<,77]%"MR46MG#^^1="M5W:#PW/)QQXN
MS48VH%?350JS_X5A^8I^LII$ZXTCGQRD5((\=.W .:9!)E^$]9@P'Y]*>>3E
MW:#Q7!*Q?4BX*9!L;[QOF="!@&YLAB0RKY$]@^!0 B_6DL_E4Q]AT*.O[P:4
MYY*8[4?*8U<U;\^@OH']JC."S2+&R!",1N+!8@%GHH7,0^$1R23ZX\N5'GM[
M-Z \E\1L+S+N#2?_[<=[0B46_SBH/_XF?WA#5K>)[=8F_]XSCN^6_S191S;-
MW[8FO?.&ZU;L1@9N:GM:[URM1"N<O AR)2Q%'=+2%J&3_)Y$GGS#43[D-MW[
M:KJ\>)TGZ$0H: UX5ILFU?*YB$6 =5DC4Q0UY>.[ -QZY3@-J/I3V"T/\F!9
MCAU(; G?U$U&P;4,S$%AH:9TM8)Z10L$QH2!)6WY\>[ C1>.TVYJ4 #L+<<V
MU/_+;N#*)&I-U#F$9&IO1DV^BK>FT+?96(=&\'!\X'#GI>,TEAH4!@?)L\D]
M_<5BOEK,IKGFU*[' :P6I>;:+@X<A//D$_N8CM.=Y"-W_ZL^Y]M'7[_L&D9:
M1U*RS"!-05"<'$67>/7P&.KD>.!ZF$D2CQ#4VY25;?O.(!F7PF=@MJ;J,2($
M:POXHK%(9YFS3]5Z]3!:9<3!.WWJ_M'I*OO+><0-9;5<3]XN%_DRK=\LW^/R
M\S1M6W>+)'.V,H 6PH**/D*(QM?6G"K;*!.JI\[@KW%"+[B!$?KN+CX>HZ"1
M,2H':'/1HVC;@,;J;)YW'*QV':&14< <8P9K4@$ED8+J6-.NM6(Z:.]4>*J\
M^"!\W"=C')#TH]G[,#E2S U,V=DQLAOPH20)@UM-XDBJW@O/X+1.$$2(Q=6^
MWV&8"3NWR!@=(\>J==&7C \&R&=<QD6_$/DFDS?KC[C<<9."X F%A^3MIINK
MA&"BAQ)"MCPJ]737CJ,1\R!5X\2\@P/H> TT8'"N]^EO2=[,K32!%>!";$K=
M,D1A @5QB))'X70WS^5P#_>:EG$G.?7@P_0DY@: \@X_X_P25]>^OE"T=&IS
M(VMIW2A?1UHH(T@ZSL:0F31/-JD['"9W*6G$T3U0LXL>Q=S$_K3CX!5)ZL5B
MOF'B]^GZXXO+U9IBQN7/7]+LLA:]G:U62/_E#^'+)"NC90H6M!0.E,  P1D+
ML39 ,B9'<@*'Q-(^Q(X+M^/P\3#8!E-5 V;KQ6*UV?Y__O()YZL;<@M)QY*4
MJQV*&3D S$,T+(-(SBLK=63EJ=8DQTRO?)BB1O:Z?LQ8+V)OPIQ53MZ4?RP6
M^:87^7XQRQ,*$+RT%*@*+5T]\HJU3:2&4(2FWZ$7\JF#@^,@]#!-(T]"[47K
M#T"I!P4T8(O>D3:(@(_$QDNRO+/%I[K@=L+Z9FS3_[F<$G&OYQ1GI-J.E 1
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M?2VC<V?U[[<K=3X5&6E7<8D"7%6*)]ZB [0^N<**,O:I-K&]X_,Q0L?=F5M
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MHY@KP_3S>9B>9D!UE+X?.8LX0O2M0&AY2>^])Z4)MY8V>QE(R86!*BQ!\*A
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M4IT_1B&RHM 88I ,K"@ZJ,!\,<-4Y3Q!U-C!Y.DP=I0ZVL36S1DV-=-"@8<
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M_*4>R]UCQ?-@8A#U9@.2)\I<@9#)NAN>Z0<L<<1A+H\\0=2X-YD&@EI?2F@
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MMC^[RSUSBAEA(*@ZF9IK";Y^FX3.,<FBY>#S4/O@8]Q$5F.KX41P:'0QW%3
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M9LZL/,9)%8SV%E@T=1XLM^"X)H39D)$LO>2AS>O.<RF/21*#8]+5#F D :H
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M0<BI1&%<$+K(R0"\/Q_3]FE-">Q&NCX?DWPGES*K>7<5?  AZB914W(=^JC
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M4_1%2N42\)SJ&&#KP-551U'1?[+06H4V(U8&D=E+36W+"+N=WCH Y6Z6;I[
M4-A2ZJI'[I$XDG2D290,BDCD983HY?T2V;&Z5YZDK?\'G@.!<;^195PM=8B[
M>TG[3W0%S/\7<QT \S*LY^M9]MHZQ5*M%ZX/#XE.< X2$CFZ/-25@G:O7<-'
MH_ I2B=NDAD9*4\ <52U'0[+Y66X. 4L4[KZ=+499K 9*/C[@J*RB\KP3^3V
MO,2R7&&=\Q+K9 YM"4J>O!-5-^\&% J\*IA9PH2RS>"I4<B?]DZ?%L -%-R_
ML=W)=!TZ<\MT23D65B3P6*=X,R[!">] N(!*"1;3?MO>3X;J;\B?-ISO%-6'
M*W@XJOTUJA>;P6ZYL?/ZK0!FQ9.7[T6"PD)M!44)'B."H$ T2Y)\YGLMC1_1
MA?V6PFF#_Q.C<Q0U]=YD<UN^%^]5Z(U3W//TYX]:[C.0G=,7 .6DM8O)0[*2
M'$U'@9:3FD&PT@8M$75I7M_730&0""K[NA8!73U() $(QF2PW&%@C)G(VMB[
MYU< - 17AQ< #5%8!P[EKNH 9:(VFB>0(BI0/%'<%YP#'@)9<R0>8YO94F=>
M #1(_7L6  W110>0&C4!@4H(;J0!K8,$%9F$Z!P'6[0-S-AD0IMJT.=? #0(
M5BT+@(;H>.IY O?/__K.!;1-9AD,.OJLP+&:4)4U^*JMYE[3!6,]>;_WL]\[
MDHY/?]<SJNX9!()E.XUT4>(S+!^ADT.3?(%<0RQE$H=HB#WBVF2&Q+EN4ZS[
M+!.,Q]S@[?0VM=T;OX?MM@,>,_I2"A1>"Y]*B74NG"8/W:<D'6)P^Q5IM*.Q
M?^_S0%2U;5,\2,5=&.!785TW5=7_U'CR#Q+!W:>3VYD),\XX]UPY$+86)7!6
MP,4Z48YL10G,F82FB?'=F\1IP-L5I.Z/3&NBW2Z N^\+[79?.;E=KAA#_G^*
MA5PCQS4XC1$2DZ5@'?%^?\SDB=_3MX1.XSWT#.*6FN[@%6'O5(,KQ<9D$)+Q
M-9\1,SGWO(ZD2XX7'85L]$(Z:D9H]'SE<X#N(-V.5G/2*(UTPW19KM9AK,[P
M79\Z:LIH+])/GRA2F0>G!07ST5*D%F.".DL+,$9!1BTPBO2?3:*HEJW4)/^;
MQ?T!4C,KO=>J"')2HJ[38P-0Z&KJ>O;LE(Y9LC8=/_M0=S;IH2%HVAWWCZ2F
M#B[@GQ=D"O!FS\4OR^N[X?KI.$J>#;,UJ:](5EY"<"Q!RBZ:PJ2WN=6,AIU$
M]1*CCX6 [V:KC*..?I&U?0B6C@4N/=WT12=0.0B(K*ZSH@M0"H8VVS;CUQXE
M:VHS-I+R]P/5 9KH %:_+A?+SU@'$"\^7#.VW:^WS0((YD6(=/HP\[IDSQ [
MOA [.DMT4HF2VXR^?X*P+J%U" 26[?31 ;R>L/ W:T)O![!^,WKUSE_]/WB1
M7VP6B]\3_CO\O%Q1Q/7BT_*J#F:Z^O0IK+[</NTJ+!R]+I MUN4 S$- IL$4
MPZ5,16"CY0W3\]Y+]JC1[3Z]@ >!JX/C6!]O9R8J=)X%8"9YHCDHNOL2 V^0
MI\RE,:%-(7O]]JX=SNX0\\ 3_"#U=0"YQ\?1OKO37S++CHDLHP.39*U_]@$"
M(Q]-6&>X,ZXD/\4,X;LT=FU1>X=O(RB<52G\ U,]QZ^'W_TE[8KB]V1L@M&8
M0FI&+CD@BD"A7HD$I2S L!2S4$$SUR;7?+H'S\=3 UM]T*_^.;_\.%^\6>!_
M8UC=:&_F3&;6: :N#JU0%NMSGC<@BQ:2X@V,IHV'?!S=4X> 31 X+.LSJFJG
MGU.S+[,O"IENXO7]Q]7RZL-'^@]N^%[?89QNBE!G>A/CL:Z$(YFC59!K46-$
MBI+WK(\:CZ;SF=E^ %ZGU%\'7N[>R5E%L@O6*XB**^*+O!M7O7>MI'?<HG:N
M3=JI[\1[5U;U0'7UGDN_+\EQ',]=GSJJI[D7Z:=W+47)0FBIP >9ZK!_ =[I
M3.B()B66,(HV532G<RUO+/+++W=+6GXBP_V9(LWK1[SB"@^H(G!5IX3G:JP=
M"N#643B8&"?HM.E[VX.ZLW$3AZ#INRZXL=74P9UZEY%ODG=%9ZT92U!"K:)R
M#,&%G"%Y;SGSCLAMTV:YBZ*)6]5&U_VR@2(Z!=37D8VY+G 1JN[!(DY$*G3/
M"PG")RV+59HWJ@;:3=.TH!I'YWL Z0 %= "ES:3.NL#WND[X>BGD-D7+&'-*
M2@E8PVWEM8-H;0;4F'2FGX9&6'J$J/[ =(C>EVV4T &>;FWX Q;\I@'TYI7^
M5?A\;S>TU-Y9)3PQJ"RHNJK9*^.A2&.2M+XXWF9*Y;&43_LJTOSN/*EB.P#R
M?>_V]1^_SF<IJ6PM\W0$M0<ER:D-QFDZF[XD*5D*I4UB[R%J>G'63H&'Y<C*
MZ11@W\XIK'G16=36*^L$V%S?#SV)*01O(=57Q((N%-DF1MB/OEZL7B<@/%*!
M'<*RYF.65Y?O,.3Y14V%XNH3";8^.7X5_G6*?5:$8;+$!&B* %4<@\!+ HF.
M/!A=D(LVTU(/)GG:)^*NP-M&S>>)Y]\__R>L\MO5/.&+_#]7UZ]>+Q:+JW"Q
ME8'2J42T&HRM7?;%9? ^*"B)JQ2#*]ZWZ8!HP<VT,RO/[12,"XZI!WO<%\"[
M>[?7F\4/\_7GY3I<S#S%FL4A@^3)QU(4U8+CS(!GQ@6OB+3[Q14[$M'[?^=>
MR-3/"IDMM=)[?=DO\T_S2\QOP^IR0=_X<?[YFZ3#&$F^O;YBU(S?<*9.G_X+
MMDAO>099PR=E0H'(Z?*I2>/,BY#(V\084[32WG[G=<7HO4+1EU]>T8'^L%Q]
M^3H0RA=9I^.ALU4VQ4#(64&6-G"M8_*I]0[F812?39IP".IV=TPT5&<'WNLM
M=W6&WB9O85ATBN5:^J8D*%$LA-H]Y460UJ 3N1$@OZ>EEQZ(EACXKF?R*(5T
M!ZFM9.;_NU';UZ6 N5@C#8+VP8"*/( GX4"BD,\9H] VBN2?IJT7ZW:8]A\%
MT]&JF!!<Z]7E[!L7YWKCW]<%?R&RD)0&9((<8>U)1BQ:L)&+%%222NSU;$[?
M<@=+]*O[.'J4C)Z@<[RNEV,+O@/3=">)=?/3_S/'%1'U\<LO^ =>;(Y<II,E
M96%0,FE?Q>S!5;%%;S+SI>ZC:I.7WH^^7EJK3G@K-E!<3W#\QV9G,W[;*W3#
MW[8 H.CB+;.&G-@806%VX#)%XJGXPKU4P;HV;X*#R.PE:3@>3G9!<72E=8C(
M_.+R5[RN%]G\]MNZ=9<T<3/YVK@8H@ 1!%TH9/'!NZ#!<:5\9E8PUZ9!>AB=
MG6!R?, \ <T1M=<!-@^X>&Z?2LE/=H6C@(!TY1![=/F4F$$'93-C6C#?Y@7J
M&*JG31].<M&?3,D= /K%!7W6@O3YQYUIF3.KLE?!>3")"U!.6W!164 1N7&2
M\^(:]9@^1,[9O< <B(;[;4]'JV;JQ-N#'-!M<%,VX@W/*C,'4LI:J^<=A!@D
M4.!FBM8V:7-O#]JNOL\GONGLPI7C(#2^]#LP5;=,O%I^^AP67V[3DU>?JQC?
M+Z__"N*=^0877][AOZ_FJZ\RGD7-)*:D089:VB&DKB7Q 9*QVHM8E&9M:F_'
MH?_L[N-QC.$$RN\]D_P2YS_A8J0AR_<^;-3L\&.$GCX/[%T)H6  ID(&Q32%
MW$HQ"KZMS47H>KW^5?/ "3&5H!.(K"D:T^1F!!X<V!Q+="G$9-OL)7WV>> A
MJ!LM#SQ$G1U<\"^OUG17K-<O$DEQ/;]I8D..F;L80:=-YKQFGX0O4"PCKU=S
MS55N@LH=!)U=/'( &N[W HZ@FDX1EC8. FZ?OK)!4;1$4+)NT&7DJ 3I+9CH
M,W&:Z RWR0H_2=K$38%C & /4!VNC:F#W:V7LWW7#.@"2@JF4I2!PG19'U,-
M!V'1.8^%PG3^E'OV_<?VAX$C]+4<17A3J_U7O/JT7(7W'W$5/N/5Y3S5R8Y;
M1JRL<84I('61H(HRX.K>.LUL=$K;X*S>"P6/?<NT;QL-03&::">N&7D7%A^N
MZVB83E:B)?,HZX"BZ.JH-Z& >6.3L#86-UZ-R,W7GMWCU^'^RN'B[@$C6VBC
MM4PP1X NOAX8ZVNL8('33[.SWJO]]BWNCY(I;Y<C5'9?Z0?(;V*U_V.^F'^Z
M^K0E7)<@)",C&9RSH'A=.,8,_2"LX";9PLU>@<Y>BO_FJR=6_2&*6XXAQ:G5
M'_Z\0[AU*:*0$;+)!93W'KPBZHWR4@2>R.;M%7OLI_Z[7SW-#3&:^@^68@<A
MZ5$OZB$GJ5V=+A]330:2RQRK.Q2M\\%;#*Q1W_Q?L*+@F.>3DRFY T!?/X'^
M R\_+N_,L'_SGVWQ[EM<I:KO#SC3F>E<UX>8XFN3=680I0F 64M)08'F3:<^
M[$'BV;WT'8B:!SN&QU9AM]A\\>'#"C^0!.N&A1G2/1,E1Q!<T_T1-;'$.5TG
MVLH4I1=*MQF/N0=Q9Q?)M<3CX6KK%HG_W]62I'B]$.1ZLG:D:R<&[4AL48*2
M1D.,7$!1P5IGG%.LY;R1)PD\N\N\)2*/4U^WJ/QA7H@:7"1\B9?_05R\"JO5
ME_GBP[5P7RSR[PO2\T7]K>M/F%EID>M0@#LZB,JC R\#@J'0/CL76-0M9X<<
MS\&T\T(ZPW5C '0 _-?SQ?P2?YG_@<3V)<6D<W+Y-T7KOZ^Q7%W\,B\X,S)G
M9(R!%UAWWF4%,>L A15IK(H8<YNFY'VHFW:,R&2 '5UQ4^>3'CZ!KS[6=Y*?
M;P[>]>TB<_09BP>7)!VR>MQ\*194UEXF;I160Z;5[/6E>^',/!N<-=5)!X;O
M;?ARO=]SN<W:/<SK>J:LR+(^HZ:0(_G7=8=A<!9\BEIR60Q3JHGQVY?"O8!I
MGPTPFRKPC(S@9JSTK#@FK%(93/!USKG4$&S*H(KTR45FO0YC6\+--^^%.O=L
M4-=>.QW8Q&L)UA:)UR3Q7>>)B>AR% F0U?=@5CAX)P7P.E4_>>0VMC&(>Y&W
M%R[]L\%E.]4-QZ._QN-B\S:5W[>TB"3%U>5VOL:;<D"85HQQ6J@"S')9%\36
M-"F34.HF0N:1Q!V/L)O'TK??^SM[-C#N1=4=&.%=9]=RK5.(%ECQ!>A2*> T
M*M"8 X]8-!WI$[XL[5D,_E?)$0W33P<PVVNEA(KU^9;D% T=&*68 B_1@-;,
MY\B"B+E-HG*TC6D]+"H]I@5F=#5U +U=)?4^"F]5*9"D(S9L,&2H!9TE8[4K
MT4C9R+'LLMUE?,WOV=HR1 V=HNE>'79.*8M@P9;K42N<#+UGP%*,K 3A/&LS
M*&=@:\M1?1>QV$16AKR<Z.M<\BP@>LV!%\]%K)/)[P\.'=YW<<PM<^"4;2^U
M$([4EF,B"*9,MK/0U6I",MGZD$5LO;/SV2Z,.L9XG%2Q'5B9??/>-C(CA?;$
M%J\9%^[HFG=U$Y=6%DM$D4[II1]6MM#O6JE!J#FP=&&("GL?E?!P)]$XDQ,>
M_^Q1!RD,8./T<Q5*\DX+P\$K='3SL@P^<'*?5(K>"&0NMQE8.L5<A1W1[_6%
M8KVFL#?2Z41+8;62EGP0&<#K;)%Q=$6TGJ+P&'UG,S-A"*)V5UR/IJH.KM^=
M7=@H!?.>0FM3.R>J5Q]%X1!R=)'[[&QNL]J^RY"QA>[WG8<P0!&=XNG;H#%&
MGA%C(@ $15Z %Q"*+E 22FFCDL6>;O;&.<Q#& * P?,0AFACZAS^H]W;S#JA
M/(\@,-7N;6;)N=0)G&%&)+3><?F4#S9.8_R$TQ(&:7/OQO@AHNW !#UIK&^C
MGJPL%XD3/\@BR<O5U$((X KGODC)Q/UI"J?RJSIY[CC!Q==(71T <?^FITQ1
M<985*:I&QI9ILO$N01'".".]8MCF3CR[OK5Q,7)PE]H0A76+Q&_;G7(45AFM
M0"=R,50P8CM+DW-6,_E83MH7U&67V@3H.UQ)'>!N[U+2%)'KQ.O^^:3K#P9\
M+!&TUED(*T44;9YZ1JT%/D%76E,$-E%7!S#\=;E(8?WQS:JN?-K^XHX3?8>S
M+=^9SX*7V960(2=5]\]G"5%Z\G 29A91*<[:M.8<0&POK65-P=E:B1W@=(?\
M;I([/\S7Z6)9=Z#4*8G,:TY!&-,<5#+$F7(1;(B22?1189N9P_O3V$O_V 27
M]M$JZS;]M2 $S_'@#-?7?SY.$NM!8D;,4]7/_W*KP9LT D%"AD2JDT'0'>A$
MG0Q (8#@465?Q[>P5H7Z.XD:8Q?"O8]^3Z)\27_G7[.HI"DY>G V*HKO>74[
M'2>NDPIUPA(S;8I%'J-J^JS3&/AX:"W!*'HXV(3\@:NX/(41V;P='6M*MA\R
MJD%YB+ 3F)4H:^&J1\C69E B)PBL8)TZHKDQ5@O5)LO;T*Q\6TV^^9)75ZMZ
MP#9"OH6V]]RCK64GO*Z.B2G0[>@U6,VXUC;J*-HLB-J7PG[-S1#</#Y';"3]
M]&]ZCBS4N?<IHQJ?UL4WNU 44"N,QD()VH)"00ZP%@4272KTBV@]/SOK<_/1
M[\)__A'(-YZ'B_6O>/FFO",UK<A=G^D<-4.Z2*6VI;(=(>82Z^94%B+3(?DV
M=85/T]:OQ1F"E9T.SC@Z&='6C("S?RY7__IY\7:U3+B^QY3SC"/991!(K*A$
M@:"/Q8 OT:0<A'2I3<O/'L1-W_'3%&DC::4OJ-4Y-6NZO']:+O,]IA)B\-$3
M&))WM9BW@,LDN1*]3R$+P[!-6GL/XJ9]2&\.M9&TTA?4B(]9"4)PGS5()\C)
M5)J#PY(AZF",Y"[KUD\ 1,6T#]W-P3-4SH>_$BXOPT4C+YO,[&=<$6D7H8[/
MRG5=XN?-TMT#G.W='W:\S[TGH2.YWE^_[6W]MFV-\N;;;B"$/EM'WDT==4M7
MD:GU,RR1$U1*'3:&0MZ?.#-6#O0ITHY. ^_Z@H?>N%#&G+/P8'S-+1HRF+X$
MBC:9LR@8N8#[K2P83PS=O3V.BZ7OLL"MM-5E4F.G%3C\=?*ICVQHNAJ^7#X-
M.B\+E]8(L+GV-SL?(22= %,P*+VWNCPW W9[$ C_WAIIP$3#0(F8P7L3((O$
MG2,?#TVC:79/TM:[L1J"F[V-U6&:Z: (X)?EXL-F^NAFYNCZY9>?</EA%3Y_
MG*<7*PSK>^^R%$8D+I4%+0R"TG7ENDN;O!"3J63%9)M#-XS.:5\8VF*PH<;.
MZ\K\FDPXXG5][\]N>(D^RL;);E,2B\B! D&53**(DBOP01?PR'/RR+3[_\E[
MU^:VDMU<^*^<.M^1]/U2=;[8GIF<J9H9NVQ/4GF_J/J"MOENB71(R3/>O_Z@
M*5%W2HOD:JYFDIT:69+-1@-/HP$T+KI12F3KV_3NS6F[]EZ7%0C+:V]O!&\5
M^<):%G")9\A*20RFCHEMDY(\E,+>;]9=,+3]97!$*75POV[=S=L?G^DCKFON
M$J^E31FL20J4%8*\&F& ^Q2*"=PZ>^2S=T=<+Y488Z)BJ%&WIXAZ1EW=T$WU
M'C>1)T^XP&AEG5;GZ*"*#$E;8[3(5C;J=S" N$XUW;Z &.Q%[">=#@#W]HHX
M6MMWSO/FC[]>?%LNOJ\;P*PVS:U<D-Q9.I:FU,*]2+9H*AJ8E"59)%NTR":0
M&T1>IZ#;%Q1/BK/'EM#4!=J_A_E5(;OC:GG3)';-KLT(=IF25SJ3&\ZJ04+.
M52S"@@F2#J=UFCRMU[R#5U?IU,T\$#'C,G=JE- G+);U+_QXO NMR2X02D(T
MUI(*YP8"J[5%W@A5!UQE,ZR&?^L2T[X^-\7'.&R=&AR_S/[&_'@#413F,EWM
M,M6V!I'8X6+@X RFVN156N$&X>*Y3Y_V3;DI) YF9A=I")\6Y?(O8B9Q9_/'
MG_ [GB_6NZIEL;=WI?3195)[4:M0)^58\#%D0KL@C8@8'3;*(1Y*XK0U4:TM
MFC:2ZL"8WLJX]322RKW-QJQD=**2(\[5BYB4*X1"?Y)8FZ&3!QQE&X-Z,(G3
MCMMJ#<$VDIH0@K<C[==.;N:.Y&_)M94BD9WG+3BM',2L7(PNH;(X!%[TJ?>@
M1=\]AM6#97MIO] @Y+0_>WO Q$:;9A^<Y@I8XN0C(DOD(]:YA%))<@]+$6Z0
MTAF.BBG]\P-$]ECH>_!O8K'_/IO/+JXN;@C/,8M05"3-E6I13O$0 W+0EOG
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M[H\XQ[_"^6=<7IQ%ST7 G(#G:G_S0!Y]S@Z\E3IE(Q4_8BCD'F$]&J5[@F!
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MC$]M2J>W$#3Q&^IQ8+03U[N<'G=MXKY;7'Q;S.L[QDT8O99)'A[Y?_ECQWH
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M&D>[9*)$VGATME7WUQU)G3JJV@DH=Y;:B<%R/4Y=BQS)3\@@8T%0AK@97#;
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MD?CBI&-I6-'2./1TVA5G;_Q-(*6I@3GLR*E-^J@GTU)+#B57Q]FBK1W'6&U
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MWSM!8O\9S+O(IPOD;>R%MV$U6WTB.D)^/[^?.G6FF'966"0W)MKJ@2<R#GR
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M#]'%Q^&T;3D+.ZT[[0M>$Y2UYO[^P%I<AO-C1LLW':#?+5:7H[?]>/;#&T7
M7]](VUBW94GK3):;12GKF%U1!R1SX-(RAX83:-H]B(X?Z]ZP\T.8Y3-=="Q<
M.A!)U:Y=M*U0"YY8UM)ZH;AYW(MVI+W=IZ++&/8N4M\V>')G%G?Y%O?I<I'^
M\75QGNL:_W55JQ_V4"//?,KA^N(UTD92##^O/_H6&J;X9$I!,C\2 ^4=!Q=<
MK#.SK90UC=NVZ;[[D(Y#%<%]YEU_\A^+2[P["I^)>V_I'_SCC'%&KFPQD%(=
MG%(G8(9H--@8E>;1EX1M-CR8Q&E5R 'X>*PZV@AE;[WR'9=Q<43-LBZ9V\M,
MV?I9+;3,<V2VT34I\V#)$X?"0AU6'!,X5PID7X3*%I..;1[:Q]$U:W-\S3^R
MOJ^6Z6M8X8?EXLLR7*QY> =G@JX6$FLH0I-WET0!%WD&E$)JK9BW2;R&@<&K
M=:4N=A'Q S=G=+Z.J"8.N);25\Q7Y_B^O$GIZN+JO!9AK9OWO5M<$%E?:Q)Z
M'1U'YQ/KQ+A'&Q:1>(FQ .E!!RI:!J[40GXO"W*=/&/8YK(ZC/!IGR)'P.04
M NP@*/D1TWE8K6:EE@O6?,VKRT$[?[3KPG@TTAN@.YUV[>@ZCX:8D(,I,J)+
M5K5Y-A^'_FG?*$=$[P3B/!&O[_GKYH#(TJY+M+#D=MA4&P,O1(_%! L6%=92
M C+C60@@"C?6>L^+:).+T,"9O.-C_NEJ.9M_^8#+V2)_^DJ'>'7F@D@H4H D
M:E)R$)%VZA.=$!938-I+W:;U]>NT=64/[H*(9]W'\<30P?7ZTH[^/9Q?X9FV
M&E4B5G$C?$UV%T!Z/H%W7F#.+FO19OCMJZ1U9=*U@M7N0N@/53=J_\W5Y=?%
MLLX=V S5D<KRK(TFGRF1)6%COFY?Z21/QBF/21T%6]L([,KL&A%AHPBD6YQ]
MQ-IDK(X,N]W?W=^YF^>4JW)V=?8A.3_D$4&PS(#/-GNF1+"FS1#=_6F>-@>L
M.1I'%]N)&/X_S>K NWD^Y!5YP*>V,.]?)KV-1>^KA^F3JUU]%!E8=8B6=P64
MSHP;1VY@;)-L-+)%?QO&6;/U[8]WU2^^[FGGN;2R3KOGL>:-T3D#;TV VM!5
MH5.%AS91Z1>(ZLJ&WP4#V^-GAS%^PNMOM;P\NQV^\BGA/)"EN.X%K"U+C-&M
M[6U6UVTO:4\)C$I1DNU8>U\.00ZM< \U]-UCQ&PE85J<C";<Q9B<GAHJ-W3_
M.5]]PS0K,_(PKONP&L.B4'2'&FUK^WBT-8F:;#XO&6:I?7&#<F^&P64;&=-
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ME"W<+>K4PL7V/[J:'YUB-G6OM!3:@_).0?"FKE'5*6CD:&*;VW9(+D;V 8>
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MOBL<;>GE=S+*$*2#^M )JF0.@=7DEN !?;0^R](81R]L^LH>NM]G^LH^BN@
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M3"(EYE3>1@9^4KC,Z[U#WW<[VH@Y]3H_UX%EL*"2S@L@I<TZT%L[[PC/B2S
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MAVG.!Q7TU'"WC>Y\X7N%'DBDSH']=*2&E(/"*07W)YF%Q:(\C35..NV!@>D
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ME87@%U/2RA!O3_=2V.JKQNDL#+*2$KI,>Y3&ZIP(-OXX OWP+45NS;D2IBV
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MN.0[./-'N>+\ZRS]P3#T%O#7))GZ[_\?4$L#!!0    ( /:$4%2#8\>I8Y\
M ,TO!  :    86UG;BUE>#$P-%\R,#(Q,3(S,7AQ-"YH=&WLO6EWVU:6+OS]
M_16XJ;YUI?M2BB1/<5Q=:]&R[*AB2VY)3BK]I1=('HHH@P"#00KKU]\]G@$
M*<FQ35)6K>XD(L&#,^ZSAV<_^V__Z]7IX<5O[X^B235-H_<?7KX]/HR^V_G^
M^U\?'7[__:N+5]%/%^_>1H]W]_:CBR+.RJ1*\BQ.O__^Z.2[Z+M)5<U^_/[[
MZ^OKW>M'NWEQ^?W%V??8U./OTSPOS>ZH&GWW][_A)_!/$X_^_O_][7_M[$2O
M\F$]-5D5#0L35V84U66274:_CDSY,=K9D:<.\]F\2"XG572P=W 0_9H7'Y.K
MF+^ODBHU?]=V_O8]__VW[^DE?QODH_G?_S9*KJ)D])_?)4\/GHZ>'3Q[,AP]
M&3]^\O3)X&G\=._@R:.#1^-'3P_B9_^S#YW\'A[GWY35/#7_^=TTR78F!M__
MX[.#6?7B.AE5DQ_W]_;^]W?!<Y7YH]J)T^0R^Y%Z"]^.<QB;?#W,T[SX\2][
M]+\7^,W..)XFZ?S'_W.13$T9G9CKZ"R?QMG_Z94PPSNE*9(Q/U@F_S8_[N/+
MZ<]K[LUC:"=-,J.]XRX=_?.GXY?'%]'^WN[COWV/SWMCXB[!Q!1_#[]KC=H;
MS1!FUA1??#C/.H?S.B^F43Z.^M=Q,8I.\BH9FM:P;NITQX"[?_6ONJR2\7Q%
M8_WK7Y[OO]!N?J$.4(L_)A6,=WB++EU,3)1D8UB$&$]\5)HJ@K^J"7P:59.D
M#!8FND[2-!J8: @-Q]#8*,KQ,1,5)J4#/HLOH;OPX3M3%/CPVWDVG$0O36;&
M255&OYH!R!83;>4%_>Y:_H8=$&?SJ*R'0U.6\.4PG\[PDRIO-A5G'Z.__N71
M#R] 4L%R@OC8[46OSU]N[T;11:O'Y23F+A=FEL9#Z.)@3F\VO]<@95*43K;3
M\/J)=@E:.S-C4Y@,>H3=")JULW-9&$,BCE\$+6?P*O@=_N16[_G"&^*F'?GH
MQ>VER&H/5;<\I"7/>%6L'-G"F?_K7WXX.-C[T@=N2>=>T"2-S# OZ'3]6&<C
M4^!3W_V]2]ZM8OIHDO9?;./)+^7H#TV!ISL:&?A76O+AQHM;MO0E: B5GJ-#
M=U#G>8U+@)_R\)(1;/MDG."I,VE^W8MF=5'6^&MIZGT:9W1N303B?%KR[YN'
M."[PQ,$TSG FH;4DD]^[\U=-XBJ*ARPW$CRR[6:R432-1P8.8E'9GFH+T(W#
M>$:2\]_P"NY.7=+;.AKC]T''8.]%.;147">E@3D;DUSL_,TDOC+TTJF!/F:7
M97297(' @,&02.!W)EFS8W<_A1MR>(^FLS2?&_/7OSSYX<5?_[+_=.\._]R<
MX47'KSYIA)L[\OYH5,!%_JV-F@[[Q7SV:1MZ<P?^AFZ$3]SE"X<WBT<CD)([
MJ1G#BQX_AJZT1\P?)1E>-3_NT%,KF@2\RY9.0']Z"<+^.!ON1GT0[".X)O!*
M.C-E1;?:P=[>\^@(],5JCD_AW7G%5V0OBLLH=K_YZU\>/WL!6G*A/QT7^32J
M8#1TL<*_-V7/O(+N?YW#LF&[B:?G?0%Z \U/M&C __$_\K_[,O*3>CH ^PGT
ML_,)*%CE?1G787X%YB09H*<SM =H7>_+Z([^F"5LYMQ\IB_(.GN^_X(W;K3E
M-N]G[?JSW1]N8Z;-<O9W_LB&SI5Y4>6S'W<>[^+(8<U =X]3F?=!7!JVX*K)
M*NVV;3+=X2[(H+]%&1=S-6B<7%W_.^ 7N+_0L/SLM\ [,+!*FHXK><4(7@&F
MU0C6LE+[S$3:@?/AQ(SJ=/&4;=AI;(YKZ>2ZR2KE<=Q+.G'.)4CN"SMEK\0[
M<-^F3,9URQF;P04%76?!MU7%@SJ-X>XJG$M@6P^FO]E)\<,/?T=O""I\]KK3
MB=_=9*O_3F[H97ZRXW?O3\\N^B<7T<GIQ?'A471V]*9_]NKXY$W4/SP\>@]?
MP8>GKZ.+GXZB_J_P5=0_>45_G1W]UX?CLZ-W1_#CB]/H]/W12=2/7IZ=_GQT
MUG]SA+\__7!RL7DWS_YJ'8;V7&RT7^J.@9*SH_/C5["3SG6O?=@]WZ6M]O[#
MT1ELK[/CP]/5NO(]97(U&X/VQ/O4P$8%RS0>M3V@/>OTM0+0>7"WH*>I&>(Q
M2.?\Y%J[\$71DMATN19>_"'<(.,Z3>>[LAS'8W3+L_\ W07DDM<;B?8PW%7O
M:Q U>726#/->-,JCU>WC9?.=Y=4JYSB"RWR"[I7"#$U"CGR[NSV7# 9!'J9P
MP10.\PRU)3K\,1Y\C0-QY ,_AD=&="=2I/1ZDF!<Q,UT@B$B#,N.:$\WXM76
M^M%#V>.(+"[*%(/%A?D72!@O1 7&. 6SAQS@@L_#</,0H[H,-HBV?MC;VXZ>
M/^N_>P.J!/ZU\_S9P<[3QX^>;L/N@%YF]ECU_$-% SN,LW@4XW'[__>CK:=[
MS[>C'_9_V/GA^?X>N^_P3:0U0H_JK"HPB+45]H;B[_%P:&8\AB%HC!A3'O/&
M*ZB[VU&61QB.QQ![S%W".9KOC)-Q14,RV0BTU%$\AR_2-+_6L>,G7;.N4>^2
MXV?Q%6C(\2 U$O7KX>SSCX8H_-WT6L! G T-2/>1RJ77 @"8U04H061PC SN
M@B33SFB?KTS095C35]#-?=NV=GR5MV\RG9I1 G.>SE=ZP#[+<NY&O^%>&L.G
M=4$?8GQ]',9[\S'O.#Y1:/T$H5]['. EY<P,.0H\@V'ELBM0%H#E4X,Q1 WQ
MML9]$K:$9X<?L)H"-D['I5ML>+^^E9#8C>2:O(U,DF%S#%SZ!ENW3'BFY' F
ME4@>.(KCNJ!3'?,T(5S!F!%C9Z@M"D>[W]H0._3KI_S:@!W0<Q(,Y@SEQ S:
MCJ-!D7\T17QI*/)=8X_*: 1=&58.Z2(KUL._]TE-W-N+9M/H?8RK,HQP!V)?
MX$0.#,R3GJA*@MS0X?W]: J;;P+3,6:Y(@_ ="S4Y@=Y 1?/SB"OJGSZXSZ,
MK,S3!+J5QL./+Z8@N9),OWT"VUL^00MH?\\!\9[LD4M@!<;"\]W]/V7$_?!\
M!5;<X]L)BE7!T!9TAU \LR*_2DHY(WF6SNE>JTNC*+.Q@ 7Y\!$V8RSW"*FR
M>!R]:_>S>U!\F&A[U1<!1V6+[[F?Q ,X"2#X6C^Y ;_)_YP4SL-V:78&8&I]
MW*%S^6.<7L,%&;[^)GSK)V%&5^LV5NE(NZ:LS(R%*D('T1$.RP];"?^**@0S
ML^ M+4B1;[F"H'G5W,K:]539Y68:Y0PT6B3W2=;#+(S [L8?]OQKJJV%K6Z+
M?S4 \FT<<-_]_6 !^O$K=\,_?;=\_<L\_QCULRKYO8[_U+M!(S]X_&*QO+D]
MOO[Q=^LDHU:*:W]SAC[KT]?1^<7IX<_1Z?N+X].3J/_F[(@<TE]ZU]W::7A+
M$,6Z>6^7@]I_.HK.WQ\='K\^/HPNCL[>D=/VM],/9XW5.#N*7I]^.'D5'9^0
M3_=]_\W1>71V]+9_@0&&BU/ZM',IS^67T,R[H[.SX[=OH[>_G1S^%+T\.CEZ
M?7QQ'OUZ]/+\^.(HVCH]HV;T;VBH?_);=/[A\/#H_!R^/#Q]]QX_@=<UFNJ?
M_*Q0][,/YQ?PI$#=HRUL\:MZ1^]Z;W$LYH2"-JOUBXMK]->?CF%.,>B#TWT,
M"WWQT_%Y].KT\ .>2%0G8$[M=G'Q)!X#[9;CD\/3L_>G9_V+(]PTM$&@C>X=
MTKYDU_04+?/GM_]Y&MC0H%#U/ -?L<N!S]_AWL <CUZ!,G&-P&G%<W/D=-V]
M_6)%KX.7OQ=-P,PGU<YJLSWG-C FRN+IHL7@(#ZYWC ,LW3I-F!9,):T'FL"
MDYG/-F0S,_YL'>:-C+6Z&$[4;YQ9]%_)< AQY_W'WB[T:!^=9=%5G-8H/Z93
M3*:J\N%'?4J]D^N_!"&V<:5+<(/X;N;LL%^TG2EX3@O!6\N%=7N4V(=0($XI
M[G:KN@ &A3[F;9]M7%4QHI.^DIE^YWRN&5CFH^2/J+]2_[^-JH=2/+\TZ(+>
M@*"ZW3?K<#+4Q21[FA,-,?F,@?AP'L#V3C$R@O-.7A9\ &-2DO".8?=,9SRQ
MF'Z168("II?Y 41)#R-,F 17'A\<!%'[8[1M\3B=F2N3U2CY1N2.WW_^P],@
M7<"N/H=-.%OWLDYC/GG8<XXZYN-Q,DR@R<LZ&5$<9E;DTSJ]9*<9/&)HH39@
M%^%DK,D&:N<4XA;1-$&<5%AT3AYNIP?&90F& &^U=H8@)4]N,@9KT1P>++,_
M+FX*S<EI11,C+B4B6B['VM_7N3K>O2MP^KP>,$)B>0RT >/R,^%[&*TQ<%>'
M@%?\A:P,[W:$N;)( CUHYKTS:^1_>*CMO!NUW>/0$<EDC%BBPYP.4V&F3%.
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M21_&3*6HGI'*YFP>RH,H2+-3HJZ6:L^0=C29!V:83T/# #J,UAO\:TIYNM
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MK&X'(F.SJD.>,[/3UQ1$*MF<!(E3UH73M.Z&*K[;;FW,GB52%@JET IOU'(
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M5@]1I\Y3KIW7Q4-#]^XR[P>G-U[G$8;/&'WOPCYQQZO0CFI2%=%M2N47T)-
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MAF,W(!Y^KRF@ADUQPHKDOFP[E1MNJ"M,Q!=EFX-=VFF+>W8J<44(:P/G),$
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MHW=510T;0T(;-MW+CE$='YT321F)HWI("KM)$\DRI)4/MW5SN2CI<X+Y"K8
M03(DG0.%)WLY,+. ]QS&.WI2]%!9(GW*1OA)XD=%\BQ,<EMR#&_:N)1_@K2>
M-IT.@S !_G=;[2)1;TC.TB'+TQ&/E"5TUT0L[?>#!F0UH,.%&M![:\035Z-
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M48MNQ^(EX7MN@HQ8&WI@;F.2CC$KD=I#D7=MMP-[I'JNE)A7G7%D2*'3-D,
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M#/:+4KC23U+G&1,$0 $JFP6?I0V5K@@:P%V.V7A6*^MUE(+NB?R2^L^<(H
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M_:3M5/W:,ESM!N^/4Y\N'TO='GLX6>F1>=_I6%Z['28$$QR188,HL<1E=M7
M=ZUL< DSMG3K2DWQ>(QJ9:L"Y.E=>!L>BF2Y5%KB\J\2&TF1KN1%M<6CG8<6
MWU"I8G2(R^2\LP'UF-B*BHG*W8I&O\:!'H[<>8"/%-+/9IY9S2?RZK7J-1DE
M)]&]H)USNE%%21:-AC:O#4/X\Z10*/1#X1VU&(46W>]?H0?@K0Q6TOW]8OMM
MW.'>Q!V>?^VXPW\ -)+^<S$=E__]_P%02P,$%     @ ]H105 "05%?MFP
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MS#8%OM'C"US 5^ETG%*YEZ>%:!B@> .E6]^5B8:W\"?BN-!1SY8M^S71''?
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M*N/O&P:XMX[(-)^#\NJL"E\;7..IN.$X=19;NVTH"EZLLWM,MJ"P@V_U29U
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MY/3GA<U,3\CH\;0SRU,G'G4.\&$@TJ33>@F'HA$VPV:.;BAYY>+K(CRQC8V
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MHF624 Q7%B )DFG*OG.][^D/;+&CHCI:DU=1I>]9T,NG=:6T#9_@4XXCD X
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M,%Y!3'-IX>]#IK>BK6*O;&2>/[,D_:%3)VNL%"4_PK:<) 2V(@8T8FDI8DL
M[*; =1I(? -?U9P&]R#B#$OD6S,WXMO)+Q ^;*-DN<NKCF*M*&A9QGFQZ&"*
M><B0,U@J5, 0F1D$1VS\P@:FH^UZNNFW_* K;;IV1$&.KJ&J9DJ<58ZE1ZF
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M%P7+2EF/AMT%>^5E5(0>!SN!$H+!&-2)9-VYJ#[W@CJY_/7]X'23Z+B.XWY
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MVNFI;//4)_571A\%C'W1.J?ZI99^V_L;.U;LS6+CF>X=?@FZ*\GTYNDOR8L
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MK=T3# J >%RGN;\5!&I /\&9/V->Q:OMAU%(2SS.'^TN-VDJ7']+=?4%K5'
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MYA?:;SFM5M]/;KRRIT6"]1!:6H3D+59'0BO0@OE>PAX2#%\%<\0.A<N4A(5
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M%BYB^FB2=E]NHE0H1"R$.L>3'T0:_B\I^.#CQ2W;?00:0FG.V($[Q-.LPB7
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M3O<Q+/;%+\?GP>'IP0<\'J@<P)S:#>2B8SP&VC'')P>G9^]/S_H71[AQ:)-
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M3F(3C0)2/@%QGPN+$X%O@K21(.\4/OQEZ]L0WI-[Y&K<K79_87I0D =)-9[
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MS,CHMNGMLUA_C.[T4,3(\?*0PM["*#ER,8!#)I;C#?[>=\LL@4+BB%V90(,
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MC0J%,1O9%FP*)\0<9W7O2('''%3;7P?5[OO8'IE->Y!QUKY_<!=_;H.C)JN
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MCR=N7N)0H$)=QO3";'V*Z<W(D^K$*=\Z1D3!!L[?(7"H8[:KQX?,#X5+S1B
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MI))>+4^9*%5+NO7%J4J9H(K!W35]K><EYD29YD"BP:D3P3@=OR'?0+VV*_9
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M!'G"%*I/\+M)@N2J!H+#9C1[_SQWW /=%/.DP"^G)V^"7^%_5GGLZPCS7'E
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M*!I+Y0B*R$9PWD>4\P_T<,X3QK^>GAVM09\K..[[]0@L5-V>APSR*9P]!<I
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MY^E4?2IZP0$L*.PZ-,]?[.[O@6GX8?M\NP]M(T21Z4&;.Y2,RV@<ITCQ6:,
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M_B%)23C=J2K$\9\K4K:R$);PW_1O>/IO>_^Q !F6A=M[NO,2R\_YNUM6QH4
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M!K2RRT5];TYFDXR\P6Y7IEX648BG!$F*+"6L.,QWC=,,*Y!V8Q6H)/07+M<
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MB<&.=.*)+VBO0#&*'.NL2%1TT[G7&]A!L<Y9/9 <U,>B_$3[\RB![13\)IF
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M"(6&] ;=4A@.DC (#--8A#$Q.?Y8CI]RS8M)4(%$& EY$%/J5-@8%#09#YV
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M"9#/3;('((<(;C!#P+]8P\\]D_^6"Q#?>6&>ANY*Y%UY\'O>VN%,0BT(MA*
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M4_4Z.7F2TM%*D]>+F2Z3MV5VG,Q5D[2K*LD*U32:;FATUM5P\N%3K6>F 0K
M,PO3J9-SG2%+P,6$*]NYQF_LU6\^9G-5SG3R.FOQ9US)-($7*#BU.3SC &_
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MA8.WG?2C^GBOMK]1!;!RY(@Z=1(]3195W8)9"W\M"YWCOZ2/39E2*M(?<M.
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M=?!:B(58IM>F1L.(2K[FNFXG\E'.4TW52 TPE]\X.A"J#;YU1K<"([PP5%T
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M?;MM6R^.?Y^WDN!LZ>P*/O_P./;+3^/8WTZJ? W_S-M%\8__'U!+ 0(4 Q0
M   ( /:$4%2_QXH;@!\  +@+ 0 9              "  0    !A;6=N+3$P
M-3%?,C R,3$R,S%X<30N:'1M4$L! A0#%     @ ]H105#;V88RM" 8 ZO]!
M !$              ( !MQ\  &%M9VXM,C R,3$R,S$N:'1M4$L! A0#%
M  @ ]H105&\I_&P-)0  IZP! !$              ( !DR@& &%M9VXM,C R
M,3$R,S$N>'-D4$L! A0#%     @ ]H105#[2SSIY,@  H 0" !4
M     ( !STT& &%M9VXM,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( /:$
M4%0EN(JX)N0  #$U"@ 5              "  7N !@!A;6=N+3(P,C$Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " #VA%!4VJ +Z-M5 0!&_0$ %
M    @ '49 < 86UG;BTR,#(Q,3(S,5]G,2YJ<&=02P$"% ,4    " #VA%!4
M :#<S[CW 0#'H0( %               @ 'AN@@ 86UG;BTR,#(Q,3(S,5]G
M,BYJ<&=02P$"% ,4    " #VA%!4\=X4-R+/ 0#SZQ( %0
M@ '+L@H 86UG;BTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ ]H105%H+
MN\5^, $ D1L. !4              ( !(((, &%M9VXM,C R,3$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( /:$4%3L/&K]:04  *X5   ;              "
M =&R#0!A;6=N+65X,3 Q-5\R,#(Q,3(S,7AQ-"YH=&U02P$"% ,4    " #V
MA%!4)Q_MW $%  #=%0  &P              @ %SN T 86UG;BUE>#$P,C-?
M,C R,3$R,S%X<30N:'1M4$L! A0#%     @ ]H105$ZO\3_I(@  ]>H  !L
M             ( !K;T- &%M9VXM97@Q,#(U7S(P,C$Q,C,Q>'$T+FAT;5!+
M 0(4 Q0    ( /:$4%2#8\>I8Y\  ,TO!  :              "  <_@#0!A
M;6=N+65X,3 T7S(P,C$Q,C,Q>'$T+FAT;5!+ 0(4 Q0    ( /:$4%0 D%17
M[9L  /D\!  :              "  6J #@!A;6=N+65X,3 U7S(P,C$Q,C,Q
M>'$T+FAT;5!+ 0(4 Q0    ( /:$4%3BB@I5$)$  &KY P :
M  "  8\<#P!A;6=N+65X,3 W7S(P,C$Q,C,Q>'$T+FAT;5!+ 0(4 Q0    (
M /:$4%3FY\UD/P8  %11   9              "  =>M#P!A;6=N+65X,C%?
M,C R,3$R,S%X<30N:'1M4$L! A0#%     @ ]H105.#+6-;8"   >$T  !D
M             ( !3;0/ &%M9VXM97@S,5\R,#(Q,3(S,7AQ-"YH=&U02P$"
M% ,4    " #VA%!4RA_'+M$%   7)0  &0              @ %<O0\ 86UG
M;BUE>#,R7S(P,C$Q,C,Q>'$T+FAT;5!+ 0(4 Q0    ( /:$4%2P%$@A=6
M .^0 P 8              "  63##P!A;6=N+65X-#,R7S(P,C$S,7AQ-"YH
8=&U02P4&     !, $P C!0  #R00

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
